data_2lu5_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2lu5 _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.446 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.436 -1.146 0 N-CA-C 111.475 0.176 . . . . 0.0 111.475 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.65 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 3.3 m -88.81 -26.92 21.43 Favored 'General case' 0 CA--C 1.568 1.64 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -167.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.512 ' HB3' ' NZ ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -152.17 158.53 43.03 Favored 'General case' 0 CA--C 1.455 -2.676 0 O-C-N 120.381 -1.449 . . . . 0.0 111.628 176.619 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -145.19 153.68 41.61 Favored 'General case' 0 N--CA 1.397 -3.081 0 O-C-N 124.081 0.863 . . . . 0.0 109.321 -175.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.1 m -132.21 132.01 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 176.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.74 136.7 47.88 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.562 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.61 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 4.4 p -134.27 106.66 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-O 121.662 0.744 . . . . 0.0 110.001 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.406 ' HB3' HD22 ' A' ' 117' ' ' LEU . 0.8 OUTLIER -112.42 140.61 47.01 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.184 -178.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -144.54 123.48 12.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -131.92 -165.58 11.38 Favored Glycine 0 N--CA 1.434 -1.483 0 C-N-CA 119.682 -1.247 . . . . 0.0 113.707 -174.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -74.83 -42.75 57.43 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 177.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -94.94 154.01 21.05 Favored Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 106.269 -2.733 . . . . 0.0 106.269 170.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.41 121.7 5.76 Favored 'Trans proline' 0 N--CA 1.42 -2.822 0 CA-C-N 121.324 2.562 . . . . 0.0 109.535 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.401 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 17.4 m -133.32 124.98 50.07 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -150.0 142.73 24.64 Favored 'General case' 0 C--N 1.26 -3.283 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.292 -178.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.35 166.74 39.93 Favored Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.459 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.3 pt -134.33 103.23 4.7 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 CA-C-O 121.134 0.493 . . . . 0.0 109.692 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.08 126.83 57.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.548 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 7.7 p30 -125.39 122.56 37.1 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.452 ' HD2' ' NE2' ' A' ' 22' ' ' GLN . 6.4 p90 -128.22 128.19 44.27 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.65 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.4 pt-20 -106.76 109.23 21.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.888 176.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.452 ' NE2' ' HD2' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -126.2 162.13 26.12 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.199 1.0 . . . . 0.0 108.944 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -154.18 149.41 27.02 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -66.42 -9.08 30.41 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.6 m -70.38 -8.67 52.51 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.677 0.791 . . . . 0.0 111.655 177.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 75.6 115.21 0.06 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 124.444 1.097 . . . . 0.0 111.212 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.63 150.49 10.06 Favored Glycine 0 N--CA 1.424 -2.127 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 178.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -57.34 131.57 45.61 Favored 'Trans proline' 0 C--O 1.248 1.011 0 C-N-CA 122.585 2.19 . . . . 0.0 110.148 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.453 HG23 ' OG ' ' A' ' 102' ' ' SER . 2.9 m -83.48 128.46 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.353 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.376 -178.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -85.52 112.81 21.26 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.548 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.7 p -137.35 138.26 45.26 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.107 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.484 -168.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 33.9 t-105 -136.23 132.27 35.63 Favored 'General case' 0 C--N 1.277 -2.559 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.711 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -151.63 138.89 6.77 Favored Glycine 0 C--O 1.208 -1.486 0 C-N-CA 119.233 -1.46 . . . . 0.0 112.991 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.7 m -116.56 142.7 46.54 Favored 'General case' 0 N--CA 1.408 -2.528 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 176.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 76.0 mt -128.71 139.17 52.62 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 118.737 0.699 . . . . 0.0 109.335 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 22.4 ptmt -117.89 138.74 51.92 Favored 'General case' 0 N--CA 1.411 -2.414 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 173.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.644 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -161.37 176.56 37.9 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -166.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.9 mt -69.08 170.89 9.1 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 175.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 91' ' ' LYS . 2.8 t -69.31 108.29 3.63 Favored 'General case' 0 C--O 1.192 -1.969 0 O-C-N 121.615 -0.678 . . . . 0.0 112.292 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -172.86 171.7 4.26 Favored 'General case' 0 CA--C 1.461 -2.467 0 C-N-CA 124.55 1.14 . . . . 0.0 108.662 174.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 89' ' ' ALA . . . -82.55 -146.23 5.99 Favored Glycine 0 C--N 1.276 -2.787 0 O-C-N 124.875 1.359 . . . . 0.0 109.779 173.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.616 ' HG ' ' O ' ' A' ' 120' ' ' HIS . 2.8 tt 172.4 140.08 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 103.709 -2.7 . . . . 0.0 103.709 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -152.66 122.23 6.84 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.01 139.05 0.99 Allowed Glycine 0 C--N 1.301 -1.396 0 O-C-N 123.768 0.667 . . . . 0.0 113.999 177.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -114.49 106.53 14.39 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 176.41 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.545 ' CE1' ' HA3' ' A' ' 138' ' ' GLY . 28.9 t-80 -130.13 89.19 2.76 Favored 'General case' 1 C--O 1.316 4.556 0 CA-C-O 122.134 0.968 . . . . 0.0 109.141 -176.709 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.461 ' CG1' ' HA ' ' A' ' 117' ' ' LEU . 94.5 t -92.56 152.0 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.357 0 CA-C-N 112.692 -2.049 . . . . 0.0 107.387 175.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -162.05 94.31 0.92 Allowed 'General case' 0 C--N 1.288 -2.074 0 O-C-N 124.083 0.864 . . . . 0.0 110.367 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.458 ' CG ' ' HB3' ' A' ' 60' ' ' ALA . 1.3 mm-40 -145.96 170.26 16.98 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 115.557 1.688 . . . . 0.0 115.557 -174.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.406 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 20.5 p90 -139.99 25.86 2.28 Favored 'General case' 0 N--CA 1.41 -2.463 0 CA-C-N 112.238 -2.255 . . . . 0.0 108.815 174.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.544 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . 84.47 129.02 1.8 Allowed Glycine 0 C--N 1.34 0.804 0 CA-C-N 114.586 -1.188 . . . . 0.0 115.447 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -140.8 -77.84 0.29 Allowed 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.578 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -157.69 133.09 8.96 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 t -73.26 4.6 4.37 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -173.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.69 -2.41 17.44 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.896 0.379 . . . . 0.0 110.348 177.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 157.56 124.72 0.81 Allowed Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.493 ' O ' ' HB3' ' A' ' 142' ' ' SER . 0.6 OUTLIER -97.67 112.78 24.52 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 113.565 0.95 . . . . 0.0 113.565 -176.399 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.7 m -75.61 -37.41 59.81 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.252 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.406 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 4.6 m -72.56 -26.68 61.82 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.621 0.724 . . . . 0.0 110.23 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.458 ' HB3' ' CG ' ' A' ' 49' ' ' GLU . . . -76.5 -8.77 57.86 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.039 -175.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.69 -93.3 0.03 OUTLIER Glycine 0 C--N 1.301 -1.384 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.345 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -95.88 53.31 0.17 Allowed 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 121.71 1.606 . . . . 0.0 113.349 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -125.73 117.06 22.64 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.919 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.514 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 52.8 p90 -87.07 138.52 31.42 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.196 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -115.51 95.84 44.35 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.642 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 56.7 Cg_endo -68.86 -10.79 30.14 Favored 'Trans proline' 0 C--O 1.213 -0.744 0 C-N-CA 124.035 3.157 . . . . 0.0 115.031 -173.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -77.12 -18.42 57.94 Favored 'General case' 0 C--O 1.199 -1.581 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -173.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 47.5 p -54.63 -84.34 0.01 OUTLIER 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 114.283 -1.326 . . . . 0.0 113.315 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.53 ' HE ' ' HB2' ' A' ' 77' ' ' GLU . 1.9 tmt_? -134.91 30.13 3.4 Favored 'General case' 0 C--N 1.249 -3.8 0 N-CA-C 103.01 -2.959 . . . . 0.0 103.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.642 ' HA ' ' O ' ' A' ' 66' ' ' PRO . 69.7 mmtt 75.19 -41.23 0.45 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.04 -169.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.452 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 1.8 t-160 -121.74 -16.97 7.55 Favored 'General case' 0 N--CA 1.426 -1.652 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.075 171.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.504 ' H ' ' HB3' ' A' ' 69' ' ' ARG . . . 108.92 16.81 10.95 Favored Glycine 0 C--N 1.358 1.8 0 C-N-CA 118.519 -1.8 . . . . 0.0 115.881 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -38.26 146.98 0.12 Allowed Glycine 0 N--CA 1.491 2.338 0 CA-C-N 117.978 0.889 . . . . 0.0 113.69 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.88 -22.4 17.53 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.097 2.531 . . . . 0.0 113.869 -166.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -86.87 -12.83 46.66 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.945 -177.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 21.4 t0 70.35 159.93 0.2 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 124.493 1.117 . . . . 0.0 111.209 -175.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.53 ' HB2' ' HE ' ' A' ' 69' ' ' ARG . 22.7 tp10 -148.47 -24.99 0.33 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -178.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.42 ' HG2' ' HG2' ' A' ' 79' ' ' ARG . 27.6 tt0 -138.67 -64.02 0.53 Allowed 'General case' 0 N--CA 1.423 -1.815 0 C-N-CA 118.237 -1.385 . . . . 0.0 110.755 -176.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.669 ' O ' ' HA ' ' A' ' 68' ' ' SER . 15.4 ptt180 -173.72 62.6 0.02 OUTLIER 'General case' 0 N--CA 1.398 -3.052 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 -173.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.443 ' HA ' ' CA ' ' A' ' 68' ' ' SER . 4.5 t60 . . . . . 0 N--CA 1.428 -1.539 0 CA-C-N 113.315 -1.766 . . . . 0.0 107.022 170.205 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 N--CA 1.432 -1.37 0 CA-C-O 121.751 0.786 . . . . 0.0 110.145 . . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.25 -178.64 47.61 Favored Glycine 1 N--CA 1.386 -4.684 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 176.192 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -128.2 129.74 46.92 Favored 'General case' 0 C--N 1.263 -3.194 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 169.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.442 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 0.6 OUTLIER -133.78 147.89 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.083 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.53 ' HA ' ' HB3' ' A' ' 42' ' ' LEU . 89.0 m -139.93 113.0 8.21 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -176.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.461 ' O ' ' HA2' ' A' ' 41' ' ' GLY . . . -83.44 150.98 25.7 Favored 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.453 ' OD1' ' HG2' ' A' ' 91' ' ' LYS . 9.8 t70 -93.13 -179.02 4.96 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 174.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.462 ' O ' ' HB ' ' A' ' 39' ' ' THR . 22.1 pttp -61.21 -16.23 42.72 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 124.459 1.104 . . . . 0.0 111.822 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.3 4.62 48.71 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.937 -0.477 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.644 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 60.96 83.17 0.06 OUTLIER Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.047 -175.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 5.1 m -155.75 111.15 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.442 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -119.44 123.97 45.37 Favored 'General case' 0 N--CA 1.415 -2.184 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.644 -178.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.66 145.38 28.01 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.711 ' HB ' ' O ' ' A' ' 33' ' ' GLY . 7.5 p -84.55 125.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -173.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.4 t -90.48 115.52 27.7 Favored 'General case' 0 N--CA 1.404 -2.735 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 168.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.43 HG12 ' O ' ' A' ' 31' ' ' VAL . 34.9 mt -92.02 118.26 37.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -107.34 156.04 19.34 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.915 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -81.28 99.69 8.76 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 122.088 0.947 . . . . 0.0 109.452 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.453 ' OG ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -97.79 171.74 8.12 Favored 'General case' 0 C--N 1.265 -3.091 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.238 -175.922 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 26.5 t -109.32 -64.51 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.368 0 C-N-CA 119.658 -0.817 . . . . 0.0 111.446 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 8.4 mt -134.18 24.97 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 121.326 0.584 . . . . 0.0 109.854 -177.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.419 ' OG ' ' HB3' ' A' ' 80' ' ' HIS . 33.3 t -68.99 88.49 0.4 Allowed 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -170.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.422 ' HB3' ' HG3' ' A' ' 22' ' ' GLN . 1.7 pt? -96.49 136.31 37.18 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 160.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -71.89 86.21 0.98 Allowed 'General case' 0 C--N 1.286 -2.174 0 CA-C-O 122.349 1.071 . . . . 0.0 112.755 -175.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 111' ' ' SER . . . 143.2 135.74 3.06 Favored Glycine 0 N--CA 1.409 -3.145 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.821 170.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -93.46 -28.03 16.35 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 122.903 -0.174 . . . . 0.0 111.434 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 48.4 m80 -91.22 -23.43 20.2 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.0 -178.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t 177.11 178.89 0.25 Allowed 'General case' 0 N--CA 1.426 -1.666 0 N-CA-C 104.083 -2.562 . . . . 0.0 104.083 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -113.43 -56.46 4.2 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 C-N-CA 124.589 1.156 . . . . 0.0 109.878 -175.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.407 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 52.5 mt -68.37 119.51 14.27 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.723 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -177.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.544 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 115.66 -19.27 14.38 Favored Glycine 0 CA--C 1.47 -2.751 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 111' ' ' SER . 4.5 mpt_? -74.85 128.45 35.61 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.702 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 0.2 OUTLIER -92.01 126.88 37.26 Favored 'General case' 0 C--N 1.258 -3.389 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.62 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.461 ' HA ' ' CG1' ' A' ' 47' ' ' VAL . 2.0 pt? -76.62 136.88 39.2 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -177.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.9 99.57 8.69 Favored 'Isoleucine or valine' 0 C--O 1.28 2.661 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.654 171.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.675 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 7.4 p -147.42 170.39 3.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 104.748 -2.316 . . . . 0.0 104.748 178.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.616 ' O ' ' HG ' ' A' ' 42' ' ' LEU . 81.7 t60 -170.89 171.25 6.06 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 103.312 -2.848 . . . . 0.0 103.312 175.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.476 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.04 87.07 0.37 Allowed 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 171.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.45 ' H ' ' HG ' ' A' ' 42' ' ' LEU . 16.3 tppt? -173.18 154.76 2.79 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.37 103.88 1.11 Allowed 'General case' 0 C--N 1.285 -2.236 0 CA-C-O 121.89 0.852 . . . . 0.0 109.991 166.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -106.51 70.31 0.82 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.549 -2.389 . . . . 0.0 104.549 175.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -68.11 161.41 26.95 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.128 -170.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.408 HD23 ' H ' ' A' ' 126' ' ' LEU . 0.3 OUTLIER -90.48 -68.92 0.76 Allowed 'General case' 0 N--CA 1.397 -3.103 0 CA-C-N 113.83 -1.532 . . . . 0.0 110.996 -167.381 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . 0.452 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -102.82 -16.55 21.41 Favored Glycine 0 N--CA 1.429 -1.773 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.984 -177.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.99 -31.51 16.3 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 117.16 0.48 . . . . 0.0 110.367 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 134' ' ' SER . . . 53.7 -89.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.972 0 O-C-N 123.709 0.63 . . . . 0.0 114.175 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -172.84 -86.19 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -96.78 162.33 13.47 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 176.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.514 ' O ' ' HB ' ' A' ' 135' ' ' THR . 10.1 pt-20 -38.9 -51.32 1.76 Allowed 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -170.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -71.62 -38.09 70.82 Favored 'General case' 0 C--N 1.311 -1.083 0 O-C-N 122.12 -0.362 . . . . 0.0 111.854 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.478 ' O ' ' HA3' ' A' ' 129' ' ' GLY . 14.4 m -72.45 -22.92 61.01 Favored 'General case' 0 C--O 1.218 -0.568 0 CA-C-O 121.488 0.661 . . . . 0.0 109.619 178.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.514 ' HB ' ' O ' ' A' ' 132' ' ' GLU . 66.4 m -67.16 -39.88 86.57 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-O 121.949 0.881 . . . . 0.0 108.845 173.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -71.3 -51.33 24.96 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.022 -1.445 . . . . 0.0 110.046 -177.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.514 ' HA ' ' HB3' ' A' ' 64' ' ' PHE . 41.1 p -74.68 -31.23 61.84 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.673 -177.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.545 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . 82.35 106.12 0.43 Allowed Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -174.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -32.84 140.31 0.04 OUTLIER 'General case' 1 C--O 1.329 5.254 0 C-N-CA 126.463 1.905 . . . . 0.0 115.47 -165.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -150.49 120.2 7.03 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.323 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -98.94 89.08 0.88 Allowed Glycine 0 N--CA 1.417 -2.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 169.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 6.2 m -42.79 -35.3 1.12 Allowed 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 126.727 2.011 . . . . 0.0 114.252 -171.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 17.9 ptt180 -125.35 5.12 7.71 Favored 'General case' 0 N--CA 1.414 -2.258 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.061 -177.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.09 -27.38 64.55 Favored 'General case' 0 C--N 1.291 -1.957 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.259 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.675 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -171.8 96.88 0.17 Allowed 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.702 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 43.4 t -140.5 147.78 40.08 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.087 -176.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.61 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.15 162.41 34.46 Favored Glycine 0 N--CA 1.403 -3.513 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 179.218 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 17.6 t -68.74 122.88 20.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.799 0.809 . . . . 0.0 111.149 175.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.625 HG12 ' O ' ' A' ' 115' ' ' ARG . 26.1 pt -111.97 146.25 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.868 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.407 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.17 155.92 15.44 Favored Glycine 2 N--CA 1.365 -6.07 0 C-N-CA 117.566 -2.254 . . . . 0.0 111.632 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.543 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 25.1 pt -63.08 105.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-N 114.854 -0.673 . . . . 0.0 110.369 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.529 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -105.62 114.15 28.14 Favored 'General case' 0 C--N 1.309 -1.168 0 O-C-N 121.9 -0.5 . . . . 0.0 110.663 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.318 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.447 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.226 -0.168 0 CA-C-O 120.629 0.252 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 p -81.65 -65.6 0.99 Allowed 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 178.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -170.78 171.98 5.89 Favored 'General case' 0 CA--C 1.488 -1.406 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -176.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -130.8 149.25 52.53 Favored 'General case' 0 N--CA 1.414 -2.225 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 172.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 149' ' ' ILE . 10.6 p -126.9 142.86 42.19 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.472 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -122.44 129.69 52.31 Favored 'General case' 0 C--N 1.286 -2.171 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.79 -177.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -129.15 111.73 23.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mp -108.08 152.12 24.95 Favored 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 120.972 -0.291 . . . . 0.0 111.243 178.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.46 ' HZ2' ' HB3' ' A' ' 9' ' ' LYS . 6.6 ttpm? -136.08 131.36 34.73 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 106.187 -1.782 . . . . 0.0 106.187 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 12' ' ' GLY . . . -104.21 148.86 16.95 Favored Glycine 0 N--CA 1.41 -3.099 0 N-CA-C 117.991 1.956 . . . . 0.0 117.991 -168.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -83.78 -19.5 34.94 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 111.629 -2.286 . . . . 0.0 104.92 168.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . 0.412 ' O ' ' HA3' ' A' ' 10' ' ' GLY . . . -142.71 144.52 14.07 Favored Glycine 0 N--CA 1.421 -2.328 1 N-CA-C 101.215 -4.754 . . . . 0.0 101.215 168.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_exo -69.74 124.82 11.47 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 CA-C-N 122.221 3.01 . . . . 0.0 112.989 -168.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.6 104.94 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.997 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.481 176.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -117.87 119.95 36.41 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.202 -0.936 . . . . 0.0 111.879 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.443 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.54 171.83 43.85 Favored Glycine 0 N--CA 1.44 -1.042 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.9 pt -143.6 131.75 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.472 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 3.8 mp -128.96 133.3 66.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.2 m-20 -117.21 126.71 53.2 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.511 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 67.8 t80 -129.03 119.63 24.59 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.415 ' CG ' ' HB3' ' A' ' 30' ' ' LYS . 10.5 pt-20 -131.14 113.53 14.01 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.352 0.596 . . . . 0.0 111.823 177.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.515 ' CG ' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -86.59 163.88 17.18 Favored 'General case' 0 N--CA 1.414 -2.228 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 168.049 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -96.45 146.92 24.35 Favored 'General case' 0 C--N 1.275 -2.669 0 C-N-CA 119.088 -1.045 . . . . 0.0 112.429 -172.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -56.64 -40.69 75.87 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.8 1.313 . . . . 0.0 109.735 178.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.4 p -81.25 -70.99 0.49 Allowed 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 168.21 161.26 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 126.413 1.885 . . . . 0.0 106.386 175.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.491 ' H ' HG23 ' A' ' 103' ' ' VAL . . . 155.6 174.01 24.96 Favored Glycine 0 N--CA 1.41 -3.077 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 174.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.9 136.88 55.13 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 121.732 1.621 . . . . 0.0 108.889 177.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 22' ' ' GLN . 30.1 m -74.17 147.6 8.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-O 121.849 0.833 . . . . 0.0 110.813 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.415 ' HB3' ' CG ' ' A' ' 21' ' ' GLU . 28.2 ttmt -99.28 115.05 28.25 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 174.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.5 p -137.58 128.62 39.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-O 121.253 0.549 . . . . 0.0 110.337 -177.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -133.37 126.88 32.28 Favored 'General case' 0 C--N 1.283 -2.285 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.467 ' H ' ' CG1' ' A' ' 97' ' ' VAL . . . -142.0 139.72 9.51 Favored Glycine 0 N--CA 1.407 -3.246 0 C-N-CA 119.162 -1.494 . . . . 0.0 112.495 178.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.443 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 42.6 t -114.19 145.64 41.43 Favored 'General case' 0 C--N 1.284 -2.27 0 N-CA-C 107.292 -1.374 . . . . 0.0 107.292 176.418 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 3.2 tp -152.09 139.44 13.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 99.9 mttt -130.62 107.36 9.13 Favored 'General case' 0 C--N 1.281 -2.393 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 176.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.649 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -131.93 174.98 19.98 Favored Glycine 0 C--N 1.282 -2.434 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -171.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.448 ' O ' ' HG3' ' A' ' 121' ' ' GLU . 93.1 mt -68.72 170.14 9.98 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 118.113 0.956 . . . . 0.0 109.881 177.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.531 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 2.0 t -70.7 105.34 3.14 Favored 'General case' 0 CA--C 1.55 0.98 0 N-CA-C 114.367 1.247 . . . . 0.0 114.367 -171.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -177.26 165.06 2.24 Favored 'General case' 0 CA--C 1.456 -2.642 0 C-N-CA 128.594 2.758 . . . . 0.0 104.918 169.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 158.49 130.32 1.16 Allowed Glycine 3 N--CA 1.376 -5.338 0 C-N-CA 118.2 -1.952 . . . . 0.0 111.166 170.198 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mp -124.44 -86.33 0.63 Allowed 'General case' 0 N--CA 1.396 -3.174 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.501 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 79.9 m-70 -172.14 162.71 5.79 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 174.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 132.75 144.83 5.32 Favored Glycine 0 C--N 1.29 -2.002 0 C-N-CA 119.288 -1.434 . . . . 0.0 113.092 174.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.644 ' CE1' ' HB ' ' A' ' 47' ' ' VAL . 30.9 t80 -165.8 96.54 0.63 Allowed 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 124.927 1.291 . . . . 0.0 108.294 175.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.451 ' HB2' ' HA ' ' A' ' 125' ' ' ASP . 0.2 OUTLIER -114.33 89.49 3.11 Favored 'General case' 0 N--CA 1.403 -2.794 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 177.599 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.644 ' HB ' ' CE1' ' A' ' 45' ' ' PHE . 14.6 p -69.85 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.927 0 CA-C-N 111.603 -2.544 . . . . 0.0 107.19 175.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.424 ' HD1' ' HB2' ' A' ' 65' ' ' ASN . 9.6 t60 -154.1 104.33 2.62 Favored 'General case' 1 C--N 1.233 -4.491 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.232 173.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HB2' ' HB3' ' A' ' 109' ' ' ASP . 1.5 mp0 -67.77 158.34 32.64 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.017 -1.447 . . . . 0.0 109.16 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.1 t80 77.95 64.01 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 123.887 1.804 . . . . 0.0 107.423 -166.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.442 ' HA3' ' OG1' ' A' ' 116' ' ' THR . . . -112.63 -126.15 4.57 Favored Glycine 0 N--CA 1.416 -2.668 0 CA-C-N 111.454 -2.612 . . . . 0.0 107.173 174.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -176.97 -71.6 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 117.946 0.873 . . . . 0.0 112.758 177.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 37.6 p30 -131.76 177.1 7.78 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.682 0.753 . . . . 0.0 112.947 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.458 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 25.9 m -84.21 6.85 21.05 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 125.919 1.688 . . . . 0.0 110.602 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.436 ' HA ' ' HZ1' ' A' ' 9' ' ' LYS . . . -83.27 -32.05 26.62 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.752 -178.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 164.24 155.83 8.54 Favored Glycine 0 N--CA 1.412 -2.911 0 N-CA-C 108.859 -1.697 . . . . 0.0 108.859 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.616 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 58.2 m -83.25 89.58 7.0 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.4 p -75.81 -58.69 3.13 Favored 'General case' 0 N--CA 1.421 -1.923 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.965 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 70.8 m -68.7 -42.68 77.39 Favored 'General case' 0 N--CA 1.425 -1.701 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.47 -25.5 54.39 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.356 -176.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.443 ' O ' HG23 ' A' ' 118' ' ' VAL . . . 49.24 -144.57 8.12 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -100.23 5.73 0.76 Allowed 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.803 2.335 . . . . 0.0 110.658 173.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.8 t60 -77.47 149.69 35.01 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.826 -169.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.48 ' HB2' ' O ' ' A' ' 80' ' ' HIS . 13.3 p90 -81.1 169.95 16.79 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.533 ' HB3' ' OG ' ' A' ' 68' ' ' SER . 53.0 t30 -105.52 143.19 26.31 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.77 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_exo -75.32 -13.58 20.71 Favored 'Trans proline' 0 C--O 1.225 -0.151 0 C-N-CA 121.79 1.66 . . . . 0.0 110.963 175.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.63 21.64 17.01 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 122.72 1.248 . . . . 0.0 108.69 -171.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.533 ' OG ' ' HB3' ' A' ' 65' ' ' ASN . 46.3 m -73.98 -1.53 20.26 Favored 'General case' 0 C--O 1.196 -1.734 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.265 174.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.565 ' HA ' ' H ' ' A' ' 79' ' ' ARG . 3.9 mmp_? -68.59 -4.03 13.91 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 129.158 2.983 . . . . 0.0 109.589 177.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -140.54 29.73 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.725 -1.125 . . . . 0.0 108.196 176.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.493 ' HB3' ' N ' ' A' ' 84' ' ' LEU . 99.0 m-70 -143.97 -93.08 0.11 Allowed 'General case' 0 CA--C 1.556 1.176 0 C-N-CA 124.249 1.02 . . . . 0.0 109.392 176.326 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.518 ' HA2' ' HB2' ' A' ' 79' ' ' ARG . . . 81.94 -63.62 4.36 Favored Glycine 0 CA--C 1.501 -0.824 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 173.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.36 161.35 35.16 Favored Glycine 0 C--N 1.264 -3.454 0 N-CA-C 107.566 -2.214 . . . . 0.0 107.566 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.435 ' HB2' ' HG3' ' A' ' 100' ' ' GLU . 19.2 Cg_endo -55.58 -30.35 74.23 Favored 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 123.877 3.051 . . . . 0.0 115.266 -174.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.7 tppt? -101.97 -5.09 25.07 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.318 0.58 . . . . 0.0 110.144 -177.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -110.38 -163.45 0.86 Allowed 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 -177.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -171.18 41.57 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.835 0.854 . . . . 0.0 111.182 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.698 ' O ' ' HG2' ' A' ' 79' ' ' ARG . 11.4 pt-20 -163.15 149.25 12.04 Favored 'General case' 0 C--O 1.161 -3.584 0 CA-C-O 116.657 -1.64 . . . . 0.0 106.721 175.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.698 ' HG2' ' O ' ' A' ' 78' ' ' GLU . 6.2 mmt180 161.84 -165.1 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 128.125 2.57 . . . . 0.0 107.848 170.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.48 ' O ' ' HB2' ' A' ' 64' ' ' PHE . 43.3 m-70 . . . . . 0 C--N 1.276 -2.629 0 C-N-CA 125.619 1.568 . . . . 0.0 108.278 171.585 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.493 ' N ' ' HB3' ' A' ' 71' ' ' HIS . 6.7 tt . . . . . 0 N--CA 1.445 -0.708 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 . . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.581 ' C ' ' HB3' ' A' ' 45' ' ' PHE . . . 176.88 178.66 46.8 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 169.496 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.481 ' N ' ' HB3' ' A' ' 45' ' ' PHE . 8.8 p30 -159.42 135.69 9.0 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 173.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 75.2 t -127.56 151.61 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.293 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.6 m -134.65 148.59 50.4 Favored 'General case' 0 N--CA 1.404 -2.758 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -149.12 153.59 37.98 Favored 'General case' 1 C--N 1.243 -4.053 0 N-CA-C 102.199 -3.26 . . . . 0.0 102.199 173.012 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.458 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 13.6 t70 -128.0 -158.24 0.86 Allowed 'General case' 0 C--N 1.251 -3.686 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.531 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 60.5 mttp -68.25 5.85 0.89 Allowed 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 124.138 0.975 . . . . 0.0 113.278 -179.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -116.76 -9.38 11.27 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 175.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.649 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 64.77 72.93 0.63 Allowed Glycine 0 C--O 1.224 -0.526 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.897 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 62.8 t -154.57 133.3 3.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -175.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.35 127.22 40.1 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-O 122.367 1.08 . . . . 0.0 113.777 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -105.75 107.04 17.83 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 102.177 -3.268 . . . . 0.0 102.177 160.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.467 ' CG1' ' H ' ' A' ' 33' ' ' GLY . 9.4 p -83.34 137.56 20.76 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.4 0 C-N-CA 117.949 -1.501 . . . . 0.0 108.806 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 45.8 m -86.99 121.05 28.92 Favored 'General case' 0 N--CA 1.387 -3.597 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 171.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.429 HD12 HG23 ' A' ' 99' ' ' ILE . 2.9 tt -90.81 115.05 29.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 175.092 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.435 ' HG3' ' HB2' ' A' ' 74' ' ' PRO . 5.6 mm-40 -106.22 157.36 17.63 Favored 'General case' 0 CA--C 1.48 -1.738 0 CA-C-N 113.89 -1.505 . . . . 0.0 111.596 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.23 96.17 10.23 Favored 'General case' 0 N--CA 1.426 -1.665 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.448 ' OG ' HD21 ' A' ' 84' ' ' LEU . 4.8 m -105.98 141.86 36.67 Favored 'General case' 0 N--CA 1.402 -2.843 0 N-CA-C 103.913 -2.625 . . . . 0.0 103.913 174.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.491 HG23 ' H ' ' A' ' 27' ' ' GLY 0.276 2.6 p -118.02 -49.48 4.02 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 C-N-CA 117.059 -1.856 . . . . 0.0 112.744 176.166 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.2 mm -81.71 -7.54 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.57 1.732 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 -170.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.445 ' OG ' HD13 ' A' ' 84' ' ' LEU . 50.8 m -79.3 84.01 5.28 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 117.726 2.491 . . . . 0.0 117.726 -172.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.515 ' HB3' ' CG ' ' A' ' 22' ' ' GLN . 1.1 pt? -140.06 82.14 1.85 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 154.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.3 m -171.62 87.15 0.09 Allowed 'General case' 1 C--N 1.233 -4.467 0 N-CA-C 101.777 -3.416 . . . . 0.0 101.777 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -111.59 157.69 14.8 Favored Glycine 3 N--CA 1.375 -5.387 0 N-CA-C 106.246 -2.742 . . . . 0.0 106.246 175.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.495 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 12.6 t70 -62.02 -41.82 98.5 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-O 121.817 0.818 . . . . 0.0 109.714 178.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.575 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 6.8 m80 -123.24 -24.84 4.58 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.138 -0.937 . . . . 0.0 112.029 177.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.2 m 59.7 -70.35 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 125.809 1.644 . . . . 0.0 114.622 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.663 HG13 ' O ' ' A' ' 151' ' ' ILE . 3.6 tt -98.15 -43.51 11.94 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 C-N-CA 124.799 1.24 . . . . 0.0 110.415 -174.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.575 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 8.1 tt -104.51 102.2 13.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -172.094 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.5 60.13 1.84 Allowed Glycine 0 CA--C 1.474 -2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.767 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.533 ' HD3' ' C ' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -119.24 90.01 3.25 Favored 'General case' 0 C--N 1.252 -3.643 0 CA-C-N 112.688 -1.756 . . . . 0.0 109.594 -176.866 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.616 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 17.9 p -95.08 132.76 39.63 Favored 'General case' 0 C--N 1.289 -2.026 0 O-C-N 121.723 -0.611 . . . . 0.0 111.858 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.498 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 4.3 pp -81.32 120.63 25.19 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 175.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.613 HG22 ' SG ' ' A' ' 57' ' ' CYS . 19.6 t -100.35 98.09 6.55 Favored 'Isoleucine or valine' 0 C--O 1.297 3.602 0 C-N-CA 116.259 -2.176 . . . . 0.0 106.987 172.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.518 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 25.4 t -148.81 171.05 2.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -160.53 171.99 17.99 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 104.093 -2.558 . . . . 0.0 104.093 169.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.448 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -69.62 87.81 0.5 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 123.064 2.665 . . . . 0.0 109.973 -178.791 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 33.2 tptt -172.55 171.97 4.43 Favored 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -171.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -78.99 117.91 20.5 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 171.439 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.451 ' OD1' ' HB3' ' A' ' 46' ' ' HIS . 3.6 t70 -139.77 78.4 1.66 Allowed 'General case' 0 CA--C 1.474 -1.951 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.451 ' HA ' ' HB2' ' A' ' 46' ' ' HIS . 25.1 t0 -177.44 158.0 1.36 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 123.766 0.666 . . . . 0.0 109.424 173.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.546 ' HA ' ' O ' ' A' ' 135' ' ' THR . 3.3 tm? -90.72 -40.48 11.83 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 124.624 1.203 . . . . 0.0 107.988 -176.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.24 -48.86 6.19 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.492 -0.861 . . . . 0.0 111.622 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.77 51.34 1.53 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.15 -105.83 0.27 Allowed Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 119.875 -1.155 . . . . 0.0 111.745 176.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -152.26 -96.18 0.13 Allowed Glycine 0 C--N 1.316 -0.556 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.652 -176.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -79.89 153.67 28.87 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.142 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -45.72 -50.75 13.43 Favored 'General case' 0 C--N 1.36 1.057 0 N-CA-C 114.522 1.304 . . . . 0.0 114.522 -176.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -80.4 -26.89 38.28 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 121.526 -0.734 . . . . 0.0 111.114 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 27.5 t -77.59 -29.14 51.84 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.667 -173.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.546 ' O ' ' HA ' ' A' ' 126' ' ' LEU . 6.6 t -76.52 -25.06 53.75 Favored 'General case' 0 C--O 1.206 -1.212 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.426 ' HA ' ' CD2' ' A' ' 126' ' ' LEU . 58.8 mtpt -71.28 -35.36 71.32 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.895 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 12.4 t -85.98 -31.75 21.89 Favored 'General case' 0 N--CA 1.412 -2.366 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.25 178.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 57.63 73.07 0.49 Allowed Glycine 0 CA--C 1.486 -1.764 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -177.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 46.5 t30 -51.58 105.8 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 122.471 1.129 . . . . 0.0 113.248 -171.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -89.29 164.54 14.89 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 114.441 -1.254 . . . . 0.0 113.664 -171.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -139.95 86.28 0.21 Allowed Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 107.25 -2.34 . . . . 0.0 107.25 175.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.431 ' HA ' HG11 ' A' ' 118' ' ' VAL . 13.8 m -61.84 -18.65 60.81 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 113.823 1.046 . . . . 0.0 113.823 -172.166 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -121.72 -46.31 2.25 Favored 'General case' 0 C--N 1.26 -3.312 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.681 177.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.9 tt -46.13 -45.06 16.26 Favored 'General case' 0 CA--C 1.495 -1.163 0 O-C-N 125.406 1.691 . . . . 0.0 111.564 -164.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.518 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -139.66 88.76 2.27 Favored 'General case' 0 N--CA 1.395 -3.192 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.2 m -130.25 140.08 50.73 Favored 'General case' 0 N--CA 1.394 -3.227 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.283 176.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -170.93 149.03 11.83 Favored Glycine 1 N--CA 1.379 -5.124 0 CA-C-N 113.831 -1.531 . . . . 0.0 109.358 -177.166 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 16.0 m -70.55 110.14 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.63 0 CA-C-O 122.104 0.954 . . . . 0.0 111.147 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.554 ' HA ' ' O ' ' A' ' 5' ' ' VAL . 9.4 tt -122.11 108.87 22.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 CA-C-N 114.652 -1.158 . . . . 0.0 109.27 175.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.496 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . -179.03 -171.25 42.02 Favored Glycine 3 CA--C 1.435 -4.936 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 175.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.663 ' O ' HG13 ' A' ' 112' ' ' ILE . 64.5 mt -64.3 104.64 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.263 -3.165 0 O-C-N 124.853 0.972 . . . . 0.0 110.576 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.465 ' HB2' ' NH2' ' A' ' 115' ' ' ARG . . . -142.17 100.09 3.65 Favored 'General case' 0 N--CA 1.433 -1.304 0 CA-C-O 121.168 0.508 . . . . 0.0 109.836 169.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 C--N 1.289 -2.043 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 177.016 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.512 -0.515 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.6 m -111.24 -36.44 5.59 Favored 'General case' 0 CA--C 1.552 1.027 0 O-C-N 123.583 0.552 . . . . 0.0 111.733 -178.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 50.1 tttm -146.65 152.52 39.01 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.602 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.96 167.73 20.39 Favored 'General case' 0 N--CA 1.406 -2.629 0 O-C-N 123.676 0.61 . . . . 0.0 109.609 175.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -137.6 131.99 44.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 123.313 0.645 . . . . 0.0 109.304 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.57 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -112.18 131.36 55.52 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -134.86 103.83 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.45 ' HB3' HD21 ' A' ' 117' ' ' LEU . 1.4 pt? -118.29 151.17 38.2 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -162.86 140.77 8.16 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.39 -158.48 8.37 Favored Glycine 0 N--CA 1.414 -2.785 0 C-N-CA 119.039 -1.553 . . . . 0.0 112.996 -176.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -71.37 -49.19 44.68 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.65 144.95 16.94 Favored Glycine 0 N--CA 1.431 -1.655 0 N-CA-C 106.55 -2.62 . . . . 0.0 106.55 172.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -76.56 124.03 7.38 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 CA-C-N 120.355 2.078 . . . . 0.0 112.96 -175.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -132.38 113.05 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 103.853 -2.647 . . . . 0.0 103.853 173.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.546 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 96.8 mt-30 -118.58 141.33 48.68 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.6 -174.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -169.69 157.86 29.74 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.482 -177.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.455 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.9 pt -135.26 102.47 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.57 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 10.3 mt -121.42 137.44 55.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -174.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -113.94 134.08 55.06 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.817 178.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.602 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.0 m-85 -123.26 134.27 54.11 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.356 0.262 . . . . 0.0 110.921 -178.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.436 ' O ' HG13 ' A' ' 29' ' ' VAL . 9.9 pt-20 -132.96 102.34 5.59 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 121.588 0.709 . . . . 0.0 112.168 175.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.9 mt-30 -106.24 113.82 27.57 Favored 'General case' 0 N--CA 1.389 -3.5 0 N-CA-C 103.872 -2.64 . . . . 0.0 103.872 175.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.562 ' H ' ' HB ' ' A' ' 103' ' ' VAL . 54.9 tttm -134.26 171.76 13.81 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.422 -169.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.452 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 5.4 mp0 -63.97 -26.12 68.44 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.87 1.268 . . . . 0.0 111.69 -177.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -33.06 28.16 Favored 'General case' 0 CA--C 1.549 0.911 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 -172.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.9 t30 64.73 97.34 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -173.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.52 ' H ' HG22 ' A' ' 103' ' ' VAL . . . 179.18 -163.34 30.81 Favored Glycine 0 CA--C 1.463 -3.196 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.416 -175.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -83.24 139.65 9.42 Favored 'Trans proline' 0 N--CA 1.42 -2.851 0 C-N-CA 122.114 1.876 . . . . 0.0 110.699 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.504 HG23 ' H ' ' A' ' 101' ' ' ASP . 18.3 m -75.14 130.24 36.29 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -88.84 100.34 13.09 Favored 'General case' 0 N--CA 1.424 -1.771 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.417 HG23 ' HA ' ' A' ' 20' ' ' PHE . 75.1 t -131.47 134.75 60.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.756 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.006 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.413 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 2.1 t-105 -141.08 129.47 22.44 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -148.94 138.86 7.15 Favored Glycine 0 N--CA 1.425 -2.083 0 C-N-CA 119.994 -1.098 . . . . 0.0 112.377 175.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.532 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 18.4 m -116.5 115.24 25.41 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 124.726 1.211 . . . . 0.0 108.746 179.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.546 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 9.2 mt -109.52 148.11 13.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 118.453 0.57 . . . . 0.0 110.732 176.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -129.79 122.98 29.86 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -146.41 175.01 26.09 Favored Glycine 0 C--N 1.294 -1.8 0 O-C-N 123.688 0.617 . . . . 0.0 111.66 -168.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.0 mt -69.52 169.79 11.88 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.472 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.5 OUTLIER -76.81 104.32 7.24 Favored 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 119.273 -0.971 . . . . 0.0 112.003 -175.932 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.448 ' HG2' ' O ' ' A' ' 39' ' ' THR . 47.2 mm-40 -177.93 171.09 1.82 Allowed 'General case' 0 CA--C 1.472 -2.054 0 C-N-CA 128.522 2.729 . . . . 0.0 104.275 170.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.72 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 159.45 115.38 0.41 Allowed Glycine 1 C--N 1.242 -4.676 0 C-N-CA 116.978 -2.534 . . . . 0.0 113.968 166.146 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -119.38 -85.6 0.65 Allowed 'General case' 0 N--CA 1.419 -2.018 0 O-C-N 124.231 0.607 . . . . 0.0 110.911 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.718 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 20.7 m80 -163.52 123.11 2.11 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.895 0.878 . . . . 0.0 108.936 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -143.94 104.63 0.34 Allowed Glycine 0 N--CA 1.435 -1.41 0 C-N-CA 118.434 -1.841 . . . . 0.0 115.425 -178.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.583 ' O ' HG11 ' A' ' 47' ' ' VAL . 19.6 m-85 -68.45 95.22 0.61 Allowed 'General case' 1 C--O 1.341 5.918 0 CA-C-O 123.391 1.567 . . . . 0.0 109.56 169.684 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.59 ' CD2' HD13 ' A' ' 117' ' ' LEU . 16.4 p-80 -83.05 78.06 9.64 Favored 'General case' 0 N--CA 1.404 -2.759 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 175.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.583 HG11 ' O ' ' A' ' 45' ' ' PHE . 3.7 p -111.2 91.57 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-N 111.223 -2.717 . . . . 0.0 110.988 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . 0.257 39.6 m-70 -138.75 159.96 40.82 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 114.586 1.328 . . . . 0.0 114.586 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.553 ' OE2' ' HA ' ' A' ' 64' ' ' PHE . 2.0 pm0 -89.48 172.82 8.71 Favored 'General case' 0 C--N 1.287 -2.151 0 C-N-CA 126.993 2.117 . . . . 0.0 115.02 -174.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.509 ' H ' ' HA ' ' A' ' 110' ' ' HIS . 55.9 t80 47.18 103.47 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 111.3 -2.682 . . . . 0.0 115.35 167.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.532 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -44.0 103.12 0.04 OUTLIER Glycine 0 C--N 1.297 -1.623 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.16 171.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -111.09 -161.17 0.74 Allowed 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -67.14 138.1 56.79 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 123.1 0.56 . . . . 0.0 109.997 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.482 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 13.4 t -58.45 -21.5 51.45 Favored 'General case' 0 C--O 1.216 -0.701 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -177.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.96 6.77 11.37 Favored 'General case' 0 C--N 1.31 -1.115 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.062 178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -150.76 109.46 0.43 Allowed Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 119.428 -1.368 . . . . 0.0 111.589 -178.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.563 ' SG ' HG23 ' A' ' 118' ' ' VAL . 4.3 p -98.5 89.35 4.38 Favored 'General case' 0 C--N 1.277 -2.576 0 C-N-CA 122.735 0.414 . . . . 0.0 111.65 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 m -80.47 -54.07 6.02 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.465 0.65 . . . . 0.0 109.924 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.9 m -71.18 -39.45 71.83 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.283 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB1' ' HB2' ' A' ' 57' ' ' CYS . . . -76.31 -5.76 48.5 Favored 'General case' 0 C--O 1.2 -1.531 0 CA-C-N 113.857 -1.52 . . . . 0.0 111.353 175.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -57.36 -142.42 0.01 OUTLIER Glycine 0 CA--C 1.558 2.737 0 N-CA-C 115.238 0.855 . . . . 0.0 115.238 178.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -76.11 53.71 3.91 Favored 'Trans proline' 0 N--CA 1.484 0.937 0 C-N-CA 122.877 2.385 . . . . 0.0 111.009 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -141.84 128.67 20.54 Favored 'General case' 0 C--N 1.28 -2.432 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.553 ' HA ' ' OE2' ' A' ' 49' ' ' GLU . 52.0 p90 -139.48 144.58 38.04 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.442 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.5 ' HB2' ' OD2' ' A' ' 109' ' ' ASP . 27.3 t-20 -68.94 143.99 95.2 Favored Pre-proline 0 C--N 1.318 -0.795 0 C-N-CA 124.015 0.926 . . . . 0.0 111.316 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.0 -15.21 39.72 Favored 'Trans proline' 0 CA--C 1.546 1.109 0 C-N-CA 123.041 2.494 . . . . 0.0 116.113 -178.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 90.2 mt -69.86 -29.23 66.41 Favored 'General case' 0 C--N 1.37 1.489 0 C-N-CA 117.615 -1.634 . . . . 0.0 111.462 -176.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.484 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 58.0 p -54.46 -21.49 10.03 Favored 'General case' 0 C--O 1.262 1.73 0 C-N-CA 125.523 1.529 . . . . 0.0 115.044 -173.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ttm180 -70.45 -19.96 62.92 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.665 -161.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -68.1 -12.06 60.2 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.233 -0.987 . . . . 0.0 112.773 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.7 -45.15 0.11 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 120.651 0.262 . . . . 0.0 111.186 177.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.38 10.42 82.13 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -173.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -150.99 144.29 11.59 Favored Glycine 0 N--CA 1.402 -3.623 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 178.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 11.8 Cg_exo -76.24 0.13 9.74 Favored 'Trans proline' 0 C--N 1.327 -0.58 0 C-N-CA 124.691 3.594 . . . . 0.0 112.38 -175.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -55.55 -26.01 40.98 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 124.973 1.309 . . . . 0.0 111.514 178.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -148.63 -86.2 0.09 Allowed 'General case' 0 CA--C 1.505 -0.775 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -123.34 110.89 15.73 Favored 'General case' 0 N--CA 1.41 -2.437 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -171.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.484 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -150.52 -60.85 0.19 Allowed 'General case' 0 C--N 1.25 -3.758 0 N-CA-C 103.298 -2.853 . . . . 0.0 103.298 -173.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 60.45 -7.37 0.08 Allowed 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 114.617 1.34 . . . . 0.0 114.617 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.417 ' H ' ' C ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER . . . . . 0 C--N 1.305 -1.337 0 N-CA-C 105.038 -2.208 . . . . 0.0 105.038 168.744 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 25.9 tp . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.77 128.37 1.13 Allowed Glycine 1 N--CA 1.395 -4.082 0 CA-C-N 114.694 -1.139 . . . . 0.0 110.708 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -89.99 171.35 9.63 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 173.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.35 129.06 11.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 121.394 -0.816 . . . . 0.0 109.083 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.3 m -140.11 96.79 3.11 Favored 'General case' 0 N--CA 1.424 -1.748 0 CA-C-O 121.24 0.543 . . . . 0.0 110.28 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.72 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -100.44 152.72 20.03 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 104.785 -2.302 . . . . 0.0 104.785 173.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.527 ' OD2' ' HG2' ' A' ' 91' ' ' LYS . 21.9 t70 -113.34 -159.74 0.7 Allowed 'General case' 1 C--N 1.223 -4.922 0 C-N-CA 116.7 -2.0 . . . . 0.0 105.992 173.731 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.527 ' HG2' ' OD2' ' A' ' 90' ' ' ASP . 18.8 ptpt -57.82 -8.08 0.87 Allowed 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -84.3 -27.15 28.02 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.62 65.53 2.29 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 114.499 0.559 . . . . 0.0 114.499 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 12.6 m -159.74 132.82 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.485 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . . . -124.64 117.89 25.28 Favored 'General case' 0 N--CA 1.412 -2.374 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -99.67 103.51 15.2 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.55 117.6 50.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.031 0.92 . . . . 0.0 112.255 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 p -142.33 101.46 3.9 Favored 'General case' 0 C--N 1.276 -2.599 0 N-CA-C 106.787 -1.561 . . . . 0.0 106.787 174.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 34.4 pt -113.91 151.11 15.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.787 -175.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.75 100.24 7.28 Favored 'General case' 0 N--CA 1.414 -2.227 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.504 ' H ' HG23 ' A' ' 29' ' ' VAL . 26.1 t0 -134.02 167.51 20.48 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.848 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.9 m -59.02 113.22 1.99 Allowed 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 114.678 1.362 . . . . 0.0 114.678 -173.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.562 ' HB ' ' H ' ' A' ' 23' ' ' LYS . 20.6 m -60.03 -11.57 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 C-N-CA 126.112 1.765 . . . . 0.0 113.053 177.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.39 -12.12 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.676 1.191 . . . . 0.0 112.25 -176.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 p -91.73 83.17 5.25 Favored 'General case' 0 C--O 1.175 -2.826 0 O-C-N 121.012 -1.055 . . . . 0.0 111.516 176.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 71.8 mt -70.11 150.65 46.33 Favored 'General case' 0 N--CA 1.396 -3.163 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.852 171.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.6 m -68.89 91.85 0.48 Allowed 'General case' 0 N--CA 1.382 -3.842 0 C-N-CA 124.956 1.302 . . . . 0.0 113.914 -173.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.416 ' O ' ' HD2' ' A' ' 110' ' ' HIS . . . -94.6 -175.67 38.55 Favored Glycine 1 N--CA 1.395 -4.097 0 N-CA-C 106.09 -2.804 . . . . 0.0 106.09 167.405 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.548 ' OD2' ' HB3' ' A' ' 49' ' ' GLU 0.25 31.3 t0 32.89 -77.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 117.442 2.386 . . . . 0.0 117.442 -175.32 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.554 ' CG ' ' HG2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -56.57 -31.8 64.57 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 125.987 1.715 . . . . 0.0 109.703 178.216 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.3 m 62.06 -178.09 0.13 Allowed 'General case' 0 N--CA 1.424 -1.755 0 C-N-CA 126.125 1.77 . . . . 0.0 112.797 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.424 HG13 ' HB ' ' A' ' 151' ' ' ILE . 10.0 tt -78.65 9.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 C-N-CA 126.547 1.939 . . . . 0.0 108.731 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 36.5 pt -91.38 -175.39 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.485 -1.526 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 -176.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.439 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . -82.14 65.08 4.14 Favored Glycine 0 N--CA 1.405 -3.397 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.718 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -66.31 131.81 46.95 Favored 'General case' 0 N--CA 1.414 -2.267 0 CA-C-O 122.553 1.168 . . . . 0.0 112.203 178.266 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.702 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 0.1 OUTLIER -70.54 122.6 20.02 Favored 'General case' 0 N--CA 1.384 -3.768 0 CA-C-N 113.853 -1.521 . . . . 0.0 111.113 -178.137 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.59 HD13 ' CD2' ' A' ' 46' ' ' HIS . 0.8 OUTLIER -87.76 140.67 29.27 Favored 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 174.06 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.563 HG23 ' SG ' ' A' ' 57' ' ' CYS . 98.8 t -109.8 105.16 18.27 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.479 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.646 171.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.474 ' CG2' ' HG ' ' A' ' 117' ' ' LEU . 0.2 OUTLIER -126.09 168.44 18.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.81 0.814 . . . . 0.0 110.397 179.596 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.421 ' CD2' ' HG ' ' A' ' 144' ' ' LEU . 2.1 t60 -172.18 156.85 4.06 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 102.909 -2.997 . . . . 0.0 102.909 162.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.2 89.61 0.46 Allowed 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? -170.4 171.37 6.61 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.718 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -76.68 111.15 11.88 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 123.771 0.67 . . . . 0.0 110.922 172.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -132.38 26.57 4.46 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 123.381 1.563 . . . . 0.0 109.177 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.414 ' HB2' ' HB2' ' A' ' 128' ' ' LYS . 24.8 m-20 -81.7 137.53 35.39 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 173.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -69.8 -56.79 6.19 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -173.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.7 1.8 43.51 Favored Glycine 0 CA--C 1.526 0.748 0 C-N-CA 121.16 -0.543 . . . . 0.0 113.483 -178.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 125' ' ' ASP . 32.0 mmmt -132.23 32.61 3.96 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -62.27 -29.32 72.73 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 115.604 -0.725 . . . . 0.0 114.834 -176.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -82.89 0.26 Allowed Glycine 0 C--O 1.221 -0.66 0 CA-C-N 117.443 0.622 . . . . 0.0 112.212 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.423 ' H ' ' HB3' ' A' ' 134' ' ' SER . 9.5 t30 -121.45 173.3 7.47 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.432 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 37.1 tt0 -49.73 -46.71 50.66 Favored 'General case' 0 CA--C 1.555 1.158 0 CA-C-N 119.844 1.202 . . . . 0.0 114.011 -172.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.1 mp0 -64.48 -39.64 94.19 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.055 0.455 . . . . 0.0 110.449 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.423 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 6.8 t -72.36 -30.89 65.13 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.098 -175.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 36.3 m -69.68 -30.97 68.76 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.299 0.571 . . . . 0.0 110.479 178.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 95.8 mttt -76.54 -37.12 57.16 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.165 0.507 . . . . 0.0 111.355 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 t -85.61 -26.42 26.08 Favored 'General case' 0 N--CA 1.416 -2.166 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.292 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.85 60.1 8.19 Favored Glycine 0 N--CA 1.431 -1.684 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 -174.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -39.62 117.38 0.72 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.936 1.294 . . . . 0.0 112.851 -174.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -143.71 161.49 38.43 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -174.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.28 81.22 1.72 Allowed Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 173.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.7 p -42.13 -38.89 1.82 Allowed 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 118.143 2.646 . . . . 0.0 118.143 -168.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.6 ptt180 -134.2 13.46 3.88 Favored 'General case' 0 C--N 1.278 -2.526 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.421 ' HG ' ' CD2' ' A' ' 120' ' ' HIS . 0.3 OUTLIER -69.07 -37.6 78.6 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -172.23 . . . . . . . . 3 3 . 1 . 003 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.43 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -150.25 106.1 3.43 Favored 'General case' 0 N--CA 1.412 -2.348 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 17.8 m -115.21 163.14 16.09 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.702 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -171.55 141.42 6.39 Favored Glycine 0 N--CA 1.416 -2.681 0 C-N-CA 119.003 -1.57 . . . . 0.0 112.143 176.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.416 HG11 ' OG1' ' A' ' 54' ' ' THR . 10.0 p -70.16 98.78 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 122.531 1.158 . . . . 0.0 108.581 174.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.718 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 24.0 mm -109.44 129.86 63.5 Favored 'Isoleucine or valine' 0 CA--C 1.464 -2.346 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.81 147.34 17.73 Favored Glycine 2 CA--C 1.425 -5.539 0 C-N-CA 116.803 -2.618 . . . . 0.0 111.466 -174.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.475 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 70.1 mt -78.64 103.63 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.9 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 173.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.514 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -125.84 128.6 47.9 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.119 -0.946 . . . . 0.0 108.476 175.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 . . . . . 0 C--N 1.292 -1.905 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.563 -174.755 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.639 ' O ' ' HD2' ' A' ' 3' ' ' LYS . 18.0 p -80.91 -42.03 22.06 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 170.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.639 ' HD2' ' O ' ' A' ' 2' ' ' THR . 5.4 mptp? -151.27 171.4 17.5 Favored 'General case' 0 C--O 1.263 1.765 0 N-CA-C 103.209 -2.885 . . . . 0.0 103.209 173.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.685 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -149.35 146.98 27.78 Favored 'General case' 0 CA--C 1.454 -2.744 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 23.1 m -119.69 155.22 22.43 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.788 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.591 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -135.7 128.94 31.89 Favored 'General case' 0 C--N 1.278 -2.504 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.345 178.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.427 ' H ' ' HB ' ' A' ' 148' ' ' VAL . 46.7 t -134.16 111.83 15.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.9 pt? -119.47 142.39 48.31 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.371 178.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.648 ' O ' ' HA ' ' A' ' 55' ' ' ALA . 2.2 tmtp? -147.91 148.42 30.79 Favored 'General case' 0 N--CA 1.408 -2.542 0 N-CA-C 102.409 -3.182 . . . . 0.0 102.409 177.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.443 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -155.01 -158.93 8.99 Favored Glycine 0 CA--C 1.479 -2.161 0 C-N-CA 118.139 -1.982 . . . . 0.0 113.381 -177.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -67.98 -46.58 70.97 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.44 95.59 0.74 Allowed Glycine 0 N--CA 1.429 -1.784 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 171.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -64.6 126.79 17.47 Favored 'Trans proline' 0 N--CA 1.441 -1.585 0 C-N-CA 122.164 1.909 . . . . 0.0 113.886 -172.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.1 m -126.0 132.37 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.381 -3.889 0 N-CA-C 102.026 -3.324 . . . . 0.0 102.026 173.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.415 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 97.8 mt-30 -121.67 138.2 54.44 Favored 'General case' 0 C--N 1.264 -3.114 0 C-N-CA 119.559 -0.856 . . . . 0.0 112.578 -169.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.69 171.31 43.68 Favored Glycine 0 N--CA 1.402 -3.628 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.433 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.6 pt -137.02 139.54 44.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.417 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 3.4 mp -127.77 127.91 68.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 60.4 m-20 -118.79 119.62 34.94 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 -176.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.617 ' CE1' ' HG ' ' A' ' 106' ' ' LEU . 11.6 p90 -131.58 141.04 49.59 Favored 'General case' 0 C--O 1.262 1.754 0 C-N-CA 118.646 -1.222 . . . . 0.0 113.095 178.058 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.408 ' HB3' ' O ' ' A' ' 2' ' ' THR . 7.2 pt-20 -133.65 95.15 3.42 Favored 'General case' 0 N--CA 1.416 -2.136 0 CA-C-O 122.268 1.033 . . . . 0.0 112.391 175.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.464 ' HG3' HG12 ' A' ' 29' ' ' VAL . 24.1 mm-40 -158.62 163.47 36.92 Favored 'General case' 0 C--O 1.257 1.477 0 C-N-CA 126.88 2.072 . . . . 0.0 108.038 170.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.595 ' HG3' ' H ' ' A' ' 24' ' ' GLU 0.257 27.7 pttt -159.7 -86.69 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.204 0 O-C-N 124.22 0.95 . . . . 0.0 112.055 164.487 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.595 ' H ' ' HG3' ' A' ' 23' ' ' LYS . 35.9 tt0 -93.2 -25.96 17.59 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 121.783 0.802 . . . . 0.0 109.578 178.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.446 ' HB2' ' OE1' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -46.93 -56.94 5.51 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.235 2.214 . . . . 0.0 114.836 -172.34 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.8 t30 75.71 139.91 0.07 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 124.971 1.308 . . . . 0.0 110.277 -174.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.471 ' H ' HG23 ' A' ' 104' ' ' ILE . . . 150.23 -170.96 30.2 Favored Glycine 0 CA--C 1.493 -1.312 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -70.08 124.02 10.55 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.413 1.409 . . . . 0.0 110.253 176.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.464 HG12 ' HG3' ' A' ' 22' ' ' GLN . 17.2 m -85.65 98.79 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.354 0 CA-C-O 121.502 0.668 . . . . 0.0 111.523 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.445 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.258 0.0 OUTLIER -90.46 108.66 19.93 Favored 'General case' 0 N--CA 1.417 -2.076 0 C-N-CA 118.486 -1.285 . . . . 0.0 109.11 171.919 . . . . . . . . 4 4 . 1 . 004 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.6 m -135.46 152.97 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.778 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 -172.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -143.58 126.92 16.72 Favored 'General case' 0 C--N 1.266 -3.051 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.946 178.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -145.34 140.27 8.93 Favored Glycine 0 N--CA 1.41 -3.075 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.697 174.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.0 m -116.6 140.23 49.63 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 176.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 25.2 pt -141.7 131.51 24.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-N 119.415 1.007 . . . . 0.0 109.025 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.421 ' HZ1' ' HB2' ' A' ' 36' ' ' LYS . 0.2 OUTLIER -112.09 132.39 54.87 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.82 175.2 23.18 Favored Glycine 0 N--CA 1.416 -2.68 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -169.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.1 mt -68.84 170.34 9.79 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -69.89 103.46 2.22 Favored 'General case' 0 C--O 1.203 -1.37 0 C-N-CA 118.016 -1.473 . . . . 0.0 110.403 -173.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.566 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.3 tt0 -176.13 141.77 0.46 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 102.798 -3.038 . . . . 0.0 102.798 170.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . -174.54 90.89 0.08 OUTLIER Glycine 0 C--N 1.276 -2.777 0 C-N-CA 117.028 -2.511 . . . . 0.0 113.334 174.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -93.4 -86.33 0.26 Allowed 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 120.512 -0.475 . . . . 0.0 111.649 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.416 ' HA ' ' H ' ' A' ' 87' ' ' VAL . 18.8 p80 166.32 135.28 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 152.46 131.4 1.68 Allowed Glycine 0 N--CA 1.413 -2.837 0 C-N-CA 118.322 -1.894 . . . . 0.0 113.785 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -133.98 139.59 46.17 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 122.063 0.935 . . . . 0.0 113.073 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -166.89 92.11 0.43 Allowed 'General case' 1 C--O 1.33 5.342 0 N-CA-C 105.183 -2.155 . . . . 0.0 105.183 172.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 117' ' ' LEU . 18.7 t -69.97 167.58 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 127.351 2.26 . . . . 0.0 109.095 176.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.521 ' NE2' ' HB2' ' A' ' 65' ' ' ASN . 56.5 t-80 -124.23 126.04 45.42 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-O 122.085 0.945 . . . . 0.0 109.873 174.033 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.589 ' CD ' ' HB3' ' A' ' 65' ' ' ASN . 2.8 pm0 -73.37 125.45 27.88 Favored 'General case' 0 C--N 1.264 -3.145 0 CA-C-N 113.62 -1.627 . . . . 0.0 108.403 174.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.53 ' HA ' ' OG ' ' A' ' 111' ' ' SER . 91.3 t80 80.13 100.17 0.06 Allowed 'General case' 0 CA--C 1.503 -0.851 0 CA-C-O 123.503 1.621 . . . . 0.0 108.776 -175.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.35 -145.97 7.52 Favored Glycine 0 N--CA 1.421 -2.332 0 CA-C-N 111.94 -2.391 . . . . 0.0 110.49 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -171.62 -85.83 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 115.597 1.703 . . . . 0.0 115.597 -171.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.499 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.7 t-20 -104.52 140.1 38.47 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -169.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 10.0 t -61.64 -27.68 68.84 Favored 'General case' 0 C--O 1.241 0.635 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . 0.648 ' HA ' ' O ' ' A' ' 9' ' ' LYS . . . -114.47 17.84 17.16 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 120.618 0.247 . . . . 0.0 111.449 -175.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.42 117.27 0.58 Allowed Glycine 0 CA--C 1.483 -1.96 0 C-N-CA 119.247 -1.454 . . . . 0.0 111.382 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.455 ' HB2' ' O ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -87.28 98.59 11.42 Favored 'General case' 0 C--N 1.28 -2.429 0 C-N-CA 122.926 0.491 . . . . 0.0 109.904 -176.544 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 m -79.07 -56.1 4.62 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.746 0.784 . . . . 0.0 109.515 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.7 m -75.32 -43.91 48.27 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.011 -174.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.59 -8.61 56.91 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.949 174.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.15 -63.69 3.48 Favored Glycine 0 CA--C 1.538 1.504 0 O-C-N 123.758 0.661 . . . . 0.0 112.772 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -64.26 -5.15 9.1 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.989 2.459 . . . . 0.0 112.75 176.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.289 23.3 p80 56.04 15.75 1.91 Allowed 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 118.504 2.779 . . . . 0.0 118.504 170.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -146.35 120.45 9.45 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 119.151 0.887 . . . . 0.0 112.757 178.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.589 ' HB3' ' CD ' ' A' ' 49' ' ' GLU . 27.7 t-20 -116.95 144.22 33.08 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 172.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -52.57 -13.19 2.17 Favored 'Trans proline' 0 CA--C 1.556 1.595 0 C-N-CA 124.466 3.444 . . . . 0.0 117.82 -177.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.551 ' C ' ' H ' ' A' ' 69' ' ' ARG . 4.1 mm? -82.62 -12.98 57.28 Favored 'General case' 0 CA--C 1.474 -1.956 0 CA-C-N 119.878 1.217 . . . . 0.0 110.396 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.51 ' HA ' ' HB3' ' A' ' 80' ' ' HIS . 74.3 m -72.94 36.4 0.08 Allowed 'General case' 0 C--O 1.215 -0.718 0 C-N-CA 124.342 1.057 . . . . 0.0 109.804 169.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.551 ' H ' ' C ' ' A' ' 67' ' ' LEU . 3.3 tmm_? -76.3 11.12 1.66 Allowed 'General case' 0 C--O 1.212 -0.895 0 C-N-CA 127.505 2.322 . . . . 0.0 107.951 -172.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.52 ' HE2' ' OD2' ' A' ' 76' ' ' ASP . 47.4 tptt -77.35 -32.47 55.1 Favored 'General case' 0 N--CA 1.396 -3.133 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t60 61.18 23.86 14.02 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.251 1.021 . . . . 0.0 110.126 178.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.73 120.99 2.65 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 119.842 -1.17 . . . . 0.0 112.218 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.39 75.78 0.13 Allowed Glycine 0 C--N 1.293 -1.812 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.503 ' O ' HD11 ' A' ' 84' ' ' LEU . 31.8 Cg_endo -62.23 -22.63 74.46 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 123.759 2.973 . . . . 0.0 114.82 -171.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mtpt -123.2 13.2 9.62 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.52 ' OD2' ' HE2' ' A' ' 70' ' ' LYS . 21.7 t70 -116.96 -67.69 0.97 Allowed 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -169.553 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.427 ' HG3' ' HG ' ' A' ' 105' ' ' SER . 6.8 tp10 60.66 111.64 0.02 OUTLIER 'General case' 0 C--O 1.256 1.406 0 CA-C-O 122.477 1.132 . . . . 0.0 110.768 -173.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -114.44 -78.21 0.58 Allowed 'General case' 0 N--CA 1.422 -1.842 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.878 -176.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.468 ' O ' ' HB2' ' A' ' 80' ' ' HIS . 29.3 tpt180 -113.98 5.35 16.1 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 117.729 -1.588 . . . . 0.0 110.767 179.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.51 ' HB3' ' HA ' ' A' ' 68' ' ' SER 0.274 18.7 t60 . . . . . 0 N--CA 1.43 -1.447 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.208 172.926 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.503 HD11 ' O ' ' A' ' 74' ' ' PRO . 4.0 pp . . . . . 0 N--CA 1.423 -1.813 0 CA-C-O 120.99 0.424 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 178.17 -178.64 48.58 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 120.054 -1.07 . . . . 0.0 111.823 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -118.45 132.72 56.23 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.473 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.7 m -136.06 132.8 50.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -176.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -132.94 96.03 3.69 Favored 'General case' 0 N--CA 1.413 -2.283 0 CA-C-O 122.643 1.211 . . . . 0.0 110.613 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.513 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -92.75 153.86 18.65 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 113.911 -1.495 . . . . 0.0 107.833 174.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.52 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 6.8 t70 -125.14 -161.65 1.04 Allowed 'General case' 0 C--N 1.255 -3.541 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -40.85 -34.82 0.43 Allowed 'General case' 0 N--CA 1.506 2.339 0 C-N-CA 127.313 2.245 . . . . 0.0 116.115 -175.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -147.82 16.62 1.11 Allowed 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 177.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.52 ' HA3' ' H ' ' A' ' 90' ' ' ASP . . . -59.34 -157.52 0.03 OUTLIER Glycine 0 C--O 1.187 -2.826 0 N-CA-C 118.731 2.252 . . . . 0.0 118.731 -164.152 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -158.49 105.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.275 -2.656 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.473 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.72 110.12 22.63 Favored 'General case' 0 N--CA 1.398 -3.048 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -85.25 103.37 14.14 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 114.664 -1.153 . . . . 0.0 110.395 -177.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -88.28 102.4 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.507 0 CA-C-O 122.309 1.052 . . . . 0.0 109.486 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.7 p -155.41 100.7 2.14 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 113.649 -1.614 . . . . 0.0 108.11 174.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.46 119.33 29.41 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -95.06 101.06 12.79 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.949 0.881 . . . . 0.0 111.486 -178.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -163.03 169.82 18.95 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 -178.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.5 t -59.4 94.42 0.02 OUTLIER 'General case' 0 C--O 1.244 0.769 0 CA-C-O 122.528 1.156 . . . . 0.0 113.402 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.441 HG21 ' CD1' ' A' ' 84' ' ' LEU . 15.5 t -118.28 -9.56 11.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 N-CA-C 103.12 -2.919 . . . . 0.0 103.12 168.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.506 HD13 ' N ' ' A' ' 105' ' ' SER . 2.7 pp -41.9 -40.68 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.709 0 C-N-CA 127.812 2.445 . . . . 0.0 114.77 -166.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.506 ' N ' HD13 ' A' ' 104' ' ' ILE . 10.1 p -85.84 90.73 8.14 Favored 'General case' 1 N--CA 1.352 -5.37 0 C-N-CA 118.385 -1.326 . . . . 0.0 108.843 176.483 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.617 ' HG ' ' CE1' ' A' ' 20' ' ' PHE . 3.7 mm? -75.42 86.89 2.57 Favored 'General case' 0 N--CA 1.393 -3.296 0 N-CA-C 104.837 -2.283 . . . . 0.0 104.837 177.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.4 m -83.13 88.35 6.9 Favored 'General case' 1 N--CA 1.357 -5.124 0 CA-C-N 113.203 -1.817 . . . . 0.0 108.702 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.73 134.43 11.88 Favored Glycine 1 N--CA 1.36 -6.38 0 N-CA-C 104.482 -3.447 . . . . 0.0 104.482 169.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.453 ' CG ' ' HG ' ' A' ' 67' ' ' LEU . 38.6 t70 -84.29 -66.92 0.84 Allowed 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 117.591 -1.644 . . . . 0.0 111.464 -177.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -100.03 -17.32 17.55 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.53 ' OG ' ' HA ' ' A' ' 50' ' ' PHE . 20.0 m -132.79 118.42 19.0 Favored 'General case' 0 N--CA 1.395 -3.22 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.498 -176.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.432 HG13 HD11 ' A' ' 113' ' ' ILE . 14.1 pt -112.6 -25.3 3.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 N-CA-C 104.749 -2.315 . . . . 0.0 104.749 166.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.432 HD11 HG13 ' A' ' 112' ' ' ILE . 2.5 mp -102.59 130.46 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 162.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 94.94 12.91 54.81 Favored Glycine 0 C--O 1.209 -1.436 0 C-N-CA 119.546 -1.312 . . . . 0.0 111.838 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.623 ' O ' ' HB ' ' A' ' 149' ' ' ILE . 15.7 mtp180 -70.88 90.07 0.79 Allowed 'General case' 0 C--O 1.207 -1.163 0 CA-C-O 120.868 0.366 . . . . 0.0 110.127 174.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 96.9 m -68.0 105.32 1.99 Allowed 'General case' 0 N--CA 1.383 -3.775 0 CA-C-O 122.519 1.152 . . . . 0.0 109.786 172.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 47' ' ' VAL . 43.1 tp -70.09 97.92 1.25 Allowed 'General case' 0 CA--C 1.477 -1.843 0 CA-C-N 113.568 -1.651 . . . . 0.0 108.443 177.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.449 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 7.2 p -91.23 100.06 10.63 Favored 'Isoleucine or valine' 1 C--O 1.313 4.419 0 C-N-CA 115.909 -2.317 . . . . 0.0 109.874 -175.6 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.29 170.23 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.767 0 CA-C-N 112.429 -2.168 . . . . 0.0 107.172 -175.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -158.16 172.28 18.69 Favored 'General case' 0 C--N 1.285 -2.216 0 N-CA-C 103.739 -2.689 . . . . 0.0 103.739 174.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.566 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.1 mp0 -66.77 89.81 0.16 Allowed 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 105.138 -2.171 . . . . 0.0 105.138 170.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.0 tttp -171.66 170.91 5.5 Favored 'General case' 0 N--CA 1.44 -0.925 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -170.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.5 104.98 15.77 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 170.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.436 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 13.1 t70 -106.92 8.03 30.35 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 122.705 1.24 . . . . 0.0 111.292 -177.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -67.19 139.46 57.42 Favored 'General case' 0 C--N 1.281 -2.398 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.155 -171.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.7 tp -62.96 -50.92 68.88 Favored 'General case' 0 C--N 1.321 -0.643 0 O-C-N 123.475 0.484 . . . . 0.0 109.916 -178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.06 -24.23 68.48 Favored Glycine 0 N--CA 1.442 -0.953 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.192 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -88.93 -47.05 8.42 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 119.931 -0.707 . . . . 0.0 111.701 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 47.6 -103.18 0.06 OUTLIER Glycine 0 C--O 1.222 -0.603 0 N-CA-C 114.847 0.699 . . . . 0.0 114.847 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -175.53 -79.03 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.603 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 21.8 t-20 -107.75 -170.23 1.66 Allowed 'General case' 0 C--O 1.258 1.545 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 174.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.4 tt0 -53.91 -42.85 69.21 Favored 'General case' 0 CA--C 1.542 0.664 0 CA-C-N 118.884 0.766 . . . . 0.0 111.745 -178.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.603 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -75.25 -39.38 59.9 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.154 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.2 m -67.99 -21.65 65.04 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -176.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -86.71 -6.29 58.88 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 122.0 0.905 . . . . 0.0 110.738 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -92.81 -39.74 11.04 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.3 p -86.47 -21.23 27.14 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 114.662 -1.154 . . . . 0.0 112.307 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.48 78.47 0.24 Allowed Glycine 0 C--O 1.254 1.383 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -177.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.436 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 55.8 t30 -47.71 142.92 4.25 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 124.967 1.307 . . . . 0.0 112.291 -176.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.425 ' HB2' HG23 ' A' ' 118' ' ' VAL . . . -150.05 170.49 18.75 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.308 -173.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.4 85.1 1.41 Allowed Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 106.547 -2.621 . . . . 0.0 106.547 169.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 51.0 m -42.47 -56.35 3.07 Favored 'General case' 0 C--O 1.194 -1.819 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -165.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.436 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 22.9 ptt180 -129.61 12.28 5.84 Favored 'General case' 0 C--N 1.254 -3.58 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -174.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.443 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 0.7 OUTLIER -58.15 -44.91 88.11 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 -173.73 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -170.3 92.21 0.2 Allowed 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 114.371 1.249 . . . . 0.0 114.371 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.449 ' SG ' ' HA ' ' A' ' 118' ' ' VAL . 13.9 p -173.53 128.74 0.43 Allowed 'General case' 0 C--O 1.211 -0.956 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 173.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 54' ' ' THR . . . 179.55 77.08 0.06 OUTLIER Glycine 0 N--CA 1.409 -3.138 0 CA-C-O 117.935 -1.481 . . . . 0.0 113.372 150.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 54.1 t -171.54 90.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 C-N-CA 125.247 1.419 . . . . 0.0 108.135 167.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.623 ' HB ' ' O ' ' A' ' 115' ' ' ARG 0.262 5.4 mt -125.13 118.3 52.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.646 0 CA-C-N 119.179 0.9 . . . . 0.0 109.966 163.229 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 178.08 155.06 13.35 Favored Glycine 2 N--CA 1.379 -5.132 0 C-N-CA 117.801 -2.142 . . . . 0.0 112.681 176.437 . . . . . . . . 3 3 . 1 . 004 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.494 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.6 tt -53.81 105.19 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 114.893 -0.654 . . . . 0.0 110.55 169.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.31 99.43 5.02 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.997 -0.681 . . . . 0.0 109.542 171.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.304 -1.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.657 178.691 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.451 ' O ' ' HB2' ' A' ' 21' ' ' GLU . . . . . . . . 0 CA--C 1.506 -0.74 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 . . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 25.3 m -121.87 -36.77 2.96 Favored 'General case' 0 CA--C 1.555 1.163 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.554 ' O ' HG12 ' A' ' 151' ' ' ILE . 17.9 ptpt -136.2 144.15 44.78 Favored 'General case' 0 N--CA 1.426 -1.67 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.718 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.468 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -135.73 151.73 50.43 Favored 'General case' 0 C--N 1.282 -2.348 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 30.4 m -115.53 138.36 46.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.637 -178.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.536 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -111.09 133.89 53.11 Favored 'General case' 0 C--N 1.284 -2.283 0 CA-C-N 114.781 -1.099 . . . . 0.0 111.48 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -134.73 104.22 5.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 122.98 0.512 . . . . 0.0 110.132 176.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.41 HD11 ' HA3' ' A' ' 147' ' ' GLY . 3.1 mm? -96.97 151.31 19.83 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.687 -178.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . 0.594 ' HD3' ' N ' ' A' ' 10' ' ' GLY . 9.9 tmtt? -150.54 137.45 19.17 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.594 ' N ' ' HD3' ' A' ' 9' ' ' LYS . . . -152.78 -169.6 18.2 Favored Glycine 0 N--CA 1.423 -2.188 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.038 -179.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -85.97 -31.12 22.26 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 113.915 -1.143 . . . . 0.0 109.376 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -109.47 -172.5 20.72 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 174.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -83.69 123.06 3.2 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-N 120.779 2.29 . . . . 0.0 111.099 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.2 p -135.9 91.78 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.097 0 C-N-CA 124.682 1.193 . . . . 0.0 108.522 174.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.614 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 16.0 mm100 -111.59 119.08 37.51 Favored 'General case' 0 C--N 1.292 -1.913 0 O-C-N 121.31 -0.869 . . . . 0.0 108.88 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -156.85 148.27 17.83 Favored Glycine 0 N--CA 1.406 -3.306 0 C-N-CA 120.206 -0.997 . . . . 0.0 112.658 -175.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.498 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 12.6 pt -135.65 103.79 4.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.536 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 3.3 mp -116.64 129.31 73.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -173.102 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.16 138.73 51.47 Favored 'General case' 0 CA--C 1.465 -2.3 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.468 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 20.3 p90 -136.63 160.97 37.2 Favored 'General case' 0 N--CA 1.412 -2.353 0 C-N-CA 119.573 -0.851 . . . . 0.0 109.99 178.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.451 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 11.2 pt-20 -127.02 104.97 8.28 Favored 'General case' 0 N--CA 1.407 -2.582 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.214 177.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.442 ' NE2' ' HB2' ' A' ' 106' ' ' LEU . 0.9 OUTLIER -85.61 133.73 34.03 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.564 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -122.58 116.78 24.45 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.138 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -76.51 -11.28 59.85 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.955 -1.021 . . . . 0.0 111.015 -177.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.6 m -90.52 -9.28 47.84 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 171.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 70.24 135.93 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.667 1.587 . . . . 0.0 112.653 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -173.37 172.56 45.27 Favored Glycine 0 CA--C 1.487 -1.659 0 C-N-CA 120.28 -0.962 . . . . 0.0 111.374 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -65.06 123.4 11.52 Favored 'Trans proline' 0 N--CA 1.444 -1.383 0 N-CA-C 105.887 -2.39 . . . . 0.0 105.887 172.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.491 ' O ' ' HG3' ' A' ' 100' ' ' GLU . 34.9 m -94.96 127.36 46.98 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-O 121.617 0.722 . . . . 0.0 112.142 -172.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -81.99 104.46 12.36 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.46 HG12 ' HA ' ' A' ' 20' ' ' PHE . 14.5 m -132.45 147.65 31.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -177.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.453 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 12.0 t90 -158.93 136.49 10.12 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -150.3 142.04 9.3 Favored Glycine 0 N--CA 1.403 -3.541 0 C-N-CA 120.405 -0.902 . . . . 0.0 111.921 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.593 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 24.8 m -114.45 133.81 55.47 Favored 'General case' 0 N--CA 1.416 -2.161 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.779 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 5.2 tt -146.83 123.97 3.47 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.106 0 CA-C-N 118.358 0.527 . . . . 0.0 110.672 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -104.63 134.42 47.82 Favored 'General case' 0 N--CA 1.415 -2.184 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.837 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.4 ' O ' ' HA ' ' A' ' 92' ' ' ASP . . . -132.08 177.39 18.73 Favored Glycine 1 N--CA 1.37 -5.705 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.262 -169.186 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.516 HD21 ' N ' ' A' ' 39' ' ' THR . 10.2 tt -67.02 177.22 1.8 Allowed 'General case' 0 C--N 1.271 -2.811 0 N-CA-C 103.124 -2.917 . . . . 0.0 103.124 168.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.516 ' N ' HD21 ' A' ' 38' ' ' LEU . 40.6 p -58.91 150.77 23.36 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 120.603 -1.311 . . . . 0.0 111.099 -165.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.58 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -60.7 158.5 12.56 Favored 'General case' 0 CA--C 1.458 -2.577 0 N-CA-C 117.981 2.586 . . . . 0.0 117.981 -155.751 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -142.2 173.86 23.55 Favored Glycine 0 C--N 1.254 -3.997 0 CA-C-N 110.8 -2.909 . . . . 0.0 107.038 -175.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.0 mt -131.66 -34.38 1.35 Allowed 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 116.879 2.177 . . . . 0.0 116.879 -164.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.648 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 19.1 t-80 -154.85 123.09 5.94 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 121.31 1.868 . . . . 0.0 109.995 -174.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.98 149.86 14.55 Favored Glycine 0 N--CA 1.424 -2.146 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.846 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.29 135.38 41.81 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.669 ' HA ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -129.15 82.74 2.1 Favored 'General case' 1 N--CA 1.362 -4.833 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.444 -161.742 . . . . . . . . 4 4 . 1 . 005 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.548 ' HB ' ' O ' ' A' ' 46' ' ' HIS . 9.3 p -174.59 162.96 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.398 -3.026 0 CA-C-N 114.119 -1.401 . . . . 0.0 110.582 165.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -147.28 112.53 5.53 Favored 'General case' 0 C--N 1.276 -2.611 0 C-N-CA 127.823 2.449 . . . . 0.0 106.994 166.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.469 ' CB ' ' HB2' ' A' ' 110' ' ' HIS . 20.2 pt-20 -83.51 86.06 7.15 Favored 'General case' 0 C--O 1.173 -2.942 0 N-CA-C 115.793 1.775 . . . . 0.0 115.793 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.498 ' N ' ' HG3' ' A' ' 115' ' ' ARG . 76.3 m-85 -169.09 91.09 0.24 Allowed 'General case' 0 C--N 1.283 -2.286 0 C-N-CA 127.439 2.296 . . . . 0.0 105.361 175.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.12 139.28 44.33 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 120.476 -0.868 . . . . 0.0 114.539 -178.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -125.55 -84.58 0.63 Allowed 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 176.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -164.75 159.7 18.94 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 9' ' ' LYS . 9.0 t -67.94 -29.01 67.96 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 117.879 0.309 . . . . 0.0 111.538 -179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.42 -22.24 28.42 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.41 110.76 0.51 Allowed Glycine 0 CA--C 1.484 -1.901 0 C-N-CA 119.366 -1.397 . . . . 0.0 111.42 -175.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.612 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 7.9 p -98.43 89.22 4.36 Favored 'General case' 0 C--N 1.281 -2.37 0 CA-C-O 121.895 0.855 . . . . 0.0 111.472 178.067 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.0 m -79.54 -47.25 15.86 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.454 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.0 m -79.78 -8.28 59.17 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.252 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.55 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -74.71 -9.28 58.42 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 115.338 -0.847 . . . . 0.0 111.989 179.303 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.88 -142.85 0.11 Allowed Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.601 -0.727 . . . . 0.0 113.697 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -65.01 8.72 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.041 0 C-N-CA 124.456 3.438 . . . . 0.0 114.843 -176.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.93 124.42 46.6 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -169.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -133.84 166.03 23.62 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -172.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.451 ' HB3' ' OE2' ' A' ' 49' ' ' GLU . 44.3 t30 -114.03 96.39 41.64 Favored Pre-proline 0 N--CA 1.428 -1.541 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -80.97 -10.27 12.76 Favored 'Trans proline' 0 N--CA 1.425 -2.509 0 C-N-CA 123.206 2.604 . . . . 0.0 111.135 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -65.63 -45.29 83.63 Favored 'General case' 0 N--CA 1.432 -1.337 0 O-C-N 123.815 0.697 . . . . 0.0 110.019 -166.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.621 ' HB2' ' O ' ' A' ' 79' ' ' ARG 0.293 7.6 m -52.31 -52.66 51.76 Favored 'General case' 0 N--CA 1.417 -2.093 0 N-CA-C 116.241 1.941 . . . . 0.0 116.241 -171.215 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.568 ' O ' ' HB2' ' A' ' 70' ' ' LYS . 72.0 ttt180 -133.97 -32.84 1.07 Allowed 'General case' 0 CA--C 1.479 -1.781 0 C-N-CA 113.998 -3.081 . . . . 0.0 111.61 167.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 69' ' ' ARG . 22.0 tptm 160.63 -77.96 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.695 1.247 . . . . 0.0 108.708 170.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 178.58 119.99 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 126.489 1.916 . . . . 0.0 108.4 177.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -156.28 -87.71 0.06 OUTLIER Glycine 0 CA--C 1.529 0.965 0 C-N-CA 118.636 -1.745 . . . . 0.0 115.355 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -146.12 4.72 Favored Glycine 0 N--CA 1.415 -2.752 0 C-N-CA 121.354 -0.45 . . . . 0.0 113.083 -173.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -106.0 1.42 0.2 Allowed 'Trans proline' 0 C--O 1.233 0.258 0 C-N-CA 124.969 3.779 . . . . 0.0 114.909 -170.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -87.4 -17.25 32.71 Favored 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -167.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.56 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 12.7 t70 -146.51 -72.71 0.23 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.662 -178.383 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.482 ' HG2' ' OD1' ' A' ' 76' ' ' ASP . 21.9 pt-20 -154.11 -56.57 0.11 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.56 ' OE1' ' HB3' ' A' ' 76' ' ' ASP . 0.6 OUTLIER 52.74 1.67 0.02 OUTLIER 'General case' 0 C--O 1.203 -1.349 0 C-N-CA 127.73 2.412 . . . . 0.0 116.95 172.873 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.621 ' O ' ' HB2' ' A' ' 68' ' ' SER . 27.0 mtt180 163.7 -26.91 0.0 OUTLIER 'General case' 0 C--O 1.189 -2.119 0 C-N-CA 125.266 1.426 . . . . 0.0 111.389 -172.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 . . . . . 0 N--CA 1.498 1.946 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -179.3 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt . . . . . 0 N--CA 1.438 -1.063 0 CA-C-O 121.696 0.76 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -146.88 -176.82 20.97 Favored Glycine 0 N--CA 1.416 -2.664 0 N-CA-C 108.881 -1.687 . . . . 0.0 108.881 -178.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.84 155.57 18.67 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 117.733 0.767 . . . . 0.0 111.822 -179.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.473 HG13 ' NE2' ' A' ' 46' ' ' HIS . 2.0 m -143.16 128.45 15.88 Favored 'Isoleucine or valine' 0 C--N 1.361 1.081 0 C-N-CA 123.585 0.754 . . . . 0.0 111.08 173.14 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 t -141.78 95.98 2.9 Favored 'General case' 0 N--CA 1.39 -3.468 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 172.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 40' ' ' GLU . . . -96.1 122.43 38.93 Favored 'General case' 0 CA--C 1.466 -2.266 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.58 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 21.6 t70 -54.15 169.76 0.16 Allowed 'General case' 0 CA--C 1.565 1.525 0 O-C-N 124.824 1.328 . . . . 0.0 111.435 177.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.551 ' HA ' ' H ' ' A' ' 40' ' ' GLU . 57.4 pttt -41.68 -23.54 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 117.233 2.309 . . . . 0.0 117.233 -175.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.4 ' HA ' ' O ' ' A' ' 37' ' ' GLY . 30.8 t70 -154.16 22.07 0.5 Allowed 'General case' 0 C--N 1.294 -1.81 0 N-CA-C 104.359 -2.46 . . . . 0.0 104.359 172.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.81 -127.57 1.4 Allowed Glycine 0 C--O 1.179 -3.313 0 CA-C-N 111.555 -2.566 . . . . 0.0 118.634 -160.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 3.3 m -161.16 136.27 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.226 0 C-N-CA 124.978 1.311 . . . . 0.0 108.207 -170.247 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.57 111.73 24.16 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 173.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -74.99 93.52 2.72 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 123.479 0.487 . . . . 0.0 109.766 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 33.7 m -91.78 111.76 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.01 0 CA-C-O 121.982 0.896 . . . . 0.0 111.007 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.3 t -149.95 100.84 2.98 Favored 'General case' 0 N--CA 1.411 -2.394 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.42 118.55 43.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.491 ' HG3' ' O ' ' A' ' 29' ' ' VAL . 5.1 mp0 -107.32 99.01 8.57 Favored 'General case' 0 N--CA 1.417 -2.108 0 C-N-CA 118.983 -1.087 . . . . 0.0 110.327 -176.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -165.88 166.33 17.64 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 173.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.1 m -94.71 80.39 3.78 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.827 -1.149 . . . . 0.0 112.939 -174.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.0 m -104.84 -18.72 6.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.801 176.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 21.3 pt -101.46 7.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.707 -170.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.1 m -66.57 167.54 10.76 Favored 'General case' 0 CA--C 1.56 1.332 0 CA-C-O 122.697 1.237 . . . . 0.0 113.003 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.442 ' HB2' ' NE2' ' A' ' 22' ' ' GLN . 3.8 tt -78.26 87.22 4.33 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-N 114.115 -1.402 . . . . 0.0 108.286 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 51.7 m -170.01 86.68 0.13 Allowed 'General case' 0 C--N 1.264 -3.144 0 N-CA-C 102.533 -3.136 . . . . 0.0 102.533 169.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 157.32 -177.45 34.16 Favored Glycine 0 C--N 1.258 -3.753 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.437 ' C ' ' H ' ' A' ' 111' ' ' SER . 18.9 t70 -81.31 -21.5 39.19 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 118.492 -1.283 . . . . 0.0 109.568 175.265 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.469 ' HB2' ' CB ' ' A' ' 49' ' ' GLU . 62.9 t-80 -88.36 40.66 0.97 Allowed 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 173.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.437 ' H ' ' C ' ' A' ' 109' ' ' ASP . 15.1 p -63.02 -64.78 0.81 Allowed 'General case' 0 C--N 1.273 -2.725 0 CA-C-O 122.724 1.25 . . . . 0.0 110.146 -175.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.404 HG23 HE21 ' A' ' 22' ' ' GLN . 28.5 pt -128.94 -22.93 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.184 176.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -81.23 170.54 1.42 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.158 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.206 -162.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -82.99 71.72 2.97 Favored Glycine 0 CA--C 1.475 -2.463 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -172.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.498 ' HG3' ' N ' ' A' ' 50' ' ' PHE . 2.6 mpt_? -79.13 141.24 37.45 Favored 'General case' 0 N--CA 1.396 -3.13 0 CA-C-N 114.603 -0.799 . . . . 0.0 110.063 -178.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.779 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 8.8 t -67.84 124.21 22.71 Favored 'General case' 0 C--N 1.274 -2.716 0 CA-C-O 122.895 1.331 . . . . 0.0 114.554 -168.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.3 tp -80.64 98.42 7.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 113.556 -1.656 . . . . 0.0 108.901 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.669 ' O ' ' HA ' ' A' ' 46' ' ' HIS . 26.9 t -91.85 100.56 11.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.864 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.529 ' HB ' ' CB ' ' A' ' 46' ' ' HIS . 12.2 p -139.98 156.98 25.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 126.539 1.936 . . . . 0.0 108.343 -175.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -171.45 166.57 6.88 Favored 'General case' 0 N--CA 1.428 -1.564 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 165.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.564 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -73.32 84.91 1.44 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 175.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.463 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 79.3 mttt -173.19 170.77 4.26 Favored 'General case' 0 CA--C 1.493 -1.228 0 C-N-CA 126.119 1.768 . . . . 0.0 108.326 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.648 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -80.44 104.48 11.01 Favored 'General case' 0 C--N 1.29 -1.998 0 O-C-N 124.145 0.903 . . . . 0.0 110.974 172.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -118.78 80.46 1.54 Allowed 'General case' 0 CA--C 1.483 -1.623 0 N-CA-C 104.267 -2.494 . . . . 0.0 104.267 173.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 16.4 t0 -125.91 139.0 53.82 Favored 'General case' 0 C--N 1.263 -3.17 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.332 -170.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.4 tp -82.03 -21.5 36.93 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.876 -172.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -102.82 13.42 56.29 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.611 ' HD3' ' O ' ' A' ' 128' ' ' LYS . 14.3 tmtt? -127.42 37.76 4.18 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.3 -54.84 34.38 Favored Glycine 0 N--CA 1.427 -1.9 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.12 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 114.34 -25.09 10.78 Favored Glycine 0 C--N 1.308 -1.004 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.907 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 33.3 t-20 -167.58 167.08 13.77 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.443 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 12.9 pt-20 -48.39 -46.59 37.34 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -61.72 -53.57 54.28 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.542 0.737 . . . . 0.0 110.412 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.6 m -69.22 -27.28 65.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 112.108 -172.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 m -78.01 -15.31 59.05 Favored 'General case' 0 CA--C 1.557 1.235 0 CA-C-O 121.801 0.81 . . . . 0.0 110.025 177.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.443 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 99.4 mttt -89.67 -40.14 12.74 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 174.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.0 m -67.43 -46.39 73.28 Favored 'General case' 0 C--N 1.284 -2.244 0 CA-C-O 121.366 0.603 . . . . 0.0 109.993 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.53 76.56 1.18 Allowed Glycine 0 N--CA 1.408 -3.208 0 N-CA-C 106.866 -2.493 . . . . 0.0 106.866 -172.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -36.21 111.22 0.13 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 125.905 1.682 . . . . 0.0 111.041 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -149.22 135.75 19.4 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.225 -173.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -70.87 108.4 2.47 Favored Glycine 0 N--CA 1.434 -1.438 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 172.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.6 m -57.01 -29.55 63.42 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 115.285 1.587 . . . . 0.0 115.285 -169.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.612 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 27.3 ttm180 -128.97 21.82 5.8 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -175.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 74.9 mt -74.46 -15.38 60.9 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.692 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.71 109.26 1.22 Allowed 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.478 175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 61.5 m -98.59 131.41 44.82 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 174.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.779 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.59 126.44 1.23 Allowed Glycine 0 N--CA 1.412 -2.919 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.873 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 m -76.18 98.43 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-O 121.691 0.758 . . . . 0.0 109.864 173.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.4 112.22 38.61 Favored 'Isoleucine or valine' 0 C--O 1.257 1.48 0 CA-C-O 122.31 1.053 . . . . 0.0 109.926 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.431 ' HA2' ' CZ ' ' A' ' 20' ' ' PHE . . . -174.68 176.76 46.93 Favored Glycine 0 CA--C 1.461 -3.294 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -175.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.554 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.35 105.05 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 107.942 -1.132 . . . . 0.0 107.942 176.727 . . . . . . . . 3 3 . 1 . 005 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.54 147.59 41.42 Favored 'General case' 0 N--CA 1.413 -2.281 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--N 1.292 -1.9 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.916 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.722 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.7 m -74.46 -23.4 58.89 Favored 'General case' 0 CA--C 1.566 1.58 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -172.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -132.37 147.8 52.4 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.873 -171.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.471 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -132.64 156.48 46.86 Favored 'General case' 0 N--CA 1.405 -2.693 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.579 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.2 t -125.96 126.91 70.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -124.91 135.1 52.55 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.005 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.501 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 14.7 m -127.61 119.77 52.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-O 121.201 0.524 . . . . 0.0 110.809 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -100.34 138.15 37.8 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.219 177.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -165.8 125.19 1.68 Allowed 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.83 -158.98 8.99 Favored Glycine 0 N--CA 1.439 -1.156 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.633 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -72.34 -61.78 1.67 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -75.62 153.43 44.2 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 172.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -83.21 123.35 3.47 Favored 'Trans proline' 0 N--CA 1.429 -2.289 0 CA-C-N 120.976 2.388 . . . . 0.0 112.389 -175.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.74 119.09 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.819 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 173.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -130.82 128.88 41.55 Favored 'General case' 0 C--N 1.269 -2.909 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.54 161.78 34.77 Favored Glycine 0 N--CA 1.399 -3.791 0 C-N-CA 119.49 -1.338 . . . . 0.0 112.201 -177.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.443 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.0 pt -142.26 133.6 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.318 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -132.31 135.03 58.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -107.11 132.94 52.45 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.471 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 22.1 t80 -127.42 138.2 52.92 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 123.619 0.768 . . . . 0.0 110.59 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.606 ' O ' HG23 ' A' ' 29' ' ' VAL . 5.7 pt-20 -117.33 119.69 35.89 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.537 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.13 135.65 33.52 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 119.299 -0.961 . . . . 0.0 108.751 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -115.43 83.75 1.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.678 0.751 . . . . 0.0 110.308 179.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -68.42 -20.21 64.64 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 124.526 1.131 . . . . 0.0 110.802 -177.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 25' ' ' SER . . . . . 0.445 ' O ' ' HB3' ' A' ' 26' ' ' ASN . 17.4 t -88.44 -5.23 58.39 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.089 177.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . 0.445 ' HB3' ' O ' ' A' ' 25' ' ' SER . 4.0 t30 77.47 113.91 0.07 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 124.682 1.193 . . . . 0.0 110.837 -173.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.82 166.41 39.6 Favored Glycine 0 CA--C 1.475 -2.455 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -177.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.434 ' HA ' ' HB2' ' A' ' 101' ' ' ASP . 58.0 Cg_endo -71.67 124.08 9.95 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 121.177 1.251 . . . . 0.0 110.774 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 21' ' ' GLU . 9.8 p -76.75 123.25 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.893 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.066 173.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -105.56 124.56 49.76 Favored 'General case' 0 C--N 1.28 -2.451 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 172.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.499 ' H ' HG21 ' A' ' 99' ' ' ILE . 34.4 m -134.33 153.27 35.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -172.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 69.4 p-90 -145.64 135.23 23.27 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 174.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.557 ' H ' HG13 ' A' ' 97' ' ' VAL . . . -148.68 139.59 7.68 Favored Glycine 0 N--CA 1.42 -2.404 0 C-N-CA 119.979 -1.105 . . . . 0.0 111.662 175.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.2 m -116.11 125.63 52.63 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.3 mm -125.04 132.19 71.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -117.67 136.16 53.52 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -171.01 174.15 44.75 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -172.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 pp -68.66 153.69 43.31 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 118.679 1.239 . . . . 0.0 109.634 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.574 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 77.3 p -69.85 107.26 3.46 Favored 'General case' 0 C--O 1.206 -1.195 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 -170.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.558 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 28.7 tt0 -175.35 115.99 0.15 Allowed 'General case' 0 C--O 1.205 -1.279 0 C-N-CA 125.653 1.581 . . . . 0.0 107.018 172.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.488 ' N ' ' HB3' ' A' ' 90' ' ' ASP . . . -164.35 114.97 0.62 Allowed Glycine 0 C--N 1.273 -2.917 0 C-N-CA 118.392 -1.861 . . . . 0.0 112.166 -174.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.2 mt -106.72 -64.76 1.15 Allowed 'General case' 0 N--CA 1.435 -1.191 0 O-C-N 123.998 0.47 . . . . 0.0 112.187 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.667 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.1 m80 -171.35 168.95 6.45 Favored 'General case' 0 CA--C 1.492 -1.255 0 C-N-CA 124.249 1.02 . . . . 0.0 108.326 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.48 ' O ' ' HG3' ' A' ' 74' ' ' PRO . . . 178.23 -169.28 40.97 Favored Glycine 0 C--N 1.282 -2.461 0 C-N-CA 119.786 -1.197 . . . . 0.0 112.056 176.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.527 ' CE1' ' HA ' ' A' ' 126' ' ' LEU . 1.3 p90 -168.16 165.67 13.15 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.686 ' CE1' ' HA3' ' A' ' 85' ' ' GLY . 18.3 m-70 -90.02 150.02 22.29 Favored 'General case' 0 CA--C 1.478 -1.808 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.507 ' HB ' ' CD2' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -172.3 89.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 173.663 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.458 ' ND1' ' HB2' ' A' ' 60' ' ' ALA . 0.2 OUTLIER -170.34 86.06 0.12 Allowed 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 163.942 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 9.0 pt-20 -93.4 117.92 30.67 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 118.094 -1.442 . . . . 0.0 110.852 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.479 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 12.0 t80 162.58 92.43 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 103.766 -2.679 . . . . 0.0 103.766 179.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -48.66 109.08 0.47 Allowed Glycine 0 N--CA 1.478 1.482 0 O-C-N 123.682 0.614 . . . . 0.0 113.714 -177.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -120.98 -80.77 0.63 Allowed 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 117.971 -1.492 . . . . 0.0 112.089 -175.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.451 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.8 t30 -144.99 156.4 43.93 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.891 -177.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.1 p -84.32 -1.51 55.5 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 124.228 1.011 . . . . 0.0 111.295 -177.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.7 20.85 4.64 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.266 -179.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 146.99 114.39 0.82 Allowed Glycine 0 N--CA 1.424 -2.133 0 C-N-CA 118.969 -1.586 . . . . 0.0 112.033 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.453 ' SG ' HG21 ' A' ' 118' ' ' VAL . 9.4 p -96.71 90.83 5.43 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.095 0.95 . . . . 0.0 112.698 -177.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.2 p -74.18 -49.23 24.49 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.075 -177.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.9 m -65.14 -23.67 67.19 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.458 ' HB2' ' ND1' ' A' ' 48' ' ' HIS . . . -76.74 -22.99 53.05 Favored 'General case' 0 N--CA 1.422 -1.864 0 C-N-CA 120.037 -0.665 . . . . 0.0 110.822 -178.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 30.62 -97.29 0.01 OUTLIER Glycine 0 N--CA 1.494 2.532 0 C-N-CA 124.881 1.229 . . . . 0.0 115.663 164.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -93.44 73.46 0.36 Allowed 'Trans proline' 0 N--CA 1.435 -1.968 0 C-N-CA 123.479 2.786 . . . . 0.0 109.932 174.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.507 ' CD2' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p-80 -36.52 137.94 0.26 Allowed 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 125.415 1.486 . . . . 0.0 114.329 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.485 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 15.7 p90 -125.28 88.17 2.83 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 170.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.576 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 16.8 m120 -106.45 89.49 4.08 Favored Pre-proline 0 CA--C 1.505 -0.781 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 5.8 Cg_exo -77.7 -12.94 16.45 Favored 'Trans proline' 0 N--CA 1.443 -1.444 0 C-N-CA 122.474 2.116 . . . . 0.0 114.842 -169.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.414 HD13 ' O ' ' A' ' 106' ' ' LEU . 13.1 mt -70.2 -25.13 63.27 Favored 'General case' 0 CA--C 1.465 -2.302 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.422 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.533 ' HA ' ' C ' ' A' ' 77' ' ' GLU . 18.0 t -93.7 -96.34 0.15 Allowed 'General case' 1 N--CA 1.377 -4.076 0 C-N-CA 114.997 -2.681 . . . . 0.0 107.272 175.922 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.465 ' HB3' ' HA ' ' A' ' 79' ' ' ARG 0.264 24.6 ttt85 -142.05 40.37 1.64 Allowed 'General case' 0 CA--C 1.492 -1.261 0 CA-C-N 119.055 0.843 . . . . 0.0 109.185 152.29 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.576 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 88.2 tttt 75.78 -33.39 0.22 Allowed 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -155.61 99.02 1.99 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -175.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.685 ' HA3' ' C ' ' A' ' 80' ' ' HIS . . . -164.56 -136.6 2.03 Favored Glycine 0 C--O 1.18 -3.234 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.752 163.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.434 ' HA2' HD21 ' A' ' 126' ' ' LEU . . . -75.98 -175.96 39.89 Favored Glycine 0 CA--C 1.547 2.061 0 CA-C-N 117.427 0.613 . . . . 0.0 114.607 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.48 ' HG3' ' O ' ' A' ' 44' ' ' GLY . 88.7 Cg_endo -102.49 0.37 0.42 Allowed 'Trans proline' 0 C--O 1.212 -0.788 0 C-N-CA 123.825 3.017 . . . . 0.0 113.633 -178.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.484 ' HG2' ' OE2' ' A' ' 100' ' ' GLU . 61.8 mttm -81.49 2.27 29.62 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -172.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -175.59 166.34 3.2 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -176.272 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.533 ' C ' ' HA ' ' A' ' 68' ' ' SER . 2.5 pm0 -122.52 84.68 2.3 Favored 'General case' 0 N--CA 1.418 -2.039 0 C-N-CA 120.161 -0.616 . . . . 0.0 111.111 171.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.451 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 0.1 OUTLIER 171.37 86.87 0.0 OUTLIER 'General case' 0 C--N 1.361 1.071 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.84 178.599 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.511 ' NH1' ' HB2' ' A' ' 80' ' ' HIS 0.289 0.0 OUTLIER 62.32 130.5 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 C-N-CA 126.481 1.912 . . . . 0.0 115.412 174.637 . . . . . . . . 4 4 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.685 ' C ' ' HA3' ' A' ' 72' ' ' GLY . 21.3 t-160 . . . . . 0 N--CA 1.488 1.459 0 CA-C-O 122.63 1.205 . . . . 0.0 107.971 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp . . . . . 0 CA--C 1.502 -0.897 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.686 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . -173.82 83.25 0.08 OUTLIER Glycine 0 N--CA 1.422 -2.282 0 C-N-CA 118.918 -1.61 . . . . 0.0 113.295 173.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -78.87 130.06 35.25 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 177.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.62 128.45 75.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.551 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 29.4 p -139.45 95.76 2.98 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -120.95 104.18 9.62 Favored 'General case' 0 N--CA 1.421 -1.895 0 C-N-CA 118.079 -1.448 . . . . 0.0 109.049 174.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.574 ' O ' ' HB ' ' A' ' 39' ' ' THR . 8.1 p-10 -132.29 -20.88 2.36 Favored 'General case' 0 CA--C 1.47 -2.131 0 CA-C-O 121.788 0.804 . . . . 0.0 109.842 -176.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -72.53 -56.94 4.59 Favored 'General case' 0 C--N 1.268 -2.966 0 CA-C-N 113.655 -1.612 . . . . 0.0 109.091 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -153.71 6.18 0.33 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.505 -170.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.12 55.3 3.13 Favored Glycine 0 N--CA 1.426 -1.987 0 C-N-CA 118.102 -1.999 . . . . 0.0 108.748 -168.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.1 m -148.84 110.09 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 104.45 -2.426 . . . . 0.0 104.45 -177.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.551 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.84 128.92 41.94 Favored 'General case' 0 C--N 1.263 -3.162 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.703 -174.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -81.92 107.84 14.96 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 171.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.557 HG13 ' H ' ' A' ' 33' ' ' GLY . 13.4 p -82.61 137.46 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.202 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.4 ' HB3' ' OE2' ' A' ' 100' ' ' GLU . 41.8 m -84.37 108.6 17.29 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.963 177.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.499 HG21 ' H ' ' A' ' 31' ' ' VAL . 28.8 mt -93.32 114.06 29.34 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.482 0 N-CA-C 106.112 -1.811 . . . . 0.0 106.112 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.484 ' OE2' ' HG2' ' A' ' 75' ' ' LYS . 1.0 OUTLIER -134.99 155.71 50.3 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 -179.738 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.434 ' HB2' ' HA ' ' A' ' 28' ' ' PRO . 7.4 p-10 -90.11 131.83 35.75 Favored 'General case' 0 C--N 1.295 -1.763 0 CA-C-O 121.721 0.772 . . . . 0.0 111.517 -178.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.507 ' H ' HG13 ' A' ' 29' ' ' VAL . 75.6 p -96.07 172.94 7.68 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 175.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.57 -54.36 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.86 174.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -130.44 -47.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.644 0 C-N-CA 120.189 -0.604 . . . . 0.0 111.94 -174.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.8 p -170.08 167.19 8.92 Favored 'General case' 0 CA--C 1.469 -2.17 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -169.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.414 ' O ' HD13 ' A' ' 67' ' ' LEU . 2.8 pp -68.84 164.28 22.33 Favored 'General case' 0 N--CA 1.391 -3.409 0 CA-C-N 113.67 -1.605 . . . . 0.0 106.687 176.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 50.0 m -86.28 88.25 7.58 Favored 'General case' 1 C--N 1.238 -4.268 0 CA-C-O 121.357 0.599 . . . . 0.0 111.681 -170.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.66 133.98 7.88 Favored Glycine 1 N--CA 1.394 -4.157 0 N-CA-C 106.957 -2.457 . . . . 0.0 106.957 167.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.414 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 23.9 t70 -122.32 -29.14 4.19 Favored 'General case' 0 C--N 1.264 -3.127 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.42 -31.82 69.17 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 174.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.463 ' OG ' HG22 ' A' ' 113' ' ' ILE . 28.5 t 173.71 -174.07 0.06 Allowed 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 168.143 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 31.4 mm -106.46 -4.98 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.98 0 N-CA-C 103.839 -2.652 . . . . 0.0 103.839 -179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.626 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 16.0 tt -104.03 157.56 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 103.409 -2.811 . . . . 0.0 103.409 163.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.8 41.57 28.16 Favored Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.536 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.806 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -135.1 129.37 33.84 Favored 'General case' 0 C--N 1.271 -2.812 0 C-N-CA 125.065 1.346 . . . . 0.0 109.068 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.886 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 11.2 p -114.86 141.45 47.9 Favored 'General case' 0 C--N 1.279 -2.468 0 CA-C-O 121.339 0.59 . . . . 0.0 112.272 177.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.528 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 2.6 pt? -88.97 105.93 18.09 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.453 HG21 ' SG ' ' A' ' 57' ' ' CYS . 17.3 t -92.93 100.39 11.2 Favored 'Isoleucine or valine' 1 C--O 1.319 4.718 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.354 169.081 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.5 HG21 ' O ' ' A' ' 45' ' ' PHE . 3.3 t -147.1 170.42 3.94 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.677 0 C-N-CA 128.879 2.872 . . . . 0.0 103.467 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -159.51 170.39 21.8 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 178.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.531 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -79.79 83.25 5.76 Favored 'General case' 0 CA--C 1.567 1.604 0 N-CA-C 105.624 -1.991 . . . . 0.0 105.624 169.288 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -172.17 174.19 4.07 Favored 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 104.694 -2.335 . . . . 0.0 104.694 -167.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.667 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -88.29 104.62 16.91 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -69.71 113.31 6.85 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 174.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -75.83 131.59 39.83 Favored 'General case' 0 N--CA 1.427 -1.593 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.918 -167.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.527 ' HA ' ' CE1' ' A' ' 45' ' ' PHE . 11.0 mt -76.1 -71.52 0.38 Allowed 'General case' 0 N--CA 1.404 -2.752 0 CA-C-N 113.617 -1.629 . . . . 0.0 113.614 -169.13 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -117.38 -7.11 12.63 Favored Glycine 0 CA--C 1.467 -2.943 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.447 -168.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.48 ' C ' ' HB ' ' A' ' 135' ' ' THR . 95.3 mttt -99.93 -42.57 6.72 Favored 'General case' 0 N--CA 1.412 -2.369 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.97 -63.0 2.85 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -171.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 153.63 -25.85 0.75 Allowed Glycine 0 C--N 1.299 -1.486 0 N-CA-C 108.101 -1.999 . . . . 0.0 108.101 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -163.54 172.88 13.77 Favored 'General case' 0 C--O 1.254 1.342 0 N-CA-C 103.376 -2.824 . . . . 0.0 103.376 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -59.57 -41.06 89.31 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-N 118.887 0.767 . . . . 0.0 112.068 -176.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.425 ' O ' ' HB3' ' A' ' 136' ' ' LYS . 35.4 tt0 -66.17 -36.98 84.52 Favored 'General case' 0 C--O 1.219 -0.532 0 CA-C-O 121.08 0.467 . . . . 0.0 110.181 177.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -68.29 -34.23 75.77 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.642 -176.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.48 ' HB ' ' C ' ' A' ' 128' ' ' LYS . 10.7 t -81.54 -6.75 59.28 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.547 1.165 . . . . 0.0 109.114 177.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.425 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 88.3 tttt -90.01 -24.43 21.22 Favored 'General case' 0 C--N 1.287 -2.117 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.257 175.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.3 m -83.36 -33.3 25.85 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.72 7.59 Favored Glycine 1 C--O 1.315 5.194 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 -171.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -35.14 106.04 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 131.271 3.828 . . . . 0.0 120.016 -166.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.402 ' HB1' ' CG1' ' A' ' 118' ' ' VAL . . . -153.05 172.38 16.96 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 102.498 -3.149 . . . . 0.0 102.498 164.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -52.32 110.01 1.06 Allowed Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 34.4 p -52.63 -32.11 40.14 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -171.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 15.9 ptt180 -120.25 -27.37 5.27 Favored 'General case' 0 C--N 1.26 -3.304 0 C-N-CA 118.472 -1.291 . . . . 0.0 108.776 174.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.73 -36.39 11.3 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 124.7 1.25 . . . . 0.0 112.798 -165.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -142.45 88.76 2.1 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.886 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 52.7 t -156.86 141.36 16.71 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.858 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -157.72 170.44 34.7 Favored Glycine 0 N--CA 1.4 -3.708 0 N-CA-C 107.214 -2.354 . . . . 0.0 107.214 177.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.71 ' HB ' ' NH1' ' A' ' 115' ' ' ARG . 27.7 m -68.84 124.26 24.15 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.017 0 CA-C-N 117.656 0.728 . . . . 0.0 111.054 178.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.806 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 0.0 OUTLIER -123.47 99.86 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.212 0.53 . . . . 0.0 111.245 179.331 . . . . . . . . 3 3 . 1 . 006 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.505 ' HA3' ' NE ' ' A' ' 115' ' ' ARG . . . 174.63 -167.47 39.75 Favored Glycine 0 CA--C 1.457 -3.586 0 C-N-CA 117.546 -2.264 . . . . 0.0 111.534 178.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 9.1 tt -68.75 105.67 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.266 1.935 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.45 140.28 49.53 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.104 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 . . . . . 0 C--N 1.297 -1.694 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.009 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.212 -0.918 0 N-CA-C 111.663 0.246 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 14.4 m -58.08 -26.41 62.53 Favored 'General case' 0 CA--C 1.571 1.776 0 N-CA-C 115.425 1.639 . . . . 0.0 115.425 -174.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -135.15 147.5 49.46 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.827 -1.171 . . . . 0.0 112.083 -172.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.551 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -139.81 154.42 47.35 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.64 172.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.412 ' HB ' ' HB1' ' A' ' 152' ' ' ALA . 39.7 t -129.69 131.03 67.02 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -121.49 132.37 54.68 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.651 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 10.9 m -127.96 109.04 18.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.729 0.776 . . . . 0.0 110.58 -178.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.47 ' O ' ' HG2' ' A' ' 15' ' ' GLN . 6.6 mp -103.47 128.49 50.64 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.664 -176.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -160.88 124.99 3.5 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 169.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.91 -173.14 22.66 Favored Glycine 0 N--CA 1.405 -3.382 0 N-CA-C 107.216 -2.354 . . . . 0.0 107.216 175.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -95.21 89.66 5.59 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 120.217 -0.593 . . . . 0.0 109.78 -178.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.59 -63.83 0.62 Allowed Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.776 178.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.493 ' HB3' ' HA ' ' A' ' 120' ' ' HIS . 31.9 Cg_exo -62.31 169.16 8.35 Favored 'Trans proline' 0 N--CA 1.432 -2.095 0 C-N-CA 123.072 2.515 . . . . 0.0 115.004 -174.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.496 HG13 ' HA3' ' A' ' 37' ' ' GLY . 16.8 m -69.86 158.01 6.31 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.038 0 CA-C-N 111.587 -2.552 . . . . 0.0 112.544 -175.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.47 ' HG2' ' O ' ' A' ' 8' ' ' LEU . 15.3 tm0? -112.52 140.56 47.17 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 104.667 -2.345 . . . . 0.0 104.667 177.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' O ' HD13 ' A' ' 8' ' ' LEU . . . -158.98 170.51 35.41 Favored Glycine 0 N--CA 1.414 -2.824 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.439 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 18.9 pt -132.46 129.05 58.87 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 176.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.418 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 43.7 mm -130.01 123.53 56.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -174.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.439 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 2.2 m-20 -112.41 126.74 55.61 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.551 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 29.7 p90 -126.78 148.34 49.93 Favored 'General case' 0 CA--C 1.495 -1.147 0 C-N-CA 118.24 -1.384 . . . . 0.0 109.912 176.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.516 ' HB3' ' O ' ' A' ' 2' ' ' THR . 1.5 pp20? -117.76 116.17 26.48 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.372 176.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -85.72 87.88 7.47 Favored 'General case' 0 N--CA 1.382 -3.854 0 CA-C-O 123.103 1.43 . . . . 0.0 108.769 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.469 ' H ' ' HB ' ' A' ' 104' ' ' ILE . 5.0 ttmp? -72.16 110.06 6.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 112.206 -2.27 . . . . 0.0 107.009 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -61.79 -24.29 66.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.03 0.443 . . . . 0.0 111.622 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 m -71.92 -19.3 61.94 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.524 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . 0.45 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 56.6 m-80 70.3 162.71 0.24 Allowed 'General case' 0 C--O 1.241 0.61 0 C-N-CA 125.194 1.398 . . . . 0.0 110.885 -175.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 138.47 -149.46 20.56 Favored Glycine 0 CA--C 1.48 -2.156 0 C-N-CA 117.762 -2.161 . . . . 0.0 114.18 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -63.26 125.69 16.25 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 123.357 2.704 . . . . 0.0 110.941 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.443 HG11 ' OD1' ' A' ' 101' ' ' ASP . 3.9 m -76.97 120.39 27.23 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.378 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -98.55 92.17 5.5 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.096 0.951 . . . . 0.0 108.506 172.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 71.5 t -133.36 146.0 32.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -175.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.5 p-90 -143.15 134.73 26.39 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.439 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -141.92 140.33 10.01 Favored Glycine 0 N--CA 1.419 -2.458 0 C-N-CA 119.796 -1.192 . . . . 0.0 112.14 178.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -116.63 151.82 35.48 Favored 'General case' 0 N--CA 1.394 -3.252 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 176.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.68 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 36.8 mm -132.24 134.06 59.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.695 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 60.6 pttt -139.0 119.96 14.42 Favored 'General case' 0 C--O 1.206 -1.207 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 175.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.535 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -169.97 174.97 44.16 Favored Glycine 0 CA--C 1.476 -2.354 0 C-N-CA 118.811 -1.662 . . . . 0.0 113.075 -171.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.3 tt -66.85 137.77 56.84 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.1 p -72.78 108.53 5.81 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 115.238 1.57 . . . . 0.0 115.238 -164.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.501 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.9 tt0 -177.78 121.79 0.11 Allowed 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 105.358 -2.09 . . . . 0.0 105.358 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.534 ' N ' ' HA ' ' A' ' 90' ' ' ASP . . . -155.82 138.67 6.14 Favored Glycine 0 CA--C 1.47 -2.774 0 C-N-CA 119.268 -1.444 . . . . 0.0 111.507 -177.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.432 HD22 ' HA ' ' A' ' 122' ' ' LYS . 3.6 mm? -126.65 -58.33 1.33 Allowed 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -170.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.52 169.3 24.61 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.583 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -130.29 113.34 1.43 Allowed Glycine 0 C--O 1.217 -0.917 0 C-N-CA 118.391 -1.861 . . . . 0.0 117.43 -170.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.597 ' O ' ' HB3' ' A' ' 124' ' ' ASP . 46.7 m-85 -168.67 108.86 0.5 Allowed 'General case' 0 C--O 1.188 -2.171 0 N-CA-C 102.752 -3.055 . . . . 0.0 102.752 170.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.418 ' HE1' ' O ' ' A' ' 122' ' ' LYS . 68.1 m-70 -149.95 85.57 1.42 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 120.881 1.673 . . . . 0.0 107.969 -175.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.403 HG12 ' N ' ' A' ' 48' ' ' HIS . 48.8 t -162.53 161.11 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 105.052 -2.203 . . . . 0.0 105.052 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.5 ' CG ' ' HA ' ' A' ' 60' ' ' ALA . 62.6 t-80 -153.46 148.41 26.62 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 168.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 0.4 OUTLIER -109.48 124.13 50.54 Favored 'General case' 0 C--N 1.257 -3.451 0 C-N-CA 124.196 0.998 . . . . 0.0 112.133 -177.764 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.415 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 11.8 t80 174.4 -50.98 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 124.864 1.266 . . . . 0.0 109.395 174.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.59 ' HA2' ' N ' ' A' ' 115' ' ' ARG . . . 95.04 109.8 2.32 Favored Glycine 0 CA--C 1.496 -1.123 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.305 -177.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -132.68 -73.09 0.51 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 117.707 -1.597 . . . . 0.0 112.878 -174.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.475 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 37.5 t-20 -161.95 152.18 17.02 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -179.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.7 m -71.73 -34.27 69.4 Favored 'General case' 0 C--O 1.208 -1.095 0 CA-C-O 121.135 0.493 . . . . 0.0 110.298 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.22 -12.72 27.63 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 120.75 -0.38 . . . . 0.0 111.956 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -154.24 111.26 0.48 Allowed Glycine 0 CA--C 1.468 -2.866 0 C-N-CA 119.077 -1.535 . . . . 0.0 110.046 -174.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.442 ' HB2' ' HB2' ' A' ' 60' ' ' ALA . 26.2 p -98.28 88.47 4.18 Favored 'General case' 0 N--CA 1.4 -2.949 0 CA-C-O 121.65 0.738 . . . . 0.0 110.851 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.0 m -79.26 -46.29 18.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.708 0.766 . . . . 0.0 110.14 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.5 m -63.71 -24.95 67.99 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.402 178.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.536 ' HB2' ' HB ' ' A' ' 116' ' ' THR . . . -75.49 -9.23 58.39 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 176.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.99 -160.49 0.78 Allowed Glycine 0 C--N 1.311 -0.854 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.97 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -74.37 54.08 3.23 Favored 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 122.74 2.293 . . . . 0.0 110.223 177.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -133.23 109.46 9.44 Favored 'General case' 0 N--CA 1.424 -1.751 0 N-CA-C 103.48 -2.785 . . . . 0.0 103.48 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.489 ' CD2' ' HB3' ' A' ' 69' ' ' ARG . 54.7 m-85 -123.77 162.06 23.93 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-O 122.06 0.934 . . . . 0.0 113.12 -174.218 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -104.56 143.3 26.41 Favored Pre-proline 0 N--CA 1.42 -1.956 0 N-CA-C 103.859 -2.645 . . . . 0.0 103.859 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -48.18 -55.31 4.16 Favored 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.98 2.453 . . . . 0.0 116.832 -168.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 95.2 mt -90.12 -4.97 57.0 Favored 'General case' 0 CA--C 1.478 -1.81 0 C-N-CA 119.142 -1.023 . . . . 0.0 108.885 -172.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.577 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 21.4 m -86.52 7.98 23.86 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.188 -1.369 . . . . 0.0 109.733 178.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.489 ' HB3' ' CD2' ' A' ' 64' ' ' PHE . 4.4 ppt_? -134.04 -30.15 1.23 Allowed 'General case' 0 N--CA 1.402 -2.832 0 CA-C-O 117.734 -1.127 . . . . 0.0 110.313 167.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.477 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 85.1 tttt 34.54 -86.04 0.0 OUTLIER 'General case' 0 C--N 1.389 2.286 0 C-N-CA 125.386 1.474 . . . . 0.0 110.968 -173.534 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.488 ' O ' ' HA2' ' A' ' 127' ' ' GLY . 55.0 t-80 -131.32 -38.75 1.18 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 172.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.0 119.58 3.05 Favored Glycine 0 N--CA 1.425 -2.059 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -170.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.3 144.11 11.51 Favored Glycine 0 N--CA 1.419 -2.454 0 C-N-CA 118.612 -1.756 . . . . 0.0 113.041 -174.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.453 ' O ' ' HB3' ' A' ' 101' ' ' ASP . 59.1 Cg_endo -74.84 -19.16 18.53 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.3 2.0 . . . . 0.0 112.99 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 101' ' ' ASP . 51.1 mtmt -120.62 -13.97 8.68 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -175.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -172.18 126.25 0.55 Allowed 'General case' 0 CA--C 1.493 -1.231 0 CA-C-N 119.593 1.088 . . . . 0.0 109.649 -173.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -138.31 171.16 14.79 Favored 'General case' 0 N--CA 1.416 -2.16 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.084 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -100.13 -74.82 0.59 Allowed 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.577 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.1 OUTLIER -130.2 26.3 5.16 Favored 'General case' 0 CA--C 1.47 -2.107 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -170.579 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 7.6 t60 . . . . . 0 N--CA 1.396 -3.155 0 CA-C-N 111.96 -2.382 . . . . 0.0 106.102 177.042 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.506 -0.75 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 . . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.42 153.96 35.07 Favored Glycine 0 CA--C 1.5 -0.851 0 O-C-N 124.194 0.933 . . . . 0.0 111.287 178.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -76.66 146.1 38.35 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.992 -171.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.583 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 17.1 m -136.9 146.26 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.558 ' HA ' ' OE1' ' A' ' 121' ' ' GLU . 7.4 t -141.62 109.57 5.79 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 174.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.461 ' HB2' ' HA2' ' A' ' 93' ' ' GLY . . . -118.07 105.78 12.21 Favored 'General case' 0 CA--C 1.47 -2.113 0 N-CA-C 104.814 -2.291 . . . . 0.0 104.814 174.157 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.534 ' HA ' ' N ' ' A' ' 41' ' ' GLY . 39.2 p30 -112.85 -77.52 0.58 Allowed 'General case' 0 C--O 1.172 -2.983 0 N-CA-C 114.793 1.405 . . . . 0.0 114.793 -164.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.425 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 87.8 tttt -83.71 -14.72 51.0 Favored 'General case' 1 C--N 1.212 -5.377 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -178.856 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -144.54 134.66 24.11 Favored 'General case' 0 N--CA 1.418 -2.037 0 N-CA-C 106.198 -1.778 . . . . 0.0 106.198 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.695 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.54 71.8 2.94 Favored Glycine 0 N--CA 1.417 -2.616 0 CA-C-O 119.279 -0.734 . . . . 0.0 111.549 -175.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.68 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 59.0 t -153.61 105.54 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.417 ' H ' ' HB ' ' A' ' 35' ' ' ILE . . . -113.11 144.48 42.57 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.463 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.33 137.27 38.99 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.987 -1.856 . . . . 0.0 105.987 175.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.74 140.32 20.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.118 0.485 . . . . 0.0 110.164 -179.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.6 m -122.47 101.58 7.57 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.494 HD11 ' H ' ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.42 118.74 54.66 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.311 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -177.415 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -148.8 97.49 2.72 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.011 -2.218 . . . . 0.0 105.011 166.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.537 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 1.1 p30 -168.02 168.19 12.11 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.339 -169.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.6 m -99.95 80.0 2.26 Favored 'General case' 0 N--CA 1.42 -1.94 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.956 168.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.556 ' C ' ' H ' ' A' ' 105' ' ' SER . 49.9 t -101.18 -11.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 123.859 0.864 . . . . 0.0 109.442 173.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.469 ' HB ' ' H ' ' A' ' 23' ' ' LYS . 0.2 OUTLIER -63.82 21.32 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.889 0 C-N-CA 124.777 1.231 . . . . 0.0 112.641 176.957 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.556 ' H ' ' C ' ' A' ' 103' ' ' VAL . 16.0 m -68.74 130.22 42.19 Favored 'General case' 0 N--CA 1.4 -2.944 0 C-N-CA 125.271 1.428 . . . . 0.0 110.148 179.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.03 173.11 3.21 Favored 'General case' 0 N--CA 1.387 -3.583 0 CA-C-N 112.953 -1.931 . . . . 0.0 107.004 172.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.5 p -64.93 116.18 6.12 Favored 'General case' 2 N--CA 1.363 -4.787 0 CA-C-O 123.58 1.657 . . . . 0.0 111.592 -165.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.57 -142.32 12.82 Favored Glycine 2 CA--C 1.425 -5.546 0 CA-C-N 110.363 -3.108 . . . . 0.0 105.343 174.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 40.11 -151.47 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 175.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -89.55 -23.81 21.91 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.158 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -131.51 -153.31 0.55 Allowed 'General case' 0 N--CA 1.41 -2.465 0 CA-C-O 122.009 0.909 . . . . 0.0 110.348 -175.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 59.0 mt -126.51 -38.2 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 N-CA-C 104.28 -2.489 . . . . 0.0 104.28 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.9 pt -91.08 99.05 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.834 0 CA-C-N 113.155 -1.839 . . . . 0.0 107.055 173.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -97.68 63.7 0.92 Allowed Glycine 2 N--CA 1.375 -5.392 0 N-CA-C 105.023 -3.231 . . . . 0.0 105.023 -175.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.59 ' N ' ' HA2' ' A' ' 51' ' ' GLY . 31.7 mtp180 -68.24 81.8 0.24 Allowed 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 -176.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.536 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 0.7 OUTLIER -163.3 97.12 0.89 Allowed 'General case' 1 N--CA 1.367 -4.592 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 -179.166 . . . . . . . . 4 4 . 1 . 007 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 16.2 mt -103.61 106.49 17.01 Favored 'General case' 0 C--N 1.251 -3.696 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.963 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.2 m -92.2 98.05 7.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 C-N-CA 117.394 -1.722 . . . . 0.0 109.384 169.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.2 t -135.51 136.21 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 122.724 1.249 . . . . 0.0 112.587 -174.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.493 ' HA ' ' HB3' ' A' ' 13' ' ' PRO . 0.4 OUTLIER -170.77 134.71 1.05 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 168.053 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.558 ' OE1' ' HA ' ' A' ' 88' ' ' THR . 1.9 mm-40 -69.63 99.74 1.35 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 122.153 0.978 . . . . 0.0 110.632 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.432 ' HA ' HD22 ' A' ' 42' ' ' LEU . 68.0 mttm -170.73 170.4 6.62 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 -170.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.63 104.13 3.24 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.597 ' HB3' ' O ' ' A' ' 45' ' ' PHE . 7.2 t70 -107.47 6.69 28.39 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -42.48 105.91 0.05 Allowed 'General case' 0 C--O 1.245 0.832 0 C-N-CA 126.882 2.073 . . . . 0.0 112.61 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -71.07 -39.93 71.92 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.574 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 71' ' ' HIS . . . -89.42 24.21 15.25 Favored Glycine 0 CA--C 1.482 -2.023 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.562 -177.208 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -136.59 -47.32 0.62 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 65.25 -78.34 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.777 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.363 -174.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 156.8 -38.05 0.57 Allowed Glycine 0 N--CA 1.417 -2.571 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.652 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 59.4 t30 -152.66 -178.91 7.16 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -54.02 -34.46 60.01 Favored 'General case' 0 C--N 1.368 1.384 0 N-CA-C 114.169 1.174 . . . . 0.0 114.169 -177.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.652 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -85.29 -38.14 19.2 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.305 0.574 . . . . 0.0 111.57 -174.568 . . . . . . . . 3 3 . 1 . 007 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.4 p -76.77 -20.78 56.06 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -81.54 -7.75 59.63 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.878 0.847 . . . . 0.0 109.642 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -85.81 -49.18 8.11 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 5.0 p -68.1 -37.42 81.15 Favored 'General case' 0 N--CA 1.417 -2.101 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.014 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.73 94.81 0.06 OUTLIER Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -32.54 123.62 0.34 Allowed 'General case' 1 C--O 1.336 5.619 0 CA-C-O 123.609 1.671 . . . . 0.0 114.049 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -140.74 120.66 13.58 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.85 -176.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -97.33 72.66 0.69 Allowed Glycine 0 C--O 1.214 -1.122 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.415 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 5.2 p -88.83 5.99 41.11 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -172.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 57.0 ttt-85 -118.26 -47.92 2.54 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.74 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.413 ' HG ' ' HD3' ' A' ' 13' ' ' PRO . 11.9 tp -60.34 -38.95 85.39 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 114.957 -1.02 . . . . 0.0 113.59 -167.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 129.96 7.13 Favored 'General case' 0 CA--C 1.481 -1.675 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 81.4 m -138.25 163.21 32.34 Favored 'General case' 0 C--N 1.291 -1.977 0 O-C-N 124.421 1.076 . . . . 0.0 108.856 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.651 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.7 170.23 43.34 Favored Glycine 0 N--CA 1.408 -3.188 0 O-C-N 123.887 0.742 . . . . 0.0 111.489 175.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.484 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 69.5 t -69.49 117.73 12.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 C-N-CA 124.148 0.979 . . . . 0.0 110.549 168.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.473 ' H ' ' HA ' ' A' ' 115' ' ' ARG . 15.7 tt -122.65 108.0 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 CA-C-O 122.229 1.014 . . . . 0.0 108.729 166.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.49 46.23 Favored Glycine 1 CA--C 1.442 -4.479 0 N-CA-C 108.262 -1.935 . . . . 0.0 108.262 178.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 8.7 tt -69.23 103.91 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 177.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HB1' ' HB ' ' A' ' 5' ' ' VAL . . . -110.27 97.12 6.66 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.386 -1.326 . . . . 0.0 110.936 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.324 -0.536 0 O-C-N 125.942 2.026 . . . . 0.0 114.489 171.157 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.811 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.647 ' O ' ' HA ' ' A' ' 21' ' ' GLU . 28.5 p -109.6 -65.24 1.17 Allowed 'General case' 0 C--O 1.161 -3.585 0 CA-C-O 119.147 -0.454 . . . . 0.0 111.569 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.2 ptpp? -135.49 171.03 15.02 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.894 0.378 . . . . 0.0 110.684 -168.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.734 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -137.19 166.82 22.83 Favored 'General case' 0 N--CA 1.419 -2.021 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -177.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.2 m -128.89 168.39 22.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 178.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.433 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -132.66 137.97 47.16 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.469 -173.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.7 t -134.28 108.55 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.7 mt -96.71 150.17 20.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -178.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -149.15 122.79 9.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.93 24.66 Favored Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.134 -1.507 . . . . 0.0 113.012 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . 0.419 ' O ' ' HD3' ' A' ' 13' ' ' PRO . 46.3 m-20 -66.24 -50.5 63.56 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 175.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.91 96.9 1.7 Allowed Glycine 0 N--CA 1.432 -1.594 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 11' ' ' ASP . 32.2 Cg_exo -57.08 127.41 25.64 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.607 2.204 . . . . 0.0 113.563 -173.329 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 11.4 m -120.58 113.02 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.804 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.597 175.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 mp0 -108.5 119.53 39.79 Favored 'General case' 0 C--N 1.294 -1.805 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.112 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.72 170.13 42.9 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 176.153 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.413 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 24.8 pt -129.4 125.4 61.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.433 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.7 mp -123.33 128.4 74.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -178.545 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.734 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 18.5 m120 -100.05 134.89 42.31 Favored 'General case' 0 CA--C 1.507 -0.701 0 CA-C-O 119.306 -0.378 . . . . 0.0 110.662 -177.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -127.75 119.6 26.11 Favored 'General case' 0 CA--C 1.503 -0.852 0 C-N-CA 118.613 -1.235 . . . . 0.0 113.585 175.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.647 ' HA ' ' O ' ' A' ' 2' ' ' THR . 58.3 mt-10 -90.22 143.9 26.35 Favored 'General case' 0 N--CA 1.425 -1.719 0 CA-C-N 114.372 -1.285 . . . . 0.0 112.734 177.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.502 ' O ' ' HG3' ' A' ' 22' ' ' GLN . 3.9 pt20 -103.11 124.9 49.43 Favored 'General case' 1 N--CA 1.375 -4.176 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 163.596 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -111.45 83.59 1.8 Allowed 'General case' 0 C--N 1.273 -2.733 0 C-N-CA 119.264 -0.974 . . . . 0.0 108.578 169.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -69.47 -27.95 65.66 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.102 -1.408 . . . . 0.0 108.736 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -71.21 -8.65 54.99 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.36 -1.291 . . . . 0.0 110.087 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.2 t30 75.88 120.44 0.05 OUTLIER 'General case' 0 C--N 1.35 0.626 0 C-N-CA 126.323 1.849 . . . . 0.0 111.195 -177.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.69 165.55 29.88 Favored Glycine 0 N--CA 1.408 -3.183 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.28 135.53 40.27 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.12 1.88 . . . . 0.0 110.692 178.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.436 HG21 ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -73.6 135.36 27.75 Favored 'Isoleucine or valine' 0 C--O 1.268 2.033 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.445 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -101.75 124.16 46.93 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 173.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.404 ' O ' HG21 ' A' ' 99' ' ' ILE . 16.5 m -137.99 152.82 26.55 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -172.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.6 t-105 -156.56 132.49 9.69 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.466 ' C ' HG11 ' A' ' 97' ' ' VAL . . . -170.63 135.84 3.69 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.545 -2.264 . . . . 0.0 112.61 169.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.442 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 5.4 p -117.8 137.09 52.98 Favored 'General case' 0 N--CA 1.395 -3.18 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 47.6 pt -131.87 146.27 33.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.052 -1.059 . . . . 0.0 110.093 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -119.23 129.61 55.03 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 176.225 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.52 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -135.15 174.3 21.24 Favored Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -173.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.81 173.53 5.19 Favored 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 123.73 0.812 . . . . 0.0 110.81 178.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.493 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 9.8 t -66.37 110.63 3.16 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-O 121.627 0.727 . . . . 0.0 111.657 -172.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . 0.267 4.6 mm-40 -165.61 177.34 7.41 Favored 'General case' 0 N--CA 1.398 -3.071 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.251 -176.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.43 -146.49 0.01 OUTLIER Glycine 0 N--CA 1.403 -3.501 0 CA-C-N 112.021 -2.354 . . . . 0.0 115.417 -177.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.535 ' CB ' ' HA ' ' A' ' 88' ' ' THR . 2.0 pt? -173.06 100.14 0.13 Allowed 'General case' 1 N--CA 1.372 -4.326 0 O-C-N 121.592 -0.946 . . . . 0.0 109.343 -161.214 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.444 ' HB3' ' HA ' ' A' ' 123' ' ' ALA . 0.4 OUTLIER 169.85 171.33 0.05 Allowed 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 103.963 -2.606 . . . . 0.0 103.963 177.43 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.491 ' HA2' ' N ' ' A' ' 125' ' ' ASP . . . 102.65 64.72 0.73 Allowed Glycine 0 C--N 1.268 -3.197 0 N-CA-C 116.248 1.259 . . . . 0.0 116.248 171.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 84' ' ' LEU . 12.8 t80 -76.72 134.85 39.09 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 117.336 -1.746 . . . . 0.0 110.07 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.46 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . 1.4 p-80 -85.91 100.61 12.22 Favored 'General case' 0 C--N 1.263 -3.175 0 CA-C-N 112.848 -1.978 . . . . 0.0 115.086 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.401 HG12 ' OE1' ' A' ' 49' ' ' GLU . 31.2 t -129.58 89.79 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.497 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 171.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.718 ' ND1' ' HB1' ' A' ' 60' ' ' ALA . 1.7 t60 -107.27 107.29 18.15 Favored 'General case' 0 C--O 1.184 -2.393 0 N-CA-C 113.323 0.861 . . . . 0.0 113.323 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' HG12 ' A' ' 47' ' ' VAL . 3.6 mp0 -90.07 136.21 33.18 Favored 'General case' 0 C--N 1.267 -2.989 0 O-C-N 120.687 -1.258 . . . . 0.0 112.665 175.202 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 t80 70.67 93.59 0.08 Allowed 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 125.968 1.707 . . . . 0.0 111.359 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.29 -91.14 1.15 Allowed Glycine 0 CA--C 1.482 -2.006 0 C-N-CA 119.066 -1.54 . . . . 0.0 113.543 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.2 t70 76.89 -25.87 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 126.996 2.118 . . . . 0.0 112.583 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 2.6 m-20 -90.35 98.84 12.01 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.435 ' HA ' HG12 ' A' ' 148' ' ' VAL . 11.4 t -56.55 -32.07 64.8 Favored 'General case' 0 C--O 1.199 -1.561 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -173.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.74 13.07 33.82 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.606 -0.683 . . . . 0.0 110.808 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -155.75 111.46 0.49 Allowed Glycine 0 N--CA 1.425 -2.095 0 C-N-CA 117.849 -2.119 . . . . 0.0 113.667 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.437 ' O ' ' HB3' ' A' ' 142' ' ' SER . 69.5 m -94.57 85.14 4.43 Favored 'General case' 0 N--CA 1.392 -3.36 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 172.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.9 m -82.31 -48.36 11.28 Favored 'General case' 0 N--CA 1.418 -2.061 0 CA-C-N 114.794 -1.093 . . . . 0.0 109.156 179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.6 p -71.57 -54.91 8.94 Favored 'General case' 0 N--CA 1.407 -2.624 0 CA-C-N 113.361 -1.745 . . . . 0.0 113.792 -172.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.718 ' HB1' ' ND1' ' A' ' 48' ' ' HIS 0.325 . . -85.81 -2.34 58.13 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 179.657 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 63' ' ' HIS . . . -43.5 -139.31 0.0 OUTLIER Glycine 0 CA--C 1.57 3.509 0 C-N-CA 124.186 0.898 . . . . 0.0 113.993 171.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -60.1 5.32 0.13 Allowed 'Trans proline' 0 CA--C 1.574 2.494 0 C-N-CA 122.706 2.271 . . . . 0.0 114.879 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.404 ' H ' ' C ' ' A' ' 61' ' ' GLY . 16.0 m170 -116.58 110.8 19.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 123.467 0.707 . . . . 0.0 109.838 178.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -74.48 152.51 39.4 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -115.77 144.35 32.45 Favored Pre-proline 0 C--N 1.309 -1.162 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.74 177.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -72.22 -13.11 28.23 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.239 1.959 . . . . 0.0 111.747 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.514 ' CB ' ' HB2' ' A' ' 109' ' ' ASP . 2.6 mm? -80.96 -9.47 59.83 Favored 'General case' 0 CA--C 1.484 -1.568 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -78.95 66.03 4.3 Favored 'General case' 0 N--CA 1.405 -2.706 0 CA-C-O 123.538 1.637 . . . . 0.0 108.719 172.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.521 ' CB ' ' HA ' ' A' ' 78' ' ' GLU . 12.5 ptp180 -117.49 23.27 11.88 Favored 'General case' 0 N--CA 1.397 -3.104 0 CA-C-N 112.204 -2.271 . . . . 0.0 105.149 175.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.9 mmmt -78.91 18.63 0.59 Allowed 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 112.363 -2.199 . . . . 0.0 111.005 176.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.492 ' H ' ' C ' ' A' ' 69' ' ' ARG . 33.6 t-80 75.3 87.59 0.09 Allowed 'General case' 0 N--CA 1.423 -1.805 0 O-C-N 125.135 1.522 . . . . 0.0 112.018 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.75 -98.4 0.17 Allowed Glycine 1 N--CA 1.385 -4.738 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 169.492 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.442 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -50.33 158.0 1.88 Allowed Glycine 0 N--CA 1.429 -1.827 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 172.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -62.14 0.09 1.47 Allowed 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 124.678 3.585 . . . . 0.0 114.454 -172.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.442 ' H ' ' C ' ' A' ' 73' ' ' GLY . 64.0 pttt -120.39 13.67 11.89 Favored 'General case' 0 C--N 1.289 -2.049 0 C-N-CA 123.047 0.539 . . . . 0.0 110.127 -175.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.466 ' HA ' ' HA ' ' A' ' 71' ' ' HIS . 3.0 m-20 71.98 76.38 0.16 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.502 177.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -78.97 87.19 4.79 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.723 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.521 ' HA ' ' CB ' ' A' ' 69' ' ' ARG . 11.6 pt-20 -57.56 26.34 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 128.704 2.801 . . . . 0.0 115.942 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -160.16 -0.56 0.07 Allowed 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.385 -174.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.8 m170 . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.563 -0.711 . . . . 0.0 111.451 -173.703 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.602 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 7.5 tt . . . . . 0 C--O 1.252 1.186 0 N-CA-C 102.597 -3.112 . . . . 0.0 102.597 . . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.512 ' N ' HD22 ' A' ' 84' ' ' LEU . . . -39.74 156.43 0.03 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 119.106 0.867 . . . . 0.0 111.486 173.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.48 160.52 19.68 Favored 'General case' 0 C--N 1.282 -2.351 0 O-C-N 122.377 -0.484 . . . . 0.0 112.105 -158.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 77.5 t -108.39 163.42 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.912 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -174.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.535 ' HA ' ' CB ' ' A' ' 42' ' ' LEU . 31.5 m -140.33 130.51 25.0 Favored 'General case' 0 C--N 1.261 -3.28 0 C-N-CA 124.437 1.095 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.523 ' CB ' ' HB3' ' A' ' 121' ' ' GLU . . . -126.12 155.16 42.08 Favored 'General case' 0 C--N 1.254 -3.583 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 174.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.41 ' C ' ' HA ' ' A' ' 39' ' ' THR . 23.9 t70 -158.36 174.96 14.34 Favored 'General case' 1 C--N 1.239 -4.232 0 N-CA-C 104.126 -2.546 . . . . 0.0 104.126 178.462 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.493 ' N ' ' HA ' ' A' ' 39' ' ' THR . 59.8 pttt -47.27 -35.85 8.32 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 176.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -90.28 -38.64 13.26 Favored 'General case' 0 CA--C 1.486 -1.503 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 176.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.52 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 89.54 112.85 1.38 Allowed Glycine 0 N--CA 1.404 -3.479 0 CA-C-N 114.675 -1.148 . . . . 0.0 112.308 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.452 ' O ' ' HB ' ' A' ' 88' ' ' THR . 6.7 p -157.71 103.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.417 -2.101 0 CA-C-O 121.953 0.883 . . . . 0.0 109.876 174.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.23 129.0 41.02 Favored 'General case' 0 N--CA 1.414 -2.228 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.713 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -69.57 143.38 53.37 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 114.378 -1.283 . . . . 0.0 109.406 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.466 HG11 ' C ' ' A' ' 33' ' ' GLY . 34.4 m -79.57 103.37 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.908 0 CA-C-O 123.855 1.788 . . . . 0.0 107.813 -177.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -86.77 107.39 18.24 Favored 'General case' 0 N--CA 1.401 -2.9 0 CA-C-N 113.059 -1.882 . . . . 0.0 111.083 -174.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.404 HG21 ' O ' ' A' ' 31' ' ' VAL . 37.5 pt -95.66 124.83 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.513 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -143.64 126.31 16.03 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -81.09 135.62 35.83 Favored 'General case' 0 C--O 1.276 2.45 0 CA-C-O 122.433 1.111 . . . . 0.0 112.601 -178.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.423 ' OG ' ' HB ' ' A' ' 29' ' ' VAL . 92.5 p -102.92 172.2 6.96 Favored 'General case' 0 N--CA 1.413 -2.3 0 CA-C-N 112.846 -1.979 . . . . 0.0 110.608 177.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.431 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 7.1 p -115.88 -53.1 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.329 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 163.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 12.8 pt -98.93 23.67 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.045 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -170.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.8 t -80.34 89.88 5.56 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 123.061 1.41 . . . . 0.0 108.721 169.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.461 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 3.0 pp -126.72 170.39 12.18 Favored 'General case' 2 N--CA 1.346 -5.643 1 N-CA-C 99.272 -4.344 . . . . 0.0 99.272 174.558 . . . . . . . . 4 3 . 1 . 008 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.1 m -74.13 93.37 2.28 Favored 'General case' 1 C--N 1.213 -5.327 0 C-N-CA 118.727 -1.189 . . . . 0.0 111.978 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.81 135.43 12.43 Favored Glycine 0 CA--C 1.456 -3.651 0 N-CA-C 106.308 -2.717 . . . . 0.0 106.308 175.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.514 ' HB2' ' CB ' ' A' ' 67' ' ' LEU . 6.1 t70 54.09 -153.78 0.28 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -171.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.534 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 62.6 m-70 -90.37 37.11 0.89 Allowed 'General case' 0 C--N 1.276 -2.602 0 C-N-CA 124.78 1.232 . . . . 0.0 109.777 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 115' ' ' ARG . 16.6 p -59.41 -27.14 65.74 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.667 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 46.1 pt -104.6 -32.94 2.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 C-N-CA 118.2 -1.4 . . . . 0.0 110.62 176.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.534 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 14.0 tt -104.09 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 120.135 -0.626 . . . . 0.0 112.684 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.76 17.89 53.02 Favored Glycine 0 N--CA 1.44 -1.065 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.895 175.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.543 ' HG3' ' O ' ' A' ' 48' ' ' HIS . 23.7 ttp180 -73.4 101.73 3.56 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 122.268 -0.548 . . . . 0.0 111.233 178.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.504 ' CG2' ' HB3' ' A' ' 146' ' ' CYS . 4.2 m -70.9 110.85 5.88 Favored 'General case' 0 C--O 1.181 -2.519 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 176.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 13.2 tp -70.03 123.87 22.64 Favored 'General case' 0 C--N 1.275 -2.673 0 C-N-CA 122.731 0.412 . . . . 0.0 111.346 -172.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.465 HG11 ' HD1' ' A' ' 48' ' ' HIS . 11.4 m -91.88 101.03 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 178.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 10.3 p -140.52 168.66 16.61 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 176.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 124' ' ' ASP . 0.3 OUTLIER -171.2 164.23 7.25 Favored 'General case' 0 CA--C 1.487 -1.456 0 N-CA-C 104.214 -2.513 . . . . 0.0 104.214 173.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.585 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 2.2 mp0 -86.9 84.17 7.39 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.585 ' HG2' ' O ' ' A' ' 121' ' ' GLU . 2.2 mmpt? -176.0 171.53 2.57 Favored 'General case' 0 CA--C 1.476 -1.903 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 -175.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.444 ' HA ' ' HB3' ' A' ' 43' ' ' HIS . . . -62.42 122.41 15.65 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 170.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.647 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 19.6 t70 -128.74 -12.83 4.79 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.943 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.491 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 0.6 OUTLIER -71.56 137.28 47.92 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.268 -174.881 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -79.2 -68.19 0.68 Allowed 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.334 -178.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.04 9.83 8.61 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 119.982 -1.104 . . . . 0.0 114.962 -176.765 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 32.2 tptt -137.43 15.29 2.97 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.8 42.94 1.85 Allowed Glycine 0 N--CA 1.473 1.135 0 N-CA-C 118.736 2.254 . . . . 0.0 118.736 -166.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 74.18 -91.38 0.72 Allowed Glycine 0 C--N 1.3 -1.431 0 N-CA-C 116.735 1.454 . . . . 0.0 116.735 171.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -100.33 158.32 15.97 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 118.595 -0.717 . . . . 0.0 110.484 -169.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -47.37 -42.48 21.77 Favored 'General case' 0 C--N 1.363 1.172 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 -178.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -79.87 -43.66 21.87 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.91 0.386 . . . . 0.0 110.958 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.7 t -70.64 -20.87 62.68 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.369 0.668 . . . . 0.0 111.878 -173.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -82.32 -18.23 42.97 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.031 0.443 . . . . 0.0 110.356 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 44.5 mtpt -101.77 -28.22 12.58 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.54 -1.264 . . . . 0.0 110.071 -178.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.9 p -74.45 -47.85 31.05 Favored 'General case' 0 N--CA 1.408 -2.527 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 173.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.16 94.06 0.13 Allowed Glycine 0 N--CA 1.417 -2.614 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.647 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 46.2 t-20 -55.81 106.03 0.23 Allowed 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 176.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.6 56.17 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -172.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.47 101.21 2.74 Favored Glycine 0 N--CA 1.428 -1.868 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.437 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 15.2 m -89.52 -7.1 55.65 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -171.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -145.19 -11.39 0.55 Allowed 'General case' 0 C--N 1.247 -3.859 0 C-N-CA 118.203 -1.399 . . . . 0.0 110.297 172.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -54.89 -42.96 72.74 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -175.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.479 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -149.82 89.88 1.65 Allowed 'General case' 0 N--CA 1.397 -3.122 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.504 ' HB3' ' CG2' ' A' ' 116' ' ' THR . 32.3 m -126.72 150.71 48.9 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 113.938 -1.483 . . . . 0.0 107.897 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.95 139.64 5.55 Favored Glycine 0 C--N 1.291 -1.957 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 178.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.435 HG12 ' HA ' ' A' ' 54' ' ' THR . 17.2 m -73.59 110.4 7.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 118.69 1.245 . . . . 0.0 111.705 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.431 ' CG2' ' HB2' ' A' ' 117' ' ' LEU . 1.4 pp -86.67 145.75 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.227 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.667 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -150.14 142.61 9.83 Favored Glycine 2 N--CA 1.382 -4.96 0 C-N-CA 117.619 -2.229 . . . . 0.0 112.395 -171.409 . . . . . . . . 3 3 . 1 . 008 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.535 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 3.4 tt -53.16 103.79 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 CA-C-O 122.088 0.947 . . . . 0.0 109.841 167.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.1 154.73 38.6 Favored 'General case' 0 N--CA 1.41 -2.436 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 174.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 . . . . . 0 C--N 1.273 -2.72 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 177.608 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.05 0 N-CA-C 111.379 0.14 . . . . 0.0 111.379 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.58 ' C ' ' HG3' ' A' ' 21' ' ' GLU . 30.1 m -119.33 -54.06 2.21 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.492 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 22.6 pttp -145.5 152.57 39.97 Favored 'General case' 0 N--CA 1.417 -2.122 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.632 -169.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.558 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.19 161.03 38.84 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 65.7 t -131.25 122.52 51.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.815 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -115.33 127.82 55.68 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.587 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.5 m -113.29 144.75 20.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 O-C-N 123.433 0.458 . . . . 0.0 110.554 -178.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 95.4 mt -127.09 135.05 50.22 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.641 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -141.04 125.86 18.06 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -154.31 178.45 31.13 Favored Glycine 0 N--CA 1.432 -1.597 0 C-N-CA 118.931 -1.604 . . . . 0.0 113.338 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -73.0 -40.4 65.23 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.56 95.57 1.45 Allowed Glycine 0 N--CA 1.434 -1.443 0 N-CA-C 106.159 -2.776 . . . . 0.0 106.159 170.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.75 127.56 14.77 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.895 1.73 . . . . 0.0 115.2 -169.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 14.0 m -123.78 114.98 43.75 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.186 0 N-CA-C 104.751 -2.314 . . . . 0.0 104.751 172.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.24 118.29 32.87 Favored 'General case' 0 C--N 1.279 -2.485 0 C-N-CA 118.309 -1.356 . . . . 0.0 109.542 -173.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.58 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.72 171.56 44.15 Favored Glycine 0 N--CA 1.412 -2.965 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.887 178.405 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.2 pt -133.46 124.58 48.79 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 mp -114.11 140.04 36.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.485 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 35.9 m-80 -99.24 150.41 22.11 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.558 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 98.2 m-85 -149.39 117.29 6.29 Favored 'General case' 0 CA--C 1.491 -1.3 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 175.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.58 ' HG3' ' C ' ' A' ' 2' ' ' THR . 4.6 mm-40 -134.39 144.12 48.01 Favored 'General case' 0 CA--C 1.477 -1.839 0 C-N-CA 118.627 -1.229 . . . . 0.0 112.578 173.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.492 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 25.3 tp60 -127.71 152.36 47.82 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.408 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -106.56 104.73 14.49 Favored 'General case' 0 C--N 1.26 -3.306 0 N-CA-C 100.511 -3.885 . . . . 0.0 100.511 169.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.318 9.9 pt-20 -63.27 -9.25 10.85 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -168.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.5 p -76.45 -61.09 2.07 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 170.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 175.57 136.55 0.05 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 126.447 1.899 . . . . 0.0 106.688 174.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.87 95.37 0.12 Allowed Glycine 1 CA--C 1.444 -4.36 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . 0.57 ' HB3' ' N ' ' A' ' 101' ' ' ASP . 38.4 Cg_exo -62.75 123.44 12.32 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 C-N-CA 121.686 1.591 . . . . 0.0 109.179 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.558 ' HB ' ' O ' ' A' ' 21' ' ' GLU . 77.8 t -88.75 148.19 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.98 0 N-CA-C 103.892 -2.632 . . . . 0.0 103.892 171.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.406 ' HD2' ' N ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -99.62 109.33 21.83 Favored 'General case' 1 C--N 1.242 -4.072 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -167.16 . . . . . . . . 4 4 . 1 . 009 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 16.1 m -124.53 152.44 30.52 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.089 -169.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 49.3 p90 -134.64 154.04 51.7 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-N 114.97 -1.013 . . . . 0.0 109.762 -175.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.466 ' O ' ' HA ' ' A' ' 96' ' ' ASP . . . -159.46 140.16 6.66 Favored Glycine 0 N--CA 1.415 -2.702 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 176.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.58 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 11.7 p -116.67 114.83 24.6 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 124.001 0.92 . . . . 0.0 110.987 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.408 ' CG1' ' HB2' ' A' ' 95' ' ' ALA . 36.8 pt -128.78 123.18 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 119.69 1.132 . . . . 0.0 110.81 175.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.615 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 21.3 ptmt -92.89 142.34 27.42 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -144.89 175.79 24.32 Favored Glycine 0 N--CA 1.421 -2.356 0 O-C-N 123.574 0.547 . . . . 0.0 112.869 -168.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.72 171.25 8.02 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.447 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 1.7 m -73.07 103.48 3.84 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.644 -1.222 . . . . 0.0 114.071 -171.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.529 ' OE2' ' HD3' ' A' ' 122' ' ' LYS . 25.5 tt0 -177.1 156.4 1.27 Allowed 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 157.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.66 -159.16 34.76 Favored Glycine 0 C--N 1.272 -2.977 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 170.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.56 ' HB3' ' H ' ' A' ' 122' ' ' LYS . 1.3 pt? -159.65 -169.85 2.71 Favored 'General case' 1 N--CA 1.364 -4.758 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.169 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -137.4 165.4 26.32 Favored 'General case' 0 C--N 1.247 -3.856 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 -178.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.569 ' HA2' ' O ' ' A' ' 85' ' ' GLY . . . -34.29 111.46 0.07 OUTLIER Glycine 0 C--O 1.249 1.074 0 O-C-N 125.723 1.889 . . . . 0.0 112.547 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -69.68 157.39 37.35 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 121.929 0.871 . . . . 0.0 112.714 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 59.6 m80 -137.82 95.02 2.97 Favored 'General case' 1 C--O 1.341 5.903 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.021 -174.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 14.1 m -106.11 156.76 6.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.455 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.738 -175.572 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.43 ' ND1' ' HB2' ' A' ' 65' ' ' ASN . 15.1 t60 -131.32 121.04 24.02 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-O 122.531 1.158 . . . . 0.0 112.083 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.49 ' OE1' ' HA3' ' A' ' 108' ' ' GLY . 0.0 OUTLIER -90.03 95.61 10.29 Favored 'General case' 0 C--N 1.273 -2.751 0 CA-C-N 113.161 -1.836 . . . . 0.0 115.609 -175.827 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.299 6.4 p90 -131.23 -5.92 3.83 Favored 'General case' 0 C--O 1.218 -0.57 0 C-N-CA 118.128 -1.429 . . . . 0.0 114.252 169.51 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.532 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . 100.98 118.58 4.34 Favored Glycine 0 N--CA 1.476 1.351 0 C-N-CA 120.058 -1.068 . . . . 0.0 112.714 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -144.86 -85.97 0.12 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 118.308 -1.357 . . . . 0.0 111.098 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.481 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 23.5 t30 -153.83 136.69 15.36 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.429 HG22 HG22 ' A' ' 148' ' ' VAL . 23.5 m -55.76 -19.11 10.02 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 125.613 1.565 . . . . 0.0 112.608 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.32 2.52 14.78 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -176.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 170.84 137.94 2.41 Favored Glycine 0 C--O 1.211 -1.283 0 C-N-CA 117.744 -2.169 . . . . 0.0 113.229 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.635 ' SG ' HG22 ' A' ' 118' ' ' VAL . 25.4 p -98.68 94.06 6.44 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 36.8 m -74.75 -52.24 12.05 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.641 -0.662 . . . . 0.0 110.998 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 m -90.31 -34.81 15.58 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-O 121.149 0.5 . . . . 0.0 110.908 -175.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.58 59.61 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -175.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.54 -65.03 3.61 Favored Glycine 0 CA--C 1.542 1.775 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -88.88 6.38 4.68 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 123.061 2.508 . . . . 0.0 114.247 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -98.86 133.78 42.67 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -176.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -109.32 170.82 7.81 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -175.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.506 ' ND2' ' HA2' ' A' ' 108' ' ' GLY . 43.9 t30 -106.49 97.16 15.68 Favored Pre-proline 0 C--O 1.213 -0.852 0 C-N-CA 123.066 0.546 . . . . 0.0 110.758 176.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.542 ' HA ' ' HA ' ' A' ' 70' ' ' LYS . 21.3 Cg_exo -62.2 -9.86 16.37 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 124.256 3.304 . . . . 0.0 114.333 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.18 -17.58 53.77 Favored 'General case' 0 C--N 1.365 1.263 0 C-N-CA 122.7 0.4 . . . . 0.0 110.784 -168.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.46 ' HB2' ' H ' ' A' ' 79' ' ' ARG . 38.6 t -84.77 -90.62 0.09 Allowed 'General case' 0 N--CA 1.41 -2.465 0 C-N-CA 116.324 -2.15 . . . . 0.0 110.554 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.425 ' HG2' ' HB3' ' A' ' 75' ' ' LYS . 15.6 tpp180 -135.87 41.71 2.67 Favored 'General case' 0 C--N 1.264 -3.119 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 66' ' ' PRO . 99.5 mttt 75.35 -153.47 0.04 OUTLIER 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.308 -177.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 5.0 p80 -67.26 83.22 0.14 Allowed 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.25 91.58 1.55 Allowed Glycine 0 CA--C 1.467 -2.939 0 C-N-CA 117.784 -2.151 . . . . 0.0 111.638 169.591 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.92 142.8 7.73 Favored Glycine 1 N--CA 1.392 -4.263 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -86.22 0.46 8.13 Favored 'Trans proline' 0 N--CA 1.437 -1.806 0 C-N-CA 122.794 2.329 . . . . 0.0 109.414 178.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.462 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -84.84 28.55 0.68 Allowed 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.154 -172.111 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.462 ' HB2' ' O ' ' A' ' 75' ' ' LYS . 5.8 t0 -179.78 39.99 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 123.209 1.48 . . . . 0.0 107.988 164.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 68.11 8.87 6.82 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 112.332 -2.213 . . . . 0.0 114.9 169.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 63.34 37.76 10.68 Favored 'General case' 0 C--N 1.366 1.322 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 176.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.46 ' H ' ' HB2' ' A' ' 68' ' ' SER 0.34 50.2 mtm180 -52.84 3.12 0.01 OUTLIER 'General case' 0 N--CA 1.521 3.118 0 N-CA-C 119.202 3.038 . . . . 0.0 119.202 -164.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.419 4.8 m80 . . . . . 0 CA--C 1.459 -2.537 0 C-N-CA 127.036 2.134 . . . . 0.0 112.708 162.043 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.43 ' H ' HG13 ' A' ' 103' ' ' VAL . 51.4 tp . . . . . 0 N--CA 1.433 -1.279 0 CA-C-O 122.521 1.153 . . . . 0.0 113.228 . . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.569 ' O ' ' HA2' ' A' ' 44' ' ' GLY . . . -139.96 138.92 9.48 Favored Glycine 0 N--CA 1.413 -2.884 0 N-CA-C 107.989 -2.044 . . . . 0.0 107.989 174.15 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -109.84 129.14 55.67 Favored 'General case' 0 CA--C 1.485 -1.527 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -175.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.551 ' HB ' ' CB ' ' A' ' 95' ' ' ALA . 2.3 m -129.21 156.21 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.223 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.04 -178.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 p -134.26 96.37 3.59 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.542 0.687 . . . . 0.0 112.224 -175.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.68 156.23 17.2 Favored 'General case' 0 N--CA 1.424 -1.766 0 C-N-CA 126.847 2.059 . . . . 0.0 108.973 177.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.46 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 15.3 t70 -137.11 -167.93 2.19 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.676 -1.602 . . . . 0.0 106.676 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.447 ' N ' ' HA ' ' A' ' 39' ' ' THR . 39.7 ttpt -43.14 -38.66 2.52 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 126.123 1.769 . . . . 0.0 114.399 -177.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -134.94 4.96 3.3 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -63.08 170.45 14.53 Favored Glycine 0 CA--C 1.474 -2.514 0 CA-C-N 112.429 -2.169 . . . . 0.0 112.999 -170.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.401 HG13 ' HB3' ' A' ' 36' ' ' LYS . 16.1 m -134.83 131.94 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.391 -3.407 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -165.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.551 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -96.11 89.68 5.25 Favored 'General case' 2 C--N 1.239 -4.237 0 N-CA-C 104.667 -2.346 . . . . 0.0 104.667 175.305 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 12.1 t70 -121.42 89.12 3.06 Favored 'General case' 0 CA--C 1.477 -1.848 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 -178.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.81 144.2 38.34 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.738 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.886 -177.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -105.27 102.32 11.81 Favored 'General case' 0 C--N 1.266 -3.055 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.463 ' H ' HD12 ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.48 147.39 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.476 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.613 -173.506 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -149.19 117.48 6.45 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.57 ' N ' ' HB3' ' A' ' 28' ' ' PRO . 20.4 t70 -165.3 159.26 17.08 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.4 m -99.92 76.85 1.98 Allowed 'General case' 0 N--CA 1.425 -1.719 0 CA-C-O 123.576 1.655 . . . . 0.0 107.568 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.43 HG13 ' H ' ' A' ' 84' ' ' LEU . 6.5 p -120.52 -16.49 6.74 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.923 0 CA-C-N 111.361 -2.654 . . . . 0.0 107.403 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 9.2 mm -81.73 2.94 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.142 0 CA-C-N 113.301 -1.772 . . . . 0.0 107.313 -176.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.449 ' HA ' ' HG2' ' A' ' 22' ' ' GLN . 20.2 m -65.53 109.22 2.27 Favored 'General case' 0 C--O 1.263 1.816 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 44.4 tp -68.91 88.9 0.4 Allowed 'General case' 0 N--CA 1.396 -3.16 0 CA-C-N 112.463 -2.153 . . . . 0.0 113.417 -175.173 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.3 t -138.11 85.01 2.07 Favored 'General case' 1 N--CA 1.35 -5.449 0 N-CA-C 100.61 -3.848 . . . . 0.0 100.61 157.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.506 ' HA2' ' ND2' ' A' ' 65' ' ' ASN . . . -121.47 -144.25 6.85 Favored Glycine 0 CA--C 1.471 -2.685 0 CA-C-N 112.822 -1.99 . . . . 0.0 109.048 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -67.52 -74.14 0.12 Allowed 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 174.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -125.16 -47.47 1.76 Allowed 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 175.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.57 ' O ' ' HG3' ' A' ' 115' ' ' ARG . 21.9 m -161.67 169.45 21.53 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.25 -39.82 16.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.449 ' HA ' ' CA ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -73.83 125.74 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.549 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.414 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 102.34 -3.97 51.1 Favored Glycine 0 CA--C 1.478 -2.266 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 171.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.57 ' HG3' ' O ' ' A' ' 111' ' ' SER . 9.3 mmt180 -101.9 159.21 15.54 Favored 'General case' 0 N--CA 1.396 -3.15 0 CA-C-N 113.153 -1.523 . . . . 0.0 107.386 -174.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 16.7 p -99.58 135.58 40.78 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 2.7 pt? -88.9 130.11 35.48 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 174.227 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.635 HG22 ' SG ' ' A' ' 57' ' ' CYS . 14.3 t -101.43 101.79 12.6 Favored 'Isoleucine or valine' 0 C--O 1.262 1.752 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.595 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 27.0 m -136.96 169.59 19.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 C-N-CA 123.744 0.818 . . . . 0.0 108.816 -177.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.436 ' O ' HD13 ' A' ' 42' ' ' LEU . 49.0 t-80 -171.65 170.13 5.76 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 171.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.47 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.8 OUTLIER -77.59 84.06 3.97 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 170.743 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.56 ' H ' ' HB3' ' A' ' 42' ' ' LEU . 58.3 mmtt -173.58 127.98 0.42 Allowed 'General case' 0 CA--C 1.464 -2.363 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -174.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -44.89 103.32 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.84 0 O-C-N 123.863 0.727 . . . . 0.0 109.743 168.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -104.22 85.66 2.41 Favored 'General case' 0 CA--C 1.458 -2.585 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 -177.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.423 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 8.1 t70 -121.25 133.66 55.16 Favored 'General case' 0 C--N 1.255 -3.512 0 CA-C-N 113.729 -1.578 . . . . 0.0 108.869 -172.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -89.58 -13.3 37.54 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.668 -178.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -96.96 -34.6 5.63 Favored Glycine 0 N--CA 1.425 -2.047 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.423 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 65.4 tttm -86.33 -49.05 7.95 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 118.894 -0.575 . . . . 0.0 110.813 178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.509 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.91 -77.86 0.0 OUTLIER Glycine 0 CA--C 1.529 0.923 0 N-CA-C 114.439 0.536 . . . . 0.0 114.439 -170.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 171.63 -97.44 0.12 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 108.969 -1.653 . . . . 0.0 108.969 -177.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -88.94 179.98 6.07 Favored 'General case' 0 CA--C 1.56 1.337 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -56.16 -32.3 64.17 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 119.347 0.976 . . . . 0.0 113.229 -178.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -75.74 -46.38 31.25 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.676 0.751 . . . . 0.0 109.747 176.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -60.97 -33.93 73.98 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.352 -175.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.509 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 9.9 t -67.97 -35.71 78.81 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-O 120.939 0.4 . . . . 0.0 111.568 178.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.25 -29.12 31.46 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.172 -176.104 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 8.8 t -86.94 -14.93 40.4 Favored 'General case' 0 N--CA 1.438 -1.046 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 177.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.74 60.6 6.75 Favored Glycine 0 CA--C 1.5 -0.876 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 -175.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -51.89 105.23 0.1 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -175.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -152.11 171.64 17.58 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 173.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -67.9 87.45 0.18 Allowed Glycine 0 C--N 1.314 -0.665 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 173.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 16.2 m -66.1 -10.09 37.38 Favored 'General case' 0 C--O 1.21 -1.003 0 C-N-CA 124.731 1.213 . . . . 0.0 113.624 -175.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 43.1 mtp-105 -116.34 -37.4 3.77 Favored 'General case' 0 C--N 1.254 -3.554 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.725 172.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.412 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 3.8 mm? -49.0 -38.19 22.57 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 115.481 1.66 . . . . 0.0 115.481 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.595 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -143.89 92.45 2.34 Favored 'General case' 0 N--CA 1.42 -1.947 0 CA-C-O 121.622 0.725 . . . . 0.0 111.253 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 3.9 m -140.13 153.2 46.61 Favored 'General case' 0 N--CA 1.419 -1.979 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 175.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.601 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.75 168.95 42.01 Favored Glycine 0 N--CA 1.406 -3.311 0 N-CA-C 107.0 -2.44 . . . . 0.0 107.0 176.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 31.4 m -70.44 122.04 21.42 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.443 1.116 . . . . 0.0 112.385 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 9.0 tt -99.25 142.68 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.756 0 N-CA-C 103.704 -2.702 . . . . 0.0 103.704 175.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.449 ' CA ' ' HA ' ' A' ' 113' ' ' ILE . . . 177.06 154.46 12.04 Favored Glycine 2 N--CA 1.387 -4.57 0 C-N-CA 117.316 -2.373 . . . . 0.0 112.957 177.246 . . . . . . . . 3 3 . 1 . 009 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 3.8 tt -66.64 105.0 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 124.483 0.755 . . . . 0.0 109.422 172.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.526 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -114.21 98.3 6.86 Favored 'General case' 0 N--CA 1.414 -2.238 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 172.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 117.898 -1.049 . . . . 0.0 109.087 -174.258 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.221 -0.432 0 N-CA-C 111.42 0.156 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.557 ' O ' ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -82.35 -35.53 27.74 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-O 121.876 0.846 . . . . 0.0 112.463 -177.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.582 ' O ' HG12 ' A' ' 151' ' ' ILE . 56.9 mtmt -138.09 135.81 36.17 Favored 'General case' 0 C--N 1.277 -2.545 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.593 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -134.05 166.74 22.03 Favored 'General case' 0 C--N 1.27 -2.872 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 -176.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.3 p -145.99 118.93 2.28 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.315 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -108.65 127.16 53.73 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.4 p -119.45 129.24 75.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 O-C-N 123.786 0.679 . . . . 0.0 110.217 -178.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 75.4 mt -107.18 141.67 38.1 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.118 -177.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -150.79 137.83 19.21 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 174.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.39 -159.32 9.25 Favored Glycine 0 N--CA 1.417 -2.625 0 C-N-CA 117.571 -2.252 . . . . 0.0 115.622 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -78.06 -31.14 50.1 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 111.91 -2.145 . . . . 0.0 109.371 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.46 172.49 14.45 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 172.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -88.39 121.87 1.41 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 CA-C-N 121.919 2.859 . . . . 0.0 112.135 -176.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 m -135.14 118.23 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.429 0 CA-C-N 113.368 -1.742 . . . . 0.0 106.548 171.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.485 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -143.35 119.5 10.78 Favored 'General case' 0 C--N 1.279 -2.468 0 C-N-CA 118.128 -1.429 . . . . 0.0 109.929 178.442 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.2 170.87 43.62 Favored Glycine 0 N--CA 1.418 -2.552 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 178.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 20.0 pt -135.85 119.52 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.871 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.433 HG12 ' HA3' ' A' ' 33' ' ' GLY . 21.9 mt -114.37 135.16 55.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -176.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.593 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -101.58 138.68 38.25 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.235 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.476 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 95.2 m-85 -132.2 120.16 21.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 123.304 0.377 . . . . 0.0 111.066 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.557 ' HB2' ' O ' ' A' ' 2' ' ' THR . 35.8 tt0 -112.17 108.24 17.42 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.785 172.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.475 ' NE2' ' H ' ' A' ' 27' ' ' GLY . 8.8 tp60 -140.71 114.8 9.15 Favored 'General case' 0 N--CA 1.405 -2.69 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 172.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -90.63 157.37 17.52 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 178.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -60.95 -23.69 65.5 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.153 0.502 . . . . 0.0 110.967 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 14.8 m -63.25 -18.4 63.52 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.996 176.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 65.1 t30 66.96 105.98 0.04 OUTLIER 'General case' 0 C--N 1.353 0.744 0 C-N-CA 125.426 1.491 . . . . 0.0 109.204 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.475 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -146.55 -170.64 15.19 Favored Glycine 0 CA--C 1.469 -2.804 0 C-N-CA 118.415 -1.85 . . . . 0.0 115.242 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.65 124.12 15.03 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.56 2.84 . . . . 0.0 110.562 178.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.451 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 47.1 t -93.44 110.99 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.988 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.286 -175.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.42 111.24 23.89 Favored 'General case' 0 N--CA 1.422 -1.87 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.403 HG23 ' HA ' ' A' ' 20' ' ' PHE . 17.2 t -138.47 132.26 41.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.175 -170.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.443 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 77.8 t90 -149.25 127.64 12.22 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.433 ' HA3' HG12 ' A' ' 18' ' ' ILE . . . -159.34 140.03 6.58 Favored Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.417 -0.896 . . . . 0.0 110.915 173.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.443 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 49.4 m -117.4 115.4 25.14 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.288 179.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.514 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 30.8 pt -109.79 138.71 36.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 118.612 0.642 . . . . 0.0 111.104 176.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.708 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 16.5 ptpt -103.65 132.7 49.67 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.327 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.487 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -148.98 178.78 26.3 Favored Glycine 1 N--CA 1.391 -4.359 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -167.758 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.469 ' HG ' ' H ' ' A' ' 39' ' ' THR . 45.3 tp -65.27 176.46 1.35 Allowed 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 171.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.469 ' H ' ' HG ' ' A' ' 38' ' ' LEU . 15.0 t -61.99 153.72 28.64 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.351 -1.468 . . . . 0.0 111.215 -166.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.7 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 11.1 pt-20 -60.67 160.32 9.43 Favored 'General case' 0 CA--C 1.476 -1.891 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -163.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -159.29 -157.57 8.62 Favored Glycine 1 C--N 1.245 -4.487 1 N-CA-C 102.442 -4.263 . . . . 0.0 102.442 -176.906 . . . . . . . . 3 2 . 1 . 010 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.4 mt -153.72 -86.63 0.06 Allowed 'General case' 0 C--N 1.274 -2.717 0 CA-C-N 120.357 2.078 . . . . 0.0 114.74 -169.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.613 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.5 t-160 -76.93 122.23 24.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 -156.416 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.78 127.01 8.8 Favored Glycine 0 N--CA 1.415 -2.75 0 C-N-CA 119.876 -1.154 . . . . 0.0 114.85 -173.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.478 ' HB3' ' CB ' ' A' ' 124' ' ' ASP . 14.9 t80 -113.31 113.03 24.7 Favored 'General case' 1 C--O 1.336 5.61 0 CA-C-O 123.41 1.576 . . . . 0.0 111.028 175.463 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.502 ' NE2' ' HG ' ' A' ' 117' ' ' LEU . 25.4 m80 -108.18 124.96 51.07 Favored 'General case' 0 N--CA 1.391 -3.38 0 CA-C-N 113.624 -1.626 . . . . 0.0 110.42 -173.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.4 p -174.65 87.35 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 CA-C-N 113.55 -1.659 . . . . 0.0 109.762 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.438 ' C ' ' HD2' ' A' ' 115' ' ' ARG . 7.0 m170 -112.49 170.74 7.96 Favored 'General case' 0 C--N 1.281 -2.387 0 N-CA-C 114.608 1.336 . . . . 0.0 114.608 167.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.58 ' HG3' ' OD1' ' A' ' 109' ' ' ASP . 36.4 tt0 -139.64 132.56 29.33 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.191 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.8 t80 76.45 26.84 0.86 Allowed 'General case' 0 C--O 1.222 -0.359 0 C-N-CA 127.349 2.26 . . . . 0.0 111.127 174.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.704 ' HA3' ' O ' ' A' ' 114' ' ' GLY . . . 33.67 -124.64 0.4 Allowed Glycine 0 C--N 1.36 1.916 0 CA-C-N 115.599 -0.728 . . . . 0.0 114.637 -172.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.2 t70 169.51 -80.71 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 125.398 1.479 . . . . 0.0 108.48 164.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -161.05 160.9 31.07 Favored 'General case' 0 N--CA 1.429 -1.509 0 N-CA-C 104.975 -2.231 . . . . 0.0 104.975 174.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.3 t -79.26 5.18 12.95 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -171.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.15 2.26 9.8 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 120.202 -0.599 . . . . 0.0 111.249 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 176.55 127.53 1.05 Allowed Glycine 0 C--O 1.195 -2.324 0 C-N-CA 118.582 -1.77 . . . . 0.0 111.558 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.796 ' SG ' HG23 ' A' ' 118' ' ' VAL . 16.7 p -99.72 89.23 4.04 Favored 'General case' 0 C--N 1.275 -2.633 0 O-C-N 121.869 -0.783 . . . . 0.0 112.131 177.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.5 m -78.85 -53.14 7.4 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.8 m -70.01 -52.99 19.67 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.498 -174.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.63 -9.45 58.67 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-O 118.418 -0.801 . . . . 0.0 112.975 176.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -36.08 -68.14 0.32 Allowed Glycine 0 N--CA 1.488 2.103 0 N-CA-C 114.864 0.705 . . . . 0.0 114.864 -173.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -94.09 7.59 2.42 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.328 2.686 . . . . 0.0 112.149 177.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 77.1 t60 -113.52 123.46 50.06 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -171.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.443 ' CD1' ' HA ' ' A' ' 137' ' ' THR . 27.1 p90 -97.75 170.55 8.91 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 126.722 2.009 . . . . 0.0 108.785 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.83 142.68 24.89 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.82 -53.98 2.77 Favored 'Trans proline' 0 N--CA 1.481 0.767 0 C-N-CA 123.204 2.603 . . . . 0.0 116.652 -168.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.816 ' O ' ' HA ' ' A' ' 78' ' ' GLU . 95.9 mt -93.0 25.97 3.0 Favored 'General case' 0 C--O 1.193 -1.913 0 O-C-N 121.786 -0.571 . . . . 0.0 111.818 -168.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.676 ' O ' ' HA ' ' A' ' 80' ' ' HIS . 28.6 m -144.74 30.36 1.2 Allowed 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.039 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.514 ' HD2' ' O ' ' A' ' 69' ' ' ARG . 4.1 tmm_? -126.08 -27.32 3.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 CA-C-O 117.639 -1.172 . . . . 0.0 110.638 -176.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 1.2 mptm? -45.32 60.34 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 119.778 3.251 . . . . 0.0 119.778 -165.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.429 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 26.6 t-80 46.43 58.65 4.4 Favored 'General case' 0 CA--C 1.567 1.598 0 N-CA-C 117.292 2.33 . . . . 0.0 117.292 165.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.62 88.44 0.38 Allowed Glycine 0 CA--C 1.495 -1.186 0 C-N-CA 116.762 -2.637 . . . . 0.0 115.57 163.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -170.13 95.38 0.11 Allowed Glycine 0 C--O 1.211 -1.334 0 C-N-CA 119.089 -1.529 . . . . 0.0 112.81 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -64.91 -40.23 21.96 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 CA-C-N 120.647 2.224 . . . . 0.0 113.583 -175.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.07 16.49 21.81 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 125.139 1.376 . . . . 0.0 110.153 -178.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -89.79 -172.02 3.39 Favored 'General case' 0 C--N 1.287 -2.126 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.747 -167.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.46 -3.45 1.04 Allowed 'General case' 0 N--CA 1.434 -1.268 0 O-C-N 122.22 -0.3 . . . . 0.0 111.072 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.816 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 33.1 tt0 -132.19 -34.79 1.23 Allowed 'General case' 0 N--CA 1.433 -1.315 0 CA-C-O 121.222 0.535 . . . . 0.0 110.276 -170.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.468 ' O ' ' HB3' ' A' ' 80' ' ' HIS . 4.5 mpt_? -93.76 -15.87 24.74 Favored 'General case' 0 CA--C 1.484 -1.571 0 C-N-CA 125.603 1.561 . . . . 0.0 107.111 -175.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.676 ' HA ' ' O ' ' A' ' 68' ' ' SER 0.258 5.0 p80 . . . . . 0 CA--C 1.459 -2.538 0 CA-C-N 113.185 -1.825 . . . . 0.0 110.332 159.498 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.557 HD11 ' N ' ' A' ' 85' ' ' GLY . 0.7 OUTLIER . . . . . 0 N--CA 1.468 0.441 0 N-CA-C 115.754 1.761 . . . . 0.0 115.754 . . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.557 ' N ' HD11 ' A' ' 84' ' ' LEU . . . -169.36 156.38 27.42 Favored Glycine 0 N--CA 1.425 -2.048 0 N-CA-C 104.483 -3.447 . . . . 0.0 104.483 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -112.61 153.0 28.26 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 120.158 1.979 . . . . 0.0 109.869 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 71.9 t -117.86 143.01 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.532 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.607 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 62.2 m -146.13 95.74 2.67 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -93.28 144.98 24.79 Favored 'General case' 0 CA--C 1.482 -1.666 0 CA-C-N 119.49 1.041 . . . . 0.0 113.097 -176.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.7 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 22.1 t70 -82.58 149.6 27.37 Favored 'General case' 0 C--N 1.278 -2.516 0 CA-C-N 113.223 -1.808 . . . . 0.0 106.83 169.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.533 ' N ' ' HB3' ' A' ' 40' ' ' GLU . 13.6 pttp -41.28 -19.39 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 127.69 2.396 . . . . 0.0 116.037 176.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -106.81 12.76 28.66 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.708 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 73.1 85.18 0.23 Allowed Glycine 0 N--CA 1.42 -2.397 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.06 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.514 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 61.3 t -157.07 103.51 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.709 -1.959 . . . . 0.0 105.709 -178.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -104.17 113.38 26.89 Favored 'General case' 0 C--N 1.273 -2.735 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.525 175.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -86.01 94.33 9.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 175.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 86.1 t -85.63 105.71 14.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.486 -175.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.2 m -152.54 116.05 4.75 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 9.4 tp -148.31 134.35 12.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.451 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 37.8 mt-10 -124.03 96.63 5.01 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.433 -175.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.404 ' O ' HG21 ' A' ' 29' ' ' VAL . 6.2 p-10 -168.81 166.71 11.4 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 170.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.5 p -60.89 91.5 0.02 OUTLIER 'General case' 0 C--O 1.245 0.851 0 CA-C-N 119.128 0.876 . . . . 0.0 113.058 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 84' ' ' LEU . 27.1 m -118.39 -14.41 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -176.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.415 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -119.24 25.92 4.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 O-C-N 120.7 -1.25 . . . . 0.0 109.476 -176.552 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.0 m -64.38 110.95 2.43 Favored 'General case' 0 C--O 1.268 2.059 0 CA-C-O 122.729 1.252 . . . . 0.0 109.831 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.44 86.37 1.15 Allowed 'General case' 0 N--CA 1.382 -3.87 0 CA-C-O 124.103 1.906 . . . . 0.0 110.63 176.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.0 m -146.56 85.75 1.65 Allowed 'General case' 2 N--CA 1.362 -4.855 0 N-CA-C 101.88 -3.378 . . . . 0.0 101.88 168.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.13 168.96 22.8 Favored Glycine 0 C--N 1.269 -3.142 0 CA-C-N 113.373 -1.74 . . . . 0.0 111.014 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.58 ' OD1' ' HG3' ' A' ' 49' ' ' GLU . 7.0 t70 -56.92 -34.89 68.41 Favored 'General case' 0 C--O 1.202 -1.43 0 CA-C-N 117.292 0.546 . . . . 0.0 110.916 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.706 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 7.9 p-80 -54.28 -17.01 2.49 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 125.385 1.474 . . . . 0.0 113.023 -178.002 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.478 ' H ' ' C ' ' A' ' 109' ' ' ASP . 23.0 t 37.47 -154.49 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 126.164 1.786 . . . . 0.0 110.297 -173.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.598 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 14.2 tt -100.32 -32.97 3.63 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.876 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 166.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.8 pt -104.02 145.93 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -178.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.704 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 95.83 -7.04 67.52 Favored Glycine 1 CA--C 1.45 -4.008 0 C-N-CA 121.234 -0.508 . . . . 0.0 112.272 162.211 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.706 ' NE ' ' HA ' ' A' ' 110' ' ' HIS . 0.3 OUTLIER -92.61 151.44 20.12 Favored 'General case' 0 C--O 1.162 -3.54 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.688 -174.146 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.543 ' H ' ' HA2' ' A' ' 51' ' ' GLY . 7.6 p -91.86 113.09 25.27 Favored 'General case' 0 N--CA 1.408 -2.531 0 O-C-N 121.537 -0.727 . . . . 0.0 109.397 173.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.502 ' HG ' ' NE2' ' A' ' 46' ' ' HIS . 22.5 tp -70.09 93.5 0.81 Allowed 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 -177.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.796 HG23 ' SG ' ' A' ' 57' ' ' CYS 0.528 60.2 t -105.1 109.22 27.0 Favored 'Isoleucine or valine' 1 C--O 1.341 5.884 0 N-CA-C 120.708 3.596 . . . . 0.0 120.708 -172.217 . . . . . . . . 4 3 . 1 . 010 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.654 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 7.3 p -148.47 171.25 2.43 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.155 0 CA-C-N 110.397 -3.092 . . . . 0.0 106.469 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 71.6 t60 -150.37 171.28 17.25 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.88 -2.267 . . . . 0.0 104.88 168.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.461 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.0 OUTLIER -69.42 85.94 0.43 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 171.449 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -173.01 171.78 4.11 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.613 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -99.09 107.58 20.0 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 118.299 0.499 . . . . 0.0 110.243 173.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.481 ' HA ' ' OD1' ' A' ' 139' ' ' ASN . 1.1 m-20 -71.33 -59.16 2.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 172.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.0 t70 67.76 141.34 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 128.024 2.529 . . . . 0.0 114.097 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.571 ' HG ' ' CD2' ' A' ' 80' ' ' HIS . 0.0 OUTLIER -90.26 -31.99 16.74 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-N 114.89 -1.05 . . . . 0.0 113.624 -176.563 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . 0.429 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -97.01 -33.98 5.84 Favored Glycine 0 N--CA 1.427 -1.904 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -105.13 50.32 0.79 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.178 -1.011 . . . . 0.0 108.873 -179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.36 -6.83 81.51 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.53 -93.17 0.25 Allowed Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 121.653 -0.308 . . . . 0.0 112.406 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.54 ' H ' ' HB2' ' A' ' 134' ' ' SER . 79.3 m-20 -121.86 -173.39 2.64 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -174.045 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -57.71 -39.32 76.96 Favored 'General case' 0 C--N 1.361 1.102 0 C-N-CA 118.65 -1.22 . . . . 0.0 109.994 176.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.536 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 5.9 tp10 -76.05 -53.86 7.72 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.051 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.54 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 2.4 m -62.06 -26.25 68.16 Favored 'General case' 0 CA--C 1.552 1.021 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -175.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 35.8 m -79.72 -18.14 51.91 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 121.852 -0.53 . . . . 0.0 110.653 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.536 ' HG3' ' O ' ' A' ' 133' ' ' GLU . 0.0 OUTLIER -85.64 -31.27 22.65 Favored 'General case' 0 C--O 1.211 -0.942 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.535 179.227 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.443 ' HA ' ' CD1' ' A' ' 64' ' ' PHE . 8.8 p -70.95 -16.01 62.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 120.916 0.389 . . . . 0.0 109.962 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.56 81.64 0.11 Allowed Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . 0.481 ' OD1' ' HA ' ' A' ' 124' ' ' ASP . 23.3 t-20 -33.07 132.05 0.16 Allowed 'General case' 0 C--O 1.291 3.263 0 CA-C-O 123.451 1.596 . . . . 0.0 114.202 -172.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.419 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -150.89 130.51 13.07 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 113.845 -1.525 . . . . 0.0 109.711 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.12 91.03 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.072 -2.011 . . . . 0.0 108.072 170.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.9 m -49.18 -18.41 0.33 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.789 2.035 . . . . 0.0 116.384 -168.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -144.59 6.51 1.25 Allowed 'General case' 0 C--N 1.269 -2.92 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.56 -22.73 58.84 Favored 'General case' 0 C--N 1.294 -1.845 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.509 -173.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -171.9 100.3 0.17 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 175.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.9 m -123.42 133.05 54.12 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.28 146.28 12.37 Favored Glycine 0 N--CA 1.404 -3.499 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 178.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 8.8 p -69.19 113.98 5.6 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-O 122.128 0.966 . . . . 0.0 111.953 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' A' ' 117' ' ' LEU . 2.5 tt -82.93 129.65 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.085 0 N-CA-C 105.067 -2.197 . . . . 0.0 105.067 170.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.598 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 177.67 156.99 17.58 Favored Glycine 2 N--CA 1.365 -6.074 0 C-N-CA 118.427 -1.844 . . . . 0.0 111.297 176.772 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.582 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.16 105.32 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 169.536 . . . . . . . . 3 3 . 1 . 010 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.16 113.34 16.91 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 . . . . . 0 C--N 1.283 -2.315 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -175.595 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.0 0.428 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 m -79.89 -28.99 39.84 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.14 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.635 ' HG3' ' O ' ' A' ' 152' ' ' ALA . 19.9 ptpt -151.74 170.87 18.69 Favored 'General case' 0 C--O 1.253 1.241 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.491 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -141.42 154.56 45.67 Favored 'General case' 0 N--CA 1.434 -1.265 0 O-C-N 124.099 0.875 . . . . 0.0 109.038 177.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.19 122.22 62.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.487 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -131.4 133.14 44.94 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.18 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.6 t -134.75 113.31 16.29 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.413 ' HB2' ' O ' ' A' ' 14' ' ' VAL . 3.1 mm? -90.83 131.03 36.72 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.409 0.683 . . . . 0.0 111.418 -176.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.1 mtpt -147.34 126.79 13.18 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 175.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.72 -158.53 8.84 Favored Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.58 -0.819 . . . . 0.0 111.754 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -63.09 -40.39 97.52 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -116.11 82.63 0.32 Allowed Glycine 0 N--CA 1.433 -1.513 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 172.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.64 127.0 11.95 Favored 'Trans proline' 0 N--CA 1.446 -1.296 0 C-N-CA 122.127 1.884 . . . . 0.0 113.901 -171.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 8' ' ' LEU . 16.5 m -111.92 117.08 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.858 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 175.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -99.13 118.31 35.57 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.639 -172.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.0 170.81 43.53 Favored Glycine 0 N--CA 1.407 -3.247 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.858 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.487 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 25.7 pt -131.38 129.24 62.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.142 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 mm -115.12 136.01 53.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.497 ' O ' HG13 ' A' ' 31' ' ' VAL . 0.8 OUTLIER -114.24 129.63 56.63 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.478 -177.583 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.491 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 53.9 m-85 -125.19 137.49 54.13 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.097 0.475 . . . . 0.0 111.684 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -116.23 106.37 13.61 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.368 177.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.8 pm0 -86.25 123.34 31.41 Favored 'General case' 0 N--CA 1.403 -2.816 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 171.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.441 ' O ' ' HB ' ' A' ' 104' ' ' ILE . 37.1 ttmt -137.55 103.16 4.97 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -170.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.26 -9.83 13.29 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 m -71.91 -23.71 61.52 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 122.877 0.471 . . . . 0.0 110.35 176.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . 0.456 ' HA ' HG13 ' A' ' 104' ' ' ILE . 45.4 t-20 72.57 135.54 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 C-N-CA 125.335 1.454 . . . . 0.0 111.034 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.52 175.33 36.67 Favored Glycine 0 CA--C 1.485 -1.785 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.619 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -65.1 123.48 11.62 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.302 2.001 . . . . 0.0 108.397 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.7 m -76.99 142.75 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.277 0 CA-C-O 121.682 0.753 . . . . 0.0 111.632 -177.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -106.28 97.07 6.92 Favored 'General case' 0 C--N 1.277 -2.544 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 173.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.497 HG13 ' O ' ' A' ' 19' ' ' ASN . 47.6 t -129.59 129.87 66.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 125.892 1.677 . . . . 0.0 107.861 -171.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -140.74 137.24 33.28 Favored 'General case' 0 C--N 1.286 -2.192 0 O-C-N 123.375 0.422 . . . . 0.0 110.186 177.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -159.59 137.9 5.34 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 170.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.469 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 44.3 t -118.63 127.74 53.88 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.4 ' CG1' ' HB1' ' A' ' 95' ' ' ALA . 33.5 pt -120.02 129.0 75.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 119.788 1.177 . . . . 0.0 110.381 174.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -96.67 123.56 40.39 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 178.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.751 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -136.48 176.29 20.44 Favored Glycine 0 C--N 1.274 -2.9 0 CA-C-N 114.502 -1.226 . . . . 0.0 110.383 -171.057 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -69.43 171.28 8.95 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 171.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -68.47 112.43 5.29 Favored 'General case' 0 C--O 1.22 -0.48 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 175.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.588 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 5.1 tp10 -128.86 178.91 6.03 Favored 'General case' 0 C--N 1.259 -3.339 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.804 -165.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.454 ' H ' ' HG3' ' A' ' 40' ' ' GLU . . . -59.44 -146.93 0.01 OUTLIER Glycine 0 CA--C 1.553 2.449 0 C-N-CA 124.633 1.111 . . . . 0.0 114.472 176.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.523 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 3.0 pp -164.66 14.47 0.05 OUTLIER 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -164.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.2 t60 -143.91 153.66 42.53 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 106.757 -1.572 . . . . 0.0 106.757 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.417 ' O ' ' HA ' ' A' ' 86' ' ' ASN . . . 163.02 -169.25 38.13 Favored Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 119.899 -1.143 . . . . 0.0 112.156 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.519 ' HA ' ' O ' ' A' ' 85' ' ' GLY . 24.1 p90 -166.6 162.65 16.67 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.458 ' H ' ' HA ' ' A' ' 84' ' ' LEU . 6.5 m170 -91.12 164.32 13.97 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -171.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.9 t -165.82 88.59 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.616 0 C-N-CA 123.81 0.844 . . . . 0.0 111.4 -174.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.488 ' HB2' ' HB3' ' A' ' 115' ' ' ARG . 31.0 p-80 -109.61 100.82 9.81 Favored 'General case' 0 CA--C 1.598 2.796 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 166.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.595 ' N ' ' HD2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -122.71 122.67 39.32 Favored 'General case' 0 CA--C 1.575 1.932 0 O-C-N 120.374 -1.454 . . . . 0.0 111.338 173.844 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.485 ' C ' ' HG2' ' A' ' 115' ' ' ARG . 61.2 t80 75.36 93.71 0.07 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 126.982 2.113 . . . . 0.0 110.961 176.277 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.589 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -55.02 134.1 48.21 Favored Glycine 0 CA--C 1.482 -1.985 0 N-CA-C 116.851 1.5 . . . . 0.0 116.851 -171.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -141.42 -87.09 0.17 Allowed 'General case' 0 CA--C 1.488 -1.439 0 C-N-CA 117.951 -1.5 . . . . 0.0 114.326 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -118.65 139.0 52.22 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.856 -169.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.486 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 10.0 t -43.58 -39.76 3.66 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 126.674 1.99 . . . . 0.0 115.385 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -134.31 15.43 3.78 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.426 0.631 . . . . 0.0 110.33 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -127.4 111.14 1.29 Allowed Glycine 0 N--CA 1.436 -1.312 0 C-N-CA 119.922 -1.132 . . . . 0.0 111.818 -177.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 118' ' ' VAL . 10.1 p -97.88 88.3 4.24 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.8 p -78.25 -61.85 1.87 Allowed 'General case' 0 N--CA 1.419 -1.99 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.277 176.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.3 m -68.15 -27.95 66.88 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.401 ' HB1' ' HB2' ' A' ' 57' ' ' CYS . . . -78.7 -9.27 59.35 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.059 0.457 . . . . 0.0 111.115 177.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.3 -64.66 3.95 Favored Glycine 0 N--CA 1.436 -1.358 0 CA-C-N 115.096 -0.957 . . . . 0.0 113.021 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.78 53.13 2.71 Favored 'Trans proline' 0 CA--C 1.552 1.403 0 C-N-CA 122.359 2.039 . . . . 0.0 114.247 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 11.4 t60 72.83 163.59 0.27 Allowed 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 124.831 1.252 . . . . 0.0 111.439 169.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.442 ' CZ ' ' HA2' ' A' ' 108' ' ' GLY . 1.5 t80 -92.79 170.81 9.41 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.641 ' OD1' ' HD2' ' A' ' 66' ' ' PRO . 61.6 t30 -69.86 140.57 88.98 Favored Pre-proline 0 CA--C 1.562 1.42 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.091 -179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.641 ' HD2' ' OD1' ' A' ' 65' ' ' ASN . 72.8 Cg_endo -76.84 -8.4 17.9 Favored 'Trans proline' 0 N--CA 1.443 -1.483 1 C-N-CA 125.314 4.01 . . . . 0.0 113.954 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -84.11 16.59 2.85 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 123.966 1.841 . . . . 0.0 109.611 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.0 p -80.43 -86.3 0.08 Allowed 'General case' 1 N--CA 1.356 -5.15 0 CA-C-N 113.362 -1.745 . . . . 0.0 108.321 175.152 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.503 ' CB ' ' HA ' ' A' ' 78' ' ' GLU . 41.8 ttt180 -135.84 10.36 3.36 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 167.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 82.5 tttt 75.14 -9.18 1.43 Allowed 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.371 1.469 . . . . 0.0 113.19 173.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 -99.35 -54.42 2.96 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 119.941 -0.703 . . . . 0.0 112.392 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.98 30.45 14.55 Favored Glycine 0 N--CA 1.474 1.174 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.229 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -70.58 143.54 37.15 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.499 -0.858 . . . . 0.0 114.734 -175.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.84 -9.31 18.2 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 124.155 3.237 . . . . 0.0 111.58 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -79.84 9.8 4.86 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.741 -178.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 63.05 78.6 0.29 Allowed 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 124.909 1.283 . . . . 0.0 111.094 176.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -137.54 -56.13 0.69 Allowed 'General case' 0 CA--C 1.5 -0.969 0 O-C-N 121.668 -0.645 . . . . 0.0 112.683 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.503 ' HA ' ' CB ' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -64.2 154.24 35.47 Favored 'General case' 0 N--CA 1.403 -2.776 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.276 -172.224 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.615 ' O ' ' HA ' ' A' ' 68' ' ' SER . 75.9 ttt180 -119.14 72.2 0.89 Allowed 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -170.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.405 ' HB2' ' HA ' ' A' ' 68' ' ' SER 0.336 2.3 m-70 . . . . . 0 N--CA 1.501 2.119 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 164.896 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.458 ' HA ' ' H ' ' A' ' 46' ' ' HIS . 2.5 pp . . . . . 0 N--CA 1.4 -2.959 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 . . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.519 ' O ' ' HA ' ' A' ' 45' ' ' PHE . . . 176.55 168.89 37.25 Favored Glycine 2 C--N 1.247 -4.379 0 N-CA-C 103.715 -3.754 . . . . 0.0 103.715 175.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.417 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 58.5 t30 -80.36 140.63 35.98 Favored 'General case' 0 C--N 1.271 -2.84 0 CA-C-N 119.501 1.65 . . . . 0.0 107.324 174.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 43.4 t -115.31 128.06 72.65 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.118 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 -177.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 62.3 m -142.19 96.54 2.97 Favored 'General case' 0 N--CA 1.413 -2.279 0 CA-C-O 118.685 -0.674 . . . . 0.0 111.405 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.564 ' HB2' ' H ' ' A' ' 94' ' ' VAL . . . -126.77 104.38 8.03 Favored 'General case' 0 C--O 1.195 -1.774 0 C-N-CA 116.459 -2.096 . . . . 0.0 108.131 169.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.588 ' HA ' ' O ' ' A' ' 40' ' ' GLU . 5.3 p-10 -127.9 -18.65 4.19 Favored 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.626 -171.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -71.73 -58.04 3.83 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.795 0.807 . . . . 0.0 109.072 -175.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -164.71 26.51 0.06 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.892 -175.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.751 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 77.46 78.95 0.74 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 114.532 -1.213 . . . . 0.0 115.338 -178.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.564 ' H ' ' HB2' ' A' ' 89' ' ' ALA . 98.7 t -159.77 105.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 177.072 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.4 ' HB1' ' CG1' ' A' ' 35' ' ' ILE . . . -107.71 122.68 47.22 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -93.21 112.86 24.93 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 124.117 0.886 . . . . 0.0 109.76 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.6 t -113.94 105.64 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-O 121.147 0.499 . . . . 0.0 109.806 178.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 50.5 m -143.52 111.63 6.19 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 174.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 pt -123.22 154.69 29.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.27 -173.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -148.96 99.42 2.97 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.884 0.85 . . . . 0.0 111.256 173.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -167.58 171.98 9.82 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 176.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.6 m -59.24 87.77 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 122.743 1.259 . . . . 0.0 112.286 -178.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 59.3 t -113.21 -10.46 12.11 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 112.733 -2.03 . . . . 0.0 106.763 175.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.456 HG13 ' HA ' ' A' ' 26' ' ' ASN . 0.2 OUTLIER -52.84 -13.71 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 C-N-CA 125.111 1.364 . . . . 0.0 114.067 -176.72 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.2 m -73.27 152.16 41.09 Favored 'General case' 0 N--CA 1.418 -2.038 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 172.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.482 ' HB2' HG12 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -65.9 121.78 15.85 Favored 'General case' 0 N--CA 1.403 -2.82 0 CA-C-O 122.01 0.91 . . . . 0.0 109.697 -177.559 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.9 m -69.86 88.07 0.55 Allowed 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 113.216 -1.811 . . . . 0.0 110.677 -174.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.442 ' HA2' ' CZ ' ' A' ' 64' ' ' PHE . . . 143.62 136.62 3.15 Favored Glycine 0 N--CA 1.409 -3.108 0 CA-C-N 114.287 -1.324 . . . . 0.0 112.296 175.313 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -66.38 -56.77 9.46 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.851 169.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -104.24 -47.09 4.24 Favored 'General case' 0 N--CA 1.435 -1.209 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.007 -173.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.416 ' CB ' ' H ' ' A' ' 51' ' ' GLY . 18.8 m -127.42 113.91 16.82 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 118.944 -1.103 . . . . 0.0 112.594 -177.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.482 HG12 ' HB2' ' A' ' 106' ' ' LEU . 2.9 mp -89.71 -38.29 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 173.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mp -102.01 145.07 12.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.83 -12.8 62.67 Favored Glycine 0 CA--C 1.495 -1.162 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 174.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.661 ' HD3' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -91.93 134.71 34.54 Favored 'General case' 0 N--CA 1.396 -3.147 0 CA-C-O 122.224 1.011 . . . . 0.0 112.967 -175.544 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.661 ' N ' ' HD3' ' A' ' 115' ' ' ARG 0.253 0.2 OUTLIER -89.0 116.74 27.52 Favored 'General case' 0 N--CA 1.394 -3.264 0 C-N-CA 126.563 1.945 . . . . 0.0 107.45 -176.188 . . . . . . . . 4 4 . 1 . 011 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 147' ' ' GLY . 2.7 pt? -79.17 144.52 34.37 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.581 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 10.7 p -109.7 111.14 34.85 Favored 'Isoleucine or valine' 0 C--O 1.273 2.314 0 C-N-CA 119.134 -1.027 . . . . 0.0 112.845 177.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 46' ' ' HIS . 24.7 m -147.81 146.48 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 C-N-CA 125.805 1.642 . . . . 0.0 110.017 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -170.08 148.65 3.42 Favored 'General case' 0 C--N 1.283 -2.326 0 N-CA-C 102.601 -3.111 . . . . 0.0 102.601 167.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.588 ' O ' ' HG3' ' A' ' 40' ' ' GLU . 1.3 mp0 -69.55 89.72 0.53 Allowed 'General case' 0 C--N 1.261 -3.276 0 CA-C-O 123.355 1.55 . . . . 0.0 113.182 -171.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -165.28 144.53 6.6 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 102.698 -3.075 . . . . 0.0 102.698 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.27 101.71 0.25 Allowed 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -173.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.425 ' HB3' ' H ' ' A' ' 45' ' ' PHE . 12.0 t70 -87.89 93.95 9.62 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 99.585 -4.228 . . . . 0.0 99.585 171.747 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -103.28 139.81 38.23 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.839 -0.745 . . . . 0.0 111.118 -170.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.483 ' HG ' ' H ' ' A' ' 127' ' ' GLY . 1.9 pt? -51.23 -74.28 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 121.703 3.964 . . . . 0.0 121.703 -162.248 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . 0.495 ' C ' ' HD2' ' A' ' 128' ' ' LYS . . . -69.97 -59.89 5.23 Favored Glycine 0 CA--C 1.47 -2.727 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.829 -170.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . 0.495 ' HD2' ' C ' ' A' ' 127' ' ' GLY . 4.4 mptp? -136.8 35.88 2.63 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.073 -174.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.45 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 59.5 -34.06 0.03 OUTLIER Glycine 0 CA--C 1.559 2.809 0 CA-C-N 119.76 1.164 . . . . 0.0 115.634 -175.29 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . 0.472 ' H ' ' C ' ' A' ' 128' ' ' LYS . . . 147.38 -24.32 1.54 Allowed Glycine 0 N--CA 1.401 -3.643 0 O-C-N 122.145 -0.62 . . . . 0.0 111.905 179.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.651 ' N ' ' HB2' ' A' ' 134' ' ' SER . 1.8 t-20 -169.61 179.78 3.65 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 118.519 -1.272 . . . . 0.0 108.042 -174.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.457 ' O ' HG21 ' A' ' 135' ' ' THR . 0.0 OUTLIER -62.6 -40.72 97.82 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.07 -1.452 . . . . 0.0 113.378 -175.136 . . . . . . . . 3 3 . 1 . 011 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -85.36 -30.84 23.33 Favored 'General case' 0 C--N 1.319 -0.749 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.171 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.651 ' HB2' ' N ' ' A' ' 131' ' ' ASN . 15.0 m -63.68 -19.68 65.1 Favored 'General case' 0 C--O 1.186 -2.284 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.464 ' HB ' ' O ' ' A' ' 128' ' ' LYS . 11.3 t -71.96 -35.4 69.54 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 175.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -73.89 -48.84 28.06 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.58 -175.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.453 HG21 ' HA ' ' A' ' 134' ' ' SER . 14.8 t -86.06 -23.66 26.65 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 114.418 -1.265 . . . . 0.0 112.816 -176.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -68.22 -66.7 2.21 Favored Glycine 0 CA--C 1.478 -2.277 0 CA-C-O 119.584 -0.565 . . . . 0.0 111.73 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 58.8 t30 -50.75 132.53 26.32 Favored 'General case' 0 N--CA 1.518 2.945 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 171.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.63 160.27 25.81 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 114.392 1.256 . . . . 0.0 114.392 -162.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.87 118.46 13.08 Favored Glycine 0 CA--C 1.49 -1.508 0 CA-C-N 113.655 -1.611 . . . . 0.0 113.046 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.535 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 8.4 m -71.43 3.43 3.81 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 124.607 1.163 . . . . 0.0 113.189 -173.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.9 mtt180 -132.16 -4.76 3.47 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 176.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.93 -40.35 32.24 Favored 'General case' 0 CA--C 1.498 -1.02 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.111 -173.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.15 108.53 0.98 Allowed 'General case' 0 N--CA 1.428 -1.569 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 m -137.43 156.78 47.78 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 177.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.527 ' N ' HG23 ' A' ' 116' ' ' THR . . . -161.1 135.0 3.76 Favored Glycine 0 C--N 1.296 -1.686 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 176.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 40.2 t -65.79 121.67 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.535 0 CA-C-O 122.36 1.076 . . . . 0.0 110.952 176.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.8 tt -113.27 141.47 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.098 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.513 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.01 148.13 15.69 Favored Glycine 3 N--CA 1.383 -4.873 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.1 pt -69.94 103.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 CA-C-O 121.373 0.606 . . . . 0.0 110.699 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.635 ' O ' ' HG3' ' A' ' 3' ' ' LYS . . . -118.5 139.12 51.93 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 175.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 . . . . . 0 C--N 1.31 -1.126 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.644 -175.035 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 120.805 0.336 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 m -92.07 -46.94 7.53 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 120.739 0.304 . . . . 0.0 110.887 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.457 ' HA ' ' OD1' ' A' ' 19' ' ' ASN . 19.0 ptpt -154.25 166.48 33.01 Favored 'General case' 0 N--CA 1.433 -1.32 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.519 -176.62 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.669 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -146.26 153.36 40.5 Favored 'General case' 0 N--CA 1.424 -1.772 0 O-C-N 124.308 1.005 . . . . 0.0 108.336 176.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.25 114.23 14.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -113.51 128.1 56.32 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -122.53 120.44 60.98 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 121.391 0.615 . . . . 0.0 110.568 178.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -108.32 149.16 29.03 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.397 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -171.07 127.06 0.7 Allowed 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.35 -156.53 7.45 Favored Glycine 0 N--CA 1.429 -1.824 0 C-N-CA 120.175 -1.012 . . . . 0.0 112.179 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.46 -39.08 60.69 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.63 1.172 . . . . 0.0 111.347 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -107.32 161.97 13.53 Favored Glycine 0 N--CA 1.436 -1.326 0 N-CA-C 108.009 -2.036 . . . . 0.0 108.009 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -84.32 123.58 3.05 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 CA-C-N 120.491 2.145 . . . . 0.0 111.254 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.3 t -132.98 127.41 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 N-CA-C 103.599 -2.741 . . . . 0.0 103.599 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -142.06 116.58 9.66 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.89 170.3 43.09 Favored Glycine 0 N--CA 1.396 -3.985 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -177.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 24.9 pt -142.6 144.0 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.979 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 179.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.2 tp -139.13 136.18 42.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 177.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.669 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.3 t-20 -97.96 147.72 24.2 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.489 ' HA ' HG13 ' A' ' 31' ' ' VAL . 61.7 m-85 -138.09 119.33 14.62 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 119.182 0.901 . . . . 0.0 110.734 173.278 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.409 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 8.7 pt-20 -112.88 101.89 9.93 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.875 0.845 . . . . 0.0 111.191 174.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pm0 -91.06 150.32 21.47 Favored 'General case' 0 N--CA 1.404 -2.729 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.453 ' N ' ' HB ' ' A' ' 103' ' ' VAL . 40.9 tptt -138.38 154.17 48.93 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 -175.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.427 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.5 mp0 -62.68 -55.31 27.98 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 123.937 0.773 . . . . 0.0 113.053 -174.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.3 m -78.24 -71.79 0.41 Allowed 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -168.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.0 p30 177.89 140.67 0.09 Allowed 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -175.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.8 174.58 35.45 Favored Glycine 0 CA--C 1.48 -2.11 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.84 178.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -90.6 131.7 1.65 Allowed 'Trans proline' 0 N--CA 1.43 -2.226 0 C-N-CA 123.062 2.508 . . . . 0.0 110.854 175.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.33 101.82 2.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 176.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' HZ1' ' CD ' ' A' ' 21' ' ' GLU 0.263 0.9 OUTLIER -92.07 92.79 8.43 Favored 'General case' 0 CA--C 1.482 -1.64 0 CA-C-O 122.735 1.255 . . . . 0.0 111.824 177.266 . . . . . . . . 4 4 . 1 . 012 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.489 HG13 ' HA ' ' A' ' 20' ' ' PHE . 17.7 m -127.82 153.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.308 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.69 -175.214 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.48 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 31.0 m-90 -126.59 148.0 49.82 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.63 -172.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -166.17 140.11 6.16 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.8 m -117.16 146.56 43.12 Favored 'General case' 0 N--CA 1.389 -3.521 0 N-CA-C 105.949 -1.871 . . . . 0.0 105.949 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.739 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 17.0 tt -139.55 155.46 25.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.7 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 31.7 mmmt -136.33 131.31 34.14 Favored 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 105.501 -2.037 . . . . 0.0 105.501 -176.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -164.52 174.72 40.57 Favored Glycine 0 C--N 1.281 -2.505 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -173.472 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.3 mt -66.71 145.05 55.97 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 65.5 p -69.54 106.73 3.11 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -164.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -175.47 161.96 2.77 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 103.765 -2.68 . . . . 0.0 103.765 178.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.446 ' HA2' ' C ' ' A' ' 121' ' ' GLU . . . 158.86 137.09 2.17 Favored Glycine 1 CA--C 1.444 -4.364 0 C-N-CA 117.33 -2.367 . . . . 0.0 112.773 167.521 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.491 ' O ' ' HB2' ' A' ' 43' ' ' HIS . 0.5 OUTLIER 177.69 63.0 0.01 OUTLIER 'General case' 0 N--CA 1.447 -0.602 0 O-C-N 124.419 0.717 . . . . 0.0 110.243 -175.193 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.491 ' HB2' ' O ' ' A' ' 42' ' ' LEU . 35.9 t60 164.95 123.26 0.01 OUTLIER 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 172.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA2' ' N ' ' A' ' 87' ' ' VAL . . . -47.66 -134.73 0.0 OUTLIER Glycine 0 N--CA 1.486 1.995 0 N-CA-C 119.798 2.679 . . . . 0.0 119.798 -172.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.468 ' CD1' ' HA3' ' A' ' 85' ' ' GLY . 13.3 m-85 -88.88 162.3 16.21 Favored 'General case' 0 CA--C 1.471 -2.07 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 177.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.17 84.64 0.11 Allowed 'General case' 1 C--O 1.337 5.682 0 C-N-CA 120.212 -0.595 . . . . 0.0 112.266 -175.732 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.66 ' HB ' ' OE2' ' A' ' 49' ' ' GLU . 10.2 m -89.34 173.19 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 130.568 3.547 . . . . 0.0 114.323 -164.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.505 ' NE2' HG22 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -170.8 86.43 0.1 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.427 1.491 . . . . 0.0 108.195 174.422 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.66 ' OE2' ' HB ' ' A' ' 47' ' ' VAL . 3.0 mp0 -87.31 89.46 8.0 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 115.153 1.538 . . . . 0.0 115.153 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -118.21 -21.52 8.14 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 113.743 -1.571 . . . . 0.0 112.193 -177.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.559 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 92.32 110.94 1.86 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.847 -172.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -153.32 -171.24 3.85 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -73.97 135.77 43.19 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 177.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 t -67.41 5.27 0.8 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -173.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.75 5.82 8.13 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.993 -0.442 . . . . 0.0 110.591 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 173.86 136.45 2.21 Favored Glycine 0 CA--C 1.484 -1.862 0 C-N-CA 117.58 -2.248 . . . . 0.0 112.542 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 61' ' ' GLY . 53.7 m -96.84 87.87 4.42 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.496 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 p -83.29 -37.12 23.88 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-O 122.159 0.981 . . . . 0.0 111.61 172.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.0 m -90.03 -40.17 12.48 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.802 -170.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.76 -16.09 35.18 Favored 'General case' 0 N--CA 1.422 -1.869 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 57' ' ' CYS . . . 37.29 -144.81 0.13 Allowed Glycine 0 CA--C 1.488 -1.628 0 CA-C-N 111.786 -2.461 . . . . 0.0 116.387 171.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -82.71 87.35 1.37 Allowed 'Trans proline' 0 N--CA 1.403 -3.827 0 C-N-CA 122.144 1.896 . . . . 0.0 110.189 177.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 77.61 110.46 0.07 Allowed 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 114.298 -1.319 . . . . 0.0 114.479 170.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -170.48 91.78 0.18 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.737 -2.029 . . . . 0.0 105.538 173.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 25.8 t-20 -111.49 89.92 11.42 Favored Pre-proline 0 C--O 1.209 -1.035 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 -178.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -77.48 -11.32 17.27 Favored 'Trans proline' 0 C--N 1.323 -0.804 0 C-N-CA 122.786 2.324 . . . . 0.0 111.259 -173.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.5 tt -45.04 -62.18 1.34 Allowed 'General case' 0 CA--C 1.492 -1.262 0 O-C-N 125.254 1.596 . . . . 0.0 109.943 -175.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.717 ' OG ' ' HA ' ' A' ' 76' ' ' ASP . 19.8 m -106.04 -86.26 0.48 Allowed 'General case' 0 N--CA 1.389 -3.483 0 C-N-CA 117.546 -1.662 . . . . 0.0 111.538 176.109 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . 0.392 21.8 ttm180 -123.99 43.48 2.98 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 114.593 -2.843 . . . . 0.0 116.169 179.405 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 53.0 mtmt 75.27 -43.04 0.49 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 125.09 1.356 . . . . 0.0 113.688 173.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -70.21 -37.44 75.06 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.608 ' HA3' ' O ' ' A' ' 80' ' ' HIS . . . 171.55 171.63 36.84 Favored Glycine 0 C--O 1.266 2.152 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.732 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.69 77.14 0.1 Allowed Glycine 0 C--O 1.215 -1.046 0 CA-C-O 118.925 -0.931 . . . . 0.0 113.377 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.433 ' HD2' ' HB3' ' A' ' 77' ' ' GLU . 42.8 Cg_endo -64.79 -42.95 13.64 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.531 2.154 . . . . 0.0 115.653 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.576 ' O ' HG13 ' A' ' 104' ' ' ILE . 58.4 pttt -119.7 26.01 9.63 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.717 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 33.6 t70 61.76 85.06 0.13 Allowed 'General case' 0 CA--C 1.487 -1.472 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 -163.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.594 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 6.2 tp10 -121.95 -35.58 3.15 Favored 'General case' 0 C--O 1.169 -3.142 0 CA-C-N 113.803 -1.544 . . . . 0.0 113.984 -164.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.594 ' HB3' ' O ' ' A' ' 77' ' ' GLU . 12.6 tt0 76.73 112.33 0.07 Allowed 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -162.008 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 75.1 -174.93 0.13 Allowed 'General case' 0 C--O 1.25 1.114 0 CA-C-N 114.537 -1.21 . . . . 0.0 109.9 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.608 ' O ' ' HA3' ' A' ' 72' ' ' GLY . 61.7 t-80 . . . . . 0 N--CA 1.488 1.432 0 C-N-CA 125.693 1.597 . . . . 0.0 107.202 -178.388 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.9 mp . . . . . 0 N--CA 1.437 -1.098 0 N-CA-C 105.377 -2.083 . . . . 0.0 105.377 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.468 ' HA3' ' CD1' ' A' ' 45' ' ' PHE . . . 172.89 154.49 10.41 Favored Glycine 0 N--CA 1.422 -2.292 0 C-N-CA 118.982 -1.58 . . . . 0.0 114.6 176.562 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.474 ' H ' HG21 ' A' ' 99' ' ' ILE . 35.1 t30 -129.65 127.85 41.4 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 169.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.621 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 6.4 m -131.59 143.3 40.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.561 0 CA-C-N 118.216 0.462 . . . . 0.0 109.799 -173.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.9 m -142.37 96.24 2.92 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.628 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.452 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -137.87 154.74 49.44 Favored 'General case' 0 C--O 1.153 -3.978 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -179.66 -27.57 0.01 OUTLIER 'General case' 0 C--N 1.255 -3.511 0 CA-C-O 122.485 1.136 . . . . 0.0 109.409 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -77.14 -49.61 14.84 Favored 'General case' 0 C--N 1.255 -3.534 0 CA-C-N 112.964 -1.925 . . . . 0.0 110.986 -177.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -132.79 -1.08 3.41 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.822 -174.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.7 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 68.67 66.16 2.39 Favored Glycine 0 C--O 1.215 -1.054 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -177.197 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.739 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 22.7 t -150.21 104.55 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.517 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -110.23 119.63 39.87 Favored 'General case' 0 N--CA 1.4 -2.938 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 174.328 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -112.59 113.19 25.21 Favored 'General case' 0 C--N 1.273 -2.751 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 -177.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 13.7 m -111.21 145.46 17.43 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.065 0 N-CA-C 114.552 1.316 . . . . 0.0 114.552 -168.729 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.0 t -143.06 102.06 3.93 Favored 'General case' 0 N--CA 1.413 -2.309 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 166.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.474 HG21 ' H ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -117.23 171.54 5.68 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -176.185 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -140.77 112.17 7.37 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.03 -0.986 . . . . 0.0 109.668 176.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . 0.439 ' OD1' ' HB3' ' A' ' 75' ' ' LYS . 2.2 t0 -130.24 168.63 16.55 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.467 ' HB2' ' HB2' ' A' ' 75' ' ' LYS . 22.0 m -76.04 123.72 26.23 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 119.408 1.003 . . . . 0.0 111.253 -174.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.453 ' HB ' ' N ' ' A' ' 23' ' ' LYS . 26.8 m -56.13 -12.09 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 C-N-CA 126.439 1.896 . . . . 0.0 114.546 -175.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.576 HG13 ' O ' ' A' ' 75' ' ' LYS . 26.3 pt -66.59 -12.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 CA-C-O 120.657 0.265 . . . . 0.0 111.136 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.565 ' HB3' ' C ' ' A' ' 75' ' ' LYS . 5.1 p -84.88 89.76 7.63 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 172.284 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -69.79 119.34 13.87 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 165.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -74.65 87.57 2.17 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.513 ' HA2' ' CB ' ' A' ' 49' ' ' GLU . . . 162.49 136.91 2.08 Favored Glycine 0 N--CA 1.405 -3.375 0 CA-C-N 114.614 -1.175 . . . . 0.0 112.398 178.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -83.28 -73.56 0.4 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.616 0.246 . . . . 0.0 110.725 176.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -87.42 -19.72 27.66 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.531 179.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.402 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t -159.32 163.74 35.41 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 105.895 -1.891 . . . . 0.0 105.895 175.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.582 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 6.4 pt -104.47 -16.95 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.853 0 C-N-CA 125.507 1.523 . . . . 0.0 108.6 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.73 138.83 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.13 177.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.556 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 93.41 -0.34 68.21 Favored Glycine 0 CA--C 1.484 -1.846 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.021 171.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.559 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 2.6 mmp_? -87.55 144.53 26.65 Favored 'General case' 0 C--O 1.175 -2.823 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 2.3 p -98.61 119.47 37.39 Favored 'General case' 0 C--N 1.286 -2.193 0 CA-C-N 119.549 1.068 . . . . 0.0 113.165 -176.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.0 tt -88.27 131.67 34.69 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.505 HG22 ' NE2' ' A' ' 48' ' ' HIS . 93.5 t -102.24 109.49 26.44 Favored 'Isoleucine or valine' 0 C--O 1.267 2.009 0 C-N-CA 118.941 -1.103 . . . . 0.0 110.668 175.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.5 p -148.14 124.3 2.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.896 0.855 . . . . 0.0 113.192 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -144.02 157.44 44.33 Favored 'General case' 0 N--CA 1.41 -2.43 0 N-CA-C 101.872 -3.381 . . . . 0.0 101.872 168.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.538 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -68.92 89.79 0.42 Allowed 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.18 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.505 ' HD3' ' H ' ' A' ' 123' ' ' ALA . 2.2 tmtp? -173.85 168.12 4.3 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -174.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.505 ' H ' ' HD3' ' A' ' 122' ' ' LYS . . . -73.72 125.02 27.15 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 121.531 0.681 . . . . 0.0 111.175 173.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -156.1 112.89 3.15 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 125.526 1.53 . . . . 0.0 107.31 176.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.48 ' O ' ' HA2' ' A' ' 138' ' ' GLY . 7.4 m-20 -128.91 129.32 45.35 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.69 -53.82 5.62 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 123.277 0.36 . . . . 0.0 111.168 -177.33 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.76 -31.24 45.1 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.65 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -93.13 -46.71 7.3 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.214 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 63.96 -82.04 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.601 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 -171.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 169.89 -67.34 0.16 Allowed Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -177.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.63 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 51.6 t30 -119.4 -175.29 2.91 Favored 'General case' 0 C--O 1.253 1.237 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 175.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.407 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 41.9 mt-10 -54.01 -34.77 60.81 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -178.003 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . 0.63 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -83.79 -38.48 21.22 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.135 -178.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.451 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 14.6 m -65.16 -29.62 70.47 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.32 -175.209 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.4 t -68.53 -27.54 66.2 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 121.469 0.652 . . . . 0.0 109.892 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -84.05 -39.51 19.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.738 -178.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.0 m -72.26 -33.47 67.52 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 115.415 -0.812 . . . . 0.0 110.044 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.48 ' HA2' ' O ' ' A' ' 125' ' ' ASP . . . 59.72 45.96 94.84 Favored Glycine 0 CA--C 1.488 -1.626 0 N-CA-C 107.373 -2.291 . . . . 0.0 107.373 -171.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -34.42 104.62 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 O-C-N 126.424 1.896 . . . . 0.0 113.679 -166.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -151.8 172.43 16.18 Favored 'General case' 0 N--CA 1.425 -1.697 0 CA-C-N 113.523 -1.672 . . . . 0.0 108.353 -176.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.92 94.78 1.0 Allowed Glycine 0 N--CA 1.429 -1.779 0 N-CA-C 107.721 -2.152 . . . . 0.0 107.721 170.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 14.3 m -43.49 -44.29 5.88 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.922 1.689 . . . . 0.0 113.998 -172.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.471 ' HA ' ' H ' ' A' ' 57' ' ' CYS . 44.8 mtm180 -115.66 -25.95 7.64 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 177.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -46.62 -35.33 5.8 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.2 1.8 . . . . 0.0 112.539 -168.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 118' ' ' VAL . . . -141.58 87.76 2.09 Favored 'General case' 0 N--CA 1.388 -3.529 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 -179.221 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.439 ' SG ' HG23 ' A' ' 118' ' ' VAL . 86.5 m -138.7 138.91 38.16 Favored 'General case' 0 N--CA 1.419 -1.996 0 CA-C-N 114.035 -1.439 . . . . 0.0 107.845 176.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.21 148.95 18.55 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 174.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 27.9 m -68.95 123.91 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.809 0 CA-C-O 122.572 1.177 . . . . 0.0 111.97 178.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.402 HD13 ' N ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -98.2 138.51 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.561 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 174.439 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.582 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -174.4 151.99 13.66 Favored Glycine 3 N--CA 1.36 -6.37 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 177.642 . . . . . . . . 3 3 . 1 . 012 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.562 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.7 pp -60.57 114.54 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 170.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.41 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -126.94 114.89 18.44 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 118.221 -0.895 . . . . 0.0 109.267 -178.492 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.447 0 CA-C-O 121.047 0.451 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.6 t -121.68 -25.08 5.15 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.041 0.924 . . . . 0.0 110.167 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -135.78 150.5 49.49 Favored 'General case' 0 N--CA 1.416 -2.166 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -178.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.523 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.52 161.44 37.91 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.98 127.82 66.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-O 121.363 0.601 . . . . 0.0 109.961 178.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.432 ' HA ' ' CG2' ' A' ' 148' ' ' VAL . . . -107.81 146.89 31.62 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.768 -177.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.585 ' N ' HG11 ' A' ' 148' ' ' VAL . 41.1 t -134.5 104.94 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 -178.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.93 151.34 22.88 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.0 tmtt? -144.27 122.01 11.9 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 175.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.38 -178.46 30.54 Favored Glycine 0 N--CA 1.414 -2.8 0 C-N-CA 117.999 -2.048 . . . . 0.0 115.939 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.3 m-20 -102.35 111.34 23.59 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 170.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.41 68.94 1.03 Allowed Glycine 0 C--N 1.289 -2.059 0 N-CA-C 104.988 -3.245 . . . . 0.0 104.988 -164.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -62.66 128.0 22.19 Favored 'Trans proline' 0 CA--C 1.503 -1.045 0 C-N-CA 123.159 2.573 . . . . 0.0 114.914 -165.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 m -115.8 123.13 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.524 0 CA-C-N 113.727 -1.579 . . . . 0.0 108.324 177.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -111.66 117.84 34.02 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.61 166.93 40.11 Favored Glycine 1 N--CA 1.383 -4.885 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.377 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.436 HD13 ' O ' ' A' ' 17' ' ' ILE . 2.5 pp -134.38 139.28 48.3 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.673 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.3 tp -136.14 133.87 50.26 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.9 m-20 -92.9 160.71 14.79 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.523 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 44.4 m-85 -143.48 118.34 9.94 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 176.081 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.404 ' O ' ' HG3' ' A' ' 21' ' ' GLU . 13.0 pt-20 -124.94 101.06 6.88 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.314 -1.354 . . . . 0.0 114.073 171.451 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.504 ' CB ' ' HA ' ' A' ' 105' ' ' SER . 22.7 mm-40 -154.29 101.46 2.38 Favored 'General case' 0 CA--C 1.507 -0.677 0 C-N-CA 124.377 1.071 . . . . 0.0 110.462 164.065 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -167.37 -73.06 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -90.34 -33.39 16.1 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.088 179.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 p -65.19 -69.57 0.29 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.887 -1.051 . . . . 0.0 112.025 -178.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 66.7 107.53 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 124.476 1.11 . . . . 0.0 110.924 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.641 ' O ' ' HB3' ' A' ' 102' ' ' SER . . . 133.33 -147.31 18.96 Favored Glycine 0 CA--C 1.487 -1.66 0 C-N-CA 119.044 -1.55 . . . . 0.0 112.044 -177.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.32 123.29 13.22 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 122.512 2.141 . . . . 0.0 111.519 -177.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.429 HG21 ' HA ' ' A' ' 102' ' ' SER . 46.4 t -95.4 95.15 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.852 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -176.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -98.19 90.76 4.96 Favored 'General case' 0 N--CA 1.411 -2.418 0 CA-C-O 122.498 1.142 . . . . 0.0 108.981 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 99' ' ' ILE . 27.3 m -124.28 151.61 29.52 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.74 0 CA-C-N 113.001 -1.909 . . . . 0.0 109.724 -175.006 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.425 ' HA ' ' CG1' ' A' ' 97' ' ' VAL . 20.9 m-90 -135.48 145.89 47.59 Favored 'General case' 0 C--N 1.267 -3.005 0 CA-C-N 114.988 -1.005 . . . . 0.0 109.026 -175.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.408 ' H ' HG12 ' A' ' 97' ' ' VAL . . . -167.46 137.7 4.76 Favored Glycine 0 N--CA 1.424 -2.158 0 C-N-CA 118.046 -2.026 . . . . 0.0 112.638 172.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 p -118.38 138.71 52.25 Favored 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.4 mm -119.61 135.82 58.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -120.5 105.57 10.97 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 173.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.93 174.84 16.78 Favored Glycine 0 C--N 1.269 -3.144 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.893 -175.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.1 tp -66.01 137.42 57.1 Favored 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 104.384 -2.45 . . . . 0.0 104.384 173.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.9 p -68.72 108.96 3.6 Favored 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 115.766 1.765 . . . . 0.0 115.766 -160.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -173.6 170.03 4.16 Favored 'General case' 0 CA--C 1.472 -2.047 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.791 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 169.2 136.55 2.08 Favored Glycine 2 C--N 1.241 -4.715 0 C-N-CA 117.481 -2.295 . . . . 0.0 113.129 167.556 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.6 mt -140.99 -50.39 0.44 Allowed 'General case' 0 N--CA 1.426 -1.672 0 O-C-N 124.553 0.796 . . . . 0.0 111.379 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -149.83 153.49 36.85 Favored 'General case' 0 C--N 1.321 -0.665 0 O-C-N 121.922 -0.486 . . . . 0.0 109.792 -175.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.536 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -96.59 107.5 3.52 Favored Glycine 0 CA--C 1.458 -3.478 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 175.297 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 124' ' ' ASP . 29.4 p90 -121.79 83.49 2.1 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.525 ' O ' HG21 ' A' ' 47' ' ' VAL . 8.2 p80 -133.04 85.47 2.22 Favored 'General case' 0 N--CA 1.387 -3.586 0 O-C-N 118.968 -2.333 . . . . 0.0 113.607 -162.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.525 HG21 ' O ' ' A' ' 46' ' ' HIS . 43.4 t -170.47 136.12 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 C-N-CA 127.753 2.421 . . . . 0.0 108.168 171.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.579 ' HB2' ' O ' ' A' ' 116' ' ' THR . 2.0 m170 -150.35 94.76 2.16 Favored 'General case' 0 C--N 1.26 -3.309 0 CA-C-N 112.458 -2.155 . . . . 0.0 109.916 170.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.87 162.37 24.0 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 176.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.9 t80 71.74 28.96 2.62 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 115' ' ' ARG . . . -72.01 -170.47 13.98 Favored Glycine 0 N--CA 1.428 -1.883 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.958 176.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -176.34 -63.04 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.552 -164.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -108.28 121.91 45.86 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.637 -173.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.1 p -70.81 2.62 4.02 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -177.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.69 19.02 11.92 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.318 0.247 . . . . 0.0 110.434 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 154.78 131.54 1.49 Allowed Glycine 0 C--N 1.309 -0.923 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.968 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.431 ' HB2' ' HG2' ' A' ' 143' ' ' ARG . 15.8 m -82.62 91.92 7.05 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.0 t -78.56 -61.37 2.03 Favored 'General case' 0 N--CA 1.426 -1.661 0 O-C-N 124.11 0.881 . . . . 0.0 110.157 172.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 13.4 m -65.43 -47.2 77.04 Favored 'General case' 0 C--O 1.214 -0.806 0 C-N-CA 122.967 0.507 . . . . 0.0 111.941 -177.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.36 -6.65 52.53 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -40.58 -71.57 0.29 Allowed Glycine 0 CA--C 1.541 1.706 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 -175.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -72.12 -17.05 28.41 Favored 'Trans proline' 0 N--CA 1.48 0.684 0 C-N-CA 122.92 2.414 . . . . 0.0 112.381 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 65.64 107.18 0.04 OUTLIER 'General case' 0 C--O 1.242 0.665 0 C-N-CA 126.611 1.965 . . . . 0.0 112.56 -177.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -130.29 84.09 2.18 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 118.306 -1.358 . . . . 0.0 108.474 166.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -119.46 90.63 42.97 Favored Pre-proline 0 C--N 1.289 -2.033 0 CA-C-N 112.5 -2.136 . . . . 0.0 108.066 173.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -30.1 -54.49 0.2 Allowed 'Trans proline' 0 N--CA 1.484 0.956 1 C-N-CA 126.735 4.957 . . . . 0.0 119.626 -168.864 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -93.84 0.47 56.24 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 118.688 -1.205 . . . . 0.0 113.843 -173.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.625 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 28.6 m -78.6 48.43 0.79 Allowed 'General case' 0 C--O 1.246 0.892 0 CA-C-O 122.386 1.089 . . . . 0.0 109.095 175.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.9 mmm180 -133.2 -28.77 1.48 Allowed 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.283 -173.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 54.3 tptt -38.84 -56.83 1.31 Allowed 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.105 0.962 . . . . 0.0 113.563 -173.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 21.2 t-80 -177.61 59.94 0.01 OUTLIER 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.161 -0.447 . . . . 0.0 110.011 176.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.453 ' CA ' ' HB3' ' A' ' 78' ' ' GLU . . . -38.93 105.98 0.05 OUTLIER Glycine 0 N--CA 1.483 1.83 0 O-C-N 123.744 0.653 . . . . 0.0 112.676 173.246 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.52 168.26 24.22 Favored Glycine 0 N--CA 1.413 -2.84 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -176.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -93.29 1.72 3.45 Favored 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 123.333 2.689 . . . . 0.0 115.985 -172.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.433 ' O ' ' HB3' ' A' ' 76' ' ' ASP . 87.1 mttt -108.5 -31.67 7.71 Favored 'General case' 0 C--O 1.262 1.715 0 C-N-CA 118.096 -1.442 . . . . 0.0 109.773 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 75' ' ' LYS . 0.8 OUTLIER 159.3 120.09 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.758 0 C-N-CA 128.301 2.64 . . . . 0.0 104.291 168.813 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 164.33 127.26 0.01 OUTLIER 'General case' 0 CA--C 1.454 -2.715 0 C-N-CA 124.459 1.104 . . . . 0.0 111.194 171.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.625 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.7 OUTLIER 162.75 -173.84 0.01 OUTLIER 'General case' 0 N--CA 1.396 -3.147 0 C-N-CA 130.885 3.674 . . . . 0.0 102.325 163.982 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.683 ' NE ' ' HA ' ' A' ' 79' ' ' ARG 0.381 1.4 mmp_? -121.01 11.25 10.95 Favored 'General case' 0 C--N 1.257 -3.415 0 N-CA-C 118.337 2.718 . . . . 0.0 118.337 -176.872 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.481 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.6 OUTLIER . . . . . 0 CA--C 1.483 -1.629 0 C-N-CA 117.37 -1.732 . . . . 0.0 110.804 170.006 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.603 HD21 ' N ' ' A' ' 85' ' ' GLY . 5.8 tt . . . . . 0 N--CA 1.433 -1.286 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 . . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . 0.603 ' N ' HD21 ' A' ' 84' ' ' LEU . . . -38.89 147.53 0.13 Allowed Glycine 0 N--CA 1.466 0.686 0 C-N-CA 125.005 1.288 . . . . 0.0 114.948 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -79.49 136.3 36.87 Favored 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 114.682 -0.759 . . . . 0.0 109.162 -166.274 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.536 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 30.3 m -134.72 126.69 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.408 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.6 t -141.28 148.2 39.42 Favored 'General case' 0 C--N 1.267 -3.001 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 -177.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.791 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -132.76 154.38 50.29 Favored 'General case' 0 C--N 1.259 -3.326 0 N-CA-C 105.362 -2.088 . . . . 0.0 105.362 178.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.543 ' C ' ' H ' ' A' ' 92' ' ' ASP . 6.9 t70 -101.65 -153.45 0.46 Allowed 'General case' 1 C--N 1.225 -4.841 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.548 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -62.66 16.82 0.01 OUTLIER 'General case' 0 CA--C 1.58 2.116 0 O-C-N 121.587 -0.696 . . . . 0.0 112.845 171.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.543 ' H ' ' C ' ' A' ' 90' ' ' ASP . 17.0 t70 -133.68 109.65 9.31 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 171.369 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -76.43 92.59 0.98 Allowed Glycine 0 C--N 1.32 -0.357 0 N-CA-C 114.911 0.725 . . . . 0.0 114.911 -170.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.7 t -158.46 103.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 176.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.481 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.18 128.75 43.37 Favored 'General case' 0 N--CA 1.398 -3.027 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.677 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -82.15 153.36 26.06 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 124.144 0.902 . . . . 0.0 110.642 -174.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.425 ' CG1' ' HA ' ' A' ' 32' ' ' TRP . 78.4 t -81.21 134.91 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 C-N-CA 124.203 1.001 . . . . 0.0 111.668 -172.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 61.5 m -122.97 123.76 41.65 Favored 'General case' 0 N--CA 1.414 -2.245 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.045 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.427 HG23 ' O ' ' A' ' 31' ' ' VAL . 31.8 pt -94.43 160.39 2.72 Favored 'Isoleucine or valine' 0 C--O 1.25 1.106 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -142.99 159.28 42.53 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-O 122.159 0.98 . . . . 0.0 113.239 -171.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.22 169.4 17.39 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 172.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.641 ' HB3' ' O ' ' A' ' 27' ' ' GLY . 10.9 p -57.34 91.94 0.01 OUTLIER 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -173.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.56 -38.16 2.07 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.225 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.063 173.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.403 ' O ' HG23 ' A' ' 104' ' ' ILE . 25.3 mm -72.37 25.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 C-N-CA 126.919 2.088 . . . . 0.0 111.936 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.504 ' HA ' ' CB ' ' A' ' 22' ' ' GLN . 16.8 p -66.95 149.65 50.32 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 121.667 -0.646 . . . . 0.0 110.831 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . 0.308 0.9 OUTLIER -80.95 86.3 6.11 Favored 'General case' 0 N--CA 1.388 -3.536 0 CA-C-O 124.647 2.165 . . . . 0.0 111.505 178.573 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.7 m -149.85 85.95 1.43 Allowed 'General case' 2 N--CA 1.367 -4.613 1 N-CA-C 100.061 -4.051 . . . . 0.0 100.061 168.457 . . . . . . . . 3 2 . 1 . 013 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -125.31 -155.99 9.21 Favored Glycine 0 C--N 1.26 -3.674 0 CA-C-N 113.46 -1.7 . . . . 0.0 109.444 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -92.2 -44.54 8.72 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . 0.418 ' O ' ' HB2' ' A' ' 111' ' ' SER . 23.1 m80 -118.64 -50.77 2.4 Favored 'General case' 0 N--CA 1.434 -1.234 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.444 175.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 110' ' ' HIS . 33.2 t 165.45 168.03 0.02 OUTLIER 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 177.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.52 ' O ' HG22 ' A' ' 149' ' ' ILE . 50.1 mm -71.72 -45.98 63.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 3.5 mp -71.71 121.25 21.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.726 -0.609 . . . . 0.0 111.764 -172.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.83 -0.05 25.81 Favored Glycine 0 CA--C 1.478 -2.225 0 C-N-CA 120.403 -0.903 . . . . 0.0 110.873 170.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.503 ' HB2' ' HB ' ' A' ' 149' ' ' ILE . 11.1 mmt180 -91.86 173.52 7.82 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.59 -178.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.579 ' O ' ' HB2' ' A' ' 48' ' ' HIS . 17.5 p -128.46 103.77 7.32 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-O 118.725 -0.655 . . . . 0.0 110.998 -173.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.578 HD22 ' O ' ' A' ' 148' ' ' VAL . 0.7 OUTLIER -76.26 137.16 39.76 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 120.312 1.414 . . . . 0.0 111.573 -178.026 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.548 ' HA ' ' HB3' ' A' ' 146' ' ' CYS . 11.5 p -92.87 125.25 45.46 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.436 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 176.11 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.8 p -148.55 130.88 6.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 C-N-CA 118.961 -1.095 . . . . 0.0 113.115 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 16.3 t-80 -154.93 151.33 28.41 Favored 'General case' 0 N--CA 1.416 -2.169 0 N-CA-C 102.348 -3.204 . . . . 0.0 102.348 163.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.487 ' O ' ' HA2' ' A' ' 41' ' ' GLY . 2.9 mp0 -70.3 99.52 1.56 Allowed 'General case' 0 C--N 1.269 -2.896 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 174.12 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -168.31 173.83 7.46 Favored 'General case' 0 C--O 1.199 -1.59 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -171.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.01 120.48 26.17 Favored 'General case' 0 C--N 1.256 -3.471 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 177.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.602 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -167.13 136.77 2.87 Favored 'General case' 0 N--CA 1.509 2.512 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.012 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -149.89 150.9 32.59 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.823 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -90.95 -39.31 12.33 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.11 -33.91 5.84 Favored Glycine 0 C--N 1.3 -1.465 0 C-N-CA 119.753 -1.213 . . . . 0.0 111.65 -175.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 49.1 tptt -118.43 41.34 2.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -176.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.91 -7.24 69.8 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 115.463 -0.79 . . . . 0.0 114.736 -176.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 144.11 -122.42 1.81 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.492 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.447 ' O ' HG23 ' A' ' 135' ' ' THR . 88.9 m-20 -99.65 -174.54 2.74 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -177.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -47.09 -52.65 14.69 Favored 'General case' 0 N--CA 1.484 1.228 0 O-C-N 123.564 0.54 . . . . 0.0 111.264 -176.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -77.71 -40.85 39.9 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.7 p -75.53 -27.17 58.59 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -175.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.447 HG23 ' O ' ' A' ' 131' ' ' ASN . 13.9 t -76.12 -33.25 59.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 176.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -74.08 -32.54 63.3 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.727 -179.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 86.4 m -79.22 -31.05 43.55 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.304 174.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.73 60.94 8.1 Favored Glycine 0 CA--C 1.484 -1.884 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -36.31 105.62 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 125.733 1.49 . . . . 0.0 111.876 -174.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HA ' ' HB2' ' A' ' 124' ' ' ASP . . . -101.8 169.93 8.48 Favored 'General case' 0 N--CA 1.429 -1.516 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.92 -169.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 143' ' ' ARG . . . -63.96 154.02 47.12 Favored Glycine 0 N--CA 1.406 -3.303 0 N-CA-C 106.481 -2.648 . . . . 0.0 106.481 169.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -57.01 8.81 0.01 OUTLIER 'General case' 0 C--N 1.262 -3.223 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.457 ' H ' ' C ' ' A' ' 141' ' ' GLY . 0.2 OUTLIER 65.67 19.17 11.39 Favored 'General case' 0 CA--C 1.467 -2.224 0 C-N-CA 125.277 1.431 . . . . 0.0 107.959 177.675 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 53.0 mt -70.94 -33.24 70.3 Favored 'General case' 0 CA--C 1.445 -3.072 0 CA-C-N 113.91 -1.495 . . . . 0.0 107.668 -176.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.487 ' O ' ' HB3' ' A' ' 146' ' ' CYS . . . -121.98 89.74 3.17 Favored 'General case' 1 N--CA 1.35 -5.458 0 CA-C-N 113.557 -1.656 . . . . 0.0 108.158 175.38 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 118' ' ' VAL . 19.9 p -171.91 127.94 0.61 Allowed 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 113.812 1.042 . . . . 0.0 113.812 169.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.542 ' HA2' ' CB ' ' A' ' 116' ' ' THR . . . -178.51 77.93 0.07 OUTLIER Glycine 0 N--CA 1.402 -3.62 0 CA-C-O 118.638 -1.09 . . . . 0.0 110.656 159.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.585 HG11 ' N ' ' A' ' 7' ' ' VAL . 13.1 p -172.58 96.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.184 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 169.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.545 ' CD1' ' HB3' ' A' ' 117' ' ' LEU . 12.2 mm -124.46 102.68 11.28 Favored 'Isoleucine or valine' 1 C--N 1.234 -4.445 0 N-CA-C 104.692 -2.336 . . . . 0.0 104.692 167.364 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -165.59 146.56 11.25 Favored Glycine 2 CA--C 1.444 -4.394 0 C-N-CA 115.941 -3.028 . . . . 0.0 112.678 175.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.515 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 0.0 OUTLIER -95.26 105.56 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.568 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 171.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.92 99.61 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.441 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.245 0.863 0 N-CA-C 105.466 -2.049 . . . . 0.0 105.466 178.07 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.207 -1.145 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 m -100.48 -27.63 13.33 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -171.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -136.66 148.62 47.51 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.169 -173.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.538 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -142.35 143.19 32.63 Favored 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 92.1 t -124.26 129.13 74.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -120.11 145.61 46.74 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.939 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 56.5 t -127.38 126.07 66.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 85.3 mt -112.1 133.08 54.47 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -142.6 133.54 25.68 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.68 -170.89 21.59 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 119.362 -1.399 . . . . 0.0 112.553 -177.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -73.31 -46.1 51.49 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -101.58 96.29 1.47 Allowed Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 171.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -71.53 127.09 12.79 Favored 'Trans proline' 0 N--CA 1.434 -1.986 0 C-N-CA 121.797 1.665 . . . . 0.0 113.968 -168.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.91 148.28 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.286 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 173.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -123.94 118.64 27.51 Favored 'General case' 0 C--N 1.259 -3.355 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -177.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -167.26 146.48 10.77 Favored Glycine 0 N--CA 1.409 -3.101 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.891 -178.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.2 pt -130.66 118.24 41.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.459 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.1 OUTLIER -114.88 133.04 62.27 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.103 -176.708 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 24.0 m-80 -109.46 119.73 40.33 Favored 'General case' 0 CA--C 1.51 -0.589 0 C-N-CA 123.309 0.644 . . . . 0.0 109.592 -173.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.486 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 56.7 m-85 -120.76 137.41 54.52 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.779 0.323 . . . . 0.0 110.617 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.522 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 9.9 pt-20 -107.89 134.0 51.45 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.418 175.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.523 ' HA ' ' O ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -126.91 112.45 15.32 Favored 'General case' 0 N--CA 1.413 -2.307 0 C-N-CA 123.777 0.831 . . . . 0.0 109.459 178.309 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.8 tttm -138.12 149.07 45.58 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.34 -173.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . 0.519 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.1 mp0 -50.51 -44.29 56.05 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 125.728 1.611 . . . . 0.0 110.332 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.6 m -51.72 -45.24 63.51 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.651 1.18 . . . . 0.0 111.913 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.8 t30 57.62 87.59 0.06 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 124.294 0.996 . . . . 0.0 111.917 -179.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.477 ' H ' HG21 ' A' ' 104' ' ' ILE . . . -132.47 -151.6 6.79 Favored Glycine 0 CA--C 1.492 -1.361 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.19 -177.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_exo -67.6 124.18 11.67 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.215 1.943 . . . . 0.0 108.01 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 13.4 p -80.01 132.69 31.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 CA-C-O 121.23 0.538 . . . . 0.0 110.5 -176.632 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -93.98 99.21 11.58 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 169.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 5.9 p -123.44 130.54 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.001 0 CA-C-N 115.311 -0.858 . . . . 0.0 108.711 -175.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -136.44 125.49 24.42 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.498 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.459 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -164.25 140.17 6.29 Favored Glycine 0 N--CA 1.41 -3.045 0 C-N-CA 119.724 -1.226 . . . . 0.0 111.933 172.745 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 16.9 m -116.04 135.46 53.93 Favored 'General case' 0 N--CA 1.404 -2.77 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 12.1 tt -125.13 136.94 59.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 118.54 0.609 . . . . 0.0 109.976 179.183 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 91.7 mttt -116.92 131.84 56.85 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.128 -2.175 . . . . 0.0 105.128 -177.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.588 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -155.0 175.8 32.91 Favored Glycine 0 C--N 1.269 -3.169 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -166.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.62 171.0 8.23 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 175.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.0 t -69.47 107.18 3.25 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.809 -175.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.551 ' OE2' ' HG2' ' A' ' 122' ' ' LYS . 22.2 tt0 -177.08 171.13 2.14 Favored 'General case' 0 N--CA 1.419 -2.011 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 171.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . 0.709 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 170.78 104.83 0.18 Allowed Glycine 1 C--N 1.251 -4.144 0 C-N-CA 119.02 -1.562 . . . . 0.0 111.843 169.543 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.414 ' HB2' ' N ' ' A' ' 123' ' ' ALA . 6.8 mp -110.78 -86.89 0.53 Allowed 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.062 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.597 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 39.4 t-80 -175.15 122.3 0.22 Allowed 'General case' 0 C--N 1.355 0.823 0 C-N-CA 118.364 -1.335 . . . . 0.0 114.35 -173.388 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.99 137.94 9.74 Favored Glycine 0 C--N 1.3 -1.432 0 N-CA-C 117.502 1.761 . . . . 0.0 117.502 164.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.436 ' CE1' HD22 ' A' ' 117' ' ' LEU . 0.7 OUTLIER -96.18 166.73 11.6 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 124.028 0.931 . . . . 0.0 109.359 170.179 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.693 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . 6.1 m80 -171.83 90.44 0.12 Allowed 'General case' 0 CA--C 1.482 -1.661 0 C-N-CA 125.298 1.439 . . . . 0.0 110.004 169.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.49 HG23 ' C ' ' A' ' 116' ' ' THR . 2.6 p -69.36 162.7 3.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 168.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.461 ' CE1' ' HD2' ' A' ' 62' ' ' PRO 0.278 0.0 OUTLIER -148.85 171.49 16.21 Favored 'General case' 0 N--CA 1.419 -1.979 0 C-N-CA 116.562 -2.055 . . . . 0.0 109.482 170.187 . . . . . . . . 4 4 . 1 . 014 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -69.57 166.35 19.16 Favored 'General case' 0 C--N 1.261 -3.273 0 N-CA-C 116.072 1.879 . . . . 0.0 116.072 -171.043 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 59' ' ' SER . 4.0 t80 72.77 33.26 1.32 Allowed 'General case' 0 N--CA 1.439 -1.023 0 C-N-CA 126.321 1.848 . . . . 0.0 107.243 172.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.424 ' HA2' ' HB1' ' A' ' 60' ' ' ALA . . . -57.56 154.84 20.49 Favored Glycine 0 C--N 1.345 1.048 0 CA-C-N 112.42 -2.173 . . . . 0.0 113.063 -178.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . 0.504 ' OD1' ' HA ' ' A' ' 57' ' ' CYS . 3.8 p30 -144.8 -85.75 0.13 Allowed 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -172.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.542 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 52.7 t30 -98.31 148.77 23.31 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.288 0.566 . . . . 0.0 112.43 -173.392 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.463 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 6.9 m -82.3 -2.93 54.26 Favored 'General case' 0 CA--C 1.56 1.349 0 C-N-CA 124.323 1.049 . . . . 0.0 111.652 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.99 17.06 7.92 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 121.097 0.475 . . . . 0.0 111.02 -177.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.542 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 143.94 117.16 1.16 Allowed Glycine 0 CA--C 1.484 -1.864 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -177.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.549 ' O ' ' HB2' ' A' ' 142' ' ' SER . 6.1 p -97.53 113.69 25.44 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -175.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.0 p -80.0 -45.42 18.44 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . 49.8 m -79.37 -29.0 41.94 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 123.445 0.698 . . . . 0.0 111.216 -174.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.424 ' HB1' ' HA2' ' A' ' 51' ' ' GLY . . . -76.71 -5.26 47.28 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 123.981 0.912 . . . . 0.0 111.19 172.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.22 52.1 0.91 Allowed Glycine 0 CA--C 1.559 2.801 0 C-N-CA 117.177 -2.439 . . . . 0.0 116.247 176.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' A' ' 59' ' ' SER . 86.9 Cg_endo -96.37 2.93 1.99 Allowed 'Trans proline' 0 C--N 1.397 3.127 0 CA-C-N 121.821 2.81 . . . . 0.0 107.322 161.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 38.9 m80 75.22 -47.75 0.61 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 125.541 1.536 . . . . 0.0 113.623 173.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.4 ' CE2' ' HB3' ' A' ' 66' ' ' PRO . 70.1 t80 -69.27 116.12 9.34 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -170.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -116.16 96.49 47.49 Favored Pre-proline 0 CA--C 1.559 1.309 0 C-N-CA 125.061 1.344 . . . . 0.0 110.089 176.82 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.4 ' HB3' ' CE2' ' A' ' 64' ' ' PHE . 96.7 Cg_endo -79.95 -18.7 10.06 Favored 'Trans proline' 0 CA--C 1.552 1.384 0 C-N-CA 123.119 2.546 . . . . 0.0 117.823 -169.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 84.0 mt -88.09 -5.32 58.52 Favored 'General case' 0 CA--C 1.484 -1.567 0 O-C-N 120.817 -1.177 . . . . 0.0 110.906 -172.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.48 ' C ' ' H ' ' A' ' 70' ' ' LYS . 17.9 m -77.92 58.05 1.85 Allowed 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 104.533 -2.395 . . . . 0.0 104.533 167.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.516 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 2.1 tmm_? -92.59 17.56 9.98 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -169.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.488 ' HB2' ' CB ' ' A' ' 78' ' ' GLU . 11.9 mptt -140.03 63.97 1.46 Allowed 'General case' 0 N--CA 1.411 -2.402 0 CA-C-N 112.705 -2.043 . . . . 0.0 109.411 175.135 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . 0.433 ' O ' ' HB3' ' A' ' 126' ' ' LEU . 20.2 t60 65.38 -37.57 0.24 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 125.313 1.445 . . . . 0.0 113.284 -178.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.13 20.68 62.34 Favored Glycine 0 N--CA 1.414 -2.816 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -175.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.603 ' O ' ' HG3' ' A' ' 77' ' ' GLU . . . -90.31 175.53 41.14 Favored Glycine 0 C--O 1.202 -1.897 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.863 -177.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.533 ' C ' ' H ' ' A' ' 76' ' ' ASP . 2.8 Cg_exo -72.07 2.34 4.99 Favored 'Trans proline' 0 N--CA 1.501 1.926 1 C-N-CA 125.717 4.278 . . . . 0.0 111.302 -170.562 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.484 ' H ' ' C ' ' A' ' 73' ' ' GLY . 60.9 tttm -76.59 27.59 0.13 Allowed 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 127.402 2.281 . . . . 0.0 109.089 178.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.533 ' H ' ' C ' ' A' ' 74' ' ' PRO 0.303 1.2 p30 77.18 10.32 2.51 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 128.453 2.701 . . . . 0.0 115.665 173.597 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.603 ' HG3' ' O ' ' A' ' 73' ' ' GLY . 1.7 mp0 33.19 108.19 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 127.639 2.375 . . . . 0.0 114.089 170.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.516 ' OE1' ' HB3' ' A' ' 69' ' ' ARG . 43.1 tt0 -34.73 -61.66 0.39 Allowed 'General case' 0 N--CA 1.507 2.392 0 O-C-N 123.914 0.759 . . . . 0.0 112.133 -177.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 75.0 mtt85 -136.62 63.64 1.57 Allowed 'General case' 0 C--N 1.286 -2.177 0 C-N-CA 118.834 -1.146 . . . . 0.0 111.056 174.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.607 ' NE2' ' HB2' ' A' ' 105' ' ' SER . 0.3 OUTLIER . . . . . 0 CA--C 1.505 -0.751 0 CA-C-O 122.729 1.252 . . . . 0.0 113.375 171.455 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.446 ' CD1' ' HA2' ' A' ' 73' ' ' GLY . 1.6 tt . . . . . 0 N--CA 1.423 -1.823 0 CA-C-O 121.645 0.736 . . . . 0.0 109.28 . . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.02 136.51 13.52 Favored Glycine 0 N--CA 1.419 -2.487 0 N-CA-C 104.853 -3.299 . . . . 0.0 104.853 165.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . 0.359 0.2 OUTLIER -92.11 128.69 38.05 Favored 'General case' 0 N--CA 1.426 -1.645 0 C-N-CA 115.171 -2.611 . . . . 0.0 113.318 -173.189 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 92.6 t -110.64 138.7 37.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.186 -174.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.5 p -140.15 95.09 2.83 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 -179.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.709 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -86.14 137.03 32.97 Favored 'General case' 0 N--CA 1.415 -2.217 0 CA-C-O 121.406 0.622 . . . . 0.0 109.945 -176.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 92' ' ' ASP . 30.8 t70 -75.23 154.62 37.44 Favored 'General case' 1 C--N 1.242 -4.103 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 174.516 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -53.07 23.07 0.0 OUTLIER 'General case' 0 CA--C 1.579 2.094 0 N-CA-C 115.839 1.792 . . . . 0.0 115.839 174.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 90' ' ' ASP . 1.5 m-20 -133.89 8.63 3.82 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 124.945 1.298 . . . . 0.0 108.787 171.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 66.8 80.08 0.2 Allowed Glycine 0 N--CA 1.44 -1.046 0 CA-C-N 114.998 -1.001 . . . . 0.0 112.564 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.571 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.5 p -161.71 113.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 34' ' ' SER . . . -136.8 144.63 43.81 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -119.58 115.14 23.38 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 175.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.413 HG13 ' CE2' ' A' ' 45' ' ' PHE . 4.3 p -102.92 103.41 15.04 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.352 0 CA-C-O 122.173 0.987 . . . . 0.0 111.714 -178.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.2 m -139.65 100.18 3.9 Favored 'General case' 0 N--CA 1.421 -1.894 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 172.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.9 mm -135.3 128.45 48.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -176.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.462 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 43.0 mt-10 -104.5 106.19 16.59 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -160.51 168.66 24.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 104.369 -2.456 . . . . 0.0 104.369 170.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.488 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 24.8 m -80.76 79.18 7.45 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 115.726 1.75 . . . . 0.0 115.726 -169.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.528 ' HA ' ' CE1' ' A' ' 80' ' ' HIS . 12.4 p -92.51 -11.62 9.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 169.476 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.523 ' O ' ' HA ' ' A' ' 22' ' ' GLN . 15.9 tt -57.87 19.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.102 0 C-N-CA 130.201 3.4 . . . . 0.0 114.235 -176.306 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.607 ' HB2' ' NE2' ' A' ' 80' ' ' HIS . 16.4 m -97.85 170.91 8.64 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 103.627 -2.731 . . . . 0.0 103.627 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.425 ' O ' HD12 ' A' ' 106' ' ' LEU . 2.6 pp -68.14 119.13 12.23 Favored 'General case' 0 N--CA 1.414 -2.24 0 C-N-CA 117.689 -1.605 . . . . 0.0 109.467 176.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 m -68.95 89.75 0.42 Allowed 'General case' 0 N--CA 1.414 -2.234 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.303 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 155.27 155.69 7.44 Favored Glycine 0 N--CA 1.401 -3.64 0 CA-C-N 114.155 -1.384 . . . . 0.0 110.501 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -69.66 -38.91 77.29 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -107.37 -48.07 3.52 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.266 -175.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.572 ' O ' ' HD2' ' A' ' 115' ' ' ARG . 15.3 m -163.04 159.92 23.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.491 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -72.79 -46.6 52.72 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.894 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.077 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 tp -67.56 127.15 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 176.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.98 11.93 58.29 Favored Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 119.611 -1.28 . . . . 0.0 110.768 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.572 ' HD2' ' O ' ' A' ' 111' ' ' SER . 0.0 OUTLIER -114.67 121.55 43.73 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.237 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.811 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 14.9 p -98.45 135.56 39.83 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-O 121.856 0.836 . . . . 0.0 111.638 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 56.2 tp -74.66 102.87 4.74 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 113.937 -1.483 . . . . 0.0 111.485 -174.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.409 HG12 ' HA ' ' A' ' 142' ' ' SER . 12.6 m -93.21 96.36 6.12 Favored 'Isoleucine or valine' 1 C--O 1.33 5.293 0 C-N-CA 116.314 -2.154 . . . . 0.0 112.821 175.035 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.446 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 7.1 p -150.5 171.57 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 113.46 -1.7 . . . . 0.0 107.992 -176.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.437 ' H ' HG22 ' A' ' 119' ' ' VAL . 82.2 t60 -152.04 170.76 19.12 Favored 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 168.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -69.77 88.37 0.54 Allowed 'General case' 0 CA--C 1.551 0.983 0 CA-C-N 123.016 2.643 . . . . 0.0 109.045 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.551 ' HG2' ' OE2' ' A' ' 40' ' ' GLU . 65.8 mttm -166.75 173.31 9.68 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 125.771 1.628 . . . . 0.0 108.318 -168.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -82.68 114.52 21.1 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 172.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.693 ' OD1' ' HB2' ' A' ' 46' ' ' HIS . 11.9 t70 -124.31 76.58 1.49 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -176.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -114.43 158.59 21.35 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.155 0.502 . . . . 0.0 110.548 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.455 ' O ' ' HA ' ' A' ' 135' ' ' THR . 3.2 tm? -87.85 -56.35 3.38 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.467 -1.242 . . . . 0.0 108.007 -179.381 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 71' ' ' HIS . . . -68.26 -40.63 87.44 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.725 -177.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -105.43 50.74 0.77 Allowed 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.25 76.73 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.588 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -67.29 0.53 Allowed Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.379 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.425 ' H ' ' CB ' ' A' ' 134' ' ' SER . 4.1 m-20 -105.99 176.81 5.04 Favored 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 119.052 -0.499 . . . . 0.0 109.945 -179.121 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -56.18 -44.07 79.02 Favored 'General case' 0 CA--C 1.567 1.634 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 176.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -71.85 -33.39 68.4 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.425 ' CB ' ' H ' ' A' ' 131' ' ' ASN . 2.3 m -68.1 -19.97 64.89 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.969 0.414 . . . . 0.0 110.887 -175.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.455 ' HA ' ' O ' ' A' ' 126' ' ' LEU . 8.8 m -74.0 -21.3 60.04 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 121.511 0.672 . . . . 0.0 109.823 178.563 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -83.24 -51.18 7.69 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.3 p -69.01 -50.59 47.46 Favored 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.965 -177.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' A' ' 126' ' ' LEU . . . 67.16 92.45 0.04 OUTLIER Glycine 0 N--CA 1.418 -2.532 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -174.508 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -31.77 136.63 0.06 Allowed 'General case' 1 C--O 1.322 4.892 0 N-CA-C 118.813 2.894 . . . . 0.0 118.813 -167.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -126.51 129.01 47.79 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 112.925 -1.943 . . . . 0.0 109.246 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -115.23 75.33 0.25 Allowed Glycine 0 N--CA 1.416 -2.665 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 176.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.549 ' HB2' ' O ' ' A' ' 57' ' ' CYS . 77.5 p -58.92 -26.82 64.69 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 123.848 0.859 . . . . 0.0 112.306 -175.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -117.52 -0.89 11.79 Favored 'General case' 0 N--CA 1.427 -1.617 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.803 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.401 ' HB3' ' HB2' ' A' ' 120' ' ' HIS . 3.9 mm? -79.05 -34.84 43.45 Favored 'General case' 0 C--N 1.282 -2.367 0 C-N-CA 117.949 -1.5 . . . . 0.0 110.393 -176.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.446 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -173.96 89.45 0.07 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 177.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.811 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 44.6 t -139.07 133.11 31.15 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 118.159 -1.416 . . . . 0.0 110.34 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.463 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -161.18 166.02 35.59 Favored Glycine 0 N--CA 1.398 -3.897 0 N-CA-C 107.967 -2.053 . . . . 0.0 107.967 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.92 122.37 20.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.086 0.47 . . . . 0.0 110.339 -178.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.403 HD12 ' CD1' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -116.26 106.5 20.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.233 . . . . . . . . 3 3 . 1 . 014 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.31 -179.29 43.08 Favored Glycine 1 N--CA 1.392 -4.268 0 N-CA-C 110.031 -1.227 . . . . 0.0 110.031 -179.125 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.419 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.3 tt -54.87 114.47 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 121.751 0.786 . . . . 0.0 112.475 -179.041 . . . . . . . . 2 2 . 1 . 014 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.93 154.9 39.06 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 176.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 . . . . . 0 C--N 1.29 -1.995 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.819 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.21 -0.987 0 CA-C-O 120.283 0.087 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.3 m -76.26 -27.92 56.88 Favored 'General case' 0 CA--C 1.562 1.434 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -175.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 151' ' ' ILE . 20.2 ptpt -152.63 167.55 28.52 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.594 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -153.02 152.5 31.45 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 175.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.3 t -134.41 138.37 49.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.449 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -109.44 134.61 51.65 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -175.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . 0.532 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 46.9 t -134.31 102.55 4.27 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.366 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 175.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . 0.436 HD22 ' H ' ' A' ' 8' ' ' LEU . 1.5 pt? -117.74 132.49 56.46 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -178.015 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -138.0 138.59 39.03 Favored 'General case' 0 C--O 1.248 0.98 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.76 -158.76 8.87 Favored Glycine 0 N--CA 1.435 -1.386 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.045 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -63.63 -50.97 67.25 Favored 'General case' 0 CA--C 1.511 -0.554 0 O-C-N 124.537 0.787 . . . . 0.0 109.167 177.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -88.65 154.95 25.32 Favored Glycine 0 N--CA 1.44 -1.1 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 175.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -86.23 124.35 2.43 Favored 'Trans proline' 0 N--CA 1.414 -3.149 0 CA-C-N 120.342 2.071 . . . . 0.0 110.072 -176.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.453 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 13.8 m -131.66 146.78 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.966 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 -179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.49 123.29 3.77 Favored 'General case' 0 C--N 1.251 -3.707 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.437 ' HA3' HG12 ' A' ' 35' ' ' ILE . . . -153.11 157.95 27.64 Favored Glycine 0 N--CA 1.396 -3.978 0 C-N-CA 119.945 -1.122 . . . . 0.0 111.068 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.407 ' O ' HG13 ' A' ' 17' ' ' ILE . 25.2 pt -123.97 102.43 11.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.519 HG13 ' HA3' ' A' ' 33' ' ' GLY . 1.8 mp -107.53 128.48 62.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.594 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 30.4 p-10 -115.91 125.74 52.98 Favored 'General case' 0 C--N 1.35 0.597 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.509 ' H ' ' HB1' ' A' ' 4' ' ' ALA . 69.0 t80 -126.03 130.1 50.48 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -171.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 14.3 pt-20 -136.5 102.59 4.99 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-O 121.317 0.58 . . . . 0.0 110.888 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.441 ' HB3' ' CZ ' ' A' ' 20' ' ' PHE . 9.4 tt0 -151.21 114.42 4.79 Favored 'General case' 0 N--CA 1.414 -2.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.67 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -174.83 -74.17 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.853 175.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -90.31 -8.78 50.0 Favored 'General case' 0 N--CA 1.431 -1.376 0 CA-C-N 114.746 -1.115 . . . . 0.0 109.652 -177.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -52.83 -50.38 63.83 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 172.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 49.58 64.1 1.9 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.066 177.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.23 -164.47 36.66 Favored Glycine 0 N--CA 1.419 -2.499 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 -174.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.39 124.83 17.04 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 C-N-CA 122.18 1.92 . . . . 0.0 111.054 -178.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.421 ' CG2' ' HB2' ' A' ' 22' ' ' GLN . 3.0 p -74.27 130.34 36.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.789 -177.667 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . 0.441 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 63.4 mttp -92.54 99.28 12.03 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.792 175.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 3.2 p -138.17 141.77 37.26 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.668 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -178.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 58.0 t90 -153.29 139.24 18.14 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.519 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -156.72 140.33 7.11 Favored Glycine 0 N--CA 1.413 -2.896 0 C-N-CA 118.757 -1.687 . . . . 0.0 113.099 176.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.5 p -114.23 134.27 55.04 Favored 'General case' 0 N--CA 1.409 -2.52 0 C-N-CA 124.379 1.071 . . . . 0.0 108.231 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.437 HG12 ' HA3' ' A' ' 16' ' ' GLY . 78.4 mt -127.6 140.23 49.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-O 121.132 0.492 . . . . 0.0 110.0 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 94.6 mttt -110.69 107.08 16.52 Favored 'General case' 0 N--CA 1.4 -2.968 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 174.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.03 175.35 22.72 Favored Glycine 0 C--N 1.292 -1.899 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -170.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . 0.575 ' HA ' ' OD1' ' A' ' 92' ' ' ASP . 2.3 pp -69.0 169.69 11.26 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 117.963 0.882 . . . . 0.0 111.42 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.444 ' HB ' ' HB2' ' A' ' 92' ' ' ASP . 2.2 t -70.2 106.24 3.23 Favored 'General case' 0 C--O 1.244 0.788 0 C-N-CA 119.475 -0.89 . . . . 0.0 111.8 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.439 ' O ' ' HB2' ' A' ' 121' ' ' GLU . 7.4 tp10 -175.06 111.88 0.13 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 125.437 1.495 . . . . 0.0 107.434 170.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.76 75.47 0.42 Allowed Glycine 0 C--N 1.264 -3.427 0 C-N-CA 118.005 -2.045 . . . . 0.0 113.72 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.85 136.66 43.94 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -55.59 121.98 10.31 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 124.64 1.176 . . . . 0.0 110.561 -172.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.69 122.7 0.86 Allowed Glycine 1 N--CA 1.381 -4.994 0 C-N-CA 119.718 -1.23 . . . . 0.0 113.3 177.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -68.81 142.69 54.81 Favored 'General case' 0 C--N 1.261 -3.262 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 162.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.639 ' CB ' ' HA ' ' A' ' 119' ' ' VAL . 21.2 m-70 -126.94 91.29 3.31 Favored 'General case' 0 N--CA 1.421 -1.882 0 CA-C-N 121.222 1.828 . . . . 0.0 106.715 -173.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 7.3 m -125.16 162.75 27.07 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -171.576 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.3 m-70 -170.81 119.46 0.53 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.407 3.083 . . . . 0.0 106.87 170.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.494 ' HB2' ' HA2' ' A' ' 108' ' ' GLY . 0.2 OUTLIER -102.59 84.11 2.38 Favored 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 117.87 -1.532 . . . . 0.0 112.957 -176.361 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.53 ' CZ ' ' HA ' ' A' ' 60' ' ' ALA . 0.6 OUTLIER 167.34 113.49 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.845 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.509 ' HA3' ' H ' ' A' ' 116' ' ' THR . . . -147.57 -154.35 6.21 Favored Glycine 0 CA--C 1.485 -1.802 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.846 178.182 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -173.96 -68.17 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.498 0 O-C-N 124.287 0.639 . . . . 0.0 110.24 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.517 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.4 t-20 -97.64 130.85 44.62 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.674 -174.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.1 t -84.06 -6.28 59.38 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -177.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.73 -25.46 13.84 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 120.95 0.405 . . . . 0.0 110.337 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.517 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -147.44 118.83 1.05 Allowed Glycine 0 N--CA 1.429 -1.807 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 -178.743 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.615 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 19.9 p -98.2 87.66 3.98 Favored 'General case' 0 C--N 1.276 -2.627 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.163 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.0 m -79.84 -39.72 30.03 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.296 177.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -53.55 -47.09 70.33 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.59 1.156 . . . . 0.0 111.794 -176.072 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.53 ' HA ' ' CZ ' ' A' ' 50' ' ' PHE . . . -76.87 -9.05 58.42 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -176.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -39.79 -64.31 1.08 Allowed Glycine 0 N--CA 1.479 1.555 0 C-N-CA 124.576 1.084 . . . . 0.0 115.363 -177.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.77 1.32 5.22 Favored 'Trans proline' 0 CA--C 1.544 0.983 0 C-N-CA 122.838 2.359 . . . . 0.0 113.399 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.296 9.1 p80 50.39 37.04 14.46 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -87.81 89.89 8.17 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 122.186 0.993 . . . . 0.0 109.644 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.478 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.4 OUTLIER -113.73 97.42 44.23 Favored Pre-proline 0 C--N 1.284 -2.278 0 CA-C-N 113.723 -1.58 . . . . 0.0 110.496 -177.954 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -84.73 -12.98 7.15 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.13 2.553 . . . . 0.0 115.995 -173.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.689 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 56.5 tp -85.43 -19.8 30.76 Favored 'General case' 1 CA--C 1.421 -4.012 0 CA-C-O 121.589 0.709 . . . . 0.0 109.19 -179.551 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.483 ' C ' ' H ' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -76.99 28.26 0.14 Allowed 'General case' 0 N--CA 1.384 -3.753 0 C-N-CA 127.741 2.416 . . . . 0.0 108.911 178.086 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.59 ' H ' ' C ' ' A' ' 67' ' ' LEU . 63.6 ttt180 -73.42 43.32 0.13 Allowed 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 128.558 2.743 . . . . 0.0 110.39 -173.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.528 ' CB ' ' HB2' ' A' ' 79' ' ' ARG . 22.6 ttmm -139.32 -18.4 0.99 Allowed 'General case' 0 C--N 1.245 -3.957 0 CA-C-N 113.894 -1.503 . . . . 0.0 108.511 166.687 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 70.33 19.31 6.52 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.105 1.762 . . . . 0.0 111.325 177.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.18 137.5 8.78 Favored Glycine 0 N--CA 1.426 -1.999 0 C-N-CA 120.433 -0.889 . . . . 0.0 114.595 176.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.36 162.46 28.64 Favored Glycine 0 N--CA 1.425 -2.07 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 175.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -73.24 -38.49 2.67 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 122.898 2.398 . . . . 0.0 112.751 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . 0.704 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.9 OUTLIER -104.55 -25.45 12.75 Favored 'General case' 0 C--O 1.202 -1.422 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.253 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 49.91 -164.61 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 129.188 2.995 . . . . 0.0 115.045 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -144.58 -56.03 0.35 Allowed 'General case' 0 N--CA 1.427 -1.609 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.47 -169.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 105' ' ' SER . 47.6 mt-10 -172.57 -30.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 125.734 1.614 . . . . 0.0 107.67 -176.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.689 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 13.9 mmt180 -87.44 41.62 0.99 Allowed 'General case' 1 N--CA 1.364 -4.736 0 C-N-CA 125.095 1.358 . . . . 0.0 109.768 -171.422 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 . . . . . 0 C--N 1.313 -1.003 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.545 -172.658 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.0 tp . . . . . 0 N--CA 1.408 -2.535 0 N-CA-C 104.762 -2.31 . . . . 0.0 104.762 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.63 175.49 25.56 Favored Glycine 0 N--CA 1.404 -3.464 0 N-CA-C 109.079 -1.609 . . . . 0.0 109.079 -177.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 97' ' ' VAL . 14.3 t30 -77.32 138.66 39.49 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 96' ' ' ASP . 13.9 p -150.74 127.12 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 178.177 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.647 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 24.7 p -141.1 122.34 14.81 Favored 'General case' 0 N--CA 1.418 -2.059 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.397 -167.356 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.526 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -109.05 103.7 12.76 Favored 'General case' 0 N--CA 1.41 -2.45 0 C-N-CA 117.031 -1.868 . . . . 0.0 106.538 173.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -93.99 -39.42 10.65 Favored 'General case' 0 CA--C 1.468 -2.199 0 CA-C-O 122.161 0.981 . . . . 0.0 109.955 -170.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.456 ' HA ' ' HE3' ' A' ' 91' ' ' LYS . 1.0 OUTLIER -85.59 5.85 29.87 Favored 'General case' 0 C--N 1.27 -2.875 0 CA-C-N 114.102 -1.408 . . . . 0.0 111.572 -177.652 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.575 ' OD1' ' HA ' ' A' ' 38' ' ' LEU . 13.4 t70 74.66 93.72 0.07 Allowed 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 123.438 0.695 . . . . 0.0 111.541 -175.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 106.17 13.22 23.67 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 116.269 1.267 . . . . 0.0 116.269 171.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.526 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 49.0 t -145.31 102.91 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.457 -2.626 0 N-CA-C 103.42 -2.807 . . . . 0.0 103.42 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -99.59 118.48 36.23 Favored 'General case' 0 N--CA 1.389 -3.477 0 C-N-CA 118.867 -1.133 . . . . 0.0 111.306 -177.794 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 87' ' ' VAL . 21.7 t70 -80.41 111.52 16.89 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.01 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.562 ' HA ' ' O ' ' A' ' 86' ' ' ASN . 13.3 p -87.7 122.92 39.98 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.455 0 CA-C-O 121.97 0.89 . . . . 0.0 109.881 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 67.9 m -122.25 105.87 10.61 Favored 'General case' 0 C--N 1.273 -2.723 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.162 176.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.474 HG22 ' O ' ' A' ' 31' ' ' VAL . 2.2 pp -93.74 154.76 3.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 178.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -125.64 160.85 28.62 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.736 1.214 . . . . 0.0 109.109 -176.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -82.76 99.69 9.81 Favored 'General case' 0 C--N 1.283 -2.297 0 C-N-CA 119.781 -0.767 . . . . 0.0 109.386 -171.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.704 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 21.5 m -95.66 162.1 13.76 Favored 'General case' 0 N--CA 1.417 -2.078 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 173.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 m -103.15 -64.51 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.5 25.54 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 -174.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 21.4 t -78.57 87.43 4.53 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 122.069 0.938 . . . . 0.0 110.28 -175.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.8 tp -70.74 120.84 16.93 Favored 'General case' 0 N--CA 1.408 -2.574 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -74.79 87.23 2.23 Favored 'General case' 0 N--CA 1.409 -2.475 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 176.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.494 ' HA2' ' HB2' ' A' ' 49' ' ' GLU . . . 155.39 136.08 2.13 Favored Glycine 0 N--CA 1.411 -2.974 0 C-N-CA 119.537 -1.316 . . . . 0.0 114.379 177.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -89.54 -52.06 5.21 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -74.49 -47.74 31.35 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.035 176.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 37.7 t 179.37 -170.59 0.13 Allowed 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.417 ' O ' ' HA3' ' A' ' 150' ' ' GLY . 9.5 mt -89.62 -23.95 6.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 177.564 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 tt -68.97 132.46 33.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.922 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.71 -9.16 72.55 Favored Glycine 0 N--CA 1.419 -2.448 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.163 174.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HD3' ' HA ' ' A' ' 50' ' ' PHE . 4.2 mmp_? -81.23 123.95 28.89 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -175.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.509 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 27.6 p -89.3 101.4 14.06 Favored 'General case' 0 N--CA 1.389 -3.481 0 C-N-CA 120.256 -0.578 . . . . 0.0 109.727 177.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.0 mp -85.23 120.38 26.66 Favored 'General case' 0 CA--C 1.473 -1.986 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 174.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.439 HG13 ' C ' ' A' ' 141' ' ' GLY . 2.4 t -92.54 115.64 31.89 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.251 0 C-N-CA 116.824 -1.951 . . . . 0.0 111.469 -172.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.652 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 42.1 t -125.0 129.38 73.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 127.729 2.412 . . . . 0.0 110.587 -166.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.488 ' CB ' ' HB3' ' A' ' 144' ' ' LEU . 12.7 t60 -159.68 148.07 17.46 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 103.774 -2.676 . . . . 0.0 103.774 169.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.439 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 4.3 pm0 -68.79 88.27 0.37 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 123.112 1.434 . . . . 0.0 109.822 178.229 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -169.51 151.15 4.33 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 -171.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.38 118.68 8.41 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 118.146 0.43 . . . . 0.0 110.121 177.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.445 ' HA ' ' H ' ' A' ' 140' ' ' ALA . 44.0 t0 -96.7 -80.86 0.43 Allowed 'General case' 0 C--O 1.187 -2.216 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.4 t70 76.19 152.02 0.13 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 128.344 2.658 . . . . 0.0 112.271 175.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.07 -64.03 1.11 Allowed 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.667 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 -17.42 72.21 Favored Glycine 0 CA--C 1.481 -2.084 0 CA-C-N 114.137 -1.392 . . . . 0.0 113.03 -170.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.0 tttp -65.86 -41.1 92.1 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . 0.667 ' HA2' ' O ' ' A' ' 134' ' ' SER . . . -75.8 69.9 2.06 Favored Glycine 0 N--CA 1.409 -3.122 0 N-CA-C 115.182 0.833 . . . . 0.0 115.182 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -141.68 23.86 2.48 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 119.457 -1.354 . . . . 0.0 114.709 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.453 ' HB3' ' CB ' ' A' ' 134' ' ' SER . 64.6 t30 -132.14 176.37 8.44 Favored 'General case' 0 N--CA 1.522 3.15 0 CA-C-O 116.132 -1.89 . . . . 0.0 107.594 178.507 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.29 -57.03 11.98 Favored 'General case' 0 C--N 1.385 2.121 0 CA-C-N 121.934 2.152 . . . . 0.0 113.458 -174.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 -86.0 -34.18 20.87 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 121.077 0.465 . . . . 0.0 110.922 176.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.667 ' O ' ' HA2' ' A' ' 129' ' ' GLY . 1.3 m -66.98 -21.8 65.95 Favored 'General case' 0 C--O 1.185 -2.335 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.69 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.603 ' HA ' ' CA ' ' A' ' 129' ' ' GLY . 5.2 t -80.0 -12.55 59.7 Favored 'General case' 0 CA--C 1.51 -0.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.939 179.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -88.25 -46.77 8.95 Favored 'General case' 0 C--N 1.275 -2.669 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.239 -175.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.7 p -85.72 -32.72 21.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 113.892 -1.503 . . . . 0.0 112.314 -178.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -77.48 -4.04 83.83 Favored Glycine 0 C--O 1.202 -1.893 0 CA-C-O 119.171 -0.794 . . . . 0.0 114.879 -173.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -142.7 104.46 4.36 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 164.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.445 ' H ' ' HA ' ' A' ' 124' ' ' ASP . . . -69.83 160.35 31.93 Favored 'General case' 1 C--O 1.33 5.307 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.252 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.439 ' C ' HG13 ' A' ' 118' ' ' VAL . . . -163.77 -151.91 6.67 Favored Glycine 1 N--CA 1.382 -4.94 0 C-N-CA 118.124 -1.988 . . . . 0.0 115.262 -165.953 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.615 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 2.9 m -46.9 7.28 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 1 C-N-CA 132.552 4.341 . . . . 0.0 120.14 -166.146 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 72.3 mtt180 -125.69 -27.58 3.36 Favored 'General case' 0 C--N 1.264 -3.138 0 C-N-CA 118.794 -1.162 . . . . 0.0 111.289 178.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.488 ' HB3' ' CB ' ' A' ' 120' ' ' HIS . 4.0 mm? -60.46 -43.69 96.65 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.084 -174.346 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.652 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -171.51 112.39 0.34 Allowed 'General case' 0 CA--C 1.49 -1.338 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 88.8 m -95.19 140.44 30.1 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.522 -177.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.08 150.67 13.35 Favored Glycine 1 N--CA 1.389 -4.474 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.607 176.319 . . . . . . . . 3 3 . 1 . 015 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.4 t -75.67 119.59 23.84 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 171.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.401 HD11 ' HB3' ' A' ' 6' ' ' ALA . 23.2 mm -118.59 102.17 12.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.368 0 N-CA-C 105.264 -2.125 . . . . 0.0 105.264 179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 112' ' ' ILE . . . 177.8 -172.5 45.15 Favored Glycine 0 CA--C 1.452 -3.902 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.256 -177.191 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.536 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.6 tt -70.67 103.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 122.108 0.956 . . . . 0.0 110.724 -178.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.53 115.36 5.27 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.778 -1.555 . . . . 0.0 111.26 -179.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 . . . . . 0 C--N 1.296 -1.75 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.797 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.482 ' HB1' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.218 -0.6 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.412 ' HA ' ' HG2' ' A' ' 21' ' ' GLU . 60.0 m -121.35 -43.45 2.41 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 110.648 177.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . 0.447 ' HB2' ' HZ2' ' A' ' 3' ' ' LYS . 0.1 OUTLIER -142.14 144.63 33.56 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.828 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.499 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -134.06 149.57 51.15 Favored 'General case' 0 N--CA 1.41 -2.452 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.4 178.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 63.3 t -120.14 127.26 75.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -177.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.465 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -107.76 129.0 55.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.996 176.546 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.7 m -134.61 102.56 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 74.5 mt -96.01 134.45 39.01 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.304 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.7 tttp -147.33 122.2 9.99 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.02 -157.86 8.6 Favored Glycine 0 N--CA 1.435 -1.402 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -89.62 94.0 9.69 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 169.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 128.21 143.74 5.71 Favored Glycine 0 C--N 1.275 -2.829 0 N-CA-C 107.309 -2.316 . . . . 0.0 107.309 -177.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -97.81 123.11 0.18 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 CA-C-N 120.367 2.083 . . . . 0.0 113.524 -178.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 p -134.7 112.18 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.333 0 CA-C-N 114.534 -1.212 . . . . 0.0 107.957 171.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -118.14 119.53 35.0 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 118.874 -1.13 . . . . 0.0 111.092 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.36 149.43 19.28 Favored Glycine 0 N--CA 1.406 -3.356 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.536 179.265 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 27.5 pt -113.82 107.21 22.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.465 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 28.1 mm -100.44 128.45 52.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.639 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 24.5 t-20 -101.0 144.21 30.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -178.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.437 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 87.0 m-85 -132.57 120.18 21.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.794 0.33 . . . . 0.0 111.531 175.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.412 ' HG2' ' HA ' ' A' ' 2' ' ' THR . 1.8 tm-20 -132.34 101.78 5.49 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 174.152 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.684 ' HG2' ' O ' ' A' ' 105' ' ' SER . 18.1 mp0 -127.51 132.21 49.98 Favored 'General case' 0 N--CA 1.387 -3.606 0 N-CA-C 103.601 -2.74 . . . . 0.0 103.601 167.109 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.3 tmtt? -131.54 168.64 17.32 Favored 'General case' 0 C--N 1.257 -3.437 0 N-CA-C 107.14 -1.429 . . . . 0.0 107.14 -173.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -62.48 -9.5 8.75 Favored 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 124.038 0.935 . . . . 0.0 111.777 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -56.86 -39.5 74.41 Favored 'General case' 0 N--CA 1.424 -1.726 0 C-N-CA 124.999 1.319 . . . . 0.0 110.528 176.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . 0.457 ' OD1' HG21 ' A' ' 103' ' ' VAL . 56.4 t30 66.76 104.08 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 123.635 0.774 . . . . 0.0 110.478 178.297 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.72 -177.0 48.13 Favored Glycine 0 CA--C 1.474 -2.477 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -175.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -57.26 123.19 13.22 Favored 'Trans proline' 0 C--O 1.24 0.61 0 C-N-CA 122.262 1.975 . . . . 0.0 111.642 -178.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 92.5 t -76.42 111.46 13.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.436 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . 0.3 0.0 OUTLIER -112.59 107.29 15.95 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.812 1.291 . . . . 0.0 112.123 177.882 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.639 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 30.8 m -137.22 154.4 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.577 0 CA-C-N 113.054 -1.885 . . . . 0.0 106.323 -172.269 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 61.6 p-90 -139.19 148.1 42.7 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.44 ' O ' ' HA ' ' A' ' 97' ' ' VAL . . . -169.57 137.75 4.68 Favored Glycine 0 N--CA 1.404 -3.444 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 171.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.3 t -117.2 131.72 56.8 Favored 'General case' 0 N--CA 1.407 -2.587 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 -177.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.567 ' H ' ' HB2' ' A' ' 95' ' ' ALA . 15.5 pt -114.91 153.18 16.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 C-N-CA 118.694 -1.203 . . . . 0.0 111.075 176.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -120.34 107.61 13.15 Favored 'General case' 0 N--CA 1.408 -2.552 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.08 174.17 17.29 Favored Glycine 0 C--N 1.295 -1.734 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 45.5 tp -69.02 171.81 7.62 Favored 'General case' 0 CA--C 1.571 1.77 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 176.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 1.6 t -69.27 110.31 4.55 Favored 'General case' 0 CA--C 1.5 -0.954 0 O-C-N 121.243 -0.911 . . . . 0.0 112.978 -178.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.494 ' HG2' ' O ' ' A' ' 39' ' ' THR . 10.3 mm-40 -170.47 171.58 6.42 Favored 'General case' 0 C--N 1.275 -2.652 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 173.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.27 -155.77 31.53 Favored Glycine 0 C--N 1.26 -3.65 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 169.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.529 ' HB3' ' O ' ' A' ' 87' ' ' VAL . 5.2 tt -178.44 149.43 0.5 Allowed 'General case' 0 N--CA 1.412 -2.337 0 N-CA-C 103.563 -2.754 . . . . 0.0 103.563 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.486 ' H ' ' HA ' ' A' ' 123' ' ' ALA . 78.2 t60 -161.34 121.6 2.68 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 173.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 124' ' ' ASP . . . 77.09 136.84 0.81 Allowed Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.726 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.449 ' HB2' ' CG1' ' A' ' 119' ' ' VAL . 0.1 OUTLIER -142.23 131.46 23.43 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 117.855 0.827 . . . . 0.0 112.204 -177.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.471 ' CE1' ' HG2' ' A' ' 49' ' ' GLU . 21.7 t-80 -82.08 89.3 6.44 Favored 'General case' 0 CA--C 1.476 -1.877 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.695 -177.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.644 ' CB ' HD22 ' A' ' 117' ' ' LEU . 6.7 m -110.47 80.89 0.55 Allowed 'Isoleucine or valine' 1 N--CA 1.379 -4.008 0 CA-C-O 122.897 1.332 . . . . 0.0 110.346 175.689 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.431 ' HA ' HH11 ' A' ' 115' ' ' ARG . 2.4 p-80 -174.72 145.24 0.88 Allowed 'General case' 0 CA--C 1.487 -1.447 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.471 ' HG2' ' CE1' ' A' ' 46' ' ' HIS 0.351 10.9 mm-40 -172.92 173.97 3.64 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 126.628 1.971 . . . . 0.0 111.554 163.423 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -110.28 75.04 0.91 Allowed 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 102.886 -3.005 . . . . 0.0 102.886 171.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -104.91 -149.97 19.72 Favored Glycine 0 CA--C 1.482 -1.984 0 CA-C-N 113.142 -1.845 . . . . 0.0 113.617 -169.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 37.9 t70 175.0 -41.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 18.1 m120 -101.13 124.93 47.61 Favored 'General case' 0 CA--C 1.498 -1.037 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.92 -173.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.3 t -84.25 -25.63 29.25 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.165 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.41 -8.6 38.21 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.218 0.533 . . . . 0.0 110.261 -178.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -144.25 110.02 0.56 Allowed Glycine 0 N--CA 1.409 -3.116 0 C-N-CA 119.486 -1.34 . . . . 0.0 109.901 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.652 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 6.7 p -96.44 86.7 4.23 Favored 'General case' 0 N--CA 1.391 -3.401 0 CA-C-O 122.32 1.057 . . . . 0.0 110.733 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 30.5 m -82.03 -47.38 12.7 Favored 'General case' 0 N--CA 1.417 -2.116 0 CA-C-N 114.043 -1.435 . . . . 0.0 109.484 174.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 p -72.03 -16.8 62.05 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.194 -176.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.496 ' HB2' ' HB2' ' A' ' 57' ' ' CYS . . . -82.48 -6.69 59.46 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.22 177.078 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . 0.522 ' HA2' ' HB3' ' A' ' 142' ' ' SER . . . -50.58 176.33 0.05 OUTLIER Glycine 0 C--N 1.355 1.592 0 CA-C-N 114.83 -1.077 . . . . 0.0 112.311 175.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.427 ' HA ' ' CE2' ' A' ' 64' ' ' PHE . 21.3 Cg_exo -68.88 55.24 0.92 Allowed 'Trans proline' 0 N--CA 1.488 1.174 0 C-N-CA 123.466 2.777 . . . . 0.0 112.137 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -159.12 87.74 0.86 Allowed 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 105.567 -2.012 . . . . 0.0 105.567 -177.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.623 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 27.2 m-85 -111.78 162.99 14.66 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 -173.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -93.5 99.15 3.05 Favored Pre-proline 0 C--O 1.248 0.975 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.325 174.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.623 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 71.0 Cg_exo -52.36 -12.04 1.42 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 125.197 3.932 . . . . 0.0 114.913 -178.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.5 mt -94.92 7.39 46.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-O 122.761 1.267 . . . . 0.0 107.996 -171.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.9 t -120.76 23.57 10.67 Favored 'General case' 0 N--CA 1.395 -3.186 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 175.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.513 ' NH2' ' HB3' ' A' ' 66' ' ' PRO . 38.6 ttp180 -132.15 -32.64 1.37 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 113.199 -1.819 . . . . 0.0 107.629 171.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 5.3 mmtp 39.32 71.12 0.18 Allowed 'General case' 0 N--CA 1.427 -1.583 0 C-N-CA 125.616 1.566 . . . . 0.0 112.814 178.332 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 69.6 -29.35 0.18 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 125.747 1.619 . . . . 0.0 114.29 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 96.5 159.59 31.97 Favored Glycine 0 N--CA 1.418 -2.541 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -173.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.81 163.22 36.97 Favored Glycine 0 C--N 1.291 -1.954 0 C-N-CA 119.227 -1.463 . . . . 0.0 111.379 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.94 -43.16 1.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 118.885 1.343 . . . . 0.0 112.044 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -120.73 -28.36 4.89 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.609 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.634 ' HA ' ' CG ' ' A' ' 80' ' ' HIS . 5.9 p-10 170.91 165.75 0.08 Allowed 'General case' 0 CA--C 1.481 -1.675 0 C-N-CA 124.287 1.035 . . . . 0.0 108.692 177.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -137.64 -73.31 0.42 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.93 -65.64 0.58 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 177.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -119.85 68.78 0.83 Allowed 'General case' 0 N--CA 1.415 -2.203 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 171.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.634 ' CG ' ' HA ' ' A' ' 76' ' ' ASP . 29.8 t-80 . . . . . 0 C--N 1.302 -1.46 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 177.635 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.442 ' O ' ' HE1' ' A' ' 45' ' ' PHE . 1.5 pt? . . . . . 0 CA--C 1.501 -0.911 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 . . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 171.4 147.54 5.71 Favored Glycine 1 N--CA 1.393 -4.189 0 C-N-CA 118.842 -1.646 . . . . 0.0 112.444 177.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -105.71 128.01 53.42 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 102.43 -3.174 . . . . 0.0 102.43 162.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.529 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 5.8 t -128.77 153.18 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 N-CA-C 102.557 -3.127 . . . . 0.0 102.557 -177.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 94' ' ' VAL . 15.4 t -139.53 149.85 44.39 Favored 'General case' 0 N--CA 1.4 -2.966 0 C-N-CA 118.594 -1.242 . . . . 0.0 110.694 -175.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.472 ' CB ' ' HB2' ' A' ' 121' ' ' GLU . . . -120.44 155.4 33.58 Favored 'General case' 2 C--N 1.224 -4.887 0 CA-C-N 114.381 -1.281 . . . . 0.0 108.725 -177.375 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -149.42 160.14 43.7 Favored 'General case' 1 C--N 1.236 -4.359 0 N-CA-C 104.311 -2.478 . . . . 0.0 104.311 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 39' ' ' THR . 0.0 OUTLIER -44.08 -31.72 1.01 Allowed 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 119.51 1.05 . . . . 0.0 112.976 172.77 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -91.53 -25.27 19.32 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.864 0.84 . . . . 0.0 109.116 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.12 85.81 0.82 Allowed Glycine 0 N--CA 1.397 -3.908 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.317 -175.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.413 ' O ' HG22 ' A' ' 88' ' ' THR . 10.8 m -136.95 102.37 2.63 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 122.312 1.053 . . . . 0.0 109.753 175.659 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB2' ' H ' ' A' ' 35' ' ' ILE . . . -96.25 145.33 25.65 Favored 'General case' 0 N--CA 1.408 -2.561 0 CA-C-N 113.966 -1.47 . . . . 0.0 112.197 172.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.03 152.83 38.65 Favored 'General case' 0 N--CA 1.412 -2.325 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 166.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 28.7 m -80.9 134.58 26.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 CA-C-O 121.864 0.84 . . . . 0.0 108.899 178.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.6 m -75.86 106.05 7.24 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.384 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 pt -121.72 122.02 65.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 174.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -146.23 151.44 37.59 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -93.07 99.28 11.91 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 117.712 -1.595 . . . . 0.0 110.831 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.1 m -102.86 142.82 33.34 Favored 'General case' 0 N--CA 1.396 -3.148 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 172.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.457 HG21 ' OD1' ' A' ' 26' ' ' ASN . 14.7 p -101.77 -46.85 11.33 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 C-N-CA 117.383 -1.727 . . . . 0.0 112.156 -178.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.9 tt -121.58 24.01 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.278 0 CA-C-O 122.308 1.051 . . . . 0.0 111.729 -171.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.684 ' O ' ' HG2' ' A' ' 22' ' ' GLN . 56.6 m -103.64 87.6 2.87 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.169 -1.582 . . . . 0.0 114.008 -177.416 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 6.1 mp -69.82 129.54 39.85 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 169.941 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.1 t -73.63 87.68 1.67 Allowed 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.857 0.836 . . . . 0.0 112.491 -170.188 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.55 135.47 2.83 Favored Glycine 0 N--CA 1.406 -3.302 0 CA-C-N 114.189 -1.368 . . . . 0.0 112.426 168.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -46.97 -70.53 0.09 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.912 0.885 . . . . 0.0 111.88 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 63.8 m80 -123.02 -34.82 3.11 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 111' ' ' SER . . . . . 0.645 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 17.5 m -96.42 106.76 19.05 Favored 'General case' 0 N--CA 1.414 -2.257 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.783 -178.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 18.1 mm -87.67 -48.11 15.38 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 168.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.3 tt -102.69 151.11 6.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.258 174.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.24 -31.01 8.99 Favored Glycine 0 CA--C 1.478 -2.268 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 172.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.653 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 28.7 ptt180 -69.46 156.43 38.87 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 124.455 1.102 . . . . 0.0 112.549 -175.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -116.06 113.94 23.86 Favored 'General case' 0 N--CA 1.388 -3.533 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 -178.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.644 HD22 ' CB ' ' A' ' 47' ' ' VAL . 4.6 mp -95.98 160.49 14.43 Favored 'General case' 0 C--N 1.268 -2.953 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -174.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.42 HG22 ' O ' ' A' ' 145' ' ' ALA 0.327 8.4 p -140.5 116.14 7.37 Favored 'Isoleucine or valine' 0 C--O 1.263 1.793 0 C-N-CA 116.324 -2.15 . . . . 0.0 114.019 -179.156 . . . . . . . . 3 3 . 1 . 016 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.449 ' CG1' ' HB2' ' A' ' 45' ' ' PHE . 19.7 m -138.49 170.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -176.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.505 ' ND1' ' HB3' ' A' ' 144' ' ' LEU . 62.7 t60 -170.44 167.95 8.03 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 105.129 -2.175 . . . . 0.0 105.129 176.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.472 ' HB2' ' CB ' ' A' ' 89' ' ' ALA . 8.9 pm0 -70.96 85.89 0.7 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 119.973 1.26 . . . . 0.0 110.467 177.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.514 ' C ' ' HA ' ' A' ' 42' ' ' LEU . 30.5 ttmt -175.7 154.99 1.65 Allowed 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.553 -176.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.486 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -60.27 107.31 0.63 Allowed 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 168.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.541 ' OD2' ' HA ' ' A' ' 140' ' ' ALA . 9.0 t70 -105.36 17.56 23.73 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.758 0.823 . . . . 0.0 108.93 -179.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -35.73 114.91 0.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.438 1.895 . . . . 0.0 111.306 -177.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -90.79 -36.39 14.28 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.137 -168.151 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.21 -27.19 56.22 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.588 -177.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -100.84 -26.01 13.91 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.955 0.378 . . . . 0.0 110.907 -178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.05 -71.6 0.95 Allowed Glycine 0 CA--C 1.529 0.937 0 N-CA-C 113.767 0.267 . . . . 0.0 113.767 -177.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 118.73 -6.47 13.83 Favored Glycine 0 C--N 1.313 -0.728 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -175.025 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 26.8 t30 -162.67 150.66 14.03 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -48.26 -51.13 27.05 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 124.122 0.889 . . . . 0.0 112.062 -176.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.38 -48.28 78.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.614 -178.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 8.2 m -62.56 -24.56 67.6 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -176.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.7 m -69.63 -35.23 75.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 122.008 0.909 . . . . 0.0 109.407 176.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -83.41 -41.15 18.45 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.776 -174.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -74.01 -52.37 12.96 Favored 'General case' 0 C--N 1.273 -2.726 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.14 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 112.95 91.69 1.96 Allowed Glycine 1 N--CA 1.388 -4.504 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -176.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -34.57 117.43 0.36 Allowed 'General case' 1 C--O 1.333 5.488 0 C-N-CA 126.233 1.813 . . . . 0.0 113.265 -173.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.541 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -153.63 142.5 21.11 Favored 'General case' 0 N--CA 1.411 -2.417 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.357 175.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.81 86.03 1.55 Allowed Glycine 0 N--CA 1.425 -2.091 0 N-CA-C 104.525 -3.43 . . . . 0.0 104.525 164.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 142' ' ' SER . . . . . 0.522 ' HB3' ' HA2' ' A' ' 61' ' ' GLY . 21.0 m -55.01 -3.89 0.06 Allowed 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 118.095 2.628 . . . . 0.0 118.095 -166.49 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.652 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 11.9 ptm180 -144.75 11.0 1.4 Allowed 'General case' 0 C--N 1.247 -3.885 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.038 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.505 ' HB3' ' ND1' ' A' ' 120' ' ' HIS . 4.6 mm? -78.6 -9.21 59.28 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.695 -175.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.42 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -170.15 109.69 0.39 Allowed 'General case' 0 CA--C 1.494 -1.186 0 C-N-CA 123.791 0.836 . . . . 0.0 108.915 173.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 38.3 m -96.43 137.06 36.08 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.02 125.38 1.2 Allowed Glycine 0 N--CA 1.424 -2.137 0 C-N-CA 118.498 -1.811 . . . . 0.0 113.434 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.653 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 75.6 t -73.51 101.48 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 171.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.482 ' HB ' HD23 ' A' ' 117' ' ' LEU . 53.7 mt -116.27 128.44 73.59 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.523 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.11 -168.49 40.35 Favored Glycine 3 CA--C 1.415 -6.186 0 N-CA-C 108.121 -1.992 . . . . 0.0 108.121 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.8 pp -67.81 121.16 16.46 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 120.096 -0.642 . . . . 0.0 111.165 179.104 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -131.75 114.75 15.13 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 174.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 . . . . . 0 C--N 1.289 -2.065 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.571 -179.31 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.55 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.2 m -112.84 -31.51 6.7 Favored 'General case' 0 CA--C 1.557 1.222 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -171.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -146.79 158.37 43.89 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.861 -174.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.558 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -143.01 150.37 39.52 Favored 'General case' 0 N--CA 1.395 -3.178 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.438 ' CG2' ' HB3' ' A' ' 152' ' ' ALA . 29.0 m -129.63 138.93 52.95 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.573 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.426 ' HB3' HG13 ' A' ' 149' ' ' ILE . . . -116.6 136.02 53.32 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 114.757 -1.11 . . . . 0.0 111.799 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.7 m -133.07 105.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.161 0.505 . . . . 0.0 110.608 175.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -114.75 151.14 34.24 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -157.43 150.45 23.44 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 175.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.15 -158.76 8.81 Favored Glycine 0 N--CA 1.414 -2.784 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 177.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -69.39 -39.19 78.12 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 124.935 1.021 . . . . 0.0 109.764 176.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.16 164.13 29.51 Favored Glycine 0 C--O 1.251 1.189 0 N-CA-C 108.704 -1.759 . . . . 0.0 108.704 174.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -83.14 123.4 3.51 Favored 'Trans proline' 0 N--CA 1.424 -2.613 0 CA-C-N 120.371 2.086 . . . . 0.0 109.739 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 12.1 m -132.21 123.52 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.667 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 178.103 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -130.32 119.58 23.03 Favored 'General case' 0 C--N 1.274 -2.685 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -166.87 166.62 39.22 Favored Glycine 0 N--CA 1.408 -3.194 0 C-N-CA 119.115 -1.517 . . . . 0.0 112.086 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . 0.412 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 11.9 tt -151.53 126.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 179.096 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.4 mp -122.87 136.6 59.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -110.61 130.3 55.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.274 0.63 . . . . 0.0 109.395 -176.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.558 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 68.0 m-85 -130.16 133.59 46.71 Favored 'General case' 0 CA--C 1.498 -1.026 0 O-C-N 123.583 0.552 . . . . 0.0 110.824 178.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.478 ' O ' HG13 ' A' ' 104' ' ' ILE . 15.8 pt-20 -106.03 103.31 12.76 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 171.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.484 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -85.78 88.37 7.54 Favored 'General case' 1 N--CA 1.371 -4.415 0 CA-C-O 122.711 1.243 . . . . 0.0 112.164 -171.876 . . . . . . . . 4 4 . 1 . 017 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . 0.425 ' HE3' ' CD ' ' A' ' 21' ' ' GLU . 96.1 mttt -76.11 106.52 7.76 Favored 'General case' 0 N--CA 1.409 -2.509 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 172.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -48.58 -39.42 23.67 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 113.693 -1.594 . . . . 0.0 113.86 -167.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.6 m -90.63 -61.96 1.56 Allowed 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 120.773 0.32 . . . . 0.0 110.461 177.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -173.56 171.47 3.87 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -177.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 162.42 163.0 14.21 Favored Glycine 0 CA--C 1.494 -1.266 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.218 175.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -62.02 124.53 14.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.326 2.017 . . . . 0.0 107.483 172.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.2 m -95.63 117.36 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -174.057 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -82.65 101.87 11.1 Favored 'General case' 0 N--CA 1.413 -2.288 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.7 m -137.13 137.73 46.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -177.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 67.0 p-90 -148.3 137.31 21.82 Favored 'General case' 0 C--N 1.269 -2.902 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -153.28 140.19 7.42 Favored Glycine 0 N--CA 1.4 -3.712 0 C-N-CA 119.779 -1.2 . . . . 0.0 111.063 176.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.7 m -115.28 141.82 47.52 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 41.1 mm -131.43 126.73 58.82 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 176.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 41.2 ttmt -108.92 131.52 54.95 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 103.884 -2.636 . . . . 0.0 103.884 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.88 175.47 39.24 Favored Glycine 0 C--N 1.273 -2.968 0 N-CA-C 110.596 -1.001 . . . . 0.0 110.596 -167.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.34 142.76 56.68 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.685 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -69.35 105.74 2.67 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -172.777 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 27.9 mt-10 -175.43 135.77 0.33 Allowed 'General case' 0 CA--C 1.478 -1.798 0 C-N-CA 129.404 3.082 . . . . 0.0 104.057 174.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.63 99.99 0.17 Allowed Glycine 0 C--N 1.265 -3.395 0 C-N-CA 116.844 -2.598 . . . . 0.0 113.341 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -103.07 -86.18 0.44 Allowed 'General case' 0 N--CA 1.446 -0.639 0 O-C-N 124.547 0.792 . . . . 0.0 111.184 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.462 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.8 p80 176.39 141.42 0.07 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.37 116.06 0.54 Allowed Glycine 0 N--CA 1.419 -2.436 0 C-N-CA 119.616 -1.278 . . . . 0.0 113.048 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -122.89 107.95 12.42 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.929 0.871 . . . . 0.0 112.876 178.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 54.4 t60 -171.11 89.73 0.13 Allowed 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.005 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.463 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -132.4 87.81 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 O-C-N 126.344 2.278 . . . . 0.0 109.284 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.488 ' CE1' ' HA3' ' A' ' 108' ' ' GLY . 8.6 t-160 -173.27 87.4 0.06 Allowed 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.239 -0.913 . . . . 0.0 110.749 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.495 ' H ' ' HB2' ' A' ' 115' ' ' ARG . 2.7 mp0 -136.51 172.25 13.29 Favored 'General case' 1 C--N 1.24 -4.173 0 CA-C-N 113.648 -1.615 . . . . 0.0 109.082 -170.956 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.407 ' HB3' ' OD1' ' A' ' 109' ' ' ASP . 26.3 p90 -69.81 171.31 9.44 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-O 121.096 0.474 . . . . 0.0 111.2 169.31 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.766 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . -59.86 120.7 23.91 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.118 -0.946 . . . . 0.0 114.282 177.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -129.72 -167.27 1.78 Allowed 'General case' 0 C--O 1.247 0.932 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 176.159 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . 0.669 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 29.9 t30 -69.47 133.86 48.23 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-O 121.369 0.604 . . . . 0.0 110.519 -179.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 54' ' ' THR . . . . . 0.548 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 1.3 p -51.41 -22.4 2.96 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 127.286 2.235 . . . . 0.0 114.44 -178.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.96 24.22 4.6 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.669 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 175.51 111.15 0.27 Allowed Glycine 0 C--O 1.196 -2.232 0 C-N-CA 117.778 -2.153 . . . . 0.0 112.566 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 60' ' ' ALA . 13.3 p -90.56 96.03 10.45 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 121.973 0.892 . . . . 0.0 110.108 -177.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.3 m -76.57 -51.56 11.41 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.885 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.1 m -91.03 -36.5 14.02 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.372 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.413 ' HB2' ' HB2' ' A' ' 57' ' ' CYS . . . -77.58 -17.69 57.59 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.67 -177.449 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.85 -63.73 3.99 Favored Glycine 0 CA--C 1.539 1.546 0 N-CA-C 114.56 0.584 . . . . 0.0 114.56 -179.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -85.78 6.37 5.6 Favored 'Trans proline' 0 C--O 1.24 0.617 0 C-N-CA 122.744 2.296 . . . . 0.0 112.092 177.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -83.1 142.37 31.31 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 121.535 0.683 . . . . 0.0 111.409 -175.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -141.4 133.88 28.33 Favored 'General case' 0 N--CA 1.411 -2.384 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 172.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -77.35 141.57 66.29 Favored Pre-proline 0 C--N 1.306 -1.317 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.508 175.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -53.5 -33.36 67.43 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 123.834 3.023 . . . . 0.0 115.726 -177.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' HB2' ' A' ' 79' ' ' ARG . 3.0 mm? -78.15 -45.4 23.35 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.648 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.4 m -67.3 31.54 0.02 OUTLIER 'General case' 0 CA--C 1.498 -1.026 0 C-N-CA 129.477 3.111 . . . . 0.0 116.62 -172.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.608 ' N ' ' HB2' ' A' ' 79' ' ' ARG . 0.0 OUTLIER -136.27 -32.55 0.85 Allowed 'General case' 0 C--N 1.245 -3.958 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.584 172.633 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.504 ' HZ2' ' CD ' ' A' ' 78' ' ' GLU . 82.2 tttt 34.67 -87.35 0.0 OUTLIER 'General case' 0 C--N 1.373 1.626 0 C-N-CA 124.526 1.13 . . . . 0.0 110.25 -170.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -178.93 12.2 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.764 0 C-N-CA 126.32 1.848 . . . . 0.0 106.994 176.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.49 134.38 3.35 Favored Glycine 0 N--CA 1.435 -1.403 0 C-N-CA 119.329 -1.415 . . . . 0.0 111.869 -175.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.59 83.95 0.09 OUTLIER Glycine 0 C--O 1.2 -2.019 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -104.21 -0.5 0.27 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.706 2.271 . . . . 0.0 115.621 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -123.41 -11.86 7.84 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 178.39 88.78 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -172.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.465 ' OE1' ' HD3' ' A' ' 79' ' ' ARG . 3.8 mm-40 -54.94 146.59 17.29 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 117.981 2.585 . . . . 0.0 117.981 -177.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.504 ' CD ' ' HZ2' ' A' ' 70' ' ' LYS . 42.4 mt-10 -138.23 -16.22 1.24 Allowed 'General case' 0 N--CA 1.415 -2.198 0 CA-C-N 112.624 -2.08 . . . . 0.0 107.313 -177.603 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.648 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -105.5 -37.31 6.84 Favored 'General case' 1 N--CA 1.358 -5.058 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 177.995 . . . . . . . . 4 4 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.408 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 45.2 m80 . . . . . 0 CA--C 1.498 -1.034 0 CA-C-N 113.344 -1.753 . . . . 0.0 110.041 176.19 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER . . . . . 0 N--CA 1.407 -2.614 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 . . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.74 132.06 3.46 Favored Glycine 1 N--CA 1.379 -5.13 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 174.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -73.8 129.22 37.48 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 118.029 -1.468 . . . . 0.0 107.545 174.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 44.6 t -110.81 128.15 67.39 Favored 'Isoleucine or valine' 0 C--N 1.36 1.024 0 O-C-N 121.441 -0.787 . . . . 0.0 109.278 -174.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.0 t -141.45 96.47 2.99 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . 0.434 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -80.11 107.21 12.72 Favored 'General case' 0 C--O 1.2 -1.523 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 175.247 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 92' ' ' ASP . 26.3 t70 -64.69 162.68 15.34 Favored 'General case' 0 C--N 1.28 -2.428 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.644 -174.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.685 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 58.5 pttt -42.13 14.78 0.0 OUTLIER 'General case' 0 CA--C 1.6 2.902 0 N-CA-C 117.652 2.464 . . . . 0.0 117.652 174.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 90' ' ' ASP . 21.3 t70 -125.51 -28.98 3.25 Favored 'General case' 0 C--N 1.296 -1.736 0 C-N-CA 126.249 1.82 . . . . 0.0 108.753 178.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 104.07 66.77 0.72 Allowed Glycine 0 C--O 1.22 -0.746 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.217 -179.147 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.7 p -160.83 117.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-N 117.387 0.594 . . . . 0.0 110.602 -175.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . . . -122.31 124.34 43.52 Favored 'General case' 0 N--CA 1.434 -1.27 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -111.41 112.56 24.39 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 34.4 m -112.74 125.79 70.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -178.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -154.56 101.09 2.31 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 169.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.8 mm -129.58 149.3 33.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -109.68 118.82 37.57 Favored 'General case' 0 C--O 1.265 1.874 0 CA-C-O 122.604 1.192 . . . . 0.0 112.365 179.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -164.95 138.59 4.83 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 113.527 -1.669 . . . . 0.0 106.689 -176.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.5 m -82.31 79.77 8.68 Favored 'General case' 0 N--CA 1.435 -1.191 0 C-N-CA 119.206 -0.998 . . . . 0.0 109.352 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . 0.447 HG22 ' HG3' ' A' ' 77' ' ' GLU . 7.5 p -108.15 -15.05 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-N 114.324 -1.307 . . . . 0.0 109.932 -177.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.484 ' CG1' ' HA ' ' A' ' 22' ' ' GLN . 0.1 OUTLIER -78.21 -3.06 5.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.369 -1.742 . . . . 0.0 111.654 -173.797 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.5 m -67.78 131.22 45.15 Favored 'General case' 0 N--CA 1.409 -2.519 0 CA-C-O 121.6 0.714 . . . . 0.0 110.866 -174.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.426 ' HG ' HG22 ' A' ' 112' ' ' ILE . 4.6 mp -68.08 87.74 0.27 Allowed 'General case' 0 N--CA 1.425 -1.687 0 CA-C-O 123.008 1.385 . . . . 0.0 107.514 168.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -166.0 87.5 0.37 Allowed 'General case' 1 N--CA 1.374 -4.253 0 N-CA-C 101.481 -3.525 . . . . 0.0 101.481 172.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.488 ' HA3' ' CE1' ' A' ' 48' ' ' HIS . . . 166.2 136.69 2.06 Favored Glycine 0 C--N 1.266 -3.314 0 CA-C-N 113.682 -1.599 . . . . 0.0 110.953 179.013 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.407 ' OD1' ' HB3' ' A' ' 50' ' ' PHE . 16.6 t70 50.15 -85.81 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 126.643 1.977 . . . . 0.0 112.18 -171.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -123.95 -47.32 1.93 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 173.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 p -168.38 -162.11 0.39 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.426 HG22 ' HG ' ' A' ' 106' ' ' LEU . 12.4 tt -104.04 25.79 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.886 0 C-N-CA 119.231 -0.987 . . . . 0.0 108.992 178.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.623 ' HA ' ' NH1' ' A' ' 115' ' ' ARG . 2.6 pp -103.56 150.39 6.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 O-C-N 121.612 -0.68 . . . . 0.0 111.563 173.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.766 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 78.53 -13.33 17.33 Favored Glycine 0 CA--C 1.532 1.102 0 N-CA-C 115.043 0.777 . . . . 0.0 115.043 176.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.623 ' NH1' ' HA ' ' A' ' 113' ' ' ILE . 0.0 OUTLIER -66.93 116.56 7.91 Favored 'General case' 0 C--O 1.253 1.248 0 CA-C-O 121.901 0.858 . . . . 0.0 112.305 -168.782 . . . . . . . . 3 3 . 1 . 017 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 18.6 p -85.75 132.51 34.12 Favored 'General case' 0 N--CA 1.384 -3.754 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.25 171.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.522 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -69.53 137.03 52.14 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 114.985 -1.007 . . . . 0.0 111.477 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.1 p -124.03 96.48 3.93 Favored 'Isoleucine or valine' 1 C--O 1.35 6.352 0 C-N-CA 115.179 -2.608 . . . . 0.0 112.107 166.519 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.486 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 24.0 m -150.62 170.54 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.081 0 C-N-CA 128.67 2.788 . . . . 0.0 105.829 178.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.468 ' NE2' ' HD2' ' A' ' 122' ' ' LYS . 29.8 p-80 -169.46 172.93 6.78 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 171.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.519 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.2 mp0 -70.01 82.67 0.49 Allowed 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 119.832 1.196 . . . . 0.0 109.492 -177.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.468 ' HD2' ' NE2' ' A' ' 120' ' ' HIS . 59.5 mttm -176.48 174.71 1.87 Allowed 'General case' 0 CA--C 1.494 -1.175 0 C-N-CA 129.403 3.081 . . . . 0.0 104.664 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -72.83 146.23 46.42 Favored 'General case' 0 C--N 1.286 -2.173 0 C-N-CA 119.286 -0.965 . . . . 0.0 110.246 171.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -129.23 -86.26 0.55 Allowed 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 174.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 52.42 -177.66 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.78 1.632 . . . . 0.0 111.017 171.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 tp -94.83 -65.05 1.01 Allowed 'General case' 0 C--N 1.288 -2.076 0 CA-C-O 122.633 1.206 . . . . 0.0 107.933 168.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.48 -5.04 48.16 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 112.931 -1.941 . . . . 0.0 115.451 -171.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 44.6 tptt -116.78 26.42 9.85 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 122.049 0.928 . . . . 0.0 109.027 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -63.34 -28.32 72.12 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 114.397 -1.274 . . . . 0.0 113.272 178.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 121.86 -80.86 0.34 Allowed Glycine 0 C--O 1.22 -0.736 0 C-N-CA 119.993 -1.099 . . . . 0.0 113.748 175.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.446 ' H ' ' HB2' ' A' ' 134' ' ' SER . 46.5 t-20 -99.08 169.27 9.53 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . 0.335 9.6 pt-20 -54.66 -45.66 73.89 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 116.273 1.953 . . . . 0.0 116.273 -173.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.98 -37.98 61.77 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.349 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.446 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 49.6 m -59.97 -30.15 68.92 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-O 120.963 0.411 . . . . 0.0 111.409 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 80.5 m -78.84 -20.16 50.29 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.958 0.885 . . . . 0.0 110.168 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 41.7 tttp -91.08 -32.83 15.72 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 -176.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.6 t -85.54 -30.43 23.39 Favored 'General case' 0 N--CA 1.409 -2.513 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.426 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.74 75.12 1.25 Allowed Glycine 0 N--CA 1.422 -2.268 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 32.3 t30 -47.32 119.95 2.93 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.277 1.431 . . . . 0.0 112.18 -174.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -132.58 137.6 47.13 Favored 'General case' 0 N--CA 1.42 -1.943 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.989 -173.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.08 89.32 0.58 Allowed Glycine 0 CA--C 1.502 -0.742 0 N-CA-C 107.581 -2.207 . . . . 0.0 107.581 170.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.6 m -47.07 -33.97 5.42 Favored 'General case' 0 C--O 1.2 -1.545 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -164.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.01 9.91 4.17 Favored 'General case' 0 C--N 1.27 -2.888 0 C-N-CA 116.162 -2.215 . . . . 0.0 109.787 178.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.9 mp -71.41 -16.3 62.39 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.861 -0.736 . . . . 0.0 112.088 -173.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . 0.486 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -170.18 101.89 0.28 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.8 m -136.12 147.34 47.74 Favored 'General case' 0 N--CA 1.407 -2.615 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' A' ' 54' ' ' THR . . . -162.38 149.64 17.98 Favored Glycine 0 N--CA 1.396 -3.988 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . 0.576 HG13 ' NH2' ' A' ' 115' ' ' ARG . 2.8 t -69.05 104.67 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 176.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.522 HG21 ' HB3' ' A' ' 117' ' ' LEU . 7.4 tt -123.47 101.57 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -176.128 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.508 ' HA3' ' NH1' ' A' ' 115' ' ' ARG . . . 176.66 -167.13 38.42 Favored Glycine 0 CA--C 1.453 -3.8 0 N-CA-C 107.889 -2.084 . . . . 0.0 107.889 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 6.3 tt -61.99 104.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.107 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.457 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . 0.438 ' HB3' ' CG2' ' A' ' 5' ' ' VAL . . . -103.31 102.04 11.98 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.631 -0.828 . . . . 0.0 110.406 -179.537 . . . . . . . . 2 2 . 1 . 017 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 pt20 . . . . . 0 C--N 1.279 -2.474 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.145 179.044 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . 0.628 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 N--CA 1.47 0.57 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 2' ' ' THR . . . . . 0.415 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 8.2 m -121.06 -37.42 2.96 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.184 -0.606 . . . . 0.0 112.033 -175.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -136.34 136.1 39.4 Favored 'General case' 0 C--O 1.25 1.109 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -174.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.668 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -156.14 103.15 2.17 Favored 'General case' 0 CA--C 1.479 -1.769 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . 0.632 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 33.9 m -110.97 134.48 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-O 121.655 0.74 . . . . 0.0 110.389 -176.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . 0.425 ' HB3' ' HA ' ' A' ' 149' ' ' ILE . . . -108.81 150.11 28.11 Favored 'General case' 0 C--N 1.28 -2.422 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.342 -175.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.2 p -134.26 119.92 32.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.248 0.547 . . . . 0.0 110.098 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -98.25 151.1 20.82 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.191 -176.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -126.26 132.44 51.69 Favored 'General case' 0 C--O 1.248 1.021 0 N-CA-C 104.791 -2.3 . . . . 0.0 104.791 177.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.61 154.53 19.68 Favored Glycine 0 N--CA 1.428 -1.834 0 C-N-CA 117.477 -2.297 . . . . 0.0 118.504 -166.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -64.99 -44.34 89.61 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 111.802 -2.199 . . . . 0.0 106.201 169.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.01 153.96 17.23 Favored Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 104.143 -3.583 . . . . 0.0 104.143 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -70.59 123.95 10.3 Favored 'Trans proline' 0 N--CA 1.442 -1.518 0 CA-C-N 121.559 2.679 . . . . 0.0 111.471 -173.074 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.97 109.27 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.124 0 CA-C-N 114.199 -1.364 . . . . 0.0 107.641 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.512 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 73.6 mt-30 -119.99 119.0 32.15 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . 0.62 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -160.14 160.0 31.26 Favored Glycine 0 N--CA 1.405 -3.428 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -174.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.5 tt -153.87 102.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 121.441 0.638 . . . . 0.0 109.546 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' VAL . 0.2 OUTLIER -106.55 139.86 26.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.22 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.668 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 8.5 t30 -113.53 120.81 42.25 Favored 'General case' 0 CA--C 1.51 -0.586 0 O-C-N 123.753 0.658 . . . . 0.0 110.757 -177.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.496 ' CD2' ' HB3' ' A' ' 84' ' ' LEU . 21.0 m-85 -119.62 135.14 54.93 Favored 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -178.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 2' ' ' THR . 13.4 mt-10 -102.45 105.43 15.99 Favored 'General case' 0 CA--C 1.551 0.999 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.652 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.628 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 15.1 mp0 -85.6 99.86 11.56 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 176.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -132.82 108.98 9.32 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 122.288 1.042 . . . . 0.0 111.593 -172.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -69.49 -10.99 60.45 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.077 178.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.5 m -59.22 -16.9 23.55 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.563 1.545 . . . . 0.0 112.311 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 74.98 116.12 0.06 Allowed 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 124.021 0.929 . . . . 0.0 112.375 177.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.93 169.67 24.5 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -62.41 123.91 13.29 Favored 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.534 2.156 . . . . 0.0 110.88 177.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.433 HG11 ' H ' ' A' ' 102' ' ' SER . 10.9 p -75.98 121.51 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.639 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -89.81 97.55 11.26 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -177.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.47 HG11 ' CD2' ' A' ' 20' ' ' PHE . 24.7 m -122.61 133.07 69.89 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.008 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.771 -171.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.479 ' HA ' HG12 ' A' ' 97' ' ' VAL . 4.8 m-90 -135.26 137.61 42.71 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.454 177.564 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -161.54 140.66 6.76 Favored Glycine 0 N--CA 1.424 -2.101 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.828 173.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 34' ' ' SER . . . . . 0.62 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 11.4 p -114.83 126.11 54.45 Favored 'General case' 0 N--CA 1.413 -2.294 0 C-N-CA 123.844 0.857 . . . . 0.0 109.622 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 3.6 mp -126.06 142.82 41.59 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 18.9 ptpt -116.26 133.26 56.22 Favored 'General case' 0 N--CA 1.413 -2.283 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 172.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -165.21 175.81 40.99 Favored Glycine 0 N--CA 1.423 -2.171 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 -165.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 mt -66.43 144.0 56.78 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -177.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.447 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 59.3 p -87.34 104.17 16.16 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 -163.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.564 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 3.7 mp0 -173.13 140.89 0.91 Allowed 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 102.173 -3.269 . . . . 0.0 102.173 175.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 173.67 116.19 0.41 Allowed Glycine 0 C--N 1.255 -3.919 0 C-N-CA 114.933 -3.508 . . . . 0.0 114.436 178.449 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.423 ' HB2' ' CB ' ' A' ' 123' ' ' ALA . 96.2 mt -142.83 -39.67 0.33 Allowed 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -179.385 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -126.02 141.52 51.92 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -173.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . 0.411 ' O ' ' HD2' ' A' ' 46' ' ' HIS . . . -105.19 88.4 0.58 Allowed Glycine 0 N--CA 1.44 -1.036 0 CA-C-N 115.156 -0.929 . . . . 0.0 111.698 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . 0.429 ' HB3' ' O ' ' A' ' 125' ' ' ASP . 0.4 OUTLIER -90.9 84.72 5.83 Favored 'General case' 1 C--O 1.352 6.481 0 CA-C-O 122.261 1.029 . . . . 0.0 112.021 -176.242 . . . . . . . . 4 4 . 1 . 018 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.411 ' HD2' ' O ' ' A' ' 44' ' ' GLY . 8.0 p80 -100.12 113.37 25.95 Favored 'General case' 0 N--CA 1.382 -3.865 0 CA-C-N 113.893 -1.503 . . . . 0.0 107.944 -171.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.0 t -164.89 87.93 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 O-C-N 125.048 1.468 . . . . 0.0 108.533 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.523 ' CD2' ' HB ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -148.31 167.73 24.42 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 124.39 1.076 . . . . 0.0 109.114 163.781 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -164.81 164.98 20.95 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 171.046 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 66.5 t80 73.61 58.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.06 166.08 30.81 Favored Glycine 0 CA--C 1.474 -2.499 0 CA-C-N 112.849 -1.978 . . . . 0.0 111.54 -175.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -151.46 -72.37 0.16 Allowed 'General case' 0 C--N 1.292 -1.913 0 O-C-N 123.875 0.397 . . . . 0.0 111.651 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -94.5 128.59 41.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.77 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.5 t -75.98 -2.3 29.85 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 122.946 0.498 . . . . 0.0 111.515 -174.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.05 -8.6 19.41 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.47 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . 0.411 ' HA2' ' HB2' ' A' ' 143' ' ' ARG . . . -176.99 137.63 3.61 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.224 -1.465 . . . . 0.0 112.758 -178.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.423 ' H ' ' HB2' ' A' ' 143' ' ' ARG . 62.3 m -91.98 88.3 6.53 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 120.385 0.136 . . . . 0.0 111.101 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.7 m -80.01 -58.14 3.3 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.75 -44.17 86.7 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.817 -176.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.47 -5.98 51.87 Favored 'General case' 0 C--O 1.196 -1.713 0 C-N-CA 124.801 1.24 . . . . 0.0 112.384 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -31.62 -138.33 0.0 OUTLIER Glycine 0 N--CA 1.513 3.832 0 C-N-CA 128.477 2.942 . . . . 0.0 116.414 -174.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -62.91 53.41 0.13 Allowed 'Trans proline' 0 CA--C 1.566 2.086 0 CA-C-N 121.043 2.421 . . . . 0.0 113.11 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -93.96 112.67 24.53 Favored 'General case' 0 N--CA 1.427 -1.605 0 C-N-CA 124.348 1.059 . . . . 0.0 110.332 175.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . 0.432 ' HB3' ' O ' ' A' ' 136' ' ' LYS . 45.5 p90 -84.21 133.16 34.6 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 103.983 -2.599 . . . . 0.0 103.983 167.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.421 ' ND2' ' HD2' ' A' ' 66' ' ' PRO . 29.1 t-20 -75.01 140.83 74.1 Favored Pre-proline 0 C--N 1.282 -2.366 0 C-N-CA 118.842 -1.143 . . . . 0.0 111.609 -171.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . 0.437 ' O ' ' HG2' ' A' ' 69' ' ' ARG . 92.1 Cg_endo -83.8 -14.21 7.73 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.532 2.154 . . . . 0.0 113.445 -176.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.647 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 2.7 tt -88.36 -17.59 30.23 Favored 'General case' 0 CA--C 1.482 -1.658 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.545 ' HA ' ' HB2' ' A' ' 79' ' ' ARG . 63.8 m -79.44 39.82 0.41 Allowed 'General case' 0 N--CA 1.407 -2.58 0 CA-C-N 114.315 -1.311 . . . . 0.0 111.502 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.437 ' HG2' ' O ' ' A' ' 66' ' ' PRO . 33.1 mmt180 -83.7 20.1 1.51 Allowed 'General case' 0 CA--C 1.49 -1.33 0 CA-C-O 122.506 1.146 . . . . 0.0 109.734 -178.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.438 ' H ' ' C ' ' A' ' 68' ' ' SER . 25.8 tptp -128.1 19.99 6.42 Favored 'General case' 0 N--CA 1.396 -3.126 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 171.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.0 m80 65.87 -48.3 0.4 Allowed 'General case' 0 N--CA 1.504 2.251 0 C-N-CA 126.349 1.86 . . . . 0.0 115.375 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.444 ' HA2' ' HG3' ' A' ' 79' ' ' ARG . . . 167.61 175.29 37.37 Favored Glycine 0 N--CA 1.415 -2.761 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -171.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . 0.45 ' O ' HD12 ' A' ' 126' ' ' LEU . . . -169.38 142.5 7.36 Favored Glycine 0 CA--C 1.475 -2.444 0 N-CA-C 106.787 -2.525 . . . . 0.0 106.787 173.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -65.01 -43.25 12.1 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 CA-C-N 120.306 2.053 . . . . 0.0 113.849 -178.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -120.89 -29.79 4.55 Favored 'General case' 0 N--CA 1.425 -1.682 0 C-N-CA 119.507 -0.877 . . . . 0.0 112.268 -178.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . 0.477 ' OD1' HG22 ' A' ' 104' ' ' ILE . 33.4 t70 -176.62 146.86 0.6 Allowed 'General case' 0 C--O 1.204 -1.301 0 CA-C-O 118.81 -0.614 . . . . 0.0 109.664 -176.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.478 ' HB2' ' HD2' ' A' ' 79' ' ' ARG . 3.1 mm-40 -158.16 -86.76 0.04 OUTLIER 'General case' 0 C--O 1.214 -0.766 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -161.25 -53.03 0.05 OUTLIER 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.1 -2.185 . . . . 0.0 105.1 -176.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.647 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 0.4 OUTLIER -34.67 -31.63 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.92 0 C-N-CA 128.635 2.774 . . . . 0.0 115.676 176.948 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.416 ' HD2' ' O ' ' A' ' 104' ' ' ILE . 31.2 t-80 . . . . . 0 N--CA 1.5 2.066 0 C-N-CA 124.341 1.056 . . . . 0.0 109.738 -171.455 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.496 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . 89.2 mt . . . . . 0 C--O 1.2 -1.508 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 . . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 177.03 165.31 32.21 Favored Glycine 0 CA--C 1.478 -2.246 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -158.57 148.33 19.49 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 p -137.24 128.38 40.71 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.627 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 88.3 m -140.42 95.21 2.84 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -135.67 106.39 6.56 Favored 'General case' 0 C--O 1.202 -1.425 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.564 ' HA ' ' N ' ' A' ' 40' ' ' GLU . 3.3 p-10 -117.26 -19.18 9.72 Favored 'General case' 0 C--N 1.275 -2.639 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.648 -174.462 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -75.77 -57.54 3.82 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.692 -175.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -154.2 -22.83 0.13 Allowed 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 114.623 -1.171 . . . . 0.0 112.27 -166.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.48 55.3 0.16 Allowed Glycine 0 N--CA 1.42 -2.386 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -173.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.0 m -141.9 102.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.85 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.627 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.81 107.75 19.38 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.233 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -83.97 124.33 30.91 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 104.665 -2.346 . . . . 0.0 104.665 173.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.479 HG12 ' HA ' ' A' ' 32' ' ' TRP . 7.1 p -83.31 135.89 23.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 C-N-CA 119.696 -0.802 . . . . 0.0 109.426 -174.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.2 m -75.46 102.24 5.12 Favored 'General case' 0 N--CA 1.389 -3.508 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . 0.419 ' HB ' ' O ' ' A' ' 31' ' ' VAL . 2.5 tt -92.8 115.72 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.7 mm-40 -133.54 157.43 45.68 Favored 'General case' 0 C--N 1.283 -2.305 0 CA-C-N 113.988 -1.46 . . . . 0.0 108.364 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -79.83 99.38 7.48 Favored 'General case' 0 N--CA 1.411 -2.405 0 CA-C-O 123.01 1.386 . . . . 0.0 109.674 176.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.433 ' H ' HG11 ' A' ' 29' ' ' VAL . 50.8 m -100.9 93.75 5.68 Favored 'General case' 0 N--CA 1.41 -2.444 0 CA-C-N 112.107 -2.315 . . . . 0.0 105.902 171.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.1 t -69.18 -47.62 73.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.825 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . 0.477 HG22 ' OD1' ' A' ' 76' ' ' ASP . 10.0 tp -70.62 26.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.576 1.955 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 30.0 t -70.89 90.16 0.8 Allowed 'General case' 0 CA--C 1.477 -1.845 0 N-CA-C 105.584 -2.006 . . . . 0.0 105.584 170.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 27.2 tp -110.42 157.93 19.03 Favored 'General case' 2 C--N 1.204 -5.728 0 N-CA-C 103.333 -2.839 . . . . 0.0 103.333 -172.547 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 m -69.08 101.22 1.38 Allowed 'General case' 1 C--N 1.226 -4.776 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 174.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.6 137.11 13.23 Favored Glycine 0 N--CA 1.41 -3.078 0 CA-C-N 114.321 -1.309 . . . . 0.0 112.723 -170.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.0 t70 61.74 -86.33 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 126.449 1.899 . . . . 0.0 114.106 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -82.82 -49.02 10.13 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 18.5 m 168.03 -85.46 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 126.357 1.863 . . . . 0.0 111.026 173.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.3 mt -109.61 -54.42 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.435 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 14.0 tt -83.74 175.64 0.72 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.024 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.377 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.424 ' H ' HG12 ' A' ' 113' ' ' ILE . . . 89.43 22.77 36.17 Favored Glycine 0 CA--C 1.478 -2.278 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.918 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.442 HH22 HD13 ' A' ' 149' ' ' ILE . 44.4 mtm180 -146.98 123.12 10.83 Favored 'General case' 0 C--O 1.2 -1.539 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.492 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 11.4 p -102.09 115.48 30.63 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 171.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -71.05 148.07 47.92 Favored 'General case' 0 CA--C 1.506 -0.716 0 O-C-N 123.865 0.728 . . . . 0.0 112.434 -170.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.523 ' HB ' ' CD2' ' A' ' 48' ' ' HIS . 1.8 p -125.63 99.64 6.14 Favored 'Isoleucine or valine' 1 C--O 1.38 7.933 0 C-N-CA 117.118 -1.833 . . . . 0.0 112.653 172.507 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 t -148.69 151.48 13.14 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 C-N-CA 126.429 1.892 . . . . 0.0 106.153 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -144.52 170.35 16.22 Favored 'General case' 0 C--O 1.243 0.712 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 175.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.4 mp0 -67.86 89.93 0.29 Allowed 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 177.129 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . 0.49 ' HG2' ' H ' ' A' ' 123' ' ' ALA . 50.8 tttm -162.99 171.58 16.31 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -174.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . 0.49 ' H ' ' HG2' ' A' ' 122' ' ' LYS . . . -123.22 107.27 11.52 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.45 -88.3 0.44 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.993 165.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . 0.429 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 21.9 t70 172.44 157.36 0.1 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.45 HD12 ' O ' ' A' ' 73' ' ' GLY . 1.6 pt? -90.62 -29.34 17.84 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -105.5 -23.59 7.5 Favored Glycine 0 N--CA 1.464 0.522 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.847 -177.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -128.48 51.99 1.95 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 177.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.86 82.2 0.41 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.37 -0.832 . . . . 0.0 114.35 -174.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.9 -127.56 8.48 Favored Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 121.376 -0.44 . . . . 0.0 112.808 174.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -98.41 -176.89 3.52 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -61.88 -50.97 70.08 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 119.074 0.852 . . . . 0.0 112.993 -175.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -64.29 -31.06 72.12 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.463 178.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 m -68.48 -38.56 81.13 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 122.724 0.41 . . . . 0.0 110.64 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.9 p -65.57 -27.23 68.28 Favored 'General case' 0 C--N 1.349 0.578 0 CA-C-O 121.121 0.486 . . . . 0.0 110.748 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . 0.432 ' O ' ' HB3' ' A' ' 64' ' ' PHE . 92.9 mttt -84.99 -16.45 40.82 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.061 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 31.0 m -87.98 -17.58 30.93 Favored 'General case' 0 CA--C 1.564 1.504 0 CA-C-O 121.841 0.829 . . . . 0.0 110.347 175.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.24 48.6 30.57 Favored Glycine 1 C--O 1.39 9.847 0 N-CA-C 108.629 -1.788 . . . . 0.0 108.629 -173.45 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -30.22 106.29 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 128.963 2.905 . . . . 0.0 114.496 -158.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -155.59 171.82 19.32 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 167.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.47 119.28 16.13 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 167.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.7 m -41.63 -46.84 3.79 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 115.484 1.661 . . . . 0.0 115.484 -166.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.724 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 0.1 OUTLIER -132.42 11.51 4.51 Favored 'General case' 0 C--N 1.288 -2.105 0 C-N-CA 118.891 -1.124 . . . . 0.0 108.529 174.845 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.6 mt -71.69 -17.33 62.23 Favored 'General case' 0 CA--C 1.497 -1.09 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.297 -170.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.35 89.67 1.59 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.724 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 53.0 m -131.2 153.95 48.92 Favored 'General case' 0 N--CA 1.424 -1.726 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.253 -178.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.74 148.65 11.58 Favored Glycine 0 N--CA 1.409 -3.136 0 N-CA-C 108.025 -2.03 . . . . 0.0 108.025 176.021 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 93.8 t -69.23 105.62 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 176.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.442 HD13 HH22 ' A' ' 115' ' ' ARG . 0.0 OUTLIER -88.74 103.2 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.703 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.07 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.36 -177.79 48.48 Favored Glycine 1 N--CA 1.383 -4.871 0 C-N-CA 119.081 -1.533 . . . . 0.0 112.266 -178.657 . . . . . . . . 3 3 . 1 . 018 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.46 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.7 tt -53.32 112.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 125.119 1.367 . . . . 0.0 113.184 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.72 99.94 3.83 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 171.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.288 -2.095 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -177.419 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.702 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.4 m -94.26 -26.81 16.46 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.39 1.09 . . . . 0.0 108.606 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -166.03 172.11 11.78 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 174.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 4' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -151.71 158.97 44.11 Favored 'General case' 0 C--N 1.287 -2.149 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 86.7 t -140.93 121.41 13.14 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.365 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -177.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.12 145.74 50.63 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 -177.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 p -135.36 125.87 44.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 O-C-N 123.66 0.6 . . . . 0.0 109.391 -179.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -125.52 144.24 50.64 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.52 -175.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -163.43 135.55 5.12 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 107.084 -1.451 . . . . 0.0 107.084 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.95 -157.17 7.99 Favored Glycine 0 C--N 1.301 -1.378 0 C-N-CA 120.233 -0.984 . . . . 0.0 112.265 -175.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -55.0 -50.95 67.73 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.262 1.025 . . . . 0.0 110.505 177.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -92.15 163.91 28.15 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -90.57 123.56 0.97 Allowed 'Trans proline' 0 N--CA 1.418 -2.921 0 CA-C-N 120.473 2.136 . . . . 0.0 111.026 -177.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 m -133.3 131.52 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.042 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 15' ' ' GLN . . . . . 0.423 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -145.97 123.17 11.52 Favored 'General case' 0 C--N 1.269 -2.933 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.604 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.97 161.64 34.89 Favored Glycine 0 N--CA 1.41 -3.042 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.0 tt -132.5 110.23 15.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 18' ' ' ILE . . . . . 0.426 ' H ' HD13 ' A' ' 18' ' ' ILE . 0.1 OUTLIER -107.65 132.84 54.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 -179.763 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 19' ' ' ASN . . . . . 0.466 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -106.05 139.62 40.3 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.904 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 20' ' ' PHE . . . . . 0.508 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 24.4 t80 -137.47 127.6 26.05 Favored 'General case' 0 C--O 1.252 1.186 0 CA-C-N 118.996 0.816 . . . . 0.0 111.577 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -134.38 102.45 5.34 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-O 121.797 0.808 . . . . 0.0 112.823 -178.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 22' ' ' GLN . . . . . 0.593 ' HG3' ' C ' ' A' ' 105' ' ' SER . 2.5 pm0 -127.71 162.91 25.47 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -178.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER 64.63 -56.39 0.27 Allowed 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.808 1.243 . . . . 0.0 113.001 176.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.72 -43.93 87.59 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.157 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.0 m -81.49 -65.85 0.96 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 171.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 57.45 96.52 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 124.33 1.052 . . . . 0.0 109.924 177.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 27' ' ' GLY . . . . . 0.484 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 140.53 -143.21 13.19 Favored Glycine 0 CA--C 1.463 -3.198 0 C-N-CA 118.545 -1.788 . . . . 0.0 108.692 -172.467 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.47 122.06 10.51 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 N-CA-C 107.403 -1.807 . . . . 0.0 107.403 175.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 29' ' ' VAL . . . . . 0.484 HG22 ' O ' ' A' ' 27' ' ' GLY . 55.7 t -102.69 113.36 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.807 0 CA-C-O 121.673 0.749 . . . . 0.0 109.927 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -84.61 102.73 13.14 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.616 -1.629 . . . . 0.0 109.799 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 31' ' ' VAL . . . . . 0.5 HG11 ' HA ' ' A' ' 20' ' ' PHE . 26.8 m -130.35 144.6 37.47 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.683 -176.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 32' ' ' TRP . . . . . 0.404 ' HA ' HG11 ' A' ' 97' ' ' VAL . 66.1 p-90 -148.12 134.67 19.76 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.587 178.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 33' ' ' GLY . . . . . 0.572 ' O ' HG23 ' A' ' 97' ' ' VAL . . . -164.03 137.9 5.0 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 119.132 -1.509 . . . . 0.0 113.119 169.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.8 m -114.23 126.62 55.25 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -177.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 35' ' ' ILE . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -130.26 133.18 64.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-O 121.261 0.553 . . . . 0.0 111.188 -177.458 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 36' ' ' LYS . . . . . 0.408 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 22.1 ptmt -106.59 133.2 51.63 Favored 'General case' 0 N--CA 1.419 -2.008 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.596 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 37' ' ' GLY . . . . . 0.45 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -157.97 174.37 35.26 Favored Glycine 0 N--CA 1.421 -2.316 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -170.246 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 tp -68.72 171.99 6.99 Favored 'General case' 0 CA--C 1.567 1.598 0 C-N-CA 123.305 0.642 . . . . 0.0 109.47 178.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 39' ' ' THR . . . . . 0.52 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 7.2 t -67.59 111.07 3.97 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.42 -0.8 . . . . 0.0 112.73 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 40' ' ' GLU . . . . . 0.523 ' H ' ' HA ' ' A' ' 90' ' ' ASP . 0.2 OUTLIER -163.56 174.15 12.15 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-O 123.127 1.441 . . . . 0.0 113.811 178.079 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.92 -144.53 0.05 OUTLIER Glycine 2 C--N 1.238 -4.901 0 CA-C-N 110.477 -3.056 . . . . 0.0 114.125 173.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 42' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 2.4 pt? -138.42 148.37 44.36 Favored 'General case' 1 N--CA 1.37 -4.428 0 CA-C-N 114.161 -1.019 . . . . 0.0 110.641 -164.933 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 43' ' ' HIS . . . . . 0.447 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 11.0 p80 -104.54 138.91 40.19 Favored 'General case' 0 CA--C 1.438 -3.335 0 C-N-CA 119.392 -0.923 . . . . 0.0 108.653 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -99.19 0.02 OUTLIER Glycine 0 N--CA 1.402 -3.577 0 O-C-N 125.215 1.572 . . . . 0.0 111.128 173.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -165.68 93.97 0.58 Allowed 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 117.716 -1.135 . . . . 0.0 111.105 -166.97 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 46' ' ' HIS . . . . . 0.597 ' CD2' ' HB2' ' A' ' 126' ' ' LEU . 14.3 t60 -170.85 86.47 0.1 Allowed 'General case' 0 C--O 1.284 2.901 0 CA-C-N 120.301 1.41 . . . . 0.0 114.493 171.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 47' ' ' VAL . . . . . 0.425 HG12 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -74.93 154.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.732 0 CA-C-N 113.553 -1.658 . . . . 0.0 107.119 165.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 48' ' ' HIS . . . . . 0.446 ' O ' ' HB2' ' A' ' 49' ' ' GLU . 25.9 p80 -159.24 114.06 2.44 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 116.511 -1.709 . . . . 0.0 107.08 172.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 49' ' ' GLU . . . . . 0.617 ' HA ' ' OE1' ' A' ' 49' ' ' GLU 0.484 0.0 OUTLIER -173.74 168.2 4.37 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 165.377 . . . . . . . . 4 4 . 1 . 019 nuclear orig core ' A' A ' 50' ' ' PHE . . . . . 0.479 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 26.8 p90 -115.22 19.46 15.59 Favored 'General case' 0 N--CA 1.404 -2.743 0 CA-C-N 112.654 -2.067 . . . . 0.0 109.108 176.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 51' ' ' GLY . . . . . 0.605 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 85.06 138.94 4.49 Favored Glycine 0 N--CA 1.47 0.959 0 N-CA-C 115.017 0.767 . . . . 0.0 115.017 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -144.9 -72.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.674 -0.81 . . . . 0.0 109.148 173.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -168.81 158.74 9.16 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 176.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 m -65.58 -48.41 72.44 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 123.633 0.773 . . . . 0.0 111.023 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.69 -7.88 42.46 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.003 -171.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.34 109.85 0.47 Allowed Glycine 0 CA--C 1.463 -3.214 0 C-N-CA 118.794 -1.669 . . . . 0.0 110.449 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 57' ' ' CYS . . . . . 0.836 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 15.8 p -101.89 87.42 3.11 Favored 'General case' 0 N--CA 1.392 -3.368 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 174.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.1 m -82.43 -50.09 9.26 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 122.755 1.265 . . . . 0.0 108.943 174.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 59' ' ' SER . . . . . 0.479 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 15.2 m -72.16 -8.15 53.11 Favored 'General case' 0 C--O 1.209 -1.038 0 CA-C-N 113.457 -1.702 . . . . 0.0 112.982 -175.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 60' ' ' ALA . . . . . 0.507 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -77.29 -7.29 55.74 Favored 'General case' 0 CA--C 1.494 -1.192 0 C-N-CA 124.785 1.234 . . . . 0.0 111.216 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.7 52.09 0.83 Allowed Glycine 0 N--CA 1.406 -3.357 0 C-N-CA 117.762 -2.161 . . . . 0.0 116.016 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 62' ' ' PRO . . . . . 0.446 ' HD3' ' C ' ' A' ' 60' ' ' ALA . 1.2 Cg_endo -90.42 -6.74 4.37 Favored 'Trans proline' 0 C--N 1.395 3.009 0 CA-C-N 121.788 2.794 . . . . 0.0 106.995 164.052 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 63' ' ' HIS . . . . . 0.411 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 31.3 m80 72.48 -58.06 0.61 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 114.149 -1.387 . . . . 0.0 111.355 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -112.63 116.52 30.31 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 122.322 -0.236 . . . . 0.0 110.936 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 65' ' ' ASN . . . . . 0.473 ' HB3' ' HG3' ' A' ' 79' ' ' ARG . 0.8 OUTLIER -77.23 144.48 71.2 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.386 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.54 -54.32 1.05 Allowed 'Trans proline' 0 CA--C 1.553 1.441 0 C-N-CA 122.907 2.404 . . . . 0.0 117.234 -170.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 67' ' ' LEU . . . . . 0.577 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 4.2 mm? -82.72 8.48 12.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.208 -1.397 . . . . 0.0 112.176 -173.262 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 68' ' ' SER . . . . . 0.59 ' HA ' ' OE1' ' A' ' 77' ' ' GLU . 69.6 m -72.2 39.27 0.07 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 122.614 1.197 . . . . 0.0 111.085 173.211 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 69' ' ' ARG . . . . . 0.571 ' H ' ' C ' ' A' ' 67' ' ' LEU . 73.6 mtt-85 -100.56 3.4 42.69 Favored 'General case' 0 N--CA 1.386 -3.674 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.673 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HB2' ' N ' ' A' ' 78' ' ' GLU . 47.8 mttp -109.31 30.06 6.96 Favored 'General case' 0 CA--C 1.495 -1.172 0 C-N-CA 118.975 -1.09 . . . . 0.0 110.768 169.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 70.56 86.11 0.13 Allowed 'General case' 0 N--CA 1.435 -1.177 0 CA-C-N 113.967 -1.47 . . . . 0.0 112.913 177.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 72' ' ' GLY . . . . . 0.532 ' HA2' ' CG ' ' A' ' 77' ' ' GLU . . . -53.54 83.1 0.01 OUTLIER Glycine 0 CA--C 1.508 -0.382 0 CA-C-N 114.59 -1.186 . . . . 0.0 112.573 169.016 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -141.84 -151.17 5.48 Favored Glycine 0 N--CA 1.401 -3.639 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 178.838 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 74' ' ' PRO . . . . . 0.426 ' CB ' ' HB3' ' A' ' 84' ' ' LEU . 98.8 Cg_endo -81.94 -41.3 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.332 0 N-CA-C 117.905 2.233 . . . . 0.0 117.905 -169.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -93.95 -26.21 16.94 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 116.446 2.017 . . . . 0.0 116.446 -162.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -171.59 143.12 1.7 Allowed 'General case' 0 CA--C 1.475 -1.931 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 -169.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' GLU . . . . . 0.59 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -160.05 151.0 19.1 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -175.845 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' GLU . . . . . 0.577 ' HB3' ' O ' ' A' ' 67' ' ' LEU . 15.4 tp10 -90.18 -19.2 24.5 Favored 'General case' 0 CA--C 1.555 1.142 0 O-C-N 123.446 0.466 . . . . 0.0 111.921 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' ARG . . . . . 0.571 ' HB2' ' C ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -101.0 -8.23 22.56 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 104.302 -2.481 . . . . 0.0 104.302 172.232 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' HIS . . . . . 0.468 ' HA ' ' HB3' ' A' ' 77' ' ' GLU . 44.2 m170 . . . . . 0 N--CA 1.45 -0.456 0 CA-C-N 113.211 -1.813 . . . . 0.0 110.901 175.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HB3' ' CB ' ' A' ' 74' ' ' PRO 0.404 1.1 pp . . . . . 0 N--CA 1.408 -2.534 0 CA-C-O 122.818 1.294 . . . . 0.0 112.608 . . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.33 87.31 0.13 Allowed Glycine 1 N--CA 1.389 -4.494 0 CA-C-N 113.771 -1.559 . . . . 0.0 110.034 177.416 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' ASN . . . . . 0.447 ' HA ' ' O ' ' A' ' 43' ' ' HIS . 24.7 t30 -72.79 128.17 34.73 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 174.091 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 42' ' ' LEU . 6.5 m -143.09 127.38 14.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 O-C-N 123.839 0.712 . . . . 0.0 110.684 -176.237 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' THR . . . . . 0.563 ' O ' ' HA ' ' A' ' 95' ' ' ALA 0.257 4.9 p -101.02 101.45 12.23 Favored 'General case' 0 CA--C 1.561 1.396 0 C-N-CA 128.175 2.59 . . . . 0.0 111.991 -176.396 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -118.92 108.27 14.59 Favored 'General case' 0 CA--C 1.473 -2.006 0 CA-C-N 120.579 1.536 . . . . 0.0 109.423 -178.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' ASP . . . . . 0.565 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 38.3 t70 -90.96 -165.43 1.35 Allowed 'General case' 0 C--N 1.278 -2.532 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.531 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' LYS . . . . . 0.565 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 21.9 ptmt -42.93 -32.17 0.6 Allowed 'General case' 0 N--CA 1.51 2.568 0 C-N-CA 126.439 1.895 . . . . 0.0 115.663 -175.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -91.22 -37.17 13.49 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-O 122.525 1.155 . . . . 0.0 107.925 -178.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' GLY . . . . . 0.45 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 91.35 78.84 1.38 Allowed Glycine 1 N--CA 1.384 -4.805 0 CA-C-N 114.173 -1.376 . . . . 0.0 111.145 -176.578 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.7 t -142.69 101.15 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.175 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 176.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 95' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.46 140.49 34.64 Favored 'General case' 0 N--CA 1.404 -2.763 0 O-C-N 123.699 0.624 . . . . 0.0 112.184 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -94.69 129.72 41.48 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 175.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 97' ' ' VAL . . . . . 0.572 HG23 ' O ' ' A' ' 33' ' ' GLY . 0.9 OUTLIER -82.45 124.08 38.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 O-C-N 123.665 0.603 . . . . 0.0 111.397 -177.377 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 98' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . 46.9 m -87.29 108.84 19.14 Favored 'General case' 0 N--CA 1.4 -2.972 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 168.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.5 tt -90.77 123.03 42.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 114.79 -1.096 . . . . 0.0 108.55 177.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 100' ' ' GLU . . . . . 0.408 ' HB3' HD21 ' A' ' 84' ' ' LEU . 7.8 tp10 -138.94 157.61 45.7 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 114.554 -1.203 . . . . 0.0 111.145 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -81.46 103.33 11.13 Favored 'General case' 0 C--N 1.275 -2.64 0 C-N-CA 126.871 2.069 . . . . 0.0 112.586 -177.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 102' ' ' SER . . . . . 0.477 ' OG ' HG21 ' A' ' 29' ' ' VAL . 23.6 p -102.58 164.84 11.43 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.407 -0.808 . . . . 0.0 110.607 169.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.7 m -108.97 -63.5 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 C-N-CA 118.517 -1.273 . . . . 0.0 112.405 175.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 13.1 tt -128.15 23.98 2.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 121.571 0.701 . . . . 0.0 111.19 -169.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 105' ' ' SER . . . . . 0.593 ' C ' ' HG3' ' A' ' 22' ' ' GLN . 13.6 m -82.0 85.15 6.77 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.345 -1.742 . . . . 0.0 111.854 -178.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 106' ' ' LEU . . . . . 0.547 ' HG ' HE21 ' A' ' 22' ' ' GLN . 7.0 mp -76.18 117.58 18.02 Favored 'General case' 0 C--O 1.195 -1.791 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 170.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 107' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 112' ' ' ILE . 9.3 m -69.48 86.71 0.45 Allowed 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 119.909 1.231 . . . . 0.0 111.717 -175.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 108' ' ' GLY . . . . . 0.48 ' HA3' ' HG3' ' A' ' 115' ' ' ARG . . . 124.45 135.57 4.46 Favored Glycine 0 N--CA 1.427 -1.935 0 CA-C-N 113.83 -1.532 . . . . 0.0 109.749 177.11 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 109' ' ' ASP . . . . . 0.458 ' HB3' ' NH1' ' A' ' 79' ' ' ARG . 18.0 t70 -78.34 -36.26 46.47 Favored 'General case' 0 CA--C 1.5 -0.968 0 C-N-CA 117.686 -1.606 . . . . 0.0 111.134 175.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -68.77 -34.01 74.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.334 -175.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t 178.35 169.64 0.79 Allowed 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 103.844 -2.651 . . . . 0.0 103.844 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 112' ' ' ILE . . . . . 0.556 ' O ' ' HG2' ' A' ' 115' ' ' ARG . 57.2 mt -93.66 -51.91 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.266 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 174.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 113' ' ' ILE . . . . . 0.555 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 3.7 mp -64.21 99.36 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.494 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.696 -170.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 114' ' ' GLY . . . . . 0.602 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 127.46 -7.67 7.04 Favored Glycine 0 N--CA 1.428 -1.891 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.557 174.165 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 115' ' ' ARG . . . . . 0.605 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 1.6 mmp_? -81.36 133.48 35.43 Favored 'General case' 0 C--O 1.198 -1.653 0 C-N-CA 119.434 -0.907 . . . . 0.0 108.804 -176.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 116' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 80.3 m -69.87 126.75 30.64 Favored 'General case' 0 C--N 1.295 -1.792 0 CA-C-O 121.114 0.483 . . . . 0.0 112.017 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 117' ' ' LEU . . . . . 0.425 ' HA ' HG12 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -75.36 97.02 3.51 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.151 174.248 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 118' ' ' VAL . . . . . 0.461 HG11 ' HB1' ' A' ' 140' ' ' ALA . 13.0 t -94.02 94.69 4.7 Favored 'Isoleucine or valine' 1 C--O 1.338 5.725 0 C-N-CA 115.78 -2.368 . . . . 0.0 110.079 -173.317 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 119' ' ' VAL . . . . . 0.442 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . 22.8 m -149.46 170.09 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 128.84 2.856 . . . . 0.0 106.636 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 120' ' ' HIS . . . . . 0.416 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 67.6 t60 -156.61 171.55 20.13 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 121' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.9 OUTLIER -70.12 83.6 0.52 Allowed 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 121.085 1.766 . . . . 0.0 106.863 173.919 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -176.63 155.65 1.37 Allowed 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 173.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.87 124.54 14.35 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 119.296 0.953 . . . . 0.0 112.853 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 124' ' ' ASP . . . . . 0.519 ' OD2' ' HB2' ' A' ' 140' ' ' ALA . 9.5 t70 -129.35 102.56 6.48 Favored 'General case' 0 CA--C 1.48 -1.742 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 -178.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -143.71 147.84 34.83 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 126' ' ' LEU . . . . . 0.597 ' HB2' ' CD2' ' A' ' 46' ' ' HIS . 43.4 tp -91.5 -28.53 17.54 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.641 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.78 -61.46 4.65 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 119.943 -1.123 . . . . 0.0 111.718 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -137.17 52.58 1.91 Allowed 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.16 0.505 . . . . 0.0 111.577 177.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.53 78.21 0.87 Allowed Glycine 0 C--N 1.297 -1.623 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.233 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -109.08 3.57 Favored Glycine 0 N--CA 1.442 -0.9 0 C-N-CA 121.752 -0.261 . . . . 0.0 112.937 175.454 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 131' ' ' ASN . . . . . 0.417 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.9 t30 -104.24 167.42 9.77 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 132' ' ' GLU . . . . . 0.499 ' O ' HG22 ' A' ' 135' ' ' THR . 8.5 mm-40 -51.78 -44.7 63.51 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -178.204 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -77.17 -24.66 51.46 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 121.829 -0.544 . . . . 0.0 112.283 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 134' ' ' SER . . . . . 0.417 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 5.7 m -80.04 -22.45 42.34 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-O 121.357 0.599 . . . . 0.0 109.819 -179.018 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 135' ' ' THR . . . . . 0.507 ' O ' HD12 ' A' ' 126' ' ' LEU . 1.8 t -81.22 -18.91 44.46 Favored 'General case' 0 N--CA 1.42 -1.945 0 C-N-CA 119.518 -0.873 . . . . 0.0 109.643 178.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -69.58 -36.63 76.43 Favored 'General case' 0 C--O 1.224 -0.283 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.081 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 137' ' ' THR . . . . . 0.411 ' HA ' ' HB3' ' A' ' 63' ' ' HIS . 13.6 t -86.56 -16.46 36.76 Favored 'General case' 0 C--O 1.26 1.647 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.893 -177.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.61 69.6 1.32 Allowed Glycine 1 C--O 1.3 4.225 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 -172.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -33.75 104.37 0.03 OUTLIER 'General case' 0 CA--C 1.482 -1.645 0 O-C-N 127.49 2.523 . . . . 0.0 116.21 -164.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 140' ' ' ALA . . . . . 0.519 ' HB2' ' OD2' ' A' ' 124' ' ' ASP . . . -153.51 170.5 20.61 Favored 'General case' 0 N--CA 1.401 -2.877 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 171.371 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 141' ' ' GLY . . . . . 0.461 ' HA3' HD22 ' A' ' 144' ' ' LEU . . . -87.4 137.17 14.43 Favored Glycine 0 C--N 1.272 -2.973 0 N-CA-C 105.718 -2.953 . . . . 0.0 105.718 165.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 24.5 m -54.59 -30.24 53.94 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -172.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 143' ' ' ARG . . . . . 0.836 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 30.8 ptt180 -124.15 15.21 9.12 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 144' ' ' LEU . . . . . 0.461 HD22 ' HA3' ' A' ' 141' ' ' GLY . 3.6 mm? -71.04 -9.09 57.44 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -175.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.44 89.29 0.75 Allowed 'General case' 0 N--CA 1.422 -1.826 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 172.057 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 146' ' ' CYS . . . . . 0.418 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 79.4 m -84.75 130.58 34.67 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 147' ' ' GLY . . . . . 0.515 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.27 127.01 1.29 Allowed Glycine 1 N--CA 1.396 -4.014 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.57 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.0 m -74.27 125.47 33.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.998 172.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 149' ' ' ILE . . . . . 0.501 HG22 ' O ' ' A' ' 115' ' ' ARG . 15.5 tt -99.41 136.65 29.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 174.244 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 150' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 177.13 167.74 35.97 Favored Glycine 2 CA--C 1.439 -4.663 0 C-N-CA 118.486 -1.816 . . . . 0.0 111.721 179.459 . . . . . . . . 3 3 . 1 . 019 nuclear orig core ' A' A ' 151' ' ' ILE . . . . . 0.548 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 5.6 tt -82.26 104.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.348 0 CA-C-O 122.178 0.99 . . . . 0.0 110.29 169.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 116.43 31.93 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.373 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 . . . . . 0 C--N 1.28 -2.441 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -177.812 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.446 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.436 -1.146 0 N-CA-C 111.475 0.176 . . . . 0.0 111.475 . . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.65 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 3.3 m -88.81 -26.92 21.43 Favored 'General case' 0 CA--C 1.568 1.64 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -167.646 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.512 ' HB3' ' NZ ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -152.17 158.53 43.03 Favored 'General case' 0 CA--C 1.455 -2.676 0 O-C-N 120.381 -1.449 . . . . 0.0 111.628 176.619 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.543 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -145.19 153.68 41.61 Favored 'General case' 0 N--CA 1.397 -3.081 0 O-C-N 124.081 0.863 . . . . 0.0 109.321 -175.971 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.1 m -132.21 132.01 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 176.889 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.74 136.7 47.88 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.562 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.61 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 4.4 p -134.27 106.66 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-O 121.662 0.744 . . . . 0.0 110.001 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.406 ' HB3' HD22 ' A' ' 117' ' ' LEU . 0.8 OUTLIER -112.42 140.61 47.01 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.184 -178.468 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -144.54 123.48 12.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -131.92 -165.58 11.38 Favored Glycine 0 N--CA 1.434 -1.483 0 C-N-CA 119.682 -1.247 . . . . 0.0 113.707 -174.874 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -74.83 -42.75 57.43 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 177.477 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -94.94 154.01 21.05 Favored Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 106.269 -2.733 . . . . 0.0 106.269 170.457 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.41 121.7 5.76 Favored 'Trans proline' 0 N--CA 1.42 -2.822 0 CA-C-N 121.324 2.562 . . . . 0.0 109.535 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.401 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 17.4 m -133.32 124.98 50.07 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -150.0 142.73 24.64 Favored 'General case' 0 C--N 1.26 -3.283 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.292 -178.673 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.35 166.74 39.93 Favored Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.459 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.3 pt -134.33 103.23 4.7 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 CA-C-O 121.134 0.493 . . . . 0.0 109.692 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.08 126.83 57.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.548 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 7.7 p30 -125.39 122.56 37.1 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.452 ' HD2' ' NE2' ' A' ' 22' ' ' GLN . 6.4 p90 -128.22 128.19 44.27 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.65 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.4 pt-20 -106.76 109.23 21.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.888 176.695 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.452 ' NE2' ' HD2' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -126.2 162.13 26.12 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.199 1.0 . . . . 0.0 108.944 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -154.18 149.41 27.02 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -66.42 -9.08 30.41 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.6 m -70.38 -8.67 52.51 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.677 0.791 . . . . 0.0 111.655 177.038 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 75.6 115.21 0.06 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 124.444 1.097 . . . . 0.0 111.212 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.63 150.49 10.06 Favored Glycine 0 N--CA 1.424 -2.127 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 178.139 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -57.34 131.57 45.61 Favored 'Trans proline' 0 C--O 1.248 1.011 0 C-N-CA 122.585 2.19 . . . . 0.0 110.148 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.453 HG23 ' OG ' ' A' ' 102' ' ' SER . 2.9 m -83.48 128.46 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.353 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.376 -178.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 5.6 mtpm? -85.52 112.81 21.26 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 176.373 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.548 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.7 p -137.35 138.26 45.26 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.107 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.484 -168.79 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 33.9 t-105 -136.23 132.27 35.63 Favored 'General case' 0 C--N 1.277 -2.559 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.452 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.711 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -151.63 138.89 6.77 Favored Glycine 0 C--O 1.208 -1.486 0 C-N-CA 119.233 -1.46 . . . . 0.0 112.991 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.7 m -116.56 142.7 46.54 Favored 'General case' 0 N--CA 1.408 -2.528 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 176.501 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.486 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 76.0 mt -128.71 139.17 52.62 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 118.737 0.699 . . . . 0.0 109.335 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.613 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 22.4 ptmt -117.89 138.74 51.92 Favored 'General case' 0 N--CA 1.411 -2.414 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 173.285 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.644 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -161.37 176.56 37.9 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -166.732 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.9 mt -69.08 170.89 9.1 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 175.098 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.462 ' HB ' ' O ' ' A' ' 91' ' ' LYS . 2.8 t -69.31 108.29 3.63 Favored 'General case' 0 C--O 1.192 -1.969 0 O-C-N 121.615 -0.678 . . . . 0.0 112.292 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -172.86 171.7 4.26 Favored 'General case' 0 CA--C 1.461 -2.467 0 C-N-CA 124.55 1.14 . . . . 0.0 108.662 174.017 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.461 ' HA2' ' O ' ' A' ' 89' ' ' ALA . . . -82.55 -146.23 5.99 Favored Glycine 0 C--N 1.276 -2.787 0 O-C-N 124.875 1.359 . . . . 0.0 109.779 173.608 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.616 ' HG ' ' O ' ' A' ' 120' ' ' HIS . 2.8 tt 172.4 140.08 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 103.709 -2.7 . . . . 0.0 103.709 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -152.66 122.23 6.84 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.01 139.05 0.99 Allowed Glycine 0 C--N 1.301 -1.396 0 O-C-N 123.768 0.667 . . . . 0.0 113.999 177.473 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.431 ' CD1' ' HB2' ' A' ' 83' ' ' ASP . 0.2 OUTLIER -114.49 106.53 14.39 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 176.41 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.545 ' CE1' ' HA3' ' A' ' 138' ' ' GLY . 28.9 t-80 -130.13 89.19 2.76 Favored 'General case' 1 C--O 1.316 4.556 0 CA-C-O 122.134 0.968 . . . . 0.0 109.141 -176.709 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.5 ' HB ' ' CA ' ' A' ' 82' ' ' GLY . 94.5 t -92.56 152.0 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.357 0 CA-C-N 112.692 -2.049 . . . . 0.0 107.387 175.085 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -162.05 94.31 0.92 Allowed 'General case' 0 C--N 1.288 -2.074 0 O-C-N 124.083 0.864 . . . . 0.0 110.367 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.458 ' CG ' ' HB3' ' A' ' 60' ' ' ALA . 1.3 mm-40 -145.96 170.26 16.98 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 115.557 1.688 . . . . 0.0 115.557 -174.769 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.406 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 20.5 p90 -139.99 25.86 2.28 Favored 'General case' 0 N--CA 1.41 -2.463 0 CA-C-N 112.238 -2.255 . . . . 0.0 108.815 174.843 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.544 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . 84.47 129.02 1.8 Allowed Glycine 0 C--N 1.34 0.804 0 CA-C-N 114.586 -1.188 . . . . 0.0 115.447 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -140.8 -77.84 0.29 Allowed 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.578 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 28.0 t30 -157.69 133.09 8.96 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.467 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.0 t -73.26 4.6 4.37 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -173.904 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.69 -2.41 17.44 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.896 0.379 . . . . 0.0 110.348 177.059 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 157.56 124.72 0.81 Allowed Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -177.097 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.493 ' O ' ' HB3' ' A' ' 142' ' ' SER . 0.6 OUTLIER -97.67 112.78 24.52 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 113.565 0.95 . . . . 0.0 113.565 -176.399 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.7 m -75.61 -37.41 59.81 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.252 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.406 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 4.6 m -72.56 -26.68 61.82 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.621 0.724 . . . . 0.0 110.23 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.458 ' HB3' ' CG ' ' A' ' 49' ' ' GLU . . . -76.5 -8.77 57.86 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.039 -175.551 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.69 -93.3 0.03 OUTLIER Glycine 0 C--N 1.301 -1.384 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.345 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -95.88 53.31 0.17 Allowed 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 121.71 1.606 . . . . 0.0 113.349 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -125.73 117.06 22.64 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.919 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.514 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 52.8 p90 -87.07 138.52 31.42 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.196 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -115.51 95.84 44.35 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.642 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 56.7 Cg_endo -68.86 -10.79 30.14 Favored 'Trans proline' 0 C--O 1.213 -0.744 0 C-N-CA 124.035 3.157 . . . . 0.0 115.031 -173.895 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -77.12 -18.42 57.94 Favored 'General case' 0 C--O 1.199 -1.581 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -173.43 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.669 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 47.5 p -54.63 -84.34 0.01 OUTLIER 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 114.283 -1.326 . . . . 0.0 113.315 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.53 ' HE ' ' HB2' ' A' ' 77' ' ' GLU . 1.9 tmt_? -134.91 30.13 3.4 Favored 'General case' 0 C--N 1.249 -3.8 0 N-CA-C 103.01 -2.959 . . . . 0.0 103.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.642 ' HA ' ' O ' ' A' ' 66' ' ' PRO . 69.7 mmtt 75.19 -41.23 0.45 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.04 -169.834 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.452 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 1.8 t-160 -121.74 -16.97 7.55 Favored 'General case' 0 N--CA 1.426 -1.652 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.075 171.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.504 ' H ' ' HB3' ' A' ' 69' ' ' ARG . . . 108.92 16.81 10.95 Favored Glycine 0 C--N 1.358 1.8 0 C-N-CA 118.519 -1.8 . . . . 0.0 115.881 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -38.26 146.98 0.12 Allowed Glycine 0 N--CA 1.491 2.338 0 CA-C-N 117.978 0.889 . . . . 0.0 113.69 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.88 -22.4 17.53 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.097 2.531 . . . . 0.0 113.869 -166.429 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -86.87 -12.83 46.66 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.945 -177.067 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 21.4 t0 70.35 159.93 0.2 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 124.493 1.117 . . . . 0.0 111.209 -175.562 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.53 ' HB2' ' HE ' ' A' ' 69' ' ' ARG . 22.7 tp10 -148.47 -24.99 0.33 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -178.57 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.42 ' HG2' ' HG2' ' A' ' 79' ' ' ARG . 27.6 tt0 -138.67 -64.02 0.53 Allowed 'General case' 0 N--CA 1.423 -1.815 0 C-N-CA 118.237 -1.385 . . . . 0.0 110.755 -176.029 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.673 ' O ' HG13 ' A' ' 81' ' ' VAL . 15.4 ptt180 -173.72 62.6 0.02 OUTLIER 'General case' 0 N--CA 1.398 -3.052 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 -173.775 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.443 ' HA ' ' CA ' ' A' ' 68' ' ' SER . 4.5 t60 -42.16 96.45 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.539 0 CA-C-N 113.315 -1.766 . . . . 0.0 107.022 170.205 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.673 HG13 ' O ' ' A' ' 79' ' ' ARG . 15.3 m -82.56 58.76 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.835 0 CA-C-O 123.979 1.847 . . . . 0.0 111.395 -176.508 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.5 ' CA ' ' HB ' ' A' ' 47' ' ' VAL . . . -175.22 174.31 46.72 Favored Glycine 0 C--N 1.266 -3.312 0 CA-C-N 110.592 -3.003 . . . . 0.0 106.497 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.431 ' HB2' ' CD1' ' A' ' 45' ' ' PHE . 19.3 m-20 -69.65 139.74 53.56 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 118.948 1.374 . . . . 0.0 108.493 179.533 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER -117.94 119.71 35.63 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-O 121.751 0.786 . . . . 0.0 110.145 -175.511 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.25 -178.64 47.61 Favored Glycine 1 N--CA 1.386 -4.684 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 176.192 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -128.2 129.74 46.92 Favored 'General case' 0 C--N 1.263 -3.194 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 169.684 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.442 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 0.6 OUTLIER -133.78 147.89 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.083 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.53 ' HA ' ' HB3' ' A' ' 42' ' ' LEU . 89.0 m -139.93 113.0 8.21 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -176.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.461 ' O ' ' HA2' ' A' ' 41' ' ' GLY . . . -83.44 150.98 25.7 Favored 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.453 ' OD1' ' HG2' ' A' ' 91' ' ' LYS . 9.8 t70 -93.13 -179.02 4.96 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 174.5 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.462 ' O ' ' HB ' ' A' ' 39' ' ' THR . 22.1 pttp -61.21 -16.23 42.72 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 124.459 1.104 . . . . 0.0 111.822 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.3 4.62 48.71 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.937 -0.477 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.644 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 60.96 83.17 0.06 OUTLIER Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.047 -175.751 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.486 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 5.1 m -155.75 111.15 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.305 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.442 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -119.44 123.97 45.37 Favored 'General case' 0 N--CA 1.415 -2.184 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.644 -178.632 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.66 145.38 28.01 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.711 ' HB ' ' O ' ' A' ' 33' ' ' GLY . 7.5 p -84.55 125.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -173.584 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.4 t -90.48 115.52 27.7 Favored 'General case' 0 N--CA 1.404 -2.735 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 168.855 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.43 HG12 ' O ' ' A' ' 31' ' ' VAL . 34.9 mt -92.02 118.26 37.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -107.34 156.04 19.34 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.915 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -81.28 99.69 8.76 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 122.088 0.947 . . . . 0.0 109.452 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.453 ' OG ' HG23 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -97.79 171.74 8.12 Favored 'General case' 0 C--N 1.265 -3.091 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.238 -175.922 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 26.5 t -109.32 -64.51 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.368 0 C-N-CA 119.658 -0.817 . . . . 0.0 111.446 -177.621 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 8.4 mt -134.18 24.97 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 121.326 0.584 . . . . 0.0 109.854 -177.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.419 ' OG ' ' HB3' ' A' ' 80' ' ' HIS . 33.3 t -68.99 88.49 0.4 Allowed 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -170.411 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.422 ' HB3' ' HG3' ' A' ' 22' ' ' GLN . 1.7 pt? -96.49 136.31 37.18 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 160.331 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -71.89 86.21 0.98 Allowed 'General case' 0 C--N 1.286 -2.174 0 CA-C-O 122.349 1.071 . . . . 0.0 112.755 -175.418 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 111' ' ' SER . . . 143.2 135.74 3.06 Favored Glycine 0 N--CA 1.409 -3.145 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.821 170.595 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.447 ' HB3' HG12 ' A' ' 81' ' ' VAL . 7.4 p-10 -93.46 -28.03 16.35 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 122.903 -0.174 . . . . 0.0 111.434 -177.336 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 48.4 m80 -91.22 -23.43 20.2 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.0 -178.98 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.655 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t 177.11 178.89 0.25 Allowed 'General case' 0 N--CA 1.426 -1.666 0 N-CA-C 104.083 -2.562 . . . . 0.0 104.083 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -113.43 -56.46 4.2 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 C-N-CA 124.589 1.156 . . . . 0.0 109.878 -175.361 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.407 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 52.5 mt -68.37 119.51 14.27 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.723 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -177.089 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.544 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 115.66 -19.27 14.38 Favored Glycine 0 CA--C 1.47 -2.751 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.655 ' CZ ' ' HB3' ' A' ' 111' ' ' SER . 4.5 mpt_? -74.85 128.45 35.61 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.702 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 0.2 OUTLIER -92.01 126.88 37.26 Favored 'General case' 0 C--N 1.258 -3.389 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.62 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.461 ' HA ' ' CG1' ' A' ' 47' ' ' VAL . 2.0 pt? -76.62 136.88 39.2 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -177.423 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.9 99.57 8.69 Favored 'Isoleucine or valine' 0 C--O 1.28 2.661 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.654 171.111 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.675 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 7.4 p -147.42 170.39 3.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 104.748 -2.316 . . . . 0.0 104.748 178.226 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.616 ' O ' ' HG ' ' A' ' 42' ' ' LEU . 81.7 t60 -170.89 171.25 6.06 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 103.312 -2.848 . . . . 0.0 103.312 175.536 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.476 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.04 87.07 0.37 Allowed 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 171.278 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.45 ' H ' ' HG ' ' A' ' 42' ' ' LEU . 16.3 tppt? -173.18 154.76 2.79 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.74 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.37 103.88 1.11 Allowed 'General case' 0 C--N 1.285 -2.236 0 CA-C-O 121.89 0.852 . . . . 0.0 109.991 166.138 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -106.51 70.31 0.82 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.549 -2.389 . . . . 0.0 104.549 175.877 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -68.11 161.41 26.95 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.128 -170.267 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.408 HD23 ' H ' ' A' ' 126' ' ' LEU . 0.3 OUTLIER -90.48 -68.92 0.76 Allowed 'General case' 0 N--CA 1.397 -3.103 0 CA-C-N 113.83 -1.532 . . . . 0.0 110.996 -167.381 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.452 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -102.82 -16.55 21.41 Favored Glycine 0 N--CA 1.429 -1.773 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.984 -177.752 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.99 -31.51 16.3 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 117.16 0.48 . . . . 0.0 110.367 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.478 ' HA3' ' O ' ' A' ' 134' ' ' SER . . . 53.7 -89.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.972 0 O-C-N 123.709 0.63 . . . . 0.0 114.175 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -172.84 -86.19 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -96.78 162.33 13.47 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 176.859 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.514 ' O ' ' HB ' ' A' ' 135' ' ' THR . 10.1 pt-20 -38.9 -51.32 1.76 Allowed 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -170.517 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -71.62 -38.09 70.82 Favored 'General case' 0 C--N 1.311 -1.083 0 O-C-N 122.12 -0.362 . . . . 0.0 111.854 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.478 ' O ' ' HA3' ' A' ' 129' ' ' GLY . 14.4 m -72.45 -22.92 61.01 Favored 'General case' 0 C--O 1.218 -0.568 0 CA-C-O 121.488 0.661 . . . . 0.0 109.619 178.479 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.514 ' HB ' ' O ' ' A' ' 132' ' ' GLU . 66.4 m -67.16 -39.88 86.57 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-O 121.949 0.881 . . . . 0.0 108.845 173.437 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -71.3 -51.33 24.96 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.022 -1.445 . . . . 0.0 110.046 -177.656 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.514 ' HA ' ' HB3' ' A' ' 64' ' ' PHE . 41.1 p -74.68 -31.23 61.84 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.673 -177.317 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.545 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . 82.35 106.12 0.43 Allowed Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -174.243 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -32.84 140.31 0.04 OUTLIER 'General case' 1 C--O 1.329 5.254 0 C-N-CA 126.463 1.905 . . . . 0.0 115.47 -165.534 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -150.49 120.2 7.03 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.323 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -98.94 89.08 0.88 Allowed Glycine 0 N--CA 1.417 -2.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 169.858 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.493 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 6.2 m -42.79 -35.3 1.12 Allowed 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 126.727 2.011 . . . . 0.0 114.252 -171.383 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 17.9 ptt180 -125.35 5.12 7.71 Favored 'General case' 0 N--CA 1.414 -2.258 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.061 -177.709 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.09 -27.38 64.55 Favored 'General case' 0 C--N 1.291 -1.957 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.259 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.675 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -171.8 96.88 0.17 Allowed 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.702 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 43.4 t -140.5 147.78 40.08 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.087 -176.63 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.61 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.15 162.41 34.46 Favored Glycine 0 N--CA 1.403 -3.513 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 179.218 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 17.6 t -68.74 122.88 20.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.799 0.809 . . . . 0.0 111.149 175.326 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.625 HG12 ' O ' ' A' ' 115' ' ' ARG . 26.1 pt -111.97 146.25 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.868 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.407 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.17 155.92 15.44 Favored Glycine 2 N--CA 1.365 -6.07 0 C-N-CA 117.566 -2.254 . . . . 0.0 111.632 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.543 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 25.1 pt -63.08 105.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-N 114.854 -0.673 . . . . 0.0 110.369 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.529 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -105.62 114.15 28.14 Favored 'General case' 0 C--N 1.309 -1.168 0 O-C-N 121.9 -0.5 . . . . 0.0 110.663 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.318 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.447 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.226 -0.168 0 CA-C-O 120.629 0.252 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 p -81.65 -65.6 0.99 Allowed 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 178.581 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -170.78 171.98 5.89 Favored 'General case' 0 CA--C 1.488 -1.406 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -176.52 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.6 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -130.8 149.25 52.53 Favored 'General case' 0 N--CA 1.414 -2.225 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 172.038 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.554 ' O ' ' HA ' ' A' ' 149' ' ' ILE . 10.6 p -126.9 142.86 42.19 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.472 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -122.44 129.69 52.31 Favored 'General case' 0 C--N 1.286 -2.171 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.79 -177.533 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -129.15 111.73 23.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mp -108.08 152.12 24.95 Favored 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 120.972 -0.291 . . . . 0.0 111.243 178.597 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.46 ' HZ2' ' HB3' ' A' ' 9' ' ' LYS . 6.6 ttpm? -136.08 131.36 34.73 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 106.187 -1.782 . . . . 0.0 106.187 175.751 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 12' ' ' GLY . . . -104.21 148.86 16.95 Favored Glycine 0 N--CA 1.41 -3.099 0 N-CA-C 117.991 1.956 . . . . 0.0 117.991 -168.32 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -83.78 -19.5 34.94 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 111.629 -2.286 . . . . 0.0 104.92 168.298 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . 0.412 ' O ' ' HA3' ' A' ' 10' ' ' GLY . . . -142.71 144.52 14.07 Favored Glycine 0 N--CA 1.421 -2.328 1 N-CA-C 101.215 -4.754 . . . . 0.0 101.215 168.858 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_exo -69.74 124.82 11.47 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 CA-C-N 122.221 3.01 . . . . 0.0 112.989 -168.053 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.6 104.94 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.997 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.481 176.224 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -117.87 119.95 36.41 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.202 -0.936 . . . . 0.0 111.879 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.443 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.54 171.83 43.85 Favored Glycine 0 N--CA 1.44 -1.042 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.9 pt -143.6 131.75 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.472 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 3.8 mp -128.96 133.3 66.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.6 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.2 m-20 -117.21 126.71 53.2 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.511 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 67.8 t80 -129.03 119.63 24.59 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.415 ' CG ' ' HB3' ' A' ' 30' ' ' LYS . 10.5 pt-20 -131.14 113.53 14.01 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.352 0.596 . . . . 0.0 111.823 177.796 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.515 ' CG ' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -86.59 163.88 17.18 Favored 'General case' 0 N--CA 1.414 -2.228 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 168.049 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -96.45 146.92 24.35 Favored 'General case' 0 C--N 1.275 -2.669 0 C-N-CA 119.088 -1.045 . . . . 0.0 112.429 -172.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -56.64 -40.69 75.87 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.8 1.313 . . . . 0.0 109.735 178.038 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.4 p -81.25 -70.99 0.49 Allowed 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.37 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 168.21 161.26 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 126.413 1.885 . . . . 0.0 106.386 175.757 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.491 ' H ' HG23 ' A' ' 103' ' ' VAL . . . 155.6 174.01 24.96 Favored Glycine 0 N--CA 1.41 -3.077 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 174.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.9 136.88 55.13 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 121.732 1.621 . . . . 0.0 108.889 177.016 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.482 HG12 ' HA ' ' A' ' 22' ' ' GLN . 30.1 m -74.17 147.6 8.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-O 121.849 0.833 . . . . 0.0 110.813 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.415 ' HB3' ' CG ' ' A' ' 21' ' ' GLU . 28.2 ttmt -99.28 115.05 28.25 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 174.435 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.549 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.5 p -137.58 128.62 39.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-O 121.253 0.549 . . . . 0.0 110.337 -177.351 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 89.1 t90 -133.37 126.88 32.28 Favored 'General case' 0 C--N 1.283 -2.285 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.98 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.467 ' H ' ' CG1' ' A' ' 97' ' ' VAL . . . -142.0 139.72 9.51 Favored Glycine 0 N--CA 1.407 -3.246 0 C-N-CA 119.162 -1.494 . . . . 0.0 112.495 178.487 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.443 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 42.6 t -114.19 145.64 41.43 Favored 'General case' 0 C--N 1.284 -2.27 0 N-CA-C 107.292 -1.374 . . . . 0.0 107.292 176.418 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.5 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 3.2 tp -152.09 139.44 13.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.508 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 99.9 mttt -130.62 107.36 9.13 Favored 'General case' 0 C--N 1.281 -2.393 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 176.614 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.649 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -131.93 174.98 19.98 Favored Glycine 0 C--N 1.282 -2.434 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -171.951 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.448 ' O ' ' HG3' ' A' ' 121' ' ' GLU . 93.1 mt -68.72 170.14 9.98 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 118.113 0.956 . . . . 0.0 109.881 177.788 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.531 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 2.0 t -70.7 105.34 3.14 Favored 'General case' 0 CA--C 1.55 0.98 0 N-CA-C 114.367 1.247 . . . . 0.0 114.367 -171.518 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -177.26 165.06 2.24 Favored 'General case' 0 CA--C 1.456 -2.642 0 C-N-CA 128.594 2.758 . . . . 0.0 104.918 169.825 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 158.49 130.32 1.16 Allowed Glycine 3 N--CA 1.376 -5.338 0 C-N-CA 118.2 -1.952 . . . . 0.0 111.166 170.198 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mp -124.44 -86.33 0.63 Allowed 'General case' 0 N--CA 1.396 -3.174 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.501 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 79.9 m-70 -172.14 162.71 5.79 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 174.33 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 132.75 144.83 5.32 Favored Glycine 0 C--N 1.29 -2.002 0 C-N-CA 119.288 -1.434 . . . . 0.0 113.092 174.502 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.644 ' CE1' ' HB ' ' A' ' 47' ' ' VAL . 30.9 t80 -165.8 96.54 0.63 Allowed 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 124.927 1.291 . . . . 0.0 108.294 175.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.451 ' HB2' ' HA ' ' A' ' 125' ' ' ASP . 0.2 OUTLIER -114.33 89.49 3.11 Favored 'General case' 0 N--CA 1.403 -2.794 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 177.599 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.644 ' HB ' ' CE1' ' A' ' 45' ' ' PHE . 14.6 p -69.85 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.927 0 CA-C-N 111.603 -2.544 . . . . 0.0 107.19 175.975 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.424 ' HD1' ' HB2' ' A' ' 65' ' ' ASN . 9.6 t60 -154.1 104.33 2.62 Favored 'General case' 1 C--N 1.233 -4.491 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.232 173.673 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.495 ' HB2' ' HB3' ' A' ' 109' ' ' ASP . 1.5 mp0 -67.77 158.34 32.64 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.017 -1.447 . . . . 0.0 109.16 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.1 t80 77.95 64.01 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 123.887 1.804 . . . . 0.0 107.423 -166.439 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.442 ' HA3' ' OG1' ' A' ' 116' ' ' THR . . . -112.63 -126.15 4.57 Favored Glycine 0 N--CA 1.416 -2.668 0 CA-C-N 111.454 -2.612 . . . . 0.0 107.173 174.634 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 33.0 t70 -176.97 -71.6 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 117.946 0.873 . . . . 0.0 112.758 177.997 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 37.6 p30 -131.76 177.1 7.78 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.682 0.753 . . . . 0.0 112.947 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.458 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 25.9 m -84.21 6.85 21.05 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 125.919 1.688 . . . . 0.0 110.602 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.436 ' HA ' ' HZ1' ' A' ' 9' ' ' LYS . . . -83.27 -32.05 26.62 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.752 -178.623 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 164.24 155.83 8.54 Favored Glycine 0 N--CA 1.412 -2.911 0 N-CA-C 108.859 -1.697 . . . . 0.0 108.859 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.616 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 58.2 m -83.25 89.58 7.0 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.4 p -75.81 -58.69 3.13 Favored 'General case' 0 N--CA 1.421 -1.923 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.965 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 70.8 m -68.7 -42.68 77.39 Favored 'General case' 0 N--CA 1.425 -1.701 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.47 -25.5 54.39 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.356 -176.605 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.443 ' O ' HG23 ' A' ' 118' ' ' VAL . . . 49.24 -144.57 8.12 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -100.23 5.73 0.76 Allowed 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.803 2.335 . . . . 0.0 110.658 173.667 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.8 t60 -77.47 149.69 35.01 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.826 -169.248 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.48 ' HB2' ' O ' ' A' ' 80' ' ' HIS . 13.3 p90 -81.1 169.95 16.79 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.533 ' HB3' ' OG ' ' A' ' 68' ' ' SER . 53.0 t30 -105.52 143.19 26.31 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.77 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_exo -75.32 -13.58 20.71 Favored 'Trans proline' 0 C--O 1.225 -0.151 0 C-N-CA 121.79 1.66 . . . . 0.0 110.963 175.167 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.63 21.64 17.01 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 122.72 1.248 . . . . 0.0 108.69 -171.802 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.655 ' HB3' ' O ' ' A' ' 82' ' ' GLY . 46.3 m -73.98 -1.53 20.26 Favored 'General case' 0 C--O 1.196 -1.734 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.265 174.274 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.565 ' HA ' ' H ' ' A' ' 79' ' ' ARG . 3.9 mmp_? -68.59 -4.03 13.91 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 129.158 2.983 . . . . 0.0 109.589 177.552 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -140.54 29.73 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.725 -1.125 . . . . 0.0 108.196 176.626 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.493 ' HB3' ' N ' ' A' ' 84' ' ' LEU . 99.0 m-70 -143.97 -93.08 0.11 Allowed 'General case' 0 CA--C 1.556 1.176 0 C-N-CA 124.249 1.02 . . . . 0.0 109.392 176.326 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.518 ' HA2' ' HB2' ' A' ' 79' ' ' ARG . . . 81.94 -63.62 4.36 Favored Glycine 0 CA--C 1.501 -0.824 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 173.049 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.36 161.35 35.16 Favored Glycine 0 C--N 1.264 -3.454 0 N-CA-C 107.566 -2.214 . . . . 0.0 107.566 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.435 ' HB2' ' HG3' ' A' ' 100' ' ' GLU . 19.2 Cg_endo -55.58 -30.35 74.23 Favored 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 123.877 3.051 . . . . 0.0 115.266 -174.663 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.7 tppt? -101.97 -5.09 25.07 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.318 0.58 . . . . 0.0 110.144 -177.778 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -110.38 -163.45 0.86 Allowed 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 -177.679 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -171.18 41.57 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.835 0.854 . . . . 0.0 111.182 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.698 ' O ' ' HG2' ' A' ' 79' ' ' ARG . 11.4 pt-20 -163.15 149.25 12.04 Favored 'General case' 0 C--O 1.161 -3.584 0 CA-C-O 116.657 -1.64 . . . . 0.0 106.721 175.313 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.698 ' HG2' ' O ' ' A' ' 78' ' ' GLU . 6.2 mmt180 161.84 -165.1 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 128.125 2.57 . . . . 0.0 107.848 170.405 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.48 ' O ' ' HB2' ' A' ' 64' ' ' PHE . 43.3 m-70 -141.07 -34.92 0.48 Allowed 'General case' 0 C--N 1.276 -2.629 0 C-N-CA 125.619 1.568 . . . . 0.0 108.278 171.585 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.5 t -90.17 -8.46 10.67 Favored 'Isoleucine or valine' 0 CA--C 1.563 1.456 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -175.012 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.655 ' O ' ' HB3' ' A' ' 68' ' ' SER . . . -141.7 159.15 26.82 Favored Glycine 0 C--O 1.214 -1.15 0 C-N-CA 119.595 -1.288 . . . . 0.0 112.503 -175.873 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -130.04 172.39 11.79 Favored 'General case' 0 C--O 1.205 -1.262 0 CA-C-N 117.358 0.579 . . . . 0.0 111.288 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.493 ' N ' ' HB3' ' A' ' 71' ' ' HIS . 6.7 tt -98.9 107.11 19.47 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -165.67 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.581 ' C ' ' HB3' ' A' ' 45' ' ' PHE . . . 176.88 178.66 46.8 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 169.496 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.481 ' N ' ' HB3' ' A' ' 45' ' ' PHE . 8.8 p30 -159.42 135.69 9.0 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 173.901 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.501 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 75.2 t -127.56 151.61 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.293 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.731 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.47 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.6 m -134.65 148.59 50.4 Favored 'General case' 0 N--CA 1.404 -2.758 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.107 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -149.12 153.59 37.98 Favored 'General case' 1 C--N 1.243 -4.053 0 N-CA-C 102.199 -3.26 . . . . 0.0 102.199 173.012 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.458 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 13.6 t70 -128.0 -158.24 0.86 Allowed 'General case' 0 C--N 1.251 -3.686 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.531 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 60.5 mttp -68.25 5.85 0.89 Allowed 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 124.138 0.975 . . . . 0.0 113.278 -179.489 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -116.76 -9.38 11.27 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 175.009 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.649 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 64.77 72.93 0.63 Allowed Glycine 0 C--O 1.224 -0.526 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.897 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.504 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 62.8 t -154.57 133.3 3.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -175.624 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.47 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.35 127.22 40.1 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-O 122.367 1.08 . . . . 0.0 113.777 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -105.75 107.04 17.83 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 102.177 -3.268 . . . . 0.0 102.177 160.863 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.467 ' CG1' ' H ' ' A' ' 33' ' ' GLY . 9.4 p -83.34 137.56 20.76 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.4 0 C-N-CA 117.949 -1.501 . . . . 0.0 108.806 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 45.8 m -86.99 121.05 28.92 Favored 'General case' 0 N--CA 1.387 -3.597 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 171.926 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.429 HD12 HG23 ' A' ' 99' ' ' ILE . 2.9 tt -90.81 115.05 29.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 175.092 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.435 ' HG3' ' HB2' ' A' ' 74' ' ' PRO . 5.6 mm-40 -106.22 157.36 17.63 Favored 'General case' 0 CA--C 1.48 -1.738 0 CA-C-N 113.89 -1.505 . . . . 0.0 111.596 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.23 96.17 10.23 Favored 'General case' 0 N--CA 1.426 -1.665 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.448 ' OG ' HD21 ' A' ' 84' ' ' LEU . 4.8 m -105.98 141.86 36.67 Favored 'General case' 0 N--CA 1.402 -2.843 0 N-CA-C 103.913 -2.625 . . . . 0.0 103.913 174.243 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.491 HG23 ' H ' ' A' ' 27' ' ' GLY 0.276 2.6 p -118.02 -49.48 4.02 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 C-N-CA 117.059 -1.856 . . . . 0.0 112.744 176.166 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.2 mm -81.71 -7.54 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.57 1.732 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 -170.814 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.445 ' OG ' HD13 ' A' ' 84' ' ' LEU . 50.8 m -79.3 84.01 5.28 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 117.726 2.491 . . . . 0.0 117.726 -172.161 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.515 ' HB3' ' CG ' ' A' ' 22' ' ' GLN . 1.1 pt? -140.06 82.14 1.85 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 154.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.3 m -171.62 87.15 0.09 Allowed 'General case' 1 C--N 1.233 -4.467 0 N-CA-C 101.777 -3.416 . . . . 0.0 101.777 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -111.59 157.69 14.8 Favored Glycine 3 N--CA 1.375 -5.387 0 N-CA-C 106.246 -2.742 . . . . 0.0 106.246 175.579 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.495 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 12.6 t70 -62.02 -41.82 98.5 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-O 121.817 0.818 . . . . 0.0 109.714 178.559 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.575 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 6.8 m80 -123.24 -24.84 4.58 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.138 -0.937 . . . . 0.0 112.029 177.078 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.2 m 59.7 -70.35 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 125.809 1.644 . . . . 0.0 114.622 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.663 HG13 ' O ' ' A' ' 151' ' ' ILE . 3.6 tt -98.15 -43.51 11.94 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 C-N-CA 124.799 1.24 . . . . 0.0 110.415 -174.91 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.575 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 8.1 tt -104.51 102.2 13.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -172.094 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.5 60.13 1.84 Allowed Glycine 0 CA--C 1.474 -2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.767 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.533 ' HD3' ' C ' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -119.24 90.01 3.25 Favored 'General case' 0 C--N 1.252 -3.643 0 CA-C-N 112.688 -1.756 . . . . 0.0 109.594 -176.866 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.616 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 17.9 p -95.08 132.76 39.63 Favored 'General case' 0 C--N 1.289 -2.026 0 O-C-N 121.723 -0.611 . . . . 0.0 111.858 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.498 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 4.3 pp -81.32 120.63 25.19 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 175.61 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.613 HG22 ' SG ' ' A' ' 57' ' ' CYS . 19.6 t -100.35 98.09 6.55 Favored 'Isoleucine or valine' 0 C--O 1.297 3.602 0 C-N-CA 116.259 -2.176 . . . . 0.0 106.987 172.938 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.518 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 25.4 t -148.81 171.05 2.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -160.53 171.99 17.99 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 104.093 -2.558 . . . . 0.0 104.093 169.547 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.448 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -69.62 87.81 0.5 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 123.064 2.665 . . . . 0.0 109.973 -178.791 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 33.2 tptt -172.55 171.97 4.43 Favored 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -171.425 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.483 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -78.99 117.91 20.5 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 171.439 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.451 ' OD1' ' HB3' ' A' ' 46' ' ' HIS . 3.6 t70 -139.77 78.4 1.66 Allowed 'General case' 0 CA--C 1.474 -1.951 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.451 ' HA ' ' HB2' ' A' ' 46' ' ' HIS . 25.1 t0 -177.44 158.0 1.36 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 123.766 0.666 . . . . 0.0 109.424 173.276 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.546 ' HA ' ' O ' ' A' ' 135' ' ' THR . 3.3 tm? -90.72 -40.48 11.83 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 124.624 1.203 . . . . 0.0 107.988 -176.732 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.24 -48.86 6.19 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.492 -0.861 . . . . 0.0 111.622 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.77 51.34 1.53 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.146 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.15 -105.83 0.27 Allowed Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 119.875 -1.155 . . . . 0.0 111.745 176.207 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -152.26 -96.18 0.13 Allowed Glycine 0 C--N 1.316 -0.556 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.652 -176.69 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -79.89 153.67 28.87 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.142 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -45.72 -50.75 13.43 Favored 'General case' 0 C--N 1.36 1.057 0 N-CA-C 114.522 1.304 . . . . 0.0 114.522 -176.66 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -80.4 -26.89 38.28 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 121.526 -0.734 . . . . 0.0 111.114 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 27.5 t -77.59 -29.14 51.84 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.667 -173.618 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.546 ' O ' ' HA ' ' A' ' 126' ' ' LEU . 6.6 t -76.52 -25.06 53.75 Favored 'General case' 0 C--O 1.206 -1.212 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.669 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.426 ' HA ' ' CD2' ' A' ' 126' ' ' LEU . 58.8 mtpt -71.28 -35.36 71.32 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.895 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 12.4 t -85.98 -31.75 21.89 Favored 'General case' 0 N--CA 1.412 -2.366 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.25 178.725 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 57.63 73.07 0.49 Allowed Glycine 0 CA--C 1.486 -1.764 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -177.709 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 46.5 t30 -51.58 105.8 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 122.471 1.129 . . . . 0.0 113.248 -171.468 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -89.29 164.54 14.89 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 114.441 -1.254 . . . . 0.0 113.664 -171.092 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -139.95 86.28 0.21 Allowed Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 107.25 -2.34 . . . . 0.0 107.25 175.351 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.431 ' HA ' HG11 ' A' ' 118' ' ' VAL . 13.8 m -61.84 -18.65 60.81 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 113.823 1.046 . . . . 0.0 113.823 -172.166 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -121.72 -46.31 2.25 Favored 'General case' 0 C--N 1.26 -3.312 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.681 177.837 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.9 tt -46.13 -45.06 16.26 Favored 'General case' 0 CA--C 1.495 -1.163 0 O-C-N 125.406 1.691 . . . . 0.0 111.564 -164.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.518 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -139.66 88.76 2.27 Favored 'General case' 0 N--CA 1.395 -3.192 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.2 m -130.25 140.08 50.73 Favored 'General case' 0 N--CA 1.394 -3.227 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.283 176.747 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.458 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -170.93 149.03 11.83 Favored Glycine 1 N--CA 1.379 -5.124 0 CA-C-N 113.831 -1.531 . . . . 0.0 109.358 -177.166 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 16.0 m -70.55 110.14 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.63 0 CA-C-O 122.104 0.954 . . . . 0.0 111.147 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.554 ' HA ' ' O ' ' A' ' 5' ' ' VAL . 9.4 tt -122.11 108.87 22.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 CA-C-N 114.652 -1.158 . . . . 0.0 109.27 175.477 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.496 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . -179.03 -171.25 42.02 Favored Glycine 3 CA--C 1.435 -4.936 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 175.99 . . . . . . . . 3 3 . 1 . 002 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.663 ' O ' HG13 ' A' ' 112' ' ' ILE . 64.5 mt -64.3 104.64 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.263 -3.165 0 O-C-N 124.853 0.972 . . . . 0.0 110.576 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.465 ' HB2' ' NH2' ' A' ' 115' ' ' ARG . . . -142.17 100.09 3.65 Favored 'General case' 0 N--CA 1.433 -1.304 0 CA-C-O 121.168 0.508 . . . . 0.0 109.836 169.311 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 C--N 1.289 -2.043 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 177.016 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.512 -0.515 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 22.6 m -111.24 -36.44 5.59 Favored 'General case' 0 CA--C 1.552 1.027 0 O-C-N 123.583 0.552 . . . . 0.0 111.733 -178.627 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 50.1 tttm -146.65 152.52 39.01 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.747 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.602 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.96 167.73 20.39 Favored 'General case' 0 N--CA 1.406 -2.629 0 O-C-N 123.676 0.61 . . . . 0.0 109.609 175.029 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -137.6 131.99 44.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 123.313 0.645 . . . . 0.0 109.304 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.57 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -112.18 131.36 55.52 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -134.86 103.83 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.038 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.45 ' HB3' HD21 ' A' ' 117' ' ' LEU . 1.4 pt? -118.29 151.17 38.2 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -162.86 140.77 8.16 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.39 -158.48 8.37 Favored Glycine 0 N--CA 1.414 -2.785 0 C-N-CA 119.039 -1.553 . . . . 0.0 112.996 -176.703 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -71.37 -49.19 44.68 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.65 144.95 16.94 Favored Glycine 0 N--CA 1.431 -1.655 0 N-CA-C 106.55 -2.62 . . . . 0.0 106.55 172.888 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -76.56 124.03 7.38 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 CA-C-N 120.355 2.078 . . . . 0.0 112.96 -175.575 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -132.38 113.05 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 103.853 -2.647 . . . . 0.0 103.853 173.236 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.546 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 96.8 mt-30 -118.58 141.33 48.68 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.6 -174.883 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.532 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -169.69 157.86 29.74 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.482 -177.218 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.455 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.9 pt -135.26 102.47 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.949 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.57 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 10.3 mt -121.42 137.44 55.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -174.847 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -113.94 134.08 55.06 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.817 178.308 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.602 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.0 m-85 -123.26 134.27 54.11 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.356 0.262 . . . . 0.0 110.921 -178.105 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.436 ' O ' HG13 ' A' ' 29' ' ' VAL . 9.9 pt-20 -132.96 102.34 5.59 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 121.588 0.709 . . . . 0.0 112.168 175.751 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 42.9 mt-30 -106.24 113.82 27.57 Favored 'General case' 0 N--CA 1.389 -3.5 0 N-CA-C 103.872 -2.64 . . . . 0.0 103.872 175.671 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.562 ' H ' ' HB ' ' A' ' 103' ' ' VAL . 54.9 tttm -134.26 171.76 13.81 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.422 -169.576 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.452 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 5.4 mp0 -63.97 -26.12 68.44 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.87 1.268 . . . . 0.0 111.69 -177.694 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -33.06 28.16 Favored 'General case' 0 CA--C 1.549 0.911 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 -172.345 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.9 t30 64.73 97.34 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -173.09 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.52 ' H ' HG22 ' A' ' 103' ' ' VAL . . . 179.18 -163.34 30.81 Favored Glycine 0 CA--C 1.463 -3.196 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.416 -175.746 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -83.24 139.65 9.42 Favored 'Trans proline' 0 N--CA 1.42 -2.851 0 C-N-CA 122.114 1.876 . . . . 0.0 110.699 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.504 HG23 ' H ' ' A' ' 101' ' ' ASP . 18.3 m -75.14 130.24 36.29 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 7.3 ttpm? -88.84 100.34 13.09 Favored 'General case' 0 N--CA 1.424 -1.771 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.157 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.417 HG23 ' HA ' ' A' ' 20' ' ' PHE . 75.1 t -131.47 134.75 60.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.756 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.006 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.413 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 2.1 t-105 -141.08 129.47 22.44 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.928 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.455 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -148.94 138.86 7.15 Favored Glycine 0 N--CA 1.425 -2.083 0 C-N-CA 119.994 -1.098 . . . . 0.0 112.377 175.04 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.532 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 18.4 m -116.5 115.24 25.41 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 124.726 1.211 . . . . 0.0 108.746 179.221 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.546 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 9.2 mt -109.52 148.11 13.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 118.453 0.57 . . . . 0.0 110.732 176.166 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -129.79 122.98 29.86 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -146.41 175.01 26.09 Favored Glycine 0 C--N 1.294 -1.8 0 O-C-N 123.688 0.617 . . . . 0.0 111.66 -168.31 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.0 mt -69.52 169.79 11.88 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.724 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.472 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.5 OUTLIER -76.81 104.32 7.24 Favored 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 119.273 -0.971 . . . . 0.0 112.003 -175.932 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.448 ' HG2' ' O ' ' A' ' 39' ' ' THR . 47.2 mm-40 -177.93 171.09 1.82 Allowed 'General case' 0 CA--C 1.472 -2.054 0 C-N-CA 128.522 2.729 . . . . 0.0 104.275 170.405 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.72 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 159.45 115.38 0.41 Allowed Glycine 1 C--N 1.242 -4.676 0 C-N-CA 116.978 -2.534 . . . . 0.0 113.968 166.146 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -119.38 -85.6 0.65 Allowed 'General case' 0 N--CA 1.419 -2.018 0 O-C-N 124.231 0.607 . . . . 0.0 110.911 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.718 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 20.7 m80 -163.52 123.11 2.11 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.895 0.878 . . . . 0.0 108.936 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -143.94 104.63 0.34 Allowed Glycine 0 N--CA 1.435 -1.41 0 C-N-CA 118.434 -1.841 . . . . 0.0 115.425 -178.684 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.583 ' O ' HG11 ' A' ' 47' ' ' VAL . 19.6 m-85 -68.45 95.22 0.61 Allowed 'General case' 1 C--O 1.341 5.918 0 CA-C-O 123.391 1.567 . . . . 0.0 109.56 169.684 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.59 ' CD2' HD13 ' A' ' 117' ' ' LEU . 16.4 p-80 -83.05 78.06 9.64 Favored 'General case' 0 N--CA 1.404 -2.759 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 175.454 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.583 HG11 ' O ' ' A' ' 45' ' ' PHE . 3.7 p -111.2 91.57 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-N 111.223 -2.717 . . . . 0.0 110.988 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . 0.257 39.6 m-70 -138.75 159.96 40.82 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 114.586 1.328 . . . . 0.0 114.586 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.553 ' OE2' ' HA ' ' A' ' 64' ' ' PHE . 2.0 pm0 -89.48 172.82 8.71 Favored 'General case' 0 C--N 1.287 -2.151 0 C-N-CA 126.993 2.117 . . . . 0.0 115.02 -174.793 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.509 ' H ' ' HA ' ' A' ' 110' ' ' HIS . 55.9 t80 47.18 103.47 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 111.3 -2.682 . . . . 0.0 115.35 167.366 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.532 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -44.0 103.12 0.04 OUTLIER Glycine 0 C--N 1.297 -1.623 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.16 171.858 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -111.09 -161.17 0.74 Allowed 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -67.14 138.1 56.79 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 123.1 0.56 . . . . 0.0 109.997 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.482 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 13.4 t -58.45 -21.5 51.45 Favored 'General case' 0 C--O 1.216 -0.701 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -177.103 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.96 6.77 11.37 Favored 'General case' 0 C--N 1.31 -1.115 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.062 178.352 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -150.76 109.46 0.43 Allowed Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 119.428 -1.368 . . . . 0.0 111.589 -178.705 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.563 ' SG ' HG23 ' A' ' 118' ' ' VAL . 4.3 p -98.5 89.35 4.38 Favored 'General case' 0 C--N 1.277 -2.576 0 C-N-CA 122.735 0.414 . . . . 0.0 111.65 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 m -80.47 -54.07 6.02 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.465 0.65 . . . . 0.0 109.924 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.9 m -71.18 -39.45 71.83 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.283 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.464 ' HB1' ' HB2' ' A' ' 57' ' ' CYS . . . -76.31 -5.76 48.5 Favored 'General case' 0 C--O 1.2 -1.531 0 CA-C-N 113.857 -1.52 . . . . 0.0 111.353 175.077 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -57.36 -142.42 0.01 OUTLIER Glycine 0 CA--C 1.558 2.737 0 N-CA-C 115.238 0.855 . . . . 0.0 115.238 178.998 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -76.11 53.71 3.91 Favored 'Trans proline' 0 N--CA 1.484 0.937 0 C-N-CA 122.877 2.385 . . . . 0.0 111.009 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -141.84 128.67 20.54 Favored 'General case' 0 C--N 1.28 -2.432 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.553 ' HA ' ' OE2' ' A' ' 49' ' ' GLU . 52.0 p90 -139.48 144.58 38.04 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.442 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.5 ' HB2' ' OD2' ' A' ' 109' ' ' ASP . 27.3 t-20 -68.94 143.99 95.2 Favored Pre-proline 0 C--N 1.318 -0.795 0 C-N-CA 124.015 0.926 . . . . 0.0 111.316 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.0 -15.21 39.72 Favored 'Trans proline' 0 CA--C 1.546 1.109 0 C-N-CA 123.041 2.494 . . . . 0.0 116.113 -178.371 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 90.2 mt -69.86 -29.23 66.41 Favored 'General case' 0 C--N 1.37 1.489 0 C-N-CA 117.615 -1.634 . . . . 0.0 111.462 -176.213 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.484 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 58.0 p -54.46 -21.49 10.03 Favored 'General case' 0 C--O 1.262 1.73 0 C-N-CA 125.523 1.529 . . . . 0.0 115.044 -173.597 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ttm180 -70.45 -19.96 62.92 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.665 -161.727 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -68.1 -12.06 60.2 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.233 -0.987 . . . . 0.0 112.773 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.1 OUTLIER -151.7 -45.15 0.11 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 120.651 0.262 . . . . 0.0 111.186 177.023 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.38 10.42 82.13 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -173.256 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.403 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -150.99 144.29 11.59 Favored Glycine 0 N--CA 1.402 -3.623 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 178.244 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.403 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 11.8 Cg_exo -76.24 0.13 9.74 Favored 'Trans proline' 0 C--N 1.327 -0.58 0 C-N-CA 124.691 3.594 . . . . 0.0 112.38 -175.452 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -55.55 -26.01 40.98 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 124.973 1.309 . . . . 0.0 111.514 178.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -148.63 -86.2 0.09 Allowed 'General case' 0 CA--C 1.505 -0.775 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.707 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 47.5 mt-10 -123.34 110.89 15.73 Favored 'General case' 0 N--CA 1.41 -2.437 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -171.532 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.484 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -150.52 -60.85 0.19 Allowed 'General case' 0 C--N 1.25 -3.758 0 N-CA-C 103.298 -2.853 . . . . 0.0 103.298 -173.98 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 60.45 -7.37 0.08 Allowed 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 114.617 1.34 . . . . 0.0 114.617 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.417 ' H ' ' C ' ' A' ' 78' ' ' GLU . 0.2 OUTLIER -89.82 -35.0 15.92 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.038 -2.208 . . . . 0.0 105.038 168.744 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 32.8 m 38.26 53.42 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.472 -2.021 0 C-N-CA 128.656 2.782 . . . . 0.0 112.466 171.131 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.4 ' N ' HG21 ' A' ' 47' ' ' VAL . . . -52.1 -34.94 40.37 Favored Glycine 0 C--O 1.207 -1.57 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.963 -173.163 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.425 ' H ' HG21 ' A' ' 47' ' ' VAL . 10.7 t70 -170.58 172.53 5.86 Favored 'General case' 0 CA--C 1.49 -1.343 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.235 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 25.9 tp -148.49 86.65 1.54 Allowed 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 -175.934 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.77 128.37 1.13 Allowed Glycine 1 N--CA 1.395 -4.082 0 CA-C-N 114.694 -1.139 . . . . 0.0 110.708 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -89.99 171.35 9.63 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 173.675 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.35 129.06 11.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 121.394 -0.816 . . . . 0.0 109.083 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.3 m -140.11 96.79 3.11 Favored 'General case' 0 N--CA 1.424 -1.748 0 CA-C-O 121.24 0.543 . . . . 0.0 110.28 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.72 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -100.44 152.72 20.03 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 104.785 -2.302 . . . . 0.0 104.785 173.126 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.527 ' OD2' ' HG2' ' A' ' 91' ' ' LYS . 21.9 t70 -113.34 -159.74 0.7 Allowed 'General case' 1 C--N 1.223 -4.922 0 C-N-CA 116.7 -2.0 . . . . 0.0 105.992 173.731 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.527 ' HG2' ' OD2' ' A' ' 90' ' ' ASP . 18.8 ptpt -57.82 -8.08 0.87 Allowed 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -84.3 -27.15 28.02 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.62 65.53 2.29 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 114.499 0.559 . . . . 0.0 114.499 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.584 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 12.6 m -159.74 132.82 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.485 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . . . -124.64 117.89 25.28 Favored 'General case' 0 N--CA 1.412 -2.374 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -99.67 103.51 15.2 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.55 117.6 50.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.031 0.92 . . . . 0.0 112.255 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 p -142.33 101.46 3.9 Favored 'General case' 0 C--N 1.276 -2.599 0 N-CA-C 106.787 -1.561 . . . . 0.0 106.787 174.267 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 34.4 pt -113.91 151.11 15.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.787 -175.99 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.75 100.24 7.28 Favored 'General case' 0 N--CA 1.414 -2.227 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.504 ' H ' HG23 ' A' ' 29' ' ' VAL . 26.1 t0 -134.02 167.51 20.48 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.848 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.9 m -59.02 113.22 1.99 Allowed 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 114.678 1.362 . . . . 0.0 114.678 -173.594 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.562 ' HB ' ' H ' ' A' ' 23' ' ' LYS . 20.6 m -60.03 -11.57 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 C-N-CA 126.112 1.765 . . . . 0.0 113.053 177.284 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.39 -12.12 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.676 1.191 . . . . 0.0 112.25 -176.199 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 p -91.73 83.17 5.25 Favored 'General case' 0 C--O 1.175 -2.826 0 O-C-N 121.012 -1.055 . . . . 0.0 111.516 176.609 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 71.8 mt -70.11 150.65 46.33 Favored 'General case' 0 N--CA 1.396 -3.163 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.852 171.325 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.6 m -68.89 91.85 0.48 Allowed 'General case' 0 N--CA 1.382 -3.842 0 C-N-CA 124.956 1.302 . . . . 0.0 113.914 -173.608 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.416 ' O ' ' HD2' ' A' ' 110' ' ' HIS . . . -94.6 -175.67 38.55 Favored Glycine 1 N--CA 1.395 -4.097 0 N-CA-C 106.09 -2.804 . . . . 0.0 106.09 167.405 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.548 ' OD2' ' HB3' ' A' ' 49' ' ' GLU 0.25 31.3 t0 32.89 -77.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 117.442 2.386 . . . . 0.0 117.442 -175.32 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.554 ' CG ' ' HG2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -56.57 -31.8 64.57 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 125.987 1.715 . . . . 0.0 109.703 178.216 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.3 m 62.06 -178.09 0.13 Allowed 'General case' 0 N--CA 1.424 -1.755 0 C-N-CA 126.125 1.77 . . . . 0.0 112.797 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.424 HG13 ' HB ' ' A' ' 151' ' ' ILE . 10.0 tt -78.65 9.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 C-N-CA 126.547 1.939 . . . . 0.0 108.731 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 36.5 pt -91.38 -175.39 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.485 -1.526 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 -176.801 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.439 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . -82.14 65.08 4.14 Favored Glycine 0 N--CA 1.405 -3.397 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.959 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.718 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -66.31 131.81 46.95 Favored 'General case' 0 N--CA 1.414 -2.267 0 CA-C-O 122.553 1.168 . . . . 0.0 112.203 178.266 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.702 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 0.1 OUTLIER -70.54 122.6 20.02 Favored 'General case' 0 N--CA 1.384 -3.768 0 CA-C-N 113.853 -1.521 . . . . 0.0 111.113 -178.137 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.59 HD13 ' CD2' ' A' ' 46' ' ' HIS . 0.8 OUTLIER -87.76 140.67 29.27 Favored 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 174.06 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.563 HG23 ' SG ' ' A' ' 57' ' ' CYS . 98.8 t -109.8 105.16 18.27 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.479 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.646 171.859 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.474 ' CG2' ' HG ' ' A' ' 117' ' ' LEU . 0.2 OUTLIER -126.09 168.44 18.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.81 0.814 . . . . 0.0 110.397 179.596 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.421 ' CD2' ' HG ' ' A' ' 144' ' ' LEU . 2.1 t60 -172.18 156.85 4.06 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 102.909 -2.997 . . . . 0.0 102.909 162.158 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.409 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.2 89.61 0.46 Allowed 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? -170.4 171.37 6.61 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.718 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -76.68 111.15 11.88 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 123.771 0.67 . . . . 0.0 110.922 172.936 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -132.38 26.57 4.46 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 123.381 1.563 . . . . 0.0 109.177 178.202 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.414 ' HB2' ' HB2' ' A' ' 128' ' ' LYS . 24.8 m-20 -81.7 137.53 35.39 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 173.52 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -69.8 -56.79 6.19 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -173.59 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.7 1.8 43.51 Favored Glycine 0 CA--C 1.526 0.748 0 C-N-CA 121.16 -0.543 . . . . 0.0 113.483 -178.849 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.414 ' HB2' ' HB2' ' A' ' 125' ' ' ASP . 32.0 mmmt -132.23 32.61 3.96 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -62.27 -29.32 72.73 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 115.604 -0.725 . . . . 0.0 114.834 -176.469 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -82.89 0.26 Allowed Glycine 0 C--O 1.221 -0.66 0 CA-C-N 117.443 0.622 . . . . 0.0 112.212 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.423 ' H ' ' HB3' ' A' ' 134' ' ' SER . 9.5 t30 -121.45 173.3 7.47 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.432 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 37.1 tt0 -49.73 -46.71 50.66 Favored 'General case' 0 CA--C 1.555 1.158 0 CA-C-N 119.844 1.202 . . . . 0.0 114.011 -172.017 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.1 mp0 -64.48 -39.64 94.19 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.055 0.455 . . . . 0.0 110.449 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.423 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 6.8 t -72.36 -30.89 65.13 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.098 -175.541 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 36.3 m -69.68 -30.97 68.76 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.299 0.571 . . . . 0.0 110.479 178.344 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.432 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 95.8 mttt -76.54 -37.12 57.16 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.165 0.507 . . . . 0.0 111.355 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 t -85.61 -26.42 26.08 Favored 'General case' 0 N--CA 1.416 -2.166 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.292 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.85 60.1 8.19 Favored Glycine 0 N--CA 1.431 -1.684 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 -174.0 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -39.62 117.38 0.72 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.936 1.294 . . . . 0.0 112.851 -174.074 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -143.71 161.49 38.43 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -174.166 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.28 81.22 1.72 Allowed Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 173.653 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.7 p -42.13 -38.89 1.82 Allowed 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 118.143 2.646 . . . . 0.0 118.143 -168.147 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.6 ptt180 -134.2 13.46 3.88 Favored 'General case' 0 C--N 1.278 -2.526 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.421 ' HG ' ' CD2' ' A' ' 120' ' ' HIS . 0.3 OUTLIER -69.07 -37.6 78.6 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -172.23 . . . . . . . . 3 3 . 1 . 003 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.43 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -150.25 106.1 3.43 Favored 'General case' 0 N--CA 1.412 -2.348 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.561 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 17.8 m -115.21 163.14 16.09 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.811 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.702 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -171.55 141.42 6.39 Favored Glycine 0 N--CA 1.416 -2.681 0 C-N-CA 119.003 -1.57 . . . . 0.0 112.143 176.93 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.416 HG11 ' OG1' ' A' ' 54' ' ' THR . 10.0 p -70.16 98.78 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 122.531 1.158 . . . . 0.0 108.581 174.035 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.718 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 24.0 mm -109.44 129.86 63.5 Favored 'Isoleucine or valine' 0 CA--C 1.464 -2.346 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.81 147.34 17.73 Favored Glycine 2 CA--C 1.425 -5.539 0 C-N-CA 116.803 -2.618 . . . . 0.0 111.466 -174.708 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.475 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 70.1 mt -78.64 103.63 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.9 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 173.916 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.514 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -125.84 128.6 47.9 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.119 -0.946 . . . . 0.0 108.476 175.668 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 . . . . . 0 C--N 1.292 -1.905 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.563 -174.755 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.639 ' O ' ' HD2' ' A' ' 3' ' ' LYS . 18.0 p -80.91 -42.03 22.06 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 170.833 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.639 ' HD2' ' O ' ' A' ' 2' ' ' THR . 5.4 mptp? -151.27 171.4 17.5 Favored 'General case' 0 C--O 1.263 1.765 0 N-CA-C 103.209 -2.885 . . . . 0.0 103.209 173.137 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.685 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -149.35 146.98 27.78 Favored 'General case' 0 CA--C 1.454 -2.744 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.841 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 23.1 m -119.69 155.22 22.43 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.788 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.244 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.591 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -135.7 128.94 31.89 Favored 'General case' 0 C--N 1.278 -2.504 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.345 178.689 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.427 ' H ' ' HB ' ' A' ' 148' ' ' VAL . 46.7 t -134.16 111.83 15.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.421 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.9 pt? -119.47 142.39 48.31 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.371 178.392 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.648 ' O ' ' HA ' ' A' ' 55' ' ' ALA . 2.2 tmtp? -147.91 148.42 30.79 Favored 'General case' 0 N--CA 1.408 -2.542 0 N-CA-C 102.409 -3.182 . . . . 0.0 102.409 177.401 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.443 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -155.01 -158.93 8.99 Favored Glycine 0 CA--C 1.479 -2.161 0 C-N-CA 118.139 -1.982 . . . . 0.0 113.381 -177.788 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -67.98 -46.58 70.97 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.018 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.44 95.59 0.74 Allowed Glycine 0 N--CA 1.429 -1.784 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 171.324 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -64.6 126.79 17.47 Favored 'Trans proline' 0 N--CA 1.441 -1.585 0 C-N-CA 122.164 1.909 . . . . 0.0 113.886 -172.553 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.1 m -126.0 132.37 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.381 -3.889 0 N-CA-C 102.026 -3.324 . . . . 0.0 102.026 173.516 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.415 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 97.8 mt-30 -121.67 138.2 54.44 Favored 'General case' 0 C--N 1.264 -3.114 0 C-N-CA 119.559 -0.856 . . . . 0.0 112.578 -169.228 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.69 171.31 43.68 Favored Glycine 0 N--CA 1.402 -3.628 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.641 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.433 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.6 pt -137.02 139.54 44.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.417 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 3.4 mp -127.77 127.91 68.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.685 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 60.4 m-20 -118.79 119.62 34.94 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 -176.489 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.617 ' CE1' ' HG ' ' A' ' 106' ' ' LEU . 11.6 p90 -131.58 141.04 49.59 Favored 'General case' 0 C--O 1.262 1.754 0 C-N-CA 118.646 -1.222 . . . . 0.0 113.095 178.058 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.408 ' HB3' ' O ' ' A' ' 2' ' ' THR . 7.2 pt-20 -133.65 95.15 3.42 Favored 'General case' 0 N--CA 1.416 -2.136 0 CA-C-O 122.268 1.033 . . . . 0.0 112.391 175.75 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.464 ' HG3' HG12 ' A' ' 29' ' ' VAL . 24.1 mm-40 -158.62 163.47 36.92 Favored 'General case' 0 C--O 1.257 1.477 0 C-N-CA 126.88 2.072 . . . . 0.0 108.038 170.417 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.595 ' HG3' ' H ' ' A' ' 24' ' ' GLU 0.257 27.7 pttt -159.7 -86.69 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.204 0 O-C-N 124.22 0.95 . . . . 0.0 112.055 164.487 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.595 ' H ' ' HG3' ' A' ' 23' ' ' LYS . 35.9 tt0 -93.2 -25.96 17.59 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 121.783 0.802 . . . . 0.0 109.578 178.844 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.446 ' HB2' ' OE1' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -46.93 -56.94 5.51 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.235 2.214 . . . . 0.0 114.836 -172.34 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.8 t30 75.71 139.91 0.07 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 124.971 1.308 . . . . 0.0 110.277 -174.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.471 ' H ' HG23 ' A' ' 104' ' ' ILE . . . 150.23 -170.96 30.2 Favored Glycine 0 CA--C 1.493 -1.312 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -70.08 124.02 10.55 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.413 1.409 . . . . 0.0 110.253 176.427 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.464 HG12 ' HG3' ' A' ' 22' ' ' GLN . 17.2 m -85.65 98.79 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.354 0 CA-C-O 121.502 0.668 . . . . 0.0 111.523 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.445 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.258 0.0 OUTLIER -90.46 108.66 19.93 Favored 'General case' 0 N--CA 1.417 -2.076 0 C-N-CA 118.486 -1.285 . . . . 0.0 109.11 171.919 . . . . . . . . 4 4 . 1 . 004 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.6 m -135.46 152.97 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.778 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 -172.861 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -143.58 126.92 16.72 Favored 'General case' 0 C--N 1.266 -3.051 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.946 178.599 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.433 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -145.34 140.27 8.93 Favored Glycine 0 N--CA 1.41 -3.075 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.697 174.165 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.0 m -116.6 140.23 49.63 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 176.075 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.469 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 25.2 pt -141.7 131.51 24.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-N 119.415 1.007 . . . . 0.0 109.025 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.421 ' HZ1' ' HB2' ' A' ' 36' ' ' LYS . 0.2 OUTLIER -112.09 132.39 54.87 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.82 175.2 23.18 Favored Glycine 0 N--CA 1.416 -2.68 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -169.693 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.1 mt -68.84 170.34 9.79 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.3 m -69.89 103.46 2.22 Favored 'General case' 0 C--O 1.203 -1.37 0 C-N-CA 118.016 -1.473 . . . . 0.0 110.403 -173.93 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.566 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.3 tt0 -176.13 141.77 0.46 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 102.798 -3.038 . . . . 0.0 102.798 170.285 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . -174.54 90.89 0.08 OUTLIER Glycine 0 C--N 1.276 -2.777 0 C-N-CA 117.028 -2.511 . . . . 0.0 113.334 174.581 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -93.4 -86.33 0.26 Allowed 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 120.512 -0.475 . . . . 0.0 111.649 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.416 ' HA ' ' H ' ' A' ' 87' ' ' VAL . 18.8 p80 166.32 135.28 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 152.46 131.4 1.68 Allowed Glycine 0 N--CA 1.413 -2.837 0 C-N-CA 118.322 -1.894 . . . . 0.0 113.785 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -133.98 139.59 46.17 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 122.063 0.935 . . . . 0.0 113.073 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -166.89 92.11 0.43 Allowed 'General case' 1 C--O 1.33 5.342 0 N-CA-C 105.183 -2.155 . . . . 0.0 105.183 172.013 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.503 HG23 ' CD1' ' A' ' 117' ' ' LEU . 18.7 t -69.97 167.58 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 127.351 2.26 . . . . 0.0 109.095 176.442 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.521 ' NE2' ' HB2' ' A' ' 65' ' ' ASN . 56.5 t-80 -124.23 126.04 45.42 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-O 122.085 0.945 . . . . 0.0 109.873 174.033 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.589 ' CD ' ' HB3' ' A' ' 65' ' ' ASN . 2.8 pm0 -73.37 125.45 27.88 Favored 'General case' 0 C--N 1.264 -3.145 0 CA-C-N 113.62 -1.627 . . . . 0.0 108.403 174.549 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.53 ' HA ' ' OG ' ' A' ' 111' ' ' SER . 91.3 t80 80.13 100.17 0.06 Allowed 'General case' 0 CA--C 1.503 -0.851 0 CA-C-O 123.503 1.621 . . . . 0.0 108.776 -175.924 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.35 -145.97 7.52 Favored Glycine 0 N--CA 1.421 -2.332 0 CA-C-N 111.94 -2.391 . . . . 0.0 110.49 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -171.62 -85.83 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 115.597 1.703 . . . . 0.0 115.597 -171.879 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.499 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.7 t-20 -104.52 140.1 38.47 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -169.818 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.506 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 10.0 t -61.64 -27.68 68.84 Favored 'General case' 0 C--O 1.241 0.635 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.172 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . 0.648 ' HA ' ' O ' ' A' ' 9' ' ' LYS . . . -114.47 17.84 17.16 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 120.618 0.247 . . . . 0.0 111.449 -175.298 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.42 117.27 0.58 Allowed Glycine 0 CA--C 1.483 -1.96 0 C-N-CA 119.247 -1.454 . . . . 0.0 111.382 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.455 ' HB2' ' O ' ' A' ' 142' ' ' SER . 0.7 OUTLIER -87.28 98.59 11.42 Favored 'General case' 0 C--N 1.28 -2.429 0 C-N-CA 122.926 0.491 . . . . 0.0 109.904 -176.544 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 m -79.07 -56.1 4.62 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.746 0.784 . . . . 0.0 109.515 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.7 m -75.32 -43.91 48.27 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.011 -174.439 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.59 -8.61 56.91 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.949 174.645 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.15 -63.69 3.48 Favored Glycine 0 CA--C 1.538 1.504 0 O-C-N 123.758 0.661 . . . . 0.0 112.772 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -64.26 -5.15 9.1 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.989 2.459 . . . . 0.0 112.75 176.871 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.289 23.3 p80 56.04 15.75 1.91 Allowed 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 118.504 2.779 . . . . 0.0 118.504 170.568 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -146.35 120.45 9.45 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 119.151 0.887 . . . . 0.0 112.757 178.241 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.589 ' HB3' ' CD ' ' A' ' 49' ' ' GLU . 27.7 t-20 -116.95 144.22 33.08 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 172.487 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -52.57 -13.19 2.17 Favored 'Trans proline' 0 CA--C 1.556 1.595 0 C-N-CA 124.466 3.444 . . . . 0.0 117.82 -177.263 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.551 ' C ' ' H ' ' A' ' 69' ' ' ARG . 4.1 mm? -82.62 -12.98 57.28 Favored 'General case' 0 CA--C 1.474 -1.956 0 CA-C-N 119.878 1.217 . . . . 0.0 110.396 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.51 ' HA ' ' HB3' ' A' ' 80' ' ' HIS . 74.3 m -72.94 36.4 0.08 Allowed 'General case' 0 C--O 1.215 -0.718 0 C-N-CA 124.342 1.057 . . . . 0.0 109.804 169.434 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.551 ' H ' ' C ' ' A' ' 67' ' ' LEU . 3.3 tmm_? -76.3 11.12 1.66 Allowed 'General case' 0 C--O 1.212 -0.895 0 C-N-CA 127.505 2.322 . . . . 0.0 107.951 -172.746 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.52 ' HE2' ' OD2' ' A' ' 76' ' ' ASP . 47.4 tptt -77.35 -32.47 55.1 Favored 'General case' 0 N--CA 1.396 -3.133 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t60 61.18 23.86 14.02 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.251 1.021 . . . . 0.0 110.126 178.613 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.73 120.99 2.65 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 119.842 -1.17 . . . . 0.0 112.218 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.39 75.78 0.13 Allowed Glycine 0 C--N 1.293 -1.812 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.503 ' O ' HD11 ' A' ' 84' ' ' LEU . 31.8 Cg_endo -62.23 -22.63 74.46 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 123.759 2.973 . . . . 0.0 114.82 -171.501 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mtpt -123.2 13.2 9.62 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.52 ' OD2' ' HE2' ' A' ' 70' ' ' LYS . 21.7 t70 -116.96 -67.69 0.97 Allowed 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -169.553 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.427 ' HG3' ' HG ' ' A' ' 105' ' ' SER . 6.8 tp10 60.66 111.64 0.02 OUTLIER 'General case' 0 C--O 1.256 1.406 0 CA-C-O 122.477 1.132 . . . . 0.0 110.768 -173.715 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 29.9 tt0 -114.44 -78.21 0.58 Allowed 'General case' 0 N--CA 1.422 -1.842 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.878 -176.761 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.468 ' O ' ' HB2' ' A' ' 80' ' ' HIS . 29.3 tpt180 -113.98 5.35 16.1 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 117.729 -1.588 . . . . 0.0 110.767 179.08 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.51 ' HB3' ' HA ' ' A' ' 68' ' ' SER 0.274 18.7 t60 173.62 -150.83 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.208 172.926 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.3 m 82.49 -32.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.106 0 C-N-CA 128.927 2.891 . . . . 0.0 108.413 -147.38 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.71 -73.34 2.36 Favored Glycine 0 CA--C 1.48 -2.118 0 N-CA-C 114.263 0.465 . . . . 0.0 114.263 166.712 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.484 ' OD2' HG21 ' A' ' 47' ' ' VAL . 22.2 m-20 -139.76 138.37 35.85 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 103.844 -2.65 . . . . 0.0 103.844 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.503 HD11 ' O ' ' A' ' 74' ' ' PRO . 4.0 pp -131.95 135.85 46.9 Favored 'General case' 0 C--N 1.271 -2.837 0 O-C-N 123.471 0.482 . . . . 0.0 110.339 -177.236 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 178.17 -178.64 48.58 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 120.054 -1.07 . . . . 0.0 111.823 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -118.45 132.72 56.23 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.923 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.473 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.7 m -136.06 132.8 50.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -176.379 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -132.94 96.03 3.69 Favored 'General case' 0 N--CA 1.413 -2.283 0 CA-C-O 122.643 1.211 . . . . 0.0 110.613 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.513 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -92.75 153.86 18.65 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 113.911 -1.495 . . . . 0.0 107.833 174.682 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.52 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 6.8 t70 -125.14 -161.65 1.04 Allowed 'General case' 0 C--N 1.255 -3.541 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 59.6 pttt -40.85 -34.82 0.43 Allowed 'General case' 0 N--CA 1.506 2.339 0 C-N-CA 127.313 2.245 . . . . 0.0 116.115 -175.319 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -147.82 16.62 1.11 Allowed 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 177.792 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.52 ' HA3' ' H ' ' A' ' 90' ' ' ASP . . . -59.34 -157.52 0.03 OUTLIER Glycine 0 C--O 1.187 -2.826 0 N-CA-C 118.731 2.252 . . . . 0.0 118.731 -164.152 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.469 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -158.49 105.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.275 -2.656 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.473 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.72 110.12 22.63 Favored 'General case' 0 N--CA 1.398 -3.048 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -85.25 103.37 14.14 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 114.664 -1.153 . . . . 0.0 110.395 -177.184 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -88.28 102.4 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.507 0 CA-C-O 122.309 1.052 . . . . 0.0 109.486 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.7 p -155.41 100.7 2.14 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 113.649 -1.614 . . . . 0.0 108.11 174.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.46 119.33 29.41 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -95.06 101.06 12.79 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.949 0.881 . . . . 0.0 111.486 -178.818 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -163.03 169.82 18.95 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 -178.422 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.5 t -59.4 94.42 0.02 OUTLIER 'General case' 0 C--O 1.244 0.769 0 CA-C-O 122.528 1.156 . . . . 0.0 113.402 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.441 HG21 ' CD1' ' A' ' 84' ' ' LEU . 15.5 t -118.28 -9.56 11.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 N-CA-C 103.12 -2.919 . . . . 0.0 103.12 168.927 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.506 HD13 ' N ' ' A' ' 105' ' ' SER . 2.7 pp -41.9 -40.68 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.709 0 C-N-CA 127.812 2.445 . . . . 0.0 114.77 -166.29 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.506 ' N ' HD13 ' A' ' 104' ' ' ILE . 10.1 p -85.84 90.73 8.14 Favored 'General case' 1 N--CA 1.352 -5.37 0 C-N-CA 118.385 -1.326 . . . . 0.0 108.843 176.483 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.617 ' HG ' ' CE1' ' A' ' 20' ' ' PHE . 3.7 mm? -75.42 86.89 2.57 Favored 'General case' 0 N--CA 1.393 -3.296 0 N-CA-C 104.837 -2.283 . . . . 0.0 104.837 177.256 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.4 m -83.13 88.35 6.9 Favored 'General case' 1 N--CA 1.357 -5.124 0 CA-C-N 113.203 -1.817 . . . . 0.0 108.702 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.73 134.43 11.88 Favored Glycine 1 N--CA 1.36 -6.38 0 N-CA-C 104.482 -3.447 . . . . 0.0 104.482 169.712 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.453 ' CG ' ' HG ' ' A' ' 67' ' ' LEU . 38.6 t70 -84.29 -66.92 0.84 Allowed 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 117.591 -1.644 . . . . 0.0 111.464 -177.074 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -100.03 -17.32 17.55 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.53 ' OG ' ' HA ' ' A' ' 50' ' ' PHE . 20.0 m -132.79 118.42 19.0 Favored 'General case' 0 N--CA 1.395 -3.22 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.498 -176.246 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.432 HG13 HD11 ' A' ' 113' ' ' ILE . 14.1 pt -112.6 -25.3 3.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 N-CA-C 104.749 -2.315 . . . . 0.0 104.749 166.283 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.432 HD11 HG13 ' A' ' 112' ' ' ILE . 2.5 mp -102.59 130.46 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 162.883 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 94.94 12.91 54.81 Favored Glycine 0 C--O 1.209 -1.436 0 C-N-CA 119.546 -1.312 . . . . 0.0 111.838 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.623 ' O ' ' HB ' ' A' ' 149' ' ' ILE . 15.7 mtp180 -70.88 90.07 0.79 Allowed 'General case' 0 C--O 1.207 -1.163 0 CA-C-O 120.868 0.366 . . . . 0.0 110.127 174.132 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 96.9 m -68.0 105.32 1.99 Allowed 'General case' 0 N--CA 1.383 -3.775 0 CA-C-O 122.519 1.152 . . . . 0.0 109.786 172.212 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.503 ' CD1' HG23 ' A' ' 47' ' ' VAL . 43.1 tp -70.09 97.92 1.25 Allowed 'General case' 0 CA--C 1.477 -1.843 0 CA-C-N 113.568 -1.651 . . . . 0.0 108.443 177.317 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.449 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 7.2 p -91.23 100.06 10.63 Favored 'Isoleucine or valine' 1 C--O 1.313 4.419 0 C-N-CA 115.909 -2.317 . . . . 0.0 109.874 -175.6 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.29 170.23 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.767 0 CA-C-N 112.429 -2.168 . . . . 0.0 107.172 -175.409 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -158.16 172.28 18.69 Favored 'General case' 0 C--N 1.285 -2.216 0 N-CA-C 103.739 -2.689 . . . . 0.0 103.739 174.002 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.566 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.1 mp0 -66.77 89.81 0.16 Allowed 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 105.138 -2.171 . . . . 0.0 105.138 170.998 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.0 tttp -171.66 170.91 5.5 Favored 'General case' 0 N--CA 1.44 -0.925 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -170.784 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.5 104.98 15.77 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 170.259 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.436 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 13.1 t70 -106.92 8.03 30.35 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 122.705 1.24 . . . . 0.0 111.292 -177.772 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 -67.19 139.46 57.42 Favored 'General case' 0 C--N 1.281 -2.398 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.155 -171.539 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.7 tp -62.96 -50.92 68.88 Favored 'General case' 0 C--N 1.321 -0.643 0 O-C-N 123.475 0.484 . . . . 0.0 109.916 -178.867 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.06 -24.23 68.48 Favored Glycine 0 N--CA 1.442 -0.953 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.192 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 3.9 mptp? -88.93 -47.05 8.42 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 119.931 -0.707 . . . . 0.0 111.701 179.285 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 47.6 -103.18 0.06 OUTLIER Glycine 0 C--O 1.222 -0.603 0 N-CA-C 114.847 0.699 . . . . 0.0 114.847 179.67 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -175.53 -79.03 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.603 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 21.8 t-20 -107.75 -170.23 1.66 Allowed 'General case' 0 C--O 1.258 1.545 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 174.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 29.4 tt0 -53.91 -42.85 69.21 Favored 'General case' 0 CA--C 1.542 0.664 0 CA-C-N 118.884 0.766 . . . . 0.0 111.745 -178.276 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.603 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -75.25 -39.38 59.9 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.154 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.2 m -67.99 -21.65 65.04 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -176.603 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.3 t -86.71 -6.29 58.88 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 122.0 0.905 . . . . 0.0 110.738 179.546 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.5 mttt -92.81 -39.74 11.04 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.856 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.3 p -86.47 -21.23 27.14 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 114.662 -1.154 . . . . 0.0 112.307 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.48 78.47 0.24 Allowed Glycine 0 C--O 1.254 1.383 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -177.946 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.436 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 55.8 t30 -47.71 142.92 4.25 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 124.967 1.307 . . . . 0.0 112.291 -176.428 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.425 ' HB2' HG23 ' A' ' 118' ' ' VAL . . . -150.05 170.49 18.75 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.308 -173.351 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.4 85.1 1.41 Allowed Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 106.547 -2.621 . . . . 0.0 106.547 169.07 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.455 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 51.0 m -42.47 -56.35 3.07 Favored 'General case' 0 C--O 1.194 -1.819 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -165.444 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.436 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 22.9 ptt180 -129.61 12.28 5.84 Favored 'General case' 0 C--N 1.254 -3.58 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -174.795 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.443 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 0.7 OUTLIER -58.15 -44.91 88.11 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 -173.73 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -170.3 92.21 0.2 Allowed 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 114.371 1.249 . . . . 0.0 114.371 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.449 ' SG ' ' HA ' ' A' ' 118' ' ' VAL . 13.9 p -173.53 128.74 0.43 Allowed 'General case' 0 C--O 1.211 -0.956 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 173.368 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.506 ' O ' ' HA ' ' A' ' 54' ' ' THR . . . 179.55 77.08 0.06 OUTLIER Glycine 0 N--CA 1.409 -3.138 0 CA-C-O 117.935 -1.481 . . . . 0.0 113.372 150.391 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.591 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 54.1 t -171.54 90.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 C-N-CA 125.247 1.419 . . . . 0.0 108.135 167.787 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.623 ' HB ' ' O ' ' A' ' 115' ' ' ARG 0.262 5.4 mt -125.13 118.3 52.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.646 0 CA-C-N 119.179 0.9 . . . . 0.0 109.966 163.229 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.415 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 178.08 155.06 13.35 Favored Glycine 2 N--CA 1.379 -5.132 0 C-N-CA 117.801 -2.142 . . . . 0.0 112.681 176.437 . . . . . . . . 3 3 . 1 . 004 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.494 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.6 tt -53.81 105.19 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 114.893 -0.654 . . . . 0.0 110.55 169.378 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -130.31 99.43 5.02 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.997 -0.681 . . . . 0.0 109.542 171.178 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.304 -1.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.657 178.691 . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.451 ' O ' ' HB2' ' A' ' 21' ' ' GLU . . . . . . . . 0 CA--C 1.506 -0.74 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 . . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 25.3 m -121.87 -36.77 2.96 Favored 'General case' 0 CA--C 1.555 1.163 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.554 ' O ' HG12 ' A' ' 151' ' ' ILE . 17.9 ptpt -136.2 144.15 44.78 Favored 'General case' 0 N--CA 1.426 -1.67 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.718 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.468 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -135.73 151.73 50.43 Favored 'General case' 0 C--N 1.282 -2.348 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 30.4 m -115.53 138.36 46.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.637 -178.392 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.536 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -111.09 133.89 53.11 Favored 'General case' 0 C--N 1.284 -2.283 0 CA-C-N 114.781 -1.099 . . . . 0.0 111.48 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -134.73 104.22 5.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 122.98 0.512 . . . . 0.0 110.132 176.209 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.41 HD11 ' HA3' ' A' ' 147' ' ' GLY . 3.1 mm? -96.97 151.31 19.83 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.687 -178.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . 0.594 ' HD3' ' N ' ' A' ' 10' ' ' GLY . 9.9 tmtt? -150.54 137.45 19.17 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.594 ' N ' ' HD3' ' A' ' 9' ' ' LYS . . . -152.78 -169.6 18.2 Favored Glycine 0 N--CA 1.423 -2.188 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.038 -179.105 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -85.97 -31.12 22.26 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 113.915 -1.143 . . . . 0.0 109.376 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -109.47 -172.5 20.72 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 174.226 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -83.69 123.06 3.2 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-N 120.779 2.29 . . . . 0.0 111.099 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.2 p -135.9 91.78 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.097 0 C-N-CA 124.682 1.193 . . . . 0.0 108.522 174.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.614 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 16.0 mm100 -111.59 119.08 37.51 Favored 'General case' 0 C--N 1.292 -1.913 0 O-C-N 121.31 -0.869 . . . . 0.0 108.88 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.593 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -156.85 148.27 17.83 Favored Glycine 0 N--CA 1.406 -3.306 0 C-N-CA 120.206 -0.997 . . . . 0.0 112.658 -175.481 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.498 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 12.6 pt -135.65 103.79 4.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.536 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 3.3 mp -116.64 129.31 73.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -173.102 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.16 138.73 51.47 Favored 'General case' 0 CA--C 1.465 -2.3 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.468 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 20.3 p90 -136.63 160.97 37.2 Favored 'General case' 0 N--CA 1.412 -2.353 0 C-N-CA 119.573 -0.851 . . . . 0.0 109.99 178.08 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.451 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 11.2 pt-20 -127.02 104.97 8.28 Favored 'General case' 0 N--CA 1.407 -2.582 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.214 177.027 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.442 ' NE2' ' HB2' ' A' ' 106' ' ' LEU . 0.9 OUTLIER -85.61 133.73 34.03 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.564 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -122.58 116.78 24.45 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.138 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 6.7 pt-20 -76.51 -11.28 59.85 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.955 -1.021 . . . . 0.0 111.015 -177.196 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.6 m -90.52 -9.28 47.84 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 171.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 70.24 135.93 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.667 1.587 . . . . 0.0 112.653 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -173.37 172.56 45.27 Favored Glycine 0 CA--C 1.487 -1.659 0 C-N-CA 120.28 -0.962 . . . . 0.0 111.374 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -65.06 123.4 11.52 Favored 'Trans proline' 0 N--CA 1.444 -1.383 0 N-CA-C 105.887 -2.39 . . . . 0.0 105.887 172.172 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.491 ' O ' ' HG3' ' A' ' 100' ' ' GLU . 34.9 m -94.96 127.36 46.98 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-O 121.617 0.722 . . . . 0.0 112.142 -172.801 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -81.99 104.46 12.36 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 177.635 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.46 HG12 ' HA ' ' A' ' 20' ' ' PHE . 14.5 m -132.45 147.65 31.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -177.279 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.453 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 12.0 t90 -158.93 136.49 10.12 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.307 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.498 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -150.3 142.04 9.3 Favored Glycine 0 N--CA 1.403 -3.541 0 C-N-CA 120.405 -0.902 . . . . 0.0 111.921 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.593 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 24.8 m -114.45 133.81 55.47 Favored 'General case' 0 N--CA 1.416 -2.161 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.803 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.779 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 5.2 tt -146.83 123.97 3.47 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.106 0 CA-C-N 118.358 0.527 . . . . 0.0 110.672 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.536 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -104.63 134.42 47.82 Favored 'General case' 0 N--CA 1.415 -2.184 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.837 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.4 ' O ' ' HA ' ' A' ' 92' ' ' ASP . . . -132.08 177.39 18.73 Favored Glycine 1 N--CA 1.37 -5.705 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.262 -169.186 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.516 HD21 ' N ' ' A' ' 39' ' ' THR . 10.2 tt -67.02 177.22 1.8 Allowed 'General case' 0 C--N 1.271 -2.811 0 N-CA-C 103.124 -2.917 . . . . 0.0 103.124 168.413 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.516 ' N ' HD21 ' A' ' 38' ' ' LEU . 40.6 p -58.91 150.77 23.36 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 120.603 -1.311 . . . . 0.0 111.099 -165.996 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.58 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -60.7 158.5 12.56 Favored 'General case' 0 CA--C 1.458 -2.577 0 N-CA-C 117.981 2.586 . . . . 0.0 117.981 -155.751 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -142.2 173.86 23.55 Favored Glycine 0 C--N 1.254 -3.997 0 CA-C-N 110.8 -2.909 . . . . 0.0 107.038 -175.537 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.0 mt -131.66 -34.38 1.35 Allowed 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 116.879 2.177 . . . . 0.0 116.879 -164.699 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.648 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 19.1 t-80 -154.85 123.09 5.94 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 121.31 1.868 . . . . 0.0 109.995 -174.887 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.98 149.86 14.55 Favored Glycine 0 N--CA 1.424 -2.146 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.846 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.29 135.38 41.81 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.669 ' HA ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -129.15 82.74 2.1 Favored 'General case' 1 N--CA 1.362 -4.833 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.444 -161.742 . . . . . . . . 4 4 . 1 . 005 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.548 ' HB ' ' O ' ' A' ' 46' ' ' HIS . 9.3 p -174.59 162.96 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.398 -3.026 0 CA-C-N 114.119 -1.401 . . . . 0.0 110.582 165.993 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -147.28 112.53 5.53 Favored 'General case' 0 C--N 1.276 -2.611 0 C-N-CA 127.823 2.449 . . . . 0.0 106.994 166.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.635 ' CD ' ' HA ' ' A' ' 81' ' ' VAL . 20.2 pt-20 -83.51 86.06 7.15 Favored 'General case' 0 C--O 1.173 -2.942 0 N-CA-C 115.793 1.775 . . . . 0.0 115.793 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.498 ' N ' ' HG3' ' A' ' 115' ' ' ARG . 76.3 m-85 -169.09 91.09 0.24 Allowed 'General case' 0 C--N 1.283 -2.286 0 C-N-CA 127.439 2.296 . . . . 0.0 105.361 175.542 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -63.12 139.28 44.33 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 120.476 -0.868 . . . . 0.0 114.539 -178.485 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -125.55 -84.58 0.63 Allowed 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 176.994 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -164.75 159.7 18.94 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.419 ' O ' ' HB3' ' A' ' 9' ' ' LYS . 9.0 t -67.94 -29.01 67.96 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 117.879 0.309 . . . . 0.0 111.538 -179.417 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.42 -22.24 28.42 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.41 110.76 0.51 Allowed Glycine 0 CA--C 1.484 -1.901 0 C-N-CA 119.366 -1.397 . . . . 0.0 111.42 -175.789 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.612 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 7.9 p -98.43 89.22 4.36 Favored 'General case' 0 C--N 1.281 -2.37 0 CA-C-O 121.895 0.855 . . . . 0.0 111.472 178.067 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.0 m -79.54 -47.25 15.86 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.454 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.0 m -79.78 -8.28 59.17 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.252 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.55 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -74.71 -9.28 58.42 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 115.338 -0.847 . . . . 0.0 111.989 179.303 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -68.88 -142.85 0.11 Allowed Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.601 -0.727 . . . . 0.0 113.697 178.822 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 55.0 Cg_endo -65.01 8.72 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.041 0 C-N-CA 124.456 3.438 . . . . 0.0 114.843 -176.736 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.93 124.42 46.6 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -169.615 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -133.84 166.03 23.62 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -172.006 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.451 ' HB3' ' OE2' ' A' ' 49' ' ' GLU . 44.3 t30 -114.03 96.39 41.64 Favored Pre-proline 0 N--CA 1.428 -1.541 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.351 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -80.97 -10.27 12.76 Favored 'Trans proline' 0 N--CA 1.425 -2.509 0 C-N-CA 123.206 2.604 . . . . 0.0 111.135 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -65.63 -45.29 83.63 Favored 'General case' 0 N--CA 1.432 -1.337 0 O-C-N 123.815 0.697 . . . . 0.0 110.019 -166.378 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.621 ' HB2' ' O ' ' A' ' 79' ' ' ARG 0.293 7.6 m -52.31 -52.66 51.76 Favored 'General case' 0 N--CA 1.417 -2.093 0 N-CA-C 116.241 1.941 . . . . 0.0 116.241 -171.215 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.568 ' O ' ' HB2' ' A' ' 70' ' ' LYS . 72.0 ttt180 -133.97 -32.84 1.07 Allowed 'General case' 0 CA--C 1.479 -1.781 0 C-N-CA 113.998 -3.081 . . . . 0.0 111.61 167.748 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.568 ' HB2' ' O ' ' A' ' 69' ' ' ARG . 22.0 tptm 160.63 -77.96 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.695 1.247 . . . . 0.0 108.708 170.171 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 178.58 119.99 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 126.489 1.916 . . . . 0.0 108.4 177.573 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -156.28 -87.71 0.06 OUTLIER Glycine 0 CA--C 1.529 0.965 0 C-N-CA 118.636 -1.745 . . . . 0.0 115.355 177.866 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -146.12 4.72 Favored Glycine 0 N--CA 1.415 -2.752 0 C-N-CA 121.354 -0.45 . . . . 0.0 113.083 -173.164 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -106.0 1.42 0.2 Allowed 'Trans proline' 0 C--O 1.233 0.258 0 C-N-CA 124.969 3.779 . . . . 0.0 114.909 -170.527 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -87.4 -17.25 32.71 Favored 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -167.275 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.56 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 12.7 t70 -146.51 -72.71 0.23 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.662 -178.383 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.482 ' HG2' ' OD1' ' A' ' 76' ' ' ASP . 21.9 pt-20 -154.11 -56.57 0.11 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.555 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.56 ' OE1' ' HB3' ' A' ' 76' ' ' ASP . 0.6 OUTLIER 52.74 1.67 0.02 OUTLIER 'General case' 0 C--O 1.203 -1.349 0 C-N-CA 127.73 2.412 . . . . 0.0 116.95 172.873 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.621 ' O ' ' HB2' ' A' ' 68' ' ' SER . 27.0 mtt180 163.7 -26.91 0.0 OUTLIER 'General case' 0 C--O 1.189 -2.119 0 C-N-CA 125.266 1.426 . . . . 0.0 111.389 -172.353 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 30.6 m-70 57.17 19.01 4.52 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.635 ' HA ' ' CD ' ' A' ' 49' ' ' GLU . 6.9 m -57.88 -15.34 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 O-C-N 124.015 0.822 . . . . 0.0 112.73 -177.043 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.423 ' HA3' HG22 ' A' ' 47' ' ' VAL . . . 140.84 -126.02 3.0 Favored Glycine 0 N--CA 1.401 -3.688 0 C-N-CA 121.289 -0.481 . . . . 0.0 112.221 174.882 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -81.59 87.42 6.26 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 123.065 1.412 . . . . 0.0 110.628 -174.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.78 89.49 4.36 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.685 -1.598 . . . . 0.0 110.355 177.286 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -146.88 -176.82 20.97 Favored Glycine 0 N--CA 1.416 -2.664 0 N-CA-C 108.881 -1.687 . . . . 0.0 108.881 -178.71 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.84 155.57 18.67 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 117.733 0.767 . . . . 0.0 111.822 -179.333 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.473 HG13 ' NE2' ' A' ' 46' ' ' HIS . 2.0 m -143.16 128.45 15.88 Favored 'Isoleucine or valine' 0 C--N 1.361 1.081 0 C-N-CA 123.585 0.754 . . . . 0.0 111.08 173.14 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 t -141.78 95.98 2.9 Favored 'General case' 0 N--CA 1.39 -3.468 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 172.206 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.477 ' O ' ' HA ' ' A' ' 40' ' ' GLU . . . -96.1 122.43 38.93 Favored 'General case' 0 CA--C 1.466 -2.266 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.832 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.58 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 21.6 t70 -54.15 169.76 0.16 Allowed 'General case' 0 CA--C 1.565 1.525 0 O-C-N 124.824 1.328 . . . . 0.0 111.435 177.468 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.551 ' HA ' ' H ' ' A' ' 40' ' ' GLU . 57.4 pttt -41.68 -23.54 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 117.233 2.309 . . . . 0.0 117.233 -175.309 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.4 ' HA ' ' O ' ' A' ' 37' ' ' GLY . 30.8 t70 -154.16 22.07 0.5 Allowed 'General case' 0 C--N 1.294 -1.81 0 N-CA-C 104.359 -2.46 . . . . 0.0 104.359 172.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.536 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.81 -127.57 1.4 Allowed Glycine 0 C--O 1.179 -3.313 0 CA-C-N 111.555 -2.566 . . . . 0.0 118.634 -160.899 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.779 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 3.3 m -161.16 136.27 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.226 0 C-N-CA 124.978 1.311 . . . . 0.0 108.207 -170.247 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.57 111.73 24.16 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 173.685 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -74.99 93.52 2.72 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 123.479 0.487 . . . . 0.0 109.766 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.453 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 33.7 m -91.78 111.76 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.01 0 CA-C-O 121.982 0.896 . . . . 0.0 111.007 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.3 t -149.95 100.84 2.98 Favored 'General case' 0 N--CA 1.411 -2.394 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.42 118.55 43.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.491 ' HG3' ' O ' ' A' ' 29' ' ' VAL . 5.1 mp0 -107.32 99.01 8.57 Favored 'General case' 0 N--CA 1.417 -2.108 0 C-N-CA 118.983 -1.087 . . . . 0.0 110.327 -176.032 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -165.88 166.33 17.64 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 173.481 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.1 m -94.71 80.39 3.78 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.827 -1.149 . . . . 0.0 112.939 -174.07 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.0 m -104.84 -18.72 6.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.801 176.428 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 21.3 pt -101.46 7.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.707 -170.804 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.1 m -66.57 167.54 10.76 Favored 'General case' 0 CA--C 1.56 1.332 0 CA-C-O 122.697 1.237 . . . . 0.0 113.003 -175.971 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.442 ' HB2' ' NE2' ' A' ' 22' ' ' GLN . 3.8 tt -78.26 87.22 4.33 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-N 114.115 -1.402 . . . . 0.0 108.286 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 51.7 m -170.01 86.68 0.13 Allowed 'General case' 0 C--N 1.264 -3.144 0 N-CA-C 102.533 -3.136 . . . . 0.0 102.533 169.904 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 157.32 -177.45 34.16 Favored Glycine 0 C--N 1.258 -3.753 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.437 ' C ' ' H ' ' A' ' 111' ' ' SER . 18.9 t70 -81.31 -21.5 39.19 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 118.492 -1.283 . . . . 0.0 109.568 175.265 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.469 ' HB2' ' CB ' ' A' ' 49' ' ' GLU . 62.9 t-80 -88.36 40.66 0.97 Allowed 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 173.598 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.437 ' H ' ' C ' ' A' ' 109' ' ' ASP . 15.1 p -63.02 -64.78 0.81 Allowed 'General case' 0 C--N 1.273 -2.725 0 CA-C-O 122.724 1.25 . . . . 0.0 110.146 -175.812 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.404 HG23 HE21 ' A' ' 22' ' ' GLN . 28.5 pt -128.94 -22.93 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.184 176.299 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -81.23 170.54 1.42 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.158 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.206 -162.448 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -82.99 71.72 2.97 Favored Glycine 0 CA--C 1.475 -2.463 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -172.62 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.498 ' HG3' ' N ' ' A' ' 50' ' ' PHE . 2.6 mpt_? -79.13 141.24 37.45 Favored 'General case' 0 N--CA 1.396 -3.13 0 CA-C-N 114.603 -0.799 . . . . 0.0 110.063 -178.739 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.779 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 8.8 t -67.84 124.21 22.71 Favored 'General case' 0 C--N 1.274 -2.716 0 CA-C-O 122.895 1.331 . . . . 0.0 114.554 -168.96 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.3 tp -80.64 98.42 7.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 113.556 -1.656 . . . . 0.0 108.901 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.669 ' O ' ' HA ' ' A' ' 46' ' ' HIS . 26.9 t -91.85 100.56 11.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.864 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.529 ' HB ' ' CB ' ' A' ' 46' ' ' HIS . 12.2 p -139.98 156.98 25.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 126.539 1.936 . . . . 0.0 108.343 -175.649 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -171.45 166.57 6.88 Favored 'General case' 0 N--CA 1.428 -1.564 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 165.117 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.564 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -73.32 84.91 1.44 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 175.605 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.463 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 79.3 mttt -173.19 170.77 4.26 Favored 'General case' 0 CA--C 1.493 -1.228 0 C-N-CA 126.119 1.768 . . . . 0.0 108.326 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.648 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -80.44 104.48 11.01 Favored 'General case' 0 C--N 1.29 -1.998 0 O-C-N 124.145 0.903 . . . . 0.0 110.974 172.253 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -118.78 80.46 1.54 Allowed 'General case' 0 CA--C 1.483 -1.623 0 N-CA-C 104.267 -2.494 . . . . 0.0 104.267 173.28 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.544 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 16.4 t0 -125.91 139.0 53.82 Favored 'General case' 0 C--N 1.263 -3.17 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.332 -170.886 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.4 tp -82.03 -21.5 36.93 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.876 -172.944 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -102.82 13.42 56.29 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.611 ' HD3' ' O ' ' A' ' 128' ' ' LYS . 14.3 tmtt? -127.42 37.76 4.18 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.3 -54.84 34.38 Favored Glycine 0 N--CA 1.427 -1.9 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.12 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 114.34 -25.09 10.78 Favored Glycine 0 C--N 1.308 -1.004 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.907 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 33.3 t-20 -167.58 167.08 13.77 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.443 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 12.9 pt-20 -48.39 -46.59 37.34 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.943 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -61.72 -53.57 54.28 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.542 0.737 . . . . 0.0 110.412 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.6 m -69.22 -27.28 65.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 112.108 -172.943 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 m -78.01 -15.31 59.05 Favored 'General case' 0 CA--C 1.557 1.235 0 CA-C-O 121.801 0.81 . . . . 0.0 110.025 177.244 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.443 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 99.4 mttt -89.67 -40.14 12.74 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 174.804 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.0 m -67.43 -46.39 73.28 Favored 'General case' 0 C--N 1.284 -2.244 0 CA-C-O 121.366 0.603 . . . . 0.0 109.993 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.53 76.56 1.18 Allowed Glycine 0 N--CA 1.408 -3.208 0 N-CA-C 106.866 -2.493 . . . . 0.0 106.866 -172.975 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -36.21 111.22 0.13 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 125.905 1.682 . . . . 0.0 111.041 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -149.22 135.75 19.4 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.225 -173.019 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -70.87 108.4 2.47 Favored Glycine 0 N--CA 1.434 -1.438 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 172.861 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.6 m -57.01 -29.55 63.42 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 115.285 1.587 . . . . 0.0 115.285 -169.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.612 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 27.3 ttm180 -128.97 21.82 5.8 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -175.496 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 74.9 mt -74.46 -15.38 60.9 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.692 -179.272 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -162.71 109.26 1.22 Allowed 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.478 175.15 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 61.5 m -98.59 131.41 44.82 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 174.401 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.779 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.59 126.44 1.23 Allowed Glycine 0 N--CA 1.412 -2.919 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.873 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 m -76.18 98.43 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-O 121.691 0.758 . . . . 0.0 109.864 173.831 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 1.7 mp -106.4 112.22 38.61 Favored 'Isoleucine or valine' 0 C--O 1.257 1.48 0 CA-C-O 122.31 1.053 . . . . 0.0 109.926 -179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.431 ' HA2' ' CZ ' ' A' ' 20' ' ' PHE . . . -174.68 176.76 46.93 Favored Glycine 0 CA--C 1.461 -3.294 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -175.981 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.554 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.35 105.05 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 107.942 -1.132 . . . . 0.0 107.942 176.727 . . . . . . . . 3 3 . 1 . 005 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.54 147.59 41.42 Favored 'General case' 0 N--CA 1.413 -2.281 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--N 1.292 -1.9 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.916 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.722 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.7 m -74.46 -23.4 58.89 Favored 'General case' 0 CA--C 1.566 1.58 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -172.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -132.37 147.8 52.4 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.873 -171.768 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.471 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -132.64 156.48 46.86 Favored 'General case' 0 N--CA 1.405 -2.693 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.579 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 47.2 t -125.96 126.91 70.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.519 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.465 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -124.91 135.1 52.55 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.005 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.501 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 14.7 m -127.61 119.77 52.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-O 121.201 0.524 . . . . 0.0 110.809 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -100.34 138.15 37.8 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.219 177.803 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -165.8 125.19 1.68 Allowed 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.83 -158.98 8.99 Favored Glycine 0 N--CA 1.439 -1.156 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.633 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -72.34 -61.78 1.67 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -75.62 153.43 44.2 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 172.63 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -83.21 123.35 3.47 Favored 'Trans proline' 0 N--CA 1.429 -2.289 0 CA-C-N 120.976 2.388 . . . . 0.0 112.389 -175.601 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.74 119.09 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.819 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 173.356 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -130.82 128.88 41.55 Favored 'General case' 0 C--N 1.269 -2.909 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.54 161.78 34.77 Favored Glycine 0 N--CA 1.399 -3.791 0 C-N-CA 119.49 -1.338 . . . . 0.0 112.201 -177.273 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.443 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.0 pt -142.26 133.6 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.318 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -132.31 135.03 58.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.337 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -107.11 132.94 52.45 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.615 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.471 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 22.1 t80 -127.42 138.2 52.92 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 123.619 0.768 . . . . 0.0 110.59 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.606 ' O ' HG23 ' A' ' 29' ' ' VAL . 5.7 pt-20 -117.33 119.69 35.89 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.537 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.13 135.65 33.52 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 119.299 -0.961 . . . . 0.0 108.751 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -115.43 83.75 1.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.678 0.751 . . . . 0.0 110.308 179.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -68.42 -20.21 64.64 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 124.526 1.131 . . . . 0.0 110.802 -177.179 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 25' ' ' SER . . . . . 0.445 ' O ' ' HB3' ' A' ' 26' ' ' ASN . 17.4 t -88.44 -5.23 58.39 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.089 177.959 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . 0.445 ' HB3' ' O ' ' A' ' 25' ' ' SER . 4.0 t30 77.47 113.91 0.07 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 124.682 1.193 . . . . 0.0 110.837 -173.227 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.82 166.41 39.6 Favored Glycine 0 CA--C 1.475 -2.455 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -177.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.434 ' HA ' ' HB2' ' A' ' 101' ' ' ASP . 58.0 Cg_endo -71.67 124.08 9.95 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 121.177 1.251 . . . . 0.0 110.774 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.606 HG23 ' O ' ' A' ' 21' ' ' GLU . 9.8 p -76.75 123.25 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.893 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.066 173.761 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -105.56 124.56 49.76 Favored 'General case' 0 C--N 1.28 -2.451 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 172.631 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.499 ' H ' HG21 ' A' ' 99' ' ' ILE . 34.4 m -134.33 153.27 35.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -172.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 69.4 p-90 -145.64 135.23 23.27 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 174.562 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.557 ' H ' HG13 ' A' ' 97' ' ' VAL . . . -148.68 139.59 7.68 Favored Glycine 0 N--CA 1.42 -2.404 0 C-N-CA 119.979 -1.105 . . . . 0.0 111.662 175.941 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.2 m -116.11 125.63 52.63 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 25.3 mm -125.04 132.19 71.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.548 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 36.0 mtmm -117.67 136.16 53.52 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.998 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -171.01 174.15 44.75 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -172.056 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 pp -68.66 153.69 43.31 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 118.679 1.239 . . . . 0.0 109.634 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.574 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 77.3 p -69.85 107.26 3.46 Favored 'General case' 0 C--O 1.206 -1.195 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 -170.036 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.558 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 28.7 tt0 -175.35 115.99 0.15 Allowed 'General case' 0 C--O 1.205 -1.279 0 C-N-CA 125.653 1.581 . . . . 0.0 107.018 172.306 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.488 ' N ' ' HB3' ' A' ' 90' ' ' ASP . . . -164.35 114.97 0.62 Allowed Glycine 0 C--N 1.273 -2.917 0 C-N-CA 118.392 -1.861 . . . . 0.0 112.166 -174.637 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.2 mt -106.72 -64.76 1.15 Allowed 'General case' 0 N--CA 1.435 -1.191 0 O-C-N 123.998 0.47 . . . . 0.0 112.187 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.667 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.1 m80 -171.35 168.95 6.45 Favored 'General case' 0 CA--C 1.492 -1.255 0 C-N-CA 124.249 1.02 . . . . 0.0 108.326 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.48 ' O ' ' HG3' ' A' ' 74' ' ' PRO . . . 178.23 -169.28 40.97 Favored Glycine 0 C--N 1.282 -2.461 0 C-N-CA 119.786 -1.197 . . . . 0.0 112.056 176.39 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.527 ' CE1' ' HA ' ' A' ' 126' ' ' LEU . 1.3 p90 -168.16 165.67 13.15 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.686 ' CE1' ' HA3' ' A' ' 85' ' ' GLY . 18.3 m-70 -90.02 150.02 22.29 Favored 'General case' 0 CA--C 1.478 -1.808 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.507 ' HB ' ' CD2' ' A' ' 63' ' ' HIS . 0.0 OUTLIER -172.3 89.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 173.663 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.458 ' ND1' ' HB2' ' A' ' 60' ' ' ALA . 0.2 OUTLIER -170.34 86.06 0.12 Allowed 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 163.942 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.479 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 9.0 pt-20 -93.4 117.92 30.67 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 118.094 -1.442 . . . . 0.0 110.852 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.479 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 12.0 t80 162.58 92.43 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 103.766 -2.679 . . . . 0.0 103.766 179.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -48.66 109.08 0.47 Allowed Glycine 0 N--CA 1.478 1.482 0 O-C-N 123.682 0.614 . . . . 0.0 113.714 -177.129 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -120.98 -80.77 0.63 Allowed 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 117.971 -1.492 . . . . 0.0 112.089 -175.583 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.451 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.8 t30 -144.99 156.4 43.93 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.891 -177.468 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 33.1 p -84.32 -1.51 55.5 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 124.228 1.011 . . . . 0.0 111.295 -177.137 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.7 20.85 4.64 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.266 -179.034 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.451 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 146.99 114.39 0.82 Allowed Glycine 0 N--CA 1.424 -2.133 0 C-N-CA 118.969 -1.586 . . . . 0.0 112.033 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.453 ' SG ' HG21 ' A' ' 118' ' ' VAL . 9.4 p -96.71 90.83 5.43 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.095 0.95 . . . . 0.0 112.698 -177.456 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.2 p -74.18 -49.23 24.49 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.075 -177.78 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.9 m -65.14 -23.67 67.19 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.767 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.458 ' HB2' ' ND1' ' A' ' 48' ' ' HIS . . . -76.74 -22.99 53.05 Favored 'General case' 0 N--CA 1.422 -1.864 0 C-N-CA 120.037 -0.665 . . . . 0.0 110.822 -178.647 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . 30.62 -97.29 0.01 OUTLIER Glycine 0 N--CA 1.494 2.532 0 C-N-CA 124.881 1.229 . . . . 0.0 115.663 164.346 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 27.9 Cg_endo -93.44 73.46 0.36 Allowed 'Trans proline' 0 N--CA 1.435 -1.968 0 C-N-CA 123.479 2.786 . . . . 0.0 109.932 174.945 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.507 ' CD2' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p-80 -36.52 137.94 0.26 Allowed 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 125.415 1.486 . . . . 0.0 114.329 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.485 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 15.7 p90 -125.28 88.17 2.83 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 170.47 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.576 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 16.8 m120 -106.45 89.49 4.08 Favored Pre-proline 0 CA--C 1.505 -0.781 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.485 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 5.8 Cg_exo -77.7 -12.94 16.45 Favored 'Trans proline' 0 N--CA 1.443 -1.444 0 C-N-CA 122.474 2.116 . . . . 0.0 114.842 -169.152 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.414 HD13 ' O ' ' A' ' 106' ' ' LEU . 13.1 mt -70.2 -25.13 63.27 Favored 'General case' 0 CA--C 1.465 -2.302 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.422 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.533 ' HA ' ' C ' ' A' ' 77' ' ' GLU . 18.0 t -93.7 -96.34 0.15 Allowed 'General case' 1 N--CA 1.377 -4.076 0 C-N-CA 114.997 -2.681 . . . . 0.0 107.272 175.922 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.465 ' HB3' ' HA ' ' A' ' 79' ' ' ARG 0.264 24.6 ttt85 -142.05 40.37 1.64 Allowed 'General case' 0 CA--C 1.492 -1.261 0 CA-C-N 119.055 0.843 . . . . 0.0 109.185 152.29 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.576 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 88.2 tttt 75.78 -33.39 0.22 Allowed 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -155.61 99.02 1.99 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -175.154 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.685 ' HA3' ' C ' ' A' ' 80' ' ' HIS . . . -164.56 -136.6 2.03 Favored Glycine 0 C--O 1.18 -3.234 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.752 163.673 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.724 ' N ' ' HA ' ' A' ' 81' ' ' VAL . . . -75.98 -175.96 39.89 Favored Glycine 0 CA--C 1.547 2.061 0 CA-C-N 117.427 0.613 . . . . 0.0 114.607 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.48 ' HG3' ' O ' ' A' ' 44' ' ' GLY . 88.7 Cg_endo -102.49 0.37 0.42 Allowed 'Trans proline' 0 C--O 1.212 -0.788 0 C-N-CA 123.825 3.017 . . . . 0.0 113.633 -178.393 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.484 ' HG2' ' OE2' ' A' ' 100' ' ' GLU . 61.8 mttm -81.49 2.27 29.62 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -172.17 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.451 ' O ' ' HB ' ' A' ' 81' ' ' VAL . 37.4 t70 -175.59 166.34 3.2 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -176.272 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.533 ' C ' ' HA ' ' A' ' 68' ' ' SER . 2.5 pm0 -122.52 84.68 2.3 Favored 'General case' 0 N--CA 1.418 -2.039 0 C-N-CA 120.161 -0.616 . . . . 0.0 111.111 171.923 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.451 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 0.1 OUTLIER 171.37 86.87 0.0 OUTLIER 'General case' 0 C--N 1.361 1.071 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.84 178.599 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.511 ' NH1' ' HB2' ' A' ' 80' ' ' HIS 0.289 0.0 OUTLIER 62.32 130.5 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 C-N-CA 126.481 1.912 . . . . 0.0 115.412 174.637 . . . . . . . . 4 4 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.685 ' C ' ' HA3' ' A' ' 72' ' ' GLY . 21.3 t-160 67.02 19.4 10.55 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.63 1.205 . . . . 0.0 107.971 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.724 ' HA ' ' N ' ' A' ' 73' ' ' GLY . 1.6 m -148.12 157.48 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.237 0 CA-C-N 113.207 -1.815 . . . . 0.0 107.595 175.481 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -128.17 -129.92 3.26 Favored Glycine 0 C--N 1.283 -2.39 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.609 ' HB3' ' O ' ' A' ' 46' ' ' HIS . 15.6 t70 -84.61 169.96 13.84 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -109.04 96.46 6.33 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 -165.692 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.686 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . -173.82 83.25 0.08 OUTLIER Glycine 0 N--CA 1.422 -2.282 0 C-N-CA 118.918 -1.61 . . . . 0.0 113.295 173.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.1 t30 -78.87 130.06 35.25 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 177.62 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.62 128.45 75.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.551 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 29.4 p -139.45 95.76 2.98 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -120.95 104.18 9.62 Favored 'General case' 0 N--CA 1.421 -1.895 0 C-N-CA 118.079 -1.448 . . . . 0.0 109.049 174.463 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.574 ' O ' ' HB ' ' A' ' 39' ' ' THR . 8.1 p-10 -132.29 -20.88 2.36 Favored 'General case' 0 CA--C 1.47 -2.131 0 CA-C-O 121.788 0.804 . . . . 0.0 109.842 -176.302 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -72.53 -56.94 4.59 Favored 'General case' 0 C--N 1.268 -2.966 0 CA-C-N 113.655 -1.612 . . . . 0.0 109.091 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -153.71 6.18 0.33 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.505 -170.013 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 82.12 55.3 3.13 Favored Glycine 0 N--CA 1.426 -1.987 0 C-N-CA 118.102 -1.999 . . . . 0.0 108.748 -168.735 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.1 m -148.84 110.09 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 104.45 -2.426 . . . . 0.0 104.45 -177.549 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.551 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.84 128.92 41.94 Favored 'General case' 0 C--N 1.263 -3.162 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.703 -174.542 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -81.92 107.84 14.96 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 171.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.557 HG13 ' H ' ' A' ' 33' ' ' GLY . 13.4 p -82.61 137.46 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.202 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.336 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.4 ' HB3' ' OE2' ' A' ' 100' ' ' GLU . 41.8 m -84.37 108.6 17.29 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.963 177.213 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.499 HG21 ' H ' ' A' ' 31' ' ' VAL . 28.8 mt -93.32 114.06 29.34 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.482 0 N-CA-C 106.112 -1.811 . . . . 0.0 106.112 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.484 ' OE2' ' HG2' ' A' ' 75' ' ' LYS . 1.0 OUTLIER -134.99 155.71 50.3 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 -179.738 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.434 ' HB2' ' HA ' ' A' ' 28' ' ' PRO . 7.4 p-10 -90.11 131.83 35.75 Favored 'General case' 0 C--N 1.295 -1.763 0 CA-C-O 121.721 0.772 . . . . 0.0 111.517 -178.862 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.507 ' H ' HG13 ' A' ' 29' ' ' VAL . 75.6 p -96.07 172.94 7.68 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 175.808 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.57 -54.36 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.86 174.265 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -130.44 -47.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.644 0 C-N-CA 120.189 -0.604 . . . . 0.0 111.94 -174.313 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.8 p -170.08 167.19 8.92 Favored 'General case' 0 CA--C 1.469 -2.17 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -169.839 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.581 ' HB2' ' OD2' ' A' ' 83' ' ' ASP . 2.8 pp -68.84 164.28 22.33 Favored 'General case' 0 N--CA 1.391 -3.409 0 CA-C-N 113.67 -1.605 . . . . 0.0 106.687 176.039 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 50.0 m -86.28 88.25 7.58 Favored 'General case' 1 C--N 1.238 -4.268 0 CA-C-O 121.357 0.599 . . . . 0.0 111.681 -170.501 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.66 133.98 7.88 Favored Glycine 1 N--CA 1.394 -4.157 0 N-CA-C 106.957 -2.457 . . . . 0.0 106.957 167.818 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.414 ' H ' ' CD ' ' A' ' 49' ' ' GLU . 23.9 t70 -122.32 -29.14 4.19 Favored 'General case' 0 C--N 1.264 -3.127 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -179.115 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.42 -31.82 69.17 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 174.162 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.463 ' OG ' HG22 ' A' ' 113' ' ' ILE . 28.5 t 173.71 -174.07 0.06 Allowed 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 168.143 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 31.4 mm -106.46 -4.98 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.98 0 N-CA-C 103.839 -2.652 . . . . 0.0 103.839 -179.184 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.626 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 16.0 tt -104.03 157.56 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 103.409 -2.811 . . . . 0.0 103.409 163.252 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.8 41.57 28.16 Favored Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.536 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.806 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -135.1 129.37 33.84 Favored 'General case' 0 C--N 1.271 -2.812 0 C-N-CA 125.065 1.346 . . . . 0.0 109.068 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.886 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 11.2 p -114.86 141.45 47.9 Favored 'General case' 0 C--N 1.279 -2.468 0 CA-C-O 121.339 0.59 . . . . 0.0 112.272 177.655 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.528 ' HB3' ' CG2' ' A' ' 149' ' ' ILE . 2.6 pt? -88.97 105.93 18.09 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.453 HG21 ' SG ' ' A' ' 57' ' ' CYS . 17.3 t -92.93 100.39 11.2 Favored 'Isoleucine or valine' 1 C--O 1.319 4.718 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.354 169.081 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.5 HG21 ' O ' ' A' ' 45' ' ' PHE . 3.3 t -147.1 170.42 3.94 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.677 0 C-N-CA 128.879 2.872 . . . . 0.0 103.467 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -159.51 170.39 21.8 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 178.175 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.531 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -79.79 83.25 5.76 Favored 'General case' 0 CA--C 1.567 1.604 0 N-CA-C 105.624 -1.991 . . . . 0.0 105.624 169.288 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -172.17 174.19 4.07 Favored 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 104.694 -2.335 . . . . 0.0 104.694 -167.515 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.667 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -88.29 104.62 16.91 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -69.71 113.31 6.85 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 174.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -75.83 131.59 39.83 Favored 'General case' 0 N--CA 1.427 -1.593 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.918 -167.788 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.527 ' HA ' ' CE1' ' A' ' 45' ' ' PHE . 11.0 mt -76.1 -71.52 0.38 Allowed 'General case' 0 N--CA 1.404 -2.752 0 CA-C-N 113.617 -1.629 . . . . 0.0 113.614 -169.13 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -117.38 -7.11 12.63 Favored Glycine 0 CA--C 1.467 -2.943 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.447 -168.676 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.48 ' C ' ' HB ' ' A' ' 135' ' ' THR . 95.3 mttt -99.93 -42.57 6.72 Favored 'General case' 0 N--CA 1.412 -2.369 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 75.97 -63.0 2.85 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -171.096 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 153.63 -25.85 0.75 Allowed Glycine 0 C--N 1.299 -1.486 0 N-CA-C 108.101 -1.999 . . . . 0.0 108.101 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -163.54 172.88 13.77 Favored 'General case' 0 C--O 1.254 1.342 0 N-CA-C 103.376 -2.824 . . . . 0.0 103.376 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -59.57 -41.06 89.31 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-N 118.887 0.767 . . . . 0.0 112.068 -176.34 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.425 ' O ' ' HB3' ' A' ' 136' ' ' LYS . 35.4 tt0 -66.17 -36.98 84.52 Favored 'General case' 0 C--O 1.219 -0.532 0 CA-C-O 121.08 0.467 . . . . 0.0 110.181 177.251 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -68.29 -34.23 75.77 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.642 -176.203 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.48 ' HB ' ' C ' ' A' ' 128' ' ' LYS . 10.7 t -81.54 -6.75 59.28 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.547 1.165 . . . . 0.0 109.114 177.354 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.425 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 88.3 tttt -90.01 -24.43 21.22 Favored 'General case' 0 C--N 1.287 -2.117 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.257 175.313 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.3 m -83.36 -33.3 25.85 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.72 7.59 Favored Glycine 1 C--O 1.315 5.194 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 -171.554 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -35.14 106.04 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 131.271 3.828 . . . . 0.0 120.016 -166.254 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.402 ' HB1' ' CG1' ' A' ' 118' ' ' VAL . . . -153.05 172.38 16.96 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 102.498 -3.149 . . . . 0.0 102.498 164.625 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -52.32 110.01 1.06 Allowed Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 34.4 p -52.63 -32.11 40.14 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -171.487 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 15.9 ptt180 -120.25 -27.37 5.27 Favored 'General case' 0 C--N 1.26 -3.304 0 C-N-CA 118.472 -1.291 . . . . 0.0 108.776 174.395 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.73 -36.39 11.3 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 124.7 1.25 . . . . 0.0 112.798 -165.989 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -142.45 88.76 2.1 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.102 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.886 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 52.7 t -156.86 141.36 16.71 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.858 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.501 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -157.72 170.44 34.7 Favored Glycine 0 N--CA 1.4 -3.708 0 N-CA-C 107.214 -2.354 . . . . 0.0 107.214 177.924 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.71 ' HB ' ' NH1' ' A' ' 115' ' ' ARG . 27.7 m -68.84 124.26 24.15 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.017 0 CA-C-N 117.656 0.728 . . . . 0.0 111.054 178.595 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.806 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 0.0 OUTLIER -123.47 99.86 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.212 0.53 . . . . 0.0 111.245 179.331 . . . . . . . . 3 3 . 1 . 006 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.505 ' HA3' ' NE ' ' A' ' 115' ' ' ARG . . . 174.63 -167.47 39.75 Favored Glycine 0 CA--C 1.457 -3.586 0 C-N-CA 117.546 -2.264 . . . . 0.0 111.534 178.316 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 9.1 tt -68.75 105.67 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.266 1.935 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -116.45 140.28 49.53 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.104 179.468 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 . . . . . 0 C--N 1.297 -1.694 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.009 . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.501 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.212 -0.918 0 N-CA-C 111.663 0.246 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.516 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 14.4 m -58.08 -26.41 62.53 Favored 'General case' 0 CA--C 1.571 1.776 0 N-CA-C 115.425 1.639 . . . . 0.0 115.425 -174.495 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -135.15 147.5 49.46 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.827 -1.171 . . . . 0.0 112.083 -172.171 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.551 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -139.81 154.42 47.35 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.64 172.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.412 ' HB ' ' HB1' ' A' ' 152' ' ' ALA . 39.7 t -129.69 131.03 67.02 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -178.403 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.484 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -121.49 132.37 54.68 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.651 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 10.9 m -127.96 109.04 18.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.729 0.776 . . . . 0.0 110.58 -178.695 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.47 ' O ' ' HG2' ' A' ' 15' ' ' GLN . 6.6 mp -103.47 128.49 50.64 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.664 -176.334 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -160.88 124.99 3.5 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 169.147 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.91 -173.14 22.66 Favored Glycine 0 N--CA 1.405 -3.382 0 N-CA-C 107.216 -2.354 . . . . 0.0 107.216 175.141 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -95.21 89.66 5.59 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 120.217 -0.593 . . . . 0.0 109.78 -178.662 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.59 -63.83 0.62 Allowed Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.776 178.217 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.493 ' HB3' ' HA ' ' A' ' 120' ' ' HIS . 31.9 Cg_exo -62.31 169.16 8.35 Favored 'Trans proline' 0 N--CA 1.432 -2.095 0 C-N-CA 123.072 2.515 . . . . 0.0 115.004 -174.823 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.496 HG13 ' HA3' ' A' ' 37' ' ' GLY . 16.8 m -69.86 158.01 6.31 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.038 0 CA-C-N 111.587 -2.552 . . . . 0.0 112.544 -175.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.47 ' HG2' ' O ' ' A' ' 8' ' ' LEU . 15.3 tm0? -112.52 140.56 47.17 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 104.667 -2.345 . . . . 0.0 104.667 177.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' O ' HD13 ' A' ' 8' ' ' LEU . . . -158.98 170.51 35.41 Favored Glycine 0 N--CA 1.414 -2.824 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.439 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 18.9 pt -132.46 129.05 58.87 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 176.677 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.418 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 43.7 mm -130.01 123.53 56.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -174.718 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.439 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 2.2 m-20 -112.41 126.74 55.61 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.478 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.551 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 29.7 p90 -126.78 148.34 49.93 Favored 'General case' 0 CA--C 1.495 -1.147 0 C-N-CA 118.24 -1.384 . . . . 0.0 109.912 176.224 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.516 ' HB3' ' O ' ' A' ' 2' ' ' THR . 1.5 pp20? -117.76 116.17 26.48 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.372 176.128 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -85.72 87.88 7.47 Favored 'General case' 0 N--CA 1.382 -3.854 0 CA-C-O 123.103 1.43 . . . . 0.0 108.769 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.469 ' H ' ' HB ' ' A' ' 104' ' ' ILE . 5.0 ttmp? -72.16 110.06 6.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 112.206 -2.27 . . . . 0.0 107.009 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -61.79 -24.29 66.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.03 0.443 . . . . 0.0 111.622 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 m -71.92 -19.3 61.94 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.524 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . 0.45 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 56.6 m-80 70.3 162.71 0.24 Allowed 'General case' 0 C--O 1.241 0.61 0 C-N-CA 125.194 1.398 . . . . 0.0 110.885 -175.493 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 138.47 -149.46 20.56 Favored Glycine 0 CA--C 1.48 -2.156 0 C-N-CA 117.762 -2.161 . . . . 0.0 114.18 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -63.26 125.69 16.25 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 123.357 2.704 . . . . 0.0 110.941 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.443 HG11 ' OD1' ' A' ' 101' ' ' ASP . 3.9 m -76.97 120.39 27.23 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.378 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -98.55 92.17 5.5 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.096 0.951 . . . . 0.0 108.506 172.259 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 71.5 t -133.36 146.0 32.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -175.889 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.5 p-90 -143.15 134.73 26.39 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.439 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -141.92 140.33 10.01 Favored Glycine 0 N--CA 1.419 -2.458 0 C-N-CA 119.796 -1.192 . . . . 0.0 112.14 178.171 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -116.63 151.82 35.48 Favored 'General case' 0 N--CA 1.394 -3.252 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 176.781 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.68 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 36.8 mm -132.24 134.06 59.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.695 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 60.6 pttt -139.0 119.96 14.42 Favored 'General case' 0 C--O 1.206 -1.207 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 175.1 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.535 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -169.97 174.97 44.16 Favored Glycine 0 CA--C 1.476 -2.354 0 C-N-CA 118.811 -1.662 . . . . 0.0 113.075 -171.793 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.3 tt -66.85 137.77 56.84 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.1 p -72.78 108.53 5.81 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 115.238 1.57 . . . . 0.0 115.238 -164.48 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.501 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.9 tt0 -177.78 121.79 0.11 Allowed 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 105.358 -2.09 . . . . 0.0 105.358 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.534 ' N ' ' HA ' ' A' ' 90' ' ' ASP . . . -155.82 138.67 6.14 Favored Glycine 0 CA--C 1.47 -2.774 0 C-N-CA 119.268 -1.444 . . . . 0.0 111.507 -177.856 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.432 HD22 ' HA ' ' A' ' 122' ' ' LYS . 3.6 mm? -126.65 -58.33 1.33 Allowed 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -170.989 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.52 169.3 24.61 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.369 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.583 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -130.29 113.34 1.43 Allowed Glycine 0 C--O 1.217 -0.917 0 C-N-CA 118.391 -1.861 . . . . 0.0 117.43 -170.317 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.597 ' O ' ' HB3' ' A' ' 124' ' ' ASP . 46.7 m-85 -168.67 108.86 0.5 Allowed 'General case' 0 C--O 1.188 -2.171 0 N-CA-C 102.752 -3.055 . . . . 0.0 102.752 170.942 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.418 ' HE1' ' O ' ' A' ' 122' ' ' LYS . 68.1 m-70 -149.95 85.57 1.42 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 120.881 1.673 . . . . 0.0 107.969 -175.573 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.478 ' HB ' ' C ' ' A' ' 82' ' ' GLY . 48.8 t -162.53 161.11 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 105.052 -2.203 . . . . 0.0 105.052 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.5 ' CG ' ' HA ' ' A' ' 60' ' ' ALA . 62.6 t-80 -153.46 148.41 26.62 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 168.266 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.415 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 0.4 OUTLIER -109.48 124.13 50.54 Favored 'General case' 0 C--N 1.257 -3.451 0 C-N-CA 124.196 0.998 . . . . 0.0 112.133 -177.764 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.415 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 11.8 t80 174.4 -50.98 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 124.864 1.266 . . . . 0.0 109.395 174.959 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.59 ' HA2' ' N ' ' A' ' 115' ' ' ARG . . . 95.04 109.8 2.32 Favored Glycine 0 CA--C 1.496 -1.123 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.305 -177.279 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -132.68 -73.09 0.51 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 117.707 -1.597 . . . . 0.0 112.878 -174.264 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.475 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 37.5 t-20 -161.95 152.18 17.02 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -179.246 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.7 m -71.73 -34.27 69.4 Favored 'General case' 0 C--O 1.208 -1.095 0 CA-C-O 121.135 0.493 . . . . 0.0 110.298 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.22 -12.72 27.63 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 120.75 -0.38 . . . . 0.0 111.956 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.475 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -154.24 111.26 0.48 Allowed Glycine 0 CA--C 1.468 -2.866 0 C-N-CA 119.077 -1.535 . . . . 0.0 110.046 -174.876 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.442 ' HB2' ' HB2' ' A' ' 60' ' ' ALA . 26.2 p -98.28 88.47 4.18 Favored 'General case' 0 N--CA 1.4 -2.949 0 CA-C-O 121.65 0.738 . . . . 0.0 110.851 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.0 m -79.26 -46.29 18.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.708 0.766 . . . . 0.0 110.14 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.5 m -63.71 -24.95 67.99 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.402 178.625 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.536 ' HB2' ' HB ' ' A' ' 116' ' ' THR . . . -75.49 -9.23 58.39 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 176.329 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.99 -160.49 0.78 Allowed Glycine 0 C--N 1.311 -0.854 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.97 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -74.37 54.08 3.23 Favored 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 122.74 2.293 . . . . 0.0 110.223 177.659 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -133.23 109.46 9.44 Favored 'General case' 0 N--CA 1.424 -1.751 0 N-CA-C 103.48 -2.785 . . . . 0.0 103.48 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.489 ' CD2' ' HB3' ' A' ' 69' ' ' ARG . 54.7 m-85 -123.77 162.06 23.93 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-O 122.06 0.934 . . . . 0.0 113.12 -174.218 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -104.56 143.3 26.41 Favored Pre-proline 0 N--CA 1.42 -1.956 0 N-CA-C 103.859 -2.645 . . . . 0.0 103.859 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -48.18 -55.31 4.16 Favored 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.98 2.453 . . . . 0.0 116.832 -168.297 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 95.2 mt -90.12 -4.97 57.0 Favored 'General case' 0 CA--C 1.478 -1.81 0 C-N-CA 119.142 -1.023 . . . . 0.0 108.885 -172.44 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.577 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 21.4 m -86.52 7.98 23.86 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.188 -1.369 . . . . 0.0 109.733 178.091 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.489 ' HB3' ' CD2' ' A' ' 64' ' ' PHE . 4.4 ppt_? -134.04 -30.15 1.23 Allowed 'General case' 0 N--CA 1.402 -2.832 0 CA-C-O 117.734 -1.127 . . . . 0.0 110.313 167.398 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.477 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 85.1 tttt 34.54 -86.04 0.0 OUTLIER 'General case' 0 C--N 1.389 2.286 0 C-N-CA 125.386 1.474 . . . . 0.0 110.968 -173.534 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.488 ' O ' ' HA2' ' A' ' 127' ' ' GLY . 55.0 t-80 -131.32 -38.75 1.18 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 172.638 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.0 119.58 3.05 Favored Glycine 0 N--CA 1.425 -2.059 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -170.511 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.3 144.11 11.51 Favored Glycine 0 N--CA 1.419 -2.454 0 C-N-CA 118.612 -1.756 . . . . 0.0 113.041 -174.695 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.453 ' O ' ' HB3' ' A' ' 101' ' ' ASP . 59.1 Cg_endo -74.84 -19.16 18.53 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.3 2.0 . . . . 0.0 112.99 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.537 ' O ' ' HA ' ' A' ' 101' ' ' ASP . 51.1 mtmt -120.62 -13.97 8.68 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -175.633 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -172.18 126.25 0.55 Allowed 'General case' 0 CA--C 1.493 -1.231 0 CA-C-N 119.593 1.088 . . . . 0.0 109.649 -173.837 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 2.9 mm-40 -138.31 171.16 14.79 Favored 'General case' 0 N--CA 1.416 -2.16 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.084 178.92 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -100.13 -74.82 0.59 Allowed 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.57 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.577 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.1 OUTLIER -130.2 26.3 5.16 Favored 'General case' 0 CA--C 1.47 -2.107 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -170.579 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 7.6 t60 -114.01 102.45 10.2 Favored 'General case' 0 N--CA 1.396 -3.155 0 CA-C-N 111.96 -2.382 . . . . 0.0 106.102 177.042 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -101.13 7.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 178.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.478 ' C ' ' HB ' ' A' ' 47' ' ' VAL . . . -79.41 11.03 33.36 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-N 113.455 -1.702 . . . . 0.0 114.047 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -112.17 169.96 8.5 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.824 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -167.64 170.63 10.89 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 123.948 0.899 . . . . 0.0 109.818 177.642 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.42 153.96 35.07 Favored Glycine 0 CA--C 1.5 -0.851 0 O-C-N 124.194 0.933 . . . . 0.0 111.287 178.0 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -76.66 146.1 38.35 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.992 -171.874 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.583 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 17.1 m -136.9 146.26 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.558 ' HA ' ' OE1' ' A' ' 121' ' ' GLU . 7.4 t -141.62 109.57 5.79 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 174.9 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.461 ' HB2' ' HA2' ' A' ' 93' ' ' GLY . . . -118.07 105.78 12.21 Favored 'General case' 0 CA--C 1.47 -2.113 0 N-CA-C 104.814 -2.291 . . . . 0.0 104.814 174.157 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.534 ' HA ' ' N ' ' A' ' 41' ' ' GLY . 39.2 p30 -112.85 -77.52 0.58 Allowed 'General case' 0 C--O 1.172 -2.983 0 N-CA-C 114.793 1.405 . . . . 0.0 114.793 -164.781 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.425 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 87.8 tttt -83.71 -14.72 51.0 Favored 'General case' 1 C--N 1.212 -5.377 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -178.856 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -144.54 134.66 24.11 Favored 'General case' 0 N--CA 1.418 -2.037 0 N-CA-C 106.198 -1.778 . . . . 0.0 106.198 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.695 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.54 71.8 2.94 Favored Glycine 0 N--CA 1.417 -2.616 0 CA-C-O 119.279 -0.734 . . . . 0.0 111.549 -175.865 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.68 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 59.0 t -153.61 105.54 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.417 ' H ' ' HB ' ' A' ' 35' ' ' ILE . . . -113.11 144.48 42.57 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.463 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.33 137.27 38.99 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.987 -1.856 . . . . 0.0 105.987 175.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 8.0 p -101.74 140.32 20.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.118 0.485 . . . . 0.0 110.164 -179.006 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.6 m -122.47 101.58 7.57 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.45 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.494 HD11 ' H ' ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.42 118.74 54.66 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.311 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -177.415 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -148.8 97.49 2.72 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.011 -2.218 . . . . 0.0 105.011 166.859 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.537 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 1.1 p30 -168.02 168.19 12.11 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.339 -169.02 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 15.6 m -99.95 80.0 2.26 Favored 'General case' 0 N--CA 1.42 -1.94 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.956 168.811 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.556 ' C ' ' H ' ' A' ' 105' ' ' SER . 49.9 t -101.18 -11.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 123.859 0.864 . . . . 0.0 109.442 173.06 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.469 ' HB ' ' H ' ' A' ' 23' ' ' LYS . 0.2 OUTLIER -63.82 21.32 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.889 0 C-N-CA 124.777 1.231 . . . . 0.0 112.641 176.957 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.556 ' H ' ' C ' ' A' ' 103' ' ' VAL . 16.0 m -68.74 130.22 42.19 Favored 'General case' 0 N--CA 1.4 -2.944 0 C-N-CA 125.271 1.428 . . . . 0.0 110.148 179.096 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.03 173.11 3.21 Favored 'General case' 0 N--CA 1.387 -3.583 0 CA-C-N 112.953 -1.931 . . . . 0.0 107.004 172.201 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.5 p -64.93 116.18 6.12 Favored 'General case' 2 N--CA 1.363 -4.787 0 CA-C-O 123.58 1.657 . . . . 0.0 111.592 -165.07 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.57 -142.32 12.82 Favored Glycine 2 CA--C 1.425 -5.546 0 CA-C-N 110.363 -3.108 . . . . 0.0 105.343 174.82 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 4.7 p-10 40.11 -151.47 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 175.153 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -89.55 -23.81 21.91 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.158 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -131.51 -153.31 0.55 Allowed 'General case' 0 N--CA 1.41 -2.465 0 CA-C-O 122.009 0.909 . . . . 0.0 110.348 -175.315 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 59.0 mt -126.51 -38.2 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 N-CA-C 104.28 -2.489 . . . . 0.0 104.28 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.9 pt -91.08 99.05 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.834 0 CA-C-N 113.155 -1.839 . . . . 0.0 107.055 173.281 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -97.68 63.7 0.92 Allowed Glycine 2 N--CA 1.375 -5.392 0 N-CA-C 105.023 -3.231 . . . . 0.0 105.023 -175.743 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.59 ' N ' ' HA2' ' A' ' 51' ' ' GLY . 31.7 mtp180 -68.24 81.8 0.24 Allowed 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 -176.983 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.536 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 0.7 OUTLIER -163.3 97.12 0.89 Allowed 'General case' 1 N--CA 1.367 -4.592 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 -179.166 . . . . . . . . 4 4 . 1 . 007 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 16.2 mt -103.61 106.49 17.01 Favored 'General case' 0 C--N 1.251 -3.696 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.963 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 8.2 m -92.2 98.05 7.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 C-N-CA 117.394 -1.722 . . . . 0.0 109.384 169.736 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.2 t -135.51 136.21 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 122.724 1.249 . . . . 0.0 112.587 -174.2 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.493 ' HA ' ' HB3' ' A' ' 13' ' ' PRO . 0.4 OUTLIER -170.77 134.71 1.05 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 168.053 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.558 ' OE1' ' HA ' ' A' ' 88' ' ' THR . 1.9 mm-40 -69.63 99.74 1.35 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 122.153 0.978 . . . . 0.0 110.632 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.432 ' HA ' HD22 ' A' ' 42' ' ' LEU . 68.0 mttm -170.73 170.4 6.62 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 -170.505 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.63 104.13 3.24 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.597 ' HB3' ' O ' ' A' ' 45' ' ' PHE . 7.2 t70 -107.47 6.69 28.39 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.419 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -42.48 105.91 0.05 Allowed 'General case' 0 C--O 1.245 0.832 0 C-N-CA 126.882 2.073 . . . . 0.0 112.61 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -71.07 -39.93 71.92 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.574 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.488 ' HA2' ' O ' ' A' ' 71' ' ' HIS . . . -89.42 24.21 15.25 Favored Glycine 0 CA--C 1.482 -2.023 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.562 -177.208 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -136.59 -47.32 0.62 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.527 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 65.25 -78.34 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.777 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.363 -174.873 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 156.8 -38.05 0.57 Allowed Glycine 0 N--CA 1.417 -2.571 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.652 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 59.4 t30 -152.66 -178.91 7.16 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -54.02 -34.46 60.01 Favored 'General case' 0 C--N 1.368 1.384 0 N-CA-C 114.169 1.174 . . . . 0.0 114.169 -177.968 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.652 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -85.29 -38.14 19.2 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.305 0.574 . . . . 0.0 111.57 -174.568 . . . . . . . . 3 3 . 1 . 007 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.4 p -76.77 -20.78 56.06 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -81.54 -7.75 59.63 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.878 0.847 . . . . 0.0 109.642 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 86.5 tttt -85.81 -49.18 8.11 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.085 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 5.0 p -68.1 -37.42 81.15 Favored 'General case' 0 N--CA 1.417 -2.101 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.014 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.73 94.81 0.06 OUTLIER Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -32.54 123.62 0.34 Allowed 'General case' 1 C--O 1.336 5.619 0 CA-C-O 123.609 1.671 . . . . 0.0 114.049 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -140.74 120.66 13.58 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.85 -176.548 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -97.33 72.66 0.69 Allowed Glycine 0 C--O 1.214 -1.122 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.415 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 5.2 p -88.83 5.99 41.11 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -172.518 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 57.0 ttt-85 -118.26 -47.92 2.54 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.74 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.413 ' HG ' ' HD3' ' A' ' 13' ' ' PRO . 11.9 tp -60.34 -38.95 85.39 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 114.957 -1.02 . . . . 0.0 113.59 -167.737 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 129.96 7.13 Favored 'General case' 0 CA--C 1.481 -1.675 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.472 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 81.4 m -138.25 163.21 32.34 Favored 'General case' 0 C--N 1.291 -1.977 0 O-C-N 124.421 1.076 . . . . 0.0 108.856 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.651 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.7 170.23 43.34 Favored Glycine 0 N--CA 1.408 -3.188 0 O-C-N 123.887 0.742 . . . . 0.0 111.489 175.602 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.484 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 69.5 t -69.49 117.73 12.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 C-N-CA 124.148 0.979 . . . . 0.0 110.549 168.408 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.473 ' H ' ' HA ' ' A' ' 115' ' ' ARG . 15.7 tt -122.65 108.0 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 CA-C-O 122.229 1.014 . . . . 0.0 108.729 166.391 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.49 46.23 Favored Glycine 1 CA--C 1.442 -4.479 0 N-CA-C 108.262 -1.935 . . . . 0.0 108.262 178.663 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.478 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 8.7 tt -69.23 103.91 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 177.186 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.412 ' HB1' ' HB ' ' A' ' 5' ' ' VAL . . . -110.27 97.12 6.66 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.386 -1.326 . . . . 0.0 110.936 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.324 -0.536 0 O-C-N 125.942 2.026 . . . . 0.0 114.489 171.157 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.811 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.647 ' O ' ' HA ' ' A' ' 21' ' ' GLU . 28.5 p -109.6 -65.24 1.17 Allowed 'General case' 0 C--O 1.161 -3.585 0 CA-C-O 119.147 -0.454 . . . . 0.0 111.569 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.2 ptpp? -135.49 171.03 15.02 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.894 0.378 . . . . 0.0 110.684 -168.427 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.734 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -137.19 166.82 22.83 Favored 'General case' 0 N--CA 1.419 -2.021 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -177.949 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 27.2 m -128.89 168.39 22.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 178.642 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.433 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -132.66 137.97 47.16 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.469 -173.06 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.7 t -134.28 108.55 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 84.7 mt -96.71 150.17 20.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -178.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -149.15 122.79 9.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.93 24.66 Favored Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.134 -1.507 . . . . 0.0 113.012 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . 0.419 ' O ' ' HD3' ' A' ' 13' ' ' PRO . 46.3 m-20 -66.24 -50.5 63.56 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 175.654 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.91 96.9 1.7 Allowed Glycine 0 N--CA 1.432 -1.594 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . 0.419 ' HD3' ' O ' ' A' ' 11' ' ' ASP . 32.2 Cg_exo -57.08 127.41 25.64 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.607 2.204 . . . . 0.0 113.563 -173.329 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 11.4 m -120.58 113.02 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.804 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.597 175.128 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 mp0 -108.5 119.53 39.79 Favored 'General case' 0 C--N 1.294 -1.805 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.112 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.442 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.72 170.13 42.9 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 176.153 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.413 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 24.8 pt -129.4 125.4 61.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.433 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.7 mp -123.33 128.4 74.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -178.545 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.734 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 18.5 m120 -100.05 134.89 42.31 Favored 'General case' 0 CA--C 1.507 -0.701 0 CA-C-O 119.306 -0.378 . . . . 0.0 110.662 -177.848 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -127.75 119.6 26.11 Favored 'General case' 0 CA--C 1.503 -0.852 0 C-N-CA 118.613 -1.235 . . . . 0.0 113.585 175.271 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.647 ' HA ' ' O ' ' A' ' 2' ' ' THR . 58.3 mt-10 -90.22 143.9 26.35 Favored 'General case' 0 N--CA 1.425 -1.719 0 CA-C-N 114.372 -1.285 . . . . 0.0 112.734 177.872 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.502 ' O ' ' HG3' ' A' ' 22' ' ' GLN . 3.9 pt20 -103.11 124.9 49.43 Favored 'General case' 1 N--CA 1.375 -4.176 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 163.596 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -111.45 83.59 1.8 Allowed 'General case' 0 C--N 1.273 -2.733 0 C-N-CA 119.264 -0.974 . . . . 0.0 108.578 169.739 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -69.47 -27.95 65.66 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.102 -1.408 . . . . 0.0 108.736 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -71.21 -8.65 54.99 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.36 -1.291 . . . . 0.0 110.087 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.2 t30 75.88 120.44 0.05 OUTLIER 'General case' 0 C--N 1.35 0.626 0 C-N-CA 126.323 1.849 . . . . 0.0 111.195 -177.444 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.69 165.55 29.88 Favored Glycine 0 N--CA 1.408 -3.183 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.7 Cg_endo -66.28 135.53 40.27 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.12 1.88 . . . . 0.0 110.692 178.46 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.436 HG21 ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -73.6 135.36 27.75 Favored 'Isoleucine or valine' 0 C--O 1.268 2.033 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.445 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -101.75 124.16 46.93 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 173.737 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.404 ' O ' HG21 ' A' ' 99' ' ' ILE . 16.5 m -137.99 152.82 26.55 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -172.57 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.6 t-105 -156.56 132.49 9.69 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.466 ' C ' HG11 ' A' ' 97' ' ' VAL . . . -170.63 135.84 3.69 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.545 -2.264 . . . . 0.0 112.61 169.684 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.442 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 5.4 p -117.8 137.09 52.98 Favored 'General case' 0 N--CA 1.395 -3.18 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 47.6 pt -131.87 146.27 33.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.052 -1.059 . . . . 0.0 110.093 175.274 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.463 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -119.23 129.61 55.03 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 176.225 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.52 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -135.15 174.3 21.24 Favored Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -173.515 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.81 173.53 5.19 Favored 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 123.73 0.812 . . . . 0.0 110.81 178.434 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.493 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 9.8 t -66.37 110.63 3.16 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-O 121.627 0.727 . . . . 0.0 111.657 -172.038 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . 0.267 4.6 mm-40 -165.61 177.34 7.41 Favored 'General case' 0 N--CA 1.398 -3.071 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.251 -176.647 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.43 -146.49 0.01 OUTLIER Glycine 0 N--CA 1.403 -3.501 0 CA-C-N 112.021 -2.354 . . . . 0.0 115.417 -177.953 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.535 ' CB ' ' HA ' ' A' ' 88' ' ' THR . 2.0 pt? -173.06 100.14 0.13 Allowed 'General case' 1 N--CA 1.372 -4.326 0 O-C-N 121.592 -0.946 . . . . 0.0 109.343 -161.214 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.444 ' HB3' ' HA ' ' A' ' 123' ' ' ALA . 0.4 OUTLIER 169.85 171.33 0.05 Allowed 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 103.963 -2.606 . . . . 0.0 103.963 177.43 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.491 ' HA2' ' N ' ' A' ' 125' ' ' ASP . . . 102.65 64.72 0.73 Allowed Glycine 0 C--N 1.268 -3.197 0 N-CA-C 116.248 1.259 . . . . 0.0 116.248 171.707 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 84' ' ' LEU . 12.8 t80 -76.72 134.85 39.09 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 117.336 -1.746 . . . . 0.0 110.07 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.46 ' HB2' ' HG ' ' A' ' 117' ' ' LEU . 1.4 p-80 -85.91 100.61 12.22 Favored 'General case' 0 C--N 1.263 -3.175 0 CA-C-N 112.848 -1.978 . . . . 0.0 115.086 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.476 ' HB ' ' HA2' ' A' ' 82' ' ' GLY . 31.2 t -129.58 89.79 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.497 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 171.569 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.718 ' ND1' ' HB1' ' A' ' 60' ' ' ALA . 1.7 t60 -107.27 107.29 18.15 Favored 'General case' 0 C--O 1.184 -2.393 0 N-CA-C 113.323 0.861 . . . . 0.0 113.323 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.401 ' OE1' HG12 ' A' ' 47' ' ' VAL . 3.6 mp0 -90.07 136.21 33.18 Favored 'General case' 0 C--N 1.267 -2.989 0 O-C-N 120.687 -1.258 . . . . 0.0 112.665 175.202 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 t80 70.67 93.59 0.08 Allowed 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 125.968 1.707 . . . . 0.0 111.359 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.29 -91.14 1.15 Allowed Glycine 0 CA--C 1.482 -2.006 0 C-N-CA 119.066 -1.54 . . . . 0.0 113.543 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.2 t70 76.89 -25.87 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 126.996 2.118 . . . . 0.0 112.583 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.427 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 2.6 m-20 -90.35 98.84 12.01 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.449 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.435 ' HA ' HG12 ' A' ' 148' ' ' VAL . 11.4 t -56.55 -32.07 64.8 Favored 'General case' 0 C--O 1.199 -1.561 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -173.441 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.74 13.07 33.82 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.606 -0.683 . . . . 0.0 110.808 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.427 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -155.75 111.46 0.49 Allowed Glycine 0 N--CA 1.425 -2.095 0 C-N-CA 117.849 -2.119 . . . . 0.0 113.667 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.437 ' O ' ' HB3' ' A' ' 142' ' ' SER . 69.5 m -94.57 85.14 4.43 Favored 'General case' 0 N--CA 1.392 -3.36 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 172.643 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.9 m -82.31 -48.36 11.28 Favored 'General case' 0 N--CA 1.418 -2.061 0 CA-C-N 114.794 -1.093 . . . . 0.0 109.156 179.083 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.6 p -71.57 -54.91 8.94 Favored 'General case' 0 N--CA 1.407 -2.624 0 CA-C-N 113.361 -1.745 . . . . 0.0 113.792 -172.433 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.718 ' HB1' ' ND1' ' A' ' 48' ' ' HIS 0.325 . . -85.81 -2.34 58.13 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 179.657 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.404 ' C ' ' H ' ' A' ' 63' ' ' HIS . . . -43.5 -139.31 0.0 OUTLIER Glycine 0 CA--C 1.57 3.509 0 C-N-CA 124.186 0.898 . . . . 0.0 113.993 171.054 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -60.1 5.32 0.13 Allowed 'Trans proline' 0 CA--C 1.574 2.494 0 C-N-CA 122.706 2.271 . . . . 0.0 114.879 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.404 ' H ' ' C ' ' A' ' 61' ' ' GLY . 16.0 m170 -116.58 110.8 19.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 123.467 0.707 . . . . 0.0 109.838 178.784 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -74.48 152.51 39.4 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.648 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -115.77 144.35 32.45 Favored Pre-proline 0 C--N 1.309 -1.162 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.74 177.025 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -72.22 -13.11 28.23 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.239 1.959 . . . . 0.0 111.747 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.514 ' CB ' ' HB2' ' A' ' 109' ' ' ASP . 2.6 mm? -80.96 -9.47 59.83 Favored 'General case' 0 CA--C 1.484 -1.568 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -78.95 66.03 4.3 Favored 'General case' 0 N--CA 1.405 -2.706 0 CA-C-O 123.538 1.637 . . . . 0.0 108.719 172.943 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.521 ' CB ' ' HA ' ' A' ' 78' ' ' GLU . 12.5 ptp180 -117.49 23.27 11.88 Favored 'General case' 0 N--CA 1.397 -3.104 0 CA-C-N 112.204 -2.271 . . . . 0.0 105.149 175.007 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.9 mmmt -78.91 18.63 0.59 Allowed 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 112.363 -2.199 . . . . 0.0 111.005 176.331 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.492 ' H ' ' C ' ' A' ' 69' ' ' ARG . 33.6 t-80 75.3 87.59 0.09 Allowed 'General case' 0 N--CA 1.423 -1.805 0 O-C-N 125.135 1.522 . . . . 0.0 112.018 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.679 ' HA2' ' O ' ' A' ' 83' ' ' ASP . . . -76.75 -98.4 0.17 Allowed Glycine 1 N--CA 1.385 -4.738 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 169.492 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.442 ' C ' ' H ' ' A' ' 75' ' ' LYS . . . -50.33 158.0 1.88 Allowed Glycine 0 N--CA 1.429 -1.827 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 172.828 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -62.14 0.09 1.47 Allowed 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 124.678 3.585 . . . . 0.0 114.454 -172.071 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.442 ' H ' ' C ' ' A' ' 73' ' ' GLY . 64.0 pttt -120.39 13.67 11.89 Favored 'General case' 0 C--N 1.289 -2.049 0 C-N-CA 123.047 0.539 . . . . 0.0 110.127 -175.059 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.466 ' HA ' ' HA ' ' A' ' 71' ' ' HIS . 3.0 m-20 71.98 76.38 0.16 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.502 177.185 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -78.97 87.19 4.79 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.723 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.521 ' HA ' ' CB ' ' A' ' 69' ' ' ARG . 11.6 pt-20 -57.56 26.34 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 128.704 2.801 . . . . 0.0 115.942 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -160.16 -0.56 0.07 Allowed 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.385 -174.152 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.8 m170 -105.16 136.16 45.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.563 -0.711 . . . . 0.0 111.451 -173.703 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.404 ' O ' HG12 ' A' ' 81' ' ' VAL . 11.1 p -98.49 70.48 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.267 2.024 0 CA-C-O 123.138 1.447 . . . . 0.0 113.722 -178.598 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.539 ' O ' ' HA ' ' A' ' 125' ' ' ASP . . . 115.93 86.4 1.29 Allowed Glycine 0 CA--C 1.468 -2.869 0 C-N-CA 117.924 -2.084 . . . . 0.0 114.217 172.663 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.679 ' O ' ' HA2' ' A' ' 72' ' ' GLY . 7.7 p-10 -164.53 140.59 6.0 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 124.102 0.961 . . . . 0.0 108.95 176.724 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.602 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 7.5 tt -174.94 177.18 2.03 Favored 'General case' 0 C--N 1.278 -2.504 0 N-CA-C 102.597 -3.112 . . . . 0.0 102.597 177.868 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.512 ' N ' HD22 ' A' ' 84' ' ' LEU . . . -39.74 156.43 0.03 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 119.106 0.867 . . . . 0.0 111.486 173.451 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.48 160.52 19.68 Favored 'General case' 0 C--N 1.282 -2.351 0 O-C-N 122.377 -0.484 . . . . 0.0 112.105 -158.293 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 77.5 t -108.39 163.42 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.912 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -174.76 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.535 ' HA ' ' CB ' ' A' ' 42' ' ' LEU . 31.5 m -140.33 130.51 25.0 Favored 'General case' 0 C--N 1.261 -3.28 0 C-N-CA 124.437 1.095 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.523 ' CB ' ' HB3' ' A' ' 121' ' ' GLU . . . -126.12 155.16 42.08 Favored 'General case' 0 C--N 1.254 -3.583 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 174.223 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.41 ' C ' ' HA ' ' A' ' 39' ' ' THR . 23.9 t70 -158.36 174.96 14.34 Favored 'General case' 1 C--N 1.239 -4.232 0 N-CA-C 104.126 -2.546 . . . . 0.0 104.126 178.462 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.493 ' N ' ' HA ' ' A' ' 39' ' ' THR . 59.8 pttt -47.27 -35.85 8.32 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 176.353 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -90.28 -38.64 13.26 Favored 'General case' 0 CA--C 1.486 -1.503 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 176.431 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.52 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 89.54 112.85 1.38 Allowed Glycine 0 N--CA 1.404 -3.479 0 CA-C-N 114.675 -1.148 . . . . 0.0 112.308 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.452 ' O ' ' HB ' ' A' ' 88' ' ' THR . 6.7 p -157.71 103.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.417 -2.101 0 CA-C-O 121.953 0.883 . . . . 0.0 109.876 174.715 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -94.23 129.0 41.02 Favored 'General case' 0 N--CA 1.414 -2.228 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.713 173.224 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -69.57 143.38 53.37 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 114.378 -1.283 . . . . 0.0 109.406 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.466 HG11 ' C ' ' A' ' 33' ' ' GLY . 34.4 m -79.57 103.37 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.908 0 CA-C-O 123.855 1.788 . . . . 0.0 107.813 -177.488 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -86.77 107.39 18.24 Favored 'General case' 0 N--CA 1.401 -2.9 0 CA-C-N 113.059 -1.882 . . . . 0.0 111.083 -174.171 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.404 HG21 ' O ' ' A' ' 31' ' ' VAL . 37.5 pt -95.66 124.83 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.513 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.718 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -143.64 126.31 16.03 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.3 p30 -81.09 135.62 35.83 Favored 'General case' 0 C--O 1.276 2.45 0 CA-C-O 122.433 1.111 . . . . 0.0 112.601 -178.453 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.423 ' OG ' ' HB ' ' A' ' 29' ' ' VAL . 92.5 p -102.92 172.2 6.96 Favored 'General case' 0 N--CA 1.413 -2.3 0 CA-C-N 112.846 -1.979 . . . . 0.0 110.608 177.678 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.431 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 7.1 p -115.88 -53.1 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.329 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 163.295 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 12.8 pt -98.93 23.67 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.045 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -170.647 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.8 t -80.34 89.88 5.56 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 123.061 1.41 . . . . 0.0 108.721 169.557 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.461 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 3.0 pp -126.72 170.39 12.18 Favored 'General case' 2 N--CA 1.346 -5.643 1 N-CA-C 99.272 -4.344 . . . . 0.0 99.272 174.558 . . . . . . . . 4 3 . 1 . 008 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.1 m -74.13 93.37 2.28 Favored 'General case' 1 C--N 1.213 -5.327 0 C-N-CA 118.727 -1.189 . . . . 0.0 111.978 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.81 135.43 12.43 Favored Glycine 0 CA--C 1.456 -3.651 0 N-CA-C 106.308 -2.717 . . . . 0.0 106.308 175.332 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.514 ' HB2' ' CB ' ' A' ' 67' ' ' LEU . 6.1 t70 54.09 -153.78 0.28 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -171.434 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.534 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 62.6 m-70 -90.37 37.11 0.89 Allowed 'General case' 0 C--N 1.276 -2.602 0 C-N-CA 124.78 1.232 . . . . 0.0 109.777 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.408 ' HA ' ' HD3' ' A' ' 115' ' ' ARG . 16.6 p -59.41 -27.14 65.74 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.667 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 46.1 pt -104.6 -32.94 2.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 C-N-CA 118.2 -1.4 . . . . 0.0 110.62 176.225 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.534 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 14.0 tt -104.09 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 120.135 -0.626 . . . . 0.0 112.684 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.76 17.89 53.02 Favored Glycine 0 N--CA 1.44 -1.065 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.895 175.111 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.543 ' HG3' ' O ' ' A' ' 48' ' ' HIS . 23.7 ttp180 -73.4 101.73 3.56 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 122.268 -0.548 . . . . 0.0 111.233 178.664 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.504 ' CG2' ' HB3' ' A' ' 146' ' ' CYS . 4.2 m -70.9 110.85 5.88 Favored 'General case' 0 C--O 1.181 -2.519 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 176.966 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.489 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 13.2 tp -70.03 123.87 22.64 Favored 'General case' 0 C--N 1.275 -2.673 0 C-N-CA 122.731 0.412 . . . . 0.0 111.346 -172.31 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.465 HG11 ' HD1' ' A' ' 48' ' ' HIS . 11.4 m -91.88 101.03 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 178.018 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.479 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 10.3 p -140.52 168.66 16.61 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 176.931 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.543 ' CD2' ' HB2' ' A' ' 124' ' ' ASP . 0.3 OUTLIER -171.2 164.23 7.25 Favored 'General case' 0 CA--C 1.487 -1.456 0 N-CA-C 104.214 -2.513 . . . . 0.0 104.214 173.871 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.585 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 2.2 mp0 -86.9 84.17 7.39 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.585 ' HG2' ' O ' ' A' ' 121' ' ' GLU . 2.2 mmpt? -176.0 171.53 2.57 Favored 'General case' 0 CA--C 1.476 -1.903 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 -175.314 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.444 ' HA ' ' HB3' ' A' ' 43' ' ' HIS . . . -62.42 122.41 15.65 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 170.063 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.647 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 19.6 t70 -128.74 -12.83 4.79 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.943 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.539 ' HA ' ' O ' ' A' ' 82' ' ' GLY . 0.6 OUTLIER -71.56 137.28 47.92 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.268 -174.881 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -79.2 -68.19 0.68 Allowed 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.334 -178.268 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.436 ' H ' ' CG ' ' A' ' 83' ' ' ASP . . . -74.04 9.83 8.61 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 119.982 -1.104 . . . . 0.0 114.962 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 32.2 tptt -137.43 15.29 2.97 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.769 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.8 42.94 1.85 Allowed Glycine 0 N--CA 1.473 1.135 0 N-CA-C 118.736 2.254 . . . . 0.0 118.736 -166.709 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 74.18 -91.38 0.72 Allowed Glycine 0 C--N 1.3 -1.431 0 N-CA-C 116.735 1.454 . . . . 0.0 116.735 171.239 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -100.33 158.32 15.97 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 118.595 -0.717 . . . . 0.0 110.484 -169.468 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -47.37 -42.48 21.77 Favored 'General case' 0 C--N 1.363 1.172 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 -178.06 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -79.87 -43.66 21.87 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.91 0.386 . . . . 0.0 110.958 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.7 t -70.64 -20.87 62.68 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.369 0.668 . . . . 0.0 111.878 -173.364 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -82.32 -18.23 42.97 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.031 0.443 . . . . 0.0 110.356 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 44.5 mtpt -101.77 -28.22 12.58 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.54 -1.264 . . . . 0.0 110.071 -178.116 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.9 p -74.45 -47.85 31.05 Favored 'General case' 0 N--CA 1.408 -2.527 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 173.092 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.16 94.06 0.13 Allowed Glycine 0 N--CA 1.417 -2.614 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.647 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 46.2 t-20 -55.81 106.03 0.23 Allowed 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 176.952 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.6 56.17 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -172.746 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.47 101.21 2.74 Favored Glycine 0 N--CA 1.428 -1.868 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.437 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 15.2 m -89.52 -7.1 55.65 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -171.504 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -145.19 -11.39 0.55 Allowed 'General case' 0 C--N 1.247 -3.859 0 C-N-CA 118.203 -1.399 . . . . 0.0 110.297 172.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -54.89 -42.96 72.74 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -175.668 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.479 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -149.82 89.88 1.65 Allowed 'General case' 0 N--CA 1.397 -3.122 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.504 ' HB3' ' CG2' ' A' ' 116' ' ' THR . 32.3 m -126.72 150.71 48.9 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 113.938 -1.483 . . . . 0.0 107.897 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.95 139.64 5.55 Favored Glycine 0 C--N 1.291 -1.957 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 178.401 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.435 HG12 ' HA ' ' A' ' 54' ' ' THR . 17.2 m -73.59 110.4 7.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 118.69 1.245 . . . . 0.0 111.705 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.431 ' CG2' ' HB2' ' A' ' 117' ' ' LEU . 1.4 pp -86.67 145.75 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.227 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.667 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -150.14 142.61 9.83 Favored Glycine 2 N--CA 1.382 -4.96 0 C-N-CA 117.619 -2.229 . . . . 0.0 112.395 -171.409 . . . . . . . . 3 3 . 1 . 008 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.535 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 3.4 tt -53.16 103.79 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 CA-C-O 122.088 0.947 . . . . 0.0 109.841 167.699 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.1 154.73 38.6 Favored 'General case' 0 N--CA 1.41 -2.436 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 174.494 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 . . . . . 0 C--N 1.273 -2.72 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 177.608 . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.05 0 N-CA-C 111.379 0.14 . . . . 0.0 111.379 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.58 ' C ' ' HG3' ' A' ' 21' ' ' GLU . 30.1 m -119.33 -54.06 2.21 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.492 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 22.6 pttp -145.5 152.57 39.97 Favored 'General case' 0 N--CA 1.417 -2.122 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.632 -169.749 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.558 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.19 161.03 38.84 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 65.7 t -131.25 122.52 51.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.815 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -115.33 127.82 55.68 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.503 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.587 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.5 m -113.29 144.75 20.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 O-C-N 123.433 0.458 . . . . 0.0 110.554 -178.634 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 95.4 mt -127.09 135.05 50.22 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.641 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -141.04 125.86 18.06 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . 0.412 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -154.31 178.45 31.13 Favored Glycine 0 N--CA 1.432 -1.597 0 C-N-CA 118.931 -1.604 . . . . 0.0 113.338 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -73.0 -40.4 65.23 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.982 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.56 95.57 1.45 Allowed Glycine 0 N--CA 1.434 -1.443 0 N-CA-C 106.159 -2.776 . . . . 0.0 106.159 170.484 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.75 127.56 14.77 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.895 1.73 . . . . 0.0 115.2 -169.345 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.51 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 14.0 m -123.78 114.98 43.75 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.186 0 N-CA-C 104.751 -2.314 . . . . 0.0 104.751 172.986 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.24 118.29 32.87 Favored 'General case' 0 C--N 1.279 -2.485 0 C-N-CA 118.309 -1.356 . . . . 0.0 109.542 -173.979 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.58 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.72 171.56 44.15 Favored Glycine 0 N--CA 1.412 -2.965 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.887 178.405 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.2 pt -133.46 124.58 48.79 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 2.4 mp -114.11 140.04 36.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.672 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.485 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 35.9 m-80 -99.24 150.41 22.11 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.736 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.558 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 98.2 m-85 -149.39 117.29 6.29 Favored 'General case' 0 CA--C 1.491 -1.3 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 175.501 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.58 ' HG3' ' C ' ' A' ' 2' ' ' THR . 4.6 mm-40 -134.39 144.12 48.01 Favored 'General case' 0 CA--C 1.477 -1.839 0 C-N-CA 118.627 -1.229 . . . . 0.0 112.578 173.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.492 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 25.3 tp60 -127.71 152.36 47.82 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.408 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.8 tttt -106.56 104.73 14.49 Favored 'General case' 0 C--N 1.26 -3.306 0 N-CA-C 100.511 -3.885 . . . . 0.0 100.511 169.386 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.318 9.9 pt-20 -63.27 -9.25 10.85 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -168.044 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.5 p -76.45 -61.09 2.07 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 170.49 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 175.57 136.55 0.05 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 126.447 1.899 . . . . 0.0 106.688 174.304 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.87 95.37 0.12 Allowed Glycine 1 CA--C 1.444 -4.36 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . 0.57 ' HB3' ' N ' ' A' ' 101' ' ' ASP . 38.4 Cg_exo -62.75 123.44 12.32 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 C-N-CA 121.686 1.591 . . . . 0.0 109.179 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.558 ' HB ' ' O ' ' A' ' 21' ' ' GLU . 77.8 t -88.75 148.19 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.98 0 N-CA-C 103.892 -2.632 . . . . 0.0 103.892 171.985 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.406 ' HD2' ' N ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -99.62 109.33 21.83 Favored 'General case' 1 C--N 1.242 -4.072 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -167.16 . . . . . . . . 4 4 . 1 . 009 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.485 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 16.1 m -124.53 152.44 30.52 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.089 -169.594 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 49.3 p90 -134.64 154.04 51.7 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-N 114.97 -1.013 . . . . 0.0 109.762 -175.65 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.466 ' O ' ' HA ' ' A' ' 96' ' ' ASP . . . -159.46 140.16 6.66 Favored Glycine 0 N--CA 1.415 -2.702 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 176.951 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.58 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 11.7 p -116.67 114.83 24.6 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 124.001 0.92 . . . . 0.0 110.987 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.408 ' CG1' ' HB2' ' A' ' 95' ' ' ALA . 36.8 pt -128.78 123.18 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 119.69 1.132 . . . . 0.0 110.81 175.248 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.615 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 21.3 ptmt -92.89 142.34 27.42 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.722 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -144.89 175.79 24.32 Favored Glycine 0 N--CA 1.421 -2.356 0 O-C-N 123.574 0.547 . . . . 0.0 112.869 -168.848 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.72 171.25 8.02 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.447 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 1.7 m -73.07 103.48 3.84 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.644 -1.222 . . . . 0.0 114.071 -171.213 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.529 ' OE2' ' HD3' ' A' ' 122' ' ' LYS . 25.5 tt0 -177.1 156.4 1.27 Allowed 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 157.643 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.66 -159.16 34.76 Favored Glycine 0 C--N 1.272 -2.977 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 170.208 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.56 ' HB3' ' H ' ' A' ' 122' ' ' LYS . 1.3 pt? -159.65 -169.85 2.71 Favored 'General case' 1 N--CA 1.364 -4.758 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.169 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 34.7 t-80 -137.4 165.4 26.32 Favored 'General case' 0 C--N 1.247 -3.856 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 -178.063 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.569 ' HA2' ' O ' ' A' ' 85' ' ' GLY . . . -34.29 111.46 0.07 OUTLIER Glycine 0 C--O 1.249 1.074 0 O-C-N 125.723 1.889 . . . . 0.0 112.547 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -69.68 157.39 37.35 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 121.929 0.871 . . . . 0.0 112.714 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.639 ' HA ' ' CA ' ' A' ' 82' ' ' GLY . 59.6 m80 -137.82 95.02 2.97 Favored 'General case' 1 C--O 1.341 5.903 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.021 -174.154 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.533 ' H ' ' HA2' ' A' ' 82' ' ' GLY . 14.1 m -106.11 156.76 6.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.455 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.738 -175.572 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.43 ' ND1' ' HB2' ' A' ' 65' ' ' ASN . 15.1 t60 -131.32 121.04 24.02 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-O 122.531 1.158 . . . . 0.0 112.083 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.49 ' OE1' ' HA3' ' A' ' 108' ' ' GLY . 0.0 OUTLIER -90.03 95.61 10.29 Favored 'General case' 0 C--N 1.273 -2.751 0 CA-C-N 113.161 -1.836 . . . . 0.0 115.609 -175.827 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.299 6.4 p90 -131.23 -5.92 3.83 Favored 'General case' 0 C--O 1.218 -0.57 0 C-N-CA 118.128 -1.429 . . . . 0.0 114.252 169.51 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.532 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . 100.98 118.58 4.34 Favored Glycine 0 N--CA 1.476 1.351 0 C-N-CA 120.058 -1.068 . . . . 0.0 112.714 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -144.86 -85.97 0.12 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 118.308 -1.357 . . . . 0.0 111.098 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.481 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 23.5 t30 -153.83 136.69 15.36 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.429 HG22 HG22 ' A' ' 148' ' ' VAL . 23.5 m -55.76 -19.11 10.02 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 125.613 1.565 . . . . 0.0 112.608 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.32 2.52 14.78 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -176.566 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.481 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 170.84 137.94 2.41 Favored Glycine 0 C--O 1.211 -1.283 0 C-N-CA 117.744 -2.169 . . . . 0.0 113.229 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.635 ' SG ' HG22 ' A' ' 118' ' ' VAL . 25.4 p -98.68 94.06 6.44 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 36.8 m -74.75 -52.24 12.05 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.641 -0.662 . . . . 0.0 110.998 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 m -90.31 -34.81 15.58 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-O 121.149 0.5 . . . . 0.0 110.908 -175.712 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.58 59.61 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -175.699 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.54 -65.03 3.61 Favored Glycine 0 CA--C 1.542 1.775 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -88.88 6.38 4.68 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 123.061 2.508 . . . . 0.0 114.247 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -98.86 133.78 42.67 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -176.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -109.32 170.82 7.81 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -175.85 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.683 ' O ' HG22 ' A' ' 81' ' ' VAL . 43.9 t30 -106.49 97.16 15.68 Favored Pre-proline 0 C--O 1.213 -0.852 0 C-N-CA 123.066 0.546 . . . . 0.0 110.758 176.782 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.542 ' HA ' ' HA ' ' A' ' 70' ' ' LYS . 21.3 Cg_exo -62.2 -9.86 16.37 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 124.256 3.304 . . . . 0.0 114.333 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.18 -17.58 53.77 Favored 'General case' 0 C--N 1.365 1.263 0 C-N-CA 122.7 0.4 . . . . 0.0 110.784 -168.939 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.46 ' HB2' ' H ' ' A' ' 79' ' ' ARG . 38.6 t -84.77 -90.62 0.09 Allowed 'General case' 0 N--CA 1.41 -2.465 0 C-N-CA 116.324 -2.15 . . . . 0.0 110.554 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.425 ' HG2' ' HB3' ' A' ' 75' ' ' LYS . 15.6 tpp180 -135.87 41.71 2.67 Favored 'General case' 0 C--N 1.264 -3.119 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.542 ' HA ' ' HA ' ' A' ' 66' ' ' PRO . 99.5 mttt 75.35 -153.47 0.04 OUTLIER 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.308 -177.259 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 5.0 p80 -67.26 83.22 0.14 Allowed 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.578 ' N ' HG13 ' A' ' 81' ' ' VAL . . . 93.25 91.58 1.55 Allowed Glycine 0 CA--C 1.467 -2.939 0 C-N-CA 117.784 -2.151 . . . . 0.0 111.638 169.591 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.92 142.8 7.73 Favored Glycine 1 N--CA 1.392 -4.263 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -86.22 0.46 8.13 Favored 'Trans proline' 0 N--CA 1.437 -1.806 0 C-N-CA 122.794 2.329 . . . . 0.0 109.414 178.909 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.462 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 0.0 OUTLIER -84.84 28.55 0.68 Allowed 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.154 -172.111 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.462 ' HB2' ' O ' ' A' ' 75' ' ' LYS . 5.8 t0 -179.78 39.99 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 123.209 1.48 . . . . 0.0 107.988 164.247 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 68.11 8.87 6.82 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 112.332 -2.213 . . . . 0.0 114.9 169.595 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 4.0 tp10 63.34 37.76 10.68 Favored 'General case' 0 C--N 1.366 1.322 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 176.244 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.46 ' H ' ' HB2' ' A' ' 68' ' ' SER 0.34 50.2 mtm180 -52.84 3.12 0.01 OUTLIER 'General case' 0 N--CA 1.521 3.118 0 N-CA-C 119.202 3.038 . . . . 0.0 119.202 -164.922 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.419 4.8 m80 163.03 28.79 0.0 OUTLIER 'General case' 0 CA--C 1.459 -2.537 0 C-N-CA 127.036 2.134 . . . . 0.0 112.708 162.043 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.683 HG22 ' O ' ' A' ' 65' ' ' ASN . 3.6 t -83.16 -23.2 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 174.076 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.639 ' CA ' ' HA ' ' A' ' 46' ' ' HIS . . . -179.07 123.44 0.85 Allowed Glycine 1 N--CA 1.379 -5.128 0 CA-C-N 113.55 -1.659 . . . . 0.0 111.218 178.662 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -69.27 107.96 3.47 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 174.358 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.43 ' H ' HG13 ' A' ' 103' ' ' VAL . 51.4 tp -68.55 89.95 0.37 Allowed 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.228 -170.149 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.569 ' O ' ' HA2' ' A' ' 44' ' ' GLY . . . -139.96 138.92 9.48 Favored Glycine 0 N--CA 1.413 -2.884 0 N-CA-C 107.989 -2.044 . . . . 0.0 107.989 174.15 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -109.84 129.14 55.67 Favored 'General case' 0 CA--C 1.485 -1.527 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -175.039 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.551 ' HB ' ' CB ' ' A' ' 95' ' ' ALA . 2.3 m -129.21 156.21 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.223 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.04 -178.387 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 p -134.26 96.37 3.59 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.542 0.687 . . . . 0.0 112.224 -175.666 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.68 156.23 17.2 Favored 'General case' 0 N--CA 1.424 -1.766 0 C-N-CA 126.847 2.059 . . . . 0.0 108.973 177.157 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.46 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 15.3 t70 -137.11 -167.93 2.19 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.676 -1.602 . . . . 0.0 106.676 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.447 ' N ' ' HA ' ' A' ' 39' ' ' THR . 39.7 ttpt -43.14 -38.66 2.52 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 126.123 1.769 . . . . 0.0 114.399 -177.588 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -134.94 4.96 3.3 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.615 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -63.08 170.45 14.53 Favored Glycine 0 CA--C 1.474 -2.514 0 CA-C-N 112.429 -2.169 . . . . 0.0 112.999 -170.814 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.401 HG13 ' HB3' ' A' ' 36' ' ' LYS . 16.1 m -134.83 131.94 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.391 -3.407 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -165.602 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.551 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -96.11 89.68 5.25 Favored 'General case' 2 C--N 1.239 -4.237 0 N-CA-C 104.667 -2.346 . . . . 0.0 104.667 175.305 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . 0.466 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 12.1 t70 -121.42 89.12 3.06 Favored 'General case' 0 CA--C 1.477 -1.848 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 -178.521 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.81 144.2 38.34 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.738 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.886 -177.659 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -105.27 102.32 11.81 Favored 'General case' 0 C--N 1.266 -3.055 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.463 ' H ' HD12 ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.48 147.39 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.476 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.613 -173.506 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 14.5 pt-20 -149.19 117.48 6.45 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.457 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.57 ' N ' ' HB3' ' A' ' 28' ' ' PRO . 20.4 t70 -165.3 159.26 17.08 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.4 m -99.92 76.85 1.98 Allowed 'General case' 0 N--CA 1.425 -1.719 0 CA-C-O 123.576 1.655 . . . . 0.0 107.568 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.43 HG13 ' H ' ' A' ' 84' ' ' LEU . 6.5 p -120.52 -16.49 6.74 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.923 0 CA-C-N 111.361 -2.654 . . . . 0.0 107.403 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.492 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 9.2 mm -81.73 2.94 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.142 0 CA-C-N 113.301 -1.772 . . . . 0.0 107.313 -176.249 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.449 ' HA ' ' HG2' ' A' ' 22' ' ' GLN . 20.2 m -65.53 109.22 2.27 Favored 'General case' 0 C--O 1.263 1.816 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 44.4 tp -68.91 88.9 0.4 Allowed 'General case' 0 N--CA 1.396 -3.16 0 CA-C-N 112.463 -2.153 . . . . 0.0 113.417 -175.173 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.3 t -138.11 85.01 2.07 Favored 'General case' 1 N--CA 1.35 -5.449 0 N-CA-C 100.61 -3.848 . . . . 0.0 100.61 157.372 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.506 ' HA2' ' ND2' ' A' ' 65' ' ' ASN . . . -121.47 -144.25 6.85 Favored Glycine 0 CA--C 1.471 -2.685 0 CA-C-N 112.822 -1.99 . . . . 0.0 109.048 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -67.52 -74.14 0.12 Allowed 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 174.62 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -125.16 -47.47 1.76 Allowed 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 175.189 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.57 ' O ' ' HG3' ' A' ' 115' ' ' ARG . 21.9 m -161.67 169.45 21.53 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 4.4 mp -82.25 -39.82 16.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.449 ' HA ' ' CA ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -73.83 125.74 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.549 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.414 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 102.34 -3.97 51.1 Favored Glycine 0 CA--C 1.478 -2.266 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 171.766 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.57 ' HG3' ' O ' ' A' ' 111' ' ' SER . 9.3 mmt180 -101.9 159.21 15.54 Favored 'General case' 0 N--CA 1.396 -3.15 0 CA-C-N 113.153 -1.523 . . . . 0.0 107.386 -174.426 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.601 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 16.7 p -99.58 135.58 40.78 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.491 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 2.7 pt? -88.9 130.11 35.48 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 174.227 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.635 HG22 ' SG ' ' A' ' 57' ' ' CYS . 14.3 t -101.43 101.79 12.6 Favored 'Isoleucine or valine' 0 C--O 1.262 1.752 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.595 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 27.0 m -136.96 169.59 19.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 C-N-CA 123.744 0.818 . . . . 0.0 108.816 -177.367 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.436 ' O ' HD13 ' A' ' 42' ' ' LEU . 49.0 t-80 -171.65 170.13 5.76 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 171.861 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.47 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.8 OUTLIER -77.59 84.06 3.97 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 170.743 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.56 ' H ' ' HB3' ' A' ' 42' ' ' LEU . 58.3 mmtt -173.58 127.98 0.42 Allowed 'General case' 0 CA--C 1.464 -2.363 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -174.61 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -44.89 103.32 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.84 0 O-C-N 123.863 0.727 . . . . 0.0 109.743 168.172 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -104.22 85.66 2.41 Favored 'General case' 0 CA--C 1.458 -2.585 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 -177.737 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.423 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 8.1 t70 -121.25 133.66 55.16 Favored 'General case' 0 C--N 1.255 -3.512 0 CA-C-N 113.729 -1.578 . . . . 0.0 108.869 -172.135 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.4 mm? -89.58 -13.3 37.54 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.668 -178.474 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -96.96 -34.6 5.63 Favored Glycine 0 N--CA 1.425 -2.047 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.423 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 65.4 tttm -86.33 -49.05 7.95 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 118.894 -0.575 . . . . 0.0 110.813 178.517 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.509 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.91 -77.86 0.0 OUTLIER Glycine 0 CA--C 1.529 0.923 0 N-CA-C 114.439 0.536 . . . . 0.0 114.439 -170.536 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 171.63 -97.44 0.12 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 108.969 -1.653 . . . . 0.0 108.969 -177.078 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -88.94 179.98 6.07 Favored 'General case' 0 CA--C 1.56 1.337 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -56.16 -32.3 64.17 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 119.347 0.976 . . . . 0.0 113.229 -178.491 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -75.74 -46.38 31.25 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.676 0.751 . . . . 0.0 109.747 176.25 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.3 m -60.97 -33.93 73.98 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.352 -175.05 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.509 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 9.9 t -67.97 -35.71 78.81 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-O 120.939 0.4 . . . . 0.0 111.568 178.708 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.25 -29.12 31.46 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.172 -176.104 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 8.8 t -86.94 -14.93 40.4 Favored 'General case' 0 N--CA 1.438 -1.046 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 177.705 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.74 60.6 6.75 Favored Glycine 0 CA--C 1.5 -0.876 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 -175.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -51.89 105.23 0.1 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -175.014 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -152.11 171.64 17.58 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 173.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -67.9 87.45 0.18 Allowed Glycine 0 C--N 1.314 -0.665 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 173.656 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 16.2 m -66.1 -10.09 37.38 Favored 'General case' 0 C--O 1.21 -1.003 0 C-N-CA 124.731 1.213 . . . . 0.0 113.624 -175.433 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 43.1 mtp-105 -116.34 -37.4 3.77 Favored 'General case' 0 C--N 1.254 -3.554 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.725 172.529 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.412 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 3.8 mm? -49.0 -38.19 22.57 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 115.481 1.66 . . . . 0.0 115.481 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.595 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -143.89 92.45 2.34 Favored 'General case' 0 N--CA 1.42 -1.947 0 CA-C-O 121.622 0.725 . . . . 0.0 111.253 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.491 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 3.9 m -140.13 153.2 46.61 Favored 'General case' 0 N--CA 1.419 -1.979 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 175.487 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.601 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.75 168.95 42.01 Favored Glycine 0 N--CA 1.406 -3.311 0 N-CA-C 107.0 -2.44 . . . . 0.0 107.0 176.482 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.481 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 31.4 m -70.44 122.04 21.42 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.443 1.116 . . . . 0.0 112.385 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 9.0 tt -99.25 142.68 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.756 0 N-CA-C 103.704 -2.702 . . . . 0.0 103.704 175.223 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.449 ' CA ' ' HA ' ' A' ' 113' ' ' ILE . . . 177.06 154.46 12.04 Favored Glycine 2 N--CA 1.387 -4.57 0 C-N-CA 117.316 -2.373 . . . . 0.0 112.957 177.246 . . . . . . . . 3 3 . 1 . 009 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 3.8 tt -66.64 105.0 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 124.483 0.755 . . . . 0.0 109.422 172.324 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.526 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -114.21 98.3 6.86 Favored 'General case' 0 N--CA 1.414 -2.238 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 172.911 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 117.898 -1.049 . . . . 0.0 109.087 -174.258 . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.448 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.221 -0.432 0 N-CA-C 111.42 0.156 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.557 ' O ' ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -82.35 -35.53 27.74 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-O 121.876 0.846 . . . . 0.0 112.463 -177.337 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.582 ' O ' HG12 ' A' ' 151' ' ' ILE . 56.9 mtmt -138.09 135.81 36.17 Favored 'General case' 0 C--N 1.277 -2.545 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.593 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -134.05 166.74 22.03 Favored 'General case' 0 C--N 1.27 -2.872 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 -176.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.3 p -145.99 118.93 2.28 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.315 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.461 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -108.65 127.16 53.73 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.328 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.4 p -119.45 129.24 75.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 O-C-N 123.786 0.679 . . . . 0.0 110.217 -178.288 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 75.4 mt -107.18 141.67 38.1 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.118 -177.67 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -150.79 137.83 19.21 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 174.509 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.39 -159.32 9.25 Favored Glycine 0 N--CA 1.417 -2.625 0 C-N-CA 117.571 -2.252 . . . . 0.0 115.622 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -78.06 -31.14 50.1 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 111.91 -2.145 . . . . 0.0 109.371 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.46 172.49 14.45 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 172.523 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -88.39 121.87 1.41 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 CA-C-N 121.919 2.859 . . . . 0.0 112.135 -176.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 m -135.14 118.23 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.429 0 CA-C-N 113.368 -1.742 . . . . 0.0 106.548 171.374 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.485 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -143.35 119.5 10.78 Favored 'General case' 0 C--N 1.279 -2.468 0 C-N-CA 118.128 -1.429 . . . . 0.0 109.929 178.442 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -171.2 170.87 43.62 Favored Glycine 0 N--CA 1.418 -2.552 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 178.592 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.461 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 20.0 pt -135.85 119.52 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.871 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.433 HG12 ' HA3' ' A' ' 33' ' ' GLY . 21.9 mt -114.37 135.16 55.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -176.758 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.593 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -101.58 138.68 38.25 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.235 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.476 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 95.2 m-85 -132.2 120.16 21.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 123.304 0.377 . . . . 0.0 111.066 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.557 ' HB2' ' O ' ' A' ' 2' ' ' THR . 35.8 tt0 -112.17 108.24 17.42 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.785 172.955 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.475 ' NE2' ' H ' ' A' ' 27' ' ' GLY . 8.8 tp60 -140.71 114.8 9.15 Favored 'General case' 0 N--CA 1.405 -2.69 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 172.481 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -90.63 157.37 17.52 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 178.087 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -60.95 -23.69 65.5 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.153 0.502 . . . . 0.0 110.967 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 14.8 m -63.25 -18.4 63.52 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.996 176.739 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 65.1 t30 66.96 105.98 0.04 OUTLIER 'General case' 0 C--N 1.353 0.744 0 C-N-CA 125.426 1.491 . . . . 0.0 109.204 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.475 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -146.55 -170.64 15.19 Favored Glycine 0 CA--C 1.469 -2.804 0 C-N-CA 118.415 -1.85 . . . . 0.0 115.242 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.65 124.12 15.03 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.56 2.84 . . . . 0.0 110.562 178.343 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.451 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 47.1 t -93.44 110.99 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.988 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.286 -175.254 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.42 111.24 23.89 Favored 'General case' 0 N--CA 1.422 -1.87 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.403 HG23 ' HA ' ' A' ' 20' ' ' PHE . 17.2 t -138.47 132.26 41.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.175 -170.033 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.443 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 77.8 t90 -149.25 127.64 12.22 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.433 ' HA3' HG12 ' A' ' 18' ' ' ILE . . . -159.34 140.03 6.58 Favored Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.417 -0.896 . . . . 0.0 110.915 173.796 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.443 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 49.4 m -117.4 115.4 25.14 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.288 179.31 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.514 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 30.8 pt -109.79 138.71 36.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 118.612 0.642 . . . . 0.0 111.104 176.355 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.708 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 16.5 ptpt -103.65 132.7 49.67 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.327 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.487 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -148.98 178.78 26.3 Favored Glycine 1 N--CA 1.391 -4.359 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -167.758 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.469 ' HG ' ' H ' ' A' ' 39' ' ' THR . 45.3 tp -65.27 176.46 1.35 Allowed 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 171.59 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.469 ' H ' ' HG ' ' A' ' 38' ' ' LEU . 15.0 t -61.99 153.72 28.64 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.351 -1.468 . . . . 0.0 111.215 -166.115 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.7 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 11.1 pt-20 -60.67 160.32 9.43 Favored 'General case' 0 CA--C 1.476 -1.891 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -163.026 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -159.29 -157.57 8.62 Favored Glycine 1 C--N 1.245 -4.487 1 N-CA-C 102.442 -4.263 . . . . 0.0 102.442 -176.906 . . . . . . . . 3 2 . 1 . 010 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.4 mt -153.72 -86.63 0.06 Allowed 'General case' 0 C--N 1.274 -2.717 0 CA-C-N 120.357 2.078 . . . . 0.0 114.74 -169.661 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.613 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.5 t-160 -76.93 122.23 24.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 -156.416 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.78 127.01 8.8 Favored Glycine 0 N--CA 1.415 -2.75 0 C-N-CA 119.876 -1.154 . . . . 0.0 114.85 -173.392 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.478 ' HB3' ' CB ' ' A' ' 124' ' ' ASP . 14.9 t80 -113.31 113.03 24.7 Favored 'General case' 1 C--O 1.336 5.61 0 CA-C-O 123.41 1.576 . . . . 0.0 111.028 175.463 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.547 ' HB3' ' O ' ' A' ' 83' ' ' ASP . 25.4 m80 -108.18 124.96 51.07 Favored 'General case' 0 N--CA 1.391 -3.38 0 CA-C-N 113.624 -1.626 . . . . 0.0 110.42 -173.708 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.46 ' HA ' ' HA3' ' A' ' 82' ' ' GLY . 9.4 p -174.65 87.35 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 CA-C-N 113.55 -1.659 . . . . 0.0 109.762 177.909 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.438 ' C ' ' HD2' ' A' ' 115' ' ' ARG . 7.0 m170 -112.49 170.74 7.96 Favored 'General case' 0 C--N 1.281 -2.387 0 N-CA-C 114.608 1.336 . . . . 0.0 114.608 167.125 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.58 ' HG3' ' OD1' ' A' ' 109' ' ' ASP . 36.4 tt0 -139.64 132.56 29.33 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.191 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.8 t80 76.45 26.84 0.86 Allowed 'General case' 0 C--O 1.222 -0.359 0 C-N-CA 127.349 2.26 . . . . 0.0 111.127 174.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.704 ' HA3' ' O ' ' A' ' 114' ' ' GLY . . . 33.67 -124.64 0.4 Allowed Glycine 0 C--N 1.36 1.916 0 CA-C-N 115.599 -0.728 . . . . 0.0 114.637 -172.542 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.2 t70 169.51 -80.71 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 125.398 1.479 . . . . 0.0 108.48 164.122 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -161.05 160.9 31.07 Favored 'General case' 0 N--CA 1.429 -1.509 0 N-CA-C 104.975 -2.231 . . . . 0.0 104.975 174.164 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 5.3 t -79.26 5.18 12.95 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -171.677 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.15 2.26 9.8 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 120.202 -0.599 . . . . 0.0 111.249 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 176.55 127.53 1.05 Allowed Glycine 0 C--O 1.195 -2.324 0 C-N-CA 118.582 -1.77 . . . . 0.0 111.558 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.796 ' SG ' HG23 ' A' ' 118' ' ' VAL . 16.7 p -99.72 89.23 4.04 Favored 'General case' 0 C--N 1.275 -2.633 0 O-C-N 121.869 -0.783 . . . . 0.0 112.131 177.395 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.5 m -78.85 -53.14 7.4 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.668 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.8 m -70.01 -52.99 19.67 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.498 -174.054 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.63 -9.45 58.67 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-O 118.418 -0.801 . . . . 0.0 112.975 176.877 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -36.08 -68.14 0.32 Allowed Glycine 0 N--CA 1.488 2.103 0 N-CA-C 114.864 0.705 . . . . 0.0 114.864 -173.624 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -94.09 7.59 2.42 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.328 2.686 . . . . 0.0 112.149 177.068 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 77.1 t60 -113.52 123.46 50.06 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -171.634 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.443 ' CD1' ' HA ' ' A' ' 137' ' ' THR . 27.1 p90 -97.75 170.55 8.91 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 126.722 2.009 . . . . 0.0 108.785 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.83 142.68 24.89 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.299 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.82 -53.98 2.77 Favored 'Trans proline' 0 N--CA 1.481 0.767 0 C-N-CA 123.204 2.603 . . . . 0.0 116.652 -168.19 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.816 ' O ' ' HA ' ' A' ' 78' ' ' GLU . 95.9 mt -93.0 25.97 3.0 Favored 'General case' 0 C--O 1.193 -1.913 0 O-C-N 121.786 -0.571 . . . . 0.0 111.818 -168.586 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.676 ' O ' ' HA ' ' A' ' 80' ' ' HIS . 28.6 m -144.74 30.36 1.2 Allowed 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.039 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.514 ' HD2' ' O ' ' A' ' 69' ' ' ARG . 4.1 tmm_? -126.08 -27.32 3.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 CA-C-O 117.639 -1.172 . . . . 0.0 110.638 -176.56 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 1.2 mptm? -45.32 60.34 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 119.778 3.251 . . . . 0.0 119.778 -165.097 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.429 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 26.6 t-80 46.43 58.65 4.4 Favored 'General case' 0 CA--C 1.567 1.598 0 N-CA-C 117.292 2.33 . . . . 0.0 117.292 165.608 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.62 88.44 0.38 Allowed Glycine 0 CA--C 1.495 -1.186 0 C-N-CA 116.762 -2.637 . . . . 0.0 115.57 163.096 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -170.13 95.38 0.11 Allowed Glycine 0 C--O 1.211 -1.334 0 C-N-CA 119.089 -1.529 . . . . 0.0 112.81 -178.995 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -64.91 -40.23 21.96 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 CA-C-N 120.647 2.224 . . . . 0.0 113.583 -175.082 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.07 16.49 21.81 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 125.139 1.376 . . . . 0.0 110.153 -178.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -89.79 -172.02 3.39 Favored 'General case' 0 C--N 1.287 -2.126 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.747 -167.174 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.469 ' HA ' ' CG1' ' A' ' 81' ' ' VAL . 0.1 OUTLIER -142.46 -3.45 1.04 Allowed 'General case' 0 N--CA 1.434 -1.268 0 O-C-N 122.22 -0.3 . . . . 0.0 111.072 -178.486 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.816 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 33.1 tt0 -132.19 -34.79 1.23 Allowed 'General case' 0 N--CA 1.433 -1.315 0 CA-C-O 121.222 0.535 . . . . 0.0 110.276 -170.076 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.468 ' O ' ' HB3' ' A' ' 80' ' ' HIS . 4.5 mpt_? -93.76 -15.87 24.74 Favored 'General case' 0 CA--C 1.484 -1.571 0 C-N-CA 125.603 1.561 . . . . 0.0 107.111 -175.812 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.676 ' HA ' ' O ' ' A' ' 68' ' ' SER 0.258 5.0 p80 164.44 142.72 0.01 OUTLIER 'General case' 0 CA--C 1.459 -2.538 0 CA-C-N 113.185 -1.825 . . . . 0.0 110.332 159.498 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.684 ' O ' ' HB2' ' A' ' 84' ' ' LEU . 9.5 p -159.79 -61.0 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.251 -3.71 0 N-CA-C 105.661 -1.977 . . . . 0.0 105.661 168.436 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.462 ' H ' ' HB3' ' A' ' 68' ' ' SER . . . 47.97 -136.62 14.72 Favored Glycine 0 C--O 1.239 0.45 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.627 ' OD2' ' HA ' ' A' ' 117' ' ' LEU . 1.9 p-10 -93.68 81.21 4.27 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 169.998 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.684 ' HB2' ' O ' ' A' ' 81' ' ' VAL . 0.7 OUTLIER -88.96 138.87 31.01 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 115.754 1.761 . . . . 0.0 115.754 -168.148 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.557 ' N ' HD11 ' A' ' 84' ' ' LEU . . . -169.36 156.38 27.42 Favored Glycine 0 N--CA 1.425 -2.048 0 N-CA-C 104.483 -3.447 . . . . 0.0 104.483 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -112.61 153.0 28.26 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 120.158 1.979 . . . . 0.0 109.869 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 71.9 t -117.86 143.01 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.532 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.607 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 62.2 m -146.13 95.74 2.67 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.2 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.431 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -93.28 144.98 24.79 Favored 'General case' 0 CA--C 1.482 -1.666 0 CA-C-N 119.49 1.041 . . . . 0.0 113.097 -176.33 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.7 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 22.1 t70 -82.58 149.6 27.37 Favored 'General case' 0 C--N 1.278 -2.516 0 CA-C-N 113.223 -1.808 . . . . 0.0 106.83 169.134 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.533 ' N ' ' HB3' ' A' ' 40' ' ' GLU . 13.6 pttp -41.28 -19.39 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 127.69 2.396 . . . . 0.0 116.037 176.572 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -106.81 12.76 28.66 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.708 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 73.1 85.18 0.23 Allowed Glycine 0 N--CA 1.42 -2.397 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.06 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.514 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 61.3 t -157.07 103.51 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.709 -1.959 . . . . 0.0 105.709 -178.752 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.607 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -104.17 113.38 26.89 Favored 'General case' 0 C--N 1.273 -2.735 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.525 175.811 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -86.01 94.33 9.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 175.147 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.443 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 86.1 t -85.63 105.71 14.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.486 -175.514 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.2 m -152.54 116.05 4.75 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 9.4 tp -148.31 134.35 12.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.451 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 37.8 mt-10 -124.03 96.63 5.01 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.433 -175.253 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.404 ' O ' HG21 ' A' ' 29' ' ' VAL . 6.2 p-10 -168.81 166.71 11.4 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 170.902 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.5 p -60.89 91.5 0.02 OUTLIER 'General case' 0 C--O 1.245 0.851 0 CA-C-N 119.128 0.876 . . . . 0.0 113.058 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.413 ' HB ' ' HB3' ' A' ' 84' ' ' LEU . 27.1 m -118.39 -14.41 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -176.67 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.415 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -119.24 25.92 4.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 O-C-N 120.7 -1.25 . . . . 0.0 109.476 -176.552 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.0 m -64.38 110.95 2.43 Favored 'General case' 0 C--O 1.268 2.059 0 CA-C-O 122.729 1.252 . . . . 0.0 109.831 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.44 86.37 1.15 Allowed 'General case' 0 N--CA 1.382 -3.87 0 CA-C-O 124.103 1.906 . . . . 0.0 110.63 176.717 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.0 m -146.56 85.75 1.65 Allowed 'General case' 2 N--CA 1.362 -4.855 0 N-CA-C 101.88 -3.378 . . . . 0.0 101.88 168.665 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.13 168.96 22.8 Favored Glycine 0 C--N 1.269 -3.142 0 CA-C-N 113.373 -1.74 . . . . 0.0 111.014 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.58 ' OD1' ' HG3' ' A' ' 49' ' ' GLU . 7.0 t70 -56.92 -34.89 68.41 Favored 'General case' 0 C--O 1.202 -1.43 0 CA-C-N 117.292 0.546 . . . . 0.0 110.916 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.706 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 7.9 p-80 -54.28 -17.01 2.49 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 125.385 1.474 . . . . 0.0 113.023 -178.002 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.478 ' H ' ' C ' ' A' ' 109' ' ' ASP . 23.0 t 37.47 -154.49 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 126.164 1.786 . . . . 0.0 110.297 -173.025 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.598 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 14.2 tt -100.32 -32.97 3.63 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.876 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 166.133 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.8 pt -104.02 145.93 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -178.773 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.704 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 95.83 -7.04 67.52 Favored Glycine 1 CA--C 1.45 -4.008 0 C-N-CA 121.234 -0.508 . . . . 0.0 112.272 162.211 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.706 ' NE ' ' HA ' ' A' ' 110' ' ' HIS . 0.3 OUTLIER -92.61 151.44 20.12 Favored 'General case' 0 C--O 1.162 -3.54 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.688 -174.146 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.543 ' H ' ' HA2' ' A' ' 51' ' ' GLY . 7.6 p -91.86 113.09 25.27 Favored 'General case' 0 N--CA 1.408 -2.531 0 O-C-N 121.537 -0.727 . . . . 0.0 109.397 173.57 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.627 ' HA ' ' OD2' ' A' ' 83' ' ' ASP . 22.5 tp -70.09 93.5 0.81 Allowed 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 -177.456 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.796 HG23 ' SG ' ' A' ' 57' ' ' CYS 0.528 60.2 t -105.1 109.22 27.0 Favored 'Isoleucine or valine' 1 C--O 1.341 5.884 0 N-CA-C 120.708 3.596 . . . . 0.0 120.708 -172.217 . . . . . . . . 4 3 . 1 . 010 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.654 ' O ' ' HB2' ' A' ' 145' ' ' ALA . 7.3 p -148.47 171.25 2.43 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.155 0 CA-C-N 110.397 -3.092 . . . . 0.0 106.469 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 71.6 t60 -150.37 171.28 17.25 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.88 -2.267 . . . . 0.0 104.88 168.198 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.461 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.0 OUTLIER -69.42 85.94 0.43 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 171.449 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -173.01 171.78 4.11 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.652 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.613 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -99.09 107.58 20.0 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 118.299 0.499 . . . . 0.0 110.243 173.448 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.481 ' HA ' ' OD1' ' A' ' 139' ' ' ASN . 1.1 m-20 -71.33 -59.16 2.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 172.522 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.0 t70 67.76 141.34 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 128.024 2.529 . . . . 0.0 114.097 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.571 ' HG ' ' CD2' ' A' ' 80' ' ' HIS . 0.0 OUTLIER -90.26 -31.99 16.74 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-N 114.89 -1.05 . . . . 0.0 113.624 -176.563 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.429 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -97.01 -33.98 5.84 Favored Glycine 0 N--CA 1.427 -1.904 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -105.13 50.32 0.79 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.178 -1.011 . . . . 0.0 108.873 -179.019 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.36 -6.83 81.51 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.53 -93.17 0.25 Allowed Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 121.653 -0.308 . . . . 0.0 112.406 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.54 ' H ' ' HB2' ' A' ' 134' ' ' SER . 79.3 m-20 -121.86 -173.39 2.64 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -174.045 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -57.71 -39.32 76.96 Favored 'General case' 0 C--N 1.361 1.102 0 C-N-CA 118.65 -1.22 . . . . 0.0 109.994 176.366 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.536 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 5.9 tp10 -76.05 -53.86 7.72 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.051 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.54 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 2.4 m -62.06 -26.25 68.16 Favored 'General case' 0 CA--C 1.552 1.021 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -175.617 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 35.8 m -79.72 -18.14 51.91 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 121.852 -0.53 . . . . 0.0 110.653 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.536 ' HG3' ' O ' ' A' ' 133' ' ' GLU . 0.0 OUTLIER -85.64 -31.27 22.65 Favored 'General case' 0 C--O 1.211 -0.942 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.535 179.227 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.443 ' HA ' ' CD1' ' A' ' 64' ' ' PHE . 8.8 p -70.95 -16.01 62.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 120.916 0.389 . . . . 0.0 109.962 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.56 81.64 0.11 Allowed Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . 0.481 ' OD1' ' HA ' ' A' ' 124' ' ' ASP . 23.3 t-20 -33.07 132.05 0.16 Allowed 'General case' 0 C--O 1.291 3.263 0 CA-C-O 123.451 1.596 . . . . 0.0 114.202 -172.306 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.419 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -150.89 130.51 13.07 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 113.845 -1.525 . . . . 0.0 109.711 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.12 91.03 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.072 -2.011 . . . . 0.0 108.072 170.935 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.9 m -49.18 -18.41 0.33 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.789 2.035 . . . . 0.0 116.384 -168.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -144.59 6.51 1.25 Allowed 'General case' 0 C--N 1.269 -2.92 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.998 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.56 -22.73 58.84 Favored 'General case' 0 C--N 1.294 -1.845 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.509 -173.478 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.654 ' HB2' ' O ' ' A' ' 119' ' ' VAL . . . -171.9 100.3 0.17 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 175.487 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.9 m -123.42 133.05 54.12 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -160.28 146.28 12.37 Favored Glycine 0 N--CA 1.404 -3.499 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 178.03 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.506 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 8.8 p -69.19 113.98 5.6 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-O 122.128 0.966 . . . . 0.0 111.953 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.426 ' HB ' ' HB2' ' A' ' 117' ' ' LEU . 2.5 tt -82.93 129.65 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.085 0 N-CA-C 105.067 -2.197 . . . . 0.0 105.067 170.283 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.598 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 177.67 156.99 17.58 Favored Glycine 2 N--CA 1.365 -6.074 0 C-N-CA 118.427 -1.844 . . . . 0.0 111.297 176.772 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.582 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.16 105.32 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 169.536 . . . . . . . . 3 3 . 1 . 010 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.16 113.34 16.91 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 . . . . . 0 C--N 1.283 -2.315 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -175.595 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.0 0.428 . . . . 0.0 111.461 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 m -79.89 -28.99 39.84 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.14 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.635 ' HG3' ' O ' ' A' ' 152' ' ' ALA . 19.9 ptpt -151.74 170.87 18.69 Favored 'General case' 0 C--O 1.253 1.241 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.491 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -141.42 154.56 45.67 Favored 'General case' 0 N--CA 1.434 -1.265 0 O-C-N 124.099 0.875 . . . . 0.0 109.038 177.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.19 122.22 62.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.487 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -131.4 133.14 44.94 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.18 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.6 t -134.75 113.31 16.29 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.413 ' HB2' ' O ' ' A' ' 14' ' ' VAL . 3.1 mm? -90.83 131.03 36.72 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.409 0.683 . . . . 0.0 111.418 -176.949 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.1 mtpt -147.34 126.79 13.18 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 175.008 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.72 -158.53 8.84 Favored Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.58 -0.819 . . . . 0.0 111.754 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -63.09 -40.39 97.52 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.91 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -116.11 82.63 0.32 Allowed Glycine 0 N--CA 1.433 -1.513 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 172.626 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.64 127.0 11.95 Favored 'Trans proline' 0 N--CA 1.446 -1.296 0 C-N-CA 122.127 1.884 . . . . 0.0 113.901 -171.739 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.413 ' O ' ' HB2' ' A' ' 8' ' ' LEU . 16.5 m -111.92 117.08 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.858 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 175.181 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -99.13 118.31 35.57 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.639 -172.493 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.469 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.0 170.81 43.53 Favored Glycine 0 N--CA 1.407 -3.247 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.858 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.487 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 25.7 pt -131.38 129.24 62.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.142 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 mm -115.12 136.01 53.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.497 ' O ' HG13 ' A' ' 31' ' ' VAL . 0.8 OUTLIER -114.24 129.63 56.63 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.478 -177.583 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.491 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 53.9 m-85 -125.19 137.49 54.13 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.097 0.475 . . . . 0.0 111.684 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -116.23 106.37 13.61 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.368 177.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.8 pm0 -86.25 123.34 31.41 Favored 'General case' 0 N--CA 1.403 -2.816 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 171.549 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.441 ' O ' ' HB ' ' A' ' 104' ' ' ILE . 37.1 ttmt -137.55 103.16 4.97 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -170.112 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.26 -9.83 13.29 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 m -71.91 -23.71 61.52 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 122.877 0.471 . . . . 0.0 110.35 176.385 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . 0.456 ' HA ' HG13 ' A' ' 104' ' ' ILE . 45.4 t-20 72.57 135.54 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 C-N-CA 125.335 1.454 . . . . 0.0 111.034 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.52 175.33 36.67 Favored Glycine 0 CA--C 1.485 -1.785 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.619 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -65.1 123.48 11.62 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.302 2.001 . . . . 0.0 108.397 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 23.7 m -76.99 142.75 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.277 0 CA-C-O 121.682 0.753 . . . . 0.0 111.632 -177.401 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -106.28 97.07 6.92 Favored 'General case' 0 C--N 1.277 -2.544 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 173.702 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.497 HG13 ' O ' ' A' ' 19' ' ' ASN . 47.6 t -129.59 129.87 66.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 125.892 1.677 . . . . 0.0 107.861 -171.846 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -140.74 137.24 33.28 Favored 'General case' 0 C--N 1.286 -2.192 0 O-C-N 123.375 0.422 . . . . 0.0 110.186 177.93 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -159.59 137.9 5.34 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 170.191 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.469 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 44.3 t -118.63 127.74 53.88 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.4 ' CG1' ' HB1' ' A' ' 95' ' ' ALA . 33.5 pt -120.02 129.0 75.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 119.788 1.177 . . . . 0.0 110.381 174.611 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 88.1 tttt -96.67 123.56 40.39 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 178.861 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.751 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -136.48 176.29 20.44 Favored Glycine 0 C--N 1.274 -2.9 0 CA-C-N 114.502 -1.226 . . . . 0.0 110.383 -171.057 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -69.43 171.28 8.95 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 171.265 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -68.47 112.43 5.29 Favored 'General case' 0 C--O 1.22 -0.48 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 175.441 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.588 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 5.1 tp10 -128.86 178.91 6.03 Favored 'General case' 0 C--N 1.259 -3.339 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.804 -165.656 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.454 ' H ' ' HG3' ' A' ' 40' ' ' GLU . . . -59.44 -146.93 0.01 OUTLIER Glycine 0 CA--C 1.553 2.449 0 C-N-CA 124.633 1.111 . . . . 0.0 114.472 176.857 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.523 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 3.0 pp -164.66 14.47 0.05 OUTLIER 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -164.486 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.2 t60 -143.91 153.66 42.53 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 106.757 -1.572 . . . . 0.0 106.757 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.417 ' O ' ' HA ' ' A' ' 86' ' ' ASN . . . 163.02 -169.25 38.13 Favored Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 119.899 -1.143 . . . . 0.0 112.156 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.519 ' HA ' ' O ' ' A' ' 85' ' ' GLY . 24.1 p90 -166.6 162.65 16.67 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.908 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.658 ' HB2' ' O ' ' A' ' 83' ' ' ASP . 6.5 m170 -91.12 164.32 13.97 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -171.005 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.9 t -165.82 88.59 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.616 0 C-N-CA 123.81 0.844 . . . . 0.0 111.4 -174.346 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.488 ' HB2' ' HB3' ' A' ' 115' ' ' ARG . 31.0 p-80 -109.61 100.82 9.81 Favored 'General case' 0 CA--C 1.598 2.796 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 166.633 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.595 ' N ' ' HD2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -122.71 122.67 39.32 Favored 'General case' 0 CA--C 1.575 1.932 0 O-C-N 120.374 -1.454 . . . . 0.0 111.338 173.844 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.485 ' C ' ' HG2' ' A' ' 115' ' ' ARG . 61.2 t80 75.36 93.71 0.07 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 126.982 2.113 . . . . 0.0 110.961 176.277 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.589 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -55.02 134.1 48.21 Favored Glycine 0 CA--C 1.482 -1.985 0 N-CA-C 116.851 1.5 . . . . 0.0 116.851 -171.719 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -141.42 -87.09 0.17 Allowed 'General case' 0 CA--C 1.488 -1.439 0 C-N-CA 117.951 -1.5 . . . . 0.0 114.326 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -118.65 139.0 52.22 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.856 -169.716 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.486 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 10.0 t -43.58 -39.76 3.66 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 126.674 1.99 . . . . 0.0 115.385 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -134.31 15.43 3.78 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.426 0.631 . . . . 0.0 110.33 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -127.4 111.14 1.29 Allowed Glycine 0 N--CA 1.436 -1.312 0 C-N-CA 119.922 -1.132 . . . . 0.0 111.818 -177.198 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.581 ' SG ' ' HB ' ' A' ' 118' ' ' VAL . 10.1 p -97.88 88.3 4.24 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.8 p -78.25 -61.85 1.87 Allowed 'General case' 0 N--CA 1.419 -1.99 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.277 176.246 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.3 m -68.15 -27.95 66.88 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.862 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.401 ' HB1' ' HB2' ' A' ' 57' ' ' CYS . . . -78.7 -9.27 59.35 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.059 0.457 . . . . 0.0 111.115 177.551 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.3 -64.66 3.95 Favored Glycine 0 N--CA 1.436 -1.358 0 CA-C-N 115.096 -0.957 . . . . 0.0 113.021 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.78 53.13 2.71 Favored 'Trans proline' 0 CA--C 1.552 1.403 0 C-N-CA 122.359 2.039 . . . . 0.0 114.247 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 11.4 t60 72.83 163.59 0.27 Allowed 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 124.831 1.252 . . . . 0.0 111.439 169.499 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.608 ' CG ' HG21 ' A' ' 81' ' ' VAL . 1.5 t80 -92.79 170.81 9.41 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.641 ' OD1' ' HD2' ' A' ' 66' ' ' PRO . 61.6 t30 -69.86 140.57 88.98 Favored Pre-proline 0 CA--C 1.562 1.42 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.091 -179.603 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.641 ' HD2' ' OD1' ' A' ' 65' ' ' ASN . 72.8 Cg_endo -76.84 -8.4 17.9 Favored 'Trans proline' 0 N--CA 1.443 -1.483 1 C-N-CA 125.314 4.01 . . . . 0.0 113.954 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -84.11 16.59 2.85 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 123.966 1.841 . . . . 0.0 109.611 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.615 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.0 p -80.43 -86.3 0.08 Allowed 'General case' 1 N--CA 1.356 -5.15 0 CA-C-N 113.362 -1.745 . . . . 0.0 108.321 175.152 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.503 ' CB ' ' HA ' ' A' ' 78' ' ' GLU . 41.8 ttt180 -135.84 10.36 3.36 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 167.624 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 82.5 tttt 75.14 -9.18 1.43 Allowed 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.371 1.469 . . . . 0.0 113.19 173.27 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 -99.35 -54.42 2.96 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 119.941 -0.703 . . . . 0.0 112.392 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 88.98 30.45 14.55 Favored Glycine 0 N--CA 1.474 1.174 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.229 179.291 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -70.58 143.54 37.15 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.499 -0.858 . . . . 0.0 114.734 -175.128 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 7.7 Cg_exo -76.84 -9.31 18.2 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 124.155 3.237 . . . . 0.0 111.58 -179.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -79.84 9.8 4.86 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.741 -178.086 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 6.1 m-20 63.05 78.6 0.29 Allowed 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 124.909 1.283 . . . . 0.0 111.094 176.268 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -137.54 -56.13 0.69 Allowed 'General case' 0 CA--C 1.5 -0.969 0 O-C-N 121.668 -0.645 . . . . 0.0 112.683 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.503 ' HA ' ' CB ' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -64.2 154.24 35.47 Favored 'General case' 0 N--CA 1.403 -2.776 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.276 -172.224 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.615 ' O ' ' HA ' ' A' ' 68' ' ' SER . 75.9 ttt180 -119.14 72.2 0.89 Allowed 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -170.84 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.405 ' HB2' ' HA ' ' A' ' 68' ' ' SER 0.336 2.3 m-70 177.48 -20.29 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.119 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 164.896 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.608 HG21 ' CG ' ' A' ' 64' ' ' PHE . 71.8 t -71.94 -57.26 7.74 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.493 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 170.234 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.427 ' O ' ' HG ' ' A' ' 84' ' ' LEU . . . 69.41 -66.02 0.57 Allowed Glycine 0 N--CA 1.435 -1.373 0 CA-C-N 113.836 -1.529 . . . . 0.0 113.226 176.66 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.658 ' O ' ' HB2' ' A' ' 46' ' ' HIS . 2.9 t70 -68.84 97.9 0.88 Allowed 'General case' 0 CA--C 1.449 -2.941 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.458 ' HA ' ' H ' ' A' ' 46' ' ' HIS . 2.5 pp -168.89 162.67 11.41 Favored 'General case' 0 N--CA 1.4 -2.959 0 C-N-CA 125.321 1.448 . . . . 0.0 108.357 -175.096 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.519 ' O ' ' HA ' ' A' ' 45' ' ' PHE . . . 176.55 168.89 37.25 Favored Glycine 2 C--N 1.247 -4.379 0 N-CA-C 103.715 -3.754 . . . . 0.0 103.715 175.538 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.417 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 58.5 t30 -80.36 140.63 35.98 Favored 'General case' 0 C--N 1.271 -2.84 0 CA-C-N 119.501 1.65 . . . . 0.0 107.324 174.947 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 43.4 t -115.31 128.06 72.65 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.118 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 -177.524 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.523 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 62.3 m -142.19 96.54 2.97 Favored 'General case' 0 N--CA 1.413 -2.279 0 CA-C-O 118.685 -0.674 . . . . 0.0 111.405 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.564 ' HB2' ' H ' ' A' ' 94' ' ' VAL . . . -126.77 104.38 8.03 Favored 'General case' 0 C--O 1.195 -1.774 0 C-N-CA 116.459 -2.096 . . . . 0.0 108.131 169.704 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.588 ' HA ' ' O ' ' A' ' 40' ' ' GLU . 5.3 p-10 -127.9 -18.65 4.19 Favored 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.626 -171.348 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 3.1 mptp? -71.73 -58.04 3.83 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.795 0.807 . . . . 0.0 109.072 -175.728 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -164.71 26.51 0.06 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.892 -175.849 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.751 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 77.46 78.95 0.74 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 114.532 -1.213 . . . . 0.0 115.338 -178.14 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.564 ' H ' ' HB2' ' A' ' 89' ' ' ALA . 98.7 t -159.77 105.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 177.072 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.4 ' HB1' ' CG1' ' A' ' 35' ' ' ILE . . . -107.71 122.68 47.22 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -93.21 112.86 24.93 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 124.117 0.886 . . . . 0.0 109.76 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.6 t -113.94 105.64 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-O 121.147 0.499 . . . . 0.0 109.806 178.204 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.41 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 50.5 m -143.52 111.63 6.19 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 174.291 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 25.1 pt -123.22 154.69 29.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.27 -173.527 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -148.96 99.42 2.97 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.884 0.85 . . . . 0.0 111.256 173.839 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.6 t70 -167.58 171.98 9.82 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 176.795 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.6 m -59.24 87.77 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 122.743 1.259 . . . . 0.0 112.286 -178.081 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 59.3 t -113.21 -10.46 12.11 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 112.733 -2.03 . . . . 0.0 106.763 175.453 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.456 HG13 ' HA ' ' A' ' 26' ' ' ASN . 0.2 OUTLIER -52.84 -13.71 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 C-N-CA 125.111 1.364 . . . . 0.0 114.067 -176.72 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.2 m -73.27 152.16 41.09 Favored 'General case' 0 N--CA 1.418 -2.038 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 172.748 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.482 ' HB2' HG12 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -65.9 121.78 15.85 Favored 'General case' 0 N--CA 1.403 -2.82 0 CA-C-O 122.01 0.91 . . . . 0.0 109.697 -177.559 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.9 m -69.86 88.07 0.55 Allowed 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 113.216 -1.811 . . . . 0.0 110.677 -174.345 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.442 ' HA2' ' CZ ' ' A' ' 64' ' ' PHE . . . 143.62 136.62 3.15 Favored Glycine 0 N--CA 1.409 -3.108 0 CA-C-N 114.287 -1.324 . . . . 0.0 112.296 175.313 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -66.38 -56.77 9.46 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.851 169.193 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -104.24 -47.09 4.24 Favored 'General case' 0 N--CA 1.435 -1.209 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.007 -173.551 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.416 ' CB ' ' H ' ' A' ' 51' ' ' GLY . 18.8 m -127.42 113.91 16.82 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 118.944 -1.103 . . . . 0.0 112.594 -177.3 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.482 HG12 ' HB2' ' A' ' 106' ' ' LEU . 2.9 mp -89.71 -38.29 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 173.349 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 4.1 mp -102.01 145.07 12.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.235 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.83 -12.8 62.67 Favored Glycine 0 CA--C 1.495 -1.162 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 174.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.661 ' HD3' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -91.93 134.71 34.54 Favored 'General case' 0 N--CA 1.396 -3.147 0 CA-C-O 122.224 1.011 . . . . 0.0 112.967 -175.544 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.661 ' N ' ' HD3' ' A' ' 115' ' ' ARG 0.253 0.2 OUTLIER -89.0 116.74 27.52 Favored 'General case' 0 N--CA 1.394 -3.264 0 C-N-CA 126.563 1.945 . . . . 0.0 107.45 -176.188 . . . . . . . . 4 4 . 1 . 011 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.471 HD21 ' O ' ' A' ' 147' ' ' GLY . 2.7 pt? -79.17 144.52 34.37 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.494 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.581 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 10.7 p -109.7 111.14 34.85 Favored 'Isoleucine or valine' 0 C--O 1.273 2.314 0 C-N-CA 119.134 -1.027 . . . . 0.0 112.845 177.368 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.45 ' CG1' ' HA ' ' A' ' 46' ' ' HIS . 24.7 m -147.81 146.48 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 C-N-CA 125.805 1.642 . . . . 0.0 110.017 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -170.08 148.65 3.42 Favored 'General case' 0 C--N 1.283 -2.326 0 N-CA-C 102.601 -3.111 . . . . 0.0 102.601 167.929 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.588 ' O ' ' HG3' ' A' ' 40' ' ' GLU . 1.3 mp0 -69.55 89.72 0.53 Allowed 'General case' 0 C--N 1.261 -3.276 0 CA-C-O 123.355 1.55 . . . . 0.0 113.182 -171.225 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -165.28 144.53 6.6 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 102.698 -3.075 . . . . 0.0 102.698 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.27 101.71 0.25 Allowed 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -173.765 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.425 ' HB3' ' H ' ' A' ' 45' ' ' PHE . 12.0 t70 -87.89 93.95 9.62 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 99.585 -4.228 . . . . 0.0 99.585 171.747 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -103.28 139.81 38.23 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.839 -0.745 . . . . 0.0 111.118 -170.335 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.483 ' HG ' ' H ' ' A' ' 127' ' ' GLY . 1.9 pt? -51.23 -74.28 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 121.703 3.964 . . . . 0.0 121.703 -162.248 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.495 ' C ' ' HD2' ' A' ' 128' ' ' LYS . . . -69.97 -59.89 5.23 Favored Glycine 0 CA--C 1.47 -2.727 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.829 -170.781 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . 0.495 ' HD2' ' C ' ' A' ' 127' ' ' GLY . 4.4 mptp? -136.8 35.88 2.63 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.073 -174.729 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.45 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 59.5 -34.06 0.03 OUTLIER Glycine 0 CA--C 1.559 2.809 0 CA-C-N 119.76 1.164 . . . . 0.0 115.634 -175.29 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . 0.472 ' H ' ' C ' ' A' ' 128' ' ' LYS . . . 147.38 -24.32 1.54 Allowed Glycine 0 N--CA 1.401 -3.643 0 O-C-N 122.145 -0.62 . . . . 0.0 111.905 179.528 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.651 ' N ' ' HB2' ' A' ' 134' ' ' SER . 1.8 t-20 -169.61 179.78 3.65 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 118.519 -1.272 . . . . 0.0 108.042 -174.862 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.457 ' O ' HG21 ' A' ' 135' ' ' THR . 0.0 OUTLIER -62.6 -40.72 97.82 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.07 -1.452 . . . . 0.0 113.378 -175.136 . . . . . . . . 3 3 . 1 . 011 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -85.36 -30.84 23.33 Favored 'General case' 0 C--N 1.319 -0.749 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.171 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.651 ' HB2' ' N ' ' A' ' 131' ' ' ASN . 15.0 m -63.68 -19.68 65.1 Favored 'General case' 0 C--O 1.186 -2.284 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.464 ' HB ' ' O ' ' A' ' 128' ' ' LYS . 11.3 t -71.96 -35.4 69.54 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 175.866 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -73.89 -48.84 28.06 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.58 -175.835 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.453 HG21 ' HA ' ' A' ' 134' ' ' SER . 14.8 t -86.06 -23.66 26.65 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 114.418 -1.265 . . . . 0.0 112.816 -176.485 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -68.22 -66.7 2.21 Favored Glycine 0 CA--C 1.478 -2.277 0 CA-C-O 119.584 -0.565 . . . . 0.0 111.73 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 58.8 t30 -50.75 132.53 26.32 Favored 'General case' 0 N--CA 1.518 2.945 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 171.343 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.63 160.27 25.81 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 114.392 1.256 . . . . 0.0 114.392 -162.817 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.87 118.46 13.08 Favored Glycine 0 CA--C 1.49 -1.508 0 CA-C-N 113.655 -1.611 . . . . 0.0 113.046 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.535 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 8.4 m -71.43 3.43 3.81 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 124.607 1.163 . . . . 0.0 113.189 -173.137 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.9 mtt180 -132.16 -4.76 3.47 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 176.557 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.93 -40.35 32.24 Favored 'General case' 0 CA--C 1.498 -1.02 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.111 -173.407 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.15 108.53 0.98 Allowed 'General case' 0 N--CA 1.428 -1.569 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 7.8 m -137.43 156.78 47.78 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 177.873 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.527 ' N ' HG23 ' A' ' 116' ' ' THR . . . -161.1 135.0 3.76 Favored Glycine 0 C--N 1.296 -1.686 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 176.905 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.468 ' HA ' ' HA ' ' A' ' 116' ' ' THR . 40.2 t -65.79 121.67 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.535 0 CA-C-O 122.36 1.076 . . . . 0.0 110.952 176.934 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.8 tt -113.27 141.47 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.098 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.513 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.01 148.13 15.69 Favored Glycine 3 N--CA 1.383 -4.873 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.448 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.1 pt -69.94 103.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 CA-C-O 121.373 0.606 . . . . 0.0 110.699 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.635 ' O ' ' HG3' ' A' ' 3' ' ' LYS . . . -118.5 139.12 51.93 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 175.842 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 . . . . . 0 C--N 1.31 -1.126 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.644 -175.035 . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 120.805 0.336 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 m -92.07 -46.94 7.53 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 120.739 0.304 . . . . 0.0 110.887 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.457 ' HA ' ' OD1' ' A' ' 19' ' ' ASN . 19.0 ptpt -154.25 166.48 33.01 Favored 'General case' 0 N--CA 1.433 -1.32 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.519 -176.62 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.669 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -146.26 153.36 40.5 Favored 'General case' 0 N--CA 1.424 -1.772 0 O-C-N 124.308 1.005 . . . . 0.0 108.336 176.377 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.25 114.23 14.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.424 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -113.51 128.1 56.32 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.697 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -122.53 120.44 60.98 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 121.391 0.615 . . . . 0.0 110.568 178.712 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -108.32 149.16 29.03 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.397 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -171.07 127.06 0.7 Allowed 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.35 -156.53 7.45 Favored Glycine 0 N--CA 1.429 -1.824 0 C-N-CA 120.175 -1.012 . . . . 0.0 112.179 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.46 -39.08 60.69 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.63 1.172 . . . . 0.0 111.347 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -107.32 161.97 13.53 Favored Glycine 0 N--CA 1.436 -1.326 0 N-CA-C 108.009 -2.036 . . . . 0.0 108.009 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -84.32 123.58 3.05 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 CA-C-N 120.491 2.145 . . . . 0.0 111.254 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.3 t -132.98 127.41 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 N-CA-C 103.599 -2.741 . . . . 0.0 103.599 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -142.06 116.58 9.66 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.89 170.3 43.09 Favored Glycine 0 N--CA 1.396 -3.985 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -177.04 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.424 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 24.9 pt -142.6 144.0 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.979 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 179.363 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.2 tp -139.13 136.18 42.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 177.488 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.669 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.3 t-20 -97.96 147.72 24.2 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.489 ' HA ' HG13 ' A' ' 31' ' ' VAL . 61.7 m-85 -138.09 119.33 14.62 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 119.182 0.901 . . . . 0.0 110.734 173.278 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.409 ' CD ' ' HZ1' ' A' ' 30' ' ' LYS . 8.7 pt-20 -112.88 101.89 9.93 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.875 0.845 . . . . 0.0 111.191 174.556 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pm0 -91.06 150.32 21.47 Favored 'General case' 0 N--CA 1.404 -2.729 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.783 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.453 ' N ' ' HB ' ' A' ' 103' ' ' VAL . 40.9 tptt -138.38 154.17 48.93 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 -175.68 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.427 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.5 mp0 -62.68 -55.31 27.98 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 123.937 0.773 . . . . 0.0 113.053 -174.534 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.3 m -78.24 -71.79 0.41 Allowed 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -168.786 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.0 p30 177.89 140.67 0.09 Allowed 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -175.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 165.8 174.58 35.45 Favored Glycine 0 CA--C 1.48 -2.11 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.84 178.973 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -90.6 131.7 1.65 Allowed 'Trans proline' 0 N--CA 1.43 -2.226 0 C-N-CA 123.062 2.508 . . . . 0.0 110.854 175.763 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.33 101.82 2.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 176.361 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' HZ1' ' CD ' ' A' ' 21' ' ' GLU 0.263 0.9 OUTLIER -92.07 92.79 8.43 Favored 'General case' 0 CA--C 1.482 -1.64 0 CA-C-O 122.735 1.255 . . . . 0.0 111.824 177.266 . . . . . . . . 4 4 . 1 . 012 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.489 HG13 ' HA ' ' A' ' 20' ' ' PHE . 17.7 m -127.82 153.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.308 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.69 -175.214 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.48 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 31.0 m-90 -126.59 148.0 49.82 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.63 -172.98 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -166.17 140.11 6.16 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.218 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.8 m -117.16 146.56 43.12 Favored 'General case' 0 N--CA 1.389 -3.521 0 N-CA-C 105.949 -1.871 . . . . 0.0 105.949 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.739 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 17.0 tt -139.55 155.46 25.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.7 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 31.7 mmmt -136.33 131.31 34.14 Favored 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 105.501 -2.037 . . . . 0.0 105.501 -176.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -164.52 174.72 40.57 Favored Glycine 0 C--N 1.281 -2.505 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -173.472 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.3 mt -66.71 145.05 55.97 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.102 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 65.5 p -69.54 106.73 3.11 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -164.587 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -175.47 161.96 2.77 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 103.765 -2.68 . . . . 0.0 103.765 178.62 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.446 ' HA2' ' C ' ' A' ' 121' ' ' GLU . . . 158.86 137.09 2.17 Favored Glycine 1 CA--C 1.444 -4.364 0 C-N-CA 117.33 -2.367 . . . . 0.0 112.773 167.521 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.491 ' O ' ' HB2' ' A' ' 43' ' ' HIS . 0.5 OUTLIER 177.69 63.0 0.01 OUTLIER 'General case' 0 N--CA 1.447 -0.602 0 O-C-N 124.419 0.717 . . . . 0.0 110.243 -175.193 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.491 ' HB2' ' O ' ' A' ' 42' ' ' LEU . 35.9 t60 164.95 123.26 0.01 OUTLIER 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 172.677 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.621 ' HA2' ' N ' ' A' ' 87' ' ' VAL . . . -47.66 -134.73 0.0 OUTLIER Glycine 0 N--CA 1.486 1.995 0 N-CA-C 119.798 2.679 . . . . 0.0 119.798 -172.931 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.482 ' O ' ' HB2' ' A' ' 83' ' ' ASP . 13.3 m-85 -88.88 162.3 16.21 Favored 'General case' 0 CA--C 1.471 -2.07 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 177.676 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.17 84.64 0.11 Allowed 'General case' 1 C--O 1.337 5.682 0 C-N-CA 120.212 -0.595 . . . . 0.0 112.266 -175.732 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.66 ' HB ' ' OE2' ' A' ' 49' ' ' GLU . 10.2 m -89.34 173.19 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 130.568 3.547 . . . . 0.0 114.323 -164.951 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.505 ' NE2' HG22 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -170.8 86.43 0.1 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.427 1.491 . . . . 0.0 108.195 174.422 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.66 ' OE2' ' HB ' ' A' ' 47' ' ' VAL . 3.0 mp0 -87.31 89.46 8.0 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 115.153 1.538 . . . . 0.0 115.153 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -118.21 -21.52 8.14 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 113.743 -1.571 . . . . 0.0 112.193 -177.827 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.559 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 92.32 110.94 1.86 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.847 -172.643 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.9 t0 -153.32 -171.24 3.85 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.351 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -73.97 135.77 43.19 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 177.599 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 t -67.41 5.27 0.8 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -173.828 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.75 5.82 8.13 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.993 -0.442 . . . . 0.0 110.591 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 173.86 136.45 2.21 Favored Glycine 0 CA--C 1.484 -1.862 0 C-N-CA 117.58 -2.248 . . . . 0.0 112.542 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.472 ' O ' ' HA2' ' A' ' 61' ' ' GLY . 53.7 m -96.84 87.87 4.42 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.496 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 p -83.29 -37.12 23.88 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-O 122.159 0.981 . . . . 0.0 111.61 172.023 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.0 m -90.03 -40.17 12.48 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.802 -170.384 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.76 -16.09 35.18 Favored 'General case' 0 N--CA 1.422 -1.869 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.472 ' HA2' ' O ' ' A' ' 57' ' ' CYS . . . 37.29 -144.81 0.13 Allowed Glycine 0 CA--C 1.488 -1.628 0 CA-C-N 111.786 -2.461 . . . . 0.0 116.387 171.721 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -82.71 87.35 1.37 Allowed 'Trans proline' 0 N--CA 1.403 -3.827 0 C-N-CA 122.144 1.896 . . . . 0.0 110.189 177.03 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 77.61 110.46 0.07 Allowed 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 114.298 -1.319 . . . . 0.0 114.479 170.248 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -170.48 91.78 0.18 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.737 -2.029 . . . . 0.0 105.538 173.031 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.49 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 25.8 t-20 -111.49 89.92 11.42 Favored Pre-proline 0 C--O 1.209 -1.035 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 -178.547 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -77.48 -11.32 17.27 Favored 'Trans proline' 0 C--N 1.323 -0.804 0 C-N-CA 122.786 2.324 . . . . 0.0 111.259 -173.412 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.5 tt -45.04 -62.18 1.34 Allowed 'General case' 0 CA--C 1.492 -1.262 0 O-C-N 125.254 1.596 . . . . 0.0 109.943 -175.195 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.717 ' OG ' ' HA ' ' A' ' 76' ' ' ASP . 19.8 m -106.04 -86.26 0.48 Allowed 'General case' 0 N--CA 1.389 -3.483 0 C-N-CA 117.546 -1.662 . . . . 0.0 111.538 176.109 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . 0.392 21.8 ttm180 -123.99 43.48 2.98 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 114.593 -2.843 . . . . 0.0 116.169 179.405 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.49 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 53.0 mtmt 75.27 -43.04 0.49 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 125.09 1.356 . . . . 0.0 113.688 173.45 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -70.21 -37.44 75.06 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.608 ' HA3' ' O ' ' A' ' 80' ' ' HIS . . . 171.55 171.63 36.84 Favored Glycine 0 C--O 1.266 2.152 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.732 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.69 77.14 0.1 Allowed Glycine 0 C--O 1.215 -1.046 0 CA-C-O 118.925 -0.931 . . . . 0.0 113.377 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.462 ' HA ' ' O ' ' A' ' 83' ' ' ASP . 42.8 Cg_endo -64.79 -42.95 13.64 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.531 2.154 . . . . 0.0 115.653 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.576 ' O ' HG13 ' A' ' 104' ' ' ILE . 58.4 pttt -119.7 26.01 9.63 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.59 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.717 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 33.6 t70 61.76 85.06 0.13 Allowed 'General case' 0 CA--C 1.487 -1.472 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 -163.921 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.594 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 6.2 tp10 -121.95 -35.58 3.15 Favored 'General case' 0 C--O 1.169 -3.142 0 CA-C-N 113.803 -1.544 . . . . 0.0 113.984 -164.961 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.594 ' HB3' ' O ' ' A' ' 77' ' ' GLU . 12.6 tt0 76.73 112.33 0.07 Allowed 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -162.008 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 75.1 -174.93 0.13 Allowed 'General case' 0 C--O 1.25 1.114 0 CA-C-N 114.537 -1.21 . . . . 0.0 109.9 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.608 ' O ' ' HA3' ' A' ' 72' ' ' GLY . 61.7 t-80 75.73 162.81 0.25 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 125.693 1.597 . . . . 0.0 107.202 -178.388 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.463 HG23 ' H ' ' A' ' 126' ' ' LEU . 3.7 p -62.36 115.49 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.04 172.746 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.433 ' C ' HG22 ' A' ' 47' ' ' VAL . . . -57.57 118.59 13.1 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 169.907 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.482 ' HB2' ' O ' ' A' ' 45' ' ' PHE . 0.5 OUTLIER -170.79 150.72 3.29 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 -172.675 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.9 mp -136.12 83.86 2.04 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 105.377 -2.083 . . . . 0.0 105.377 159.042 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.468 ' HA3' ' CD1' ' A' ' 45' ' ' PHE . . . 172.89 154.49 10.41 Favored Glycine 0 N--CA 1.422 -2.292 0 C-N-CA 118.982 -1.58 . . . . 0.0 114.6 176.562 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.474 ' H ' HG21 ' A' ' 99' ' ' ILE . 35.1 t30 -129.65 127.85 41.4 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 169.977 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.621 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 6.4 m -131.59 143.3 40.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.561 0 CA-C-N 118.216 0.462 . . . . 0.0 109.799 -173.427 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.9 m -142.37 96.24 2.92 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.628 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.452 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -137.87 154.74 49.44 Favored 'General case' 0 C--O 1.153 -3.978 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 7.9 p-10 -179.66 -27.57 0.01 OUTLIER 'General case' 0 C--N 1.255 -3.511 0 CA-C-O 122.485 1.136 . . . . 0.0 109.409 179.158 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -77.14 -49.61 14.84 Favored 'General case' 0 C--N 1.255 -3.534 0 CA-C-N 112.964 -1.925 . . . . 0.0 110.986 -177.59 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 32.8 t70 -132.79 -1.08 3.41 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.822 -174.842 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.7 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 68.67 66.16 2.39 Favored Glycine 0 C--O 1.215 -1.054 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -177.197 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.739 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 22.7 t -150.21 104.55 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.517 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -110.23 119.63 39.87 Favored 'General case' 0 N--CA 1.4 -2.938 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 174.328 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -112.59 113.19 25.21 Favored 'General case' 0 C--N 1.273 -2.751 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 -177.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.48 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 13.7 m -111.21 145.46 17.43 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.065 0 N-CA-C 114.552 1.316 . . . . 0.0 114.552 -168.729 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.0 t -143.06 102.06 3.93 Favored 'General case' 0 N--CA 1.413 -2.309 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 166.105 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.474 HG21 ' H ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -117.23 171.54 5.68 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -176.185 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -140.77 112.17 7.37 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.03 -0.986 . . . . 0.0 109.668 176.271 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . 0.439 ' OD1' ' HB3' ' A' ' 75' ' ' LYS . 2.2 t0 -130.24 168.63 16.55 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.779 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.467 ' HB2' ' HB2' ' A' ' 75' ' ' LYS . 22.0 m -76.04 123.72 26.23 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 119.408 1.003 . . . . 0.0 111.253 -174.101 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.453 ' HB ' ' N ' ' A' ' 23' ' ' LYS . 26.8 m -56.13 -12.09 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 C-N-CA 126.439 1.896 . . . . 0.0 114.546 -175.533 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.576 HG13 ' O ' ' A' ' 75' ' ' LYS . 26.3 pt -66.59 -12.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 CA-C-O 120.657 0.265 . . . . 0.0 111.136 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.565 ' HB3' ' C ' ' A' ' 75' ' ' LYS . 5.1 p -84.88 89.76 7.63 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 172.284 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 2.0 pt? -69.79 119.34 13.87 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 165.147 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -74.65 87.57 2.17 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.513 ' HA2' ' CB ' ' A' ' 49' ' ' GLU . . . 162.49 136.91 2.08 Favored Glycine 0 N--CA 1.405 -3.375 0 CA-C-N 114.614 -1.175 . . . . 0.0 112.398 178.337 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -83.28 -73.56 0.4 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.616 0.246 . . . . 0.0 110.725 176.322 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -87.42 -19.72 27.66 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.531 179.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.402 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t -159.32 163.74 35.41 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 105.895 -1.891 . . . . 0.0 105.895 175.302 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.582 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 6.4 pt -104.47 -16.95 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.853 0 C-N-CA 125.507 1.523 . . . . 0.0 108.6 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 37.4 pt -103.73 138.83 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.13 177.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.556 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 93.41 -0.34 68.21 Favored Glycine 0 CA--C 1.484 -1.846 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.021 171.261 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.559 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 2.6 mmp_? -87.55 144.53 26.65 Favored 'General case' 0 C--O 1.175 -2.823 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 2.3 p -98.61 119.47 37.39 Favored 'General case' 0 C--N 1.286 -2.193 0 CA-C-N 119.549 1.068 . . . . 0.0 113.165 -176.848 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 3.0 tt -88.27 131.67 34.69 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.338 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.505 HG22 ' NE2' ' A' ' 48' ' ' HIS . 93.5 t -102.24 109.49 26.44 Favored 'Isoleucine or valine' 0 C--O 1.267 2.009 0 C-N-CA 118.941 -1.103 . . . . 0.0 110.668 175.281 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.5 p -148.14 124.3 2.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.896 0.855 . . . . 0.0 113.192 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -144.02 157.44 44.33 Favored 'General case' 0 N--CA 1.41 -2.43 0 N-CA-C 101.872 -3.381 . . . . 0.0 101.872 168.207 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.538 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -68.92 89.79 0.42 Allowed 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.18 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.505 ' HD3' ' H ' ' A' ' 123' ' ' ALA . 2.2 tmtp? -173.85 168.12 4.3 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -174.857 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.505 ' H ' ' HD3' ' A' ' 122' ' ' LYS . . . -73.72 125.02 27.15 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 121.531 0.681 . . . . 0.0 111.175 173.548 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -156.1 112.89 3.15 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 125.526 1.53 . . . . 0.0 107.31 176.613 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.48 ' O ' ' HA2' ' A' ' 138' ' ' GLY . 7.4 m-20 -128.91 129.32 45.35 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.463 ' H ' HG23 ' A' ' 81' ' ' VAL . 3.3 mm? -82.69 -53.82 5.62 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 123.277 0.36 . . . . 0.0 111.168 -177.33 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.76 -31.24 45.1 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.65 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -93.13 -46.71 7.3 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.214 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 63.96 -82.04 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.601 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 -171.575 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 169.89 -67.34 0.16 Allowed Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -177.637 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.63 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 51.6 t30 -119.4 -175.29 2.91 Favored 'General case' 0 C--O 1.253 1.237 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 175.271 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.407 ' H ' ' CG ' ' A' ' 131' ' ' ASN . 41.9 mt-10 -54.01 -34.77 60.81 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -178.003 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . 0.63 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -83.79 -38.48 21.22 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.135 -178.951 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.451 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 14.6 m -65.16 -29.62 70.47 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.32 -175.209 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 11.4 t -68.53 -27.54 66.2 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 121.469 0.652 . . . . 0.0 109.892 179.124 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -84.05 -39.51 19.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.738 -178.967 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.0 m -72.26 -33.47 67.52 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 115.415 -0.812 . . . . 0.0 110.044 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.48 ' HA2' ' O ' ' A' ' 125' ' ' ASP . . . 59.72 45.96 94.84 Favored Glycine 0 CA--C 1.488 -1.626 0 N-CA-C 107.373 -2.291 . . . . 0.0 107.373 -171.431 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -34.42 104.62 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 O-C-N 126.424 1.896 . . . . 0.0 113.679 -166.23 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -151.8 172.43 16.18 Favored 'General case' 0 N--CA 1.425 -1.697 0 CA-C-N 113.523 -1.672 . . . . 0.0 108.353 -176.668 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.92 94.78 1.0 Allowed Glycine 0 N--CA 1.429 -1.779 0 N-CA-C 107.721 -2.152 . . . . 0.0 107.721 170.521 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.412 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 14.3 m -43.49 -44.29 5.88 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.922 1.689 . . . . 0.0 113.998 -172.919 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.471 ' HA ' ' H ' ' A' ' 57' ' ' CYS . 44.8 mtm180 -115.66 -25.95 7.64 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 177.904 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -46.62 -35.33 5.8 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.2 1.8 . . . . 0.0 112.539 -168.314 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.5 ' O ' ' HA ' ' A' ' 118' ' ' VAL . . . -141.58 87.76 2.09 Favored 'General case' 0 N--CA 1.388 -3.529 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 -179.221 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.439 ' SG ' HG23 ' A' ' 118' ' ' VAL . 86.5 m -138.7 138.91 38.16 Favored 'General case' 0 N--CA 1.419 -1.996 0 CA-C-N 114.035 -1.439 . . . . 0.0 107.845 176.331 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.21 148.95 18.55 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 174.851 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 27.9 m -68.95 123.91 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.809 0 CA-C-O 122.572 1.177 . . . . 0.0 111.97 178.665 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.402 HD13 ' N ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -98.2 138.51 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.561 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 174.439 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.582 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -174.4 151.99 13.66 Favored Glycine 3 N--CA 1.36 -6.37 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 177.642 . . . . . . . . 3 3 . 1 . 012 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.562 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.7 pp -60.57 114.54 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 170.382 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.41 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -126.94 114.89 18.44 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 118.221 -0.895 . . . . 0.0 109.267 -178.492 . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.45 -0.447 0 CA-C-O 121.047 0.451 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 11.6 t -121.68 -25.08 5.15 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.041 0.924 . . . . 0.0 110.167 -179.977 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -135.78 150.5 49.49 Favored 'General case' 0 N--CA 1.416 -2.166 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -178.443 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.523 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.52 161.44 37.91 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.98 127.82 66.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-O 121.363 0.601 . . . . 0.0 109.961 178.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.432 ' HA ' ' CG2' ' A' ' 148' ' ' VAL . . . -107.81 146.89 31.62 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.768 -177.847 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.585 ' N ' HG11 ' A' ' 148' ' ' VAL . 41.1 t -134.5 104.94 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 -178.366 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.93 151.34 22.88 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.0 tmtt? -144.27 122.01 11.9 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 175.768 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.38 -178.46 30.54 Favored Glycine 0 N--CA 1.414 -2.8 0 C-N-CA 117.999 -2.048 . . . . 0.0 115.939 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.3 m-20 -102.35 111.34 23.59 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 170.146 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.41 68.94 1.03 Allowed Glycine 0 C--N 1.289 -2.059 0 N-CA-C 104.988 -3.245 . . . . 0.0 104.988 -164.958 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -62.66 128.0 22.19 Favored 'Trans proline' 0 CA--C 1.503 -1.045 0 C-N-CA 123.159 2.573 . . . . 0.0 114.914 -165.435 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 m -115.8 123.13 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.524 0 CA-C-N 113.727 -1.579 . . . . 0.0 108.324 177.529 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -111.66 117.84 34.02 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.61 166.93 40.11 Favored Glycine 1 N--CA 1.383 -4.885 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.377 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.436 HD13 ' O ' ' A' ' 17' ' ' ILE . 2.5 pp -134.38 139.28 48.3 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.673 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.856 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.3 tp -136.14 133.87 50.26 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.9 m-20 -92.9 160.71 14.79 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.239 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.523 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 44.4 m-85 -143.48 118.34 9.94 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 176.081 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.404 ' O ' ' HG3' ' A' ' 21' ' ' GLU . 13.0 pt-20 -124.94 101.06 6.88 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.314 -1.354 . . . . 0.0 114.073 171.451 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.504 ' CB ' ' HA ' ' A' ' 105' ' ' SER . 22.7 mm-40 -154.29 101.46 2.38 Favored 'General case' 0 CA--C 1.507 -0.677 0 C-N-CA 124.377 1.071 . . . . 0.0 110.462 164.065 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -167.37 -73.06 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.399 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -90.34 -33.39 16.1 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.088 179.028 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 p -65.19 -69.57 0.29 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.887 -1.051 . . . . 0.0 112.025 -178.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 66.7 107.53 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 124.476 1.11 . . . . 0.0 110.924 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.641 ' O ' ' HB3' ' A' ' 102' ' ' SER . . . 133.33 -147.31 18.96 Favored Glycine 0 CA--C 1.487 -1.66 0 C-N-CA 119.044 -1.55 . . . . 0.0 112.044 -177.157 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.32 123.29 13.22 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 122.512 2.141 . . . . 0.0 111.519 -177.408 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.429 HG21 ' HA ' ' A' ' 102' ' ' SER . 46.4 t -95.4 95.15 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.852 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -176.75 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -98.19 90.76 4.96 Favored 'General case' 0 N--CA 1.411 -2.418 0 CA-C-O 122.498 1.142 . . . . 0.0 108.981 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.427 ' O ' HG23 ' A' ' 99' ' ' ILE . 27.3 m -124.28 151.61 29.52 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.74 0 CA-C-N 113.001 -1.909 . . . . 0.0 109.724 -175.006 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.425 ' HA ' ' CG1' ' A' ' 97' ' ' VAL . 20.9 m-90 -135.48 145.89 47.59 Favored 'General case' 0 C--N 1.267 -3.005 0 CA-C-N 114.988 -1.005 . . . . 0.0 109.026 -175.447 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.408 ' H ' HG12 ' A' ' 97' ' ' VAL . . . -167.46 137.7 4.76 Favored Glycine 0 N--CA 1.424 -2.158 0 C-N-CA 118.046 -2.026 . . . . 0.0 112.638 172.772 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 p -118.38 138.71 52.25 Favored 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.4 mm -119.61 135.82 58.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -120.5 105.57 10.97 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 173.404 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.93 174.84 16.78 Favored Glycine 0 C--N 1.269 -3.144 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.893 -175.71 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.1 tp -66.01 137.42 57.1 Favored 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 104.384 -2.45 . . . . 0.0 104.384 173.281 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 17.9 p -68.72 108.96 3.6 Favored 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 115.766 1.765 . . . . 0.0 115.766 -160.123 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -173.6 170.03 4.16 Favored 'General case' 0 CA--C 1.472 -2.047 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.791 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 169.2 136.55 2.08 Favored Glycine 2 C--N 1.241 -4.715 0 C-N-CA 117.481 -2.295 . . . . 0.0 113.129 167.556 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.6 mt -140.99 -50.39 0.44 Allowed 'General case' 0 N--CA 1.426 -1.672 0 O-C-N 124.553 0.796 . . . . 0.0 111.379 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -149.83 153.49 36.85 Favored 'General case' 0 C--N 1.321 -0.665 0 O-C-N 121.922 -0.486 . . . . 0.0 109.792 -175.993 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.536 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -96.59 107.5 3.52 Favored Glycine 0 CA--C 1.458 -3.478 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 175.297 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.602 ' CG ' ' HB3' ' A' ' 124' ' ' ASP . 29.4 p90 -121.79 83.49 2.1 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.525 ' O ' HG21 ' A' ' 47' ' ' VAL . 8.2 p80 -133.04 85.47 2.22 Favored 'General case' 0 N--CA 1.387 -3.586 0 O-C-N 118.968 -2.333 . . . . 0.0 113.607 -162.47 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.552 ' HB ' ' O ' ' A' ' 82' ' ' GLY . 43.4 t -170.47 136.12 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 C-N-CA 127.753 2.421 . . . . 0.0 108.168 171.698 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.579 ' HB2' ' O ' ' A' ' 116' ' ' THR . 2.0 m170 -150.35 94.76 2.16 Favored 'General case' 0 C--N 1.26 -3.309 0 CA-C-N 112.458 -2.155 . . . . 0.0 109.916 170.386 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.87 162.37 24.0 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 176.829 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.9 t80 71.74 28.96 2.62 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.461 ' HA3' ' HA ' ' A' ' 115' ' ' ARG . . . -72.01 -170.47 13.98 Favored Glycine 0 N--CA 1.428 -1.883 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.958 176.164 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -176.34 -63.04 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.552 -164.984 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -108.28 121.91 45.86 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.637 -173.437 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.1 p -70.81 2.62 4.02 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -177.889 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.69 19.02 11.92 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.318 0.247 . . . . 0.0 110.434 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 154.78 131.54 1.49 Allowed Glycine 0 C--N 1.309 -0.923 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.968 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.431 ' HB2' ' HG2' ' A' ' 143' ' ' ARG . 15.8 m -82.62 91.92 7.05 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.0 t -78.56 -61.37 2.03 Favored 'General case' 0 N--CA 1.426 -1.661 0 O-C-N 124.11 0.881 . . . . 0.0 110.157 172.486 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 13.4 m -65.43 -47.2 77.04 Favored 'General case' 0 C--O 1.214 -0.806 0 C-N-CA 122.967 0.507 . . . . 0.0 111.941 -177.107 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.36 -6.65 52.53 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.097 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -40.58 -71.57 0.29 Allowed Glycine 0 CA--C 1.541 1.706 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 -175.266 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -72.12 -17.05 28.41 Favored 'Trans proline' 0 N--CA 1.48 0.684 0 C-N-CA 122.92 2.414 . . . . 0.0 112.381 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 65.64 107.18 0.04 OUTLIER 'General case' 0 C--O 1.242 0.665 0 C-N-CA 126.611 1.965 . . . . 0.0 112.56 -177.771 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -130.29 84.09 2.18 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 118.306 -1.358 . . . . 0.0 108.474 166.261 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -119.46 90.63 42.97 Favored Pre-proline 0 C--N 1.289 -2.033 0 CA-C-N 112.5 -2.136 . . . . 0.0 108.066 173.647 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -30.1 -54.49 0.2 Allowed 'Trans proline' 0 N--CA 1.484 0.956 1 C-N-CA 126.735 4.957 . . . . 0.0 119.626 -168.864 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -93.84 0.47 56.24 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 118.688 -1.205 . . . . 0.0 113.843 -173.31 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.625 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 28.6 m -78.6 48.43 0.79 Allowed 'General case' 0 C--O 1.246 0.892 0 CA-C-O 122.386 1.089 . . . . 0.0 109.095 175.992 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 12.9 mmm180 -133.2 -28.77 1.48 Allowed 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.283 -173.189 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 54.3 tptt -38.84 -56.83 1.31 Allowed 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.105 0.962 . . . . 0.0 113.563 -173.227 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 21.2 t-80 -177.61 59.94 0.01 OUTLIER 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.161 -0.447 . . . . 0.0 110.011 176.334 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.453 ' CA ' ' HB3' ' A' ' 78' ' ' GLU . . . -38.93 105.98 0.05 OUTLIER Glycine 0 N--CA 1.483 1.83 0 O-C-N 123.744 0.653 . . . . 0.0 112.676 173.246 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.52 168.26 24.22 Favored Glycine 0 N--CA 1.413 -2.84 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -176.842 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -93.29 1.72 3.45 Favored 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 123.333 2.689 . . . . 0.0 115.985 -172.653 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.433 ' O ' ' HB3' ' A' ' 76' ' ' ASP . 87.1 mttt -108.5 -31.67 7.71 Favored 'General case' 0 C--O 1.262 1.715 0 C-N-CA 118.096 -1.442 . . . . 0.0 109.773 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.433 ' HB3' ' O ' ' A' ' 75' ' ' LYS . 0.8 OUTLIER 159.3 120.09 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.758 0 C-N-CA 128.301 2.64 . . . . 0.0 104.291 168.813 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 164.33 127.26 0.01 OUTLIER 'General case' 0 CA--C 1.454 -2.715 0 C-N-CA 124.459 1.104 . . . . 0.0 111.194 171.52 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.625 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.7 OUTLIER 162.75 -173.84 0.01 OUTLIER 'General case' 0 N--CA 1.396 -3.147 0 C-N-CA 130.885 3.674 . . . . 0.0 102.325 163.982 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.683 ' NE ' ' HA ' ' A' ' 79' ' ' ARG 0.381 1.4 mmp_? -121.01 11.25 10.95 Favored 'General case' 0 C--N 1.257 -3.415 0 N-CA-C 118.337 2.718 . . . . 0.0 118.337 -176.872 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.481 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -138.8 -67.03 0.47 Allowed 'General case' 0 CA--C 1.483 -1.629 0 C-N-CA 117.37 -1.732 . . . . 0.0 110.804 170.006 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 7.1 p 174.33 89.57 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.273 -2.737 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 179.371 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.552 ' O ' ' HB ' ' A' ' 47' ' ' VAL . . . -112.43 -34.07 1.99 Allowed Glycine 0 CA--C 1.47 -2.749 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.98 -174.962 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -168.21 172.05 8.91 Favored 'General case' 0 N--CA 1.438 -1.056 0 O-C-N 124.305 0.65 . . . . 0.0 110.333 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.603 HD21 ' N ' ' A' ' 85' ' ' GLY . 5.8 tt -138.23 170.9 15.21 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 125.391 1.682 . . . . 0.0 106.546 -174.44 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . 0.603 ' N ' HD21 ' A' ' 84' ' ' LEU . . . -38.89 147.53 0.13 Allowed Glycine 0 N--CA 1.466 0.686 0 C-N-CA 125.005 1.288 . . . . 0.0 114.948 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -79.49 136.3 36.87 Favored 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 114.682 -0.759 . . . . 0.0 109.162 -166.274 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.536 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 30.3 m -134.72 126.69 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.408 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.435 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.6 t -141.28 148.2 39.42 Favored 'General case' 0 C--N 1.267 -3.001 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 -177.571 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.791 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -132.76 154.38 50.29 Favored 'General case' 0 C--N 1.259 -3.326 0 N-CA-C 105.362 -2.088 . . . . 0.0 105.362 178.931 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.543 ' C ' ' H ' ' A' ' 92' ' ' ASP . 6.9 t70 -101.65 -153.45 0.46 Allowed 'General case' 1 C--N 1.225 -4.841 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.548 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 95.0 mttt -62.66 16.82 0.01 OUTLIER 'General case' 0 CA--C 1.58 2.116 0 O-C-N 121.587 -0.696 . . . . 0.0 112.845 171.405 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.543 ' H ' ' C ' ' A' ' 90' ' ' ASP . 17.0 t70 -133.68 109.65 9.31 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 171.369 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -76.43 92.59 0.98 Allowed Glycine 0 C--N 1.32 -0.357 0 N-CA-C 114.911 0.725 . . . . 0.0 114.911 -170.456 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.7 t -158.46 103.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 176.016 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.481 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.18 128.75 43.37 Favored 'General case' 0 N--CA 1.398 -3.027 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.677 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -82.15 153.36 26.06 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 124.144 0.902 . . . . 0.0 110.642 -174.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.425 ' CG1' ' HA ' ' A' ' 32' ' ' TRP . 78.4 t -81.21 134.91 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 C-N-CA 124.203 1.001 . . . . 0.0 111.668 -172.694 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 61.5 m -122.97 123.76 41.65 Favored 'General case' 0 N--CA 1.414 -2.245 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.045 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.427 HG23 ' O ' ' A' ' 31' ' ' VAL . 31.8 pt -94.43 160.39 2.72 Favored 'Isoleucine or valine' 0 C--O 1.25 1.106 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 49.8 mt-10 -142.99 159.28 42.53 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-O 122.159 0.98 . . . . 0.0 113.239 -171.494 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.22 169.4 17.39 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 172.007 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.641 ' HB3' ' O ' ' A' ' 27' ' ' GLY . 10.9 p -57.34 91.94 0.01 OUTLIER 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -173.764 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.56 -38.16 2.07 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.225 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.063 173.014 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.403 ' O ' HG23 ' A' ' 104' ' ' ILE . 25.3 mm -72.37 25.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 C-N-CA 126.919 2.088 . . . . 0.0 111.936 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.504 ' HA ' ' CB ' ' A' ' 22' ' ' GLN . 16.8 p -66.95 149.65 50.32 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 121.667 -0.646 . . . . 0.0 110.831 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . 0.308 0.9 OUTLIER -80.95 86.3 6.11 Favored 'General case' 0 N--CA 1.388 -3.536 0 CA-C-O 124.647 2.165 . . . . 0.0 111.505 178.573 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.7 m -149.85 85.95 1.43 Allowed 'General case' 2 N--CA 1.367 -4.613 1 N-CA-C 100.061 -4.051 . . . . 0.0 100.061 168.457 . . . . . . . . 3 2 . 1 . 013 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -125.31 -155.99 9.21 Favored Glycine 0 C--N 1.26 -3.674 0 CA-C-N 113.46 -1.7 . . . . 0.0 109.444 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -92.2 -44.54 8.72 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . 0.418 ' O ' ' HB2' ' A' ' 111' ' ' SER . 23.1 m80 -118.64 -50.77 2.4 Favored 'General case' 0 N--CA 1.434 -1.234 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.444 175.018 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.418 ' HB2' ' O ' ' A' ' 110' ' ' HIS . 33.2 t 165.45 168.03 0.02 OUTLIER 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 177.182 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.52 ' O ' HG22 ' A' ' 149' ' ' ILE . 50.1 mm -71.72 -45.98 63.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 3.5 mp -71.71 121.25 21.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.726 -0.609 . . . . 0.0 111.764 -172.663 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.83 -0.05 25.81 Favored Glycine 0 CA--C 1.478 -2.225 0 C-N-CA 120.403 -0.903 . . . . 0.0 110.873 170.1 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.503 ' HB2' ' HB ' ' A' ' 149' ' ' ILE . 11.1 mmt180 -91.86 173.52 7.82 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.59 -178.708 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.579 ' O ' ' HB2' ' A' ' 48' ' ' HIS . 17.5 p -128.46 103.77 7.32 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-O 118.725 -0.655 . . . . 0.0 110.998 -173.301 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.578 HD22 ' O ' ' A' ' 148' ' ' VAL . 0.7 OUTLIER -76.26 137.16 39.76 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 120.312 1.414 . . . . 0.0 111.573 -178.026 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.548 ' HA ' ' HB3' ' A' ' 146' ' ' CYS . 11.5 p -92.87 125.25 45.46 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.436 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 176.11 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.8 p -148.55 130.88 6.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 C-N-CA 118.961 -1.095 . . . . 0.0 113.115 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 16.3 t-80 -154.93 151.33 28.41 Favored 'General case' 0 N--CA 1.416 -2.169 0 N-CA-C 102.348 -3.204 . . . . 0.0 102.348 163.168 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.487 ' O ' ' HA2' ' A' ' 41' ' ' GLY . 2.9 mp0 -70.3 99.52 1.56 Allowed 'General case' 0 C--N 1.269 -2.896 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 174.12 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -168.31 173.83 7.46 Favored 'General case' 0 C--O 1.199 -1.59 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -171.834 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.01 120.48 26.17 Favored 'General case' 0 C--N 1.256 -3.471 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 177.733 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.602 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -167.13 136.77 2.87 Favored 'General case' 0 N--CA 1.509 2.512 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.012 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -149.89 150.9 32.59 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.823 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -90.95 -39.31 12.33 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.11 -33.91 5.84 Favored Glycine 0 C--N 1.3 -1.465 0 C-N-CA 119.753 -1.213 . . . . 0.0 111.65 -175.375 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 49.1 tptt -118.43 41.34 2.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -176.964 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.91 -7.24 69.8 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 115.463 -0.79 . . . . 0.0 114.736 -176.288 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 144.11 -122.42 1.81 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.492 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.447 ' O ' HG23 ' A' ' 135' ' ' THR . 88.9 m-20 -99.65 -174.54 2.74 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -177.583 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -47.09 -52.65 14.69 Favored 'General case' 0 N--CA 1.484 1.228 0 O-C-N 123.564 0.54 . . . . 0.0 111.264 -176.699 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -77.71 -40.85 39.9 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.7 p -75.53 -27.17 58.59 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -175.708 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.447 HG23 ' O ' ' A' ' 131' ' ' ASN . 13.9 t -76.12 -33.25 59.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 176.237 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -74.08 -32.54 63.3 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.727 -179.321 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 86.4 m -79.22 -31.05 43.55 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.304 174.788 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.73 60.94 8.1 Favored Glycine 0 CA--C 1.484 -1.884 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -36.31 105.62 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 125.733 1.49 . . . . 0.0 111.876 -174.694 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.421 ' HA ' ' HB2' ' A' ' 124' ' ' ASP . . . -101.8 169.93 8.48 Favored 'General case' 0 N--CA 1.429 -1.516 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.92 -169.838 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.457 ' C ' ' H ' ' A' ' 143' ' ' ARG . . . -63.96 154.02 47.12 Favored Glycine 0 N--CA 1.406 -3.303 0 N-CA-C 106.481 -2.648 . . . . 0.0 106.481 169.921 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -57.01 8.81 0.01 OUTLIER 'General case' 0 C--N 1.262 -3.223 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.457 ' H ' ' C ' ' A' ' 141' ' ' GLY . 0.2 OUTLIER 65.67 19.17 11.39 Favored 'General case' 0 CA--C 1.467 -2.224 0 C-N-CA 125.277 1.431 . . . . 0.0 107.959 177.675 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 53.0 mt -70.94 -33.24 70.3 Favored 'General case' 0 CA--C 1.445 -3.072 0 CA-C-N 113.91 -1.495 . . . . 0.0 107.668 -176.723 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.487 ' O ' ' HB3' ' A' ' 146' ' ' CYS . . . -121.98 89.74 3.17 Favored 'General case' 1 N--CA 1.35 -5.458 0 CA-C-N 113.557 -1.656 . . . . 0.0 108.158 175.38 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.548 ' HB3' ' HA ' ' A' ' 118' ' ' VAL . 19.9 p -171.91 127.94 0.61 Allowed 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 113.812 1.042 . . . . 0.0 113.812 169.95 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.542 ' HA2' ' CB ' ' A' ' 116' ' ' THR . . . -178.51 77.93 0.07 OUTLIER Glycine 0 N--CA 1.402 -3.62 0 CA-C-O 118.638 -1.09 . . . . 0.0 110.656 159.009 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.585 HG11 ' N ' ' A' ' 7' ' ' VAL . 13.1 p -172.58 96.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.184 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 169.727 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.545 ' CD1' ' HB3' ' A' ' 117' ' ' LEU . 12.2 mm -124.46 102.68 11.28 Favored 'Isoleucine or valine' 1 C--N 1.234 -4.445 0 N-CA-C 104.692 -2.336 . . . . 0.0 104.692 167.364 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -165.59 146.56 11.25 Favored Glycine 2 CA--C 1.444 -4.394 0 C-N-CA 115.941 -3.028 . . . . 0.0 112.678 175.458 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.515 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 0.0 OUTLIER -95.26 105.56 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.568 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 171.98 . . . . . . . . 3 3 . 1 . 013 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.92 99.61 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.441 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.245 0.863 0 N-CA-C 105.466 -2.049 . . . . 0.0 105.466 178.07 . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.207 -1.145 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 m -100.48 -27.63 13.33 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -171.536 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -136.66 148.62 47.51 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.169 -173.255 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.538 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -142.35 143.19 32.63 Favored 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 92.1 t -124.26 129.13 74.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.689 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -120.11 145.61 46.74 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.939 -177.22 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 56.5 t -127.38 126.07 66.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 85.3 mt -112.1 133.08 54.47 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -142.6 133.54 25.68 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.68 -170.89 21.59 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 119.362 -1.399 . . . . 0.0 112.553 -177.312 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -73.31 -46.1 51.49 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -101.58 96.29 1.47 Allowed Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 171.089 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -71.53 127.09 12.79 Favored 'Trans proline' 0 N--CA 1.434 -1.986 0 C-N-CA 121.797 1.665 . . . . 0.0 113.968 -168.48 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.91 148.28 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.286 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 173.309 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -123.94 118.64 27.51 Favored 'General case' 0 C--N 1.259 -3.355 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -177.178 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.413 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -167.26 146.48 10.77 Favored Glycine 0 N--CA 1.409 -3.101 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.891 -178.03 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.2 pt -130.66 118.24 41.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.459 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.1 OUTLIER -114.88 133.04 62.27 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.103 -176.708 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 24.0 m-80 -109.46 119.73 40.33 Favored 'General case' 0 CA--C 1.51 -0.589 0 C-N-CA 123.309 0.644 . . . . 0.0 109.592 -173.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.486 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 56.7 m-85 -120.76 137.41 54.52 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.779 0.323 . . . . 0.0 110.617 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.522 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 9.9 pt-20 -107.89 134.0 51.45 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.418 175.809 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.523 ' HA ' ' O ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -126.91 112.45 15.32 Favored 'General case' 0 N--CA 1.413 -2.307 0 C-N-CA 123.777 0.831 . . . . 0.0 109.459 178.309 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.8 tttm -138.12 149.07 45.58 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.34 -173.032 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . 0.519 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.1 mp0 -50.51 -44.29 56.05 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 125.728 1.611 . . . . 0.0 110.332 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.6 m -51.72 -45.24 63.51 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.651 1.18 . . . . 0.0 111.913 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.8 t30 57.62 87.59 0.06 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 124.294 0.996 . . . . 0.0 111.917 -179.037 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.477 ' H ' HG21 ' A' ' 104' ' ' ILE . . . -132.47 -151.6 6.79 Favored Glycine 0 CA--C 1.492 -1.361 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.19 -177.093 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_exo -67.6 124.18 11.67 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.215 1.943 . . . . 0.0 108.01 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.462 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 13.4 p -80.01 132.69 31.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 CA-C-O 121.23 0.538 . . . . 0.0 110.5 -176.632 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -93.98 99.21 11.58 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 169.734 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 5.9 p -123.44 130.54 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.001 0 CA-C-N 115.311 -0.858 . . . . 0.0 108.711 -175.015 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -136.44 125.49 24.42 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.498 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.459 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -164.25 140.17 6.29 Favored Glycine 0 N--CA 1.41 -3.045 0 C-N-CA 119.724 -1.226 . . . . 0.0 111.933 172.745 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.43 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 16.9 m -116.04 135.46 53.93 Favored 'General case' 0 N--CA 1.404 -2.77 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 12.1 tt -125.13 136.94 59.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 118.54 0.609 . . . . 0.0 109.976 179.183 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.596 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 91.7 mttt -116.92 131.84 56.85 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.128 -2.175 . . . . 0.0 105.128 -177.839 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.588 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -155.0 175.8 32.91 Favored Glycine 0 C--N 1.269 -3.169 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -166.751 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.62 171.0 8.23 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 175.274 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.0 t -69.47 107.18 3.25 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.809 -175.153 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.551 ' OE2' ' HG2' ' A' ' 122' ' ' LYS . 22.2 tt0 -177.08 171.13 2.14 Favored 'General case' 0 N--CA 1.419 -2.011 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 171.473 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . 0.709 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 170.78 104.83 0.18 Allowed Glycine 1 C--N 1.251 -4.144 0 C-N-CA 119.02 -1.562 . . . . 0.0 111.843 169.543 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.414 ' HB2' ' N ' ' A' ' 123' ' ' ALA . 6.8 mp -110.78 -86.89 0.53 Allowed 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.062 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.597 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 39.4 t-80 -175.15 122.3 0.22 Allowed 'General case' 0 C--N 1.355 0.823 0 C-N-CA 118.364 -1.335 . . . . 0.0 114.35 -173.388 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 102.99 137.94 9.74 Favored Glycine 0 C--N 1.3 -1.432 0 N-CA-C 117.502 1.761 . . . . 0.0 117.502 164.635 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.436 ' CE1' HD22 ' A' ' 117' ' ' LEU . 0.7 OUTLIER -96.18 166.73 11.6 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 124.028 0.931 . . . . 0.0 109.359 170.179 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.693 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . 6.1 m80 -171.83 90.44 0.12 Allowed 'General case' 0 CA--C 1.482 -1.661 0 C-N-CA 125.298 1.439 . . . . 0.0 110.004 169.414 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.532 HG11 ' OD1' ' A' ' 83' ' ' ASP . 2.6 p -69.36 162.7 3.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 168.942 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.461 ' CE1' ' HD2' ' A' ' 62' ' ' PRO 0.278 0.0 OUTLIER -148.85 171.49 16.21 Favored 'General case' 0 N--CA 1.419 -1.979 0 C-N-CA 116.562 -2.055 . . . . 0.0 109.482 170.187 . . . . . . . . 4 4 . 1 . 014 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.472 ' HB3' ' CG2' ' A' ' 81' ' ' VAL . 1.9 pm0 -69.57 166.35 19.16 Favored 'General case' 0 C--N 1.261 -3.273 0 N-CA-C 116.072 1.879 . . . . 0.0 116.072 -171.043 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.558 ' CD2' ' HB3' ' A' ' 59' ' ' SER . 4.0 t80 72.77 33.26 1.32 Allowed 'General case' 0 N--CA 1.439 -1.023 0 C-N-CA 126.321 1.848 . . . . 0.0 107.243 172.022 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.424 ' HA2' ' HB1' ' A' ' 60' ' ' ALA . . . -57.56 154.84 20.49 Favored Glycine 0 C--N 1.345 1.048 0 CA-C-N 112.42 -2.173 . . . . 0.0 113.063 -178.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . 0.504 ' OD1' ' HA ' ' A' ' 57' ' ' CYS . 3.8 p30 -144.8 -85.75 0.13 Allowed 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -172.901 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.542 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 52.7 t30 -98.31 148.77 23.31 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.288 0.566 . . . . 0.0 112.43 -173.392 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.463 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 6.9 m -82.3 -2.93 54.26 Favored 'General case' 0 CA--C 1.56 1.349 0 C-N-CA 124.323 1.049 . . . . 0.0 111.652 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.99 17.06 7.92 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 121.097 0.475 . . . . 0.0 111.02 -177.828 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.542 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 143.94 117.16 1.16 Allowed Glycine 0 CA--C 1.484 -1.864 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -177.374 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.549 ' O ' ' HB2' ' A' ' 142' ' ' SER . 6.1 p -97.53 113.69 25.44 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -175.949 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.0 p -80.0 -45.42 18.44 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.558 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . 49.8 m -79.37 -29.0 41.94 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 123.445 0.698 . . . . 0.0 111.216 -174.724 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.424 ' HB1' ' HA2' ' A' ' 51' ' ' GLY . . . -76.71 -5.26 47.28 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 123.981 0.912 . . . . 0.0 111.19 172.443 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.22 52.1 0.91 Allowed Glycine 0 CA--C 1.559 2.801 0 C-N-CA 117.177 -2.439 . . . . 0.0 116.247 176.369 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.518 ' HD3' ' O ' ' A' ' 59' ' ' SER . 86.9 Cg_endo -96.37 2.93 1.99 Allowed 'Trans proline' 0 C--N 1.397 3.127 0 CA-C-N 121.821 2.81 . . . . 0.0 107.322 161.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 38.9 m80 75.22 -47.75 0.61 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 125.541 1.536 . . . . 0.0 113.623 173.772 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.4 ' CE2' ' HB3' ' A' ' 66' ' ' PRO . 70.1 t80 -69.27 116.12 9.34 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -170.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.421 ' HB2' HG13 ' A' ' 81' ' ' VAL . 5.5 p30 -116.16 96.49 47.49 Favored Pre-proline 0 CA--C 1.559 1.309 0 C-N-CA 125.061 1.344 . . . . 0.0 110.089 176.82 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.4 ' HB3' ' CE2' ' A' ' 64' ' ' PHE . 96.7 Cg_endo -79.95 -18.7 10.06 Favored 'Trans proline' 0 CA--C 1.552 1.384 0 C-N-CA 123.119 2.546 . . . . 0.0 117.823 -169.203 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 84.0 mt -88.09 -5.32 58.52 Favored 'General case' 0 CA--C 1.484 -1.567 0 O-C-N 120.817 -1.177 . . . . 0.0 110.906 -172.719 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.48 ' C ' ' H ' ' A' ' 70' ' ' LYS . 17.9 m -77.92 58.05 1.85 Allowed 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 104.533 -2.395 . . . . 0.0 104.533 167.039 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.516 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 2.1 tmm_? -92.59 17.56 9.98 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -169.329 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.488 ' HB2' ' CB ' ' A' ' 78' ' ' GLU . 11.9 mptt -140.03 63.97 1.46 Allowed 'General case' 0 N--CA 1.411 -2.402 0 CA-C-N 112.705 -2.043 . . . . 0.0 109.411 175.135 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . 0.433 ' O ' ' HB3' ' A' ' 126' ' ' LEU . 20.2 t60 65.38 -37.57 0.24 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 125.313 1.445 . . . . 0.0 113.284 -178.984 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.13 20.68 62.34 Favored Glycine 0 N--CA 1.414 -2.816 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -175.517 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.603 ' O ' ' HG3' ' A' ' 77' ' ' GLU . . . -90.31 175.53 41.14 Favored Glycine 0 C--O 1.202 -1.897 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.863 -177.107 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.533 ' C ' ' H ' ' A' ' 76' ' ' ASP . 2.8 Cg_exo -72.07 2.34 4.99 Favored 'Trans proline' 0 N--CA 1.501 1.926 1 C-N-CA 125.717 4.278 . . . . 0.0 111.302 -170.562 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.484 ' H ' ' C ' ' A' ' 73' ' ' GLY . 60.9 tttm -76.59 27.59 0.13 Allowed 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 127.402 2.281 . . . . 0.0 109.089 178.669 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.533 ' H ' ' C ' ' A' ' 74' ' ' PRO 0.303 1.2 p30 77.18 10.32 2.51 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 128.453 2.701 . . . . 0.0 115.665 173.597 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.603 ' HG3' ' O ' ' A' ' 73' ' ' GLY . 1.7 mp0 33.19 108.19 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 127.639 2.375 . . . . 0.0 114.089 170.999 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.516 ' OE1' ' HB3' ' A' ' 69' ' ' ARG . 43.1 tt0 -34.73 -61.66 0.39 Allowed 'General case' 0 N--CA 1.507 2.392 0 O-C-N 123.914 0.759 . . . . 0.0 112.133 -177.747 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 75.0 mtt85 -136.62 63.64 1.57 Allowed 'General case' 0 C--N 1.286 -2.177 0 C-N-CA 118.834 -1.146 . . . . 0.0 111.056 174.778 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.607 ' NE2' ' HB2' ' A' ' 105' ' ' SER . 0.3 OUTLIER -38.86 94.26 0.01 OUTLIER 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 122.729 1.252 . . . . 0.0 113.375 171.455 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.472 ' CG2' ' HB3' ' A' ' 49' ' ' GLU . 3.3 p -80.97 -10.73 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.616 0 CA-C-N 112.224 -2.262 . . . . 0.0 105.379 169.496 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.531 ' O ' ' HB2' ' A' ' 80' ' ' HIS . . . -123.6 -132.25 3.91 Favored Glycine 1 N--CA 1.369 -5.825 0 CA-C-N 111.942 -2.39 . . . . 0.0 108.27 169.517 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.532 ' OD1' HG11 ' A' ' 47' ' ' VAL . 2.0 p-10 -164.4 165.9 21.12 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 177.992 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.446 ' CD1' ' HA2' ' A' ' 73' ' ' GLY . 1.6 tt -144.46 87.76 1.89 Allowed 'General case' 0 N--CA 1.423 -1.823 0 C-N-CA 118.342 -1.343 . . . . 0.0 109.28 161.483 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.02 136.51 13.52 Favored Glycine 0 N--CA 1.419 -2.487 0 N-CA-C 104.853 -3.299 . . . . 0.0 104.853 165.665 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . 0.359 0.2 OUTLIER -92.11 128.69 38.05 Favored 'General case' 0 N--CA 1.426 -1.645 0 C-N-CA 115.171 -2.611 . . . . 0.0 113.318 -173.189 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.592 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 92.6 t -110.64 138.7 37.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.186 -174.945 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.5 p -140.15 95.09 2.83 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 -179.07 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.709 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -86.14 137.03 32.97 Favored 'General case' 0 N--CA 1.415 -2.217 0 CA-C-O 121.406 0.622 . . . . 0.0 109.945 -176.966 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.522 ' C ' ' H ' ' A' ' 92' ' ' ASP . 30.8 t70 -75.23 154.62 37.44 Favored 'General case' 1 C--N 1.242 -4.103 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 174.516 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -53.07 23.07 0.0 OUTLIER 'General case' 0 CA--C 1.579 2.094 0 N-CA-C 115.839 1.792 . . . . 0.0 115.839 174.488 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.522 ' H ' ' C ' ' A' ' 90' ' ' ASP . 1.5 m-20 -133.89 8.63 3.82 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 124.945 1.298 . . . . 0.0 108.787 171.674 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 66.8 80.08 0.2 Allowed Glycine 0 N--CA 1.44 -1.046 0 CA-C-N 114.998 -1.001 . . . . 0.0 112.564 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.571 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.5 p -161.71 113.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.43 ' O ' ' HA ' ' A' ' 34' ' ' SER . . . -136.8 144.63 43.81 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.807 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -119.58 115.14 23.38 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 175.381 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.413 HG13 ' CE2' ' A' ' 45' ' ' PHE . 4.3 p -102.92 103.41 15.04 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.352 0 CA-C-O 122.173 0.987 . . . . 0.0 111.714 -178.472 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.2 m -139.65 100.18 3.9 Favored 'General case' 0 N--CA 1.421 -1.894 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 172.736 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.9 mm -135.3 128.45 48.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -176.471 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.462 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 43.0 mt-10 -104.5 106.19 16.59 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.155 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -160.51 168.66 24.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 104.369 -2.456 . . . . 0.0 104.369 170.722 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.488 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 24.8 m -80.76 79.18 7.45 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 115.726 1.75 . . . . 0.0 115.726 -169.344 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.528 ' HA ' ' CE1' ' A' ' 80' ' ' HIS . 12.4 p -92.51 -11.62 9.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 169.476 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.523 ' O ' ' HA ' ' A' ' 22' ' ' GLN . 15.9 tt -57.87 19.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.102 0 C-N-CA 130.201 3.4 . . . . 0.0 114.235 -176.306 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.607 ' HB2' ' NE2' ' A' ' 80' ' ' HIS . 16.4 m -97.85 170.91 8.64 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 103.627 -2.731 . . . . 0.0 103.627 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.425 ' O ' HD12 ' A' ' 106' ' ' LEU . 2.6 pp -68.14 119.13 12.23 Favored 'General case' 0 N--CA 1.414 -2.24 0 C-N-CA 117.689 -1.605 . . . . 0.0 109.467 176.274 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 m -68.95 89.75 0.42 Allowed 'General case' 0 N--CA 1.414 -2.234 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.303 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 155.27 155.69 7.44 Favored Glycine 0 N--CA 1.401 -3.64 0 CA-C-N 114.155 -1.384 . . . . 0.0 110.501 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -69.66 -38.91 77.29 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -107.37 -48.07 3.52 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.266 -175.946 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.572 ' O ' ' HD2' ' A' ' 115' ' ' ARG . 15.3 m -163.04 159.92 23.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.61 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.491 ' H ' HD12 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -72.79 -46.6 52.72 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.894 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.077 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 tp -67.56 127.15 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 176.766 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.98 11.93 58.29 Favored Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 119.611 -1.28 . . . . 0.0 110.768 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.572 ' HD2' ' O ' ' A' ' 111' ' ' SER . 0.0 OUTLIER -114.67 121.55 43.73 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.237 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.811 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 14.9 p -98.45 135.56 39.83 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-O 121.856 0.836 . . . . 0.0 111.638 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.479 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 56.2 tp -74.66 102.87 4.74 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 113.937 -1.483 . . . . 0.0 111.485 -174.442 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.409 HG12 ' HA ' ' A' ' 142' ' ' SER . 12.6 m -93.21 96.36 6.12 Favored 'Isoleucine or valine' 1 C--O 1.33 5.293 0 C-N-CA 116.314 -2.154 . . . . 0.0 112.821 175.035 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.446 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 7.1 p -150.5 171.57 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 113.46 -1.7 . . . . 0.0 107.992 -176.836 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.437 ' H ' HG22 ' A' ' 119' ' ' VAL . 82.2 t60 -152.04 170.76 19.12 Favored 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 168.419 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -69.77 88.37 0.54 Allowed 'General case' 0 CA--C 1.551 0.983 0 CA-C-N 123.016 2.643 . . . . 0.0 109.045 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.551 ' HG2' ' OE2' ' A' ' 40' ' ' GLU . 65.8 mttm -166.75 173.31 9.68 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 125.771 1.628 . . . . 0.0 108.318 -168.226 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.597 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -82.68 114.52 21.1 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 172.149 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.693 ' OD1' ' HB2' ' A' ' 46' ' ' HIS . 11.9 t70 -124.31 76.58 1.49 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -176.717 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -114.43 158.59 21.35 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.155 0.502 . . . . 0.0 110.548 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.455 ' O ' ' HA ' ' A' ' 135' ' ' THR . 3.2 tm? -87.85 -56.35 3.38 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.467 -1.242 . . . . 0.0 108.007 -179.381 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 71' ' ' HIS . . . -68.26 -40.63 87.44 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.725 -177.83 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -105.43 50.74 0.77 Allowed 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.25 76.73 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.588 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -67.29 0.53 Allowed Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.379 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.425 ' H ' ' CB ' ' A' ' 134' ' ' SER . 4.1 m-20 -105.99 176.81 5.04 Favored 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 119.052 -0.499 . . . . 0.0 109.945 -179.121 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -56.18 -44.07 79.02 Favored 'General case' 0 CA--C 1.567 1.634 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 176.203 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -71.85 -33.39 68.4 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.425 ' CB ' ' H ' ' A' ' 131' ' ' ASN . 2.3 m -68.1 -19.97 64.89 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.969 0.414 . . . . 0.0 110.887 -175.733 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.455 ' HA ' ' O ' ' A' ' 126' ' ' LEU . 8.8 m -74.0 -21.3 60.04 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 121.511 0.672 . . . . 0.0 109.823 178.563 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -83.24 -51.18 7.69 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.3 p -69.01 -50.59 47.46 Favored 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.965 -177.504 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . 0.43 ' CA ' ' HA ' ' A' ' 126' ' ' LEU . . . 67.16 92.45 0.04 OUTLIER Glycine 0 N--CA 1.418 -2.532 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -174.508 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -31.77 136.63 0.06 Allowed 'General case' 1 C--O 1.322 4.892 0 N-CA-C 118.813 2.894 . . . . 0.0 118.813 -167.037 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -126.51 129.01 47.79 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 112.925 -1.943 . . . . 0.0 109.246 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -115.23 75.33 0.25 Allowed Glycine 0 N--CA 1.416 -2.665 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 176.428 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.549 ' HB2' ' O ' ' A' ' 57' ' ' CYS . 77.5 p -58.92 -26.82 64.69 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 123.848 0.859 . . . . 0.0 112.306 -175.611 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -117.52 -0.89 11.79 Favored 'General case' 0 N--CA 1.427 -1.617 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.803 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.401 ' HB3' ' HB2' ' A' ' 120' ' ' HIS . 3.9 mm? -79.05 -34.84 43.45 Favored 'General case' 0 C--N 1.282 -2.367 0 C-N-CA 117.949 -1.5 . . . . 0.0 110.393 -176.655 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.446 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -173.96 89.45 0.07 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 177.62 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.811 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 44.6 t -139.07 133.11 31.15 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 118.159 -1.416 . . . . 0.0 110.34 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.463 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -161.18 166.02 35.59 Favored Glycine 0 N--CA 1.398 -3.897 0 N-CA-C 107.967 -2.053 . . . . 0.0 107.967 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.92 122.37 20.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.086 0.47 . . . . 0.0 110.339 -178.727 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.403 HD12 ' CD1' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -116.26 106.5 20.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.233 . . . . . . . . 3 3 . 1 . 014 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -172.31 -179.29 43.08 Favored Glycine 1 N--CA 1.392 -4.268 0 N-CA-C 110.031 -1.227 . . . . 0.0 110.031 -179.125 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.419 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.3 tt -54.87 114.47 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 121.751 0.786 . . . . 0.0 112.475 -179.041 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -149.93 154.9 39.06 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 176.655 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 . . . . . 0 C--N 1.29 -1.995 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.819 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.481 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.21 -0.987 0 CA-C-O 120.283 0.087 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.3 m -76.26 -27.92 56.88 Favored 'General case' 0 CA--C 1.562 1.434 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -175.932 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 151' ' ' ILE . 20.2 ptpt -152.63 167.55 28.52 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.594 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -153.02 152.5 31.45 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 175.439 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.3 t -134.41 138.37 49.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.449 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -109.44 134.61 51.65 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -175.443 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . 0.532 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 46.9 t -134.31 102.55 4.27 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.366 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 175.654 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . 0.436 HD22 ' H ' ' A' ' 8' ' ' LEU . 1.5 pt? -117.74 132.49 56.46 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -178.015 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -138.0 138.59 39.03 Favored 'General case' 0 C--O 1.248 0.98 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.76 -158.76 8.87 Favored Glycine 0 N--CA 1.435 -1.386 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.045 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -63.63 -50.97 67.25 Favored 'General case' 0 CA--C 1.511 -0.554 0 O-C-N 124.537 0.787 . . . . 0.0 109.167 177.218 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -88.65 154.95 25.32 Favored Glycine 0 N--CA 1.44 -1.1 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 175.234 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -86.23 124.35 2.43 Favored 'Trans proline' 0 N--CA 1.414 -3.149 0 CA-C-N 120.342 2.071 . . . . 0.0 110.072 -176.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.453 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 13.8 m -131.66 146.78 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.966 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 -179.372 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.49 123.29 3.77 Favored 'General case' 0 C--N 1.251 -3.707 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.437 ' HA3' HG12 ' A' ' 35' ' ' ILE . . . -153.11 157.95 27.64 Favored Glycine 0 N--CA 1.396 -3.978 0 C-N-CA 119.945 -1.122 . . . . 0.0 111.068 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.407 ' O ' HG13 ' A' ' 17' ' ' ILE . 25.2 pt -123.97 102.43 11.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.519 HG13 ' HA3' ' A' ' 33' ' ' GLY . 1.8 mp -107.53 128.48 62.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.594 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 30.4 p-10 -115.91 125.74 52.98 Favored 'General case' 0 C--N 1.35 0.597 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.509 ' H ' ' HB1' ' A' ' 4' ' ' ALA . 69.0 t80 -126.03 130.1 50.48 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -171.007 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.481 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 14.3 pt-20 -136.5 102.59 4.99 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-O 121.317 0.58 . . . . 0.0 110.888 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.441 ' HB3' ' CZ ' ' A' ' 20' ' ' PHE . 9.4 tt0 -151.21 114.42 4.79 Favored 'General case' 0 N--CA 1.414 -2.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.67 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -174.83 -74.17 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.853 175.424 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -90.31 -8.78 50.0 Favored 'General case' 0 N--CA 1.431 -1.376 0 CA-C-N 114.746 -1.115 . . . . 0.0 109.652 -177.726 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -52.83 -50.38 63.83 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 172.937 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 49.58 64.1 1.9 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.066 177.027 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.23 -164.47 36.66 Favored Glycine 0 N--CA 1.419 -2.499 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 -174.986 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.39 124.83 17.04 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 C-N-CA 122.18 1.92 . . . . 0.0 111.054 -178.156 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.421 ' CG2' ' HB2' ' A' ' 22' ' ' GLN . 3.0 p -74.27 130.34 36.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.789 -177.667 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . 0.441 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 63.4 mttp -92.54 99.28 12.03 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.792 175.561 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.511 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 3.2 p -138.17 141.77 37.26 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.668 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -178.217 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 58.0 t90 -153.29 139.24 18.14 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.519 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -156.72 140.33 7.11 Favored Glycine 0 N--CA 1.413 -2.896 0 C-N-CA 118.757 -1.687 . . . . 0.0 113.099 176.573 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.5 p -114.23 134.27 55.04 Favored 'General case' 0 N--CA 1.409 -2.52 0 C-N-CA 124.379 1.071 . . . . 0.0 108.231 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.437 HG12 ' HA3' ' A' ' 16' ' ' GLY . 78.4 mt -127.6 140.23 49.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-O 121.132 0.492 . . . . 0.0 110.0 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.453 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 94.6 mttt -110.69 107.08 16.52 Favored 'General case' 0 N--CA 1.4 -2.968 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 174.683 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.03 175.35 22.72 Favored Glycine 0 C--N 1.292 -1.899 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -170.792 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . 0.575 ' HA ' ' OD1' ' A' ' 92' ' ' ASP . 2.3 pp -69.0 169.69 11.26 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 117.963 0.882 . . . . 0.0 111.42 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.444 ' HB ' ' HB2' ' A' ' 92' ' ' ASP . 2.2 t -70.2 106.24 3.23 Favored 'General case' 0 C--O 1.244 0.788 0 C-N-CA 119.475 -0.89 . . . . 0.0 111.8 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.439 ' O ' ' HB2' ' A' ' 121' ' ' GLU . 7.4 tp10 -175.06 111.88 0.13 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 125.437 1.495 . . . . 0.0 107.434 170.929 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.76 75.47 0.42 Allowed Glycine 0 C--N 1.264 -3.427 0 C-N-CA 118.005 -2.045 . . . . 0.0 113.72 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.85 136.66 43.94 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 39.7 m80 -55.59 121.98 10.31 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 124.64 1.176 . . . . 0.0 110.561 -172.68 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.69 122.7 0.86 Allowed Glycine 1 N--CA 1.381 -4.994 0 C-N-CA 119.718 -1.23 . . . . 0.0 113.3 177.982 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -68.81 142.69 54.81 Favored 'General case' 0 C--N 1.261 -3.262 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 162.624 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.639 ' CB ' ' HA ' ' A' ' 119' ' ' VAL . 21.2 m-70 -126.94 91.29 3.31 Favored 'General case' 0 N--CA 1.421 -1.882 0 CA-C-N 121.222 1.828 . . . . 0.0 106.715 -173.712 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.496 ' HB ' ' O ' ' A' ' 81' ' ' VAL . 7.3 m -125.16 162.75 27.07 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -171.576 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.3 m-70 -170.81 119.46 0.53 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.407 3.083 . . . . 0.0 106.87 170.456 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.494 ' HB2' ' HA2' ' A' ' 108' ' ' GLY . 0.2 OUTLIER -102.59 84.11 2.38 Favored 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 117.87 -1.532 . . . . 0.0 112.957 -176.361 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.53 ' CZ ' ' HA ' ' A' ' 60' ' ' ALA . 0.6 OUTLIER 167.34 113.49 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.845 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.509 ' HA3' ' H ' ' A' ' 116' ' ' THR . . . -147.57 -154.35 6.21 Favored Glycine 0 CA--C 1.485 -1.802 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.846 178.182 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -173.96 -68.17 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.498 0 O-C-N 124.287 0.639 . . . . 0.0 110.24 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.517 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.4 t-20 -97.64 130.85 44.62 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.674 -174.53 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.1 t -84.06 -6.28 59.38 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -177.475 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.73 -25.46 13.84 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 120.95 0.405 . . . . 0.0 110.337 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.517 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -147.44 118.83 1.05 Allowed Glycine 0 N--CA 1.429 -1.807 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 -178.743 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.615 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 19.9 p -98.2 87.66 3.98 Favored 'General case' 0 C--N 1.276 -2.627 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.163 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.0 m -79.84 -39.72 30.03 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.296 177.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -53.55 -47.09 70.33 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.59 1.156 . . . . 0.0 111.794 -176.072 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.53 ' HA ' ' CZ ' ' A' ' 50' ' ' PHE . . . -76.87 -9.05 58.42 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -176.226 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -39.79 -64.31 1.08 Allowed Glycine 0 N--CA 1.479 1.555 0 C-N-CA 124.576 1.084 . . . . 0.0 115.363 -177.392 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.77 1.32 5.22 Favored 'Trans proline' 0 CA--C 1.544 0.983 0 C-N-CA 122.838 2.359 . . . . 0.0 113.399 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.296 9.1 p80 50.39 37.04 14.46 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -87.81 89.89 8.17 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 122.186 0.993 . . . . 0.0 109.644 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.478 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.4 OUTLIER -113.73 97.42 44.23 Favored Pre-proline 0 C--N 1.284 -2.278 0 CA-C-N 113.723 -1.58 . . . . 0.0 110.496 -177.954 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 50.0 Cg_endo -84.73 -12.98 7.15 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.13 2.553 . . . . 0.0 115.995 -173.296 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.689 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 56.5 tp -85.43 -19.8 30.76 Favored 'General case' 1 CA--C 1.421 -4.012 0 CA-C-O 121.589 0.709 . . . . 0.0 109.19 -179.551 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.483 ' C ' ' H ' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -76.99 28.26 0.14 Allowed 'General case' 0 N--CA 1.384 -3.753 0 C-N-CA 127.741 2.416 . . . . 0.0 108.911 178.086 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.59 ' H ' ' C ' ' A' ' 67' ' ' LEU . 63.6 ttt180 -73.42 43.32 0.13 Allowed 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 128.558 2.743 . . . . 0.0 110.39 -173.763 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.528 ' CB ' ' HB2' ' A' ' 79' ' ' ARG . 22.6 ttmm -139.32 -18.4 0.99 Allowed 'General case' 0 C--N 1.245 -3.957 0 CA-C-N 113.894 -1.503 . . . . 0.0 108.511 166.687 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 70.33 19.31 6.52 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.105 1.762 . . . . 0.0 111.325 177.64 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.18 137.5 8.78 Favored Glycine 0 N--CA 1.426 -1.999 0 C-N-CA 120.433 -0.889 . . . . 0.0 114.595 176.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.36 162.46 28.64 Favored Glycine 0 N--CA 1.425 -2.07 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 175.559 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -73.24 -38.49 2.67 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 122.898 2.398 . . . . 0.0 112.751 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . 0.704 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.9 OUTLIER -104.55 -25.45 12.75 Favored 'General case' 0 C--O 1.202 -1.422 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.253 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 49.91 -164.61 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 129.188 2.995 . . . . 0.0 115.045 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -144.58 -56.03 0.35 Allowed 'General case' 0 N--CA 1.427 -1.609 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.47 -169.144 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.454 ' HA ' ' HA ' ' A' ' 105' ' ' SER . 47.6 mt-10 -172.57 -30.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 125.734 1.614 . . . . 0.0 107.67 -176.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.689 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 13.9 mmt180 -87.44 41.62 0.99 Allowed 'General case' 1 N--CA 1.364 -4.736 0 C-N-CA 125.095 1.358 . . . . 0.0 109.768 -171.422 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.682 ' HB3' ' O ' ' A' ' 82' ' ' GLY . 9.5 t-160 -95.08 13.32 25.59 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.545 -172.658 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.496 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 48.7 t 71.25 26.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 123.493 1.616 . . . . 0.0 107.229 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.682 ' O ' ' HB3' ' A' ' 80' ' ' HIS . . . 116.35 -146.45 18.84 Favored Glycine 0 N--CA 1.409 -3.149 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 -169.93 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -170.8 124.89 0.67 Allowed 'General case' 0 CA--C 1.474 -1.951 0 CA-C-N 118.753 1.276 . . . . 0.0 107.734 174.272 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 10.0 tp -161.39 171.77 17.66 Favored 'General case' 0 N--CA 1.408 -2.535 0 N-CA-C 104.762 -2.31 . . . . 0.0 104.762 -178.351 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.63 175.49 25.56 Favored Glycine 0 N--CA 1.404 -3.464 0 N-CA-C 109.079 -1.609 . . . . 0.0 109.079 -177.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 97' ' ' VAL . 14.3 t30 -77.32 138.66 39.49 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.754 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.493 ' HA ' ' O ' ' A' ' 96' ' ' ASP . 13.9 p -150.74 127.12 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 178.177 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.647 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 24.7 p -141.1 122.34 14.81 Favored 'General case' 0 N--CA 1.418 -2.059 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.397 -167.356 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.526 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -109.05 103.7 12.76 Favored 'General case' 0 N--CA 1.41 -2.45 0 C-N-CA 117.031 -1.868 . . . . 0.0 106.538 173.892 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -93.99 -39.42 10.65 Favored 'General case' 0 CA--C 1.468 -2.199 0 CA-C-O 122.161 0.981 . . . . 0.0 109.955 -170.031 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.456 ' HA ' ' HE3' ' A' ' 91' ' ' LYS . 1.0 OUTLIER -85.59 5.85 29.87 Favored 'General case' 0 C--N 1.27 -2.875 0 CA-C-N 114.102 -1.408 . . . . 0.0 111.572 -177.652 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.575 ' OD1' ' HA ' ' A' ' 38' ' ' LEU . 13.4 t70 74.66 93.72 0.07 Allowed 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 123.438 0.695 . . . . 0.0 111.541 -175.815 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 106.17 13.22 23.67 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 116.269 1.267 . . . . 0.0 116.269 171.978 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.526 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 49.0 t -145.31 102.91 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.457 -2.626 0 N-CA-C 103.42 -2.807 . . . . 0.0 103.42 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.647 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -99.59 118.48 36.23 Favored 'General case' 0 N--CA 1.389 -3.477 0 C-N-CA 118.867 -1.133 . . . . 0.0 111.306 -177.794 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . 0.493 ' O ' ' HA ' ' A' ' 87' ' ' VAL . 21.7 t70 -80.41 111.52 16.89 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.01 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.562 ' HA ' ' O ' ' A' ' 86' ' ' ASN . 13.3 p -87.7 122.92 39.98 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.455 0 CA-C-O 121.97 0.89 . . . . 0.0 109.881 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 67.9 m -122.25 105.87 10.61 Favored 'General case' 0 C--N 1.273 -2.723 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.162 176.415 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.474 HG22 ' O ' ' A' ' 31' ' ' VAL . 2.2 pp -93.74 154.76 3.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 178.417 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -125.64 160.85 28.62 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.736 1.214 . . . . 0.0 109.109 -176.321 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -82.76 99.69 9.81 Favored 'General case' 0 C--N 1.283 -2.297 0 C-N-CA 119.781 -0.767 . . . . 0.0 109.386 -171.221 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.704 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 21.5 m -95.66 162.1 13.76 Favored 'General case' 0 N--CA 1.417 -2.078 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 173.133 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 9.9 m -103.15 -64.51 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.535 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 26.8 mt -133.5 25.54 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 -174.132 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.454 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 21.4 t -78.57 87.43 4.53 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 122.069 0.938 . . . . 0.0 110.28 -175.503 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.8 tp -70.74 120.84 16.93 Favored 'General case' 0 N--CA 1.408 -2.574 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -74.79 87.23 2.23 Favored 'General case' 0 N--CA 1.409 -2.475 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 176.066 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.494 ' HA2' ' HB2' ' A' ' 49' ' ' GLU . . . 155.39 136.08 2.13 Favored Glycine 0 N--CA 1.411 -2.974 0 C-N-CA 119.537 -1.316 . . . . 0.0 114.379 177.634 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -89.54 -52.06 5.21 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.846 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -74.49 -47.74 31.35 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.035 176.563 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 37.7 t 179.37 -170.59 0.13 Allowed 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.417 ' O ' ' HA3' ' A' ' 150' ' ' GLY . 9.5 mt -89.62 -23.95 6.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 177.564 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 tt -68.97 132.46 33.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.922 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.71 -9.16 72.55 Favored Glycine 0 N--CA 1.419 -2.448 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.163 174.945 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.425 ' HD3' ' HA ' ' A' ' 50' ' ' PHE . 4.2 mmp_? -81.23 123.95 28.89 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -175.72 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.509 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 27.6 p -89.3 101.4 14.06 Favored 'General case' 0 N--CA 1.389 -3.481 0 C-N-CA 120.256 -0.578 . . . . 0.0 109.727 177.875 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 8.0 mp -85.23 120.38 26.66 Favored 'General case' 0 CA--C 1.473 -1.986 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 174.239 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.439 HG13 ' C ' ' A' ' 141' ' ' GLY . 2.4 t -92.54 115.64 31.89 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.251 0 C-N-CA 116.824 -1.951 . . . . 0.0 111.469 -172.452 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.652 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 42.1 t -125.0 129.38 73.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 127.729 2.412 . . . . 0.0 110.587 -166.388 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.488 ' CB ' ' HB3' ' A' ' 144' ' ' LEU . 12.7 t60 -159.68 148.07 17.46 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 103.774 -2.676 . . . . 0.0 103.774 169.949 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.439 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 4.3 pm0 -68.79 88.27 0.37 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 123.112 1.434 . . . . 0.0 109.822 178.229 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -169.51 151.15 4.33 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 -171.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.38 118.68 8.41 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 118.146 0.43 . . . . 0.0 110.121 177.738 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.445 ' HA ' ' H ' ' A' ' 140' ' ' ALA . 44.0 t0 -96.7 -80.86 0.43 Allowed 'General case' 0 C--O 1.187 -2.216 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.459 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.4 t70 76.19 152.02 0.13 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 128.344 2.658 . . . . 0.0 112.271 175.28 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.07 -64.03 1.11 Allowed 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.667 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 -17.42 72.21 Favored Glycine 0 CA--C 1.481 -2.084 0 CA-C-N 114.137 -1.392 . . . . 0.0 113.03 -170.434 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.0 tttp -65.86 -41.1 92.1 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.172 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . 0.667 ' HA2' ' O ' ' A' ' 134' ' ' SER . . . -75.8 69.9 2.06 Favored Glycine 0 N--CA 1.409 -3.122 0 N-CA-C 115.182 0.833 . . . . 0.0 115.182 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -141.68 23.86 2.48 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 119.457 -1.354 . . . . 0.0 114.709 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.453 ' HB3' ' CB ' ' A' ' 134' ' ' SER . 64.6 t30 -132.14 176.37 8.44 Favored 'General case' 0 N--CA 1.522 3.15 0 CA-C-O 116.132 -1.89 . . . . 0.0 107.594 178.507 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.29 -57.03 11.98 Favored 'General case' 0 C--N 1.385 2.121 0 CA-C-N 121.934 2.152 . . . . 0.0 113.458 -174.803 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 -86.0 -34.18 20.87 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 121.077 0.465 . . . . 0.0 110.922 176.906 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.667 ' O ' ' HA2' ' A' ' 129' ' ' GLY . 1.3 m -66.98 -21.8 65.95 Favored 'General case' 0 C--O 1.185 -2.335 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.69 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.603 ' HA ' ' CA ' ' A' ' 129' ' ' GLY . 5.2 t -80.0 -12.55 59.7 Favored 'General case' 0 CA--C 1.51 -0.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.939 179.515 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -88.25 -46.77 8.95 Favored 'General case' 0 C--N 1.275 -2.669 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.239 -175.935 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.7 p -85.72 -32.72 21.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 113.892 -1.503 . . . . 0.0 112.314 -178.52 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -77.48 -4.04 83.83 Favored Glycine 0 C--O 1.202 -1.893 0 CA-C-O 119.171 -0.794 . . . . 0.0 114.879 -173.23 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -142.7 104.46 4.36 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 164.97 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.445 ' H ' ' HA ' ' A' ' 124' ' ' ASP . . . -69.83 160.35 31.93 Favored 'General case' 1 C--O 1.33 5.307 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.252 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.439 ' C ' HG13 ' A' ' 118' ' ' VAL . . . -163.77 -151.91 6.67 Favored Glycine 1 N--CA 1.382 -4.94 0 C-N-CA 118.124 -1.988 . . . . 0.0 115.262 -165.953 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.615 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 2.9 m -46.9 7.28 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 1 C-N-CA 132.552 4.341 . . . . 0.0 120.14 -166.146 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 72.3 mtt180 -125.69 -27.58 3.36 Favored 'General case' 0 C--N 1.264 -3.138 0 C-N-CA 118.794 -1.162 . . . . 0.0 111.289 178.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.488 ' HB3' ' CB ' ' A' ' 120' ' ' HIS . 4.0 mm? -60.46 -43.69 96.65 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.084 -174.346 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.652 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -171.51 112.39 0.34 Allowed 'General case' 0 CA--C 1.49 -1.338 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.547 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.438 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 88.8 m -95.19 140.44 30.1 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.522 -177.397 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.532 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.08 150.67 13.35 Favored Glycine 1 N--CA 1.389 -4.474 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.607 176.319 . . . . . . . . 3 3 . 1 . 015 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.4 t -75.67 119.59 23.84 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 171.356 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.401 HD11 ' HB3' ' A' ' 6' ' ' ALA . 23.2 mm -118.59 102.17 12.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.368 0 N-CA-C 105.264 -2.125 . . . . 0.0 105.264 179.09 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.417 ' HA3' ' O ' ' A' ' 112' ' ' ILE . . . 177.8 -172.5 45.15 Favored Glycine 0 CA--C 1.452 -3.902 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.256 -177.191 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.536 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.6 tt -70.67 103.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 122.108 0.956 . . . . 0.0 110.724 -178.959 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.53 115.36 5.27 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.778 -1.555 . . . . 0.0 111.26 -179.077 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 . . . . . 0 C--N 1.296 -1.75 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.797 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.482 ' HB1' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.218 -0.6 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.412 ' HA ' ' HG2' ' A' ' 21' ' ' GLU . 60.0 m -121.35 -43.45 2.41 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 110.648 177.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . 0.447 ' HB2' ' HZ2' ' A' ' 3' ' ' LYS . 0.1 OUTLIER -142.14 144.63 33.56 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.828 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.499 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -134.06 149.57 51.15 Favored 'General case' 0 N--CA 1.41 -2.452 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.4 178.688 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 63.3 t -120.14 127.26 75.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -177.57 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.465 ' HB1' ' H ' ' A' ' 18' ' ' ILE . . . -107.76 129.0 55.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.996 176.546 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.7 m -134.61 102.56 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 74.5 mt -96.01 134.45 39.01 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.304 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.7 tttp -147.33 122.2 9.99 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.954 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.02 -157.86 8.6 Favored Glycine 0 N--CA 1.435 -1.402 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -89.62 94.0 9.69 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 169.285 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 128.21 143.74 5.71 Favored Glycine 0 C--N 1.275 -2.829 0 N-CA-C 107.309 -2.316 . . . . 0.0 107.309 -177.053 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -97.81 123.11 0.18 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 CA-C-N 120.367 2.083 . . . . 0.0 113.524 -178.828 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 p -134.7 112.18 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.333 0 CA-C-N 114.534 -1.212 . . . . 0.0 107.957 171.751 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -118.14 119.53 35.0 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 118.874 -1.13 . . . . 0.0 111.092 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -159.36 149.43 19.28 Favored Glycine 0 N--CA 1.406 -3.356 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.536 179.265 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 27.5 pt -113.82 107.21 22.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.465 ' H ' ' HB1' ' A' ' 6' ' ' ALA . 28.1 mm -100.44 128.45 52.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.639 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 24.5 t-20 -101.0 144.21 30.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -178.543 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.437 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 87.0 m-85 -132.57 120.18 21.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.794 0.33 . . . . 0.0 111.531 175.17 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.412 ' HG2' ' HA ' ' A' ' 2' ' ' THR . 1.8 tm-20 -132.34 101.78 5.49 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 174.152 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.684 ' HG2' ' O ' ' A' ' 105' ' ' SER . 18.1 mp0 -127.51 132.21 49.98 Favored 'General case' 0 N--CA 1.387 -3.606 0 N-CA-C 103.601 -2.74 . . . . 0.0 103.601 167.109 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 6.3 tmtt? -131.54 168.64 17.32 Favored 'General case' 0 C--N 1.257 -3.437 0 N-CA-C 107.14 -1.429 . . . . 0.0 107.14 -173.21 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 10.3 pt-20 -62.48 -9.5 8.75 Favored 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 124.038 0.935 . . . . 0.0 111.777 178.708 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -56.86 -39.5 74.41 Favored 'General case' 0 N--CA 1.424 -1.726 0 C-N-CA 124.999 1.319 . . . . 0.0 110.528 176.444 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . 0.457 ' OD1' HG21 ' A' ' 103' ' ' VAL . 56.4 t30 66.76 104.08 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 123.635 0.774 . . . . 0.0 110.478 178.297 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.72 -177.0 48.13 Favored Glycine 0 CA--C 1.474 -2.477 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -175.18 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -57.26 123.19 13.22 Favored 'Trans proline' 0 C--O 1.24 0.61 0 C-N-CA 122.262 1.975 . . . . 0.0 111.642 -178.787 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 92.5 t -76.42 111.46 13.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.436 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . 0.3 0.0 OUTLIER -112.59 107.29 15.95 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.812 1.291 . . . . 0.0 112.123 177.882 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.639 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 30.8 m -137.22 154.4 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.577 0 CA-C-N 113.054 -1.885 . . . . 0.0 106.323 -172.269 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 61.6 p-90 -139.19 148.1 42.7 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.44 ' O ' ' HA ' ' A' ' 97' ' ' VAL . . . -169.57 137.75 4.68 Favored Glycine 0 N--CA 1.404 -3.444 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 171.975 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.3 t -117.2 131.72 56.8 Favored 'General case' 0 N--CA 1.407 -2.587 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 -177.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.567 ' H ' ' HB2' ' A' ' 95' ' ' ALA . 15.5 pt -114.91 153.18 16.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 C-N-CA 118.694 -1.203 . . . . 0.0 111.075 176.582 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 48.4 mtmt -120.34 107.61 13.15 Favored 'General case' 0 N--CA 1.408 -2.552 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 177.24 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.08 174.17 17.29 Favored Glycine 0 C--N 1.295 -1.734 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 45.5 tp -69.02 171.81 7.62 Favored 'General case' 0 CA--C 1.571 1.77 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 176.289 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.497 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 1.6 t -69.27 110.31 4.55 Favored 'General case' 0 CA--C 1.5 -0.954 0 O-C-N 121.243 -0.911 . . . . 0.0 112.978 -178.354 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.494 ' HG2' ' O ' ' A' ' 39' ' ' THR . 10.3 mm-40 -170.47 171.58 6.42 Favored 'General case' 0 C--N 1.275 -2.652 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 173.927 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.27 -155.77 31.53 Favored Glycine 0 C--N 1.26 -3.65 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 169.344 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.529 ' HB3' ' O ' ' A' ' 87' ' ' VAL . 5.2 tt -178.44 149.43 0.5 Allowed 'General case' 0 N--CA 1.412 -2.337 0 N-CA-C 103.563 -2.754 . . . . 0.0 103.563 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.486 ' H ' ' HA ' ' A' ' 123' ' ' ALA . 78.2 t60 -161.34 121.6 2.68 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 173.32 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.454 ' O ' ' HB3' ' A' ' 124' ' ' ASP . . . 77.09 136.84 0.81 Allowed Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.726 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.449 ' HB2' ' CG1' ' A' ' 119' ' ' VAL . 0.1 OUTLIER -142.23 131.46 23.43 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 117.855 0.827 . . . . 0.0 112.204 -177.952 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.591 ' HA ' ' O ' ' A' ' 82' ' ' GLY . 21.7 t-80 -82.08 89.3 6.44 Favored 'General case' 0 CA--C 1.476 -1.877 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.695 -177.074 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.644 ' CB ' HD22 ' A' ' 117' ' ' LEU . 6.7 m -110.47 80.89 0.55 Allowed 'Isoleucine or valine' 1 N--CA 1.379 -4.008 0 CA-C-O 122.897 1.332 . . . . 0.0 110.346 175.689 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.501 ' HD1' ' CA ' ' A' ' 82' ' ' GLY . 2.4 p-80 -174.72 145.24 0.88 Allowed 'General case' 0 CA--C 1.487 -1.447 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.98 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.471 ' HG2' ' CE1' ' A' ' 46' ' ' HIS 0.351 10.9 mm-40 -172.92 173.97 3.64 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 126.628 1.971 . . . . 0.0 111.554 163.423 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -110.28 75.04 0.91 Allowed 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 102.886 -3.005 . . . . 0.0 102.886 171.671 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -104.91 -149.97 19.72 Favored Glycine 0 CA--C 1.482 -1.984 0 CA-C-N 113.142 -1.845 . . . . 0.0 113.617 -169.114 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 37.9 t70 175.0 -41.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.438 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 18.1 m120 -101.13 124.93 47.61 Favored 'General case' 0 CA--C 1.498 -1.037 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.92 -173.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.3 t -84.25 -25.63 29.25 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.165 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.41 -8.6 38.21 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.218 0.533 . . . . 0.0 110.261 -178.806 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.438 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -144.25 110.02 0.56 Allowed Glycine 0 N--CA 1.409 -3.116 0 C-N-CA 119.486 -1.34 . . . . 0.0 109.901 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.652 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 6.7 p -96.44 86.7 4.23 Favored 'General case' 0 N--CA 1.391 -3.401 0 CA-C-O 122.32 1.057 . . . . 0.0 110.733 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 30.5 m -82.03 -47.38 12.7 Favored 'General case' 0 N--CA 1.417 -2.116 0 CA-C-N 114.043 -1.435 . . . . 0.0 109.484 174.026 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 p -72.03 -16.8 62.05 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.194 -176.791 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.496 ' HB2' ' HB2' ' A' ' 57' ' ' CYS . . . -82.48 -6.69 59.46 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.22 177.078 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . 0.522 ' HA2' ' HB3' ' A' ' 142' ' ' SER . . . -50.58 176.33 0.05 OUTLIER Glycine 0 C--N 1.355 1.592 0 CA-C-N 114.83 -1.077 . . . . 0.0 112.311 175.625 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.427 ' HA ' ' CE2' ' A' ' 64' ' ' PHE . 21.3 Cg_exo -68.88 55.24 0.92 Allowed 'Trans proline' 0 N--CA 1.488 1.174 0 C-N-CA 123.466 2.777 . . . . 0.0 112.137 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -159.12 87.74 0.86 Allowed 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 105.567 -2.012 . . . . 0.0 105.567 -177.214 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.623 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 27.2 m-85 -111.78 162.99 14.66 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 -173.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -93.5 99.15 3.05 Favored Pre-proline 0 C--O 1.248 0.975 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.325 174.143 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.623 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 71.0 Cg_exo -52.36 -12.04 1.42 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 125.197 3.932 . . . . 0.0 114.913 -178.507 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.5 mt -94.92 7.39 46.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-O 122.761 1.267 . . . . 0.0 107.996 -171.212 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.9 t -120.76 23.57 10.67 Favored 'General case' 0 N--CA 1.395 -3.186 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 175.536 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.513 ' NH2' ' HB3' ' A' ' 66' ' ' PRO . 38.6 ttp180 -132.15 -32.64 1.37 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 113.199 -1.819 . . . . 0.0 107.629 171.978 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 5.3 mmtp 39.32 71.12 0.18 Allowed 'General case' 0 N--CA 1.427 -1.583 0 C-N-CA 125.616 1.566 . . . . 0.0 112.814 178.332 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 69.6 -29.35 0.18 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 125.747 1.619 . . . . 0.0 114.29 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 96.5 159.59 31.97 Favored Glycine 0 N--CA 1.418 -2.541 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -173.028 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.81 163.22 36.97 Favored Glycine 0 C--N 1.291 -1.954 0 C-N-CA 119.227 -1.463 . . . . 0.0 111.379 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.94 -43.16 1.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 118.885 1.343 . . . . 0.0 112.044 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -120.73 -28.36 4.89 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.609 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.634 ' HA ' ' CG ' ' A' ' 80' ' ' HIS . 5.9 p-10 170.91 165.75 0.08 Allowed 'General case' 0 CA--C 1.481 -1.675 0 C-N-CA 124.287 1.035 . . . . 0.0 108.692 177.347 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -137.64 -73.31 0.42 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER -135.93 -65.64 0.58 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 177.716 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -119.85 68.78 0.83 Allowed 'General case' 0 N--CA 1.415 -2.203 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 171.645 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.634 ' CG ' ' HA ' ' A' ' 76' ' ' ASP . 29.8 t-80 -86.49 66.21 9.4 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 177.635 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.526 HG13 ' O ' ' A' ' 106' ' ' LEU . 25.2 m -114.87 -15.02 10.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.406 -176.43 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.591 ' O ' ' HA ' ' A' ' 46' ' ' HIS . . . -79.89 -1.76 87.69 Favored Glycine 0 CA--C 1.492 -1.391 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.451 177.418 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.535 ' HB2' ' CB ' ' A' ' 126' ' ' LEU . 4.3 t70 -167.48 115.31 0.78 Allowed 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 125.664 1.586 . . . . 0.0 106.91 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.442 ' O ' ' HE1' ' A' ' 45' ' ' PHE . 1.5 pt? -170.06 82.1 0.11 Allowed 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 164.599 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 171.4 147.54 5.71 Favored Glycine 1 N--CA 1.393 -4.189 0 C-N-CA 118.842 -1.646 . . . . 0.0 112.444 177.719 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -105.71 128.01 53.42 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 102.43 -3.174 . . . . 0.0 102.43 162.463 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.529 ' O ' ' HB3' ' A' ' 42' ' ' LEU . 5.8 t -128.77 153.18 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 N-CA-C 102.557 -3.127 . . . . 0.0 102.557 -177.953 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.413 HG22 ' O ' ' A' ' 94' ' ' VAL . 15.4 t -139.53 149.85 44.39 Favored 'General case' 0 N--CA 1.4 -2.966 0 C-N-CA 118.594 -1.242 . . . . 0.0 110.694 -175.886 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.472 ' CB ' ' HB2' ' A' ' 121' ' ' GLU . . . -120.44 155.4 33.58 Favored 'General case' 2 C--N 1.224 -4.887 0 CA-C-N 114.381 -1.281 . . . . 0.0 108.725 -177.375 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -149.42 160.14 43.7 Favored 'General case' 1 C--N 1.236 -4.359 0 N-CA-C 104.311 -2.478 . . . . 0.0 104.311 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.497 ' HB3' ' HB ' ' A' ' 39' ' ' THR . 0.0 OUTLIER -44.08 -31.72 1.01 Allowed 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 119.51 1.05 . . . . 0.0 112.976 172.77 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -91.53 -25.27 19.32 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.864 0.84 . . . . 0.0 109.116 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 83.12 85.81 0.82 Allowed Glycine 0 N--CA 1.397 -3.908 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.317 -175.955 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.413 ' O ' HG22 ' A' ' 88' ' ' THR . 10.8 m -136.95 102.37 2.63 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 122.312 1.053 . . . . 0.0 109.753 175.659 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.567 ' HB2' ' H ' ' A' ' 35' ' ' ILE . . . -96.25 145.33 25.65 Favored 'General case' 0 N--CA 1.408 -2.561 0 CA-C-N 113.966 -1.47 . . . . 0.0 112.197 172.656 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.03 152.83 38.65 Favored 'General case' 0 N--CA 1.412 -2.325 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 166.163 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.44 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 28.7 m -80.9 134.58 26.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 CA-C-O 121.864 0.84 . . . . 0.0 108.899 178.427 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 19.6 m -75.86 106.05 7.24 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.384 -176.392 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 pt -121.72 122.02 65.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 174.051 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -146.23 151.44 37.59 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.386 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -93.07 99.28 11.91 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 117.712 -1.595 . . . . 0.0 110.831 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 53.1 m -102.86 142.82 33.34 Favored 'General case' 0 N--CA 1.396 -3.148 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 172.233 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.457 HG21 ' OD1' ' A' ' 26' ' ' ASN . 14.7 p -101.77 -46.85 11.33 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 C-N-CA 117.383 -1.727 . . . . 0.0 112.156 -178.852 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.9 tt -121.58 24.01 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.278 0 CA-C-O 122.308 1.051 . . . . 0.0 111.729 -171.29 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.684 ' O ' ' HG2' ' A' ' 22' ' ' GLN . 56.6 m -103.64 87.6 2.87 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.169 -1.582 . . . . 0.0 114.008 -177.416 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.526 ' O ' HG13 ' A' ' 81' ' ' VAL . 6.1 mp -69.82 129.54 39.85 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 169.941 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.441 ' HA ' ' CG1' ' A' ' 81' ' ' VAL . 13.1 t -73.63 87.68 1.67 Allowed 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.857 0.836 . . . . 0.0 112.491 -170.188 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.55 135.47 2.83 Favored Glycine 0 N--CA 1.406 -3.302 0 CA-C-N 114.189 -1.368 . . . . 0.0 112.426 168.226 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -46.97 -70.53 0.09 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.912 0.885 . . . . 0.0 111.88 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 63.8 m80 -123.02 -34.82 3.11 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 111' ' ' SER . . . . . 0.645 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 17.5 m -96.42 106.76 19.05 Favored 'General case' 0 N--CA 1.414 -2.257 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.783 -178.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 18.1 mm -87.67 -48.11 15.38 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 168.775 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.3 tt -102.69 151.11 6.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.258 174.498 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.24 -31.01 8.99 Favored Glycine 0 CA--C 1.478 -2.268 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 172.754 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.653 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 28.7 ptt180 -69.46 156.43 38.87 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 124.455 1.102 . . . . 0.0 112.549 -175.628 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -116.06 113.94 23.86 Favored 'General case' 0 N--CA 1.388 -3.533 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 -178.636 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.644 HD22 ' CB ' ' A' ' 47' ' ' VAL . 4.6 mp -95.98 160.49 14.43 Favored 'General case' 0 C--N 1.268 -2.953 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -174.201 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.42 HG22 ' O ' ' A' ' 145' ' ' ALA 0.327 8.4 p -140.5 116.14 7.37 Favored 'Isoleucine or valine' 0 C--O 1.263 1.793 0 C-N-CA 116.324 -2.15 . . . . 0.0 114.019 -179.156 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.449 ' CG1' ' HB2' ' A' ' 45' ' ' PHE . 19.7 m -138.49 170.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -176.837 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.505 ' ND1' ' HB3' ' A' ' 144' ' ' LEU . 62.7 t60 -170.44 167.95 8.03 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 105.129 -2.175 . . . . 0.0 105.129 176.59 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.472 ' HB2' ' CB ' ' A' ' 89' ' ' ALA . 8.9 pm0 -70.96 85.89 0.7 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 119.973 1.26 . . . . 0.0 110.467 177.202 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.514 ' C ' ' HA ' ' A' ' 42' ' ' LEU . 30.5 ttmt -175.7 154.99 1.65 Allowed 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.553 -176.677 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.486 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -60.27 107.31 0.63 Allowed 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 168.901 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.541 ' OD2' ' HA ' ' A' ' 140' ' ' ALA . 9.0 t70 -105.36 17.56 23.73 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.758 0.823 . . . . 0.0 108.93 -179.136 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -35.73 114.91 0.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.438 1.895 . . . . 0.0 111.306 -177.818 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.535 ' CB ' ' HB2' ' A' ' 83' ' ' ASP . 0.2 OUTLIER -90.79 -36.39 14.28 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.137 -168.151 . . . . . . . . 3 3 . 1 . 016 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.21 -27.19 56.22 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.588 -177.453 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -100.84 -26.01 13.91 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.955 0.378 . . . . 0.0 110.907 -178.893 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.05 -71.6 0.95 Allowed Glycine 0 CA--C 1.529 0.937 0 N-CA-C 113.767 0.267 . . . . 0.0 113.767 -177.229 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 118.73 -6.47 13.83 Favored Glycine 0 C--N 1.313 -0.728 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -175.025 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 26.8 t30 -162.67 150.66 14.03 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -48.26 -51.13 27.05 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 124.122 0.889 . . . . 0.0 112.062 -176.992 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.38 -48.28 78.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.614 -178.727 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 8.2 m -62.56 -24.56 67.6 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -176.545 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.7 m -69.63 -35.23 75.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 122.008 0.909 . . . . 0.0 109.407 176.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -83.41 -41.15 18.45 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.776 -174.052 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -74.01 -52.37 12.96 Favored 'General case' 0 C--N 1.273 -2.726 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.14 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 112.95 91.69 1.96 Allowed Glycine 1 N--CA 1.388 -4.504 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -176.167 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -34.57 117.43 0.36 Allowed 'General case' 1 C--O 1.333 5.488 0 C-N-CA 126.233 1.813 . . . . 0.0 113.265 -173.149 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.541 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -153.63 142.5 21.11 Favored 'General case' 0 N--CA 1.411 -2.417 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.357 175.198 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.81 86.03 1.55 Allowed Glycine 0 N--CA 1.425 -2.091 0 N-CA-C 104.525 -3.43 . . . . 0.0 104.525 164.166 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 142' ' ' SER . . . . . 0.522 ' HB3' ' HA2' ' A' ' 61' ' ' GLY . 21.0 m -55.01 -3.89 0.06 Allowed 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 118.095 2.628 . . . . 0.0 118.095 -166.49 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.652 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 11.9 ptm180 -144.75 11.0 1.4 Allowed 'General case' 0 C--N 1.247 -3.885 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.038 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.505 ' HB3' ' ND1' ' A' ' 120' ' ' HIS . 4.6 mm? -78.6 -9.21 59.28 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.695 -175.906 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.42 ' O ' HG22 ' A' ' 118' ' ' VAL . . . -170.15 109.69 0.39 Allowed 'General case' 0 CA--C 1.494 -1.186 0 C-N-CA 123.791 0.836 . . . . 0.0 108.915 173.638 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 38.3 m -96.43 137.06 36.08 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.02 125.38 1.2 Allowed Glycine 0 N--CA 1.424 -2.137 0 C-N-CA 118.498 -1.811 . . . . 0.0 113.434 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.653 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 75.6 t -73.51 101.48 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 171.733 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.482 ' HB ' HD23 ' A' ' 117' ' ' LEU . 53.7 mt -116.27 128.44 73.59 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.523 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.11 -168.49 40.35 Favored Glycine 3 CA--C 1.415 -6.186 0 N-CA-C 108.121 -1.992 . . . . 0.0 108.121 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.499 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.8 pp -67.81 121.16 16.46 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 120.096 -0.642 . . . . 0.0 111.165 179.104 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -131.75 114.75 15.13 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 174.126 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 . . . . . 0 C--N 1.289 -2.065 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.571 -179.31 . . . . . . . . 0 0 . 1 . 016 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.55 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.2 m -112.84 -31.51 6.7 Favored 'General case' 0 CA--C 1.557 1.222 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -171.641 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.1 pttt -146.79 158.37 43.89 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.861 -174.856 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.558 ' HB2' ' H ' ' A' ' 20' ' ' PHE . . . -143.01 150.37 39.52 Favored 'General case' 0 N--CA 1.395 -3.178 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.438 ' CG2' ' HB3' ' A' ' 152' ' ' ALA . 29.0 m -129.63 138.93 52.95 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.573 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.426 ' HB3' HG13 ' A' ' 149' ' ' ILE . . . -116.6 136.02 53.32 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 114.757 -1.11 . . . . 0.0 111.799 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.7 m -133.07 105.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.161 0.505 . . . . 0.0 110.608 175.922 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -114.75 151.14 34.24 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.651 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -157.43 150.45 23.44 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 175.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.15 -158.76 8.81 Favored Glycine 0 N--CA 1.414 -2.784 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 177.679 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -69.39 -39.19 78.12 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 124.935 1.021 . . . . 0.0 109.764 176.468 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.16 164.13 29.51 Favored Glycine 0 C--O 1.251 1.189 0 N-CA-C 108.704 -1.759 . . . . 0.0 108.704 174.461 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -83.14 123.4 3.51 Favored 'Trans proline' 0 N--CA 1.424 -2.613 0 CA-C-N 120.371 2.086 . . . . 0.0 109.739 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 12.1 m -132.21 123.52 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.667 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 178.103 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -130.32 119.58 23.03 Favored 'General case' 0 C--N 1.274 -2.685 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.667 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -166.87 166.62 39.22 Favored Glycine 0 N--CA 1.408 -3.194 0 C-N-CA 119.115 -1.517 . . . . 0.0 112.086 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . 0.412 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 11.9 tt -151.53 126.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 179.096 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.4 mp -122.87 136.6 59.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -178.185 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 25.1 t-20 -110.61 130.3 55.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.274 0.63 . . . . 0.0 109.395 -176.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.558 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 68.0 m-85 -130.16 133.59 46.71 Favored 'General case' 0 CA--C 1.498 -1.026 0 O-C-N 123.583 0.552 . . . . 0.0 110.824 178.183 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.478 ' O ' HG13 ' A' ' 104' ' ' ILE . 15.8 pt-20 -106.03 103.31 12.76 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 171.659 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.484 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -85.78 88.37 7.54 Favored 'General case' 1 N--CA 1.371 -4.415 0 CA-C-O 122.711 1.243 . . . . 0.0 112.164 -171.876 . . . . . . . . 4 4 . 1 . 017 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . 0.425 ' HE3' ' CD ' ' A' ' 21' ' ' GLU . 96.1 mttt -76.11 106.52 7.76 Favored 'General case' 0 N--CA 1.409 -2.509 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 172.647 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 28.7 tt0 -48.58 -39.42 23.67 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 113.693 -1.594 . . . . 0.0 113.86 -167.384 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.6 m -90.63 -61.96 1.56 Allowed 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 120.773 0.32 . . . . 0.0 110.461 177.368 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -173.56 171.47 3.87 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -177.908 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 162.42 163.0 14.21 Favored Glycine 0 CA--C 1.494 -1.266 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.218 175.881 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -62.02 124.53 14.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.326 2.017 . . . . 0.0 107.483 172.116 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 35.2 m -95.63 117.36 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -174.057 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 19.2 ttpt -82.65 101.87 11.1 Favored 'General case' 0 N--CA 1.413 -2.288 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 35.7 m -137.13 137.73 46.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -177.06 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 67.0 p-90 -148.3 137.31 21.82 Favored 'General case' 0 C--N 1.269 -2.902 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.54 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.412 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -153.28 140.19 7.42 Favored Glycine 0 N--CA 1.4 -3.712 0 C-N-CA 119.779 -1.2 . . . . 0.0 111.063 176.888 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.7 m -115.28 141.82 47.52 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.476 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 41.1 mm -131.43 126.73 58.82 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 176.533 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.516 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 41.2 ttmt -108.92 131.52 54.95 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 103.884 -2.636 . . . . 0.0 103.884 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.88 175.47 39.24 Favored Glycine 0 C--N 1.273 -2.968 0 N-CA-C 110.596 -1.001 . . . . 0.0 110.596 -167.478 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.34 142.76 56.68 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.496 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.685 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -69.35 105.74 2.67 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -172.777 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.519 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 27.9 mt-10 -175.43 135.77 0.33 Allowed 'General case' 0 CA--C 1.478 -1.798 0 C-N-CA 129.404 3.082 . . . . 0.0 104.057 174.743 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.63 99.99 0.17 Allowed Glycine 0 C--N 1.265 -3.395 0 C-N-CA 116.844 -2.598 . . . . 0.0 113.341 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -103.07 -86.18 0.44 Allowed 'General case' 0 N--CA 1.446 -0.639 0 O-C-N 124.547 0.792 . . . . 0.0 111.184 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.462 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.8 p80 176.39 141.42 0.07 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.37 116.06 0.54 Allowed Glycine 0 N--CA 1.419 -2.436 0 C-N-CA 119.616 -1.278 . . . . 0.0 113.048 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -122.89 107.95 12.42 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.929 0.871 . . . . 0.0 112.876 178.744 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.517 ' HA ' ' HB ' ' A' ' 81' ' ' VAL . 54.4 t60 -171.11 89.73 0.13 Allowed 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.005 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.718 ' O ' ' HA3' ' A' ' 82' ' ' GLY . 51.5 t -132.4 87.81 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 O-C-N 126.344 2.278 . . . . 0.0 109.284 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.488 ' CE1' ' HA3' ' A' ' 108' ' ' GLY . 8.6 t-160 -173.27 87.4 0.06 Allowed 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.239 -0.913 . . . . 0.0 110.749 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.495 ' H ' ' HB2' ' A' ' 115' ' ' ARG . 2.7 mp0 -136.51 172.25 13.29 Favored 'General case' 1 C--N 1.24 -4.173 0 CA-C-N 113.648 -1.615 . . . . 0.0 109.082 -170.956 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.407 ' HB3' ' OD1' ' A' ' 109' ' ' ASP . 26.3 p90 -69.81 171.31 9.44 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-O 121.096 0.474 . . . . 0.0 111.2 169.31 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.766 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . -59.86 120.7 23.91 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.118 -0.946 . . . . 0.0 114.282 177.373 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 5.5 t0 -129.72 -167.27 1.78 Allowed 'General case' 0 C--O 1.247 0.932 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 176.159 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . 0.669 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 29.9 t30 -69.47 133.86 48.23 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-O 121.369 0.604 . . . . 0.0 110.519 -179.595 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 54' ' ' THR . . . . . 0.548 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 1.3 p -51.41 -22.4 2.96 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 127.286 2.235 . . . . 0.0 114.44 -178.629 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.96 24.22 4.6 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.669 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 175.51 111.15 0.27 Allowed Glycine 0 C--O 1.196 -2.232 0 C-N-CA 117.778 -2.153 . . . . 0.0 112.566 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.413 ' HB2' ' HB2' ' A' ' 60' ' ' ALA . 13.3 p -90.56 96.03 10.45 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 121.973 0.892 . . . . 0.0 110.108 -177.877 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.3 m -76.57 -51.56 11.41 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.885 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.1 m -91.03 -36.5 14.02 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.372 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.413 ' HB2' ' HB2' ' A' ' 57' ' ' CYS . . . -77.58 -17.69 57.59 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.67 -177.449 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.85 -63.73 3.99 Favored Glycine 0 CA--C 1.539 1.546 0 N-CA-C 114.56 0.584 . . . . 0.0 114.56 -179.466 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -85.78 6.37 5.6 Favored 'Trans proline' 0 C--O 1.24 0.617 0 C-N-CA 122.744 2.296 . . . . 0.0 112.092 177.891 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -83.1 142.37 31.31 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 121.535 0.683 . . . . 0.0 111.409 -175.914 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -141.4 133.88 28.33 Favored 'General case' 0 N--CA 1.411 -2.384 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 172.014 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 9.4 t30 -77.35 141.57 66.29 Favored Pre-proline 0 C--N 1.306 -1.317 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.508 175.91 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -53.5 -33.36 67.43 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 123.834 3.023 . . . . 0.0 115.726 -177.279 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.47 ' O ' ' HB2' ' A' ' 79' ' ' ARG . 3.0 mm? -78.15 -45.4 23.35 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.648 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.4 m -67.3 31.54 0.02 OUTLIER 'General case' 0 CA--C 1.498 -1.026 0 C-N-CA 129.477 3.111 . . . . 0.0 116.62 -172.88 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.608 ' N ' ' HB2' ' A' ' 79' ' ' ARG . 0.0 OUTLIER -136.27 -32.55 0.85 Allowed 'General case' 0 C--N 1.245 -3.958 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.584 172.633 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.504 ' HZ2' ' CD ' ' A' ' 78' ' ' GLU . 82.2 tttt 34.67 -87.35 0.0 OUTLIER 'General case' 0 C--N 1.373 1.626 0 C-N-CA 124.526 1.13 . . . . 0.0 110.25 -170.941 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -178.93 12.2 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.764 0 C-N-CA 126.32 1.848 . . . . 0.0 106.994 176.961 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.49 134.38 3.35 Favored Glycine 0 N--CA 1.435 -1.403 0 C-N-CA 119.329 -1.415 . . . . 0.0 111.869 -175.382 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.59 83.95 0.09 OUTLIER Glycine 0 C--O 1.2 -2.019 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 59.9 Cg_endo -104.21 -0.5 0.27 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.706 2.271 . . . . 0.0 115.621 -176.541 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -123.41 -11.86 7.84 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 178.39 88.78 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -172.413 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.465 ' OE1' ' HD3' ' A' ' 79' ' ' ARG . 3.8 mm-40 -54.94 146.59 17.29 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 117.981 2.585 . . . . 0.0 117.981 -177.485 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.504 ' CD ' ' HZ2' ' A' ' 70' ' ' LYS . 42.4 mt-10 -138.23 -16.22 1.24 Allowed 'General case' 0 N--CA 1.415 -2.198 0 CA-C-N 112.624 -2.08 . . . . 0.0 107.313 -177.603 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.648 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -105.5 -37.31 6.84 Favored 'General case' 1 N--CA 1.358 -5.058 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 177.995 . . . . . . . . 4 4 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.455 ' C ' ' H ' ' A' ' 82' ' ' GLY . 45.2 m80 70.69 74.73 0.2 Allowed 'General case' 0 CA--C 1.498 -1.034 0 CA-C-N 113.344 -1.753 . . . . 0.0 110.041 176.19 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.517 ' HB ' ' HA ' ' A' ' 46' ' ' HIS . 28.3 m -77.66 24.43 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.014 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.718 ' HA3' ' O ' ' A' ' 47' ' ' VAL . . . 68.26 -69.53 0.35 Allowed Glycine 0 N--CA 1.478 1.49 0 C-N-CA 124.033 0.825 . . . . 0.0 113.803 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.423 ' O ' HG22 ' A' ' 81' ' ' VAL . 8.8 t70 -100.15 127.48 46.4 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 175.602 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -123.29 87.98 2.84 Favored 'General case' 0 N--CA 1.407 -2.614 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 172.83 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.74 132.06 3.46 Favored Glycine 1 N--CA 1.379 -5.13 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 174.868 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -73.8 129.22 37.48 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 118.029 -1.468 . . . . 0.0 107.545 174.805 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.437 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 44.6 t -110.81 128.15 67.39 Favored 'Isoleucine or valine' 0 C--N 1.36 1.024 0 O-C-N 121.441 -0.787 . . . . 0.0 109.278 -174.67 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.0 t -141.45 96.47 2.99 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.122 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . 0.434 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -80.11 107.21 12.72 Favored 'General case' 0 C--O 1.2 -1.523 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 175.247 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.565 ' C ' ' H ' ' A' ' 92' ' ' ASP . 26.3 t70 -64.69 162.68 15.34 Favored 'General case' 0 C--N 1.28 -2.428 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.644 -174.132 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.685 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 58.5 pttt -42.13 14.78 0.0 OUTLIER 'General case' 0 CA--C 1.6 2.902 0 N-CA-C 117.652 2.464 . . . . 0.0 117.652 174.601 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . 0.565 ' H ' ' C ' ' A' ' 90' ' ' ASP . 21.3 t70 -125.51 -28.98 3.25 Favored 'General case' 0 C--N 1.296 -1.736 0 C-N-CA 126.249 1.82 . . . . 0.0 108.753 178.555 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 104.07 66.77 0.72 Allowed Glycine 0 C--O 1.22 -0.746 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.217 -179.147 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . 0.476 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.7 p -160.83 117.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-N 117.387 0.594 . . . . 0.0 110.602 -175.123 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.443 ' HB2' ' HB ' ' A' ' 35' ' ' ILE . . . -122.31 124.34 43.52 Favored 'General case' 0 N--CA 1.434 -1.27 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -111.41 112.56 24.39 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 34.4 m -112.74 125.79 70.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -178.061 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -154.56 101.09 2.31 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 169.968 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.8 mm -129.58 149.3 33.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -109.68 118.82 37.57 Favored 'General case' 0 C--O 1.265 1.874 0 CA-C-O 122.604 1.192 . . . . 0.0 112.365 179.17 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -164.95 138.59 4.83 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 113.527 -1.669 . . . . 0.0 106.689 -176.124 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 58.5 m -82.31 79.77 8.68 Favored 'General case' 0 N--CA 1.435 -1.191 0 C-N-CA 119.206 -0.998 . . . . 0.0 109.352 175.04 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . 0.447 HG22 ' HG3' ' A' ' 77' ' ' GLU . 7.5 p -108.15 -15.05 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-N 114.324 -1.307 . . . . 0.0 109.932 -177.664 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.484 ' CG1' ' HA ' ' A' ' 22' ' ' GLN . 0.1 OUTLIER -78.21 -3.06 5.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.369 -1.742 . . . . 0.0 111.654 -173.797 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.5 m -67.78 131.22 45.15 Favored 'General case' 0 N--CA 1.409 -2.519 0 CA-C-O 121.6 0.714 . . . . 0.0 110.866 -174.071 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.426 ' HG ' HG22 ' A' ' 112' ' ' ILE . 4.6 mp -68.08 87.74 0.27 Allowed 'General case' 0 N--CA 1.425 -1.687 0 CA-C-O 123.008 1.385 . . . . 0.0 107.514 168.78 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -166.0 87.5 0.37 Allowed 'General case' 1 N--CA 1.374 -4.253 0 N-CA-C 101.481 -3.525 . . . . 0.0 101.481 172.596 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.488 ' HA3' ' CE1' ' A' ' 48' ' ' HIS . . . 166.2 136.69 2.06 Favored Glycine 0 C--N 1.266 -3.314 0 CA-C-N 113.682 -1.599 . . . . 0.0 110.953 179.013 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.407 ' OD1' ' HB3' ' A' ' 50' ' ' PHE . 16.6 t70 50.15 -85.81 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 126.643 1.977 . . . . 0.0 112.18 -171.784 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -123.95 -47.32 1.93 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 173.5 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 10.3 p -168.38 -162.11 0.39 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 179.589 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.426 HG22 ' HG ' ' A' ' 106' ' ' LEU . 12.4 tt -104.04 25.79 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.886 0 C-N-CA 119.231 -0.987 . . . . 0.0 108.992 178.905 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.623 ' HA ' ' NH1' ' A' ' 115' ' ' ARG . 2.6 pp -103.56 150.39 6.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 O-C-N 121.612 -0.68 . . . . 0.0 111.563 173.458 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.766 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 78.53 -13.33 17.33 Favored Glycine 0 CA--C 1.532 1.102 0 N-CA-C 115.043 0.777 . . . . 0.0 115.043 176.71 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.623 ' NH1' ' HA ' ' A' ' 113' ' ' ILE . 0.0 OUTLIER -66.93 116.56 7.91 Favored 'General case' 0 C--O 1.253 1.248 0 CA-C-O 121.901 0.858 . . . . 0.0 112.305 -168.782 . . . . . . . . 3 3 . 1 . 017 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.514 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 18.6 p -85.75 132.51 34.12 Favored 'General case' 0 N--CA 1.384 -3.754 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.25 171.156 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.522 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -69.53 137.03 52.14 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 114.985 -1.007 . . . . 0.0 111.477 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 12.1 p -124.03 96.48 3.93 Favored 'Isoleucine or valine' 1 C--O 1.35 6.352 0 C-N-CA 115.179 -2.608 . . . . 0.0 112.107 166.519 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.486 ' O ' ' HB1' ' A' ' 145' ' ' ALA . 24.0 m -150.62 170.54 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.081 0 C-N-CA 128.67 2.788 . . . . 0.0 105.829 178.257 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.468 ' NE2' ' HD2' ' A' ' 122' ' ' LYS . 29.8 p-80 -169.46 172.93 6.78 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 171.979 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.519 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.2 mp0 -70.01 82.67 0.49 Allowed 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 119.832 1.196 . . . . 0.0 109.492 -177.438 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.468 ' HD2' ' NE2' ' A' ' 120' ' ' HIS . 59.5 mttm -176.48 174.71 1.87 Allowed 'General case' 0 CA--C 1.494 -1.175 0 C-N-CA 129.403 3.081 . . . . 0.0 104.664 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.462 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -72.83 146.23 46.42 Favored 'General case' 0 C--N 1.286 -2.173 0 C-N-CA 119.286 -0.965 . . . . 0.0 110.246 171.515 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -129.23 -86.26 0.55 Allowed 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 174.083 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 52.42 -177.66 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.78 1.632 . . . . 0.0 111.017 171.899 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 tp -94.83 -65.05 1.01 Allowed 'General case' 0 C--N 1.288 -2.076 0 CA-C-O 122.633 1.206 . . . . 0.0 107.933 168.126 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.48 -5.04 48.16 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 112.931 -1.941 . . . . 0.0 115.451 -171.295 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 44.6 tptt -116.78 26.42 9.85 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 122.049 0.928 . . . . 0.0 109.027 178.29 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -63.34 -28.32 72.12 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 114.397 -1.274 . . . . 0.0 113.272 178.816 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 121.86 -80.86 0.34 Allowed Glycine 0 C--O 1.22 -0.736 0 C-N-CA 119.993 -1.099 . . . . 0.0 113.748 175.229 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.446 ' H ' ' HB2' ' A' ' 134' ' ' SER . 46.5 t-20 -99.08 169.27 9.53 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.238 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . 0.335 9.6 pt-20 -54.66 -45.66 73.89 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 116.273 1.953 . . . . 0.0 116.273 -173.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.98 -37.98 61.77 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.349 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.446 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 49.6 m -59.97 -30.15 68.92 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-O 120.963 0.411 . . . . 0.0 111.409 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 80.5 m -78.84 -20.16 50.29 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.958 0.885 . . . . 0.0 110.168 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 41.7 tttp -91.08 -32.83 15.72 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 -176.453 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.6 t -85.54 -30.43 23.39 Favored 'General case' 0 N--CA 1.409 -2.513 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.426 178.958 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.74 75.12 1.25 Allowed Glycine 0 N--CA 1.422 -2.268 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.525 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 32.3 t30 -47.32 119.95 2.93 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.277 1.431 . . . . 0.0 112.18 -174.609 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -132.58 137.6 47.13 Favored 'General case' 0 N--CA 1.42 -1.943 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.989 -173.081 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.08 89.32 0.58 Allowed Glycine 0 CA--C 1.502 -0.742 0 N-CA-C 107.581 -2.207 . . . . 0.0 107.581 170.592 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.6 m -47.07 -33.97 5.42 Favored 'General case' 0 C--O 1.2 -1.545 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -164.766 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.01 9.91 4.17 Favored 'General case' 0 C--N 1.27 -2.888 0 C-N-CA 116.162 -2.215 . . . . 0.0 109.787 178.309 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.9 mp -71.41 -16.3 62.39 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.861 -0.736 . . . . 0.0 112.088 -173.134 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . 0.486 ' HB1' ' O ' ' A' ' 119' ' ' VAL . . . -170.18 101.89 0.28 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.8 m -136.12 147.34 47.74 Favored 'General case' 0 N--CA 1.407 -2.615 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.548 ' HA2' ' O ' ' A' ' 54' ' ' THR . . . -162.38 149.64 17.98 Favored Glycine 0 N--CA 1.396 -3.988 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . 0.576 HG13 ' NH2' ' A' ' 115' ' ' ARG . 2.8 t -69.05 104.67 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 176.195 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.522 HG21 ' HB3' ' A' ' 117' ' ' LEU . 7.4 tt -123.47 101.57 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -176.128 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.508 ' HA3' ' NH1' ' A' ' 115' ' ' ARG . . . 176.66 -167.13 38.42 Favored Glycine 0 CA--C 1.453 -3.8 0 N-CA-C 107.889 -2.084 . . . . 0.0 107.889 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 6.3 tt -61.99 104.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.107 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.457 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . 0.438 ' HB3' ' CG2' ' A' ' 5' ' ' VAL . . . -103.31 102.04 11.98 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.631 -0.828 . . . . 0.0 110.406 -179.537 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 pt20 . . . . . 0 C--N 1.279 -2.474 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.145 179.044 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . 0.628 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 N--CA 1.47 0.57 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 2' ' ' THR . . . . . 0.415 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 8.2 m -121.06 -37.42 2.96 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.184 -0.606 . . . . 0.0 112.033 -175.719 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -136.34 136.1 39.4 Favored 'General case' 0 C--O 1.25 1.109 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -174.487 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.668 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -156.14 103.15 2.17 Favored 'General case' 0 CA--C 1.479 -1.769 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.473 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . 0.632 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 33.9 m -110.97 134.48 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-O 121.655 0.74 . . . . 0.0 110.389 -176.009 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . 0.425 ' HB3' ' HA ' ' A' ' 149' ' ' ILE . . . -108.81 150.11 28.11 Favored 'General case' 0 C--N 1.28 -2.422 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.342 -175.867 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.2 p -134.26 119.92 32.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.248 0.547 . . . . 0.0 110.098 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.7 mp -98.25 151.1 20.82 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.191 -176.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 28.6 mmmt -126.26 132.44 51.69 Favored 'General case' 0 C--O 1.248 1.021 0 N-CA-C 104.791 -2.3 . . . . 0.0 104.791 177.536 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.61 154.53 19.68 Favored Glycine 0 N--CA 1.428 -1.834 0 C-N-CA 117.477 -2.297 . . . . 0.0 118.504 -166.235 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -64.99 -44.34 89.61 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 111.802 -2.199 . . . . 0.0 106.201 169.502 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.01 153.96 17.23 Favored Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 104.143 -3.583 . . . . 0.0 104.143 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -70.59 123.95 10.3 Favored 'Trans proline' 0 N--CA 1.442 -1.518 0 CA-C-N 121.559 2.679 . . . . 0.0 111.471 -173.074 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.97 109.27 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.124 0 CA-C-N 114.199 -1.364 . . . . 0.0 107.641 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.512 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 73.6 mt-30 -119.99 119.0 32.15 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.864 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . 0.62 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -160.14 160.0 31.26 Favored Glycine 0 N--CA 1.405 -3.428 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -174.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.5 tt -153.87 102.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 121.441 0.638 . . . . 0.0 109.546 -178.726 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.632 ' O ' ' HA ' ' A' ' 5' ' ' VAL . 0.2 OUTLIER -106.55 139.86 26.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.22 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.668 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 8.5 t30 -113.53 120.81 42.25 Favored 'General case' 0 CA--C 1.51 -0.586 0 O-C-N 123.753 0.658 . . . . 0.0 110.757 -177.509 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.496 ' CD2' ' HB3' ' A' ' 84' ' ' LEU . 21.0 m-85 -119.62 135.14 54.93 Favored 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -178.612 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . 0.415 ' HG2' ' O ' ' A' ' 2' ' ' THR . 13.4 mt-10 -102.45 105.43 15.99 Favored 'General case' 0 CA--C 1.551 0.999 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.652 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.628 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 15.1 mp0 -85.6 99.86 11.56 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 176.67 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -132.82 108.98 9.32 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 122.288 1.042 . . . . 0.0 111.593 -172.696 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -69.49 -10.99 60.45 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.077 178.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.5 m -59.22 -16.9 23.55 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.563 1.545 . . . . 0.0 112.311 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 74.98 116.12 0.06 Allowed 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 124.021 0.929 . . . . 0.0 112.375 177.858 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.93 169.67 24.5 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -62.41 123.91 13.29 Favored 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.534 2.156 . . . . 0.0 110.88 177.662 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.433 HG11 ' H ' ' A' ' 102' ' ' SER . 10.9 p -75.98 121.51 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.639 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 67.8 mttm -89.81 97.55 11.26 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -177.041 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.47 HG11 ' CD2' ' A' ' 20' ' ' PHE . 24.7 m -122.61 133.07 69.89 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.008 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.771 -171.512 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.479 ' HA ' HG12 ' A' ' 97' ' ' VAL . 4.8 m-90 -135.26 137.61 42.71 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.454 177.564 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.431 ' HA3' ' CG2' ' A' ' 18' ' ' ILE . . . -161.54 140.66 6.76 Favored Glycine 0 N--CA 1.424 -2.101 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.828 173.795 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 34' ' ' SER . . . . . 0.62 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 11.4 p -114.83 126.11 54.45 Favored 'General case' 0 N--CA 1.413 -2.294 0 C-N-CA 123.844 0.857 . . . . 0.0 109.622 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 3.6 mp -126.06 142.82 41.59 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 18.9 ptpt -116.26 133.26 56.22 Favored 'General case' 0 N--CA 1.413 -2.283 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 172.845 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -165.21 175.81 40.99 Favored Glycine 0 N--CA 1.423 -2.171 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 -165.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 mt -66.43 144.0 56.78 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -177.843 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.447 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 59.3 p -87.34 104.17 16.16 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 -163.493 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.564 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 3.7 mp0 -173.13 140.89 0.91 Allowed 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 102.173 -3.269 . . . . 0.0 102.173 175.996 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 173.67 116.19 0.41 Allowed Glycine 0 C--N 1.255 -3.919 0 C-N-CA 114.933 -3.508 . . . . 0.0 114.436 178.449 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.423 ' HB2' ' CB ' ' A' ' 123' ' ' ALA . 96.2 mt -142.83 -39.67 0.33 Allowed 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -179.385 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -126.02 141.52 51.92 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -173.846 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . 0.411 ' O ' ' HD2' ' A' ' 46' ' ' HIS . . . -105.19 88.4 0.58 Allowed Glycine 0 N--CA 1.44 -1.036 0 CA-C-N 115.156 -0.929 . . . . 0.0 111.698 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.429 ' HB3' ' O ' ' A' ' 125' ' ' ASP . 0.4 OUTLIER -90.9 84.72 5.83 Favored 'General case' 1 C--O 1.352 6.481 0 CA-C-O 122.261 1.029 . . . . 0.0 112.021 -176.242 . . . . . . . . 4 4 . 1 . 018 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.532 ' HB2' ' HB2' ' A' ' 83' ' ' ASP . 8.0 p80 -100.12 113.37 25.95 Favored 'General case' 0 N--CA 1.382 -3.865 0 CA-C-N 113.893 -1.503 . . . . 0.0 107.944 -171.824 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.0 t -164.89 87.93 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 O-C-N 125.048 1.468 . . . . 0.0 108.533 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.523 ' CD2' ' HB ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -148.31 167.73 24.42 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 124.39 1.076 . . . . 0.0 109.114 163.781 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.2 OUTLIER -164.81 164.98 20.95 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 171.046 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 66.5 t80 73.61 58.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.06 166.08 30.81 Favored Glycine 0 CA--C 1.474 -2.499 0 CA-C-N 112.849 -1.978 . . . . 0.0 111.54 -175.623 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -151.46 -72.37 0.16 Allowed 'General case' 0 C--N 1.292 -1.913 0 O-C-N 123.875 0.397 . . . . 0.0 111.651 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -94.5 128.59 41.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.77 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.5 t -75.98 -2.3 29.85 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 122.946 0.498 . . . . 0.0 111.515 -174.903 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.05 -8.6 19.41 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.47 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . 0.411 ' HA2' ' HB2' ' A' ' 143' ' ' ARG . . . -176.99 137.63 3.61 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.224 -1.465 . . . . 0.0 112.758 -178.75 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.423 ' H ' ' HB2' ' A' ' 143' ' ' ARG . 62.3 m -91.98 88.3 6.53 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 120.385 0.136 . . . . 0.0 111.101 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.7 m -80.01 -58.14 3.3 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.75 -44.17 86.7 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.817 -176.786 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.47 -5.98 51.87 Favored 'General case' 0 C--O 1.196 -1.713 0 C-N-CA 124.801 1.24 . . . . 0.0 112.384 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -31.62 -138.33 0.0 OUTLIER Glycine 0 N--CA 1.513 3.832 0 C-N-CA 128.477 2.942 . . . . 0.0 116.414 -174.263 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -62.91 53.41 0.13 Allowed 'Trans proline' 0 CA--C 1.566 2.086 0 CA-C-N 121.043 2.421 . . . . 0.0 113.11 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -93.96 112.67 24.53 Favored 'General case' 0 N--CA 1.427 -1.605 0 C-N-CA 124.348 1.059 . . . . 0.0 110.332 175.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . 0.432 ' HB3' ' O ' ' A' ' 136' ' ' LYS . 45.5 p90 -84.21 133.16 34.6 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 103.983 -2.599 . . . . 0.0 103.983 167.506 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.421 ' ND2' ' HD2' ' A' ' 66' ' ' PRO . 29.1 t-20 -75.01 140.83 74.1 Favored Pre-proline 0 C--N 1.282 -2.366 0 C-N-CA 118.842 -1.143 . . . . 0.0 111.609 -171.859 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . 0.437 ' O ' ' HG2' ' A' ' 69' ' ' ARG . 92.1 Cg_endo -83.8 -14.21 7.73 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.532 2.154 . . . . 0.0 113.445 -176.805 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.647 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 2.7 tt -88.36 -17.59 30.23 Favored 'General case' 0 CA--C 1.482 -1.658 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.545 ' HA ' ' HB2' ' A' ' 79' ' ' ARG . 63.8 m -79.44 39.82 0.41 Allowed 'General case' 0 N--CA 1.407 -2.58 0 CA-C-N 114.315 -1.311 . . . . 0.0 111.502 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.437 ' HG2' ' O ' ' A' ' 66' ' ' PRO . 33.1 mmt180 -83.7 20.1 1.51 Allowed 'General case' 0 CA--C 1.49 -1.33 0 CA-C-O 122.506 1.146 . . . . 0.0 109.734 -178.494 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.438 ' H ' ' C ' ' A' ' 68' ' ' SER . 25.8 tptp -128.1 19.99 6.42 Favored 'General case' 0 N--CA 1.396 -3.126 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 171.03 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.0 m80 65.87 -48.3 0.4 Allowed 'General case' 0 N--CA 1.504 2.251 0 C-N-CA 126.349 1.86 . . . . 0.0 115.375 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.444 ' HA2' ' HG3' ' A' ' 79' ' ' ARG . . . 167.61 175.29 37.37 Favored Glycine 0 N--CA 1.415 -2.761 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -171.836 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.45 ' O ' HD12 ' A' ' 126' ' ' LEU . . . -169.38 142.5 7.36 Favored Glycine 0 CA--C 1.475 -2.444 0 N-CA-C 106.787 -2.525 . . . . 0.0 106.787 173.516 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -65.01 -43.25 12.1 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 CA-C-N 120.306 2.053 . . . . 0.0 113.849 -178.2 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.7 OUTLIER -120.89 -29.79 4.55 Favored 'General case' 0 N--CA 1.425 -1.682 0 C-N-CA 119.507 -0.877 . . . . 0.0 112.268 -178.317 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . 0.477 ' OD1' HG22 ' A' ' 104' ' ' ILE . 33.4 t70 -176.62 146.86 0.6 Allowed 'General case' 0 C--O 1.204 -1.301 0 CA-C-O 118.81 -0.614 . . . . 0.0 109.664 -176.68 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.478 ' HB2' ' HD2' ' A' ' 79' ' ' ARG . 3.1 mm-40 -158.16 -86.76 0.04 OUTLIER 'General case' 0 C--O 1.214 -0.766 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 1.5 tm-20 -161.25 -53.03 0.05 OUTLIER 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.1 -2.185 . . . . 0.0 105.1 -176.695 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.647 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 0.4 OUTLIER -34.67 -31.63 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.92 0 C-N-CA 128.635 2.774 . . . . 0.0 115.676 176.948 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.416 ' HD2' ' O ' ' A' ' 104' ' ' ILE . 31.2 t-80 71.92 -27.67 0.18 Allowed 'General case' 0 N--CA 1.5 2.066 0 C-N-CA 124.341 1.056 . . . . 0.0 109.738 -171.455 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.633 ' H ' ' C ' ' A' ' 79' ' ' ARG 0.397 12.2 p 59.45 50.22 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.153 0 C-N-CA 129.422 3.089 . . . . 0.0 109.6 -179.558 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 48.78 -78.05 0.0 OUTLIER Glycine 0 N--CA 1.487 2.096 0 CA-C-N 110.764 -2.926 . . . . 0.0 115.814 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.597 ' OD1' ' HA ' ' A' ' 117' ' ' LEU . 81.8 m-20 -79.93 174.13 11.9 Favored 'General case' 0 C--N 1.293 -1.889 0 C-N-CA 125.678 1.591 . . . . 0.0 109.857 -178.491 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.496 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . 89.2 mt -143.82 87.53 1.92 Allowed 'General case' 0 C--N 1.272 -2.794 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 177.03 165.31 32.21 Favored Glycine 0 CA--C 1.478 -2.246 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -158.57 148.33 19.49 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 p -137.24 128.38 40.71 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.627 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 88.3 m -140.42 95.21 2.84 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.589 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -135.67 106.39 6.56 Favored 'General case' 0 C--O 1.202 -1.425 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.564 ' HA ' ' N ' ' A' ' 40' ' ' GLU . 3.3 p-10 -117.26 -19.18 9.72 Favored 'General case' 0 C--N 1.275 -2.639 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.648 -174.462 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -75.77 -57.54 3.82 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.692 -175.852 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -154.2 -22.83 0.13 Allowed 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 114.623 -1.171 . . . . 0.0 112.27 -166.34 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.48 55.3 0.16 Allowed Glycine 0 N--CA 1.42 -2.386 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -173.65 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.0 m -141.9 102.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.85 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.627 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.81 107.75 19.38 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.233 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -83.97 124.33 30.91 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 104.665 -2.346 . . . . 0.0 104.665 173.206 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.479 HG12 ' HA ' ' A' ' 32' ' ' TRP . 7.1 p -83.31 135.89 23.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 C-N-CA 119.696 -0.802 . . . . 0.0 109.426 -174.003 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.2 m -75.46 102.24 5.12 Favored 'General case' 0 N--CA 1.389 -3.508 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.134 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . 0.419 ' HB ' ' O ' ' A' ' 31' ' ' VAL . 2.5 tt -92.8 115.72 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.593 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.7 mm-40 -133.54 157.43 45.68 Favored 'General case' 0 C--N 1.283 -2.305 0 CA-C-N 113.988 -1.46 . . . . 0.0 108.364 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -79.83 99.38 7.48 Favored 'General case' 0 N--CA 1.411 -2.405 0 CA-C-O 123.01 1.386 . . . . 0.0 109.674 176.497 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.433 ' H ' HG11 ' A' ' 29' ' ' VAL . 50.8 m -100.9 93.75 5.68 Favored 'General case' 0 N--CA 1.41 -2.444 0 CA-C-N 112.107 -2.315 . . . . 0.0 105.902 171.53 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.1 t -69.18 -47.62 73.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.825 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . 0.477 HG22 ' OD1' ' A' ' 76' ' ' ASP . 10.0 tp -70.62 26.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.576 1.955 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 30.0 t -70.89 90.16 0.8 Allowed 'General case' 0 CA--C 1.477 -1.845 0 N-CA-C 105.584 -2.006 . . . . 0.0 105.584 170.227 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 27.2 tp -110.42 157.93 19.03 Favored 'General case' 2 C--N 1.204 -5.728 0 N-CA-C 103.333 -2.839 . . . . 0.0 103.333 -172.547 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 m -69.08 101.22 1.38 Allowed 'General case' 1 C--N 1.226 -4.776 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 174.505 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.6 137.11 13.23 Favored Glycine 0 N--CA 1.41 -3.078 0 CA-C-N 114.321 -1.309 . . . . 0.0 112.723 -170.122 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.0 t70 61.74 -86.33 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 126.449 1.899 . . . . 0.0 114.106 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 16.2 m80 -82.82 -49.02 10.13 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 175.441 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 18.5 m 168.03 -85.46 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 126.357 1.863 . . . . 0.0 111.026 173.114 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.3 mt -109.61 -54.42 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.435 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 14.0 tt -83.74 175.64 0.72 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.024 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.377 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.424 ' H ' HG12 ' A' ' 113' ' ' ILE . . . 89.43 22.77 36.17 Favored Glycine 0 CA--C 1.478 -2.278 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.918 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.442 HH22 HD13 ' A' ' 149' ' ' ILE . 44.4 mtm180 -146.98 123.12 10.83 Favored 'General case' 0 C--O 1.2 -1.539 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.492 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 11.4 p -102.09 115.48 30.63 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 171.688 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.597 ' HA ' ' OD1' ' A' ' 83' ' ' ASP . 2.2 pt? -71.05 148.07 47.92 Favored 'General case' 0 CA--C 1.506 -0.716 0 O-C-N 123.865 0.728 . . . . 0.0 112.434 -170.98 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.523 ' HB ' ' CD2' ' A' ' 48' ' ' HIS . 1.8 p -125.63 99.64 6.14 Favored 'Isoleucine or valine' 1 C--O 1.38 7.933 0 C-N-CA 117.118 -1.833 . . . . 0.0 112.653 172.507 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 t -148.69 151.48 13.14 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 C-N-CA 126.429 1.892 . . . . 0.0 106.153 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -144.52 170.35 16.22 Favored 'General case' 0 C--O 1.243 0.712 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 175.272 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.4 mp0 -67.86 89.93 0.29 Allowed 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 177.129 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . 0.49 ' HG2' ' H ' ' A' ' 123' ' ' ALA . 50.8 tttm -162.99 171.58 16.31 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -174.799 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . 0.49 ' H ' ' HG2' ' A' ' 122' ' ' LYS . . . -123.22 107.27 11.52 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.45 -88.3 0.44 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.993 165.629 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . 0.429 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 21.9 t70 172.44 157.36 0.1 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.215 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.45 HD12 ' O ' ' A' ' 73' ' ' GLY . 1.6 pt? -90.62 -29.34 17.84 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -105.5 -23.59 7.5 Favored Glycine 0 N--CA 1.464 0.522 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.847 -177.986 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -128.48 51.99 1.95 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 177.209 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.86 82.2 0.41 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.37 -0.832 . . . . 0.0 114.35 -174.963 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.9 -127.56 8.48 Favored Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 121.376 -0.44 . . . . 0.0 112.808 174.796 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -98.41 -176.89 3.52 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -61.88 -50.97 70.08 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 119.074 0.852 . . . . 0.0 112.993 -175.98 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -64.29 -31.06 72.12 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.463 178.063 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 m -68.48 -38.56 81.13 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 122.724 0.41 . . . . 0.0 110.64 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.9 p -65.57 -27.23 68.28 Favored 'General case' 0 C--N 1.349 0.578 0 CA-C-O 121.121 0.486 . . . . 0.0 110.748 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . 0.432 ' O ' ' HB3' ' A' ' 64' ' ' PHE . 92.9 mttt -84.99 -16.45 40.82 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.061 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 31.0 m -87.98 -17.58 30.93 Favored 'General case' 0 CA--C 1.564 1.504 0 CA-C-O 121.841 0.829 . . . . 0.0 110.347 175.755 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.24 48.6 30.57 Favored Glycine 1 C--O 1.39 9.847 0 N-CA-C 108.629 -1.788 . . . . 0.0 108.629 -173.45 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -30.22 106.29 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 128.963 2.905 . . . . 0.0 114.496 -158.752 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -155.59 171.82 19.32 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 167.67 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.47 119.28 16.13 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 167.522 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.7 m -41.63 -46.84 3.79 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 115.484 1.661 . . . . 0.0 115.484 -166.878 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.724 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 0.1 OUTLIER -132.42 11.51 4.51 Favored 'General case' 0 C--N 1.288 -2.105 0 C-N-CA 118.891 -1.124 . . . . 0.0 108.529 174.845 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.6 mt -71.69 -17.33 62.23 Favored 'General case' 0 CA--C 1.497 -1.09 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.297 -170.633 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.35 89.67 1.59 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.96 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.724 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 53.0 m -131.2 153.95 48.92 Favored 'General case' 0 N--CA 1.424 -1.726 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.253 -178.742 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.492 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.74 148.65 11.58 Favored Glycine 0 N--CA 1.409 -3.136 0 N-CA-C 108.025 -2.03 . . . . 0.0 108.025 176.021 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 93.8 t -69.23 105.62 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 176.814 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.442 HD13 HH22 ' A' ' 115' ' ' ARG . 0.0 OUTLIER -88.74 103.2 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.703 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.07 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.435 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.36 -177.79 48.48 Favored Glycine 1 N--CA 1.383 -4.871 0 C-N-CA 119.081 -1.533 . . . . 0.0 112.266 -178.657 . . . . . . . . 3 3 . 1 . 018 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.46 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.7 tt -53.32 112.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 125.119 1.367 . . . . 0.0 113.184 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.72 99.94 3.83 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 171.801 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.288 -2.095 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -177.419 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.702 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.4 m -94.26 -26.81 16.46 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.39 1.09 . . . . 0.0 108.606 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -166.03 172.11 11.78 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 174.626 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 4' ' ' ALA . . . . . 0.548 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -151.71 158.97 44.11 Favored 'General case' 0 C--N 1.287 -2.149 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.538 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 86.7 t -140.93 121.41 13.14 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.365 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -177.855 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.12 145.74 50.63 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 -177.47 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 p -135.36 125.87 44.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 O-C-N 123.66 0.6 . . . . 0.0 109.391 -179.15 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 1.4 pt? -125.52 144.24 50.64 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.52 -175.07 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -163.43 135.55 5.12 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 107.084 -1.451 . . . . 0.0 107.084 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.95 -157.17 7.99 Favored Glycine 0 C--N 1.301 -1.378 0 C-N-CA 120.233 -0.984 . . . . 0.0 112.265 -175.863 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -55.0 -50.95 67.73 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.262 1.025 . . . . 0.0 110.505 177.051 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -92.15 163.91 28.15 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -90.57 123.56 0.97 Allowed 'Trans proline' 0 N--CA 1.418 -2.921 0 CA-C-N 120.473 2.136 . . . . 0.0 111.026 -177.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 m -133.3 131.52 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.042 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 15' ' ' GLN . . . . . 0.423 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -145.97 123.17 11.52 Favored 'General case' 0 C--N 1.269 -2.933 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.604 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.97 161.64 34.89 Favored Glycine 0 N--CA 1.41 -3.042 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.0 tt -132.5 110.23 15.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 18' ' ' ILE . . . . . 0.426 ' H ' HD13 ' A' ' 18' ' ' ILE . 0.1 OUTLIER -107.65 132.84 54.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 -179.763 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 19' ' ' ASN . . . . . 0.466 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -106.05 139.62 40.3 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.904 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 20' ' ' PHE . . . . . 0.508 ' H ' ' HB2' ' A' ' 4' ' ' ALA . 24.4 t80 -137.47 127.6 26.05 Favored 'General case' 0 C--O 1.252 1.186 0 CA-C-N 118.996 0.816 . . . . 0.0 111.577 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -134.38 102.45 5.34 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-O 121.797 0.808 . . . . 0.0 112.823 -178.625 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 22' ' ' GLN . . . . . 0.593 ' HG3' ' C ' ' A' ' 105' ' ' SER . 2.5 pm0 -127.71 162.91 25.47 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -178.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER 64.63 -56.39 0.27 Allowed 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.808 1.243 . . . . 0.0 113.001 176.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.72 -43.93 87.59 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.157 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.0 m -81.49 -65.85 0.96 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 171.459 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 57.45 96.52 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 124.33 1.052 . . . . 0.0 109.924 177.83 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 27' ' ' GLY . . . . . 0.484 ' O ' HG22 ' A' ' 29' ' ' VAL . . . 140.53 -143.21 13.19 Favored Glycine 0 CA--C 1.463 -3.198 0 C-N-CA 118.545 -1.788 . . . . 0.0 108.692 -172.467 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.47 122.06 10.51 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 N-CA-C 107.403 -1.807 . . . . 0.0 107.403 175.549 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 29' ' ' VAL . . . . . 0.484 HG22 ' O ' ' A' ' 27' ' ' GLY . 55.7 t -102.69 113.36 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.807 0 CA-C-O 121.673 0.749 . . . . 0.0 109.927 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -84.61 102.73 13.14 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.616 -1.629 . . . . 0.0 109.799 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 31' ' ' VAL . . . . . 0.5 HG11 ' HA ' ' A' ' 20' ' ' PHE . 26.8 m -130.35 144.6 37.47 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.683 -176.002 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 32' ' ' TRP . . . . . 0.404 ' HA ' HG11 ' A' ' 97' ' ' VAL . 66.1 p-90 -148.12 134.67 19.76 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.587 178.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 33' ' ' GLY . . . . . 0.572 ' O ' HG23 ' A' ' 97' ' ' VAL . . . -164.03 137.9 5.0 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 119.132 -1.509 . . . . 0.0 113.119 169.36 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.8 m -114.23 126.62 55.25 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -177.468 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 35' ' ' ILE . . . . . 0.423 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -130.26 133.18 64.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-O 121.261 0.553 . . . . 0.0 111.188 -177.458 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 36' ' ' LYS . . . . . 0.408 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 22.1 ptmt -106.59 133.2 51.63 Favored 'General case' 0 N--CA 1.419 -2.008 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.596 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 37' ' ' GLY . . . . . 0.45 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -157.97 174.37 35.26 Favored Glycine 0 N--CA 1.421 -2.316 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -170.246 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 tp -68.72 171.99 6.99 Favored 'General case' 0 CA--C 1.567 1.598 0 C-N-CA 123.305 0.642 . . . . 0.0 109.47 178.307 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 39' ' ' THR . . . . . 0.52 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 7.2 t -67.59 111.07 3.97 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.42 -0.8 . . . . 0.0 112.73 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 40' ' ' GLU . . . . . 0.523 ' H ' ' HA ' ' A' ' 90' ' ' ASP . 0.2 OUTLIER -163.56 174.15 12.15 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-O 123.127 1.441 . . . . 0.0 113.811 178.079 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.92 -144.53 0.05 OUTLIER Glycine 2 C--N 1.238 -4.901 0 CA-C-N 110.477 -3.056 . . . . 0.0 114.125 173.754 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 42' ' ' LEU . . . . . 0.549 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 2.4 pt? -138.42 148.37 44.36 Favored 'General case' 1 N--CA 1.37 -4.428 0 CA-C-N 114.161 -1.019 . . . . 0.0 110.641 -164.933 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 43' ' ' HIS . . . . . 0.447 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 11.0 p80 -104.54 138.91 40.19 Favored 'General case' 0 CA--C 1.438 -3.335 0 C-N-CA 119.392 -0.923 . . . . 0.0 108.653 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -99.19 0.02 OUTLIER Glycine 0 N--CA 1.402 -3.577 0 O-C-N 125.215 1.572 . . . . 0.0 111.128 173.341 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 45' ' ' PHE . . . . . 0.643 ' HB3' ' O ' ' A' ' 83' ' ' ASP . 2.5 m-85 -165.68 93.97 0.58 Allowed 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 117.716 -1.135 . . . . 0.0 111.105 -166.97 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 46' ' ' HIS . . . . . 0.597 ' CD2' ' HB2' ' A' ' 126' ' ' LEU . 14.3 t60 -170.85 86.47 0.1 Allowed 'General case' 0 C--O 1.284 2.901 0 CA-C-N 120.301 1.41 . . . . 0.0 114.493 171.886 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 47' ' ' VAL . . . . . 0.515 HG22 ' OD1' ' A' ' 83' ' ' ASP . 51.5 t -74.93 154.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.732 0 CA-C-N 113.553 -1.658 . . . . 0.0 107.119 165.156 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 48' ' ' HIS . . . . . 0.446 ' O ' ' HB2' ' A' ' 49' ' ' GLU . 25.9 p80 -159.24 114.06 2.44 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 116.511 -1.709 . . . . 0.0 107.08 172.514 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 49' ' ' GLU . . . . . 0.617 ' HA ' ' OE1' ' A' ' 49' ' ' GLU 0.484 0.0 OUTLIER -173.74 168.2 4.37 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 165.377 . . . . . . . . 4 4 . 1 . 019 nuclear orig full ' A' A ' 50' ' ' PHE . . . . . 0.479 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 26.8 p90 -115.22 19.46 15.59 Favored 'General case' 0 N--CA 1.404 -2.743 0 CA-C-N 112.654 -2.067 . . . . 0.0 109.108 176.751 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 51' ' ' GLY . . . . . 0.605 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 85.06 138.94 4.49 Favored Glycine 0 N--CA 1.47 0.959 0 N-CA-C 115.017 0.767 . . . . 0.0 115.017 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -144.9 -72.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.674 -0.81 . . . . 0.0 109.148 173.643 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -168.81 158.74 9.16 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 176.536 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 m -65.58 -48.41 72.44 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 123.633 0.773 . . . . 0.0 111.023 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.69 -7.88 42.46 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.003 -171.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.34 109.85 0.47 Allowed Glycine 0 CA--C 1.463 -3.214 0 C-N-CA 118.794 -1.669 . . . . 0.0 110.449 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 57' ' ' CYS . . . . . 0.836 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 15.8 p -101.89 87.42 3.11 Favored 'General case' 0 N--CA 1.392 -3.368 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 174.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.1 m -82.43 -50.09 9.26 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 122.755 1.265 . . . . 0.0 108.943 174.662 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 59' ' ' SER . . . . . 0.479 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 15.2 m -72.16 -8.15 53.11 Favored 'General case' 0 C--O 1.209 -1.038 0 CA-C-N 113.457 -1.702 . . . . 0.0 112.982 -175.151 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 60' ' ' ALA . . . . . 0.507 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -77.29 -7.29 55.74 Favored 'General case' 0 CA--C 1.494 -1.192 0 C-N-CA 124.785 1.234 . . . . 0.0 111.216 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.7 52.09 0.83 Allowed Glycine 0 N--CA 1.406 -3.357 0 C-N-CA 117.762 -2.161 . . . . 0.0 116.016 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 62' ' ' PRO . . . . . 0.446 ' HD3' ' C ' ' A' ' 60' ' ' ALA . 1.2 Cg_endo -90.42 -6.74 4.37 Favored 'Trans proline' 0 C--N 1.395 3.009 0 CA-C-N 121.788 2.794 . . . . 0.0 106.995 164.052 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 63' ' ' HIS . . . . . 0.411 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 31.3 m80 72.48 -58.06 0.61 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 114.149 -1.387 . . . . 0.0 111.355 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -112.63 116.52 30.31 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 122.322 -0.236 . . . . 0.0 110.936 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 65' ' ' ASN . . . . . 0.473 ' HB3' ' HG3' ' A' ' 79' ' ' ARG . 0.8 OUTLIER -77.23 144.48 71.2 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.386 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.54 -54.32 1.05 Allowed 'Trans proline' 0 CA--C 1.553 1.441 0 C-N-CA 122.907 2.404 . . . . 0.0 117.234 -170.556 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 67' ' ' LEU . . . . . 0.577 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 4.2 mm? -82.72 8.48 12.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.208 -1.397 . . . . 0.0 112.176 -173.262 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 68' ' ' SER . . . . . 0.59 ' HA ' ' OE1' ' A' ' 77' ' ' GLU . 69.6 m -72.2 39.27 0.07 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 122.614 1.197 . . . . 0.0 111.085 173.211 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 69' ' ' ARG . . . . . 0.571 ' H ' ' C ' ' A' ' 67' ' ' LEU . 73.6 mtt-85 -100.56 3.4 42.69 Favored 'General case' 0 N--CA 1.386 -3.674 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.673 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' LYS . . . . . 0.401 ' HB2' ' N ' ' A' ' 78' ' ' GLU . 47.8 mttp -109.31 30.06 6.96 Favored 'General case' 0 CA--C 1.495 -1.172 0 C-N-CA 118.975 -1.09 . . . . 0.0 110.768 169.797 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 70.56 86.11 0.13 Allowed 'General case' 0 N--CA 1.435 -1.177 0 CA-C-N 113.967 -1.47 . . . . 0.0 112.913 177.183 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLY . . . . . 0.532 ' HA2' ' CG ' ' A' ' 77' ' ' GLU . . . -53.54 83.1 0.01 OUTLIER Glycine 0 CA--C 1.508 -0.382 0 CA-C-N 114.59 -1.186 . . . . 0.0 112.573 169.016 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' GLY . . . . . 0.466 ' O ' ' HA3' ' A' ' 82' ' ' GLY . . . -141.84 -151.17 5.48 Favored Glycine 0 N--CA 1.401 -3.639 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 178.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' PRO . . . . . 0.426 ' CB ' ' HB3' ' A' ' 84' ' ' LEU . 98.8 Cg_endo -81.94 -41.3 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.332 0 N-CA-C 117.905 2.233 . . . . 0.0 117.905 -169.335 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -93.95 -26.21 16.94 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 116.446 2.017 . . . . 0.0 116.446 -162.488 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -171.59 143.12 1.7 Allowed 'General case' 0 CA--C 1.475 -1.931 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 -169.477 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' GLU . . . . . 0.59 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -160.05 151.0 19.1 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -175.845 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' GLU . . . . . 0.577 ' HB3' ' O ' ' A' ' 67' ' ' LEU . 15.4 tp10 -90.18 -19.2 24.5 Favored 'General case' 0 CA--C 1.555 1.142 0 O-C-N 123.446 0.466 . . . . 0.0 111.921 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' ARG . . . . . 0.571 ' HB2' ' C ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -101.0 -8.23 22.56 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 104.302 -2.481 . . . . 0.0 104.302 172.232 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' HIS . . . . . 0.468 ' HA ' ' HB3' ' A' ' 77' ' ' GLU . 44.2 m170 76.06 -0.47 3.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 113.211 -1.813 . . . . 0.0 110.901 175.873 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' VAL . . . . . 0.472 HG21 ' HB3' ' A' ' 79' ' ' ARG . 24.7 m -82.05 80.64 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 CA-C-O 123.633 1.682 . . . . 0.0 112.56 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' GLY . . . . . 0.466 ' HA3' ' O ' ' A' ' 73' ' ' GLY . . . -152.12 118.89 0.93 Allowed Glycine 1 C--N 1.251 -4.165 0 CA-C-N 112.656 -2.065 . . . . 0.0 110.668 176.186 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' ASP . . . . . 0.643 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 7.7 p-10 -92.95 169.16 10.65 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 175.492 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HB3' ' CB ' ' A' ' 74' ' ' PRO 0.404 1.1 pp -136.53 89.05 2.42 Favored 'General case' 0 N--CA 1.408 -2.534 0 CA-C-O 122.818 1.294 . . . . 0.0 112.608 170.634 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.33 87.31 0.13 Allowed Glycine 1 N--CA 1.389 -4.494 0 CA-C-N 113.771 -1.559 . . . . 0.0 110.034 177.416 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' ASN . . . . . 0.447 ' HA ' ' O ' ' A' ' 43' ' ' HIS . 24.7 t30 -72.79 128.17 34.73 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 174.091 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' VAL . . . . . 0.549 ' O ' ' HA ' ' A' ' 42' ' ' LEU . 6.5 m -143.09 127.38 14.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 O-C-N 123.839 0.712 . . . . 0.0 110.684 -176.237 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' THR . . . . . 0.563 ' O ' ' HA ' ' A' ' 95' ' ' ALA 0.257 4.9 p -101.02 101.45 12.23 Favored 'General case' 0 CA--C 1.561 1.396 0 C-N-CA 128.175 2.59 . . . . 0.0 111.991 -176.396 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -118.92 108.27 14.59 Favored 'General case' 0 CA--C 1.473 -2.006 0 CA-C-N 120.579 1.536 . . . . 0.0 109.423 -178.646 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' ASP . . . . . 0.565 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 38.3 t70 -90.96 -165.43 1.35 Allowed 'General case' 0 C--N 1.278 -2.532 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.531 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' LYS . . . . . 0.565 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 21.9 ptmt -42.93 -32.17 0.6 Allowed 'General case' 0 N--CA 1.51 2.568 0 C-N-CA 126.439 1.895 . . . . 0.0 115.663 -175.124 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -91.22 -37.17 13.49 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-O 122.525 1.155 . . . . 0.0 107.925 -178.168 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' GLY . . . . . 0.45 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 91.35 78.84 1.38 Allowed Glycine 1 N--CA 1.384 -4.805 0 CA-C-N 114.173 -1.376 . . . . 0.0 111.145 -176.578 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.7 t -142.69 101.15 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.175 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 176.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ALA . . . . . 0.563 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.46 140.49 34.64 Favored 'General case' 0 N--CA 1.404 -2.763 0 O-C-N 123.699 0.624 . . . . 0.0 112.184 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -94.69 129.72 41.48 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 175.147 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' VAL . . . . . 0.572 HG23 ' O ' ' A' ' 33' ' ' GLY . 0.9 OUTLIER -82.45 124.08 38.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 O-C-N 123.665 0.603 . . . . 0.0 111.397 -177.377 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' SER . . . . . 0.425 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . 46.9 m -87.29 108.84 19.14 Favored 'General case' 0 N--CA 1.4 -2.972 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 168.352 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.5 tt -90.77 123.03 42.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 114.79 -1.096 . . . . 0.0 108.55 177.061 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 100' ' ' GLU . . . . . 0.408 ' HB3' HD21 ' A' ' 84' ' ' LEU . 7.8 tp10 -138.94 157.61 45.7 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 114.554 -1.203 . . . . 0.0 111.145 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -81.46 103.33 11.13 Favored 'General case' 0 C--N 1.275 -2.64 0 C-N-CA 126.871 2.069 . . . . 0.0 112.586 -177.105 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 102' ' ' SER . . . . . 0.477 ' OG ' HG21 ' A' ' 29' ' ' VAL . 23.6 p -102.58 164.84 11.43 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.407 -0.808 . . . . 0.0 110.607 169.978 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.7 m -108.97 -63.5 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 C-N-CA 118.517 -1.273 . . . . 0.0 112.405 175.318 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 13.1 tt -128.15 23.98 2.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 121.571 0.701 . . . . 0.0 111.19 -169.252 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 105' ' ' SER . . . . . 0.593 ' C ' ' HG3' ' A' ' 22' ' ' GLN . 13.6 m -82.0 85.15 6.77 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.345 -1.742 . . . . 0.0 111.854 -178.263 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 106' ' ' LEU . . . . . 0.547 ' HG ' HE21 ' A' ' 22' ' ' GLN . 7.0 mp -76.18 117.58 18.02 Favored 'General case' 0 C--O 1.195 -1.791 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 170.599 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 107' ' ' SER . . . . . 0.552 ' O ' ' HA ' ' A' ' 112' ' ' ILE . 9.3 m -69.48 86.71 0.45 Allowed 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 119.909 1.231 . . . . 0.0 111.717 -175.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 108' ' ' GLY . . . . . 0.48 ' HA3' ' HG3' ' A' ' 115' ' ' ARG . . . 124.45 135.57 4.46 Favored Glycine 0 N--CA 1.427 -1.935 0 CA-C-N 113.83 -1.532 . . . . 0.0 109.749 177.11 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 109' ' ' ASP . . . . . 0.458 ' HB3' ' NH1' ' A' ' 79' ' ' ARG . 18.0 t70 -78.34 -36.26 46.47 Favored 'General case' 0 CA--C 1.5 -0.968 0 C-N-CA 117.686 -1.606 . . . . 0.0 111.134 175.705 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -68.77 -34.01 74.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.334 -175.099 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t 178.35 169.64 0.79 Allowed 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 103.844 -2.651 . . . . 0.0 103.844 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 112' ' ' ILE . . . . . 0.556 ' O ' ' HG2' ' A' ' 115' ' ' ARG . 57.2 mt -93.66 -51.91 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.266 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 174.092 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 113' ' ' ILE . . . . . 0.555 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 3.7 mp -64.21 99.36 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.494 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.696 -170.333 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 114' ' ' GLY . . . . . 0.602 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 127.46 -7.67 7.04 Favored Glycine 0 N--CA 1.428 -1.891 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.557 174.165 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 115' ' ' ARG . . . . . 0.605 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 1.6 mmp_? -81.36 133.48 35.43 Favored 'General case' 0 C--O 1.198 -1.653 0 C-N-CA 119.434 -0.907 . . . . 0.0 108.804 -176.536 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 116' ' ' THR . . . . . 0.515 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 80.3 m -69.87 126.75 30.64 Favored 'General case' 0 C--N 1.295 -1.792 0 CA-C-O 121.114 0.483 . . . . 0.0 112.017 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 117' ' ' LEU . . . . . 0.425 ' HA ' HG12 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -75.36 97.02 3.51 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.151 174.248 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 118' ' ' VAL . . . . . 0.461 HG11 ' HB1' ' A' ' 140' ' ' ALA . 13.0 t -94.02 94.69 4.7 Favored 'Isoleucine or valine' 1 C--O 1.338 5.725 0 C-N-CA 115.78 -2.368 . . . . 0.0 110.079 -173.317 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 119' ' ' VAL . . . . . 0.442 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . 22.8 m -149.46 170.09 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 128.84 2.856 . . . . 0.0 106.636 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 120' ' ' HIS . . . . . 0.416 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 67.6 t60 -156.61 171.55 20.13 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.838 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 121' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.9 OUTLIER -70.12 83.6 0.52 Allowed 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 121.085 1.766 . . . . 0.0 106.863 173.919 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -176.63 155.65 1.37 Allowed 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 173.201 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.87 124.54 14.35 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 119.296 0.953 . . . . 0.0 112.853 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 124' ' ' ASP . . . . . 0.519 ' OD2' ' HB2' ' A' ' 140' ' ' ALA . 9.5 t70 -129.35 102.56 6.48 Favored 'General case' 0 CA--C 1.48 -1.742 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 -178.206 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -143.71 147.84 34.83 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.365 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 126' ' ' LEU . . . . . 0.597 ' HB2' ' CD2' ' A' ' 46' ' ' HIS . 43.4 tp -91.5 -28.53 17.54 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.641 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.78 -61.46 4.65 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 119.943 -1.123 . . . . 0.0 111.718 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -137.17 52.58 1.91 Allowed 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.16 0.505 . . . . 0.0 111.577 177.817 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.53 78.21 0.87 Allowed Glycine 0 C--N 1.297 -1.623 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.233 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -109.08 3.57 Favored Glycine 0 N--CA 1.442 -0.9 0 C-N-CA 121.752 -0.261 . . . . 0.0 112.937 175.454 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 131' ' ' ASN . . . . . 0.417 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.9 t30 -104.24 167.42 9.77 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -179.547 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 132' ' ' GLU . . . . . 0.499 ' O ' HG22 ' A' ' 135' ' ' THR . 8.5 mm-40 -51.78 -44.7 63.51 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -178.204 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -77.17 -24.66 51.46 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 121.829 -0.544 . . . . 0.0 112.283 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 134' ' ' SER . . . . . 0.417 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 5.7 m -80.04 -22.45 42.34 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-O 121.357 0.599 . . . . 0.0 109.819 -179.018 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 135' ' ' THR . . . . . 0.507 ' O ' HD12 ' A' ' 126' ' ' LEU . 1.8 t -81.22 -18.91 44.46 Favored 'General case' 0 N--CA 1.42 -1.945 0 C-N-CA 119.518 -0.873 . . . . 0.0 109.643 178.827 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -69.58 -36.63 76.43 Favored 'General case' 0 C--O 1.224 -0.283 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.081 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 137' ' ' THR . . . . . 0.411 ' HA ' ' HB3' ' A' ' 63' ' ' HIS . 13.6 t -86.56 -16.46 36.76 Favored 'General case' 0 C--O 1.26 1.647 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.893 -177.297 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.61 69.6 1.32 Allowed Glycine 1 C--O 1.3 4.225 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 -172.059 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -33.75 104.37 0.03 OUTLIER 'General case' 0 CA--C 1.482 -1.645 0 O-C-N 127.49 2.523 . . . . 0.0 116.21 -164.421 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 140' ' ' ALA . . . . . 0.519 ' HB2' ' OD2' ' A' ' 124' ' ' ASP . . . -153.51 170.5 20.61 Favored 'General case' 0 N--CA 1.401 -2.877 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 171.371 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 141' ' ' GLY . . . . . 0.461 ' HA3' HD22 ' A' ' 144' ' ' LEU . . . -87.4 137.17 14.43 Favored Glycine 0 C--N 1.272 -2.973 0 N-CA-C 105.718 -2.953 . . . . 0.0 105.718 165.976 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 24.5 m -54.59 -30.24 53.94 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -172.965 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 143' ' ' ARG . . . . . 0.836 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 30.8 ptt180 -124.15 15.21 9.12 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 144' ' ' LEU . . . . . 0.461 HD22 ' HA3' ' A' ' 141' ' ' GLY . 3.6 mm? -71.04 -9.09 57.44 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -175.728 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.44 89.29 0.75 Allowed 'General case' 0 N--CA 1.422 -1.826 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 172.057 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 146' ' ' CYS . . . . . 0.418 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 79.4 m -84.75 130.58 34.67 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 147' ' ' GLY . . . . . 0.515 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.27 127.01 1.29 Allowed Glycine 1 N--CA 1.396 -4.014 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.57 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.0 m -74.27 125.47 33.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.998 172.852 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 149' ' ' ILE . . . . . 0.501 HG22 ' O ' ' A' ' 115' ' ' ARG . 15.5 tt -99.41 136.65 29.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 174.244 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 150' ' ' GLY . . . . . 0.555 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 177.13 167.74 35.97 Favored Glycine 2 CA--C 1.439 -4.663 0 C-N-CA 118.486 -1.816 . . . . 0.0 111.721 179.459 . . . . . . . . 3 3 . 1 . 019 nuclear orig full ' A' A ' 151' ' ' ILE . . . . . 0.548 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 5.6 tt -82.26 104.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.348 0 CA-C-O 122.178 0.99 . . . . 0.0 110.29 169.941 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -107.75 116.43 31.93 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.373 178.977 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 . . . . . 0 C--N 1.28 -2.441 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -177.812 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.436 -1.146 0 N-CA-C 111.475 0.176 . . . . 0.0 111.475 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.659 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 3.3 m -88.81 -26.92 21.43 Favored 'General case' 0 CA--C 1.568 1.64 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -167.646 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.527 ' HB3' ' NZ ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -152.17 158.53 43.03 Favored 'General case' 0 CA--C 1.455 -2.676 0 O-C-N 120.381 -1.449 . . . . 0.0 111.628 176.619 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -145.19 153.68 41.61 Favored 'General case' 0 N--CA 1.397 -3.081 0 O-C-N 124.081 0.863 . . . . 0.0 109.321 -175.971 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.1 m -132.21 132.01 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 176.889 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.74 136.7 47.88 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.562 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.624 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 4.4 p -134.27 106.66 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-O 121.662 0.744 . . . . 0.0 110.001 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.464 ' H ' HD23 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -112.42 140.61 47.01 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.184 -178.468 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -144.54 123.48 12.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -131.92 -165.58 11.38 Favored Glycine 0 N--CA 1.434 -1.483 0 C-N-CA 119.682 -1.247 . . . . 0.0 113.707 -174.874 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -74.83 -42.75 57.43 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 177.477 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -94.94 154.01 21.05 Favored Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 106.269 -2.733 . . . . 0.0 106.269 170.457 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.41 121.7 5.76 Favored 'Trans proline' 0 N--CA 1.42 -2.822 0 CA-C-N 121.324 2.562 . . . . 0.0 109.535 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 17.4 m -133.32 124.98 50.07 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -150.0 142.73 24.64 Favored 'General case' 0 C--N 1.26 -3.283 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.292 -178.673 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.35 166.74 39.93 Favored Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.471 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.3 pt -134.33 103.23 4.7 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 CA-C-O 121.134 0.493 . . . . 0.0 109.692 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.08 126.83 57.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.575 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 7.7 p30 -125.39 122.56 37.1 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.471 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 6.4 p90 -128.22 128.19 44.27 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.659 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.4 pt-20 -106.76 109.23 21.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.888 176.695 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.497 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -126.2 162.13 26.12 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.199 1.0 . . . . 0.0 108.944 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -154.18 149.41 27.02 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -66.42 -9.08 30.41 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.6 m -70.38 -8.67 52.51 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.677 0.791 . . . . 0.0 111.655 177.038 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 75.6 115.21 0.06 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 124.444 1.097 . . . . 0.0 111.212 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.63 150.49 10.06 Favored Glycine 0 N--CA 1.424 -2.127 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 178.139 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -57.34 131.57 45.61 Favored 'Trans proline' 0 C--O 1.248 1.011 0 C-N-CA 122.585 2.19 . . . . 0.0 110.148 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.462 HG22 ' OG ' ' A' ' 102' ' ' SER . 2.9 m -83.48 128.46 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.353 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.376 -178.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 5.6 mtpm? -85.52 112.81 21.26 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 176.373 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.7 p -137.35 138.26 45.26 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.107 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.484 -168.79 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.467 ' HA ' HG11 ' A' ' 97' ' ' VAL . 33.9 t-105 -136.23 132.27 35.63 Favored 'General case' 0 C--N 1.277 -2.559 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.714 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -151.63 138.89 6.77 Favored Glycine 0 C--O 1.208 -1.486 0 C-N-CA 119.233 -1.46 . . . . 0.0 112.991 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.7 m -116.56 142.7 46.54 Favored 'General case' 0 N--CA 1.408 -2.528 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 176.501 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 76.0 mt -128.71 139.17 52.62 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 118.737 0.699 . . . . 0.0 109.335 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.655 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 22.4 ptmt -117.89 138.74 51.92 Favored 'General case' 0 N--CA 1.411 -2.414 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 173.285 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.649 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -161.37 176.56 37.9 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -166.732 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.9 mt -69.08 170.89 9.1 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 175.098 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.468 ' HB ' ' O ' ' A' ' 91' ' ' LYS . 2.8 t -69.31 108.29 3.63 Favored 'General case' 0 C--O 1.192 -1.969 0 O-C-N 121.615 -0.678 . . . . 0.0 112.292 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -172.86 171.7 4.26 Favored 'General case' 0 CA--C 1.461 -2.467 0 C-N-CA 124.55 1.14 . . . . 0.0 108.662 174.017 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 89' ' ' ALA . . . -82.55 -146.23 5.99 Favored Glycine 0 C--N 1.276 -2.787 0 O-C-N 124.875 1.359 . . . . 0.0 109.779 173.608 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 120' ' ' HIS . 2.8 tt 172.4 140.08 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 103.709 -2.7 . . . . 0.0 103.709 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -152.66 122.23 6.84 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.01 139.05 0.99 Allowed Glycine 0 C--N 1.301 -1.396 0 O-C-N 123.768 0.667 . . . . 0.0 113.999 177.473 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -114.49 106.53 14.39 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 176.41 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.548 ' CE1' ' HA3' ' A' ' 138' ' ' GLY . 28.9 t-80 -130.13 89.19 2.76 Favored 'General case' 1 C--O 1.316 4.556 0 CA-C-O 122.134 0.968 . . . . 0.0 109.141 -176.709 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.603 HG13 ' HA ' ' A' ' 117' ' ' LEU . 94.5 t -92.56 152.0 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.357 0 CA-C-N 112.692 -2.049 . . . . 0.0 107.387 175.085 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -162.05 94.31 0.92 Allowed 'General case' 0 C--N 1.288 -2.074 0 O-C-N 124.083 0.864 . . . . 0.0 110.367 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.54 ' CG ' ' HB2' ' A' ' 60' ' ' ALA . 1.3 mm-40 -145.96 170.26 16.98 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 115.557 1.688 . . . . 0.0 115.557 -174.769 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.417 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 20.5 p90 -139.99 25.86 2.28 Favored 'General case' 0 N--CA 1.41 -2.463 0 CA-C-N 112.238 -2.255 . . . . 0.0 108.815 174.843 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . 84.47 129.02 1.8 Allowed Glycine 0 C--N 1.34 0.804 0 CA-C-N 114.586 -1.188 . . . . 0.0 115.447 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -140.8 -77.84 0.29 Allowed 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.578 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.4 ' O ' HG21 ' A' ' 116' ' ' THR . 28.0 t30 -157.69 133.09 8.96 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.431 ' HB ' HG23 ' A' ' 148' ' ' VAL . 13.0 t -73.26 4.6 4.37 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -173.904 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.69 -2.41 17.44 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.896 0.379 . . . . 0.0 110.348 177.059 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 157.56 124.72 0.81 Allowed Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.492 ' O ' ' HB3' ' A' ' 142' ' ' SER . 0.6 OUTLIER -97.67 112.78 24.52 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 113.565 0.95 . . . . 0.0 113.565 -176.399 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.7 m -75.61 -37.41 59.81 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.252 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.417 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 4.6 m -72.56 -26.68 61.82 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.621 0.724 . . . . 0.0 110.23 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.54 ' HB2' ' CG ' ' A' ' 49' ' ' GLU . . . -76.5 -8.77 57.86 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.039 -175.551 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.69 -93.3 0.03 OUTLIER Glycine 0 C--N 1.301 -1.384 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.345 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -95.88 53.31 0.17 Allowed 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 121.71 1.606 . . . . 0.0 113.349 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -125.73 117.06 22.64 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.919 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.561 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 52.8 p90 -87.07 138.52 31.42 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.196 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -115.51 95.84 44.35 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.568 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 56.7 Cg_endo -68.86 -10.79 30.14 Favored 'Trans proline' 0 C--O 1.213 -0.744 0 C-N-CA 124.035 3.157 . . . . 0.0 115.031 -173.895 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -77.12 -18.42 57.94 Favored 'General case' 0 C--O 1.199 -1.581 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -173.43 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 47.5 p -54.63 -84.34 0.01 OUTLIER 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 114.283 -1.326 . . . . 0.0 113.315 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.556 ' HB3' ' H ' ' A' ' 72' ' ' GLY . 1.9 tmt_? -134.91 30.13 3.4 Favored 'General case' 0 C--N 1.249 -3.8 0 N-CA-C 103.01 -2.959 . . . . 0.0 103.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 66' ' ' PRO . 69.7 mmtt 75.19 -41.23 0.45 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.04 -169.834 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.466 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 1.8 t-160 -121.74 -16.97 7.55 Favored 'General case' 0 N--CA 1.426 -1.652 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.075 171.437 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.556 ' H ' ' HB3' ' A' ' 69' ' ' ARG . . . 108.92 16.81 10.95 Favored Glycine 0 C--N 1.358 1.8 0 C-N-CA 118.519 -1.8 . . . . 0.0 115.881 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -38.26 146.98 0.12 Allowed Glycine 0 N--CA 1.491 2.338 0 CA-C-N 117.978 0.889 . . . . 0.0 113.69 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.88 -22.4 17.53 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.097 2.531 . . . . 0.0 113.869 -166.429 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -86.87 -12.83 46.66 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.945 -177.067 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 21.4 t0 70.35 159.93 0.2 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 124.493 1.117 . . . . 0.0 111.209 -175.562 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.503 ' HB2' ' NE ' ' A' ' 69' ' ' ARG . 22.7 tp10 -148.47 -24.99 0.33 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -178.57 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.462 ' HG2' ' HG2' ' A' ' 79' ' ' ARG . 27.6 tt0 -138.67 -64.02 0.53 Allowed 'General case' 0 N--CA 1.423 -1.815 0 C-N-CA 118.237 -1.385 . . . . 0.0 110.755 -176.029 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.695 ' O ' ' HA ' ' A' ' 68' ' ' SER . 15.4 ptt180 -173.72 62.6 0.02 OUTLIER 'General case' 0 N--CA 1.398 -3.052 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 -173.775 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 4.5 t60 . . . . . 0 N--CA 1.428 -1.539 0 CA-C-N 113.315 -1.766 . . . . 0.0 107.022 170.205 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.432 -1.37 0 CA-C-O 121.751 0.786 . . . . 0.0 110.145 . . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.25 -178.64 47.61 Favored Glycine 1 N--CA 1.386 -4.684 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 176.192 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -128.2 129.74 46.92 Favored 'General case' 0 C--N 1.263 -3.194 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 169.684 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.582 HG23 HD22 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -133.78 147.89 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.083 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.529 ' HA ' ' HB3' ' A' ' 42' ' ' LEU . 89.0 m -139.93 113.0 8.21 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -176.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.464 ' O ' ' HA2' ' A' ' 41' ' ' GLY . . . -83.44 150.98 25.7 Favored 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.468 ' OD1' ' HG2' ' A' ' 91' ' ' LYS . 9.8 t70 -93.13 -179.02 4.96 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 174.5 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' O ' ' HB ' ' A' ' 39' ' ' THR . 22.1 pttp -61.21 -16.23 42.72 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 124.459 1.104 . . . . 0.0 111.822 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.3 4.62 48.71 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.937 -0.477 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.655 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 60.96 83.17 0.06 OUTLIER Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.047 -175.751 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 5.1 m -155.75 111.15 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.305 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.572 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -119.44 123.97 45.37 Favored 'General case' 0 N--CA 1.415 -2.184 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.644 -178.632 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.66 145.38 28.01 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.714 ' HB ' ' O ' ' A' ' 33' ' ' GLY . 7.5 p -84.55 125.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -173.584 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.4 t -90.48 115.52 27.7 Favored 'General case' 0 N--CA 1.404 -2.735 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 168.855 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 31' ' ' VAL . 34.9 mt -92.02 118.26 37.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -107.34 156.04 19.34 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.915 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -81.28 99.69 8.76 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 122.088 0.947 . . . . 0.0 109.452 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -97.79 171.74 8.12 Favored 'General case' 0 C--N 1.265 -3.091 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.238 -175.922 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.553 HG12 HG13 ' A' ' 104' ' ' ILE . 26.5 t -109.32 -64.51 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.368 0 C-N-CA 119.658 -0.817 . . . . 0.0 111.446 -177.621 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.553 HG13 HG12 ' A' ' 103' ' ' VAL . 8.4 mt -134.18 24.97 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 121.326 0.584 . . . . 0.0 109.854 -177.986 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.427 ' OG ' ' HB3' ' A' ' 80' ' ' HIS . 33.3 t -68.99 88.49 0.4 Allowed 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -170.411 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.562 ' H ' HD23 ' A' ' 106' ' ' LEU . 1.7 pt? -96.49 136.31 37.18 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 160.331 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -71.89 86.21 0.98 Allowed 'General case' 0 C--N 1.286 -2.174 0 CA-C-O 122.349 1.071 . . . . 0.0 112.755 -175.418 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 111' ' ' SER . . . 143.2 135.74 3.06 Favored Glycine 0 N--CA 1.409 -3.145 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.821 170.595 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -93.46 -28.03 16.35 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 122.903 -0.174 . . . . 0.0 111.434 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 48.4 m80 -91.22 -23.43 20.2 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.0 -178.98 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.668 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t 177.11 178.89 0.25 Allowed 'General case' 0 N--CA 1.426 -1.666 0 N-CA-C 104.083 -2.562 . . . . 0.0 104.083 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -113.43 -56.46 4.2 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 C-N-CA 124.589 1.156 . . . . 0.0 109.878 -175.361 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.47 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 52.5 mt -68.37 119.51 14.27 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.723 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -177.089 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.547 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 115.66 -19.27 14.38 Favored Glycine 0 CA--C 1.47 -2.751 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.668 ' CZ ' ' HB3' ' A' ' 111' ' ' SER . 4.5 mpt_? -74.85 128.45 35.61 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 0.2 OUTLIER -92.01 126.88 37.26 Favored 'General case' 0 C--N 1.258 -3.389 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.62 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.603 ' HA ' HG13 ' A' ' 47' ' ' VAL . 2.0 pt? -76.62 136.88 39.2 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -177.423 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.9 99.57 8.69 Favored 'Isoleucine or valine' 0 C--O 1.28 2.661 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.654 171.111 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.682 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.4 p -147.42 170.39 3.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 104.748 -2.316 . . . . 0.0 104.748 178.226 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.599 ' O ' ' HG ' ' A' ' 42' ' ' LEU . 81.7 t60 -170.89 171.25 6.06 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 103.312 -2.848 . . . . 0.0 103.312 175.536 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.526 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.04 87.07 0.37 Allowed 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 171.278 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.499 ' H ' ' HG ' ' A' ' 42' ' ' LEU . 16.3 tppt? -173.18 154.76 2.79 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.74 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.37 103.88 1.11 Allowed 'General case' 0 C--N 1.285 -2.236 0 CA-C-O 121.89 0.852 . . . . 0.0 109.991 166.138 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -106.51 70.31 0.82 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.549 -2.389 . . . . 0.0 104.549 175.877 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -68.11 161.41 26.95 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.128 -170.267 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.534 ' H ' HD22 ' A' ' 126' ' ' LEU . 0.3 OUTLIER -90.48 -68.92 0.76 Allowed 'General case' 0 N--CA 1.397 -3.103 0 CA-C-N 113.83 -1.532 . . . . 0.0 110.996 -167.381 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 127' ' ' GLY . . . . . 0.466 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -102.82 -16.55 21.41 Favored Glycine 0 N--CA 1.429 -1.773 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.984 -177.752 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.99 -31.51 16.3 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 117.16 0.48 . . . . 0.0 110.367 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 134' ' ' SER . . . 53.7 -89.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.972 0 O-C-N 123.709 0.63 . . . . 0.0 114.175 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -172.84 -86.19 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -96.78 162.33 13.47 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 176.859 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.518 ' O ' ' HB ' ' A' ' 135' ' ' THR . 10.1 pt-20 -38.9 -51.32 1.76 Allowed 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -170.517 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -71.62 -38.09 70.82 Favored 'General case' 0 C--N 1.311 -1.083 0 O-C-N 122.12 -0.362 . . . . 0.0 111.854 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.483 ' O ' ' HA3' ' A' ' 129' ' ' GLY . 14.4 m -72.45 -22.92 61.01 Favored 'General case' 0 C--O 1.218 -0.568 0 CA-C-O 121.488 0.661 . . . . 0.0 109.619 178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' ' 132' ' ' GLU . 66.4 m -67.16 -39.88 86.57 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-O 121.949 0.881 . . . . 0.0 108.845 173.437 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -71.3 -51.33 24.96 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.022 -1.445 . . . . 0.0 110.046 -177.656 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.561 ' HA ' ' HB3' ' A' ' 64' ' ' PHE . 41.1 p -74.68 -31.23 61.84 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.673 -177.317 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.548 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . 82.35 106.12 0.43 Allowed Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -174.243 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -32.84 140.31 0.04 OUTLIER 'General case' 1 C--O 1.329 5.254 0 C-N-CA 126.463 1.905 . . . . 0.0 115.47 -165.534 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -150.49 120.2 7.03 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.323 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -98.94 89.08 0.88 Allowed Glycine 0 N--CA 1.417 -2.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 169.858 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 6.2 m -42.79 -35.3 1.12 Allowed 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 126.727 2.011 . . . . 0.0 114.252 -171.383 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 17.9 ptt180 -125.35 5.12 7.71 Favored 'General case' 0 N--CA 1.414 -2.258 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.061 -177.709 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.09 -27.38 64.55 Favored 'General case' 0 C--N 1.291 -1.957 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.259 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.682 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.8 96.88 0.17 Allowed 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 43.4 t -140.5 147.78 40.08 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.087 -176.63 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.624 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.15 162.41 34.46 Favored Glycine 0 N--CA 1.403 -3.513 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 179.218 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 54' ' ' THR . 17.6 t -68.74 122.88 20.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.799 0.809 . . . . 0.0 111.149 175.326 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.647 HG12 ' O ' ' A' ' 115' ' ' ARG . 26.1 pt -111.97 146.25 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.868 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.17 155.92 15.44 Favored Glycine 2 N--CA 1.365 -6.07 0 C-N-CA 117.566 -2.254 . . . . 0.0 111.632 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.572 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 25.1 pt -63.08 105.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-N 114.854 -0.673 . . . . 0.0 110.369 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.53 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -105.62 114.15 28.14 Favored 'General case' 0 C--N 1.309 -1.168 0 O-C-N 121.9 -0.5 . . . . 0.0 110.663 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.318 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.226 -0.168 0 CA-C-O 120.629 0.252 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 p -81.65 -65.6 0.99 Allowed 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 178.581 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -170.78 171.98 5.89 Favored 'General case' 0 CA--C 1.488 -1.406 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -176.52 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.629 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -130.8 149.25 52.53 Favored 'General case' 0 N--CA 1.414 -2.225 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 172.038 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 149' ' ' ILE . 10.6 p -126.9 142.86 42.19 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -122.44 129.69 52.31 Favored 'General case' 0 C--N 1.286 -2.171 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.79 -177.533 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -129.15 111.73 23.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mp -108.08 152.12 24.95 Favored 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 120.972 -0.291 . . . . 0.0 111.243 178.597 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -136.08 131.36 34.73 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 106.187 -1.782 . . . . 0.0 106.187 175.751 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 12' ' ' GLY . . . -104.21 148.86 16.95 Favored Glycine 0 N--CA 1.41 -3.099 0 N-CA-C 117.991 1.956 . . . . 0.0 117.991 -168.32 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -83.78 -19.5 34.94 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 111.629 -2.286 . . . . 0.0 104.92 168.298 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 12' ' ' GLY . . . . . 0.42 ' O ' ' HA3' ' A' ' 10' ' ' GLY . . . -142.71 144.52 14.07 Favored Glycine 0 N--CA 1.421 -2.328 1 N-CA-C 101.215 -4.754 . . . . 0.0 101.215 168.858 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_exo -69.74 124.82 11.47 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 CA-C-N 122.221 3.01 . . . . 0.0 112.989 -168.053 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.6 104.94 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.997 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.481 176.224 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -117.87 119.95 36.41 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.202 -0.936 . . . . 0.0 111.879 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA3' HD12 ' A' ' 35' ' ' ILE . . . -170.54 171.83 43.85 Favored Glycine 0 N--CA 1.44 -1.042 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.9 pt -143.6 131.75 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.622 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 mp -128.96 133.3 66.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.623 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.2 m-20 -117.21 126.71 53.2 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.629 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 67.8 t80 -129.03 119.63 24.59 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.426 ' CG ' ' HB3' ' A' ' 30' ' ' LYS . 10.5 pt-20 -131.14 113.53 14.01 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.352 0.596 . . . . 0.0 111.823 177.796 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.688 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -86.59 163.88 17.18 Favored 'General case' 0 N--CA 1.414 -2.228 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 168.049 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -96.45 146.92 24.35 Favored 'General case' 0 C--N 1.275 -2.669 0 C-N-CA 119.088 -1.045 . . . . 0.0 112.429 -172.896 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -56.64 -40.69 75.87 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.8 1.313 . . . . 0.0 109.735 178.038 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.4 p -81.25 -70.99 0.49 Allowed 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.37 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 168.21 161.26 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 126.413 1.885 . . . . 0.0 106.386 175.757 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.582 ' H ' HG23 ' A' ' 103' ' ' VAL . . . 155.6 174.01 24.96 Favored Glycine 0 N--CA 1.41 -3.077 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 174.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.9 136.88 55.13 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 121.732 1.621 . . . . 0.0 108.889 177.016 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.595 HG12 ' HA ' ' A' ' 22' ' ' GLN . 30.1 m -74.17 147.6 8.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-O 121.849 0.833 . . . . 0.0 110.813 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.454 ' HA ' HD11 ' A' ' 99' ' ' ILE . 28.2 ttmt -99.28 115.05 28.25 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 174.435 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.5 p -137.58 128.62 39.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-O 121.253 0.549 . . . . 0.0 110.337 -177.351 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.401 ' HA ' HG11 ' A' ' 97' ' ' VAL . 89.1 t90 -133.37 126.88 32.28 Favored 'General case' 0 C--N 1.283 -2.285 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.63 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -142.0 139.72 9.51 Favored Glycine 0 N--CA 1.407 -3.246 0 C-N-CA 119.162 -1.494 . . . . 0.0 112.495 178.487 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.43 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 42.6 t -114.19 145.64 41.43 Favored 'General case' 0 C--N 1.284 -2.27 0 N-CA-C 107.292 -1.374 . . . . 0.0 107.292 176.418 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.646 HG22 ' HB2' ' A' ' 95' ' ' ALA . 3.2 tp -152.09 139.44 13.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 99.9 mttt -130.62 107.36 9.13 Favored 'General case' 0 C--N 1.281 -2.393 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 176.614 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.666 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -131.93 174.98 19.98 Favored Glycine 0 C--N 1.282 -2.434 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -171.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 121' ' ' GLU . 93.1 mt -68.72 170.14 9.98 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 118.113 0.956 . . . . 0.0 109.881 177.788 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 2.0 t -70.7 105.34 3.14 Favored 'General case' 0 CA--C 1.55 0.98 0 N-CA-C 114.367 1.247 . . . . 0.0 114.367 -171.518 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -177.26 165.06 2.24 Favored 'General case' 0 CA--C 1.456 -2.642 0 C-N-CA 128.594 2.758 . . . . 0.0 104.918 169.825 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 158.49 130.32 1.16 Allowed Glycine 3 N--CA 1.376 -5.338 0 C-N-CA 118.2 -1.952 . . . . 0.0 111.166 170.198 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mp -124.44 -86.33 0.63 Allowed 'General case' 0 N--CA 1.396 -3.174 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.491 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 79.9 m-70 -172.14 162.71 5.79 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 174.33 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 132.75 144.83 5.32 Favored Glycine 0 C--N 1.29 -2.002 0 C-N-CA 119.288 -1.434 . . . . 0.0 113.092 174.502 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' HB ' ' A' ' 47' ' ' VAL . 30.9 t80 -165.8 96.54 0.63 Allowed 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 124.927 1.291 . . . . 0.0 108.294 175.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 125' ' ' ASP . 0.2 OUTLIER -114.33 89.49 3.11 Favored 'General case' 0 N--CA 1.403 -2.794 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 177.599 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.64 ' HB ' ' CE1' ' A' ' 45' ' ' PHE . 14.6 p -69.85 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.927 0 CA-C-N 111.603 -2.544 . . . . 0.0 107.19 175.975 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.6 t60 -154.1 104.33 2.62 Favored 'General case' 1 C--N 1.233 -4.491 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.232 173.673 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.572 ' HB2' ' HB3' ' A' ' 109' ' ' ASP . 1.5 mp0 -67.77 158.34 32.64 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.017 -1.447 . . . . 0.0 109.16 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.1 t80 77.95 64.01 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 123.887 1.804 . . . . 0.0 107.423 -166.439 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.475 ' HA3' ' OG1' ' A' ' 116' ' ' THR . . . -112.63 -126.15 4.57 Favored Glycine 0 N--CA 1.416 -2.668 0 CA-C-N 111.454 -2.612 . . . . 0.0 107.173 174.634 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.436 ' H ' HG23 ' A' ' 116' ' ' THR . 33.0 t70 -176.97 -71.6 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 117.946 0.873 . . . . 0.0 112.758 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 37.6 p30 -131.76 177.1 7.78 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.682 0.753 . . . . 0.0 112.947 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.474 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 25.9 m -84.21 6.85 21.05 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 125.919 1.688 . . . . 0.0 110.602 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.27 -32.05 26.62 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.752 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 164.24 155.83 8.54 Favored Glycine 0 N--CA 1.412 -2.911 0 N-CA-C 108.859 -1.697 . . . . 0.0 108.859 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.62 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.2 m -83.25 89.58 7.0 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.4 p -75.81 -58.69 3.13 Favored 'General case' 0 N--CA 1.421 -1.923 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.965 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 70.8 m -68.7 -42.68 77.39 Favored 'General case' 0 N--CA 1.425 -1.701 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.47 -25.5 54.39 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.356 -176.605 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' HG21 ' A' ' 118' ' ' VAL . . . 49.24 -144.57 8.12 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -100.23 5.73 0.76 Allowed 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.803 2.335 . . . . 0.0 110.658 173.667 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.8 t60 -77.47 149.69 35.01 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.826 -169.248 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.481 ' HB2' ' O ' ' A' ' 80' ' ' HIS . 13.3 p90 -81.1 169.95 16.79 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.537 ' HB3' ' OG ' ' A' ' 68' ' ' SER . 53.0 t30 -105.52 143.19 26.31 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.77 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_exo -75.32 -13.58 20.71 Favored 'Trans proline' 0 C--O 1.225 -0.151 0 C-N-CA 121.79 1.66 . . . . 0.0 110.963 175.167 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.63 21.64 17.01 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 122.72 1.248 . . . . 0.0 108.69 -171.802 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.537 ' OG ' ' HB3' ' A' ' 65' ' ' ASN . 46.3 m -73.98 -1.53 20.26 Favored 'General case' 0 C--O 1.196 -1.734 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.265 174.274 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.645 ' HA ' ' H ' ' A' ' 79' ' ' ARG . 3.9 mmp_? -68.59 -4.03 13.91 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 129.158 2.983 . . . . 0.0 109.589 177.552 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -140.54 29.73 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.725 -1.125 . . . . 0.0 108.196 176.626 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.5 ' HB3' ' N ' ' A' ' 84' ' ' LEU . 99.0 m-70 -143.97 -93.08 0.11 Allowed 'General case' 0 CA--C 1.556 1.176 0 C-N-CA 124.249 1.02 . . . . 0.0 109.392 176.326 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.601 ' HA2' ' HB2' ' A' ' 79' ' ' ARG . . . 81.94 -63.62 4.36 Favored Glycine 0 CA--C 1.501 -0.824 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 173.049 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.36 161.35 35.16 Favored Glycine 0 C--N 1.264 -3.454 0 N-CA-C 107.566 -2.214 . . . . 0.0 107.566 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.565 ' HA ' ' HG ' ' A' ' 84' ' ' LEU . 19.2 Cg_endo -55.58 -30.35 74.23 Favored 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 123.877 3.051 . . . . 0.0 115.266 -174.663 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.7 tppt? -101.97 -5.09 25.07 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.318 0.58 . . . . 0.0 110.144 -177.778 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -110.38 -163.45 0.86 Allowed 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 -177.679 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -171.18 41.57 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.835 0.854 . . . . 0.0 111.182 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.702 ' O ' ' HG2' ' A' ' 79' ' ' ARG . 11.4 pt-20 -163.15 149.25 12.04 Favored 'General case' 0 C--O 1.161 -3.584 0 CA-C-O 116.657 -1.64 . . . . 0.0 106.721 175.313 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.702 ' HG2' ' O ' ' A' ' 78' ' ' GLU . 6.2 mmt180 161.84 -165.1 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 128.125 2.57 . . . . 0.0 107.848 170.405 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' A' ' 64' ' ' PHE . 43.3 m-70 . . . . . 0 C--N 1.276 -2.629 0 C-N-CA 125.619 1.568 . . . . 0.0 108.278 171.585 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.565 ' HG ' ' HA ' ' A' ' 74' ' ' PRO . 6.7 tt . . . . . 0 N--CA 1.445 -0.708 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.592 ' C ' ' HB3' ' A' ' 45' ' ' PHE . . . 176.88 178.66 46.8 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 169.496 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.489 ' N ' ' HB3' ' A' ' 45' ' ' PHE . 8.8 p30 -159.42 135.69 9.0 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 173.901 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 75.2 t -127.56 151.61 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.293 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.731 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.6 m -134.65 148.59 50.4 Favored 'General case' 0 N--CA 1.404 -2.758 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.107 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -149.12 153.59 37.98 Favored 'General case' 1 C--N 1.243 -4.053 0 N-CA-C 102.199 -3.26 . . . . 0.0 102.199 173.012 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 13.6 t70 -128.0 -158.24 0.86 Allowed 'General case' 0 C--N 1.251 -3.686 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.547 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 60.5 mttp -68.25 5.85 0.89 Allowed 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 124.138 0.975 . . . . 0.0 113.278 -179.489 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -116.76 -9.38 11.27 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 175.009 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 64.77 72.93 0.63 Allowed Glycine 0 C--O 1.224 -0.526 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.897 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 62.8 t -154.57 133.3 3.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -175.624 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.646 ' HB2' HG22 ' A' ' 35' ' ' ILE . . . -94.35 127.22 40.1 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-O 122.367 1.08 . . . . 0.0 113.777 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -105.75 107.04 17.83 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 102.177 -3.268 . . . . 0.0 102.177 160.863 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.63 HG11 ' H ' ' A' ' 33' ' ' GLY . 9.4 p -83.34 137.56 20.76 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.4 0 C-N-CA 117.949 -1.501 . . . . 0.0 108.806 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 45.8 m -86.99 121.05 28.92 Favored 'General case' 0 N--CA 1.387 -3.597 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 171.926 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.454 HD11 ' HA ' ' A' ' 30' ' ' LYS . 2.9 tt -90.81 115.05 29.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 175.092 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.492 ' HG3' ' HB2' ' A' ' 74' ' ' PRO . 5.6 mm-40 -106.22 157.36 17.63 Favored 'General case' 0 CA--C 1.48 -1.738 0 CA-C-N 113.89 -1.505 . . . . 0.0 111.596 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.23 96.17 10.23 Favored 'General case' 0 N--CA 1.426 -1.665 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.454 ' OG ' HD21 ' A' ' 84' ' ' LEU . 4.8 m -105.98 141.86 36.67 Favored 'General case' 0 N--CA 1.402 -2.843 0 N-CA-C 103.913 -2.625 . . . . 0.0 103.913 174.243 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.582 HG23 ' H ' ' A' ' 27' ' ' GLY 0.276 2.6 p -118.02 -49.48 4.02 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 C-N-CA 117.059 -1.856 . . . . 0.0 112.744 176.166 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.2 mm -81.71 -7.54 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.57 1.732 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 -170.814 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.491 ' OG ' HD13 ' A' ' 84' ' ' LEU . 50.8 m -79.3 84.01 5.28 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 117.726 2.491 . . . . 0.0 117.726 -172.161 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.688 ' HB3' ' HG3' ' A' ' 22' ' ' GLN . 1.1 pt? -140.06 82.14 1.85 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 154.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.3 m -171.62 87.15 0.09 Allowed 'General case' 1 C--N 1.233 -4.467 0 N-CA-C 101.777 -3.416 . . . . 0.0 101.777 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -111.59 157.69 14.8 Favored Glycine 3 N--CA 1.375 -5.387 0 N-CA-C 106.246 -2.742 . . . . 0.0 106.246 175.579 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.572 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 12.6 t70 -62.02 -41.82 98.5 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-O 121.817 0.818 . . . . 0.0 109.714 178.559 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.577 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 6.8 m80 -123.24 -24.84 4.58 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.138 -0.937 . . . . 0.0 112.029 177.078 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.2 m 59.7 -70.35 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 125.809 1.644 . . . . 0.0 114.622 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.676 HG13 ' O ' ' A' ' 151' ' ' ILE . 3.6 tt -98.15 -43.51 11.94 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 C-N-CA 124.799 1.24 . . . . 0.0 110.415 -174.91 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 8.1 tt -104.51 102.2 13.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -172.094 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.5 60.13 1.84 Allowed Glycine 0 CA--C 1.474 -2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.767 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.545 ' HD3' ' C ' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -119.24 90.01 3.25 Favored 'General case' 0 C--N 1.252 -3.643 0 CA-C-N 112.688 -1.756 . . . . 0.0 109.594 -176.866 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.614 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 17.9 p -95.08 132.76 39.63 Favored 'General case' 0 C--N 1.289 -2.026 0 O-C-N 121.723 -0.611 . . . . 0.0 111.858 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.532 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -81.32 120.63 25.19 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 175.61 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.62 HG22 ' SG ' ' A' ' 57' ' ' CYS . 19.6 t -100.35 98.09 6.55 Favored 'Isoleucine or valine' 0 C--O 1.297 3.602 0 C-N-CA 116.259 -2.176 . . . . 0.0 106.987 172.938 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.525 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 25.4 t -148.81 171.05 2.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -160.53 171.99 17.99 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 104.093 -2.558 . . . . 0.0 104.093 169.547 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -69.62 87.81 0.5 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 123.064 2.665 . . . . 0.0 109.973 -178.791 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 33.2 tptt -172.55 171.97 4.43 Favored 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -171.425 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -78.99 117.91 20.5 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 171.439 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 46' ' ' HIS . 3.6 t70 -139.77 78.4 1.66 Allowed 'General case' 0 CA--C 1.474 -1.951 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.613 ' HA ' ' HB2' ' A' ' 46' ' ' HIS . 25.1 t0 -177.44 158.0 1.36 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 123.766 0.666 . . . . 0.0 109.424 173.276 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 135' ' ' THR . 3.3 tm? -90.72 -40.48 11.83 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 124.624 1.203 . . . . 0.0 107.988 -176.732 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.24 -48.86 6.19 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.492 -0.861 . . . . 0.0 111.622 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.77 51.34 1.53 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.146 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.15 -105.83 0.27 Allowed Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 119.875 -1.155 . . . . 0.0 111.745 176.207 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -152.26 -96.18 0.13 Allowed Glycine 0 C--N 1.316 -0.556 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.652 -176.69 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -79.89 153.67 28.87 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.142 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -45.72 -50.75 13.43 Favored 'General case' 0 C--N 1.36 1.057 0 N-CA-C 114.522 1.304 . . . . 0.0 114.522 -176.66 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -80.4 -26.89 38.28 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 121.526 -0.734 . . . . 0.0 111.114 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 27.5 t -77.59 -29.14 51.84 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.667 -173.618 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 126' ' ' LEU . 6.6 t -76.52 -25.06 53.75 Favored 'General case' 0 C--O 1.206 -1.212 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.669 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 126' ' ' LEU . 58.8 mtpt -71.28 -35.36 71.32 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.895 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 12.4 t -85.98 -31.75 21.89 Favored 'General case' 0 N--CA 1.412 -2.366 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.25 178.725 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 57.63 73.07 0.49 Allowed Glycine 0 CA--C 1.486 -1.764 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -177.709 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -51.58 105.8 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 122.471 1.129 . . . . 0.0 113.248 -171.468 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -89.29 164.54 14.89 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 114.441 -1.254 . . . . 0.0 113.664 -171.092 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -139.95 86.28 0.21 Allowed Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 107.25 -2.34 . . . . 0.0 107.25 175.351 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.504 ' HA ' HG13 ' A' ' 118' ' ' VAL . 13.8 m -61.84 -18.65 60.81 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 113.823 1.046 . . . . 0.0 113.823 -172.166 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -121.72 -46.31 2.25 Favored 'General case' 0 C--N 1.26 -3.312 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.681 177.837 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.9 tt -46.13 -45.06 16.26 Favored 'General case' 0 CA--C 1.495 -1.163 0 O-C-N 125.406 1.691 . . . . 0.0 111.564 -164.948 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -139.66 88.76 2.27 Favored 'General case' 0 N--CA 1.395 -3.192 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.2 m -130.25 140.08 50.73 Favored 'General case' 0 N--CA 1.394 -3.227 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.283 176.747 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -170.93 149.03 11.83 Favored Glycine 1 N--CA 1.379 -5.124 0 CA-C-N 113.831 -1.531 . . . . 0.0 109.358 -177.166 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 16.0 m -70.55 110.14 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.63 0 CA-C-O 122.104 0.954 . . . . 0.0 111.147 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.545 ' C ' ' HD3' ' A' ' 115' ' ' ARG . 9.4 tt -122.11 108.87 22.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 CA-C-N 114.652 -1.158 . . . . 0.0 109.27 175.477 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.497 ' HA3' ' HG2' ' A' ' 115' ' ' ARG . . . -179.03 -171.25 42.02 Favored Glycine 3 CA--C 1.435 -4.936 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 175.99 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.676 ' O ' HG13 ' A' ' 112' ' ' ILE . 64.5 mt -64.3 104.64 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.263 -3.165 0 O-C-N 124.853 0.972 . . . . 0.0 110.576 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.462 ' HB2' ' NH2' ' A' ' 115' ' ' ARG . . . -142.17 100.09 3.65 Favored 'General case' 0 N--CA 1.433 -1.304 0 CA-C-O 121.168 0.508 . . . . 0.0 109.836 169.311 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 C--N 1.289 -2.043 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 177.016 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 CA--C 1.512 -0.515 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 22.6 m -111.24 -36.44 5.59 Favored 'General case' 0 CA--C 1.552 1.027 0 O-C-N 123.583 0.552 . . . . 0.0 111.733 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.402 ' HG2' ' N ' ' A' ' 4' ' ' ALA . 50.1 tttm -146.65 152.52 39.01 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.937 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.96 167.73 20.39 Favored 'General case' 0 N--CA 1.406 -2.629 0 O-C-N 123.676 0.61 . . . . 0.0 109.609 175.029 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -137.6 131.99 44.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 123.313 0.645 . . . . 0.0 109.304 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.671 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -112.18 131.36 55.52 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -134.86 103.83 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.038 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.561 ' HB3' HD21 ' A' ' 117' ' ' LEU . 1.4 pt? -118.29 151.17 38.2 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -162.86 140.77 8.16 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.39 -158.48 8.37 Favored Glycine 0 N--CA 1.414 -2.785 0 C-N-CA 119.039 -1.553 . . . . 0.0 112.996 -176.703 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -71.37 -49.19 44.68 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.65 144.95 16.94 Favored Glycine 0 N--CA 1.431 -1.655 0 N-CA-C 106.55 -2.62 . . . . 0.0 106.55 172.888 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -76.56 124.03 7.38 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 CA-C-N 120.355 2.078 . . . . 0.0 112.96 -175.575 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -132.38 113.05 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 103.853 -2.647 . . . . 0.0 103.853 173.236 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.573 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 96.8 mt-30 -118.58 141.33 48.68 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.6 -174.883 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -169.69 157.86 29.74 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.482 -177.218 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.463 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.9 pt -135.26 102.47 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.949 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.671 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 10.3 mt -121.42 137.44 55.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -174.847 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -113.94 134.08 55.06 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.817 178.308 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.937 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.0 m-85 -123.26 134.27 54.11 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.356 0.262 . . . . 0.0 110.921 -178.105 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.9 pt-20 -132.96 102.34 5.59 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 121.588 0.709 . . . . 0.0 112.168 175.751 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.468 ' H ' ' HB3' ' A' ' 1' ' ' ALA . 42.9 mt-30 -106.24 113.82 27.57 Favored 'General case' 0 N--CA 1.389 -3.5 0 N-CA-C 103.872 -2.64 . . . . 0.0 103.872 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.586 ' H ' ' HB ' ' A' ' 103' ' ' VAL . 54.9 tttm -134.26 171.76 13.81 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.422 -169.576 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.518 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 5.4 mp0 -63.97 -26.12 68.44 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.87 1.268 . . . . 0.0 111.69 -177.694 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -33.06 28.16 Favored 'General case' 0 CA--C 1.549 0.911 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 -172.345 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.9 t30 64.73 97.34 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -173.09 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.633 ' H ' HG22 ' A' ' 103' ' ' VAL . . . 179.18 -163.34 30.81 Favored Glycine 0 CA--C 1.463 -3.196 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.416 -175.746 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -83.24 139.65 9.42 Favored 'Trans proline' 0 N--CA 1.42 -2.851 0 C-N-CA 122.114 1.876 . . . . 0.0 110.699 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.654 HG22 ' H ' ' A' ' 101' ' ' ASP . 18.3 m -75.14 130.24 36.29 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' HB3' ' CD ' ' A' ' 21' ' ' GLU . 7.3 ttpm? -88.84 100.34 13.09 Favored 'General case' 0 N--CA 1.424 -1.771 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.157 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 ' HA ' ' A' ' 20' ' ' PHE . 75.1 t -131.47 134.75 60.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.756 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.006 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 2.1 t-105 -141.08 129.47 22.44 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -148.94 138.86 7.15 Favored Glycine 0 N--CA 1.425 -2.083 0 C-N-CA 119.994 -1.098 . . . . 0.0 112.377 175.04 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.542 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 18.4 m -116.5 115.24 25.41 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 124.726 1.211 . . . . 0.0 108.746 179.221 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.573 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 9.2 mt -109.52 148.11 13.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 118.453 0.57 . . . . 0.0 110.732 176.166 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -129.79 122.98 29.86 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -146.41 175.01 26.09 Favored Glycine 0 C--N 1.294 -1.8 0 O-C-N 123.688 0.617 . . . . 0.0 111.66 -168.31 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.0 mt -69.52 169.79 11.88 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.724 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.5 OUTLIER -76.81 104.32 7.24 Favored 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 119.273 -0.971 . . . . 0.0 112.003 -175.932 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.433 ' HG2' ' O ' ' A' ' 39' ' ' THR . 47.2 mm-40 -177.93 171.09 1.82 Allowed 'General case' 0 CA--C 1.472 -2.054 0 C-N-CA 128.522 2.729 . . . . 0.0 104.275 170.405 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.726 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 159.45 115.38 0.41 Allowed Glycine 1 C--N 1.242 -4.676 0 C-N-CA 116.978 -2.534 . . . . 0.0 113.968 166.146 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -119.38 -85.6 0.65 Allowed 'General case' 0 N--CA 1.419 -2.018 0 O-C-N 124.231 0.607 . . . . 0.0 110.911 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.733 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 20.7 m80 -163.52 123.11 2.11 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.895 0.878 . . . . 0.0 108.936 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.462 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . -143.94 104.63 0.34 Allowed Glycine 0 N--CA 1.435 -1.41 0 C-N-CA 118.434 -1.841 . . . . 0.0 115.425 -178.684 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.593 ' O ' HG12 ' A' ' 47' ' ' VAL . 19.6 m-85 -68.45 95.22 0.61 Allowed 'General case' 1 C--O 1.341 5.918 0 CA-C-O 123.391 1.567 . . . . 0.0 109.56 169.684 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.615 ' CD2' HD12 ' A' ' 117' ' ' LEU . 16.4 p-80 -83.05 78.06 9.64 Favored 'General case' 0 N--CA 1.404 -2.759 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 175.454 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 45' ' ' PHE . 3.7 p -111.2 91.57 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-N 111.223 -2.717 . . . . 0.0 110.988 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . 0.257 39.6 m-70 -138.75 159.96 40.82 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 114.586 1.328 . . . . 0.0 114.586 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.56 ' HB3' ' OD2' ' A' ' 109' ' ' ASP . 2.0 pm0 -89.48 172.82 8.71 Favored 'General case' 0 C--N 1.287 -2.151 0 C-N-CA 126.993 2.117 . . . . 0.0 115.02 -174.793 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.521 ' H ' ' HA ' ' A' ' 110' ' ' HIS . 55.9 t80 47.18 103.47 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 111.3 -2.682 . . . . 0.0 115.35 167.366 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -44.0 103.12 0.04 OUTLIER Glycine 0 C--N 1.297 -1.623 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.16 171.858 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -111.09 -161.17 0.74 Allowed 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -67.14 138.1 56.79 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 123.1 0.56 . . . . 0.0 109.997 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.492 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 13.4 t -58.45 -21.5 51.45 Favored 'General case' 0 C--O 1.216 -0.701 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -177.103 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.96 6.77 11.37 Favored 'General case' 0 C--N 1.31 -1.115 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.062 178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -150.76 109.46 0.43 Allowed Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 119.428 -1.368 . . . . 0.0 111.589 -178.705 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.596 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 4.3 p -98.5 89.35 4.38 Favored 'General case' 0 C--N 1.277 -2.576 0 C-N-CA 122.735 0.414 . . . . 0.0 111.65 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 m -80.47 -54.07 6.02 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.465 0.65 . . . . 0.0 109.924 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.9 m -71.18 -39.45 71.83 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.283 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.596 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.31 -5.76 48.5 Favored 'General case' 0 C--O 1.2 -1.531 0 CA-C-N 113.857 -1.52 . . . . 0.0 111.353 175.077 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -57.36 -142.42 0.01 OUTLIER Glycine 0 CA--C 1.558 2.737 0 N-CA-C 115.238 0.855 . . . . 0.0 115.238 178.998 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -76.11 53.71 3.91 Favored 'Trans proline' 0 N--CA 1.484 0.937 0 C-N-CA 122.877 2.385 . . . . 0.0 111.009 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -141.84 128.67 20.54 Favored 'General case' 0 C--N 1.28 -2.432 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.546 ' HA ' ' OE2' ' A' ' 49' ' ' GLU . 52.0 p90 -139.48 144.58 38.04 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.442 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OD2' ' A' ' 109' ' ' ASP . 27.3 t-20 -68.94 143.99 95.2 Favored Pre-proline 0 C--N 1.318 -0.795 0 C-N-CA 124.015 0.926 . . . . 0.0 111.316 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.0 -15.21 39.72 Favored 'Trans proline' 0 CA--C 1.546 1.109 0 C-N-CA 123.041 2.494 . . . . 0.0 116.113 -178.371 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 90.2 mt -69.86 -29.23 66.41 Favored 'General case' 0 C--N 1.37 1.489 0 C-N-CA 117.615 -1.634 . . . . 0.0 111.462 -176.213 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.41 ' HB3' ' CD2' ' A' ' 80' ' ' HIS . 58.0 p -54.46 -21.49 10.03 Favored 'General case' 0 C--O 1.262 1.73 0 C-N-CA 125.523 1.529 . . . . 0.0 115.044 -173.597 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ttm180 -70.45 -19.96 62.92 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.665 -161.727 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -68.1 -12.06 60.2 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.233 -0.987 . . . . 0.0 112.773 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 77' ' ' GLU . 0.1 OUTLIER -151.7 -45.15 0.11 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 120.651 0.262 . . . . 0.0 111.186 177.023 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.38 10.42 82.13 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -173.256 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -150.99 144.29 11.59 Favored Glycine 0 N--CA 1.402 -3.623 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 178.244 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 11.8 Cg_exo -76.24 0.13 9.74 Favored 'Trans proline' 0 C--N 1.327 -0.58 0 C-N-CA 124.691 3.594 . . . . 0.0 112.38 -175.452 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -55.55 -26.01 40.98 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 124.973 1.309 . . . . 0.0 111.514 178.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -148.63 -86.2 0.09 Allowed 'General case' 0 CA--C 1.505 -0.775 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.707 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.404 ' O ' ' HB2' ' A' ' 71' ' ' HIS . 47.5 mt-10 -123.34 110.89 15.73 Favored 'General case' 0 N--CA 1.41 -2.437 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -171.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -150.52 -60.85 0.19 Allowed 'General case' 0 C--N 1.25 -3.758 0 N-CA-C 103.298 -2.853 . . . . 0.0 103.298 -173.98 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 60.45 -7.37 0.08 Allowed 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 114.617 1.34 . . . . 0.0 114.617 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 65' ' ' ASN . 0.2 OUTLIER . . . . . 0 C--N 1.305 -1.337 0 N-CA-C 105.038 -2.208 . . . . 0.0 105.038 168.744 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 74' ' ' PRO . 25.9 tp . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.77 128.37 1.13 Allowed Glycine 1 N--CA 1.395 -4.082 0 CA-C-N 114.694 -1.139 . . . . 0.0 110.708 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -89.99 171.35 9.63 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 173.675 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.35 129.06 11.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 121.394 -0.816 . . . . 0.0 109.083 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.3 m -140.11 96.79 3.11 Favored 'General case' 0 N--CA 1.424 -1.748 0 CA-C-O 121.24 0.543 . . . . 0.0 110.28 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.726 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -100.44 152.72 20.03 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 104.785 -2.302 . . . . 0.0 104.785 173.126 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.538 ' OD2' ' HG2' ' A' ' 91' ' ' LYS . 21.9 t70 -113.34 -159.74 0.7 Allowed 'General case' 1 C--N 1.223 -4.922 0 C-N-CA 116.7 -2.0 . . . . 0.0 105.992 173.731 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.538 ' HG2' ' OD2' ' A' ' 90' ' ' ASP . 18.8 ptpt -57.82 -8.08 0.87 Allowed 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -84.3 -27.15 28.02 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.62 65.53 2.29 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 114.499 0.559 . . . . 0.0 114.499 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 12.6 m -159.74 132.82 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.563 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -124.64 117.89 25.28 Favored 'General case' 0 N--CA 1.412 -2.374 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -99.67 103.51 15.2 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.55 117.6 50.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.031 0.92 . . . . 0.0 112.255 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 p -142.33 101.46 3.9 Favored 'General case' 0 C--N 1.276 -2.599 0 N-CA-C 106.787 -1.561 . . . . 0.0 106.787 174.267 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 34.4 pt -113.91 151.11 15.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.787 -175.99 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.75 100.24 7.28 Favored 'General case' 0 N--CA 1.414 -2.227 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.654 ' H ' HG22 ' A' ' 29' ' ' VAL . 26.1 t0 -134.02 167.51 20.48 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.848 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.9 m -59.02 113.22 1.99 Allowed 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 114.678 1.362 . . . . 0.0 114.678 -173.594 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.633 HG22 ' H ' ' A' ' 27' ' ' GLY . 20.6 m -60.03 -11.57 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 C-N-CA 126.112 1.765 . . . . 0.0 113.053 177.284 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.39 -12.12 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.676 1.191 . . . . 0.0 112.25 -176.199 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 p -91.73 83.17 5.25 Favored 'General case' 0 C--O 1.175 -2.826 0 O-C-N 121.012 -1.055 . . . . 0.0 111.516 176.609 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 71.8 mt -70.11 150.65 46.33 Favored 'General case' 0 N--CA 1.396 -3.163 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.852 171.325 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.6 m -68.89 91.85 0.48 Allowed 'General case' 0 N--CA 1.382 -3.842 0 C-N-CA 124.956 1.302 . . . . 0.0 113.914 -173.608 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.415 ' O ' ' HD2' ' A' ' 110' ' ' HIS . . . -94.6 -175.67 38.55 Favored Glycine 1 N--CA 1.395 -4.097 0 N-CA-C 106.09 -2.804 . . . . 0.0 106.09 167.405 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.56 ' OD2' ' HB3' ' A' ' 49' ' ' GLU 0.25 31.3 t0 32.89 -77.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 117.442 2.386 . . . . 0.0 117.442 -175.32 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.558 ' CG ' ' HG2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -56.57 -31.8 64.57 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 125.987 1.715 . . . . 0.0 109.703 178.216 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.3 m 62.06 -178.09 0.13 Allowed 'General case' 0 N--CA 1.424 -1.755 0 C-N-CA 126.125 1.77 . . . . 0.0 112.797 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.512 HG13 ' HB ' ' A' ' 151' ' ' ILE . 10.0 tt -78.65 9.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 C-N-CA 126.547 1.939 . . . . 0.0 108.731 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 36.5 pt -91.38 -175.39 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.485 -1.526 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 -176.801 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.436 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . -82.14 65.08 4.14 Favored Glycine 0 N--CA 1.405 -3.397 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.959 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.734 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -66.31 131.81 46.95 Favored 'General case' 0 N--CA 1.414 -2.267 0 CA-C-O 122.553 1.168 . . . . 0.0 112.203 178.266 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.734 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 0.1 OUTLIER -70.54 122.6 20.02 Favored 'General case' 0 N--CA 1.384 -3.768 0 CA-C-N 113.853 -1.521 . . . . 0.0 111.113 -178.137 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.615 HD12 ' CD2' ' A' ' 46' ' ' HIS . 0.8 OUTLIER -87.76 140.67 29.27 Favored 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 174.06 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.574 HG22 ' SG ' ' A' ' 57' ' ' CYS . 98.8 t -109.8 105.16 18.27 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.479 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.646 171.859 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -126.09 168.44 18.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.81 0.814 . . . . 0.0 110.397 179.596 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.435 ' CD2' ' HG ' ' A' ' 144' ' ' LEU . 2.1 t60 -172.18 156.85 4.06 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 102.909 -2.997 . . . . 0.0 102.909 162.158 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.437 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.2 89.61 0.46 Allowed 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? -170.4 171.37 6.61 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.733 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -76.68 111.15 11.88 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 123.771 0.67 . . . . 0.0 110.922 172.936 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.462 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 8.5 t0 -132.38 26.57 4.46 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 123.381 1.563 . . . . 0.0 109.177 178.202 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.499 ' HB2' ' HB2' ' A' ' 128' ' ' LYS . 24.8 m-20 -81.7 137.53 35.39 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 173.52 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -69.8 -56.79 6.19 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -173.59 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.7 1.8 43.51 Favored Glycine 0 CA--C 1.526 0.748 0 C-N-CA 121.16 -0.543 . . . . 0.0 113.483 -178.849 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.499 ' HB2' ' HB2' ' A' ' 125' ' ' ASP . 32.0 mmmt -132.23 32.61 3.96 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -62.27 -29.32 72.73 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 115.604 -0.725 . . . . 0.0 114.834 -176.469 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -82.89 0.26 Allowed Glycine 0 C--O 1.221 -0.66 0 CA-C-N 117.443 0.622 . . . . 0.0 112.212 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.453 ' H ' ' HB3' ' A' ' 134' ' ' SER . 9.5 t30 -121.45 173.3 7.47 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.461 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 37.1 tt0 -49.73 -46.71 50.66 Favored 'General case' 0 CA--C 1.555 1.158 0 CA-C-N 119.844 1.202 . . . . 0.0 114.011 -172.017 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.1 mp0 -64.48 -39.64 94.19 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.055 0.455 . . . . 0.0 110.449 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 6.8 t -72.36 -30.89 65.13 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.098 -175.541 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 36.3 m -69.68 -30.97 68.76 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.299 0.571 . . . . 0.0 110.479 178.344 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.461 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 95.8 mttt -76.54 -37.12 57.16 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.165 0.507 . . . . 0.0 111.355 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 t -85.61 -26.42 26.08 Favored 'General case' 0 N--CA 1.416 -2.166 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.292 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.85 60.1 8.19 Favored Glycine 0 N--CA 1.431 -1.684 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 -174.0 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -39.62 117.38 0.72 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.936 1.294 . . . . 0.0 112.851 -174.074 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -143.71 161.49 38.43 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -174.166 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.28 81.22 1.72 Allowed Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 173.653 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.7 p -42.13 -38.89 1.82 Allowed 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 118.143 2.646 . . . . 0.0 118.143 -168.147 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.6 ptt180 -134.2 13.46 3.88 Favored 'General case' 0 C--N 1.278 -2.526 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.435 ' HG ' ' CD2' ' A' ' 120' ' ' HIS . 0.3 OUTLIER -69.07 -37.6 78.6 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -172.23 . . . . . . . . 3 3 . 1 . 003 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -150.25 106.1 3.43 Favored 'General case' 0 N--CA 1.412 -2.348 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 17.8 m -115.21 163.14 16.09 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.811 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.734 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -171.55 141.42 6.39 Favored Glycine 0 N--CA 1.416 -2.681 0 C-N-CA 119.003 -1.57 . . . . 0.0 112.143 176.93 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.423 HG12 ' OG1' ' A' ' 54' ' ' THR . 10.0 p -70.16 98.78 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 122.531 1.158 . . . . 0.0 108.581 174.035 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.734 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 24.0 mm -109.44 129.86 63.5 Favored 'Isoleucine or valine' 0 CA--C 1.464 -2.346 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.81 147.34 17.73 Favored Glycine 2 CA--C 1.425 -5.539 0 C-N-CA 116.803 -2.618 . . . . 0.0 111.466 -174.708 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' ' 112' ' ' ILE . 70.1 mt -78.64 103.63 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.9 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 173.916 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.575 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -125.84 128.6 47.9 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.119 -0.946 . . . . 0.0 108.476 175.668 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 . . . . . 0 C--N 1.292 -1.905 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.563 -174.755 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.658 ' O ' ' HD2' ' A' ' 3' ' ' LYS . 18.0 p -80.91 -42.03 22.06 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 170.833 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.658 ' HD2' ' O ' ' A' ' 2' ' ' THR . 5.4 mptp? -151.27 171.4 17.5 Favored 'General case' 0 C--O 1.263 1.765 0 N-CA-C 103.209 -2.885 . . . . 0.0 103.209 173.137 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.693 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -149.35 146.98 27.78 Favored 'General case' 0 CA--C 1.454 -2.744 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.841 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 152' ' ' ALA . 23.1 m -119.69 155.22 22.43 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.788 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.244 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -135.7 128.94 31.89 Favored 'General case' 0 C--N 1.278 -2.504 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.345 178.689 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.498 ' H ' ' HB ' ' A' ' 148' ' ' VAL . 46.7 t -134.16 111.83 15.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.521 ' H ' HD23 ' A' ' 8' ' ' LEU . 1.9 pt? -119.47 142.39 48.31 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.371 178.392 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.665 ' O ' ' HA ' ' A' ' 55' ' ' ALA . 2.2 tmtp? -147.91 148.42 30.79 Favored 'General case' 0 N--CA 1.408 -2.542 0 N-CA-C 102.409 -3.182 . . . . 0.0 102.409 177.401 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -155.01 -158.93 8.99 Favored Glycine 0 CA--C 1.479 -2.161 0 C-N-CA 118.139 -1.982 . . . . 0.0 113.381 -177.788 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -67.98 -46.58 70.97 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.44 95.59 0.74 Allowed Glycine 0 N--CA 1.429 -1.784 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 171.324 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -64.6 126.79 17.47 Favored 'Trans proline' 0 N--CA 1.441 -1.585 0 C-N-CA 122.164 1.909 . . . . 0.0 113.886 -172.553 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.1 m -126.0 132.37 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.381 -3.889 0 N-CA-C 102.026 -3.324 . . . . 0.0 102.026 173.516 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.431 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 97.8 mt-30 -121.67 138.2 54.44 Favored 'General case' 0 C--N 1.264 -3.114 0 C-N-CA 119.559 -0.856 . . . . 0.0 112.578 -169.228 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.493 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -170.69 171.31 43.68 Favored Glycine 0 N--CA 1.402 -3.628 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.451 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.6 pt -137.02 139.54 44.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.552 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -127.77 127.91 68.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.693 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 60.4 m-20 -118.79 119.62 34.94 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 -176.489 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.634 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 11.6 p90 -131.58 141.04 49.59 Favored 'General case' 0 C--O 1.262 1.754 0 C-N-CA 118.646 -1.222 . . . . 0.0 113.095 178.058 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.428 ' HB3' ' O ' ' A' ' 2' ' ' THR . 7.2 pt-20 -133.65 95.15 3.42 Favored 'General case' 0 N--CA 1.416 -2.136 0 CA-C-O 122.268 1.033 . . . . 0.0 112.391 175.75 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HG3' HG12 ' A' ' 29' ' ' VAL . 24.1 mm-40 -158.62 163.47 36.92 Favored 'General case' 0 C--O 1.257 1.477 0 C-N-CA 126.88 2.072 . . . . 0.0 108.038 170.417 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.654 ' HG3' ' H ' ' A' ' 24' ' ' GLU 0.257 27.7 pttt -159.7 -86.69 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.204 0 O-C-N 124.22 0.95 . . . . 0.0 112.055 164.487 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.654 ' H ' ' HG3' ' A' ' 23' ' ' LYS . 35.9 tt0 -93.2 -25.96 17.59 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 121.783 0.802 . . . . 0.0 109.578 178.844 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.44 ' HB2' ' OE1' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -46.93 -56.94 5.51 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.235 2.214 . . . . 0.0 114.836 -172.34 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.8 t30 75.71 139.91 0.07 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 124.971 1.308 . . . . 0.0 110.277 -174.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.588 ' H ' HG21 ' A' ' 104' ' ' ILE . . . 150.23 -170.96 30.2 Favored Glycine 0 CA--C 1.493 -1.312 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -70.08 124.02 10.55 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.413 1.409 . . . . 0.0 110.253 176.427 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG12 ' HG3' ' A' ' 22' ' ' GLN . 17.2 m -85.65 98.79 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.354 0 CA-C-O 121.502 0.668 . . . . 0.0 111.523 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.258 0.0 OUTLIER -90.46 108.66 19.93 Favored 'General case' 0 N--CA 1.417 -2.076 0 C-N-CA 118.486 -1.285 . . . . 0.0 109.11 171.919 . . . . . . . . 4 4 . 1 . 004 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.6 m -135.46 152.97 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.778 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 -172.861 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -143.58 126.92 16.72 Favored 'General case' 0 C--N 1.266 -3.051 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.946 178.599 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -145.34 140.27 8.93 Favored Glycine 0 N--CA 1.41 -3.075 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.697 174.165 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.0 m -116.6 140.23 49.63 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 176.075 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.493 HG22 ' HA3' ' A' ' 16' ' ' GLY . 25.2 pt -141.7 131.51 24.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-N 119.415 1.007 . . . . 0.0 109.025 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.2 OUTLIER -112.09 132.39 54.87 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 121' ' ' GLU . . . -142.82 175.2 23.18 Favored Glycine 0 N--CA 1.416 -2.68 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -169.693 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.1 mt -68.84 170.34 9.79 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.426 ' CA ' ' HA ' ' A' ' 91' ' ' LYS . 1.3 m -69.89 103.46 2.22 Favored 'General case' 0 C--O 1.203 -1.37 0 C-N-CA 118.016 -1.473 . . . . 0.0 110.403 -173.93 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.3 tt0 -176.13 141.77 0.46 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 102.798 -3.038 . . . . 0.0 102.798 170.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . -174.54 90.89 0.08 OUTLIER Glycine 0 C--N 1.276 -2.777 0 C-N-CA 117.028 -2.511 . . . . 0.0 113.334 174.581 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -93.4 -86.33 0.26 Allowed 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 120.512 -0.475 . . . . 0.0 111.649 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.495 ' HA ' ' H ' ' A' ' 87' ' ' VAL . 18.8 p80 166.32 135.28 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 152.46 131.4 1.68 Allowed Glycine 0 N--CA 1.413 -2.837 0 C-N-CA 118.322 -1.894 . . . . 0.0 113.785 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -133.98 139.59 46.17 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 122.063 0.935 . . . . 0.0 113.073 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -166.89 92.11 0.43 Allowed 'General case' 1 C--O 1.33 5.342 0 N-CA-C 105.183 -2.155 . . . . 0.0 105.183 172.013 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.596 HG13 ' HA ' ' A' ' 117' ' ' LEU . 18.7 t -69.97 167.58 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 127.351 2.26 . . . . 0.0 109.095 176.442 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.538 ' NE2' ' HB2' ' A' ' 65' ' ' ASN . 56.5 t-80 -124.23 126.04 45.42 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-O 122.085 0.945 . . . . 0.0 109.873 174.033 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.604 ' CD ' ' HB3' ' A' ' 65' ' ' ASN . 2.8 pm0 -73.37 125.45 27.88 Favored 'General case' 0 C--N 1.264 -3.145 0 CA-C-N 113.62 -1.627 . . . . 0.0 108.403 174.549 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.54 ' HA ' ' OG ' ' A' ' 111' ' ' SER . 91.3 t80 80.13 100.17 0.06 Allowed 'General case' 0 CA--C 1.503 -0.851 0 CA-C-O 123.503 1.621 . . . . 0.0 108.776 -175.924 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.35 -145.97 7.52 Favored Glycine 0 N--CA 1.421 -2.332 0 CA-C-N 111.94 -2.391 . . . . 0.0 110.49 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -171.62 -85.83 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 115.597 1.703 . . . . 0.0 115.597 -171.879 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.497 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.7 t-20 -104.52 140.1 38.47 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -169.818 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 10.0 t -61.64 -27.68 68.84 Favored 'General case' 0 C--O 1.241 0.635 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.172 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 55' ' ' ALA . . . . . 0.665 ' HA ' ' O ' ' A' ' 9' ' ' LYS . . . -114.47 17.84 17.16 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 120.618 0.247 . . . . 0.0 111.449 -175.298 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.42 117.27 0.58 Allowed Glycine 0 CA--C 1.483 -1.96 0 C-N-CA 119.247 -1.454 . . . . 0.0 111.382 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.464 ' HB3' HG21 ' A' ' 116' ' ' THR . 0.7 OUTLIER -87.28 98.59 11.42 Favored 'General case' 0 C--N 1.28 -2.429 0 C-N-CA 122.926 0.491 . . . . 0.0 109.904 -176.544 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 m -79.07 -56.1 4.62 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.746 0.784 . . . . 0.0 109.515 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.7 m -75.32 -43.91 48.27 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.011 -174.439 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.59 -8.61 56.91 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.949 174.645 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.15 -63.69 3.48 Favored Glycine 0 CA--C 1.538 1.504 0 O-C-N 123.758 0.661 . . . . 0.0 112.772 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -64.26 -5.15 9.1 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.989 2.459 . . . . 0.0 112.75 176.871 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.289 23.3 p80 56.04 15.75 1.91 Allowed 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 118.504 2.779 . . . . 0.0 118.504 170.568 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -146.35 120.45 9.45 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 119.151 0.887 . . . . 0.0 112.757 178.241 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.604 ' HB3' ' CD ' ' A' ' 49' ' ' GLU . 27.7 t-20 -116.95 144.22 33.08 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 172.487 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -52.57 -13.19 2.17 Favored 'Trans proline' 0 CA--C 1.556 1.595 0 C-N-CA 124.466 3.444 . . . . 0.0 117.82 -177.263 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.522 ' C ' ' H ' ' A' ' 69' ' ' ARG . 4.1 mm? -82.62 -12.98 57.28 Favored 'General case' 0 CA--C 1.474 -1.956 0 CA-C-N 119.878 1.217 . . . . 0.0 110.396 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.601 ' HA ' ' HB3' ' A' ' 80' ' ' HIS . 74.3 m -72.94 36.4 0.08 Allowed 'General case' 0 C--O 1.215 -0.718 0 C-N-CA 124.342 1.057 . . . . 0.0 109.804 169.434 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 67' ' ' LEU . 3.3 tmm_? -76.3 11.12 1.66 Allowed 'General case' 0 C--O 1.212 -0.895 0 C-N-CA 127.505 2.322 . . . . 0.0 107.951 -172.746 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 76' ' ' ASP . 47.4 tptt -77.35 -32.47 55.1 Favored 'General case' 0 N--CA 1.396 -3.133 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t60 61.18 23.86 14.02 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.251 1.021 . . . . 0.0 110.126 178.613 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.73 120.99 2.65 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 119.842 -1.17 . . . . 0.0 112.218 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.39 75.78 0.13 Allowed Glycine 0 C--N 1.293 -1.812 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.525 ' O ' HD13 ' A' ' 84' ' ' LEU . 31.8 Cg_endo -62.23 -22.63 74.46 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 123.759 2.973 . . . . 0.0 114.82 -171.501 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mtpt -123.2 13.2 9.62 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.519 ' OD2' ' HE2' ' A' ' 70' ' ' LYS . 21.7 t70 -116.96 -67.69 0.97 Allowed 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -169.553 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 60.66 111.64 0.02 OUTLIER 'General case' 0 C--O 1.256 1.406 0 CA-C-O 122.477 1.132 . . . . 0.0 110.768 -173.715 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.421 ' CB ' ' HD3' ' A' ' 70' ' ' LYS . 29.9 tt0 -114.44 -78.21 0.58 Allowed 'General case' 0 N--CA 1.422 -1.842 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.878 -176.761 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.489 ' O ' ' HB2' ' A' ' 80' ' ' HIS . 29.3 tpt180 -113.98 5.35 16.1 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 117.729 -1.588 . . . . 0.0 110.767 179.08 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 68' ' ' SER 0.274 18.7 t60 . . . . . 0 N--CA 1.43 -1.447 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.208 172.926 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.525 HD13 ' O ' ' A' ' 74' ' ' PRO . 4.0 pp . . . . . 0 N--CA 1.423 -1.813 0 CA-C-O 120.99 0.424 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 178.17 -178.64 48.58 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 120.054 -1.07 . . . . 0.0 111.823 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -118.45 132.72 56.23 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.923 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.545 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.7 m -136.06 132.8 50.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -176.379 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -132.94 96.03 3.69 Favored 'General case' 0 N--CA 1.413 -2.283 0 CA-C-O 122.643 1.211 . . . . 0.0 110.613 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.516 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -92.75 153.86 18.65 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 113.911 -1.495 . . . . 0.0 107.833 174.682 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.593 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 6.8 t70 -125.14 -161.65 1.04 Allowed 'General case' 0 C--N 1.255 -3.541 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.426 ' HA ' ' CA ' ' A' ' 39' ' ' THR . 59.6 pttt -40.85 -34.82 0.43 Allowed 'General case' 0 N--CA 1.506 2.339 0 C-N-CA 127.313 2.245 . . . . 0.0 116.115 -175.319 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -147.82 16.62 1.11 Allowed 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 177.792 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.593 ' HA3' ' H ' ' A' ' 90' ' ' ASP . . . -59.34 -157.52 0.03 OUTLIER Glycine 0 C--O 1.187 -2.826 0 N-CA-C 118.731 2.252 . . . . 0.0 118.731 -164.152 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -158.49 105.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.275 -2.656 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.545 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.72 110.12 22.63 Favored 'General case' 0 N--CA 1.398 -3.048 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -85.25 103.37 14.14 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 114.664 -1.153 . . . . 0.0 110.395 -177.184 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -88.28 102.4 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.507 0 CA-C-O 122.309 1.052 . . . . 0.0 109.486 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.7 p -155.41 100.7 2.14 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 113.649 -1.614 . . . . 0.0 108.11 174.178 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.46 119.33 29.41 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -95.06 101.06 12.79 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.949 0.881 . . . . 0.0 111.486 -178.818 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -163.03 169.82 18.95 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 -178.422 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.5 t -59.4 94.42 0.02 OUTLIER 'General case' 0 C--O 1.244 0.769 0 CA-C-O 122.528 1.156 . . . . 0.0 113.402 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' CD1' ' A' ' 84' ' ' LEU . 15.5 t -118.28 -9.56 11.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 N-CA-C 103.12 -2.919 . . . . 0.0 103.12 168.927 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.588 HG21 ' H ' ' A' ' 27' ' ' GLY . 2.7 pp -41.9 -40.68 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.709 0 C-N-CA 127.812 2.445 . . . . 0.0 114.77 -166.29 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.51 ' N ' HD12 ' A' ' 104' ' ' ILE . 10.1 p -85.84 90.73 8.14 Favored 'General case' 1 N--CA 1.352 -5.37 0 C-N-CA 118.385 -1.326 . . . . 0.0 108.843 176.483 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.626 ' HG ' ' CE1' ' A' ' 20' ' ' PHE . 3.7 mm? -75.42 86.89 2.57 Favored 'General case' 0 N--CA 1.393 -3.296 0 N-CA-C 104.837 -2.283 . . . . 0.0 104.837 177.256 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.4 m -83.13 88.35 6.9 Favored 'General case' 1 N--CA 1.357 -5.124 0 CA-C-N 113.203 -1.817 . . . . 0.0 108.702 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.73 134.43 11.88 Favored Glycine 1 N--CA 1.36 -6.38 0 N-CA-C 104.482 -3.447 . . . . 0.0 104.482 169.712 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' HG ' ' A' ' 67' ' ' LEU . 38.6 t70 -84.29 -66.92 0.84 Allowed 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 117.591 -1.644 . . . . 0.0 111.464 -177.074 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -100.03 -17.32 17.55 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.54 ' OG ' ' HA ' ' A' ' 50' ' ' PHE . 20.0 m -132.79 118.42 19.0 Favored 'General case' 0 N--CA 1.395 -3.22 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.498 -176.246 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.554 HG13 HD12 ' A' ' 113' ' ' ILE . 14.1 pt -112.6 -25.3 3.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 N-CA-C 104.749 -2.315 . . . . 0.0 104.749 166.283 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.554 HD12 HG13 ' A' ' 112' ' ' ILE . 2.5 mp -102.59 130.46 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 162.883 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 94.94 12.91 54.81 Favored Glycine 0 C--O 1.209 -1.436 0 C-N-CA 119.546 -1.312 . . . . 0.0 111.838 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.633 ' O ' ' HB ' ' A' ' 149' ' ' ILE . 15.7 mtp180 -70.88 90.07 0.79 Allowed 'General case' 0 C--O 1.207 -1.163 0 CA-C-O 120.868 0.366 . . . . 0.0 110.127 174.132 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.464 HG21 ' HB3' ' A' ' 57' ' ' CYS . 96.9 m -68.0 105.32 1.99 Allowed 'General case' 0 N--CA 1.383 -3.775 0 CA-C-O 122.519 1.152 . . . . 0.0 109.786 172.212 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.596 ' HA ' HG13 ' A' ' 47' ' ' VAL . 43.1 tp -70.09 97.92 1.25 Allowed 'General case' 0 CA--C 1.477 -1.843 0 CA-C-N 113.568 -1.651 . . . . 0.0 108.443 177.317 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 140' ' ' ALA . 7.2 p -91.23 100.06 10.63 Favored 'Isoleucine or valine' 1 C--O 1.313 4.419 0 C-N-CA 115.909 -2.317 . . . . 0.0 109.874 -175.6 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.29 170.23 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.767 0 CA-C-N 112.429 -2.168 . . . . 0.0 107.172 -175.409 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -158.16 172.28 18.69 Favored 'General case' 0 C--N 1.285 -2.216 0 N-CA-C 103.739 -2.689 . . . . 0.0 103.739 174.002 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.572 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.1 mp0 -66.77 89.81 0.16 Allowed 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 105.138 -2.171 . . . . 0.0 105.138 170.998 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.0 tttp -171.66 170.91 5.5 Favored 'General case' 0 N--CA 1.44 -0.925 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -170.784 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.5 104.98 15.77 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 170.259 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.449 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 13.1 t70 -106.92 8.03 30.35 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 122.705 1.24 . . . . 0.0 111.292 -177.772 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.428 ' HB3' ' HD3' ' A' ' 128' ' ' LYS . 5.5 t70 -67.19 139.46 57.42 Favored 'General case' 0 C--N 1.281 -2.398 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.155 -171.539 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.7 tp -62.96 -50.92 68.88 Favored 'General case' 0 C--N 1.321 -0.643 0 O-C-N 123.475 0.484 . . . . 0.0 109.916 -178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.06 -24.23 68.48 Favored Glycine 0 N--CA 1.442 -0.953 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.192 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.428 ' HD3' ' HB3' ' A' ' 125' ' ' ASP . 3.9 mptp? -88.93 -47.05 8.42 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 119.931 -0.707 . . . . 0.0 111.701 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.6 -103.18 0.06 OUTLIER Glycine 0 C--O 1.222 -0.603 0 N-CA-C 114.847 0.699 . . . . 0.0 114.847 179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -175.53 -79.03 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.606 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 21.8 t-20 -107.75 -170.23 1.66 Allowed 'General case' 0 C--O 1.258 1.545 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 174.428 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.441 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 29.4 tt0 -53.91 -42.85 69.21 Favored 'General case' 0 CA--C 1.542 0.664 0 CA-C-N 118.884 0.766 . . . . 0.0 111.745 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.606 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -75.25 -39.38 59.9 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.154 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.2 m -67.99 -21.65 65.04 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -176.603 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.446 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 12.3 t -86.71 -6.29 58.88 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 122.0 0.905 . . . . 0.0 110.738 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.441 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 89.5 mttt -92.81 -39.74 11.04 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.3 p -86.47 -21.23 27.14 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 114.662 -1.154 . . . . 0.0 112.307 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.48 78.47 0.24 Allowed Glycine 0 C--O 1.254 1.383 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -177.946 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 55.8 t30 -47.71 142.92 4.25 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 124.967 1.307 . . . . 0.0 112.291 -176.428 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -150.05 170.49 18.75 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.308 -173.351 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.4 85.1 1.41 Allowed Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 106.547 -2.621 . . . . 0.0 106.547 169.07 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.448 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 51.0 m -42.47 -56.35 3.07 Favored 'General case' 0 C--O 1.194 -1.819 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -165.444 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.434 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 22.9 ptt180 -129.61 12.28 5.84 Favored 'General case' 0 C--N 1.254 -3.58 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -174.795 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.456 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 0.7 OUTLIER -58.15 -44.91 88.11 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 -173.73 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -170.3 92.21 0.2 Allowed 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 114.371 1.249 . . . . 0.0 114.371 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 118' ' ' VAL . 13.9 p -173.53 128.74 0.43 Allowed 'General case' 0 C--O 1.211 -0.956 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 173.368 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 54' ' ' THR . . . 179.55 77.08 0.06 OUTLIER Glycine 0 N--CA 1.409 -3.138 0 CA-C-O 117.935 -1.481 . . . . 0.0 113.372 150.391 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.606 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 54.1 t -171.54 90.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 C-N-CA 125.247 1.419 . . . . 0.0 108.135 167.787 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.633 ' HB ' ' O ' ' A' ' 115' ' ' ARG 0.262 5.4 mt -125.13 118.3 52.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.646 0 CA-C-N 119.179 0.9 . . . . 0.0 109.966 163.229 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.08 155.06 13.35 Favored Glycine 2 N--CA 1.379 -5.132 0 C-N-CA 117.801 -2.142 . . . . 0.0 112.681 176.437 . . . . . . . . 3 3 . 1 . 004 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.6 tt -53.81 105.19 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 114.893 -0.654 . . . . 0.0 110.55 169.378 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.414 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -130.31 99.43 5.02 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.997 -0.681 . . . . 0.0 109.542 171.178 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.304 -1.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.657 178.691 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 21' ' ' GLU . . . . . . . . 0 CA--C 1.506 -0.74 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 25.3 m -121.87 -36.77 2.96 Favored 'General case' 0 CA--C 1.555 1.163 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.574 ' O ' HG12 ' A' ' 151' ' ' ILE . 17.9 ptpt -136.2 144.15 44.78 Favored 'General case' 0 N--CA 1.426 -1.67 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.718 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.557 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -135.73 151.73 50.43 Favored 'General case' 0 C--N 1.282 -2.348 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 30.4 m -115.53 138.36 46.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.637 -178.392 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.707 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -111.09 133.89 53.11 Favored 'General case' 0 C--N 1.284 -2.283 0 CA-C-N 114.781 -1.099 . . . . 0.0 111.48 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -134.73 104.22 5.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 122.98 0.512 . . . . 0.0 110.132 176.209 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.479 HD13 ' HA3' ' A' ' 147' ' ' GLY . 3.1 mm? -96.97 151.31 19.83 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.687 -178.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.599 ' HD3' ' N ' ' A' ' 10' ' ' GLY . 9.9 tmtt? -150.54 137.45 19.17 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.599 ' N ' ' HD3' ' A' ' 9' ' ' LYS . . . -152.78 -169.6 18.2 Favored Glycine 0 N--CA 1.423 -2.188 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.038 -179.105 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -85.97 -31.12 22.26 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 113.915 -1.143 . . . . 0.0 109.376 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -109.47 -172.5 20.72 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 174.226 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -83.69 123.06 3.2 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-N 120.779 2.29 . . . . 0.0 111.099 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.414 HG23 HD11 ' A' ' 35' ' ' ILE . 5.2 p -135.9 91.78 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.097 0 C-N-CA 124.682 1.193 . . . . 0.0 108.522 174.875 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.624 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 16.0 mm100 -111.59 119.08 37.51 Favored 'General case' 0 C--N 1.292 -1.913 0 O-C-N 121.31 -0.869 . . . . 0.0 108.88 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -156.85 148.27 17.83 Favored Glycine 0 N--CA 1.406 -3.306 0 C-N-CA 120.206 -0.997 . . . . 0.0 112.658 -175.481 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.511 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 12.6 pt -135.65 103.79 4.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.707 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.3 mp -116.64 129.31 73.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -173.102 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.16 138.73 51.47 Favored 'General case' 0 CA--C 1.465 -2.3 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.557 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 20.3 p90 -136.63 160.97 37.2 Favored 'General case' 0 N--CA 1.412 -2.353 0 C-N-CA 119.573 -0.851 . . . . 0.0 109.99 178.08 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 11.2 pt-20 -127.02 104.97 8.28 Favored 'General case' 0 N--CA 1.407 -2.582 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.214 177.027 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.552 HE21 ' C ' ' A' ' 22' ' ' GLN . 0.0 OUTLIER -85.61 133.73 34.03 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.564 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -122.58 116.78 24.45 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.138 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.437 ' H ' ' HG2' ' A' ' 24' ' ' GLU . 6.7 pt-20 -76.51 -11.28 59.85 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.955 -1.021 . . . . 0.0 111.015 -177.196 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.6 m -90.52 -9.28 47.84 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 171.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 70.24 135.93 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.667 1.587 . . . . 0.0 112.653 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -173.37 172.56 45.27 Favored Glycine 0 CA--C 1.487 -1.659 0 C-N-CA 120.28 -0.962 . . . . 0.0 111.374 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -65.06 123.4 11.52 Favored 'Trans proline' 0 N--CA 1.444 -1.383 0 N-CA-C 105.887 -2.39 . . . . 0.0 105.887 172.172 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.495 ' O ' ' HG3' ' A' ' 100' ' ' GLU . 34.9 m -94.96 127.36 46.98 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-O 121.617 0.722 . . . . 0.0 112.142 -172.801 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 21' ' ' GLU . 0.7 OUTLIER -81.99 104.46 12.36 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 177.635 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.518 HG12 ' HA ' ' A' ' 20' ' ' PHE . 14.5 m -132.45 147.65 31.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -177.279 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.436 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 12.0 t90 -158.93 136.49 10.12 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.307 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -150.3 142.04 9.3 Favored Glycine 0 N--CA 1.403 -3.541 0 C-N-CA 120.405 -0.902 . . . . 0.0 111.921 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.607 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 24.8 m -114.45 133.81 55.47 Favored 'General case' 0 N--CA 1.416 -2.161 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.803 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.751 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 5.2 tt -146.83 123.97 3.47 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.106 0 CA-C-N 118.358 0.527 . . . . 0.0 110.672 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.592 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -104.63 134.42 47.82 Favored 'General case' 0 N--CA 1.415 -2.184 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.837 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -132.08 177.39 18.73 Favored Glycine 1 N--CA 1.37 -5.705 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.262 -169.186 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.529 HD23 ' N ' ' A' ' 39' ' ' THR . 10.2 tt -67.02 177.22 1.8 Allowed 'General case' 0 C--N 1.271 -2.811 0 N-CA-C 103.124 -2.917 . . . . 0.0 103.124 168.413 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 91' ' ' LYS . 40.6 p -58.91 150.77 23.36 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 120.603 -1.311 . . . . 0.0 111.099 -165.996 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.587 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -60.7 158.5 12.56 Favored 'General case' 0 CA--C 1.458 -2.577 0 N-CA-C 117.981 2.586 . . . . 0.0 117.981 -155.751 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -142.2 173.86 23.55 Favored Glycine 0 C--N 1.254 -3.997 0 CA-C-N 110.8 -2.909 . . . . 0.0 107.038 -175.537 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.0 mt -131.66 -34.38 1.35 Allowed 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 116.879 2.177 . . . . 0.0 116.879 -164.699 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 19.1 t-80 -154.85 123.09 5.94 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 121.31 1.868 . . . . 0.0 109.995 -174.887 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.98 149.86 14.55 Favored Glycine 0 N--CA 1.424 -2.146 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.846 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.29 135.38 41.81 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.68 ' HA ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -129.15 82.74 2.1 Favored 'General case' 1 N--CA 1.362 -4.833 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.444 -161.742 . . . . . . . . 4 4 . 1 . 005 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 46' ' ' HIS . 9.3 p -174.59 162.96 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.398 -3.026 0 CA-C-N 114.119 -1.401 . . . . 0.0 110.582 165.993 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -147.28 112.53 5.53 Favored 'General case' 0 C--N 1.276 -2.611 0 C-N-CA 127.823 2.449 . . . . 0.0 106.994 166.844 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.581 ' HB3' ' HB2' ' A' ' 110' ' ' HIS . 20.2 pt-20 -83.51 86.06 7.15 Favored 'General case' 0 C--O 1.173 -2.942 0 N-CA-C 115.793 1.775 . . . . 0.0 115.793 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.51 ' N ' ' HG3' ' A' ' 115' ' ' ARG . 76.3 m-85 -169.09 91.09 0.24 Allowed 'General case' 0 C--N 1.283 -2.286 0 C-N-CA 127.439 2.296 . . . . 0.0 105.361 175.542 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' NE ' ' A' ' 115' ' ' ARG . . . -63.12 139.28 44.33 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 120.476 -0.868 . . . . 0.0 114.539 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -125.55 -84.58 0.63 Allowed 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 176.994 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -164.75 159.7 18.94 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.432 ' O ' ' HB3' ' A' ' 9' ' ' LYS . 9.0 t -67.94 -29.01 67.96 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 117.879 0.309 . . . . 0.0 111.538 -179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.42 -22.24 28.42 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.41 110.76 0.51 Allowed Glycine 0 CA--C 1.484 -1.901 0 C-N-CA 119.366 -1.397 . . . . 0.0 111.42 -175.789 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.622 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 7.9 p -98.43 89.22 4.36 Favored 'General case' 0 C--N 1.281 -2.37 0 CA-C-O 121.895 0.855 . . . . 0.0 111.472 178.067 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.0 m -79.54 -47.25 15.86 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.454 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.0 m -79.78 -8.28 59.17 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.252 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.558 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -74.71 -9.28 58.42 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 115.338 -0.847 . . . . 0.0 111.989 179.303 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.412 ' HA3' ' HD2' ' A' ' 62' ' ' PRO . . . -68.88 -142.85 0.11 Allowed Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.601 -0.727 . . . . 0.0 113.697 178.822 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.412 ' HD2' ' HA3' ' A' ' 61' ' ' GLY . 55.0 Cg_endo -65.01 8.72 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.041 0 C-N-CA 124.456 3.438 . . . . 0.0 114.843 -176.736 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.93 124.42 46.6 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -169.615 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -133.84 166.03 23.62 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -172.006 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB3' ' OE2' ' A' ' 49' ' ' GLU . 44.3 t30 -114.03 96.39 41.64 Favored Pre-proline 0 N--CA 1.428 -1.541 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.351 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -80.97 -10.27 12.76 Favored 'Trans proline' 0 N--CA 1.425 -2.509 0 C-N-CA 123.206 2.604 . . . . 0.0 111.135 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -65.63 -45.29 83.63 Favored 'General case' 0 N--CA 1.432 -1.337 0 O-C-N 123.815 0.697 . . . . 0.0 110.019 -166.378 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.626 ' HB2' ' O ' ' A' ' 79' ' ' ARG 0.293 7.6 m -52.31 -52.66 51.76 Favored 'General case' 0 N--CA 1.417 -2.093 0 N-CA-C 116.241 1.941 . . . . 0.0 116.241 -171.215 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.58 ' O ' ' HB2' ' A' ' 70' ' ' LYS . 72.0 ttt180 -133.97 -32.84 1.07 Allowed 'General case' 0 CA--C 1.479 -1.781 0 C-N-CA 113.998 -3.081 . . . . 0.0 111.61 167.748 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.58 ' HB2' ' O ' ' A' ' 69' ' ' ARG . 22.0 tptm 160.63 -77.96 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.695 1.247 . . . . 0.0 108.708 170.171 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 178.58 119.99 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 126.489 1.916 . . . . 0.0 108.4 177.573 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.408 ' N ' ' HB3' ' A' ' 78' ' ' GLU . . . -156.28 -87.71 0.06 OUTLIER Glycine 0 CA--C 1.529 0.965 0 C-N-CA 118.636 -1.745 . . . . 0.0 115.355 177.866 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -146.12 4.72 Favored Glycine 0 N--CA 1.415 -2.752 0 C-N-CA 121.354 -0.45 . . . . 0.0 113.083 -173.164 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -106.0 1.42 0.2 Allowed 'Trans proline' 0 C--O 1.233 0.258 0 C-N-CA 124.969 3.779 . . . . 0.0 114.909 -170.527 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -87.4 -17.25 32.71 Favored 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -167.275 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.57 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 12.7 t70 -146.51 -72.71 0.23 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.662 -178.383 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.526 ' HG3' ' H ' ' A' ' 78' ' ' GLU . 21.9 pt-20 -154.11 -56.57 0.11 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.555 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.57 ' OE1' ' HB3' ' A' ' 76' ' ' ASP . 0.6 OUTLIER 52.74 1.67 0.02 OUTLIER 'General case' 0 C--O 1.203 -1.349 0 C-N-CA 127.73 2.412 . . . . 0.0 116.95 172.873 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.626 ' O ' ' HB2' ' A' ' 68' ' ' SER . 27.0 mtt180 163.7 -26.91 0.0 OUTLIER 'General case' 0 C--O 1.189 -2.119 0 C-N-CA 125.266 1.426 . . . . 0.0 111.389 -172.353 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.402 ' HB2' ' CB ' ' A' ' 68' ' ' SER . 30.6 m-70 . . . . . 0 N--CA 1.498 1.946 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt . . . . . 0 N--CA 1.438 -1.063 0 CA-C-O 121.696 0.76 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -146.88 -176.82 20.97 Favored Glycine 0 N--CA 1.416 -2.664 0 N-CA-C 108.881 -1.687 . . . . 0.0 108.881 -178.71 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.84 155.57 18.67 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 117.733 0.767 . . . . 0.0 111.822 -179.333 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.484 HG13 ' NE2' ' A' ' 46' ' ' HIS . 2.0 m -143.16 128.45 15.88 Favored 'Isoleucine or valine' 0 C--N 1.361 1.081 0 C-N-CA 123.585 0.754 . . . . 0.0 111.08 173.14 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 t -141.78 95.98 2.9 Favored 'General case' 0 N--CA 1.39 -3.468 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 172.206 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.1 122.43 38.93 Favored 'General case' 0 CA--C 1.466 -2.266 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.832 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.606 ' HB3' ' HA3' ' A' ' 93' ' ' GLY . 21.6 t70 -54.15 169.76 0.16 Allowed 'General case' 0 CA--C 1.565 1.525 0 O-C-N 124.824 1.328 . . . . 0.0 111.435 177.468 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.594 ' HA ' ' HA ' ' A' ' 39' ' ' THR . 57.4 pttt -41.68 -23.54 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 117.233 2.309 . . . . 0.0 117.233 -175.309 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -154.16 22.07 0.5 Allowed 'General case' 0 C--N 1.294 -1.81 0 N-CA-C 104.359 -2.46 . . . . 0.0 104.359 172.496 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.606 ' HA3' ' HB3' ' A' ' 90' ' ' ASP . . . -83.81 -127.57 1.4 Allowed Glycine 0 C--O 1.179 -3.313 0 CA-C-N 111.555 -2.566 . . . . 0.0 118.634 -160.899 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 3.3 m -161.16 136.27 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.226 0 C-N-CA 124.978 1.311 . . . . 0.0 108.207 -170.247 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.57 111.73 24.16 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 173.685 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -74.99 93.52 2.72 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 123.479 0.487 . . . . 0.0 109.766 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 33.7 m -91.78 111.76 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.01 0 CA-C-O 121.982 0.896 . . . . 0.0 111.007 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.3 t -149.95 100.84 2.98 Favored 'General case' 0 N--CA 1.411 -2.394 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.42 118.55 43.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.495 ' HG3' ' O ' ' A' ' 29' ' ' VAL . 5.1 mp0 -107.32 99.01 8.57 Favored 'General case' 0 N--CA 1.417 -2.108 0 C-N-CA 118.983 -1.087 . . . . 0.0 110.327 -176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -165.88 166.33 17.64 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 173.481 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.1 m -94.71 80.39 3.78 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.827 -1.149 . . . . 0.0 112.939 -174.07 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.0 m -104.84 -18.72 6.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.801 176.428 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 21.3 pt -101.46 7.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.707 -170.804 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.453 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 6.1 m -66.57 167.54 10.76 Favored 'General case' 0 CA--C 1.56 1.332 0 CA-C-O 122.697 1.237 . . . . 0.0 113.003 -175.971 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.443 ' HG ' ' HB2' ' A' ' 111' ' ' SER . 3.8 tt -78.26 87.22 4.33 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-N 114.115 -1.402 . . . . 0.0 108.286 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 51.7 m -170.01 86.68 0.13 Allowed 'General case' 0 C--N 1.264 -3.144 0 N-CA-C 102.533 -3.136 . . . . 0.0 102.533 169.904 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 157.32 -177.45 34.16 Favored Glycine 0 C--N 1.258 -3.753 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 49' ' ' GLU . 18.9 t70 -81.31 -21.5 39.19 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 118.492 -1.283 . . . . 0.0 109.568 175.265 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.581 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 62.9 t-80 -88.36 40.66 0.97 Allowed 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 173.598 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.443 ' HB2' ' HG ' ' A' ' 106' ' ' LEU . 15.1 p -63.02 -64.78 0.81 Allowed 'General case' 0 C--N 1.273 -2.725 0 CA-C-O 122.724 1.25 . . . . 0.0 110.146 -175.812 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.5 pt -128.94 -22.93 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.184 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -81.23 170.54 1.42 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.158 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.206 -162.448 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -82.99 71.72 2.97 Favored Glycine 0 CA--C 1.475 -2.463 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -172.62 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.51 ' HG3' ' N ' ' A' ' 50' ' ' PHE . 2.6 mpt_? -79.13 141.24 37.45 Favored 'General case' 0 N--CA 1.396 -3.13 0 CA-C-N 114.603 -0.799 . . . . 0.0 110.063 -178.739 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.8 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 8.8 t -67.84 124.21 22.71 Favored 'General case' 0 C--N 1.274 -2.716 0 CA-C-O 122.895 1.331 . . . . 0.0 114.554 -168.96 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.3 tp -80.64 98.42 7.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 113.556 -1.656 . . . . 0.0 108.901 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.68 ' O ' ' HA ' ' A' ' 46' ' ' HIS . 26.9 t -91.85 100.56 11.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.864 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.571 ' HB ' ' CB ' ' A' ' 46' ' ' HIS . 12.2 p -139.98 156.98 25.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 126.539 1.936 . . . . 0.0 108.343 -175.649 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -171.45 166.57 6.88 Favored 'General case' 0 N--CA 1.428 -1.564 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 165.117 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.567 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.2 mp0 -73.32 84.91 1.44 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 175.605 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 79.3 mttt -173.19 170.77 4.26 Favored 'General case' 0 CA--C 1.493 -1.228 0 C-N-CA 126.119 1.768 . . . . 0.0 108.326 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.661 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -80.44 104.48 11.01 Favored 'General case' 0 C--N 1.29 -1.998 0 O-C-N 124.145 0.903 . . . . 0.0 110.974 172.253 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -118.78 80.46 1.54 Allowed 'General case' 0 CA--C 1.483 -1.623 0 N-CA-C 104.267 -2.494 . . . . 0.0 104.267 173.28 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.712 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 16.4 t0 -125.91 139.0 53.82 Favored 'General case' 0 C--N 1.263 -3.17 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.332 -170.886 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.4 tp -82.03 -21.5 36.93 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.876 -172.944 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -102.82 13.42 56.29 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.712 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 14.3 tmtt? -127.42 37.76 4.18 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.3 -54.84 34.38 Favored Glycine 0 N--CA 1.427 -1.9 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.12 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 114.34 -25.09 10.78 Favored Glycine 0 C--N 1.308 -1.004 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.907 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 33.3 t-20 -167.58 167.08 13.77 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.438 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 12.9 pt-20 -48.39 -46.59 37.34 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.943 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -61.72 -53.57 54.28 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.542 0.737 . . . . 0.0 110.412 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.6 m -69.22 -27.28 65.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 112.108 -172.943 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 m -78.01 -15.31 59.05 Favored 'General case' 0 CA--C 1.557 1.235 0 CA-C-O 121.801 0.81 . . . . 0.0 110.025 177.244 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 99.4 mttt -89.67 -40.14 12.74 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 174.804 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.0 m -67.43 -46.39 73.28 Favored 'General case' 0 C--N 1.284 -2.244 0 CA-C-O 121.366 0.603 . . . . 0.0 109.993 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.53 76.56 1.18 Allowed Glycine 0 N--CA 1.408 -3.208 0 N-CA-C 106.866 -2.493 . . . . 0.0 106.866 -172.975 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -36.21 111.22 0.13 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 125.905 1.682 . . . . 0.0 111.041 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -149.22 135.75 19.4 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.225 -173.019 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 144' ' ' LEU . . . -70.87 108.4 2.47 Favored Glycine 0 N--CA 1.434 -1.438 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 172.861 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.6 m -57.01 -29.55 63.42 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 115.285 1.587 . . . . 0.0 115.285 -169.974 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.622 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 27.3 ttm180 -128.97 21.82 5.8 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -175.496 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.406 ' CD1' ' HA3' ' A' ' 141' ' ' GLY . 74.9 mt -74.46 -15.38 60.9 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.692 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.416 ' HB1' HD12 ' A' ' 8' ' ' LEU . . . -162.71 109.26 1.22 Allowed 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.478 175.15 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 61.5 m -98.59 131.41 44.82 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 174.401 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.8 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.59 126.44 1.23 Allowed Glycine 0 N--CA 1.412 -2.919 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.873 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 m -76.18 98.43 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-O 121.691 0.758 . . . . 0.0 109.864 173.831 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.406 HG13 ' CB ' ' A' ' 6' ' ' ALA . 1.7 mp -106.4 112.22 38.61 Favored 'Isoleucine or valine' 0 C--O 1.257 1.48 0 CA-C-O 122.31 1.053 . . . . 0.0 109.926 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.443 ' HA2' ' CZ ' ' A' ' 20' ' ' PHE . . . -174.68 176.76 46.93 Favored Glycine 0 CA--C 1.461 -3.294 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -175.981 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.35 105.05 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 107.942 -1.132 . . . . 0.0 107.942 176.727 . . . . . . . . 3 3 . 1 . 005 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.54 147.59 41.42 Favored 'General case' 0 N--CA 1.413 -2.281 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--N 1.292 -1.9 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.916 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.722 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.7 m -74.46 -23.4 58.89 Favored 'General case' 0 CA--C 1.566 1.58 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -172.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -132.37 147.8 52.4 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.873 -171.768 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.639 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -132.64 156.48 46.86 Favored 'General case' 0 N--CA 1.405 -2.693 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.579 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 47.2 t -125.96 126.91 70.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.555 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -124.91 135.1 52.55 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.005 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 14.7 m -127.61 119.77 52.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-O 121.201 0.524 . . . . 0.0 110.809 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -100.34 138.15 37.8 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.219 177.803 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -165.8 125.19 1.68 Allowed 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.83 -158.98 8.99 Favored Glycine 0 N--CA 1.439 -1.156 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.633 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -72.34 -61.78 1.67 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -75.62 153.43 44.2 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 172.63 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -83.21 123.35 3.47 Favored 'Trans proline' 0 N--CA 1.429 -2.289 0 CA-C-N 120.976 2.388 . . . . 0.0 112.389 -175.601 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.74 119.09 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.819 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 173.356 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 52.3 tt0 -130.82 128.88 41.55 Favored 'General case' 0 C--N 1.269 -2.909 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.545 ' HA3' HD13 ' A' ' 35' ' ' ILE . . . -170.54 161.78 34.77 Favored Glycine 0 N--CA 1.399 -3.791 0 C-N-CA 119.49 -1.338 . . . . 0.0 112.201 -177.273 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.46 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.0 pt -142.26 133.6 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.318 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -132.31 135.03 58.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.337 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -107.11 132.94 52.45 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.615 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.639 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 22.1 t80 -127.42 138.2 52.92 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 123.619 0.768 . . . . 0.0 110.59 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 29' ' ' VAL . 5.7 pt-20 -117.33 119.69 35.89 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.537 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.13 135.65 33.52 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 119.299 -0.961 . . . . 0.0 108.751 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -115.43 83.75 1.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.678 0.751 . . . . 0.0 110.308 179.647 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -68.42 -20.21 64.64 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 124.526 1.131 . . . . 0.0 110.802 -177.179 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 25' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 26' ' ' ASN . 17.4 t -88.44 -5.23 58.39 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.089 177.959 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' SER . 4.0 t30 77.47 113.91 0.07 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 124.682 1.193 . . . . 0.0 110.837 -173.227 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.82 166.41 39.6 Favored Glycine 0 CA--C 1.475 -2.455 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -177.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' HB2' ' A' ' 101' ' ' ASP . 58.0 Cg_endo -71.67 124.08 9.95 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 121.177 1.251 . . . . 0.0 110.774 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.584 HG12 ' H ' ' A' ' 102' ' ' SER . 9.8 p -76.75 123.25 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.893 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.066 173.761 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -105.56 124.56 49.76 Favored 'General case' 0 C--N 1.28 -2.451 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 172.631 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.597 ' H ' HG23 ' A' ' 99' ' ' ILE . 34.4 m -134.33 153.27 35.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -172.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 69.4 p-90 -145.64 135.23 23.27 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 174.562 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.745 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -148.68 139.59 7.68 Favored Glycine 0 N--CA 1.42 -2.404 0 C-N-CA 119.979 -1.105 . . . . 0.0 111.662 175.941 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.2 m -116.11 125.63 52.63 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HA3' ' A' ' 16' ' ' GLY . 25.3 mm -125.04 132.19 71.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 36.0 mtmm -117.67 136.16 53.52 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.998 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -171.01 174.15 44.75 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -172.056 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 pp -68.66 153.69 43.31 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 118.679 1.239 . . . . 0.0 109.634 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.59 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 77.3 p -69.85 107.26 3.46 Favored 'General case' 0 C--O 1.206 -1.195 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 -170.036 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 28.7 tt0 -175.35 115.99 0.15 Allowed 'General case' 0 C--O 1.205 -1.279 0 C-N-CA 125.653 1.581 . . . . 0.0 107.018 172.306 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 90' ' ' ASP . . . -164.35 114.97 0.62 Allowed Glycine 0 C--N 1.273 -2.917 0 C-N-CA 118.392 -1.861 . . . . 0.0 112.166 -174.637 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.2 mt -106.72 -64.76 1.15 Allowed 'General case' 0 N--CA 1.435 -1.191 0 O-C-N 123.998 0.47 . . . . 0.0 112.187 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.67 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 24.6 m-70 -171.35 168.95 6.45 Favored 'General case' 0 CA--C 1.492 -1.255 0 C-N-CA 124.249 1.02 . . . . 0.0 108.326 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.467 ' O ' ' HG3' ' A' ' 74' ' ' PRO . . . 178.23 -169.28 40.97 Favored Glycine 0 C--N 1.282 -2.461 0 C-N-CA 119.786 -1.197 . . . . 0.0 112.056 176.39 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 126' ' ' LEU . 1.3 p90 -168.16 165.67 13.15 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.316 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.697 ' CE1' ' HA3' ' A' ' 85' ' ' GLY . 18.3 m-70 -90.02 150.02 22.29 Favored 'General case' 0 CA--C 1.478 -1.808 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' O ' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -172.3 89.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 173.663 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.34 86.06 0.12 Allowed 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 163.942 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.492 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 9.0 pt-20 -93.4 117.92 30.67 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 118.094 -1.442 . . . . 0.0 110.852 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 12.0 t80 162.58 92.43 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 103.766 -2.679 . . . . 0.0 103.766 179.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -48.66 109.08 0.47 Allowed Glycine 0 N--CA 1.478 1.482 0 O-C-N 123.682 0.614 . . . . 0.0 113.714 -177.129 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -120.98 -80.77 0.63 Allowed 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 117.971 -1.492 . . . . 0.0 112.089 -175.583 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.8 t30 -144.99 156.4 43.93 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.891 -177.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 148' ' ' VAL . 33.1 p -84.32 -1.51 55.5 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 124.228 1.011 . . . . 0.0 111.295 -177.137 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.7 20.85 4.64 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.266 -179.034 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 146.99 114.39 0.82 Allowed Glycine 0 N--CA 1.424 -2.133 0 C-N-CA 118.969 -1.586 . . . . 0.0 112.033 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.466 ' SG ' HG23 ' A' ' 118' ' ' VAL . 9.4 p -96.71 90.83 5.43 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.095 0.95 . . . . 0.0 112.698 -177.456 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.2 p -74.18 -49.23 24.49 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.075 -177.78 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.9 m -65.14 -23.67 67.19 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.767 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.74 -22.99 53.05 Favored 'General case' 0 N--CA 1.422 -1.864 0 C-N-CA 120.037 -0.665 . . . . 0.0 110.822 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.403 ' HA3' ' HD3' ' A' ' 62' ' ' PRO . . . 30.62 -97.29 0.01 OUTLIER Glycine 0 N--CA 1.494 2.532 0 C-N-CA 124.881 1.229 . . . . 0.0 115.663 164.346 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD3' ' HA3' ' A' ' 61' ' ' GLY . 27.9 Cg_endo -93.44 73.46 0.36 Allowed 'Trans proline' 0 N--CA 1.435 -1.968 0 C-N-CA 123.479 2.786 . . . . 0.0 109.932 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.511 ' CD2' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p-80 -36.52 137.94 0.26 Allowed 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 125.415 1.486 . . . . 0.0 114.329 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.483 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 15.7 p90 -125.28 88.17 2.83 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 170.47 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 16.8 m120 -106.45 89.49 4.08 Favored Pre-proline 0 CA--C 1.505 -0.781 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 5.8 Cg_exo -77.7 -12.94 16.45 Favored 'Trans proline' 0 N--CA 1.443 -1.444 0 C-N-CA 122.474 2.116 . . . . 0.0 114.842 -169.152 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.425 HD12 ' O ' ' A' ' 106' ' ' LEU . 13.1 mt -70.2 -25.13 63.27 Favored 'General case' 0 CA--C 1.465 -2.302 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.422 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.559 ' HA ' ' C ' ' A' ' 77' ' ' GLU . 18.0 t -93.7 -96.34 0.15 Allowed 'General case' 1 N--CA 1.377 -4.076 0 C-N-CA 114.997 -2.681 . . . . 0.0 107.272 175.922 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HB3' ' HA ' ' A' ' 79' ' ' ARG 0.264 24.6 ttt85 -142.05 40.37 1.64 Allowed 'General case' 0 CA--C 1.492 -1.261 0 CA-C-N 119.055 0.843 . . . . 0.0 109.185 152.29 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 88.2 tttt 75.78 -33.39 0.22 Allowed 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -155.61 99.02 1.99 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -175.154 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.691 ' HA3' ' C ' ' A' ' 80' ' ' HIS . . . -164.56 -136.6 2.03 Favored Glycine 0 C--O 1.18 -3.234 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.752 163.673 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.56 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -75.98 -175.96 39.89 Favored Glycine 0 CA--C 1.547 2.061 0 CA-C-N 117.427 0.613 . . . . 0.0 114.607 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HG3' ' O ' ' A' ' 44' ' ' GLY . 88.7 Cg_endo -102.49 0.37 0.42 Allowed 'Trans proline' 0 C--O 1.212 -0.788 0 C-N-CA 123.825 3.017 . . . . 0.0 113.633 -178.393 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.5 ' HG2' ' OE2' ' A' ' 100' ' ' GLU . 61.8 mttm -81.49 2.27 29.62 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -172.17 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -175.59 166.34 3.2 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -176.272 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.559 ' C ' ' HA ' ' A' ' 68' ' ' SER . 2.5 pm0 -122.52 84.68 2.3 Favored 'General case' 0 N--CA 1.418 -2.039 0 C-N-CA 120.161 -0.616 . . . . 0.0 111.111 171.923 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.445 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 0.1 OUTLIER 171.37 86.87 0.0 OUTLIER 'General case' 0 C--N 1.361 1.071 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.84 178.599 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.562 ' HA ' ' HB3' ' A' ' 69' ' ' ARG 0.289 0.0 OUTLIER 62.32 130.5 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 C-N-CA 126.481 1.912 . . . . 0.0 115.412 174.637 . . . . . . . . 4 4 . 1 . 006 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.691 ' C ' ' HA3' ' A' ' 72' ' ' GLY . 21.3 t-160 . . . . . 0 N--CA 1.488 1.459 0 CA-C-O 122.63 1.205 . . . . 0.0 107.971 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp . . . . . 0 CA--C 1.502 -0.897 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 . . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.697 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . -173.82 83.25 0.08 OUTLIER Glycine 0 N--CA 1.422 -2.282 0 C-N-CA 118.918 -1.61 . . . . 0.0 113.295 173.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.437 ' HB2' ' HG3' ' A' ' 74' ' ' PRO . 9.1 t30 -78.87 130.06 35.25 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.62 128.45 75.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.553 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 29.4 p -139.45 95.76 2.98 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -120.95 104.18 9.62 Favored 'General case' 0 N--CA 1.421 -1.895 0 C-N-CA 118.079 -1.448 . . . . 0.0 109.049 174.463 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' A' ' 39' ' ' THR . 8.1 p-10 -132.29 -20.88 2.36 Favored 'General case' 0 CA--C 1.47 -2.131 0 CA-C-O 121.788 0.804 . . . . 0.0 109.842 -176.302 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -72.53 -56.94 4.59 Favored 'General case' 0 C--N 1.268 -2.966 0 CA-C-N 113.655 -1.612 . . . . 0.0 109.091 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -153.71 6.18 0.33 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.505 -170.013 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 82.12 55.3 3.13 Favored Glycine 0 N--CA 1.426 -1.987 0 C-N-CA 118.102 -1.999 . . . . 0.0 108.748 -168.735 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.1 m -148.84 110.09 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 104.45 -2.426 . . . . 0.0 104.45 -177.549 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.553 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.84 128.92 41.94 Favored 'General case' 0 C--N 1.263 -3.162 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.703 -174.542 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -81.92 107.84 14.96 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 171.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.745 HG11 ' H ' ' A' ' 33' ' ' GLY . 13.4 p -82.61 137.46 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.202 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.336 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB3' ' OE2' ' A' ' 100' ' ' GLU . 41.8 m -84.37 108.6 17.29 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.963 177.213 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.597 HG23 ' H ' ' A' ' 31' ' ' VAL . 28.8 mt -93.32 114.06 29.34 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.482 0 N-CA-C 106.112 -1.811 . . . . 0.0 106.112 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.5 ' OE2' ' HG2' ' A' ' 75' ' ' LYS . 1.0 OUTLIER -134.99 155.71 50.3 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 -179.738 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.47 ' HB2' ' HA ' ' A' ' 28' ' ' PRO . 7.4 p-10 -90.11 131.83 35.75 Favored 'General case' 0 C--N 1.295 -1.763 0 CA-C-O 121.721 0.772 . . . . 0.0 111.517 -178.862 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 29' ' ' VAL . 75.6 p -96.07 172.94 7.68 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 175.808 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.57 -54.36 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.86 174.265 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -130.44 -47.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.644 0 C-N-CA 120.189 -0.604 . . . . 0.0 111.94 -174.313 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.8 p -170.08 167.19 8.92 Favored 'General case' 0 CA--C 1.469 -2.17 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -169.839 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.425 ' O ' HD12 ' A' ' 67' ' ' LEU . 2.8 pp -68.84 164.28 22.33 Favored 'General case' 0 N--CA 1.391 -3.409 0 CA-C-N 113.67 -1.605 . . . . 0.0 106.687 176.039 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.408 ' HA ' ' HB2' ' A' ' 67' ' ' LEU . 50.0 m -86.28 88.25 7.58 Favored 'General case' 1 C--N 1.238 -4.268 0 CA-C-O 121.357 0.599 . . . . 0.0 111.681 -170.501 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.66 133.98 7.88 Favored Glycine 1 N--CA 1.394 -4.157 0 N-CA-C 106.957 -2.457 . . . . 0.0 106.957 167.818 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -122.32 -29.14 4.19 Favored 'General case' 0 C--N 1.264 -3.127 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.42 -31.82 69.17 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 174.162 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' HG22 ' A' ' 113' ' ' ILE . 28.5 t 173.71 -174.07 0.06 Allowed 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 168.143 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 31.4 mm -106.46 -4.98 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.98 0 N-CA-C 103.839 -2.652 . . . . 0.0 103.839 -179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.538 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 16.0 tt -104.03 157.56 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 103.409 -2.811 . . . . 0.0 103.409 163.252 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.8 41.57 28.16 Favored Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.536 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.813 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -135.1 129.37 33.84 Favored 'General case' 0 C--N 1.271 -2.812 0 C-N-CA 125.065 1.346 . . . . 0.0 109.068 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.891 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 11.2 p -114.86 141.45 47.9 Favored 'General case' 0 C--N 1.279 -2.468 0 CA-C-O 121.339 0.59 . . . . 0.0 112.272 177.655 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.623 ' HB3' HG21 ' A' ' 149' ' ' ILE . 2.6 pt? -88.97 105.93 18.09 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.466 HG23 ' SG ' ' A' ' 57' ' ' CYS . 17.3 t -92.93 100.39 11.2 Favored 'Isoleucine or valine' 1 C--O 1.319 4.718 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.354 169.081 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 45' ' ' PHE . 3.3 t -147.1 170.42 3.94 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.677 0 C-N-CA 128.879 2.872 . . . . 0.0 103.467 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -159.51 170.39 21.8 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 178.175 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.531 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -79.79 83.25 5.76 Favored 'General case' 0 CA--C 1.567 1.604 0 N-CA-C 105.624 -1.991 . . . . 0.0 105.624 169.288 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -172.17 174.19 4.07 Favored 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 104.694 -2.335 . . . . 0.0 104.694 -167.515 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.67 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -88.29 104.62 16.91 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -69.71 113.31 6.85 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 174.97 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -75.83 131.59 39.83 Favored 'General case' 0 N--CA 1.427 -1.593 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.918 -167.788 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.56 HD22 ' HA2' ' A' ' 73' ' ' GLY . 11.0 mt -76.1 -71.52 0.38 Allowed 'General case' 0 N--CA 1.404 -2.752 0 CA-C-N 113.617 -1.629 . . . . 0.0 113.614 -169.13 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -117.38 -7.11 12.63 Favored Glycine 0 CA--C 1.467 -2.943 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.447 -168.676 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.481 ' O ' ' HB ' ' A' ' 135' ' ' THR . 95.3 mttt -99.93 -42.57 6.72 Favored 'General case' 0 N--CA 1.412 -2.369 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' N ' ' A' ' 135' ' ' THR . . . 75.97 -63.0 2.85 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -171.096 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 153.63 -25.85 0.75 Allowed Glycine 0 C--N 1.299 -1.486 0 N-CA-C 108.101 -1.999 . . . . 0.0 108.101 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -163.54 172.88 13.77 Favored 'General case' 0 C--O 1.254 1.342 0 N-CA-C 103.376 -2.824 . . . . 0.0 103.376 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -59.57 -41.06 89.31 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-N 118.887 0.767 . . . . 0.0 112.068 -176.34 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 136' ' ' LYS . 35.4 tt0 -66.17 -36.98 84.52 Favored 'General case' 0 C--O 1.219 -0.532 0 CA-C-O 121.08 0.467 . . . . 0.0 110.181 177.251 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -68.29 -34.23 75.77 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.642 -176.203 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.481 ' HB ' ' O ' ' A' ' 128' ' ' LYS . 10.7 t -81.54 -6.75 59.28 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.547 1.165 . . . . 0.0 109.114 177.354 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 88.3 tttt -90.01 -24.43 21.22 Favored 'General case' 0 C--N 1.287 -2.117 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.257 175.313 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.3 m -83.36 -33.3 25.85 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.72 7.59 Favored Glycine 1 C--O 1.315 5.194 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 -171.554 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -35.14 106.04 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 131.271 3.828 . . . . 0.0 120.016 -166.254 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.404 ' HB3' ' CG1' ' A' ' 118' ' ' VAL . . . -153.05 172.38 16.96 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 102.498 -3.149 . . . . 0.0 102.498 164.625 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -52.32 110.01 1.06 Allowed Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 34.4 p -52.63 -32.11 40.14 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -171.487 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 15.9 ptt180 -120.25 -27.37 5.27 Favored 'General case' 0 C--N 1.26 -3.304 0 C-N-CA 118.472 -1.291 . . . . 0.0 108.776 174.395 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.73 -36.39 11.3 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 124.7 1.25 . . . . 0.0 112.798 -165.989 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -142.45 88.76 2.1 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.102 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.891 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 52.7 t -156.86 141.36 16.71 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.858 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -157.72 170.44 34.7 Favored Glycine 0 N--CA 1.4 -3.708 0 N-CA-C 107.214 -2.354 . . . . 0.0 107.214 177.924 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.735 ' HB ' ' NH1' ' A' ' 115' ' ' ARG . 27.7 m -68.84 124.26 24.15 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.017 0 CA-C-N 117.656 0.728 . . . . 0.0 111.054 178.595 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.813 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 0.0 OUTLIER -123.47 99.86 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.212 0.53 . . . . 0.0 111.245 179.331 . . . . . . . . 3 3 . 1 . 006 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.504 ' HA3' ' NE ' ' A' ' 115' ' ' ARG . . . 174.63 -167.47 39.75 Favored Glycine 0 CA--C 1.457 -3.586 0 C-N-CA 117.546 -2.264 . . . . 0.0 111.534 178.316 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 9.1 tt -68.75 105.67 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.266 1.935 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -116.45 140.28 49.53 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.104 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 . . . . . 0 C--N 1.297 -1.694 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.009 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.212 -0.918 0 N-CA-C 111.663 0.246 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.524 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 14.4 m -58.08 -26.41 62.53 Favored 'General case' 0 CA--C 1.571 1.776 0 N-CA-C 115.425 1.639 . . . . 0.0 115.425 -174.495 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -135.15 147.5 49.46 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.827 -1.171 . . . . 0.0 112.083 -172.171 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.836 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -139.81 154.42 47.35 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.64 172.519 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.554 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 39.7 t -129.69 131.03 67.02 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -121.49 132.37 54.68 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.664 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 10.9 m -127.96 109.04 18.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.729 0.776 . . . . 0.0 110.58 -178.695 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' A' ' 15' ' ' GLN . 6.6 mp -103.47 128.49 50.64 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.664 -176.334 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -160.88 124.99 3.5 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 169.147 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.91 -173.14 22.66 Favored Glycine 0 N--CA 1.405 -3.382 0 N-CA-C 107.216 -2.354 . . . . 0.0 107.216 175.141 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -95.21 89.66 5.59 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 120.217 -0.593 . . . . 0.0 109.78 -178.662 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.59 -63.83 0.62 Allowed Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.776 178.217 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.663 ' HB3' ' HA ' ' A' ' 120' ' ' HIS . 31.9 Cg_exo -62.31 169.16 8.35 Favored 'Trans proline' 0 N--CA 1.432 -2.095 0 C-N-CA 123.072 2.515 . . . . 0.0 115.004 -174.823 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.558 HG12 ' HA3' ' A' ' 37' ' ' GLY . 16.8 m -69.86 158.01 6.31 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.038 0 CA-C-N 111.587 -2.552 . . . . 0.0 112.544 -175.07 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.505 ' HA ' ' HB2' ' A' ' 8' ' ' LEU . 15.3 tm0? -112.52 140.56 47.17 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 104.667 -2.345 . . . . 0.0 104.667 177.224 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' HD13 ' A' ' 8' ' ' LEU . . . -158.98 170.51 35.41 Favored Glycine 0 N--CA 1.414 -2.824 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.449 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 18.9 pt -132.46 129.05 58.87 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 176.677 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.506 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 43.7 mm -130.01 123.53 56.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -174.718 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 2.2 m-20 -112.41 126.74 55.61 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.478 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.836 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 29.7 p90 -126.78 148.34 49.93 Favored 'General case' 0 CA--C 1.495 -1.147 0 C-N-CA 118.24 -1.384 . . . . 0.0 109.912 176.224 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.534 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 1.5 pp20? -117.76 116.17 26.48 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.372 176.128 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -85.72 87.88 7.47 Favored 'General case' 0 N--CA 1.382 -3.854 0 CA-C-O 123.103 1.43 . . . . 0.0 108.769 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.537 ' H ' ' HB ' ' A' ' 104' ' ' ILE . 5.0 ttmp? -72.16 110.06 6.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 112.206 -2.27 . . . . 0.0 107.009 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -61.79 -24.29 66.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.03 0.443 . . . . 0.0 111.622 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 m -71.92 -19.3 61.94 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.524 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.458 ' HA ' HG13 ' A' ' 104' ' ' ILE . 56.6 m-80 70.3 162.71 0.24 Allowed 'General case' 0 C--O 1.241 0.61 0 C-N-CA 125.194 1.398 . . . . 0.0 110.885 -175.493 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 138.47 -149.46 20.56 Favored Glycine 0 CA--C 1.48 -2.156 0 C-N-CA 117.762 -2.161 . . . . 0.0 114.18 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -63.26 125.69 16.25 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 123.357 2.704 . . . . 0.0 110.941 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.656 HG12 HG23 ' A' ' 104' ' ' ILE . 3.9 m -76.97 120.39 27.23 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.378 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -98.55 92.17 5.5 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.096 0.951 . . . . 0.0 108.506 172.259 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 71.5 t -133.36 146.0 32.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -175.889 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.5 p-90 -143.15 134.73 26.39 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.456 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -141.92 140.33 10.01 Favored Glycine 0 N--CA 1.419 -2.458 0 C-N-CA 119.796 -1.192 . . . . 0.0 112.14 178.171 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -116.63 151.82 35.48 Favored 'General case' 0 N--CA 1.394 -3.252 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 176.781 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.671 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 36.8 mm -132.24 134.06 59.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.683 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 60.6 pttt -139.0 119.96 14.42 Favored 'General case' 0 C--O 1.206 -1.207 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 175.1 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.558 ' HA3' HG12 ' A' ' 14' ' ' VAL . . . -169.97 174.97 44.16 Favored Glycine 0 CA--C 1.476 -2.354 0 C-N-CA 118.811 -1.662 . . . . 0.0 113.075 -171.793 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.3 tt -66.85 137.77 56.84 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.1 p -72.78 108.53 5.81 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 115.238 1.57 . . . . 0.0 115.238 -164.48 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.51 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.9 tt0 -177.78 121.79 0.11 Allowed 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 105.358 -2.09 . . . . 0.0 105.358 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' HA ' ' A' ' 90' ' ' ASP . . . -155.82 138.67 6.14 Favored Glycine 0 CA--C 1.47 -2.774 0 C-N-CA 119.268 -1.444 . . . . 0.0 111.507 -177.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 122' ' ' LYS . 3.6 mm? -126.65 -58.33 1.33 Allowed 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -170.989 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.52 169.3 24.61 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.369 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -130.29 113.34 1.43 Allowed Glycine 0 C--O 1.217 -0.917 0 C-N-CA 118.391 -1.861 . . . . 0.0 117.43 -170.317 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.596 ' O ' ' HB3' ' A' ' 124' ' ' ASP . 46.7 m-85 -168.67 108.86 0.5 Allowed 'General case' 0 C--O 1.188 -2.171 0 N-CA-C 102.752 -3.055 . . . . 0.0 102.752 170.942 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.449 ' HB3' HG22 ' A' ' 119' ' ' VAL . 68.1 m-70 -149.95 85.57 1.42 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 120.881 1.673 . . . . 0.0 107.969 -175.573 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.514 HG13 HG21 ' A' ' 149' ' ' ILE . 48.8 t -162.53 161.11 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 105.052 -2.203 . . . . 0.0 105.052 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' A' ' 60' ' ' ALA . 62.6 t-80 -153.46 148.41 26.62 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 168.266 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 0.4 OUTLIER -109.48 124.13 50.54 Favored 'General case' 0 C--N 1.257 -3.451 0 C-N-CA 124.196 0.998 . . . . 0.0 112.133 -177.764 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 11.8 t80 174.4 -50.98 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 124.864 1.266 . . . . 0.0 109.395 174.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.599 ' HA2' ' N ' ' A' ' 115' ' ' ARG . . . 95.04 109.8 2.32 Favored Glycine 0 CA--C 1.496 -1.123 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.305 -177.279 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -132.68 -73.09 0.51 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 117.707 -1.597 . . . . 0.0 112.878 -174.264 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 37.5 t-20 -161.95 152.18 17.02 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -179.246 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.7 m -71.73 -34.27 69.4 Favored 'General case' 0 C--O 1.208 -1.095 0 CA-C-O 121.135 0.493 . . . . 0.0 110.298 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.22 -12.72 27.63 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 120.75 -0.38 . . . . 0.0 111.956 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -154.24 111.26 0.48 Allowed Glycine 0 CA--C 1.468 -2.866 0 C-N-CA 119.077 -1.535 . . . . 0.0 110.046 -174.876 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.408 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 26.2 p -98.28 88.47 4.18 Favored 'General case' 0 N--CA 1.4 -2.949 0 CA-C-O 121.65 0.738 . . . . 0.0 110.851 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.0 m -79.26 -46.29 18.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.708 0.766 . . . . 0.0 110.14 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.5 m -63.71 -24.95 67.99 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.402 178.625 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.902 ' HB2' ' HB ' ' A' ' 116' ' ' THR . . . -75.49 -9.23 58.39 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 176.329 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.99 -160.49 0.78 Allowed Glycine 0 C--N 1.311 -0.854 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.97 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -74.37 54.08 3.23 Favored 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 122.74 2.293 . . . . 0.0 110.223 177.659 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -133.23 109.46 9.44 Favored 'General case' 0 N--CA 1.424 -1.751 0 N-CA-C 103.48 -2.785 . . . . 0.0 103.48 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.498 ' CD2' ' HB3' ' A' ' 69' ' ' ARG . 54.7 m-85 -123.77 162.06 23.93 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-O 122.06 0.934 . . . . 0.0 113.12 -174.218 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -104.56 143.3 26.41 Favored Pre-proline 0 N--CA 1.42 -1.956 0 N-CA-C 103.859 -2.645 . . . . 0.0 103.859 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -48.18 -55.31 4.16 Favored 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.98 2.453 . . . . 0.0 116.832 -168.297 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 95.2 mt -90.12 -4.97 57.0 Favored 'General case' 0 CA--C 1.478 -1.81 0 C-N-CA 119.142 -1.023 . . . . 0.0 108.885 -172.44 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 21.4 m -86.52 7.98 23.86 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.188 -1.369 . . . . 0.0 109.733 178.091 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HB3' ' CD2' ' A' ' 64' ' ' PHE . 4.4 ppt_? -134.04 -30.15 1.23 Allowed 'General case' 0 N--CA 1.402 -2.832 0 CA-C-O 117.734 -1.127 . . . . 0.0 110.313 167.398 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.485 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 85.1 tttt 34.54 -86.04 0.0 OUTLIER 'General case' 0 C--N 1.389 2.286 0 C-N-CA 125.386 1.474 . . . . 0.0 110.968 -173.534 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.506 ' O ' ' HA2' ' A' ' 127' ' ' GLY . 55.0 t-80 -131.32 -38.75 1.18 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 172.638 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.0 119.58 3.05 Favored Glycine 0 N--CA 1.425 -2.059 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -170.511 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.3 144.11 11.51 Favored Glycine 0 N--CA 1.419 -2.454 0 C-N-CA 118.612 -1.756 . . . . 0.0 113.041 -174.695 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 101' ' ' ASP . 59.1 Cg_endo -74.84 -19.16 18.53 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.3 2.0 . . . . 0.0 112.99 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 101' ' ' ASP . 51.1 mtmt -120.62 -13.97 8.68 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -175.633 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -172.18 126.25 0.55 Allowed 'General case' 0 CA--C 1.493 -1.231 0 CA-C-N 119.593 1.088 . . . . 0.0 109.649 -173.837 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.424 ' H ' ' HB2' ' A' ' 102' ' ' SER . 2.9 mm-40 -138.31 171.16 14.79 Favored 'General case' 0 N--CA 1.416 -2.16 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.084 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -100.13 -74.82 0.59 Allowed 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.57 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.562 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.1 OUTLIER -130.2 26.3 5.16 Favored 'General case' 0 CA--C 1.47 -2.107 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -170.579 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 7.6 t60 . . . . . 0 N--CA 1.396 -3.155 0 CA-C-N 111.96 -2.382 . . . . 0.0 106.102 177.042 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.506 -0.75 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.42 153.96 35.07 Favored Glycine 0 CA--C 1.5 -0.851 0 O-C-N 124.194 0.933 . . . . 0.0 111.287 178.0 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -76.66 146.1 38.35 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.992 -171.874 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.66 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 17.1 m -136.9 146.26 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.548 ' HA ' ' OE1' ' A' ' 121' ' ' GLU . 7.4 t -141.62 109.57 5.79 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 174.9 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.586 ' HB1' ' HA2' ' A' ' 93' ' ' GLY . . . -118.07 105.78 12.21 Favored 'General case' 0 CA--C 1.47 -2.113 0 N-CA-C 104.814 -2.291 . . . . 0.0 104.814 174.157 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.527 ' HA ' ' N ' ' A' ' 41' ' ' GLY . 39.2 p30 -112.85 -77.52 0.58 Allowed 'General case' 0 C--O 1.172 -2.983 0 N-CA-C 114.793 1.405 . . . . 0.0 114.793 -164.781 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -83.71 -14.72 51.0 Favored 'General case' 1 C--N 1.212 -5.377 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -144.54 134.66 24.11 Favored 'General case' 0 N--CA 1.418 -2.037 0 N-CA-C 106.198 -1.778 . . . . 0.0 106.198 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.683 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.54 71.8 2.94 Favored Glycine 0 N--CA 1.417 -2.616 0 CA-C-O 119.279 -0.734 . . . . 0.0 111.549 -175.865 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.671 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 59.0 t -153.61 105.54 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.495 ' H ' ' HB ' ' A' ' 35' ' ' ILE . . . -113.11 144.48 42.57 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.463 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.33 137.27 38.99 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.987 -1.856 . . . . 0.0 105.987 175.959 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.456 HG11 ' H ' ' A' ' 33' ' ' GLY . 8.0 p -101.74 140.32 20.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.118 0.485 . . . . 0.0 110.164 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.6 m -122.47 101.58 7.57 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.45 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.686 HD13 ' H ' ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.42 118.74 54.66 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.311 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -177.415 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -148.8 97.49 2.72 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.011 -2.218 . . . . 0.0 105.011 166.859 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.545 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 1.1 p30 -168.02 168.19 12.11 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.339 -169.02 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.424 ' HB2' ' H ' ' A' ' 77' ' ' GLU . 15.6 m -99.95 80.0 2.26 Favored 'General case' 0 N--CA 1.42 -1.94 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.956 168.811 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.531 ' C ' ' H ' ' A' ' 105' ' ' SER . 49.9 t -101.18 -11.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 123.859 0.864 . . . . 0.0 109.442 173.06 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.656 HG23 HG12 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -63.82 21.32 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.889 0 C-N-CA 124.777 1.231 . . . . 0.0 112.641 176.957 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.531 ' H ' ' C ' ' A' ' 103' ' ' VAL . 16.0 m -68.74 130.22 42.19 Favored 'General case' 0 N--CA 1.4 -2.944 0 C-N-CA 125.271 1.428 . . . . 0.0 110.148 179.096 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.03 173.11 3.21 Favored 'General case' 0 N--CA 1.387 -3.583 0 CA-C-N 112.953 -1.931 . . . . 0.0 107.004 172.201 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.5 p -64.93 116.18 6.12 Favored 'General case' 2 N--CA 1.363 -4.787 0 CA-C-O 123.58 1.657 . . . . 0.0 111.592 -165.07 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.57 -142.32 12.82 Favored Glycine 2 CA--C 1.425 -5.546 0 CA-C-N 110.363 -3.108 . . . . 0.0 105.343 174.82 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 49' ' ' GLU . 4.7 p-10 40.11 -151.47 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -89.55 -23.81 21.91 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.158 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -131.51 -153.31 0.55 Allowed 'General case' 0 N--CA 1.41 -2.465 0 CA-C-O 122.009 0.909 . . . . 0.0 110.348 -175.315 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 59.0 mt -126.51 -38.2 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 N-CA-C 104.28 -2.489 . . . . 0.0 104.28 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.9 pt -91.08 99.05 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.834 0 CA-C-N 113.155 -1.839 . . . . 0.0 107.055 173.281 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -97.68 63.7 0.92 Allowed Glycine 2 N--CA 1.375 -5.392 0 N-CA-C 105.023 -3.231 . . . . 0.0 105.023 -175.743 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.599 ' N ' ' HA2' ' A' ' 51' ' ' GLY . 31.7 mtp180 -68.24 81.8 0.24 Allowed 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 -176.983 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.902 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 0.7 OUTLIER -163.3 97.12 0.89 Allowed 'General case' 1 N--CA 1.367 -4.592 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 -179.166 . . . . . . . . 4 4 . 1 . 007 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.485 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 16.2 mt -103.61 106.49 17.01 Favored 'General case' 0 C--N 1.251 -3.696 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.963 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.628 HG13 ' HB1' ' A' ' 60' ' ' ALA . 8.2 m -92.2 98.05 7.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 C-N-CA 117.394 -1.722 . . . . 0.0 109.384 169.736 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.449 HG22 ' HB3' ' A' ' 46' ' ' HIS . 9.2 t -135.51 136.21 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 122.724 1.249 . . . . 0.0 112.587 -174.2 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.663 ' HA ' ' HB3' ' A' ' 13' ' ' PRO . 0.4 OUTLIER -170.77 134.71 1.05 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 168.053 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.548 ' OE1' ' HA ' ' A' ' 88' ' ' THR . 1.9 mm-40 -69.63 99.74 1.35 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 122.153 0.978 . . . . 0.0 110.632 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.562 ' HA ' HD23 ' A' ' 42' ' ' LEU . 68.0 mttm -170.73 170.4 6.62 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 -170.505 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.63 104.13 3.24 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.596 ' HB3' ' O ' ' A' ' 45' ' ' PHE . 7.2 t70 -107.47 6.69 28.39 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.419 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -42.48 105.91 0.05 Allowed 'General case' 0 C--O 1.245 0.832 0 C-N-CA 126.882 2.073 . . . . 0.0 112.61 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -71.07 -39.93 71.92 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.574 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 127' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 71' ' ' HIS . . . -89.42 24.21 15.25 Favored Glycine 0 CA--C 1.482 -2.023 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.562 -177.208 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -136.59 -47.32 0.62 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.527 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 65.25 -78.34 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.777 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.363 -174.873 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 156.8 -38.05 0.57 Allowed Glycine 0 N--CA 1.417 -2.571 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.656 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 59.4 t30 -152.66 -178.91 7.16 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -54.02 -34.46 60.01 Favored 'General case' 0 C--N 1.368 1.384 0 N-CA-C 114.169 1.174 . . . . 0.0 114.169 -177.968 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.656 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -85.29 -38.14 19.2 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.305 0.574 . . . . 0.0 111.57 -174.568 . . . . . . . . 3 3 . 1 . 007 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.4 p -76.77 -20.78 56.06 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -81.54 -7.75 59.63 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.878 0.847 . . . . 0.0 109.642 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 86.5 tttt -85.81 -49.18 8.11 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.085 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 5.0 p -68.1 -37.42 81.15 Favored 'General case' 0 N--CA 1.417 -2.101 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.014 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.73 94.81 0.06 OUTLIER Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -32.54 123.62 0.34 Allowed 'General case' 1 C--O 1.336 5.619 0 CA-C-O 123.609 1.671 . . . . 0.0 114.049 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.414 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -140.74 120.66 13.58 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.85 -176.548 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -97.33 72.66 0.69 Allowed Glycine 0 C--O 1.214 -1.122 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.408 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 5.2 p -88.83 5.99 41.11 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -172.518 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 57.0 ttt-85 -118.26 -47.92 2.54 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.74 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.438 ' HG ' ' HD3' ' A' ' 13' ' ' PRO . 11.9 tp -60.34 -38.95 85.39 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 114.957 -1.02 . . . . 0.0 113.59 -167.737 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 129.96 7.13 Favored 'General case' 0 CA--C 1.481 -1.675 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.485 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 81.4 m -138.25 163.21 32.34 Favored 'General case' 0 C--N 1.291 -1.977 0 O-C-N 124.421 1.076 . . . . 0.0 108.856 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.664 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.7 170.23 43.34 Favored Glycine 0 N--CA 1.408 -3.188 0 O-C-N 123.887 0.742 . . . . 0.0 111.489 175.602 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.546 HG13 ' HG2' ' A' ' 115' ' ' ARG . 69.5 t -69.49 117.73 12.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 C-N-CA 124.148 0.979 . . . . 0.0 110.549 168.408 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.528 ' H ' ' HA ' ' A' ' 115' ' ' ARG . 15.7 tt -122.65 108.0 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 CA-C-O 122.229 1.014 . . . . 0.0 108.729 166.391 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.49 46.23 Favored Glycine 1 CA--C 1.442 -4.479 0 N-CA-C 108.262 -1.935 . . . . 0.0 108.262 178.663 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 8.7 tt -69.23 103.91 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 177.186 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.554 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -110.27 97.12 6.66 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.386 -1.326 . . . . 0.0 110.936 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 mp0 . . . . . 0 C--N 1.324 -0.536 0 O-C-N 125.942 2.026 . . . . 0.0 114.489 171.157 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.811 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.609 ' O ' ' HA ' ' A' ' 21' ' ' GLU . 28.5 p -109.6 -65.24 1.17 Allowed 'General case' 0 C--O 1.161 -3.585 0 CA-C-O 119.147 -0.454 . . . . 0.0 111.569 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.2 ptpp? -135.49 171.03 15.02 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.894 0.378 . . . . 0.0 110.684 -168.427 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -137.19 166.82 22.83 Favored 'General case' 0 N--CA 1.419 -2.021 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -177.949 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 152' ' ' ALA . 27.2 m -128.89 168.39 22.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.566 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -132.66 137.97 47.16 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.469 -173.06 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.7 t -134.28 108.55 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.434 HD21 ' HB3' ' A' ' 117' ' ' LEU . 84.7 mt -96.71 150.17 20.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -149.15 122.79 9.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.93 24.66 Favored Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.134 -1.507 . . . . 0.0 113.012 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 11' ' ' ASP . . . . . 0.425 ' O ' ' HD3' ' A' ' 13' ' ' PRO . 46.3 m-20 -66.24 -50.5 63.56 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 175.654 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.91 96.9 1.7 Allowed Glycine 0 N--CA 1.432 -1.594 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' O ' ' A' ' 11' ' ' ASP . 32.2 Cg_exo -57.08 127.41 25.64 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.607 2.204 . . . . 0.0 113.563 -173.329 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 11.4 m -120.58 113.02 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.804 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.597 175.128 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 mp0 -108.5 119.53 39.79 Favored 'General case' 0 C--N 1.294 -1.805 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.112 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.72 170.13 42.9 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 176.153 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.431 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 24.8 pt -129.4 125.4 61.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' HE2' ' A' ' 46' ' ' HIS . 3.7 mp -123.33 128.4 74.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -178.545 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.735 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 18.5 m120 -100.05 134.89 42.31 Favored 'General case' 0 CA--C 1.507 -0.701 0 CA-C-O 119.306 -0.378 . . . . 0.0 110.662 -177.848 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -127.75 119.6 26.11 Favored 'General case' 0 CA--C 1.503 -0.852 0 C-N-CA 118.613 -1.235 . . . . 0.0 113.585 175.271 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.609 ' HA ' ' O ' ' A' ' 2' ' ' THR . 58.3 mt-10 -90.22 143.9 26.35 Favored 'General case' 0 N--CA 1.425 -1.719 0 CA-C-N 114.372 -1.285 . . . . 0.0 112.734 177.872 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.576 ' HB2' ' HA ' ' A' ' 106' ' ' LEU . 3.9 pt20 -103.11 124.9 49.43 Favored 'General case' 1 N--CA 1.375 -4.176 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 163.596 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -111.45 83.59 1.8 Allowed 'General case' 0 C--N 1.273 -2.733 0 C-N-CA 119.264 -0.974 . . . . 0.0 108.578 169.739 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -69.47 -27.95 65.66 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.102 -1.408 . . . . 0.0 108.736 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -71.21 -8.65 54.99 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.36 -1.291 . . . . 0.0 110.087 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.2 t30 75.88 120.44 0.05 OUTLIER 'General case' 0 C--N 1.35 0.626 0 C-N-CA 126.323 1.849 . . . . 0.0 111.195 -177.444 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.69 165.55 29.88 Favored Glycine 0 N--CA 1.408 -3.183 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HB3' ' HB2' ' A' ' 101' ' ' ASP . 37.7 Cg_endo -66.28 135.53 40.27 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.12 1.88 . . . . 0.0 110.692 178.46 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.594 HG23 ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -73.6 135.36 27.75 Favored 'Isoleucine or valine' 0 C--O 1.268 2.033 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.445 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -101.75 124.16 46.93 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 173.737 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.414 ' O ' HG22 ' A' ' 99' ' ' ILE . 16.5 m -137.99 152.82 26.55 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -172.57 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.6 t-105 -156.56 132.49 9.69 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.891 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.475 ' C ' HG12 ' A' ' 97' ' ' VAL . . . -170.63 135.84 3.69 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.545 -2.264 . . . . 0.0 112.61 169.684 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.437 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 5.4 p -117.8 137.09 52.98 Favored 'General case' 0 N--CA 1.395 -3.18 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.411 HG22 ' HA3' ' A' ' 16' ' ' GLY . 47.6 pt -131.87 146.27 33.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.052 -1.059 . . . . 0.0 110.093 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -119.23 129.61 55.03 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 176.225 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.583 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -135.15 174.3 21.24 Favored Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -173.515 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.81 173.53 5.19 Favored 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 123.73 0.812 . . . . 0.0 110.81 178.434 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.497 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 9.8 t -66.37 110.63 3.16 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-O 121.627 0.727 . . . . 0.0 111.657 -172.038 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . 0.267 4.6 mm-40 -165.61 177.34 7.41 Favored 'General case' 0 N--CA 1.398 -3.071 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.251 -176.647 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.43 -146.49 0.01 OUTLIER Glycine 0 N--CA 1.403 -3.501 0 CA-C-N 112.021 -2.354 . . . . 0.0 115.417 -177.953 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' CB ' ' HA ' ' A' ' 88' ' ' THR . 2.0 pt? -173.06 100.14 0.13 Allowed 'General case' 1 N--CA 1.372 -4.326 0 O-C-N 121.592 -0.946 . . . . 0.0 109.343 -161.214 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.526 ' HB3' ' HA ' ' A' ' 123' ' ' ALA . 0.4 OUTLIER 169.85 171.33 0.05 Allowed 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 103.963 -2.606 . . . . 0.0 103.963 177.43 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' ' N ' ' A' ' 125' ' ' ASP . . . 102.65 64.72 0.73 Allowed Glycine 0 C--N 1.268 -3.197 0 N-CA-C 116.248 1.259 . . . . 0.0 116.248 171.707 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.611 ' CG ' ' HB3' ' A' ' 84' ' ' LEU . 12.8 t80 -76.72 134.85 39.09 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 117.336 -1.746 . . . . 0.0 110.07 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.644 ' HE2' HG12 ' A' ' 18' ' ' ILE . 1.4 p-80 -85.91 100.61 12.22 Favored 'General case' 0 C--N 1.263 -3.175 0 CA-C-N 112.848 -1.978 . . . . 0.0 115.086 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.407 HG12 ' OE1' ' A' ' 49' ' ' GLU . 31.2 t -129.58 89.79 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.497 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 171.569 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.709 ' CE1' ' HB3' ' A' ' 60' ' ' ALA . 1.7 t60 -107.27 107.29 18.15 Favored 'General case' 0 C--O 1.184 -2.393 0 N-CA-C 113.323 0.861 . . . . 0.0 113.323 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 60' ' ' ALA . 3.6 mp0 -90.07 136.21 33.18 Favored 'General case' 0 C--N 1.267 -2.989 0 O-C-N 120.687 -1.258 . . . . 0.0 112.665 175.202 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 t80 70.67 93.59 0.08 Allowed 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 125.968 1.707 . . . . 0.0 111.359 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.29 -91.14 1.15 Allowed Glycine 0 CA--C 1.482 -2.006 0 C-N-CA 119.066 -1.54 . . . . 0.0 113.543 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.2 t70 76.89 -25.87 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 126.996 2.118 . . . . 0.0 112.583 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 2.6 m-20 -90.35 98.84 12.01 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.449 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.49 ' HA ' HG13 ' A' ' 148' ' ' VAL . 11.4 t -56.55 -32.07 64.8 Favored 'General case' 0 C--O 1.199 -1.561 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -173.441 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.74 13.07 33.82 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.606 -0.683 . . . . 0.0 110.808 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.448 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -155.75 111.46 0.49 Allowed Glycine 0 N--CA 1.425 -2.095 0 C-N-CA 117.849 -2.119 . . . . 0.0 113.667 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 142' ' ' SER . 69.5 m -94.57 85.14 4.43 Favored 'General case' 0 N--CA 1.392 -3.36 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 172.643 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.9 m -82.31 -48.36 11.28 Favored 'General case' 0 N--CA 1.418 -2.061 0 CA-C-N 114.794 -1.093 . . . . 0.0 109.156 179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.6 p -71.57 -54.91 8.94 Favored 'General case' 0 N--CA 1.407 -2.624 0 CA-C-N 113.361 -1.745 . . . . 0.0 113.792 -172.433 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.709 ' HB3' ' CE1' ' A' ' 48' ' ' HIS 0.325 . . -85.81 -2.34 58.13 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 179.657 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -43.5 -139.31 0.0 OUTLIER Glycine 0 CA--C 1.57 3.509 0 C-N-CA 124.186 0.898 . . . . 0.0 113.993 171.054 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -60.1 5.32 0.13 Allowed 'Trans proline' 0 CA--C 1.574 2.494 0 C-N-CA 122.706 2.271 . . . . 0.0 114.879 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -116.58 110.8 19.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 123.467 0.707 . . . . 0.0 109.838 178.784 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -74.48 152.51 39.4 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.648 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -115.77 144.35 32.45 Favored Pre-proline 0 C--N 1.309 -1.162 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.74 177.025 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -72.22 -13.11 28.23 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.239 1.959 . . . . 0.0 111.747 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 109' ' ' ASP . 2.6 mm? -80.96 -9.47 59.83 Favored 'General case' 0 CA--C 1.484 -1.568 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -78.95 66.03 4.3 Favored 'General case' 0 N--CA 1.405 -2.706 0 CA-C-O 123.538 1.637 . . . . 0.0 108.719 172.943 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.636 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 12.5 ptp180 -117.49 23.27 11.88 Favored 'General case' 0 N--CA 1.397 -3.104 0 CA-C-N 112.204 -2.271 . . . . 0.0 105.149 175.007 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.9 mmmt -78.91 18.63 0.59 Allowed 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 112.363 -2.199 . . . . 0.0 111.005 176.331 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 33.6 t-80 75.3 87.59 0.09 Allowed 'General case' 0 N--CA 1.423 -1.805 0 O-C-N 125.135 1.522 . . . . 0.0 112.018 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.75 -98.4 0.17 Allowed Glycine 1 N--CA 1.385 -4.738 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 169.492 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -50.33 158.0 1.88 Allowed Glycine 0 N--CA 1.429 -1.827 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 172.828 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.434 ' HA ' ' NE2' ' A' ' 71' ' ' HIS . 47.4 Cg_endo -62.14 0.09 1.47 Allowed 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 124.678 3.585 . . . . 0.0 114.454 -172.071 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -120.39 13.67 11.89 Favored 'General case' 0 C--N 1.289 -2.049 0 C-N-CA 123.047 0.539 . . . . 0.0 110.127 -175.059 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 71' ' ' HIS . 3.0 m-20 71.98 76.38 0.16 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.502 177.185 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -78.97 87.19 4.79 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.723 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 69' ' ' ARG . 11.6 pt-20 -57.56 26.34 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 128.704 2.801 . . . . 0.0 115.942 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -160.16 -0.56 0.07 Allowed 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.385 -174.152 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.8 m170 . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.563 -0.711 . . . . 0.0 111.451 -173.703 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.611 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 7.5 tt . . . . . 0 C--O 1.252 1.186 0 N-CA-C 102.597 -3.112 . . . . 0.0 102.597 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.522 ' N ' HD23 ' A' ' 84' ' ' LEU . . . -39.74 156.43 0.03 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 119.106 0.867 . . . . 0.0 111.486 173.451 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 33.4 p30 -85.48 160.52 19.68 Favored 'General case' 0 C--N 1.282 -2.351 0 O-C-N 122.377 -0.484 . . . . 0.0 112.105 -158.293 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 77.5 t -108.39 163.42 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.912 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -174.76 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.561 ' HA ' ' CB ' ' A' ' 42' ' ' LEU . 31.5 m -140.33 130.51 25.0 Favored 'General case' 0 C--N 1.261 -3.28 0 C-N-CA 124.437 1.095 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.54 ' CB ' ' HB3' ' A' ' 121' ' ' GLU . . . -126.12 155.16 42.08 Favored 'General case' 0 C--N 1.254 -3.583 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 174.223 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.418 ' C ' ' HA ' ' A' ' 39' ' ' THR . 23.9 t70 -158.36 174.96 14.34 Favored 'General case' 1 C--N 1.239 -4.232 0 N-CA-C 104.126 -2.546 . . . . 0.0 104.126 178.462 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.497 ' N ' ' HA ' ' A' ' 39' ' ' THR . 59.8 pttt -47.27 -35.85 8.32 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 176.353 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -90.28 -38.64 13.26 Favored 'General case' 0 CA--C 1.486 -1.503 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 176.431 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.583 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 89.54 112.85 1.38 Allowed Glycine 0 N--CA 1.404 -3.479 0 CA-C-N 114.675 -1.148 . . . . 0.0 112.308 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.484 ' O ' ' HB ' ' A' ' 88' ' ' THR . 6.7 p -157.71 103.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.417 -2.101 0 CA-C-O 121.953 0.883 . . . . 0.0 109.876 174.715 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.403 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . -94.23 129.0 41.02 Favored 'General case' 0 N--CA 1.414 -2.228 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.713 173.224 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -69.57 143.38 53.37 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 114.378 -1.283 . . . . 0.0 109.406 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.475 HG12 ' C ' ' A' ' 33' ' ' GLY . 34.4 m -79.57 103.37 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.908 0 CA-C-O 123.855 1.788 . . . . 0.0 107.813 -177.488 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -86.77 107.39 18.24 Favored 'General case' 0 N--CA 1.401 -2.9 0 CA-C-N 113.059 -1.882 . . . . 0.0 111.083 -174.171 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 31' ' ' VAL . 37.5 pt -95.66 124.83 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.513 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.718 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -143.64 126.31 16.03 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.46 ' HB2' ' HB3' ' A' ' 28' ' ' PRO . 4.3 p30 -81.09 135.62 35.83 Favored 'General case' 0 C--O 1.276 2.45 0 CA-C-O 122.433 1.111 . . . . 0.0 112.601 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.427 ' OG ' ' HB ' ' A' ' 29' ' ' VAL . 92.5 p -102.92 172.2 6.96 Favored 'General case' 0 N--CA 1.413 -2.3 0 CA-C-N 112.846 -1.979 . . . . 0.0 110.608 177.678 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.452 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 7.1 p -115.88 -53.1 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.329 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 163.295 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 12.8 pt -98.93 23.67 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.045 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -170.647 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.8 t -80.34 89.88 5.56 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 123.061 1.41 . . . . 0.0 108.721 169.557 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.576 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 3.0 pp -126.72 170.39 12.18 Favored 'General case' 2 N--CA 1.346 -5.643 1 N-CA-C 99.272 -4.344 . . . . 0.0 99.272 174.558 . . . . . . . . 4 3 . 1 . 008 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.1 m -74.13 93.37 2.28 Favored 'General case' 1 C--N 1.213 -5.327 0 C-N-CA 118.727 -1.189 . . . . 0.0 111.978 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.81 135.43 12.43 Favored Glycine 0 CA--C 1.456 -3.651 0 N-CA-C 106.308 -2.717 . . . . 0.0 106.308 175.332 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.526 ' HB2' ' CB ' ' A' ' 67' ' ' LEU . 6.1 t70 54.09 -153.78 0.28 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -171.434 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.543 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 72.5 m80 -90.37 37.11 0.89 Allowed 'General case' 0 C--N 1.276 -2.602 0 C-N-CA 124.78 1.232 . . . . 0.0 109.777 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 115' ' ' ARG . 16.6 p -59.41 -27.14 65.74 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.671 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 46.1 pt -104.6 -32.94 2.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 C-N-CA 118.2 -1.4 . . . . 0.0 110.62 176.225 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.543 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 14.0 tt -104.09 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 120.135 -0.626 . . . . 0.0 112.684 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.76 17.89 53.02 Favored Glycine 0 N--CA 1.44 -1.065 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.895 175.111 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.549 ' HG3' ' O ' ' A' ' 48' ' ' HIS . 23.7 ttp180 -73.4 101.73 3.56 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 122.268 -0.548 . . . . 0.0 111.233 178.664 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 146' ' ' CYS . 4.2 m -70.9 110.85 5.88 Favored 'General case' 0 C--O 1.181 -2.519 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 176.966 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.537 ' HG ' ' HB2' ' A' ' 46' ' ' HIS . 13.2 tp -70.03 123.87 22.64 Favored 'General case' 0 C--N 1.275 -2.673 0 C-N-CA 122.731 0.412 . . . . 0.0 111.346 -172.31 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.582 HG22 ' HB2' ' A' ' 48' ' ' HIS . 11.4 m -91.88 101.03 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 178.018 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.487 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 10.3 p -140.52 168.66 16.61 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 176.931 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 124' ' ' ASP . 0.3 OUTLIER -171.2 164.23 7.25 Favored 'General case' 0 CA--C 1.487 -1.456 0 N-CA-C 104.214 -2.513 . . . . 0.0 104.214 173.871 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.58 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 2.2 mp0 -86.9 84.17 7.39 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.58 ' HG2' ' O ' ' A' ' 121' ' ' GLU . 2.2 mmpt? -176.0 171.53 2.57 Favored 'General case' 0 CA--C 1.476 -1.903 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 -175.314 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 43' ' ' HIS . . . -62.42 122.41 15.65 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 170.063 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 19.6 t70 -128.74 -12.83 4.79 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.943 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.502 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 0.6 OUTLIER -71.56 137.28 47.92 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.268 -174.881 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -79.2 -68.19 0.68 Allowed 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.334 -178.268 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.04 9.83 8.61 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 119.982 -1.104 . . . . 0.0 114.962 -176.765 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.404 ' HB3' ' CG ' ' A' ' 125' ' ' ASP . 32.2 tptt -137.43 15.29 2.97 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.8 42.94 1.85 Allowed Glycine 0 N--CA 1.473 1.135 0 N-CA-C 118.736 2.254 . . . . 0.0 118.736 -166.709 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 74.18 -91.38 0.72 Allowed Glycine 0 C--N 1.3 -1.431 0 N-CA-C 116.735 1.454 . . . . 0.0 116.735 171.239 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -100.33 158.32 15.97 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 118.595 -0.717 . . . . 0.0 110.484 -169.468 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -47.37 -42.48 21.77 Favored 'General case' 0 C--N 1.363 1.172 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 -178.06 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -79.87 -43.66 21.87 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.91 0.386 . . . . 0.0 110.958 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.7 t -70.64 -20.87 62.68 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.369 0.668 . . . . 0.0 111.878 -173.364 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -82.32 -18.23 42.97 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.031 0.443 . . . . 0.0 110.356 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 44.5 mtpt -101.77 -28.22 12.58 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.54 -1.264 . . . . 0.0 110.071 -178.116 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.9 p -74.45 -47.85 31.05 Favored 'General case' 0 N--CA 1.408 -2.527 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 173.092 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.16 94.06 0.13 Allowed Glycine 0 N--CA 1.417 -2.614 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.66 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 46.2 t-20 -55.81 106.03 0.23 Allowed 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 176.952 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.6 56.17 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -172.746 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.47 101.21 2.74 Favored Glycine 0 N--CA 1.428 -1.868 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 15.2 m -89.52 -7.1 55.65 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -171.504 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -145.19 -11.39 0.55 Allowed 'General case' 0 C--N 1.247 -3.859 0 C-N-CA 118.203 -1.399 . . . . 0.0 110.297 172.882 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -54.89 -42.96 72.74 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -175.668 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -149.82 89.88 1.65 Allowed 'General case' 0 N--CA 1.397 -3.122 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.563 ' HB3' HG22 ' A' ' 116' ' ' THR . 32.3 m -126.72 150.71 48.9 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 113.938 -1.483 . . . . 0.0 107.897 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.95 139.64 5.55 Favored Glycine 0 C--N 1.291 -1.957 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 178.401 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 54' ' ' THR . 17.2 m -73.59 110.4 7.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 118.69 1.245 . . . . 0.0 111.705 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.456 HG23 ' HB2' ' A' ' 117' ' ' LEU . 1.4 pp -86.67 145.75 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.227 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.671 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -150.14 142.61 9.83 Favored Glycine 2 N--CA 1.382 -4.96 0 C-N-CA 117.619 -2.229 . . . . 0.0 112.395 -171.409 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.612 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 3.4 tt -53.16 103.79 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 CA-C-O 122.088 0.947 . . . . 0.0 109.841 167.699 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.409 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -150.1 154.73 38.6 Favored 'General case' 0 N--CA 1.41 -2.436 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 174.494 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 . . . . . 0 C--N 1.273 -2.72 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 177.608 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.05 0 N-CA-C 111.379 0.14 . . . . 0.0 111.379 . . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.595 ' C ' ' HG3' ' A' ' 21' ' ' GLU . 30.1 m -119.33 -54.06 2.21 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.51 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 22.6 pttp -145.5 152.57 39.97 Favored 'General case' 0 N--CA 1.417 -2.122 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.632 -169.749 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.773 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.19 161.03 38.84 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 65.7 t -131.25 122.52 51.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.815 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -115.33 127.82 55.68 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.503 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.581 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.5 m -113.29 144.75 20.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 O-C-N 123.433 0.458 . . . . 0.0 110.554 -178.634 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 95.4 mt -127.09 135.05 50.22 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.641 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -141.04 125.86 18.06 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 10' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -154.31 178.45 31.13 Favored Glycine 0 N--CA 1.432 -1.597 0 C-N-CA 118.931 -1.604 . . . . 0.0 113.338 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -73.0 -40.4 65.23 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.982 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.56 95.57 1.45 Allowed Glycine 0 N--CA 1.434 -1.443 0 N-CA-C 106.159 -2.776 . . . . 0.0 106.159 170.484 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.75 127.56 14.77 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.895 1.73 . . . . 0.0 115.2 -169.345 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 14.0 m -123.78 114.98 43.75 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.186 0 N-CA-C 104.751 -2.314 . . . . 0.0 104.751 172.986 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.24 118.29 32.87 Favored 'General case' 0 C--N 1.279 -2.485 0 C-N-CA 118.309 -1.356 . . . . 0.0 109.542 -173.979 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.72 171.56 44.15 Favored Glycine 0 N--CA 1.412 -2.965 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.887 178.405 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.2 pt -133.46 124.58 48.79 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.413 ' HA ' ' HA3' ' A' ' 33' ' ' GLY . 2.4 mp -114.11 140.04 36.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.489 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 35.9 m-80 -99.24 150.41 22.11 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.736 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.773 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 98.2 m-85 -149.39 117.29 6.29 Favored 'General case' 0 CA--C 1.491 -1.3 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 175.501 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.595 ' HG3' ' C ' ' A' ' 2' ' ' THR . 4.6 mm-40 -134.39 144.12 48.01 Favored 'General case' 0 CA--C 1.477 -1.839 0 C-N-CA 118.627 -1.229 . . . . 0.0 112.578 173.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.543 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 25.3 tp60 -127.71 152.36 47.82 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.408 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.457 ' H ' HE21 ' A' ' 22' ' ' GLN . 84.8 tttt -106.56 104.73 14.49 Favored 'General case' 0 C--N 1.26 -3.306 0 N-CA-C 100.511 -3.885 . . . . 0.0 100.511 169.386 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.318 9.9 pt-20 -63.27 -9.25 10.85 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -168.044 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.5 p -76.45 -61.09 2.07 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 170.49 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 175.57 136.55 0.05 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 126.447 1.899 . . . . 0.0 106.688 174.304 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.87 95.37 0.12 Allowed Glycine 1 CA--C 1.444 -4.36 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 28' ' ' PRO . . . . . 0.585 ' HB3' ' N ' ' A' ' 101' ' ' ASP . 38.4 Cg_exo -62.75 123.44 12.32 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 C-N-CA 121.686 1.591 . . . . 0.0 109.179 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.553 ' HB ' ' O ' ' A' ' 21' ' ' GLU . 77.8 t -88.75 148.19 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.98 0 N-CA-C 103.892 -2.632 . . . . 0.0 103.892 171.985 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HD2' ' N ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -99.62 109.33 21.83 Favored 'General case' 1 C--N 1.242 -4.072 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -167.16 . . . . . . . . 4 4 . 1 . 009 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 16.1 m -124.53 152.44 30.52 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.089 -169.594 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 49.3 p90 -134.64 154.04 51.7 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-N 114.97 -1.013 . . . . 0.0 109.762 -175.65 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 96' ' ' ASP . . . -159.46 140.16 6.66 Favored Glycine 0 N--CA 1.415 -2.702 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 176.951 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.563 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 11.7 p -116.67 114.83 24.6 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 124.001 0.92 . . . . 0.0 110.987 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.546 HG22 ' HA3' ' A' ' 16' ' ' GLY . 36.8 pt -128.78 123.18 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 119.69 1.132 . . . . 0.0 110.81 175.248 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 21.3 ptmt -92.89 142.34 27.42 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.722 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.472 ' HA2' HG12 ' A' ' 14' ' ' VAL . . . -144.89 175.79 24.32 Favored Glycine 0 N--CA 1.421 -2.356 0 O-C-N 123.574 0.547 . . . . 0.0 112.869 -168.848 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.72 171.25 8.02 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 m -73.07 103.48 3.84 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.644 -1.222 . . . . 0.0 114.071 -171.213 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.536 ' OE2' ' HD3' ' A' ' 122' ' ' LYS . 25.5 tt0 -177.1 156.4 1.27 Allowed 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 157.643 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.66 -159.16 34.76 Favored Glycine 0 C--N 1.272 -2.977 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 170.208 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.586 ' HB3' ' H ' ' A' ' 122' ' ' LYS . 1.3 pt? -159.65 -169.85 2.71 Favored 'General case' 1 N--CA 1.364 -4.758 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.169 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.443 ' H ' ' HA ' ' A' ' 123' ' ' ALA . 34.7 t-80 -137.4 165.4 26.32 Favored 'General case' 0 C--N 1.247 -3.856 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 -178.063 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.58 ' HA2' ' O ' ' A' ' 85' ' ' GLY . . . -34.29 111.46 0.07 OUTLIER Glycine 0 C--O 1.249 1.074 0 O-C-N 125.723 1.889 . . . . 0.0 112.547 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -69.68 157.39 37.35 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 121.929 0.871 . . . . 0.0 112.714 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.427 ' HB3' HD23 ' A' ' 126' ' ' LEU . 59.6 m80 -137.82 95.02 2.97 Favored 'General case' 1 C--O 1.341 5.903 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.021 -174.154 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.494 HG11 ' HB2' ' A' ' 117' ' ' LEU . 14.1 m -106.11 156.76 6.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.455 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.738 -175.572 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.44 ' ND1' ' HB2' ' A' ' 65' ' ' ASN . 15.1 t60 -131.32 121.04 24.02 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-O 122.531 1.158 . . . . 0.0 112.083 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.493 ' OE1' ' HA3' ' A' ' 108' ' ' GLY . 0.0 OUTLIER -90.03 95.61 10.29 Favored 'General case' 0 C--N 1.273 -2.751 0 CA-C-N 113.161 -1.836 . . . . 0.0 115.609 -175.827 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.299 6.4 p90 -131.23 -5.92 3.83 Favored 'General case' 0 C--O 1.218 -0.57 0 C-N-CA 118.128 -1.429 . . . . 0.0 114.252 169.51 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . 100.98 118.58 4.34 Favored Glycine 0 N--CA 1.476 1.351 0 C-N-CA 120.058 -1.068 . . . . 0.0 112.714 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -144.86 -85.97 0.12 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 118.308 -1.357 . . . . 0.0 111.098 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 23.5 t30 -153.83 136.69 15.36 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.481 HG23 HG22 ' A' ' 148' ' ' VAL . 23.5 m -55.76 -19.11 10.02 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 125.613 1.565 . . . . 0.0 112.608 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.32 2.52 14.78 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -176.566 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 170.84 137.94 2.41 Favored Glycine 0 C--O 1.211 -1.283 0 C-N-CA 117.744 -2.169 . . . . 0.0 113.229 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.642 ' SG ' HG22 ' A' ' 118' ' ' VAL . 25.4 p -98.68 94.06 6.44 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 36.8 m -74.75 -52.24 12.05 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.641 -0.662 . . . . 0.0 110.998 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 m -90.31 -34.81 15.58 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-O 121.149 0.5 . . . . 0.0 110.908 -175.712 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.58 59.61 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -175.699 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.54 -65.03 3.61 Favored Glycine 0 CA--C 1.542 1.775 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -88.88 6.38 4.68 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 123.061 2.508 . . . . 0.0 114.247 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -98.86 133.78 42.67 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -176.358 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -109.32 170.82 7.81 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -175.85 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.522 ' ND2' ' HA2' ' A' ' 108' ' ' GLY . 43.9 t30 -106.49 97.16 15.68 Favored Pre-proline 0 C--O 1.213 -0.852 0 C-N-CA 123.066 0.546 . . . . 0.0 110.758 176.782 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 70' ' ' LYS . 21.3 Cg_exo -62.2 -9.86 16.37 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 124.256 3.304 . . . . 0.0 114.333 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.18 -17.58 53.77 Favored 'General case' 0 C--N 1.365 1.263 0 C-N-CA 122.7 0.4 . . . . 0.0 110.784 -168.939 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 38.6 t -84.77 -90.62 0.09 Allowed 'General case' 0 N--CA 1.41 -2.465 0 C-N-CA 116.324 -2.15 . . . . 0.0 110.554 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.512 ' HG2' ' HB3' ' A' ' 75' ' ' LYS . 15.6 tpp180 -135.87 41.71 2.67 Favored 'General case' 0 C--N 1.264 -3.119 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 66' ' ' PRO . 99.5 mttt 75.35 -153.47 0.04 OUTLIER 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.308 -177.259 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 5.0 p80 -67.26 83.22 0.14 Allowed 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.25 91.58 1.55 Allowed Glycine 0 CA--C 1.467 -2.939 0 C-N-CA 117.784 -2.151 . . . . 0.0 111.638 169.591 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.92 142.8 7.73 Favored Glycine 1 N--CA 1.392 -4.263 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -86.22 0.46 8.13 Favored 'Trans proline' 0 N--CA 1.437 -1.806 0 C-N-CA 122.794 2.329 . . . . 0.0 109.414 178.909 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.512 ' HB3' ' HG2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -84.84 28.55 0.68 Allowed 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.154 -172.111 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.514 ' HB3' ' HA ' ' A' ' 68' ' ' SER . 5.8 t0 -179.78 39.99 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 123.209 1.48 . . . . 0.0 107.988 164.247 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 68.11 8.87 6.82 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 112.332 -2.213 . . . . 0.0 114.9 169.595 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' HG23 ' A' ' 103' ' ' VAL . 4.0 tp10 63.34 37.76 10.68 Favored 'General case' 0 C--N 1.366 1.322 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 176.244 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.408 ' H ' ' HB2' ' A' ' 68' ' ' SER 0.34 50.2 mtm180 -52.84 3.12 0.01 OUTLIER 'General case' 0 N--CA 1.521 3.118 0 N-CA-C 119.202 3.038 . . . . 0.0 119.202 -164.922 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.419 4.8 m80 . . . . . 0 CA--C 1.459 -2.537 0 C-N-CA 127.036 2.134 . . . . 0.0 112.708 162.043 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.439 ' N ' HG11 ' A' ' 103' ' ' VAL . 51.4 tp . . . . . 0 N--CA 1.433 -1.279 0 CA-C-O 122.521 1.153 . . . . 0.0 113.228 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.58 ' O ' ' HA2' ' A' ' 44' ' ' GLY . . . -139.96 138.92 9.48 Favored Glycine 0 N--CA 1.413 -2.884 0 N-CA-C 107.989 -2.044 . . . . 0.0 107.989 174.15 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -109.84 129.14 55.67 Favored 'General case' 0 CA--C 1.485 -1.527 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -175.039 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.907 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.3 m -129.21 156.21 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.223 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.04 -178.387 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 p -134.26 96.37 3.59 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.542 0.687 . . . . 0.0 112.224 -175.666 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.68 156.23 17.2 Favored 'General case' 0 N--CA 1.424 -1.766 0 C-N-CA 126.847 2.059 . . . . 0.0 108.973 177.157 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.581 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 15.3 t70 -137.11 -167.93 2.19 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.676 -1.602 . . . . 0.0 106.676 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -43.14 -38.66 2.52 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 126.123 1.769 . . . . 0.0 114.399 -177.588 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -134.94 4.96 3.3 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.643 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -63.08 170.45 14.53 Favored Glycine 0 CA--C 1.474 -2.514 0 CA-C-N 112.429 -2.169 . . . . 0.0 112.999 -170.814 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.506 HG12 ' HB3' ' A' ' 36' ' ' LYS . 16.1 m -134.83 131.94 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.391 -3.407 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -165.602 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.907 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.11 89.68 5.25 Favored 'General case' 2 C--N 1.239 -4.237 0 N-CA-C 104.667 -2.346 . . . . 0.0 104.667 175.305 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 96' ' ' ASP . . . . . 0.48 ' OD2' ' HB3' ' A' ' 34' ' ' SER . 12.1 t70 -121.42 89.12 3.06 Favored 'General case' 0 CA--C 1.477 -1.848 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 -178.521 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.81 144.2 38.34 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.738 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.886 -177.659 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -105.27 102.32 11.81 Favored 'General case' 0 C--N 1.266 -3.055 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.597 HD13 ' H ' ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.48 147.39 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.476 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.613 -173.506 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.408 ' HB3' ' HG3' ' A' ' 30' ' ' LYS . 14.5 pt-20 -149.19 117.48 6.45 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.585 ' N ' ' HB3' ' A' ' 28' ' ' PRO . 20.4 t70 -165.3 159.26 17.08 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.4 m -99.92 76.85 1.98 Allowed 'General case' 0 N--CA 1.425 -1.719 0 CA-C-O 123.576 1.655 . . . . 0.0 107.568 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.439 HG11 ' N ' ' A' ' 84' ' ' LEU . 6.5 p -120.52 -16.49 6.74 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.923 0 CA-C-N 111.361 -2.654 . . . . 0.0 107.403 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 9.2 mm -81.73 2.94 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.142 0 CA-C-N 113.301 -1.772 . . . . 0.0 107.313 -176.249 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' ' HG2' ' A' ' 22' ' ' GLN . 20.2 m -65.53 109.22 2.27 Favored 'General case' 0 C--O 1.263 1.816 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.408 HD13 HD12 ' A' ' 112' ' ' ILE . 44.4 tp -68.91 88.9 0.4 Allowed 'General case' 0 N--CA 1.396 -3.16 0 CA-C-N 112.463 -2.153 . . . . 0.0 113.417 -175.173 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.3 t -138.11 85.01 2.07 Favored 'General case' 1 N--CA 1.35 -5.449 0 N-CA-C 100.61 -3.848 . . . . 0.0 100.61 157.372 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.522 ' HA2' ' ND2' ' A' ' 65' ' ' ASN . . . -121.47 -144.25 6.85 Favored Glycine 0 CA--C 1.471 -2.685 0 CA-C-N 112.822 -1.99 . . . . 0.0 109.048 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -67.52 -74.14 0.12 Allowed 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 174.62 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -125.16 -47.47 1.76 Allowed 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 175.189 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.578 ' O ' ' HG3' ' A' ' 115' ' ' ARG . 21.9 m -161.67 169.45 21.53 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.408 HD12 HD13 ' A' ' 106' ' ' LEU . 4.4 mp -82.25 -39.82 16.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.01 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.45 ' HA ' ' CA ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -73.83 125.74 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.549 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.34 -3.97 51.1 Favored Glycine 0 CA--C 1.478 -2.266 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 171.766 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.613 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . 9.3 mmt180 -101.9 159.21 15.54 Favored 'General case' 0 N--CA 1.396 -3.15 0 CA-C-N 113.153 -1.523 . . . . 0.0 107.386 -174.426 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.596 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 16.7 p -99.58 135.58 40.78 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 2.7 pt? -88.9 130.11 35.48 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 174.227 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.642 HG22 ' SG ' ' A' ' 57' ' ' CYS . 14.3 t -101.43 101.79 12.6 Favored 'Isoleucine or valine' 0 C--O 1.262 1.752 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.61 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 27.0 m -136.96 169.59 19.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 C-N-CA 123.744 0.818 . . . . 0.0 108.816 -177.367 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.454 ' O ' HD13 ' A' ' 42' ' ' LEU . 49.0 t-80 -171.65 170.13 5.76 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 171.861 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.525 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 0.8 OUTLIER -77.59 84.06 3.97 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 170.743 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.586 ' H ' ' HB3' ' A' ' 42' ' ' LEU . 58.3 mmtt -173.58 127.98 0.42 Allowed 'General case' 0 CA--C 1.464 -2.363 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -174.61 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.443 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -44.89 103.32 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.84 0 O-C-N 123.863 0.727 . . . . 0.0 109.743 168.172 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -104.22 85.66 2.41 Favored 'General case' 0 CA--C 1.458 -2.585 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 -177.737 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 8.1 t70 -121.25 133.66 55.16 Favored 'General case' 0 C--N 1.255 -3.512 0 CA-C-N 113.729 -1.578 . . . . 0.0 108.869 -172.135 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.427 HD23 ' HB3' ' A' ' 46' ' ' HIS . 2.4 mm? -89.58 -13.3 37.54 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.668 -178.474 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -96.96 -34.6 5.63 Favored Glycine 0 N--CA 1.425 -2.047 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.459 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 65.4 tttm -86.33 -49.05 7.95 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 118.894 -0.575 . . . . 0.0 110.813 178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.59 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.91 -77.86 0.0 OUTLIER Glycine 0 CA--C 1.529 0.923 0 N-CA-C 114.439 0.536 . . . . 0.0 114.439 -170.536 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 171.63 -97.44 0.12 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 108.969 -1.653 . . . . 0.0 108.969 -177.078 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -88.94 179.98 6.07 Favored 'General case' 0 CA--C 1.56 1.337 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -56.16 -32.3 64.17 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 119.347 0.976 . . . . 0.0 113.229 -178.491 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -75.74 -46.38 31.25 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.676 0.751 . . . . 0.0 109.747 176.25 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.42 ' HA ' HG22 ' A' ' 137' ' ' THR . 1.3 m -60.97 -33.93 73.98 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.352 -175.05 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.59 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 9.9 t -67.97 -35.71 78.81 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-O 120.939 0.4 . . . . 0.0 111.568 178.708 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.25 -29.12 31.46 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.172 -176.104 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.42 HG22 ' HA ' ' A' ' 134' ' ' SER . 8.8 t -86.94 -14.93 40.4 Favored 'General case' 0 N--CA 1.438 -1.046 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 177.705 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.74 60.6 6.75 Favored Glycine 0 CA--C 1.5 -0.876 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 -175.922 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -51.89 105.23 0.1 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -175.014 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -152.11 171.64 17.58 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 173.993 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -67.9 87.45 0.18 Allowed Glycine 0 C--N 1.314 -0.665 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 173.656 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 16.2 m -66.1 -10.09 37.38 Favored 'General case' 0 C--O 1.21 -1.003 0 C-N-CA 124.731 1.213 . . . . 0.0 113.624 -175.433 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 43.1 mtp-105 -116.34 -37.4 3.77 Favored 'General case' 0 C--N 1.254 -3.554 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.725 172.529 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.422 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 3.8 mm? -49.0 -38.19 22.57 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 115.481 1.66 . . . . 0.0 115.481 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -143.89 92.45 2.34 Favored 'General case' 0 N--CA 1.42 -1.947 0 CA-C-O 121.622 0.725 . . . . 0.0 111.253 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 3.9 m -140.13 153.2 46.61 Favored 'General case' 0 N--CA 1.419 -1.979 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 175.487 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.75 168.95 42.01 Favored Glycine 0 N--CA 1.406 -3.311 0 N-CA-C 107.0 -2.44 . . . . 0.0 107.0 176.482 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.481 HG22 HG23 ' A' ' 54' ' ' THR . 31.4 m -70.44 122.04 21.42 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.443 1.116 . . . . 0.0 112.385 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.402 ' HB ' HD22 ' A' ' 117' ' ' LEU . 9.0 tt -99.25 142.68 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.756 0 N-CA-C 103.704 -2.702 . . . . 0.0 103.704 175.223 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.45 ' CA ' ' HA ' ' A' ' 113' ' ' ILE . . . 177.06 154.46 12.04 Favored Glycine 2 N--CA 1.387 -4.57 0 C-N-CA 117.316 -2.373 . . . . 0.0 112.957 177.246 . . . . . . . . 3 3 . 1 . 009 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 3.8 tt -66.64 105.0 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 124.483 0.755 . . . . 0.0 109.422 172.324 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.571 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -114.21 98.3 6.86 Favored 'General case' 0 N--CA 1.414 -2.238 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 172.911 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 117.898 -1.049 . . . . 0.0 109.087 -174.258 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.443 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.221 -0.432 0 N-CA-C 111.42 0.156 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.575 ' HA ' ' HG3' ' A' ' 21' ' ' GLU . 9.2 p -82.35 -35.53 27.74 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-O 121.876 0.846 . . . . 0.0 112.463 -177.337 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.599 ' O ' HG12 ' A' ' 151' ' ' ILE . 56.9 mtmt -138.09 135.81 36.17 Favored 'General case' 0 C--N 1.277 -2.545 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.616 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -134.05 166.74 22.03 Favored 'General case' 0 C--N 1.27 -2.872 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 -176.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.3 p -145.99 118.93 2.28 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.315 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -108.65 127.16 53.73 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.328 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.4 p -119.45 129.24 75.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 O-C-N 123.786 0.679 . . . . 0.0 110.217 -178.288 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.405 HD13 ' HB1' ' A' ' 145' ' ' ALA . 75.4 mt -107.18 141.67 38.1 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.118 -177.67 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -150.79 137.83 19.21 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 174.509 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.39 -159.32 9.25 Favored Glycine 0 N--CA 1.417 -2.625 0 C-N-CA 117.571 -2.252 . . . . 0.0 115.622 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -78.06 -31.14 50.1 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 111.91 -2.145 . . . . 0.0 109.371 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.46 172.49 14.45 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 172.523 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -88.39 121.87 1.41 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 CA-C-N 121.919 2.859 . . . . 0.0 112.135 -176.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 m -135.14 118.23 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.429 0 CA-C-N 113.368 -1.742 . . . . 0.0 106.548 171.374 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.495 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -143.35 119.5 10.78 Favored 'General case' 0 C--N 1.279 -2.468 0 C-N-CA 118.128 -1.429 . . . . 0.0 109.929 178.442 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.547 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -171.2 170.87 43.62 Favored Glycine 0 N--CA 1.418 -2.552 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 178.592 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 20.0 pt -135.85 119.52 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.871 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.479 HG12 ' HA3' ' A' ' 33' ' ' GLY . 21.9 mt -114.37 135.16 55.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -176.758 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.616 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.1 m-20 -101.58 138.68 38.25 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.551 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 95.2 m-85 -132.2 120.16 21.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 123.304 0.377 . . . . 0.0 111.066 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HG3' ' HA ' ' A' ' 2' ' ' THR . 35.8 tt0 -112.17 108.24 17.42 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.785 172.955 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.538 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 8.8 tp60 -140.71 114.8 9.15 Favored 'General case' 0 N--CA 1.405 -2.69 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 172.481 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -90.63 157.37 17.52 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 178.087 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -60.95 -23.69 65.5 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.153 0.502 . . . . 0.0 110.967 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 14.8 m -63.25 -18.4 63.52 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.996 176.739 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 65.1 t30 66.96 105.98 0.04 OUTLIER 'General case' 0 C--N 1.353 0.744 0 C-N-CA 125.426 1.491 . . . . 0.0 109.204 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.513 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -146.55 -170.64 15.19 Favored Glycine 0 CA--C 1.469 -2.804 0 C-N-CA 118.415 -1.85 . . . . 0.0 115.242 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.65 124.12 15.03 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.56 2.84 . . . . 0.0 110.562 178.343 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 47.1 t -93.44 110.99 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.988 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.286 -175.254 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.42 111.24 23.89 Favored 'General case' 0 N--CA 1.422 -1.87 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.476 HG22 ' HA ' ' A' ' 20' ' ' PHE . 17.2 t -138.47 132.26 41.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.175 -170.033 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.447 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 77.8 t90 -149.25 127.64 12.22 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.479 ' HA3' HG12 ' A' ' 18' ' ' ILE . . . -159.34 140.03 6.58 Favored Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.417 -0.896 . . . . 0.0 110.915 173.796 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 49.4 m -117.4 115.4 25.14 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.288 179.31 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.547 HG22 ' HA3' ' A' ' 16' ' ' GLY . 30.8 pt -109.79 138.71 36.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 118.612 0.642 . . . . 0.0 111.104 176.355 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.759 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 16.5 ptpt -103.65 132.7 49.67 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.327 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.488 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -148.98 178.78 26.3 Favored Glycine 1 N--CA 1.391 -4.359 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -167.758 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.473 ' HG ' ' H ' ' A' ' 39' ' ' THR . 45.3 tp -65.27 176.46 1.35 Allowed 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 171.59 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.473 ' H ' ' HG ' ' A' ' 38' ' ' LEU . 15.0 t -61.99 153.72 28.64 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.351 -1.468 . . . . 0.0 111.215 -166.115 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.712 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 11.1 pt-20 -60.67 160.32 9.43 Favored 'General case' 0 CA--C 1.476 -1.891 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -163.026 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -159.29 -157.57 8.62 Favored Glycine 1 C--N 1.245 -4.487 1 N-CA-C 102.442 -4.263 . . . . 0.0 102.442 -176.906 . . . . . . . . 3 2 . 1 . 010 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.4 mt -153.72 -86.63 0.06 Allowed 'General case' 0 C--N 1.274 -2.717 0 CA-C-N 120.357 2.078 . . . . 0.0 114.74 -169.661 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.626 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.5 t-160 -76.93 122.23 24.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 -156.416 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.78 127.01 8.8 Favored Glycine 0 N--CA 1.415 -2.75 0 C-N-CA 119.876 -1.154 . . . . 0.0 114.85 -173.392 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.542 ' H ' ' HB2' ' A' ' 124' ' ' ASP . 14.9 t80 -113.31 113.03 24.7 Favored 'General case' 1 C--O 1.336 5.61 0 CA-C-O 123.41 1.576 . . . . 0.0 111.028 175.463 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.509 ' NE2' ' HG ' ' A' ' 117' ' ' LEU . 25.4 m80 -108.18 124.96 51.07 Favored 'General case' 0 N--CA 1.391 -3.38 0 CA-C-N 113.624 -1.626 . . . . 0.0 110.42 -173.708 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.4 p -174.65 87.35 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 CA-C-N 113.55 -1.659 . . . . 0.0 109.762 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.423 ' C ' ' HD2' ' A' ' 115' ' ' ARG . 7.0 m170 -112.49 170.74 7.96 Favored 'General case' 0 C--N 1.281 -2.387 0 N-CA-C 114.608 1.336 . . . . 0.0 114.608 167.125 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.588 ' HG3' ' OD1' ' A' ' 109' ' ' ASP . 36.4 tt0 -139.64 132.56 29.33 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.191 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.8 t80 76.45 26.84 0.86 Allowed 'General case' 0 C--O 1.222 -0.359 0 C-N-CA 127.349 2.26 . . . . 0.0 111.127 174.966 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.727 ' H ' ' HD3' ' A' ' 115' ' ' ARG . . . 33.67 -124.64 0.4 Allowed Glycine 0 C--N 1.36 1.916 0 CA-C-N 115.599 -0.728 . . . . 0.0 114.637 -172.542 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.2 t70 169.51 -80.71 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 125.398 1.479 . . . . 0.0 108.48 164.122 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -161.05 160.9 31.07 Favored 'General case' 0 N--CA 1.429 -1.509 0 N-CA-C 104.975 -2.231 . . . . 0.0 104.975 174.164 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.48 ' HB ' HG12 ' A' ' 148' ' ' VAL . 5.3 t -79.26 5.18 12.95 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -171.677 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.15 2.26 9.8 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 120.202 -0.599 . . . . 0.0 111.249 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 176.55 127.53 1.05 Allowed Glycine 0 C--O 1.195 -2.324 0 C-N-CA 118.582 -1.77 . . . . 0.0 111.558 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.812 ' SG ' HG21 ' A' ' 118' ' ' VAL . 16.7 p -99.72 89.23 4.04 Favored 'General case' 0 C--N 1.275 -2.633 0 O-C-N 121.869 -0.783 . . . . 0.0 112.131 177.395 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.5 m -78.85 -53.14 7.4 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.668 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.8 m -70.01 -52.99 19.67 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.498 -174.054 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' A' ' 49' ' ' GLU . . . -76.63 -9.45 58.67 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-O 118.418 -0.801 . . . . 0.0 112.975 176.877 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -36.08 -68.14 0.32 Allowed Glycine 0 N--CA 1.488 2.103 0 N-CA-C 114.864 0.705 . . . . 0.0 114.864 -173.624 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -94.09 7.59 2.42 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.328 2.686 . . . . 0.0 112.149 177.068 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 77.1 t60 -113.52 123.46 50.06 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -171.634 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.444 ' CD1' ' HA ' ' A' ' 137' ' ' THR . 27.1 p90 -97.75 170.55 8.91 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 126.722 2.009 . . . . 0.0 108.785 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.83 142.68 24.89 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.299 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.82 -53.98 2.77 Favored 'Trans proline' 0 N--CA 1.481 0.767 0 C-N-CA 123.204 2.603 . . . . 0.0 116.652 -168.19 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.828 ' O ' ' HA ' ' A' ' 78' ' ' GLU . 95.9 mt -93.0 25.97 3.0 Favored 'General case' 0 C--O 1.193 -1.913 0 O-C-N 121.786 -0.571 . . . . 0.0 111.818 -168.586 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.63 ' O ' ' HA ' ' A' ' 80' ' ' HIS . 28.6 m -144.74 30.36 1.2 Allowed 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.039 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.509 ' O ' ' HD2' ' A' ' 69' ' ' ARG . 4.1 tmm_? -126.08 -27.32 3.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 CA-C-O 117.639 -1.172 . . . . 0.0 110.638 -176.56 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 1.2 mptm? -45.32 60.34 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 119.778 3.251 . . . . 0.0 119.778 -165.097 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.405 ' N ' ' O ' ' A' ' 69' ' ' ARG . 82.8 t60 46.43 58.65 4.4 Favored 'General case' 0 CA--C 1.567 1.598 0 N-CA-C 117.292 2.33 . . . . 0.0 117.292 165.608 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.62 88.44 0.38 Allowed Glycine 0 CA--C 1.495 -1.186 0 C-N-CA 116.762 -2.637 . . . . 0.0 115.57 163.096 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.439 ' H ' ' CD2' ' A' ' 80' ' ' HIS . . . -170.13 95.38 0.11 Allowed Glycine 0 C--O 1.211 -1.334 0 C-N-CA 119.089 -1.529 . . . . 0.0 112.81 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -64.91 -40.23 21.96 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 CA-C-N 120.647 2.224 . . . . 0.0 113.583 -175.082 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.07 16.49 21.81 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 125.139 1.376 . . . . 0.0 110.153 -178.417 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -89.79 -172.02 3.39 Favored 'General case' 0 C--N 1.287 -2.126 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.747 -167.174 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.46 -3.45 1.04 Allowed 'General case' 0 N--CA 1.434 -1.268 0 O-C-N 122.22 -0.3 . . . . 0.0 111.072 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.828 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 33.1 tt0 -132.19 -34.79 1.23 Allowed 'General case' 0 N--CA 1.433 -1.315 0 CA-C-O 121.222 0.535 . . . . 0.0 110.276 -170.076 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.475 ' O ' ' HB3' ' A' ' 80' ' ' HIS . 4.5 mpt_? -93.76 -15.87 24.74 Favored 'General case' 0 CA--C 1.484 -1.571 0 C-N-CA 125.603 1.561 . . . . 0.0 107.111 -175.812 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.63 ' HA ' ' O ' ' A' ' 68' ' ' SER 0.258 5.0 p80 . . . . . 0 CA--C 1.459 -2.538 0 CA-C-N 113.185 -1.825 . . . . 0.0 110.332 159.498 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.558 HD13 ' N ' ' A' ' 85' ' ' GLY . 0.7 OUTLIER . . . . . 0 N--CA 1.468 0.441 0 N-CA-C 115.754 1.761 . . . . 0.0 115.754 . . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.558 ' N ' HD13 ' A' ' 84' ' ' LEU . . . -169.36 156.38 27.42 Favored Glycine 0 N--CA 1.425 -2.048 0 N-CA-C 104.483 -3.447 . . . . 0.0 104.483 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -112.61 153.0 28.26 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 120.158 1.979 . . . . 0.0 109.869 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 71.9 t -117.86 143.01 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.532 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.626 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 62.2 m -146.13 95.74 2.67 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.2 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -93.28 144.98 24.79 Favored 'General case' 0 CA--C 1.482 -1.666 0 CA-C-N 119.49 1.041 . . . . 0.0 113.097 -176.33 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.712 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 22.1 t70 -82.58 149.6 27.37 Favored 'General case' 0 C--N 1.278 -2.516 0 CA-C-N 113.223 -1.808 . . . . 0.0 106.83 169.134 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.537 ' N ' ' HB3' ' A' ' 40' ' ' GLU . 13.6 pttp -41.28 -19.39 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 127.69 2.396 . . . . 0.0 116.037 176.572 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -106.81 12.76 28.66 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.759 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 73.1 85.18 0.23 Allowed Glycine 0 N--CA 1.42 -2.397 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.06 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 61.3 t -157.07 103.51 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.709 -1.959 . . . . 0.0 105.709 -178.752 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -104.17 113.38 26.89 Favored 'General case' 0 C--N 1.273 -2.735 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.525 175.811 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -86.01 94.33 9.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 175.147 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 86.1 t -85.63 105.71 14.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.486 -175.514 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.2 m -152.54 116.05 4.75 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 9.4 tp -148.31 134.35 12.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 37.8 mt-10 -124.03 96.63 5.01 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.433 -175.253 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.401 ' O ' HG21 ' A' ' 29' ' ' VAL . 6.2 p-10 -168.81 166.71 11.4 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 170.902 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.5 p -60.89 91.5 0.02 OUTLIER 'General case' 0 C--O 1.245 0.851 0 CA-C-N 119.128 0.876 . . . . 0.0 113.058 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 84' ' ' LEU . 27.1 m -118.39 -14.41 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -176.67 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -119.24 25.92 4.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 O-C-N 120.7 -1.25 . . . . 0.0 109.476 -176.552 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.0 m -64.38 110.95 2.43 Favored 'General case' 0 C--O 1.268 2.059 0 CA-C-O 122.729 1.252 . . . . 0.0 109.831 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.44 86.37 1.15 Allowed 'General case' 0 N--CA 1.382 -3.87 0 CA-C-O 124.103 1.906 . . . . 0.0 110.63 176.717 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.0 m -146.56 85.75 1.65 Allowed 'General case' 2 N--CA 1.362 -4.855 0 N-CA-C 101.88 -3.378 . . . . 0.0 101.88 168.665 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.13 168.96 22.8 Favored Glycine 0 C--N 1.269 -3.142 0 CA-C-N 113.373 -1.74 . . . . 0.0 111.014 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.588 ' OD1' ' HG3' ' A' ' 49' ' ' GLU . 7.0 t70 -56.92 -34.89 68.41 Favored 'General case' 0 C--O 1.202 -1.43 0 CA-C-N 117.292 0.546 . . . . 0.0 110.916 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.739 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 7.9 p-80 -54.28 -17.01 2.49 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 125.385 1.474 . . . . 0.0 113.023 -178.002 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.449 ' O ' ' HD2' ' A' ' 110' ' ' HIS . 23.0 t 37.47 -154.49 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 126.164 1.786 . . . . 0.0 110.297 -173.025 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.608 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 14.2 tt -100.32 -32.97 3.63 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.876 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 166.133 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.8 pt -104.02 145.93 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -178.773 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.71 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 95.83 -7.04 67.52 Favored Glycine 1 CA--C 1.45 -4.008 0 C-N-CA 121.234 -0.508 . . . . 0.0 112.272 162.211 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.739 ' NE ' ' HA ' ' A' ' 110' ' ' HIS . 0.3 OUTLIER -92.61 151.44 20.12 Favored 'General case' 0 C--O 1.162 -3.54 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.688 -174.146 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.555 ' H ' ' HA2' ' A' ' 51' ' ' GLY . 7.6 p -91.86 113.09 25.27 Favored 'General case' 0 N--CA 1.408 -2.531 0 O-C-N 121.537 -0.727 . . . . 0.0 109.397 173.57 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.509 ' HG ' ' NE2' ' A' ' 46' ' ' HIS . 22.5 tp -70.09 93.5 0.81 Allowed 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 -177.456 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.812 HG21 ' SG ' ' A' ' 57' ' ' CYS 0.528 60.2 t -105.1 109.22 27.0 Favored 'Isoleucine or valine' 1 C--O 1.341 5.884 0 N-CA-C 120.708 3.596 . . . . 0.0 120.708 -172.217 . . . . . . . . 4 3 . 1 . 010 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.674 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.3 p -148.47 171.25 2.43 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.155 0 CA-C-N 110.397 -3.092 . . . . 0.0 106.469 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 71.6 t60 -150.37 171.28 17.25 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.88 -2.267 . . . . 0.0 104.88 168.198 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.526 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.0 OUTLIER -69.42 85.94 0.43 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 171.449 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -173.01 171.78 4.11 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.652 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -99.09 107.58 20.0 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 118.299 0.499 . . . . 0.0 110.243 173.448 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.542 ' HB2' ' H ' ' A' ' 45' ' ' PHE . 1.1 m-20 -71.33 -59.16 2.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 172.522 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.0 t70 67.76 141.34 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 128.024 2.529 . . . . 0.0 114.097 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.587 ' HG ' ' CD2' ' A' ' 80' ' ' HIS . 0.0 OUTLIER -90.26 -31.99 16.74 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-N 114.89 -1.05 . . . . 0.0 113.624 -176.563 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.01 -33.98 5.84 Favored Glycine 0 N--CA 1.427 -1.904 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -105.13 50.32 0.79 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.178 -1.011 . . . . 0.0 108.873 -179.019 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.36 -6.83 81.51 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.53 -93.17 0.25 Allowed Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 121.653 -0.308 . . . . 0.0 112.406 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.557 ' H ' ' HB2' ' A' ' 134' ' ' SER . 79.3 m-20 -121.86 -173.39 2.64 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -174.045 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -57.71 -39.32 76.96 Favored 'General case' 0 C--N 1.361 1.102 0 C-N-CA 118.65 -1.22 . . . . 0.0 109.994 176.366 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.547 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 5.9 tp10 -76.05 -53.86 7.72 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.051 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.557 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 2.4 m -62.06 -26.25 68.16 Favored 'General case' 0 CA--C 1.552 1.021 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -175.617 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 35.8 m -79.72 -18.14 51.91 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 121.852 -0.53 . . . . 0.0 110.653 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.547 ' HG3' ' O ' ' A' ' 133' ' ' GLU . 0.0 OUTLIER -85.64 -31.27 22.65 Favored 'General case' 0 C--O 1.211 -0.942 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.535 179.227 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.444 ' HA ' ' CD1' ' A' ' 64' ' ' PHE . 8.8 p -70.95 -16.01 62.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 120.916 0.389 . . . . 0.0 109.962 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.56 81.64 0.11 Allowed Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 139' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 124' ' ' ASP . 23.3 t-20 -33.07 132.05 0.16 Allowed 'General case' 0 C--O 1.291 3.263 0 CA-C-O 123.451 1.596 . . . . 0.0 114.202 -172.306 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.419 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -150.89 130.51 13.07 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 113.845 -1.525 . . . . 0.0 109.711 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.12 91.03 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.072 -2.011 . . . . 0.0 108.072 170.935 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.9 m -49.18 -18.41 0.33 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.789 2.035 . . . . 0.0 116.384 -168.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -144.59 6.51 1.25 Allowed 'General case' 0 C--N 1.269 -2.92 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.998 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.56 -22.73 58.84 Favored 'General case' 0 C--N 1.294 -1.845 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.509 -173.478 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.9 100.3 0.17 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 175.487 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.9 m -123.42 133.05 54.12 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -160.28 146.28 12.37 Favored Glycine 0 N--CA 1.404 -3.499 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 178.03 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 8.8 p -69.19 113.98 5.6 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-O 122.128 0.966 . . . . 0.0 111.953 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.472 HD12 HD13 ' A' ' 117' ' ' LEU . 2.5 tt -82.93 129.65 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.085 0 N-CA-C 105.067 -2.197 . . . . 0.0 105.067 170.283 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.608 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 177.67 156.99 17.58 Favored Glycine 2 N--CA 1.365 -6.074 0 C-N-CA 118.427 -1.844 . . . . 0.0 111.297 176.772 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.599 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.16 105.32 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 169.536 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.16 113.34 16.91 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 . . . . . 0 C--N 1.283 -2.315 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -175.595 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.432 ' HA ' HE22 ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.0 0.428 . . . . 0.0 111.461 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 m -79.89 -28.99 39.84 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.14 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.652 ' HG3' ' O ' ' A' ' 152' ' ' ALA . 19.9 ptpt -151.74 170.87 18.69 Favored 'General case' 0 C--O 1.253 1.241 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.731 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.42 154.56 45.67 Favored 'General case' 0 N--CA 1.434 -1.265 0 O-C-N 124.099 0.875 . . . . 0.0 109.038 177.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.19 122.22 62.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.512 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -131.4 133.14 44.94 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.18 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.6 t -134.75 113.31 16.29 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.428 ' HB2' ' O ' ' A' ' 14' ' ' VAL . 3.1 mm? -90.83 131.03 36.72 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.409 0.683 . . . . 0.0 111.418 -176.949 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.1 mtpt -147.34 126.79 13.18 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 175.008 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.72 -158.53 8.84 Favored Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.58 -0.819 . . . . 0.0 111.754 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -63.09 -40.39 97.52 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.91 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -116.11 82.63 0.32 Allowed Glycine 0 N--CA 1.433 -1.513 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 172.626 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.64 127.0 11.95 Favored 'Trans proline' 0 N--CA 1.446 -1.296 0 C-N-CA 122.127 1.884 . . . . 0.0 113.901 -171.739 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.428 ' O ' ' HB2' ' A' ' 8' ' ' LEU . 16.5 m -111.92 117.08 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.858 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 175.181 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -99.13 118.31 35.57 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.639 -172.493 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.0 170.81 43.53 Favored Glycine 0 N--CA 1.407 -3.247 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.858 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 25.7 pt -131.38 129.24 62.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.142 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 mm -115.12 136.01 53.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.507 ' O ' HG13 ' A' ' 31' ' ' VAL . 2.9 m-20 -114.24 129.63 56.63 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.478 -177.583 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.731 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 53.9 m-85 -125.19 137.49 54.13 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.097 0.475 . . . . 0.0 111.684 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -116.23 106.37 13.61 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.368 177.923 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.432 HE22 ' HA ' ' A' ' 1' ' ' ALA . 2.8 pm0 -86.25 123.34 31.41 Favored 'General case' 0 N--CA 1.403 -2.816 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 171.549 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 104' ' ' ILE . 37.1 ttmt -137.55 103.16 4.97 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -170.112 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.26 -9.83 13.29 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 m -71.91 -23.71 61.52 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 122.877 0.471 . . . . 0.0 110.35 176.385 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.556 ' HA ' HG13 ' A' ' 104' ' ' ILE . 45.4 t-20 72.57 135.54 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 C-N-CA 125.335 1.454 . . . . 0.0 111.034 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.52 175.33 36.67 Favored Glycine 0 CA--C 1.485 -1.785 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.619 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -65.1 123.48 11.62 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.302 2.001 . . . . 0.0 108.397 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HB ' HG23 ' A' ' 31' ' ' VAL . 23.7 m -76.99 142.75 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.277 0 CA-C-O 121.682 0.753 . . . . 0.0 111.632 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -106.28 97.07 6.92 Favored 'General case' 0 C--N 1.277 -2.544 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 173.702 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.507 HG13 ' O ' ' A' ' 19' ' ' ASN . 47.6 t -129.59 129.87 66.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 125.892 1.677 . . . . 0.0 107.861 -171.846 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -140.74 137.24 33.28 Favored 'General case' 0 C--N 1.286 -2.192 0 O-C-N 123.375 0.422 . . . . 0.0 110.186 177.93 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -159.59 137.9 5.34 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 170.191 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.47 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 44.3 t -118.63 127.74 53.88 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.44 HG22 ' HA3' ' A' ' 16' ' ' GLY . 33.5 pt -120.02 129.0 75.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 119.788 1.177 . . . . 0.0 110.381 174.611 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 88.1 tttt -96.67 123.56 40.39 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 178.861 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.759 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -136.48 176.29 20.44 Favored Glycine 0 C--N 1.274 -2.9 0 CA-C-N 114.502 -1.226 . . . . 0.0 110.383 -171.057 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -69.43 171.28 8.95 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 171.265 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -68.47 112.43 5.29 Favored 'General case' 0 C--O 1.22 -0.48 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 175.441 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.596 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 5.1 tp10 -128.86 178.91 6.03 Favored 'General case' 0 C--N 1.259 -3.339 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.804 -165.656 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.418 ' H ' ' HG3' ' A' ' 40' ' ' GLU . . . -59.44 -146.93 0.01 OUTLIER Glycine 0 CA--C 1.553 2.449 0 C-N-CA 124.633 1.111 . . . . 0.0 114.472 176.857 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 3.0 pp -164.66 14.47 0.05 OUTLIER 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -164.486 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.2 t60 -143.91 153.66 42.53 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 106.757 -1.572 . . . . 0.0 106.757 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . 163.02 -169.25 38.13 Favored Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 119.899 -1.143 . . . . 0.0 112.156 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.575 ' HA ' ' O ' ' A' ' 85' ' ' GLY . 24.1 p90 -166.6 162.65 16.67 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.908 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.613 ' H ' ' HA ' ' A' ' 84' ' ' LEU . 1.0 OUTLIER -91.12 164.32 13.97 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -171.005 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.476 HG13 ' HD2' ' A' ' 64' ' ' PHE . 52.9 t -165.82 88.59 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.616 0 C-N-CA 123.81 0.844 . . . . 0.0 111.4 -174.346 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.559 ' HB2' ' HB3' ' A' ' 115' ' ' ARG . 31.0 p-80 -109.61 100.82 9.81 Favored 'General case' 0 CA--C 1.598 2.796 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 166.633 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' N ' ' HD2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -122.71 122.67 39.32 Favored 'General case' 0 CA--C 1.575 1.932 0 O-C-N 120.374 -1.454 . . . . 0.0 111.338 173.844 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' C ' ' HG2' ' A' ' 115' ' ' ARG . 61.2 t80 75.36 93.71 0.07 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 126.982 2.113 . . . . 0.0 110.961 176.277 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.651 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -55.02 134.1 48.21 Favored Glycine 0 CA--C 1.482 -1.985 0 N-CA-C 116.851 1.5 . . . . 0.0 116.851 -171.719 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -141.42 -87.09 0.17 Allowed 'General case' 0 CA--C 1.488 -1.439 0 C-N-CA 117.951 -1.5 . . . . 0.0 114.326 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -118.65 139.0 52.22 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.856 -169.716 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.539 ' HA ' HG23 ' A' ' 148' ' ' VAL . 10.0 t -43.58 -39.76 3.66 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 126.674 1.99 . . . . 0.0 115.385 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -134.31 15.43 3.78 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.426 0.631 . . . . 0.0 110.33 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -127.4 111.14 1.29 Allowed Glycine 0 N--CA 1.436 -1.312 0 C-N-CA 119.922 -1.132 . . . . 0.0 111.818 -177.198 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.566 ' SG ' ' HB ' ' A' ' 118' ' ' VAL . 10.1 p -97.88 88.3 4.24 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.8 p -78.25 -61.85 1.87 Allowed 'General case' 0 N--CA 1.419 -1.99 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.277 176.246 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.3 m -68.15 -27.95 66.88 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.862 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.47 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -78.7 -9.27 59.35 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.059 0.457 . . . . 0.0 111.115 177.551 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.3 -64.66 3.95 Favored Glycine 0 N--CA 1.436 -1.358 0 CA-C-N 115.096 -0.957 . . . . 0.0 113.021 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.78 53.13 2.71 Favored 'Trans proline' 0 CA--C 1.552 1.403 0 C-N-CA 122.359 2.039 . . . . 0.0 114.247 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 72.83 163.59 0.27 Allowed 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 124.831 1.252 . . . . 0.0 111.439 169.499 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.476 ' HD2' HG13 ' A' ' 47' ' ' VAL . 1.5 t80 -92.79 170.81 9.41 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.651 ' OD1' ' HD2' ' A' ' 66' ' ' PRO . 61.6 t30 -69.86 140.57 88.98 Favored Pre-proline 0 CA--C 1.562 1.42 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.091 -179.603 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.651 ' HD2' ' OD1' ' A' ' 65' ' ' ASN . 72.8 Cg_endo -76.84 -8.4 17.9 Favored 'Trans proline' 0 N--CA 1.443 -1.483 1 C-N-CA 125.314 4.01 . . . . 0.0 113.954 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -84.11 16.59 2.85 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 123.966 1.841 . . . . 0.0 109.611 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.653 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.0 p -80.43 -86.3 0.08 Allowed 'General case' 1 N--CA 1.356 -5.15 0 CA-C-N 113.362 -1.745 . . . . 0.0 108.321 175.152 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.651 ' HB2' ' HA ' ' A' ' 78' ' ' GLU . 41.8 ttt180 -135.84 10.36 3.36 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 167.624 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 82.5 tttt 75.14 -9.18 1.43 Allowed 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.371 1.469 . . . . 0.0 113.19 173.27 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 -99.35 -54.42 2.96 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 119.941 -0.703 . . . . 0.0 112.392 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.41 ' HA2' ' HG2' ' A' ' 78' ' ' GLU . . . 88.98 30.45 14.55 Favored Glycine 0 N--CA 1.474 1.174 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.229 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.444 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -70.58 143.54 37.15 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.499 -0.858 . . . . 0.0 114.734 -175.128 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 7.7 Cg_exo -76.84 -9.31 18.2 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 124.155 3.237 . . . . 0.0 111.58 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -79.84 9.8 4.86 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.741 -178.086 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB2' ' HB3' ' A' ' 101' ' ' ASP . 6.1 m-20 63.05 78.6 0.29 Allowed 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 124.909 1.283 . . . . 0.0 111.094 176.268 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -137.54 -56.13 0.69 Allowed 'General case' 0 CA--C 1.5 -0.969 0 O-C-N 121.668 -0.645 . . . . 0.0 112.683 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.651 ' HA ' ' HB2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -64.2 154.24 35.47 Favored 'General case' 0 N--CA 1.403 -2.776 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.276 -172.224 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.653 ' O ' ' HA ' ' A' ' 68' ' ' SER . 75.9 ttt180 -119.14 72.2 0.89 Allowed 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -170.84 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.336 2.3 m-70 . . . . . 0 N--CA 1.501 2.119 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 164.896 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.613 ' HA ' ' H ' ' A' ' 46' ' ' HIS . 2.5 pp . . . . . 0 N--CA 1.4 -2.959 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 45' ' ' PHE . . . 176.55 168.89 37.25 Favored Glycine 2 C--N 1.247 -4.379 0 N-CA-C 103.715 -3.754 . . . . 0.0 103.715 175.538 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.424 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 58.5 t30 -80.36 140.63 35.98 Favored 'General case' 0 C--N 1.271 -2.84 0 CA-C-N 119.501 1.65 . . . . 0.0 107.324 174.947 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.455 HG12 ' HG3' ' A' ' 121' ' ' GLU . 43.4 t -115.31 128.06 72.65 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.118 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 -177.524 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 62.3 m -142.19 96.54 2.97 Favored 'General case' 0 N--CA 1.413 -2.279 0 CA-C-O 118.685 -0.674 . . . . 0.0 111.405 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.585 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -126.77 104.38 8.03 Favored 'General case' 0 C--O 1.195 -1.774 0 C-N-CA 116.459 -2.096 . . . . 0.0 108.131 169.704 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' A' ' 40' ' ' GLU . 5.3 p-10 -127.9 -18.65 4.19 Favored 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.626 -171.348 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.463 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 3.1 mptp? -71.73 -58.04 3.83 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.795 0.807 . . . . 0.0 109.072 -175.728 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -164.71 26.51 0.06 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.892 -175.849 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.759 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 77.46 78.95 0.74 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 114.532 -1.213 . . . . 0.0 115.338 -178.14 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.453 ' H ' ' HB1' ' A' ' 89' ' ' ALA . 98.7 t -159.77 105.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 177.072 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.419 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -107.71 122.68 47.22 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -93.21 112.86 24.93 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 124.117 0.886 . . . . 0.0 109.76 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.6 t -113.94 105.64 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-O 121.147 0.499 . . . . 0.0 109.806 178.204 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 50.5 m -143.52 111.63 6.19 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 174.291 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.438 HD12 HG21 ' A' ' 103' ' ' VAL . 25.1 pt -123.22 154.69 29.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.27 -173.527 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -148.96 99.42 2.97 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.884 0.85 . . . . 0.0 111.256 173.839 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 76' ' ' ASP . 5.6 t70 -167.58 171.98 9.82 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.6 m -59.24 87.77 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 122.743 1.259 . . . . 0.0 112.286 -178.081 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.438 HG21 HD12 ' A' ' 99' ' ' ILE . 59.3 t -113.21 -10.46 12.11 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 112.733 -2.03 . . . . 0.0 106.763 175.453 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.556 HG13 ' HA ' ' A' ' 26' ' ' ASN . 0.2 OUTLIER -52.84 -13.71 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 C-N-CA 125.111 1.364 . . . . 0.0 114.067 -176.72 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.2 m -73.27 152.16 41.09 Favored 'General case' 0 N--CA 1.418 -2.038 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 172.748 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.562 ' HB2' HG12 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -65.9 121.78 15.85 Favored 'General case' 0 N--CA 1.403 -2.82 0 CA-C-O 122.01 0.91 . . . . 0.0 109.697 -177.559 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.9 m -69.86 88.07 0.55 Allowed 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 113.216 -1.811 . . . . 0.0 110.677 -174.345 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.472 ' HA2' ' CZ ' ' A' ' 64' ' ' PHE . . . 143.62 136.62 3.15 Favored Glycine 0 N--CA 1.409 -3.108 0 CA-C-N 114.287 -1.324 . . . . 0.0 112.296 175.313 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -66.38 -56.77 9.46 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.851 169.193 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -104.24 -47.09 4.24 Favored 'General case' 0 N--CA 1.435 -1.209 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.007 -173.551 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.443 ' CB ' ' H ' ' A' ' 51' ' ' GLY . 18.8 m -127.42 113.91 16.82 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 118.944 -1.103 . . . . 0.0 112.594 -177.3 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.562 HG12 ' HB2' ' A' ' 106' ' ' LEU . 2.9 mp -89.71 -38.29 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 173.349 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.434 HD12 ' HB ' ' A' ' 112' ' ' ILE . 4.1 mp -102.01 145.07 12.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.83 -12.8 62.67 Favored Glycine 0 CA--C 1.495 -1.162 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 174.825 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.673 ' HD3' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -91.93 134.71 34.54 Favored 'General case' 0 N--CA 1.396 -3.147 0 CA-C-O 122.224 1.011 . . . . 0.0 112.967 -175.544 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.673 ' N ' ' HD3' ' A' ' 115' ' ' ARG 0.253 0.2 OUTLIER -89.0 116.74 27.52 Favored 'General case' 0 N--CA 1.394 -3.264 0 C-N-CA 126.563 1.945 . . . . 0.0 107.45 -176.188 . . . . . . . . 4 4 . 1 . 011 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 147' ' ' GLY . 2.7 pt? -79.17 144.52 34.37 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.494 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.566 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 10.7 p -109.7 111.14 34.85 Favored 'Isoleucine or valine' 0 C--O 1.273 2.314 0 C-N-CA 119.134 -1.027 . . . . 0.0 112.845 177.368 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 46' ' ' HIS . 24.7 m -147.81 146.48 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 C-N-CA 125.805 1.642 . . . . 0.0 110.017 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -170.08 148.65 3.42 Favored 'General case' 0 C--N 1.283 -2.326 0 N-CA-C 102.601 -3.111 . . . . 0.0 102.601 167.929 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.596 ' O ' ' HG3' ' A' ' 40' ' ' GLU . 1.3 mp0 -69.55 89.72 0.53 Allowed 'General case' 0 C--N 1.261 -3.276 0 CA-C-O 123.355 1.55 . . . . 0.0 113.182 -171.225 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -165.28 144.53 6.6 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 102.698 -3.075 . . . . 0.0 102.698 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.27 101.71 0.25 Allowed 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -173.765 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.52 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 12.0 t70 -87.89 93.95 9.62 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 99.585 -4.228 . . . . 0.0 99.585 171.747 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -103.28 139.81 38.23 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.839 -0.745 . . . . 0.0 111.118 -170.335 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.527 ' HG ' ' H ' ' A' ' 127' ' ' GLY . 1.9 pt? -51.23 -74.28 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 121.703 3.964 . . . . 0.0 121.703 -162.248 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 127' ' ' GLY . . . . . 0.527 ' H ' ' HG ' ' A' ' 126' ' ' LEU . . . -69.97 -59.89 5.23 Favored Glycine 0 CA--C 1.47 -2.727 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.829 -170.781 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.508 ' HD2' ' C ' ' A' ' 127' ' ' GLY . 4.4 mptp? -136.8 35.88 2.63 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.073 -174.729 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.493 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 59.5 -34.06 0.03 OUTLIER Glycine 0 CA--C 1.559 2.809 0 CA-C-N 119.76 1.164 . . . . 0.0 115.634 -175.29 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 130' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 128' ' ' LYS . . . 147.38 -24.32 1.54 Allowed Glycine 0 N--CA 1.401 -3.643 0 O-C-N 122.145 -0.62 . . . . 0.0 111.905 179.528 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.661 ' N ' ' HB2' ' A' ' 134' ' ' SER . 61.0 t30 -169.61 179.78 3.65 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 118.519 -1.272 . . . . 0.0 108.042 -174.862 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.466 ' O ' HG22 ' A' ' 135' ' ' THR . 0.0 OUTLIER -62.6 -40.72 97.82 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.07 -1.452 . . . . 0.0 113.378 -175.136 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -85.36 -30.84 23.33 Favored 'General case' 0 C--N 1.319 -0.749 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.171 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.661 ' HB2' ' N ' ' A' ' 131' ' ' ASN . 15.0 m -63.68 -19.68 65.1 Favored 'General case' 0 C--O 1.186 -2.284 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.493 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.3 t -71.96 -35.4 69.54 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 175.866 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -73.89 -48.84 28.06 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.58 -175.835 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 134' ' ' SER . 14.8 t -86.06 -23.66 26.65 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 114.418 -1.265 . . . . 0.0 112.816 -176.485 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -68.22 -66.7 2.21 Favored Glycine 0 CA--C 1.478 -2.277 0 CA-C-O 119.584 -0.565 . . . . 0.0 111.73 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 58.8 t30 -50.75 132.53 26.32 Favored 'General case' 0 N--CA 1.518 2.945 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 171.343 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.63 160.27 25.81 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 114.392 1.256 . . . . 0.0 114.392 -162.817 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.87 118.46 13.08 Favored Glycine 0 CA--C 1.49 -1.508 0 CA-C-N 113.655 -1.611 . . . . 0.0 113.046 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.553 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 8.4 m -71.43 3.43 3.81 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 124.607 1.163 . . . . 0.0 113.189 -173.137 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.9 mtt180 -132.16 -4.76 3.47 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 176.557 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.93 -40.35 32.24 Favored 'General case' 0 CA--C 1.498 -1.02 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.111 -173.407 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.15 108.53 0.98 Allowed 'General case' 0 N--CA 1.428 -1.569 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.444 ' HB3' HG22 ' A' ' 116' ' ' THR . 7.8 m -137.43 156.78 47.78 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 177.873 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -161.1 135.0 3.76 Favored Glycine 0 C--N 1.296 -1.686 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 176.905 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.539 HG23 ' HA ' ' A' ' 54' ' ' THR . 40.2 t -65.79 121.67 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.535 0 CA-C-O 122.36 1.076 . . . . 0.0 110.952 176.934 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.8 tt -113.27 141.47 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.098 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.513 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.01 148.13 15.69 Favored Glycine 3 N--CA 1.383 -4.873 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.517 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.1 pt -69.94 103.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 CA-C-O 121.373 0.606 . . . . 0.0 110.699 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.652 ' O ' ' HG3' ' A' ' 3' ' ' LYS . . . -118.5 139.12 51.93 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 175.842 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 . . . . . 0 C--N 1.31 -1.126 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.644 -175.035 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 120.805 0.336 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 m -92.07 -46.94 7.53 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 120.739 0.304 . . . . 0.0 110.887 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.448 ' HA ' ' OD1' ' A' ' 19' ' ' ASN . 19.0 ptpt -154.25 166.48 33.01 Favored 'General case' 0 N--CA 1.433 -1.32 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.519 -176.62 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.666 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -146.26 153.36 40.5 Favored 'General case' 0 N--CA 1.424 -1.772 0 O-C-N 124.308 1.005 . . . . 0.0 108.336 176.377 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.25 114.23 14.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -113.51 128.1 56.32 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.697 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -122.53 120.44 60.98 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 121.391 0.615 . . . . 0.0 110.568 178.712 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -108.32 149.16 29.03 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.397 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -171.07 127.06 0.7 Allowed 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.35 -156.53 7.45 Favored Glycine 0 N--CA 1.429 -1.824 0 C-N-CA 120.175 -1.012 . . . . 0.0 112.179 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.46 -39.08 60.69 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.63 1.172 . . . . 0.0 111.347 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -107.32 161.97 13.53 Favored Glycine 0 N--CA 1.436 -1.326 0 N-CA-C 108.009 -2.036 . . . . 0.0 108.009 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -84.32 123.58 3.05 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 CA-C-N 120.491 2.145 . . . . 0.0 111.254 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.3 t -132.98 127.41 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 N-CA-C 103.599 -2.741 . . . . 0.0 103.599 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -142.06 116.58 9.66 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.89 170.3 43.09 Favored Glycine 0 N--CA 1.396 -3.985 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -177.04 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 24.9 pt -142.6 144.0 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.979 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 179.363 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.2 tp -139.13 136.18 42.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 177.488 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.666 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.3 t-20 -97.96 147.72 24.2 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.533 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 61.7 m-85 -138.09 119.33 14.62 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 119.182 0.901 . . . . 0.0 110.734 173.278 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -112.88 101.89 9.93 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.875 0.845 . . . . 0.0 111.191 174.556 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pm0 -91.06 150.32 21.47 Favored 'General case' 0 N--CA 1.404 -2.729 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.783 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.545 ' HB3' HG21 ' A' ' 103' ' ' VAL . 40.9 tptt -138.38 154.17 48.93 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 -175.68 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.5 mp0 -62.68 -55.31 27.98 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 123.937 0.773 . . . . 0.0 113.053 -174.534 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.3 m -78.24 -71.79 0.41 Allowed 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -168.786 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.0 p30 177.89 140.67 0.09 Allowed 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -175.884 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.422 ' N ' HG22 ' A' ' 103' ' ' VAL . . . 165.8 174.58 35.45 Favored Glycine 0 CA--C 1.48 -2.11 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.84 178.973 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -90.6 131.7 1.65 Allowed 'Trans proline' 0 N--CA 1.43 -2.226 0 C-N-CA 123.062 2.508 . . . . 0.0 110.854 175.763 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.33 101.82 2.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 176.361 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.263 0.9 OUTLIER -92.07 92.79 8.43 Favored 'General case' 0 CA--C 1.482 -1.64 0 CA-C-O 122.735 1.255 . . . . 0.0 111.824 177.266 . . . . . . . . 4 4 . 1 . 012 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.498 HG11 ' HA ' ' A' ' 20' ' ' PHE . 17.7 m -127.82 153.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.308 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.69 -175.214 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.51 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 31.0 m-90 -126.59 148.0 49.82 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.63 -172.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -166.17 140.11 6.16 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.218 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.8 m -117.16 146.56 43.12 Favored 'General case' 0 N--CA 1.389 -3.521 0 N-CA-C 105.949 -1.871 . . . . 0.0 105.949 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.725 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 17.0 tt -139.55 155.46 25.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 31.7 mmmt -136.33 131.31 34.14 Favored 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 105.501 -2.037 . . . . 0.0 105.501 -176.533 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -164.52 174.72 40.57 Favored Glycine 0 C--N 1.281 -2.505 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -173.472 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.3 mt -66.71 145.05 55.97 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.102 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.433 HG22 ' CA ' ' A' ' 92' ' ' ASP . 65.5 p -69.54 106.73 3.11 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -164.587 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -175.47 161.96 2.77 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 103.765 -2.68 . . . . 0.0 103.765 178.62 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.463 ' HA2' ' C ' ' A' ' 121' ' ' GLU . . . 158.86 137.09 2.17 Favored Glycine 1 CA--C 1.444 -4.364 0 C-N-CA 117.33 -2.367 . . . . 0.0 112.773 167.521 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.506 ' O ' ' HB2' ' A' ' 43' ' ' HIS . 0.5 OUTLIER 177.69 63.0 0.01 OUTLIER 'General case' 0 N--CA 1.447 -0.602 0 O-C-N 124.419 0.717 . . . . 0.0 110.243 -175.193 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.506 ' HB2' ' O ' ' A' ' 42' ' ' LEU . 35.9 t60 164.95 123.26 0.01 OUTLIER 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 172.677 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.629 ' HA2' ' N ' ' A' ' 87' ' ' VAL . . . -47.66 -134.73 0.0 OUTLIER Glycine 0 N--CA 1.486 1.995 0 N-CA-C 119.798 2.679 . . . . 0.0 119.798 -172.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.481 ' CD1' ' HA3' ' A' ' 85' ' ' GLY . 13.3 m-85 -88.88 162.3 16.21 Favored 'General case' 0 CA--C 1.471 -2.07 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 177.676 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.17 84.64 0.11 Allowed 'General case' 1 C--O 1.337 5.682 0 C-N-CA 120.212 -0.595 . . . . 0.0 112.266 -175.732 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.677 ' HB ' ' OE2' ' A' ' 49' ' ' GLU . 10.2 m -89.34 173.19 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 130.568 3.547 . . . . 0.0 114.323 -164.951 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.512 ' NE2' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -170.8 86.43 0.1 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.427 1.491 . . . . 0.0 108.195 174.422 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.677 ' OE2' ' HB ' ' A' ' 47' ' ' VAL . 3.0 mp0 -87.31 89.46 8.0 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 115.153 1.538 . . . . 0.0 115.153 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -118.21 -21.52 8.14 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 113.743 -1.571 . . . . 0.0 112.193 -177.827 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.57 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 92.32 110.94 1.86 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.847 -172.643 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.415 ' OD2' ' HA ' ' A' ' 57' ' ' CYS . 9.9 t0 -153.32 -171.24 3.85 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.351 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -73.97 135.77 43.19 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 177.599 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.438 ' HB ' HG13 ' A' ' 148' ' ' VAL . 9.4 t -67.41 5.27 0.8 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -173.828 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.75 5.82 8.13 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.993 -0.442 . . . . 0.0 110.591 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 173.86 136.45 2.21 Favored Glycine 0 CA--C 1.484 -1.862 0 C-N-CA 117.58 -2.248 . . . . 0.0 112.542 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 143' ' ' ARG . 53.7 m -96.84 87.87 4.42 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.496 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 p -83.29 -37.12 23.88 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-O 122.159 0.981 . . . . 0.0 111.61 172.023 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.0 m -90.03 -40.17 12.48 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.802 -170.384 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.76 -16.09 35.18 Favored 'General case' 0 N--CA 1.422 -1.869 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 57' ' ' CYS . . . 37.29 -144.81 0.13 Allowed Glycine 0 CA--C 1.488 -1.628 0 CA-C-N 111.786 -2.461 . . . . 0.0 116.387 171.721 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -82.71 87.35 1.37 Allowed 'Trans proline' 0 N--CA 1.403 -3.827 0 C-N-CA 122.144 1.896 . . . . 0.0 110.189 177.03 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.427 ' HB2' ' HA3' ' A' ' 138' ' ' GLY . 10.9 t-80 77.61 110.46 0.07 Allowed 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 114.298 -1.319 . . . . 0.0 114.479 170.248 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -170.48 91.78 0.18 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.737 -2.029 . . . . 0.0 105.538 173.031 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 3.0 t30 -111.49 89.92 11.42 Favored Pre-proline 0 C--O 1.209 -1.035 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 -178.547 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -77.48 -11.32 17.27 Favored 'Trans proline' 0 C--N 1.323 -0.804 0 C-N-CA 122.786 2.324 . . . . 0.0 111.259 -173.412 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.427 ' HB3' HD22 ' A' ' 65' ' ' ASN . 4.5 tt -45.04 -62.18 1.34 Allowed 'General case' 0 CA--C 1.492 -1.262 0 O-C-N 125.254 1.596 . . . . 0.0 109.943 -175.195 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.689 ' OG ' ' HA ' ' A' ' 76' ' ' ASP . 19.8 m -106.04 -86.26 0.48 Allowed 'General case' 0 N--CA 1.389 -3.483 0 C-N-CA 117.546 -1.662 . . . . 0.0 111.538 176.109 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.406 ' HD2' ' OE2' ' A' ' 78' ' ' GLU 0.392 21.8 ttm180 -123.99 43.48 2.98 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 114.593 -2.843 . . . . 0.0 116.169 179.405 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 53.0 mtmt 75.27 -43.04 0.49 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 125.09 1.356 . . . . 0.0 113.688 173.45 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -70.21 -37.44 75.06 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.614 ' HA3' ' O ' ' A' ' 80' ' ' HIS . . . 171.55 171.63 36.84 Favored Glycine 0 C--O 1.266 2.152 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.732 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.69 77.14 0.1 Allowed Glycine 0 C--O 1.215 -1.046 0 CA-C-O 118.925 -0.931 . . . . 0.0 113.377 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 77' ' ' GLU . 42.8 Cg_endo -64.79 -42.95 13.64 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.531 2.154 . . . . 0.0 115.653 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.579 ' O ' HG13 ' A' ' 104' ' ' ILE . 58.4 pttt -119.7 26.01 9.63 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.59 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.689 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 33.6 t70 61.76 85.06 0.13 Allowed 'General case' 0 CA--C 1.487 -1.472 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 -163.921 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.596 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 6.2 tp10 -121.95 -35.58 3.15 Favored 'General case' 0 C--O 1.169 -3.142 0 CA-C-N 113.803 -1.544 . . . . 0.0 113.984 -164.961 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.596 ' HB3' ' O ' ' A' ' 77' ' ' GLU . 12.6 tt0 76.73 112.33 0.07 Allowed 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -162.008 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 75.1 -174.93 0.13 Allowed 'General case' 0 C--O 1.25 1.114 0 CA-C-N 114.537 -1.21 . . . . 0.0 109.9 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.614 ' O ' ' HA3' ' A' ' 72' ' ' GLY . 61.7 t-80 . . . . . 0 N--CA 1.488 1.432 0 C-N-CA 125.693 1.597 . . . . 0.0 107.202 -178.388 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.9 mp . . . . . 0 N--CA 1.437 -1.098 0 N-CA-C 105.377 -2.083 . . . . 0.0 105.377 . . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.481 ' HA3' ' CD1' ' A' ' 45' ' ' PHE . . . 172.89 154.49 10.41 Favored Glycine 0 N--CA 1.422 -2.292 0 C-N-CA 118.982 -1.58 . . . . 0.0 114.6 176.562 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.55 ' H ' HG21 ' A' ' 99' ' ' ILE . 35.1 t30 -129.65 127.85 41.4 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 169.977 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.629 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 6.4 m -131.59 143.3 40.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.561 0 CA-C-N 118.216 0.462 . . . . 0.0 109.799 -173.427 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.9 m -142.37 96.24 2.92 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.628 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.556 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -137.87 154.74 49.44 Favored 'General case' 0 C--O 1.153 -3.978 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.415 ' O ' ' HB ' ' A' ' 39' ' ' THR . 7.9 p-10 -179.66 -27.57 0.01 OUTLIER 'General case' 0 C--N 1.255 -3.511 0 CA-C-O 122.485 1.136 . . . . 0.0 109.409 179.158 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -77.14 -49.61 14.84 Favored 'General case' 0 C--N 1.255 -3.534 0 CA-C-N 112.964 -1.925 . . . . 0.0 110.986 -177.59 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.433 ' CA ' HG22 ' A' ' 39' ' ' THR . 32.8 t70 -132.79 -1.08 3.41 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.822 -174.842 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.687 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 68.67 66.16 2.39 Favored Glycine 0 C--O 1.215 -1.054 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -177.197 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.725 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 22.7 t -150.21 104.55 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -110.23 119.63 39.87 Favored 'General case' 0 N--CA 1.4 -2.938 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 174.328 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -112.59 113.19 25.21 Favored 'General case' 0 C--N 1.273 -2.751 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 -177.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 13.7 m -111.21 145.46 17.43 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.065 0 N-CA-C 114.552 1.316 . . . . 0.0 114.552 -168.729 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.0 t -143.06 102.06 3.93 Favored 'General case' 0 N--CA 1.413 -2.309 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 166.105 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.55 HG21 ' H ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -117.23 171.54 5.68 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -176.185 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -140.77 112.17 7.37 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.03 -0.986 . . . . 0.0 109.668 176.271 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 101' ' ' ASP . . . . . 0.438 ' OD1' ' HB3' ' A' ' 75' ' ' LYS . 2.2 t0 -130.24 168.63 16.55 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.779 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB2' ' HB2' ' A' ' 75' ' ' LYS . 22.0 m -76.04 123.72 26.23 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 119.408 1.003 . . . . 0.0 111.253 -174.101 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.545 HG21 ' HB3' ' A' ' 23' ' ' LYS . 26.8 m -56.13 -12.09 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 C-N-CA 126.439 1.896 . . . . 0.0 114.546 -175.533 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 75' ' ' LYS . 26.3 pt -66.59 -12.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 CA-C-O 120.657 0.265 . . . . 0.0 111.136 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.569 ' HB3' ' C ' ' A' ' 75' ' ' LYS . 5.1 p -84.88 89.76 7.63 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 172.284 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.502 ' H ' HD23 ' A' ' 106' ' ' LEU . 2.0 pt? -69.79 119.34 13.87 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 165.147 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -74.65 87.57 2.17 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.533 ' HA2' ' CB ' ' A' ' 49' ' ' GLU . . . 162.49 136.91 2.08 Favored Glycine 0 N--CA 1.405 -3.375 0 CA-C-N 114.614 -1.175 . . . . 0.0 112.398 178.337 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -83.28 -73.56 0.4 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.616 0.246 . . . . 0.0 110.725 176.322 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -87.42 -19.72 27.66 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.531 179.069 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t -159.32 163.74 35.41 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 105.895 -1.891 . . . . 0.0 105.895 175.302 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.59 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 6.4 pt -104.47 -16.95 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.853 0 C-N-CA 125.507 1.523 . . . . 0.0 108.6 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.444 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 37.4 pt -103.73 138.83 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.13 177.856 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.561 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 93.41 -0.34 68.21 Favored Glycine 0 CA--C 1.484 -1.846 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.021 171.261 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.57 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 2.6 mmp_? -87.55 144.53 26.65 Favored 'General case' 0 C--O 1.175 -2.823 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 2.3 p -98.61 119.47 37.39 Favored 'General case' 0 C--N 1.286 -2.193 0 CA-C-N 119.549 1.068 . . . . 0.0 113.165 -176.848 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.447 ' HG ' HG12 ' A' ' 47' ' ' VAL . 3.0 tt -88.27 131.67 34.69 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 145' ' ' ALA . 93.5 t -102.24 109.49 26.44 Favored 'Isoleucine or valine' 0 C--O 1.267 2.009 0 C-N-CA 118.941 -1.103 . . . . 0.0 110.668 175.281 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.5 p -148.14 124.3 2.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.896 0.855 . . . . 0.0 113.192 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -144.02 157.44 44.33 Favored 'General case' 0 N--CA 1.41 -2.43 0 N-CA-C 101.872 -3.381 . . . . 0.0 101.872 168.207 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.561 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.2 mp0 -68.92 89.79 0.42 Allowed 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.18 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HD3' ' H ' ' A' ' 123' ' ' ALA . 2.2 tmtp? -173.85 168.12 4.3 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -174.857 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.566 ' H ' ' HD3' ' A' ' 122' ' ' LYS . . . -73.72 125.02 27.15 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 121.531 0.681 . . . . 0.0 111.175 173.548 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -156.1 112.89 3.15 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 125.526 1.53 . . . . 0.0 107.31 176.613 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.502 ' O ' ' HA2' ' A' ' 138' ' ' GLY . 7.4 m-20 -128.91 129.32 45.35 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.69 -53.82 5.62 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 123.277 0.36 . . . . 0.0 111.168 -177.33 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.76 -31.24 45.1 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.65 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -93.13 -46.71 7.3 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.214 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 63.96 -82.04 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.601 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 169.89 -67.34 0.16 Allowed Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -177.637 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.636 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 51.6 t30 -119.4 -175.29 2.91 Favored 'General case' 0 C--O 1.253 1.237 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 175.271 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -54.01 -34.77 60.81 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -178.003 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 133' ' ' GLU . . . . . 0.636 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -83.79 -38.48 21.22 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.135 -178.951 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.476 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 14.6 m -65.16 -29.62 70.47 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.32 -175.209 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.418 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.4 t -68.53 -27.54 66.2 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 121.469 0.652 . . . . 0.0 109.892 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -84.05 -39.51 19.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.738 -178.967 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.0 m -72.26 -33.47 67.52 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 115.415 -0.812 . . . . 0.0 110.044 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 125' ' ' ASP . . . 59.72 45.96 94.84 Favored Glycine 0 CA--C 1.488 -1.626 0 N-CA-C 107.373 -2.291 . . . . 0.0 107.373 -171.431 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -34.42 104.62 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 O-C-N 126.424 1.896 . . . . 0.0 113.679 -166.23 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -151.8 172.43 16.18 Favored 'General case' 0 N--CA 1.425 -1.697 0 CA-C-N 113.523 -1.672 . . . . 0.0 108.353 -176.668 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.92 94.78 1.0 Allowed Glycine 0 N--CA 1.429 -1.779 0 N-CA-C 107.721 -2.152 . . . . 0.0 107.721 170.521 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.409 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 14.3 m -43.49 -44.29 5.88 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.922 1.689 . . . . 0.0 113.998 -172.919 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 57' ' ' CYS . 44.8 mtm180 -115.66 -25.95 7.64 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 177.904 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -46.62 -35.33 5.8 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.2 1.8 . . . . 0.0 112.539 -168.314 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 118' ' ' VAL . . . -141.58 87.76 2.09 Favored 'General case' 0 N--CA 1.388 -3.529 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 -179.221 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.445 ' SG ' HG22 ' A' ' 118' ' ' VAL . 86.5 m -138.7 138.91 38.16 Favored 'General case' 0 N--CA 1.419 -1.996 0 CA-C-N 114.035 -1.439 . . . . 0.0 107.845 176.331 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.21 148.95 18.55 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 174.851 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 27.9 m -68.95 123.91 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.809 0 CA-C-O 122.572 1.177 . . . . 0.0 111.97 178.665 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.409 HD13 ' N ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -98.2 138.51 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.561 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 174.439 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.59 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -174.4 151.99 13.66 Favored Glycine 3 N--CA 1.36 -6.37 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 177.642 . . . . . . . . 3 3 . 1 . 012 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.7 pp -60.57 114.54 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 170.382 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.409 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -126.94 114.89 18.44 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 118.221 -0.895 . . . . 0.0 109.267 -178.492 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.481 ' HA ' HD11 ' A' ' 151' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.447 0 CA-C-O 121.047 0.451 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.401 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 11.6 t -121.68 -25.08 5.15 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.041 0.924 . . . . 0.0 110.167 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -135.78 150.5 49.49 Favored 'General case' 0 N--CA 1.416 -2.166 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -178.443 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.52 161.44 37.91 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.98 127.82 66.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-O 121.363 0.601 . . . . 0.0 109.961 178.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.65 ' HA ' HG21 ' A' ' 148' ' ' VAL . . . -107.81 146.89 31.62 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.768 -177.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.618 ' N ' HG11 ' A' ' 148' ' ' VAL . 41.1 t -134.5 104.94 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 -178.366 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.93 151.34 22.88 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.0 tmtt? -144.27 122.01 11.9 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 175.768 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.38 -178.46 30.54 Favored Glycine 0 N--CA 1.414 -2.8 0 C-N-CA 117.999 -2.048 . . . . 0.0 115.939 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.3 m-20 -102.35 111.34 23.59 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 170.146 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.41 68.94 1.03 Allowed Glycine 0 C--N 1.289 -2.059 0 N-CA-C 104.988 -3.245 . . . . 0.0 104.988 -164.958 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -62.66 128.0 22.19 Favored 'Trans proline' 0 CA--C 1.503 -1.045 0 C-N-CA 123.159 2.573 . . . . 0.0 114.914 -165.435 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 m -115.8 123.13 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.524 0 CA-C-N 113.727 -1.579 . . . . 0.0 108.324 177.529 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -111.66 117.84 34.02 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.61 166.93 40.11 Favored Glycine 1 N--CA 1.383 -4.885 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.377 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.445 ' O ' HD12 ' A' ' 17' ' ' ILE . 2.5 pp -134.38 139.28 48.3 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.673 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.856 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.3 tp -136.14 133.87 50.26 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.9 m-20 -92.9 160.71 14.79 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.239 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 44.4 m-85 -143.48 118.34 9.94 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 176.081 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.402 ' HG3' ' O ' ' A' ' 21' ' ' GLU . 13.0 pt-20 -124.94 101.06 6.88 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.314 -1.354 . . . . 0.0 114.073 171.451 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.514 ' HB3' ' HA ' ' A' ' 105' ' ' SER . 22.7 mm-40 -154.29 101.46 2.38 Favored 'General case' 0 CA--C 1.507 -0.677 0 C-N-CA 124.377 1.071 . . . . 0.0 110.462 164.065 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -167.37 -73.06 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.399 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -90.34 -33.39 16.1 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.088 179.028 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 p -65.19 -69.57 0.29 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.887 -1.051 . . . . 0.0 112.025 -178.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 66.7 107.53 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 124.476 1.11 . . . . 0.0 110.924 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.652 ' O ' ' HB3' ' A' ' 102' ' ' SER . . . 133.33 -147.31 18.96 Favored Glycine 0 CA--C 1.487 -1.66 0 C-N-CA 119.044 -1.55 . . . . 0.0 112.044 -177.157 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.32 123.29 13.22 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 122.512 2.141 . . . . 0.0 111.519 -177.408 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.553 HG23 ' HA ' ' A' ' 102' ' ' SER . 46.4 t -95.4 95.15 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.852 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -176.75 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -98.19 90.76 4.96 Favored 'General case' 0 N--CA 1.411 -2.418 0 CA-C-O 122.498 1.142 . . . . 0.0 108.981 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.436 ' O ' HG22 ' A' ' 99' ' ' ILE . 27.3 m -124.28 151.61 29.52 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.74 0 CA-C-N 113.001 -1.909 . . . . 0.0 109.724 -175.006 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.449 ' HA ' ' CG1' ' A' ' 97' ' ' VAL . 20.9 m-90 -135.48 145.89 47.59 Favored 'General case' 0 C--N 1.267 -3.005 0 CA-C-N 114.988 -1.005 . . . . 0.0 109.026 -175.447 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.538 ' H ' HG13 ' A' ' 97' ' ' VAL . . . -167.46 137.7 4.76 Favored Glycine 0 N--CA 1.424 -2.158 0 C-N-CA 118.046 -2.026 . . . . 0.0 112.638 172.772 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 p -118.38 138.71 52.25 Favored 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.4 mm -119.61 135.82 58.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -120.5 105.57 10.97 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 173.404 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.93 174.84 16.78 Favored Glycine 0 C--N 1.269 -3.144 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.893 -175.71 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.1 tp -66.01 137.42 57.1 Favored 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 104.384 -2.45 . . . . 0.0 104.384 173.281 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.449 ' HB ' ' HA ' ' A' ' 91' ' ' LYS . 17.9 p -68.72 108.96 3.6 Favored 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 115.766 1.765 . . . . 0.0 115.766 -160.123 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -173.6 170.03 4.16 Favored 'General case' 0 CA--C 1.472 -2.047 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.798 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 169.2 136.55 2.08 Favored Glycine 2 C--N 1.241 -4.715 0 C-N-CA 117.481 -2.295 . . . . 0.0 113.129 167.556 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.6 mt -140.99 -50.39 0.44 Allowed 'General case' 0 N--CA 1.426 -1.672 0 O-C-N 124.553 0.796 . . . . 0.0 111.379 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -149.83 153.49 36.85 Favored 'General case' 0 C--N 1.321 -0.665 0 O-C-N 121.922 -0.486 . . . . 0.0 109.792 -175.993 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.632 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -96.59 107.5 3.52 Favored Glycine 0 CA--C 1.458 -3.478 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 175.297 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CG ' ' HB3' ' A' ' 124' ' ' ASP . 29.4 p90 -121.79 83.49 2.1 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.56 ' HB2' HD12 ' A' ' 117' ' ' LEU . 8.2 p80 -133.04 85.47 2.22 Favored 'General case' 0 N--CA 1.387 -3.586 0 O-C-N 118.968 -2.333 . . . . 0.0 113.607 -162.47 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 46' ' ' HIS . 43.4 t -170.47 136.12 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 C-N-CA 127.753 2.421 . . . . 0.0 108.168 171.698 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.625 ' HB2' ' O ' ' A' ' 116' ' ' THR . 2.0 m170 -150.35 94.76 2.16 Favored 'General case' 0 C--N 1.26 -3.309 0 CA-C-N 112.458 -2.155 . . . . 0.0 109.916 170.386 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.87 162.37 24.0 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 176.829 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.9 t80 71.74 28.96 2.62 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.612 ' HA3' ' HA ' ' A' ' 115' ' ' ARG . . . -72.01 -170.47 13.98 Favored Glycine 0 N--CA 1.428 -1.883 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.958 176.164 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -176.34 -63.04 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.552 -164.984 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -108.28 121.91 45.86 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.637 -173.437 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.1 p -70.81 2.62 4.02 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -177.889 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.69 19.02 11.92 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.318 0.247 . . . . 0.0 110.434 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 154.78 131.54 1.49 Allowed Glycine 0 C--N 1.309 -0.923 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.968 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.462 ' HB2' ' HG2' ' A' ' 143' ' ' ARG . 15.8 m -82.62 91.92 7.05 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.0 t -78.56 -61.37 2.03 Favored 'General case' 0 N--CA 1.426 -1.661 0 O-C-N 124.11 0.881 . . . . 0.0 110.157 172.486 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 13.4 m -65.43 -47.2 77.04 Favored 'General case' 0 C--O 1.214 -0.806 0 C-N-CA 122.967 0.507 . . . . 0.0 111.941 -177.107 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.477 ' HB1' ' HB3' ' A' ' 48' ' ' HIS . . . -76.36 -6.65 52.53 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -40.58 -71.57 0.29 Allowed Glycine 0 CA--C 1.541 1.706 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 -175.266 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -72.12 -17.05 28.41 Favored 'Trans proline' 0 N--CA 1.48 0.684 0 C-N-CA 122.92 2.414 . . . . 0.0 112.381 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 65.64 107.18 0.04 OUTLIER 'General case' 0 C--O 1.242 0.665 0 C-N-CA 126.611 1.965 . . . . 0.0 112.56 -177.771 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -130.29 84.09 2.18 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 118.306 -1.358 . . . . 0.0 108.474 166.261 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -119.46 90.63 42.97 Favored Pre-proline 0 C--N 1.289 -2.033 0 CA-C-N 112.5 -2.136 . . . . 0.0 108.066 173.647 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -30.1 -54.49 0.2 Allowed 'Trans proline' 0 N--CA 1.484 0.956 1 C-N-CA 126.735 4.957 . . . . 0.0 119.626 -168.864 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -93.84 0.47 56.24 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 118.688 -1.205 . . . . 0.0 113.843 -173.31 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.639 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 28.6 m -78.6 48.43 0.79 Allowed 'General case' 0 C--O 1.246 0.892 0 CA-C-O 122.386 1.089 . . . . 0.0 109.095 175.992 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 69' ' ' ARG . 12.9 mmm180 -133.2 -28.77 1.48 Allowed 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.283 -173.189 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 54.3 tptt -38.84 -56.83 1.31 Allowed 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.105 0.962 . . . . 0.0 113.563 -173.227 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.493 ' H ' ' HA ' ' A' ' 78' ' ' GLU . 21.2 t-80 -177.61 59.94 0.01 OUTLIER 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.161 -0.447 . . . . 0.0 110.011 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.511 ' HA2' ' HB3' ' A' ' 78' ' ' GLU . . . -38.93 105.98 0.05 OUTLIER Glycine 0 N--CA 1.483 1.83 0 O-C-N 123.744 0.653 . . . . 0.0 112.676 173.246 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.52 168.26 24.22 Favored Glycine 0 N--CA 1.413 -2.84 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -176.842 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -93.29 1.72 3.45 Favored 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 123.333 2.689 . . . . 0.0 115.985 -172.653 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 76' ' ' ASP . 87.1 mttt -108.5 -31.67 7.71 Favored 'General case' 0 C--O 1.262 1.715 0 C-N-CA 118.096 -1.442 . . . . 0.0 109.773 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 75' ' ' LYS . 0.8 OUTLIER 159.3 120.09 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.758 0 C-N-CA 128.301 2.64 . . . . 0.0 104.291 168.813 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 164.33 127.26 0.01 OUTLIER 'General case' 0 CA--C 1.454 -2.715 0 C-N-CA 124.459 1.104 . . . . 0.0 111.194 171.52 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.639 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.7 OUTLIER 162.75 -173.84 0.01 OUTLIER 'General case' 0 N--CA 1.396 -3.147 0 C-N-CA 130.885 3.674 . . . . 0.0 102.325 163.982 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.671 ' HA ' ' NE ' ' A' ' 79' ' ' ARG 0.381 1.4 mmp_? -121.01 11.25 10.95 Favored 'General case' 0 C--N 1.257 -3.415 0 N-CA-C 118.337 2.718 . . . . 0.0 118.337 -176.872 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.507 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.6 OUTLIER . . . . . 0 CA--C 1.483 -1.629 0 C-N-CA 117.37 -1.732 . . . . 0.0 110.804 170.006 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.639 HD23 ' H ' ' A' ' 85' ' ' GLY . 5.8 tt . . . . . 0 N--CA 1.433 -1.286 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 85' ' ' GLY . . . . . 0.639 ' H ' HD23 ' A' ' 84' ' ' LEU . . . -38.89 147.53 0.13 Allowed Glycine 0 N--CA 1.466 0.686 0 C-N-CA 125.005 1.288 . . . . 0.0 114.948 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -79.49 136.3 36.87 Favored 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 114.682 -0.759 . . . . 0.0 109.162 -166.274 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.729 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 30.3 m -134.72 126.69 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.408 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.6 t -141.28 148.2 39.42 Favored 'General case' 0 C--N 1.267 -3.001 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 -177.571 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.798 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -132.76 154.38 50.29 Favored 'General case' 0 C--N 1.259 -3.326 0 N-CA-C 105.362 -2.088 . . . . 0.0 105.362 178.931 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.499 ' C ' ' H ' ' A' ' 92' ' ' ASP . 6.9 t70 -101.65 -153.45 0.46 Allowed 'General case' 1 C--N 1.225 -4.841 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.548 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HA ' ' HB ' ' A' ' 39' ' ' THR . 95.0 mttt -62.66 16.82 0.01 OUTLIER 'General case' 0 CA--C 1.58 2.116 0 O-C-N 121.587 -0.696 . . . . 0.0 112.845 171.405 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 90' ' ' ASP . 17.0 t70 -133.68 109.65 9.31 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 171.369 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -76.43 92.59 0.98 Allowed Glycine 0 C--N 1.32 -0.357 0 N-CA-C 114.911 0.725 . . . . 0.0 114.911 -170.456 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.7 t -158.46 103.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 176.016 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.729 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.18 128.75 43.37 Favored 'General case' 0 N--CA 1.398 -3.027 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.677 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -82.15 153.36 26.06 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 124.144 0.902 . . . . 0.0 110.642 -174.94 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.538 HG13 ' H ' ' A' ' 33' ' ' GLY . 78.4 t -81.21 134.91 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 C-N-CA 124.203 1.001 . . . . 0.0 111.668 -172.694 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 61.5 m -122.97 123.76 41.65 Favored 'General case' 0 N--CA 1.414 -2.245 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.045 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 31' ' ' VAL . 31.8 pt -94.43 160.39 2.72 Favored 'Isoleucine or valine' 0 C--O 1.25 1.106 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.407 ' OE1' ' HA ' ' A' ' 84' ' ' LEU . 49.8 mt-10 -142.99 159.28 42.53 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-O 122.159 0.98 . . . . 0.0 113.239 -171.494 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.22 169.4 17.39 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 172.007 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.652 ' HB3' ' O ' ' A' ' 27' ' ' GLY . 10.9 p -57.34 91.94 0.01 OUTLIER 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -173.764 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.56 -38.16 2.07 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.225 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.063 173.014 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.405 ' O ' HG22 ' A' ' 104' ' ' ILE . 25.3 mm -72.37 25.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 C-N-CA 126.919 2.088 . . . . 0.0 111.936 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 16.8 p -66.95 149.65 50.32 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 121.667 -0.646 . . . . 0.0 110.831 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . 0.308 0.9 OUTLIER -80.95 86.3 6.11 Favored 'General case' 0 N--CA 1.388 -3.536 0 CA-C-O 124.647 2.165 . . . . 0.0 111.505 178.573 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.7 m -149.85 85.95 1.43 Allowed 'General case' 2 N--CA 1.367 -4.613 1 N-CA-C 100.061 -4.051 . . . . 0.0 100.061 168.457 . . . . . . . . 3 2 . 1 . 013 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -125.31 -155.99 9.21 Favored Glycine 0 C--N 1.26 -3.674 0 CA-C-N 113.46 -1.7 . . . . 0.0 109.444 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -92.2 -44.54 8.72 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 111' ' ' SER . 23.1 m80 -118.64 -50.77 2.4 Favored 'General case' 0 N--CA 1.434 -1.234 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.444 175.018 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 110' ' ' HIS . 33.2 t 165.45 168.03 0.02 OUTLIER 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 177.182 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.522 ' O ' HG22 ' A' ' 149' ' ' ILE . 50.1 mm -71.72 -45.98 63.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.483 ' H ' HD12 ' A' ' 113' ' ' ILE . 3.5 mp -71.71 121.25 21.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.726 -0.609 . . . . 0.0 111.764 -172.663 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.83 -0.05 25.81 Favored Glycine 0 CA--C 1.478 -2.225 0 C-N-CA 120.403 -0.903 . . . . 0.0 110.873 170.1 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.612 ' HA ' ' HA3' ' A' ' 51' ' ' GLY . 11.1 mmt180 -91.86 173.52 7.82 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.59 -178.708 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.625 ' O ' ' HB2' ' A' ' 48' ' ' HIS . 17.5 p -128.46 103.77 7.32 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-O 118.725 -0.655 . . . . 0.0 110.998 -173.301 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' A' ' 148' ' ' VAL . 0.7 OUTLIER -76.26 137.16 39.76 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 120.312 1.414 . . . . 0.0 111.573 -178.026 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.721 ' HA ' ' HB3' ' A' ' 146' ' ' CYS . 11.5 p -92.87 125.25 45.46 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.436 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 176.11 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.8 p -148.55 130.88 6.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 C-N-CA 118.961 -1.095 . . . . 0.0 113.115 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 16.3 t-80 -154.93 151.33 28.41 Favored 'General case' 0 N--CA 1.416 -2.169 0 N-CA-C 102.348 -3.204 . . . . 0.0 102.348 163.168 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 41' ' ' GLY . 2.9 mp0 -70.3 99.52 1.56 Allowed 'General case' 0 C--N 1.269 -2.896 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 174.12 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -168.31 173.83 7.46 Favored 'General case' 0 C--O 1.199 -1.59 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -171.834 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.01 120.48 26.17 Favored 'General case' 0 C--N 1.256 -3.471 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 177.733 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.613 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -167.13 136.77 2.87 Favored 'General case' 0 N--CA 1.509 2.512 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.012 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -149.89 150.9 32.59 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.823 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -90.95 -39.31 12.33 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.11 -33.91 5.84 Favored Glycine 0 C--N 1.3 -1.465 0 C-N-CA 119.753 -1.213 . . . . 0.0 111.65 -175.375 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 49.1 tptt -118.43 41.34 2.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -176.964 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.91 -7.24 69.8 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 115.463 -0.79 . . . . 0.0 114.736 -176.288 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 144.11 -122.42 1.81 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.492 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.452 ' O ' HG22 ' A' ' 135' ' ' THR . 88.9 m-20 -99.65 -174.54 2.74 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -177.583 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -47.09 -52.65 14.69 Favored 'General case' 0 N--CA 1.484 1.228 0 O-C-N 123.564 0.54 . . . . 0.0 111.264 -176.699 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -77.71 -40.85 39.9 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.7 p -75.53 -27.17 58.59 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -175.708 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 131' ' ' ASN . 13.9 t -76.12 -33.25 59.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 176.237 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -74.08 -32.54 63.3 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.727 -179.321 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 86.4 m -79.22 -31.05 43.55 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.304 174.788 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.73 60.94 8.1 Favored Glycine 0 CA--C 1.484 -1.884 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -36.31 105.62 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 125.733 1.49 . . . . 0.0 111.876 -174.694 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 124' ' ' ASP . . . -101.8 169.93 8.48 Favored 'General case' 0 N--CA 1.429 -1.516 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.92 -169.838 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' A' ' 143' ' ' ARG . . . -63.96 154.02 47.12 Favored Glycine 0 N--CA 1.406 -3.303 0 N-CA-C 106.481 -2.648 . . . . 0.0 106.481 169.921 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -57.01 8.81 0.01 OUTLIER 'General case' 0 C--N 1.262 -3.223 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.462 ' HG2' ' HB2' ' A' ' 57' ' ' CYS . 0.2 OUTLIER 65.67 19.17 11.39 Favored 'General case' 0 CA--C 1.467 -2.224 0 C-N-CA 125.277 1.431 . . . . 0.0 107.959 177.675 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 53.0 mt -70.94 -33.24 70.3 Favored 'General case' 0 CA--C 1.445 -3.072 0 CA-C-N 113.91 -1.495 . . . . 0.0 107.668 -176.723 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.432 ' O ' ' HB3' ' A' ' 146' ' ' CYS . . . -121.98 89.74 3.17 Favored 'General case' 1 N--CA 1.35 -5.458 0 CA-C-N 113.557 -1.656 . . . . 0.0 108.158 175.38 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 118' ' ' VAL . 19.9 p -171.91 127.94 0.61 Allowed 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 113.812 1.042 . . . . 0.0 113.812 169.95 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.614 ' HA2' ' HB ' ' A' ' 116' ' ' THR . . . -178.51 77.93 0.07 OUTLIER Glycine 0 N--CA 1.402 -3.62 0 CA-C-O 118.638 -1.09 . . . . 0.0 110.656 159.009 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 6' ' ' ALA . 13.1 p -172.58 96.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.184 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 169.727 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.559 ' HB ' ' HB2' ' A' ' 115' ' ' ARG . 12.2 mm -124.46 102.68 11.28 Favored 'Isoleucine or valine' 1 C--N 1.234 -4.445 0 N-CA-C 104.692 -2.336 . . . . 0.0 104.692 167.364 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -165.59 146.56 11.25 Favored Glycine 2 CA--C 1.444 -4.394 0 C-N-CA 115.941 -3.028 . . . . 0.0 112.678 175.458 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.545 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 0.0 OUTLIER -95.26 105.56 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.568 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 171.98 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.92 99.61 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.441 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.245 0.863 0 N-CA-C 105.466 -2.049 . . . . 0.0 105.466 178.07 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.207 -1.145 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 . . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 m -100.48 -27.63 13.33 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -171.536 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -136.66 148.62 47.51 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.169 -173.255 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -142.35 143.19 32.63 Favored 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 92.1 t -124.26 129.13 74.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.406 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -120.11 145.61 46.74 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.939 -177.22 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 56.5 t -127.38 126.07 66.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 85.3 mt -112.1 133.08 54.47 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -142.6 133.54 25.68 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.68 -170.89 21.59 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 119.362 -1.399 . . . . 0.0 112.553 -177.312 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -73.31 -46.1 51.49 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -101.58 96.29 1.47 Allowed Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 171.089 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -71.53 127.09 12.79 Favored 'Trans proline' 0 N--CA 1.434 -1.986 0 C-N-CA 121.797 1.665 . . . . 0.0 113.968 -168.48 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.91 148.28 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.286 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 173.309 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -123.94 118.64 27.51 Favored 'General case' 0 C--N 1.259 -3.355 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -177.178 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -167.26 146.48 10.77 Favored Glycine 0 N--CA 1.409 -3.101 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.891 -178.03 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.2 pt -130.66 118.24 41.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.742 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.1 OUTLIER -114.88 133.04 62.27 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.103 -176.708 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 24.0 m-80 -109.46 119.73 40.33 Favored 'General case' 0 CA--C 1.51 -0.589 0 C-N-CA 123.309 0.644 . . . . 0.0 109.592 -173.976 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.7 m-85 -120.76 137.41 54.52 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.779 0.323 . . . . 0.0 110.617 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 9.9 pt-20 -107.89 134.0 51.45 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.418 175.809 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.571 ' HA ' ' O ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -126.91 112.45 15.32 Favored 'General case' 0 N--CA 1.413 -2.307 0 C-N-CA 123.777 0.831 . . . . 0.0 109.459 178.309 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.8 tttm -138.12 149.07 45.58 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.34 -173.032 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.609 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.1 mp0 -50.51 -44.29 56.05 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 125.728 1.611 . . . . 0.0 110.332 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.6 m -51.72 -45.24 63.51 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.651 1.18 . . . . 0.0 111.913 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.432 ' HA ' HG23 ' A' ' 104' ' ' ILE . 9.8 t30 57.62 87.59 0.06 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 124.294 0.996 . . . . 0.0 111.917 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.528 ' H ' HD13 ' A' ' 104' ' ' ILE . . . -132.47 -151.6 6.79 Favored Glycine 0 CA--C 1.492 -1.361 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.19 -177.093 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_exo -67.6 124.18 11.67 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.215 1.943 . . . . 0.0 108.01 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.682 HG11 HG12 ' A' ' 103' ' ' VAL . 13.4 p -80.01 132.69 31.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 CA-C-O 121.23 0.538 . . . . 0.0 110.5 -176.632 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -93.98 99.21 11.58 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 169.734 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 5.9 p -123.44 130.54 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.001 0 CA-C-N 115.311 -0.858 . . . . 0.0 108.711 -175.015 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -136.44 125.49 24.42 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.498 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.742 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -164.25 140.17 6.29 Favored Glycine 0 N--CA 1.41 -3.045 0 C-N-CA 119.724 -1.226 . . . . 0.0 111.933 172.745 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 16.9 m -116.04 135.46 53.93 Favored 'General case' 0 N--CA 1.404 -2.77 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.531 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 12.1 tt -125.13 136.94 59.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 118.54 0.609 . . . . 0.0 109.976 179.183 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 91.7 mttt -116.92 131.84 56.85 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.128 -2.175 . . . . 0.0 105.128 -177.839 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.592 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -155.0 175.8 32.91 Favored Glycine 0 C--N 1.269 -3.169 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -166.751 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.62 171.0 8.23 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 175.274 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.0 t -69.47 107.18 3.25 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.809 -175.153 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.571 ' OE2' ' HG2' ' A' ' 122' ' ' LYS . 22.2 tt0 -177.08 171.13 2.14 Favored 'General case' 0 N--CA 1.419 -2.011 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 171.473 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 41' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 170.78 104.83 0.18 Allowed Glycine 1 C--N 1.251 -4.144 0 C-N-CA 119.02 -1.562 . . . . 0.0 111.843 169.543 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' N ' ' A' ' 123' ' ' ALA . 6.8 mp -110.78 -86.89 0.53 Allowed 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.062 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.657 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.4 t-80 -175.15 122.3 0.22 Allowed 'General case' 0 C--N 1.355 0.823 0 C-N-CA 118.364 -1.335 . . . . 0.0 114.35 -173.388 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.456 ' H ' ' H ' ' A' ' 87' ' ' VAL . . . 102.99 137.94 9.74 Favored Glycine 0 C--N 1.3 -1.432 0 N-CA-C 117.502 1.761 . . . . 0.0 117.502 164.635 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -96.18 166.73 11.6 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 124.028 0.931 . . . . 0.0 109.359 170.179 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.715 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . 6.1 m80 -171.83 90.44 0.12 Allowed 'General case' 0 CA--C 1.482 -1.661 0 C-N-CA 125.298 1.439 . . . . 0.0 110.004 169.414 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.627 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 2.6 p -69.36 162.7 3.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 168.942 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.49 ' CE1' ' HD2' ' A' ' 62' ' ' PRO 0.278 0.0 OUTLIER -148.85 171.49 16.21 Favored 'General case' 0 N--CA 1.419 -1.979 0 C-N-CA 116.562 -2.055 . . . . 0.0 109.482 170.187 . . . . . . . . 4 4 . 1 . 014 nuclear build core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -69.57 166.35 19.16 Favored 'General case' 0 C--N 1.261 -3.273 0 N-CA-C 116.072 1.879 . . . . 0.0 116.072 -171.043 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 59' ' ' SER . 4.0 t80 72.77 33.26 1.32 Allowed 'General case' 0 N--CA 1.439 -1.023 0 C-N-CA 126.321 1.848 . . . . 0.0 107.243 172.022 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.422 ' HA2' ' HB2' ' A' ' 60' ' ' ALA . . . -57.56 154.84 20.49 Favored Glycine 0 C--N 1.345 1.048 0 CA-C-N 112.42 -2.173 . . . . 0.0 113.063 -178.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.537 ' OD1' ' HA ' ' A' ' 57' ' ' CYS . 3.8 p30 -144.8 -85.75 0.13 Allowed 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -172.901 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.55 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 52.7 t30 -98.31 148.77 23.31 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.288 0.566 . . . . 0.0 112.43 -173.392 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.577 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 6.9 m -82.3 -2.93 54.26 Favored 'General case' 0 CA--C 1.56 1.349 0 C-N-CA 124.323 1.049 . . . . 0.0 111.652 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.99 17.06 7.92 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 121.097 0.475 . . . . 0.0 111.02 -177.828 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.55 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 143.94 117.16 1.16 Allowed Glycine 0 CA--C 1.484 -1.864 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -177.374 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.587 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -97.53 113.69 25.44 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -175.949 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.0 p -80.0 -45.42 18.44 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.576 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . 49.8 m -79.37 -29.0 41.94 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 123.445 0.698 . . . . 0.0 111.216 -174.724 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.71 -5.26 47.28 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 123.981 0.912 . . . . 0.0 111.19 172.443 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.22 52.1 0.91 Allowed Glycine 0 CA--C 1.559 2.801 0 C-N-CA 117.177 -2.439 . . . . 0.0 116.247 176.369 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.529 ' HD3' ' O ' ' A' ' 59' ' ' SER . 86.9 Cg_endo -96.37 2.93 1.99 Allowed 'Trans proline' 0 C--N 1.397 3.127 0 CA-C-N 121.821 2.81 . . . . 0.0 107.322 161.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 68.3 m-70 75.22 -47.75 0.61 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 125.541 1.536 . . . . 0.0 113.623 173.772 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -69.27 116.12 9.34 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -170.655 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -116.16 96.49 47.49 Favored Pre-proline 0 CA--C 1.559 1.309 0 C-N-CA 125.061 1.344 . . . . 0.0 110.089 176.82 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.95 -18.7 10.06 Favored 'Trans proline' 0 CA--C 1.552 1.384 0 C-N-CA 123.119 2.546 . . . . 0.0 117.823 -169.203 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.421 ' HB3' ' HB2' ' A' ' 79' ' ' ARG . 84.0 mt -88.09 -5.32 58.52 Favored 'General case' 0 CA--C 1.484 -1.567 0 O-C-N 120.817 -1.177 . . . . 0.0 110.906 -172.719 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.433 ' C ' ' H ' ' A' ' 70' ' ' LYS . 17.9 m -77.92 58.05 1.85 Allowed 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 104.533 -2.395 . . . . 0.0 104.533 167.039 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.526 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 2.1 tmm_? -92.59 17.56 9.98 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -169.329 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.503 ' HB2' ' CB ' ' A' ' 78' ' ' GLU . 11.9 mptt -140.03 63.97 1.46 Allowed 'General case' 0 N--CA 1.411 -2.402 0 CA-C-N 112.705 -2.043 . . . . 0.0 109.411 175.135 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 71' ' ' HIS . . . . . 0.446 ' O ' ' HB3' ' A' ' 126' ' ' LEU . 20.2 t60 65.38 -37.57 0.24 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 125.313 1.445 . . . . 0.0 113.284 -178.984 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.13 20.68 62.34 Favored Glycine 0 N--CA 1.414 -2.816 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -175.517 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 77' ' ' GLU . . . -90.31 175.53 41.14 Favored Glycine 0 C--O 1.202 -1.897 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.863 -177.107 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.515 ' C ' ' H ' ' A' ' 76' ' ' ASP . 2.8 Cg_exo -72.07 2.34 4.99 Favored 'Trans proline' 0 N--CA 1.501 1.926 1 C-N-CA 125.717 4.278 . . . . 0.0 111.302 -170.562 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.414 ' H ' ' C ' ' A' ' 73' ' ' GLY . 60.9 tttm -76.59 27.59 0.13 Allowed 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 127.402 2.281 . . . . 0.0 109.089 178.669 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 74' ' ' PRO 0.303 1.2 p30 77.18 10.32 2.51 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 128.453 2.701 . . . . 0.0 115.665 173.597 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.604 ' HG3' ' O ' ' A' ' 73' ' ' GLY . 1.7 mp0 33.19 108.19 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 127.639 2.375 . . . . 0.0 114.089 170.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 69' ' ' ARG . 43.1 tt0 -34.73 -61.66 0.39 Allowed 'General case' 0 N--CA 1.507 2.392 0 O-C-N 123.914 0.759 . . . . 0.0 112.133 -177.747 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.421 ' HB2' ' HB3' ' A' ' 67' ' ' LEU . 75.0 mtt85 -136.62 63.64 1.57 Allowed 'General case' 0 C--N 1.286 -2.177 0 C-N-CA 118.834 -1.146 . . . . 0.0 111.056 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.6 ' NE2' ' HB2' ' A' ' 105' ' ' SER . 0.3 OUTLIER . . . . . 0 CA--C 1.505 -0.751 0 CA-C-O 122.729 1.252 . . . . 0.0 113.375 171.455 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.454 ' CD1' ' HA2' ' A' ' 73' ' ' GLY . 1.6 tt . . . . . 0 N--CA 1.423 -1.823 0 CA-C-O 121.645 0.736 . . . . 0.0 109.28 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.02 136.51 13.52 Favored Glycine 0 N--CA 1.419 -2.487 0 N-CA-C 104.853 -3.299 . . . . 0.0 104.853 165.665 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.415 ' HA ' ' HA2' ' A' ' 44' ' ' GLY 0.359 23.2 p30 -92.11 128.69 38.05 Favored 'General case' 0 N--CA 1.426 -1.645 0 C-N-CA 115.171 -2.611 . . . . 0.0 113.318 -173.189 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.657 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 92.6 t -110.64 138.7 37.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.186 -174.945 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.5 p -140.15 95.09 2.83 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 -179.07 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -86.14 137.03 32.97 Favored 'General case' 0 N--CA 1.415 -2.217 0 CA-C-O 121.406 0.622 . . . . 0.0 109.945 -176.966 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 92' ' ' ASP . 30.8 t70 -75.23 154.62 37.44 Favored 'General case' 1 C--N 1.242 -4.103 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 174.516 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -53.07 23.07 0.0 OUTLIER 'General case' 0 CA--C 1.579 2.094 0 N-CA-C 115.839 1.792 . . . . 0.0 115.839 174.488 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 90' ' ' ASP . 1.5 m-20 -133.89 8.63 3.82 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 124.945 1.298 . . . . 0.0 108.787 171.674 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.635 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 66.8 80.08 0.2 Allowed Glycine 0 N--CA 1.44 -1.046 0 CA-C-N 114.998 -1.001 . . . . 0.0 112.564 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.5 p -161.71 113.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 34' ' ' SER . . . -136.8 144.63 43.81 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.807 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -119.58 115.14 23.38 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 175.381 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.434 HG11 ' CE2' ' A' ' 45' ' ' PHE . 4.3 p -102.92 103.41 15.04 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.352 0 CA-C-O 122.173 0.987 . . . . 0.0 111.714 -178.472 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.2 m -139.65 100.18 3.9 Favored 'General case' 0 N--CA 1.421 -1.894 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 172.736 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.9 mm -135.3 128.45 48.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -176.471 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 43.0 mt-10 -104.5 106.19 16.59 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.155 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -160.51 168.66 24.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 104.369 -2.456 . . . . 0.0 104.369 170.722 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.504 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 24.8 m -80.76 79.18 7.45 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 115.726 1.75 . . . . 0.0 115.726 -169.344 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.682 HG12 HG11 ' A' ' 29' ' ' VAL . 12.4 p -92.51 -11.62 9.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 169.476 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 22' ' ' GLN . 15.9 tt -57.87 19.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.102 0 C-N-CA 130.201 3.4 . . . . 0.0 114.235 -176.306 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.6 ' HB2' ' NE2' ' A' ' 80' ' ' HIS . 16.4 m -97.85 170.91 8.64 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 103.627 -2.731 . . . . 0.0 103.627 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.428 HD12 ' O ' ' A' ' 106' ' ' LEU . 2.6 pp -68.14 119.13 12.23 Favored 'General case' 0 N--CA 1.414 -2.24 0 C-N-CA 117.689 -1.605 . . . . 0.0 109.467 176.274 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 m -68.95 89.75 0.42 Allowed 'General case' 0 N--CA 1.414 -2.234 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.303 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 155.27 155.69 7.44 Favored Glycine 0 N--CA 1.401 -3.64 0 CA-C-N 114.155 -1.384 . . . . 0.0 110.501 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -69.66 -38.91 77.29 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -107.37 -48.07 3.52 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.266 -175.946 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.56 ' O ' ' HD2' ' A' ' 115' ' ' ARG . 15.3 m -163.04 159.92 23.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.61 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.701 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -72.79 -46.6 52.72 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.894 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.077 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 tp -67.56 127.15 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 176.766 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.98 11.93 58.29 Favored Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 119.611 -1.28 . . . . 0.0 110.768 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.56 ' HD2' ' O ' ' A' ' 111' ' ' SER . 0.0 OUTLIER -114.67 121.55 43.73 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.237 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.809 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 14.9 p -98.45 135.56 39.83 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-O 121.856 0.836 . . . . 0.0 111.638 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 56.2 tp -74.66 102.87 4.74 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 113.937 -1.483 . . . . 0.0 111.485 -174.442 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 142' ' ' SER . 12.6 m -93.21 96.36 6.12 Favored 'Isoleucine or valine' 1 C--O 1.33 5.293 0 C-N-CA 116.314 -2.154 . . . . 0.0 112.821 175.035 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.1 p -150.5 171.57 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 113.46 -1.7 . . . . 0.0 107.992 -176.836 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.465 ' HB2' ' HB3' ' A' ' 144' ' ' LEU . 82.2 t60 -152.04 170.76 19.12 Favored 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 168.419 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -69.77 88.37 0.54 Allowed 'General case' 0 CA--C 1.551 0.983 0 CA-C-N 123.016 2.643 . . . . 0.0 109.045 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.571 ' HG2' ' OE2' ' A' ' 40' ' ' GLU . 65.8 mttm -166.75 173.31 9.68 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 125.771 1.628 . . . . 0.0 108.318 -168.226 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.616 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -82.68 114.52 21.1 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 172.149 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.715 ' OD1' ' HB2' ' A' ' 46' ' ' HIS . 11.9 t70 -124.31 76.58 1.49 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -176.717 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -114.43 158.59 21.35 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.155 0.502 . . . . 0.0 110.548 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 135' ' ' THR . 3.2 tm? -87.85 -56.35 3.38 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.467 -1.242 . . . . 0.0 108.007 -179.381 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 127' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 71' ' ' HIS . . . -68.26 -40.63 87.44 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.725 -177.83 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -105.43 50.74 0.77 Allowed 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.25 76.73 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.588 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -67.29 0.53 Allowed Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.379 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' CB ' ' A' ' 134' ' ' SER . 4.1 m-20 -105.99 176.81 5.04 Favored 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 119.052 -0.499 . . . . 0.0 109.945 -179.121 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -56.18 -44.07 79.02 Favored 'General case' 0 CA--C 1.567 1.634 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 176.203 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -71.85 -33.39 68.4 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.461 ' CB ' ' H ' ' A' ' 131' ' ' ASN . 2.3 m -68.1 -19.97 64.89 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.969 0.414 . . . . 0.0 110.887 -175.733 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.472 ' HA ' ' O ' ' A' ' 126' ' ' LEU . 8.8 m -74.0 -21.3 60.04 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 121.511 0.672 . . . . 0.0 109.823 178.563 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -83.24 -51.18 7.69 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.3 p -69.01 -50.59 47.46 Favored 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.965 -177.504 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 138' ' ' GLY . . . . . 0.438 ' CA ' ' HA ' ' A' ' 126' ' ' LEU . . . 67.16 92.45 0.04 OUTLIER Glycine 0 N--CA 1.418 -2.532 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -174.508 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -31.77 136.63 0.06 Allowed 'General case' 1 C--O 1.322 4.892 0 N-CA-C 118.813 2.894 . . . . 0.0 118.813 -167.037 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -126.51 129.01 47.79 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 112.925 -1.943 . . . . 0.0 109.246 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -115.23 75.33 0.25 Allowed Glycine 0 N--CA 1.416 -2.665 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 176.428 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.568 ' HB2' ' O ' ' A' ' 57' ' ' CYS . 77.5 p -58.92 -26.82 64.69 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 123.848 0.859 . . . . 0.0 112.306 -175.611 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -117.52 -0.89 11.79 Favored 'General case' 0 N--CA 1.427 -1.617 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.803 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.465 ' HB3' ' HB2' ' A' ' 120' ' ' HIS . 3.9 mm? -79.05 -34.84 43.45 Favored 'General case' 0 C--N 1.282 -2.367 0 C-N-CA 117.949 -1.5 . . . . 0.0 110.393 -176.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -173.96 89.45 0.07 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 177.62 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.809 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 44.6 t -139.07 133.11 31.15 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 118.159 -1.416 . . . . 0.0 110.34 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.577 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -161.18 166.02 35.59 Favored Glycine 0 N--CA 1.398 -3.897 0 N-CA-C 107.967 -2.053 . . . . 0.0 107.967 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.92 122.37 20.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.086 0.47 . . . . 0.0 110.339 -178.727 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.413 HD11 ' CD1' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -116.26 106.5 20.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.233 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.447 ' HA2' ' HB ' ' A' ' 112' ' ' ILE . . . -172.31 -179.29 43.08 Favored Glycine 1 N--CA 1.392 -4.268 0 N-CA-C 110.031 -1.227 . . . . 0.0 110.031 -179.125 . . . . . . . . 3 3 . 1 . 014 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.483 ' H ' HG12 ' A' ' 112' ' ' ILE . 11.3 tt -54.87 114.47 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 121.751 0.786 . . . . 0.0 112.475 -179.041 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.57 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -149.93 154.9 39.06 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 176.655 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 . . . . . 0 C--N 1.29 -1.995 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.819 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.21 -0.987 0 CA-C-O 120.283 0.087 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 9.3 m -76.26 -27.92 56.88 Favored 'General case' 0 CA--C 1.562 1.434 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -175.932 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.463 ' O ' ' HB ' ' A' ' 151' ' ' ILE . 20.2 ptpt -152.63 167.55 28.52 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -153.02 152.5 31.45 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 175.439 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.3 t -134.41 138.37 49.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -109.44 134.61 51.65 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -175.443 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 7' ' ' VAL . . . . . 0.551 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 46.9 t -134.31 102.55 4.27 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.366 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 175.654 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.496 ' H ' HD23 ' A' ' 8' ' ' LEU . 1.5 pt? -117.74 132.49 56.46 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -178.015 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -138.0 138.59 39.03 Favored 'General case' 0 C--O 1.248 0.98 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.76 -158.76 8.87 Favored Glycine 0 N--CA 1.435 -1.386 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.045 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -63.63 -50.97 67.25 Favored 'General case' 0 CA--C 1.511 -0.554 0 O-C-N 124.537 0.787 . . . . 0.0 109.167 177.218 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -88.65 154.95 25.32 Favored Glycine 0 N--CA 1.44 -1.1 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 175.234 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -86.23 124.35 2.43 Favored 'Trans proline' 0 N--CA 1.414 -3.149 0 CA-C-N 120.342 2.071 . . . . 0.0 110.072 -176.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 13.8 m -131.66 146.78 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.966 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 -179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -159.49 123.29 3.77 Favored 'General case' 0 C--N 1.251 -3.707 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.491 ' HA3' HG12 ' A' ' 35' ' ' ILE . . . -153.11 157.95 27.64 Favored Glycine 0 N--CA 1.396 -3.978 0 C-N-CA 119.945 -1.122 . . . . 0.0 111.068 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 25.2 pt -123.97 102.43 11.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.593 HG13 ' HA3' ' A' ' 33' ' ' GLY . 1.8 mp -107.53 128.48 62.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.652 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 30.4 p-10 -115.91 125.74 52.98 Favored 'General case' 0 C--N 1.35 0.597 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.656 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 69.0 t80 -126.03 130.1 50.48 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -171.007 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 14.3 pt-20 -136.5 102.59 4.99 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-O 121.317 0.58 . . . . 0.0 110.888 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.457 ' HB3' ' CZ ' ' A' ' 20' ' ' PHE . 9.4 tt0 -151.21 114.42 4.79 Favored 'General case' 0 N--CA 1.414 -2.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.67 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -174.83 -74.17 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.853 175.424 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -90.31 -8.78 50.0 Favored 'General case' 0 N--CA 1.431 -1.376 0 CA-C-N 114.746 -1.115 . . . . 0.0 109.652 -177.726 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -52.83 -50.38 63.83 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 172.937 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.7 t-20 49.58 64.1 1.9 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.066 177.027 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.23 -164.47 36.66 Favored Glycine 0 N--CA 1.419 -2.499 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 -174.986 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.39 124.83 17.04 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 C-N-CA 122.18 1.92 . . . . 0.0 111.054 -178.156 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.437 ' CG2' ' HB2' ' A' ' 22' ' ' GLN . 3.0 p -74.27 130.34 36.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.789 -177.667 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.46 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 63.4 mttp -92.54 99.28 12.03 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.792 175.561 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.573 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 3.2 p -138.17 141.77 37.26 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.668 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -178.217 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 58.0 t90 -153.29 139.24 18.14 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -156.72 140.33 7.11 Favored Glycine 0 N--CA 1.413 -2.896 0 C-N-CA 118.757 -1.687 . . . . 0.0 113.099 176.573 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.5 p -114.23 134.27 55.04 Favored 'General case' 0 N--CA 1.409 -2.52 0 C-N-CA 124.379 1.071 . . . . 0.0 108.231 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.62 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 78.4 mt -127.6 140.23 49.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-O 121.132 0.492 . . . . 0.0 110.0 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 94.6 mttt -110.69 107.08 16.52 Favored 'General case' 0 N--CA 1.4 -2.968 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 174.683 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.03 175.35 22.72 Favored Glycine 0 C--N 1.292 -1.899 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -170.792 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 38' ' ' LEU . . . . . 0.596 ' HA ' ' OD1' ' A' ' 92' ' ' ASP . 2.3 pp -69.0 169.69 11.26 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 117.963 0.882 . . . . 0.0 111.42 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.556 ' HB ' ' HB2' ' A' ' 92' ' ' ASP . 2.2 t -70.2 106.24 3.23 Favored 'General case' 0 C--O 1.244 0.788 0 C-N-CA 119.475 -0.89 . . . . 0.0 111.8 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.43 ' O ' ' HB2' ' A' ' 121' ' ' GLU . 7.4 tp10 -175.06 111.88 0.13 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 125.437 1.495 . . . . 0.0 107.434 170.929 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.76 75.47 0.42 Allowed Glycine 0 C--N 1.264 -3.427 0 C-N-CA 118.005 -2.045 . . . . 0.0 113.72 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.85 136.66 43.94 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -55.59 121.98 10.31 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 124.64 1.176 . . . . 0.0 110.561 -172.68 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.69 122.7 0.86 Allowed Glycine 1 N--CA 1.381 -4.994 0 C-N-CA 119.718 -1.23 . . . . 0.0 113.3 177.982 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -68.81 142.69 54.81 Favored 'General case' 0 C--N 1.261 -3.262 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 162.624 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.637 ' CB ' ' HA ' ' A' ' 119' ' ' VAL . 21.2 m-70 -126.94 91.29 3.31 Favored 'General case' 0 N--CA 1.421 -1.882 0 CA-C-N 121.222 1.828 . . . . 0.0 106.715 -173.712 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.49 HG12 HD23 ' A' ' 117' ' ' LEU . 7.3 m -125.16 162.75 27.07 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -171.576 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.3 m-70 -170.81 119.46 0.53 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.407 3.083 . . . . 0.0 106.87 170.456 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.558 ' HB2' ' HA2' ' A' ' 108' ' ' GLY . 0.2 OUTLIER -102.59 84.11 2.38 Favored 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 117.87 -1.532 . . . . 0.0 112.957 -176.361 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.541 ' CZ ' ' HA ' ' A' ' 60' ' ' ALA . 0.6 OUTLIER 167.34 113.49 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.845 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA3' ' H ' ' A' ' 116' ' ' THR . . . -147.57 -154.35 6.21 Favored Glycine 0 CA--C 1.485 -1.802 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.846 178.182 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -173.96 -68.17 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.498 0 O-C-N 124.287 0.639 . . . . 0.0 110.24 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.523 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.4 t-20 -97.64 130.85 44.62 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.674 -174.53 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.1 t -84.06 -6.28 59.38 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -177.475 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.73 -25.46 13.84 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 120.95 0.405 . . . . 0.0 110.337 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.523 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -147.44 118.83 1.05 Allowed Glycine 0 N--CA 1.429 -1.807 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 -178.743 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.593 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 19.9 p -98.2 87.66 3.98 Favored 'General case' 0 C--N 1.276 -2.627 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.163 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.0 m -79.84 -39.72 30.03 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.296 177.956 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -53.55 -47.09 70.33 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.59 1.156 . . . . 0.0 111.794 -176.072 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.541 ' HA ' ' CZ ' ' A' ' 50' ' ' PHE . . . -76.87 -9.05 58.42 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -176.226 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -39.79 -64.31 1.08 Allowed Glycine 0 N--CA 1.479 1.555 0 C-N-CA 124.576 1.084 . . . . 0.0 115.363 -177.392 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.77 1.32 5.22 Favored 'Trans proline' 0 CA--C 1.544 0.983 0 C-N-CA 122.838 2.359 . . . . 0.0 113.399 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.296 9.1 p80 50.39 37.04 14.46 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -87.81 89.89 8.17 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 122.186 0.993 . . . . 0.0 109.644 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.467 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.4 OUTLIER -113.73 97.42 44.23 Favored Pre-proline 0 C--N 1.284 -2.278 0 CA-C-N 113.723 -1.58 . . . . 0.0 110.496 -177.954 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.411 ' O ' ' HB2' ' A' ' 69' ' ' ARG . 50.0 Cg_endo -84.73 -12.98 7.15 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.13 2.553 . . . . 0.0 115.995 -173.296 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.622 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 56.5 tp -85.43 -19.8 30.76 Favored 'General case' 1 CA--C 1.421 -4.012 0 CA-C-O 121.589 0.709 . . . . 0.0 109.19 -179.551 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.484 ' C ' ' H ' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -76.99 28.26 0.14 Allowed 'General case' 0 N--CA 1.384 -3.753 0 C-N-CA 127.741 2.416 . . . . 0.0 108.911 178.086 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.565 ' H ' ' C ' ' A' ' 67' ' ' LEU . 63.6 ttt180 -73.42 43.32 0.13 Allowed 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 128.558 2.743 . . . . 0.0 110.39 -173.763 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.575 ' CB ' ' HB2' ' A' ' 79' ' ' ARG . 22.6 ttmm -139.32 -18.4 0.99 Allowed 'General case' 0 C--N 1.245 -3.957 0 CA-C-N 113.894 -1.503 . . . . 0.0 108.511 166.687 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 70.33 19.31 6.52 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.105 1.762 . . . . 0.0 111.325 177.64 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.18 137.5 8.78 Favored Glycine 0 N--CA 1.426 -1.999 0 C-N-CA 120.433 -0.889 . . . . 0.0 114.595 176.077 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.36 162.46 28.64 Favored Glycine 0 N--CA 1.425 -2.07 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 175.559 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -73.24 -38.49 2.67 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 122.898 2.398 . . . . 0.0 112.751 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.743 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.9 OUTLIER -104.55 -25.45 12.75 Favored 'General case' 0 C--O 1.202 -1.422 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.253 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 49.91 -164.61 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 129.188 2.995 . . . . 0.0 115.045 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -144.58 -56.03 0.35 Allowed 'General case' 0 N--CA 1.427 -1.609 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.47 -169.144 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 105' ' ' SER . 47.6 mt-10 -172.57 -30.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 125.734 1.614 . . . . 0.0 107.67 -176.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.622 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 13.9 mmt180 -87.44 41.62 0.99 Allowed 'General case' 1 N--CA 1.364 -4.736 0 C-N-CA 125.095 1.358 . . . . 0.0 109.768 -171.422 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 . . . . . 0 C--N 1.313 -1.003 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.545 -172.658 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.519 HD11 HG21 ' A' ' 18' ' ' ILE . 10.0 tp . . . . . 0 N--CA 1.408 -2.535 0 N-CA-C 104.762 -2.31 . . . . 0.0 104.762 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.63 175.49 25.56 Favored Glycine 0 N--CA 1.404 -3.464 0 N-CA-C 109.079 -1.609 . . . . 0.0 109.079 -177.848 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.566 ' O ' ' HA ' ' A' ' 97' ' ' VAL . 14.3 t30 -77.32 138.66 39.49 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.754 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.779 HG22 ' HB1' ' A' ' 95' ' ' ALA . 13.9 p -150.74 127.12 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 178.177 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.673 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 24.7 p -141.1 122.34 14.81 Favored 'General case' 0 N--CA 1.418 -2.059 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.397 -167.356 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -109.05 103.7 12.76 Favored 'General case' 0 N--CA 1.41 -2.45 0 C-N-CA 117.031 -1.868 . . . . 0.0 106.538 173.892 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -93.99 -39.42 10.65 Favored 'General case' 0 CA--C 1.468 -2.199 0 CA-C-O 122.161 0.981 . . . . 0.0 109.955 -170.031 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.521 ' HE3' ' HA ' ' A' ' 91' ' ' LYS . 1.0 OUTLIER -85.59 5.85 29.87 Favored 'General case' 0 C--N 1.27 -2.875 0 CA-C-N 114.102 -1.408 . . . . 0.0 111.572 -177.652 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.596 ' OD1' ' HA ' ' A' ' 38' ' ' LEU . 13.4 t70 74.66 93.72 0.07 Allowed 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 123.438 0.695 . . . . 0.0 111.541 -175.815 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 106.17 13.22 23.67 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 116.269 1.267 . . . . 0.0 116.269 171.978 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 49.0 t -145.31 102.91 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.457 -2.626 0 N-CA-C 103.42 -2.807 . . . . 0.0 103.42 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.779 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -99.59 118.48 36.23 Favored 'General case' 0 N--CA 1.389 -3.477 0 C-N-CA 118.867 -1.133 . . . . 0.0 111.306 -177.794 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 96' ' ' ASP . . . . . 0.47 ' O ' ' HA ' ' A' ' 87' ' ' VAL . 21.7 t70 -80.41 111.52 16.89 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.01 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.566 ' HA ' ' O ' ' A' ' 86' ' ' ASN . 13.3 p -87.7 122.92 39.98 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.455 0 CA-C-O 121.97 0.89 . . . . 0.0 109.881 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 67.9 m -122.25 105.87 10.61 Favored 'General case' 0 C--N 1.273 -2.723 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.162 176.415 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.566 HG21 HG13 ' A' ' 31' ' ' VAL . 2.2 pp -93.74 154.76 3.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 178.417 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -125.64 160.85 28.62 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.736 1.214 . . . . 0.0 109.109 -176.321 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -82.76 99.69 9.81 Favored 'General case' 0 C--N 1.283 -2.297 0 C-N-CA 119.781 -0.767 . . . . 0.0 109.386 -171.221 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.743 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 21.5 m -95.66 162.1 13.76 Favored 'General case' 0 N--CA 1.417 -2.078 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 173.133 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.4 HG23 ' H ' ' A' ' 104' ' ' ILE . 9.9 m -103.15 -64.51 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.535 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.4 ' H ' HG23 ' A' ' 103' ' ' VAL . 26.8 mt -133.5 25.54 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 -174.132 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 21.4 t -78.57 87.43 4.53 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 122.069 0.938 . . . . 0.0 110.28 -175.503 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.8 tp -70.74 120.84 16.93 Favored 'General case' 0 N--CA 1.408 -2.574 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -74.79 87.23 2.23 Favored 'General case' 0 N--CA 1.409 -2.475 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 176.066 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.558 ' HA2' ' HB2' ' A' ' 49' ' ' GLU . . . 155.39 136.08 2.13 Favored Glycine 0 N--CA 1.411 -2.974 0 C-N-CA 119.537 -1.316 . . . . 0.0 114.379 177.634 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -89.54 -52.06 5.21 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.846 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -74.49 -47.74 31.35 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.035 176.563 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 37.7 t 179.37 -170.59 0.13 Allowed 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.572 HG22 ' HA2' ' A' ' 150' ' ' GLY . 9.5 mt -89.62 -23.95 6.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 177.564 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 tt -68.97 132.46 33.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.922 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.71 -9.16 72.55 Favored Glycine 0 N--CA 1.419 -2.448 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.163 174.945 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.407 ' HD3' ' HA ' ' A' ' 50' ' ' PHE . 4.2 mmp_? -81.23 123.95 28.89 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -175.72 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.547 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 27.6 p -89.3 101.4 14.06 Favored 'General case' 0 N--CA 1.389 -3.481 0 C-N-CA 120.256 -0.578 . . . . 0.0 109.727 177.875 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.49 HD23 HG12 ' A' ' 47' ' ' VAL . 8.0 mp -85.23 120.38 26.66 Favored 'General case' 0 CA--C 1.473 -1.986 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 174.239 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.433 HG11 ' C ' ' A' ' 141' ' ' GLY . 2.4 t -92.54 115.64 31.89 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.251 0 C-N-CA 116.824 -1.951 . . . . 0.0 111.469 -172.452 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.664 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 42.1 t -125.0 129.38 73.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 127.729 2.412 . . . . 0.0 110.587 -166.388 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.509 ' CB ' ' HB3' ' A' ' 144' ' ' LEU . 12.7 t60 -159.68 148.07 17.46 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 103.774 -2.676 . . . . 0.0 103.774 169.949 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.445 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 4.3 pm0 -68.79 88.27 0.37 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 123.112 1.434 . . . . 0.0 109.822 178.229 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -169.51 151.15 4.33 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 -171.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.38 118.68 8.41 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 118.146 0.43 . . . . 0.0 110.121 177.738 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.583 ' HA ' ' H ' ' A' ' 140' ' ' ALA . 44.0 t0 -96.7 -80.86 0.43 Allowed 'General case' 0 C--O 1.187 -2.216 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.459 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.4 t70 76.19 152.02 0.13 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 128.344 2.658 . . . . 0.0 112.271 175.28 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.07 -64.03 1.11 Allowed 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.667 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 -17.42 72.21 Favored Glycine 0 CA--C 1.481 -2.084 0 CA-C-N 114.137 -1.392 . . . . 0.0 113.03 -170.434 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.0 tttp -65.86 -41.1 92.1 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.172 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 129' ' ' GLY . . . . . 0.686 ' HA2' ' O ' ' A' ' 134' ' ' SER . . . -75.8 69.9 2.06 Favored Glycine 0 N--CA 1.409 -3.122 0 N-CA-C 115.182 0.833 . . . . 0.0 115.182 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -141.68 23.86 2.48 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 119.457 -1.354 . . . . 0.0 114.709 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.478 ' HB3' ' CB ' ' A' ' 134' ' ' SER . 64.6 t30 -132.14 176.37 8.44 Favored 'General case' 0 N--CA 1.522 3.15 0 CA-C-O 116.132 -1.89 . . . . 0.0 107.594 178.507 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.29 -57.03 11.98 Favored 'General case' 0 C--N 1.385 2.121 0 CA-C-N 121.934 2.152 . . . . 0.0 113.458 -174.803 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 -86.0 -34.18 20.87 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 121.077 0.465 . . . . 0.0 110.922 176.906 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.686 ' O ' ' HA2' ' A' ' 129' ' ' GLY . 1.3 m -66.98 -21.8 65.95 Favored 'General case' 0 C--O 1.185 -2.335 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.69 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.607 ' HA ' ' CA ' ' A' ' 129' ' ' GLY . 5.2 t -80.0 -12.55 59.7 Favored 'General case' 0 CA--C 1.51 -0.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.939 179.515 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -88.25 -46.77 8.95 Favored 'General case' 0 C--N 1.275 -2.669 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.239 -175.935 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.7 p -85.72 -32.72 21.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 113.892 -1.503 . . . . 0.0 112.314 -178.52 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -77.48 -4.04 83.83 Favored Glycine 0 C--O 1.202 -1.893 0 CA-C-O 119.171 -0.794 . . . . 0.0 114.879 -173.23 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -142.7 104.46 4.36 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 164.97 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.583 ' H ' ' HA ' ' A' ' 124' ' ' ASP . . . -69.83 160.35 31.93 Favored 'General case' 1 C--O 1.33 5.307 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.252 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.433 ' C ' HG11 ' A' ' 118' ' ' VAL . . . -163.77 -151.91 6.67 Favored Glycine 1 N--CA 1.382 -4.94 0 C-N-CA 118.124 -1.988 . . . . 0.0 115.262 -165.953 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.593 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 2.9 m -46.9 7.28 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 1 C-N-CA 132.552 4.341 . . . . 0.0 120.14 -166.146 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 72.3 mtt180 -125.69 -27.58 3.36 Favored 'General case' 0 C--N 1.264 -3.138 0 C-N-CA 118.794 -1.162 . . . . 0.0 111.289 178.993 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.509 ' HB3' ' CB ' ' A' ' 120' ' ' HIS . 4.0 mm? -60.46 -43.69 96.65 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.084 -174.346 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.664 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.51 112.39 0.34 Allowed 'General case' 0 CA--C 1.49 -1.338 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.547 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.428 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 88.8 m -95.19 140.44 30.1 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.522 -177.397 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.551 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.08 150.67 13.35 Favored Glycine 1 N--CA 1.389 -4.474 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.607 176.319 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.4 t -75.67 119.59 23.84 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 171.356 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.447 HD12 ' HB1' ' A' ' 6' ' ' ALA . 23.2 mm -118.59 102.17 12.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.368 0 N-CA-C 105.264 -2.125 . . . . 0.0 105.264 179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.572 ' HA2' HG22 ' A' ' 112' ' ' ILE . . . 177.8 -172.5 45.15 Favored Glycine 0 CA--C 1.452 -3.902 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.256 -177.191 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.58 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.6 tt -70.67 103.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 122.108 0.956 . . . . 0.0 110.724 -178.959 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.53 115.36 5.27 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.778 -1.555 . . . . 0.0 111.26 -179.077 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 . . . . . 0 C--N 1.296 -1.75 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.797 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.575 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.218 -0.6 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.489 ' HA ' ' HG2' ' A' ' 21' ' ' GLU . 60.0 m -121.35 -43.45 2.41 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 110.648 177.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.14 144.63 33.56 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.567 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.06 149.57 51.15 Favored 'General case' 0 N--CA 1.41 -2.452 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.4 178.688 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 63.3 t -120.14 127.26 75.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -177.57 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.596 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -107.76 129.0 55.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.996 176.546 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.7 m -134.61 102.56 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 74.5 mt -96.01 134.45 39.01 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.304 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.7 tttp -147.33 122.2 9.99 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.954 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.02 -157.86 8.6 Favored Glycine 0 N--CA 1.435 -1.402 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -89.62 94.0 9.69 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 169.285 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 128.21 143.74 5.71 Favored Glycine 0 C--N 1.275 -2.829 0 N-CA-C 107.309 -2.316 . . . . 0.0 107.309 -177.053 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -97.81 123.11 0.18 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 CA-C-N 120.367 2.083 . . . . 0.0 113.524 -178.828 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 p -134.7 112.18 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.333 0 CA-C-N 114.534 -1.212 . . . . 0.0 107.957 171.751 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -118.14 119.53 35.0 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 118.874 -1.13 . . . . 0.0 111.092 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -159.36 149.43 19.28 Favored Glycine 0 N--CA 1.406 -3.356 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.536 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 27.5 pt -113.82 107.21 22.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.596 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 28.1 mm -100.44 128.45 52.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.635 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 4.3 t30 -101.0 144.21 30.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -178.543 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.567 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 87.0 m-85 -132.57 120.18 21.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.794 0.33 . . . . 0.0 111.531 175.17 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.489 ' HG2' ' HA ' ' A' ' 2' ' ' THR . 1.8 tm-20 -132.34 101.78 5.49 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 174.152 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.691 ' HG2' ' O ' ' A' ' 105' ' ' SER . 18.1 mp0 -127.51 132.21 49.98 Favored 'General case' 0 N--CA 1.387 -3.606 0 N-CA-C 103.601 -2.74 . . . . 0.0 103.601 167.109 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.442 ' HD3' ' H ' ' A' ' 24' ' ' GLU . 6.3 tmtt? -131.54 168.64 17.32 Favored 'General case' 0 C--N 1.257 -3.437 0 N-CA-C 107.14 -1.429 . . . . 0.0 107.14 -173.21 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.442 ' H ' ' HD3' ' A' ' 23' ' ' LYS . 10.3 pt-20 -62.48 -9.5 8.75 Favored 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 124.038 0.935 . . . . 0.0 111.777 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -56.86 -39.5 74.41 Favored 'General case' 0 N--CA 1.424 -1.726 0 C-N-CA 124.999 1.319 . . . . 0.0 110.528 176.444 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 26' ' ' ASN . . . . . 0.467 ' OD1' HG22 ' A' ' 103' ' ' VAL . 56.4 t30 66.76 104.08 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 123.635 0.774 . . . . 0.0 110.478 178.297 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.72 -177.0 48.13 Favored Glycine 0 CA--C 1.474 -2.477 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -175.18 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -57.26 123.19 13.22 Favored 'Trans proline' 0 C--O 1.24 0.61 0 C-N-CA 122.262 1.975 . . . . 0.0 111.642 -178.787 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 92.5 t -76.42 111.46 13.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.436 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . 0.3 0.0 OUTLIER -112.59 107.29 15.95 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.812 1.291 . . . . 0.0 112.123 177.882 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.635 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 30.8 m -137.22 154.4 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.577 0 CA-C-N 113.054 -1.885 . . . . 0.0 106.323 -172.269 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 61.6 p-90 -139.19 148.1 42.7 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' VAL . . . -169.57 137.75 4.68 Favored Glycine 0 N--CA 1.404 -3.444 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 171.975 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.3 t -117.2 131.72 56.8 Favored 'General case' 0 N--CA 1.407 -2.587 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 -177.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.721 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 15.5 pt -114.91 153.18 16.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 C-N-CA 118.694 -1.203 . . . . 0.0 111.075 176.582 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.416 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 48.4 mtmt -120.34 107.61 13.15 Favored 'General case' 0 N--CA 1.408 -2.552 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 177.24 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.08 174.17 17.29 Favored Glycine 0 C--N 1.295 -1.734 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 45.5 tp -69.02 171.81 7.62 Favored 'General case' 0 CA--C 1.571 1.77 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 176.289 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 1.6 t -69.27 110.31 4.55 Favored 'General case' 0 CA--C 1.5 -0.954 0 O-C-N 121.243 -0.911 . . . . 0.0 112.978 -178.354 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 39' ' ' THR . 10.3 mm-40 -170.47 171.58 6.42 Favored 'General case' 0 C--N 1.275 -2.652 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 173.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.27 -155.77 31.53 Favored Glycine 0 C--N 1.26 -3.65 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 169.344 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.691 HD22 ' HB ' ' A' ' 87' ' ' VAL . 5.2 tt -178.44 149.43 0.5 Allowed 'General case' 0 N--CA 1.412 -2.337 0 N-CA-C 103.563 -2.754 . . . . 0.0 103.563 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.603 ' N ' HD23 ' A' ' 42' ' ' LEU . 78.2 t60 -161.34 121.6 2.68 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 173.32 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HB3' ' A' ' 124' ' ' ASP . . . 77.09 136.84 0.81 Allowed Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.726 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HB2' ' CG1' ' A' ' 119' ' ' VAL . 0.1 OUTLIER -142.23 131.46 23.43 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 117.855 0.827 . . . . 0.0 112.204 -177.952 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 46' ' ' HIS . . . . . 0.508 ' HB2' HD23 ' A' ' 126' ' ' LEU . 21.7 t-80 -82.08 89.3 6.44 Favored 'General case' 0 CA--C 1.476 -1.877 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.695 -177.074 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.625 ' CB ' HD23 ' A' ' 117' ' ' LEU . 6.7 m -110.47 80.89 0.55 Allowed 'Isoleucine or valine' 1 N--CA 1.379 -4.008 0 CA-C-O 122.897 1.332 . . . . 0.0 110.346 175.689 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.502 ' HA ' HH11 ' A' ' 115' ' ' ARG . 2.4 p-80 -174.72 145.24 0.88 Allowed 'General case' 0 CA--C 1.487 -1.447 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.98 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' CE1' ' A' ' 46' ' ' HIS 0.351 10.9 mm-40 -172.92 173.97 3.64 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 126.628 1.971 . . . . 0.0 111.554 163.423 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -110.28 75.04 0.91 Allowed 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 102.886 -3.005 . . . . 0.0 102.886 171.671 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' HA ' ' A' ' 115' ' ' ARG . . . -104.91 -149.97 19.72 Favored Glycine 0 CA--C 1.482 -1.984 0 CA-C-N 113.142 -1.845 . . . . 0.0 113.617 -169.114 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 37.9 t70 175.0 -41.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 89.4 m-20 -101.13 124.93 47.61 Favored 'General case' 0 CA--C 1.498 -1.037 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.92 -173.201 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.3 t -84.25 -25.63 29.25 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.165 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.41 -8.6 38.21 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.218 0.533 . . . . 0.0 110.261 -178.806 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -144.25 110.02 0.56 Allowed Glycine 0 N--CA 1.409 -3.116 0 C-N-CA 119.486 -1.34 . . . . 0.0 109.901 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.775 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.7 p -96.44 86.7 4.23 Favored 'General case' 0 N--CA 1.391 -3.401 0 CA-C-O 122.32 1.057 . . . . 0.0 110.733 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 30.5 m -82.03 -47.38 12.7 Favored 'General case' 0 N--CA 1.417 -2.116 0 CA-C-N 114.043 -1.435 . . . . 0.0 109.484 174.026 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 p -72.03 -16.8 62.05 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.194 -176.791 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -82.48 -6.69 59.46 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.22 177.078 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 61' ' ' GLY . . . . . 0.665 ' HA2' ' HB3' ' A' ' 142' ' ' SER . . . -50.58 176.33 0.05 OUTLIER Glycine 0 C--N 1.355 1.592 0 CA-C-N 114.83 -1.077 . . . . 0.0 112.311 175.625 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.48 ' HA ' ' CE2' ' A' ' 64' ' ' PHE . 21.3 Cg_exo -68.88 55.24 0.92 Allowed 'Trans proline' 0 N--CA 1.488 1.174 0 C-N-CA 123.466 2.777 . . . . 0.0 112.137 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -159.12 87.74 0.86 Allowed 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 105.567 -2.012 . . . . 0.0 105.567 -177.214 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.641 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 27.2 m-85 -111.78 162.99 14.66 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 -173.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -93.5 99.15 3.05 Favored Pre-proline 0 C--O 1.248 0.975 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.325 174.143 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.641 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 71.0 Cg_exo -52.36 -12.04 1.42 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 125.197 3.932 . . . . 0.0 114.913 -178.507 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.5 mt -94.92 7.39 46.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-O 122.761 1.267 . . . . 0.0 107.996 -171.212 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.9 t -120.76 23.57 10.67 Favored 'General case' 0 N--CA 1.395 -3.186 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 175.536 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.521 ' NH2' ' HB3' ' A' ' 66' ' ' PRO . 38.6 ttp180 -132.15 -32.64 1.37 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 113.199 -1.819 . . . . 0.0 107.629 171.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 78' ' ' GLU 0.256 5.3 mmtp 39.32 71.12 0.18 Allowed 'General case' 0 N--CA 1.427 -1.583 0 C-N-CA 125.616 1.566 . . . . 0.0 112.814 178.332 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 69.6 -29.35 0.18 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 125.747 1.619 . . . . 0.0 114.29 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 96.5 159.59 31.97 Favored Glycine 0 N--CA 1.418 -2.541 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -173.028 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.81 163.22 36.97 Favored Glycine 0 C--N 1.291 -1.954 0 C-N-CA 119.227 -1.463 . . . . 0.0 111.379 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.94 -43.16 1.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 118.885 1.343 . . . . 0.0 112.044 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -120.73 -28.36 4.89 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.609 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.639 ' HA ' ' CG ' ' A' ' 80' ' ' HIS . 5.9 p-10 170.91 165.75 0.08 Allowed 'General case' 0 CA--C 1.481 -1.675 0 C-N-CA 124.287 1.035 . . . . 0.0 108.692 177.347 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -137.64 -73.31 0.42 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.411 ' HB3' ' HG3' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -135.93 -65.64 0.58 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 177.716 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -119.85 68.78 0.83 Allowed 'General case' 0 N--CA 1.415 -2.203 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 171.645 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.639 ' CG ' ' HA ' ' A' ' 76' ' ' ASP . 29.8 t-80 . . . . . 0 C--N 1.302 -1.46 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 177.635 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.442 ' O ' ' HE1' ' A' ' 45' ' ' PHE . 1.5 pt? . . . . . 0 CA--C 1.501 -0.911 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 171.4 147.54 5.71 Favored Glycine 1 N--CA 1.393 -4.189 0 C-N-CA 118.842 -1.646 . . . . 0.0 112.444 177.719 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -105.71 128.01 53.42 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 102.43 -3.174 . . . . 0.0 102.43 162.463 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.691 ' HB ' HD22 ' A' ' 42' ' ' LEU . 5.8 t -128.77 153.18 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 N-CA-C 102.557 -3.127 . . . . 0.0 102.557 -177.953 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 94' ' ' VAL . 15.4 t -139.53 149.85 44.39 Favored 'General case' 0 N--CA 1.4 -2.966 0 C-N-CA 118.594 -1.242 . . . . 0.0 110.694 -175.886 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.504 ' CB ' ' HB2' ' A' ' 121' ' ' GLU . . . -120.44 155.4 33.58 Favored 'General case' 2 C--N 1.224 -4.887 0 CA-C-N 114.381 -1.281 . . . . 0.0 108.725 -177.375 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -149.42 160.14 43.7 Favored 'General case' 1 C--N 1.236 -4.359 0 N-CA-C 104.311 -2.478 . . . . 0.0 104.311 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.595 ' HB3' ' HB ' ' A' ' 39' ' ' THR . 0.0 OUTLIER -44.08 -31.72 1.01 Allowed 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 119.51 1.05 . . . . 0.0 112.976 172.77 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -91.53 -25.27 19.32 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.864 0.84 . . . . 0.0 109.116 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 36' ' ' LYS . . . 83.12 85.81 0.82 Allowed Glycine 0 N--CA 1.397 -3.908 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.317 -175.955 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 88' ' ' THR . 10.8 m -136.95 102.37 2.63 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 122.312 1.053 . . . . 0.0 109.753 175.659 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.721 ' HB3' ' H ' ' A' ' 35' ' ' ILE . . . -96.25 145.33 25.65 Favored 'General case' 0 N--CA 1.408 -2.561 0 CA-C-N 113.966 -1.47 . . . . 0.0 112.197 172.656 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.03 152.83 38.65 Favored 'General case' 0 N--CA 1.412 -2.325 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 166.163 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 28.7 m -80.9 134.58 26.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 CA-C-O 121.864 0.84 . . . . 0.0 108.899 178.427 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.404 ' OG ' HG22 ' A' ' 87' ' ' VAL . 19.6 m -75.86 106.05 7.24 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.384 -176.392 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 pt -121.72 122.02 65.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 174.051 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -146.23 151.44 37.59 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.386 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -93.07 99.28 11.91 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 117.712 -1.595 . . . . 0.0 110.831 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.46 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 53.1 m -102.86 142.82 33.34 Favored 'General case' 0 N--CA 1.396 -3.148 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 172.233 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.467 HG22 ' OD1' ' A' ' 26' ' ' ASN . 14.7 p -101.77 -46.85 11.33 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 C-N-CA 117.383 -1.727 . . . . 0.0 112.156 -178.852 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.9 tt -121.58 24.01 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.278 0 CA-C-O 122.308 1.051 . . . . 0.0 111.729 -171.29 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.691 ' O ' ' HG2' ' A' ' 22' ' ' GLN . 56.6 m -103.64 87.6 2.87 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.169 -1.582 . . . . 0.0 114.008 -177.416 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 6.1 mp -69.82 129.54 39.85 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 169.941 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.1 t -73.63 87.68 1.67 Allowed 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.857 0.836 . . . . 0.0 112.491 -170.188 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.55 135.47 2.83 Favored Glycine 0 N--CA 1.406 -3.302 0 CA-C-N 114.189 -1.368 . . . . 0.0 112.426 168.226 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -46.97 -70.53 0.09 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.912 0.885 . . . . 0.0 111.88 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 63.8 m80 -123.02 -34.82 3.11 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.653 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 17.5 m -96.42 106.76 19.05 Favored 'General case' 0 N--CA 1.414 -2.257 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.783 -178.136 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 18.1 mm -87.67 -48.11 15.38 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 168.775 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.3 tt -102.69 151.11 6.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.258 174.498 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.24 -31.01 8.99 Favored Glycine 0 CA--C 1.478 -2.268 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 172.754 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.674 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 28.7 ptt180 -69.46 156.43 38.87 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 124.455 1.102 . . . . 0.0 112.549 -175.628 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -116.06 113.94 23.86 Favored 'General case' 0 N--CA 1.388 -3.533 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 -178.636 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.764 HD22 ' HB ' ' A' ' 149' ' ' ILE . 4.6 mp -95.98 160.49 14.43 Favored 'General case' 0 C--N 1.268 -2.953 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -174.201 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 145' ' ' ALA 0.327 8.4 p -140.5 116.14 7.37 Favored 'Isoleucine or valine' 0 C--O 1.263 1.793 0 C-N-CA 116.324 -2.15 . . . . 0.0 114.019 -179.156 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 45' ' ' PHE . 19.7 m -138.49 170.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -176.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.513 ' ND1' ' HB3' ' A' ' 144' ' ' LEU . 62.7 t60 -170.44 167.95 8.03 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 105.129 -2.175 . . . . 0.0 105.129 176.59 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.504 ' HB2' ' CB ' ' A' ' 89' ' ' ALA . 8.9 pm0 -70.96 85.89 0.7 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 119.973 1.26 . . . . 0.0 110.467 177.202 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.536 ' C ' ' HA ' ' A' ' 42' ' ' LEU . 30.5 ttmt -175.7 154.99 1.65 Allowed 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.553 -176.677 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.562 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -60.27 107.31 0.63 Allowed 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 168.901 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.531 ' OD2' ' HA ' ' A' ' 140' ' ' ALA . 9.0 t70 -105.36 17.56 23.73 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.758 0.823 . . . . 0.0 108.93 -179.136 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -35.73 114.91 0.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.438 1.895 . . . . 0.0 111.306 -177.818 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.508 HD23 ' HB2' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -90.79 -36.39 14.28 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.137 -168.151 . . . . . . . . 3 3 . 1 . 016 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.21 -27.19 56.22 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.588 -177.453 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -100.84 -26.01 13.91 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.955 0.378 . . . . 0.0 110.907 -178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.05 -71.6 0.95 Allowed Glycine 0 CA--C 1.529 0.937 0 N-CA-C 113.767 0.267 . . . . 0.0 113.767 -177.229 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 118.73 -6.47 13.83 Favored Glycine 0 C--N 1.313 -0.728 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -175.025 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 26.8 t30 -162.67 150.66 14.03 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -48.26 -51.13 27.05 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 124.122 0.889 . . . . 0.0 112.062 -176.992 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.38 -48.28 78.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.614 -178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 8.2 m -62.56 -24.56 67.6 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -176.545 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.7 m -69.63 -35.23 75.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 122.008 0.909 . . . . 0.0 109.407 176.999 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -83.41 -41.15 18.45 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.776 -174.052 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -74.01 -52.37 12.96 Favored 'General case' 0 C--N 1.273 -2.726 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.14 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 112.95 91.69 1.96 Allowed Glycine 1 N--CA 1.388 -4.504 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -176.167 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -34.57 117.43 0.36 Allowed 'General case' 1 C--O 1.333 5.488 0 C-N-CA 126.233 1.813 . . . . 0.0 113.265 -173.149 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.531 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -153.63 142.5 21.11 Favored 'General case' 0 N--CA 1.411 -2.417 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.357 175.198 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.81 86.03 1.55 Allowed Glycine 0 N--CA 1.425 -2.091 0 N-CA-C 104.525 -3.43 . . . . 0.0 104.525 164.166 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 142' ' ' SER . . . . . 0.665 ' HB3' ' HA2' ' A' ' 61' ' ' GLY . 21.0 m -55.01 -3.89 0.06 Allowed 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 118.095 2.628 . . . . 0.0 118.095 -166.49 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.668 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 11.9 ptm180 -144.75 11.0 1.4 Allowed 'General case' 0 C--N 1.247 -3.885 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.038 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.513 ' HB3' ' ND1' ' A' ' 120' ' ' HIS . 4.6 mm? -78.6 -9.21 59.28 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.695 -175.906 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.15 109.69 0.39 Allowed 'General case' 0 CA--C 1.494 -1.186 0 C-N-CA 123.791 0.836 . . . . 0.0 108.915 173.638 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 38.3 m -96.43 137.06 36.08 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.02 125.38 1.2 Allowed Glycine 0 N--CA 1.424 -2.137 0 C-N-CA 118.498 -1.811 . . . . 0.0 113.434 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.674 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 75.6 t -73.51 101.48 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 171.733 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.764 ' HB ' HD22 ' A' ' 117' ' ' LEU . 53.7 mt -116.27 128.44 73.59 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.523 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.11 -168.49 40.35 Favored Glycine 3 CA--C 1.415 -6.186 0 N-CA-C 108.121 -1.992 . . . . 0.0 108.121 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.519 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.8 pp -67.81 121.16 16.46 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 120.096 -0.642 . . . . 0.0 111.165 179.104 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -131.75 114.75 15.13 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 174.126 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 . . . . . 0 C--N 1.289 -2.065 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.571 -179.31 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.55 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 26.2 m -112.84 -31.51 6.7 Favored 'General case' 0 CA--C 1.557 1.222 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -171.641 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 3' ' ' LYS . . . . . 0.454 ' HB2' HD21 ' A' ' 19' ' ' ASN . 62.1 pttt -146.79 158.37 43.89 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.861 -174.856 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.781 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -143.01 150.37 39.52 Favored 'General case' 0 N--CA 1.395 -3.178 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.486 ' CG2' ' HB3' ' A' ' 152' ' ' ALA . 29.0 m -129.63 138.93 52.95 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.573 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.572 ' HB2' HG13 ' A' ' 149' ' ' ILE . . . -116.6 136.02 53.32 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 114.757 -1.11 . . . . 0.0 111.799 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.7 m -133.07 105.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.161 0.505 . . . . 0.0 110.608 175.922 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.424 HD23 HD21 ' A' ' 117' ' ' LEU . 0.4 OUTLIER -114.75 151.14 34.24 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.651 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -157.43 150.45 23.44 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 175.54 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.15 -158.76 8.81 Favored Glycine 0 N--CA 1.414 -2.784 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 177.679 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -69.39 -39.19 78.12 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 124.935 1.021 . . . . 0.0 109.764 176.468 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.16 164.13 29.51 Favored Glycine 0 C--O 1.251 1.189 0 N-CA-C 108.704 -1.759 . . . . 0.0 108.704 174.461 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -83.14 123.4 3.51 Favored 'Trans proline' 0 N--CA 1.424 -2.613 0 CA-C-N 120.371 2.086 . . . . 0.0 109.739 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 14' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 12.1 m -132.21 123.52 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.667 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 178.103 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -130.32 119.58 23.03 Favored 'General case' 0 C--N 1.274 -2.685 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -166.87 166.62 39.22 Favored Glycine 0 N--CA 1.408 -3.194 0 C-N-CA 119.115 -1.517 . . . . 0.0 112.086 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.422 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 11.9 tt -151.53 126.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 179.096 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.486 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -122.87 136.6 59.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -178.185 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.454 HD21 ' HB2' ' A' ' 3' ' ' LYS . 25.1 t-20 -110.61 130.3 55.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.274 0.63 . . . . 0.0 109.395 -176.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.781 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 68.0 m-85 -130.16 133.59 46.71 Favored 'General case' 0 CA--C 1.498 -1.026 0 O-C-N 123.583 0.552 . . . . 0.0 110.824 178.183 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.484 ' O ' HG13 ' A' ' 104' ' ' ILE . 15.8 pt-20 -106.03 103.31 12.76 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 171.659 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.501 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -85.78 88.37 7.54 Favored 'General case' 1 N--CA 1.371 -4.415 0 CA-C-O 122.711 1.243 . . . . 0.0 112.164 -171.876 . . . . . . . . 4 4 . 1 . 017 nuclear build core ' A' A ' 23' ' ' LYS . . . . . 0.435 ' HE3' ' CD ' ' A' ' 21' ' ' GLU . 96.1 mttt -76.11 106.52 7.76 Favored 'General case' 0 N--CA 1.409 -2.509 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 172.647 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HG3' ' HB2' ' A' ' 106' ' ' LEU . 28.7 tt0 -48.58 -39.42 23.67 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 113.693 -1.594 . . . . 0.0 113.86 -167.384 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.6 m -90.63 -61.96 1.56 Allowed 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 120.773 0.32 . . . . 0.0 110.461 177.368 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -173.56 171.47 3.87 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -177.908 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 162.42 163.0 14.21 Favored Glycine 0 CA--C 1.494 -1.266 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.218 175.881 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -62.02 124.53 14.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.326 2.017 . . . . 0.0 107.483 172.116 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.447 ' HB ' HG13 ' A' ' 31' ' ' VAL . 35.2 m -95.63 117.36 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -174.057 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HE2' ' HB3' ' A' ' 30' ' ' LYS . 19.2 ttpt -82.65 101.87 11.1 Favored 'General case' 0 N--CA 1.413 -2.288 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.894 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.447 HG13 ' HB ' ' A' ' 29' ' ' VAL . 35.7 m -137.13 137.73 46.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 67.0 p-90 -148.3 137.31 21.82 Favored 'General case' 0 C--N 1.269 -2.902 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.54 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -153.28 140.19 7.42 Favored Glycine 0 N--CA 1.4 -3.712 0 C-N-CA 119.779 -1.2 . . . . 0.0 111.063 176.888 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.7 m -115.28 141.82 47.52 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.722 ' HB ' ' HB3' ' A' ' 95' ' ' ALA . 41.1 mm -131.43 126.73 58.82 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 176.533 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 41.2 ttmt -108.92 131.52 54.95 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 103.884 -2.636 . . . . 0.0 103.884 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.88 175.47 39.24 Favored Glycine 0 C--N 1.273 -2.968 0 N-CA-C 110.596 -1.001 . . . . 0.0 110.596 -167.478 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.34 142.76 56.68 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.496 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.68 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -69.35 105.74 2.67 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -172.777 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.529 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 27.9 mt-10 -175.43 135.77 0.33 Allowed 'General case' 0 CA--C 1.478 -1.798 0 C-N-CA 129.404 3.082 . . . . 0.0 104.057 174.743 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.63 99.99 0.17 Allowed Glycine 0 C--N 1.265 -3.395 0 C-N-CA 116.844 -2.598 . . . . 0.0 113.341 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -103.07 -86.18 0.44 Allowed 'General case' 0 N--CA 1.446 -0.639 0 O-C-N 124.547 0.792 . . . . 0.0 111.184 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.485 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.8 p80 176.39 141.42 0.07 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.37 116.06 0.54 Allowed Glycine 0 N--CA 1.419 -2.436 0 C-N-CA 119.616 -1.278 . . . . 0.0 113.048 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -122.89 107.95 12.42 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.929 0.871 . . . . 0.0 112.876 178.744 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 54.4 t60 -171.11 89.73 0.13 Allowed 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.005 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.488 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -132.4 87.81 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 O-C-N 126.344 2.278 . . . . 0.0 109.284 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.477 ' CE1' ' HA3' ' A' ' 108' ' ' GLY . 8.6 t-160 -173.27 87.4 0.06 Allowed 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.239 -0.913 . . . . 0.0 110.749 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.597 ' H ' ' HB2' ' A' ' 115' ' ' ARG . 2.7 mp0 -136.51 172.25 13.29 Favored 'General case' 1 C--N 1.24 -4.173 0 CA-C-N 113.648 -1.615 . . . . 0.0 109.082 -170.956 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.413 ' HB3' ' OD1' ' A' ' 109' ' ' ASP . 26.3 p90 -69.81 171.31 9.44 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-O 121.096 0.474 . . . . 0.0 111.2 169.31 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.775 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . -59.86 120.7 23.91 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.118 -0.946 . . . . 0.0 114.282 177.373 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CG ' ' HA ' ' A' ' 57' ' ' CYS . 5.5 t0 -129.72 -167.27 1.78 Allowed 'General case' 0 C--O 1.247 0.932 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 176.159 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 53' ' ' ASN . . . . . 0.679 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 29.9 t30 -69.47 133.86 48.23 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-O 121.369 0.604 . . . . 0.0 110.519 -179.595 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 54' ' ' THR . . . . . 0.561 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 1.3 p -51.41 -22.4 2.96 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 127.286 2.235 . . . . 0.0 114.44 -178.629 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.96 24.22 4.6 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.679 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 175.51 111.15 0.27 Allowed Glycine 0 C--O 1.196 -2.232 0 C-N-CA 117.778 -2.153 . . . . 0.0 112.566 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 13.3 p -90.56 96.03 10.45 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 121.973 0.892 . . . . 0.0 110.108 -177.877 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.3 m -76.57 -51.56 11.41 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.885 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.1 m -91.03 -36.5 14.02 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.372 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.492 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -77.58 -17.69 57.59 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.67 -177.449 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.85 -63.73 3.99 Favored Glycine 0 CA--C 1.539 1.546 0 N-CA-C 114.56 0.584 . . . . 0.0 114.56 -179.466 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -85.78 6.37 5.6 Favored 'Trans proline' 0 C--O 1.24 0.617 0 C-N-CA 122.744 2.296 . . . . 0.0 112.092 177.891 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -83.1 142.37 31.31 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 121.535 0.683 . . . . 0.0 111.409 -175.914 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -141.4 133.88 28.33 Favored 'General case' 0 N--CA 1.411 -2.384 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 172.014 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.411 ' CG ' ' H ' ' A' ' 109' ' ' ASP . 9.4 t30 -77.35 141.57 66.29 Favored Pre-proline 0 C--N 1.306 -1.317 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.508 175.91 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -53.5 -33.36 67.43 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 123.834 3.023 . . . . 0.0 115.726 -177.279 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.488 ' O ' ' HB2' ' A' ' 79' ' ' ARG . 3.0 mm? -78.15 -45.4 23.35 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.4 m -67.3 31.54 0.02 OUTLIER 'General case' 0 CA--C 1.498 -1.026 0 C-N-CA 129.477 3.111 . . . . 0.0 116.62 -172.88 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.611 ' N ' ' HB2' ' A' ' 79' ' ' ARG . 0.0 OUTLIER -136.27 -32.55 0.85 Allowed 'General case' 0 C--N 1.245 -3.958 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.584 172.633 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.492 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 82.2 tttt 34.67 -87.35 0.0 OUTLIER 'General case' 0 C--N 1.373 1.626 0 C-N-CA 124.526 1.13 . . . . 0.0 110.25 -170.941 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -178.93 12.2 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.764 0 C-N-CA 126.32 1.848 . . . . 0.0 106.994 176.961 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.49 134.38 3.35 Favored Glycine 0 N--CA 1.435 -1.403 0 C-N-CA 119.329 -1.415 . . . . 0.0 111.869 -175.382 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.59 83.95 0.09 OUTLIER Glycine 0 C--O 1.2 -2.019 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.429 ' HA ' HD11 ' A' ' 84' ' ' LEU . 59.9 Cg_endo -104.21 -0.5 0.27 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.706 2.271 . . . . 0.0 115.621 -176.541 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -123.41 -11.86 7.84 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 178.39 88.78 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -172.413 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.533 ' HG3' HG23 ' A' ' 103' ' ' VAL . 3.8 mm-40 -54.94 146.59 17.29 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 117.981 2.585 . . . . 0.0 117.981 -177.485 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -138.23 -16.22 1.24 Allowed 'General case' 0 N--CA 1.415 -2.198 0 CA-C-N 112.624 -2.08 . . . . 0.0 107.313 -177.603 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.611 ' HB2' ' N ' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -105.5 -37.31 6.84 Favored 'General case' 1 N--CA 1.358 -5.058 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 177.995 . . . . . . . . 4 4 . 1 . 017 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.463 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 45.2 m80 . . . . . 0 CA--C 1.498 -1.034 0 CA-C-N 113.344 -1.753 . . . . 0.0 110.041 176.19 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' A' ' 74' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.407 -2.614 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 . . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.74 132.06 3.46 Favored Glycine 1 N--CA 1.379 -5.13 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 174.868 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -73.8 129.22 37.48 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 118.029 -1.468 . . . . 0.0 107.545 174.805 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 44.6 t -110.81 128.15 67.39 Favored 'Isoleucine or valine' 0 C--N 1.36 1.024 0 O-C-N 121.441 -0.787 . . . . 0.0 109.278 -174.67 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.0 t -141.45 96.47 2.99 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.122 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -80.11 107.21 12.72 Favored 'General case' 0 C--O 1.2 -1.523 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 175.247 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 92' ' ' ASP . 26.3 t70 -64.69 162.68 15.34 Favored 'General case' 0 C--N 1.28 -2.428 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.644 -174.132 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.68 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 58.5 pttt -42.13 14.78 0.0 OUTLIER 'General case' 0 CA--C 1.6 2.902 0 N-CA-C 117.652 2.464 . . . . 0.0 117.652 174.601 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 92' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 90' ' ' ASP . 21.3 t70 -125.51 -28.98 3.25 Favored 'General case' 0 C--N 1.296 -1.736 0 C-N-CA 126.249 1.82 . . . . 0.0 108.753 178.555 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 104.07 66.77 0.72 Allowed Glycine 0 C--O 1.22 -0.746 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.217 -179.147 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 94' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.7 p -160.83 117.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-N 117.387 0.594 . . . . 0.0 110.602 -175.123 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.722 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -122.31 124.34 43.52 Favored 'General case' 0 N--CA 1.434 -1.27 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -111.41 112.56 24.39 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.886 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.418 HG11 HG22 ' A' ' 87' ' ' VAL . 34.4 m -112.74 125.79 70.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -178.061 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -154.56 101.09 2.31 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 169.968 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.8 mm -129.58 149.3 33.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -109.68 118.82 37.57 Favored 'General case' 0 C--O 1.265 1.874 0 CA-C-O 122.604 1.192 . . . . 0.0 112.365 179.17 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -164.95 138.59 4.83 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 113.527 -1.669 . . . . 0.0 106.689 -176.124 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.405 ' O ' ' HB2' ' A' ' 77' ' ' GLU . 58.5 m -82.31 79.77 8.68 Favored 'General case' 0 N--CA 1.435 -1.191 0 C-N-CA 119.206 -0.998 . . . . 0.0 109.352 175.04 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 103' ' ' VAL . . . . . 0.533 HG23 ' HG3' ' A' ' 77' ' ' GLU . 7.5 p -108.15 -15.05 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-N 114.324 -1.307 . . . . 0.0 109.932 -177.664 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.501 ' CG1' ' HA ' ' A' ' 22' ' ' GLN . 0.1 OUTLIER -78.21 -3.06 5.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.369 -1.742 . . . . 0.0 111.654 -173.797 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.5 m -67.78 131.22 45.15 Favored 'General case' 0 N--CA 1.409 -2.519 0 CA-C-O 121.6 0.714 . . . . 0.0 110.866 -174.071 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.587 ' HG ' HG22 ' A' ' 112' ' ' ILE . 4.6 mp -68.08 87.74 0.27 Allowed 'General case' 0 N--CA 1.425 -1.687 0 CA-C-O 123.008 1.385 . . . . 0.0 107.514 168.78 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -166.0 87.5 0.37 Allowed 'General case' 1 N--CA 1.374 -4.253 0 N-CA-C 101.481 -3.525 . . . . 0.0 101.481 172.596 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.477 ' HA3' ' CE1' ' A' ' 48' ' ' HIS . . . 166.2 136.69 2.06 Favored Glycine 0 C--N 1.266 -3.314 0 CA-C-N 113.682 -1.599 . . . . 0.0 110.953 179.013 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.413 ' OD1' ' HB3' ' A' ' 50' ' ' PHE . 16.6 t70 50.15 -85.81 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 126.643 1.977 . . . . 0.0 112.18 -171.784 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -123.95 -47.32 1.93 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 173.5 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 111' ' ' SER . . . . . 0.403 ' OG ' HG13 ' A' ' 113' ' ' ILE . 10.3 p -168.38 -162.11 0.39 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.587 HG22 ' HG ' ' A' ' 106' ' ' LEU . 12.4 tt -104.04 25.79 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.886 0 C-N-CA 119.231 -0.987 . . . . 0.0 108.992 178.905 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.604 ' HA ' ' NH1' ' A' ' 115' ' ' ARG . 2.6 pp -103.56 150.39 6.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 O-C-N 121.612 -0.68 . . . . 0.0 111.563 173.458 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.775 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 78.53 -13.33 17.33 Favored Glycine 0 CA--C 1.532 1.102 0 N-CA-C 115.043 0.777 . . . . 0.0 115.043 176.71 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.632 ' NH2' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -66.93 116.56 7.91 Favored 'General case' 0 C--O 1.253 1.248 0 CA-C-O 121.901 0.858 . . . . 0.0 112.305 -168.782 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 18.6 p -85.75 132.51 34.12 Favored 'General case' 0 N--CA 1.384 -3.754 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.25 171.156 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.787 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -69.53 137.03 52.14 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 114.985 -1.007 . . . . 0.0 111.477 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.551 HG22 ' HB1' ' A' ' 140' ' ' ALA . 12.1 p -124.03 96.48 3.93 Favored 'Isoleucine or valine' 1 C--O 1.35 6.352 0 C-N-CA 115.179 -2.608 . . . . 0.0 112.107 166.519 . . . . . . . . 3 3 . 1 . 017 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.477 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 24.0 m -150.62 170.54 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.081 0 C-N-CA 128.67 2.788 . . . . 0.0 105.829 178.257 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.466 ' NE2' ' HD2' ' A' ' 122' ' ' LYS . 29.8 p-80 -169.46 172.93 6.78 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 171.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.529 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.2 mp0 -70.01 82.67 0.49 Allowed 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 119.832 1.196 . . . . 0.0 109.492 -177.438 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.466 ' HD2' ' NE2' ' A' ' 120' ' ' HIS . 59.5 mttm -176.48 174.71 1.87 Allowed 'General case' 0 CA--C 1.494 -1.175 0 C-N-CA 129.403 3.081 . . . . 0.0 104.664 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -72.83 146.23 46.42 Favored 'General case' 0 C--N 1.286 -2.173 0 C-N-CA 119.286 -0.965 . . . . 0.0 110.246 171.515 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -129.23 -86.26 0.55 Allowed 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 174.083 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 52.42 -177.66 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.78 1.632 . . . . 0.0 111.017 171.899 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 tp -94.83 -65.05 1.01 Allowed 'General case' 0 C--N 1.288 -2.076 0 CA-C-O 122.633 1.206 . . . . 0.0 107.933 168.126 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.48 -5.04 48.16 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 112.931 -1.941 . . . . 0.0 115.451 -171.295 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 128' ' ' LYS . . . . . 0.438 ' HA ' ' HD2' ' A' ' 128' ' ' LYS . 44.6 tptt -116.78 26.42 9.85 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 122.049 0.928 . . . . 0.0 109.027 178.29 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -63.34 -28.32 72.12 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 114.397 -1.274 . . . . 0.0 113.272 178.816 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 121.86 -80.86 0.34 Allowed Glycine 0 C--O 1.22 -0.736 0 C-N-CA 119.993 -1.099 . . . . 0.0 113.748 175.229 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.484 ' H ' ' HB2' ' A' ' 134' ' ' SER . 46.5 t-20 -99.08 169.27 9.53 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.238 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . 0.335 9.6 pt-20 -54.66 -45.66 73.89 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 116.273 1.953 . . . . 0.0 116.273 -173.984 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.98 -37.98 61.77 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.349 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.484 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 49.6 m -59.97 -30.15 68.92 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-O 120.963 0.411 . . . . 0.0 111.409 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 80.5 m -78.84 -20.16 50.29 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.958 0.885 . . . . 0.0 110.168 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 41.7 tttp -91.08 -32.83 15.72 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 -176.453 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.443 HG22 ' HA ' ' A' ' 134' ' ' SER . 9.6 t -85.54 -30.43 23.39 Favored 'General case' 0 N--CA 1.409 -2.513 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.426 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.74 75.12 1.25 Allowed Glycine 0 N--CA 1.422 -2.268 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.525 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 32.3 t30 -47.32 119.95 2.93 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.277 1.431 . . . . 0.0 112.18 -174.609 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.551 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -132.58 137.6 47.13 Favored 'General case' 0 N--CA 1.42 -1.943 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.989 -173.081 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.08 89.32 0.58 Allowed Glycine 0 CA--C 1.502 -0.742 0 N-CA-C 107.581 -2.207 . . . . 0.0 107.581 170.592 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.6 m -47.07 -33.97 5.42 Favored 'General case' 0 C--O 1.2 -1.545 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -164.766 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.01 9.91 4.17 Favored 'General case' 0 C--N 1.27 -2.888 0 C-N-CA 116.162 -2.215 . . . . 0.0 109.787 178.309 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.9 mp -71.41 -16.3 62.39 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.861 -0.736 . . . . 0.0 112.088 -173.134 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 145' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.18 101.89 0.28 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.8 m -136.12 147.34 47.74 Favored 'General case' 0 N--CA 1.407 -2.615 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.561 ' HA2' ' O ' ' A' ' 54' ' ' THR . . . -162.38 149.64 17.98 Favored Glycine 0 N--CA 1.396 -3.988 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 148' ' ' VAL . . . . . 0.632 HG13 ' NH2' ' A' ' 115' ' ' ARG . 2.8 t -69.05 104.67 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 176.195 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.787 HG21 ' HB3' ' A' ' 117' ' ' LEU . 7.4 tt -123.47 101.57 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -176.128 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.492 ' HA3' ' NH1' ' A' ' 115' ' ' ARG . . . 176.66 -167.13 38.42 Favored Glycine 0 CA--C 1.453 -3.8 0 N-CA-C 107.889 -2.084 . . . . 0.0 107.889 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 6.3 tt -61.99 104.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.107 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.457 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.486 ' HB3' ' CG2' ' A' ' 5' ' ' VAL . . . -103.31 102.04 11.98 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.631 -0.828 . . . . 0.0 110.406 -179.537 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 pt20 . . . . . 0 C--N 1.279 -2.474 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.145 179.044 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 1' ' ' ALA . . . . . 0.637 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 N--CA 1.47 0.57 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 2' ' ' THR . . . . . 0.421 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 8.2 m -121.06 -37.42 2.96 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.184 -0.606 . . . . 0.0 112.033 -175.719 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -136.34 136.1 39.4 Favored 'General case' 0 C--O 1.25 1.109 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -174.487 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -156.14 103.15 2.17 Favored 'General case' 0 CA--C 1.479 -1.769 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.473 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.634 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 33.9 m -110.97 134.48 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-O 121.655 0.74 . . . . 0.0 110.389 -176.009 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 6' ' ' ALA . . . . . 0.695 ' HB2' ' HA ' ' A' ' 149' ' ' ILE . . . -108.81 150.11 28.11 Favored 'General case' 0 C--N 1.28 -2.422 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.342 -175.867 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.2 p -134.26 119.92 32.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.248 0.547 . . . . 0.0 110.098 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.406 ' O ' ' HD2' ' A' ' 9' ' ' LYS . 5.7 mp -98.25 151.1 20.82 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.191 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 9' ' ' LYS . . . . . 0.406 ' HD2' ' O ' ' A' ' 8' ' ' LEU . 28.6 mmmt -126.26 132.44 51.69 Favored 'General case' 0 C--O 1.248 1.021 0 N-CA-C 104.791 -2.3 . . . . 0.0 104.791 177.536 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.61 154.53 19.68 Favored Glycine 0 N--CA 1.428 -1.834 0 C-N-CA 117.477 -2.297 . . . . 0.0 118.504 -166.235 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -64.99 -44.34 89.61 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 111.802 -2.199 . . . . 0.0 106.201 169.502 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.01 153.96 17.23 Favored Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 104.143 -3.583 . . . . 0.0 104.143 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -70.59 123.95 10.3 Favored 'Trans proline' 0 N--CA 1.442 -1.518 0 CA-C-N 121.559 2.679 . . . . 0.0 111.471 -173.074 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.97 109.27 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.124 0 CA-C-N 114.199 -1.364 . . . . 0.0 107.641 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.481 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 73.6 mt-30 -119.99 119.0 32.15 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.864 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 16' ' ' GLY . . . . . 0.622 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -160.14 160.0 31.26 Favored Glycine 0 N--CA 1.405 -3.428 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -174.493 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 17' ' ' ILE . . . . . 0.461 HG13 ' HB ' ' A' ' 5' ' ' VAL . 11.5 tt -153.87 102.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 121.441 0.638 . . . . 0.0 109.546 -178.726 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.657 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.2 OUTLIER -106.55 139.86 26.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.22 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.688 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 8.5 t30 -113.53 120.81 42.25 Favored 'General case' 0 CA--C 1.51 -0.586 0 O-C-N 123.753 0.658 . . . . 0.0 110.757 -177.509 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 84' ' ' LEU . 21.0 m-85 -119.62 135.14 54.93 Favored 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -178.612 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' HG23 ' A' ' 29' ' ' VAL . 13.4 mt-10 -102.45 105.43 15.99 Favored 'General case' 0 CA--C 1.551 0.999 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.652 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.637 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 15.1 mp0 -85.6 99.86 11.56 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 176.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -132.82 108.98 9.32 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 122.288 1.042 . . . . 0.0 111.593 -172.696 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -69.49 -10.99 60.45 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.077 178.785 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.5 m -59.22 -16.9 23.55 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.563 1.545 . . . . 0.0 112.311 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 4.6 t30 74.98 116.12 0.06 Allowed 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 124.021 0.929 . . . . 0.0 112.375 177.858 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.93 169.67 24.5 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -62.41 123.91 13.29 Favored 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.534 2.156 . . . . 0.0 110.88 177.662 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.503 HG23 ' HB2' ' A' ' 21' ' ' GLU . 10.9 p -75.98 121.51 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.639 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HA ' HD11 ' A' ' 99' ' ' ILE . 67.8 mttm -89.81 97.55 11.26 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -177.041 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' HA ' ' A' ' 20' ' ' PHE . 24.7 m -122.61 133.07 69.89 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.008 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.771 -171.512 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.537 ' HA ' HG11 ' A' ' 97' ' ' VAL . 4.8 m-90 -135.26 137.61 42.71 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.454 177.564 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.657 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -161.54 140.66 6.76 Favored Glycine 0 N--CA 1.424 -2.101 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.828 173.795 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 34' ' ' SER . . . . . 0.622 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 11.4 p -114.83 126.11 54.45 Favored 'General case' 0 N--CA 1.413 -2.294 0 C-N-CA 123.844 0.857 . . . . 0.0 109.622 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.566 HG13 ' HA3' ' A' ' 16' ' ' GLY . 3.6 mp -126.06 142.82 41.59 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 18.9 ptpt -116.26 133.26 56.22 Favored 'General case' 0 N--CA 1.413 -2.283 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 172.845 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -165.21 175.81 40.99 Favored Glycine 0 N--CA 1.423 -2.171 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 -165.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 mt -66.43 144.0 56.78 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -177.843 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.465 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 59.3 p -87.34 104.17 16.16 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 -163.493 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 3.7 mp0 -173.13 140.89 0.91 Allowed 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 102.173 -3.269 . . . . 0.0 102.173 175.996 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 173.67 116.19 0.41 Allowed Glycine 0 C--N 1.255 -3.919 0 C-N-CA 114.933 -3.508 . . . . 0.0 114.436 178.449 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.668 ' HB2' ' HB2' ' A' ' 123' ' ' ALA . 96.2 mt -142.83 -39.67 0.33 Allowed 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -179.385 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -126.02 141.52 51.92 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -173.846 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.19 88.4 0.58 Allowed Glycine 0 N--CA 1.44 -1.036 0 CA-C-N 115.156 -0.929 . . . . 0.0 111.698 -178.854 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 45' ' ' PHE . . . . . 0.443 ' HB3' ' O ' ' A' ' 125' ' ' ASP . 0.4 OUTLIER -90.9 84.72 5.83 Favored 'General case' 1 C--O 1.352 6.481 0 CA-C-O 122.261 1.029 . . . . 0.0 112.021 -176.242 . . . . . . . . 4 4 . 1 . 018 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 50.9 p-80 -100.12 113.37 25.95 Favored 'General case' 0 N--CA 1.382 -3.865 0 CA-C-N 113.893 -1.503 . . . . 0.0 107.944 -171.824 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.0 t -164.89 87.93 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 O-C-N 125.048 1.468 . . . . 0.0 108.533 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -148.31 167.73 24.42 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 124.39 1.076 . . . . 0.0 109.114 163.781 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.402 ' HA ' ' HG2' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -164.81 164.98 20.95 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 171.046 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 66.5 t80 73.61 58.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.06 166.08 30.81 Favored Glycine 0 CA--C 1.474 -2.499 0 CA-C-N 112.849 -1.978 . . . . 0.0 111.54 -175.623 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -151.46 -72.37 0.16 Allowed 'General case' 0 C--N 1.292 -1.913 0 O-C-N 123.875 0.397 . . . . 0.0 111.651 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -94.5 128.59 41.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.77 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.5 t -75.98 -2.3 29.85 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 122.946 0.498 . . . . 0.0 111.515 -174.903 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.05 -8.6 19.41 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.47 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 56' ' ' GLY . . . . . 0.459 ' HA2' ' HB2' ' A' ' 143' ' ' ARG . . . -176.99 137.63 3.61 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.224 -1.465 . . . . 0.0 112.758 -178.75 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.439 ' H ' ' HB2' ' A' ' 143' ' ' ARG . 62.3 m -91.98 88.3 6.53 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 120.385 0.136 . . . . 0.0 111.101 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.7 m -80.01 -58.14 3.3 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.75 -44.17 86.7 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.817 -176.786 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.47 -5.98 51.87 Favored 'General case' 0 C--O 1.196 -1.713 0 C-N-CA 124.801 1.24 . . . . 0.0 112.384 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -31.62 -138.33 0.0 OUTLIER Glycine 0 N--CA 1.513 3.832 0 C-N-CA 128.477 2.942 . . . . 0.0 116.414 -174.263 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -62.91 53.41 0.13 Allowed 'Trans proline' 0 CA--C 1.566 2.086 0 CA-C-N 121.043 2.421 . . . . 0.0 113.11 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -93.96 112.67 24.53 Favored 'General case' 0 N--CA 1.427 -1.605 0 C-N-CA 124.348 1.059 . . . . 0.0 110.332 175.919 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' A' ' 136' ' ' LYS . 45.5 p90 -84.21 133.16 34.6 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 103.983 -2.599 . . . . 0.0 103.983 167.506 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.433 ' ND2' ' HD2' ' A' ' 66' ' ' PRO . 29.1 t-20 -75.01 140.83 74.1 Favored Pre-proline 0 C--N 1.282 -2.366 0 C-N-CA 118.842 -1.143 . . . . 0.0 111.609 -171.859 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 66' ' ' PRO . . . . . 0.458 ' O ' ' HG2' ' A' ' 69' ' ' ARG . 92.1 Cg_endo -83.8 -14.21 7.73 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.532 2.154 . . . . 0.0 113.445 -176.805 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.724 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 2.7 tt -88.36 -17.59 30.23 Favored 'General case' 0 CA--C 1.482 -1.658 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 79' ' ' ARG . 63.8 m -79.44 39.82 0.41 Allowed 'General case' 0 N--CA 1.407 -2.58 0 CA-C-N 114.315 -1.311 . . . . 0.0 111.502 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 66' ' ' PRO . 33.1 mmt180 -83.7 20.1 1.51 Allowed 'General case' 0 CA--C 1.49 -1.33 0 CA-C-O 122.506 1.146 . . . . 0.0 109.734 -178.494 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 79' ' ' ARG . 25.8 tptp -128.1 19.99 6.42 Favored 'General case' 0 N--CA 1.396 -3.126 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 171.03 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.0 m80 65.87 -48.3 0.4 Allowed 'General case' 0 N--CA 1.504 2.251 0 C-N-CA 126.349 1.86 . . . . 0.0 115.375 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.516 ' HA2' ' HG3' ' A' ' 79' ' ' ARG . . . 167.61 175.29 37.37 Favored Glycine 0 N--CA 1.415 -2.761 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -171.836 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' O ' HD11 ' A' ' 126' ' ' LEU . . . -169.38 142.5 7.36 Favored Glycine 0 CA--C 1.475 -2.444 0 N-CA-C 106.787 -2.525 . . . . 0.0 106.787 173.516 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -65.01 -43.25 12.1 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 CA-C-N 120.306 2.053 . . . . 0.0 113.849 -178.2 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.7 OUTLIER -120.89 -29.79 4.55 Favored 'General case' 0 N--CA 1.425 -1.682 0 C-N-CA 119.507 -0.877 . . . . 0.0 112.268 -178.317 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 104' ' ' ILE . 33.4 t70 -176.62 146.86 0.6 Allowed 'General case' 0 C--O 1.204 -1.301 0 CA-C-O 118.81 -0.614 . . . . 0.0 109.664 -176.68 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 79' ' ' ARG . 3.1 mm-40 -158.16 -86.76 0.04 OUTLIER 'General case' 0 C--O 1.214 -0.766 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 70' ' ' LYS . 1.5 tm-20 -161.25 -53.03 0.05 OUTLIER 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.1 -2.185 . . . . 0.0 105.1 -176.695 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.724 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 0.4 OUTLIER -34.67 -31.63 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.92 0 C-N-CA 128.635 2.774 . . . . 0.0 115.676 176.948 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' O ' ' A' ' 106' ' ' LEU . 86.3 t60 . . . . . 0 N--CA 1.5 2.066 0 C-N-CA 124.341 1.056 . . . . 0.0 109.738 -171.455 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.505 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . 89.2 mt . . . . . 0 C--O 1.2 -1.508 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 177.03 165.31 32.21 Favored Glycine 0 CA--C 1.478 -2.246 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -158.57 148.33 19.49 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.944 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 p -137.24 128.38 40.71 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.636 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 88.3 m -140.42 95.21 2.84 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -135.67 106.39 6.56 Favored 'General case' 0 C--O 1.202 -1.425 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.57 ' HA ' ' N ' ' A' ' 40' ' ' GLU . 3.3 p-10 -117.26 -19.18 9.72 Favored 'General case' 0 C--N 1.275 -2.639 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.648 -174.462 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -75.77 -57.54 3.82 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.692 -175.852 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -154.2 -22.83 0.13 Allowed 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 114.623 -1.171 . . . . 0.0 112.27 -166.34 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.48 55.3 0.16 Allowed Glycine 0 N--CA 1.42 -2.386 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -173.65 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.0 m -141.9 102.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.85 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.81 107.75 19.38 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.233 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -83.97 124.33 30.91 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 104.665 -2.346 . . . . 0.0 104.665 173.206 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.537 HG11 ' HA ' ' A' ' 32' ' ' TRP . 7.1 p -83.31 135.89 23.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 C-N-CA 119.696 -0.802 . . . . 0.0 109.426 -174.003 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.2 m -75.46 102.24 5.12 Favored 'General case' 0 N--CA 1.389 -3.508 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.134 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 31' ' ' VAL . 2.5 tt -92.8 115.72 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.593 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.7 mm-40 -133.54 157.43 45.68 Favored 'General case' 0 C--N 1.283 -2.305 0 CA-C-N 113.988 -1.46 . . . . 0.0 108.364 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -79.83 99.38 7.48 Favored 'General case' 0 N--CA 1.411 -2.405 0 CA-C-O 123.01 1.386 . . . . 0.0 109.674 176.497 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.491 ' H ' HG12 ' A' ' 29' ' ' VAL . 50.8 m -100.9 93.75 5.68 Favored 'General case' 0 N--CA 1.41 -2.444 0 CA-C-N 112.107 -2.315 . . . . 0.0 105.902 171.53 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.1 t -69.18 -47.62 73.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.825 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 104' ' ' ILE . . . . . 0.482 HG22 ' OD1' ' A' ' 76' ' ' ASP . 10.0 tp -70.62 26.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.576 1.955 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 30.0 t -70.89 90.16 0.8 Allowed 'General case' 0 CA--C 1.477 -1.845 0 N-CA-C 105.584 -2.006 . . . . 0.0 105.584 170.227 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.432 ' O ' ' CE1' ' A' ' 80' ' ' HIS . 27.2 tp -110.42 157.93 19.03 Favored 'General case' 2 C--N 1.204 -5.728 0 N-CA-C 103.333 -2.839 . . . . 0.0 103.333 -172.547 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 m -69.08 101.22 1.38 Allowed 'General case' 1 C--N 1.226 -4.776 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 174.505 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.6 137.11 13.23 Favored Glycine 0 N--CA 1.41 -3.078 0 CA-C-N 114.321 -1.309 . . . . 0.0 112.723 -170.122 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.0 t70 61.74 -86.33 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 126.449 1.899 . . . . 0.0 114.106 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 110' ' ' HIS . . . . . 0.408 ' HB2' ' O ' ' A' ' 113' ' ' ILE . 16.2 m80 -82.82 -49.02 10.13 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 175.441 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 18.5 m 168.03 -85.46 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 126.357 1.863 . . . . 0.0 111.026 173.114 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.3 mt -109.61 -54.42 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 14.0 tt -83.74 175.64 0.72 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.024 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.377 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.44 ' H ' HG12 ' A' ' 113' ' ' ILE . . . 89.43 22.77 36.17 Favored Glycine 0 CA--C 1.478 -2.278 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.918 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.427 HH22 HD12 ' A' ' 149' ' ' ILE . 44.4 mtm180 -146.98 123.12 10.83 Favored 'General case' 0 C--O 1.2 -1.539 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 11.4 p -102.09 115.48 30.63 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 171.688 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -71.05 148.07 47.92 Favored 'General case' 0 CA--C 1.506 -0.716 0 O-C-N 123.865 0.728 . . . . 0.0 112.434 -170.98 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.547 HG22 ' HB3' ' A' ' 140' ' ' ALA . 1.8 p -125.63 99.64 6.14 Favored 'Isoleucine or valine' 1 C--O 1.38 7.933 0 C-N-CA 117.118 -1.833 . . . . 0.0 112.653 172.507 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 t -148.69 151.48 13.14 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 C-N-CA 126.429 1.892 . . . . 0.0 106.153 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -144.52 170.35 16.22 Favored 'General case' 0 C--O 1.243 0.712 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 175.272 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.4 mp0 -67.86 89.93 0.29 Allowed 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 177.129 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 122' ' ' LYS . . . . . 0.5 ' HG2' ' H ' ' A' ' 123' ' ' ALA . 50.8 tttm -162.99 171.58 16.31 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -174.799 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 123' ' ' ALA . . . . . 0.668 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . . . -123.22 107.27 11.52 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.45 -88.3 0.44 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.993 165.629 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 125' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 21.9 t70 172.44 157.36 0.1 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.215 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.515 ' H ' HD23 ' A' ' 126' ' ' LEU . 1.6 pt? -90.62 -29.34 17.84 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -105.5 -23.59 7.5 Favored Glycine 0 N--CA 1.464 0.522 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.847 -177.986 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -128.48 51.99 1.95 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 177.209 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.86 82.2 0.41 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.37 -0.832 . . . . 0.0 114.35 -174.963 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.9 -127.56 8.48 Favored Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 121.376 -0.44 . . . . 0.0 112.808 174.796 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -98.41 -176.89 3.52 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.436 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 39.1 tt0 -61.88 -50.97 70.08 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 119.074 0.852 . . . . 0.0 112.993 -175.98 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -64.29 -31.06 72.12 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.463 178.063 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 m -68.48 -38.56 81.13 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 122.724 0.41 . . . . 0.0 110.64 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.9 p -65.57 -27.23 68.28 Favored 'General case' 0 C--N 1.349 0.578 0 CA-C-O 121.121 0.486 . . . . 0.0 110.748 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 136' ' ' LYS . . . . . 0.436 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 92.9 mttt -84.99 -16.45 40.82 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.061 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 31.0 m -87.98 -17.58 30.93 Favored 'General case' 0 CA--C 1.564 1.504 0 CA-C-O 121.841 0.829 . . . . 0.0 110.347 175.755 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.24 48.6 30.57 Favored Glycine 1 C--O 1.39 9.847 0 N-CA-C 108.629 -1.788 . . . . 0.0 108.629 -173.45 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -30.22 106.29 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 128.963 2.905 . . . . 0.0 114.496 -158.752 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.547 ' HB3' HG22 ' A' ' 118' ' ' VAL . . . -155.59 171.82 19.32 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 167.67 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.47 119.28 16.13 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 167.522 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.7 m -41.63 -46.84 3.79 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 115.484 1.661 . . . . 0.0 115.484 -166.878 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.732 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 0.1 OUTLIER -132.42 11.51 4.51 Favored 'General case' 0 C--N 1.288 -2.105 0 C-N-CA 118.891 -1.124 . . . . 0.0 108.529 174.845 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.6 mt -71.69 -17.33 62.23 Favored 'General case' 0 CA--C 1.497 -1.09 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.297 -170.633 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.35 89.67 1.59 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.96 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.732 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 53.0 m -131.2 153.95 48.92 Favored 'General case' 0 N--CA 1.424 -1.726 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.253 -178.742 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.74 148.65 11.58 Favored Glycine 0 N--CA 1.409 -3.136 0 N-CA-C 108.025 -2.03 . . . . 0.0 108.025 176.021 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 93.8 t -69.23 105.62 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 176.814 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.695 ' HA ' ' HB2' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -88.74 103.2 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.703 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.07 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.36 -177.79 48.48 Favored Glycine 1 N--CA 1.383 -4.871 0 C-N-CA 119.081 -1.533 . . . . 0.0 112.266 -178.657 . . . . . . . . 3 3 . 1 . 018 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.7 tt -53.32 112.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 125.119 1.367 . . . . 0.0 113.184 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.72 99.94 3.83 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 171.801 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.288 -2.095 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -177.419 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.702 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.4 m -94.26 -26.81 16.46 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.39 1.09 . . . . 0.0 108.606 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -166.03 172.11 11.78 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 174.626 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 4' ' ' ALA . . . . . 0.719 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -151.71 158.97 44.11 Favored 'General case' 0 C--N 1.287 -2.149 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.538 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 5' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 86.7 t -140.93 121.41 13.14 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.365 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -177.855 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.12 145.74 50.63 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 -177.47 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 p -135.36 125.87 44.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 O-C-N 123.66 0.6 . . . . 0.0 109.391 -179.15 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 8' ' ' LEU . . . . . 0.454 ' H ' HD23 ' A' ' 8' ' ' LEU . 1.4 pt? -125.52 144.24 50.64 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.52 -175.07 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -163.43 135.55 5.12 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 107.084 -1.451 . . . . 0.0 107.084 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.95 -157.17 7.99 Favored Glycine 0 C--N 1.301 -1.378 0 C-N-CA 120.233 -0.984 . . . . 0.0 112.265 -175.863 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -55.0 -50.95 67.73 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.262 1.025 . . . . 0.0 110.505 177.051 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -92.15 163.91 28.15 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -90.57 123.56 0.97 Allowed 'Trans proline' 0 N--CA 1.418 -2.921 0 CA-C-N 120.473 2.136 . . . . 0.0 111.026 -177.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 m -133.3 131.52 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.042 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 15' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -145.97 123.17 11.52 Favored 'General case' 0 C--N 1.269 -2.933 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.604 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.97 161.64 34.89 Favored Glycine 0 N--CA 1.41 -3.042 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.0 tt -132.5 110.23 15.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 18' ' ' ILE . . . . . 0.512 HD13 ' H ' ' A' ' 18' ' ' ILE . 0.1 OUTLIER -107.65 132.84 54.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 -179.763 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 19' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 2.7 m-20 -106.05 139.62 40.3 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 20' ' ' PHE . . . . . 0.719 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 24.4 t80 -137.47 127.6 26.05 Favored 'General case' 0 C--O 1.252 1.186 0 CA-C-N 118.996 0.816 . . . . 0.0 111.577 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -134.38 102.45 5.34 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-O 121.797 0.808 . . . . 0.0 112.823 -178.625 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 22' ' ' GLN . . . . . 0.681 HE21 ' HG ' ' A' ' 106' ' ' LEU . 2.5 pm0 -127.71 162.91 25.47 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -178.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER 64.63 -56.39 0.27 Allowed 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.808 1.243 . . . . 0.0 113.001 176.352 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.72 -43.93 87.59 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.157 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.0 m -81.49 -65.85 0.96 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 171.459 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 57.45 96.52 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 124.33 1.052 . . . . 0.0 109.924 177.83 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 27' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 29' ' ' VAL . . . 140.53 -143.21 13.19 Favored Glycine 0 CA--C 1.463 -3.198 0 C-N-CA 118.545 -1.788 . . . . 0.0 108.692 -172.467 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.47 122.06 10.51 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 N-CA-C 107.403 -1.807 . . . . 0.0 107.403 175.549 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 29' ' ' VAL . . . . . 0.737 HG12 HG13 ' A' ' 31' ' ' VAL . 55.7 t -102.69 113.36 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.807 0 CA-C-O 121.673 0.749 . . . . 0.0 109.927 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -84.61 102.73 13.14 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.616 -1.629 . . . . 0.0 109.799 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 31' ' ' VAL . . . . . 0.737 HG13 HG12 ' A' ' 29' ' ' VAL . 26.8 m -130.35 144.6 37.47 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.683 -176.002 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 32' ' ' TRP . . . . . 0.409 ' HA ' HG11 ' A' ' 97' ' ' VAL . 66.1 p-90 -148.12 134.67 19.76 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.587 178.333 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 33' ' ' GLY . . . . . 0.566 ' O ' HG22 ' A' ' 97' ' ' VAL . . . -164.03 137.9 5.0 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 119.132 -1.509 . . . . 0.0 113.119 169.36 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.8 m -114.23 126.62 55.25 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -177.468 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -130.26 133.18 64.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-O 121.261 0.553 . . . . 0.0 111.188 -177.458 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 36' ' ' LYS . . . . . 0.453 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 22.1 ptmt -106.59 133.2 51.63 Favored 'General case' 0 N--CA 1.419 -2.008 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.596 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 37' ' ' GLY . . . . . 0.521 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -157.97 174.37 35.26 Favored Glycine 0 N--CA 1.421 -2.316 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -170.246 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 tp -68.72 171.99 6.99 Favored 'General case' 0 CA--C 1.567 1.598 0 C-N-CA 123.305 0.642 . . . . 0.0 109.47 178.307 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 39' ' ' THR . . . . . 0.517 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 7.2 t -67.59 111.07 3.97 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.42 -0.8 . . . . 0.0 112.73 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 40' ' ' GLU . . . . . 0.576 ' H ' ' HA ' ' A' ' 90' ' ' ASP . 0.2 OUTLIER -163.56 174.15 12.15 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-O 123.127 1.441 . . . . 0.0 113.811 178.079 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.92 -144.53 0.05 OUTLIER Glycine 2 C--N 1.238 -4.901 0 CA-C-N 110.477 -3.056 . . . . 0.0 114.125 173.754 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 42' ' ' LEU . . . . . 0.59 ' HB3' HG22 ' A' ' 88' ' ' THR . 2.4 pt? -138.42 148.37 44.36 Favored 'General case' 1 N--CA 1.37 -4.428 0 CA-C-N 114.161 -1.019 . . . . 0.0 110.641 -164.933 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 43' ' ' HIS . . . . . 0.474 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 11.0 p80 -104.54 138.91 40.19 Favored 'General case' 0 CA--C 1.438 -3.335 0 C-N-CA 119.392 -0.923 . . . . 0.0 108.653 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -99.19 0.02 OUTLIER Glycine 0 N--CA 1.402 -3.577 0 O-C-N 125.215 1.572 . . . . 0.0 111.128 173.341 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -165.68 93.97 0.58 Allowed 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 117.716 -1.135 . . . . 0.0 111.105 -166.97 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 10.9 t-160 -170.85 86.47 0.1 Allowed 'General case' 0 C--O 1.284 2.901 0 CA-C-N 120.301 1.41 . . . . 0.0 114.493 171.886 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -74.93 154.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.732 0 CA-C-N 113.553 -1.658 . . . . 0.0 107.119 165.156 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 48' ' ' HIS . . . . . 0.428 ' O ' ' HB2' ' A' ' 49' ' ' GLU . 25.9 p80 -159.24 114.06 2.44 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 116.511 -1.709 . . . . 0.0 107.08 172.514 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 49' ' ' GLU . . . . . 0.604 ' HA ' ' OE1' ' A' ' 49' ' ' GLU 0.484 0.0 OUTLIER -173.74 168.2 4.37 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 165.377 . . . . . . . . 4 4 . 1 . 019 nuclear build core ' A' A ' 50' ' ' PHE . . . . . 0.49 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 26.8 p90 -115.22 19.46 15.59 Favored 'General case' 0 N--CA 1.404 -2.743 0 CA-C-N 112.654 -2.067 . . . . 0.0 109.108 176.751 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 51' ' ' GLY . . . . . 0.616 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 85.06 138.94 4.49 Favored Glycine 0 N--CA 1.47 0.959 0 N-CA-C 115.017 0.767 . . . . 0.0 115.017 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -144.9 -72.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.674 -0.81 . . . . 0.0 109.148 173.643 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -168.81 158.74 9.16 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 176.536 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 m -65.58 -48.41 72.44 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 123.633 0.773 . . . . 0.0 111.023 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.69 -7.88 42.46 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.003 -171.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.34 109.85 0.47 Allowed Glycine 0 CA--C 1.463 -3.214 0 C-N-CA 118.794 -1.669 . . . . 0.0 110.449 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 57' ' ' CYS . . . . . 0.847 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 15.8 p -101.89 87.42 3.11 Favored 'General case' 0 N--CA 1.392 -3.368 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 174.543 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.1 m -82.43 -50.09 9.26 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 122.755 1.265 . . . . 0.0 108.943 174.662 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 59' ' ' SER . . . . . 0.49 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 15.2 m -72.16 -8.15 53.11 Favored 'General case' 0 C--O 1.209 -1.038 0 CA-C-N 113.457 -1.702 . . . . 0.0 112.982 -175.151 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 60' ' ' ALA . . . . . 0.582 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . . . -77.29 -7.29 55.74 Favored 'General case' 0 CA--C 1.494 -1.192 0 C-N-CA 124.785 1.234 . . . . 0.0 111.216 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.7 52.09 0.83 Allowed Glycine 0 N--CA 1.406 -3.357 0 C-N-CA 117.762 -2.161 . . . . 0.0 116.016 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 62' ' ' PRO . . . . . 0.478 ' HD3' ' C ' ' A' ' 60' ' ' ALA . 1.2 Cg_endo -90.42 -6.74 4.37 Favored 'Trans proline' 0 C--N 1.395 3.009 0 CA-C-N 121.788 2.794 . . . . 0.0 106.995 164.052 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 63' ' ' HIS . . . . . 0.449 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 64.0 m-70 72.48 -58.06 0.61 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 114.149 -1.387 . . . . 0.0 111.355 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -112.63 116.52 30.31 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 122.322 -0.236 . . . . 0.0 110.936 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 65' ' ' ASN . . . . . 0.516 ' HB3' ' HG3' ' A' ' 79' ' ' ARG . 0.8 OUTLIER -77.23 144.48 71.2 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.386 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.54 -54.32 1.05 Allowed 'Trans proline' 0 CA--C 1.553 1.441 0 C-N-CA 122.907 2.404 . . . . 0.0 117.234 -170.556 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 67' ' ' LEU . . . . . 0.59 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 4.2 mm? -82.72 8.48 12.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.208 -1.397 . . . . 0.0 112.176 -173.262 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 68' ' ' SER . . . . . 0.614 ' HA ' ' OE1' ' A' ' 77' ' ' GLU . 69.6 m -72.2 39.27 0.07 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 122.614 1.197 . . . . 0.0 111.085 173.211 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 69' ' ' ARG . . . . . 0.541 ' H ' ' C ' ' A' ' 67' ' ' LEU . 73.6 mtt-85 -100.56 3.4 42.69 Favored 'General case' 0 N--CA 1.386 -3.674 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.673 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 70' ' ' LYS . . . . . 0.413 ' HB2' ' N ' ' A' ' 78' ' ' GLU . 47.8 mttp -109.31 30.06 6.96 Favored 'General case' 0 CA--C 1.495 -1.172 0 C-N-CA 118.975 -1.09 . . . . 0.0 110.768 169.797 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 70.56 86.11 0.13 Allowed 'General case' 0 N--CA 1.435 -1.177 0 CA-C-N 113.967 -1.47 . . . . 0.0 112.913 177.183 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 72' ' ' GLY . . . . . 0.55 ' HA2' ' CG ' ' A' ' 77' ' ' GLU . . . -53.54 83.1 0.01 OUTLIER Glycine 0 CA--C 1.508 -0.382 0 CA-C-N 114.59 -1.186 . . . . 0.0 112.573 169.016 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -141.84 -151.17 5.48 Favored Glycine 0 N--CA 1.401 -3.639 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 178.838 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 74' ' ' PRO . . . . . 0.433 ' CB ' ' HB3' ' A' ' 84' ' ' LEU . 98.8 Cg_endo -81.94 -41.3 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.332 0 N-CA-C 117.905 2.233 . . . . 0.0 117.905 -169.335 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -93.95 -26.21 16.94 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 116.446 2.017 . . . . 0.0 116.446 -162.488 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -171.59 143.12 1.7 Allowed 'General case' 0 CA--C 1.475 -1.931 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 -169.477 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 77' ' ' GLU . . . . . 0.614 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -160.05 151.0 19.1 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -175.845 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 78' ' ' GLU . . . . . 0.59 ' HB3' ' O ' ' A' ' 67' ' ' LEU . 15.4 tp10 -90.18 -19.2 24.5 Favored 'General case' 0 CA--C 1.555 1.142 0 O-C-N 123.446 0.466 . . . . 0.0 111.921 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HB2' ' C ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -101.0 -8.23 22.56 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 104.302 -2.481 . . . . 0.0 104.302 172.232 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 80' ' ' HIS . . . . . 0.479 ' HA ' ' HB3' ' A' ' 77' ' ' GLU . 18.8 m-70 . . . . . 0 N--CA 1.45 -0.456 0 CA-C-N 113.211 -1.813 . . . . 0.0 110.901 175.873 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 84' ' ' LEU . . . . . 0.444 HD22 ' HB3' ' A' ' 100' ' ' GLU 0.404 1.1 pp . . . . . 0 N--CA 1.408 -2.534 0 CA-C-O 122.818 1.294 . . . . 0.0 112.608 . . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.33 87.31 0.13 Allowed Glycine 1 N--CA 1.389 -4.494 0 CA-C-N 113.771 -1.559 . . . . 0.0 110.034 177.416 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 86' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 43' ' ' HIS . 24.7 t30 -72.79 128.17 34.73 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 174.091 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 87' ' ' VAL . . . . . 0.625 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 6.5 m -143.09 127.38 14.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 O-C-N 123.839 0.712 . . . . 0.0 110.684 -176.237 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' THR . . . . . 0.59 HG22 ' HB3' ' A' ' 42' ' ' LEU 0.257 4.9 p -101.02 101.45 12.23 Favored 'General case' 0 CA--C 1.561 1.396 0 C-N-CA 128.175 2.59 . . . . 0.0 111.991 -176.396 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 89' ' ' ALA . . . . . 0.407 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -118.92 108.27 14.59 Favored 'General case' 0 CA--C 1.473 -2.006 0 CA-C-N 120.579 1.536 . . . . 0.0 109.423 -178.646 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' H ' ' A' ' 40' ' ' GLU . 38.3 t70 -90.96 -165.43 1.35 Allowed 'General case' 0 C--N 1.278 -2.532 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.531 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 91' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 21.9 ptmt -42.93 -32.17 0.6 Allowed 'General case' 0 N--CA 1.51 2.568 0 C-N-CA 126.439 1.895 . . . . 0.0 115.663 -175.124 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -91.22 -37.17 13.49 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-O 122.525 1.155 . . . . 0.0 107.925 -178.168 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' GLY . . . . . 0.521 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 91.35 78.84 1.38 Allowed Glycine 1 N--CA 1.384 -4.805 0 CA-C-N 114.173 -1.376 . . . . 0.0 111.145 -176.578 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.7 t -142.69 101.15 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.175 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 176.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 95' ' ' ALA . . . . . 0.625 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -100.46 140.49 34.64 Favored 'General case' 0 N--CA 1.404 -2.763 0 O-C-N 123.699 0.624 . . . . 0.0 112.184 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -94.69 129.72 41.48 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 175.147 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 97' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 33' ' ' GLY . 0.9 OUTLIER -82.45 124.08 38.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 O-C-N 123.665 0.603 . . . . 0.0 111.397 -177.377 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 98' ' ' SER . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . 46.9 m -87.29 108.84 19.14 Favored 'General case' 0 N--CA 1.4 -2.972 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 168.352 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 99' ' ' ILE . . . . . 0.412 ' HA ' ' CG2' ' A' ' 31' ' ' VAL . 3.5 tt -90.77 123.03 42.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 114.79 -1.096 . . . . 0.0 108.55 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 100' ' ' GLU . . . . . 0.444 ' HB3' HD22 ' A' ' 84' ' ' LEU . 7.8 tp10 -138.94 157.61 45.7 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 114.554 -1.203 . . . . 0.0 111.145 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -81.46 103.33 11.13 Favored 'General case' 0 C--N 1.275 -2.64 0 C-N-CA 126.871 2.069 . . . . 0.0 112.586 -177.105 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' HG21 ' A' ' 29' ' ' VAL . 23.6 p -102.58 164.84 11.43 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.407 -0.808 . . . . 0.0 110.607 169.978 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.7 m -108.97 -63.5 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 C-N-CA 118.517 -1.273 . . . . 0.0 112.405 175.318 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 13.1 tt -128.15 23.98 2.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 121.571 0.701 . . . . 0.0 111.19 -169.252 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 105' ' ' SER . . . . . 0.6 ' C ' ' HG3' ' A' ' 22' ' ' GLN . 13.6 m -82.0 85.15 6.77 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.345 -1.742 . . . . 0.0 111.854 -178.263 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 106' ' ' LEU . . . . . 0.681 ' HG ' HE21 ' A' ' 22' ' ' GLN . 7.0 mp -76.18 117.58 18.02 Favored 'General case' 0 C--O 1.195 -1.791 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 170.599 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 107' ' ' SER . . . . . 0.554 ' O ' ' HA ' ' A' ' 112' ' ' ILE . 9.3 m -69.48 86.71 0.45 Allowed 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 119.909 1.231 . . . . 0.0 111.717 -175.092 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 108' ' ' GLY . . . . . 0.574 ' HA3' ' HG3' ' A' ' 115' ' ' ARG . . . 124.45 135.57 4.46 Favored Glycine 0 N--CA 1.427 -1.935 0 CA-C-N 113.83 -1.532 . . . . 0.0 109.749 177.11 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 109' ' ' ASP . . . . . 0.471 ' HB3' ' NH1' ' A' ' 79' ' ' ARG . 18.0 t70 -78.34 -36.26 46.47 Favored 'General case' 0 CA--C 1.5 -0.968 0 C-N-CA 117.686 -1.606 . . . . 0.0 111.134 175.705 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -68.77 -34.01 74.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.334 -175.099 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t 178.35 169.64 0.79 Allowed 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 103.844 -2.651 . . . . 0.0 103.844 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 112' ' ' ILE . . . . . 0.596 HG22 ' HA2' ' A' ' 150' ' ' GLY . 57.2 mt -93.66 -51.91 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.266 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 174.092 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 113' ' ' ILE . . . . . 0.687 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 3.7 mp -64.21 99.36 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.494 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.696 -170.333 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 114' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 127.46 -7.67 7.04 Favored Glycine 0 N--CA 1.428 -1.891 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.557 174.165 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 115' ' ' ARG . . . . . 0.616 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 1.6 mmp_? -81.36 133.48 35.43 Favored 'General case' 0 C--O 1.198 -1.653 0 C-N-CA 119.434 -0.907 . . . . 0.0 108.804 -176.536 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 80.3 m -69.87 126.75 30.64 Favored 'General case' 0 C--N 1.295 -1.792 0 CA-C-O 121.114 0.483 . . . . 0.0 112.017 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 117' ' ' LEU . . . . . 0.531 ' HA ' HG13 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -75.36 97.02 3.51 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.151 174.248 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 118' ' ' VAL . . . . . 0.55 HG12 ' HB3' ' A' ' 140' ' ' ALA . 13.0 t -94.02 94.69 4.7 Favored 'Isoleucine or valine' 1 C--O 1.338 5.725 0 C-N-CA 115.78 -2.368 . . . . 0.0 110.079 -173.317 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 119' ' ' VAL . . . . . 0.462 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . 22.8 m -149.46 170.09 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 128.84 2.856 . . . . 0.0 106.636 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 120' ' ' HIS . . . . . 0.423 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 67.6 t60 -156.61 171.55 20.13 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.838 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 121' ' ' GLU . . . . . 0.543 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 0.9 OUTLIER -70.12 83.6 0.52 Allowed 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 121.085 1.766 . . . . 0.0 106.863 173.919 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -176.63 155.65 1.37 Allowed 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 173.201 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.87 124.54 14.35 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 119.296 0.953 . . . . 0.0 112.853 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 124' ' ' ASP . . . . . 0.59 ' OD2' ' HB2' ' A' ' 140' ' ' ALA . 9.5 t70 -129.35 102.56 6.48 Favored 'General case' 0 CA--C 1.48 -1.742 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 -178.206 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -143.71 147.84 34.83 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.365 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 126' ' ' LEU . . . . . 0.513 HD12 ' O ' ' A' ' 135' ' ' THR . 43.4 tp -91.5 -28.53 17.54 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.641 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.78 -61.46 4.65 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 119.943 -1.123 . . . . 0.0 111.718 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -137.17 52.58 1.91 Allowed 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.16 0.505 . . . . 0.0 111.577 177.817 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.53 78.21 0.87 Allowed Glycine 0 C--N 1.297 -1.623 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.233 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -109.08 3.57 Favored Glycine 0 N--CA 1.442 -0.9 0 C-N-CA 121.752 -0.261 . . . . 0.0 112.937 175.454 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 131' ' ' ASN . . . . . 0.459 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.9 t30 -104.24 167.42 9.77 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 132' ' ' GLU . . . . . 0.507 ' O ' HG22 ' A' ' 135' ' ' THR . 8.5 mm-40 -51.78 -44.7 63.51 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -178.204 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -77.17 -24.66 51.46 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 121.829 -0.544 . . . . 0.0 112.283 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 134' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 5.7 m -80.04 -22.45 42.34 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-O 121.357 0.599 . . . . 0.0 109.819 -179.018 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 135' ' ' THR . . . . . 0.513 ' O ' HD12 ' A' ' 126' ' ' LEU . 1.8 t -81.22 -18.91 44.46 Favored 'General case' 0 N--CA 1.42 -1.945 0 C-N-CA 119.518 -0.873 . . . . 0.0 109.643 178.827 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -69.58 -36.63 76.43 Favored 'General case' 0 C--O 1.224 -0.283 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.081 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 137' ' ' THR . . . . . 0.449 ' HA ' ' HB3' ' A' ' 63' ' ' HIS . 13.6 t -86.56 -16.46 36.76 Favored 'General case' 0 C--O 1.26 1.647 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.893 -177.297 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.61 69.6 1.32 Allowed Glycine 1 C--O 1.3 4.225 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 -172.059 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -33.75 104.37 0.03 OUTLIER 'General case' 0 CA--C 1.482 -1.645 0 O-C-N 127.49 2.523 . . . . 0.0 116.21 -164.421 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 140' ' ' ALA . . . . . 0.59 ' HB2' ' OD2' ' A' ' 124' ' ' ASP . . . -153.51 170.5 20.61 Favored 'General case' 0 N--CA 1.401 -2.877 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 171.371 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 141' ' ' GLY . . . . . 0.548 ' HA3' HD23 ' A' ' 144' ' ' LEU . . . -87.4 137.17 14.43 Favored Glycine 0 C--N 1.272 -2.973 0 N-CA-C 105.718 -2.953 . . . . 0.0 105.718 165.976 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 24.5 m -54.59 -30.24 53.94 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -172.965 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 143' ' ' ARG . . . . . 0.847 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 30.8 ptt180 -124.15 15.21 9.12 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 144' ' ' LEU . . . . . 0.548 HD23 ' HA3' ' A' ' 141' ' ' GLY . 3.6 mm? -71.04 -9.09 57.44 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -175.728 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.44 89.29 0.75 Allowed 'General case' 0 N--CA 1.422 -1.826 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 172.057 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 146' ' ' CYS . . . . . 0.418 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 79.4 m -84.75 130.58 34.67 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.27 127.01 1.29 Allowed Glycine 1 N--CA 1.396 -4.014 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.57 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.0 m -74.27 125.47 33.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.998 172.852 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 149' ' ' ILE . . . . . 0.515 HG22 ' O ' ' A' ' 115' ' ' ARG . 15.5 tt -99.41 136.65 29.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 174.244 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 150' ' ' GLY . . . . . 0.687 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 177.13 167.74 35.97 Favored Glycine 2 CA--C 1.439 -4.663 0 C-N-CA 118.486 -1.816 . . . . 0.0 111.721 179.459 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 151' ' ' ILE . . . . . 0.667 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 5.6 tt -82.26 104.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.348 0 CA-C-O 122.178 0.99 . . . . 0.0 110.29 169.941 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 152' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -107.75 116.43 31.93 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.373 178.977 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 . . . . . 0 C--N 1.28 -2.441 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -177.812 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.436 -1.146 0 N-CA-C 111.475 0.176 . . . . 0.0 111.475 . . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.659 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 3.3 m -88.81 -26.92 21.43 Favored 'General case' 0 CA--C 1.568 1.64 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -167.646 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.527 ' HB3' ' NZ ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -152.17 158.53 43.03 Favored 'General case' 0 CA--C 1.455 -2.676 0 O-C-N 120.381 -1.449 . . . . 0.0 111.628 176.619 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -145.19 153.68 41.61 Favored 'General case' 0 N--CA 1.397 -3.081 0 O-C-N 124.081 0.863 . . . . 0.0 109.321 -175.971 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.1 m -132.21 132.01 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 176.889 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.74 136.7 47.88 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.562 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.624 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 4.4 p -134.27 106.66 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-O 121.662 0.744 . . . . 0.0 110.001 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.464 ' H ' HD23 ' A' ' 8' ' ' LEU . 0.8 OUTLIER -112.42 140.61 47.01 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.184 -178.468 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -144.54 123.48 12.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -131.92 -165.58 11.38 Favored Glycine 0 N--CA 1.434 -1.483 0 C-N-CA 119.682 -1.247 . . . . 0.0 113.707 -174.874 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -74.83 -42.75 57.43 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 177.477 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -94.94 154.01 21.05 Favored Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 106.269 -2.733 . . . . 0.0 106.269 170.457 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.41 121.7 5.76 Favored 'Trans proline' 0 N--CA 1.42 -2.822 0 CA-C-N 121.324 2.562 . . . . 0.0 109.535 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 17.4 m -133.32 124.98 50.07 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -150.0 142.73 24.64 Favored 'General case' 0 C--N 1.26 -3.283 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.292 -178.673 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.35 166.74 39.93 Favored Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.471 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.3 pt -134.33 103.23 4.7 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 CA-C-O 121.134 0.493 . . . . 0.0 109.692 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.08 126.83 57.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.575 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 7.7 p30 -125.39 122.56 37.1 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.471 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 6.4 p90 -128.22 128.19 44.27 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.659 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.4 pt-20 -106.76 109.23 21.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.888 176.695 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.497 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -126.2 162.13 26.12 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.199 1.0 . . . . 0.0 108.944 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -154.18 149.41 27.02 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -66.42 -9.08 30.41 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.6 m -70.38 -8.67 52.51 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.677 0.791 . . . . 0.0 111.655 177.038 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 75.6 115.21 0.06 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 124.444 1.097 . . . . 0.0 111.212 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.63 150.49 10.06 Favored Glycine 0 N--CA 1.424 -2.127 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 178.139 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -57.34 131.57 45.61 Favored 'Trans proline' 0 C--O 1.248 1.011 0 C-N-CA 122.585 2.19 . . . . 0.0 110.148 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.462 HG22 ' OG ' ' A' ' 102' ' ' SER . 2.9 m -83.48 128.46 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.353 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.376 -178.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 5.6 mtpm? -85.52 112.81 21.26 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 176.373 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.7 p -137.35 138.26 45.26 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.107 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.484 -168.79 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.467 ' HA ' HG11 ' A' ' 97' ' ' VAL . 33.9 t-105 -136.23 132.27 35.63 Favored 'General case' 0 C--N 1.277 -2.559 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.714 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -151.63 138.89 6.77 Favored Glycine 0 C--O 1.208 -1.486 0 C-N-CA 119.233 -1.46 . . . . 0.0 112.991 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.7 m -116.56 142.7 46.54 Favored 'General case' 0 N--CA 1.408 -2.528 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 176.501 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 76.0 mt -128.71 139.17 52.62 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 118.737 0.699 . . . . 0.0 109.335 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.655 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 22.4 ptmt -117.89 138.74 51.92 Favored 'General case' 0 N--CA 1.411 -2.414 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 173.285 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.649 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -161.37 176.56 37.9 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -166.732 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.9 mt -69.08 170.89 9.1 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 175.098 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.468 ' HB ' ' O ' ' A' ' 91' ' ' LYS . 2.8 t -69.31 108.29 3.63 Favored 'General case' 0 C--O 1.192 -1.969 0 O-C-N 121.615 -0.678 . . . . 0.0 112.292 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -172.86 171.7 4.26 Favored 'General case' 0 CA--C 1.461 -2.467 0 C-N-CA 124.55 1.14 . . . . 0.0 108.662 174.017 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 89' ' ' ALA . . . -82.55 -146.23 5.99 Favored Glycine 0 C--N 1.276 -2.787 0 O-C-N 124.875 1.359 . . . . 0.0 109.779 173.608 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 120' ' ' HIS . 2.8 tt 172.4 140.08 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 103.709 -2.7 . . . . 0.0 103.709 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -152.66 122.23 6.84 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.01 139.05 0.99 Allowed Glycine 0 C--N 1.301 -1.396 0 O-C-N 123.768 0.667 . . . . 0.0 113.999 177.473 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.443 ' CD1' ' HB2' ' A' ' 83' ' ' ASP . 0.2 OUTLIER -114.49 106.53 14.39 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 176.41 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.548 ' CE1' ' HA3' ' A' ' 138' ' ' GLY . 28.9 t-80 -130.13 89.19 2.76 Favored 'General case' 1 C--O 1.316 4.556 0 CA-C-O 122.134 0.968 . . . . 0.0 109.141 -176.709 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.603 HG13 ' HA ' ' A' ' 117' ' ' LEU . 94.5 t -92.56 152.0 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.357 0 CA-C-N 112.692 -2.049 . . . . 0.0 107.387 175.085 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -162.05 94.31 0.92 Allowed 'General case' 0 C--N 1.288 -2.074 0 O-C-N 124.083 0.864 . . . . 0.0 110.367 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.54 ' CG ' ' HB2' ' A' ' 60' ' ' ALA . 1.3 mm-40 -145.96 170.26 16.98 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 115.557 1.688 . . . . 0.0 115.557 -174.769 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.417 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 20.5 p90 -139.99 25.86 2.28 Favored 'General case' 0 N--CA 1.41 -2.463 0 CA-C-N 112.238 -2.255 . . . . 0.0 108.815 174.843 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . 84.47 129.02 1.8 Allowed Glycine 0 C--N 1.34 0.804 0 CA-C-N 114.586 -1.188 . . . . 0.0 115.447 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -140.8 -77.84 0.29 Allowed 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.578 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.4 ' O ' HG21 ' A' ' 116' ' ' THR . 28.0 t30 -157.69 133.09 8.96 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.431 ' HB ' HG23 ' A' ' 148' ' ' VAL . 13.0 t -73.26 4.6 4.37 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -173.904 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.69 -2.41 17.44 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.896 0.379 . . . . 0.0 110.348 177.059 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 157.56 124.72 0.81 Allowed Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -177.097 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.492 ' O ' ' HB3' ' A' ' 142' ' ' SER . 0.6 OUTLIER -97.67 112.78 24.52 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 113.565 0.95 . . . . 0.0 113.565 -176.399 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.7 m -75.61 -37.41 59.81 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.252 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.417 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 4.6 m -72.56 -26.68 61.82 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.621 0.724 . . . . 0.0 110.23 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.54 ' HB2' ' CG ' ' A' ' 49' ' ' GLU . . . -76.5 -8.77 57.86 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.039 -175.551 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.69 -93.3 0.03 OUTLIER Glycine 0 C--N 1.301 -1.384 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.345 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -95.88 53.31 0.17 Allowed 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 121.71 1.606 . . . . 0.0 113.349 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -125.73 117.06 22.64 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.919 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.561 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 52.8 p90 -87.07 138.52 31.42 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.196 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -115.51 95.84 44.35 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.568 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 56.7 Cg_endo -68.86 -10.79 30.14 Favored 'Trans proline' 0 C--O 1.213 -0.744 0 C-N-CA 124.035 3.157 . . . . 0.0 115.031 -173.895 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -77.12 -18.42 57.94 Favored 'General case' 0 C--O 1.199 -1.581 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -173.43 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 47.5 p -54.63 -84.34 0.01 OUTLIER 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 114.283 -1.326 . . . . 0.0 113.315 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.556 ' HB3' ' H ' ' A' ' 72' ' ' GLY . 1.9 tmt_? -134.91 30.13 3.4 Favored 'General case' 0 C--N 1.249 -3.8 0 N-CA-C 103.01 -2.959 . . . . 0.0 103.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 66' ' ' PRO . 69.7 mmtt 75.19 -41.23 0.45 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.04 -169.834 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.466 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 1.8 t-160 -121.74 -16.97 7.55 Favored 'General case' 0 N--CA 1.426 -1.652 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.075 171.437 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.556 ' H ' ' HB3' ' A' ' 69' ' ' ARG . . . 108.92 16.81 10.95 Favored Glycine 0 C--N 1.358 1.8 0 C-N-CA 118.519 -1.8 . . . . 0.0 115.881 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -38.26 146.98 0.12 Allowed Glycine 0 N--CA 1.491 2.338 0 CA-C-N 117.978 0.889 . . . . 0.0 113.69 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.88 -22.4 17.53 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.097 2.531 . . . . 0.0 113.869 -166.429 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -86.87 -12.83 46.66 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.945 -177.067 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 21.4 t0 70.35 159.93 0.2 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 124.493 1.117 . . . . 0.0 111.209 -175.562 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.503 ' HB2' ' NE ' ' A' ' 69' ' ' ARG . 22.7 tp10 -148.47 -24.99 0.33 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -178.57 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.462 ' HG2' ' HG2' ' A' ' 79' ' ' ARG . 27.6 tt0 -138.67 -64.02 0.53 Allowed 'General case' 0 N--CA 1.423 -1.815 0 C-N-CA 118.237 -1.385 . . . . 0.0 110.755 -176.029 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.695 ' O ' ' HA ' ' A' ' 68' ' ' SER . 15.4 ptt180 -173.72 62.6 0.02 OUTLIER 'General case' 0 N--CA 1.398 -3.052 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 -173.775 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 4.5 t60 -42.16 96.45 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.539 0 CA-C-N 113.315 -1.766 . . . . 0.0 107.022 170.205 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 79' ' ' ARG . 15.3 m -82.56 58.76 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.835 0 CA-C-O 123.979 1.847 . . . . 0.0 111.395 -176.508 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.524 ' CA ' ' HB ' ' A' ' 47' ' ' VAL . . . -175.22 174.31 46.72 Favored Glycine 0 C--N 1.266 -3.312 0 CA-C-N 110.592 -3.003 . . . . 0.0 106.497 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.443 ' HB2' ' CD1' ' A' ' 45' ' ' PHE . 19.3 m-20 -69.65 139.74 53.56 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 118.948 1.374 . . . . 0.0 108.493 179.533 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -117.94 119.71 35.63 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-O 121.751 0.786 . . . . 0.0 110.145 -175.511 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.25 -178.64 47.61 Favored Glycine 1 N--CA 1.386 -4.684 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 176.192 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -128.2 129.74 46.92 Favored 'General case' 0 C--N 1.263 -3.194 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 169.684 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.582 HG23 HD22 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -133.78 147.89 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.083 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.529 ' HA ' ' HB3' ' A' ' 42' ' ' LEU . 89.0 m -139.93 113.0 8.21 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -176.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.464 ' O ' ' HA2' ' A' ' 41' ' ' GLY . . . -83.44 150.98 25.7 Favored 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.468 ' OD1' ' HG2' ' A' ' 91' ' ' LYS . 9.8 t70 -93.13 -179.02 4.96 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 174.5 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' O ' ' HB ' ' A' ' 39' ' ' THR . 22.1 pttp -61.21 -16.23 42.72 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 124.459 1.104 . . . . 0.0 111.822 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.3 4.62 48.71 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.937 -0.477 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.655 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 60.96 83.17 0.06 OUTLIER Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.047 -175.751 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 5.1 m -155.75 111.15 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.305 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.572 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -119.44 123.97 45.37 Favored 'General case' 0 N--CA 1.415 -2.184 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.644 -178.632 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.66 145.38 28.01 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.714 ' HB ' ' O ' ' A' ' 33' ' ' GLY . 7.5 p -84.55 125.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -173.584 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.4 t -90.48 115.52 27.7 Favored 'General case' 0 N--CA 1.404 -2.735 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 168.855 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 31' ' ' VAL . 34.9 mt -92.02 118.26 37.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -107.34 156.04 19.34 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.915 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -81.28 99.69 8.76 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 122.088 0.947 . . . . 0.0 109.452 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -97.79 171.74 8.12 Favored 'General case' 0 C--N 1.265 -3.091 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.238 -175.922 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.553 HG12 HG13 ' A' ' 104' ' ' ILE . 26.5 t -109.32 -64.51 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.368 0 C-N-CA 119.658 -0.817 . . . . 0.0 111.446 -177.621 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.553 HG13 HG12 ' A' ' 103' ' ' VAL . 8.4 mt -134.18 24.97 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 121.326 0.584 . . . . 0.0 109.854 -177.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.427 ' OG ' ' HB3' ' A' ' 80' ' ' HIS . 33.3 t -68.99 88.49 0.4 Allowed 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -170.411 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.562 ' H ' HD23 ' A' ' 106' ' ' LEU . 1.7 pt? -96.49 136.31 37.18 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 160.331 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -71.89 86.21 0.98 Allowed 'General case' 0 C--N 1.286 -2.174 0 CA-C-O 122.349 1.071 . . . . 0.0 112.755 -175.418 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 111' ' ' SER . . . 143.2 135.74 3.06 Favored Glycine 0 N--CA 1.409 -3.145 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.821 170.595 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.518 ' HB3' HG11 ' A' ' 81' ' ' VAL . 7.4 p-10 -93.46 -28.03 16.35 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 122.903 -0.174 . . . . 0.0 111.434 -177.336 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 48.4 m80 -91.22 -23.43 20.2 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.0 -178.98 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.668 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t 177.11 178.89 0.25 Allowed 'General case' 0 N--CA 1.426 -1.666 0 N-CA-C 104.083 -2.562 . . . . 0.0 104.083 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -113.43 -56.46 4.2 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 C-N-CA 124.589 1.156 . . . . 0.0 109.878 -175.361 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.47 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 52.5 mt -68.37 119.51 14.27 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.723 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -177.089 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.547 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 115.66 -19.27 14.38 Favored Glycine 0 CA--C 1.47 -2.751 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.668 ' CZ ' ' HB3' ' A' ' 111' ' ' SER . 4.5 mpt_? -74.85 128.45 35.61 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 0.2 OUTLIER -92.01 126.88 37.26 Favored 'General case' 0 C--N 1.258 -3.389 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.62 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.603 ' HA ' HG13 ' A' ' 47' ' ' VAL . 2.0 pt? -76.62 136.88 39.2 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -177.423 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.9 99.57 8.69 Favored 'Isoleucine or valine' 0 C--O 1.28 2.661 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.654 171.111 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.682 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.4 p -147.42 170.39 3.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 104.748 -2.316 . . . . 0.0 104.748 178.226 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.599 ' O ' ' HG ' ' A' ' 42' ' ' LEU . 81.7 t60 -170.89 171.25 6.06 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 103.312 -2.848 . . . . 0.0 103.312 175.536 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.526 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.04 87.07 0.37 Allowed 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 171.278 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.499 ' H ' ' HG ' ' A' ' 42' ' ' LEU . 16.3 tppt? -173.18 154.76 2.79 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.74 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.37 103.88 1.11 Allowed 'General case' 0 C--N 1.285 -2.236 0 CA-C-O 121.89 0.852 . . . . 0.0 109.991 166.138 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -106.51 70.31 0.82 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.549 -2.389 . . . . 0.0 104.549 175.877 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -68.11 161.41 26.95 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.128 -170.267 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.534 ' H ' HD22 ' A' ' 126' ' ' LEU . 0.3 OUTLIER -90.48 -68.92 0.76 Allowed 'General case' 0 N--CA 1.397 -3.103 0 CA-C-N 113.83 -1.532 . . . . 0.0 110.996 -167.381 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 127' ' ' GLY . . . . . 0.466 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -102.82 -16.55 21.41 Favored Glycine 0 N--CA 1.429 -1.773 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.984 -177.752 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.99 -31.51 16.3 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 117.16 0.48 . . . . 0.0 110.367 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 134' ' ' SER . . . 53.7 -89.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.972 0 O-C-N 123.709 0.63 . . . . 0.0 114.175 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -172.84 -86.19 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -96.78 162.33 13.47 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 176.859 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.518 ' O ' ' HB ' ' A' ' 135' ' ' THR . 10.1 pt-20 -38.9 -51.32 1.76 Allowed 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -170.517 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -71.62 -38.09 70.82 Favored 'General case' 0 C--N 1.311 -1.083 0 O-C-N 122.12 -0.362 . . . . 0.0 111.854 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.483 ' O ' ' HA3' ' A' ' 129' ' ' GLY . 14.4 m -72.45 -22.92 61.01 Favored 'General case' 0 C--O 1.218 -0.568 0 CA-C-O 121.488 0.661 . . . . 0.0 109.619 178.479 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' ' 132' ' ' GLU . 66.4 m -67.16 -39.88 86.57 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-O 121.949 0.881 . . . . 0.0 108.845 173.437 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -71.3 -51.33 24.96 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.022 -1.445 . . . . 0.0 110.046 -177.656 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.561 ' HA ' ' HB3' ' A' ' 64' ' ' PHE . 41.1 p -74.68 -31.23 61.84 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.673 -177.317 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.548 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . 82.35 106.12 0.43 Allowed Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -174.243 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -32.84 140.31 0.04 OUTLIER 'General case' 1 C--O 1.329 5.254 0 C-N-CA 126.463 1.905 . . . . 0.0 115.47 -165.534 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -150.49 120.2 7.03 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.323 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -98.94 89.08 0.88 Allowed Glycine 0 N--CA 1.417 -2.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 169.858 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 6.2 m -42.79 -35.3 1.12 Allowed 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 126.727 2.011 . . . . 0.0 114.252 -171.383 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 17.9 ptt180 -125.35 5.12 7.71 Favored 'General case' 0 N--CA 1.414 -2.258 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.061 -177.709 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.09 -27.38 64.55 Favored 'General case' 0 C--N 1.291 -1.957 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.259 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.682 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.8 96.88 0.17 Allowed 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 43.4 t -140.5 147.78 40.08 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.087 -176.63 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.624 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.15 162.41 34.46 Favored Glycine 0 N--CA 1.403 -3.513 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 179.218 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 54' ' ' THR . 17.6 t -68.74 122.88 20.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.799 0.809 . . . . 0.0 111.149 175.326 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.647 HG12 ' O ' ' A' ' 115' ' ' ARG . 26.1 pt -111.97 146.25 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.868 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.17 155.92 15.44 Favored Glycine 2 N--CA 1.365 -6.07 0 C-N-CA 117.566 -2.254 . . . . 0.0 111.632 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.572 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 25.1 pt -63.08 105.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-N 114.854 -0.673 . . . . 0.0 110.369 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.53 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -105.62 114.15 28.14 Favored 'General case' 0 C--N 1.309 -1.168 0 O-C-N 121.9 -0.5 . . . . 0.0 110.663 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.318 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.226 -0.168 0 CA-C-O 120.629 0.252 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 p -81.65 -65.6 0.99 Allowed 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 178.581 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -170.78 171.98 5.89 Favored 'General case' 0 CA--C 1.488 -1.406 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -176.52 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.629 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -130.8 149.25 52.53 Favored 'General case' 0 N--CA 1.414 -2.225 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 172.038 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 149' ' ' ILE . 10.6 p -126.9 142.86 42.19 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -122.44 129.69 52.31 Favored 'General case' 0 C--N 1.286 -2.171 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.79 -177.533 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -129.15 111.73 23.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mp -108.08 152.12 24.95 Favored 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 120.972 -0.291 . . . . 0.0 111.243 178.597 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -136.08 131.36 34.73 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 106.187 -1.782 . . . . 0.0 106.187 175.751 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 12' ' ' GLY . . . -104.21 148.86 16.95 Favored Glycine 0 N--CA 1.41 -3.099 0 N-CA-C 117.991 1.956 . . . . 0.0 117.991 -168.32 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -83.78 -19.5 34.94 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 111.629 -2.286 . . . . 0.0 104.92 168.298 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 12' ' ' GLY . . . . . 0.42 ' O ' ' HA3' ' A' ' 10' ' ' GLY . . . -142.71 144.52 14.07 Favored Glycine 0 N--CA 1.421 -2.328 1 N-CA-C 101.215 -4.754 . . . . 0.0 101.215 168.858 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_exo -69.74 124.82 11.47 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 CA-C-N 122.221 3.01 . . . . 0.0 112.989 -168.053 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.6 104.94 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.997 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.481 176.224 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -117.87 119.95 36.41 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.202 -0.936 . . . . 0.0 111.879 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA3' HD12 ' A' ' 35' ' ' ILE . . . -170.54 171.83 43.85 Favored Glycine 0 N--CA 1.44 -1.042 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.9 pt -143.6 131.75 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.622 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 mp -128.96 133.3 66.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.623 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.2 m-20 -117.21 126.71 53.2 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.629 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 67.8 t80 -129.03 119.63 24.59 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.426 ' CG ' ' HB3' ' A' ' 30' ' ' LYS . 10.5 pt-20 -131.14 113.53 14.01 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.352 0.596 . . . . 0.0 111.823 177.796 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.688 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -86.59 163.88 17.18 Favored 'General case' 0 N--CA 1.414 -2.228 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 168.049 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -96.45 146.92 24.35 Favored 'General case' 0 C--N 1.275 -2.669 0 C-N-CA 119.088 -1.045 . . . . 0.0 112.429 -172.896 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -56.64 -40.69 75.87 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.8 1.313 . . . . 0.0 109.735 178.038 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.4 p -81.25 -70.99 0.49 Allowed 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.37 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 168.21 161.26 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 126.413 1.885 . . . . 0.0 106.386 175.757 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.582 ' H ' HG23 ' A' ' 103' ' ' VAL . . . 155.6 174.01 24.96 Favored Glycine 0 N--CA 1.41 -3.077 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 174.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.9 136.88 55.13 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 121.732 1.621 . . . . 0.0 108.889 177.016 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.595 HG12 ' HA ' ' A' ' 22' ' ' GLN . 30.1 m -74.17 147.6 8.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-O 121.849 0.833 . . . . 0.0 110.813 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.454 ' HA ' HD11 ' A' ' 99' ' ' ILE . 28.2 ttmt -99.28 115.05 28.25 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 174.435 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.5 p -137.58 128.62 39.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-O 121.253 0.549 . . . . 0.0 110.337 -177.351 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.401 ' HA ' HG11 ' A' ' 97' ' ' VAL . 89.1 t90 -133.37 126.88 32.28 Favored 'General case' 0 C--N 1.283 -2.285 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.63 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -142.0 139.72 9.51 Favored Glycine 0 N--CA 1.407 -3.246 0 C-N-CA 119.162 -1.494 . . . . 0.0 112.495 178.487 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.43 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 42.6 t -114.19 145.64 41.43 Favored 'General case' 0 C--N 1.284 -2.27 0 N-CA-C 107.292 -1.374 . . . . 0.0 107.292 176.418 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.646 HG22 ' HB2' ' A' ' 95' ' ' ALA . 3.2 tp -152.09 139.44 13.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 99.9 mttt -130.62 107.36 9.13 Favored 'General case' 0 C--N 1.281 -2.393 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 176.614 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.666 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -131.93 174.98 19.98 Favored Glycine 0 C--N 1.282 -2.434 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -171.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 121' ' ' GLU . 93.1 mt -68.72 170.14 9.98 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 118.113 0.956 . . . . 0.0 109.881 177.788 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 2.0 t -70.7 105.34 3.14 Favored 'General case' 0 CA--C 1.55 0.98 0 N-CA-C 114.367 1.247 . . . . 0.0 114.367 -171.518 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -177.26 165.06 2.24 Favored 'General case' 0 CA--C 1.456 -2.642 0 C-N-CA 128.594 2.758 . . . . 0.0 104.918 169.825 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 158.49 130.32 1.16 Allowed Glycine 3 N--CA 1.376 -5.338 0 C-N-CA 118.2 -1.952 . . . . 0.0 111.166 170.198 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mp -124.44 -86.33 0.63 Allowed 'General case' 0 N--CA 1.396 -3.174 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.491 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 79.9 m-70 -172.14 162.71 5.79 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 174.33 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 132.75 144.83 5.32 Favored Glycine 0 C--N 1.29 -2.002 0 C-N-CA 119.288 -1.434 . . . . 0.0 113.092 174.502 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' HB ' ' A' ' 47' ' ' VAL . 30.9 t80 -165.8 96.54 0.63 Allowed 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 124.927 1.291 . . . . 0.0 108.294 175.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 125' ' ' ASP . 0.2 OUTLIER -114.33 89.49 3.11 Favored 'General case' 0 N--CA 1.403 -2.794 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 177.599 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.64 ' HB ' ' CE1' ' A' ' 45' ' ' PHE . 14.6 p -69.85 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.927 0 CA-C-N 111.603 -2.544 . . . . 0.0 107.19 175.975 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.6 t60 -154.1 104.33 2.62 Favored 'General case' 1 C--N 1.233 -4.491 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.232 173.673 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.572 ' HB2' ' HB3' ' A' ' 109' ' ' ASP . 1.5 mp0 -67.77 158.34 32.64 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.017 -1.447 . . . . 0.0 109.16 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.1 t80 77.95 64.01 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 123.887 1.804 . . . . 0.0 107.423 -166.439 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' HA3' ' OG1' ' A' ' 116' ' ' THR . . . -112.63 -126.15 4.57 Favored Glycine 0 N--CA 1.416 -2.668 0 CA-C-N 111.454 -2.612 . . . . 0.0 107.173 174.634 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.436 ' H ' HG23 ' A' ' 116' ' ' THR . 33.0 t70 -176.97 -71.6 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 117.946 0.873 . . . . 0.0 112.758 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 37.6 p30 -131.76 177.1 7.78 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.682 0.753 . . . . 0.0 112.947 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.474 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 25.9 m -84.21 6.85 21.05 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 125.919 1.688 . . . . 0.0 110.602 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.27 -32.05 26.62 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.752 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 164.24 155.83 8.54 Favored Glycine 0 N--CA 1.412 -2.911 0 N-CA-C 108.859 -1.697 . . . . 0.0 108.859 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.62 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.2 m -83.25 89.58 7.0 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.4 p -75.81 -58.69 3.13 Favored 'General case' 0 N--CA 1.421 -1.923 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.965 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 70.8 m -68.7 -42.68 77.39 Favored 'General case' 0 N--CA 1.425 -1.701 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.47 -25.5 54.39 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.356 -176.605 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' HG21 ' A' ' 118' ' ' VAL . . . 49.24 -144.57 8.12 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -100.23 5.73 0.76 Allowed 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.803 2.335 . . . . 0.0 110.658 173.667 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.8 t60 -77.47 149.69 35.01 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.826 -169.248 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.481 ' HB2' ' O ' ' A' ' 80' ' ' HIS . 13.3 p90 -81.1 169.95 16.79 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.537 ' HB3' ' OG ' ' A' ' 68' ' ' SER . 53.0 t30 -105.52 143.19 26.31 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.77 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_exo -75.32 -13.58 20.71 Favored 'Trans proline' 0 C--O 1.225 -0.151 0 C-N-CA 121.79 1.66 . . . . 0.0 110.963 175.167 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.63 21.64 17.01 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 122.72 1.248 . . . . 0.0 108.69 -171.802 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.651 ' HB3' ' O ' ' A' ' 82' ' ' GLY . 46.3 m -73.98 -1.53 20.26 Favored 'General case' 0 C--O 1.196 -1.734 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.265 174.274 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.645 ' HA ' ' H ' ' A' ' 79' ' ' ARG . 3.9 mmp_? -68.59 -4.03 13.91 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 129.158 2.983 . . . . 0.0 109.589 177.552 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -140.54 29.73 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.725 -1.125 . . . . 0.0 108.196 176.626 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.5 ' HB3' ' N ' ' A' ' 84' ' ' LEU . 99.0 m-70 -143.97 -93.08 0.11 Allowed 'General case' 0 CA--C 1.556 1.176 0 C-N-CA 124.249 1.02 . . . . 0.0 109.392 176.326 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.601 ' HA2' ' HB2' ' A' ' 79' ' ' ARG . . . 81.94 -63.62 4.36 Favored Glycine 0 CA--C 1.501 -0.824 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 173.049 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.36 161.35 35.16 Favored Glycine 0 C--N 1.264 -3.454 0 N-CA-C 107.566 -2.214 . . . . 0.0 107.566 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.565 ' HA ' ' HG ' ' A' ' 84' ' ' LEU . 19.2 Cg_endo -55.58 -30.35 74.23 Favored 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 123.877 3.051 . . . . 0.0 115.266 -174.663 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.7 tppt? -101.97 -5.09 25.07 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.318 0.58 . . . . 0.0 110.144 -177.778 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -110.38 -163.45 0.86 Allowed 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 -177.679 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -171.18 41.57 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.835 0.854 . . . . 0.0 111.182 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.702 ' O ' ' HG2' ' A' ' 79' ' ' ARG . 11.4 pt-20 -163.15 149.25 12.04 Favored 'General case' 0 C--O 1.161 -3.584 0 CA-C-O 116.657 -1.64 . . . . 0.0 106.721 175.313 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.702 ' HG2' ' O ' ' A' ' 78' ' ' GLU . 6.2 mmt180 161.84 -165.1 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 128.125 2.57 . . . . 0.0 107.848 170.405 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' A' ' 64' ' ' PHE . 43.3 m-70 -141.07 -34.92 0.48 Allowed 'General case' 0 C--N 1.276 -2.629 0 C-N-CA 125.619 1.568 . . . . 0.0 108.278 171.585 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.5 t -90.17 -8.46 10.67 Favored 'Isoleucine or valine' 0 CA--C 1.563 1.456 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -175.012 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.651 ' O ' ' HB3' ' A' ' 68' ' ' SER . . . -141.7 159.15 26.82 Favored Glycine 0 C--O 1.214 -1.15 0 C-N-CA 119.595 -1.288 . . . . 0.0 112.503 -175.873 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -130.04 172.39 11.79 Favored 'General case' 0 C--O 1.205 -1.262 0 CA-C-N 117.358 0.579 . . . . 0.0 111.288 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.565 ' HG ' ' HA ' ' A' ' 74' ' ' PRO . 6.7 tt -98.9 107.11 19.47 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -165.67 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.592 ' C ' ' HB3' ' A' ' 45' ' ' PHE . . . 176.88 178.66 46.8 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 169.496 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.489 ' N ' ' HB3' ' A' ' 45' ' ' PHE . 8.8 p30 -159.42 135.69 9.0 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 173.901 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 75.2 t -127.56 151.61 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.293 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.731 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.6 m -134.65 148.59 50.4 Favored 'General case' 0 N--CA 1.404 -2.758 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.107 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -149.12 153.59 37.98 Favored 'General case' 1 C--N 1.243 -4.053 0 N-CA-C 102.199 -3.26 . . . . 0.0 102.199 173.012 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 13.6 t70 -128.0 -158.24 0.86 Allowed 'General case' 0 C--N 1.251 -3.686 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.547 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 60.5 mttp -68.25 5.85 0.89 Allowed 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 124.138 0.975 . . . . 0.0 113.278 -179.489 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -116.76 -9.38 11.27 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 175.009 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 64.77 72.93 0.63 Allowed Glycine 0 C--O 1.224 -0.526 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.897 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 62.8 t -154.57 133.3 3.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -175.624 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.646 ' HB2' HG22 ' A' ' 35' ' ' ILE . . . -94.35 127.22 40.1 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-O 122.367 1.08 . . . . 0.0 113.777 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -105.75 107.04 17.83 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 102.177 -3.268 . . . . 0.0 102.177 160.863 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.63 HG11 ' H ' ' A' ' 33' ' ' GLY . 9.4 p -83.34 137.56 20.76 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.4 0 C-N-CA 117.949 -1.501 . . . . 0.0 108.806 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 45.8 m -86.99 121.05 28.92 Favored 'General case' 0 N--CA 1.387 -3.597 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 171.926 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.454 HD11 ' HA ' ' A' ' 30' ' ' LYS . 2.9 tt -90.81 115.05 29.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 175.092 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.492 ' HG3' ' HB2' ' A' ' 74' ' ' PRO . 5.6 mm-40 -106.22 157.36 17.63 Favored 'General case' 0 CA--C 1.48 -1.738 0 CA-C-N 113.89 -1.505 . . . . 0.0 111.596 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.23 96.17 10.23 Favored 'General case' 0 N--CA 1.426 -1.665 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.454 ' OG ' HD21 ' A' ' 84' ' ' LEU . 4.8 m -105.98 141.86 36.67 Favored 'General case' 0 N--CA 1.402 -2.843 0 N-CA-C 103.913 -2.625 . . . . 0.0 103.913 174.243 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.582 HG23 ' H ' ' A' ' 27' ' ' GLY 0.276 2.6 p -118.02 -49.48 4.02 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 C-N-CA 117.059 -1.856 . . . . 0.0 112.744 176.166 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.2 mm -81.71 -7.54 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.57 1.732 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 -170.814 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.491 ' OG ' HD13 ' A' ' 84' ' ' LEU . 50.8 m -79.3 84.01 5.28 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 117.726 2.491 . . . . 0.0 117.726 -172.161 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.688 ' HB3' ' HG3' ' A' ' 22' ' ' GLN . 1.1 pt? -140.06 82.14 1.85 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 154.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.3 m -171.62 87.15 0.09 Allowed 'General case' 1 C--N 1.233 -4.467 0 N-CA-C 101.777 -3.416 . . . . 0.0 101.777 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -111.59 157.69 14.8 Favored Glycine 3 N--CA 1.375 -5.387 0 N-CA-C 106.246 -2.742 . . . . 0.0 106.246 175.579 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.572 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 12.6 t70 -62.02 -41.82 98.5 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-O 121.817 0.818 . . . . 0.0 109.714 178.559 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.577 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 6.8 m80 -123.24 -24.84 4.58 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.138 -0.937 . . . . 0.0 112.029 177.078 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.2 m 59.7 -70.35 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 125.809 1.644 . . . . 0.0 114.622 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.676 HG13 ' O ' ' A' ' 151' ' ' ILE . 3.6 tt -98.15 -43.51 11.94 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 C-N-CA 124.799 1.24 . . . . 0.0 110.415 -174.91 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 8.1 tt -104.51 102.2 13.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -172.094 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.5 60.13 1.84 Allowed Glycine 0 CA--C 1.474 -2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.767 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.545 ' HD3' ' C ' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -119.24 90.01 3.25 Favored 'General case' 0 C--N 1.252 -3.643 0 CA-C-N 112.688 -1.756 . . . . 0.0 109.594 -176.866 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.614 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 17.9 p -95.08 132.76 39.63 Favored 'General case' 0 C--N 1.289 -2.026 0 O-C-N 121.723 -0.611 . . . . 0.0 111.858 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.532 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -81.32 120.63 25.19 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 175.61 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.62 HG22 ' SG ' ' A' ' 57' ' ' CYS . 19.6 t -100.35 98.09 6.55 Favored 'Isoleucine or valine' 0 C--O 1.297 3.602 0 C-N-CA 116.259 -2.176 . . . . 0.0 106.987 172.938 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.525 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 25.4 t -148.81 171.05 2.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -160.53 171.99 17.99 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 104.093 -2.558 . . . . 0.0 104.093 169.547 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -69.62 87.81 0.5 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 123.064 2.665 . . . . 0.0 109.973 -178.791 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 33.2 tptt -172.55 171.97 4.43 Favored 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -171.425 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -78.99 117.91 20.5 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 171.439 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 46' ' ' HIS . 3.6 t70 -139.77 78.4 1.66 Allowed 'General case' 0 CA--C 1.474 -1.951 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.613 ' HA ' ' HB2' ' A' ' 46' ' ' HIS . 25.1 t0 -177.44 158.0 1.36 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 123.766 0.666 . . . . 0.0 109.424 173.276 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 135' ' ' THR . 3.3 tm? -90.72 -40.48 11.83 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 124.624 1.203 . . . . 0.0 107.988 -176.732 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.24 -48.86 6.19 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.492 -0.861 . . . . 0.0 111.622 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.77 51.34 1.53 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.146 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.15 -105.83 0.27 Allowed Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 119.875 -1.155 . . . . 0.0 111.745 176.207 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -152.26 -96.18 0.13 Allowed Glycine 0 C--N 1.316 -0.556 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.652 -176.69 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -79.89 153.67 28.87 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.142 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -45.72 -50.75 13.43 Favored 'General case' 0 C--N 1.36 1.057 0 N-CA-C 114.522 1.304 . . . . 0.0 114.522 -176.66 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -80.4 -26.89 38.28 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 121.526 -0.734 . . . . 0.0 111.114 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 27.5 t -77.59 -29.14 51.84 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.667 -173.618 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 126' ' ' LEU . 6.6 t -76.52 -25.06 53.75 Favored 'General case' 0 C--O 1.206 -1.212 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.669 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 126' ' ' LEU . 58.8 mtpt -71.28 -35.36 71.32 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.895 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 12.4 t -85.98 -31.75 21.89 Favored 'General case' 0 N--CA 1.412 -2.366 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.25 178.725 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 57.63 73.07 0.49 Allowed Glycine 0 CA--C 1.486 -1.764 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -177.709 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 1.7 t-20 -51.58 105.8 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 122.471 1.129 . . . . 0.0 113.248 -171.468 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -89.29 164.54 14.89 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 114.441 -1.254 . . . . 0.0 113.664 -171.092 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -139.95 86.28 0.21 Allowed Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 107.25 -2.34 . . . . 0.0 107.25 175.351 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.504 ' HA ' HG13 ' A' ' 118' ' ' VAL . 13.8 m -61.84 -18.65 60.81 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 113.823 1.046 . . . . 0.0 113.823 -172.166 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -121.72 -46.31 2.25 Favored 'General case' 0 C--N 1.26 -3.312 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.681 177.837 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.9 tt -46.13 -45.06 16.26 Favored 'General case' 0 CA--C 1.495 -1.163 0 O-C-N 125.406 1.691 . . . . 0.0 111.564 -164.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -139.66 88.76 2.27 Favored 'General case' 0 N--CA 1.395 -3.192 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.2 m -130.25 140.08 50.73 Favored 'General case' 0 N--CA 1.394 -3.227 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.283 176.747 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -170.93 149.03 11.83 Favored Glycine 1 N--CA 1.379 -5.124 0 CA-C-N 113.831 -1.531 . . . . 0.0 109.358 -177.166 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 16.0 m -70.55 110.14 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.63 0 CA-C-O 122.104 0.954 . . . . 0.0 111.147 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.545 ' C ' ' HD3' ' A' ' 115' ' ' ARG . 9.4 tt -122.11 108.87 22.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 CA-C-N 114.652 -1.158 . . . . 0.0 109.27 175.477 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.497 ' HA3' ' HG2' ' A' ' 115' ' ' ARG . . . -179.03 -171.25 42.02 Favored Glycine 3 CA--C 1.435 -4.936 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 175.99 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.676 ' O ' HG13 ' A' ' 112' ' ' ILE . 64.5 mt -64.3 104.64 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.263 -3.165 0 O-C-N 124.853 0.972 . . . . 0.0 110.576 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.462 ' HB2' ' NH2' ' A' ' 115' ' ' ARG . . . -142.17 100.09 3.65 Favored 'General case' 0 N--CA 1.433 -1.304 0 CA-C-O 121.168 0.508 . . . . 0.0 109.836 169.311 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 C--N 1.289 -2.043 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 177.016 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 CA--C 1.512 -0.515 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 . . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 22.6 m -111.24 -36.44 5.59 Favored 'General case' 0 CA--C 1.552 1.027 0 O-C-N 123.583 0.552 . . . . 0.0 111.733 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.402 ' HG2' ' N ' ' A' ' 4' ' ' ALA . 50.1 tttm -146.65 152.52 39.01 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.937 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.96 167.73 20.39 Favored 'General case' 0 N--CA 1.406 -2.629 0 O-C-N 123.676 0.61 . . . . 0.0 109.609 175.029 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -137.6 131.99 44.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 123.313 0.645 . . . . 0.0 109.304 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.671 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -112.18 131.36 55.52 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -134.86 103.83 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.038 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.561 ' HB3' HD21 ' A' ' 117' ' ' LEU . 1.4 pt? -118.29 151.17 38.2 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -162.86 140.77 8.16 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.39 -158.48 8.37 Favored Glycine 0 N--CA 1.414 -2.785 0 C-N-CA 119.039 -1.553 . . . . 0.0 112.996 -176.703 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -71.37 -49.19 44.68 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.65 144.95 16.94 Favored Glycine 0 N--CA 1.431 -1.655 0 N-CA-C 106.55 -2.62 . . . . 0.0 106.55 172.888 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -76.56 124.03 7.38 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 CA-C-N 120.355 2.078 . . . . 0.0 112.96 -175.575 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -132.38 113.05 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 103.853 -2.647 . . . . 0.0 103.853 173.236 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.573 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 96.8 mt-30 -118.58 141.33 48.68 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.6 -174.883 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -169.69 157.86 29.74 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.482 -177.218 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.463 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.9 pt -135.26 102.47 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.949 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.671 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 10.3 mt -121.42 137.44 55.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -174.847 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -113.94 134.08 55.06 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.817 178.308 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.937 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.0 m-85 -123.26 134.27 54.11 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.356 0.262 . . . . 0.0 110.921 -178.105 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.9 pt-20 -132.96 102.34 5.59 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 121.588 0.709 . . . . 0.0 112.168 175.751 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.468 ' H ' ' HB3' ' A' ' 1' ' ' ALA . 42.9 mt-30 -106.24 113.82 27.57 Favored 'General case' 0 N--CA 1.389 -3.5 0 N-CA-C 103.872 -2.64 . . . . 0.0 103.872 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.586 ' H ' ' HB ' ' A' ' 103' ' ' VAL . 54.9 tttm -134.26 171.76 13.81 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.422 -169.576 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.518 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 5.4 mp0 -63.97 -26.12 68.44 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.87 1.268 . . . . 0.0 111.69 -177.694 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -33.06 28.16 Favored 'General case' 0 CA--C 1.549 0.911 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 -172.345 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.9 t30 64.73 97.34 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -173.09 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.633 ' H ' HG22 ' A' ' 103' ' ' VAL . . . 179.18 -163.34 30.81 Favored Glycine 0 CA--C 1.463 -3.196 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.416 -175.746 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -83.24 139.65 9.42 Favored 'Trans proline' 0 N--CA 1.42 -2.851 0 C-N-CA 122.114 1.876 . . . . 0.0 110.699 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.654 HG22 ' H ' ' A' ' 101' ' ' ASP . 18.3 m -75.14 130.24 36.29 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' HB3' ' CD ' ' A' ' 21' ' ' GLU . 7.3 ttpm? -88.84 100.34 13.09 Favored 'General case' 0 N--CA 1.424 -1.771 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.157 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 ' HA ' ' A' ' 20' ' ' PHE . 75.1 t -131.47 134.75 60.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.756 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.006 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 2.1 t-105 -141.08 129.47 22.44 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -148.94 138.86 7.15 Favored Glycine 0 N--CA 1.425 -2.083 0 C-N-CA 119.994 -1.098 . . . . 0.0 112.377 175.04 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.542 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 18.4 m -116.5 115.24 25.41 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 124.726 1.211 . . . . 0.0 108.746 179.221 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.573 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 9.2 mt -109.52 148.11 13.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 118.453 0.57 . . . . 0.0 110.732 176.166 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -129.79 122.98 29.86 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -146.41 175.01 26.09 Favored Glycine 0 C--N 1.294 -1.8 0 O-C-N 123.688 0.617 . . . . 0.0 111.66 -168.31 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.0 mt -69.52 169.79 11.88 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.724 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.5 OUTLIER -76.81 104.32 7.24 Favored 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 119.273 -0.971 . . . . 0.0 112.003 -175.932 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.433 ' HG2' ' O ' ' A' ' 39' ' ' THR . 47.2 mm-40 -177.93 171.09 1.82 Allowed 'General case' 0 CA--C 1.472 -2.054 0 C-N-CA 128.522 2.729 . . . . 0.0 104.275 170.405 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.726 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 159.45 115.38 0.41 Allowed Glycine 1 C--N 1.242 -4.676 0 C-N-CA 116.978 -2.534 . . . . 0.0 113.968 166.146 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -119.38 -85.6 0.65 Allowed 'General case' 0 N--CA 1.419 -2.018 0 O-C-N 124.231 0.607 . . . . 0.0 110.911 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.733 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 20.7 m80 -163.52 123.11 2.11 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.895 0.878 . . . . 0.0 108.936 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.462 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . -143.94 104.63 0.34 Allowed Glycine 0 N--CA 1.435 -1.41 0 C-N-CA 118.434 -1.841 . . . . 0.0 115.425 -178.684 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.593 ' O ' HG12 ' A' ' 47' ' ' VAL . 19.6 m-85 -68.45 95.22 0.61 Allowed 'General case' 1 C--O 1.341 5.918 0 CA-C-O 123.391 1.567 . . . . 0.0 109.56 169.684 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.615 ' CD2' HD12 ' A' ' 117' ' ' LEU . 16.4 p-80 -83.05 78.06 9.64 Favored 'General case' 0 N--CA 1.404 -2.759 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 175.454 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 45' ' ' PHE . 3.7 p -111.2 91.57 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-N 111.223 -2.717 . . . . 0.0 110.988 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . 0.257 39.6 m-70 -138.75 159.96 40.82 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 114.586 1.328 . . . . 0.0 114.586 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.56 ' HB3' ' OD2' ' A' ' 109' ' ' ASP . 2.0 pm0 -89.48 172.82 8.71 Favored 'General case' 0 C--N 1.287 -2.151 0 C-N-CA 126.993 2.117 . . . . 0.0 115.02 -174.793 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.521 ' H ' ' HA ' ' A' ' 110' ' ' HIS . 55.9 t80 47.18 103.47 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 111.3 -2.682 . . . . 0.0 115.35 167.366 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -44.0 103.12 0.04 OUTLIER Glycine 0 C--N 1.297 -1.623 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.16 171.858 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -111.09 -161.17 0.74 Allowed 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -67.14 138.1 56.79 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 123.1 0.56 . . . . 0.0 109.997 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.492 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 13.4 t -58.45 -21.5 51.45 Favored 'General case' 0 C--O 1.216 -0.701 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -177.103 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.96 6.77 11.37 Favored 'General case' 0 C--N 1.31 -1.115 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.062 178.352 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -150.76 109.46 0.43 Allowed Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 119.428 -1.368 . . . . 0.0 111.589 -178.705 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.596 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 4.3 p -98.5 89.35 4.38 Favored 'General case' 0 C--N 1.277 -2.576 0 C-N-CA 122.735 0.414 . . . . 0.0 111.65 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 m -80.47 -54.07 6.02 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.465 0.65 . . . . 0.0 109.924 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.9 m -71.18 -39.45 71.83 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.283 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.596 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.31 -5.76 48.5 Favored 'General case' 0 C--O 1.2 -1.531 0 CA-C-N 113.857 -1.52 . . . . 0.0 111.353 175.077 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -57.36 -142.42 0.01 OUTLIER Glycine 0 CA--C 1.558 2.737 0 N-CA-C 115.238 0.855 . . . . 0.0 115.238 178.998 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -76.11 53.71 3.91 Favored 'Trans proline' 0 N--CA 1.484 0.937 0 C-N-CA 122.877 2.385 . . . . 0.0 111.009 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -141.84 128.67 20.54 Favored 'General case' 0 C--N 1.28 -2.432 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.546 ' HA ' ' OE2' ' A' ' 49' ' ' GLU . 52.0 p90 -139.48 144.58 38.04 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.442 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OD2' ' A' ' 109' ' ' ASP . 27.3 t-20 -68.94 143.99 95.2 Favored Pre-proline 0 C--N 1.318 -0.795 0 C-N-CA 124.015 0.926 . . . . 0.0 111.316 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.0 -15.21 39.72 Favored 'Trans proline' 0 CA--C 1.546 1.109 0 C-N-CA 123.041 2.494 . . . . 0.0 116.113 -178.371 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 90.2 mt -69.86 -29.23 66.41 Favored 'General case' 0 C--N 1.37 1.489 0 C-N-CA 117.615 -1.634 . . . . 0.0 111.462 -176.213 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.41 ' HB3' ' CD2' ' A' ' 80' ' ' HIS . 58.0 p -54.46 -21.49 10.03 Favored 'General case' 0 C--O 1.262 1.73 0 C-N-CA 125.523 1.529 . . . . 0.0 115.044 -173.597 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ttm180 -70.45 -19.96 62.92 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.665 -161.727 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -68.1 -12.06 60.2 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.233 -0.987 . . . . 0.0 112.773 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 77' ' ' GLU . 0.1 OUTLIER -151.7 -45.15 0.11 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 120.651 0.262 . . . . 0.0 111.186 177.023 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.38 10.42 82.13 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -173.256 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -150.99 144.29 11.59 Favored Glycine 0 N--CA 1.402 -3.623 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 178.244 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 11.8 Cg_exo -76.24 0.13 9.74 Favored 'Trans proline' 0 C--N 1.327 -0.58 0 C-N-CA 124.691 3.594 . . . . 0.0 112.38 -175.452 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -55.55 -26.01 40.98 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 124.973 1.309 . . . . 0.0 111.514 178.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -148.63 -86.2 0.09 Allowed 'General case' 0 CA--C 1.505 -0.775 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.707 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.404 ' O ' ' HB2' ' A' ' 71' ' ' HIS . 47.5 mt-10 -123.34 110.89 15.73 Favored 'General case' 0 N--CA 1.41 -2.437 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -171.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -150.52 -60.85 0.19 Allowed 'General case' 0 C--N 1.25 -3.758 0 N-CA-C 103.298 -2.853 . . . . 0.0 103.298 -173.98 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 60.45 -7.37 0.08 Allowed 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 114.617 1.34 . . . . 0.0 114.617 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 65' ' ' ASN . 0.2 OUTLIER -89.82 -35.0 15.92 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.038 -2.208 . . . . 0.0 105.038 168.744 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.585 HG11 ' HB2' ' A' ' 105' ' ' SER . 32.8 m 38.26 53.42 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.472 -2.021 0 C-N-CA 128.656 2.782 . . . . 0.0 112.466 171.131 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.407 ' N ' HG23 ' A' ' 47' ' ' VAL . . . -52.1 -34.94 40.37 Favored Glycine 0 C--O 1.207 -1.57 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.963 -173.163 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.45 ' H ' HG23 ' A' ' 47' ' ' VAL . 10.7 t70 -170.58 172.53 5.86 Favored 'General case' 0 CA--C 1.49 -1.343 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.235 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 74' ' ' PRO . 25.9 tp -148.49 86.65 1.54 Allowed 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 -175.934 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.77 128.37 1.13 Allowed Glycine 1 N--CA 1.395 -4.082 0 CA-C-N 114.694 -1.139 . . . . 0.0 110.708 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -89.99 171.35 9.63 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 173.675 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.35 129.06 11.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 121.394 -0.816 . . . . 0.0 109.083 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.3 m -140.11 96.79 3.11 Favored 'General case' 0 N--CA 1.424 -1.748 0 CA-C-O 121.24 0.543 . . . . 0.0 110.28 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.726 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -100.44 152.72 20.03 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 104.785 -2.302 . . . . 0.0 104.785 173.126 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.538 ' OD2' ' HG2' ' A' ' 91' ' ' LYS . 21.9 t70 -113.34 -159.74 0.7 Allowed 'General case' 1 C--N 1.223 -4.922 0 C-N-CA 116.7 -2.0 . . . . 0.0 105.992 173.731 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.538 ' HG2' ' OD2' ' A' ' 90' ' ' ASP . 18.8 ptpt -57.82 -8.08 0.87 Allowed 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -84.3 -27.15 28.02 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.62 65.53 2.29 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 114.499 0.559 . . . . 0.0 114.499 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 12.6 m -159.74 132.82 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.563 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -124.64 117.89 25.28 Favored 'General case' 0 N--CA 1.412 -2.374 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -99.67 103.51 15.2 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.55 117.6 50.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.031 0.92 . . . . 0.0 112.255 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 p -142.33 101.46 3.9 Favored 'General case' 0 C--N 1.276 -2.599 0 N-CA-C 106.787 -1.561 . . . . 0.0 106.787 174.267 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 34.4 pt -113.91 151.11 15.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.787 -175.99 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.75 100.24 7.28 Favored 'General case' 0 N--CA 1.414 -2.227 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.654 ' H ' HG22 ' A' ' 29' ' ' VAL . 26.1 t0 -134.02 167.51 20.48 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.848 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.9 m -59.02 113.22 1.99 Allowed 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 114.678 1.362 . . . . 0.0 114.678 -173.594 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.633 HG22 ' H ' ' A' ' 27' ' ' GLY . 20.6 m -60.03 -11.57 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 C-N-CA 126.112 1.765 . . . . 0.0 113.053 177.284 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.39 -12.12 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.676 1.191 . . . . 0.0 112.25 -176.199 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.585 ' HB2' HG11 ' A' ' 81' ' ' VAL . 2.5 p -91.73 83.17 5.25 Favored 'General case' 0 C--O 1.175 -2.826 0 O-C-N 121.012 -1.055 . . . . 0.0 111.516 176.609 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 71.8 mt -70.11 150.65 46.33 Favored 'General case' 0 N--CA 1.396 -3.163 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.852 171.325 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.6 m -68.89 91.85 0.48 Allowed 'General case' 0 N--CA 1.382 -3.842 0 C-N-CA 124.956 1.302 . . . . 0.0 113.914 -173.608 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.415 ' O ' ' HD2' ' A' ' 110' ' ' HIS . . . -94.6 -175.67 38.55 Favored Glycine 1 N--CA 1.395 -4.097 0 N-CA-C 106.09 -2.804 . . . . 0.0 106.09 167.405 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.56 ' OD2' ' HB3' ' A' ' 49' ' ' GLU 0.25 31.3 t0 32.89 -77.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 117.442 2.386 . . . . 0.0 117.442 -175.32 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.558 ' CG ' ' HG2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -56.57 -31.8 64.57 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 125.987 1.715 . . . . 0.0 109.703 178.216 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.3 m 62.06 -178.09 0.13 Allowed 'General case' 0 N--CA 1.424 -1.755 0 C-N-CA 126.125 1.77 . . . . 0.0 112.797 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.512 HG13 ' HB ' ' A' ' 151' ' ' ILE . 10.0 tt -78.65 9.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 C-N-CA 126.547 1.939 . . . . 0.0 108.731 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 36.5 pt -91.38 -175.39 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.485 -1.526 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 -176.801 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.436 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . -82.14 65.08 4.14 Favored Glycine 0 N--CA 1.405 -3.397 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.959 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.734 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -66.31 131.81 46.95 Favored 'General case' 0 N--CA 1.414 -2.267 0 CA-C-O 122.553 1.168 . . . . 0.0 112.203 178.266 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.734 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 0.1 OUTLIER -70.54 122.6 20.02 Favored 'General case' 0 N--CA 1.384 -3.768 0 CA-C-N 113.853 -1.521 . . . . 0.0 111.113 -178.137 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.615 HD12 ' CD2' ' A' ' 46' ' ' HIS . 0.8 OUTLIER -87.76 140.67 29.27 Favored 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 174.06 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.574 HG22 ' SG ' ' A' ' 57' ' ' CYS . 98.8 t -109.8 105.16 18.27 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.479 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.646 171.859 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -126.09 168.44 18.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.81 0.814 . . . . 0.0 110.397 179.596 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.435 ' CD2' ' HG ' ' A' ' 144' ' ' LEU . 2.1 t60 -172.18 156.85 4.06 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 102.909 -2.997 . . . . 0.0 102.909 162.158 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.437 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.2 89.61 0.46 Allowed 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? -170.4 171.37 6.61 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.733 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -76.68 111.15 11.88 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 123.771 0.67 . . . . 0.0 110.922 172.936 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.462 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 8.5 t0 -132.38 26.57 4.46 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 123.381 1.563 . . . . 0.0 109.177 178.202 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.499 ' HB2' ' HB2' ' A' ' 128' ' ' LYS . 24.8 m-20 -81.7 137.53 35.39 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 173.52 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -69.8 -56.79 6.19 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -173.59 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.7 1.8 43.51 Favored Glycine 0 CA--C 1.526 0.748 0 C-N-CA 121.16 -0.543 . . . . 0.0 113.483 -178.849 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.499 ' HB2' ' HB2' ' A' ' 125' ' ' ASP . 32.0 mmmt -132.23 32.61 3.96 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -62.27 -29.32 72.73 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 115.604 -0.725 . . . . 0.0 114.834 -176.469 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -82.89 0.26 Allowed Glycine 0 C--O 1.221 -0.66 0 CA-C-N 117.443 0.622 . . . . 0.0 112.212 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.453 ' H ' ' HB3' ' A' ' 134' ' ' SER . 9.5 t30 -121.45 173.3 7.47 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.461 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 37.1 tt0 -49.73 -46.71 50.66 Favored 'General case' 0 CA--C 1.555 1.158 0 CA-C-N 119.844 1.202 . . . . 0.0 114.011 -172.017 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.1 mp0 -64.48 -39.64 94.19 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.055 0.455 . . . . 0.0 110.449 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 6.8 t -72.36 -30.89 65.13 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.098 -175.541 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 36.3 m -69.68 -30.97 68.76 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.299 0.571 . . . . 0.0 110.479 178.344 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.461 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 95.8 mttt -76.54 -37.12 57.16 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.165 0.507 . . . . 0.0 111.355 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 t -85.61 -26.42 26.08 Favored 'General case' 0 N--CA 1.416 -2.166 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.292 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.85 60.1 8.19 Favored Glycine 0 N--CA 1.431 -1.684 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 -174.0 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -39.62 117.38 0.72 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.936 1.294 . . . . 0.0 112.851 -174.074 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -143.71 161.49 38.43 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -174.166 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.28 81.22 1.72 Allowed Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 173.653 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.7 p -42.13 -38.89 1.82 Allowed 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 118.143 2.646 . . . . 0.0 118.143 -168.147 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.6 ptt180 -134.2 13.46 3.88 Favored 'General case' 0 C--N 1.278 -2.526 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.435 ' HG ' ' CD2' ' A' ' 120' ' ' HIS . 0.3 OUTLIER -69.07 -37.6 78.6 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -172.23 . . . . . . . . 3 3 . 1 . 003 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -150.25 106.1 3.43 Favored 'General case' 0 N--CA 1.412 -2.348 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 17.8 m -115.21 163.14 16.09 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.811 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.734 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -171.55 141.42 6.39 Favored Glycine 0 N--CA 1.416 -2.681 0 C-N-CA 119.003 -1.57 . . . . 0.0 112.143 176.93 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.423 HG12 ' OG1' ' A' ' 54' ' ' THR . 10.0 p -70.16 98.78 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 122.531 1.158 . . . . 0.0 108.581 174.035 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.734 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 24.0 mm -109.44 129.86 63.5 Favored 'Isoleucine or valine' 0 CA--C 1.464 -2.346 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.81 147.34 17.73 Favored Glycine 2 CA--C 1.425 -5.539 0 C-N-CA 116.803 -2.618 . . . . 0.0 111.466 -174.708 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' ' 112' ' ' ILE . 70.1 mt -78.64 103.63 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.9 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 173.916 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.575 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -125.84 128.6 47.9 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.119 -0.946 . . . . 0.0 108.476 175.668 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 . . . . . 0 C--N 1.292 -1.905 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.563 -174.755 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.658 ' O ' ' HD2' ' A' ' 3' ' ' LYS . 18.0 p -80.91 -42.03 22.06 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 170.833 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.658 ' HD2' ' O ' ' A' ' 2' ' ' THR . 5.4 mptp? -151.27 171.4 17.5 Favored 'General case' 0 C--O 1.263 1.765 0 N-CA-C 103.209 -2.885 . . . . 0.0 103.209 173.137 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.693 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -149.35 146.98 27.78 Favored 'General case' 0 CA--C 1.454 -2.744 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 152' ' ' ALA . 23.1 m -119.69 155.22 22.43 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.788 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.244 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -135.7 128.94 31.89 Favored 'General case' 0 C--N 1.278 -2.504 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.345 178.689 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.498 ' H ' ' HB ' ' A' ' 148' ' ' VAL . 46.7 t -134.16 111.83 15.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.521 ' H ' HD23 ' A' ' 8' ' ' LEU . 1.9 pt? -119.47 142.39 48.31 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.371 178.392 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.665 ' O ' ' HA ' ' A' ' 55' ' ' ALA . 2.2 tmtp? -147.91 148.42 30.79 Favored 'General case' 0 N--CA 1.408 -2.542 0 N-CA-C 102.409 -3.182 . . . . 0.0 102.409 177.401 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -155.01 -158.93 8.99 Favored Glycine 0 CA--C 1.479 -2.161 0 C-N-CA 118.139 -1.982 . . . . 0.0 113.381 -177.788 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -67.98 -46.58 70.97 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.018 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.44 95.59 0.74 Allowed Glycine 0 N--CA 1.429 -1.784 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 171.324 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -64.6 126.79 17.47 Favored 'Trans proline' 0 N--CA 1.441 -1.585 0 C-N-CA 122.164 1.909 . . . . 0.0 113.886 -172.553 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.1 m -126.0 132.37 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.381 -3.889 0 N-CA-C 102.026 -3.324 . . . . 0.0 102.026 173.516 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.431 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 97.8 mt-30 -121.67 138.2 54.44 Favored 'General case' 0 C--N 1.264 -3.114 0 C-N-CA 119.559 -0.856 . . . . 0.0 112.578 -169.228 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.493 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -170.69 171.31 43.68 Favored Glycine 0 N--CA 1.402 -3.628 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.451 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.6 pt -137.02 139.54 44.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.552 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -127.77 127.91 68.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.693 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 60.4 m-20 -118.79 119.62 34.94 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 -176.489 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.634 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 11.6 p90 -131.58 141.04 49.59 Favored 'General case' 0 C--O 1.262 1.754 0 C-N-CA 118.646 -1.222 . . . . 0.0 113.095 178.058 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.428 ' HB3' ' O ' ' A' ' 2' ' ' THR . 7.2 pt-20 -133.65 95.15 3.42 Favored 'General case' 0 N--CA 1.416 -2.136 0 CA-C-O 122.268 1.033 . . . . 0.0 112.391 175.75 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HG3' HG12 ' A' ' 29' ' ' VAL . 24.1 mm-40 -158.62 163.47 36.92 Favored 'General case' 0 C--O 1.257 1.477 0 C-N-CA 126.88 2.072 . . . . 0.0 108.038 170.417 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.654 ' HG3' ' H ' ' A' ' 24' ' ' GLU 0.257 27.7 pttt -159.7 -86.69 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.204 0 O-C-N 124.22 0.95 . . . . 0.0 112.055 164.487 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.654 ' H ' ' HG3' ' A' ' 23' ' ' LYS . 35.9 tt0 -93.2 -25.96 17.59 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 121.783 0.802 . . . . 0.0 109.578 178.844 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.44 ' HB2' ' OE1' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -46.93 -56.94 5.51 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.235 2.214 . . . . 0.0 114.836 -172.34 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.8 t30 75.71 139.91 0.07 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 124.971 1.308 . . . . 0.0 110.277 -174.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.588 ' H ' HG21 ' A' ' 104' ' ' ILE . . . 150.23 -170.96 30.2 Favored Glycine 0 CA--C 1.493 -1.312 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -70.08 124.02 10.55 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.413 1.409 . . . . 0.0 110.253 176.427 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG12 ' HG3' ' A' ' 22' ' ' GLN . 17.2 m -85.65 98.79 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.354 0 CA-C-O 121.502 0.668 . . . . 0.0 111.523 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.258 0.0 OUTLIER -90.46 108.66 19.93 Favored 'General case' 0 N--CA 1.417 -2.076 0 C-N-CA 118.486 -1.285 . . . . 0.0 109.11 171.919 . . . . . . . . 4 4 . 1 . 004 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.6 m -135.46 152.97 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.778 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 -172.861 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -143.58 126.92 16.72 Favored 'General case' 0 C--N 1.266 -3.051 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.946 178.599 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -145.34 140.27 8.93 Favored Glycine 0 N--CA 1.41 -3.075 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.697 174.165 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.0 m -116.6 140.23 49.63 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 176.075 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.493 HG22 ' HA3' ' A' ' 16' ' ' GLY . 25.2 pt -141.7 131.51 24.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-N 119.415 1.007 . . . . 0.0 109.025 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.2 OUTLIER -112.09 132.39 54.87 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 121' ' ' GLU . . . -142.82 175.2 23.18 Favored Glycine 0 N--CA 1.416 -2.68 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -169.693 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.1 mt -68.84 170.34 9.79 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.426 ' CA ' ' HA ' ' A' ' 91' ' ' LYS . 1.3 m -69.89 103.46 2.22 Favored 'General case' 0 C--O 1.203 -1.37 0 C-N-CA 118.016 -1.473 . . . . 0.0 110.403 -173.93 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.3 tt0 -176.13 141.77 0.46 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 102.798 -3.038 . . . . 0.0 102.798 170.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . -174.54 90.89 0.08 OUTLIER Glycine 0 C--N 1.276 -2.777 0 C-N-CA 117.028 -2.511 . . . . 0.0 113.334 174.581 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -93.4 -86.33 0.26 Allowed 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 120.512 -0.475 . . . . 0.0 111.649 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.495 ' HA ' ' H ' ' A' ' 87' ' ' VAL . 18.8 p80 166.32 135.28 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 152.46 131.4 1.68 Allowed Glycine 0 N--CA 1.413 -2.837 0 C-N-CA 118.322 -1.894 . . . . 0.0 113.785 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -133.98 139.59 46.17 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 122.063 0.935 . . . . 0.0 113.073 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 70.1 t60 -166.89 92.11 0.43 Allowed 'General case' 1 C--O 1.33 5.342 0 N-CA-C 105.183 -2.155 . . . . 0.0 105.183 172.013 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.596 HG13 ' HA ' ' A' ' 117' ' ' LEU . 18.7 t -69.97 167.58 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 127.351 2.26 . . . . 0.0 109.095 176.442 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.538 ' NE2' ' HB2' ' A' ' 65' ' ' ASN . 56.5 t-80 -124.23 126.04 45.42 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-O 122.085 0.945 . . . . 0.0 109.873 174.033 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.604 ' CD ' ' HB3' ' A' ' 65' ' ' ASN . 2.8 pm0 -73.37 125.45 27.88 Favored 'General case' 0 C--N 1.264 -3.145 0 CA-C-N 113.62 -1.627 . . . . 0.0 108.403 174.549 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.54 ' HA ' ' OG ' ' A' ' 111' ' ' SER . 91.3 t80 80.13 100.17 0.06 Allowed 'General case' 0 CA--C 1.503 -0.851 0 CA-C-O 123.503 1.621 . . . . 0.0 108.776 -175.924 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.35 -145.97 7.52 Favored Glycine 0 N--CA 1.421 -2.332 0 CA-C-N 111.94 -2.391 . . . . 0.0 110.49 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -171.62 -85.83 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 115.597 1.703 . . . . 0.0 115.597 -171.879 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.497 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.7 t-20 -104.52 140.1 38.47 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -169.818 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 10.0 t -61.64 -27.68 68.84 Favored 'General case' 0 C--O 1.241 0.635 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.172 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 55' ' ' ALA . . . . . 0.665 ' HA ' ' O ' ' A' ' 9' ' ' LYS . . . -114.47 17.84 17.16 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 120.618 0.247 . . . . 0.0 111.449 -175.298 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.42 117.27 0.58 Allowed Glycine 0 CA--C 1.483 -1.96 0 C-N-CA 119.247 -1.454 . . . . 0.0 111.382 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.464 ' HB3' HG21 ' A' ' 116' ' ' THR . 0.7 OUTLIER -87.28 98.59 11.42 Favored 'General case' 0 C--N 1.28 -2.429 0 C-N-CA 122.926 0.491 . . . . 0.0 109.904 -176.544 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 m -79.07 -56.1 4.62 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.746 0.784 . . . . 0.0 109.515 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.7 m -75.32 -43.91 48.27 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.011 -174.439 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.59 -8.61 56.91 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.949 174.645 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.15 -63.69 3.48 Favored Glycine 0 CA--C 1.538 1.504 0 O-C-N 123.758 0.661 . . . . 0.0 112.772 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -64.26 -5.15 9.1 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.989 2.459 . . . . 0.0 112.75 176.871 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.289 23.3 p80 56.04 15.75 1.91 Allowed 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 118.504 2.779 . . . . 0.0 118.504 170.568 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -146.35 120.45 9.45 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 119.151 0.887 . . . . 0.0 112.757 178.241 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.604 ' HB3' ' CD ' ' A' ' 49' ' ' GLU . 27.7 t-20 -116.95 144.22 33.08 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 172.487 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -52.57 -13.19 2.17 Favored 'Trans proline' 0 CA--C 1.556 1.595 0 C-N-CA 124.466 3.444 . . . . 0.0 117.82 -177.263 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.522 ' C ' ' H ' ' A' ' 69' ' ' ARG . 4.1 mm? -82.62 -12.98 57.28 Favored 'General case' 0 CA--C 1.474 -1.956 0 CA-C-N 119.878 1.217 . . . . 0.0 110.396 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.601 ' HA ' ' HB3' ' A' ' 80' ' ' HIS . 74.3 m -72.94 36.4 0.08 Allowed 'General case' 0 C--O 1.215 -0.718 0 C-N-CA 124.342 1.057 . . . . 0.0 109.804 169.434 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 67' ' ' LEU . 3.3 tmm_? -76.3 11.12 1.66 Allowed 'General case' 0 C--O 1.212 -0.895 0 C-N-CA 127.505 2.322 . . . . 0.0 107.951 -172.746 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 76' ' ' ASP . 47.4 tptt -77.35 -32.47 55.1 Favored 'General case' 0 N--CA 1.396 -3.133 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t60 61.18 23.86 14.02 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.251 1.021 . . . . 0.0 110.126 178.613 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.73 120.99 2.65 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 119.842 -1.17 . . . . 0.0 112.218 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.39 75.78 0.13 Allowed Glycine 0 C--N 1.293 -1.812 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.525 ' O ' HD13 ' A' ' 84' ' ' LEU . 31.8 Cg_endo -62.23 -22.63 74.46 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 123.759 2.973 . . . . 0.0 114.82 -171.501 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mtpt -123.2 13.2 9.62 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.519 ' OD2' ' HE2' ' A' ' 70' ' ' LYS . 21.7 t70 -116.96 -67.69 0.97 Allowed 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -169.553 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 60.66 111.64 0.02 OUTLIER 'General case' 0 C--O 1.256 1.406 0 CA-C-O 122.477 1.132 . . . . 0.0 110.768 -173.715 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.421 ' CB ' ' HD3' ' A' ' 70' ' ' LYS . 29.9 tt0 -114.44 -78.21 0.58 Allowed 'General case' 0 N--CA 1.422 -1.842 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.878 -176.761 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.489 ' O ' ' HB2' ' A' ' 80' ' ' HIS . 29.3 tpt180 -113.98 5.35 16.1 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 117.729 -1.588 . . . . 0.0 110.767 179.08 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 68' ' ' SER 0.274 18.7 t60 173.62 -150.83 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.208 172.926 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.3 m 82.49 -32.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.106 0 C-N-CA 128.927 2.891 . . . . 0.0 108.413 -147.38 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.71 -73.34 2.36 Favored Glycine 0 CA--C 1.48 -2.118 0 N-CA-C 114.263 0.465 . . . . 0.0 114.263 166.712 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.459 ' OD2' HG21 ' A' ' 47' ' ' VAL . 22.2 m-20 -139.76 138.37 35.85 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 103.844 -2.65 . . . . 0.0 103.844 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.525 HD13 ' O ' ' A' ' 74' ' ' PRO . 4.0 pp -131.95 135.85 46.9 Favored 'General case' 0 C--N 1.271 -2.837 0 O-C-N 123.471 0.482 . . . . 0.0 110.339 -177.236 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 178.17 -178.64 48.58 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 120.054 -1.07 . . . . 0.0 111.823 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -118.45 132.72 56.23 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.923 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.545 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.7 m -136.06 132.8 50.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -176.379 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -132.94 96.03 3.69 Favored 'General case' 0 N--CA 1.413 -2.283 0 CA-C-O 122.643 1.211 . . . . 0.0 110.613 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.516 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -92.75 153.86 18.65 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 113.911 -1.495 . . . . 0.0 107.833 174.682 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.593 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 6.8 t70 -125.14 -161.65 1.04 Allowed 'General case' 0 C--N 1.255 -3.541 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.426 ' HA ' ' CA ' ' A' ' 39' ' ' THR . 59.6 pttt -40.85 -34.82 0.43 Allowed 'General case' 0 N--CA 1.506 2.339 0 C-N-CA 127.313 2.245 . . . . 0.0 116.115 -175.319 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -147.82 16.62 1.11 Allowed 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 177.792 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.593 ' HA3' ' H ' ' A' ' 90' ' ' ASP . . . -59.34 -157.52 0.03 OUTLIER Glycine 0 C--O 1.187 -2.826 0 N-CA-C 118.731 2.252 . . . . 0.0 118.731 -164.152 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -158.49 105.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.275 -2.656 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.545 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.72 110.12 22.63 Favored 'General case' 0 N--CA 1.398 -3.048 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -85.25 103.37 14.14 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 114.664 -1.153 . . . . 0.0 110.395 -177.184 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -88.28 102.4 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.507 0 CA-C-O 122.309 1.052 . . . . 0.0 109.486 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.7 p -155.41 100.7 2.14 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 113.649 -1.614 . . . . 0.0 108.11 174.178 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.46 119.33 29.41 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -95.06 101.06 12.79 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.949 0.881 . . . . 0.0 111.486 -178.818 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -163.03 169.82 18.95 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 -178.422 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.5 t -59.4 94.42 0.02 OUTLIER 'General case' 0 C--O 1.244 0.769 0 CA-C-O 122.528 1.156 . . . . 0.0 113.402 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' CD1' ' A' ' 84' ' ' LEU . 15.5 t -118.28 -9.56 11.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 N-CA-C 103.12 -2.919 . . . . 0.0 103.12 168.927 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.588 HG21 ' H ' ' A' ' 27' ' ' GLY . 2.7 pp -41.9 -40.68 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.709 0 C-N-CA 127.812 2.445 . . . . 0.0 114.77 -166.29 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.51 ' N ' HD12 ' A' ' 104' ' ' ILE . 10.1 p -85.84 90.73 8.14 Favored 'General case' 1 N--CA 1.352 -5.37 0 C-N-CA 118.385 -1.326 . . . . 0.0 108.843 176.483 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.626 ' HG ' ' CE1' ' A' ' 20' ' ' PHE . 3.7 mm? -75.42 86.89 2.57 Favored 'General case' 0 N--CA 1.393 -3.296 0 N-CA-C 104.837 -2.283 . . . . 0.0 104.837 177.256 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.4 m -83.13 88.35 6.9 Favored 'General case' 1 N--CA 1.357 -5.124 0 CA-C-N 113.203 -1.817 . . . . 0.0 108.702 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.73 134.43 11.88 Favored Glycine 1 N--CA 1.36 -6.38 0 N-CA-C 104.482 -3.447 . . . . 0.0 104.482 169.712 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' HG ' ' A' ' 67' ' ' LEU . 38.6 t70 -84.29 -66.92 0.84 Allowed 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 117.591 -1.644 . . . . 0.0 111.464 -177.074 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -100.03 -17.32 17.55 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.54 ' OG ' ' HA ' ' A' ' 50' ' ' PHE . 20.0 m -132.79 118.42 19.0 Favored 'General case' 0 N--CA 1.395 -3.22 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.498 -176.246 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.554 HG13 HD12 ' A' ' 113' ' ' ILE . 14.1 pt -112.6 -25.3 3.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 N-CA-C 104.749 -2.315 . . . . 0.0 104.749 166.283 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.554 HD12 HG13 ' A' ' 112' ' ' ILE . 2.5 mp -102.59 130.46 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 162.883 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 94.94 12.91 54.81 Favored Glycine 0 C--O 1.209 -1.436 0 C-N-CA 119.546 -1.312 . . . . 0.0 111.838 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.633 ' O ' ' HB ' ' A' ' 149' ' ' ILE . 15.7 mtp180 -70.88 90.07 0.79 Allowed 'General case' 0 C--O 1.207 -1.163 0 CA-C-O 120.868 0.366 . . . . 0.0 110.127 174.132 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.464 HG21 ' HB3' ' A' ' 57' ' ' CYS . 96.9 m -68.0 105.32 1.99 Allowed 'General case' 0 N--CA 1.383 -3.775 0 CA-C-O 122.519 1.152 . . . . 0.0 109.786 172.212 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.596 ' HA ' HG13 ' A' ' 47' ' ' VAL . 43.1 tp -70.09 97.92 1.25 Allowed 'General case' 0 CA--C 1.477 -1.843 0 CA-C-N 113.568 -1.651 . . . . 0.0 108.443 177.317 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 140' ' ' ALA . 7.2 p -91.23 100.06 10.63 Favored 'Isoleucine or valine' 1 C--O 1.313 4.419 0 C-N-CA 115.909 -2.317 . . . . 0.0 109.874 -175.6 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.29 170.23 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.767 0 CA-C-N 112.429 -2.168 . . . . 0.0 107.172 -175.409 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -158.16 172.28 18.69 Favored 'General case' 0 C--N 1.285 -2.216 0 N-CA-C 103.739 -2.689 . . . . 0.0 103.739 174.002 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.572 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.1 mp0 -66.77 89.81 0.16 Allowed 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 105.138 -2.171 . . . . 0.0 105.138 170.998 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.0 tttp -171.66 170.91 5.5 Favored 'General case' 0 N--CA 1.44 -0.925 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -170.784 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.5 104.98 15.77 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 170.259 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.449 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 13.1 t70 -106.92 8.03 30.35 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 122.705 1.24 . . . . 0.0 111.292 -177.772 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.428 ' HB3' ' HD3' ' A' ' 128' ' ' LYS . 5.5 t70 -67.19 139.46 57.42 Favored 'General case' 0 C--N 1.281 -2.398 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.155 -171.539 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.7 tp -62.96 -50.92 68.88 Favored 'General case' 0 C--N 1.321 -0.643 0 O-C-N 123.475 0.484 . . . . 0.0 109.916 -178.867 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.06 -24.23 68.48 Favored Glycine 0 N--CA 1.442 -0.953 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.192 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.428 ' HD3' ' HB3' ' A' ' 125' ' ' ASP . 3.9 mptp? -88.93 -47.05 8.42 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 119.931 -0.707 . . . . 0.0 111.701 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.6 -103.18 0.06 OUTLIER Glycine 0 C--O 1.222 -0.603 0 N-CA-C 114.847 0.699 . . . . 0.0 114.847 179.67 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -175.53 -79.03 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.606 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 21.8 t-20 -107.75 -170.23 1.66 Allowed 'General case' 0 C--O 1.258 1.545 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 174.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.441 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 29.4 tt0 -53.91 -42.85 69.21 Favored 'General case' 0 CA--C 1.542 0.664 0 CA-C-N 118.884 0.766 . . . . 0.0 111.745 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.606 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -75.25 -39.38 59.9 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.154 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.2 m -67.99 -21.65 65.04 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -176.603 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.446 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 12.3 t -86.71 -6.29 58.88 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 122.0 0.905 . . . . 0.0 110.738 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.441 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 89.5 mttt -92.81 -39.74 11.04 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.3 p -86.47 -21.23 27.14 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 114.662 -1.154 . . . . 0.0 112.307 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.48 78.47 0.24 Allowed Glycine 0 C--O 1.254 1.383 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -177.946 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 55.8 t30 -47.71 142.92 4.25 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 124.967 1.307 . . . . 0.0 112.291 -176.428 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -150.05 170.49 18.75 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.308 -173.351 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.4 85.1 1.41 Allowed Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 106.547 -2.621 . . . . 0.0 106.547 169.07 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.448 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 51.0 m -42.47 -56.35 3.07 Favored 'General case' 0 C--O 1.194 -1.819 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -165.444 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.434 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 22.9 ptt180 -129.61 12.28 5.84 Favored 'General case' 0 C--N 1.254 -3.58 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -174.795 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.456 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 0.7 OUTLIER -58.15 -44.91 88.11 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 -173.73 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -170.3 92.21 0.2 Allowed 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 114.371 1.249 . . . . 0.0 114.371 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 118' ' ' VAL . 13.9 p -173.53 128.74 0.43 Allowed 'General case' 0 C--O 1.211 -0.956 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 173.368 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 54' ' ' THR . . . 179.55 77.08 0.06 OUTLIER Glycine 0 N--CA 1.409 -3.138 0 CA-C-O 117.935 -1.481 . . . . 0.0 113.372 150.391 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.606 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 54.1 t -171.54 90.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 C-N-CA 125.247 1.419 . . . . 0.0 108.135 167.787 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.633 ' HB ' ' O ' ' A' ' 115' ' ' ARG 0.262 5.4 mt -125.13 118.3 52.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.646 0 CA-C-N 119.179 0.9 . . . . 0.0 109.966 163.229 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.08 155.06 13.35 Favored Glycine 2 N--CA 1.379 -5.132 0 C-N-CA 117.801 -2.142 . . . . 0.0 112.681 176.437 . . . . . . . . 3 3 . 1 . 004 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.6 tt -53.81 105.19 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 114.893 -0.654 . . . . 0.0 110.55 169.378 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.414 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -130.31 99.43 5.02 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.997 -0.681 . . . . 0.0 109.542 171.178 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.304 -1.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.657 178.691 . . . . . . . . 0 0 . 1 . 004 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 21' ' ' GLU . . . . . . . . 0 CA--C 1.506 -0.74 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 . . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 25.3 m -121.87 -36.77 2.96 Favored 'General case' 0 CA--C 1.555 1.163 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.574 ' O ' HG12 ' A' ' 151' ' ' ILE . 17.9 ptpt -136.2 144.15 44.78 Favored 'General case' 0 N--CA 1.426 -1.67 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.718 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.557 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -135.73 151.73 50.43 Favored 'General case' 0 C--N 1.282 -2.348 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 30.4 m -115.53 138.36 46.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.637 -178.392 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.707 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -111.09 133.89 53.11 Favored 'General case' 0 C--N 1.284 -2.283 0 CA-C-N 114.781 -1.099 . . . . 0.0 111.48 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -134.73 104.22 5.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 122.98 0.512 . . . . 0.0 110.132 176.209 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.479 HD13 ' HA3' ' A' ' 147' ' ' GLY . 3.1 mm? -96.97 151.31 19.83 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.687 -178.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.599 ' HD3' ' N ' ' A' ' 10' ' ' GLY . 9.9 tmtt? -150.54 137.45 19.17 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.599 ' N ' ' HD3' ' A' ' 9' ' ' LYS . . . -152.78 -169.6 18.2 Favored Glycine 0 N--CA 1.423 -2.188 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.038 -179.105 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -85.97 -31.12 22.26 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 113.915 -1.143 . . . . 0.0 109.376 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -109.47 -172.5 20.72 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 174.226 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -83.69 123.06 3.2 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-N 120.779 2.29 . . . . 0.0 111.099 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.414 HG23 HD11 ' A' ' 35' ' ' ILE . 5.2 p -135.9 91.78 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.097 0 C-N-CA 124.682 1.193 . . . . 0.0 108.522 174.875 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.624 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 16.0 mm100 -111.59 119.08 37.51 Favored 'General case' 0 C--N 1.292 -1.913 0 O-C-N 121.31 -0.869 . . . . 0.0 108.88 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -156.85 148.27 17.83 Favored Glycine 0 N--CA 1.406 -3.306 0 C-N-CA 120.206 -0.997 . . . . 0.0 112.658 -175.481 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.511 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 12.6 pt -135.65 103.79 4.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.707 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.3 mp -116.64 129.31 73.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -173.102 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.16 138.73 51.47 Favored 'General case' 0 CA--C 1.465 -2.3 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.557 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 20.3 p90 -136.63 160.97 37.2 Favored 'General case' 0 N--CA 1.412 -2.353 0 C-N-CA 119.573 -0.851 . . . . 0.0 109.99 178.08 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 11.2 pt-20 -127.02 104.97 8.28 Favored 'General case' 0 N--CA 1.407 -2.582 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.214 177.027 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.552 HE21 ' C ' ' A' ' 22' ' ' GLN . 0.0 OUTLIER -85.61 133.73 34.03 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.564 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -122.58 116.78 24.45 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.138 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.437 ' H ' ' HG2' ' A' ' 24' ' ' GLU . 6.7 pt-20 -76.51 -11.28 59.85 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.955 -1.021 . . . . 0.0 111.015 -177.196 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.6 m -90.52 -9.28 47.84 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 171.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 70.24 135.93 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.667 1.587 . . . . 0.0 112.653 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -173.37 172.56 45.27 Favored Glycine 0 CA--C 1.487 -1.659 0 C-N-CA 120.28 -0.962 . . . . 0.0 111.374 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -65.06 123.4 11.52 Favored 'Trans proline' 0 N--CA 1.444 -1.383 0 N-CA-C 105.887 -2.39 . . . . 0.0 105.887 172.172 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.495 ' O ' ' HG3' ' A' ' 100' ' ' GLU . 34.9 m -94.96 127.36 46.98 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-O 121.617 0.722 . . . . 0.0 112.142 -172.801 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 21' ' ' GLU . 0.7 OUTLIER -81.99 104.46 12.36 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 177.635 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.518 HG12 ' HA ' ' A' ' 20' ' ' PHE . 14.5 m -132.45 147.65 31.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -177.279 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.436 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 12.0 t90 -158.93 136.49 10.12 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.307 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -150.3 142.04 9.3 Favored Glycine 0 N--CA 1.403 -3.541 0 C-N-CA 120.405 -0.902 . . . . 0.0 111.921 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.607 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 24.8 m -114.45 133.81 55.47 Favored 'General case' 0 N--CA 1.416 -2.161 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.803 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.751 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 5.2 tt -146.83 123.97 3.47 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.106 0 CA-C-N 118.358 0.527 . . . . 0.0 110.672 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.592 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -104.63 134.42 47.82 Favored 'General case' 0 N--CA 1.415 -2.184 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.837 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -132.08 177.39 18.73 Favored Glycine 1 N--CA 1.37 -5.705 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.262 -169.186 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.529 HD23 ' N ' ' A' ' 39' ' ' THR . 10.2 tt -67.02 177.22 1.8 Allowed 'General case' 0 C--N 1.271 -2.811 0 N-CA-C 103.124 -2.917 . . . . 0.0 103.124 168.413 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 91' ' ' LYS . 40.6 p -58.91 150.77 23.36 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 120.603 -1.311 . . . . 0.0 111.099 -165.996 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.587 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -60.7 158.5 12.56 Favored 'General case' 0 CA--C 1.458 -2.577 0 N-CA-C 117.981 2.586 . . . . 0.0 117.981 -155.751 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -142.2 173.86 23.55 Favored Glycine 0 C--N 1.254 -3.997 0 CA-C-N 110.8 -2.909 . . . . 0.0 107.038 -175.537 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.0 mt -131.66 -34.38 1.35 Allowed 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 116.879 2.177 . . . . 0.0 116.879 -164.699 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 19.1 t-80 -154.85 123.09 5.94 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 121.31 1.868 . . . . 0.0 109.995 -174.887 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.98 149.86 14.55 Favored Glycine 0 N--CA 1.424 -2.146 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.846 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.29 135.38 41.81 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.68 ' HA ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -129.15 82.74 2.1 Favored 'General case' 1 N--CA 1.362 -4.833 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.444 -161.742 . . . . . . . . 4 4 . 1 . 005 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 46' ' ' HIS . 9.3 p -174.59 162.96 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.398 -3.026 0 CA-C-N 114.119 -1.401 . . . . 0.0 110.582 165.993 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -147.28 112.53 5.53 Favored 'General case' 0 C--N 1.276 -2.611 0 C-N-CA 127.823 2.449 . . . . 0.0 106.994 166.844 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.642 ' CD ' ' HA ' ' A' ' 81' ' ' VAL . 20.2 pt-20 -83.51 86.06 7.15 Favored 'General case' 0 C--O 1.173 -2.942 0 N-CA-C 115.793 1.775 . . . . 0.0 115.793 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.51 ' N ' ' HG3' ' A' ' 115' ' ' ARG . 76.3 m-85 -169.09 91.09 0.24 Allowed 'General case' 0 C--N 1.283 -2.286 0 C-N-CA 127.439 2.296 . . . . 0.0 105.361 175.542 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' NE ' ' A' ' 115' ' ' ARG . . . -63.12 139.28 44.33 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 120.476 -0.868 . . . . 0.0 114.539 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -125.55 -84.58 0.63 Allowed 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 176.994 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -164.75 159.7 18.94 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.432 ' O ' ' HB3' ' A' ' 9' ' ' LYS . 9.0 t -67.94 -29.01 67.96 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 117.879 0.309 . . . . 0.0 111.538 -179.417 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.42 -22.24 28.42 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.41 110.76 0.51 Allowed Glycine 0 CA--C 1.484 -1.901 0 C-N-CA 119.366 -1.397 . . . . 0.0 111.42 -175.789 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.622 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 7.9 p -98.43 89.22 4.36 Favored 'General case' 0 C--N 1.281 -2.37 0 CA-C-O 121.895 0.855 . . . . 0.0 111.472 178.067 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.0 m -79.54 -47.25 15.86 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.454 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.0 m -79.78 -8.28 59.17 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.252 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.558 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -74.71 -9.28 58.42 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 115.338 -0.847 . . . . 0.0 111.989 179.303 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.412 ' HA3' ' HD2' ' A' ' 62' ' ' PRO . . . -68.88 -142.85 0.11 Allowed Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.601 -0.727 . . . . 0.0 113.697 178.822 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.412 ' HD2' ' HA3' ' A' ' 61' ' ' GLY . 55.0 Cg_endo -65.01 8.72 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.041 0 C-N-CA 124.456 3.438 . . . . 0.0 114.843 -176.736 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.93 124.42 46.6 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -169.615 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -133.84 166.03 23.62 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -172.006 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB3' ' OE2' ' A' ' 49' ' ' GLU . 44.3 t30 -114.03 96.39 41.64 Favored Pre-proline 0 N--CA 1.428 -1.541 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.351 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -80.97 -10.27 12.76 Favored 'Trans proline' 0 N--CA 1.425 -2.509 0 C-N-CA 123.206 2.604 . . . . 0.0 111.135 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -65.63 -45.29 83.63 Favored 'General case' 0 N--CA 1.432 -1.337 0 O-C-N 123.815 0.697 . . . . 0.0 110.019 -166.378 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.626 ' HB2' ' O ' ' A' ' 79' ' ' ARG 0.293 7.6 m -52.31 -52.66 51.76 Favored 'General case' 0 N--CA 1.417 -2.093 0 N-CA-C 116.241 1.941 . . . . 0.0 116.241 -171.215 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.58 ' O ' ' HB2' ' A' ' 70' ' ' LYS . 72.0 ttt180 -133.97 -32.84 1.07 Allowed 'General case' 0 CA--C 1.479 -1.781 0 C-N-CA 113.998 -3.081 . . . . 0.0 111.61 167.748 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.58 ' HB2' ' O ' ' A' ' 69' ' ' ARG . 22.0 tptm 160.63 -77.96 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.695 1.247 . . . . 0.0 108.708 170.171 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 178.58 119.99 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 126.489 1.916 . . . . 0.0 108.4 177.573 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.408 ' N ' ' HB3' ' A' ' 78' ' ' GLU . . . -156.28 -87.71 0.06 OUTLIER Glycine 0 CA--C 1.529 0.965 0 C-N-CA 118.636 -1.745 . . . . 0.0 115.355 177.866 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -146.12 4.72 Favored Glycine 0 N--CA 1.415 -2.752 0 C-N-CA 121.354 -0.45 . . . . 0.0 113.083 -173.164 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -106.0 1.42 0.2 Allowed 'Trans proline' 0 C--O 1.233 0.258 0 C-N-CA 124.969 3.779 . . . . 0.0 114.909 -170.527 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -87.4 -17.25 32.71 Favored 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -167.275 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.57 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 12.7 t70 -146.51 -72.71 0.23 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.662 -178.383 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.526 ' HG3' ' H ' ' A' ' 78' ' ' GLU . 21.9 pt-20 -154.11 -56.57 0.11 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.555 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.57 ' OE1' ' HB3' ' A' ' 76' ' ' ASP . 0.6 OUTLIER 52.74 1.67 0.02 OUTLIER 'General case' 0 C--O 1.203 -1.349 0 C-N-CA 127.73 2.412 . . . . 0.0 116.95 172.873 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.658 ' HB3' HG13 ' A' ' 81' ' ' VAL . 27.0 mtt180 163.7 -26.91 0.0 OUTLIER 'General case' 0 C--O 1.189 -2.119 0 C-N-CA 125.266 1.426 . . . . 0.0 111.389 -172.353 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.402 ' HB2' ' CB ' ' A' ' 68' ' ' SER . 30.6 m-70 57.17 19.01 4.52 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.658 HG13 ' HB3' ' A' ' 79' ' ' ARG . 6.9 m -57.88 -15.34 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 O-C-N 124.015 0.822 . . . . 0.0 112.73 -177.043 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.474 ' HA3' HG21 ' A' ' 47' ' ' VAL . . . 140.84 -126.02 3.0 Favored Glycine 0 N--CA 1.401 -3.688 0 C-N-CA 121.289 -0.481 . . . . 0.0 112.221 174.882 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -81.59 87.42 6.26 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 123.065 1.412 . . . . 0.0 110.628 -174.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.78 89.49 4.36 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.685 -1.598 . . . . 0.0 110.355 177.286 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -146.88 -176.82 20.97 Favored Glycine 0 N--CA 1.416 -2.664 0 N-CA-C 108.881 -1.687 . . . . 0.0 108.881 -178.71 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.84 155.57 18.67 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 117.733 0.767 . . . . 0.0 111.822 -179.333 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.484 HG13 ' NE2' ' A' ' 46' ' ' HIS . 2.0 m -143.16 128.45 15.88 Favored 'Isoleucine or valine' 0 C--N 1.361 1.081 0 C-N-CA 123.585 0.754 . . . . 0.0 111.08 173.14 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 t -141.78 95.98 2.9 Favored 'General case' 0 N--CA 1.39 -3.468 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 172.206 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.1 122.43 38.93 Favored 'General case' 0 CA--C 1.466 -2.266 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.832 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.606 ' HB3' ' HA3' ' A' ' 93' ' ' GLY . 21.6 t70 -54.15 169.76 0.16 Allowed 'General case' 0 CA--C 1.565 1.525 0 O-C-N 124.824 1.328 . . . . 0.0 111.435 177.468 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.594 ' HA ' ' HA ' ' A' ' 39' ' ' THR . 57.4 pttt -41.68 -23.54 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 117.233 2.309 . . . . 0.0 117.233 -175.309 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -154.16 22.07 0.5 Allowed 'General case' 0 C--N 1.294 -1.81 0 N-CA-C 104.359 -2.46 . . . . 0.0 104.359 172.496 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.606 ' HA3' ' HB3' ' A' ' 90' ' ' ASP . . . -83.81 -127.57 1.4 Allowed Glycine 0 C--O 1.179 -3.313 0 CA-C-N 111.555 -2.566 . . . . 0.0 118.634 -160.899 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 3.3 m -161.16 136.27 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.226 0 C-N-CA 124.978 1.311 . . . . 0.0 108.207 -170.247 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.57 111.73 24.16 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 173.685 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -74.99 93.52 2.72 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 123.479 0.487 . . . . 0.0 109.766 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 33.7 m -91.78 111.76 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.01 0 CA-C-O 121.982 0.896 . . . . 0.0 111.007 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.3 t -149.95 100.84 2.98 Favored 'General case' 0 N--CA 1.411 -2.394 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.42 118.55 43.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.495 ' HG3' ' O ' ' A' ' 29' ' ' VAL . 5.1 mp0 -107.32 99.01 8.57 Favored 'General case' 0 N--CA 1.417 -2.108 0 C-N-CA 118.983 -1.087 . . . . 0.0 110.327 -176.032 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -165.88 166.33 17.64 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 173.481 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.1 m -94.71 80.39 3.78 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.827 -1.149 . . . . 0.0 112.939 -174.07 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.0 m -104.84 -18.72 6.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.801 176.428 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 21.3 pt -101.46 7.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.707 -170.804 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.453 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 6.1 m -66.57 167.54 10.76 Favored 'General case' 0 CA--C 1.56 1.332 0 CA-C-O 122.697 1.237 . . . . 0.0 113.003 -175.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.443 ' HG ' ' HB2' ' A' ' 111' ' ' SER . 3.8 tt -78.26 87.22 4.33 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-N 114.115 -1.402 . . . . 0.0 108.286 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 51.7 m -170.01 86.68 0.13 Allowed 'General case' 0 C--N 1.264 -3.144 0 N-CA-C 102.533 -3.136 . . . . 0.0 102.533 169.904 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 157.32 -177.45 34.16 Favored Glycine 0 C--N 1.258 -3.753 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 49' ' ' GLU . 18.9 t70 -81.31 -21.5 39.19 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 118.492 -1.283 . . . . 0.0 109.568 175.265 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.581 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 62.9 t-80 -88.36 40.66 0.97 Allowed 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 173.598 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.443 ' HB2' ' HG ' ' A' ' 106' ' ' LEU . 15.1 p -63.02 -64.78 0.81 Allowed 'General case' 0 C--N 1.273 -2.725 0 CA-C-O 122.724 1.25 . . . . 0.0 110.146 -175.812 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 28.5 pt -128.94 -22.93 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.184 176.299 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -81.23 170.54 1.42 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.158 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.206 -162.448 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -82.99 71.72 2.97 Favored Glycine 0 CA--C 1.475 -2.463 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -172.62 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.51 ' HG3' ' N ' ' A' ' 50' ' ' PHE . 2.6 mpt_? -79.13 141.24 37.45 Favored 'General case' 0 N--CA 1.396 -3.13 0 CA-C-N 114.603 -0.799 . . . . 0.0 110.063 -178.739 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.8 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 8.8 t -67.84 124.21 22.71 Favored 'General case' 0 C--N 1.274 -2.716 0 CA-C-O 122.895 1.331 . . . . 0.0 114.554 -168.96 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.3 tp -80.64 98.42 7.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 113.556 -1.656 . . . . 0.0 108.901 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.68 ' O ' ' HA ' ' A' ' 46' ' ' HIS . 26.9 t -91.85 100.56 11.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.864 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.571 ' HB ' ' CB ' ' A' ' 46' ' ' HIS . 12.2 p -139.98 156.98 25.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 126.539 1.936 . . . . 0.0 108.343 -175.649 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -171.45 166.57 6.88 Favored 'General case' 0 N--CA 1.428 -1.564 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 165.117 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.567 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.2 mp0 -73.32 84.91 1.44 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 175.605 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 79.3 mttt -173.19 170.77 4.26 Favored 'General case' 0 CA--C 1.493 -1.228 0 C-N-CA 126.119 1.768 . . . . 0.0 108.326 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.661 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -80.44 104.48 11.01 Favored 'General case' 0 C--N 1.29 -1.998 0 O-C-N 124.145 0.903 . . . . 0.0 110.974 172.253 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -118.78 80.46 1.54 Allowed 'General case' 0 CA--C 1.483 -1.623 0 N-CA-C 104.267 -2.494 . . . . 0.0 104.267 173.28 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.712 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 16.4 t0 -125.91 139.0 53.82 Favored 'General case' 0 C--N 1.263 -3.17 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.332 -170.886 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.4 tp -82.03 -21.5 36.93 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.876 -172.944 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -102.82 13.42 56.29 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.712 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 14.3 tmtt? -127.42 37.76 4.18 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.3 -54.84 34.38 Favored Glycine 0 N--CA 1.427 -1.9 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.12 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 114.34 -25.09 10.78 Favored Glycine 0 C--N 1.308 -1.004 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.907 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 33.3 t-20 -167.58 167.08 13.77 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.438 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 12.9 pt-20 -48.39 -46.59 37.34 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.943 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -61.72 -53.57 54.28 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.542 0.737 . . . . 0.0 110.412 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.6 m -69.22 -27.28 65.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 112.108 -172.943 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 m -78.01 -15.31 59.05 Favored 'General case' 0 CA--C 1.557 1.235 0 CA-C-O 121.801 0.81 . . . . 0.0 110.025 177.244 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 99.4 mttt -89.67 -40.14 12.74 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 174.804 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.0 m -67.43 -46.39 73.28 Favored 'General case' 0 C--N 1.284 -2.244 0 CA-C-O 121.366 0.603 . . . . 0.0 109.993 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.53 76.56 1.18 Allowed Glycine 0 N--CA 1.408 -3.208 0 N-CA-C 106.866 -2.493 . . . . 0.0 106.866 -172.975 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -36.21 111.22 0.13 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 125.905 1.682 . . . . 0.0 111.041 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -149.22 135.75 19.4 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.225 -173.019 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 144' ' ' LEU . . . -70.87 108.4 2.47 Favored Glycine 0 N--CA 1.434 -1.438 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 172.861 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.6 m -57.01 -29.55 63.42 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 115.285 1.587 . . . . 0.0 115.285 -169.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.622 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 27.3 ttm180 -128.97 21.82 5.8 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -175.496 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.406 ' CD1' ' HA3' ' A' ' 141' ' ' GLY . 74.9 mt -74.46 -15.38 60.9 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.692 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.416 ' HB1' HD12 ' A' ' 8' ' ' LEU . . . -162.71 109.26 1.22 Allowed 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.478 175.15 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 61.5 m -98.59 131.41 44.82 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 174.401 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.8 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.59 126.44 1.23 Allowed Glycine 0 N--CA 1.412 -2.919 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.873 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 m -76.18 98.43 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-O 121.691 0.758 . . . . 0.0 109.864 173.831 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.406 HG13 ' CB ' ' A' ' 6' ' ' ALA . 1.7 mp -106.4 112.22 38.61 Favored 'Isoleucine or valine' 0 C--O 1.257 1.48 0 CA-C-O 122.31 1.053 . . . . 0.0 109.926 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.443 ' HA2' ' CZ ' ' A' ' 20' ' ' PHE . . . -174.68 176.76 46.93 Favored Glycine 0 CA--C 1.461 -3.294 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -175.981 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.35 105.05 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 107.942 -1.132 . . . . 0.0 107.942 176.727 . . . . . . . . 3 3 . 1 . 005 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.54 147.59 41.42 Favored 'General case' 0 N--CA 1.413 -2.281 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--N 1.292 -1.9 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.916 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.722 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.7 m -74.46 -23.4 58.89 Favored 'General case' 0 CA--C 1.566 1.58 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -172.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -132.37 147.8 52.4 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.873 -171.768 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.639 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -132.64 156.48 46.86 Favored 'General case' 0 N--CA 1.405 -2.693 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.579 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 47.2 t -125.96 126.91 70.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.555 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -124.91 135.1 52.55 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.005 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 14.7 m -127.61 119.77 52.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-O 121.201 0.524 . . . . 0.0 110.809 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -100.34 138.15 37.8 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.219 177.803 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -165.8 125.19 1.68 Allowed 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.83 -158.98 8.99 Favored Glycine 0 N--CA 1.439 -1.156 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.633 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -72.34 -61.78 1.67 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -75.62 153.43 44.2 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 172.63 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -83.21 123.35 3.47 Favored 'Trans proline' 0 N--CA 1.429 -2.289 0 CA-C-N 120.976 2.388 . . . . 0.0 112.389 -175.601 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.74 119.09 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.819 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 173.356 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 52.3 tt0 -130.82 128.88 41.55 Favored 'General case' 0 C--N 1.269 -2.909 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.545 ' HA3' HD13 ' A' ' 35' ' ' ILE . . . -170.54 161.78 34.77 Favored Glycine 0 N--CA 1.399 -3.791 0 C-N-CA 119.49 -1.338 . . . . 0.0 112.201 -177.273 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.46 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.0 pt -142.26 133.6 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.318 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -132.31 135.03 58.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.337 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -107.11 132.94 52.45 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.615 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.639 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 22.1 t80 -127.42 138.2 52.92 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 123.619 0.768 . . . . 0.0 110.59 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 29' ' ' VAL . 5.7 pt-20 -117.33 119.69 35.89 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.537 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.13 135.65 33.52 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 119.299 -0.961 . . . . 0.0 108.751 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -115.43 83.75 1.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.678 0.751 . . . . 0.0 110.308 179.647 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -68.42 -20.21 64.64 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 124.526 1.131 . . . . 0.0 110.802 -177.179 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 25' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 26' ' ' ASN . 17.4 t -88.44 -5.23 58.39 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.089 177.959 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' SER . 4.0 t30 77.47 113.91 0.07 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 124.682 1.193 . . . . 0.0 110.837 -173.227 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.82 166.41 39.6 Favored Glycine 0 CA--C 1.475 -2.455 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -177.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' HB2' ' A' ' 101' ' ' ASP . 58.0 Cg_endo -71.67 124.08 9.95 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 121.177 1.251 . . . . 0.0 110.774 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.584 HG12 ' H ' ' A' ' 102' ' ' SER . 9.8 p -76.75 123.25 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.893 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.066 173.761 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -105.56 124.56 49.76 Favored 'General case' 0 C--N 1.28 -2.451 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 172.631 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.597 ' H ' HG23 ' A' ' 99' ' ' ILE . 34.4 m -134.33 153.27 35.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -172.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 69.4 p-90 -145.64 135.23 23.27 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 174.562 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.745 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -148.68 139.59 7.68 Favored Glycine 0 N--CA 1.42 -2.404 0 C-N-CA 119.979 -1.105 . . . . 0.0 111.662 175.941 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.2 m -116.11 125.63 52.63 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HA3' ' A' ' 16' ' ' GLY . 25.3 mm -125.04 132.19 71.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 36.0 mtmm -117.67 136.16 53.52 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.998 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -171.01 174.15 44.75 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -172.056 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 pp -68.66 153.69 43.31 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 118.679 1.239 . . . . 0.0 109.634 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.59 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 77.3 p -69.85 107.26 3.46 Favored 'General case' 0 C--O 1.206 -1.195 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 -170.036 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 28.7 tt0 -175.35 115.99 0.15 Allowed 'General case' 0 C--O 1.205 -1.279 0 C-N-CA 125.653 1.581 . . . . 0.0 107.018 172.306 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 90' ' ' ASP . . . -164.35 114.97 0.62 Allowed Glycine 0 C--N 1.273 -2.917 0 C-N-CA 118.392 -1.861 . . . . 0.0 112.166 -174.637 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.2 mt -106.72 -64.76 1.15 Allowed 'General case' 0 N--CA 1.435 -1.191 0 O-C-N 123.998 0.47 . . . . 0.0 112.187 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.67 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 24.6 m-70 -171.35 168.95 6.45 Favored 'General case' 0 CA--C 1.492 -1.255 0 C-N-CA 124.249 1.02 . . . . 0.0 108.326 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.467 ' O ' ' HG3' ' A' ' 74' ' ' PRO . . . 178.23 -169.28 40.97 Favored Glycine 0 C--N 1.282 -2.461 0 C-N-CA 119.786 -1.197 . . . . 0.0 112.056 176.39 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 126' ' ' LEU . 1.3 p90 -168.16 165.67 13.15 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.316 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.697 ' CE1' ' HA3' ' A' ' 85' ' ' GLY . 18.3 m-70 -90.02 150.02 22.29 Favored 'General case' 0 CA--C 1.478 -1.808 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' O ' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -172.3 89.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 173.663 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.34 86.06 0.12 Allowed 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 163.942 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.492 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 9.0 pt-20 -93.4 117.92 30.67 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 118.094 -1.442 . . . . 0.0 110.852 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 12.0 t80 162.58 92.43 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 103.766 -2.679 . . . . 0.0 103.766 179.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -48.66 109.08 0.47 Allowed Glycine 0 N--CA 1.478 1.482 0 O-C-N 123.682 0.614 . . . . 0.0 113.714 -177.129 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -120.98 -80.77 0.63 Allowed 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 117.971 -1.492 . . . . 0.0 112.089 -175.583 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.8 t30 -144.99 156.4 43.93 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.891 -177.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 148' ' ' VAL . 33.1 p -84.32 -1.51 55.5 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 124.228 1.011 . . . . 0.0 111.295 -177.137 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.7 20.85 4.64 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.266 -179.034 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 146.99 114.39 0.82 Allowed Glycine 0 N--CA 1.424 -2.133 0 C-N-CA 118.969 -1.586 . . . . 0.0 112.033 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.466 ' SG ' HG23 ' A' ' 118' ' ' VAL . 9.4 p -96.71 90.83 5.43 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.095 0.95 . . . . 0.0 112.698 -177.456 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.2 p -74.18 -49.23 24.49 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.075 -177.78 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.9 m -65.14 -23.67 67.19 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.767 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.74 -22.99 53.05 Favored 'General case' 0 N--CA 1.422 -1.864 0 C-N-CA 120.037 -0.665 . . . . 0.0 110.822 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.403 ' HA3' ' HD3' ' A' ' 62' ' ' PRO . . . 30.62 -97.29 0.01 OUTLIER Glycine 0 N--CA 1.494 2.532 0 C-N-CA 124.881 1.229 . . . . 0.0 115.663 164.346 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD3' ' HA3' ' A' ' 61' ' ' GLY . 27.9 Cg_endo -93.44 73.46 0.36 Allowed 'Trans proline' 0 N--CA 1.435 -1.968 0 C-N-CA 123.479 2.786 . . . . 0.0 109.932 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.511 ' CD2' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p-80 -36.52 137.94 0.26 Allowed 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 125.415 1.486 . . . . 0.0 114.329 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.483 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 15.7 p90 -125.28 88.17 2.83 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 170.47 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 16.8 m120 -106.45 89.49 4.08 Favored Pre-proline 0 CA--C 1.505 -0.781 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 5.8 Cg_exo -77.7 -12.94 16.45 Favored 'Trans proline' 0 N--CA 1.443 -1.444 0 C-N-CA 122.474 2.116 . . . . 0.0 114.842 -169.152 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.425 HD12 ' O ' ' A' ' 106' ' ' LEU . 13.1 mt -70.2 -25.13 63.27 Favored 'General case' 0 CA--C 1.465 -2.302 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.422 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.559 ' HA ' ' C ' ' A' ' 77' ' ' GLU . 18.0 t -93.7 -96.34 0.15 Allowed 'General case' 1 N--CA 1.377 -4.076 0 C-N-CA 114.997 -2.681 . . . . 0.0 107.272 175.922 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HB3' ' HA ' ' A' ' 79' ' ' ARG 0.264 24.6 ttt85 -142.05 40.37 1.64 Allowed 'General case' 0 CA--C 1.492 -1.261 0 CA-C-N 119.055 0.843 . . . . 0.0 109.185 152.29 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 88.2 tttt 75.78 -33.39 0.22 Allowed 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -155.61 99.02 1.99 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -175.154 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.691 ' HA3' ' C ' ' A' ' 80' ' ' HIS . . . -164.56 -136.6 2.03 Favored Glycine 0 C--O 1.18 -3.234 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.752 163.673 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.713 ' N ' ' HA ' ' A' ' 81' ' ' VAL . . . -75.98 -175.96 39.89 Favored Glycine 0 CA--C 1.547 2.061 0 CA-C-N 117.427 0.613 . . . . 0.0 114.607 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HG3' ' O ' ' A' ' 44' ' ' GLY . 88.7 Cg_endo -102.49 0.37 0.42 Allowed 'Trans proline' 0 C--O 1.212 -0.788 0 C-N-CA 123.825 3.017 . . . . 0.0 113.633 -178.393 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.5 ' HG2' ' OE2' ' A' ' 100' ' ' GLU . 61.8 mttm -81.49 2.27 29.62 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -172.17 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.433 ' O ' ' HB ' ' A' ' 81' ' ' VAL . 37.4 t70 -175.59 166.34 3.2 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -176.272 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.559 ' C ' ' HA ' ' A' ' 68' ' ' SER . 2.5 pm0 -122.52 84.68 2.3 Favored 'General case' 0 N--CA 1.418 -2.039 0 C-N-CA 120.161 -0.616 . . . . 0.0 111.111 171.923 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.566 ' H ' HG23 ' A' ' 81' ' ' VAL . 0.1 OUTLIER 171.37 86.87 0.0 OUTLIER 'General case' 0 C--N 1.361 1.071 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.84 178.599 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.562 ' HA ' ' HB3' ' A' ' 69' ' ' ARG 0.289 0.0 OUTLIER 62.32 130.5 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 C-N-CA 126.481 1.912 . . . . 0.0 115.412 174.637 . . . . . . . . 4 4 . 1 . 006 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.691 ' C ' ' HA3' ' A' ' 72' ' ' GLY . 21.3 t-160 67.02 19.4 10.55 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.63 1.205 . . . . 0.0 107.971 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.713 ' HA ' ' N ' ' A' ' 73' ' ' GLY . 1.6 m -148.12 157.48 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.237 0 CA-C-N 113.207 -1.815 . . . . 0.0 107.595 175.481 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -128.17 -129.92 3.26 Favored Glycine 0 C--N 1.283 -2.39 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.616 ' HB3' ' O ' ' A' ' 46' ' ' HIS . 15.6 t70 -84.61 169.96 13.84 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -109.04 96.46 6.33 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 -165.692 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.697 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . -173.82 83.25 0.08 OUTLIER Glycine 0 N--CA 1.422 -2.282 0 C-N-CA 118.918 -1.61 . . . . 0.0 113.295 173.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.437 ' HB2' ' HG3' ' A' ' 74' ' ' PRO . 9.1 t30 -78.87 130.06 35.25 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.62 128.45 75.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.553 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 29.4 p -139.45 95.76 2.98 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -120.95 104.18 9.62 Favored 'General case' 0 N--CA 1.421 -1.895 0 C-N-CA 118.079 -1.448 . . . . 0.0 109.049 174.463 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' A' ' 39' ' ' THR . 8.1 p-10 -132.29 -20.88 2.36 Favored 'General case' 0 CA--C 1.47 -2.131 0 CA-C-O 121.788 0.804 . . . . 0.0 109.842 -176.302 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -72.53 -56.94 4.59 Favored 'General case' 0 C--N 1.268 -2.966 0 CA-C-N 113.655 -1.612 . . . . 0.0 109.091 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -153.71 6.18 0.33 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.505 -170.013 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 82.12 55.3 3.13 Favored Glycine 0 N--CA 1.426 -1.987 0 C-N-CA 118.102 -1.999 . . . . 0.0 108.748 -168.735 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.1 m -148.84 110.09 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 104.45 -2.426 . . . . 0.0 104.45 -177.549 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.553 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.84 128.92 41.94 Favored 'General case' 0 C--N 1.263 -3.162 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.703 -174.542 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -81.92 107.84 14.96 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 171.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.745 HG11 ' H ' ' A' ' 33' ' ' GLY . 13.4 p -82.61 137.46 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.202 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.336 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB3' ' OE2' ' A' ' 100' ' ' GLU . 41.8 m -84.37 108.6 17.29 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.963 177.213 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.597 HG23 ' H ' ' A' ' 31' ' ' VAL . 28.8 mt -93.32 114.06 29.34 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.482 0 N-CA-C 106.112 -1.811 . . . . 0.0 106.112 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.5 ' OE2' ' HG2' ' A' ' 75' ' ' LYS . 1.0 OUTLIER -134.99 155.71 50.3 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 -179.738 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.47 ' HB2' ' HA ' ' A' ' 28' ' ' PRO . 7.4 p-10 -90.11 131.83 35.75 Favored 'General case' 0 C--N 1.295 -1.763 0 CA-C-O 121.721 0.772 . . . . 0.0 111.517 -178.862 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 29' ' ' VAL . 75.6 p -96.07 172.94 7.68 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 175.808 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.57 -54.36 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.86 174.265 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -130.44 -47.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.644 0 C-N-CA 120.189 -0.604 . . . . 0.0 111.94 -174.313 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.8 p -170.08 167.19 8.92 Favored 'General case' 0 CA--C 1.469 -2.17 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -169.839 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.583 ' HB2' ' OD2' ' A' ' 83' ' ' ASP . 2.8 pp -68.84 164.28 22.33 Favored 'General case' 0 N--CA 1.391 -3.409 0 CA-C-N 113.67 -1.605 . . . . 0.0 106.687 176.039 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.408 ' HA ' ' HB2' ' A' ' 67' ' ' LEU . 50.0 m -86.28 88.25 7.58 Favored 'General case' 1 C--N 1.238 -4.268 0 CA-C-O 121.357 0.599 . . . . 0.0 111.681 -170.501 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.66 133.98 7.88 Favored Glycine 1 N--CA 1.394 -4.157 0 N-CA-C 106.957 -2.457 . . . . 0.0 106.957 167.818 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -122.32 -29.14 4.19 Favored 'General case' 0 C--N 1.264 -3.127 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.42 -31.82 69.17 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 174.162 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' HG22 ' A' ' 113' ' ' ILE . 28.5 t 173.71 -174.07 0.06 Allowed 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 168.143 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 31.4 mm -106.46 -4.98 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.98 0 N-CA-C 103.839 -2.652 . . . . 0.0 103.839 -179.184 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.538 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 16.0 tt -104.03 157.56 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 103.409 -2.811 . . . . 0.0 103.409 163.252 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.8 41.57 28.16 Favored Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.536 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.813 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -135.1 129.37 33.84 Favored 'General case' 0 C--N 1.271 -2.812 0 C-N-CA 125.065 1.346 . . . . 0.0 109.068 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.891 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 11.2 p -114.86 141.45 47.9 Favored 'General case' 0 C--N 1.279 -2.468 0 CA-C-O 121.339 0.59 . . . . 0.0 112.272 177.655 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.623 ' HB3' HG21 ' A' ' 149' ' ' ILE . 2.6 pt? -88.97 105.93 18.09 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.466 HG23 ' SG ' ' A' ' 57' ' ' CYS . 17.3 t -92.93 100.39 11.2 Favored 'Isoleucine or valine' 1 C--O 1.319 4.718 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.354 169.081 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 45' ' ' PHE . 3.3 t -147.1 170.42 3.94 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.677 0 C-N-CA 128.879 2.872 . . . . 0.0 103.467 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -159.51 170.39 21.8 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 178.175 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.531 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -79.79 83.25 5.76 Favored 'General case' 0 CA--C 1.567 1.604 0 N-CA-C 105.624 -1.991 . . . . 0.0 105.624 169.288 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -172.17 174.19 4.07 Favored 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 104.694 -2.335 . . . . 0.0 104.694 -167.515 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.67 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -88.29 104.62 16.91 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -69.71 113.31 6.85 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 174.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -75.83 131.59 39.83 Favored 'General case' 0 N--CA 1.427 -1.593 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.918 -167.788 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.56 HD22 ' HA2' ' A' ' 73' ' ' GLY . 11.0 mt -76.1 -71.52 0.38 Allowed 'General case' 0 N--CA 1.404 -2.752 0 CA-C-N 113.617 -1.629 . . . . 0.0 113.614 -169.13 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -117.38 -7.11 12.63 Favored Glycine 0 CA--C 1.467 -2.943 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.447 -168.676 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.481 ' O ' ' HB ' ' A' ' 135' ' ' THR . 95.3 mttt -99.93 -42.57 6.72 Favored 'General case' 0 N--CA 1.412 -2.369 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' N ' ' A' ' 135' ' ' THR . . . 75.97 -63.0 2.85 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -171.096 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 153.63 -25.85 0.75 Allowed Glycine 0 C--N 1.299 -1.486 0 N-CA-C 108.101 -1.999 . . . . 0.0 108.101 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -163.54 172.88 13.77 Favored 'General case' 0 C--O 1.254 1.342 0 N-CA-C 103.376 -2.824 . . . . 0.0 103.376 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -59.57 -41.06 89.31 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-N 118.887 0.767 . . . . 0.0 112.068 -176.34 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 136' ' ' LYS . 35.4 tt0 -66.17 -36.98 84.52 Favored 'General case' 0 C--O 1.219 -0.532 0 CA-C-O 121.08 0.467 . . . . 0.0 110.181 177.251 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -68.29 -34.23 75.77 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.642 -176.203 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.481 ' HB ' ' O ' ' A' ' 128' ' ' LYS . 10.7 t -81.54 -6.75 59.28 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.547 1.165 . . . . 0.0 109.114 177.354 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 88.3 tttt -90.01 -24.43 21.22 Favored 'General case' 0 C--N 1.287 -2.117 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.257 175.313 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.3 m -83.36 -33.3 25.85 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.72 7.59 Favored Glycine 1 C--O 1.315 5.194 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 -171.554 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -35.14 106.04 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 131.271 3.828 . . . . 0.0 120.016 -166.254 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.404 ' HB3' ' CG1' ' A' ' 118' ' ' VAL . . . -153.05 172.38 16.96 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 102.498 -3.149 . . . . 0.0 102.498 164.625 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -52.32 110.01 1.06 Allowed Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 34.4 p -52.63 -32.11 40.14 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -171.487 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 15.9 ptt180 -120.25 -27.37 5.27 Favored 'General case' 0 C--N 1.26 -3.304 0 C-N-CA 118.472 -1.291 . . . . 0.0 108.776 174.395 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.73 -36.39 11.3 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 124.7 1.25 . . . . 0.0 112.798 -165.989 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -142.45 88.76 2.1 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.102 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.891 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 52.7 t -156.86 141.36 16.71 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.858 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -157.72 170.44 34.7 Favored Glycine 0 N--CA 1.4 -3.708 0 N-CA-C 107.214 -2.354 . . . . 0.0 107.214 177.924 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.735 ' HB ' ' NH1' ' A' ' 115' ' ' ARG . 27.7 m -68.84 124.26 24.15 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.017 0 CA-C-N 117.656 0.728 . . . . 0.0 111.054 178.595 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.813 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 0.0 OUTLIER -123.47 99.86 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.212 0.53 . . . . 0.0 111.245 179.331 . . . . . . . . 3 3 . 1 . 006 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.504 ' HA3' ' NE ' ' A' ' 115' ' ' ARG . . . 174.63 -167.47 39.75 Favored Glycine 0 CA--C 1.457 -3.586 0 C-N-CA 117.546 -2.264 . . . . 0.0 111.534 178.316 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 9.1 tt -68.75 105.67 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.266 1.935 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -116.45 140.28 49.53 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.104 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 . . . . . 0 C--N 1.297 -1.694 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.009 . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.212 -0.918 0 N-CA-C 111.663 0.246 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.524 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 14.4 m -58.08 -26.41 62.53 Favored 'General case' 0 CA--C 1.571 1.776 0 N-CA-C 115.425 1.639 . . . . 0.0 115.425 -174.495 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -135.15 147.5 49.46 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.827 -1.171 . . . . 0.0 112.083 -172.171 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.836 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -139.81 154.42 47.35 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.64 172.519 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.554 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 39.7 t -129.69 131.03 67.02 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -178.403 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -121.49 132.37 54.68 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.664 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 10.9 m -127.96 109.04 18.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.729 0.776 . . . . 0.0 110.58 -178.695 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' A' ' 15' ' ' GLN . 6.6 mp -103.47 128.49 50.64 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.664 -176.334 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -160.88 124.99 3.5 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 169.147 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.91 -173.14 22.66 Favored Glycine 0 N--CA 1.405 -3.382 0 N-CA-C 107.216 -2.354 . . . . 0.0 107.216 175.141 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -95.21 89.66 5.59 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 120.217 -0.593 . . . . 0.0 109.78 -178.662 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.59 -63.83 0.62 Allowed Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.776 178.217 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.663 ' HB3' ' HA ' ' A' ' 120' ' ' HIS . 31.9 Cg_exo -62.31 169.16 8.35 Favored 'Trans proline' 0 N--CA 1.432 -2.095 0 C-N-CA 123.072 2.515 . . . . 0.0 115.004 -174.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.558 HG12 ' HA3' ' A' ' 37' ' ' GLY . 16.8 m -69.86 158.01 6.31 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.038 0 CA-C-N 111.587 -2.552 . . . . 0.0 112.544 -175.07 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.505 ' HA ' ' HB2' ' A' ' 8' ' ' LEU . 15.3 tm0? -112.52 140.56 47.17 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 104.667 -2.345 . . . . 0.0 104.667 177.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' HD13 ' A' ' 8' ' ' LEU . . . -158.98 170.51 35.41 Favored Glycine 0 N--CA 1.414 -2.824 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.449 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 18.9 pt -132.46 129.05 58.87 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 176.677 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.506 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 43.7 mm -130.01 123.53 56.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -174.718 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 2.2 m-20 -112.41 126.74 55.61 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.478 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.836 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 29.7 p90 -126.78 148.34 49.93 Favored 'General case' 0 CA--C 1.495 -1.147 0 C-N-CA 118.24 -1.384 . . . . 0.0 109.912 176.224 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.534 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 1.5 pp20? -117.76 116.17 26.48 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.372 176.128 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -85.72 87.88 7.47 Favored 'General case' 0 N--CA 1.382 -3.854 0 CA-C-O 123.103 1.43 . . . . 0.0 108.769 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.537 ' H ' ' HB ' ' A' ' 104' ' ' ILE . 5.0 ttmp? -72.16 110.06 6.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 112.206 -2.27 . . . . 0.0 107.009 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -61.79 -24.29 66.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.03 0.443 . . . . 0.0 111.622 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 m -71.92 -19.3 61.94 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.524 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.458 ' HA ' HG13 ' A' ' 104' ' ' ILE . 56.6 m-80 70.3 162.71 0.24 Allowed 'General case' 0 C--O 1.241 0.61 0 C-N-CA 125.194 1.398 . . . . 0.0 110.885 -175.493 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 138.47 -149.46 20.56 Favored Glycine 0 CA--C 1.48 -2.156 0 C-N-CA 117.762 -2.161 . . . . 0.0 114.18 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -63.26 125.69 16.25 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 123.357 2.704 . . . . 0.0 110.941 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.656 HG12 HG23 ' A' ' 104' ' ' ILE . 3.9 m -76.97 120.39 27.23 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.378 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -98.55 92.17 5.5 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.096 0.951 . . . . 0.0 108.506 172.259 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 71.5 t -133.36 146.0 32.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -175.889 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.5 p-90 -143.15 134.73 26.39 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.456 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -141.92 140.33 10.01 Favored Glycine 0 N--CA 1.419 -2.458 0 C-N-CA 119.796 -1.192 . . . . 0.0 112.14 178.171 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -116.63 151.82 35.48 Favored 'General case' 0 N--CA 1.394 -3.252 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 176.781 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.671 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 36.8 mm -132.24 134.06 59.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.683 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 60.6 pttt -139.0 119.96 14.42 Favored 'General case' 0 C--O 1.206 -1.207 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 175.1 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.558 ' HA3' HG12 ' A' ' 14' ' ' VAL . . . -169.97 174.97 44.16 Favored Glycine 0 CA--C 1.476 -2.354 0 C-N-CA 118.811 -1.662 . . . . 0.0 113.075 -171.793 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.3 tt -66.85 137.77 56.84 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.1 p -72.78 108.53 5.81 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 115.238 1.57 . . . . 0.0 115.238 -164.48 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.51 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.9 tt0 -177.78 121.79 0.11 Allowed 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 105.358 -2.09 . . . . 0.0 105.358 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' HA ' ' A' ' 90' ' ' ASP . . . -155.82 138.67 6.14 Favored Glycine 0 CA--C 1.47 -2.774 0 C-N-CA 119.268 -1.444 . . . . 0.0 111.507 -177.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 122' ' ' LYS . 3.6 mm? -126.65 -58.33 1.33 Allowed 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -170.989 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.52 169.3 24.61 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.369 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -130.29 113.34 1.43 Allowed Glycine 0 C--O 1.217 -0.917 0 C-N-CA 118.391 -1.861 . . . . 0.0 117.43 -170.317 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.596 ' O ' ' HB3' ' A' ' 124' ' ' ASP . 46.7 m-85 -168.67 108.86 0.5 Allowed 'General case' 0 C--O 1.188 -2.171 0 N-CA-C 102.752 -3.055 . . . . 0.0 102.752 170.942 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.449 ' HB3' HG22 ' A' ' 119' ' ' VAL . 68.1 m-70 -149.95 85.57 1.42 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 120.881 1.673 . . . . 0.0 107.969 -175.573 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.514 HG13 HG21 ' A' ' 149' ' ' ILE . 48.8 t -162.53 161.11 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 105.052 -2.203 . . . . 0.0 105.052 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' A' ' 60' ' ' ALA . 62.6 t-80 -153.46 148.41 26.62 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 168.266 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 0.4 OUTLIER -109.48 124.13 50.54 Favored 'General case' 0 C--N 1.257 -3.451 0 C-N-CA 124.196 0.998 . . . . 0.0 112.133 -177.764 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 11.8 t80 174.4 -50.98 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 124.864 1.266 . . . . 0.0 109.395 174.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.599 ' HA2' ' N ' ' A' ' 115' ' ' ARG . . . 95.04 109.8 2.32 Favored Glycine 0 CA--C 1.496 -1.123 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.305 -177.279 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -132.68 -73.09 0.51 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 117.707 -1.597 . . . . 0.0 112.878 -174.264 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 37.5 t-20 -161.95 152.18 17.02 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -179.246 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.7 m -71.73 -34.27 69.4 Favored 'General case' 0 C--O 1.208 -1.095 0 CA-C-O 121.135 0.493 . . . . 0.0 110.298 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.22 -12.72 27.63 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 120.75 -0.38 . . . . 0.0 111.956 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -154.24 111.26 0.48 Allowed Glycine 0 CA--C 1.468 -2.866 0 C-N-CA 119.077 -1.535 . . . . 0.0 110.046 -174.876 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.408 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 26.2 p -98.28 88.47 4.18 Favored 'General case' 0 N--CA 1.4 -2.949 0 CA-C-O 121.65 0.738 . . . . 0.0 110.851 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.0 m -79.26 -46.29 18.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.708 0.766 . . . . 0.0 110.14 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.5 m -63.71 -24.95 67.99 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.402 178.625 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.902 ' HB2' ' HB ' ' A' ' 116' ' ' THR . . . -75.49 -9.23 58.39 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 176.329 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.99 -160.49 0.78 Allowed Glycine 0 C--N 1.311 -0.854 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.97 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -74.37 54.08 3.23 Favored 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 122.74 2.293 . . . . 0.0 110.223 177.659 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -133.23 109.46 9.44 Favored 'General case' 0 N--CA 1.424 -1.751 0 N-CA-C 103.48 -2.785 . . . . 0.0 103.48 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.498 ' CD2' ' HB3' ' A' ' 69' ' ' ARG . 54.7 m-85 -123.77 162.06 23.93 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-O 122.06 0.934 . . . . 0.0 113.12 -174.218 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -104.56 143.3 26.41 Favored Pre-proline 0 N--CA 1.42 -1.956 0 N-CA-C 103.859 -2.645 . . . . 0.0 103.859 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -48.18 -55.31 4.16 Favored 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.98 2.453 . . . . 0.0 116.832 -168.297 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 95.2 mt -90.12 -4.97 57.0 Favored 'General case' 0 CA--C 1.478 -1.81 0 C-N-CA 119.142 -1.023 . . . . 0.0 108.885 -172.44 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 21.4 m -86.52 7.98 23.86 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.188 -1.369 . . . . 0.0 109.733 178.091 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HB3' ' CD2' ' A' ' 64' ' ' PHE . 4.4 ppt_? -134.04 -30.15 1.23 Allowed 'General case' 0 N--CA 1.402 -2.832 0 CA-C-O 117.734 -1.127 . . . . 0.0 110.313 167.398 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.485 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 85.1 tttt 34.54 -86.04 0.0 OUTLIER 'General case' 0 C--N 1.389 2.286 0 C-N-CA 125.386 1.474 . . . . 0.0 110.968 -173.534 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.506 ' O ' ' HA2' ' A' ' 127' ' ' GLY . 55.0 t-80 -131.32 -38.75 1.18 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 172.638 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.0 119.58 3.05 Favored Glycine 0 N--CA 1.425 -2.059 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -170.511 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.3 144.11 11.51 Favored Glycine 0 N--CA 1.419 -2.454 0 C-N-CA 118.612 -1.756 . . . . 0.0 113.041 -174.695 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 101' ' ' ASP . 59.1 Cg_endo -74.84 -19.16 18.53 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.3 2.0 . . . . 0.0 112.99 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 101' ' ' ASP . 51.1 mtmt -120.62 -13.97 8.68 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -175.633 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -172.18 126.25 0.55 Allowed 'General case' 0 CA--C 1.493 -1.231 0 CA-C-N 119.593 1.088 . . . . 0.0 109.649 -173.837 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.424 ' H ' ' HB2' ' A' ' 102' ' ' SER . 2.9 mm-40 -138.31 171.16 14.79 Favored 'General case' 0 N--CA 1.416 -2.16 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.084 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -100.13 -74.82 0.59 Allowed 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.57 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.562 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.1 OUTLIER -130.2 26.3 5.16 Favored 'General case' 0 CA--C 1.47 -2.107 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -170.579 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 7.6 t60 -114.01 102.45 10.2 Favored 'General case' 0 N--CA 1.396 -3.155 0 CA-C-N 111.96 -2.382 . . . . 0.0 106.102 177.042 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -101.13 7.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 178.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.487 ' C ' ' HB ' ' A' ' 47' ' ' VAL . . . -79.41 11.03 33.36 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-N 113.455 -1.702 . . . . 0.0 114.047 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -112.17 169.96 8.5 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.824 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -167.64 170.63 10.89 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 123.948 0.899 . . . . 0.0 109.818 177.642 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.42 153.96 35.07 Favored Glycine 0 CA--C 1.5 -0.851 0 O-C-N 124.194 0.933 . . . . 0.0 111.287 178.0 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -76.66 146.1 38.35 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.992 -171.874 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.66 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 17.1 m -136.9 146.26 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.548 ' HA ' ' OE1' ' A' ' 121' ' ' GLU . 7.4 t -141.62 109.57 5.79 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 174.9 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.586 ' HB1' ' HA2' ' A' ' 93' ' ' GLY . . . -118.07 105.78 12.21 Favored 'General case' 0 CA--C 1.47 -2.113 0 N-CA-C 104.814 -2.291 . . . . 0.0 104.814 174.157 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.527 ' HA ' ' N ' ' A' ' 41' ' ' GLY . 39.2 p30 -112.85 -77.52 0.58 Allowed 'General case' 0 C--O 1.172 -2.983 0 N-CA-C 114.793 1.405 . . . . 0.0 114.793 -164.781 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -83.71 -14.72 51.0 Favored 'General case' 1 C--N 1.212 -5.377 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -144.54 134.66 24.11 Favored 'General case' 0 N--CA 1.418 -2.037 0 N-CA-C 106.198 -1.778 . . . . 0.0 106.198 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.683 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.54 71.8 2.94 Favored Glycine 0 N--CA 1.417 -2.616 0 CA-C-O 119.279 -0.734 . . . . 0.0 111.549 -175.865 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.671 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 59.0 t -153.61 105.54 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.495 ' H ' ' HB ' ' A' ' 35' ' ' ILE . . . -113.11 144.48 42.57 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.463 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.33 137.27 38.99 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.987 -1.856 . . . . 0.0 105.987 175.959 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.456 HG11 ' H ' ' A' ' 33' ' ' GLY . 8.0 p -101.74 140.32 20.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.118 0.485 . . . . 0.0 110.164 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.6 m -122.47 101.58 7.57 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.45 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.686 HD13 ' H ' ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.42 118.74 54.66 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.311 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -177.415 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -148.8 97.49 2.72 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.011 -2.218 . . . . 0.0 105.011 166.859 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.545 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 1.1 p30 -168.02 168.19 12.11 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.339 -169.02 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.424 ' HB2' ' H ' ' A' ' 77' ' ' GLU . 15.6 m -99.95 80.0 2.26 Favored 'General case' 0 N--CA 1.42 -1.94 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.956 168.811 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.531 ' C ' ' H ' ' A' ' 105' ' ' SER . 49.9 t -101.18 -11.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 123.859 0.864 . . . . 0.0 109.442 173.06 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.656 HG23 HG12 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -63.82 21.32 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.889 0 C-N-CA 124.777 1.231 . . . . 0.0 112.641 176.957 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.531 ' H ' ' C ' ' A' ' 103' ' ' VAL . 16.0 m -68.74 130.22 42.19 Favored 'General case' 0 N--CA 1.4 -2.944 0 C-N-CA 125.271 1.428 . . . . 0.0 110.148 179.096 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.03 173.11 3.21 Favored 'General case' 0 N--CA 1.387 -3.583 0 CA-C-N 112.953 -1.931 . . . . 0.0 107.004 172.201 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.5 p -64.93 116.18 6.12 Favored 'General case' 2 N--CA 1.363 -4.787 0 CA-C-O 123.58 1.657 . . . . 0.0 111.592 -165.07 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.57 -142.32 12.82 Favored Glycine 2 CA--C 1.425 -5.546 0 CA-C-N 110.363 -3.108 . . . . 0.0 105.343 174.82 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 49' ' ' GLU . 4.7 p-10 40.11 -151.47 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -89.55 -23.81 21.91 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.158 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -131.51 -153.31 0.55 Allowed 'General case' 0 N--CA 1.41 -2.465 0 CA-C-O 122.009 0.909 . . . . 0.0 110.348 -175.315 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 59.0 mt -126.51 -38.2 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 N-CA-C 104.28 -2.489 . . . . 0.0 104.28 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.9 pt -91.08 99.05 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.834 0 CA-C-N 113.155 -1.839 . . . . 0.0 107.055 173.281 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -97.68 63.7 0.92 Allowed Glycine 2 N--CA 1.375 -5.392 0 N-CA-C 105.023 -3.231 . . . . 0.0 105.023 -175.743 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.599 ' N ' ' HA2' ' A' ' 51' ' ' GLY . 31.7 mtp180 -68.24 81.8 0.24 Allowed 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 -176.983 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.902 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 0.7 OUTLIER -163.3 97.12 0.89 Allowed 'General case' 1 N--CA 1.367 -4.592 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 -179.166 . . . . . . . . 4 4 . 1 . 007 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.485 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 16.2 mt -103.61 106.49 17.01 Favored 'General case' 0 C--N 1.251 -3.696 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.963 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.628 HG13 ' HB1' ' A' ' 60' ' ' ALA . 8.2 m -92.2 98.05 7.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 C-N-CA 117.394 -1.722 . . . . 0.0 109.384 169.736 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.449 HG22 ' HB3' ' A' ' 46' ' ' HIS . 9.2 t -135.51 136.21 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 122.724 1.249 . . . . 0.0 112.587 -174.2 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.663 ' HA ' ' HB3' ' A' ' 13' ' ' PRO . 0.4 OUTLIER -170.77 134.71 1.05 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 168.053 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.548 ' OE1' ' HA ' ' A' ' 88' ' ' THR . 1.9 mm-40 -69.63 99.74 1.35 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 122.153 0.978 . . . . 0.0 110.632 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.562 ' HA ' HD23 ' A' ' 42' ' ' LEU . 68.0 mttm -170.73 170.4 6.62 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 -170.505 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.63 104.13 3.24 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.596 ' HB3' ' O ' ' A' ' 45' ' ' PHE . 7.2 t70 -107.47 6.69 28.39 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.419 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -42.48 105.91 0.05 Allowed 'General case' 0 C--O 1.245 0.832 0 C-N-CA 126.882 2.073 . . . . 0.0 112.61 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -71.07 -39.93 71.92 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.574 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 127' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 71' ' ' HIS . . . -89.42 24.21 15.25 Favored Glycine 0 CA--C 1.482 -2.023 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.562 -177.208 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -136.59 -47.32 0.62 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.527 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 65.25 -78.34 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.777 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.363 -174.873 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 156.8 -38.05 0.57 Allowed Glycine 0 N--CA 1.417 -2.571 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.656 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 59.4 t30 -152.66 -178.91 7.16 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -54.02 -34.46 60.01 Favored 'General case' 0 C--N 1.368 1.384 0 N-CA-C 114.169 1.174 . . . . 0.0 114.169 -177.968 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.656 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -85.29 -38.14 19.2 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.305 0.574 . . . . 0.0 111.57 -174.568 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.4 p -76.77 -20.78 56.06 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -81.54 -7.75 59.63 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.878 0.847 . . . . 0.0 109.642 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 86.5 tttt -85.81 -49.18 8.11 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.085 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 5.0 p -68.1 -37.42 81.15 Favored 'General case' 0 N--CA 1.417 -2.101 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.014 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.73 94.81 0.06 OUTLIER Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -32.54 123.62 0.34 Allowed 'General case' 1 C--O 1.336 5.619 0 CA-C-O 123.609 1.671 . . . . 0.0 114.049 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.414 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -140.74 120.66 13.58 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.85 -176.548 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -97.33 72.66 0.69 Allowed Glycine 0 C--O 1.214 -1.122 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.408 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 5.2 p -88.83 5.99 41.11 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -172.518 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 57.0 ttt-85 -118.26 -47.92 2.54 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.74 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.438 ' HG ' ' HD3' ' A' ' 13' ' ' PRO . 11.9 tp -60.34 -38.95 85.39 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 114.957 -1.02 . . . . 0.0 113.59 -167.737 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 129.96 7.13 Favored 'General case' 0 CA--C 1.481 -1.675 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.485 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 81.4 m -138.25 163.21 32.34 Favored 'General case' 0 C--N 1.291 -1.977 0 O-C-N 124.421 1.076 . . . . 0.0 108.856 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.664 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.7 170.23 43.34 Favored Glycine 0 N--CA 1.408 -3.188 0 O-C-N 123.887 0.742 . . . . 0.0 111.489 175.602 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.546 HG13 ' HG2' ' A' ' 115' ' ' ARG . 69.5 t -69.49 117.73 12.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 C-N-CA 124.148 0.979 . . . . 0.0 110.549 168.408 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.528 ' H ' ' HA ' ' A' ' 115' ' ' ARG . 15.7 tt -122.65 108.0 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 CA-C-O 122.229 1.014 . . . . 0.0 108.729 166.391 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.49 46.23 Favored Glycine 1 CA--C 1.442 -4.479 0 N-CA-C 108.262 -1.935 . . . . 0.0 108.262 178.663 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 8.7 tt -69.23 103.91 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 177.186 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.554 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -110.27 97.12 6.66 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.386 -1.326 . . . . 0.0 110.936 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 2.5 mp0 . . . . . 0 C--N 1.324 -0.536 0 O-C-N 125.942 2.026 . . . . 0.0 114.489 171.157 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.811 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.609 ' O ' ' HA ' ' A' ' 21' ' ' GLU . 28.5 p -109.6 -65.24 1.17 Allowed 'General case' 0 C--O 1.161 -3.585 0 CA-C-O 119.147 -0.454 . . . . 0.0 111.569 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.2 ptpp? -135.49 171.03 15.02 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.894 0.378 . . . . 0.0 110.684 -168.427 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -137.19 166.82 22.83 Favored 'General case' 0 N--CA 1.419 -2.021 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -177.949 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 152' ' ' ALA . 27.2 m -128.89 168.39 22.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.566 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -132.66 137.97 47.16 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.469 -173.06 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.7 t -134.28 108.55 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.434 HD21 ' HB3' ' A' ' 117' ' ' LEU . 84.7 mt -96.71 150.17 20.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -149.15 122.79 9.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.93 24.66 Favored Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.134 -1.507 . . . . 0.0 113.012 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 11' ' ' ASP . . . . . 0.425 ' O ' ' HD3' ' A' ' 13' ' ' PRO . 46.3 m-20 -66.24 -50.5 63.56 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 175.654 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.91 96.9 1.7 Allowed Glycine 0 N--CA 1.432 -1.594 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' O ' ' A' ' 11' ' ' ASP . 32.2 Cg_exo -57.08 127.41 25.64 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.607 2.204 . . . . 0.0 113.563 -173.329 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 11.4 m -120.58 113.02 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.804 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.597 175.128 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 mp0 -108.5 119.53 39.79 Favored 'General case' 0 C--N 1.294 -1.805 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.112 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.72 170.13 42.9 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 176.153 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.431 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 24.8 pt -129.4 125.4 61.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' HE2' ' A' ' 46' ' ' HIS . 3.7 mp -123.33 128.4 74.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -178.545 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.735 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 18.5 m120 -100.05 134.89 42.31 Favored 'General case' 0 CA--C 1.507 -0.701 0 CA-C-O 119.306 -0.378 . . . . 0.0 110.662 -177.848 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -127.75 119.6 26.11 Favored 'General case' 0 CA--C 1.503 -0.852 0 C-N-CA 118.613 -1.235 . . . . 0.0 113.585 175.271 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.609 ' HA ' ' O ' ' A' ' 2' ' ' THR . 58.3 mt-10 -90.22 143.9 26.35 Favored 'General case' 0 N--CA 1.425 -1.719 0 CA-C-N 114.372 -1.285 . . . . 0.0 112.734 177.872 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.576 ' HB2' ' HA ' ' A' ' 106' ' ' LEU . 3.9 pt20 -103.11 124.9 49.43 Favored 'General case' 1 N--CA 1.375 -4.176 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 163.596 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -111.45 83.59 1.8 Allowed 'General case' 0 C--N 1.273 -2.733 0 C-N-CA 119.264 -0.974 . . . . 0.0 108.578 169.739 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -69.47 -27.95 65.66 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.102 -1.408 . . . . 0.0 108.736 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -71.21 -8.65 54.99 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.36 -1.291 . . . . 0.0 110.087 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.2 t30 75.88 120.44 0.05 OUTLIER 'General case' 0 C--N 1.35 0.626 0 C-N-CA 126.323 1.849 . . . . 0.0 111.195 -177.444 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.69 165.55 29.88 Favored Glycine 0 N--CA 1.408 -3.183 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HB3' ' HB2' ' A' ' 101' ' ' ASP . 37.7 Cg_endo -66.28 135.53 40.27 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.12 1.88 . . . . 0.0 110.692 178.46 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.594 HG23 ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -73.6 135.36 27.75 Favored 'Isoleucine or valine' 0 C--O 1.268 2.033 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.445 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -101.75 124.16 46.93 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 173.737 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.414 ' O ' HG22 ' A' ' 99' ' ' ILE . 16.5 m -137.99 152.82 26.55 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -172.57 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.6 t-105 -156.56 132.49 9.69 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.891 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' C ' HG12 ' A' ' 97' ' ' VAL . . . -170.63 135.84 3.69 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.545 -2.264 . . . . 0.0 112.61 169.684 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.437 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 5.4 p -117.8 137.09 52.98 Favored 'General case' 0 N--CA 1.395 -3.18 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.411 HG22 ' HA3' ' A' ' 16' ' ' GLY . 47.6 pt -131.87 146.27 33.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.052 -1.059 . . . . 0.0 110.093 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -119.23 129.61 55.03 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 176.225 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.583 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -135.15 174.3 21.24 Favored Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -173.515 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.81 173.53 5.19 Favored 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 123.73 0.812 . . . . 0.0 110.81 178.434 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.497 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 9.8 t -66.37 110.63 3.16 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-O 121.627 0.727 . . . . 0.0 111.657 -172.038 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . 0.267 4.6 mm-40 -165.61 177.34 7.41 Favored 'General case' 0 N--CA 1.398 -3.071 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.251 -176.647 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.43 -146.49 0.01 OUTLIER Glycine 0 N--CA 1.403 -3.501 0 CA-C-N 112.021 -2.354 . . . . 0.0 115.417 -177.953 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' CB ' ' HA ' ' A' ' 88' ' ' THR . 2.0 pt? -173.06 100.14 0.13 Allowed 'General case' 1 N--CA 1.372 -4.326 0 O-C-N 121.592 -0.946 . . . . 0.0 109.343 -161.214 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.526 ' HB3' ' HA ' ' A' ' 123' ' ' ALA . 0.4 OUTLIER 169.85 171.33 0.05 Allowed 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 103.963 -2.606 . . . . 0.0 103.963 177.43 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' ' N ' ' A' ' 125' ' ' ASP . . . 102.65 64.72 0.73 Allowed Glycine 0 C--N 1.268 -3.197 0 N-CA-C 116.248 1.259 . . . . 0.0 116.248 171.707 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.611 ' CG ' ' HB3' ' A' ' 84' ' ' LEU . 12.8 t80 -76.72 134.85 39.09 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 117.336 -1.746 . . . . 0.0 110.07 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.644 ' HE2' HG12 ' A' ' 18' ' ' ILE . 1.4 p-80 -85.91 100.61 12.22 Favored 'General case' 0 C--N 1.263 -3.175 0 CA-C-N 112.848 -1.978 . . . . 0.0 115.086 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.577 ' HB ' ' HA2' ' A' ' 82' ' ' GLY . 31.2 t -129.58 89.79 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.497 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 171.569 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.709 ' CE1' ' HB3' ' A' ' 60' ' ' ALA . 1.7 t60 -107.27 107.29 18.15 Favored 'General case' 0 C--O 1.184 -2.393 0 N-CA-C 113.323 0.861 . . . . 0.0 113.323 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 60' ' ' ALA . 3.6 mp0 -90.07 136.21 33.18 Favored 'General case' 0 C--N 1.267 -2.989 0 O-C-N 120.687 -1.258 . . . . 0.0 112.665 175.202 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 t80 70.67 93.59 0.08 Allowed 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 125.968 1.707 . . . . 0.0 111.359 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.29 -91.14 1.15 Allowed Glycine 0 CA--C 1.482 -2.006 0 C-N-CA 119.066 -1.54 . . . . 0.0 113.543 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.2 t70 76.89 -25.87 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 126.996 2.118 . . . . 0.0 112.583 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 2.6 m-20 -90.35 98.84 12.01 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.449 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.49 ' HA ' HG13 ' A' ' 148' ' ' VAL . 11.4 t -56.55 -32.07 64.8 Favored 'General case' 0 C--O 1.199 -1.561 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -173.441 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.74 13.07 33.82 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.606 -0.683 . . . . 0.0 110.808 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.448 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -155.75 111.46 0.49 Allowed Glycine 0 N--CA 1.425 -2.095 0 C-N-CA 117.849 -2.119 . . . . 0.0 113.667 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 142' ' ' SER . 69.5 m -94.57 85.14 4.43 Favored 'General case' 0 N--CA 1.392 -3.36 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 172.643 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.9 m -82.31 -48.36 11.28 Favored 'General case' 0 N--CA 1.418 -2.061 0 CA-C-N 114.794 -1.093 . . . . 0.0 109.156 179.083 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.6 p -71.57 -54.91 8.94 Favored 'General case' 0 N--CA 1.407 -2.624 0 CA-C-N 113.361 -1.745 . . . . 0.0 113.792 -172.433 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.709 ' HB3' ' CE1' ' A' ' 48' ' ' HIS 0.325 . . -85.81 -2.34 58.13 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 179.657 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -43.5 -139.31 0.0 OUTLIER Glycine 0 CA--C 1.57 3.509 0 C-N-CA 124.186 0.898 . . . . 0.0 113.993 171.054 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -60.1 5.32 0.13 Allowed 'Trans proline' 0 CA--C 1.574 2.494 0 C-N-CA 122.706 2.271 . . . . 0.0 114.879 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -116.58 110.8 19.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 123.467 0.707 . . . . 0.0 109.838 178.784 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -74.48 152.51 39.4 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.648 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -115.77 144.35 32.45 Favored Pre-proline 0 C--N 1.309 -1.162 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.74 177.025 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -72.22 -13.11 28.23 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.239 1.959 . . . . 0.0 111.747 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 109' ' ' ASP . 2.6 mm? -80.96 -9.47 59.83 Favored 'General case' 0 CA--C 1.484 -1.568 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -78.95 66.03 4.3 Favored 'General case' 0 N--CA 1.405 -2.706 0 CA-C-O 123.538 1.637 . . . . 0.0 108.719 172.943 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.636 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 12.5 ptp180 -117.49 23.27 11.88 Favored 'General case' 0 N--CA 1.397 -3.104 0 CA-C-N 112.204 -2.271 . . . . 0.0 105.149 175.007 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.9 mmmt -78.91 18.63 0.59 Allowed 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 112.363 -2.199 . . . . 0.0 111.005 176.331 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 33.6 t-80 75.3 87.59 0.09 Allowed 'General case' 0 N--CA 1.423 -1.805 0 O-C-N 125.135 1.522 . . . . 0.0 112.018 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.684 ' HA2' ' O ' ' A' ' 83' ' ' ASP . . . -76.75 -98.4 0.17 Allowed Glycine 1 N--CA 1.385 -4.738 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 169.492 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -50.33 158.0 1.88 Allowed Glycine 0 N--CA 1.429 -1.827 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 172.828 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.434 ' HA ' ' NE2' ' A' ' 71' ' ' HIS . 47.4 Cg_endo -62.14 0.09 1.47 Allowed 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 124.678 3.585 . . . . 0.0 114.454 -172.071 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -120.39 13.67 11.89 Favored 'General case' 0 C--N 1.289 -2.049 0 C-N-CA 123.047 0.539 . . . . 0.0 110.127 -175.059 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 71' ' ' HIS . 3.0 m-20 71.98 76.38 0.16 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.502 177.185 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -78.97 87.19 4.79 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.723 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 69' ' ' ARG . 11.6 pt-20 -57.56 26.34 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 128.704 2.801 . . . . 0.0 115.942 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -160.16 -0.56 0.07 Allowed 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.385 -174.152 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.8 m170 -105.16 136.16 45.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.563 -0.711 . . . . 0.0 111.451 -173.703 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.415 ' O ' HG13 ' A' ' 81' ' ' VAL . 11.1 p -98.49 70.48 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.267 2.024 0 CA-C-O 123.138 1.447 . . . . 0.0 113.722 -178.598 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.577 ' HA2' ' HB ' ' A' ' 47' ' ' VAL . . . 115.93 86.4 1.29 Allowed Glycine 0 CA--C 1.468 -2.869 0 C-N-CA 117.924 -2.084 . . . . 0.0 114.217 172.663 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.684 ' O ' ' HA2' ' A' ' 72' ' ' GLY . 7.7 p-10 -164.53 140.59 6.0 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 124.102 0.961 . . . . 0.0 108.95 176.724 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.611 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 7.5 tt -174.94 177.18 2.03 Favored 'General case' 0 C--N 1.278 -2.504 0 N-CA-C 102.597 -3.112 . . . . 0.0 102.597 177.868 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.522 ' N ' HD23 ' A' ' 84' ' ' LEU . . . -39.74 156.43 0.03 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 119.106 0.867 . . . . 0.0 111.486 173.451 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 33.4 p30 -85.48 160.52 19.68 Favored 'General case' 0 C--N 1.282 -2.351 0 O-C-N 122.377 -0.484 . . . . 0.0 112.105 -158.293 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 77.5 t -108.39 163.42 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.912 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -174.76 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.561 ' HA ' ' CB ' ' A' ' 42' ' ' LEU . 31.5 m -140.33 130.51 25.0 Favored 'General case' 0 C--N 1.261 -3.28 0 C-N-CA 124.437 1.095 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.54 ' CB ' ' HB3' ' A' ' 121' ' ' GLU . . . -126.12 155.16 42.08 Favored 'General case' 0 C--N 1.254 -3.583 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 174.223 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.418 ' C ' ' HA ' ' A' ' 39' ' ' THR . 23.9 t70 -158.36 174.96 14.34 Favored 'General case' 1 C--N 1.239 -4.232 0 N-CA-C 104.126 -2.546 . . . . 0.0 104.126 178.462 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.497 ' N ' ' HA ' ' A' ' 39' ' ' THR . 59.8 pttt -47.27 -35.85 8.32 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 176.353 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -90.28 -38.64 13.26 Favored 'General case' 0 CA--C 1.486 -1.503 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 176.431 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.583 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 89.54 112.85 1.38 Allowed Glycine 0 N--CA 1.404 -3.479 0 CA-C-N 114.675 -1.148 . . . . 0.0 112.308 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.484 ' O ' ' HB ' ' A' ' 88' ' ' THR . 6.7 p -157.71 103.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.417 -2.101 0 CA-C-O 121.953 0.883 . . . . 0.0 109.876 174.715 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.403 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . -94.23 129.0 41.02 Favored 'General case' 0 N--CA 1.414 -2.228 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.713 173.224 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -69.57 143.38 53.37 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 114.378 -1.283 . . . . 0.0 109.406 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.475 HG12 ' C ' ' A' ' 33' ' ' GLY . 34.4 m -79.57 103.37 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.908 0 CA-C-O 123.855 1.788 . . . . 0.0 107.813 -177.488 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -86.77 107.39 18.24 Favored 'General case' 0 N--CA 1.401 -2.9 0 CA-C-N 113.059 -1.882 . . . . 0.0 111.083 -174.171 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 31' ' ' VAL . 37.5 pt -95.66 124.83 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.513 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.718 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -143.64 126.31 16.03 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.46 ' HB2' ' HB3' ' A' ' 28' ' ' PRO . 4.3 p30 -81.09 135.62 35.83 Favored 'General case' 0 C--O 1.276 2.45 0 CA-C-O 122.433 1.111 . . . . 0.0 112.601 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.427 ' OG ' ' HB ' ' A' ' 29' ' ' VAL . 92.5 p -102.92 172.2 6.96 Favored 'General case' 0 N--CA 1.413 -2.3 0 CA-C-N 112.846 -1.979 . . . . 0.0 110.608 177.678 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.452 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 7.1 p -115.88 -53.1 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.329 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 163.295 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 12.8 pt -98.93 23.67 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.045 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -170.647 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.8 t -80.34 89.88 5.56 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 123.061 1.41 . . . . 0.0 108.721 169.557 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.576 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 3.0 pp -126.72 170.39 12.18 Favored 'General case' 2 N--CA 1.346 -5.643 1 N-CA-C 99.272 -4.344 . . . . 0.0 99.272 174.558 . . . . . . . . 4 3 . 1 . 008 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.1 m -74.13 93.37 2.28 Favored 'General case' 1 C--N 1.213 -5.327 0 C-N-CA 118.727 -1.189 . . . . 0.0 111.978 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.81 135.43 12.43 Favored Glycine 0 CA--C 1.456 -3.651 0 N-CA-C 106.308 -2.717 . . . . 0.0 106.308 175.332 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.526 ' HB2' ' CB ' ' A' ' 67' ' ' LEU . 6.1 t70 54.09 -153.78 0.28 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -171.434 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.543 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 72.5 m80 -90.37 37.11 0.89 Allowed 'General case' 0 C--N 1.276 -2.602 0 C-N-CA 124.78 1.232 . . . . 0.0 109.777 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 115' ' ' ARG . 16.6 p -59.41 -27.14 65.74 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.671 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 46.1 pt -104.6 -32.94 2.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 C-N-CA 118.2 -1.4 . . . . 0.0 110.62 176.225 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.543 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 14.0 tt -104.09 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 120.135 -0.626 . . . . 0.0 112.684 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.76 17.89 53.02 Favored Glycine 0 N--CA 1.44 -1.065 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.895 175.111 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.549 ' HG3' ' O ' ' A' ' 48' ' ' HIS . 23.7 ttp180 -73.4 101.73 3.56 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 122.268 -0.548 . . . . 0.0 111.233 178.664 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 146' ' ' CYS . 4.2 m -70.9 110.85 5.88 Favored 'General case' 0 C--O 1.181 -2.519 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 176.966 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.537 ' HG ' ' HB2' ' A' ' 46' ' ' HIS . 13.2 tp -70.03 123.87 22.64 Favored 'General case' 0 C--N 1.275 -2.673 0 C-N-CA 122.731 0.412 . . . . 0.0 111.346 -172.31 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.582 HG22 ' HB2' ' A' ' 48' ' ' HIS . 11.4 m -91.88 101.03 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 178.018 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.487 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 10.3 p -140.52 168.66 16.61 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 176.931 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 124' ' ' ASP . 0.3 OUTLIER -171.2 164.23 7.25 Favored 'General case' 0 CA--C 1.487 -1.456 0 N-CA-C 104.214 -2.513 . . . . 0.0 104.214 173.871 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.58 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 2.2 mp0 -86.9 84.17 7.39 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.58 ' HG2' ' O ' ' A' ' 121' ' ' GLU . 2.2 mmpt? -176.0 171.53 2.57 Favored 'General case' 0 CA--C 1.476 -1.903 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 -175.314 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 43' ' ' HIS . . . -62.42 122.41 15.65 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 170.063 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 19.6 t70 -128.74 -12.83 4.79 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.943 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' A' ' 82' ' ' GLY . 0.6 OUTLIER -71.56 137.28 47.92 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.268 -174.881 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -79.2 -68.19 0.68 Allowed 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.334 -178.268 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 127' ' ' GLY . . . . . 0.478 ' H ' ' CG ' ' A' ' 83' ' ' ASP . . . -74.04 9.83 8.61 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 119.982 -1.104 . . . . 0.0 114.962 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.404 ' HB3' ' CG ' ' A' ' 125' ' ' ASP . 32.2 tptt -137.43 15.29 2.97 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.8 42.94 1.85 Allowed Glycine 0 N--CA 1.473 1.135 0 N-CA-C 118.736 2.254 . . . . 0.0 118.736 -166.709 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 74.18 -91.38 0.72 Allowed Glycine 0 C--N 1.3 -1.431 0 N-CA-C 116.735 1.454 . . . . 0.0 116.735 171.239 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -100.33 158.32 15.97 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 118.595 -0.717 . . . . 0.0 110.484 -169.468 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -47.37 -42.48 21.77 Favored 'General case' 0 C--N 1.363 1.172 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 -178.06 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -79.87 -43.66 21.87 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.91 0.386 . . . . 0.0 110.958 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.7 t -70.64 -20.87 62.68 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.369 0.668 . . . . 0.0 111.878 -173.364 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -82.32 -18.23 42.97 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.031 0.443 . . . . 0.0 110.356 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 44.5 mtpt -101.77 -28.22 12.58 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.54 -1.264 . . . . 0.0 110.071 -178.116 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.9 p -74.45 -47.85 31.05 Favored 'General case' 0 N--CA 1.408 -2.527 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 173.092 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.16 94.06 0.13 Allowed Glycine 0 N--CA 1.417 -2.614 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.66 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 46.2 t-20 -55.81 106.03 0.23 Allowed 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 176.952 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.6 56.17 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -172.746 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.47 101.21 2.74 Favored Glycine 0 N--CA 1.428 -1.868 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 15.2 m -89.52 -7.1 55.65 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -171.504 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -145.19 -11.39 0.55 Allowed 'General case' 0 C--N 1.247 -3.859 0 C-N-CA 118.203 -1.399 . . . . 0.0 110.297 172.882 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -54.89 -42.96 72.74 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -175.668 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -149.82 89.88 1.65 Allowed 'General case' 0 N--CA 1.397 -3.122 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.563 ' HB3' HG22 ' A' ' 116' ' ' THR . 32.3 m -126.72 150.71 48.9 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 113.938 -1.483 . . . . 0.0 107.897 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.95 139.64 5.55 Favored Glycine 0 C--N 1.291 -1.957 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 178.401 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 54' ' ' THR . 17.2 m -73.59 110.4 7.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 118.69 1.245 . . . . 0.0 111.705 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.456 HG23 ' HB2' ' A' ' 117' ' ' LEU . 1.4 pp -86.67 145.75 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.227 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.671 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -150.14 142.61 9.83 Favored Glycine 2 N--CA 1.382 -4.96 0 C-N-CA 117.619 -2.229 . . . . 0.0 112.395 -171.409 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.612 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 3.4 tt -53.16 103.79 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 CA-C-O 122.088 0.947 . . . . 0.0 109.841 167.699 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.409 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -150.1 154.73 38.6 Favored 'General case' 0 N--CA 1.41 -2.436 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 174.494 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 . . . . . 0 C--N 1.273 -2.72 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 177.608 . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.05 0 N-CA-C 111.379 0.14 . . . . 0.0 111.379 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.595 ' C ' ' HG3' ' A' ' 21' ' ' GLU . 30.1 m -119.33 -54.06 2.21 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.51 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 22.6 pttp -145.5 152.57 39.97 Favored 'General case' 0 N--CA 1.417 -2.122 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.632 -169.749 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.773 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.19 161.03 38.84 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 65.7 t -131.25 122.52 51.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.815 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -115.33 127.82 55.68 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.503 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.581 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.5 m -113.29 144.75 20.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 O-C-N 123.433 0.458 . . . . 0.0 110.554 -178.634 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 95.4 mt -127.09 135.05 50.22 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.641 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -141.04 125.86 18.06 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 10' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -154.31 178.45 31.13 Favored Glycine 0 N--CA 1.432 -1.597 0 C-N-CA 118.931 -1.604 . . . . 0.0 113.338 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -73.0 -40.4 65.23 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.982 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.56 95.57 1.45 Allowed Glycine 0 N--CA 1.434 -1.443 0 N-CA-C 106.159 -2.776 . . . . 0.0 106.159 170.484 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.75 127.56 14.77 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.895 1.73 . . . . 0.0 115.2 -169.345 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 14.0 m -123.78 114.98 43.75 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.186 0 N-CA-C 104.751 -2.314 . . . . 0.0 104.751 172.986 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.24 118.29 32.87 Favored 'General case' 0 C--N 1.279 -2.485 0 C-N-CA 118.309 -1.356 . . . . 0.0 109.542 -173.979 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.72 171.56 44.15 Favored Glycine 0 N--CA 1.412 -2.965 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.887 178.405 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.2 pt -133.46 124.58 48.79 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.413 ' HA ' ' HA3' ' A' ' 33' ' ' GLY . 2.4 mp -114.11 140.04 36.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.489 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 35.9 m-80 -99.24 150.41 22.11 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.736 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.773 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 98.2 m-85 -149.39 117.29 6.29 Favored 'General case' 0 CA--C 1.491 -1.3 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 175.501 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.595 ' HG3' ' C ' ' A' ' 2' ' ' THR . 4.6 mm-40 -134.39 144.12 48.01 Favored 'General case' 0 CA--C 1.477 -1.839 0 C-N-CA 118.627 -1.229 . . . . 0.0 112.578 173.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.543 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 25.3 tp60 -127.71 152.36 47.82 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.408 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.457 ' H ' HE21 ' A' ' 22' ' ' GLN . 84.8 tttt -106.56 104.73 14.49 Favored 'General case' 0 C--N 1.26 -3.306 0 N-CA-C 100.511 -3.885 . . . . 0.0 100.511 169.386 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.318 9.9 pt-20 -63.27 -9.25 10.85 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -168.044 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.5 p -76.45 -61.09 2.07 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 170.49 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 175.57 136.55 0.05 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 126.447 1.899 . . . . 0.0 106.688 174.304 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.87 95.37 0.12 Allowed Glycine 1 CA--C 1.444 -4.36 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 28' ' ' PRO . . . . . 0.585 ' HB3' ' N ' ' A' ' 101' ' ' ASP . 38.4 Cg_exo -62.75 123.44 12.32 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 C-N-CA 121.686 1.591 . . . . 0.0 109.179 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.553 ' HB ' ' O ' ' A' ' 21' ' ' GLU . 77.8 t -88.75 148.19 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.98 0 N-CA-C 103.892 -2.632 . . . . 0.0 103.892 171.985 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HD2' ' N ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -99.62 109.33 21.83 Favored 'General case' 1 C--N 1.242 -4.072 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -167.16 . . . . . . . . 4 4 . 1 . 009 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 16.1 m -124.53 152.44 30.52 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.089 -169.594 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 49.3 p90 -134.64 154.04 51.7 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-N 114.97 -1.013 . . . . 0.0 109.762 -175.65 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 96' ' ' ASP . . . -159.46 140.16 6.66 Favored Glycine 0 N--CA 1.415 -2.702 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 176.951 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.563 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 11.7 p -116.67 114.83 24.6 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 124.001 0.92 . . . . 0.0 110.987 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.546 HG22 ' HA3' ' A' ' 16' ' ' GLY . 36.8 pt -128.78 123.18 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 119.69 1.132 . . . . 0.0 110.81 175.248 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 21.3 ptmt -92.89 142.34 27.42 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.722 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.472 ' HA2' HG12 ' A' ' 14' ' ' VAL . . . -144.89 175.79 24.32 Favored Glycine 0 N--CA 1.421 -2.356 0 O-C-N 123.574 0.547 . . . . 0.0 112.869 -168.848 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.72 171.25 8.02 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 m -73.07 103.48 3.84 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.644 -1.222 . . . . 0.0 114.071 -171.213 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.536 ' OE2' ' HD3' ' A' ' 122' ' ' LYS . 25.5 tt0 -177.1 156.4 1.27 Allowed 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 157.643 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.66 -159.16 34.76 Favored Glycine 0 C--N 1.272 -2.977 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 170.208 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.586 ' HB3' ' H ' ' A' ' 122' ' ' LYS . 1.3 pt? -159.65 -169.85 2.71 Favored 'General case' 1 N--CA 1.364 -4.758 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.169 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.443 ' H ' ' HA ' ' A' ' 123' ' ' ALA . 34.7 t-80 -137.4 165.4 26.32 Favored 'General case' 0 C--N 1.247 -3.856 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 -178.063 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.58 ' HA2' ' O ' ' A' ' 85' ' ' GLY . . . -34.29 111.46 0.07 OUTLIER Glycine 0 C--O 1.249 1.074 0 O-C-N 125.723 1.889 . . . . 0.0 112.547 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -69.68 157.39 37.35 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 121.929 0.871 . . . . 0.0 112.714 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.738 ' HA ' ' HA3' ' A' ' 82' ' ' GLY . 59.6 m80 -137.82 95.02 2.97 Favored 'General case' 1 C--O 1.341 5.903 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.021 -174.154 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.528 ' H ' ' HA2' ' A' ' 82' ' ' GLY . 14.1 m -106.11 156.76 6.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.455 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.738 -175.572 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.44 ' ND1' ' HB2' ' A' ' 65' ' ' ASN . 15.1 t60 -131.32 121.04 24.02 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-O 122.531 1.158 . . . . 0.0 112.083 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.493 ' OE1' ' HA3' ' A' ' 108' ' ' GLY . 0.0 OUTLIER -90.03 95.61 10.29 Favored 'General case' 0 C--N 1.273 -2.751 0 CA-C-N 113.161 -1.836 . . . . 0.0 115.609 -175.827 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.299 6.4 p90 -131.23 -5.92 3.83 Favored 'General case' 0 C--O 1.218 -0.57 0 C-N-CA 118.128 -1.429 . . . . 0.0 114.252 169.51 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . 100.98 118.58 4.34 Favored Glycine 0 N--CA 1.476 1.351 0 C-N-CA 120.058 -1.068 . . . . 0.0 112.714 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -144.86 -85.97 0.12 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 118.308 -1.357 . . . . 0.0 111.098 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 23.5 t30 -153.83 136.69 15.36 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.481 HG23 HG22 ' A' ' 148' ' ' VAL . 23.5 m -55.76 -19.11 10.02 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 125.613 1.565 . . . . 0.0 112.608 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.32 2.52 14.78 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -176.566 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 170.84 137.94 2.41 Favored Glycine 0 C--O 1.211 -1.283 0 C-N-CA 117.744 -2.169 . . . . 0.0 113.229 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.642 ' SG ' HG22 ' A' ' 118' ' ' VAL . 25.4 p -98.68 94.06 6.44 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 36.8 m -74.75 -52.24 12.05 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.641 -0.662 . . . . 0.0 110.998 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 m -90.31 -34.81 15.58 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-O 121.149 0.5 . . . . 0.0 110.908 -175.712 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.58 59.61 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -175.699 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.54 -65.03 3.61 Favored Glycine 0 CA--C 1.542 1.775 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -88.88 6.38 4.68 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 123.061 2.508 . . . . 0.0 114.247 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 50.5 t-80 -98.86 133.78 42.67 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -176.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -109.32 170.82 7.81 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -175.85 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.692 ' O ' HG22 ' A' ' 81' ' ' VAL . 43.9 t30 -106.49 97.16 15.68 Favored Pre-proline 0 C--O 1.213 -0.852 0 C-N-CA 123.066 0.546 . . . . 0.0 110.758 176.782 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 70' ' ' LYS . 21.3 Cg_exo -62.2 -9.86 16.37 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 124.256 3.304 . . . . 0.0 114.333 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.18 -17.58 53.77 Favored 'General case' 0 C--N 1.365 1.263 0 C-N-CA 122.7 0.4 . . . . 0.0 110.784 -168.939 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 38.6 t -84.77 -90.62 0.09 Allowed 'General case' 0 N--CA 1.41 -2.465 0 C-N-CA 116.324 -2.15 . . . . 0.0 110.554 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.512 ' HG2' ' HB3' ' A' ' 75' ' ' LYS . 15.6 tpp180 -135.87 41.71 2.67 Favored 'General case' 0 C--N 1.264 -3.119 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 66' ' ' PRO . 99.5 mttt 75.35 -153.47 0.04 OUTLIER 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.308 -177.259 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 5.0 p80 -67.26 83.22 0.14 Allowed 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.592 ' N ' HG11 ' A' ' 81' ' ' VAL . . . 93.25 91.58 1.55 Allowed Glycine 0 CA--C 1.467 -2.939 0 C-N-CA 117.784 -2.151 . . . . 0.0 111.638 169.591 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.92 142.8 7.73 Favored Glycine 1 N--CA 1.392 -4.263 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -86.22 0.46 8.13 Favored 'Trans proline' 0 N--CA 1.437 -1.806 0 C-N-CA 122.794 2.329 . . . . 0.0 109.414 178.909 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.512 ' HB3' ' HG2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -84.84 28.55 0.68 Allowed 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.154 -172.111 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.514 ' HB3' ' HA ' ' A' ' 68' ' ' SER . 5.8 t0 -179.78 39.99 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 123.209 1.48 . . . . 0.0 107.988 164.247 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 68.11 8.87 6.82 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 112.332 -2.213 . . . . 0.0 114.9 169.595 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' HG23 ' A' ' 103' ' ' VAL . 4.0 tp10 63.34 37.76 10.68 Favored 'General case' 0 C--N 1.366 1.322 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 176.244 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.408 ' H ' ' HB2' ' A' ' 68' ' ' SER 0.34 50.2 mtm180 -52.84 3.12 0.01 OUTLIER 'General case' 0 N--CA 1.521 3.118 0 N-CA-C 119.202 3.038 . . . . 0.0 119.202 -164.922 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.419 4.8 m80 163.03 28.79 0.0 OUTLIER 'General case' 0 CA--C 1.459 -2.537 0 C-N-CA 127.036 2.134 . . . . 0.0 112.708 162.043 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.692 HG22 ' O ' ' A' ' 65' ' ' ASN . 3.6 t -83.16 -23.2 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 174.076 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.738 ' HA3' ' HA ' ' A' ' 46' ' ' HIS . . . -179.07 123.44 0.85 Allowed Glycine 1 N--CA 1.379 -5.128 0 CA-C-N 113.55 -1.659 . . . . 0.0 111.218 178.662 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -69.27 107.96 3.47 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 174.358 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.576 ' H ' HG11 ' A' ' 103' ' ' VAL . 51.4 tp -68.55 89.95 0.37 Allowed 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.228 -170.149 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.58 ' O ' ' HA2' ' A' ' 44' ' ' GLY . . . -139.96 138.92 9.48 Favored Glycine 0 N--CA 1.413 -2.884 0 N-CA-C 107.989 -2.044 . . . . 0.0 107.989 174.15 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -109.84 129.14 55.67 Favored 'General case' 0 CA--C 1.485 -1.527 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -175.039 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.907 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.3 m -129.21 156.21 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.223 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.04 -178.387 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 p -134.26 96.37 3.59 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.542 0.687 . . . . 0.0 112.224 -175.666 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.68 156.23 17.2 Favored 'General case' 0 N--CA 1.424 -1.766 0 C-N-CA 126.847 2.059 . . . . 0.0 108.973 177.157 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.581 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 15.3 t70 -137.11 -167.93 2.19 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.676 -1.602 . . . . 0.0 106.676 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -43.14 -38.66 2.52 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 126.123 1.769 . . . . 0.0 114.399 -177.588 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -134.94 4.96 3.3 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.643 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -63.08 170.45 14.53 Favored Glycine 0 CA--C 1.474 -2.514 0 CA-C-N 112.429 -2.169 . . . . 0.0 112.999 -170.814 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.506 HG12 ' HB3' ' A' ' 36' ' ' LYS . 16.1 m -134.83 131.94 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.391 -3.407 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -165.602 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.907 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.11 89.68 5.25 Favored 'General case' 2 C--N 1.239 -4.237 0 N-CA-C 104.667 -2.346 . . . . 0.0 104.667 175.305 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ASP . . . . . 0.48 ' OD2' ' HB3' ' A' ' 34' ' ' SER . 12.1 t70 -121.42 89.12 3.06 Favored 'General case' 0 CA--C 1.477 -1.848 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 -178.521 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.81 144.2 38.34 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.738 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.886 -177.659 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -105.27 102.32 11.81 Favored 'General case' 0 C--N 1.266 -3.055 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.597 HD13 ' H ' ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.48 147.39 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.476 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.613 -173.506 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.408 ' HB3' ' HG3' ' A' ' 30' ' ' LYS . 14.5 pt-20 -149.19 117.48 6.45 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.585 ' N ' ' HB3' ' A' ' 28' ' ' PRO . 20.4 t70 -165.3 159.26 17.08 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.4 m -99.92 76.85 1.98 Allowed 'General case' 0 N--CA 1.425 -1.719 0 CA-C-O 123.576 1.655 . . . . 0.0 107.568 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.576 HG11 ' H ' ' A' ' 84' ' ' LEU . 6.5 p -120.52 -16.49 6.74 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.923 0 CA-C-N 111.361 -2.654 . . . . 0.0 107.403 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 9.2 mm -81.73 2.94 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.142 0 CA-C-N 113.301 -1.772 . . . . 0.0 107.313 -176.249 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' ' HG2' ' A' ' 22' ' ' GLN . 20.2 m -65.53 109.22 2.27 Favored 'General case' 0 C--O 1.263 1.816 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.408 HD13 HD12 ' A' ' 112' ' ' ILE . 44.4 tp -68.91 88.9 0.4 Allowed 'General case' 0 N--CA 1.396 -3.16 0 CA-C-N 112.463 -2.153 . . . . 0.0 113.417 -175.173 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.3 t -138.11 85.01 2.07 Favored 'General case' 1 N--CA 1.35 -5.449 0 N-CA-C 100.61 -3.848 . . . . 0.0 100.61 157.372 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.522 ' HA2' ' ND2' ' A' ' 65' ' ' ASN . . . -121.47 -144.25 6.85 Favored Glycine 0 CA--C 1.471 -2.685 0 CA-C-N 112.822 -1.99 . . . . 0.0 109.048 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -67.52 -74.14 0.12 Allowed 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 174.62 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -125.16 -47.47 1.76 Allowed 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 175.189 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.578 ' O ' ' HG3' ' A' ' 115' ' ' ARG . 21.9 m -161.67 169.45 21.53 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.408 HD12 HD13 ' A' ' 106' ' ' LEU . 4.4 mp -82.25 -39.82 16.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.01 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.45 ' HA ' ' CA ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -73.83 125.74 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.549 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.34 -3.97 51.1 Favored Glycine 0 CA--C 1.478 -2.266 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 171.766 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.613 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . 9.3 mmt180 -101.9 159.21 15.54 Favored 'General case' 0 N--CA 1.396 -3.15 0 CA-C-N 113.153 -1.523 . . . . 0.0 107.386 -174.426 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.596 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 16.7 p -99.58 135.58 40.78 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 2.7 pt? -88.9 130.11 35.48 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 174.227 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.642 HG22 ' SG ' ' A' ' 57' ' ' CYS . 14.3 t -101.43 101.79 12.6 Favored 'Isoleucine or valine' 0 C--O 1.262 1.752 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.61 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 27.0 m -136.96 169.59 19.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 C-N-CA 123.744 0.818 . . . . 0.0 108.816 -177.367 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.454 ' O ' HD13 ' A' ' 42' ' ' LEU . 49.0 t-80 -171.65 170.13 5.76 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 171.861 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.525 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 0.8 OUTLIER -77.59 84.06 3.97 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 170.743 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.586 ' H ' ' HB3' ' A' ' 42' ' ' LEU . 58.3 mmtt -173.58 127.98 0.42 Allowed 'General case' 0 CA--C 1.464 -2.363 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -174.61 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.443 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -44.89 103.32 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.84 0 O-C-N 123.863 0.727 . . . . 0.0 109.743 168.172 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -104.22 85.66 2.41 Favored 'General case' 0 CA--C 1.458 -2.585 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 -177.737 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 8.1 t70 -121.25 133.66 55.16 Favored 'General case' 0 C--N 1.255 -3.512 0 CA-C-N 113.729 -1.578 . . . . 0.0 108.869 -172.135 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.427 HD23 ' HB3' ' A' ' 46' ' ' HIS . 2.4 mm? -89.58 -13.3 37.54 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.668 -178.474 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -96.96 -34.6 5.63 Favored Glycine 0 N--CA 1.425 -2.047 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.459 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 65.4 tttm -86.33 -49.05 7.95 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 118.894 -0.575 . . . . 0.0 110.813 178.517 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.59 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.91 -77.86 0.0 OUTLIER Glycine 0 CA--C 1.529 0.923 0 N-CA-C 114.439 0.536 . . . . 0.0 114.439 -170.536 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 171.63 -97.44 0.12 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 108.969 -1.653 . . . . 0.0 108.969 -177.078 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -88.94 179.98 6.07 Favored 'General case' 0 CA--C 1.56 1.337 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -56.16 -32.3 64.17 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 119.347 0.976 . . . . 0.0 113.229 -178.491 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -75.74 -46.38 31.25 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.676 0.751 . . . . 0.0 109.747 176.25 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.42 ' HA ' HG22 ' A' ' 137' ' ' THR . 1.3 m -60.97 -33.93 73.98 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.352 -175.05 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.59 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 9.9 t -67.97 -35.71 78.81 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-O 120.939 0.4 . . . . 0.0 111.568 178.708 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.25 -29.12 31.46 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.172 -176.104 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.42 HG22 ' HA ' ' A' ' 134' ' ' SER . 8.8 t -86.94 -14.93 40.4 Favored 'General case' 0 N--CA 1.438 -1.046 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 177.705 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.74 60.6 6.75 Favored Glycine 0 CA--C 1.5 -0.876 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 -175.922 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -51.89 105.23 0.1 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -175.014 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -152.11 171.64 17.58 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 173.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -67.9 87.45 0.18 Allowed Glycine 0 C--N 1.314 -0.665 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 173.656 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 16.2 m -66.1 -10.09 37.38 Favored 'General case' 0 C--O 1.21 -1.003 0 C-N-CA 124.731 1.213 . . . . 0.0 113.624 -175.433 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 43.1 mtp-105 -116.34 -37.4 3.77 Favored 'General case' 0 C--N 1.254 -3.554 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.725 172.529 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.422 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 3.8 mm? -49.0 -38.19 22.57 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 115.481 1.66 . . . . 0.0 115.481 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -143.89 92.45 2.34 Favored 'General case' 0 N--CA 1.42 -1.947 0 CA-C-O 121.622 0.725 . . . . 0.0 111.253 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 3.9 m -140.13 153.2 46.61 Favored 'General case' 0 N--CA 1.419 -1.979 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 175.487 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.75 168.95 42.01 Favored Glycine 0 N--CA 1.406 -3.311 0 N-CA-C 107.0 -2.44 . . . . 0.0 107.0 176.482 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.481 HG22 HG23 ' A' ' 54' ' ' THR . 31.4 m -70.44 122.04 21.42 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.443 1.116 . . . . 0.0 112.385 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.402 ' HB ' HD22 ' A' ' 117' ' ' LEU . 9.0 tt -99.25 142.68 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.756 0 N-CA-C 103.704 -2.702 . . . . 0.0 103.704 175.223 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.45 ' CA ' ' HA ' ' A' ' 113' ' ' ILE . . . 177.06 154.46 12.04 Favored Glycine 2 N--CA 1.387 -4.57 0 C-N-CA 117.316 -2.373 . . . . 0.0 112.957 177.246 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 3.8 tt -66.64 105.0 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 124.483 0.755 . . . . 0.0 109.422 172.324 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.571 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -114.21 98.3 6.86 Favored 'General case' 0 N--CA 1.414 -2.238 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 172.911 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 117.898 -1.049 . . . . 0.0 109.087 -174.258 . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.443 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.221 -0.432 0 N-CA-C 111.42 0.156 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.575 ' HA ' ' HG3' ' A' ' 21' ' ' GLU . 9.2 p -82.35 -35.53 27.74 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-O 121.876 0.846 . . . . 0.0 112.463 -177.337 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.599 ' O ' HG12 ' A' ' 151' ' ' ILE . 56.9 mtmt -138.09 135.81 36.17 Favored 'General case' 0 C--N 1.277 -2.545 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.616 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -134.05 166.74 22.03 Favored 'General case' 0 C--N 1.27 -2.872 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 -176.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.3 p -145.99 118.93 2.28 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.315 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -108.65 127.16 53.73 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.328 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.4 p -119.45 129.24 75.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 O-C-N 123.786 0.679 . . . . 0.0 110.217 -178.288 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.405 HD13 ' HB1' ' A' ' 145' ' ' ALA . 75.4 mt -107.18 141.67 38.1 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.118 -177.67 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -150.79 137.83 19.21 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 174.509 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.39 -159.32 9.25 Favored Glycine 0 N--CA 1.417 -2.625 0 C-N-CA 117.571 -2.252 . . . . 0.0 115.622 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -78.06 -31.14 50.1 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 111.91 -2.145 . . . . 0.0 109.371 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.46 172.49 14.45 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 172.523 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -88.39 121.87 1.41 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 CA-C-N 121.919 2.859 . . . . 0.0 112.135 -176.92 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 m -135.14 118.23 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.429 0 CA-C-N 113.368 -1.742 . . . . 0.0 106.548 171.374 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.495 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -143.35 119.5 10.78 Favored 'General case' 0 C--N 1.279 -2.468 0 C-N-CA 118.128 -1.429 . . . . 0.0 109.929 178.442 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.547 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -171.2 170.87 43.62 Favored Glycine 0 N--CA 1.418 -2.552 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 178.592 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 20.0 pt -135.85 119.52 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.871 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.479 HG12 ' HA3' ' A' ' 33' ' ' GLY . 21.9 mt -114.37 135.16 55.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -176.758 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.616 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.1 m-20 -101.58 138.68 38.25 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.235 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.551 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 95.2 m-85 -132.2 120.16 21.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 123.304 0.377 . . . . 0.0 111.066 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HG3' ' HA ' ' A' ' 2' ' ' THR . 35.8 tt0 -112.17 108.24 17.42 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.785 172.955 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.538 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 8.8 tp60 -140.71 114.8 9.15 Favored 'General case' 0 N--CA 1.405 -2.69 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 172.481 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -90.63 157.37 17.52 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 178.087 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -60.95 -23.69 65.5 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.153 0.502 . . . . 0.0 110.967 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 14.8 m -63.25 -18.4 63.52 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.996 176.739 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 65.1 t30 66.96 105.98 0.04 OUTLIER 'General case' 0 C--N 1.353 0.744 0 C-N-CA 125.426 1.491 . . . . 0.0 109.204 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.513 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -146.55 -170.64 15.19 Favored Glycine 0 CA--C 1.469 -2.804 0 C-N-CA 118.415 -1.85 . . . . 0.0 115.242 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.65 124.12 15.03 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.56 2.84 . . . . 0.0 110.562 178.343 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 47.1 t -93.44 110.99 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.988 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.286 -175.254 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.42 111.24 23.89 Favored 'General case' 0 N--CA 1.422 -1.87 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.476 HG22 ' HA ' ' A' ' 20' ' ' PHE . 17.2 t -138.47 132.26 41.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.175 -170.033 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.447 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 77.8 t90 -149.25 127.64 12.22 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.479 ' HA3' HG12 ' A' ' 18' ' ' ILE . . . -159.34 140.03 6.58 Favored Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.417 -0.896 . . . . 0.0 110.915 173.796 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 49.4 m -117.4 115.4 25.14 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.288 179.31 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.547 HG22 ' HA3' ' A' ' 16' ' ' GLY . 30.8 pt -109.79 138.71 36.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 118.612 0.642 . . . . 0.0 111.104 176.355 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.759 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 16.5 ptpt -103.65 132.7 49.67 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.327 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.488 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -148.98 178.78 26.3 Favored Glycine 1 N--CA 1.391 -4.359 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -167.758 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.473 ' HG ' ' H ' ' A' ' 39' ' ' THR . 45.3 tp -65.27 176.46 1.35 Allowed 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 171.59 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.473 ' H ' ' HG ' ' A' ' 38' ' ' LEU . 15.0 t -61.99 153.72 28.64 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.351 -1.468 . . . . 0.0 111.215 -166.115 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.712 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 11.1 pt-20 -60.67 160.32 9.43 Favored 'General case' 0 CA--C 1.476 -1.891 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -163.026 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -159.29 -157.57 8.62 Favored Glycine 1 C--N 1.245 -4.487 1 N-CA-C 102.442 -4.263 . . . . 0.0 102.442 -176.906 . . . . . . . . 3 2 . 1 . 010 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.4 mt -153.72 -86.63 0.06 Allowed 'General case' 0 C--N 1.274 -2.717 0 CA-C-N 120.357 2.078 . . . . 0.0 114.74 -169.661 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.626 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.5 t-160 -76.93 122.23 24.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 -156.416 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.78 127.01 8.8 Favored Glycine 0 N--CA 1.415 -2.75 0 C-N-CA 119.876 -1.154 . . . . 0.0 114.85 -173.392 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.542 ' H ' ' HB2' ' A' ' 124' ' ' ASP . 14.9 t80 -113.31 113.03 24.7 Favored 'General case' 1 C--O 1.336 5.61 0 CA-C-O 123.41 1.576 . . . . 0.0 111.028 175.463 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.542 ' HB3' ' O ' ' A' ' 83' ' ' ASP . 25.4 m80 -108.18 124.96 51.07 Favored 'General case' 0 N--CA 1.391 -3.38 0 CA-C-N 113.624 -1.626 . . . . 0.0 110.42 -173.708 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.56 ' HA ' ' HA3' ' A' ' 82' ' ' GLY . 9.4 p -174.65 87.35 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 CA-C-N 113.55 -1.659 . . . . 0.0 109.762 177.909 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.423 ' C ' ' HD2' ' A' ' 115' ' ' ARG . 7.0 m170 -112.49 170.74 7.96 Favored 'General case' 0 C--N 1.281 -2.387 0 N-CA-C 114.608 1.336 . . . . 0.0 114.608 167.125 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.588 ' HG3' ' OD1' ' A' ' 109' ' ' ASP . 36.4 tt0 -139.64 132.56 29.33 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.191 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.8 t80 76.45 26.84 0.86 Allowed 'General case' 0 C--O 1.222 -0.359 0 C-N-CA 127.349 2.26 . . . . 0.0 111.127 174.966 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.727 ' H ' ' HD3' ' A' ' 115' ' ' ARG . . . 33.67 -124.64 0.4 Allowed Glycine 0 C--N 1.36 1.916 0 CA-C-N 115.599 -0.728 . . . . 0.0 114.637 -172.542 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.2 t70 169.51 -80.71 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 125.398 1.479 . . . . 0.0 108.48 164.122 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -161.05 160.9 31.07 Favored 'General case' 0 N--CA 1.429 -1.509 0 N-CA-C 104.975 -2.231 . . . . 0.0 104.975 174.164 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.48 ' HB ' HG12 ' A' ' 148' ' ' VAL . 5.3 t -79.26 5.18 12.95 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -171.677 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.15 2.26 9.8 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 120.202 -0.599 . . . . 0.0 111.249 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 176.55 127.53 1.05 Allowed Glycine 0 C--O 1.195 -2.324 0 C-N-CA 118.582 -1.77 . . . . 0.0 111.558 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.812 ' SG ' HG21 ' A' ' 118' ' ' VAL . 16.7 p -99.72 89.23 4.04 Favored 'General case' 0 C--N 1.275 -2.633 0 O-C-N 121.869 -0.783 . . . . 0.0 112.131 177.395 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.5 m -78.85 -53.14 7.4 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.668 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.8 m -70.01 -52.99 19.67 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.498 -174.054 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' A' ' 49' ' ' GLU . . . -76.63 -9.45 58.67 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-O 118.418 -0.801 . . . . 0.0 112.975 176.877 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -36.08 -68.14 0.32 Allowed Glycine 0 N--CA 1.488 2.103 0 N-CA-C 114.864 0.705 . . . . 0.0 114.864 -173.624 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -94.09 7.59 2.42 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.328 2.686 . . . . 0.0 112.149 177.068 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 77.1 t60 -113.52 123.46 50.06 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -171.634 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.444 ' CD1' ' HA ' ' A' ' 137' ' ' THR . 27.1 p90 -97.75 170.55 8.91 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 126.722 2.009 . . . . 0.0 108.785 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.83 142.68 24.89 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.299 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.82 -53.98 2.77 Favored 'Trans proline' 0 N--CA 1.481 0.767 0 C-N-CA 123.204 2.603 . . . . 0.0 116.652 -168.19 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.828 ' O ' ' HA ' ' A' ' 78' ' ' GLU . 95.9 mt -93.0 25.97 3.0 Favored 'General case' 0 C--O 1.193 -1.913 0 O-C-N 121.786 -0.571 . . . . 0.0 111.818 -168.586 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.63 ' O ' ' HA ' ' A' ' 80' ' ' HIS . 28.6 m -144.74 30.36 1.2 Allowed 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.039 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.509 ' O ' ' HD2' ' A' ' 69' ' ' ARG . 4.1 tmm_? -126.08 -27.32 3.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 CA-C-O 117.639 -1.172 . . . . 0.0 110.638 -176.56 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 1.2 mptm? -45.32 60.34 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 119.778 3.251 . . . . 0.0 119.778 -165.097 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.405 ' N ' ' O ' ' A' ' 69' ' ' ARG . 82.8 t60 46.43 58.65 4.4 Favored 'General case' 0 CA--C 1.567 1.598 0 N-CA-C 117.292 2.33 . . . . 0.0 117.292 165.608 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.62 88.44 0.38 Allowed Glycine 0 CA--C 1.495 -1.186 0 C-N-CA 116.762 -2.637 . . . . 0.0 115.57 163.096 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.439 ' H ' ' CD2' ' A' ' 80' ' ' HIS . . . -170.13 95.38 0.11 Allowed Glycine 0 C--O 1.211 -1.334 0 C-N-CA 119.089 -1.529 . . . . 0.0 112.81 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -64.91 -40.23 21.96 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 CA-C-N 120.647 2.224 . . . . 0.0 113.583 -175.082 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.07 16.49 21.81 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 125.139 1.376 . . . . 0.0 110.153 -178.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -89.79 -172.02 3.39 Favored 'General case' 0 C--N 1.287 -2.126 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.747 -167.174 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.476 ' HA ' ' CG1' ' A' ' 81' ' ' VAL . 0.1 OUTLIER -142.46 -3.45 1.04 Allowed 'General case' 0 N--CA 1.434 -1.268 0 O-C-N 122.22 -0.3 . . . . 0.0 111.072 -178.486 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.828 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 33.1 tt0 -132.19 -34.79 1.23 Allowed 'General case' 0 N--CA 1.433 -1.315 0 CA-C-O 121.222 0.535 . . . . 0.0 110.276 -170.076 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.475 ' O ' ' HB3' ' A' ' 80' ' ' HIS . 4.5 mpt_? -93.76 -15.87 24.74 Favored 'General case' 0 CA--C 1.484 -1.571 0 C-N-CA 125.603 1.561 . . . . 0.0 107.111 -175.812 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.63 ' HA ' ' O ' ' A' ' 68' ' ' SER 0.258 5.0 p80 164.44 142.72 0.01 OUTLIER 'General case' 0 CA--C 1.459 -2.538 0 CA-C-N 113.185 -1.825 . . . . 0.0 110.332 159.498 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.673 ' O ' ' HB2' ' A' ' 84' ' ' LEU . 9.5 p -159.79 -61.0 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.251 -3.71 0 N-CA-C 105.661 -1.977 . . . . 0.0 105.661 168.436 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.56 ' HA3' ' HA ' ' A' ' 47' ' ' VAL . . . 47.97 -136.62 14.72 Favored Glycine 0 C--O 1.239 0.45 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.653 ' OD2' ' HA ' ' A' ' 117' ' ' LEU . 1.9 p-10 -93.68 81.21 4.27 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 169.998 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.673 ' HB2' ' O ' ' A' ' 81' ' ' VAL . 0.7 OUTLIER -88.96 138.87 31.01 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 115.754 1.761 . . . . 0.0 115.754 -168.148 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.558 ' N ' HD13 ' A' ' 84' ' ' LEU . . . -169.36 156.38 27.42 Favored Glycine 0 N--CA 1.425 -2.048 0 N-CA-C 104.483 -3.447 . . . . 0.0 104.483 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -112.61 153.0 28.26 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 120.158 1.979 . . . . 0.0 109.869 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 71.9 t -117.86 143.01 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.532 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.626 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 62.2 m -146.13 95.74 2.67 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.2 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -93.28 144.98 24.79 Favored 'General case' 0 CA--C 1.482 -1.666 0 CA-C-N 119.49 1.041 . . . . 0.0 113.097 -176.33 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.712 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 22.1 t70 -82.58 149.6 27.37 Favored 'General case' 0 C--N 1.278 -2.516 0 CA-C-N 113.223 -1.808 . . . . 0.0 106.83 169.134 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.537 ' N ' ' HB3' ' A' ' 40' ' ' GLU . 13.6 pttp -41.28 -19.39 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 127.69 2.396 . . . . 0.0 116.037 176.572 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -106.81 12.76 28.66 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.759 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 73.1 85.18 0.23 Allowed Glycine 0 N--CA 1.42 -2.397 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.06 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 61.3 t -157.07 103.51 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.709 -1.959 . . . . 0.0 105.709 -178.752 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -104.17 113.38 26.89 Favored 'General case' 0 C--N 1.273 -2.735 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.525 175.811 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -86.01 94.33 9.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 175.147 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 86.1 t -85.63 105.71 14.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.486 -175.514 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.2 m -152.54 116.05 4.75 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 9.4 tp -148.31 134.35 12.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 37.8 mt-10 -124.03 96.63 5.01 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.433 -175.253 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.401 ' O ' HG21 ' A' ' 29' ' ' VAL . 6.2 p-10 -168.81 166.71 11.4 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 170.902 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.5 p -60.89 91.5 0.02 OUTLIER 'General case' 0 C--O 1.245 0.851 0 CA-C-N 119.128 0.876 . . . . 0.0 113.058 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 84' ' ' LEU . 27.1 m -118.39 -14.41 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -176.67 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -119.24 25.92 4.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 O-C-N 120.7 -1.25 . . . . 0.0 109.476 -176.552 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.0 m -64.38 110.95 2.43 Favored 'General case' 0 C--O 1.268 2.059 0 CA-C-O 122.729 1.252 . . . . 0.0 109.831 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.44 86.37 1.15 Allowed 'General case' 0 N--CA 1.382 -3.87 0 CA-C-O 124.103 1.906 . . . . 0.0 110.63 176.717 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.0 m -146.56 85.75 1.65 Allowed 'General case' 2 N--CA 1.362 -4.855 0 N-CA-C 101.88 -3.378 . . . . 0.0 101.88 168.665 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.13 168.96 22.8 Favored Glycine 0 C--N 1.269 -3.142 0 CA-C-N 113.373 -1.74 . . . . 0.0 111.014 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.588 ' OD1' ' HG3' ' A' ' 49' ' ' GLU . 7.0 t70 -56.92 -34.89 68.41 Favored 'General case' 0 C--O 1.202 -1.43 0 CA-C-N 117.292 0.546 . . . . 0.0 110.916 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.739 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 7.9 p-80 -54.28 -17.01 2.49 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 125.385 1.474 . . . . 0.0 113.023 -178.002 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.449 ' O ' ' HD2' ' A' ' 110' ' ' HIS . 23.0 t 37.47 -154.49 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 126.164 1.786 . . . . 0.0 110.297 -173.025 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.608 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 14.2 tt -100.32 -32.97 3.63 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.876 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 166.133 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.8 pt -104.02 145.93 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -178.773 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.71 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 95.83 -7.04 67.52 Favored Glycine 1 CA--C 1.45 -4.008 0 C-N-CA 121.234 -0.508 . . . . 0.0 112.272 162.211 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.739 ' NE ' ' HA ' ' A' ' 110' ' ' HIS . 0.3 OUTLIER -92.61 151.44 20.12 Favored 'General case' 0 C--O 1.162 -3.54 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.688 -174.146 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.555 ' H ' ' HA2' ' A' ' 51' ' ' GLY . 7.6 p -91.86 113.09 25.27 Favored 'General case' 0 N--CA 1.408 -2.531 0 O-C-N 121.537 -0.727 . . . . 0.0 109.397 173.57 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.653 ' HA ' ' OD2' ' A' ' 83' ' ' ASP . 22.5 tp -70.09 93.5 0.81 Allowed 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 -177.456 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.812 HG21 ' SG ' ' A' ' 57' ' ' CYS 0.528 60.2 t -105.1 109.22 27.0 Favored 'Isoleucine or valine' 1 C--O 1.341 5.884 0 N-CA-C 120.708 3.596 . . . . 0.0 120.708 -172.217 . . . . . . . . 4 3 . 1 . 010 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.674 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.3 p -148.47 171.25 2.43 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.155 0 CA-C-N 110.397 -3.092 . . . . 0.0 106.469 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 71.6 t60 -150.37 171.28 17.25 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.88 -2.267 . . . . 0.0 104.88 168.198 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.526 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.0 OUTLIER -69.42 85.94 0.43 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 171.449 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -173.01 171.78 4.11 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.652 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -99.09 107.58 20.0 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 118.299 0.499 . . . . 0.0 110.243 173.448 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.542 ' HB2' ' H ' ' A' ' 45' ' ' PHE . 1.1 m-20 -71.33 -59.16 2.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 172.522 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.0 t70 67.76 141.34 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 128.024 2.529 . . . . 0.0 114.097 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.587 ' HG ' ' CD2' ' A' ' 80' ' ' HIS . 0.0 OUTLIER -90.26 -31.99 16.74 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-N 114.89 -1.05 . . . . 0.0 113.624 -176.563 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.01 -33.98 5.84 Favored Glycine 0 N--CA 1.427 -1.904 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 178.851 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -105.13 50.32 0.79 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.178 -1.011 . . . . 0.0 108.873 -179.019 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.36 -6.83 81.51 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.53 -93.17 0.25 Allowed Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 121.653 -0.308 . . . . 0.0 112.406 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.557 ' H ' ' HB2' ' A' ' 134' ' ' SER . 79.3 m-20 -121.86 -173.39 2.64 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -174.045 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -57.71 -39.32 76.96 Favored 'General case' 0 C--N 1.361 1.102 0 C-N-CA 118.65 -1.22 . . . . 0.0 109.994 176.366 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.547 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 5.9 tp10 -76.05 -53.86 7.72 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.051 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.557 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 2.4 m -62.06 -26.25 68.16 Favored 'General case' 0 CA--C 1.552 1.021 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -175.617 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 35.8 m -79.72 -18.14 51.91 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 121.852 -0.53 . . . . 0.0 110.653 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.547 ' HG3' ' O ' ' A' ' 133' ' ' GLU . 0.0 OUTLIER -85.64 -31.27 22.65 Favored 'General case' 0 C--O 1.211 -0.942 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.535 179.227 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.444 ' HA ' ' CD1' ' A' ' 64' ' ' PHE . 8.8 p -70.95 -16.01 62.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 120.916 0.389 . . . . 0.0 109.962 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.56 81.64 0.11 Allowed Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 124' ' ' ASP . 23.3 t-20 -33.07 132.05 0.16 Allowed 'General case' 0 C--O 1.291 3.263 0 CA-C-O 123.451 1.596 . . . . 0.0 114.202 -172.306 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.419 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -150.89 130.51 13.07 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 113.845 -1.525 . . . . 0.0 109.711 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.12 91.03 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.072 -2.011 . . . . 0.0 108.072 170.935 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.9 m -49.18 -18.41 0.33 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.789 2.035 . . . . 0.0 116.384 -168.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -144.59 6.51 1.25 Allowed 'General case' 0 C--N 1.269 -2.92 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.998 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.56 -22.73 58.84 Favored 'General case' 0 C--N 1.294 -1.845 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.509 -173.478 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.9 100.3 0.17 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 175.487 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.9 m -123.42 133.05 54.12 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -160.28 146.28 12.37 Favored Glycine 0 N--CA 1.404 -3.499 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 178.03 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 8.8 p -69.19 113.98 5.6 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-O 122.128 0.966 . . . . 0.0 111.953 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.472 HD12 HD13 ' A' ' 117' ' ' LEU . 2.5 tt -82.93 129.65 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.085 0 N-CA-C 105.067 -2.197 . . . . 0.0 105.067 170.283 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.608 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 177.67 156.99 17.58 Favored Glycine 2 N--CA 1.365 -6.074 0 C-N-CA 118.427 -1.844 . . . . 0.0 111.297 176.772 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.599 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.16 105.32 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 169.536 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.16 113.34 16.91 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 . . . . . 0 C--N 1.283 -2.315 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -175.595 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.432 ' HA ' HE22 ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.0 0.428 . . . . 0.0 111.461 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 m -79.89 -28.99 39.84 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.14 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.652 ' HG3' ' O ' ' A' ' 152' ' ' ALA . 19.9 ptpt -151.74 170.87 18.69 Favored 'General case' 0 C--O 1.253 1.241 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.731 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.42 154.56 45.67 Favored 'General case' 0 N--CA 1.434 -1.265 0 O-C-N 124.099 0.875 . . . . 0.0 109.038 177.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.19 122.22 62.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.512 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -131.4 133.14 44.94 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.18 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.6 t -134.75 113.31 16.29 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.428 ' HB2' ' O ' ' A' ' 14' ' ' VAL . 3.1 mm? -90.83 131.03 36.72 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.409 0.683 . . . . 0.0 111.418 -176.949 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.1 mtpt -147.34 126.79 13.18 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 175.008 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.72 -158.53 8.84 Favored Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.58 -0.819 . . . . 0.0 111.754 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -63.09 -40.39 97.52 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.91 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -116.11 82.63 0.32 Allowed Glycine 0 N--CA 1.433 -1.513 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 172.626 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.64 127.0 11.95 Favored 'Trans proline' 0 N--CA 1.446 -1.296 0 C-N-CA 122.127 1.884 . . . . 0.0 113.901 -171.739 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.428 ' O ' ' HB2' ' A' ' 8' ' ' LEU . 16.5 m -111.92 117.08 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.858 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 175.181 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -99.13 118.31 35.57 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.639 -172.493 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.0 170.81 43.53 Favored Glycine 0 N--CA 1.407 -3.247 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.858 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 25.7 pt -131.38 129.24 62.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.142 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 mm -115.12 136.01 53.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.507 ' O ' HG13 ' A' ' 31' ' ' VAL . 2.9 m-20 -114.24 129.63 56.63 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.478 -177.583 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.731 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 53.9 m-85 -125.19 137.49 54.13 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.097 0.475 . . . . 0.0 111.684 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -116.23 106.37 13.61 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.368 177.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.432 HE22 ' HA ' ' A' ' 1' ' ' ALA . 2.8 pm0 -86.25 123.34 31.41 Favored 'General case' 0 N--CA 1.403 -2.816 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 171.549 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 104' ' ' ILE . 37.1 ttmt -137.55 103.16 4.97 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -170.112 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.26 -9.83 13.29 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 m -71.91 -23.71 61.52 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 122.877 0.471 . . . . 0.0 110.35 176.385 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.556 ' HA ' HG13 ' A' ' 104' ' ' ILE . 45.4 t-20 72.57 135.54 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 C-N-CA 125.335 1.454 . . . . 0.0 111.034 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.52 175.33 36.67 Favored Glycine 0 CA--C 1.485 -1.785 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.619 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -65.1 123.48 11.62 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.302 2.001 . . . . 0.0 108.397 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HB ' HG23 ' A' ' 31' ' ' VAL . 23.7 m -76.99 142.75 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.277 0 CA-C-O 121.682 0.753 . . . . 0.0 111.632 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -106.28 97.07 6.92 Favored 'General case' 0 C--N 1.277 -2.544 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 173.702 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.507 HG13 ' O ' ' A' ' 19' ' ' ASN . 47.6 t -129.59 129.87 66.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 125.892 1.677 . . . . 0.0 107.861 -171.846 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -140.74 137.24 33.28 Favored 'General case' 0 C--N 1.286 -2.192 0 O-C-N 123.375 0.422 . . . . 0.0 110.186 177.93 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -159.59 137.9 5.34 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 170.191 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.47 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 44.3 t -118.63 127.74 53.88 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.44 HG22 ' HA3' ' A' ' 16' ' ' GLY . 33.5 pt -120.02 129.0 75.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 119.788 1.177 . . . . 0.0 110.381 174.611 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 88.1 tttt -96.67 123.56 40.39 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 178.861 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.759 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -136.48 176.29 20.44 Favored Glycine 0 C--N 1.274 -2.9 0 CA-C-N 114.502 -1.226 . . . . 0.0 110.383 -171.057 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -69.43 171.28 8.95 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 171.265 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -68.47 112.43 5.29 Favored 'General case' 0 C--O 1.22 -0.48 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 175.441 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.596 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 5.1 tp10 -128.86 178.91 6.03 Favored 'General case' 0 C--N 1.259 -3.339 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.804 -165.656 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.418 ' H ' ' HG3' ' A' ' 40' ' ' GLU . . . -59.44 -146.93 0.01 OUTLIER Glycine 0 CA--C 1.553 2.449 0 C-N-CA 124.633 1.111 . . . . 0.0 114.472 176.857 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 3.0 pp -164.66 14.47 0.05 OUTLIER 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -164.486 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.2 t60 -143.91 153.66 42.53 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 106.757 -1.572 . . . . 0.0 106.757 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . 163.02 -169.25 38.13 Favored Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 119.899 -1.143 . . . . 0.0 112.156 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.575 ' HA ' ' O ' ' A' ' 85' ' ' GLY . 24.1 p90 -166.6 162.65 16.67 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.908 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.67 ' HB2' ' O ' ' A' ' 83' ' ' ASP . 6.5 m170 -91.12 164.32 13.97 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -171.005 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.476 HG13 ' HD2' ' A' ' 64' ' ' PHE . 52.9 t -165.82 88.59 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.616 0 C-N-CA 123.81 0.844 . . . . 0.0 111.4 -174.346 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.559 ' HB2' ' HB3' ' A' ' 115' ' ' ARG . 31.0 p-80 -109.61 100.82 9.81 Favored 'General case' 0 CA--C 1.598 2.796 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 166.633 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' N ' ' HD2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -122.71 122.67 39.32 Favored 'General case' 0 CA--C 1.575 1.932 0 O-C-N 120.374 -1.454 . . . . 0.0 111.338 173.844 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' C ' ' HG2' ' A' ' 115' ' ' ARG . 61.2 t80 75.36 93.71 0.07 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 126.982 2.113 . . . . 0.0 110.961 176.277 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.651 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -55.02 134.1 48.21 Favored Glycine 0 CA--C 1.482 -1.985 0 N-CA-C 116.851 1.5 . . . . 0.0 116.851 -171.719 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -141.42 -87.09 0.17 Allowed 'General case' 0 CA--C 1.488 -1.439 0 C-N-CA 117.951 -1.5 . . . . 0.0 114.326 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -118.65 139.0 52.22 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.856 -169.716 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.539 ' HA ' HG23 ' A' ' 148' ' ' VAL . 10.0 t -43.58 -39.76 3.66 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 126.674 1.99 . . . . 0.0 115.385 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -134.31 15.43 3.78 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.426 0.631 . . . . 0.0 110.33 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -127.4 111.14 1.29 Allowed Glycine 0 N--CA 1.436 -1.312 0 C-N-CA 119.922 -1.132 . . . . 0.0 111.818 -177.198 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.566 ' SG ' ' HB ' ' A' ' 118' ' ' VAL . 10.1 p -97.88 88.3 4.24 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.8 p -78.25 -61.85 1.87 Allowed 'General case' 0 N--CA 1.419 -1.99 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.277 176.246 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.3 m -68.15 -27.95 66.88 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.862 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.47 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -78.7 -9.27 59.35 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.059 0.457 . . . . 0.0 111.115 177.551 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.3 -64.66 3.95 Favored Glycine 0 N--CA 1.436 -1.358 0 CA-C-N 115.096 -0.957 . . . . 0.0 113.021 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.78 53.13 2.71 Favored 'Trans proline' 0 CA--C 1.552 1.403 0 C-N-CA 122.359 2.039 . . . . 0.0 114.247 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 31.6 t-80 72.83 163.59 0.27 Allowed 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 124.831 1.252 . . . . 0.0 111.439 169.499 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.621 ' CG ' HG22 ' A' ' 81' ' ' VAL . 1.5 t80 -92.79 170.81 9.41 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.651 ' OD1' ' HD2' ' A' ' 66' ' ' PRO . 61.6 t30 -69.86 140.57 88.98 Favored Pre-proline 0 CA--C 1.562 1.42 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.091 -179.603 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.651 ' HD2' ' OD1' ' A' ' 65' ' ' ASN . 72.8 Cg_endo -76.84 -8.4 17.9 Favored 'Trans proline' 0 N--CA 1.443 -1.483 1 C-N-CA 125.314 4.01 . . . . 0.0 113.954 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -84.11 16.59 2.85 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 123.966 1.841 . . . . 0.0 109.611 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.653 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.0 p -80.43 -86.3 0.08 Allowed 'General case' 1 N--CA 1.356 -5.15 0 CA-C-N 113.362 -1.745 . . . . 0.0 108.321 175.152 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.651 ' HB2' ' HA ' ' A' ' 78' ' ' GLU . 41.8 ttt180 -135.84 10.36 3.36 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 167.624 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 82.5 tttt 75.14 -9.18 1.43 Allowed 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.371 1.469 . . . . 0.0 113.19 173.27 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 -99.35 -54.42 2.96 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 119.941 -0.703 . . . . 0.0 112.392 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.41 ' HA2' ' HG2' ' A' ' 78' ' ' GLU . . . 88.98 30.45 14.55 Favored Glycine 0 N--CA 1.474 1.174 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.229 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.444 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -70.58 143.54 37.15 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.499 -0.858 . . . . 0.0 114.734 -175.128 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 7.7 Cg_exo -76.84 -9.31 18.2 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 124.155 3.237 . . . . 0.0 111.58 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -79.84 9.8 4.86 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.741 -178.086 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB2' ' HB3' ' A' ' 101' ' ' ASP . 6.1 m-20 63.05 78.6 0.29 Allowed 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 124.909 1.283 . . . . 0.0 111.094 176.268 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -137.54 -56.13 0.69 Allowed 'General case' 0 CA--C 1.5 -0.969 0 O-C-N 121.668 -0.645 . . . . 0.0 112.683 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.651 ' HA ' ' HB2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -64.2 154.24 35.47 Favored 'General case' 0 N--CA 1.403 -2.776 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.276 -172.224 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.653 ' O ' ' HA ' ' A' ' 68' ' ' SER . 75.9 ttt180 -119.14 72.2 0.89 Allowed 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -170.84 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.336 2.3 m-70 177.48 -20.29 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.119 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 164.896 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 ' CG ' ' A' ' 64' ' ' PHE . 71.8 t -71.94 -57.26 7.74 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.493 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 170.234 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.453 ' O ' ' HG ' ' A' ' 84' ' ' LEU . . . 69.41 -66.02 0.57 Allowed Glycine 0 N--CA 1.435 -1.373 0 CA-C-N 113.836 -1.529 . . . . 0.0 113.226 176.66 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.67 ' O ' ' HB2' ' A' ' 46' ' ' HIS . 2.9 t70 -68.84 97.9 0.88 Allowed 'General case' 0 CA--C 1.449 -2.941 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.613 ' HA ' ' H ' ' A' ' 46' ' ' HIS . 2.5 pp -168.89 162.67 11.41 Favored 'General case' 0 N--CA 1.4 -2.959 0 C-N-CA 125.321 1.448 . . . . 0.0 108.357 -175.096 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 45' ' ' PHE . . . 176.55 168.89 37.25 Favored Glycine 2 C--N 1.247 -4.379 0 N-CA-C 103.715 -3.754 . . . . 0.0 103.715 175.538 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.424 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 58.5 t30 -80.36 140.63 35.98 Favored 'General case' 0 C--N 1.271 -2.84 0 CA-C-N 119.501 1.65 . . . . 0.0 107.324 174.947 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.455 HG12 ' HG3' ' A' ' 121' ' ' GLU . 43.4 t -115.31 128.06 72.65 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.118 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 -177.524 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 62.3 m -142.19 96.54 2.97 Favored 'General case' 0 N--CA 1.413 -2.279 0 CA-C-O 118.685 -0.674 . . . . 0.0 111.405 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.585 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -126.77 104.38 8.03 Favored 'General case' 0 C--O 1.195 -1.774 0 C-N-CA 116.459 -2.096 . . . . 0.0 108.131 169.704 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' A' ' 40' ' ' GLU . 5.3 p-10 -127.9 -18.65 4.19 Favored 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.626 -171.348 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.463 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 3.1 mptp? -71.73 -58.04 3.83 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.795 0.807 . . . . 0.0 109.072 -175.728 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -164.71 26.51 0.06 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.892 -175.849 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.759 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 77.46 78.95 0.74 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 114.532 -1.213 . . . . 0.0 115.338 -178.14 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.453 ' H ' ' HB1' ' A' ' 89' ' ' ALA . 98.7 t -159.77 105.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 177.072 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.419 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -107.71 122.68 47.22 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -93.21 112.86 24.93 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 124.117 0.886 . . . . 0.0 109.76 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.6 t -113.94 105.64 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-O 121.147 0.499 . . . . 0.0 109.806 178.204 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 50.5 m -143.52 111.63 6.19 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 174.291 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.438 HD12 HG21 ' A' ' 103' ' ' VAL . 25.1 pt -123.22 154.69 29.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.27 -173.527 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -148.96 99.42 2.97 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.884 0.85 . . . . 0.0 111.256 173.839 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 76' ' ' ASP . 5.6 t70 -167.58 171.98 9.82 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.6 m -59.24 87.77 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 122.743 1.259 . . . . 0.0 112.286 -178.081 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.438 HG21 HD12 ' A' ' 99' ' ' ILE . 59.3 t -113.21 -10.46 12.11 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 112.733 -2.03 . . . . 0.0 106.763 175.453 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.556 HG13 ' HA ' ' A' ' 26' ' ' ASN . 0.2 OUTLIER -52.84 -13.71 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 C-N-CA 125.111 1.364 . . . . 0.0 114.067 -176.72 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.2 m -73.27 152.16 41.09 Favored 'General case' 0 N--CA 1.418 -2.038 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 172.748 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.562 ' HB2' HG12 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -65.9 121.78 15.85 Favored 'General case' 0 N--CA 1.403 -2.82 0 CA-C-O 122.01 0.91 . . . . 0.0 109.697 -177.559 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.9 m -69.86 88.07 0.55 Allowed 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 113.216 -1.811 . . . . 0.0 110.677 -174.345 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.472 ' HA2' ' CZ ' ' A' ' 64' ' ' PHE . . . 143.62 136.62 3.15 Favored Glycine 0 N--CA 1.409 -3.108 0 CA-C-N 114.287 -1.324 . . . . 0.0 112.296 175.313 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -66.38 -56.77 9.46 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.851 169.193 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -104.24 -47.09 4.24 Favored 'General case' 0 N--CA 1.435 -1.209 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.007 -173.551 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.443 ' CB ' ' H ' ' A' ' 51' ' ' GLY . 18.8 m -127.42 113.91 16.82 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 118.944 -1.103 . . . . 0.0 112.594 -177.3 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.562 HG12 ' HB2' ' A' ' 106' ' ' LEU . 2.9 mp -89.71 -38.29 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 173.349 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.434 HD12 ' HB ' ' A' ' 112' ' ' ILE . 4.1 mp -102.01 145.07 12.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.83 -12.8 62.67 Favored Glycine 0 CA--C 1.495 -1.162 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 174.825 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.673 ' HD3' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -91.93 134.71 34.54 Favored 'General case' 0 N--CA 1.396 -3.147 0 CA-C-O 122.224 1.011 . . . . 0.0 112.967 -175.544 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.673 ' N ' ' HD3' ' A' ' 115' ' ' ARG 0.253 0.2 OUTLIER -89.0 116.74 27.52 Favored 'General case' 0 N--CA 1.394 -3.264 0 C-N-CA 126.563 1.945 . . . . 0.0 107.45 -176.188 . . . . . . . . 4 4 . 1 . 011 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 147' ' ' GLY . 2.7 pt? -79.17 144.52 34.37 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.494 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.566 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 10.7 p -109.7 111.14 34.85 Favored 'Isoleucine or valine' 0 C--O 1.273 2.314 0 C-N-CA 119.134 -1.027 . . . . 0.0 112.845 177.368 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 46' ' ' HIS . 24.7 m -147.81 146.48 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 C-N-CA 125.805 1.642 . . . . 0.0 110.017 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -170.08 148.65 3.42 Favored 'General case' 0 C--N 1.283 -2.326 0 N-CA-C 102.601 -3.111 . . . . 0.0 102.601 167.929 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.596 ' O ' ' HG3' ' A' ' 40' ' ' GLU . 1.3 mp0 -69.55 89.72 0.53 Allowed 'General case' 0 C--N 1.261 -3.276 0 CA-C-O 123.355 1.55 . . . . 0.0 113.182 -171.225 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -165.28 144.53 6.6 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 102.698 -3.075 . . . . 0.0 102.698 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.27 101.71 0.25 Allowed 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -173.765 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.52 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 12.0 t70 -87.89 93.95 9.62 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 99.585 -4.228 . . . . 0.0 99.585 171.747 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -103.28 139.81 38.23 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.839 -0.745 . . . . 0.0 111.118 -170.335 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.527 ' HG ' ' H ' ' A' ' 127' ' ' GLY . 1.9 pt? -51.23 -74.28 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 121.703 3.964 . . . . 0.0 121.703 -162.248 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 127' ' ' GLY . . . . . 0.527 ' H ' ' HG ' ' A' ' 126' ' ' LEU . . . -69.97 -59.89 5.23 Favored Glycine 0 CA--C 1.47 -2.727 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.829 -170.781 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.508 ' HD2' ' C ' ' A' ' 127' ' ' GLY . 4.4 mptp? -136.8 35.88 2.63 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.073 -174.729 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.493 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 59.5 -34.06 0.03 OUTLIER Glycine 0 CA--C 1.559 2.809 0 CA-C-N 119.76 1.164 . . . . 0.0 115.634 -175.29 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 130' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 128' ' ' LYS . . . 147.38 -24.32 1.54 Allowed Glycine 0 N--CA 1.401 -3.643 0 O-C-N 122.145 -0.62 . . . . 0.0 111.905 179.528 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.661 ' N ' ' HB2' ' A' ' 134' ' ' SER . 61.0 t30 -169.61 179.78 3.65 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 118.519 -1.272 . . . . 0.0 108.042 -174.862 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.466 ' O ' HG22 ' A' ' 135' ' ' THR . 0.0 OUTLIER -62.6 -40.72 97.82 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.07 -1.452 . . . . 0.0 113.378 -175.136 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -85.36 -30.84 23.33 Favored 'General case' 0 C--N 1.319 -0.749 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.171 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.661 ' HB2' ' N ' ' A' ' 131' ' ' ASN . 15.0 m -63.68 -19.68 65.1 Favored 'General case' 0 C--O 1.186 -2.284 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.493 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.3 t -71.96 -35.4 69.54 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 175.866 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -73.89 -48.84 28.06 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.58 -175.835 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 134' ' ' SER . 14.8 t -86.06 -23.66 26.65 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 114.418 -1.265 . . . . 0.0 112.816 -176.485 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -68.22 -66.7 2.21 Favored Glycine 0 CA--C 1.478 -2.277 0 CA-C-O 119.584 -0.565 . . . . 0.0 111.73 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 58.8 t30 -50.75 132.53 26.32 Favored 'General case' 0 N--CA 1.518 2.945 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 171.343 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.63 160.27 25.81 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 114.392 1.256 . . . . 0.0 114.392 -162.817 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.87 118.46 13.08 Favored Glycine 0 CA--C 1.49 -1.508 0 CA-C-N 113.655 -1.611 . . . . 0.0 113.046 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.553 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 8.4 m -71.43 3.43 3.81 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 124.607 1.163 . . . . 0.0 113.189 -173.137 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.9 mtt180 -132.16 -4.76 3.47 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 176.557 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.93 -40.35 32.24 Favored 'General case' 0 CA--C 1.498 -1.02 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.111 -173.407 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.15 108.53 0.98 Allowed 'General case' 0 N--CA 1.428 -1.569 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.444 ' HB3' HG22 ' A' ' 116' ' ' THR . 7.8 m -137.43 156.78 47.78 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 177.873 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -161.1 135.0 3.76 Favored Glycine 0 C--N 1.296 -1.686 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 176.905 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.539 HG23 ' HA ' ' A' ' 54' ' ' THR . 40.2 t -65.79 121.67 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.535 0 CA-C-O 122.36 1.076 . . . . 0.0 110.952 176.934 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.8 tt -113.27 141.47 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.098 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.513 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.01 148.13 15.69 Favored Glycine 3 N--CA 1.383 -4.873 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.517 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.1 pt -69.94 103.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 CA-C-O 121.373 0.606 . . . . 0.0 110.699 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.652 ' O ' ' HG3' ' A' ' 3' ' ' LYS . . . -118.5 139.12 51.93 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 175.842 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 . . . . . 0 C--N 1.31 -1.126 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.644 -175.035 . . . . . . . . 0 0 . 1 . 011 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 120.805 0.336 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 m -92.07 -46.94 7.53 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 120.739 0.304 . . . . 0.0 110.887 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.448 ' HA ' ' OD1' ' A' ' 19' ' ' ASN . 19.0 ptpt -154.25 166.48 33.01 Favored 'General case' 0 N--CA 1.433 -1.32 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.519 -176.62 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.666 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -146.26 153.36 40.5 Favored 'General case' 0 N--CA 1.424 -1.772 0 O-C-N 124.308 1.005 . . . . 0.0 108.336 176.377 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.25 114.23 14.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -113.51 128.1 56.32 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.697 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -122.53 120.44 60.98 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 121.391 0.615 . . . . 0.0 110.568 178.712 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -108.32 149.16 29.03 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.397 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -171.07 127.06 0.7 Allowed 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.35 -156.53 7.45 Favored Glycine 0 N--CA 1.429 -1.824 0 C-N-CA 120.175 -1.012 . . . . 0.0 112.179 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.46 -39.08 60.69 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.63 1.172 . . . . 0.0 111.347 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -107.32 161.97 13.53 Favored Glycine 0 N--CA 1.436 -1.326 0 N-CA-C 108.009 -2.036 . . . . 0.0 108.009 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -84.32 123.58 3.05 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 CA-C-N 120.491 2.145 . . . . 0.0 111.254 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.3 t -132.98 127.41 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 N-CA-C 103.599 -2.741 . . . . 0.0 103.599 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -142.06 116.58 9.66 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.89 170.3 43.09 Favored Glycine 0 N--CA 1.396 -3.985 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -177.04 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 24.9 pt -142.6 144.0 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.979 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 179.363 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.2 tp -139.13 136.18 42.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 177.488 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.666 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.3 t-20 -97.96 147.72 24.2 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.533 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 61.7 m-85 -138.09 119.33 14.62 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 119.182 0.901 . . . . 0.0 110.734 173.278 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -112.88 101.89 9.93 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.875 0.845 . . . . 0.0 111.191 174.556 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pm0 -91.06 150.32 21.47 Favored 'General case' 0 N--CA 1.404 -2.729 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.783 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.545 ' HB3' HG21 ' A' ' 103' ' ' VAL . 40.9 tptt -138.38 154.17 48.93 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 -175.68 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.5 mp0 -62.68 -55.31 27.98 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 123.937 0.773 . . . . 0.0 113.053 -174.534 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.3 m -78.24 -71.79 0.41 Allowed 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -168.786 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.0 p30 177.89 140.67 0.09 Allowed 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -175.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.422 ' N ' HG22 ' A' ' 103' ' ' VAL . . . 165.8 174.58 35.45 Favored Glycine 0 CA--C 1.48 -2.11 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.84 178.973 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -90.6 131.7 1.65 Allowed 'Trans proline' 0 N--CA 1.43 -2.226 0 C-N-CA 123.062 2.508 . . . . 0.0 110.854 175.763 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.33 101.82 2.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 176.361 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.263 0.9 OUTLIER -92.07 92.79 8.43 Favored 'General case' 0 CA--C 1.482 -1.64 0 CA-C-O 122.735 1.255 . . . . 0.0 111.824 177.266 . . . . . . . . 4 4 . 1 . 012 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.498 HG11 ' HA ' ' A' ' 20' ' ' PHE . 17.7 m -127.82 153.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.308 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.69 -175.214 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.51 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 31.0 m-90 -126.59 148.0 49.82 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.63 -172.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -166.17 140.11 6.16 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.218 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.8 m -117.16 146.56 43.12 Favored 'General case' 0 N--CA 1.389 -3.521 0 N-CA-C 105.949 -1.871 . . . . 0.0 105.949 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.725 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 17.0 tt -139.55 155.46 25.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 31.7 mmmt -136.33 131.31 34.14 Favored 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 105.501 -2.037 . . . . 0.0 105.501 -176.533 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -164.52 174.72 40.57 Favored Glycine 0 C--N 1.281 -2.505 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -173.472 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.3 mt -66.71 145.05 55.97 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.102 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.433 HG22 ' CA ' ' A' ' 92' ' ' ASP . 65.5 p -69.54 106.73 3.11 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -164.587 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -175.47 161.96 2.77 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 103.765 -2.68 . . . . 0.0 103.765 178.62 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.463 ' HA2' ' C ' ' A' ' 121' ' ' GLU . . . 158.86 137.09 2.17 Favored Glycine 1 CA--C 1.444 -4.364 0 C-N-CA 117.33 -2.367 . . . . 0.0 112.773 167.521 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.506 ' O ' ' HB2' ' A' ' 43' ' ' HIS . 0.5 OUTLIER 177.69 63.0 0.01 OUTLIER 'General case' 0 N--CA 1.447 -0.602 0 O-C-N 124.419 0.717 . . . . 0.0 110.243 -175.193 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.506 ' HB2' ' O ' ' A' ' 42' ' ' LEU . 35.9 t60 164.95 123.26 0.01 OUTLIER 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 172.677 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.629 ' HA2' ' N ' ' A' ' 87' ' ' VAL . . . -47.66 -134.73 0.0 OUTLIER Glycine 0 N--CA 1.486 1.995 0 N-CA-C 119.798 2.679 . . . . 0.0 119.798 -172.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.496 ' O ' ' HB2' ' A' ' 83' ' ' ASP . 13.3 m-85 -88.88 162.3 16.21 Favored 'General case' 0 CA--C 1.471 -2.07 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 177.676 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.17 84.64 0.11 Allowed 'General case' 1 C--O 1.337 5.682 0 C-N-CA 120.212 -0.595 . . . . 0.0 112.266 -175.732 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.677 ' HB ' ' OE2' ' A' ' 49' ' ' GLU . 10.2 m -89.34 173.19 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 130.568 3.547 . . . . 0.0 114.323 -164.951 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.512 ' NE2' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -170.8 86.43 0.1 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.427 1.491 . . . . 0.0 108.195 174.422 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.677 ' OE2' ' HB ' ' A' ' 47' ' ' VAL . 3.0 mp0 -87.31 89.46 8.0 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 115.153 1.538 . . . . 0.0 115.153 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -118.21 -21.52 8.14 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 113.743 -1.571 . . . . 0.0 112.193 -177.827 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.57 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 92.32 110.94 1.86 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.847 -172.643 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.415 ' OD2' ' HA ' ' A' ' 57' ' ' CYS . 9.9 t0 -153.32 -171.24 3.85 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.351 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -73.97 135.77 43.19 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 177.599 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.438 ' HB ' HG13 ' A' ' 148' ' ' VAL . 9.4 t -67.41 5.27 0.8 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -173.828 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.75 5.82 8.13 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.993 -0.442 . . . . 0.0 110.591 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 173.86 136.45 2.21 Favored Glycine 0 CA--C 1.484 -1.862 0 C-N-CA 117.58 -2.248 . . . . 0.0 112.542 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 143' ' ' ARG . 53.7 m -96.84 87.87 4.42 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.496 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 p -83.29 -37.12 23.88 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-O 122.159 0.981 . . . . 0.0 111.61 172.023 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.0 m -90.03 -40.17 12.48 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.802 -170.384 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.76 -16.09 35.18 Favored 'General case' 0 N--CA 1.422 -1.869 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 57' ' ' CYS . . . 37.29 -144.81 0.13 Allowed Glycine 0 CA--C 1.488 -1.628 0 CA-C-N 111.786 -2.461 . . . . 0.0 116.387 171.721 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -82.71 87.35 1.37 Allowed 'Trans proline' 0 N--CA 1.403 -3.827 0 C-N-CA 122.144 1.896 . . . . 0.0 110.189 177.03 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.427 ' HB2' ' HA3' ' A' ' 138' ' ' GLY . 10.9 t-80 77.61 110.46 0.07 Allowed 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 114.298 -1.319 . . . . 0.0 114.479 170.248 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -170.48 91.78 0.18 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.737 -2.029 . . . . 0.0 105.538 173.031 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 3.0 t30 -111.49 89.92 11.42 Favored Pre-proline 0 C--O 1.209 -1.035 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 -178.547 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -77.48 -11.32 17.27 Favored 'Trans proline' 0 C--N 1.323 -0.804 0 C-N-CA 122.786 2.324 . . . . 0.0 111.259 -173.412 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.427 ' HB3' HD22 ' A' ' 65' ' ' ASN . 4.5 tt -45.04 -62.18 1.34 Allowed 'General case' 0 CA--C 1.492 -1.262 0 O-C-N 125.254 1.596 . . . . 0.0 109.943 -175.195 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.689 ' OG ' ' HA ' ' A' ' 76' ' ' ASP . 19.8 m -106.04 -86.26 0.48 Allowed 'General case' 0 N--CA 1.389 -3.483 0 C-N-CA 117.546 -1.662 . . . . 0.0 111.538 176.109 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.406 ' HD2' ' OE2' ' A' ' 78' ' ' GLU 0.392 21.8 ttm180 -123.99 43.48 2.98 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 114.593 -2.843 . . . . 0.0 116.169 179.405 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 53.0 mtmt 75.27 -43.04 0.49 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 125.09 1.356 . . . . 0.0 113.688 173.45 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -70.21 -37.44 75.06 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.614 ' HA3' ' O ' ' A' ' 80' ' ' HIS . . . 171.55 171.63 36.84 Favored Glycine 0 C--O 1.266 2.152 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.732 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.69 77.14 0.1 Allowed Glycine 0 C--O 1.215 -1.046 0 CA-C-O 118.925 -0.931 . . . . 0.0 113.377 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 77' ' ' GLU . 42.8 Cg_endo -64.79 -42.95 13.64 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.531 2.154 . . . . 0.0 115.653 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.579 ' O ' HG13 ' A' ' 104' ' ' ILE . 58.4 pttt -119.7 26.01 9.63 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.59 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.689 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 33.6 t70 61.76 85.06 0.13 Allowed 'General case' 0 CA--C 1.487 -1.472 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 -163.921 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.596 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 6.2 tp10 -121.95 -35.58 3.15 Favored 'General case' 0 C--O 1.169 -3.142 0 CA-C-N 113.803 -1.544 . . . . 0.0 113.984 -164.961 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.596 ' HB3' ' O ' ' A' ' 77' ' ' GLU . 12.6 tt0 76.73 112.33 0.07 Allowed 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -162.008 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 75.1 -174.93 0.13 Allowed 'General case' 0 C--O 1.25 1.114 0 CA-C-N 114.537 -1.21 . . . . 0.0 109.9 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.614 ' O ' ' HA3' ' A' ' 72' ' ' GLY . 61.7 t-80 75.73 162.81 0.25 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 125.693 1.597 . . . . 0.0 107.202 -178.388 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.513 HG23 ' H ' ' A' ' 126' ' ' LEU . 3.7 p -62.36 115.49 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.04 172.746 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.441 ' C ' HG22 ' A' ' 47' ' ' VAL . . . -57.57 118.59 13.1 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 169.907 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.496 ' HB2' ' O ' ' A' ' 45' ' ' PHE . 0.5 OUTLIER -170.79 150.72 3.29 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 -172.675 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.9 mp -136.12 83.86 2.04 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 105.377 -2.083 . . . . 0.0 105.377 159.042 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.481 ' HA3' ' CD1' ' A' ' 45' ' ' PHE . . . 172.89 154.49 10.41 Favored Glycine 0 N--CA 1.422 -2.292 0 C-N-CA 118.982 -1.58 . . . . 0.0 114.6 176.562 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.55 ' H ' HG21 ' A' ' 99' ' ' ILE . 35.1 t30 -129.65 127.85 41.4 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 169.977 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.629 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 6.4 m -131.59 143.3 40.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.561 0 CA-C-N 118.216 0.462 . . . . 0.0 109.799 -173.427 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.9 m -142.37 96.24 2.92 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.628 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.556 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -137.87 154.74 49.44 Favored 'General case' 0 C--O 1.153 -3.978 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.415 ' O ' ' HB ' ' A' ' 39' ' ' THR . 7.9 p-10 -179.66 -27.57 0.01 OUTLIER 'General case' 0 C--N 1.255 -3.511 0 CA-C-O 122.485 1.136 . . . . 0.0 109.409 179.158 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -77.14 -49.61 14.84 Favored 'General case' 0 C--N 1.255 -3.534 0 CA-C-N 112.964 -1.925 . . . . 0.0 110.986 -177.59 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.433 ' CA ' HG22 ' A' ' 39' ' ' THR . 32.8 t70 -132.79 -1.08 3.41 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.822 -174.842 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.687 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 68.67 66.16 2.39 Favored Glycine 0 C--O 1.215 -1.054 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -177.197 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.725 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 22.7 t -150.21 104.55 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -110.23 119.63 39.87 Favored 'General case' 0 N--CA 1.4 -2.938 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 174.328 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -112.59 113.19 25.21 Favored 'General case' 0 C--N 1.273 -2.751 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 -177.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 13.7 m -111.21 145.46 17.43 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.065 0 N-CA-C 114.552 1.316 . . . . 0.0 114.552 -168.729 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.0 t -143.06 102.06 3.93 Favored 'General case' 0 N--CA 1.413 -2.309 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 166.105 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.55 HG21 ' H ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -117.23 171.54 5.68 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -176.185 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -140.77 112.17 7.37 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.03 -0.986 . . . . 0.0 109.668 176.271 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 101' ' ' ASP . . . . . 0.438 ' OD1' ' HB3' ' A' ' 75' ' ' LYS . 2.2 t0 -130.24 168.63 16.55 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.779 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB2' ' HB2' ' A' ' 75' ' ' LYS . 22.0 m -76.04 123.72 26.23 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 119.408 1.003 . . . . 0.0 111.253 -174.101 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.545 HG21 ' HB3' ' A' ' 23' ' ' LYS . 26.8 m -56.13 -12.09 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 C-N-CA 126.439 1.896 . . . . 0.0 114.546 -175.533 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 75' ' ' LYS . 26.3 pt -66.59 -12.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 CA-C-O 120.657 0.265 . . . . 0.0 111.136 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.569 ' HB3' ' C ' ' A' ' 75' ' ' LYS . 5.1 p -84.88 89.76 7.63 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 172.284 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.502 ' H ' HD23 ' A' ' 106' ' ' LEU . 2.0 pt? -69.79 119.34 13.87 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 165.147 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -74.65 87.57 2.17 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.533 ' HA2' ' CB ' ' A' ' 49' ' ' GLU . . . 162.49 136.91 2.08 Favored Glycine 0 N--CA 1.405 -3.375 0 CA-C-N 114.614 -1.175 . . . . 0.0 112.398 178.337 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -83.28 -73.56 0.4 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.616 0.246 . . . . 0.0 110.725 176.322 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -87.42 -19.72 27.66 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.531 179.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t -159.32 163.74 35.41 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 105.895 -1.891 . . . . 0.0 105.895 175.302 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.59 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 6.4 pt -104.47 -16.95 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.853 0 C-N-CA 125.507 1.523 . . . . 0.0 108.6 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.444 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 37.4 pt -103.73 138.83 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.13 177.856 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.561 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 93.41 -0.34 68.21 Favored Glycine 0 CA--C 1.484 -1.846 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.021 171.261 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.57 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 2.6 mmp_? -87.55 144.53 26.65 Favored 'General case' 0 C--O 1.175 -2.823 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 2.3 p -98.61 119.47 37.39 Favored 'General case' 0 C--N 1.286 -2.193 0 CA-C-N 119.549 1.068 . . . . 0.0 113.165 -176.848 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.447 ' HG ' HG12 ' A' ' 47' ' ' VAL . 3.0 tt -88.27 131.67 34.69 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 145' ' ' ALA . 93.5 t -102.24 109.49 26.44 Favored 'Isoleucine or valine' 0 C--O 1.267 2.009 0 C-N-CA 118.941 -1.103 . . . . 0.0 110.668 175.281 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.5 p -148.14 124.3 2.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.896 0.855 . . . . 0.0 113.192 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -144.02 157.44 44.33 Favored 'General case' 0 N--CA 1.41 -2.43 0 N-CA-C 101.872 -3.381 . . . . 0.0 101.872 168.207 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.561 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 1.2 mp0 -68.92 89.79 0.42 Allowed 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.18 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HD3' ' H ' ' A' ' 123' ' ' ALA . 2.2 tmtp? -173.85 168.12 4.3 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -174.857 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.566 ' H ' ' HD3' ' A' ' 122' ' ' LYS . . . -73.72 125.02 27.15 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 121.531 0.681 . . . . 0.0 111.175 173.548 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -156.1 112.89 3.15 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 125.526 1.53 . . . . 0.0 107.31 176.613 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.502 ' O ' ' HA2' ' A' ' 138' ' ' GLY . 7.4 m-20 -128.91 129.32 45.35 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.513 ' H ' HG23 ' A' ' 81' ' ' VAL . 3.3 mm? -82.69 -53.82 5.62 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 123.277 0.36 . . . . 0.0 111.168 -177.33 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.76 -31.24 45.1 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.65 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -93.13 -46.71 7.3 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.214 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 63.96 -82.04 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.601 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 169.89 -67.34 0.16 Allowed Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -177.637 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.636 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 51.6 t30 -119.4 -175.29 2.91 Favored 'General case' 0 C--O 1.253 1.237 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 175.271 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -54.01 -34.77 60.81 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -178.003 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 133' ' ' GLU . . . . . 0.636 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -83.79 -38.48 21.22 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.135 -178.951 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.476 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 14.6 m -65.16 -29.62 70.47 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.32 -175.209 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.418 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.4 t -68.53 -27.54 66.2 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 121.469 0.652 . . . . 0.0 109.892 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -84.05 -39.51 19.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.738 -178.967 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.0 m -72.26 -33.47 67.52 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 115.415 -0.812 . . . . 0.0 110.044 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 125' ' ' ASP . . . 59.72 45.96 94.84 Favored Glycine 0 CA--C 1.488 -1.626 0 N-CA-C 107.373 -2.291 . . . . 0.0 107.373 -171.431 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -34.42 104.62 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 O-C-N 126.424 1.896 . . . . 0.0 113.679 -166.23 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -151.8 172.43 16.18 Favored 'General case' 0 N--CA 1.425 -1.697 0 CA-C-N 113.523 -1.672 . . . . 0.0 108.353 -176.668 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.92 94.78 1.0 Allowed Glycine 0 N--CA 1.429 -1.779 0 N-CA-C 107.721 -2.152 . . . . 0.0 107.721 170.521 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.409 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 14.3 m -43.49 -44.29 5.88 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.922 1.689 . . . . 0.0 113.998 -172.919 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 57' ' ' CYS . 44.8 mtm180 -115.66 -25.95 7.64 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 177.904 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -46.62 -35.33 5.8 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.2 1.8 . . . . 0.0 112.539 -168.314 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 118' ' ' VAL . . . -141.58 87.76 2.09 Favored 'General case' 0 N--CA 1.388 -3.529 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 -179.221 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.445 ' SG ' HG22 ' A' ' 118' ' ' VAL . 86.5 m -138.7 138.91 38.16 Favored 'General case' 0 N--CA 1.419 -1.996 0 CA-C-N 114.035 -1.439 . . . . 0.0 107.845 176.331 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.21 148.95 18.55 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 174.851 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 27.9 m -68.95 123.91 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.809 0 CA-C-O 122.572 1.177 . . . . 0.0 111.97 178.665 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.409 HD13 ' N ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -98.2 138.51 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.561 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 174.439 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.59 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -174.4 151.99 13.66 Favored Glycine 3 N--CA 1.36 -6.37 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 177.642 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.7 pp -60.57 114.54 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 170.382 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.409 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -126.94 114.89 18.44 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 118.221 -0.895 . . . . 0.0 109.267 -178.492 . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.481 ' HA ' HD11 ' A' ' 151' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.447 0 CA-C-O 121.047 0.451 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.401 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 11.6 t -121.68 -25.08 5.15 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.041 0.924 . . . . 0.0 110.167 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -135.78 150.5 49.49 Favored 'General case' 0 N--CA 1.416 -2.166 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -178.443 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.52 161.44 37.91 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.98 127.82 66.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-O 121.363 0.601 . . . . 0.0 109.961 178.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.65 ' HA ' HG21 ' A' ' 148' ' ' VAL . . . -107.81 146.89 31.62 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.768 -177.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.618 ' N ' HG11 ' A' ' 148' ' ' VAL . 41.1 t -134.5 104.94 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 -178.366 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.93 151.34 22.88 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.0 tmtt? -144.27 122.01 11.9 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 175.768 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.38 -178.46 30.54 Favored Glycine 0 N--CA 1.414 -2.8 0 C-N-CA 117.999 -2.048 . . . . 0.0 115.939 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.3 m-20 -102.35 111.34 23.59 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 170.146 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.41 68.94 1.03 Allowed Glycine 0 C--N 1.289 -2.059 0 N-CA-C 104.988 -3.245 . . . . 0.0 104.988 -164.958 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -62.66 128.0 22.19 Favored 'Trans proline' 0 CA--C 1.503 -1.045 0 C-N-CA 123.159 2.573 . . . . 0.0 114.914 -165.435 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 m -115.8 123.13 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.524 0 CA-C-N 113.727 -1.579 . . . . 0.0 108.324 177.529 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -111.66 117.84 34.02 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.61 166.93 40.11 Favored Glycine 1 N--CA 1.383 -4.885 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.377 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.445 ' O ' HD12 ' A' ' 17' ' ' ILE . 2.5 pp -134.38 139.28 48.3 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.673 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.856 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.3 tp -136.14 133.87 50.26 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.9 m-20 -92.9 160.71 14.79 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.239 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 44.4 m-85 -143.48 118.34 9.94 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 176.081 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.402 ' HG3' ' O ' ' A' ' 21' ' ' GLU . 13.0 pt-20 -124.94 101.06 6.88 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.314 -1.354 . . . . 0.0 114.073 171.451 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.514 ' HB3' ' HA ' ' A' ' 105' ' ' SER . 22.7 mm-40 -154.29 101.46 2.38 Favored 'General case' 0 CA--C 1.507 -0.677 0 C-N-CA 124.377 1.071 . . . . 0.0 110.462 164.065 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -167.37 -73.06 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.399 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -90.34 -33.39 16.1 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.088 179.028 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 p -65.19 -69.57 0.29 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.887 -1.051 . . . . 0.0 112.025 -178.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 66.7 107.53 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 124.476 1.11 . . . . 0.0 110.924 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.652 ' O ' ' HB3' ' A' ' 102' ' ' SER . . . 133.33 -147.31 18.96 Favored Glycine 0 CA--C 1.487 -1.66 0 C-N-CA 119.044 -1.55 . . . . 0.0 112.044 -177.157 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.32 123.29 13.22 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 122.512 2.141 . . . . 0.0 111.519 -177.408 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.553 HG23 ' HA ' ' A' ' 102' ' ' SER . 46.4 t -95.4 95.15 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.852 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -176.75 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -98.19 90.76 4.96 Favored 'General case' 0 N--CA 1.411 -2.418 0 CA-C-O 122.498 1.142 . . . . 0.0 108.981 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.436 ' O ' HG22 ' A' ' 99' ' ' ILE . 27.3 m -124.28 151.61 29.52 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.74 0 CA-C-N 113.001 -1.909 . . . . 0.0 109.724 -175.006 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.449 ' HA ' ' CG1' ' A' ' 97' ' ' VAL . 20.9 m-90 -135.48 145.89 47.59 Favored 'General case' 0 C--N 1.267 -3.005 0 CA-C-N 114.988 -1.005 . . . . 0.0 109.026 -175.447 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.538 ' H ' HG13 ' A' ' 97' ' ' VAL . . . -167.46 137.7 4.76 Favored Glycine 0 N--CA 1.424 -2.158 0 C-N-CA 118.046 -2.026 . . . . 0.0 112.638 172.772 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 p -118.38 138.71 52.25 Favored 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.4 mm -119.61 135.82 58.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -120.5 105.57 10.97 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 173.404 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.93 174.84 16.78 Favored Glycine 0 C--N 1.269 -3.144 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.893 -175.71 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.1 tp -66.01 137.42 57.1 Favored 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 104.384 -2.45 . . . . 0.0 104.384 173.281 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.449 ' HB ' ' HA ' ' A' ' 91' ' ' LYS . 17.9 p -68.72 108.96 3.6 Favored 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 115.766 1.765 . . . . 0.0 115.766 -160.123 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -173.6 170.03 4.16 Favored 'General case' 0 CA--C 1.472 -2.047 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.798 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 169.2 136.55 2.08 Favored Glycine 2 C--N 1.241 -4.715 0 C-N-CA 117.481 -2.295 . . . . 0.0 113.129 167.556 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.6 mt -140.99 -50.39 0.44 Allowed 'General case' 0 N--CA 1.426 -1.672 0 O-C-N 124.553 0.796 . . . . 0.0 111.379 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -149.83 153.49 36.85 Favored 'General case' 0 C--N 1.321 -0.665 0 O-C-N 121.922 -0.486 . . . . 0.0 109.792 -175.993 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.632 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -96.59 107.5 3.52 Favored Glycine 0 CA--C 1.458 -3.478 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 175.297 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CG ' ' HB3' ' A' ' 124' ' ' ASP . 29.4 p90 -121.79 83.49 2.1 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.56 ' HB2' HD12 ' A' ' 117' ' ' LEU . 8.2 p80 -133.04 85.47 2.22 Favored 'General case' 0 N--CA 1.387 -3.586 0 O-C-N 118.968 -2.333 . . . . 0.0 113.607 -162.47 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.536 ' HB ' ' O ' ' A' ' 82' ' ' GLY . 43.4 t -170.47 136.12 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 C-N-CA 127.753 2.421 . . . . 0.0 108.168 171.698 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.625 ' HB2' ' O ' ' A' ' 116' ' ' THR . 2.0 m170 -150.35 94.76 2.16 Favored 'General case' 0 C--N 1.26 -3.309 0 CA-C-N 112.458 -2.155 . . . . 0.0 109.916 170.386 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.403 ' HG3' ' CG1' ' A' ' 81' ' ' VAL . 0.4 OUTLIER -80.87 162.37 24.0 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 176.829 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.9 t80 71.74 28.96 2.62 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.612 ' HA3' ' HA ' ' A' ' 115' ' ' ARG . . . -72.01 -170.47 13.98 Favored Glycine 0 N--CA 1.428 -1.883 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.958 176.164 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -176.34 -63.04 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.552 -164.984 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -108.28 121.91 45.86 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.637 -173.437 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.1 p -70.81 2.62 4.02 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -177.889 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.69 19.02 11.92 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.318 0.247 . . . . 0.0 110.434 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 154.78 131.54 1.49 Allowed Glycine 0 C--N 1.309 -0.923 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.968 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.462 ' HB2' ' HG2' ' A' ' 143' ' ' ARG . 15.8 m -82.62 91.92 7.05 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.0 t -78.56 -61.37 2.03 Favored 'General case' 0 N--CA 1.426 -1.661 0 O-C-N 124.11 0.881 . . . . 0.0 110.157 172.486 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 13.4 m -65.43 -47.2 77.04 Favored 'General case' 0 C--O 1.214 -0.806 0 C-N-CA 122.967 0.507 . . . . 0.0 111.941 -177.107 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.477 ' HB1' ' HB3' ' A' ' 48' ' ' HIS . . . -76.36 -6.65 52.53 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -40.58 -71.57 0.29 Allowed Glycine 0 CA--C 1.541 1.706 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 -175.266 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -72.12 -17.05 28.41 Favored 'Trans proline' 0 N--CA 1.48 0.684 0 C-N-CA 122.92 2.414 . . . . 0.0 112.381 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER 65.64 107.18 0.04 OUTLIER 'General case' 0 C--O 1.242 0.665 0 C-N-CA 126.611 1.965 . . . . 0.0 112.56 -177.771 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -130.29 84.09 2.18 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 118.306 -1.358 . . . . 0.0 108.474 166.261 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -119.46 90.63 42.97 Favored Pre-proline 0 C--N 1.289 -2.033 0 CA-C-N 112.5 -2.136 . . . . 0.0 108.066 173.647 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -30.1 -54.49 0.2 Allowed 'Trans proline' 0 N--CA 1.484 0.956 1 C-N-CA 126.735 4.957 . . . . 0.0 119.626 -168.864 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -93.84 0.47 56.24 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 118.688 -1.205 . . . . 0.0 113.843 -173.31 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.639 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 28.6 m -78.6 48.43 0.79 Allowed 'General case' 0 C--O 1.246 0.892 0 CA-C-O 122.386 1.089 . . . . 0.0 109.095 175.992 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 69' ' ' ARG . 12.9 mmm180 -133.2 -28.77 1.48 Allowed 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.283 -173.189 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 54.3 tptt -38.84 -56.83 1.31 Allowed 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.105 0.962 . . . . 0.0 113.563 -173.227 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.493 ' H ' ' HA ' ' A' ' 78' ' ' GLU . 21.2 t-80 -177.61 59.94 0.01 OUTLIER 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.161 -0.447 . . . . 0.0 110.011 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.511 ' HA2' ' HB3' ' A' ' 78' ' ' GLU . . . -38.93 105.98 0.05 OUTLIER Glycine 0 N--CA 1.483 1.83 0 O-C-N 123.744 0.653 . . . . 0.0 112.676 173.246 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.52 168.26 24.22 Favored Glycine 0 N--CA 1.413 -2.84 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -176.842 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -93.29 1.72 3.45 Favored 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 123.333 2.689 . . . . 0.0 115.985 -172.653 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 76' ' ' ASP . 87.1 mttt -108.5 -31.67 7.71 Favored 'General case' 0 C--O 1.262 1.715 0 C-N-CA 118.096 -1.442 . . . . 0.0 109.773 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 75' ' ' LYS . 0.8 OUTLIER 159.3 120.09 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.758 0 C-N-CA 128.301 2.64 . . . . 0.0 104.291 168.813 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 164.33 127.26 0.01 OUTLIER 'General case' 0 CA--C 1.454 -2.715 0 C-N-CA 124.459 1.104 . . . . 0.0 111.194 171.52 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.639 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.7 OUTLIER 162.75 -173.84 0.01 OUTLIER 'General case' 0 N--CA 1.396 -3.147 0 C-N-CA 130.885 3.674 . . . . 0.0 102.325 163.982 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.671 ' HA ' ' NE ' ' A' ' 79' ' ' ARG 0.381 1.4 mmp_? -121.01 11.25 10.95 Favored 'General case' 0 C--N 1.257 -3.415 0 N-CA-C 118.337 2.718 . . . . 0.0 118.337 -176.872 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.507 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -138.8 -67.03 0.47 Allowed 'General case' 0 CA--C 1.483 -1.629 0 C-N-CA 117.37 -1.732 . . . . 0.0 110.804 170.006 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.45 HG22 HG11 ' A' ' 47' ' ' VAL . 7.1 p 174.33 89.57 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.273 -2.737 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.536 ' O ' ' HB ' ' A' ' 47' ' ' VAL . . . -112.43 -34.07 1.99 Allowed Glycine 0 CA--C 1.47 -2.749 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.98 -174.962 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -168.21 172.05 8.91 Favored 'General case' 0 N--CA 1.438 -1.056 0 O-C-N 124.305 0.65 . . . . 0.0 110.333 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.639 HD23 ' H ' ' A' ' 85' ' ' GLY . 5.8 tt -138.23 170.9 15.21 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 125.391 1.682 . . . . 0.0 106.546 -174.44 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' GLY . . . . . 0.639 ' H ' HD23 ' A' ' 84' ' ' LEU . . . -38.89 147.53 0.13 Allowed Glycine 0 N--CA 1.466 0.686 0 C-N-CA 125.005 1.288 . . . . 0.0 114.948 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -79.49 136.3 36.87 Favored 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 114.682 -0.759 . . . . 0.0 109.162 -166.274 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.729 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 30.3 m -134.72 126.69 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.408 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.6 t -141.28 148.2 39.42 Favored 'General case' 0 C--N 1.267 -3.001 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 -177.571 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.798 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -132.76 154.38 50.29 Favored 'General case' 0 C--N 1.259 -3.326 0 N-CA-C 105.362 -2.088 . . . . 0.0 105.362 178.931 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.499 ' C ' ' H ' ' A' ' 92' ' ' ASP . 6.9 t70 -101.65 -153.45 0.46 Allowed 'General case' 1 C--N 1.225 -4.841 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.548 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HA ' ' HB ' ' A' ' 39' ' ' THR . 95.0 mttt -62.66 16.82 0.01 OUTLIER 'General case' 0 CA--C 1.58 2.116 0 O-C-N 121.587 -0.696 . . . . 0.0 112.845 171.405 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 90' ' ' ASP . 17.0 t70 -133.68 109.65 9.31 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 171.369 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -76.43 92.59 0.98 Allowed Glycine 0 C--N 1.32 -0.357 0 N-CA-C 114.911 0.725 . . . . 0.0 114.911 -170.456 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.7 t -158.46 103.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 176.016 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.729 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.18 128.75 43.37 Favored 'General case' 0 N--CA 1.398 -3.027 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.677 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -82.15 153.36 26.06 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 124.144 0.902 . . . . 0.0 110.642 -174.94 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.538 HG13 ' H ' ' A' ' 33' ' ' GLY . 78.4 t -81.21 134.91 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 C-N-CA 124.203 1.001 . . . . 0.0 111.668 -172.694 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 61.5 m -122.97 123.76 41.65 Favored 'General case' 0 N--CA 1.414 -2.245 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.045 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 31' ' ' VAL . 31.8 pt -94.43 160.39 2.72 Favored 'Isoleucine or valine' 0 C--O 1.25 1.106 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.407 ' OE1' ' HA ' ' A' ' 84' ' ' LEU . 49.8 mt-10 -142.99 159.28 42.53 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-O 122.159 0.98 . . . . 0.0 113.239 -171.494 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.22 169.4 17.39 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 172.007 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.652 ' HB3' ' O ' ' A' ' 27' ' ' GLY . 10.9 p -57.34 91.94 0.01 OUTLIER 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -173.764 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.56 -38.16 2.07 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.225 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.063 173.014 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.405 ' O ' HG22 ' A' ' 104' ' ' ILE . 25.3 mm -72.37 25.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 C-N-CA 126.919 2.088 . . . . 0.0 111.936 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 16.8 p -66.95 149.65 50.32 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 121.667 -0.646 . . . . 0.0 110.831 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . 0.308 0.9 OUTLIER -80.95 86.3 6.11 Favored 'General case' 0 N--CA 1.388 -3.536 0 CA-C-O 124.647 2.165 . . . . 0.0 111.505 178.573 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.7 m -149.85 85.95 1.43 Allowed 'General case' 2 N--CA 1.367 -4.613 1 N-CA-C 100.061 -4.051 . . . . 0.0 100.061 168.457 . . . . . . . . 3 2 . 1 . 013 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -125.31 -155.99 9.21 Favored Glycine 0 C--N 1.26 -3.674 0 CA-C-N 113.46 -1.7 . . . . 0.0 109.444 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -92.2 -44.54 8.72 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 111' ' ' SER . 23.1 m80 -118.64 -50.77 2.4 Favored 'General case' 0 N--CA 1.434 -1.234 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.444 175.018 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 110' ' ' HIS . 33.2 t 165.45 168.03 0.02 OUTLIER 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 177.182 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.522 ' O ' HG22 ' A' ' 149' ' ' ILE . 50.1 mm -71.72 -45.98 63.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.483 ' H ' HD12 ' A' ' 113' ' ' ILE . 3.5 mp -71.71 121.25 21.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.726 -0.609 . . . . 0.0 111.764 -172.663 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.83 -0.05 25.81 Favored Glycine 0 CA--C 1.478 -2.225 0 C-N-CA 120.403 -0.903 . . . . 0.0 110.873 170.1 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.612 ' HA ' ' HA3' ' A' ' 51' ' ' GLY . 11.1 mmt180 -91.86 173.52 7.82 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.59 -178.708 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.625 ' O ' ' HB2' ' A' ' 48' ' ' HIS . 17.5 p -128.46 103.77 7.32 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-O 118.725 -0.655 . . . . 0.0 110.998 -173.301 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' A' ' 148' ' ' VAL . 0.7 OUTLIER -76.26 137.16 39.76 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 120.312 1.414 . . . . 0.0 111.573 -178.026 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.721 ' HA ' ' HB3' ' A' ' 146' ' ' CYS . 11.5 p -92.87 125.25 45.46 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.436 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 176.11 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.8 p -148.55 130.88 6.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 C-N-CA 118.961 -1.095 . . . . 0.0 113.115 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 16.3 t-80 -154.93 151.33 28.41 Favored 'General case' 0 N--CA 1.416 -2.169 0 N-CA-C 102.348 -3.204 . . . . 0.0 102.348 163.168 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 41' ' ' GLY . 2.9 mp0 -70.3 99.52 1.56 Allowed 'General case' 0 C--N 1.269 -2.896 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 174.12 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -168.31 173.83 7.46 Favored 'General case' 0 C--O 1.199 -1.59 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -171.834 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.01 120.48 26.17 Favored 'General case' 0 C--N 1.256 -3.471 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 177.733 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.613 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -167.13 136.77 2.87 Favored 'General case' 0 N--CA 1.509 2.512 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.012 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -149.89 150.9 32.59 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.823 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -90.95 -39.31 12.33 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.11 -33.91 5.84 Favored Glycine 0 C--N 1.3 -1.465 0 C-N-CA 119.753 -1.213 . . . . 0.0 111.65 -175.375 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 49.1 tptt -118.43 41.34 2.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -176.964 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.91 -7.24 69.8 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 115.463 -0.79 . . . . 0.0 114.736 -176.288 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 144.11 -122.42 1.81 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.492 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.452 ' O ' HG22 ' A' ' 135' ' ' THR . 88.9 m-20 -99.65 -174.54 2.74 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -177.583 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -47.09 -52.65 14.69 Favored 'General case' 0 N--CA 1.484 1.228 0 O-C-N 123.564 0.54 . . . . 0.0 111.264 -176.699 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -77.71 -40.85 39.9 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.7 p -75.53 -27.17 58.59 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -175.708 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 131' ' ' ASN . 13.9 t -76.12 -33.25 59.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 176.237 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -74.08 -32.54 63.3 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.727 -179.321 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 86.4 m -79.22 -31.05 43.55 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.304 174.788 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.73 60.94 8.1 Favored Glycine 0 CA--C 1.484 -1.884 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -36.31 105.62 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 125.733 1.49 . . . . 0.0 111.876 -174.694 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 124' ' ' ASP . . . -101.8 169.93 8.48 Favored 'General case' 0 N--CA 1.429 -1.516 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.92 -169.838 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' A' ' 143' ' ' ARG . . . -63.96 154.02 47.12 Favored Glycine 0 N--CA 1.406 -3.303 0 N-CA-C 106.481 -2.648 . . . . 0.0 106.481 169.921 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -57.01 8.81 0.01 OUTLIER 'General case' 0 C--N 1.262 -3.223 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.462 ' HG2' ' HB2' ' A' ' 57' ' ' CYS . 0.2 OUTLIER 65.67 19.17 11.39 Favored 'General case' 0 CA--C 1.467 -2.224 0 C-N-CA 125.277 1.431 . . . . 0.0 107.959 177.675 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 53.0 mt -70.94 -33.24 70.3 Favored 'General case' 0 CA--C 1.445 -3.072 0 CA-C-N 113.91 -1.495 . . . . 0.0 107.668 -176.723 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.432 ' O ' ' HB3' ' A' ' 146' ' ' CYS . . . -121.98 89.74 3.17 Favored 'General case' 1 N--CA 1.35 -5.458 0 CA-C-N 113.557 -1.656 . . . . 0.0 108.158 175.38 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 118' ' ' VAL . 19.9 p -171.91 127.94 0.61 Allowed 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 113.812 1.042 . . . . 0.0 113.812 169.95 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.614 ' HA2' ' HB ' ' A' ' 116' ' ' THR . . . -178.51 77.93 0.07 OUTLIER Glycine 0 N--CA 1.402 -3.62 0 CA-C-O 118.638 -1.09 . . . . 0.0 110.656 159.009 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 6' ' ' ALA . 13.1 p -172.58 96.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.184 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 169.727 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.559 ' HB ' ' HB2' ' A' ' 115' ' ' ARG . 12.2 mm -124.46 102.68 11.28 Favored 'Isoleucine or valine' 1 C--N 1.234 -4.445 0 N-CA-C 104.692 -2.336 . . . . 0.0 104.692 167.364 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -165.59 146.56 11.25 Favored Glycine 2 CA--C 1.444 -4.394 0 C-N-CA 115.941 -3.028 . . . . 0.0 112.678 175.458 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.545 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 0.0 OUTLIER -95.26 105.56 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.568 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 171.98 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.92 99.61 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.441 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.245 0.863 0 N-CA-C 105.466 -2.049 . . . . 0.0 105.466 178.07 . . . . . . . . 0 0 . 1 . 013 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.207 -1.145 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 m -100.48 -27.63 13.33 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -171.536 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -136.66 148.62 47.51 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.169 -173.255 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -142.35 143.19 32.63 Favored 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 92.1 t -124.26 129.13 74.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.406 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -120.11 145.61 46.74 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.939 -177.22 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 56.5 t -127.38 126.07 66.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 85.3 mt -112.1 133.08 54.47 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -142.6 133.54 25.68 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.68 -170.89 21.59 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 119.362 -1.399 . . . . 0.0 112.553 -177.312 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -73.31 -46.1 51.49 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -101.58 96.29 1.47 Allowed Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 171.089 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -71.53 127.09 12.79 Favored 'Trans proline' 0 N--CA 1.434 -1.986 0 C-N-CA 121.797 1.665 . . . . 0.0 113.968 -168.48 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.91 148.28 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.286 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 173.309 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -123.94 118.64 27.51 Favored 'General case' 0 C--N 1.259 -3.355 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -177.178 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -167.26 146.48 10.77 Favored Glycine 0 N--CA 1.409 -3.101 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.891 -178.03 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.2 pt -130.66 118.24 41.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.742 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.1 OUTLIER -114.88 133.04 62.27 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.103 -176.708 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 24.0 m-80 -109.46 119.73 40.33 Favored 'General case' 0 CA--C 1.51 -0.589 0 C-N-CA 123.309 0.644 . . . . 0.0 109.592 -173.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.7 m-85 -120.76 137.41 54.52 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.779 0.323 . . . . 0.0 110.617 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 9.9 pt-20 -107.89 134.0 51.45 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.418 175.809 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.571 ' HA ' ' O ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -126.91 112.45 15.32 Favored 'General case' 0 N--CA 1.413 -2.307 0 C-N-CA 123.777 0.831 . . . . 0.0 109.459 178.309 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.8 tttm -138.12 149.07 45.58 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.34 -173.032 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.609 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.1 mp0 -50.51 -44.29 56.05 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 125.728 1.611 . . . . 0.0 110.332 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.6 m -51.72 -45.24 63.51 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.651 1.18 . . . . 0.0 111.913 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.432 ' HA ' HG23 ' A' ' 104' ' ' ILE . 9.8 t30 57.62 87.59 0.06 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 124.294 0.996 . . . . 0.0 111.917 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.528 ' H ' HD13 ' A' ' 104' ' ' ILE . . . -132.47 -151.6 6.79 Favored Glycine 0 CA--C 1.492 -1.361 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.19 -177.093 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_exo -67.6 124.18 11.67 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.215 1.943 . . . . 0.0 108.01 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.682 HG11 HG12 ' A' ' 103' ' ' VAL . 13.4 p -80.01 132.69 31.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 CA-C-O 121.23 0.538 . . . . 0.0 110.5 -176.632 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -93.98 99.21 11.58 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 169.734 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 5.9 p -123.44 130.54 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.001 0 CA-C-N 115.311 -0.858 . . . . 0.0 108.711 -175.015 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -136.44 125.49 24.42 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.498 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.742 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -164.25 140.17 6.29 Favored Glycine 0 N--CA 1.41 -3.045 0 C-N-CA 119.724 -1.226 . . . . 0.0 111.933 172.745 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 16.9 m -116.04 135.46 53.93 Favored 'General case' 0 N--CA 1.404 -2.77 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.531 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 12.1 tt -125.13 136.94 59.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 118.54 0.609 . . . . 0.0 109.976 179.183 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 91.7 mttt -116.92 131.84 56.85 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.128 -2.175 . . . . 0.0 105.128 -177.839 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.592 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -155.0 175.8 32.91 Favored Glycine 0 C--N 1.269 -3.169 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -166.751 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.62 171.0 8.23 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 175.274 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.0 t -69.47 107.18 3.25 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.809 -175.153 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.571 ' OE2' ' HG2' ' A' ' 122' ' ' LYS . 22.2 tt0 -177.08 171.13 2.14 Favored 'General case' 0 N--CA 1.419 -2.011 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 171.473 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 41' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 170.78 104.83 0.18 Allowed Glycine 1 C--N 1.251 -4.144 0 C-N-CA 119.02 -1.562 . . . . 0.0 111.843 169.543 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' N ' ' A' ' 123' ' ' ALA . 6.8 mp -110.78 -86.89 0.53 Allowed 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.062 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.657 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.4 t-80 -175.15 122.3 0.22 Allowed 'General case' 0 C--N 1.355 0.823 0 C-N-CA 118.364 -1.335 . . . . 0.0 114.35 -173.388 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.456 ' H ' ' H ' ' A' ' 87' ' ' VAL . . . 102.99 137.94 9.74 Favored Glycine 0 C--N 1.3 -1.432 0 N-CA-C 117.502 1.761 . . . . 0.0 117.502 164.635 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -96.18 166.73 11.6 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 124.028 0.931 . . . . 0.0 109.359 170.179 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.715 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . 6.1 m80 -171.83 90.44 0.12 Allowed 'General case' 0 CA--C 1.482 -1.661 0 C-N-CA 125.298 1.439 . . . . 0.0 110.004 169.414 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.627 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 2.6 p -69.36 162.7 3.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 168.942 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.49 ' CE1' ' HD2' ' A' ' 62' ' ' PRO 0.278 0.0 OUTLIER -148.85 171.49 16.21 Favored 'General case' 0 N--CA 1.419 -1.979 0 C-N-CA 116.562 -2.055 . . . . 0.0 109.482 170.187 . . . . . . . . 4 4 . 1 . 014 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.481 ' HB3' ' CG2' ' A' ' 81' ' ' VAL . 1.9 pm0 -69.57 166.35 19.16 Favored 'General case' 0 C--N 1.261 -3.273 0 N-CA-C 116.072 1.879 . . . . 0.0 116.072 -171.043 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 59' ' ' SER . 4.0 t80 72.77 33.26 1.32 Allowed 'General case' 0 N--CA 1.439 -1.023 0 C-N-CA 126.321 1.848 . . . . 0.0 107.243 172.022 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.422 ' HA2' ' HB2' ' A' ' 60' ' ' ALA . . . -57.56 154.84 20.49 Favored Glycine 0 C--N 1.345 1.048 0 CA-C-N 112.42 -2.173 . . . . 0.0 113.063 -178.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.537 ' OD1' ' HA ' ' A' ' 57' ' ' CYS . 3.8 p30 -144.8 -85.75 0.13 Allowed 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -172.901 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.55 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 52.7 t30 -98.31 148.77 23.31 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.288 0.566 . . . . 0.0 112.43 -173.392 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.577 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 6.9 m -82.3 -2.93 54.26 Favored 'General case' 0 CA--C 1.56 1.349 0 C-N-CA 124.323 1.049 . . . . 0.0 111.652 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.99 17.06 7.92 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 121.097 0.475 . . . . 0.0 111.02 -177.828 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.55 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 143.94 117.16 1.16 Allowed Glycine 0 CA--C 1.484 -1.864 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -177.374 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.587 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -97.53 113.69 25.44 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -175.949 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.0 p -80.0 -45.42 18.44 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.576 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . 49.8 m -79.37 -29.0 41.94 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 123.445 0.698 . . . . 0.0 111.216 -174.724 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.71 -5.26 47.28 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 123.981 0.912 . . . . 0.0 111.19 172.443 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.22 52.1 0.91 Allowed Glycine 0 CA--C 1.559 2.801 0 C-N-CA 117.177 -2.439 . . . . 0.0 116.247 176.369 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.529 ' HD3' ' O ' ' A' ' 59' ' ' SER . 86.9 Cg_endo -96.37 2.93 1.99 Allowed 'Trans proline' 0 C--N 1.397 3.127 0 CA-C-N 121.821 2.81 . . . . 0.0 107.322 161.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 68.3 m-70 75.22 -47.75 0.61 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 125.541 1.536 . . . . 0.0 113.623 173.772 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -69.27 116.12 9.34 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -170.655 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.584 ' HB2' HG13 ' A' ' 81' ' ' VAL . 5.5 p30 -116.16 96.49 47.49 Favored Pre-proline 0 CA--C 1.559 1.309 0 C-N-CA 125.061 1.344 . . . . 0.0 110.089 176.82 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.95 -18.7 10.06 Favored 'Trans proline' 0 CA--C 1.552 1.384 0 C-N-CA 123.119 2.546 . . . . 0.0 117.823 -169.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.421 ' HB3' ' HB2' ' A' ' 79' ' ' ARG . 84.0 mt -88.09 -5.32 58.52 Favored 'General case' 0 CA--C 1.484 -1.567 0 O-C-N 120.817 -1.177 . . . . 0.0 110.906 -172.719 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.433 ' C ' ' H ' ' A' ' 70' ' ' LYS . 17.9 m -77.92 58.05 1.85 Allowed 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 104.533 -2.395 . . . . 0.0 104.533 167.039 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.526 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 2.1 tmm_? -92.59 17.56 9.98 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -169.329 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.503 ' HB2' ' CB ' ' A' ' 78' ' ' GLU . 11.9 mptt -140.03 63.97 1.46 Allowed 'General case' 0 N--CA 1.411 -2.402 0 CA-C-N 112.705 -2.043 . . . . 0.0 109.411 175.135 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 71' ' ' HIS . . . . . 0.446 ' O ' ' HB3' ' A' ' 126' ' ' LEU . 20.2 t60 65.38 -37.57 0.24 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 125.313 1.445 . . . . 0.0 113.284 -178.984 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.13 20.68 62.34 Favored Glycine 0 N--CA 1.414 -2.816 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -175.517 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 77' ' ' GLU . . . -90.31 175.53 41.14 Favored Glycine 0 C--O 1.202 -1.897 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.863 -177.107 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.515 ' C ' ' H ' ' A' ' 76' ' ' ASP . 2.8 Cg_exo -72.07 2.34 4.99 Favored 'Trans proline' 0 N--CA 1.501 1.926 1 C-N-CA 125.717 4.278 . . . . 0.0 111.302 -170.562 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.414 ' H ' ' C ' ' A' ' 73' ' ' GLY . 60.9 tttm -76.59 27.59 0.13 Allowed 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 127.402 2.281 . . . . 0.0 109.089 178.669 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 74' ' ' PRO 0.303 1.2 p30 77.18 10.32 2.51 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 128.453 2.701 . . . . 0.0 115.665 173.597 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.604 ' HG3' ' O ' ' A' ' 73' ' ' GLY . 1.7 mp0 33.19 108.19 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 127.639 2.375 . . . . 0.0 114.089 170.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 69' ' ' ARG . 43.1 tt0 -34.73 -61.66 0.39 Allowed 'General case' 0 N--CA 1.507 2.392 0 O-C-N 123.914 0.759 . . . . 0.0 112.133 -177.747 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.421 ' HB2' ' HB3' ' A' ' 67' ' ' LEU . 75.0 mtt85 -136.62 63.64 1.57 Allowed 'General case' 0 C--N 1.286 -2.177 0 C-N-CA 118.834 -1.146 . . . . 0.0 111.056 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.6 ' NE2' ' HB2' ' A' ' 105' ' ' SER . 0.3 OUTLIER -38.86 94.26 0.01 OUTLIER 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 122.729 1.252 . . . . 0.0 113.375 171.455 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.584 HG13 ' HB2' ' A' ' 65' ' ' ASN . 3.3 p -80.97 -10.73 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.616 0 CA-C-N 112.224 -2.262 . . . . 0.0 105.379 169.496 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.539 ' O ' ' HB2' ' A' ' 80' ' ' HIS . . . -123.6 -132.25 3.91 Favored Glycine 1 N--CA 1.369 -5.825 0 CA-C-N 111.942 -2.39 . . . . 0.0 108.27 169.517 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.554 ' OD1' HG12 ' A' ' 47' ' ' VAL . 2.0 p-10 -164.4 165.9 21.12 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 177.992 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.454 ' CD1' ' HA2' ' A' ' 73' ' ' GLY . 1.6 tt -144.46 87.76 1.89 Allowed 'General case' 0 N--CA 1.423 -1.823 0 C-N-CA 118.342 -1.343 . . . . 0.0 109.28 161.483 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.02 136.51 13.52 Favored Glycine 0 N--CA 1.419 -2.487 0 N-CA-C 104.853 -3.299 . . . . 0.0 104.853 165.665 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.415 ' HA ' ' HA2' ' A' ' 44' ' ' GLY 0.359 23.2 p30 -92.11 128.69 38.05 Favored 'General case' 0 N--CA 1.426 -1.645 0 C-N-CA 115.171 -2.611 . . . . 0.0 113.318 -173.189 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.657 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 92.6 t -110.64 138.7 37.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.186 -174.945 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.5 p -140.15 95.09 2.83 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 -179.07 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -86.14 137.03 32.97 Favored 'General case' 0 N--CA 1.415 -2.217 0 CA-C-O 121.406 0.622 . . . . 0.0 109.945 -176.966 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 92' ' ' ASP . 30.8 t70 -75.23 154.62 37.44 Favored 'General case' 1 C--N 1.242 -4.103 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 174.516 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -53.07 23.07 0.0 OUTLIER 'General case' 0 CA--C 1.579 2.094 0 N-CA-C 115.839 1.792 . . . . 0.0 115.839 174.488 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 90' ' ' ASP . 1.5 m-20 -133.89 8.63 3.82 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 124.945 1.298 . . . . 0.0 108.787 171.674 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.635 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 66.8 80.08 0.2 Allowed Glycine 0 N--CA 1.44 -1.046 0 CA-C-N 114.998 -1.001 . . . . 0.0 112.564 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.5 p -161.71 113.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 34' ' ' SER . . . -136.8 144.63 43.81 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.807 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -119.58 115.14 23.38 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 175.381 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.434 HG11 ' CE2' ' A' ' 45' ' ' PHE . 4.3 p -102.92 103.41 15.04 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.352 0 CA-C-O 122.173 0.987 . . . . 0.0 111.714 -178.472 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.2 m -139.65 100.18 3.9 Favored 'General case' 0 N--CA 1.421 -1.894 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 172.736 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.9 mm -135.3 128.45 48.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -176.471 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 43.0 mt-10 -104.5 106.19 16.59 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.155 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -160.51 168.66 24.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 104.369 -2.456 . . . . 0.0 104.369 170.722 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.504 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 24.8 m -80.76 79.18 7.45 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 115.726 1.75 . . . . 0.0 115.726 -169.344 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.682 HG12 HG11 ' A' ' 29' ' ' VAL . 12.4 p -92.51 -11.62 9.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 169.476 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 22' ' ' GLN . 15.9 tt -57.87 19.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.102 0 C-N-CA 130.201 3.4 . . . . 0.0 114.235 -176.306 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.6 ' HB2' ' NE2' ' A' ' 80' ' ' HIS . 16.4 m -97.85 170.91 8.64 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 103.627 -2.731 . . . . 0.0 103.627 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.428 HD12 ' O ' ' A' ' 106' ' ' LEU . 2.6 pp -68.14 119.13 12.23 Favored 'General case' 0 N--CA 1.414 -2.24 0 C-N-CA 117.689 -1.605 . . . . 0.0 109.467 176.274 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 m -68.95 89.75 0.42 Allowed 'General case' 0 N--CA 1.414 -2.234 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.303 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 155.27 155.69 7.44 Favored Glycine 0 N--CA 1.401 -3.64 0 CA-C-N 114.155 -1.384 . . . . 0.0 110.501 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.466 ' HB3' HG23 ' A' ' 81' ' ' VAL . 16.9 p-10 -69.66 -38.91 77.29 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 174.696 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -107.37 -48.07 3.52 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.266 -175.946 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.56 ' O ' ' HD2' ' A' ' 115' ' ' ARG . 15.3 m -163.04 159.92 23.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.61 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.701 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -72.79 -46.6 52.72 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.894 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.077 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 tp -67.56 127.15 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 176.766 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.98 11.93 58.29 Favored Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 119.611 -1.28 . . . . 0.0 110.768 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.56 ' HD2' ' O ' ' A' ' 111' ' ' SER . 0.0 OUTLIER -114.67 121.55 43.73 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.237 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.809 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 14.9 p -98.45 135.56 39.83 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-O 121.856 0.836 . . . . 0.0 111.638 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 56.2 tp -74.66 102.87 4.74 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 113.937 -1.483 . . . . 0.0 111.485 -174.442 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 142' ' ' SER . 12.6 m -93.21 96.36 6.12 Favored 'Isoleucine or valine' 1 C--O 1.33 5.293 0 C-N-CA 116.314 -2.154 . . . . 0.0 112.821 175.035 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.1 p -150.5 171.57 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 113.46 -1.7 . . . . 0.0 107.992 -176.836 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.465 ' HB2' ' HB3' ' A' ' 144' ' ' LEU . 82.2 t60 -152.04 170.76 19.12 Favored 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 168.419 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -69.77 88.37 0.54 Allowed 'General case' 0 CA--C 1.551 0.983 0 CA-C-N 123.016 2.643 . . . . 0.0 109.045 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.571 ' HG2' ' OE2' ' A' ' 40' ' ' GLU . 65.8 mttm -166.75 173.31 9.68 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 125.771 1.628 . . . . 0.0 108.318 -168.226 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.616 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -82.68 114.52 21.1 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 172.149 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.715 ' OD1' ' HB2' ' A' ' 46' ' ' HIS . 11.9 t70 -124.31 76.58 1.49 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -176.717 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -114.43 158.59 21.35 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.155 0.502 . . . . 0.0 110.548 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 135' ' ' THR . 3.2 tm? -87.85 -56.35 3.38 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.467 -1.242 . . . . 0.0 108.007 -179.381 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 127' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 71' ' ' HIS . . . -68.26 -40.63 87.44 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.725 -177.83 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -105.43 50.74 0.77 Allowed 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.25 76.73 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.588 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -67.29 0.53 Allowed Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.379 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' CB ' ' A' ' 134' ' ' SER . 4.1 m-20 -105.99 176.81 5.04 Favored 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 119.052 -0.499 . . . . 0.0 109.945 -179.121 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -56.18 -44.07 79.02 Favored 'General case' 0 CA--C 1.567 1.634 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 176.203 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -71.85 -33.39 68.4 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.461 ' CB ' ' H ' ' A' ' 131' ' ' ASN . 2.3 m -68.1 -19.97 64.89 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.969 0.414 . . . . 0.0 110.887 -175.733 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.472 ' HA ' ' O ' ' A' ' 126' ' ' LEU . 8.8 m -74.0 -21.3 60.04 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 121.511 0.672 . . . . 0.0 109.823 178.563 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -83.24 -51.18 7.69 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.3 p -69.01 -50.59 47.46 Favored 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.965 -177.504 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 138' ' ' GLY . . . . . 0.438 ' CA ' ' HA ' ' A' ' 126' ' ' LEU . . . 67.16 92.45 0.04 OUTLIER Glycine 0 N--CA 1.418 -2.532 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -174.508 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -31.77 136.63 0.06 Allowed 'General case' 1 C--O 1.322 4.892 0 N-CA-C 118.813 2.894 . . . . 0.0 118.813 -167.037 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -126.51 129.01 47.79 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 112.925 -1.943 . . . . 0.0 109.246 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -115.23 75.33 0.25 Allowed Glycine 0 N--CA 1.416 -2.665 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 176.428 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.568 ' HB2' ' O ' ' A' ' 57' ' ' CYS . 77.5 p -58.92 -26.82 64.69 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 123.848 0.859 . . . . 0.0 112.306 -175.611 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -117.52 -0.89 11.79 Favored 'General case' 0 N--CA 1.427 -1.617 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.803 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.465 ' HB3' ' HB2' ' A' ' 120' ' ' HIS . 3.9 mm? -79.05 -34.84 43.45 Favored 'General case' 0 C--N 1.282 -2.367 0 C-N-CA 117.949 -1.5 . . . . 0.0 110.393 -176.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -173.96 89.45 0.07 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 177.62 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.809 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 44.6 t -139.07 133.11 31.15 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 118.159 -1.416 . . . . 0.0 110.34 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.577 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -161.18 166.02 35.59 Favored Glycine 0 N--CA 1.398 -3.897 0 N-CA-C 107.967 -2.053 . . . . 0.0 107.967 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.92 122.37 20.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.086 0.47 . . . . 0.0 110.339 -178.727 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.413 HD11 ' CD1' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -116.26 106.5 20.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.233 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.447 ' HA2' ' HB ' ' A' ' 112' ' ' ILE . . . -172.31 -179.29 43.08 Favored Glycine 1 N--CA 1.392 -4.268 0 N-CA-C 110.031 -1.227 . . . . 0.0 110.031 -179.125 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.483 ' H ' HG12 ' A' ' 112' ' ' ILE . 11.3 tt -54.87 114.47 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 121.751 0.786 . . . . 0.0 112.475 -179.041 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.57 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -149.93 154.9 39.06 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 176.655 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 . . . . . 0 C--N 1.29 -1.995 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.819 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.21 -0.987 0 CA-C-O 120.283 0.087 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 9.3 m -76.26 -27.92 56.88 Favored 'General case' 0 CA--C 1.562 1.434 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -175.932 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.463 ' O ' ' HB ' ' A' ' 151' ' ' ILE . 20.2 ptpt -152.63 167.55 28.52 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -153.02 152.5 31.45 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 175.439 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.3 t -134.41 138.37 49.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -109.44 134.61 51.65 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -175.443 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 7' ' ' VAL . . . . . 0.551 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 46.9 t -134.31 102.55 4.27 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.366 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 175.654 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.496 ' H ' HD23 ' A' ' 8' ' ' LEU . 1.5 pt? -117.74 132.49 56.46 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -178.015 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -138.0 138.59 39.03 Favored 'General case' 0 C--O 1.248 0.98 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.76 -158.76 8.87 Favored Glycine 0 N--CA 1.435 -1.386 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.045 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -63.63 -50.97 67.25 Favored 'General case' 0 CA--C 1.511 -0.554 0 O-C-N 124.537 0.787 . . . . 0.0 109.167 177.218 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -88.65 154.95 25.32 Favored Glycine 0 N--CA 1.44 -1.1 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 175.234 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -86.23 124.35 2.43 Favored 'Trans proline' 0 N--CA 1.414 -3.149 0 CA-C-N 120.342 2.071 . . . . 0.0 110.072 -176.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 13.8 m -131.66 146.78 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.966 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 -179.372 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 52.0 tt0 -159.49 123.29 3.77 Favored 'General case' 0 C--N 1.251 -3.707 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.491 ' HA3' HG12 ' A' ' 35' ' ' ILE . . . -153.11 157.95 27.64 Favored Glycine 0 N--CA 1.396 -3.978 0 C-N-CA 119.945 -1.122 . . . . 0.0 111.068 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 25.2 pt -123.97 102.43 11.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.593 HG13 ' HA3' ' A' ' 33' ' ' GLY . 1.8 mp -107.53 128.48 62.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.652 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 30.4 p-10 -115.91 125.74 52.98 Favored 'General case' 0 C--N 1.35 0.597 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.656 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 69.0 t80 -126.03 130.1 50.48 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -171.007 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 14.3 pt-20 -136.5 102.59 4.99 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-O 121.317 0.58 . . . . 0.0 110.888 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.457 ' HB3' ' CZ ' ' A' ' 20' ' ' PHE . 9.4 tt0 -151.21 114.42 4.79 Favored 'General case' 0 N--CA 1.414 -2.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.67 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -174.83 -74.17 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.853 175.424 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -90.31 -8.78 50.0 Favored 'General case' 0 N--CA 1.431 -1.376 0 CA-C-N 114.746 -1.115 . . . . 0.0 109.652 -177.726 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -52.83 -50.38 63.83 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 172.937 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 32.7 t-20 49.58 64.1 1.9 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.066 177.027 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.23 -164.47 36.66 Favored Glycine 0 N--CA 1.419 -2.499 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 -174.986 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.39 124.83 17.04 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 C-N-CA 122.18 1.92 . . . . 0.0 111.054 -178.156 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.437 ' CG2' ' HB2' ' A' ' 22' ' ' GLN . 3.0 p -74.27 130.34 36.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.789 -177.667 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.46 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 63.4 mttp -92.54 99.28 12.03 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.792 175.561 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.573 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 3.2 p -138.17 141.77 37.26 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.668 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -178.217 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 58.0 t90 -153.29 139.24 18.14 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -156.72 140.33 7.11 Favored Glycine 0 N--CA 1.413 -2.896 0 C-N-CA 118.757 -1.687 . . . . 0.0 113.099 176.573 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.5 p -114.23 134.27 55.04 Favored 'General case' 0 N--CA 1.409 -2.52 0 C-N-CA 124.379 1.071 . . . . 0.0 108.231 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.62 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 78.4 mt -127.6 140.23 49.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-O 121.132 0.492 . . . . 0.0 110.0 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 94.6 mttt -110.69 107.08 16.52 Favored 'General case' 0 N--CA 1.4 -2.968 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 174.683 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.03 175.35 22.72 Favored Glycine 0 C--N 1.292 -1.899 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -170.792 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 38' ' ' LEU . . . . . 0.596 ' HA ' ' OD1' ' A' ' 92' ' ' ASP . 2.3 pp -69.0 169.69 11.26 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 117.963 0.882 . . . . 0.0 111.42 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.556 ' HB ' ' HB2' ' A' ' 92' ' ' ASP . 2.2 t -70.2 106.24 3.23 Favored 'General case' 0 C--O 1.244 0.788 0 C-N-CA 119.475 -0.89 . . . . 0.0 111.8 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.43 ' O ' ' HB2' ' A' ' 121' ' ' GLU . 7.4 tp10 -175.06 111.88 0.13 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 125.437 1.495 . . . . 0.0 107.434 170.929 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.76 75.47 0.42 Allowed Glycine 0 C--N 1.264 -3.427 0 C-N-CA 118.005 -2.045 . . . . 0.0 113.72 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.85 136.66 43.94 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 92.8 m-70 -55.59 121.98 10.31 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 124.64 1.176 . . . . 0.0 110.561 -172.68 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.69 122.7 0.86 Allowed Glycine 1 N--CA 1.381 -4.994 0 C-N-CA 119.718 -1.23 . . . . 0.0 113.3 177.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -68.81 142.69 54.81 Favored 'General case' 0 C--N 1.261 -3.262 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 162.624 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.637 ' CB ' ' HA ' ' A' ' 119' ' ' VAL . 21.2 m-70 -126.94 91.29 3.31 Favored 'General case' 0 N--CA 1.421 -1.882 0 CA-C-N 121.222 1.828 . . . . 0.0 106.715 -173.712 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 81' ' ' VAL . 7.3 m -125.16 162.75 27.07 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -171.576 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.3 m-70 -170.81 119.46 0.53 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.407 3.083 . . . . 0.0 106.87 170.456 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.558 ' HB2' ' HA2' ' A' ' 108' ' ' GLY . 0.2 OUTLIER -102.59 84.11 2.38 Favored 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 117.87 -1.532 . . . . 0.0 112.957 -176.361 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.541 ' CZ ' ' HA ' ' A' ' 60' ' ' ALA . 0.6 OUTLIER 167.34 113.49 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.845 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA3' ' H ' ' A' ' 116' ' ' THR . . . -147.57 -154.35 6.21 Favored Glycine 0 CA--C 1.485 -1.802 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.846 178.182 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -173.96 -68.17 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.498 0 O-C-N 124.287 0.639 . . . . 0.0 110.24 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.523 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.4 t-20 -97.64 130.85 44.62 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.674 -174.53 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.1 t -84.06 -6.28 59.38 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -177.475 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.73 -25.46 13.84 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 120.95 0.405 . . . . 0.0 110.337 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.523 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -147.44 118.83 1.05 Allowed Glycine 0 N--CA 1.429 -1.807 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 -178.743 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.593 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 19.9 p -98.2 87.66 3.98 Favored 'General case' 0 C--N 1.276 -2.627 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.163 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.0 m -79.84 -39.72 30.03 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.296 177.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -53.55 -47.09 70.33 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.59 1.156 . . . . 0.0 111.794 -176.072 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.541 ' HA ' ' CZ ' ' A' ' 50' ' ' PHE . . . -76.87 -9.05 58.42 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -176.226 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -39.79 -64.31 1.08 Allowed Glycine 0 N--CA 1.479 1.555 0 C-N-CA 124.576 1.084 . . . . 0.0 115.363 -177.392 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.77 1.32 5.22 Favored 'Trans proline' 0 CA--C 1.544 0.983 0 C-N-CA 122.838 2.359 . . . . 0.0 113.399 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.296 9.1 p80 50.39 37.04 14.46 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -87.81 89.89 8.17 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 122.186 0.993 . . . . 0.0 109.644 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.467 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.4 OUTLIER -113.73 97.42 44.23 Favored Pre-proline 0 C--N 1.284 -2.278 0 CA-C-N 113.723 -1.58 . . . . 0.0 110.496 -177.954 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.411 ' O ' ' HB2' ' A' ' 69' ' ' ARG . 50.0 Cg_endo -84.73 -12.98 7.15 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.13 2.553 . . . . 0.0 115.995 -173.296 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.622 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 56.5 tp -85.43 -19.8 30.76 Favored 'General case' 1 CA--C 1.421 -4.012 0 CA-C-O 121.589 0.709 . . . . 0.0 109.19 -179.551 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.484 ' C ' ' H ' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -76.99 28.26 0.14 Allowed 'General case' 0 N--CA 1.384 -3.753 0 C-N-CA 127.741 2.416 . . . . 0.0 108.911 178.086 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.565 ' H ' ' C ' ' A' ' 67' ' ' LEU . 63.6 ttt180 -73.42 43.32 0.13 Allowed 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 128.558 2.743 . . . . 0.0 110.39 -173.763 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.575 ' CB ' ' HB2' ' A' ' 79' ' ' ARG . 22.6 ttmm -139.32 -18.4 0.99 Allowed 'General case' 0 C--N 1.245 -3.957 0 CA-C-N 113.894 -1.503 . . . . 0.0 108.511 166.687 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 70.33 19.31 6.52 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.105 1.762 . . . . 0.0 111.325 177.64 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.18 137.5 8.78 Favored Glycine 0 N--CA 1.426 -1.999 0 C-N-CA 120.433 -0.889 . . . . 0.0 114.595 176.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.36 162.46 28.64 Favored Glycine 0 N--CA 1.425 -2.07 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 175.559 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -73.24 -38.49 2.67 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 122.898 2.398 . . . . 0.0 112.751 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.743 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.9 OUTLIER -104.55 -25.45 12.75 Favored 'General case' 0 C--O 1.202 -1.422 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.253 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 49.91 -164.61 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 129.188 2.995 . . . . 0.0 115.045 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -144.58 -56.03 0.35 Allowed 'General case' 0 N--CA 1.427 -1.609 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.47 -169.144 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 105' ' ' SER . 47.6 mt-10 -172.57 -30.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 125.734 1.614 . . . . 0.0 107.67 -176.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.622 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 13.9 mmt180 -87.44 41.62 0.99 Allowed 'General case' 1 N--CA 1.364 -4.736 0 C-N-CA 125.095 1.358 . . . . 0.0 109.768 -171.422 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.692 ' HB3' ' O ' ' A' ' 82' ' ' GLY . 9.5 t-160 -95.08 13.32 25.59 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.545 -172.658 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.492 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 48.7 t 71.25 26.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 123.493 1.616 . . . . 0.0 107.229 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.692 ' O ' ' HB3' ' A' ' 80' ' ' HIS . . . 116.35 -146.45 18.84 Favored Glycine 0 N--CA 1.409 -3.149 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 -169.93 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -170.8 124.89 0.67 Allowed 'General case' 0 CA--C 1.474 -1.951 0 CA-C-N 118.753 1.276 . . . . 0.0 107.734 174.272 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.519 HD11 HG21 ' A' ' 18' ' ' ILE . 10.0 tp -161.39 171.77 17.66 Favored 'General case' 0 N--CA 1.408 -2.535 0 N-CA-C 104.762 -2.31 . . . . 0.0 104.762 -178.351 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.63 175.49 25.56 Favored Glycine 0 N--CA 1.404 -3.464 0 N-CA-C 109.079 -1.609 . . . . 0.0 109.079 -177.848 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.566 ' O ' ' HA ' ' A' ' 97' ' ' VAL . 14.3 t30 -77.32 138.66 39.49 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.754 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.779 HG22 ' HB1' ' A' ' 95' ' ' ALA . 13.9 p -150.74 127.12 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 178.177 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.673 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 24.7 p -141.1 122.34 14.81 Favored 'General case' 0 N--CA 1.418 -2.059 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.397 -167.356 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -109.05 103.7 12.76 Favored 'General case' 0 N--CA 1.41 -2.45 0 C-N-CA 117.031 -1.868 . . . . 0.0 106.538 173.892 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -93.99 -39.42 10.65 Favored 'General case' 0 CA--C 1.468 -2.199 0 CA-C-O 122.161 0.981 . . . . 0.0 109.955 -170.031 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.521 ' HE3' ' HA ' ' A' ' 91' ' ' LYS . 1.0 OUTLIER -85.59 5.85 29.87 Favored 'General case' 0 C--N 1.27 -2.875 0 CA-C-N 114.102 -1.408 . . . . 0.0 111.572 -177.652 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.596 ' OD1' ' HA ' ' A' ' 38' ' ' LEU . 13.4 t70 74.66 93.72 0.07 Allowed 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 123.438 0.695 . . . . 0.0 111.541 -175.815 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 106.17 13.22 23.67 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 116.269 1.267 . . . . 0.0 116.269 171.978 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 49.0 t -145.31 102.91 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.457 -2.626 0 N-CA-C 103.42 -2.807 . . . . 0.0 103.42 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.779 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -99.59 118.48 36.23 Favored 'General case' 0 N--CA 1.389 -3.477 0 C-N-CA 118.867 -1.133 . . . . 0.0 111.306 -177.794 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ASP . . . . . 0.47 ' O ' ' HA ' ' A' ' 87' ' ' VAL . 21.7 t70 -80.41 111.52 16.89 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.01 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.566 ' HA ' ' O ' ' A' ' 86' ' ' ASN . 13.3 p -87.7 122.92 39.98 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.455 0 CA-C-O 121.97 0.89 . . . . 0.0 109.881 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 67.9 m -122.25 105.87 10.61 Favored 'General case' 0 C--N 1.273 -2.723 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.162 176.415 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.566 HG21 HG13 ' A' ' 31' ' ' VAL . 2.2 pp -93.74 154.76 3.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 178.417 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -125.64 160.85 28.62 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.736 1.214 . . . . 0.0 109.109 -176.321 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -82.76 99.69 9.81 Favored 'General case' 0 C--N 1.283 -2.297 0 C-N-CA 119.781 -0.767 . . . . 0.0 109.386 -171.221 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.743 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 21.5 m -95.66 162.1 13.76 Favored 'General case' 0 N--CA 1.417 -2.078 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 173.133 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.4 HG23 ' H ' ' A' ' 104' ' ' ILE . 9.9 m -103.15 -64.51 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.535 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.4 ' H ' HG23 ' A' ' 103' ' ' VAL . 26.8 mt -133.5 25.54 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 -174.132 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 21.4 t -78.57 87.43 4.53 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 122.069 0.938 . . . . 0.0 110.28 -175.503 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.8 tp -70.74 120.84 16.93 Favored 'General case' 0 N--CA 1.408 -2.574 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -74.79 87.23 2.23 Favored 'General case' 0 N--CA 1.409 -2.475 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 176.066 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.558 ' HA2' ' HB2' ' A' ' 49' ' ' GLU . . . 155.39 136.08 2.13 Favored Glycine 0 N--CA 1.411 -2.974 0 C-N-CA 119.537 -1.316 . . . . 0.0 114.379 177.634 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -89.54 -52.06 5.21 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.846 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -74.49 -47.74 31.35 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.035 176.563 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 37.7 t 179.37 -170.59 0.13 Allowed 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.572 HG22 ' HA2' ' A' ' 150' ' ' GLY . 9.5 mt -89.62 -23.95 6.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 177.564 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 tt -68.97 132.46 33.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.922 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.71 -9.16 72.55 Favored Glycine 0 N--CA 1.419 -2.448 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.163 174.945 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.407 ' HD3' ' HA ' ' A' ' 50' ' ' PHE . 4.2 mmp_? -81.23 123.95 28.89 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -175.72 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.547 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 27.6 p -89.3 101.4 14.06 Favored 'General case' 0 N--CA 1.389 -3.481 0 C-N-CA 120.256 -0.578 . . . . 0.0 109.727 177.875 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.49 HD23 HG12 ' A' ' 47' ' ' VAL . 8.0 mp -85.23 120.38 26.66 Favored 'General case' 0 CA--C 1.473 -1.986 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 174.239 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.433 HG11 ' C ' ' A' ' 141' ' ' GLY . 2.4 t -92.54 115.64 31.89 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.251 0 C-N-CA 116.824 -1.951 . . . . 0.0 111.469 -172.452 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.664 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 42.1 t -125.0 129.38 73.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 127.729 2.412 . . . . 0.0 110.587 -166.388 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.509 ' CB ' ' HB3' ' A' ' 144' ' ' LEU . 12.7 t60 -159.68 148.07 17.46 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 103.774 -2.676 . . . . 0.0 103.774 169.949 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.445 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 4.3 pm0 -68.79 88.27 0.37 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 123.112 1.434 . . . . 0.0 109.822 178.229 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -169.51 151.15 4.33 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 -171.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.38 118.68 8.41 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 118.146 0.43 . . . . 0.0 110.121 177.738 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.583 ' HA ' ' H ' ' A' ' 140' ' ' ALA . 44.0 t0 -96.7 -80.86 0.43 Allowed 'General case' 0 C--O 1.187 -2.216 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.459 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.4 t70 76.19 152.02 0.13 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 128.344 2.658 . . . . 0.0 112.271 175.28 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.07 -64.03 1.11 Allowed 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.667 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 -17.42 72.21 Favored Glycine 0 CA--C 1.481 -2.084 0 CA-C-N 114.137 -1.392 . . . . 0.0 113.03 -170.434 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.0 tttp -65.86 -41.1 92.1 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.172 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 129' ' ' GLY . . . . . 0.686 ' HA2' ' O ' ' A' ' 134' ' ' SER . . . -75.8 69.9 2.06 Favored Glycine 0 N--CA 1.409 -3.122 0 N-CA-C 115.182 0.833 . . . . 0.0 115.182 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -141.68 23.86 2.48 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 119.457 -1.354 . . . . 0.0 114.709 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.478 ' HB3' ' CB ' ' A' ' 134' ' ' SER . 64.6 t30 -132.14 176.37 8.44 Favored 'General case' 0 N--CA 1.522 3.15 0 CA-C-O 116.132 -1.89 . . . . 0.0 107.594 178.507 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.29 -57.03 11.98 Favored 'General case' 0 C--N 1.385 2.121 0 CA-C-N 121.934 2.152 . . . . 0.0 113.458 -174.803 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 -86.0 -34.18 20.87 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 121.077 0.465 . . . . 0.0 110.922 176.906 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.686 ' O ' ' HA2' ' A' ' 129' ' ' GLY . 1.3 m -66.98 -21.8 65.95 Favored 'General case' 0 C--O 1.185 -2.335 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.69 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.607 ' HA ' ' CA ' ' A' ' 129' ' ' GLY . 5.2 t -80.0 -12.55 59.7 Favored 'General case' 0 CA--C 1.51 -0.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.939 179.515 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -88.25 -46.77 8.95 Favored 'General case' 0 C--N 1.275 -2.669 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.239 -175.935 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.7 p -85.72 -32.72 21.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 113.892 -1.503 . . . . 0.0 112.314 -178.52 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -77.48 -4.04 83.83 Favored Glycine 0 C--O 1.202 -1.893 0 CA-C-O 119.171 -0.794 . . . . 0.0 114.879 -173.23 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 139' ' ' ASN . . . . . 0.414 HD21 HG11 ' A' ' 81' ' ' VAL . 45.3 t-20 -142.7 104.46 4.36 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 164.97 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.583 ' H ' ' HA ' ' A' ' 124' ' ' ASP . . . -69.83 160.35 31.93 Favored 'General case' 1 C--O 1.33 5.307 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.252 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.433 ' C ' HG11 ' A' ' 118' ' ' VAL . . . -163.77 -151.91 6.67 Favored Glycine 1 N--CA 1.382 -4.94 0 C-N-CA 118.124 -1.988 . . . . 0.0 115.262 -165.953 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.593 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 2.9 m -46.9 7.28 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 1 C-N-CA 132.552 4.341 . . . . 0.0 120.14 -166.146 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 72.3 mtt180 -125.69 -27.58 3.36 Favored 'General case' 0 C--N 1.264 -3.138 0 C-N-CA 118.794 -1.162 . . . . 0.0 111.289 178.993 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.509 ' HB3' ' CB ' ' A' ' 120' ' ' HIS . 4.0 mm? -60.46 -43.69 96.65 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.084 -174.346 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.664 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.51 112.39 0.34 Allowed 'General case' 0 CA--C 1.49 -1.338 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.547 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.428 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 88.8 m -95.19 140.44 30.1 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.522 -177.397 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.551 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.08 150.67 13.35 Favored Glycine 1 N--CA 1.389 -4.474 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.607 176.319 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.4 t -75.67 119.59 23.84 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 171.356 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.447 HD12 ' HB1' ' A' ' 6' ' ' ALA . 23.2 mm -118.59 102.17 12.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.368 0 N-CA-C 105.264 -2.125 . . . . 0.0 105.264 179.09 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.572 ' HA2' HG22 ' A' ' 112' ' ' ILE . . . 177.8 -172.5 45.15 Favored Glycine 0 CA--C 1.452 -3.902 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.256 -177.191 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.58 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.6 tt -70.67 103.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 122.108 0.956 . . . . 0.0 110.724 -178.959 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.53 115.36 5.27 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.778 -1.555 . . . . 0.0 111.26 -179.077 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 . . . . . 0 C--N 1.296 -1.75 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.797 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.575 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.218 -0.6 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.489 ' HA ' ' HG2' ' A' ' 21' ' ' GLU . 60.0 m -121.35 -43.45 2.41 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 110.648 177.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.14 144.63 33.56 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.567 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.06 149.57 51.15 Favored 'General case' 0 N--CA 1.41 -2.452 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.4 178.688 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 63.3 t -120.14 127.26 75.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -177.57 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.596 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -107.76 129.0 55.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.996 176.546 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.7 m -134.61 102.56 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 74.5 mt -96.01 134.45 39.01 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.304 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.7 tttp -147.33 122.2 9.99 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.954 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.02 -157.86 8.6 Favored Glycine 0 N--CA 1.435 -1.402 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -89.62 94.0 9.69 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 169.285 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 128.21 143.74 5.71 Favored Glycine 0 C--N 1.275 -2.829 0 N-CA-C 107.309 -2.316 . . . . 0.0 107.309 -177.053 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -97.81 123.11 0.18 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 CA-C-N 120.367 2.083 . . . . 0.0 113.524 -178.828 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 p -134.7 112.18 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.333 0 CA-C-N 114.534 -1.212 . . . . 0.0 107.957 171.751 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -118.14 119.53 35.0 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 118.874 -1.13 . . . . 0.0 111.092 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -159.36 149.43 19.28 Favored Glycine 0 N--CA 1.406 -3.356 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.536 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 27.5 pt -113.82 107.21 22.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.596 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 28.1 mm -100.44 128.45 52.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.635 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 4.3 t30 -101.0 144.21 30.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -178.543 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.567 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 87.0 m-85 -132.57 120.18 21.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.794 0.33 . . . . 0.0 111.531 175.17 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.489 ' HG2' ' HA ' ' A' ' 2' ' ' THR . 1.8 tm-20 -132.34 101.78 5.49 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 174.152 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.691 ' HG2' ' O ' ' A' ' 105' ' ' SER . 18.1 mp0 -127.51 132.21 49.98 Favored 'General case' 0 N--CA 1.387 -3.606 0 N-CA-C 103.601 -2.74 . . . . 0.0 103.601 167.109 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.442 ' HD3' ' H ' ' A' ' 24' ' ' GLU . 6.3 tmtt? -131.54 168.64 17.32 Favored 'General case' 0 C--N 1.257 -3.437 0 N-CA-C 107.14 -1.429 . . . . 0.0 107.14 -173.21 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.442 ' H ' ' HD3' ' A' ' 23' ' ' LYS . 10.3 pt-20 -62.48 -9.5 8.75 Favored 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 124.038 0.935 . . . . 0.0 111.777 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -56.86 -39.5 74.41 Favored 'General case' 0 N--CA 1.424 -1.726 0 C-N-CA 124.999 1.319 . . . . 0.0 110.528 176.444 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 26' ' ' ASN . . . . . 0.467 ' OD1' HG22 ' A' ' 103' ' ' VAL . 56.4 t30 66.76 104.08 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 123.635 0.774 . . . . 0.0 110.478 178.297 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.72 -177.0 48.13 Favored Glycine 0 CA--C 1.474 -2.477 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -175.18 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -57.26 123.19 13.22 Favored 'Trans proline' 0 C--O 1.24 0.61 0 C-N-CA 122.262 1.975 . . . . 0.0 111.642 -178.787 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 92.5 t -76.42 111.46 13.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.436 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . 0.3 0.0 OUTLIER -112.59 107.29 15.95 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.812 1.291 . . . . 0.0 112.123 177.882 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.635 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 30.8 m -137.22 154.4 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.577 0 CA-C-N 113.054 -1.885 . . . . 0.0 106.323 -172.269 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 61.6 p-90 -139.19 148.1 42.7 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' VAL . . . -169.57 137.75 4.68 Favored Glycine 0 N--CA 1.404 -3.444 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 171.975 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.3 t -117.2 131.72 56.8 Favored 'General case' 0 N--CA 1.407 -2.587 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 -177.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.721 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 15.5 pt -114.91 153.18 16.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 C-N-CA 118.694 -1.203 . . . . 0.0 111.075 176.582 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.416 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 48.4 mtmt -120.34 107.61 13.15 Favored 'General case' 0 N--CA 1.408 -2.552 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 177.24 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.08 174.17 17.29 Favored Glycine 0 C--N 1.295 -1.734 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 45.5 tp -69.02 171.81 7.62 Favored 'General case' 0 CA--C 1.571 1.77 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 176.289 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 1.6 t -69.27 110.31 4.55 Favored 'General case' 0 CA--C 1.5 -0.954 0 O-C-N 121.243 -0.911 . . . . 0.0 112.978 -178.354 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 39' ' ' THR . 10.3 mm-40 -170.47 171.58 6.42 Favored 'General case' 0 C--N 1.275 -2.652 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 173.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.27 -155.77 31.53 Favored Glycine 0 C--N 1.26 -3.65 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 169.344 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.691 HD22 ' HB ' ' A' ' 87' ' ' VAL . 5.2 tt -178.44 149.43 0.5 Allowed 'General case' 0 N--CA 1.412 -2.337 0 N-CA-C 103.563 -2.754 . . . . 0.0 103.563 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.603 ' N ' HD23 ' A' ' 42' ' ' LEU . 78.2 t60 -161.34 121.6 2.68 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 173.32 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HB3' ' A' ' 124' ' ' ASP . . . 77.09 136.84 0.81 Allowed Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.726 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HB2' ' CG1' ' A' ' 119' ' ' VAL . 0.1 OUTLIER -142.23 131.46 23.43 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 117.855 0.827 . . . . 0.0 112.204 -177.952 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.598 ' HA ' ' O ' ' A' ' 82' ' ' GLY . 21.7 t-80 -82.08 89.3 6.44 Favored 'General case' 0 CA--C 1.476 -1.877 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.695 -177.074 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.625 ' CB ' HD23 ' A' ' 117' ' ' LEU . 6.7 m -110.47 80.89 0.55 Allowed 'Isoleucine or valine' 1 N--CA 1.379 -4.008 0 CA-C-O 122.897 1.332 . . . . 0.0 110.346 175.689 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.502 ' HA ' HH11 ' A' ' 115' ' ' ARG . 2.4 p-80 -174.72 145.24 0.88 Allowed 'General case' 0 CA--C 1.487 -1.447 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.98 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' CE1' ' A' ' 46' ' ' HIS 0.351 10.9 mm-40 -172.92 173.97 3.64 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 126.628 1.971 . . . . 0.0 111.554 163.423 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -110.28 75.04 0.91 Allowed 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 102.886 -3.005 . . . . 0.0 102.886 171.671 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' HA ' ' A' ' 115' ' ' ARG . . . -104.91 -149.97 19.72 Favored Glycine 0 CA--C 1.482 -1.984 0 CA-C-N 113.142 -1.845 . . . . 0.0 113.617 -169.114 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 37.9 t70 175.0 -41.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 89.4 m-20 -101.13 124.93 47.61 Favored 'General case' 0 CA--C 1.498 -1.037 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.92 -173.201 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.3 t -84.25 -25.63 29.25 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.165 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.41 -8.6 38.21 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.218 0.533 . . . . 0.0 110.261 -178.806 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -144.25 110.02 0.56 Allowed Glycine 0 N--CA 1.409 -3.116 0 C-N-CA 119.486 -1.34 . . . . 0.0 109.901 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.775 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.7 p -96.44 86.7 4.23 Favored 'General case' 0 N--CA 1.391 -3.401 0 CA-C-O 122.32 1.057 . . . . 0.0 110.733 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 30.5 m -82.03 -47.38 12.7 Favored 'General case' 0 N--CA 1.417 -2.116 0 CA-C-N 114.043 -1.435 . . . . 0.0 109.484 174.026 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 p -72.03 -16.8 62.05 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.194 -176.791 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -82.48 -6.69 59.46 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.22 177.078 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 61' ' ' GLY . . . . . 0.665 ' HA2' ' HB3' ' A' ' 142' ' ' SER . . . -50.58 176.33 0.05 OUTLIER Glycine 0 C--N 1.355 1.592 0 CA-C-N 114.83 -1.077 . . . . 0.0 112.311 175.625 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.48 ' HA ' ' CE2' ' A' ' 64' ' ' PHE . 21.3 Cg_exo -68.88 55.24 0.92 Allowed 'Trans proline' 0 N--CA 1.488 1.174 0 C-N-CA 123.466 2.777 . . . . 0.0 112.137 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -159.12 87.74 0.86 Allowed 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 105.567 -2.012 . . . . 0.0 105.567 -177.214 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.641 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 27.2 m-85 -111.78 162.99 14.66 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 -173.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -93.5 99.15 3.05 Favored Pre-proline 0 C--O 1.248 0.975 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.325 174.143 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.641 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 71.0 Cg_exo -52.36 -12.04 1.42 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 125.197 3.932 . . . . 0.0 114.913 -178.507 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.5 mt -94.92 7.39 46.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-O 122.761 1.267 . . . . 0.0 107.996 -171.212 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.9 t -120.76 23.57 10.67 Favored 'General case' 0 N--CA 1.395 -3.186 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 175.536 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.521 ' NH2' ' HB3' ' A' ' 66' ' ' PRO . 38.6 ttp180 -132.15 -32.64 1.37 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 113.199 -1.819 . . . . 0.0 107.629 171.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 78' ' ' GLU 0.256 5.3 mmtp 39.32 71.12 0.18 Allowed 'General case' 0 N--CA 1.427 -1.583 0 C-N-CA 125.616 1.566 . . . . 0.0 112.814 178.332 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 69.6 -29.35 0.18 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 125.747 1.619 . . . . 0.0 114.29 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 96.5 159.59 31.97 Favored Glycine 0 N--CA 1.418 -2.541 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -173.028 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.81 163.22 36.97 Favored Glycine 0 C--N 1.291 -1.954 0 C-N-CA 119.227 -1.463 . . . . 0.0 111.379 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.94 -43.16 1.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 118.885 1.343 . . . . 0.0 112.044 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -120.73 -28.36 4.89 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.609 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.639 ' HA ' ' CG ' ' A' ' 80' ' ' HIS . 5.9 p-10 170.91 165.75 0.08 Allowed 'General case' 0 CA--C 1.481 -1.675 0 C-N-CA 124.287 1.035 . . . . 0.0 108.692 177.347 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -137.64 -73.31 0.42 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' HB3' ' HG3' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -135.93 -65.64 0.58 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 177.716 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -119.85 68.78 0.83 Allowed 'General case' 0 N--CA 1.415 -2.203 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 171.645 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.639 ' CG ' ' HA ' ' A' ' 76' ' ' ASP . 29.8 t-80 -86.49 66.21 9.4 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 177.635 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.536 HG11 ' O ' ' A' ' 106' ' ' LEU . 25.2 m -114.87 -15.02 10.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.406 -176.43 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 46' ' ' HIS . . . -79.89 -1.76 87.69 Favored Glycine 0 CA--C 1.492 -1.391 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.451 177.418 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.601 ' HB2' ' HB2' ' A' ' 126' ' ' LEU . 4.3 t70 -167.48 115.31 0.78 Allowed 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 125.664 1.586 . . . . 0.0 106.91 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.449 HD22 ' HA ' ' A' ' 81' ' ' VAL . 1.5 pt? -170.06 82.1 0.11 Allowed 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 164.599 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 171.4 147.54 5.71 Favored Glycine 1 N--CA 1.393 -4.189 0 C-N-CA 118.842 -1.646 . . . . 0.0 112.444 177.719 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -105.71 128.01 53.42 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 102.43 -3.174 . . . . 0.0 102.43 162.463 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.691 ' HB ' HD22 ' A' ' 42' ' ' LEU . 5.8 t -128.77 153.18 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 N-CA-C 102.557 -3.127 . . . . 0.0 102.557 -177.953 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 94' ' ' VAL . 15.4 t -139.53 149.85 44.39 Favored 'General case' 0 N--CA 1.4 -2.966 0 C-N-CA 118.594 -1.242 . . . . 0.0 110.694 -175.886 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.504 ' CB ' ' HB2' ' A' ' 121' ' ' GLU . . . -120.44 155.4 33.58 Favored 'General case' 2 C--N 1.224 -4.887 0 CA-C-N 114.381 -1.281 . . . . 0.0 108.725 -177.375 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -149.42 160.14 43.7 Favored 'General case' 1 C--N 1.236 -4.359 0 N-CA-C 104.311 -2.478 . . . . 0.0 104.311 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.595 ' HB3' ' HB ' ' A' ' 39' ' ' THR . 0.0 OUTLIER -44.08 -31.72 1.01 Allowed 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 119.51 1.05 . . . . 0.0 112.976 172.77 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -91.53 -25.27 19.32 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.864 0.84 . . . . 0.0 109.116 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 36' ' ' LYS . . . 83.12 85.81 0.82 Allowed Glycine 0 N--CA 1.397 -3.908 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.317 -175.955 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 88' ' ' THR . 10.8 m -136.95 102.37 2.63 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 122.312 1.053 . . . . 0.0 109.753 175.659 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.721 ' HB3' ' H ' ' A' ' 35' ' ' ILE . . . -96.25 145.33 25.65 Favored 'General case' 0 N--CA 1.408 -2.561 0 CA-C-N 113.966 -1.47 . . . . 0.0 112.197 172.656 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.03 152.83 38.65 Favored 'General case' 0 N--CA 1.412 -2.325 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 166.163 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 28.7 m -80.9 134.58 26.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 CA-C-O 121.864 0.84 . . . . 0.0 108.899 178.427 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.404 ' OG ' HG22 ' A' ' 87' ' ' VAL . 19.6 m -75.86 106.05 7.24 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.384 -176.392 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 pt -121.72 122.02 65.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 174.051 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -146.23 151.44 37.59 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.386 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -93.07 99.28 11.91 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 117.712 -1.595 . . . . 0.0 110.831 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.46 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 53.1 m -102.86 142.82 33.34 Favored 'General case' 0 N--CA 1.396 -3.148 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 172.233 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.467 HG22 ' OD1' ' A' ' 26' ' ' ASN . 14.7 p -101.77 -46.85 11.33 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 C-N-CA 117.383 -1.727 . . . . 0.0 112.156 -178.852 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.9 tt -121.58 24.01 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.278 0 CA-C-O 122.308 1.051 . . . . 0.0 111.729 -171.29 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.691 ' O ' ' HG2' ' A' ' 22' ' ' GLN . 56.6 m -103.64 87.6 2.87 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.169 -1.582 . . . . 0.0 114.008 -177.416 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.536 ' O ' HG11 ' A' ' 81' ' ' VAL . 6.1 mp -69.82 129.54 39.85 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 169.941 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.444 ' HA ' HG11 ' A' ' 81' ' ' VAL . 13.1 t -73.63 87.68 1.67 Allowed 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.857 0.836 . . . . 0.0 112.491 -170.188 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.55 135.47 2.83 Favored Glycine 0 N--CA 1.406 -3.302 0 CA-C-N 114.189 -1.368 . . . . 0.0 112.426 168.226 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -46.97 -70.53 0.09 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.912 0.885 . . . . 0.0 111.88 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 63.8 m80 -123.02 -34.82 3.11 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.653 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 17.5 m -96.42 106.76 19.05 Favored 'General case' 0 N--CA 1.414 -2.257 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.783 -178.136 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 18.1 mm -87.67 -48.11 15.38 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 168.775 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.3 tt -102.69 151.11 6.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.258 174.498 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.24 -31.01 8.99 Favored Glycine 0 CA--C 1.478 -2.268 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 172.754 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.674 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 28.7 ptt180 -69.46 156.43 38.87 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 124.455 1.102 . . . . 0.0 112.549 -175.628 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -116.06 113.94 23.86 Favored 'General case' 0 N--CA 1.388 -3.533 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 -178.636 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.764 HD22 ' HB ' ' A' ' 149' ' ' ILE . 4.6 mp -95.98 160.49 14.43 Favored 'General case' 0 C--N 1.268 -2.953 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -174.201 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 145' ' ' ALA 0.327 8.4 p -140.5 116.14 7.37 Favored 'Isoleucine or valine' 0 C--O 1.263 1.793 0 C-N-CA 116.324 -2.15 . . . . 0.0 114.019 -179.156 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 45' ' ' PHE . 19.7 m -138.49 170.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -176.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.513 ' ND1' ' HB3' ' A' ' 144' ' ' LEU . 62.7 t60 -170.44 167.95 8.03 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 105.129 -2.175 . . . . 0.0 105.129 176.59 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.504 ' HB2' ' CB ' ' A' ' 89' ' ' ALA . 8.9 pm0 -70.96 85.89 0.7 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 119.973 1.26 . . . . 0.0 110.467 177.202 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.536 ' C ' ' HA ' ' A' ' 42' ' ' LEU . 30.5 ttmt -175.7 154.99 1.65 Allowed 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.553 -176.677 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.562 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -60.27 107.31 0.63 Allowed 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 168.901 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.531 ' OD2' ' HA ' ' A' ' 140' ' ' ALA . 9.0 t70 -105.36 17.56 23.73 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.758 0.823 . . . . 0.0 108.93 -179.136 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -35.73 114.91 0.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.438 1.895 . . . . 0.0 111.306 -177.818 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 83' ' ' ASP . 0.2 OUTLIER -90.79 -36.39 14.28 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.137 -168.151 . . . . . . . . 3 3 . 1 . 016 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.21 -27.19 56.22 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.588 -177.453 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -100.84 -26.01 13.91 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.955 0.378 . . . . 0.0 110.907 -178.893 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.05 -71.6 0.95 Allowed Glycine 0 CA--C 1.529 0.937 0 N-CA-C 113.767 0.267 . . . . 0.0 113.767 -177.229 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 118.73 -6.47 13.83 Favored Glycine 0 C--N 1.313 -0.728 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -175.025 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 26.8 t30 -162.67 150.66 14.03 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -48.26 -51.13 27.05 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 124.122 0.889 . . . . 0.0 112.062 -176.992 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.38 -48.28 78.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.614 -178.727 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 8.2 m -62.56 -24.56 67.6 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -176.545 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.7 m -69.63 -35.23 75.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 122.008 0.909 . . . . 0.0 109.407 176.999 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -83.41 -41.15 18.45 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.776 -174.052 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -74.01 -52.37 12.96 Favored 'General case' 0 C--N 1.273 -2.726 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.14 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 112.95 91.69 1.96 Allowed Glycine 1 N--CA 1.388 -4.504 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -176.167 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -34.57 117.43 0.36 Allowed 'General case' 1 C--O 1.333 5.488 0 C-N-CA 126.233 1.813 . . . . 0.0 113.265 -173.149 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.531 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -153.63 142.5 21.11 Favored 'General case' 0 N--CA 1.411 -2.417 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.357 175.198 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.81 86.03 1.55 Allowed Glycine 0 N--CA 1.425 -2.091 0 N-CA-C 104.525 -3.43 . . . . 0.0 104.525 164.166 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 142' ' ' SER . . . . . 0.665 ' HB3' ' HA2' ' A' ' 61' ' ' GLY . 21.0 m -55.01 -3.89 0.06 Allowed 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 118.095 2.628 . . . . 0.0 118.095 -166.49 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.668 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 11.9 ptm180 -144.75 11.0 1.4 Allowed 'General case' 0 C--N 1.247 -3.885 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.038 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.513 ' HB3' ' ND1' ' A' ' 120' ' ' HIS . 4.6 mm? -78.6 -9.21 59.28 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.695 -175.906 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.15 109.69 0.39 Allowed 'General case' 0 CA--C 1.494 -1.186 0 C-N-CA 123.791 0.836 . . . . 0.0 108.915 173.638 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 38.3 m -96.43 137.06 36.08 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.02 125.38 1.2 Allowed Glycine 0 N--CA 1.424 -2.137 0 C-N-CA 118.498 -1.811 . . . . 0.0 113.434 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.674 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 75.6 t -73.51 101.48 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 171.733 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.764 ' HB ' HD22 ' A' ' 117' ' ' LEU . 53.7 mt -116.27 128.44 73.59 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.523 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.11 -168.49 40.35 Favored Glycine 3 CA--C 1.415 -6.186 0 N-CA-C 108.121 -1.992 . . . . 0.0 108.121 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.519 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.8 pp -67.81 121.16 16.46 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 120.096 -0.642 . . . . 0.0 111.165 179.104 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -131.75 114.75 15.13 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 174.126 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 . . . . . 0 C--N 1.289 -2.065 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.571 -179.31 . . . . . . . . 0 0 . 1 . 016 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.55 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 26.2 m -112.84 -31.51 6.7 Favored 'General case' 0 CA--C 1.557 1.222 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -171.641 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 3' ' ' LYS . . . . . 0.454 ' HB2' HD21 ' A' ' 19' ' ' ASN . 62.1 pttt -146.79 158.37 43.89 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.861 -174.856 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.781 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -143.01 150.37 39.52 Favored 'General case' 0 N--CA 1.395 -3.178 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.486 ' CG2' ' HB3' ' A' ' 152' ' ' ALA . 29.0 m -129.63 138.93 52.95 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.573 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.572 ' HB2' HG13 ' A' ' 149' ' ' ILE . . . -116.6 136.02 53.32 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 114.757 -1.11 . . . . 0.0 111.799 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.7 m -133.07 105.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.161 0.505 . . . . 0.0 110.608 175.922 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.424 HD23 HD21 ' A' ' 117' ' ' LEU . 0.4 OUTLIER -114.75 151.14 34.24 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.651 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -157.43 150.45 23.44 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 175.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.15 -158.76 8.81 Favored Glycine 0 N--CA 1.414 -2.784 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 177.679 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -69.39 -39.19 78.12 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 124.935 1.021 . . . . 0.0 109.764 176.468 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.16 164.13 29.51 Favored Glycine 0 C--O 1.251 1.189 0 N-CA-C 108.704 -1.759 . . . . 0.0 108.704 174.461 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -83.14 123.4 3.51 Favored 'Trans proline' 0 N--CA 1.424 -2.613 0 CA-C-N 120.371 2.086 . . . . 0.0 109.739 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 14' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 12.1 m -132.21 123.52 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.667 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 178.103 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -130.32 119.58 23.03 Favored 'General case' 0 C--N 1.274 -2.685 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.667 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -166.87 166.62 39.22 Favored Glycine 0 N--CA 1.408 -3.194 0 C-N-CA 119.115 -1.517 . . . . 0.0 112.086 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.422 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 11.9 tt -151.53 126.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 179.096 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.486 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -122.87 136.6 59.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -178.185 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.454 HD21 ' HB2' ' A' ' 3' ' ' LYS . 25.1 t-20 -110.61 130.3 55.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.274 0.63 . . . . 0.0 109.395 -176.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.781 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 68.0 m-85 -130.16 133.59 46.71 Favored 'General case' 0 CA--C 1.498 -1.026 0 O-C-N 123.583 0.552 . . . . 0.0 110.824 178.183 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.484 ' O ' HG13 ' A' ' 104' ' ' ILE . 15.8 pt-20 -106.03 103.31 12.76 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 171.659 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.501 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -85.78 88.37 7.54 Favored 'General case' 1 N--CA 1.371 -4.415 0 CA-C-O 122.711 1.243 . . . . 0.0 112.164 -171.876 . . . . . . . . 4 4 . 1 . 017 nuclear build full ' A' A ' 23' ' ' LYS . . . . . 0.435 ' HE3' ' CD ' ' A' ' 21' ' ' GLU . 96.1 mttt -76.11 106.52 7.76 Favored 'General case' 0 N--CA 1.409 -2.509 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 172.647 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HG3' ' HB2' ' A' ' 106' ' ' LEU . 28.7 tt0 -48.58 -39.42 23.67 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 113.693 -1.594 . . . . 0.0 113.86 -167.384 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.6 m -90.63 -61.96 1.56 Allowed 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 120.773 0.32 . . . . 0.0 110.461 177.368 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -173.56 171.47 3.87 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -177.908 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 162.42 163.0 14.21 Favored Glycine 0 CA--C 1.494 -1.266 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.218 175.881 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -62.02 124.53 14.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.326 2.017 . . . . 0.0 107.483 172.116 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.447 ' HB ' HG13 ' A' ' 31' ' ' VAL . 35.2 m -95.63 117.36 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -174.057 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HE2' ' HB3' ' A' ' 30' ' ' LYS . 19.2 ttpt -82.65 101.87 11.1 Favored 'General case' 0 N--CA 1.413 -2.288 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.894 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.447 HG13 ' HB ' ' A' ' 29' ' ' VAL . 35.7 m -137.13 137.73 46.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 67.0 p-90 -148.3 137.31 21.82 Favored 'General case' 0 C--N 1.269 -2.902 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.54 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -153.28 140.19 7.42 Favored Glycine 0 N--CA 1.4 -3.712 0 C-N-CA 119.779 -1.2 . . . . 0.0 111.063 176.888 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.7 m -115.28 141.82 47.52 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.722 ' HB ' ' HB3' ' A' ' 95' ' ' ALA . 41.1 mm -131.43 126.73 58.82 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 176.533 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 41.2 ttmt -108.92 131.52 54.95 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 103.884 -2.636 . . . . 0.0 103.884 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.88 175.47 39.24 Favored Glycine 0 C--N 1.273 -2.968 0 N-CA-C 110.596 -1.001 . . . . 0.0 110.596 -167.478 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.34 142.76 56.68 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.496 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.68 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -69.35 105.74 2.67 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -172.777 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.529 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 27.9 mt-10 -175.43 135.77 0.33 Allowed 'General case' 0 CA--C 1.478 -1.798 0 C-N-CA 129.404 3.082 . . . . 0.0 104.057 174.743 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.63 99.99 0.17 Allowed Glycine 0 C--N 1.265 -3.395 0 C-N-CA 116.844 -2.598 . . . . 0.0 113.341 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -103.07 -86.18 0.44 Allowed 'General case' 0 N--CA 1.446 -0.639 0 O-C-N 124.547 0.792 . . . . 0.0 111.184 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.485 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.8 p80 176.39 141.42 0.07 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.37 116.06 0.54 Allowed Glycine 0 N--CA 1.419 -2.436 0 C-N-CA 119.616 -1.278 . . . . 0.0 113.048 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -122.89 107.95 12.42 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.929 0.871 . . . . 0.0 112.876 178.744 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.597 ' HA ' ' HB ' ' A' ' 81' ' ' VAL . 54.4 t60 -171.11 89.73 0.13 Allowed 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.005 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.724 ' O ' ' HA3' ' A' ' 82' ' ' GLY . 51.5 t -132.4 87.81 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 O-C-N 126.344 2.278 . . . . 0.0 109.284 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.477 ' CE1' ' HA3' ' A' ' 108' ' ' GLY . 8.6 t-160 -173.27 87.4 0.06 Allowed 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.239 -0.913 . . . . 0.0 110.749 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.597 ' H ' ' HB2' ' A' ' 115' ' ' ARG . 2.7 mp0 -136.51 172.25 13.29 Favored 'General case' 1 C--N 1.24 -4.173 0 CA-C-N 113.648 -1.615 . . . . 0.0 109.082 -170.956 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.413 ' HB3' ' OD1' ' A' ' 109' ' ' ASP . 26.3 p90 -69.81 171.31 9.44 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-O 121.096 0.474 . . . . 0.0 111.2 169.31 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.775 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . -59.86 120.7 23.91 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.118 -0.946 . . . . 0.0 114.282 177.373 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CG ' ' HA ' ' A' ' 57' ' ' CYS . 5.5 t0 -129.72 -167.27 1.78 Allowed 'General case' 0 C--O 1.247 0.932 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 176.159 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 53' ' ' ASN . . . . . 0.679 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 29.9 t30 -69.47 133.86 48.23 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-O 121.369 0.604 . . . . 0.0 110.519 -179.595 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 54' ' ' THR . . . . . 0.561 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 1.3 p -51.41 -22.4 2.96 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 127.286 2.235 . . . . 0.0 114.44 -178.629 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.96 24.22 4.6 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.679 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 175.51 111.15 0.27 Allowed Glycine 0 C--O 1.196 -2.232 0 C-N-CA 117.778 -2.153 . . . . 0.0 112.566 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 13.3 p -90.56 96.03 10.45 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 121.973 0.892 . . . . 0.0 110.108 -177.877 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.3 m -76.57 -51.56 11.41 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.885 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.1 m -91.03 -36.5 14.02 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.372 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.492 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -77.58 -17.69 57.59 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.67 -177.449 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.85 -63.73 3.99 Favored Glycine 0 CA--C 1.539 1.546 0 N-CA-C 114.56 0.584 . . . . 0.0 114.56 -179.466 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -85.78 6.37 5.6 Favored 'Trans proline' 0 C--O 1.24 0.617 0 C-N-CA 122.744 2.296 . . . . 0.0 112.092 177.891 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -83.1 142.37 31.31 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 121.535 0.683 . . . . 0.0 111.409 -175.914 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -141.4 133.88 28.33 Favored 'General case' 0 N--CA 1.411 -2.384 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 172.014 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.411 ' CG ' ' H ' ' A' ' 109' ' ' ASP . 9.4 t30 -77.35 141.57 66.29 Favored Pre-proline 0 C--N 1.306 -1.317 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.508 175.91 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -53.5 -33.36 67.43 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 123.834 3.023 . . . . 0.0 115.726 -177.279 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.488 ' O ' ' HB2' ' A' ' 79' ' ' ARG . 3.0 mm? -78.15 -45.4 23.35 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.4 m -67.3 31.54 0.02 OUTLIER 'General case' 0 CA--C 1.498 -1.026 0 C-N-CA 129.477 3.111 . . . . 0.0 116.62 -172.88 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.611 ' N ' ' HB2' ' A' ' 79' ' ' ARG . 0.0 OUTLIER -136.27 -32.55 0.85 Allowed 'General case' 0 C--N 1.245 -3.958 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.584 172.633 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.492 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 82.2 tttt 34.67 -87.35 0.0 OUTLIER 'General case' 0 C--N 1.373 1.626 0 C-N-CA 124.526 1.13 . . . . 0.0 110.25 -170.941 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -178.93 12.2 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.764 0 C-N-CA 126.32 1.848 . . . . 0.0 106.994 176.961 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.49 134.38 3.35 Favored Glycine 0 N--CA 1.435 -1.403 0 C-N-CA 119.329 -1.415 . . . . 0.0 111.869 -175.382 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.59 83.95 0.09 OUTLIER Glycine 0 C--O 1.2 -2.019 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.429 ' HA ' HD11 ' A' ' 84' ' ' LEU . 59.9 Cg_endo -104.21 -0.5 0.27 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.706 2.271 . . . . 0.0 115.621 -176.541 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -123.41 -11.86 7.84 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 178.39 88.78 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -172.413 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.533 ' HG3' HG23 ' A' ' 103' ' ' VAL . 3.8 mm-40 -54.94 146.59 17.29 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 117.981 2.585 . . . . 0.0 117.981 -177.485 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -138.23 -16.22 1.24 Allowed 'General case' 0 N--CA 1.415 -2.198 0 CA-C-N 112.624 -2.08 . . . . 0.0 107.313 -177.603 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.611 ' HB2' ' N ' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -105.5 -37.31 6.84 Favored 'General case' 1 N--CA 1.358 -5.058 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 177.995 . . . . . . . . 4 4 . 1 . 017 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.463 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 45.2 m80 70.69 74.73 0.2 Allowed 'General case' 0 CA--C 1.498 -1.034 0 CA-C-N 113.344 -1.753 . . . . 0.0 110.041 176.19 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.597 ' HB ' ' HA ' ' A' ' 46' ' ' HIS . 28.3 m -77.66 24.43 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.014 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.724 ' HA3' ' O ' ' A' ' 47' ' ' VAL . . . 68.26 -69.53 0.35 Allowed Glycine 0 N--CA 1.478 1.49 0 C-N-CA 124.033 0.825 . . . . 0.0 113.803 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.434 ' O ' HG23 ' A' ' 81' ' ' VAL . 8.8 t70 -100.15 127.48 46.4 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 175.602 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -123.29 87.98 2.84 Favored 'General case' 0 N--CA 1.407 -2.614 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 172.83 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.74 132.06 3.46 Favored Glycine 1 N--CA 1.379 -5.13 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 174.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -73.8 129.22 37.48 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 118.029 -1.468 . . . . 0.0 107.545 174.805 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 44.6 t -110.81 128.15 67.39 Favored 'Isoleucine or valine' 0 C--N 1.36 1.024 0 O-C-N 121.441 -0.787 . . . . 0.0 109.278 -174.67 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.0 t -141.45 96.47 2.99 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.122 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -80.11 107.21 12.72 Favored 'General case' 0 C--O 1.2 -1.523 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 175.247 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 92' ' ' ASP . 26.3 t70 -64.69 162.68 15.34 Favored 'General case' 0 C--N 1.28 -2.428 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.644 -174.132 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.68 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 58.5 pttt -42.13 14.78 0.0 OUTLIER 'General case' 0 CA--C 1.6 2.902 0 N-CA-C 117.652 2.464 . . . . 0.0 117.652 174.601 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 92' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 90' ' ' ASP . 21.3 t70 -125.51 -28.98 3.25 Favored 'General case' 0 C--N 1.296 -1.736 0 C-N-CA 126.249 1.82 . . . . 0.0 108.753 178.555 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 104.07 66.77 0.72 Allowed Glycine 0 C--O 1.22 -0.746 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.217 -179.147 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 94' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.7 p -160.83 117.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-N 117.387 0.594 . . . . 0.0 110.602 -175.123 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.722 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -122.31 124.34 43.52 Favored 'General case' 0 N--CA 1.434 -1.27 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -111.41 112.56 24.39 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.418 HG11 HG22 ' A' ' 87' ' ' VAL . 34.4 m -112.74 125.79 70.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -178.061 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -154.56 101.09 2.31 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 169.968 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.8 mm -129.58 149.3 33.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -109.68 118.82 37.57 Favored 'General case' 0 C--O 1.265 1.874 0 CA-C-O 122.604 1.192 . . . . 0.0 112.365 179.17 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -164.95 138.59 4.83 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 113.527 -1.669 . . . . 0.0 106.689 -176.124 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.405 ' O ' ' HB2' ' A' ' 77' ' ' GLU . 58.5 m -82.31 79.77 8.68 Favored 'General case' 0 N--CA 1.435 -1.191 0 C-N-CA 119.206 -0.998 . . . . 0.0 109.352 175.04 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 103' ' ' VAL . . . . . 0.533 HG23 ' HG3' ' A' ' 77' ' ' GLU . 7.5 p -108.15 -15.05 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-N 114.324 -1.307 . . . . 0.0 109.932 -177.664 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.501 ' CG1' ' HA ' ' A' ' 22' ' ' GLN . 0.1 OUTLIER -78.21 -3.06 5.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.369 -1.742 . . . . 0.0 111.654 -173.797 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.5 m -67.78 131.22 45.15 Favored 'General case' 0 N--CA 1.409 -2.519 0 CA-C-O 121.6 0.714 . . . . 0.0 110.866 -174.071 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.587 ' HG ' HG22 ' A' ' 112' ' ' ILE . 4.6 mp -68.08 87.74 0.27 Allowed 'General case' 0 N--CA 1.425 -1.687 0 CA-C-O 123.008 1.385 . . . . 0.0 107.514 168.78 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -166.0 87.5 0.37 Allowed 'General case' 1 N--CA 1.374 -4.253 0 N-CA-C 101.481 -3.525 . . . . 0.0 101.481 172.596 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.477 ' HA3' ' CE1' ' A' ' 48' ' ' HIS . . . 166.2 136.69 2.06 Favored Glycine 0 C--N 1.266 -3.314 0 CA-C-N 113.682 -1.599 . . . . 0.0 110.953 179.013 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.413 ' OD1' ' HB3' ' A' ' 50' ' ' PHE . 16.6 t70 50.15 -85.81 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 126.643 1.977 . . . . 0.0 112.18 -171.784 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -123.95 -47.32 1.93 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 173.5 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 111' ' ' SER . . . . . 0.403 ' OG ' HG13 ' A' ' 113' ' ' ILE . 10.3 p -168.38 -162.11 0.39 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.587 HG22 ' HG ' ' A' ' 106' ' ' LEU . 12.4 tt -104.04 25.79 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.886 0 C-N-CA 119.231 -0.987 . . . . 0.0 108.992 178.905 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.604 ' HA ' ' NH1' ' A' ' 115' ' ' ARG . 2.6 pp -103.56 150.39 6.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 O-C-N 121.612 -0.68 . . . . 0.0 111.563 173.458 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.775 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 78.53 -13.33 17.33 Favored Glycine 0 CA--C 1.532 1.102 0 N-CA-C 115.043 0.777 . . . . 0.0 115.043 176.71 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.632 ' NH2' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -66.93 116.56 7.91 Favored 'General case' 0 C--O 1.253 1.248 0 CA-C-O 121.901 0.858 . . . . 0.0 112.305 -168.782 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 18.6 p -85.75 132.51 34.12 Favored 'General case' 0 N--CA 1.384 -3.754 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.25 171.156 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.787 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -69.53 137.03 52.14 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 114.985 -1.007 . . . . 0.0 111.477 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.551 HG22 ' HB1' ' A' ' 140' ' ' ALA . 12.1 p -124.03 96.48 3.93 Favored 'Isoleucine or valine' 1 C--O 1.35 6.352 0 C-N-CA 115.179 -2.608 . . . . 0.0 112.107 166.519 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.477 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 24.0 m -150.62 170.54 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.081 0 C-N-CA 128.67 2.788 . . . . 0.0 105.829 178.257 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.466 ' NE2' ' HD2' ' A' ' 122' ' ' LYS . 29.8 p-80 -169.46 172.93 6.78 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 171.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.529 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.2 mp0 -70.01 82.67 0.49 Allowed 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 119.832 1.196 . . . . 0.0 109.492 -177.438 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.466 ' HD2' ' NE2' ' A' ' 120' ' ' HIS . 59.5 mttm -176.48 174.71 1.87 Allowed 'General case' 0 CA--C 1.494 -1.175 0 C-N-CA 129.403 3.081 . . . . 0.0 104.664 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -72.83 146.23 46.42 Favored 'General case' 0 C--N 1.286 -2.173 0 C-N-CA 119.286 -0.965 . . . . 0.0 110.246 171.515 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -129.23 -86.26 0.55 Allowed 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 174.083 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 52.42 -177.66 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.78 1.632 . . . . 0.0 111.017 171.899 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 tp -94.83 -65.05 1.01 Allowed 'General case' 0 C--N 1.288 -2.076 0 CA-C-O 122.633 1.206 . . . . 0.0 107.933 168.126 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.48 -5.04 48.16 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 112.931 -1.941 . . . . 0.0 115.451 -171.295 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 128' ' ' LYS . . . . . 0.438 ' HA ' ' HD2' ' A' ' 128' ' ' LYS . 44.6 tptt -116.78 26.42 9.85 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 122.049 0.928 . . . . 0.0 109.027 178.29 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -63.34 -28.32 72.12 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 114.397 -1.274 . . . . 0.0 113.272 178.816 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 121.86 -80.86 0.34 Allowed Glycine 0 C--O 1.22 -0.736 0 C-N-CA 119.993 -1.099 . . . . 0.0 113.748 175.229 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.484 ' H ' ' HB2' ' A' ' 134' ' ' SER . 46.5 t-20 -99.08 169.27 9.53 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.238 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . 0.335 9.6 pt-20 -54.66 -45.66 73.89 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 116.273 1.953 . . . . 0.0 116.273 -173.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.98 -37.98 61.77 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.349 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.484 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 49.6 m -59.97 -30.15 68.92 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-O 120.963 0.411 . . . . 0.0 111.409 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 80.5 m -78.84 -20.16 50.29 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.958 0.885 . . . . 0.0 110.168 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 41.7 tttp -91.08 -32.83 15.72 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 -176.453 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.443 HG22 ' HA ' ' A' ' 134' ' ' SER . 9.6 t -85.54 -30.43 23.39 Favored 'General case' 0 N--CA 1.409 -2.513 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.426 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.74 75.12 1.25 Allowed Glycine 0 N--CA 1.422 -2.268 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.525 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 32.3 t30 -47.32 119.95 2.93 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.277 1.431 . . . . 0.0 112.18 -174.609 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.551 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -132.58 137.6 47.13 Favored 'General case' 0 N--CA 1.42 -1.943 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.989 -173.081 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.08 89.32 0.58 Allowed Glycine 0 CA--C 1.502 -0.742 0 N-CA-C 107.581 -2.207 . . . . 0.0 107.581 170.592 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.6 m -47.07 -33.97 5.42 Favored 'General case' 0 C--O 1.2 -1.545 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -164.766 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.01 9.91 4.17 Favored 'General case' 0 C--N 1.27 -2.888 0 C-N-CA 116.162 -2.215 . . . . 0.0 109.787 178.309 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.9 mp -71.41 -16.3 62.39 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.861 -0.736 . . . . 0.0 112.088 -173.134 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 145' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.18 101.89 0.28 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.8 m -136.12 147.34 47.74 Favored 'General case' 0 N--CA 1.407 -2.615 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.561 ' HA2' ' O ' ' A' ' 54' ' ' THR . . . -162.38 149.64 17.98 Favored Glycine 0 N--CA 1.396 -3.988 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 148' ' ' VAL . . . . . 0.632 HG13 ' NH2' ' A' ' 115' ' ' ARG . 2.8 t -69.05 104.67 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 176.195 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.787 HG21 ' HB3' ' A' ' 117' ' ' LEU . 7.4 tt -123.47 101.57 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -176.128 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.492 ' HA3' ' NH1' ' A' ' 115' ' ' ARG . . . 176.66 -167.13 38.42 Favored Glycine 0 CA--C 1.453 -3.8 0 N-CA-C 107.889 -2.084 . . . . 0.0 107.889 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 6.3 tt -61.99 104.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.107 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.457 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.486 ' HB3' ' CG2' ' A' ' 5' ' ' VAL . . . -103.31 102.04 11.98 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.631 -0.828 . . . . 0.0 110.406 -179.537 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 pt20 . . . . . 0 C--N 1.279 -2.474 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.145 179.044 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 1' ' ' ALA . . . . . 0.637 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 N--CA 1.47 0.57 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 2' ' ' THR . . . . . 0.421 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 8.2 m -121.06 -37.42 2.96 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.184 -0.606 . . . . 0.0 112.033 -175.719 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -136.34 136.1 39.4 Favored 'General case' 0 C--O 1.25 1.109 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -174.487 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -156.14 103.15 2.17 Favored 'General case' 0 CA--C 1.479 -1.769 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.473 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.634 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 33.9 m -110.97 134.48 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-O 121.655 0.74 . . . . 0.0 110.389 -176.009 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 6' ' ' ALA . . . . . 0.695 ' HB2' ' HA ' ' A' ' 149' ' ' ILE . . . -108.81 150.11 28.11 Favored 'General case' 0 C--N 1.28 -2.422 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.342 -175.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.2 p -134.26 119.92 32.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.248 0.547 . . . . 0.0 110.098 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.406 ' O ' ' HD2' ' A' ' 9' ' ' LYS . 5.7 mp -98.25 151.1 20.82 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.191 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 9' ' ' LYS . . . . . 0.406 ' HD2' ' O ' ' A' ' 8' ' ' LEU . 28.6 mmmt -126.26 132.44 51.69 Favored 'General case' 0 C--O 1.248 1.021 0 N-CA-C 104.791 -2.3 . . . . 0.0 104.791 177.536 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.61 154.53 19.68 Favored Glycine 0 N--CA 1.428 -1.834 0 C-N-CA 117.477 -2.297 . . . . 0.0 118.504 -166.235 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -64.99 -44.34 89.61 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 111.802 -2.199 . . . . 0.0 106.201 169.502 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.01 153.96 17.23 Favored Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 104.143 -3.583 . . . . 0.0 104.143 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -70.59 123.95 10.3 Favored 'Trans proline' 0 N--CA 1.442 -1.518 0 CA-C-N 121.559 2.679 . . . . 0.0 111.471 -173.074 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.97 109.27 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.124 0 CA-C-N 114.199 -1.364 . . . . 0.0 107.641 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.481 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 73.6 mt-30 -119.99 119.0 32.15 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.864 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 16' ' ' GLY . . . . . 0.622 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -160.14 160.0 31.26 Favored Glycine 0 N--CA 1.405 -3.428 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -174.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 17' ' ' ILE . . . . . 0.461 HG13 ' HB ' ' A' ' 5' ' ' VAL . 11.5 tt -153.87 102.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 121.441 0.638 . . . . 0.0 109.546 -178.726 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.657 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.2 OUTLIER -106.55 139.86 26.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.22 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.688 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 8.5 t30 -113.53 120.81 42.25 Favored 'General case' 0 CA--C 1.51 -0.586 0 O-C-N 123.753 0.658 . . . . 0.0 110.757 -177.509 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 84' ' ' LEU . 21.0 m-85 -119.62 135.14 54.93 Favored 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -178.612 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' HG23 ' A' ' 29' ' ' VAL . 13.4 mt-10 -102.45 105.43 15.99 Favored 'General case' 0 CA--C 1.551 0.999 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.652 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.637 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 15.1 mp0 -85.6 99.86 11.56 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 176.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -132.82 108.98 9.32 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 122.288 1.042 . . . . 0.0 111.593 -172.696 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -69.49 -10.99 60.45 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.077 178.785 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.5 m -59.22 -16.9 23.55 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.563 1.545 . . . . 0.0 112.311 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 4.6 t30 74.98 116.12 0.06 Allowed 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 124.021 0.929 . . . . 0.0 112.375 177.858 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.93 169.67 24.5 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -62.41 123.91 13.29 Favored 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.534 2.156 . . . . 0.0 110.88 177.662 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.503 HG23 ' HB2' ' A' ' 21' ' ' GLU . 10.9 p -75.98 121.51 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.639 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HA ' HD11 ' A' ' 99' ' ' ILE . 67.8 mttm -89.81 97.55 11.26 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -177.041 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' HA ' ' A' ' 20' ' ' PHE . 24.7 m -122.61 133.07 69.89 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.008 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.771 -171.512 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.537 ' HA ' HG11 ' A' ' 97' ' ' VAL . 4.8 m-90 -135.26 137.61 42.71 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.454 177.564 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.657 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -161.54 140.66 6.76 Favored Glycine 0 N--CA 1.424 -2.101 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.828 173.795 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 34' ' ' SER . . . . . 0.622 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 11.4 p -114.83 126.11 54.45 Favored 'General case' 0 N--CA 1.413 -2.294 0 C-N-CA 123.844 0.857 . . . . 0.0 109.622 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.566 HG13 ' HA3' ' A' ' 16' ' ' GLY . 3.6 mp -126.06 142.82 41.59 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 18.9 ptpt -116.26 133.26 56.22 Favored 'General case' 0 N--CA 1.413 -2.283 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 172.845 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -165.21 175.81 40.99 Favored Glycine 0 N--CA 1.423 -2.171 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 -165.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 mt -66.43 144.0 56.78 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -177.843 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.465 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 59.3 p -87.34 104.17 16.16 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 -163.493 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 3.7 mp0 -173.13 140.89 0.91 Allowed 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 102.173 -3.269 . . . . 0.0 102.173 175.996 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 173.67 116.19 0.41 Allowed Glycine 0 C--N 1.255 -3.919 0 C-N-CA 114.933 -3.508 . . . . 0.0 114.436 178.449 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.668 ' HB2' ' HB2' ' A' ' 123' ' ' ALA . 96.2 mt -142.83 -39.67 0.33 Allowed 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -179.385 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -126.02 141.52 51.92 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -173.846 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 44' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' A' ' 46' ' ' HIS . . . -105.19 88.4 0.58 Allowed Glycine 0 N--CA 1.44 -1.036 0 CA-C-N 115.156 -0.929 . . . . 0.0 111.698 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.443 ' HB3' ' O ' ' A' ' 125' ' ' ASP . 0.4 OUTLIER -90.9 84.72 5.83 Favored 'General case' 1 C--O 1.352 6.481 0 CA-C-O 122.261 1.029 . . . . 0.0 112.021 -176.242 . . . . . . . . 4 4 . 1 . 018 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.849 ' HB2' ' HB2' ' A' ' 83' ' ' ASP . 8.0 p80 -100.12 113.37 25.95 Favored 'General case' 0 N--CA 1.382 -3.865 0 CA-C-N 113.893 -1.503 . . . . 0.0 107.944 -171.824 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.0 t -164.89 87.93 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 O-C-N 125.048 1.468 . . . . 0.0 108.533 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 1.5 m170 -148.31 167.73 24.42 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 124.39 1.076 . . . . 0.0 109.114 163.781 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.402 ' HA ' ' HG2' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -164.81 164.98 20.95 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 171.046 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 66.5 t80 73.61 58.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.06 166.08 30.81 Favored Glycine 0 CA--C 1.474 -2.499 0 CA-C-N 112.849 -1.978 . . . . 0.0 111.54 -175.623 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -151.46 -72.37 0.16 Allowed 'General case' 0 C--N 1.292 -1.913 0 O-C-N 123.875 0.397 . . . . 0.0 111.651 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -94.5 128.59 41.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.77 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.5 t -75.98 -2.3 29.85 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 122.946 0.498 . . . . 0.0 111.515 -174.903 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.05 -8.6 19.41 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.47 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 56' ' ' GLY . . . . . 0.459 ' HA2' ' HB2' ' A' ' 143' ' ' ARG . . . -176.99 137.63 3.61 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.224 -1.465 . . . . 0.0 112.758 -178.75 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.439 ' H ' ' HB2' ' A' ' 143' ' ' ARG . 62.3 m -91.98 88.3 6.53 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 120.385 0.136 . . . . 0.0 111.101 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.7 m -80.01 -58.14 3.3 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.75 -44.17 86.7 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.817 -176.786 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.47 -5.98 51.87 Favored 'General case' 0 C--O 1.196 -1.713 0 C-N-CA 124.801 1.24 . . . . 0.0 112.384 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -31.62 -138.33 0.0 OUTLIER Glycine 0 N--CA 1.513 3.832 0 C-N-CA 128.477 2.942 . . . . 0.0 116.414 -174.263 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -62.91 53.41 0.13 Allowed 'Trans proline' 0 CA--C 1.566 2.086 0 CA-C-N 121.043 2.421 . . . . 0.0 113.11 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -93.96 112.67 24.53 Favored 'General case' 0 N--CA 1.427 -1.605 0 C-N-CA 124.348 1.059 . . . . 0.0 110.332 175.919 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' A' ' 136' ' ' LYS . 45.5 p90 -84.21 133.16 34.6 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 103.983 -2.599 . . . . 0.0 103.983 167.506 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.433 ' ND2' ' HD2' ' A' ' 66' ' ' PRO . 29.1 t-20 -75.01 140.83 74.1 Favored Pre-proline 0 C--N 1.282 -2.366 0 C-N-CA 118.842 -1.143 . . . . 0.0 111.609 -171.859 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 66' ' ' PRO . . . . . 0.458 ' O ' ' HG2' ' A' ' 69' ' ' ARG . 92.1 Cg_endo -83.8 -14.21 7.73 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.532 2.154 . . . . 0.0 113.445 -176.805 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.724 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 2.7 tt -88.36 -17.59 30.23 Favored 'General case' 0 CA--C 1.482 -1.658 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 79' ' ' ARG . 63.8 m -79.44 39.82 0.41 Allowed 'General case' 0 N--CA 1.407 -2.58 0 CA-C-N 114.315 -1.311 . . . . 0.0 111.502 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 66' ' ' PRO . 33.1 mmt180 -83.7 20.1 1.51 Allowed 'General case' 0 CA--C 1.49 -1.33 0 CA-C-O 122.506 1.146 . . . . 0.0 109.734 -178.494 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 79' ' ' ARG . 25.8 tptp -128.1 19.99 6.42 Favored 'General case' 0 N--CA 1.396 -3.126 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 171.03 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.0 m80 65.87 -48.3 0.4 Allowed 'General case' 0 N--CA 1.504 2.251 0 C-N-CA 126.349 1.86 . . . . 0.0 115.375 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.516 ' HA2' ' HG3' ' A' ' 79' ' ' ARG . . . 167.61 175.29 37.37 Favored Glycine 0 N--CA 1.415 -2.761 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -171.836 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' O ' HD11 ' A' ' 126' ' ' LEU . . . -169.38 142.5 7.36 Favored Glycine 0 CA--C 1.475 -2.444 0 N-CA-C 106.787 -2.525 . . . . 0.0 106.787 173.516 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -65.01 -43.25 12.1 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 CA-C-N 120.306 2.053 . . . . 0.0 113.849 -178.2 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.7 OUTLIER -120.89 -29.79 4.55 Favored 'General case' 0 N--CA 1.425 -1.682 0 C-N-CA 119.507 -0.877 . . . . 0.0 112.268 -178.317 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 104' ' ' ILE . 33.4 t70 -176.62 146.86 0.6 Allowed 'General case' 0 C--O 1.204 -1.301 0 CA-C-O 118.81 -0.614 . . . . 0.0 109.664 -176.68 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 79' ' ' ARG . 3.1 mm-40 -158.16 -86.76 0.04 OUTLIER 'General case' 0 C--O 1.214 -0.766 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 70' ' ' LYS . 1.5 tm-20 -161.25 -53.03 0.05 OUTLIER 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.1 -2.185 . . . . 0.0 105.1 -176.695 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.724 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 0.4 OUTLIER -34.67 -31.63 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.92 0 C-N-CA 128.635 2.774 . . . . 0.0 115.676 176.948 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.432 ' CE1' ' O ' ' A' ' 106' ' ' LEU . 86.3 t60 71.92 -27.67 0.18 Allowed 'General case' 0 N--CA 1.5 2.066 0 C-N-CA 124.341 1.056 . . . . 0.0 109.738 -171.455 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.62 ' H ' ' C ' ' A' ' 79' ' ' ARG 0.397 12.2 p 59.45 50.22 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.153 0 C-N-CA 129.422 3.089 . . . . 0.0 109.6 -179.558 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 48.78 -78.05 0.0 OUTLIER Glycine 0 N--CA 1.487 2.096 0 CA-C-N 110.764 -2.926 . . . . 0.0 115.814 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.849 ' HB2' ' HB2' ' A' ' 46' ' ' HIS . 81.8 m-20 -79.93 174.13 11.9 Favored 'General case' 0 C--N 1.293 -1.889 0 C-N-CA 125.678 1.591 . . . . 0.0 109.857 -178.491 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.505 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . 89.2 mt -143.82 87.53 1.92 Allowed 'General case' 0 C--N 1.272 -2.794 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 177.03 165.31 32.21 Favored Glycine 0 CA--C 1.478 -2.246 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -158.57 148.33 19.49 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.944 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 p -137.24 128.38 40.71 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.636 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 88.3 m -140.42 95.21 2.84 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.589 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -135.67 106.39 6.56 Favored 'General case' 0 C--O 1.202 -1.425 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.57 ' HA ' ' N ' ' A' ' 40' ' ' GLU . 3.3 p-10 -117.26 -19.18 9.72 Favored 'General case' 0 C--N 1.275 -2.639 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.648 -174.462 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -75.77 -57.54 3.82 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.692 -175.852 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -154.2 -22.83 0.13 Allowed 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 114.623 -1.171 . . . . 0.0 112.27 -166.34 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.48 55.3 0.16 Allowed Glycine 0 N--CA 1.42 -2.386 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -173.65 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.0 m -141.9 102.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.85 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.81 107.75 19.38 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.233 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -83.97 124.33 30.91 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 104.665 -2.346 . . . . 0.0 104.665 173.206 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.537 HG11 ' HA ' ' A' ' 32' ' ' TRP . 7.1 p -83.31 135.89 23.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 C-N-CA 119.696 -0.802 . . . . 0.0 109.426 -174.003 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.2 m -75.46 102.24 5.12 Favored 'General case' 0 N--CA 1.389 -3.508 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.134 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 31' ' ' VAL . 2.5 tt -92.8 115.72 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.593 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.7 mm-40 -133.54 157.43 45.68 Favored 'General case' 0 C--N 1.283 -2.305 0 CA-C-N 113.988 -1.46 . . . . 0.0 108.364 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -79.83 99.38 7.48 Favored 'General case' 0 N--CA 1.411 -2.405 0 CA-C-O 123.01 1.386 . . . . 0.0 109.674 176.497 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.491 ' H ' HG12 ' A' ' 29' ' ' VAL . 50.8 m -100.9 93.75 5.68 Favored 'General case' 0 N--CA 1.41 -2.444 0 CA-C-N 112.107 -2.315 . . . . 0.0 105.902 171.53 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.1 t -69.18 -47.62 73.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.825 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 104' ' ' ILE . . . . . 0.482 HG22 ' OD1' ' A' ' 76' ' ' ASP . 10.0 tp -70.62 26.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.576 1.955 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 30.0 t -70.89 90.16 0.8 Allowed 'General case' 0 CA--C 1.477 -1.845 0 N-CA-C 105.584 -2.006 . . . . 0.0 105.584 170.227 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.432 ' O ' ' CE1' ' A' ' 80' ' ' HIS . 27.2 tp -110.42 157.93 19.03 Favored 'General case' 2 C--N 1.204 -5.728 0 N-CA-C 103.333 -2.839 . . . . 0.0 103.333 -172.547 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 m -69.08 101.22 1.38 Allowed 'General case' 1 C--N 1.226 -4.776 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 174.505 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.6 137.11 13.23 Favored Glycine 0 N--CA 1.41 -3.078 0 CA-C-N 114.321 -1.309 . . . . 0.0 112.723 -170.122 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.0 t70 61.74 -86.33 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 126.449 1.899 . . . . 0.0 114.106 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 110' ' ' HIS . . . . . 0.408 ' HB2' ' O ' ' A' ' 113' ' ' ILE . 16.2 m80 -82.82 -49.02 10.13 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 175.441 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 18.5 m 168.03 -85.46 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 126.357 1.863 . . . . 0.0 111.026 173.114 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.3 mt -109.61 -54.42 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 14.0 tt -83.74 175.64 0.72 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.024 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.377 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.44 ' H ' HG12 ' A' ' 113' ' ' ILE . . . 89.43 22.77 36.17 Favored Glycine 0 CA--C 1.478 -2.278 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.918 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.427 HH22 HD12 ' A' ' 149' ' ' ILE . 44.4 mtm180 -146.98 123.12 10.83 Favored 'General case' 0 C--O 1.2 -1.539 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 11.4 p -102.09 115.48 30.63 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 171.688 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.605 ' HA ' ' OD1' ' A' ' 83' ' ' ASP . 2.2 pt? -71.05 148.07 47.92 Favored 'General case' 0 CA--C 1.506 -0.716 0 O-C-N 123.865 0.728 . . . . 0.0 112.434 -170.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.547 HG22 ' HB3' ' A' ' 140' ' ' ALA . 1.8 p -125.63 99.64 6.14 Favored 'Isoleucine or valine' 1 C--O 1.38 7.933 0 C-N-CA 117.118 -1.833 . . . . 0.0 112.653 172.507 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 t -148.69 151.48 13.14 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 C-N-CA 126.429 1.892 . . . . 0.0 106.153 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -144.52 170.35 16.22 Favored 'General case' 0 C--O 1.243 0.712 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 175.272 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.4 mp0 -67.86 89.93 0.29 Allowed 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 177.129 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 122' ' ' LYS . . . . . 0.5 ' HG2' ' H ' ' A' ' 123' ' ' ALA . 50.8 tttm -162.99 171.58 16.31 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -174.799 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 123' ' ' ALA . . . . . 0.668 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . . . -123.22 107.27 11.52 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.45 -88.3 0.44 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.993 165.629 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 125' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 21.9 t70 172.44 157.36 0.1 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.215 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.515 ' H ' HD23 ' A' ' 126' ' ' LEU . 1.6 pt? -90.62 -29.34 17.84 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -105.5 -23.59 7.5 Favored Glycine 0 N--CA 1.464 0.522 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.847 -177.986 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -128.48 51.99 1.95 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 177.209 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.86 82.2 0.41 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.37 -0.832 . . . . 0.0 114.35 -174.963 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.9 -127.56 8.48 Favored Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 121.376 -0.44 . . . . 0.0 112.808 174.796 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -98.41 -176.89 3.52 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.436 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 39.1 tt0 -61.88 -50.97 70.08 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 119.074 0.852 . . . . 0.0 112.993 -175.98 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -64.29 -31.06 72.12 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.463 178.063 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 m -68.48 -38.56 81.13 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 122.724 0.41 . . . . 0.0 110.64 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.9 p -65.57 -27.23 68.28 Favored 'General case' 0 C--N 1.349 0.578 0 CA-C-O 121.121 0.486 . . . . 0.0 110.748 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 136' ' ' LYS . . . . . 0.436 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 92.9 mttt -84.99 -16.45 40.82 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.061 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 31.0 m -87.98 -17.58 30.93 Favored 'General case' 0 CA--C 1.564 1.504 0 CA-C-O 121.841 0.829 . . . . 0.0 110.347 175.755 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.24 48.6 30.57 Favored Glycine 1 C--O 1.39 9.847 0 N-CA-C 108.629 -1.788 . . . . 0.0 108.629 -173.45 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -30.22 106.29 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 128.963 2.905 . . . . 0.0 114.496 -158.752 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.547 ' HB3' HG22 ' A' ' 118' ' ' VAL . . . -155.59 171.82 19.32 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 167.67 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.47 119.28 16.13 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 167.522 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.7 m -41.63 -46.84 3.79 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 115.484 1.661 . . . . 0.0 115.484 -166.878 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.732 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 0.1 OUTLIER -132.42 11.51 4.51 Favored 'General case' 0 C--N 1.288 -2.105 0 C-N-CA 118.891 -1.124 . . . . 0.0 108.529 174.845 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.6 mt -71.69 -17.33 62.23 Favored 'General case' 0 CA--C 1.497 -1.09 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.297 -170.633 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.35 89.67 1.59 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.96 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.732 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 53.0 m -131.2 153.95 48.92 Favored 'General case' 0 N--CA 1.424 -1.726 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.253 -178.742 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.74 148.65 11.58 Favored Glycine 0 N--CA 1.409 -3.136 0 N-CA-C 108.025 -2.03 . . . . 0.0 108.025 176.021 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 93.8 t -69.23 105.62 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 176.814 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.695 ' HA ' ' HB2' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -88.74 103.2 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.703 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.07 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.36 -177.79 48.48 Favored Glycine 1 N--CA 1.383 -4.871 0 C-N-CA 119.081 -1.533 . . . . 0.0 112.266 -178.657 . . . . . . . . 3 3 . 1 . 018 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.7 tt -53.32 112.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 125.119 1.367 . . . . 0.0 113.184 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.72 99.94 3.83 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 171.801 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.288 -2.095 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -177.419 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.702 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.4 m -94.26 -26.81 16.46 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.39 1.09 . . . . 0.0 108.606 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -166.03 172.11 11.78 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 174.626 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 4' ' ' ALA . . . . . 0.719 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -151.71 158.97 44.11 Favored 'General case' 0 C--N 1.287 -2.149 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.538 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 5' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 86.7 t -140.93 121.41 13.14 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.365 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -177.855 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.12 145.74 50.63 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 -177.47 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 p -135.36 125.87 44.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 O-C-N 123.66 0.6 . . . . 0.0 109.391 -179.15 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 8' ' ' LEU . . . . . 0.454 ' H ' HD23 ' A' ' 8' ' ' LEU . 1.4 pt? -125.52 144.24 50.64 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.52 -175.07 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -163.43 135.55 5.12 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 107.084 -1.451 . . . . 0.0 107.084 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.95 -157.17 7.99 Favored Glycine 0 C--N 1.301 -1.378 0 C-N-CA 120.233 -0.984 . . . . 0.0 112.265 -175.863 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -55.0 -50.95 67.73 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.262 1.025 . . . . 0.0 110.505 177.051 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -92.15 163.91 28.15 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -90.57 123.56 0.97 Allowed 'Trans proline' 0 N--CA 1.418 -2.921 0 CA-C-N 120.473 2.136 . . . . 0.0 111.026 -177.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 m -133.3 131.52 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.042 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 15' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -145.97 123.17 11.52 Favored 'General case' 0 C--N 1.269 -2.933 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.604 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.97 161.64 34.89 Favored Glycine 0 N--CA 1.41 -3.042 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.0 tt -132.5 110.23 15.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 18' ' ' ILE . . . . . 0.512 HD13 ' H ' ' A' ' 18' ' ' ILE . 0.1 OUTLIER -107.65 132.84 54.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 -179.763 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 19' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 2.7 m-20 -106.05 139.62 40.3 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.904 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 20' ' ' PHE . . . . . 0.719 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 24.4 t80 -137.47 127.6 26.05 Favored 'General case' 0 C--O 1.252 1.186 0 CA-C-N 118.996 0.816 . . . . 0.0 111.577 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -134.38 102.45 5.34 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-O 121.797 0.808 . . . . 0.0 112.823 -178.625 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 22' ' ' GLN . . . . . 0.681 HE21 ' HG ' ' A' ' 106' ' ' LEU . 2.5 pm0 -127.71 162.91 25.47 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -178.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER 64.63 -56.39 0.27 Allowed 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.808 1.243 . . . . 0.0 113.001 176.352 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.72 -43.93 87.59 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.157 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.0 m -81.49 -65.85 0.96 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 171.459 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 57.45 96.52 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 124.33 1.052 . . . . 0.0 109.924 177.83 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 27' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 29' ' ' VAL . . . 140.53 -143.21 13.19 Favored Glycine 0 CA--C 1.463 -3.198 0 C-N-CA 118.545 -1.788 . . . . 0.0 108.692 -172.467 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.47 122.06 10.51 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 N-CA-C 107.403 -1.807 . . . . 0.0 107.403 175.549 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 29' ' ' VAL . . . . . 0.737 HG12 HG13 ' A' ' 31' ' ' VAL . 55.7 t -102.69 113.36 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.807 0 CA-C-O 121.673 0.749 . . . . 0.0 109.927 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -84.61 102.73 13.14 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.616 -1.629 . . . . 0.0 109.799 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 31' ' ' VAL . . . . . 0.737 HG13 HG12 ' A' ' 29' ' ' VAL . 26.8 m -130.35 144.6 37.47 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.683 -176.002 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 32' ' ' TRP . . . . . 0.409 ' HA ' HG11 ' A' ' 97' ' ' VAL . 66.1 p-90 -148.12 134.67 19.76 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.587 178.333 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 33' ' ' GLY . . . . . 0.566 ' O ' HG22 ' A' ' 97' ' ' VAL . . . -164.03 137.9 5.0 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 119.132 -1.509 . . . . 0.0 113.119 169.36 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.8 m -114.23 126.62 55.25 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -177.468 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -130.26 133.18 64.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-O 121.261 0.553 . . . . 0.0 111.188 -177.458 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 36' ' ' LYS . . . . . 0.453 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 22.1 ptmt -106.59 133.2 51.63 Favored 'General case' 0 N--CA 1.419 -2.008 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.596 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 37' ' ' GLY . . . . . 0.521 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -157.97 174.37 35.26 Favored Glycine 0 N--CA 1.421 -2.316 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -170.246 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 tp -68.72 171.99 6.99 Favored 'General case' 0 CA--C 1.567 1.598 0 C-N-CA 123.305 0.642 . . . . 0.0 109.47 178.307 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 39' ' ' THR . . . . . 0.517 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 7.2 t -67.59 111.07 3.97 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.42 -0.8 . . . . 0.0 112.73 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 40' ' ' GLU . . . . . 0.576 ' H ' ' HA ' ' A' ' 90' ' ' ASP . 0.2 OUTLIER -163.56 174.15 12.15 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-O 123.127 1.441 . . . . 0.0 113.811 178.079 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.92 -144.53 0.05 OUTLIER Glycine 2 C--N 1.238 -4.901 0 CA-C-N 110.477 -3.056 . . . . 0.0 114.125 173.754 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 42' ' ' LEU . . . . . 0.59 ' HB3' HG22 ' A' ' 88' ' ' THR . 2.4 pt? -138.42 148.37 44.36 Favored 'General case' 1 N--CA 1.37 -4.428 0 CA-C-N 114.161 -1.019 . . . . 0.0 110.641 -164.933 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 43' ' ' HIS . . . . . 0.474 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 11.0 p80 -104.54 138.91 40.19 Favored 'General case' 0 CA--C 1.438 -3.335 0 C-N-CA 119.392 -0.923 . . . . 0.0 108.653 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -99.19 0.02 OUTLIER Glycine 0 N--CA 1.402 -3.577 0 O-C-N 125.215 1.572 . . . . 0.0 111.128 173.341 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 45' ' ' PHE . . . . . 0.649 ' HB3' ' O ' ' A' ' 83' ' ' ASP . 2.5 m-85 -165.68 93.97 0.58 Allowed 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 117.716 -1.135 . . . . 0.0 111.105 -166.97 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 46' ' ' HIS . . . . . 0.605 ' CD2' ' HB2' ' A' ' 126' ' ' LEU . 14.3 t60 -170.85 86.47 0.1 Allowed 'General case' 0 C--O 1.284 2.901 0 CA-C-N 120.301 1.41 . . . . 0.0 114.493 171.886 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -74.93 154.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.732 0 CA-C-N 113.553 -1.658 . . . . 0.0 107.119 165.156 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 48' ' ' HIS . . . . . 0.49 ' HA ' ' HB ' ' A' ' 81' ' ' VAL . 25.9 p80 -159.24 114.06 2.44 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 116.511 -1.709 . . . . 0.0 107.08 172.514 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 49' ' ' GLU . . . . . 0.604 ' HA ' ' OE1' ' A' ' 49' ' ' GLU 0.484 0.0 OUTLIER -173.74 168.2 4.37 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 165.377 . . . . . . . . 4 4 . 1 . 019 nuclear build full ' A' A ' 50' ' ' PHE . . . . . 0.49 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 26.8 p90 -115.22 19.46 15.59 Favored 'General case' 0 N--CA 1.404 -2.743 0 CA-C-N 112.654 -2.067 . . . . 0.0 109.108 176.751 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 51' ' ' GLY . . . . . 0.616 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 85.06 138.94 4.49 Favored Glycine 0 N--CA 1.47 0.959 0 N-CA-C 115.017 0.767 . . . . 0.0 115.017 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -144.9 -72.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.674 -0.81 . . . . 0.0 109.148 173.643 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -168.81 158.74 9.16 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 176.536 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 m -65.58 -48.41 72.44 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 123.633 0.773 . . . . 0.0 111.023 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.69 -7.88 42.46 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.003 -171.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.34 109.85 0.47 Allowed Glycine 0 CA--C 1.463 -3.214 0 C-N-CA 118.794 -1.669 . . . . 0.0 110.449 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 57' ' ' CYS . . . . . 0.847 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 15.8 p -101.89 87.42 3.11 Favored 'General case' 0 N--CA 1.392 -3.368 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 174.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.1 m -82.43 -50.09 9.26 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 122.755 1.265 . . . . 0.0 108.943 174.662 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 59' ' ' SER . . . . . 0.49 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 15.2 m -72.16 -8.15 53.11 Favored 'General case' 0 C--O 1.209 -1.038 0 CA-C-N 113.457 -1.702 . . . . 0.0 112.982 -175.151 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 60' ' ' ALA . . . . . 0.582 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . . . -77.29 -7.29 55.74 Favored 'General case' 0 CA--C 1.494 -1.192 0 C-N-CA 124.785 1.234 . . . . 0.0 111.216 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.7 52.09 0.83 Allowed Glycine 0 N--CA 1.406 -3.357 0 C-N-CA 117.762 -2.161 . . . . 0.0 116.016 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 62' ' ' PRO . . . . . 0.478 ' HD3' ' C ' ' A' ' 60' ' ' ALA . 1.2 Cg_endo -90.42 -6.74 4.37 Favored 'Trans proline' 0 C--N 1.395 3.009 0 CA-C-N 121.788 2.794 . . . . 0.0 106.995 164.052 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 63' ' ' HIS . . . . . 0.449 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 64.0 m-70 72.48 -58.06 0.61 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 114.149 -1.387 . . . . 0.0 111.355 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -112.63 116.52 30.31 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 122.322 -0.236 . . . . 0.0 110.936 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 65' ' ' ASN . . . . . 0.516 ' HB3' ' HG3' ' A' ' 79' ' ' ARG . 0.8 OUTLIER -77.23 144.48 71.2 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.386 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.54 -54.32 1.05 Allowed 'Trans proline' 0 CA--C 1.553 1.441 0 C-N-CA 122.907 2.404 . . . . 0.0 117.234 -170.556 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 67' ' ' LEU . . . . . 0.59 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 4.2 mm? -82.72 8.48 12.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.208 -1.397 . . . . 0.0 112.176 -173.262 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 68' ' ' SER . . . . . 0.614 ' HA ' ' OE1' ' A' ' 77' ' ' GLU . 69.6 m -72.2 39.27 0.07 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 122.614 1.197 . . . . 0.0 111.085 173.211 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 69' ' ' ARG . . . . . 0.541 ' H ' ' C ' ' A' ' 67' ' ' LEU . 73.6 mtt-85 -100.56 3.4 42.69 Favored 'General case' 0 N--CA 1.386 -3.674 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.673 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 70' ' ' LYS . . . . . 0.413 ' HB2' ' N ' ' A' ' 78' ' ' GLU . 47.8 mttp -109.31 30.06 6.96 Favored 'General case' 0 CA--C 1.495 -1.172 0 C-N-CA 118.975 -1.09 . . . . 0.0 110.768 169.797 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 70.56 86.11 0.13 Allowed 'General case' 0 N--CA 1.435 -1.177 0 CA-C-N 113.967 -1.47 . . . . 0.0 112.913 177.183 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLY . . . . . 0.55 ' HA2' ' CG ' ' A' ' 77' ' ' GLU . . . -53.54 83.1 0.01 OUTLIER Glycine 0 CA--C 1.508 -0.382 0 CA-C-N 114.59 -1.186 . . . . 0.0 112.573 169.016 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' GLY . . . . . 0.476 ' O ' ' HA3' ' A' ' 82' ' ' GLY . . . -141.84 -151.17 5.48 Favored Glycine 0 N--CA 1.401 -3.639 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 178.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' PRO . . . . . 0.433 ' CB ' ' HB3' ' A' ' 84' ' ' LEU . 98.8 Cg_endo -81.94 -41.3 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.332 0 N-CA-C 117.905 2.233 . . . . 0.0 117.905 -169.335 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -93.95 -26.21 16.94 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 116.446 2.017 . . . . 0.0 116.446 -162.488 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -171.59 143.12 1.7 Allowed 'General case' 0 CA--C 1.475 -1.931 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 -169.477 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 77' ' ' GLU . . . . . 0.614 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -160.05 151.0 19.1 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -175.845 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 78' ' ' GLU . . . . . 0.59 ' HB3' ' O ' ' A' ' 67' ' ' LEU . 15.4 tp10 -90.18 -19.2 24.5 Favored 'General case' 0 CA--C 1.555 1.142 0 O-C-N 123.446 0.466 . . . . 0.0 111.921 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HB2' ' C ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -101.0 -8.23 22.56 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 104.302 -2.481 . . . . 0.0 104.302 172.232 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 80' ' ' HIS . . . . . 0.479 ' HA ' ' HB3' ' A' ' 77' ' ' GLU . 18.8 m-70 76.06 -0.47 3.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 113.211 -1.813 . . . . 0.0 110.901 175.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' VAL . . . . . 0.509 HG22 ' HB3' ' A' ' 79' ' ' ARG . 24.7 m -82.05 80.64 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 CA-C-O 123.633 1.682 . . . . 0.0 112.56 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 82' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 73' ' ' GLY . . . -152.12 118.89 0.93 Allowed Glycine 1 C--N 1.251 -4.165 0 CA-C-N 112.656 -2.065 . . . . 0.0 110.668 176.186 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 83' ' ' ASP . . . . . 0.649 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 7.7 p-10 -92.95 169.16 10.65 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 175.492 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' LEU . . . . . 0.444 HD22 ' HB3' ' A' ' 100' ' ' GLU 0.404 1.1 pp -136.53 89.05 2.42 Favored 'General case' 0 N--CA 1.408 -2.534 0 CA-C-O 122.818 1.294 . . . . 0.0 112.608 170.634 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.33 87.31 0.13 Allowed Glycine 1 N--CA 1.389 -4.494 0 CA-C-N 113.771 -1.559 . . . . 0.0 110.034 177.416 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 86' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 43' ' ' HIS . 24.7 t30 -72.79 128.17 34.73 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 174.091 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 87' ' ' VAL . . . . . 0.625 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 6.5 m -143.09 127.38 14.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 O-C-N 123.839 0.712 . . . . 0.0 110.684 -176.237 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' THR . . . . . 0.59 HG22 ' HB3' ' A' ' 42' ' ' LEU 0.257 4.9 p -101.02 101.45 12.23 Favored 'General case' 0 CA--C 1.561 1.396 0 C-N-CA 128.175 2.59 . . . . 0.0 111.991 -176.396 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 89' ' ' ALA . . . . . 0.407 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -118.92 108.27 14.59 Favored 'General case' 0 CA--C 1.473 -2.006 0 CA-C-N 120.579 1.536 . . . . 0.0 109.423 -178.646 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' H ' ' A' ' 40' ' ' GLU . 38.3 t70 -90.96 -165.43 1.35 Allowed 'General case' 0 C--N 1.278 -2.532 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.531 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 91' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 21.9 ptmt -42.93 -32.17 0.6 Allowed 'General case' 0 N--CA 1.51 2.568 0 C-N-CA 126.439 1.895 . . . . 0.0 115.663 -175.124 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -91.22 -37.17 13.49 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-O 122.525 1.155 . . . . 0.0 107.925 -178.168 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' GLY . . . . . 0.521 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 91.35 78.84 1.38 Allowed Glycine 1 N--CA 1.384 -4.805 0 CA-C-N 114.173 -1.376 . . . . 0.0 111.145 -176.578 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.7 t -142.69 101.15 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.175 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 176.835 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ALA . . . . . 0.625 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -100.46 140.49 34.64 Favored 'General case' 0 N--CA 1.404 -2.763 0 O-C-N 123.699 0.624 . . . . 0.0 112.184 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -94.69 129.72 41.48 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 175.147 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 97' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 33' ' ' GLY . 0.9 OUTLIER -82.45 124.08 38.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 O-C-N 123.665 0.603 . . . . 0.0 111.397 -177.377 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 98' ' ' SER . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . 46.9 m -87.29 108.84 19.14 Favored 'General case' 0 N--CA 1.4 -2.972 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 168.352 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 99' ' ' ILE . . . . . 0.412 ' HA ' ' CG2' ' A' ' 31' ' ' VAL . 3.5 tt -90.77 123.03 42.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 114.79 -1.096 . . . . 0.0 108.55 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 100' ' ' GLU . . . . . 0.444 ' HB3' HD22 ' A' ' 84' ' ' LEU . 7.8 tp10 -138.94 157.61 45.7 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 114.554 -1.203 . . . . 0.0 111.145 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -81.46 103.33 11.13 Favored 'General case' 0 C--N 1.275 -2.64 0 C-N-CA 126.871 2.069 . . . . 0.0 112.586 -177.105 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' HG21 ' A' ' 29' ' ' VAL . 23.6 p -102.58 164.84 11.43 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.407 -0.808 . . . . 0.0 110.607 169.978 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.7 m -108.97 -63.5 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 C-N-CA 118.517 -1.273 . . . . 0.0 112.405 175.318 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 13.1 tt -128.15 23.98 2.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 121.571 0.701 . . . . 0.0 111.19 -169.252 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 105' ' ' SER . . . . . 0.6 ' C ' ' HG3' ' A' ' 22' ' ' GLN . 13.6 m -82.0 85.15 6.77 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.345 -1.742 . . . . 0.0 111.854 -178.263 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 106' ' ' LEU . . . . . 0.681 ' HG ' HE21 ' A' ' 22' ' ' GLN . 7.0 mp -76.18 117.58 18.02 Favored 'General case' 0 C--O 1.195 -1.791 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 170.599 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 107' ' ' SER . . . . . 0.554 ' O ' ' HA ' ' A' ' 112' ' ' ILE . 9.3 m -69.48 86.71 0.45 Allowed 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 119.909 1.231 . . . . 0.0 111.717 -175.092 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 108' ' ' GLY . . . . . 0.574 ' HA3' ' HG3' ' A' ' 115' ' ' ARG . . . 124.45 135.57 4.46 Favored Glycine 0 N--CA 1.427 -1.935 0 CA-C-N 113.83 -1.532 . . . . 0.0 109.749 177.11 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 109' ' ' ASP . . . . . 0.471 ' HB3' ' NH1' ' A' ' 79' ' ' ARG . 18.0 t70 -78.34 -36.26 46.47 Favored 'General case' 0 CA--C 1.5 -0.968 0 C-N-CA 117.686 -1.606 . . . . 0.0 111.134 175.705 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -68.77 -34.01 74.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.334 -175.099 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t 178.35 169.64 0.79 Allowed 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 103.844 -2.651 . . . . 0.0 103.844 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 112' ' ' ILE . . . . . 0.596 HG22 ' HA2' ' A' ' 150' ' ' GLY . 57.2 mt -93.66 -51.91 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.266 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 174.092 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 113' ' ' ILE . . . . . 0.687 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 3.7 mp -64.21 99.36 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.494 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.696 -170.333 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 114' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 127.46 -7.67 7.04 Favored Glycine 0 N--CA 1.428 -1.891 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.557 174.165 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 115' ' ' ARG . . . . . 0.616 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 1.6 mmp_? -81.36 133.48 35.43 Favored 'General case' 0 C--O 1.198 -1.653 0 C-N-CA 119.434 -0.907 . . . . 0.0 108.804 -176.536 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 80.3 m -69.87 126.75 30.64 Favored 'General case' 0 C--N 1.295 -1.792 0 CA-C-O 121.114 0.483 . . . . 0.0 112.017 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 117' ' ' LEU . . . . . 0.531 ' HA ' HG13 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -75.36 97.02 3.51 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.151 174.248 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 118' ' ' VAL . . . . . 0.55 HG12 ' HB3' ' A' ' 140' ' ' ALA . 13.0 t -94.02 94.69 4.7 Favored 'Isoleucine or valine' 1 C--O 1.338 5.725 0 C-N-CA 115.78 -2.368 . . . . 0.0 110.079 -173.317 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 119' ' ' VAL . . . . . 0.462 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . 22.8 m -149.46 170.09 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 128.84 2.856 . . . . 0.0 106.636 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 120' ' ' HIS . . . . . 0.423 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 67.6 t60 -156.61 171.55 20.13 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.838 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 121' ' ' GLU . . . . . 0.543 ' CD ' ' H ' ' A' ' 121' ' ' GLU . 0.9 OUTLIER -70.12 83.6 0.52 Allowed 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 121.085 1.766 . . . . 0.0 106.863 173.919 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -176.63 155.65 1.37 Allowed 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 173.201 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.87 124.54 14.35 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 119.296 0.953 . . . . 0.0 112.853 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 124' ' ' ASP . . . . . 0.59 ' OD2' ' HB2' ' A' ' 140' ' ' ALA . 9.5 t70 -129.35 102.56 6.48 Favored 'General case' 0 CA--C 1.48 -1.742 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 -178.206 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -143.71 147.84 34.83 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.365 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 126' ' ' LEU . . . . . 0.605 ' HB2' ' CD2' ' A' ' 46' ' ' HIS . 43.4 tp -91.5 -28.53 17.54 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.641 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.78 -61.46 4.65 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 119.943 -1.123 . . . . 0.0 111.718 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -137.17 52.58 1.91 Allowed 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.16 0.505 . . . . 0.0 111.577 177.817 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.53 78.21 0.87 Allowed Glycine 0 C--N 1.297 -1.623 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.233 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -109.08 3.57 Favored Glycine 0 N--CA 1.442 -0.9 0 C-N-CA 121.752 -0.261 . . . . 0.0 112.937 175.454 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 131' ' ' ASN . . . . . 0.459 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.9 t30 -104.24 167.42 9.77 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -179.547 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 132' ' ' GLU . . . . . 0.507 ' O ' HG22 ' A' ' 135' ' ' THR . 8.5 mm-40 -51.78 -44.7 63.51 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -178.204 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -77.17 -24.66 51.46 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 121.829 -0.544 . . . . 0.0 112.283 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 134' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 5.7 m -80.04 -22.45 42.34 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-O 121.357 0.599 . . . . 0.0 109.819 -179.018 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 135' ' ' THR . . . . . 0.513 ' O ' HD12 ' A' ' 126' ' ' LEU . 1.8 t -81.22 -18.91 44.46 Favored 'General case' 0 N--CA 1.42 -1.945 0 C-N-CA 119.518 -0.873 . . . . 0.0 109.643 178.827 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -69.58 -36.63 76.43 Favored 'General case' 0 C--O 1.224 -0.283 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.081 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 137' ' ' THR . . . . . 0.449 ' HA ' ' HB3' ' A' ' 63' ' ' HIS . 13.6 t -86.56 -16.46 36.76 Favored 'General case' 0 C--O 1.26 1.647 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.893 -177.297 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.61 69.6 1.32 Allowed Glycine 1 C--O 1.3 4.225 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 -172.059 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.0 t30 -33.75 104.37 0.03 OUTLIER 'General case' 0 CA--C 1.482 -1.645 0 O-C-N 127.49 2.523 . . . . 0.0 116.21 -164.421 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 140' ' ' ALA . . . . . 0.59 ' HB2' ' OD2' ' A' ' 124' ' ' ASP . . . -153.51 170.5 20.61 Favored 'General case' 0 N--CA 1.401 -2.877 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 171.371 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 141' ' ' GLY . . . . . 0.548 ' HA3' HD23 ' A' ' 144' ' ' LEU . . . -87.4 137.17 14.43 Favored Glycine 0 C--N 1.272 -2.973 0 N-CA-C 105.718 -2.953 . . . . 0.0 105.718 165.976 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 24.5 m -54.59 -30.24 53.94 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -172.965 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 143' ' ' ARG . . . . . 0.847 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 30.8 ptt180 -124.15 15.21 9.12 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 144' ' ' LEU . . . . . 0.548 HD23 ' HA3' ' A' ' 141' ' ' GLY . 3.6 mm? -71.04 -9.09 57.44 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -175.728 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.44 89.29 0.75 Allowed 'General case' 0 N--CA 1.422 -1.826 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 172.057 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 146' ' ' CYS . . . . . 0.418 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 79.4 m -84.75 130.58 34.67 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.27 127.01 1.29 Allowed Glycine 1 N--CA 1.396 -4.014 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.57 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.0 m -74.27 125.47 33.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.998 172.852 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 149' ' ' ILE . . . . . 0.515 HG22 ' O ' ' A' ' 115' ' ' ARG . 15.5 tt -99.41 136.65 29.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 174.244 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 150' ' ' GLY . . . . . 0.687 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 177.13 167.74 35.97 Favored Glycine 2 CA--C 1.439 -4.663 0 C-N-CA 118.486 -1.816 . . . . 0.0 111.721 179.459 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 151' ' ' ILE . . . . . 0.667 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 5.6 tt -82.26 104.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.348 0 CA-C-O 122.178 0.99 . . . . 0.0 110.29 169.941 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 152' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -107.75 116.43 31.93 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.373 178.977 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 . . . . . 0 C--N 1.28 -2.441 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -177.812 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.436 -1.146 0 N-CA-C 111.475 0.176 . . . . 0.0 111.475 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.659 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 3.3 m -88.81 -26.92 21.43 Favored 'General case' 0 CA--C 1.568 1.64 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -167.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.527 ' HB3' ' NZ ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -152.17 158.53 43.03 Favored 'General case' 0 CA--C 1.455 -2.676 0 O-C-N 120.381 -1.449 . . . . 0.0 111.628 176.619 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -145.19 153.68 41.61 Favored 'General case' 0 N--CA 1.397 -3.081 0 O-C-N 124.081 0.863 . . . . 0.0 109.321 -175.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.1 m -132.21 132.01 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 176.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.74 136.7 47.88 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.562 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.624 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 4.4 p -134.27 106.66 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-O 121.662 0.744 . . . . 0.0 110.001 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.464 HD23 ' H ' ' A' ' 8' ' ' LEU . 0.8 OUTLIER -112.42 140.61 47.01 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.184 -178.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -144.54 123.48 12.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -131.92 -165.58 11.38 Favored Glycine 0 N--CA 1.434 -1.483 0 C-N-CA 119.682 -1.247 . . . . 0.0 113.707 -174.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -74.83 -42.75 57.43 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 177.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -94.94 154.01 21.05 Favored Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 106.269 -2.733 . . . . 0.0 106.269 170.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.41 121.7 5.76 Favored 'Trans proline' 0 N--CA 1.42 -2.822 0 CA-C-N 121.324 2.562 . . . . 0.0 109.535 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 17.4 m -133.32 124.98 50.07 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -150.0 142.73 24.64 Favored 'General case' 0 C--N 1.26 -3.283 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.292 -178.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.35 166.74 39.93 Favored Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.471 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.3 pt -134.33 103.23 4.7 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 CA-C-O 121.134 0.493 . . . . 0.0 109.692 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.08 126.83 57.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.575 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 7.7 p30 -125.39 122.56 37.1 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.471 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 6.4 p90 -128.22 128.19 44.27 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.659 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.4 pt-20 -106.76 109.23 21.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.888 176.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.497 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -126.2 162.13 26.12 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.199 1.0 . . . . 0.0 108.944 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -154.18 149.41 27.02 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -66.42 -9.08 30.41 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.6 m -70.38 -8.67 52.51 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.677 0.791 . . . . 0.0 111.655 177.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 75.6 115.21 0.06 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 124.444 1.097 . . . . 0.0 111.212 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.63 150.49 10.06 Favored Glycine 0 N--CA 1.424 -2.127 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 178.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -57.34 131.57 45.61 Favored 'Trans proline' 0 C--O 1.248 1.011 0 C-N-CA 122.585 2.19 . . . . 0.0 110.148 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.462 HG22 ' OG ' ' A' ' 102' ' ' SER . 2.9 m -83.48 128.46 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.353 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.376 -178.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 5.6 mtpm? -85.52 112.81 21.26 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 176.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.7 p -137.35 138.26 45.26 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.107 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.484 -168.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.467 ' HA ' HG11 ' A' ' 97' ' ' VAL . 33.9 t-105 -136.23 132.27 35.63 Favored 'General case' 0 C--N 1.277 -2.559 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.714 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -151.63 138.89 6.77 Favored Glycine 0 C--O 1.208 -1.486 0 C-N-CA 119.233 -1.46 . . . . 0.0 112.991 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.7 m -116.56 142.7 46.54 Favored 'General case' 0 N--CA 1.408 -2.528 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 176.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 76.0 mt -128.71 139.17 52.62 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 118.737 0.699 . . . . 0.0 109.335 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.655 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 22.4 ptmt -117.89 138.74 51.92 Favored 'General case' 0 N--CA 1.411 -2.414 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 173.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.649 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -161.37 176.56 37.9 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -166.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.9 mt -69.08 170.89 9.1 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 175.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.468 ' HB ' ' O ' ' A' ' 91' ' ' LYS . 2.8 t -69.31 108.29 3.63 Favored 'General case' 0 C--O 1.192 -1.969 0 O-C-N 121.615 -0.678 . . . . 0.0 112.292 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -172.86 171.7 4.26 Favored 'General case' 0 CA--C 1.461 -2.467 0 C-N-CA 124.55 1.14 . . . . 0.0 108.662 174.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 89' ' ' ALA . . . -82.55 -146.23 5.99 Favored Glycine 0 C--N 1.276 -2.787 0 O-C-N 124.875 1.359 . . . . 0.0 109.779 173.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 120' ' ' HIS . 2.8 tt 172.4 140.08 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 103.709 -2.7 . . . . 0.0 103.709 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -152.66 122.23 6.84 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.01 139.05 0.99 Allowed Glycine 0 C--N 1.301 -1.396 0 O-C-N 123.768 0.667 . . . . 0.0 113.999 177.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 0.2 OUTLIER -114.49 106.53 14.39 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 176.41 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.548 ' CE1' ' HA3' ' A' ' 138' ' ' GLY . 28.9 t-80 -130.13 89.19 2.76 Favored 'General case' 1 C--O 1.316 4.556 0 CA-C-O 122.134 0.968 . . . . 0.0 109.141 -176.709 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.603 HG13 ' HA ' ' A' ' 117' ' ' LEU . 94.5 t -92.56 152.0 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.357 0 CA-C-N 112.692 -2.049 . . . . 0.0 107.387 175.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -162.05 94.31 0.92 Allowed 'General case' 0 C--N 1.288 -2.074 0 O-C-N 124.083 0.864 . . . . 0.0 110.367 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.54 ' CG ' ' HB2' ' A' ' 60' ' ' ALA . 1.3 mm-40 -145.96 170.26 16.98 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 115.557 1.688 . . . . 0.0 115.557 -174.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.417 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 20.5 p90 -139.99 25.86 2.28 Favored 'General case' 0 N--CA 1.41 -2.463 0 CA-C-N 112.238 -2.255 . . . . 0.0 108.815 174.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . 84.47 129.02 1.8 Allowed Glycine 0 C--N 1.34 0.804 0 CA-C-N 114.586 -1.188 . . . . 0.0 115.447 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -140.8 -77.84 0.29 Allowed 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.578 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.4 ' O ' HG21 ' A' ' 116' ' ' THR . 28.0 t30 -157.69 133.09 8.96 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.431 ' HB ' HG23 ' A' ' 148' ' ' VAL . 13.0 t -73.26 4.6 4.37 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -173.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.69 -2.41 17.44 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.896 0.379 . . . . 0.0 110.348 177.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 157.56 124.72 0.81 Allowed Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.492 ' O ' ' HB3' ' A' ' 142' ' ' SER . 0.6 OUTLIER -97.67 112.78 24.52 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 113.565 0.95 . . . . 0.0 113.565 -176.399 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.7 m -75.61 -37.41 59.81 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.252 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.417 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 4.6 m -72.56 -26.68 61.82 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.621 0.724 . . . . 0.0 110.23 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.54 ' HB2' ' CG ' ' A' ' 49' ' ' GLU . . . -76.5 -8.77 57.86 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.039 -175.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.69 -93.3 0.03 OUTLIER Glycine 0 C--N 1.301 -1.384 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.345 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -95.88 53.31 0.17 Allowed 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 121.71 1.606 . . . . 0.0 113.349 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -125.73 117.06 22.64 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.919 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.561 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 52.8 p90 -87.07 138.52 31.42 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.196 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -115.51 95.84 44.35 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.568 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 56.7 Cg_endo -68.86 -10.79 30.14 Favored 'Trans proline' 0 C--O 1.213 -0.744 0 C-N-CA 124.035 3.157 . . . . 0.0 115.031 -173.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -77.12 -18.42 57.94 Favored 'General case' 0 C--O 1.199 -1.581 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -173.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 47.5 p -54.63 -84.34 0.01 OUTLIER 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 114.283 -1.326 . . . . 0.0 113.315 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.556 ' HB3' ' H ' ' A' ' 72' ' ' GLY . 1.9 tmt_? -134.91 30.13 3.4 Favored 'General case' 0 C--N 1.249 -3.8 0 N-CA-C 103.01 -2.959 . . . . 0.0 103.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 66' ' ' PRO . 69.7 mmtt 75.19 -41.23 0.45 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.04 -169.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.466 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 1.8 t-160 -121.74 -16.97 7.55 Favored 'General case' 0 N--CA 1.426 -1.652 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.075 171.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.556 ' H ' ' HB3' ' A' ' 69' ' ' ARG . . . 108.92 16.81 10.95 Favored Glycine 0 C--N 1.358 1.8 0 C-N-CA 118.519 -1.8 . . . . 0.0 115.881 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -38.26 146.98 0.12 Allowed Glycine 0 N--CA 1.491 2.338 0 CA-C-N 117.978 0.889 . . . . 0.0 113.69 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.88 -22.4 17.53 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.097 2.531 . . . . 0.0 113.869 -166.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -86.87 -12.83 46.66 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.945 -177.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 21.4 t0 70.35 159.93 0.2 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 124.493 1.117 . . . . 0.0 111.209 -175.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.503 ' HB2' ' NE ' ' A' ' 69' ' ' ARG . 22.7 tp10 -148.47 -24.99 0.33 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -178.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.462 ' HG2' ' HG2' ' A' ' 79' ' ' ARG . 27.6 tt0 -138.67 -64.02 0.53 Allowed 'General case' 0 N--CA 1.423 -1.815 0 C-N-CA 118.237 -1.385 . . . . 0.0 110.755 -176.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.695 ' O ' ' HA ' ' A' ' 68' ' ' SER . 15.4 ptt180 -173.72 62.6 0.02 OUTLIER 'General case' 0 N--CA 1.398 -3.052 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 -173.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 4.5 t60 . . . . . 0 N--CA 1.428 -1.539 0 CA-C-N 113.315 -1.766 . . . . 0.0 107.022 170.205 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER . . . . . 0 N--CA 1.432 -1.37 0 CA-C-O 121.751 0.786 . . . . 0.0 110.145 . . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.25 -178.64 47.61 Favored Glycine 1 N--CA 1.386 -4.684 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 176.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -128.2 129.74 46.92 Favored 'General case' 0 C--N 1.263 -3.194 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 169.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.582 HG23 HD22 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -133.78 147.89 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.083 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.529 ' HA ' ' HB3' ' A' ' 42' ' ' LEU . 89.0 m -139.93 113.0 8.21 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -176.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.464 ' O ' ' HA2' ' A' ' 41' ' ' GLY . . . -83.44 150.98 25.7 Favored 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.468 ' OD1' ' HG2' ' A' ' 91' ' ' LYS . 9.8 t70 -93.13 -179.02 4.96 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 174.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.468 ' HG2' ' OD1' ' A' ' 90' ' ' ASP . 22.1 pttp -61.21 -16.23 42.72 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 124.459 1.104 . . . . 0.0 111.822 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.3 4.62 48.71 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.937 -0.477 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.655 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 60.96 83.17 0.06 OUTLIER Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.047 -175.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 5.1 m -155.75 111.15 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.572 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -119.44 123.97 45.37 Favored 'General case' 0 N--CA 1.415 -2.184 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.644 -178.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.66 145.38 28.01 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.714 ' HB ' ' O ' ' A' ' 33' ' ' GLY . 7.5 p -84.55 125.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -173.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.4 t -90.48 115.52 27.7 Favored 'General case' 0 N--CA 1.404 -2.735 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 168.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 31' ' ' VAL . 34.9 mt -92.02 118.26 37.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -107.34 156.04 19.34 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.915 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -81.28 99.69 8.76 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 122.088 0.947 . . . . 0.0 109.452 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -97.79 171.74 8.12 Favored 'General case' 0 C--N 1.265 -3.091 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.238 -175.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.553 HG12 HG13 ' A' ' 104' ' ' ILE . 26.5 t -109.32 -64.51 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.368 0 C-N-CA 119.658 -0.817 . . . . 0.0 111.446 -177.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.553 HG13 HG12 ' A' ' 103' ' ' VAL . 8.4 mt -134.18 24.97 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 121.326 0.584 . . . . 0.0 109.854 -177.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.427 ' OG ' ' HB3' ' A' ' 80' ' ' HIS . 33.3 t -68.99 88.49 0.4 Allowed 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -170.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.562 HD23 ' H ' ' A' ' 106' ' ' LEU . 1.7 pt? -96.49 136.31 37.18 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 160.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -71.89 86.21 0.98 Allowed 'General case' 0 C--N 1.286 -2.174 0 CA-C-O 122.349 1.071 . . . . 0.0 112.755 -175.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 111' ' ' SER . . . 143.2 135.74 3.06 Favored Glycine 0 N--CA 1.409 -3.145 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.821 170.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 7.4 p-10 -93.46 -28.03 16.35 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 122.903 -0.174 . . . . 0.0 111.434 -177.336 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 48.4 m80 -91.22 -23.43 20.2 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.0 -178.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.668 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t 177.11 178.89 0.25 Allowed 'General case' 0 N--CA 1.426 -1.666 0 N-CA-C 104.083 -2.562 . . . . 0.0 104.083 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -113.43 -56.46 4.2 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 C-N-CA 124.589 1.156 . . . . 0.0 109.878 -175.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.47 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 52.5 mt -68.37 119.51 14.27 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.723 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -177.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.547 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 115.66 -19.27 14.38 Favored Glycine 0 CA--C 1.47 -2.751 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.668 ' CZ ' ' HB3' ' A' ' 111' ' ' SER . 4.5 mpt_? -74.85 128.45 35.61 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 0.2 OUTLIER -92.01 126.88 37.26 Favored 'General case' 0 C--N 1.258 -3.389 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.62 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.603 ' HA ' HG13 ' A' ' 47' ' ' VAL . 2.0 pt? -76.62 136.88 39.2 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -177.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.9 99.57 8.69 Favored 'Isoleucine or valine' 0 C--O 1.28 2.661 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.654 171.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.682 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.4 p -147.42 170.39 3.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 104.748 -2.316 . . . . 0.0 104.748 178.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.599 ' O ' ' HG ' ' A' ' 42' ' ' LEU . 81.7 t60 -170.89 171.25 6.06 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 103.312 -2.848 . . . . 0.0 103.312 175.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.526 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.04 87.07 0.37 Allowed 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 171.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.499 ' H ' ' HG ' ' A' ' 42' ' ' LEU . 16.3 tppt? -173.18 154.76 2.79 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.37 103.88 1.11 Allowed 'General case' 0 C--N 1.285 -2.236 0 CA-C-O 121.89 0.852 . . . . 0.0 109.991 166.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -106.51 70.31 0.82 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.549 -2.389 . . . . 0.0 104.549 175.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -68.11 161.41 26.95 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.128 -170.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.534 ' H ' HD22 ' A' ' 126' ' ' LEU . 0.3 OUTLIER -90.48 -68.92 0.76 Allowed 'General case' 0 N--CA 1.397 -3.103 0 CA-C-N 113.83 -1.532 . . . . 0.0 110.996 -167.381 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . 0.466 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -102.82 -16.55 21.41 Favored Glycine 0 N--CA 1.429 -1.773 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.984 -177.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.99 -31.51 16.3 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 117.16 0.48 . . . . 0.0 110.367 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 134' ' ' SER . . . 53.7 -89.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.972 0 O-C-N 123.709 0.63 . . . . 0.0 114.175 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -172.84 -86.19 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -96.78 162.33 13.47 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 176.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.518 ' O ' ' HB ' ' A' ' 135' ' ' THR . 10.1 pt-20 -38.9 -51.32 1.76 Allowed 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -170.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -71.62 -38.09 70.82 Favored 'General case' 0 C--N 1.311 -1.083 0 O-C-N 122.12 -0.362 . . . . 0.0 111.854 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.483 ' O ' ' HA3' ' A' ' 129' ' ' GLY . 14.4 m -72.45 -22.92 61.01 Favored 'General case' 0 C--O 1.218 -0.568 0 CA-C-O 121.488 0.661 . . . . 0.0 109.619 178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' ' 132' ' ' GLU . 66.4 m -67.16 -39.88 86.57 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-O 121.949 0.881 . . . . 0.0 108.845 173.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -71.3 -51.33 24.96 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.022 -1.445 . . . . 0.0 110.046 -177.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.561 ' HA ' ' HB3' ' A' ' 64' ' ' PHE . 41.1 p -74.68 -31.23 61.84 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.673 -177.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.548 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . 82.35 106.12 0.43 Allowed Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -174.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -32.84 140.31 0.04 OUTLIER 'General case' 1 C--O 1.329 5.254 0 C-N-CA 126.463 1.905 . . . . 0.0 115.47 -165.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -150.49 120.2 7.03 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.323 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -98.94 89.08 0.88 Allowed Glycine 0 N--CA 1.417 -2.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 169.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 6.2 m -42.79 -35.3 1.12 Allowed 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 126.727 2.011 . . . . 0.0 114.252 -171.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 17.9 ptt180 -125.35 5.12 7.71 Favored 'General case' 0 N--CA 1.414 -2.258 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.061 -177.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.09 -27.38 64.55 Favored 'General case' 0 C--N 1.291 -1.957 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.259 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.682 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.8 96.88 0.17 Allowed 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 43.4 t -140.5 147.78 40.08 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.087 -176.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.624 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.15 162.41 34.46 Favored Glycine 0 N--CA 1.403 -3.513 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 179.218 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 54' ' ' THR . 17.6 t -68.74 122.88 20.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.799 0.809 . . . . 0.0 111.149 175.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.647 HG12 ' O ' ' A' ' 115' ' ' ARG . 26.1 pt -111.97 146.25 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.868 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.17 155.92 15.44 Favored Glycine 2 N--CA 1.365 -6.07 0 C-N-CA 117.566 -2.254 . . . . 0.0 111.632 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.572 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 25.1 pt -63.08 105.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-N 114.854 -0.673 . . . . 0.0 110.369 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.53 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -105.62 114.15 28.14 Favored 'General case' 0 C--N 1.309 -1.168 0 O-C-N 121.9 -0.5 . . . . 0.0 110.663 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.318 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.226 -0.168 0 CA-C-O 120.629 0.252 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 p -81.65 -65.6 0.99 Allowed 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 178.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -170.78 171.98 5.89 Favored 'General case' 0 CA--C 1.488 -1.406 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -176.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.629 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -130.8 149.25 52.53 Favored 'General case' 0 N--CA 1.414 -2.225 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 172.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 149' ' ' ILE . 10.6 p -126.9 142.86 42.19 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -122.44 129.69 52.31 Favored 'General case' 0 C--N 1.286 -2.171 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.79 -177.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -129.15 111.73 23.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mp -108.08 152.12 24.95 Favored 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 120.972 -0.291 . . . . 0.0 111.243 178.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -136.08 131.36 34.73 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 106.187 -1.782 . . . . 0.0 106.187 175.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 12' ' ' GLY . . . -104.21 148.86 16.95 Favored Glycine 0 N--CA 1.41 -3.099 0 N-CA-C 117.991 1.956 . . . . 0.0 117.991 -168.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -83.78 -19.5 34.94 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 111.629 -2.286 . . . . 0.0 104.92 168.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . 0.42 ' O ' ' HA3' ' A' ' 10' ' ' GLY . . . -142.71 144.52 14.07 Favored Glycine 0 N--CA 1.421 -2.328 1 N-CA-C 101.215 -4.754 . . . . 0.0 101.215 168.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_exo -69.74 124.82 11.47 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 CA-C-N 122.221 3.01 . . . . 0.0 112.989 -168.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.6 104.94 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.997 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.481 176.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -117.87 119.95 36.41 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.202 -0.936 . . . . 0.0 111.879 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA3' HD12 ' A' ' 35' ' ' ILE . . . -170.54 171.83 43.85 Favored Glycine 0 N--CA 1.44 -1.042 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.9 pt -143.6 131.75 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.622 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 mp -128.96 133.3 66.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.623 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.2 m-20 -117.21 126.71 53.2 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.629 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 67.8 t80 -129.03 119.63 24.59 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.426 ' CG ' ' HB3' ' A' ' 30' ' ' LYS . 10.5 pt-20 -131.14 113.53 14.01 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.352 0.596 . . . . 0.0 111.823 177.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.688 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -86.59 163.88 17.18 Favored 'General case' 0 N--CA 1.414 -2.228 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 168.049 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -96.45 146.92 24.35 Favored 'General case' 0 C--N 1.275 -2.669 0 C-N-CA 119.088 -1.045 . . . . 0.0 112.429 -172.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -56.64 -40.69 75.87 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.8 1.313 . . . . 0.0 109.735 178.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.4 p -81.25 -70.99 0.49 Allowed 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 168.21 161.26 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 126.413 1.885 . . . . 0.0 106.386 175.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.582 ' H ' HG23 ' A' ' 103' ' ' VAL . . . 155.6 174.01 24.96 Favored Glycine 0 N--CA 1.41 -3.077 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 174.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.9 136.88 55.13 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 121.732 1.621 . . . . 0.0 108.889 177.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.595 HG12 ' HA ' ' A' ' 22' ' ' GLN . 30.1 m -74.17 147.6 8.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-O 121.849 0.833 . . . . 0.0 110.813 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.454 ' HA ' HD11 ' A' ' 99' ' ' ILE . 28.2 ttmt -99.28 115.05 28.25 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 174.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.5 p -137.58 128.62 39.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-O 121.253 0.549 . . . . 0.0 110.337 -177.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.401 ' HA ' HG11 ' A' ' 97' ' ' VAL . 89.1 t90 -133.37 126.88 32.28 Favored 'General case' 0 C--N 1.283 -2.285 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.63 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -142.0 139.72 9.51 Favored Glycine 0 N--CA 1.407 -3.246 0 C-N-CA 119.162 -1.494 . . . . 0.0 112.495 178.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.43 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 42.6 t -114.19 145.64 41.43 Favored 'General case' 0 C--N 1.284 -2.27 0 N-CA-C 107.292 -1.374 . . . . 0.0 107.292 176.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.646 HG22 ' HB2' ' A' ' 95' ' ' ALA . 3.2 tp -152.09 139.44 13.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 99.9 mttt -130.62 107.36 9.13 Favored 'General case' 0 C--N 1.281 -2.393 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 176.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.666 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -131.93 174.98 19.98 Favored Glycine 0 C--N 1.282 -2.434 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -171.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 121' ' ' GLU . 93.1 mt -68.72 170.14 9.98 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 118.113 0.956 . . . . 0.0 109.881 177.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 2.0 t -70.7 105.34 3.14 Favored 'General case' 0 CA--C 1.55 0.98 0 N-CA-C 114.367 1.247 . . . . 0.0 114.367 -171.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -177.26 165.06 2.24 Favored 'General case' 0 CA--C 1.456 -2.642 0 C-N-CA 128.594 2.758 . . . . 0.0 104.918 169.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 158.49 130.32 1.16 Allowed Glycine 3 N--CA 1.376 -5.338 0 C-N-CA 118.2 -1.952 . . . . 0.0 111.166 170.198 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mp -124.44 -86.33 0.63 Allowed 'General case' 0 N--CA 1.396 -3.174 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.491 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 79.9 m-70 -172.14 162.71 5.79 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 174.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 132.75 144.83 5.32 Favored Glycine 0 C--N 1.29 -2.002 0 C-N-CA 119.288 -1.434 . . . . 0.0 113.092 174.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' HB ' ' A' ' 47' ' ' VAL . 30.9 t80 -165.8 96.54 0.63 Allowed 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 124.927 1.291 . . . . 0.0 108.294 175.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 125' ' ' ASP . 0.2 OUTLIER -114.33 89.49 3.11 Favored 'General case' 0 N--CA 1.403 -2.794 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 177.599 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.64 ' HB ' ' CE1' ' A' ' 45' ' ' PHE . 14.6 p -69.85 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.927 0 CA-C-N 111.603 -2.544 . . . . 0.0 107.19 175.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.6 t60 -154.1 104.33 2.62 Favored 'General case' 1 C--N 1.233 -4.491 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.232 173.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.572 ' HB2' ' HB3' ' A' ' 109' ' ' ASP . 1.5 mp0 -67.77 158.34 32.64 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.017 -1.447 . . . . 0.0 109.16 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.1 t80 77.95 64.01 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 123.887 1.804 . . . . 0.0 107.423 -166.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.475 ' HA3' ' OG1' ' A' ' 116' ' ' THR . . . -112.63 -126.15 4.57 Favored Glycine 0 N--CA 1.416 -2.668 0 CA-C-N 111.454 -2.612 . . . . 0.0 107.173 174.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.436 ' H ' HG23 ' A' ' 116' ' ' THR . 33.0 t70 -176.97 -71.6 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 117.946 0.873 . . . . 0.0 112.758 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 37.6 p30 -131.76 177.1 7.78 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.682 0.753 . . . . 0.0 112.947 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.474 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 25.9 m -84.21 6.85 21.05 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 125.919 1.688 . . . . 0.0 110.602 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.27 -32.05 26.62 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.752 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 164.24 155.83 8.54 Favored Glycine 0 N--CA 1.412 -2.911 0 N-CA-C 108.859 -1.697 . . . . 0.0 108.859 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.62 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.2 m -83.25 89.58 7.0 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.4 p -75.81 -58.69 3.13 Favored 'General case' 0 N--CA 1.421 -1.923 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.965 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 70.8 m -68.7 -42.68 77.39 Favored 'General case' 0 N--CA 1.425 -1.701 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.47 -25.5 54.39 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.356 -176.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' HG21 ' A' ' 118' ' ' VAL . . . 49.24 -144.57 8.12 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -100.23 5.73 0.76 Allowed 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.803 2.335 . . . . 0.0 110.658 173.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.8 t60 -77.47 149.69 35.01 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.826 -169.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.481 ' HB2' ' O ' ' A' ' 80' ' ' HIS . 13.3 p90 -81.1 169.95 16.79 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.537 ' HB3' ' OG ' ' A' ' 68' ' ' SER . 53.0 t30 -105.52 143.19 26.31 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.77 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_exo -75.32 -13.58 20.71 Favored 'Trans proline' 0 C--O 1.225 -0.151 0 C-N-CA 121.79 1.66 . . . . 0.0 110.963 175.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.63 21.64 17.01 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 122.72 1.248 . . . . 0.0 108.69 -171.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.537 ' OG ' ' HB3' ' A' ' 65' ' ' ASN . 46.3 m -73.98 -1.53 20.26 Favored 'General case' 0 C--O 1.196 -1.734 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.265 174.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.645 ' HA ' ' H ' ' A' ' 79' ' ' ARG . 3.9 mmp_? -68.59 -4.03 13.91 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 129.158 2.983 . . . . 0.0 109.589 177.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -140.54 29.73 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.725 -1.125 . . . . 0.0 108.196 176.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.5 ' HB3' ' N ' ' A' ' 84' ' ' LEU . 99.0 m-70 -143.97 -93.08 0.11 Allowed 'General case' 0 CA--C 1.556 1.176 0 C-N-CA 124.249 1.02 . . . . 0.0 109.392 176.326 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.601 ' HA2' ' HB2' ' A' ' 79' ' ' ARG . . . 81.94 -63.62 4.36 Favored Glycine 0 CA--C 1.501 -0.824 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 173.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.36 161.35 35.16 Favored Glycine 0 C--N 1.264 -3.454 0 N-CA-C 107.566 -2.214 . . . . 0.0 107.566 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.565 ' HA ' ' HG ' ' A' ' 84' ' ' LEU . 19.2 Cg_endo -55.58 -30.35 74.23 Favored 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 123.877 3.051 . . . . 0.0 115.266 -174.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.7 tppt? -101.97 -5.09 25.07 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.318 0.58 . . . . 0.0 110.144 -177.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -110.38 -163.45 0.86 Allowed 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 -177.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -171.18 41.57 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.835 0.854 . . . . 0.0 111.182 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.702 ' O ' ' HG2' ' A' ' 79' ' ' ARG . 11.4 pt-20 -163.15 149.25 12.04 Favored 'General case' 0 C--O 1.161 -3.584 0 CA-C-O 116.657 -1.64 . . . . 0.0 106.721 175.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.702 ' HG2' ' O ' ' A' ' 78' ' ' GLU . 6.2 mmt180 161.84 -165.1 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 128.125 2.57 . . . . 0.0 107.848 170.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' A' ' 64' ' ' PHE . 43.3 m-70 . . . . . 0 C--N 1.276 -2.629 0 C-N-CA 125.619 1.568 . . . . 0.0 108.278 171.585 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.565 ' HG ' ' HA ' ' A' ' 74' ' ' PRO . 6.7 tt . . . . . 0 N--CA 1.445 -0.708 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.592 ' C ' ' HB3' ' A' ' 45' ' ' PHE . . . 176.88 178.66 46.8 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 169.496 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.489 ' N ' ' HB3' ' A' ' 45' ' ' PHE . 8.8 p30 -159.42 135.69 9.0 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 173.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 75.2 t -127.56 151.61 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.293 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.6 m -134.65 148.59 50.4 Favored 'General case' 0 N--CA 1.404 -2.758 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -149.12 153.59 37.98 Favored 'General case' 1 C--N 1.243 -4.053 0 N-CA-C 102.199 -3.26 . . . . 0.0 102.199 173.012 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 13.6 t70 -128.0 -158.24 0.86 Allowed 'General case' 0 C--N 1.251 -3.686 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.547 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 60.5 mttp -68.25 5.85 0.89 Allowed 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 124.138 0.975 . . . . 0.0 113.278 -179.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -116.76 -9.38 11.27 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 175.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 64.77 72.93 0.63 Allowed Glycine 0 C--O 1.224 -0.526 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.897 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 62.8 t -154.57 133.3 3.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -175.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.646 ' HB2' HG22 ' A' ' 35' ' ' ILE . . . -94.35 127.22 40.1 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-O 122.367 1.08 . . . . 0.0 113.777 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -105.75 107.04 17.83 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 102.177 -3.268 . . . . 0.0 102.177 160.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.63 HG11 ' H ' ' A' ' 33' ' ' GLY . 9.4 p -83.34 137.56 20.76 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.4 0 C-N-CA 117.949 -1.501 . . . . 0.0 108.806 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 45.8 m -86.99 121.05 28.92 Favored 'General case' 0 N--CA 1.387 -3.597 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 171.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.454 HD11 ' HA ' ' A' ' 30' ' ' LYS . 2.9 tt -90.81 115.05 29.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 175.092 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.492 ' HG3' ' HB2' ' A' ' 74' ' ' PRO . 5.6 mm-40 -106.22 157.36 17.63 Favored 'General case' 0 CA--C 1.48 -1.738 0 CA-C-N 113.89 -1.505 . . . . 0.0 111.596 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.23 96.17 10.23 Favored 'General case' 0 N--CA 1.426 -1.665 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.454 ' OG ' HD21 ' A' ' 84' ' ' LEU . 4.8 m -105.98 141.86 36.67 Favored 'General case' 0 N--CA 1.402 -2.843 0 N-CA-C 103.913 -2.625 . . . . 0.0 103.913 174.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.582 HG23 ' H ' ' A' ' 27' ' ' GLY 0.276 2.6 p -118.02 -49.48 4.02 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 C-N-CA 117.059 -1.856 . . . . 0.0 112.744 176.166 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.2 mm -81.71 -7.54 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.57 1.732 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 -170.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.491 ' OG ' HD13 ' A' ' 84' ' ' LEU . 50.8 m -79.3 84.01 5.28 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 117.726 2.491 . . . . 0.0 117.726 -172.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.688 ' HB3' ' HG3' ' A' ' 22' ' ' GLN . 1.1 pt? -140.06 82.14 1.85 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 154.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.3 m -171.62 87.15 0.09 Allowed 'General case' 1 C--N 1.233 -4.467 0 N-CA-C 101.777 -3.416 . . . . 0.0 101.777 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -111.59 157.69 14.8 Favored Glycine 3 N--CA 1.375 -5.387 0 N-CA-C 106.246 -2.742 . . . . 0.0 106.246 175.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.572 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 12.6 t70 -62.02 -41.82 98.5 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-O 121.817 0.818 . . . . 0.0 109.714 178.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.577 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 6.8 m80 -123.24 -24.84 4.58 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.138 -0.937 . . . . 0.0 112.029 177.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.2 m 59.7 -70.35 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 125.809 1.644 . . . . 0.0 114.622 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.676 HG13 ' O ' ' A' ' 151' ' ' ILE . 3.6 tt -98.15 -43.51 11.94 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 C-N-CA 124.799 1.24 . . . . 0.0 110.415 -174.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 8.1 tt -104.51 102.2 13.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -172.094 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.5 60.13 1.84 Allowed Glycine 0 CA--C 1.474 -2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.767 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.545 ' HD3' ' C ' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -119.24 90.01 3.25 Favored 'General case' 0 C--N 1.252 -3.643 0 CA-C-N 112.688 -1.756 . . . . 0.0 109.594 -176.866 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.614 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 17.9 p -95.08 132.76 39.63 Favored 'General case' 0 C--N 1.289 -2.026 0 O-C-N 121.723 -0.611 . . . . 0.0 111.858 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.532 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -81.32 120.63 25.19 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 175.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.62 HG22 ' SG ' ' A' ' 57' ' ' CYS . 19.6 t -100.35 98.09 6.55 Favored 'Isoleucine or valine' 0 C--O 1.297 3.602 0 C-N-CA 116.259 -2.176 . . . . 0.0 106.987 172.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.525 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 25.4 t -148.81 171.05 2.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -160.53 171.99 17.99 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 104.093 -2.558 . . . . 0.0 104.093 169.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -69.62 87.81 0.5 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 123.064 2.665 . . . . 0.0 109.973 -178.791 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 33.2 tptt -172.55 171.97 4.43 Favored 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -171.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -78.99 117.91 20.5 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 171.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 46' ' ' HIS . 3.6 t70 -139.77 78.4 1.66 Allowed 'General case' 0 CA--C 1.474 -1.951 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.613 ' HA ' ' HB2' ' A' ' 46' ' ' HIS . 25.1 t0 -177.44 158.0 1.36 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 123.766 0.666 . . . . 0.0 109.424 173.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 135' ' ' THR . 3.3 tm? -90.72 -40.48 11.83 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 124.624 1.203 . . . . 0.0 107.988 -176.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.24 -48.86 6.19 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.492 -0.861 . . . . 0.0 111.622 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.77 51.34 1.53 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.15 -105.83 0.27 Allowed Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 119.875 -1.155 . . . . 0.0 111.745 176.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -152.26 -96.18 0.13 Allowed Glycine 0 C--N 1.316 -0.556 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.652 -176.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -79.89 153.67 28.87 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.142 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -45.72 -50.75 13.43 Favored 'General case' 0 C--N 1.36 1.057 0 N-CA-C 114.522 1.304 . . . . 0.0 114.522 -176.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -80.4 -26.89 38.28 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 121.526 -0.734 . . . . 0.0 111.114 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 27.5 t -77.59 -29.14 51.84 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.667 -173.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 126' ' ' LEU . 6.6 t -76.52 -25.06 53.75 Favored 'General case' 0 C--O 1.206 -1.212 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 126' ' ' LEU . 58.8 mtpt -71.28 -35.36 71.32 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.895 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 12.4 t -85.98 -31.75 21.89 Favored 'General case' 0 N--CA 1.412 -2.366 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.25 178.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 57.63 73.07 0.49 Allowed Glycine 0 CA--C 1.486 -1.764 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -177.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 46.5 t30 -51.58 105.8 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 122.471 1.129 . . . . 0.0 113.248 -171.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -89.29 164.54 14.89 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 114.441 -1.254 . . . . 0.0 113.664 -171.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -139.95 86.28 0.21 Allowed Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 107.25 -2.34 . . . . 0.0 107.25 175.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.504 ' HA ' HG13 ' A' ' 118' ' ' VAL . 13.8 m -61.84 -18.65 60.81 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 113.823 1.046 . . . . 0.0 113.823 -172.166 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -121.72 -46.31 2.25 Favored 'General case' 0 C--N 1.26 -3.312 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.681 177.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.9 tt -46.13 -45.06 16.26 Favored 'General case' 0 CA--C 1.495 -1.163 0 O-C-N 125.406 1.691 . . . . 0.0 111.564 -164.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -139.66 88.76 2.27 Favored 'General case' 0 N--CA 1.395 -3.192 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.2 m -130.25 140.08 50.73 Favored 'General case' 0 N--CA 1.394 -3.227 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.283 176.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -170.93 149.03 11.83 Favored Glycine 1 N--CA 1.379 -5.124 0 CA-C-N 113.831 -1.531 . . . . 0.0 109.358 -177.166 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 16.0 m -70.55 110.14 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.63 0 CA-C-O 122.104 0.954 . . . . 0.0 111.147 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.545 ' C ' ' HD3' ' A' ' 115' ' ' ARG . 9.4 tt -122.11 108.87 22.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 CA-C-N 114.652 -1.158 . . . . 0.0 109.27 175.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.497 ' HA3' ' HG2' ' A' ' 115' ' ' ARG . . . -179.03 -171.25 42.02 Favored Glycine 3 CA--C 1.435 -4.936 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 175.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.676 ' O ' HG13 ' A' ' 112' ' ' ILE . 64.5 mt -64.3 104.64 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.263 -3.165 0 O-C-N 124.853 0.972 . . . . 0.0 110.576 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.462 ' HB2' ' NH2' ' A' ' 115' ' ' ARG . . . -142.17 100.09 3.65 Favored 'General case' 0 N--CA 1.433 -1.304 0 CA-C-O 121.168 0.508 . . . . 0.0 109.836 169.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 C--N 1.289 -2.043 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 177.016 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 CA--C 1.512 -0.515 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 22.6 m -111.24 -36.44 5.59 Favored 'General case' 0 CA--C 1.552 1.027 0 O-C-N 123.583 0.552 . . . . 0.0 111.733 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.402 ' HG2' ' N ' ' A' ' 4' ' ' ALA . 50.1 tttm -146.65 152.52 39.01 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.937 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.96 167.73 20.39 Favored 'General case' 0 N--CA 1.406 -2.629 0 O-C-N 123.676 0.61 . . . . 0.0 109.609 175.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -137.6 131.99 44.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 123.313 0.645 . . . . 0.0 109.304 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.671 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -112.18 131.36 55.52 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -134.86 103.83 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.561 ' HB3' HD21 ' A' ' 117' ' ' LEU . 1.4 pt? -118.29 151.17 38.2 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -162.86 140.77 8.16 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.39 -158.48 8.37 Favored Glycine 0 N--CA 1.414 -2.785 0 C-N-CA 119.039 -1.553 . . . . 0.0 112.996 -176.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -71.37 -49.19 44.68 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.65 144.95 16.94 Favored Glycine 0 N--CA 1.431 -1.655 0 N-CA-C 106.55 -2.62 . . . . 0.0 106.55 172.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -76.56 124.03 7.38 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 CA-C-N 120.355 2.078 . . . . 0.0 112.96 -175.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -132.38 113.05 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 103.853 -2.647 . . . . 0.0 103.853 173.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.573 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 96.8 mt-30 -118.58 141.33 48.68 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.6 -174.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -169.69 157.86 29.74 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.482 -177.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.463 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.9 pt -135.26 102.47 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.671 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 10.3 mt -121.42 137.44 55.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -174.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -113.94 134.08 55.06 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.817 178.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.937 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.0 m-85 -123.26 134.27 54.11 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.356 0.262 . . . . 0.0 110.921 -178.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.9 pt-20 -132.96 102.34 5.59 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 121.588 0.709 . . . . 0.0 112.168 175.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.468 ' H ' ' HB3' ' A' ' 1' ' ' ALA . 42.9 mt-30 -106.24 113.82 27.57 Favored 'General case' 0 N--CA 1.389 -3.5 0 N-CA-C 103.872 -2.64 . . . . 0.0 103.872 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.586 ' H ' ' HB ' ' A' ' 103' ' ' VAL . 54.9 tttm -134.26 171.76 13.81 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.422 -169.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.518 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 5.4 mp0 -63.97 -26.12 68.44 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.87 1.268 . . . . 0.0 111.69 -177.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -33.06 28.16 Favored 'General case' 0 CA--C 1.549 0.911 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 -172.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.9 t30 64.73 97.34 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -173.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.633 ' H ' HG22 ' A' ' 103' ' ' VAL . . . 179.18 -163.34 30.81 Favored Glycine 0 CA--C 1.463 -3.196 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.416 -175.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -83.24 139.65 9.42 Favored 'Trans proline' 0 N--CA 1.42 -2.851 0 C-N-CA 122.114 1.876 . . . . 0.0 110.699 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.654 HG22 ' H ' ' A' ' 101' ' ' ASP . 18.3 m -75.14 130.24 36.29 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.409 ' HB3' ' CD ' ' A' ' 21' ' ' GLU . 7.3 ttpm? -88.84 100.34 13.09 Favored 'General case' 0 N--CA 1.424 -1.771 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 ' HA ' ' A' ' 20' ' ' PHE . 75.1 t -131.47 134.75 60.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.756 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.006 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 2.1 t-105 -141.08 129.47 22.44 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -148.94 138.86 7.15 Favored Glycine 0 N--CA 1.425 -2.083 0 C-N-CA 119.994 -1.098 . . . . 0.0 112.377 175.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.542 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 18.4 m -116.5 115.24 25.41 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 124.726 1.211 . . . . 0.0 108.746 179.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.573 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 9.2 mt -109.52 148.11 13.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 118.453 0.57 . . . . 0.0 110.732 176.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -129.79 122.98 29.86 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -146.41 175.01 26.09 Favored Glycine 0 C--N 1.294 -1.8 0 O-C-N 123.688 0.617 . . . . 0.0 111.66 -168.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.0 mt -69.52 169.79 11.88 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.5 OUTLIER -76.81 104.32 7.24 Favored 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 119.273 -0.971 . . . . 0.0 112.003 -175.932 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.433 ' HG2' ' O ' ' A' ' 39' ' ' THR . 47.2 mm-40 -177.93 171.09 1.82 Allowed 'General case' 0 CA--C 1.472 -2.054 0 C-N-CA 128.522 2.729 . . . . 0.0 104.275 170.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.726 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 159.45 115.38 0.41 Allowed Glycine 1 C--N 1.242 -4.676 0 C-N-CA 116.978 -2.534 . . . . 0.0 113.968 166.146 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -119.38 -85.6 0.65 Allowed 'General case' 0 N--CA 1.419 -2.018 0 O-C-N 124.231 0.607 . . . . 0.0 110.911 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.733 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 20.7 m80 -163.52 123.11 2.11 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.895 0.878 . . . . 0.0 108.936 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.462 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . -143.94 104.63 0.34 Allowed Glycine 0 N--CA 1.435 -1.41 0 C-N-CA 118.434 -1.841 . . . . 0.0 115.425 -178.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.593 ' O ' HG12 ' A' ' 47' ' ' VAL . 19.6 m-85 -68.45 95.22 0.61 Allowed 'General case' 1 C--O 1.341 5.918 0 CA-C-O 123.391 1.567 . . . . 0.0 109.56 169.684 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.615 ' CD2' HD12 ' A' ' 117' ' ' LEU . 16.4 p-80 -83.05 78.06 9.64 Favored 'General case' 0 N--CA 1.404 -2.759 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 175.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 45' ' ' PHE . 3.7 p -111.2 91.57 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-N 111.223 -2.717 . . . . 0.0 110.988 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . 0.257 39.6 m-70 -138.75 159.96 40.82 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 114.586 1.328 . . . . 0.0 114.586 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.56 ' HB3' ' OD2' ' A' ' 109' ' ' ASP . 2.0 pm0 -89.48 172.82 8.71 Favored 'General case' 0 C--N 1.287 -2.151 0 C-N-CA 126.993 2.117 . . . . 0.0 115.02 -174.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.521 ' H ' ' HA ' ' A' ' 110' ' ' HIS . 55.9 t80 47.18 103.47 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 111.3 -2.682 . . . . 0.0 115.35 167.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -44.0 103.12 0.04 OUTLIER Glycine 0 C--N 1.297 -1.623 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.16 171.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -111.09 -161.17 0.74 Allowed 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -67.14 138.1 56.79 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 123.1 0.56 . . . . 0.0 109.997 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.492 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 13.4 t -58.45 -21.5 51.45 Favored 'General case' 0 C--O 1.216 -0.701 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -177.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.96 6.77 11.37 Favored 'General case' 0 C--N 1.31 -1.115 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.062 178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -150.76 109.46 0.43 Allowed Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 119.428 -1.368 . . . . 0.0 111.589 -178.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.596 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 4.3 p -98.5 89.35 4.38 Favored 'General case' 0 C--N 1.277 -2.576 0 C-N-CA 122.735 0.414 . . . . 0.0 111.65 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 m -80.47 -54.07 6.02 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.465 0.65 . . . . 0.0 109.924 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.9 m -71.18 -39.45 71.83 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.283 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.596 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.31 -5.76 48.5 Favored 'General case' 0 C--O 1.2 -1.531 0 CA-C-N 113.857 -1.52 . . . . 0.0 111.353 175.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -57.36 -142.42 0.01 OUTLIER Glycine 0 CA--C 1.558 2.737 0 N-CA-C 115.238 0.855 . . . . 0.0 115.238 178.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -76.11 53.71 3.91 Favored 'Trans proline' 0 N--CA 1.484 0.937 0 C-N-CA 122.877 2.385 . . . . 0.0 111.009 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -141.84 128.67 20.54 Favored 'General case' 0 C--N 1.28 -2.432 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.546 ' HA ' ' OE2' ' A' ' 49' ' ' GLU . 52.0 p90 -139.48 144.58 38.04 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.442 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OD2' ' A' ' 109' ' ' ASP . 27.3 t-20 -68.94 143.99 95.2 Favored Pre-proline 0 C--N 1.318 -0.795 0 C-N-CA 124.015 0.926 . . . . 0.0 111.316 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.0 -15.21 39.72 Favored 'Trans proline' 0 CA--C 1.546 1.109 0 C-N-CA 123.041 2.494 . . . . 0.0 116.113 -178.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 90.2 mt -69.86 -29.23 66.41 Favored 'General case' 0 C--N 1.37 1.489 0 C-N-CA 117.615 -1.634 . . . . 0.0 111.462 -176.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.41 ' HB3' ' CD2' ' A' ' 80' ' ' HIS . 58.0 p -54.46 -21.49 10.03 Favored 'General case' 0 C--O 1.262 1.73 0 C-N-CA 125.523 1.529 . . . . 0.0 115.044 -173.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ttm180 -70.45 -19.96 62.92 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.665 -161.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -68.1 -12.06 60.2 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.233 -0.987 . . . . 0.0 112.773 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 77' ' ' GLU . 0.1 OUTLIER -151.7 -45.15 0.11 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 120.651 0.262 . . . . 0.0 111.186 177.023 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.38 10.42 82.13 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -173.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -150.99 144.29 11.59 Favored Glycine 0 N--CA 1.402 -3.623 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 178.244 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 11.8 Cg_exo -76.24 0.13 9.74 Favored 'Trans proline' 0 C--N 1.327 -0.58 0 C-N-CA 124.691 3.594 . . . . 0.0 112.38 -175.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -55.55 -26.01 40.98 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 124.973 1.309 . . . . 0.0 111.514 178.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -148.63 -86.2 0.09 Allowed 'General case' 0 CA--C 1.505 -0.775 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.404 ' O ' ' HB2' ' A' ' 71' ' ' HIS . 47.5 mt-10 -123.34 110.89 15.73 Favored 'General case' 0 N--CA 1.41 -2.437 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -171.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -150.52 -60.85 0.19 Allowed 'General case' 0 C--N 1.25 -3.758 0 N-CA-C 103.298 -2.853 . . . . 0.0 103.298 -173.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 60.45 -7.37 0.08 Allowed 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 114.617 1.34 . . . . 0.0 114.617 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 65' ' ' ASN . 0.2 OUTLIER . . . . . 0 C--N 1.305 -1.337 0 N-CA-C 105.038 -2.208 . . . . 0.0 105.038 168.744 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 74' ' ' PRO . 25.9 tp . . . . . 0 N--CA 1.431 -1.411 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.77 128.37 1.13 Allowed Glycine 1 N--CA 1.395 -4.082 0 CA-C-N 114.694 -1.139 . . . . 0.0 110.708 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -89.99 171.35 9.63 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 173.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.35 129.06 11.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 121.394 -0.816 . . . . 0.0 109.083 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.3 m -140.11 96.79 3.11 Favored 'General case' 0 N--CA 1.424 -1.748 0 CA-C-O 121.24 0.543 . . . . 0.0 110.28 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.726 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -100.44 152.72 20.03 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 104.785 -2.302 . . . . 0.0 104.785 173.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.538 ' OD2' ' HG2' ' A' ' 91' ' ' LYS . 21.9 t70 -113.34 -159.74 0.7 Allowed 'General case' 1 C--N 1.223 -4.922 0 C-N-CA 116.7 -2.0 . . . . 0.0 105.992 173.731 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.538 ' HG2' ' OD2' ' A' ' 90' ' ' ASP . 18.8 ptpt -57.82 -8.08 0.87 Allowed 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -84.3 -27.15 28.02 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.62 65.53 2.29 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 114.499 0.559 . . . . 0.0 114.499 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 12.6 m -159.74 132.82 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.563 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -124.64 117.89 25.28 Favored 'General case' 0 N--CA 1.412 -2.374 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -99.67 103.51 15.2 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.55 117.6 50.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.031 0.92 . . . . 0.0 112.255 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 p -142.33 101.46 3.9 Favored 'General case' 0 C--N 1.276 -2.599 0 N-CA-C 106.787 -1.561 . . . . 0.0 106.787 174.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 34.4 pt -113.91 151.11 15.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.787 -175.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.75 100.24 7.28 Favored 'General case' 0 N--CA 1.414 -2.227 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.654 ' H ' HG22 ' A' ' 29' ' ' VAL . 26.1 t0 -134.02 167.51 20.48 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.848 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.9 m -59.02 113.22 1.99 Allowed 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 114.678 1.362 . . . . 0.0 114.678 -173.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.633 HG22 ' H ' ' A' ' 27' ' ' GLY . 20.6 m -60.03 -11.57 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 C-N-CA 126.112 1.765 . . . . 0.0 113.053 177.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.39 -12.12 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.676 1.191 . . . . 0.0 112.25 -176.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 2.5 p -91.73 83.17 5.25 Favored 'General case' 0 C--O 1.175 -2.826 0 O-C-N 121.012 -1.055 . . . . 0.0 111.516 176.609 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 71.8 mt -70.11 150.65 46.33 Favored 'General case' 0 N--CA 1.396 -3.163 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.852 171.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.6 m -68.89 91.85 0.48 Allowed 'General case' 0 N--CA 1.382 -3.842 0 C-N-CA 124.956 1.302 . . . . 0.0 113.914 -173.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.415 ' O ' ' HD2' ' A' ' 110' ' ' HIS . . . -94.6 -175.67 38.55 Favored Glycine 1 N--CA 1.395 -4.097 0 N-CA-C 106.09 -2.804 . . . . 0.0 106.09 167.405 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.56 ' OD2' ' HB3' ' A' ' 49' ' ' GLU 0.25 31.3 t0 32.89 -77.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 117.442 2.386 . . . . 0.0 117.442 -175.32 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.558 ' CG ' ' HG2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -56.57 -31.8 64.57 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 125.987 1.715 . . . . 0.0 109.703 178.216 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.3 m 62.06 -178.09 0.13 Allowed 'General case' 0 N--CA 1.424 -1.755 0 C-N-CA 126.125 1.77 . . . . 0.0 112.797 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.512 HG13 ' HB ' ' A' ' 151' ' ' ILE . 10.0 tt -78.65 9.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 C-N-CA 126.547 1.939 . . . . 0.0 108.731 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 36.5 pt -91.38 -175.39 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.485 -1.526 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 -176.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.436 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . -82.14 65.08 4.14 Favored Glycine 0 N--CA 1.405 -3.397 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.734 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -66.31 131.81 46.95 Favored 'General case' 0 N--CA 1.414 -2.267 0 CA-C-O 122.553 1.168 . . . . 0.0 112.203 178.266 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.734 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 0.1 OUTLIER -70.54 122.6 20.02 Favored 'General case' 0 N--CA 1.384 -3.768 0 CA-C-N 113.853 -1.521 . . . . 0.0 111.113 -178.137 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.615 HD12 ' CD2' ' A' ' 46' ' ' HIS . 0.8 OUTLIER -87.76 140.67 29.27 Favored 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 174.06 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.574 HG22 ' SG ' ' A' ' 57' ' ' CYS . 98.8 t -109.8 105.16 18.27 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.479 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.646 171.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -126.09 168.44 18.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.81 0.814 . . . . 0.0 110.397 179.596 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.435 ' CD2' ' HG ' ' A' ' 144' ' ' LEU . 2.1 t60 -172.18 156.85 4.06 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 102.909 -2.997 . . . . 0.0 102.909 162.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.437 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.2 89.61 0.46 Allowed 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? -170.4 171.37 6.61 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.733 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -76.68 111.15 11.88 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 123.771 0.67 . . . . 0.0 110.922 172.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.462 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 8.5 t0 -132.38 26.57 4.46 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 123.381 1.563 . . . . 0.0 109.177 178.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.499 ' HB2' ' HB2' ' A' ' 128' ' ' LYS . 24.8 m-20 -81.7 137.53 35.39 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 173.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -69.8 -56.79 6.19 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -173.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.7 1.8 43.51 Favored Glycine 0 CA--C 1.526 0.748 0 C-N-CA 121.16 -0.543 . . . . 0.0 113.483 -178.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.499 ' HB2' ' HB2' ' A' ' 125' ' ' ASP . 32.0 mmmt -132.23 32.61 3.96 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -62.27 -29.32 72.73 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 115.604 -0.725 . . . . 0.0 114.834 -176.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -82.89 0.26 Allowed Glycine 0 C--O 1.221 -0.66 0 CA-C-N 117.443 0.622 . . . . 0.0 112.212 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.453 ' H ' ' HB3' ' A' ' 134' ' ' SER . 9.5 t30 -121.45 173.3 7.47 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.461 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 37.1 tt0 -49.73 -46.71 50.66 Favored 'General case' 0 CA--C 1.555 1.158 0 CA-C-N 119.844 1.202 . . . . 0.0 114.011 -172.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.1 mp0 -64.48 -39.64 94.19 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.055 0.455 . . . . 0.0 110.449 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 6.8 t -72.36 -30.89 65.13 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.098 -175.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 36.3 m -69.68 -30.97 68.76 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.299 0.571 . . . . 0.0 110.479 178.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.461 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 95.8 mttt -76.54 -37.12 57.16 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.165 0.507 . . . . 0.0 111.355 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 t -85.61 -26.42 26.08 Favored 'General case' 0 N--CA 1.416 -2.166 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.292 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.85 60.1 8.19 Favored Glycine 0 N--CA 1.431 -1.684 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 -174.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -39.62 117.38 0.72 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.936 1.294 . . . . 0.0 112.851 -174.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -143.71 161.49 38.43 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -174.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.28 81.22 1.72 Allowed Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 173.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.7 p -42.13 -38.89 1.82 Allowed 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 118.143 2.646 . . . . 0.0 118.143 -168.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.6 ptt180 -134.2 13.46 3.88 Favored 'General case' 0 C--N 1.278 -2.526 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.435 ' HG ' ' CD2' ' A' ' 120' ' ' HIS . 0.3 OUTLIER -69.07 -37.6 78.6 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -172.23 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -150.25 106.1 3.43 Favored 'General case' 0 N--CA 1.412 -2.348 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 17.8 m -115.21 163.14 16.09 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.734 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -171.55 141.42 6.39 Favored Glycine 0 N--CA 1.416 -2.681 0 C-N-CA 119.003 -1.57 . . . . 0.0 112.143 176.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.423 HG12 ' OG1' ' A' ' 54' ' ' THR . 10.0 p -70.16 98.78 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 122.531 1.158 . . . . 0.0 108.581 174.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.734 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 24.0 mm -109.44 129.86 63.5 Favored 'Isoleucine or valine' 0 CA--C 1.464 -2.346 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.81 147.34 17.73 Favored Glycine 2 CA--C 1.425 -5.539 0 C-N-CA 116.803 -2.618 . . . . 0.0 111.466 -174.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' ' 112' ' ' ILE . 70.1 mt -78.64 103.63 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.9 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 173.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.575 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -125.84 128.6 47.9 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.119 -0.946 . . . . 0.0 108.476 175.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 . . . . . 0 C--N 1.292 -1.905 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.563 -174.755 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.658 ' O ' ' HD2' ' A' ' 3' ' ' LYS . 18.0 p -80.91 -42.03 22.06 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 170.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.658 ' HD2' ' O ' ' A' ' 2' ' ' THR . 5.4 mptp? -151.27 171.4 17.5 Favored 'General case' 0 C--O 1.263 1.765 0 N-CA-C 103.209 -2.885 . . . . 0.0 103.209 173.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.693 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -149.35 146.98 27.78 Favored 'General case' 0 CA--C 1.454 -2.744 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 152' ' ' ALA . 23.1 m -119.69 155.22 22.43 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.788 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -135.7 128.94 31.89 Favored 'General case' 0 C--N 1.278 -2.504 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.345 178.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.498 ' H ' ' HB ' ' A' ' 148' ' ' VAL . 46.7 t -134.16 111.83 15.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.521 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.9 pt? -119.47 142.39 48.31 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.371 178.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.665 ' O ' ' HA ' ' A' ' 55' ' ' ALA . 2.2 tmtp? -147.91 148.42 30.79 Favored 'General case' 0 N--CA 1.408 -2.542 0 N-CA-C 102.409 -3.182 . . . . 0.0 102.409 177.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -155.01 -158.93 8.99 Favored Glycine 0 CA--C 1.479 -2.161 0 C-N-CA 118.139 -1.982 . . . . 0.0 113.381 -177.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -67.98 -46.58 70.97 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.44 95.59 0.74 Allowed Glycine 0 N--CA 1.429 -1.784 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 171.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -64.6 126.79 17.47 Favored 'Trans proline' 0 N--CA 1.441 -1.585 0 C-N-CA 122.164 1.909 . . . . 0.0 113.886 -172.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.1 m -126.0 132.37 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.381 -3.889 0 N-CA-C 102.026 -3.324 . . . . 0.0 102.026 173.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.431 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 97.8 mt-30 -121.67 138.2 54.44 Favored 'General case' 0 C--N 1.264 -3.114 0 C-N-CA 119.559 -0.856 . . . . 0.0 112.578 -169.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.493 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -170.69 171.31 43.68 Favored Glycine 0 N--CA 1.402 -3.628 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.451 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.6 pt -137.02 139.54 44.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.552 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -127.77 127.91 68.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.693 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 60.4 m-20 -118.79 119.62 34.94 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 -176.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.634 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 11.6 p90 -131.58 141.04 49.59 Favored 'General case' 0 C--O 1.262 1.754 0 C-N-CA 118.646 -1.222 . . . . 0.0 113.095 178.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.428 ' HB3' ' O ' ' A' ' 2' ' ' THR . 7.2 pt-20 -133.65 95.15 3.42 Favored 'General case' 0 N--CA 1.416 -2.136 0 CA-C-O 122.268 1.033 . . . . 0.0 112.391 175.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HG3' HG12 ' A' ' 29' ' ' VAL . 24.1 mm-40 -158.62 163.47 36.92 Favored 'General case' 0 C--O 1.257 1.477 0 C-N-CA 126.88 2.072 . . . . 0.0 108.038 170.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.654 ' HG3' ' H ' ' A' ' 24' ' ' GLU 0.257 27.7 pttt -159.7 -86.69 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.204 0 O-C-N 124.22 0.95 . . . . 0.0 112.055 164.487 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.654 ' H ' ' HG3' ' A' ' 23' ' ' LYS . 35.9 tt0 -93.2 -25.96 17.59 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 121.783 0.802 . . . . 0.0 109.578 178.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.44 ' HB2' ' OE1' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -46.93 -56.94 5.51 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.235 2.214 . . . . 0.0 114.836 -172.34 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.8 t30 75.71 139.91 0.07 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 124.971 1.308 . . . . 0.0 110.277 -174.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.588 ' H ' HG21 ' A' ' 104' ' ' ILE . . . 150.23 -170.96 30.2 Favored Glycine 0 CA--C 1.493 -1.312 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -70.08 124.02 10.55 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.413 1.409 . . . . 0.0 110.253 176.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.581 HG12 ' HG3' ' A' ' 22' ' ' GLN . 17.2 m -85.65 98.79 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.354 0 CA-C-O 121.502 0.668 . . . . 0.0 111.523 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.258 0.0 OUTLIER -90.46 108.66 19.93 Favored 'General case' 0 N--CA 1.417 -2.076 0 C-N-CA 118.486 -1.285 . . . . 0.0 109.11 171.919 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.6 m -135.46 152.97 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.778 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 -172.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -143.58 126.92 16.72 Favored 'General case' 0 C--N 1.266 -3.051 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.946 178.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -145.34 140.27 8.93 Favored Glycine 0 N--CA 1.41 -3.075 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.697 174.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.0 m -116.6 140.23 49.63 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 176.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.493 HG22 ' HA3' ' A' ' 16' ' ' GLY . 25.2 pt -141.7 131.51 24.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-N 119.415 1.007 . . . . 0.0 109.025 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.2 OUTLIER -112.09 132.39 54.87 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 121' ' ' GLU . . . -142.82 175.2 23.18 Favored Glycine 0 N--CA 1.416 -2.68 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -169.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.1 mt -68.84 170.34 9.79 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.426 ' CA ' ' HA ' ' A' ' 91' ' ' LYS . 1.3 m -69.89 103.46 2.22 Favored 'General case' 0 C--O 1.203 -1.37 0 C-N-CA 118.016 -1.473 . . . . 0.0 110.403 -173.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.3 tt0 -176.13 141.77 0.46 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 102.798 -3.038 . . . . 0.0 102.798 170.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . -174.54 90.89 0.08 OUTLIER Glycine 0 C--N 1.276 -2.777 0 C-N-CA 117.028 -2.511 . . . . 0.0 113.334 174.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -93.4 -86.33 0.26 Allowed 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 120.512 -0.475 . . . . 0.0 111.649 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.495 ' HA ' ' H ' ' A' ' 87' ' ' VAL . 18.8 p80 166.32 135.28 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 152.46 131.4 1.68 Allowed Glycine 0 N--CA 1.413 -2.837 0 C-N-CA 118.322 -1.894 . . . . 0.0 113.785 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -133.98 139.59 46.17 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 122.063 0.935 . . . . 0.0 113.073 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -166.89 92.11 0.43 Allowed 'General case' 1 C--O 1.33 5.342 0 N-CA-C 105.183 -2.155 . . . . 0.0 105.183 172.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.596 HG13 ' HA ' ' A' ' 117' ' ' LEU . 18.7 t -69.97 167.58 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 127.351 2.26 . . . . 0.0 109.095 176.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.538 ' NE2' ' HB2' ' A' ' 65' ' ' ASN . 56.5 t-80 -124.23 126.04 45.42 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-O 122.085 0.945 . . . . 0.0 109.873 174.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.604 ' CD ' ' HB3' ' A' ' 65' ' ' ASN . 2.8 pm0 -73.37 125.45 27.88 Favored 'General case' 0 C--N 1.264 -3.145 0 CA-C-N 113.62 -1.627 . . . . 0.0 108.403 174.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.54 ' HA ' ' OG ' ' A' ' 111' ' ' SER . 91.3 t80 80.13 100.17 0.06 Allowed 'General case' 0 CA--C 1.503 -0.851 0 CA-C-O 123.503 1.621 . . . . 0.0 108.776 -175.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.35 -145.97 7.52 Favored Glycine 0 N--CA 1.421 -2.332 0 CA-C-N 111.94 -2.391 . . . . 0.0 110.49 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -171.62 -85.83 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 115.597 1.703 . . . . 0.0 115.597 -171.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.497 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.7 t-20 -104.52 140.1 38.47 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -169.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 10.0 t -61.64 -27.68 68.84 Favored 'General case' 0 C--O 1.241 0.635 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . 0.665 ' HA ' ' O ' ' A' ' 9' ' ' LYS . . . -114.47 17.84 17.16 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 120.618 0.247 . . . . 0.0 111.449 -175.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.42 117.27 0.58 Allowed Glycine 0 CA--C 1.483 -1.96 0 C-N-CA 119.247 -1.454 . . . . 0.0 111.382 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.464 ' HB3' HG21 ' A' ' 116' ' ' THR . 0.7 OUTLIER -87.28 98.59 11.42 Favored 'General case' 0 C--N 1.28 -2.429 0 C-N-CA 122.926 0.491 . . . . 0.0 109.904 -176.544 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 m -79.07 -56.1 4.62 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.746 0.784 . . . . 0.0 109.515 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.7 m -75.32 -43.91 48.27 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.011 -174.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.59 -8.61 56.91 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.949 174.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.15 -63.69 3.48 Favored Glycine 0 CA--C 1.538 1.504 0 O-C-N 123.758 0.661 . . . . 0.0 112.772 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -64.26 -5.15 9.1 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.989 2.459 . . . . 0.0 112.75 176.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.289 23.3 p80 56.04 15.75 1.91 Allowed 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 118.504 2.779 . . . . 0.0 118.504 170.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -146.35 120.45 9.45 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 119.151 0.887 . . . . 0.0 112.757 178.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.604 ' HB3' ' CD ' ' A' ' 49' ' ' GLU . 27.7 t-20 -116.95 144.22 33.08 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 172.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -52.57 -13.19 2.17 Favored 'Trans proline' 0 CA--C 1.556 1.595 0 C-N-CA 124.466 3.444 . . . . 0.0 117.82 -177.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.522 ' C ' ' H ' ' A' ' 69' ' ' ARG . 4.1 mm? -82.62 -12.98 57.28 Favored 'General case' 0 CA--C 1.474 -1.956 0 CA-C-N 119.878 1.217 . . . . 0.0 110.396 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.601 ' HA ' ' HB3' ' A' ' 80' ' ' HIS . 74.3 m -72.94 36.4 0.08 Allowed 'General case' 0 C--O 1.215 -0.718 0 C-N-CA 124.342 1.057 . . . . 0.0 109.804 169.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 67' ' ' LEU . 3.3 tmm_? -76.3 11.12 1.66 Allowed 'General case' 0 C--O 1.212 -0.895 0 C-N-CA 127.505 2.322 . . . . 0.0 107.951 -172.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 76' ' ' ASP . 47.4 tptt -77.35 -32.47 55.1 Favored 'General case' 0 N--CA 1.396 -3.133 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t60 61.18 23.86 14.02 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.251 1.021 . . . . 0.0 110.126 178.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.73 120.99 2.65 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 119.842 -1.17 . . . . 0.0 112.218 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.39 75.78 0.13 Allowed Glycine 0 C--N 1.293 -1.812 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.525 ' O ' HD13 ' A' ' 84' ' ' LEU . 31.8 Cg_endo -62.23 -22.63 74.46 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 123.759 2.973 . . . . 0.0 114.82 -171.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mtpt -123.2 13.2 9.62 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.519 ' OD2' ' HE2' ' A' ' 70' ' ' LYS . 21.7 t70 -116.96 -67.69 0.97 Allowed 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -169.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 60.66 111.64 0.02 OUTLIER 'General case' 0 C--O 1.256 1.406 0 CA-C-O 122.477 1.132 . . . . 0.0 110.768 -173.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.421 ' CB ' ' HD3' ' A' ' 70' ' ' LYS . 29.9 tt0 -114.44 -78.21 0.58 Allowed 'General case' 0 N--CA 1.422 -1.842 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.878 -176.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.489 ' O ' ' HB2' ' A' ' 80' ' ' HIS . 29.3 tpt180 -113.98 5.35 16.1 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 117.729 -1.588 . . . . 0.0 110.767 179.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 68' ' ' SER 0.274 18.7 t60 . . . . . 0 N--CA 1.43 -1.447 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.208 172.926 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.525 HD13 ' O ' ' A' ' 74' ' ' PRO . 4.0 pp . . . . . 0 N--CA 1.423 -1.813 0 CA-C-O 120.99 0.424 . . . . 0.0 110.339 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 178.17 -178.64 48.58 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 120.054 -1.07 . . . . 0.0 111.823 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -118.45 132.72 56.23 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.545 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.7 m -136.06 132.8 50.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -176.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -132.94 96.03 3.69 Favored 'General case' 0 N--CA 1.413 -2.283 0 CA-C-O 122.643 1.211 . . . . 0.0 110.613 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.516 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -92.75 153.86 18.65 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 113.911 -1.495 . . . . 0.0 107.833 174.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.593 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 6.8 t70 -125.14 -161.65 1.04 Allowed 'General case' 0 C--N 1.255 -3.541 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.426 ' HA ' ' CA ' ' A' ' 39' ' ' THR . 59.6 pttt -40.85 -34.82 0.43 Allowed 'General case' 0 N--CA 1.506 2.339 0 C-N-CA 127.313 2.245 . . . . 0.0 116.115 -175.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -147.82 16.62 1.11 Allowed 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 177.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.593 ' HA3' ' H ' ' A' ' 90' ' ' ASP . . . -59.34 -157.52 0.03 OUTLIER Glycine 0 C--O 1.187 -2.826 0 N-CA-C 118.731 2.252 . . . . 0.0 118.731 -164.152 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -158.49 105.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.275 -2.656 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.545 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.72 110.12 22.63 Favored 'General case' 0 N--CA 1.398 -3.048 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -85.25 103.37 14.14 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 114.664 -1.153 . . . . 0.0 110.395 -177.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -88.28 102.4 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.507 0 CA-C-O 122.309 1.052 . . . . 0.0 109.486 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.7 p -155.41 100.7 2.14 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 113.649 -1.614 . . . . 0.0 108.11 174.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.46 119.33 29.41 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -95.06 101.06 12.79 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.949 0.881 . . . . 0.0 111.486 -178.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -163.03 169.82 18.95 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 -178.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.5 t -59.4 94.42 0.02 OUTLIER 'General case' 0 C--O 1.244 0.769 0 CA-C-O 122.528 1.156 . . . . 0.0 113.402 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' CD1' ' A' ' 84' ' ' LEU . 15.5 t -118.28 -9.56 11.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 N-CA-C 103.12 -2.919 . . . . 0.0 103.12 168.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.588 HG21 ' H ' ' A' ' 27' ' ' GLY . 2.7 pp -41.9 -40.68 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.709 0 C-N-CA 127.812 2.445 . . . . 0.0 114.77 -166.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.51 ' N ' HD12 ' A' ' 104' ' ' ILE . 10.1 p -85.84 90.73 8.14 Favored 'General case' 1 N--CA 1.352 -5.37 0 C-N-CA 118.385 -1.326 . . . . 0.0 108.843 176.483 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.626 ' HG ' ' CE1' ' A' ' 20' ' ' PHE . 3.7 mm? -75.42 86.89 2.57 Favored 'General case' 0 N--CA 1.393 -3.296 0 N-CA-C 104.837 -2.283 . . . . 0.0 104.837 177.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.4 m -83.13 88.35 6.9 Favored 'General case' 1 N--CA 1.357 -5.124 0 CA-C-N 113.203 -1.817 . . . . 0.0 108.702 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.73 134.43 11.88 Favored Glycine 1 N--CA 1.36 -6.38 0 N-CA-C 104.482 -3.447 . . . . 0.0 104.482 169.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' HG ' ' A' ' 67' ' ' LEU . 38.6 t70 -84.29 -66.92 0.84 Allowed 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 117.591 -1.644 . . . . 0.0 111.464 -177.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -100.03 -17.32 17.55 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.54 ' OG ' ' HA ' ' A' ' 50' ' ' PHE . 20.0 m -132.79 118.42 19.0 Favored 'General case' 0 N--CA 1.395 -3.22 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.498 -176.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.554 HG13 HD12 ' A' ' 113' ' ' ILE . 14.1 pt -112.6 -25.3 3.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 N-CA-C 104.749 -2.315 . . . . 0.0 104.749 166.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.554 HD12 HG13 ' A' ' 112' ' ' ILE . 2.5 mp -102.59 130.46 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 162.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 94.94 12.91 54.81 Favored Glycine 0 C--O 1.209 -1.436 0 C-N-CA 119.546 -1.312 . . . . 0.0 111.838 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.633 ' O ' ' HB ' ' A' ' 149' ' ' ILE . 15.7 mtp180 -70.88 90.07 0.79 Allowed 'General case' 0 C--O 1.207 -1.163 0 CA-C-O 120.868 0.366 . . . . 0.0 110.127 174.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.464 HG21 ' HB3' ' A' ' 57' ' ' CYS . 96.9 m -68.0 105.32 1.99 Allowed 'General case' 0 N--CA 1.383 -3.775 0 CA-C-O 122.519 1.152 . . . . 0.0 109.786 172.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.596 ' HA ' HG13 ' A' ' 47' ' ' VAL . 43.1 tp -70.09 97.92 1.25 Allowed 'General case' 0 CA--C 1.477 -1.843 0 CA-C-N 113.568 -1.651 . . . . 0.0 108.443 177.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 140' ' ' ALA . 7.2 p -91.23 100.06 10.63 Favored 'Isoleucine or valine' 1 C--O 1.313 4.419 0 C-N-CA 115.909 -2.317 . . . . 0.0 109.874 -175.6 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.29 170.23 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.767 0 CA-C-N 112.429 -2.168 . . . . 0.0 107.172 -175.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -158.16 172.28 18.69 Favored 'General case' 0 C--N 1.285 -2.216 0 N-CA-C 103.739 -2.689 . . . . 0.0 103.739 174.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.572 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.1 mp0 -66.77 89.81 0.16 Allowed 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 105.138 -2.171 . . . . 0.0 105.138 170.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.0 tttp -171.66 170.91 5.5 Favored 'General case' 0 N--CA 1.44 -0.925 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -170.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.5 104.98 15.77 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 170.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.449 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 13.1 t70 -106.92 8.03 30.35 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 122.705 1.24 . . . . 0.0 111.292 -177.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.428 ' HB3' ' HD3' ' A' ' 128' ' ' LYS . 5.5 t70 -67.19 139.46 57.42 Favored 'General case' 0 C--N 1.281 -2.398 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.155 -171.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.7 tp -62.96 -50.92 68.88 Favored 'General case' 0 C--N 1.321 -0.643 0 O-C-N 123.475 0.484 . . . . 0.0 109.916 -178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.06 -24.23 68.48 Favored Glycine 0 N--CA 1.442 -0.953 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.192 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.428 ' HD3' ' HB3' ' A' ' 125' ' ' ASP . 3.9 mptp? -88.93 -47.05 8.42 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 119.931 -0.707 . . . . 0.0 111.701 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.6 -103.18 0.06 OUTLIER Glycine 0 C--O 1.222 -0.603 0 N-CA-C 114.847 0.699 . . . . 0.0 114.847 179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -175.53 -79.03 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.606 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 21.8 t-20 -107.75 -170.23 1.66 Allowed 'General case' 0 C--O 1.258 1.545 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 174.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.441 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 29.4 tt0 -53.91 -42.85 69.21 Favored 'General case' 0 CA--C 1.542 0.664 0 CA-C-N 118.884 0.766 . . . . 0.0 111.745 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.606 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -75.25 -39.38 59.9 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.154 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.2 m -67.99 -21.65 65.04 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -176.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.446 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 12.3 t -86.71 -6.29 58.88 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 122.0 0.905 . . . . 0.0 110.738 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.441 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 89.5 mttt -92.81 -39.74 11.04 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.3 p -86.47 -21.23 27.14 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 114.662 -1.154 . . . . 0.0 112.307 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.48 78.47 0.24 Allowed Glycine 0 C--O 1.254 1.383 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -177.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 55.8 t30 -47.71 142.92 4.25 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 124.967 1.307 . . . . 0.0 112.291 -176.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -150.05 170.49 18.75 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.308 -173.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.4 85.1 1.41 Allowed Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 106.547 -2.621 . . . . 0.0 106.547 169.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.448 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 51.0 m -42.47 -56.35 3.07 Favored 'General case' 0 C--O 1.194 -1.819 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -165.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.434 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 22.9 ptt180 -129.61 12.28 5.84 Favored 'General case' 0 C--N 1.254 -3.58 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -174.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.456 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 0.7 OUTLIER -58.15 -44.91 88.11 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 -173.73 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -170.3 92.21 0.2 Allowed 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 114.371 1.249 . . . . 0.0 114.371 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 118' ' ' VAL . 13.9 p -173.53 128.74 0.43 Allowed 'General case' 0 C--O 1.211 -0.956 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 173.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 54' ' ' THR . . . 179.55 77.08 0.06 OUTLIER Glycine 0 N--CA 1.409 -3.138 0 CA-C-O 117.935 -1.481 . . . . 0.0 113.372 150.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.606 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 54.1 t -171.54 90.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 C-N-CA 125.247 1.419 . . . . 0.0 108.135 167.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.633 ' HB ' ' O ' ' A' ' 115' ' ' ARG 0.262 5.4 mt -125.13 118.3 52.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.646 0 CA-C-N 119.179 0.9 . . . . 0.0 109.966 163.229 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.08 155.06 13.35 Favored Glycine 2 N--CA 1.379 -5.132 0 C-N-CA 117.801 -2.142 . . . . 0.0 112.681 176.437 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.6 tt -53.81 105.19 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 114.893 -0.654 . . . . 0.0 110.55 169.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.414 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -130.31 99.43 5.02 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.997 -0.681 . . . . 0.0 109.542 171.178 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.304 -1.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.657 178.691 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 21' ' ' GLU . . . . . . . . 0 CA--C 1.506 -0.74 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 25.3 m -121.87 -36.77 2.96 Favored 'General case' 0 CA--C 1.555 1.163 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.574 ' O ' HG12 ' A' ' 151' ' ' ILE . 17.9 ptpt -136.2 144.15 44.78 Favored 'General case' 0 N--CA 1.426 -1.67 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.718 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.557 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -135.73 151.73 50.43 Favored 'General case' 0 C--N 1.282 -2.348 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 30.4 m -115.53 138.36 46.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.637 -178.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.707 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -111.09 133.89 53.11 Favored 'General case' 0 C--N 1.284 -2.283 0 CA-C-N 114.781 -1.099 . . . . 0.0 111.48 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -134.73 104.22 5.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 122.98 0.512 . . . . 0.0 110.132 176.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.479 HD13 ' HA3' ' A' ' 147' ' ' GLY . 3.1 mm? -96.97 151.31 19.83 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.687 -178.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.599 ' HD3' ' N ' ' A' ' 10' ' ' GLY . 9.9 tmtt? -150.54 137.45 19.17 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.599 ' N ' ' HD3' ' A' ' 9' ' ' LYS . . . -152.78 -169.6 18.2 Favored Glycine 0 N--CA 1.423 -2.188 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.038 -179.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -85.97 -31.12 22.26 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 113.915 -1.143 . . . . 0.0 109.376 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -109.47 -172.5 20.72 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 174.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -83.69 123.06 3.2 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-N 120.779 2.29 . . . . 0.0 111.099 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.414 HG23 HD11 ' A' ' 35' ' ' ILE . 5.2 p -135.9 91.78 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.097 0 C-N-CA 124.682 1.193 . . . . 0.0 108.522 174.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.624 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 16.0 mm100 -111.59 119.08 37.51 Favored 'General case' 0 C--N 1.292 -1.913 0 O-C-N 121.31 -0.869 . . . . 0.0 108.88 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -156.85 148.27 17.83 Favored Glycine 0 N--CA 1.406 -3.306 0 C-N-CA 120.206 -0.997 . . . . 0.0 112.658 -175.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.511 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 12.6 pt -135.65 103.79 4.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.707 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.3 mp -116.64 129.31 73.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -173.102 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.16 138.73 51.47 Favored 'General case' 0 CA--C 1.465 -2.3 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.557 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 20.3 p90 -136.63 160.97 37.2 Favored 'General case' 0 N--CA 1.412 -2.353 0 C-N-CA 119.573 -0.851 . . . . 0.0 109.99 178.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 11.2 pt-20 -127.02 104.97 8.28 Favored 'General case' 0 N--CA 1.407 -2.582 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.214 177.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.537 HE21 HG22 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -85.61 133.73 34.03 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.564 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -122.58 116.78 24.45 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.138 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.437 ' H ' ' HG2' ' A' ' 24' ' ' GLU . 6.7 pt-20 -76.51 -11.28 59.85 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.955 -1.021 . . . . 0.0 111.015 -177.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.6 m -90.52 -9.28 47.84 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 171.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 70.24 135.93 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.667 1.587 . . . . 0.0 112.653 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -173.37 172.56 45.27 Favored Glycine 0 CA--C 1.487 -1.659 0 C-N-CA 120.28 -0.962 . . . . 0.0 111.374 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -65.06 123.4 11.52 Favored 'Trans proline' 0 N--CA 1.444 -1.383 0 N-CA-C 105.887 -2.39 . . . . 0.0 105.887 172.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.495 ' O ' ' HG3' ' A' ' 100' ' ' GLU . 34.9 m -94.96 127.36 46.98 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-O 121.617 0.722 . . . . 0.0 112.142 -172.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 21' ' ' GLU . 0.7 OUTLIER -81.99 104.46 12.36 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 177.635 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.518 HG12 ' HA ' ' A' ' 20' ' ' PHE . 14.5 m -132.45 147.65 31.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -177.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.436 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 12.0 t90 -158.93 136.49 10.12 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -150.3 142.04 9.3 Favored Glycine 0 N--CA 1.403 -3.541 0 C-N-CA 120.405 -0.902 . . . . 0.0 111.921 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.607 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 24.8 m -114.45 133.81 55.47 Favored 'General case' 0 N--CA 1.416 -2.161 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.751 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 5.2 tt -146.83 123.97 3.47 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.106 0 CA-C-N 118.358 0.527 . . . . 0.0 110.672 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.592 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -104.63 134.42 47.82 Favored 'General case' 0 N--CA 1.415 -2.184 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.837 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -132.08 177.39 18.73 Favored Glycine 1 N--CA 1.37 -5.705 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.262 -169.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.529 HD23 ' N ' ' A' ' 39' ' ' THR . 10.2 tt -67.02 177.22 1.8 Allowed 'General case' 0 C--N 1.271 -2.811 0 N-CA-C 103.124 -2.917 . . . . 0.0 103.124 168.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 91' ' ' LYS . 40.6 p -58.91 150.77 23.36 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 120.603 -1.311 . . . . 0.0 111.099 -165.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.587 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -60.7 158.5 12.56 Favored 'General case' 0 CA--C 1.458 -2.577 0 N-CA-C 117.981 2.586 . . . . 0.0 117.981 -155.751 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -142.2 173.86 23.55 Favored Glycine 0 C--N 1.254 -3.997 0 CA-C-N 110.8 -2.909 . . . . 0.0 107.038 -175.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.0 mt -131.66 -34.38 1.35 Allowed 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 116.879 2.177 . . . . 0.0 116.879 -164.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 19.1 t-80 -154.85 123.09 5.94 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 121.31 1.868 . . . . 0.0 109.995 -174.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.98 149.86 14.55 Favored Glycine 0 N--CA 1.424 -2.146 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.846 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.29 135.38 41.81 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.68 ' HA ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -129.15 82.74 2.1 Favored 'General case' 1 N--CA 1.362 -4.833 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.444 -161.742 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 46' ' ' HIS . 9.3 p -174.59 162.96 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.398 -3.026 0 CA-C-N 114.119 -1.401 . . . . 0.0 110.582 165.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -147.28 112.53 5.53 Favored 'General case' 0 C--N 1.276 -2.611 0 C-N-CA 127.823 2.449 . . . . 0.0 106.994 166.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.581 ' HB3' ' HB2' ' A' ' 110' ' ' HIS . 20.2 pt-20 -83.51 86.06 7.15 Favored 'General case' 0 C--O 1.173 -2.942 0 N-CA-C 115.793 1.775 . . . . 0.0 115.793 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.51 ' N ' ' HG3' ' A' ' 115' ' ' ARG . 76.3 m-85 -169.09 91.09 0.24 Allowed 'General case' 0 C--N 1.283 -2.286 0 C-N-CA 127.439 2.296 . . . . 0.0 105.361 175.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' NE ' ' A' ' 115' ' ' ARG . . . -63.12 139.28 44.33 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 120.476 -0.868 . . . . 0.0 114.539 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -125.55 -84.58 0.63 Allowed 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 176.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -164.75 159.7 18.94 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.432 ' O ' ' HB3' ' A' ' 9' ' ' LYS . 9.0 t -67.94 -29.01 67.96 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 117.879 0.309 . . . . 0.0 111.538 -179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.42 -22.24 28.42 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.41 110.76 0.51 Allowed Glycine 0 CA--C 1.484 -1.901 0 C-N-CA 119.366 -1.397 . . . . 0.0 111.42 -175.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.622 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 7.9 p -98.43 89.22 4.36 Favored 'General case' 0 C--N 1.281 -2.37 0 CA-C-O 121.895 0.855 . . . . 0.0 111.472 178.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.0 m -79.54 -47.25 15.86 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.454 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.0 m -79.78 -8.28 59.17 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.252 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.558 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -74.71 -9.28 58.42 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 115.338 -0.847 . . . . 0.0 111.989 179.303 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.412 ' HA3' ' HD2' ' A' ' 62' ' ' PRO . . . -68.88 -142.85 0.11 Allowed Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.601 -0.727 . . . . 0.0 113.697 178.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.412 ' HD2' ' HA3' ' A' ' 61' ' ' GLY . 55.0 Cg_endo -65.01 8.72 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.041 0 C-N-CA 124.456 3.438 . . . . 0.0 114.843 -176.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.93 124.42 46.6 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -169.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -133.84 166.03 23.62 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -172.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB3' ' OE2' ' A' ' 49' ' ' GLU . 44.3 t30 -114.03 96.39 41.64 Favored Pre-proline 0 N--CA 1.428 -1.541 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -80.97 -10.27 12.76 Favored 'Trans proline' 0 N--CA 1.425 -2.509 0 C-N-CA 123.206 2.604 . . . . 0.0 111.135 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -65.63 -45.29 83.63 Favored 'General case' 0 N--CA 1.432 -1.337 0 O-C-N 123.815 0.697 . . . . 0.0 110.019 -166.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.626 ' HB2' ' O ' ' A' ' 79' ' ' ARG 0.293 7.6 m -52.31 -52.66 51.76 Favored 'General case' 0 N--CA 1.417 -2.093 0 N-CA-C 116.241 1.941 . . . . 0.0 116.241 -171.215 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.58 ' O ' ' HB2' ' A' ' 70' ' ' LYS . 72.0 ttt180 -133.97 -32.84 1.07 Allowed 'General case' 0 CA--C 1.479 -1.781 0 C-N-CA 113.998 -3.081 . . . . 0.0 111.61 167.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.58 ' HB2' ' O ' ' A' ' 69' ' ' ARG . 22.0 tptm 160.63 -77.96 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.695 1.247 . . . . 0.0 108.708 170.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 178.58 119.99 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 126.489 1.916 . . . . 0.0 108.4 177.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.408 ' N ' ' HB3' ' A' ' 78' ' ' GLU . . . -156.28 -87.71 0.06 OUTLIER Glycine 0 CA--C 1.529 0.965 0 C-N-CA 118.636 -1.745 . . . . 0.0 115.355 177.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -146.12 4.72 Favored Glycine 0 N--CA 1.415 -2.752 0 C-N-CA 121.354 -0.45 . . . . 0.0 113.083 -173.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -106.0 1.42 0.2 Allowed 'Trans proline' 0 C--O 1.233 0.258 0 C-N-CA 124.969 3.779 . . . . 0.0 114.909 -170.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -87.4 -17.25 32.71 Favored 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -167.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.57 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 12.7 t70 -146.51 -72.71 0.23 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.662 -178.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.526 ' HG3' ' H ' ' A' ' 78' ' ' GLU . 21.9 pt-20 -154.11 -56.57 0.11 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.57 ' OE1' ' HB3' ' A' ' 76' ' ' ASP . 0.6 OUTLIER 52.74 1.67 0.02 OUTLIER 'General case' 0 C--O 1.203 -1.349 0 C-N-CA 127.73 2.412 . . . . 0.0 116.95 172.873 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.626 ' O ' ' HB2' ' A' ' 68' ' ' SER . 27.0 mtt180 163.7 -26.91 0.0 OUTLIER 'General case' 0 C--O 1.189 -2.119 0 C-N-CA 125.266 1.426 . . . . 0.0 111.389 -172.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.402 ' HB2' ' CB ' ' A' ' 68' ' ' SER . 30.6 m-70 . . . . . 0 N--CA 1.498 1.946 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -179.3 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt . . . . . 0 N--CA 1.438 -1.063 0 CA-C-O 121.696 0.76 . . . . 0.0 110.355 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -146.88 -176.82 20.97 Favored Glycine 0 N--CA 1.416 -2.664 0 N-CA-C 108.881 -1.687 . . . . 0.0 108.881 -178.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.84 155.57 18.67 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 117.733 0.767 . . . . 0.0 111.822 -179.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.484 HG13 ' NE2' ' A' ' 46' ' ' HIS . 2.0 m -143.16 128.45 15.88 Favored 'Isoleucine or valine' 0 C--N 1.361 1.081 0 C-N-CA 123.585 0.754 . . . . 0.0 111.08 173.14 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 t -141.78 95.98 2.9 Favored 'General case' 0 N--CA 1.39 -3.468 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 172.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.1 122.43 38.93 Favored 'General case' 0 CA--C 1.466 -2.266 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.606 ' HB3' ' HA3' ' A' ' 93' ' ' GLY . 21.6 t70 -54.15 169.76 0.16 Allowed 'General case' 0 CA--C 1.565 1.525 0 O-C-N 124.824 1.328 . . . . 0.0 111.435 177.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.594 ' HA ' ' HA ' ' A' ' 39' ' ' THR . 57.4 pttt -41.68 -23.54 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 117.233 2.309 . . . . 0.0 117.233 -175.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -154.16 22.07 0.5 Allowed 'General case' 0 C--N 1.294 -1.81 0 N-CA-C 104.359 -2.46 . . . . 0.0 104.359 172.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.606 ' HA3' ' HB3' ' A' ' 90' ' ' ASP . . . -83.81 -127.57 1.4 Allowed Glycine 0 C--O 1.179 -3.313 0 CA-C-N 111.555 -2.566 . . . . 0.0 118.634 -160.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 3.3 m -161.16 136.27 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.226 0 C-N-CA 124.978 1.311 . . . . 0.0 108.207 -170.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.57 111.73 24.16 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 173.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -74.99 93.52 2.72 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 123.479 0.487 . . . . 0.0 109.766 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 33.7 m -91.78 111.76 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.01 0 CA-C-O 121.982 0.896 . . . . 0.0 111.007 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.3 t -149.95 100.84 2.98 Favored 'General case' 0 N--CA 1.411 -2.394 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.42 118.55 43.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.495 ' HG3' ' O ' ' A' ' 29' ' ' VAL . 5.1 mp0 -107.32 99.01 8.57 Favored 'General case' 0 N--CA 1.417 -2.108 0 C-N-CA 118.983 -1.087 . . . . 0.0 110.327 -176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -165.88 166.33 17.64 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 173.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.1 m -94.71 80.39 3.78 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.827 -1.149 . . . . 0.0 112.939 -174.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.0 m -104.84 -18.72 6.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.801 176.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 21.3 pt -101.46 7.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.707 -170.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.453 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 6.1 m -66.57 167.54 10.76 Favored 'General case' 0 CA--C 1.56 1.332 0 CA-C-O 122.697 1.237 . . . . 0.0 113.003 -175.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.448 ' HB2' ' NE2' ' A' ' 22' ' ' GLN . 3.8 tt -78.26 87.22 4.33 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-N 114.115 -1.402 . . . . 0.0 108.286 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 51.7 m -170.01 86.68 0.13 Allowed 'General case' 0 C--N 1.264 -3.144 0 N-CA-C 102.533 -3.136 . . . . 0.0 102.533 169.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 157.32 -177.45 34.16 Favored Glycine 0 C--N 1.258 -3.753 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 49' ' ' GLU . 18.9 t70 -81.31 -21.5 39.19 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 118.492 -1.283 . . . . 0.0 109.568 175.265 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.581 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 62.9 t-80 -88.36 40.66 0.97 Allowed 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 173.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.443 ' HB2' ' HG ' ' A' ' 106' ' ' LEU . 15.1 p -63.02 -64.78 0.81 Allowed 'General case' 0 C--N 1.273 -2.725 0 CA-C-O 122.724 1.25 . . . . 0.0 110.146 -175.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.537 HG22 HE21 ' A' ' 22' ' ' GLN . 28.5 pt -128.94 -22.93 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.184 176.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -81.23 170.54 1.42 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.158 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.206 -162.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -82.99 71.72 2.97 Favored Glycine 0 CA--C 1.475 -2.463 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -172.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.51 ' HG3' ' N ' ' A' ' 50' ' ' PHE . 2.6 mpt_? -79.13 141.24 37.45 Favored 'General case' 0 N--CA 1.396 -3.13 0 CA-C-N 114.603 -0.799 . . . . 0.0 110.063 -178.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.8 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 8.8 t -67.84 124.21 22.71 Favored 'General case' 0 C--N 1.274 -2.716 0 CA-C-O 122.895 1.331 . . . . 0.0 114.554 -168.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.3 tp -80.64 98.42 7.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 113.556 -1.656 . . . . 0.0 108.901 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.68 ' O ' ' HA ' ' A' ' 46' ' ' HIS . 26.9 t -91.85 100.56 11.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.864 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.571 ' HB ' ' CB ' ' A' ' 46' ' ' HIS . 12.2 p -139.98 156.98 25.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 126.539 1.936 . . . . 0.0 108.343 -175.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -171.45 166.57 6.88 Favored 'General case' 0 N--CA 1.428 -1.564 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 165.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.567 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -73.32 84.91 1.44 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 175.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 79.3 mttt -173.19 170.77 4.26 Favored 'General case' 0 CA--C 1.493 -1.228 0 C-N-CA 126.119 1.768 . . . . 0.0 108.326 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.661 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -80.44 104.48 11.01 Favored 'General case' 0 C--N 1.29 -1.998 0 O-C-N 124.145 0.903 . . . . 0.0 110.974 172.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -118.78 80.46 1.54 Allowed 'General case' 0 CA--C 1.483 -1.623 0 N-CA-C 104.267 -2.494 . . . . 0.0 104.267 173.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.712 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 16.4 t0 -125.91 139.0 53.82 Favored 'General case' 0 C--N 1.263 -3.17 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.332 -170.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.4 tp -82.03 -21.5 36.93 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.876 -172.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -102.82 13.42 56.29 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.712 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 14.3 tmtt? -127.42 37.76 4.18 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.3 -54.84 34.38 Favored Glycine 0 N--CA 1.427 -1.9 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.12 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 114.34 -25.09 10.78 Favored Glycine 0 C--N 1.308 -1.004 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.907 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 33.3 t-20 -167.58 167.08 13.77 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.438 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 12.9 pt-20 -48.39 -46.59 37.34 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -61.72 -53.57 54.28 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.542 0.737 . . . . 0.0 110.412 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.6 m -69.22 -27.28 65.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 112.108 -172.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 m -78.01 -15.31 59.05 Favored 'General case' 0 CA--C 1.557 1.235 0 CA-C-O 121.801 0.81 . . . . 0.0 110.025 177.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 99.4 mttt -89.67 -40.14 12.74 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 174.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.0 m -67.43 -46.39 73.28 Favored 'General case' 0 C--N 1.284 -2.244 0 CA-C-O 121.366 0.603 . . . . 0.0 109.993 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.53 76.56 1.18 Allowed Glycine 0 N--CA 1.408 -3.208 0 N-CA-C 106.866 -2.493 . . . . 0.0 106.866 -172.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -36.21 111.22 0.13 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 125.905 1.682 . . . . 0.0 111.041 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -149.22 135.75 19.4 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.225 -173.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 144' ' ' LEU . . . -70.87 108.4 2.47 Favored Glycine 0 N--CA 1.434 -1.438 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 172.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.6 m -57.01 -29.55 63.42 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 115.285 1.587 . . . . 0.0 115.285 -169.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.622 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 27.3 ttm180 -128.97 21.82 5.8 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -175.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.406 ' CD1' ' HA3' ' A' ' 141' ' ' GLY . 74.9 mt -74.46 -15.38 60.9 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.692 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.416 ' HB1' HD12 ' A' ' 8' ' ' LEU . . . -162.71 109.26 1.22 Allowed 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.478 175.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 61.5 m -98.59 131.41 44.82 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 174.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.8 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.59 126.44 1.23 Allowed Glycine 0 N--CA 1.412 -2.919 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.873 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 m -76.18 98.43 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-O 121.691 0.758 . . . . 0.0 109.864 173.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.406 HG13 ' CB ' ' A' ' 6' ' ' ALA . 1.7 mp -106.4 112.22 38.61 Favored 'Isoleucine or valine' 0 C--O 1.257 1.48 0 CA-C-O 122.31 1.053 . . . . 0.0 109.926 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.443 ' HA2' ' CZ ' ' A' ' 20' ' ' PHE . . . -174.68 176.76 46.93 Favored Glycine 0 CA--C 1.461 -3.294 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -175.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.35 105.05 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 107.942 -1.132 . . . . 0.0 107.942 176.727 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.54 147.59 41.42 Favored 'General case' 0 N--CA 1.413 -2.281 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--N 1.292 -1.9 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.916 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.722 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.7 m -74.46 -23.4 58.89 Favored 'General case' 0 CA--C 1.566 1.58 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -172.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -132.37 147.8 52.4 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.873 -171.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.639 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -132.64 156.48 46.86 Favored 'General case' 0 N--CA 1.405 -2.693 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.579 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 47.2 t -125.96 126.91 70.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.555 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -124.91 135.1 52.55 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.005 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 14.7 m -127.61 119.77 52.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-O 121.201 0.524 . . . . 0.0 110.809 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -100.34 138.15 37.8 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.219 177.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -165.8 125.19 1.68 Allowed 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.83 -158.98 8.99 Favored Glycine 0 N--CA 1.439 -1.156 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.633 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -72.34 -61.78 1.67 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -75.62 153.43 44.2 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 172.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -83.21 123.35 3.47 Favored 'Trans proline' 0 N--CA 1.429 -2.289 0 CA-C-N 120.976 2.388 . . . . 0.0 112.389 -175.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.74 119.09 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.819 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 173.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -130.82 128.88 41.55 Favored 'General case' 0 C--N 1.269 -2.909 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.545 ' HA3' HD13 ' A' ' 35' ' ' ILE . . . -170.54 161.78 34.77 Favored Glycine 0 N--CA 1.399 -3.791 0 C-N-CA 119.49 -1.338 . . . . 0.0 112.201 -177.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.46 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.0 pt -142.26 133.6 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.318 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -132.31 135.03 58.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -107.11 132.94 52.45 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.639 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 22.1 t80 -127.42 138.2 52.92 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 123.619 0.768 . . . . 0.0 110.59 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 29' ' ' VAL . 5.7 pt-20 -117.33 119.69 35.89 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.537 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.13 135.65 33.52 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 119.299 -0.961 . . . . 0.0 108.751 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -115.43 83.75 1.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.678 0.751 . . . . 0.0 110.308 179.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -68.42 -20.21 64.64 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 124.526 1.131 . . . . 0.0 110.802 -177.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 26' ' ' ASN . 17.4 t -88.44 -5.23 58.39 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.089 177.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' SER . 4.0 t30 77.47 113.91 0.07 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 124.682 1.193 . . . . 0.0 110.837 -173.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.82 166.41 39.6 Favored Glycine 0 CA--C 1.475 -2.455 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -177.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' HB2' ' A' ' 101' ' ' ASP . 58.0 Cg_endo -71.67 124.08 9.95 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 121.177 1.251 . . . . 0.0 110.774 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.584 HG12 ' H ' ' A' ' 102' ' ' SER . 9.8 p -76.75 123.25 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.893 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.066 173.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -105.56 124.56 49.76 Favored 'General case' 0 C--N 1.28 -2.451 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 172.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.597 ' H ' HG23 ' A' ' 99' ' ' ILE . 34.4 m -134.33 153.27 35.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -172.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 69.4 p-90 -145.64 135.23 23.27 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 174.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.745 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -148.68 139.59 7.68 Favored Glycine 0 N--CA 1.42 -2.404 0 C-N-CA 119.979 -1.105 . . . . 0.0 111.662 175.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.2 m -116.11 125.63 52.63 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HA3' ' A' ' 16' ' ' GLY . 25.3 mm -125.04 132.19 71.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 36.0 mtmm -117.67 136.16 53.52 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -171.01 174.15 44.75 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -172.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 pp -68.66 153.69 43.31 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 118.679 1.239 . . . . 0.0 109.634 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.59 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 77.3 p -69.85 107.26 3.46 Favored 'General case' 0 C--O 1.206 -1.195 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 -170.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 28.7 tt0 -175.35 115.99 0.15 Allowed 'General case' 0 C--O 1.205 -1.279 0 C-N-CA 125.653 1.581 . . . . 0.0 107.018 172.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 90' ' ' ASP . . . -164.35 114.97 0.62 Allowed Glycine 0 C--N 1.273 -2.917 0 C-N-CA 118.392 -1.861 . . . . 0.0 112.166 -174.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.2 mt -106.72 -64.76 1.15 Allowed 'General case' 0 N--CA 1.435 -1.191 0 O-C-N 123.998 0.47 . . . . 0.0 112.187 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.67 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.1 m80 -171.35 168.95 6.45 Favored 'General case' 0 CA--C 1.492 -1.255 0 C-N-CA 124.249 1.02 . . . . 0.0 108.326 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.467 ' O ' ' HG3' ' A' ' 74' ' ' PRO . . . 178.23 -169.28 40.97 Favored Glycine 0 C--N 1.282 -2.461 0 C-N-CA 119.786 -1.197 . . . . 0.0 112.056 176.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 126' ' ' LEU . 1.3 p90 -168.16 165.67 13.15 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.697 ' CE1' ' HA3' ' A' ' 85' ' ' GLY . 18.3 m-70 -90.02 150.02 22.29 Favored 'General case' 0 CA--C 1.478 -1.808 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' O ' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -172.3 89.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 173.663 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.34 86.06 0.12 Allowed 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 163.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.492 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 9.0 pt-20 -93.4 117.92 30.67 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 118.094 -1.442 . . . . 0.0 110.852 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 12.0 t80 162.58 92.43 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 103.766 -2.679 . . . . 0.0 103.766 179.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -48.66 109.08 0.47 Allowed Glycine 0 N--CA 1.478 1.482 0 O-C-N 123.682 0.614 . . . . 0.0 113.714 -177.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -120.98 -80.77 0.63 Allowed 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 117.971 -1.492 . . . . 0.0 112.089 -175.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.8 t30 -144.99 156.4 43.93 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.891 -177.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 148' ' ' VAL . 33.1 p -84.32 -1.51 55.5 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 124.228 1.011 . . . . 0.0 111.295 -177.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.7 20.85 4.64 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.266 -179.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 146.99 114.39 0.82 Allowed Glycine 0 N--CA 1.424 -2.133 0 C-N-CA 118.969 -1.586 . . . . 0.0 112.033 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.466 ' SG ' HG23 ' A' ' 118' ' ' VAL . 9.4 p -96.71 90.83 5.43 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.095 0.95 . . . . 0.0 112.698 -177.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.2 p -74.18 -49.23 24.49 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.075 -177.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.9 m -65.14 -23.67 67.19 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.74 -22.99 53.05 Favored 'General case' 0 N--CA 1.422 -1.864 0 C-N-CA 120.037 -0.665 . . . . 0.0 110.822 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.403 ' HA3' ' HD3' ' A' ' 62' ' ' PRO . . . 30.62 -97.29 0.01 OUTLIER Glycine 0 N--CA 1.494 2.532 0 C-N-CA 124.881 1.229 . . . . 0.0 115.663 164.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD3' ' HA3' ' A' ' 61' ' ' GLY . 27.9 Cg_endo -93.44 73.46 0.36 Allowed 'Trans proline' 0 N--CA 1.435 -1.968 0 C-N-CA 123.479 2.786 . . . . 0.0 109.932 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.511 ' CD2' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p-80 -36.52 137.94 0.26 Allowed 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 125.415 1.486 . . . . 0.0 114.329 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.483 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 15.7 p90 -125.28 88.17 2.83 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 170.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 16.8 m120 -106.45 89.49 4.08 Favored Pre-proline 0 CA--C 1.505 -0.781 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 5.8 Cg_exo -77.7 -12.94 16.45 Favored 'Trans proline' 0 N--CA 1.443 -1.444 0 C-N-CA 122.474 2.116 . . . . 0.0 114.842 -169.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.425 HD12 ' O ' ' A' ' 106' ' ' LEU . 13.1 mt -70.2 -25.13 63.27 Favored 'General case' 0 CA--C 1.465 -2.302 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.422 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.559 ' HA ' ' C ' ' A' ' 77' ' ' GLU . 18.0 t -93.7 -96.34 0.15 Allowed 'General case' 1 N--CA 1.377 -4.076 0 C-N-CA 114.997 -2.681 . . . . 0.0 107.272 175.922 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HB3' ' HA ' ' A' ' 79' ' ' ARG 0.264 24.6 ttt85 -142.05 40.37 1.64 Allowed 'General case' 0 CA--C 1.492 -1.261 0 CA-C-N 119.055 0.843 . . . . 0.0 109.185 152.29 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 88.2 tttt 75.78 -33.39 0.22 Allowed 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -155.61 99.02 1.99 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -175.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.691 ' HA3' ' C ' ' A' ' 80' ' ' HIS . . . -164.56 -136.6 2.03 Favored Glycine 0 C--O 1.18 -3.234 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.752 163.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.56 ' HA2' HD22 ' A' ' 126' ' ' LEU . . . -75.98 -175.96 39.89 Favored Glycine 0 CA--C 1.547 2.061 0 CA-C-N 117.427 0.613 . . . . 0.0 114.607 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HG3' ' O ' ' A' ' 44' ' ' GLY . 88.7 Cg_endo -102.49 0.37 0.42 Allowed 'Trans proline' 0 C--O 1.212 -0.788 0 C-N-CA 123.825 3.017 . . . . 0.0 113.633 -178.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.5 ' HG2' ' OE2' ' A' ' 100' ' ' GLU . 61.8 mttm -81.49 2.27 29.62 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -172.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 37.4 t70 -175.59 166.34 3.2 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -176.272 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.559 ' C ' ' HA ' ' A' ' 68' ' ' SER . 2.5 pm0 -122.52 84.68 2.3 Favored 'General case' 0 N--CA 1.418 -2.039 0 C-N-CA 120.161 -0.616 . . . . 0.0 111.111 171.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.445 ' O ' ' HG3' ' A' ' 79' ' ' ARG . 0.1 OUTLIER 171.37 86.87 0.0 OUTLIER 'General case' 0 C--N 1.361 1.071 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.84 178.599 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.562 ' HA ' ' HB3' ' A' ' 69' ' ' ARG 0.289 0.0 OUTLIER 62.32 130.5 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 C-N-CA 126.481 1.912 . . . . 0.0 115.412 174.637 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.691 ' C ' ' HA3' ' A' ' 72' ' ' GLY . 21.3 t-160 . . . . . 0 N--CA 1.488 1.459 0 CA-C-O 122.63 1.205 . . . . 0.0 107.971 -178.936 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp . . . . . 0 CA--C 1.502 -0.897 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.697 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . -173.82 83.25 0.08 OUTLIER Glycine 0 N--CA 1.422 -2.282 0 C-N-CA 118.918 -1.61 . . . . 0.0 113.295 173.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.437 ' HB2' ' HG3' ' A' ' 74' ' ' PRO . 9.1 t30 -78.87 130.06 35.25 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.62 128.45 75.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.553 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 29.4 p -139.45 95.76 2.98 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -120.95 104.18 9.62 Favored 'General case' 0 N--CA 1.421 -1.895 0 C-N-CA 118.079 -1.448 . . . . 0.0 109.049 174.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' A' ' 39' ' ' THR . 8.1 p-10 -132.29 -20.88 2.36 Favored 'General case' 0 CA--C 1.47 -2.131 0 CA-C-O 121.788 0.804 . . . . 0.0 109.842 -176.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -72.53 -56.94 4.59 Favored 'General case' 0 C--N 1.268 -2.966 0 CA-C-N 113.655 -1.612 . . . . 0.0 109.091 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -153.71 6.18 0.33 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.505 -170.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 82.12 55.3 3.13 Favored Glycine 0 N--CA 1.426 -1.987 0 C-N-CA 118.102 -1.999 . . . . 0.0 108.748 -168.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.1 m -148.84 110.09 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 104.45 -2.426 . . . . 0.0 104.45 -177.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.553 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.84 128.92 41.94 Favored 'General case' 0 C--N 1.263 -3.162 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.703 -174.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -81.92 107.84 14.96 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 171.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.745 HG11 ' H ' ' A' ' 33' ' ' GLY . 13.4 p -82.61 137.46 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.202 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB3' ' OE2' ' A' ' 100' ' ' GLU . 41.8 m -84.37 108.6 17.29 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.963 177.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.597 HG23 ' H ' ' A' ' 31' ' ' VAL . 28.8 mt -93.32 114.06 29.34 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.482 0 N-CA-C 106.112 -1.811 . . . . 0.0 106.112 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.5 ' OE2' ' HG2' ' A' ' 75' ' ' LYS . 1.0 OUTLIER -134.99 155.71 50.3 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 -179.738 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.47 ' HB2' ' HA ' ' A' ' 28' ' ' PRO . 7.4 p-10 -90.11 131.83 35.75 Favored 'General case' 0 C--N 1.295 -1.763 0 CA-C-O 121.721 0.772 . . . . 0.0 111.517 -178.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 29' ' ' VAL . 75.6 p -96.07 172.94 7.68 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 175.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.57 -54.36 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.86 174.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -130.44 -47.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.644 0 C-N-CA 120.189 -0.604 . . . . 0.0 111.94 -174.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.8 p -170.08 167.19 8.92 Favored 'General case' 0 CA--C 1.469 -2.17 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -169.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.425 ' O ' HD12 ' A' ' 67' ' ' LEU . 2.8 pp -68.84 164.28 22.33 Favored 'General case' 0 N--CA 1.391 -3.409 0 CA-C-N 113.67 -1.605 . . . . 0.0 106.687 176.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.408 ' HA ' ' HB2' ' A' ' 67' ' ' LEU . 50.0 m -86.28 88.25 7.58 Favored 'General case' 1 C--N 1.238 -4.268 0 CA-C-O 121.357 0.599 . . . . 0.0 111.681 -170.501 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.66 133.98 7.88 Favored Glycine 1 N--CA 1.394 -4.157 0 N-CA-C 106.957 -2.457 . . . . 0.0 106.957 167.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -122.32 -29.14 4.19 Favored 'General case' 0 C--N 1.264 -3.127 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.42 -31.82 69.17 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 174.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' HG22 ' A' ' 113' ' ' ILE . 28.5 t 173.71 -174.07 0.06 Allowed 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 168.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 31.4 mm -106.46 -4.98 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.98 0 N-CA-C 103.839 -2.652 . . . . 0.0 103.839 -179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.538 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 16.0 tt -104.03 157.56 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 103.409 -2.811 . . . . 0.0 103.409 163.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.8 41.57 28.16 Favored Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.536 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.813 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -135.1 129.37 33.84 Favored 'General case' 0 C--N 1.271 -2.812 0 C-N-CA 125.065 1.346 . . . . 0.0 109.068 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.891 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 11.2 p -114.86 141.45 47.9 Favored 'General case' 0 C--N 1.279 -2.468 0 CA-C-O 121.339 0.59 . . . . 0.0 112.272 177.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.623 ' HB3' HG21 ' A' ' 149' ' ' ILE . 2.6 pt? -88.97 105.93 18.09 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.466 HG23 ' SG ' ' A' ' 57' ' ' CYS . 17.3 t -92.93 100.39 11.2 Favored 'Isoleucine or valine' 1 C--O 1.319 4.718 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.354 169.081 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 45' ' ' PHE . 3.3 t -147.1 170.42 3.94 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.677 0 C-N-CA 128.879 2.872 . . . . 0.0 103.467 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -159.51 170.39 21.8 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 178.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.531 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -79.79 83.25 5.76 Favored 'General case' 0 CA--C 1.567 1.604 0 N-CA-C 105.624 -1.991 . . . . 0.0 105.624 169.288 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -172.17 174.19 4.07 Favored 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 104.694 -2.335 . . . . 0.0 104.694 -167.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.67 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -88.29 104.62 16.91 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -69.71 113.31 6.85 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 174.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -75.83 131.59 39.83 Favored 'General case' 0 N--CA 1.427 -1.593 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.918 -167.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.56 HD22 ' HA2' ' A' ' 73' ' ' GLY . 11.0 mt -76.1 -71.52 0.38 Allowed 'General case' 0 N--CA 1.404 -2.752 0 CA-C-N 113.617 -1.629 . . . . 0.0 113.614 -169.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -117.38 -7.11 12.63 Favored Glycine 0 CA--C 1.467 -2.943 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.447 -168.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.481 ' O ' ' HB ' ' A' ' 135' ' ' THR . 95.3 mttt -99.93 -42.57 6.72 Favored 'General case' 0 N--CA 1.412 -2.369 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' N ' ' A' ' 135' ' ' THR . . . 75.97 -63.0 2.85 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -171.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 153.63 -25.85 0.75 Allowed Glycine 0 C--N 1.299 -1.486 0 N-CA-C 108.101 -1.999 . . . . 0.0 108.101 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -163.54 172.88 13.77 Favored 'General case' 0 C--O 1.254 1.342 0 N-CA-C 103.376 -2.824 . . . . 0.0 103.376 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -59.57 -41.06 89.31 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-N 118.887 0.767 . . . . 0.0 112.068 -176.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 136' ' ' LYS . 35.4 tt0 -66.17 -36.98 84.52 Favored 'General case' 0 C--O 1.219 -0.532 0 CA-C-O 121.08 0.467 . . . . 0.0 110.181 177.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -68.29 -34.23 75.77 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.642 -176.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.481 ' HB ' ' O ' ' A' ' 128' ' ' LYS . 10.7 t -81.54 -6.75 59.28 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.547 1.165 . . . . 0.0 109.114 177.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 88.3 tttt -90.01 -24.43 21.22 Favored 'General case' 0 C--N 1.287 -2.117 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.257 175.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.3 m -83.36 -33.3 25.85 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.72 7.59 Favored Glycine 1 C--O 1.315 5.194 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 -171.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -35.14 106.04 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 131.271 3.828 . . . . 0.0 120.016 -166.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.404 ' HB3' ' CG1' ' A' ' 118' ' ' VAL . . . -153.05 172.38 16.96 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 102.498 -3.149 . . . . 0.0 102.498 164.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -52.32 110.01 1.06 Allowed Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 34.4 p -52.63 -32.11 40.14 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -171.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 15.9 ptt180 -120.25 -27.37 5.27 Favored 'General case' 0 C--N 1.26 -3.304 0 C-N-CA 118.472 -1.291 . . . . 0.0 108.776 174.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.73 -36.39 11.3 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 124.7 1.25 . . . . 0.0 112.798 -165.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -142.45 88.76 2.1 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.891 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 52.7 t -156.86 141.36 16.71 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.858 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -157.72 170.44 34.7 Favored Glycine 0 N--CA 1.4 -3.708 0 N-CA-C 107.214 -2.354 . . . . 0.0 107.214 177.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.735 ' HB ' ' NH1' ' A' ' 115' ' ' ARG . 27.7 m -68.84 124.26 24.15 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.017 0 CA-C-N 117.656 0.728 . . . . 0.0 111.054 178.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.813 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 0.0 OUTLIER -123.47 99.86 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.212 0.53 . . . . 0.0 111.245 179.331 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.504 ' HA3' ' NE ' ' A' ' 115' ' ' ARG . . . 174.63 -167.47 39.75 Favored Glycine 0 CA--C 1.457 -3.586 0 C-N-CA 117.546 -2.264 . . . . 0.0 111.534 178.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 9.1 tt -68.75 105.67 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.266 1.935 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -116.45 140.28 49.53 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.104 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 . . . . . 0 C--N 1.297 -1.694 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.009 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.212 -0.918 0 N-CA-C 111.663 0.246 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.524 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 14.4 m -58.08 -26.41 62.53 Favored 'General case' 0 CA--C 1.571 1.776 0 N-CA-C 115.425 1.639 . . . . 0.0 115.425 -174.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -135.15 147.5 49.46 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.827 -1.171 . . . . 0.0 112.083 -172.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.836 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -139.81 154.42 47.35 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.64 172.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.554 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 39.7 t -129.69 131.03 67.02 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -121.49 132.37 54.68 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.664 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 10.9 m -127.96 109.04 18.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.729 0.776 . . . . 0.0 110.58 -178.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' A' ' 15' ' ' GLN . 6.6 mp -103.47 128.49 50.64 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.664 -176.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -160.88 124.99 3.5 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 169.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.91 -173.14 22.66 Favored Glycine 0 N--CA 1.405 -3.382 0 N-CA-C 107.216 -2.354 . . . . 0.0 107.216 175.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -95.21 89.66 5.59 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 120.217 -0.593 . . . . 0.0 109.78 -178.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.59 -63.83 0.62 Allowed Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.776 178.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.663 ' HB3' ' HA ' ' A' ' 120' ' ' HIS . 31.9 Cg_exo -62.31 169.16 8.35 Favored 'Trans proline' 0 N--CA 1.432 -2.095 0 C-N-CA 123.072 2.515 . . . . 0.0 115.004 -174.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.558 HG12 ' HA3' ' A' ' 37' ' ' GLY . 16.8 m -69.86 158.01 6.31 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.038 0 CA-C-N 111.587 -2.552 . . . . 0.0 112.544 -175.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.505 ' HA ' ' HB2' ' A' ' 8' ' ' LEU . 15.3 tm0? -112.52 140.56 47.17 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 104.667 -2.345 . . . . 0.0 104.667 177.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' HD13 ' A' ' 8' ' ' LEU . . . -158.98 170.51 35.41 Favored Glycine 0 N--CA 1.414 -2.824 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.449 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 18.9 pt -132.46 129.05 58.87 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 176.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.506 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 43.7 mm -130.01 123.53 56.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -174.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 2.2 m-20 -112.41 126.74 55.61 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.836 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 29.7 p90 -126.78 148.34 49.93 Favored 'General case' 0 CA--C 1.495 -1.147 0 C-N-CA 118.24 -1.384 . . . . 0.0 109.912 176.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.534 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 1.5 pp20? -117.76 116.17 26.48 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.372 176.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -85.72 87.88 7.47 Favored 'General case' 0 N--CA 1.382 -3.854 0 CA-C-O 123.103 1.43 . . . . 0.0 108.769 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.537 ' H ' ' HB ' ' A' ' 104' ' ' ILE . 5.0 ttmp? -72.16 110.06 6.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 112.206 -2.27 . . . . 0.0 107.009 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -61.79 -24.29 66.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.03 0.443 . . . . 0.0 111.622 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 m -71.92 -19.3 61.94 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.524 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.458 ' HA ' HG13 ' A' ' 104' ' ' ILE . 56.6 m-80 70.3 162.71 0.24 Allowed 'General case' 0 C--O 1.241 0.61 0 C-N-CA 125.194 1.398 . . . . 0.0 110.885 -175.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 138.47 -149.46 20.56 Favored Glycine 0 CA--C 1.48 -2.156 0 C-N-CA 117.762 -2.161 . . . . 0.0 114.18 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -63.26 125.69 16.25 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 123.357 2.704 . . . . 0.0 110.941 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.656 HG12 HG23 ' A' ' 104' ' ' ILE . 3.9 m -76.97 120.39 27.23 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.378 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -98.55 92.17 5.5 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.096 0.951 . . . . 0.0 108.506 172.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 71.5 t -133.36 146.0 32.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -175.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.5 p-90 -143.15 134.73 26.39 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.456 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -141.92 140.33 10.01 Favored Glycine 0 N--CA 1.419 -2.458 0 C-N-CA 119.796 -1.192 . . . . 0.0 112.14 178.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -116.63 151.82 35.48 Favored 'General case' 0 N--CA 1.394 -3.252 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 176.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.671 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 36.8 mm -132.24 134.06 59.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.683 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 60.6 pttt -139.0 119.96 14.42 Favored 'General case' 0 C--O 1.206 -1.207 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 175.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.558 ' HA3' HG12 ' A' ' 14' ' ' VAL . . . -169.97 174.97 44.16 Favored Glycine 0 CA--C 1.476 -2.354 0 C-N-CA 118.811 -1.662 . . . . 0.0 113.075 -171.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.3 tt -66.85 137.77 56.84 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.1 p -72.78 108.53 5.81 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 115.238 1.57 . . . . 0.0 115.238 -164.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.51 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.9 tt0 -177.78 121.79 0.11 Allowed 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 105.358 -2.09 . . . . 0.0 105.358 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' HA ' ' A' ' 90' ' ' ASP . . . -155.82 138.67 6.14 Favored Glycine 0 CA--C 1.47 -2.774 0 C-N-CA 119.268 -1.444 . . . . 0.0 111.507 -177.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 122' ' ' LYS . 3.6 mm? -126.65 -58.33 1.33 Allowed 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -170.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.52 169.3 24.61 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -130.29 113.34 1.43 Allowed Glycine 0 C--O 1.217 -0.917 0 C-N-CA 118.391 -1.861 . . . . 0.0 117.43 -170.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.596 ' O ' ' HB3' ' A' ' 124' ' ' ASP . 46.7 m-85 -168.67 108.86 0.5 Allowed 'General case' 0 C--O 1.188 -2.171 0 N-CA-C 102.752 -3.055 . . . . 0.0 102.752 170.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.449 ' HB3' HG22 ' A' ' 119' ' ' VAL . 68.1 m-70 -149.95 85.57 1.42 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 120.881 1.673 . . . . 0.0 107.969 -175.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.514 HG13 HG21 ' A' ' 149' ' ' ILE . 48.8 t -162.53 161.11 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 105.052 -2.203 . . . . 0.0 105.052 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' A' ' 60' ' ' ALA . 62.6 t-80 -153.46 148.41 26.62 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 168.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 0.4 OUTLIER -109.48 124.13 50.54 Favored 'General case' 0 C--N 1.257 -3.451 0 C-N-CA 124.196 0.998 . . . . 0.0 112.133 -177.764 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 11.8 t80 174.4 -50.98 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 124.864 1.266 . . . . 0.0 109.395 174.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.599 ' HA2' ' N ' ' A' ' 115' ' ' ARG . . . 95.04 109.8 2.32 Favored Glycine 0 CA--C 1.496 -1.123 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.305 -177.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -132.68 -73.09 0.51 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 117.707 -1.597 . . . . 0.0 112.878 -174.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 37.5 t-20 -161.95 152.18 17.02 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -179.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.7 m -71.73 -34.27 69.4 Favored 'General case' 0 C--O 1.208 -1.095 0 CA-C-O 121.135 0.493 . . . . 0.0 110.298 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.22 -12.72 27.63 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 120.75 -0.38 . . . . 0.0 111.956 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -154.24 111.26 0.48 Allowed Glycine 0 CA--C 1.468 -2.866 0 C-N-CA 119.077 -1.535 . . . . 0.0 110.046 -174.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.408 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 26.2 p -98.28 88.47 4.18 Favored 'General case' 0 N--CA 1.4 -2.949 0 CA-C-O 121.65 0.738 . . . . 0.0 110.851 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.0 m -79.26 -46.29 18.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.708 0.766 . . . . 0.0 110.14 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.5 m -63.71 -24.95 67.99 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.402 178.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.902 ' HB2' ' HB ' ' A' ' 116' ' ' THR . . . -75.49 -9.23 58.39 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 176.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.99 -160.49 0.78 Allowed Glycine 0 C--N 1.311 -0.854 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.97 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -74.37 54.08 3.23 Favored 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 122.74 2.293 . . . . 0.0 110.223 177.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -133.23 109.46 9.44 Favored 'General case' 0 N--CA 1.424 -1.751 0 N-CA-C 103.48 -2.785 . . . . 0.0 103.48 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.498 ' CD2' ' HB3' ' A' ' 69' ' ' ARG . 54.7 m-85 -123.77 162.06 23.93 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-O 122.06 0.934 . . . . 0.0 113.12 -174.218 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -104.56 143.3 26.41 Favored Pre-proline 0 N--CA 1.42 -1.956 0 N-CA-C 103.859 -2.645 . . . . 0.0 103.859 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -48.18 -55.31 4.16 Favored 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.98 2.453 . . . . 0.0 116.832 -168.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 95.2 mt -90.12 -4.97 57.0 Favored 'General case' 0 CA--C 1.478 -1.81 0 C-N-CA 119.142 -1.023 . . . . 0.0 108.885 -172.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 21.4 m -86.52 7.98 23.86 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.188 -1.369 . . . . 0.0 109.733 178.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HB3' ' CD2' ' A' ' 64' ' ' PHE . 4.4 ppt_? -134.04 -30.15 1.23 Allowed 'General case' 0 N--CA 1.402 -2.832 0 CA-C-O 117.734 -1.127 . . . . 0.0 110.313 167.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.485 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 85.1 tttt 34.54 -86.04 0.0 OUTLIER 'General case' 0 C--N 1.389 2.286 0 C-N-CA 125.386 1.474 . . . . 0.0 110.968 -173.534 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.506 ' O ' ' HA2' ' A' ' 127' ' ' GLY . 55.0 t-80 -131.32 -38.75 1.18 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 172.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.0 119.58 3.05 Favored Glycine 0 N--CA 1.425 -2.059 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -170.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.3 144.11 11.51 Favored Glycine 0 N--CA 1.419 -2.454 0 C-N-CA 118.612 -1.756 . . . . 0.0 113.041 -174.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 101' ' ' ASP . 59.1 Cg_endo -74.84 -19.16 18.53 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.3 2.0 . . . . 0.0 112.99 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 101' ' ' ASP . 51.1 mtmt -120.62 -13.97 8.68 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -175.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -172.18 126.25 0.55 Allowed 'General case' 0 CA--C 1.493 -1.231 0 CA-C-N 119.593 1.088 . . . . 0.0 109.649 -173.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.424 ' H ' ' HB2' ' A' ' 102' ' ' SER . 2.9 mm-40 -138.31 171.16 14.79 Favored 'General case' 0 N--CA 1.416 -2.16 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.084 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -100.13 -74.82 0.59 Allowed 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.562 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.1 OUTLIER -130.2 26.3 5.16 Favored 'General case' 0 CA--C 1.47 -2.107 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -170.579 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 7.6 t60 . . . . . 0 N--CA 1.396 -3.155 0 CA-C-N 111.96 -2.382 . . . . 0.0 106.102 177.042 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 CA--C 1.506 -0.75 0 N-CA-C 109.818 -0.438 . . . . 0.0 109.818 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.42 153.96 35.07 Favored Glycine 0 CA--C 1.5 -0.851 0 O-C-N 124.194 0.933 . . . . 0.0 111.287 178.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -76.66 146.1 38.35 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.992 -171.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.66 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 17.1 m -136.9 146.26 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.548 ' HA ' ' OE1' ' A' ' 121' ' ' GLU . 7.4 t -141.62 109.57 5.79 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 174.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.586 ' HB1' ' HA2' ' A' ' 93' ' ' GLY . . . -118.07 105.78 12.21 Favored 'General case' 0 CA--C 1.47 -2.113 0 N-CA-C 104.814 -2.291 . . . . 0.0 104.814 174.157 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.527 ' HA ' ' N ' ' A' ' 41' ' ' GLY . 39.2 p30 -112.85 -77.52 0.58 Allowed 'General case' 0 C--O 1.172 -2.983 0 N-CA-C 114.793 1.405 . . . . 0.0 114.793 -164.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -83.71 -14.72 51.0 Favored 'General case' 1 C--N 1.212 -5.377 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -144.54 134.66 24.11 Favored 'General case' 0 N--CA 1.418 -2.037 0 N-CA-C 106.198 -1.778 . . . . 0.0 106.198 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.683 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.54 71.8 2.94 Favored Glycine 0 N--CA 1.417 -2.616 0 CA-C-O 119.279 -0.734 . . . . 0.0 111.549 -175.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.671 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 59.0 t -153.61 105.54 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.495 ' H ' ' HB ' ' A' ' 35' ' ' ILE . . . -113.11 144.48 42.57 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.463 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.33 137.27 38.99 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.987 -1.856 . . . . 0.0 105.987 175.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.456 HG11 ' H ' ' A' ' 33' ' ' GLY . 8.0 p -101.74 140.32 20.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.118 0.485 . . . . 0.0 110.164 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.6 m -122.47 101.58 7.57 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.686 ' H ' HD13 ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.42 118.74 54.66 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.311 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -177.415 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -148.8 97.49 2.72 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.011 -2.218 . . . . 0.0 105.011 166.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.545 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 1.1 p30 -168.02 168.19 12.11 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.339 -169.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.424 ' HB2' ' H ' ' A' ' 77' ' ' GLU . 15.6 m -99.95 80.0 2.26 Favored 'General case' 0 N--CA 1.42 -1.94 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.956 168.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.531 ' C ' ' H ' ' A' ' 105' ' ' SER . 49.9 t -101.18 -11.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 123.859 0.864 . . . . 0.0 109.442 173.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.656 HG23 HG12 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -63.82 21.32 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.889 0 C-N-CA 124.777 1.231 . . . . 0.0 112.641 176.957 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.531 ' H ' ' C ' ' A' ' 103' ' ' VAL . 16.0 m -68.74 130.22 42.19 Favored 'General case' 0 N--CA 1.4 -2.944 0 C-N-CA 125.271 1.428 . . . . 0.0 110.148 179.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.03 173.11 3.21 Favored 'General case' 0 N--CA 1.387 -3.583 0 CA-C-N 112.953 -1.931 . . . . 0.0 107.004 172.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.5 p -64.93 116.18 6.12 Favored 'General case' 2 N--CA 1.363 -4.787 0 CA-C-O 123.58 1.657 . . . . 0.0 111.592 -165.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.57 -142.32 12.82 Favored Glycine 2 CA--C 1.425 -5.546 0 CA-C-N 110.363 -3.108 . . . . 0.0 105.343 174.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 49' ' ' GLU . 4.7 p-10 40.11 -151.47 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -89.55 -23.81 21.91 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.158 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -131.51 -153.31 0.55 Allowed 'General case' 0 N--CA 1.41 -2.465 0 CA-C-O 122.009 0.909 . . . . 0.0 110.348 -175.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 59.0 mt -126.51 -38.2 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 N-CA-C 104.28 -2.489 . . . . 0.0 104.28 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.9 pt -91.08 99.05 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.834 0 CA-C-N 113.155 -1.839 . . . . 0.0 107.055 173.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -97.68 63.7 0.92 Allowed Glycine 2 N--CA 1.375 -5.392 0 N-CA-C 105.023 -3.231 . . . . 0.0 105.023 -175.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.599 ' N ' ' HA2' ' A' ' 51' ' ' GLY . 31.7 mtp180 -68.24 81.8 0.24 Allowed 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 -176.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.902 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 0.7 OUTLIER -163.3 97.12 0.89 Allowed 'General case' 1 N--CA 1.367 -4.592 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 -179.166 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.485 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 16.2 mt -103.61 106.49 17.01 Favored 'General case' 0 C--N 1.251 -3.696 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.963 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.628 HG13 ' HB1' ' A' ' 60' ' ' ALA . 8.2 m -92.2 98.05 7.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 C-N-CA 117.394 -1.722 . . . . 0.0 109.384 169.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.449 HG22 ' HB3' ' A' ' 46' ' ' HIS . 9.2 t -135.51 136.21 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 122.724 1.249 . . . . 0.0 112.587 -174.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.663 ' HA ' ' HB3' ' A' ' 13' ' ' PRO . 0.4 OUTLIER -170.77 134.71 1.05 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 168.053 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.548 ' OE1' ' HA ' ' A' ' 88' ' ' THR . 1.9 mm-40 -69.63 99.74 1.35 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 122.153 0.978 . . . . 0.0 110.632 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.562 ' HA ' HD23 ' A' ' 42' ' ' LEU . 68.0 mttm -170.73 170.4 6.62 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 -170.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.63 104.13 3.24 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.596 ' HB3' ' O ' ' A' ' 45' ' ' PHE . 7.2 t70 -107.47 6.69 28.39 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -42.48 105.91 0.05 Allowed 'General case' 0 C--O 1.245 0.832 0 C-N-CA 126.882 2.073 . . . . 0.0 112.61 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -71.07 -39.93 71.92 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.574 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 71' ' ' HIS . . . -89.42 24.21 15.25 Favored Glycine 0 CA--C 1.482 -2.023 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.562 -177.208 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -136.59 -47.32 0.62 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 65.25 -78.34 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.777 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.363 -174.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 156.8 -38.05 0.57 Allowed Glycine 0 N--CA 1.417 -2.571 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.656 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 59.4 t30 -152.66 -178.91 7.16 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -54.02 -34.46 60.01 Favored 'General case' 0 C--N 1.368 1.384 0 N-CA-C 114.169 1.174 . . . . 0.0 114.169 -177.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.656 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -85.29 -38.14 19.2 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.305 0.574 . . . . 0.0 111.57 -174.568 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.4 p -76.77 -20.78 56.06 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -81.54 -7.75 59.63 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.878 0.847 . . . . 0.0 109.642 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 86.5 tttt -85.81 -49.18 8.11 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 5.0 p -68.1 -37.42 81.15 Favored 'General case' 0 N--CA 1.417 -2.101 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.014 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.73 94.81 0.06 OUTLIER Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -32.54 123.62 0.34 Allowed 'General case' 1 C--O 1.336 5.619 0 CA-C-O 123.609 1.671 . . . . 0.0 114.049 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.414 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -140.74 120.66 13.58 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.85 -176.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -97.33 72.66 0.69 Allowed Glycine 0 C--O 1.214 -1.122 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.408 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 5.2 p -88.83 5.99 41.11 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -172.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 57.0 ttt-85 -118.26 -47.92 2.54 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.74 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.438 ' HG ' ' HD3' ' A' ' 13' ' ' PRO . 11.9 tp -60.34 -38.95 85.39 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 114.957 -1.02 . . . . 0.0 113.59 -167.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 129.96 7.13 Favored 'General case' 0 CA--C 1.481 -1.675 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.485 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 81.4 m -138.25 163.21 32.34 Favored 'General case' 0 C--N 1.291 -1.977 0 O-C-N 124.421 1.076 . . . . 0.0 108.856 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.664 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.7 170.23 43.34 Favored Glycine 0 N--CA 1.408 -3.188 0 O-C-N 123.887 0.742 . . . . 0.0 111.489 175.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.546 HG13 ' HG2' ' A' ' 115' ' ' ARG . 69.5 t -69.49 117.73 12.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 C-N-CA 124.148 0.979 . . . . 0.0 110.549 168.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.528 ' H ' ' HA ' ' A' ' 115' ' ' ARG . 15.7 tt -122.65 108.0 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 CA-C-O 122.229 1.014 . . . . 0.0 108.729 166.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.49 46.23 Favored Glycine 1 CA--C 1.442 -4.479 0 N-CA-C 108.262 -1.935 . . . . 0.0 108.262 178.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 8.7 tt -69.23 103.91 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 177.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.554 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -110.27 97.12 6.66 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.386 -1.326 . . . . 0.0 110.936 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.324 -0.536 0 O-C-N 125.942 2.026 . . . . 0.0 114.489 171.157 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.811 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.609 ' O ' ' HA ' ' A' ' 21' ' ' GLU . 28.5 p -109.6 -65.24 1.17 Allowed 'General case' 0 C--O 1.161 -3.585 0 CA-C-O 119.147 -0.454 . . . . 0.0 111.569 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.2 ptpp? -135.49 171.03 15.02 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.894 0.378 . . . . 0.0 110.684 -168.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -137.19 166.82 22.83 Favored 'General case' 0 N--CA 1.419 -2.021 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -177.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 152' ' ' ALA . 27.2 m -128.89 168.39 22.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.566 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -132.66 137.97 47.16 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.469 -173.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.7 t -134.28 108.55 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.434 HD21 ' HB3' ' A' ' 117' ' ' LEU . 84.7 mt -96.71 150.17 20.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -149.15 122.79 9.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.93 24.66 Favored Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.134 -1.507 . . . . 0.0 113.012 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . 0.425 ' O ' ' HD3' ' A' ' 13' ' ' PRO . 46.3 m-20 -66.24 -50.5 63.56 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 175.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.91 96.9 1.7 Allowed Glycine 0 N--CA 1.432 -1.594 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' O ' ' A' ' 11' ' ' ASP . 32.2 Cg_exo -57.08 127.41 25.64 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.607 2.204 . . . . 0.0 113.563 -173.329 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 11.4 m -120.58 113.02 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.804 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.597 175.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 mp0 -108.5 119.53 39.79 Favored 'General case' 0 C--N 1.294 -1.805 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.112 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.72 170.13 42.9 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 176.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.431 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 24.8 pt -129.4 125.4 61.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' HE2' ' A' ' 46' ' ' HIS . 3.7 mp -123.33 128.4 74.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -178.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.735 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 18.5 m120 -100.05 134.89 42.31 Favored 'General case' 0 CA--C 1.507 -0.701 0 CA-C-O 119.306 -0.378 . . . . 0.0 110.662 -177.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -127.75 119.6 26.11 Favored 'General case' 0 CA--C 1.503 -0.852 0 C-N-CA 118.613 -1.235 . . . . 0.0 113.585 175.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.609 ' HA ' ' O ' ' A' ' 2' ' ' THR . 58.3 mt-10 -90.22 143.9 26.35 Favored 'General case' 0 N--CA 1.425 -1.719 0 CA-C-N 114.372 -1.285 . . . . 0.0 112.734 177.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.576 ' HB2' ' HA ' ' A' ' 106' ' ' LEU . 3.9 pt20 -103.11 124.9 49.43 Favored 'General case' 1 N--CA 1.375 -4.176 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 163.596 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -111.45 83.59 1.8 Allowed 'General case' 0 C--N 1.273 -2.733 0 C-N-CA 119.264 -0.974 . . . . 0.0 108.578 169.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -69.47 -27.95 65.66 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.102 -1.408 . . . . 0.0 108.736 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -71.21 -8.65 54.99 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.36 -1.291 . . . . 0.0 110.087 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.2 t30 75.88 120.44 0.05 OUTLIER 'General case' 0 C--N 1.35 0.626 0 C-N-CA 126.323 1.849 . . . . 0.0 111.195 -177.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.69 165.55 29.88 Favored Glycine 0 N--CA 1.408 -3.183 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HB3' ' HB2' ' A' ' 101' ' ' ASP . 37.7 Cg_endo -66.28 135.53 40.27 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.12 1.88 . . . . 0.0 110.692 178.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.594 HG23 ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -73.6 135.36 27.75 Favored 'Isoleucine or valine' 0 C--O 1.268 2.033 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.445 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -101.75 124.16 46.93 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 173.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.414 ' O ' HG22 ' A' ' 99' ' ' ILE . 16.5 m -137.99 152.82 26.55 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -172.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.6 t-105 -156.56 132.49 9.69 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.475 ' C ' HG12 ' A' ' 97' ' ' VAL . . . -170.63 135.84 3.69 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.545 -2.264 . . . . 0.0 112.61 169.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.437 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 5.4 p -117.8 137.09 52.98 Favored 'General case' 0 N--CA 1.395 -3.18 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.411 HG22 ' HA3' ' A' ' 16' ' ' GLY . 47.6 pt -131.87 146.27 33.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.052 -1.059 . . . . 0.0 110.093 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -119.23 129.61 55.03 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 176.225 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.583 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -135.15 174.3 21.24 Favored Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -173.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.81 173.53 5.19 Favored 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 123.73 0.812 . . . . 0.0 110.81 178.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.497 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 9.8 t -66.37 110.63 3.16 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-O 121.627 0.727 . . . . 0.0 111.657 -172.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . 0.267 4.6 mm-40 -165.61 177.34 7.41 Favored 'General case' 0 N--CA 1.398 -3.071 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.251 -176.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.43 -146.49 0.01 OUTLIER Glycine 0 N--CA 1.403 -3.501 0 CA-C-N 112.021 -2.354 . . . . 0.0 115.417 -177.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.561 ' CB ' ' HA ' ' A' ' 88' ' ' THR . 2.0 pt? -173.06 100.14 0.13 Allowed 'General case' 1 N--CA 1.372 -4.326 0 O-C-N 121.592 -0.946 . . . . 0.0 109.343 -161.214 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.526 ' HB3' ' HA ' ' A' ' 123' ' ' ALA . 0.4 OUTLIER 169.85 171.33 0.05 Allowed 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 103.963 -2.606 . . . . 0.0 103.963 177.43 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' ' N ' ' A' ' 125' ' ' ASP . . . 102.65 64.72 0.73 Allowed Glycine 0 C--N 1.268 -3.197 0 N-CA-C 116.248 1.259 . . . . 0.0 116.248 171.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.611 ' CG ' ' HB3' ' A' ' 84' ' ' LEU . 12.8 t80 -76.72 134.85 39.09 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 117.336 -1.746 . . . . 0.0 110.07 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.644 ' HE2' HG12 ' A' ' 18' ' ' ILE . 1.4 p-80 -85.91 100.61 12.22 Favored 'General case' 0 C--N 1.263 -3.175 0 CA-C-N 112.848 -1.978 . . . . 0.0 115.086 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.407 HG12 ' OE1' ' A' ' 49' ' ' GLU . 31.2 t -129.58 89.79 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.497 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 171.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.709 ' CE1' ' HB3' ' A' ' 60' ' ' ALA . 1.7 t60 -107.27 107.29 18.15 Favored 'General case' 0 C--O 1.184 -2.393 0 N-CA-C 113.323 0.861 . . . . 0.0 113.323 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 60' ' ' ALA . 3.6 mp0 -90.07 136.21 33.18 Favored 'General case' 0 C--N 1.267 -2.989 0 O-C-N 120.687 -1.258 . . . . 0.0 112.665 175.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 t80 70.67 93.59 0.08 Allowed 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 125.968 1.707 . . . . 0.0 111.359 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.29 -91.14 1.15 Allowed Glycine 0 CA--C 1.482 -2.006 0 C-N-CA 119.066 -1.54 . . . . 0.0 113.543 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.2 t70 76.89 -25.87 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 126.996 2.118 . . . . 0.0 112.583 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 2.6 m-20 -90.35 98.84 12.01 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.49 ' HA ' HG13 ' A' ' 148' ' ' VAL . 11.4 t -56.55 -32.07 64.8 Favored 'General case' 0 C--O 1.199 -1.561 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -173.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.74 13.07 33.82 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.606 -0.683 . . . . 0.0 110.808 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.448 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -155.75 111.46 0.49 Allowed Glycine 0 N--CA 1.425 -2.095 0 C-N-CA 117.849 -2.119 . . . . 0.0 113.667 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 142' ' ' SER . 69.5 m -94.57 85.14 4.43 Favored 'General case' 0 N--CA 1.392 -3.36 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 172.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.9 m -82.31 -48.36 11.28 Favored 'General case' 0 N--CA 1.418 -2.061 0 CA-C-N 114.794 -1.093 . . . . 0.0 109.156 179.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.6 p -71.57 -54.91 8.94 Favored 'General case' 0 N--CA 1.407 -2.624 0 CA-C-N 113.361 -1.745 . . . . 0.0 113.792 -172.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.709 ' HB3' ' CE1' ' A' ' 48' ' ' HIS 0.325 . . -85.81 -2.34 58.13 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 179.657 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -43.5 -139.31 0.0 OUTLIER Glycine 0 CA--C 1.57 3.509 0 C-N-CA 124.186 0.898 . . . . 0.0 113.993 171.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -60.1 5.32 0.13 Allowed 'Trans proline' 0 CA--C 1.574 2.494 0 C-N-CA 122.706 2.271 . . . . 0.0 114.879 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -116.58 110.8 19.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 123.467 0.707 . . . . 0.0 109.838 178.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -74.48 152.51 39.4 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -115.77 144.35 32.45 Favored Pre-proline 0 C--N 1.309 -1.162 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.74 177.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -72.22 -13.11 28.23 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.239 1.959 . . . . 0.0 111.747 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 109' ' ' ASP . 2.6 mm? -80.96 -9.47 59.83 Favored 'General case' 0 CA--C 1.484 -1.568 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -78.95 66.03 4.3 Favored 'General case' 0 N--CA 1.405 -2.706 0 CA-C-O 123.538 1.637 . . . . 0.0 108.719 172.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.636 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 12.5 ptp180 -117.49 23.27 11.88 Favored 'General case' 0 N--CA 1.397 -3.104 0 CA-C-N 112.204 -2.271 . . . . 0.0 105.149 175.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.9 mmmt -78.91 18.63 0.59 Allowed 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 112.363 -2.199 . . . . 0.0 111.005 176.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 33.6 t-80 75.3 87.59 0.09 Allowed 'General case' 0 N--CA 1.423 -1.805 0 O-C-N 125.135 1.522 . . . . 0.0 112.018 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . -76.75 -98.4 0.17 Allowed Glycine 1 N--CA 1.385 -4.738 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 169.492 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -50.33 158.0 1.88 Allowed Glycine 0 N--CA 1.429 -1.827 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 172.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.434 ' HA ' ' NE2' ' A' ' 71' ' ' HIS . 47.4 Cg_endo -62.14 0.09 1.47 Allowed 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 124.678 3.585 . . . . 0.0 114.454 -172.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -120.39 13.67 11.89 Favored 'General case' 0 C--N 1.289 -2.049 0 C-N-CA 123.047 0.539 . . . . 0.0 110.127 -175.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 71' ' ' HIS . 3.0 m-20 71.98 76.38 0.16 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.502 177.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -78.97 87.19 4.79 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.723 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 69' ' ' ARG . 11.6 pt-20 -57.56 26.34 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 128.704 2.801 . . . . 0.0 115.942 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -160.16 -0.56 0.07 Allowed 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.385 -174.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.8 m170 . . . . . 0 N--CA 1.491 1.59 0 O-C-N 121.563 -0.711 . . . . 0.0 111.451 -173.703 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.611 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 7.5 tt . . . . . 0 C--O 1.252 1.186 0 N-CA-C 102.597 -3.112 . . . . 0.0 102.597 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.522 ' N ' HD23 ' A' ' 84' ' ' LEU . . . -39.74 156.43 0.03 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 119.106 0.867 . . . . 0.0 111.486 173.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.48 160.52 19.68 Favored 'General case' 0 C--N 1.282 -2.351 0 O-C-N 122.377 -0.484 . . . . 0.0 112.105 -158.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 77.5 t -108.39 163.42 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.912 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -174.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.561 ' HA ' ' CB ' ' A' ' 42' ' ' LEU . 31.5 m -140.33 130.51 25.0 Favored 'General case' 0 C--N 1.261 -3.28 0 C-N-CA 124.437 1.095 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.54 ' CB ' ' HB3' ' A' ' 121' ' ' GLU . . . -126.12 155.16 42.08 Favored 'General case' 0 C--N 1.254 -3.583 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 174.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.418 ' C ' ' HA ' ' A' ' 39' ' ' THR . 23.9 t70 -158.36 174.96 14.34 Favored 'General case' 1 C--N 1.239 -4.232 0 N-CA-C 104.126 -2.546 . . . . 0.0 104.126 178.462 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.497 ' N ' ' HA ' ' A' ' 39' ' ' THR . 59.8 pttt -47.27 -35.85 8.32 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 176.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -90.28 -38.64 13.26 Favored 'General case' 0 CA--C 1.486 -1.503 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 176.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.583 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 89.54 112.85 1.38 Allowed Glycine 0 N--CA 1.404 -3.479 0 CA-C-N 114.675 -1.148 . . . . 0.0 112.308 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.484 ' O ' ' HB ' ' A' ' 88' ' ' THR . 6.7 p -157.71 103.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.417 -2.101 0 CA-C-O 121.953 0.883 . . . . 0.0 109.876 174.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.403 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . -94.23 129.0 41.02 Favored 'General case' 0 N--CA 1.414 -2.228 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.713 173.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -69.57 143.38 53.37 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 114.378 -1.283 . . . . 0.0 109.406 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.475 HG12 ' C ' ' A' ' 33' ' ' GLY . 34.4 m -79.57 103.37 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.908 0 CA-C-O 123.855 1.788 . . . . 0.0 107.813 -177.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -86.77 107.39 18.24 Favored 'General case' 0 N--CA 1.401 -2.9 0 CA-C-N 113.059 -1.882 . . . . 0.0 111.083 -174.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 31' ' ' VAL . 37.5 pt -95.66 124.83 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.513 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -143.64 126.31 16.03 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.46 ' HB2' ' HB3' ' A' ' 28' ' ' PRO . 4.3 p30 -81.09 135.62 35.83 Favored 'General case' 0 C--O 1.276 2.45 0 CA-C-O 122.433 1.111 . . . . 0.0 112.601 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.427 ' OG ' ' HB ' ' A' ' 29' ' ' VAL . 92.5 p -102.92 172.2 6.96 Favored 'General case' 0 N--CA 1.413 -2.3 0 CA-C-N 112.846 -1.979 . . . . 0.0 110.608 177.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.452 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 7.1 p -115.88 -53.1 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.329 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 163.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 12.8 pt -98.93 23.67 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.045 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -170.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.8 t -80.34 89.88 5.56 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 123.061 1.41 . . . . 0.0 108.721 169.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.576 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 3.0 pp -126.72 170.39 12.18 Favored 'General case' 2 N--CA 1.346 -5.643 1 N-CA-C 99.272 -4.344 . . . . 0.0 99.272 174.558 . . . . . . . . 4 3 . 1 . 008 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.1 m -74.13 93.37 2.28 Favored 'General case' 1 C--N 1.213 -5.327 0 C-N-CA 118.727 -1.189 . . . . 0.0 111.978 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.81 135.43 12.43 Favored Glycine 0 CA--C 1.456 -3.651 0 N-CA-C 106.308 -2.717 . . . . 0.0 106.308 175.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.526 ' HB2' ' CB ' ' A' ' 67' ' ' LEU . 6.1 t70 54.09 -153.78 0.28 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -171.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.543 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 62.6 m-70 -90.37 37.11 0.89 Allowed 'General case' 0 C--N 1.276 -2.602 0 C-N-CA 124.78 1.232 . . . . 0.0 109.777 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 115' ' ' ARG . 16.6 p -59.41 -27.14 65.74 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.671 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 46.1 pt -104.6 -32.94 2.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 C-N-CA 118.2 -1.4 . . . . 0.0 110.62 176.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.543 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 14.0 tt -104.09 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 120.135 -0.626 . . . . 0.0 112.684 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.76 17.89 53.02 Favored Glycine 0 N--CA 1.44 -1.065 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.895 175.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.549 ' HG3' ' O ' ' A' ' 48' ' ' HIS . 23.7 ttp180 -73.4 101.73 3.56 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 122.268 -0.548 . . . . 0.0 111.233 178.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 146' ' ' CYS . 4.2 m -70.9 110.85 5.88 Favored 'General case' 0 C--O 1.181 -2.519 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 176.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.537 ' HG ' ' HB2' ' A' ' 46' ' ' HIS . 13.2 tp -70.03 123.87 22.64 Favored 'General case' 0 C--N 1.275 -2.673 0 C-N-CA 122.731 0.412 . . . . 0.0 111.346 -172.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.582 HG22 ' HB2' ' A' ' 48' ' ' HIS . 11.4 m -91.88 101.03 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 178.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.487 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 10.3 p -140.52 168.66 16.61 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 176.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 124' ' ' ASP . 0.3 OUTLIER -171.2 164.23 7.25 Favored 'General case' 0 CA--C 1.487 -1.456 0 N-CA-C 104.214 -2.513 . . . . 0.0 104.214 173.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.58 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 2.2 mp0 -86.9 84.17 7.39 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.58 ' HG2' ' O ' ' A' ' 121' ' ' GLU . 2.2 mmpt? -176.0 171.53 2.57 Favored 'General case' 0 CA--C 1.476 -1.903 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 -175.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 43' ' ' HIS . . . -62.42 122.41 15.65 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 170.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 19.6 t70 -128.74 -12.83 4.79 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.943 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.502 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 0.6 OUTLIER -71.56 137.28 47.92 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.268 -174.881 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -79.2 -68.19 0.68 Allowed 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.334 -178.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -74.04 9.83 8.61 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 119.982 -1.104 . . . . 0.0 114.962 -176.765 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.404 ' HB3' ' CG ' ' A' ' 125' ' ' ASP . 32.2 tptt -137.43 15.29 2.97 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.8 42.94 1.85 Allowed Glycine 0 N--CA 1.473 1.135 0 N-CA-C 118.736 2.254 . . . . 0.0 118.736 -166.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 74.18 -91.38 0.72 Allowed Glycine 0 C--N 1.3 -1.431 0 N-CA-C 116.735 1.454 . . . . 0.0 116.735 171.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -100.33 158.32 15.97 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 118.595 -0.717 . . . . 0.0 110.484 -169.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -47.37 -42.48 21.77 Favored 'General case' 0 C--N 1.363 1.172 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 -178.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -79.87 -43.66 21.87 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.91 0.386 . . . . 0.0 110.958 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.7 t -70.64 -20.87 62.68 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.369 0.668 . . . . 0.0 111.878 -173.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -82.32 -18.23 42.97 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.031 0.443 . . . . 0.0 110.356 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 44.5 mtpt -101.77 -28.22 12.58 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.54 -1.264 . . . . 0.0 110.071 -178.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.9 p -74.45 -47.85 31.05 Favored 'General case' 0 N--CA 1.408 -2.527 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 173.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.16 94.06 0.13 Allowed Glycine 0 N--CA 1.417 -2.614 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.66 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 46.2 t-20 -55.81 106.03 0.23 Allowed 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 176.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.6 56.17 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -172.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.47 101.21 2.74 Favored Glycine 0 N--CA 1.428 -1.868 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 15.2 m -89.52 -7.1 55.65 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -171.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -145.19 -11.39 0.55 Allowed 'General case' 0 C--N 1.247 -3.859 0 C-N-CA 118.203 -1.399 . . . . 0.0 110.297 172.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -54.89 -42.96 72.74 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -175.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -149.82 89.88 1.65 Allowed 'General case' 0 N--CA 1.397 -3.122 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.563 ' HB3' HG22 ' A' ' 116' ' ' THR . 32.3 m -126.72 150.71 48.9 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 113.938 -1.483 . . . . 0.0 107.897 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.95 139.64 5.55 Favored Glycine 0 C--N 1.291 -1.957 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 178.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 54' ' ' THR . 17.2 m -73.59 110.4 7.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 118.69 1.245 . . . . 0.0 111.705 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.456 HG23 ' HB2' ' A' ' 117' ' ' LEU . 1.4 pp -86.67 145.75 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.227 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.671 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -150.14 142.61 9.83 Favored Glycine 2 N--CA 1.382 -4.96 0 C-N-CA 117.619 -2.229 . . . . 0.0 112.395 -171.409 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.612 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 3.4 tt -53.16 103.79 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 CA-C-O 122.088 0.947 . . . . 0.0 109.841 167.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.409 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -150.1 154.73 38.6 Favored 'General case' 0 N--CA 1.41 -2.436 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 174.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 . . . . . 0 C--N 1.273 -2.72 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 177.608 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.05 0 N-CA-C 111.379 0.14 . . . . 0.0 111.379 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.595 ' C ' ' HG3' ' A' ' 21' ' ' GLU . 30.1 m -119.33 -54.06 2.21 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.51 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 22.6 pttp -145.5 152.57 39.97 Favored 'General case' 0 N--CA 1.417 -2.122 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.632 -169.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.773 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.19 161.03 38.84 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 65.7 t -131.25 122.52 51.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.815 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -115.33 127.82 55.68 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.581 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.5 m -113.29 144.75 20.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 O-C-N 123.433 0.458 . . . . 0.0 110.554 -178.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 95.4 mt -127.09 135.05 50.22 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.641 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -141.04 125.86 18.06 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -154.31 178.45 31.13 Favored Glycine 0 N--CA 1.432 -1.597 0 C-N-CA 118.931 -1.604 . . . . 0.0 113.338 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -73.0 -40.4 65.23 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.56 95.57 1.45 Allowed Glycine 0 N--CA 1.434 -1.443 0 N-CA-C 106.159 -2.776 . . . . 0.0 106.159 170.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.75 127.56 14.77 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.895 1.73 . . . . 0.0 115.2 -169.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 14.0 m -123.78 114.98 43.75 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.186 0 N-CA-C 104.751 -2.314 . . . . 0.0 104.751 172.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.24 118.29 32.87 Favored 'General case' 0 C--N 1.279 -2.485 0 C-N-CA 118.309 -1.356 . . . . 0.0 109.542 -173.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.72 171.56 44.15 Favored Glycine 0 N--CA 1.412 -2.965 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.887 178.405 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.2 pt -133.46 124.58 48.79 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.413 ' HA ' ' HA3' ' A' ' 33' ' ' GLY . 2.4 mp -114.11 140.04 36.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.489 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 35.9 m-80 -99.24 150.41 22.11 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.773 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 98.2 m-85 -149.39 117.29 6.29 Favored 'General case' 0 CA--C 1.491 -1.3 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 175.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.595 ' HG3' ' C ' ' A' ' 2' ' ' THR . 4.6 mm-40 -134.39 144.12 48.01 Favored 'General case' 0 CA--C 1.477 -1.839 0 C-N-CA 118.627 -1.229 . . . . 0.0 112.578 173.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.543 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 25.3 tp60 -127.71 152.36 47.82 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.408 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.457 ' H ' HE21 ' A' ' 22' ' ' GLN . 84.8 tttt -106.56 104.73 14.49 Favored 'General case' 0 C--N 1.26 -3.306 0 N-CA-C 100.511 -3.885 . . . . 0.0 100.511 169.386 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.318 9.9 pt-20 -63.27 -9.25 10.85 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -168.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.5 p -76.45 -61.09 2.07 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 170.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 175.57 136.55 0.05 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 126.447 1.899 . . . . 0.0 106.688 174.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.87 95.37 0.12 Allowed Glycine 1 CA--C 1.444 -4.36 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . 0.585 ' HB3' ' N ' ' A' ' 101' ' ' ASP . 38.4 Cg_exo -62.75 123.44 12.32 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 C-N-CA 121.686 1.591 . . . . 0.0 109.179 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.553 ' HB ' ' O ' ' A' ' 21' ' ' GLU . 77.8 t -88.75 148.19 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.98 0 N-CA-C 103.892 -2.632 . . . . 0.0 103.892 171.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HD2' ' N ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -99.62 109.33 21.83 Favored 'General case' 1 C--N 1.242 -4.072 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -167.16 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 16.1 m -124.53 152.44 30.52 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.089 -169.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 49.3 p90 -134.64 154.04 51.7 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-N 114.97 -1.013 . . . . 0.0 109.762 -175.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 96' ' ' ASP . . . -159.46 140.16 6.66 Favored Glycine 0 N--CA 1.415 -2.702 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 176.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.563 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 11.7 p -116.67 114.83 24.6 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 124.001 0.92 . . . . 0.0 110.987 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.546 HG22 ' HA3' ' A' ' 16' ' ' GLY . 36.8 pt -128.78 123.18 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 119.69 1.132 . . . . 0.0 110.81 175.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 21.3 ptmt -92.89 142.34 27.42 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.472 ' HA2' HG12 ' A' ' 14' ' ' VAL . . . -144.89 175.79 24.32 Favored Glycine 0 N--CA 1.421 -2.356 0 O-C-N 123.574 0.547 . . . . 0.0 112.869 -168.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.72 171.25 8.02 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 m -73.07 103.48 3.84 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.644 -1.222 . . . . 0.0 114.071 -171.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.536 ' OE2' ' HD3' ' A' ' 122' ' ' LYS . 25.5 tt0 -177.1 156.4 1.27 Allowed 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 157.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.66 -159.16 34.76 Favored Glycine 0 C--N 1.272 -2.977 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 170.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.586 ' HB3' ' H ' ' A' ' 122' ' ' LYS . 1.3 pt? -159.65 -169.85 2.71 Favored 'General case' 1 N--CA 1.364 -4.758 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.169 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.443 ' H ' ' HA ' ' A' ' 123' ' ' ALA . 34.7 t-80 -137.4 165.4 26.32 Favored 'General case' 0 C--N 1.247 -3.856 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 -178.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.58 ' HA2' ' O ' ' A' ' 85' ' ' GLY . . . -34.29 111.46 0.07 OUTLIER Glycine 0 C--O 1.249 1.074 0 O-C-N 125.723 1.889 . . . . 0.0 112.547 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -69.68 157.39 37.35 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 121.929 0.871 . . . . 0.0 112.714 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.427 ' HB3' HD23 ' A' ' 126' ' ' LEU . 59.6 m80 -137.82 95.02 2.97 Favored 'General case' 1 C--O 1.341 5.903 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.021 -174.154 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.494 HG11 ' HB2' ' A' ' 117' ' ' LEU . 14.1 m -106.11 156.76 6.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.455 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.738 -175.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.44 ' ND1' ' HB2' ' A' ' 65' ' ' ASN . 15.1 t60 -131.32 121.04 24.02 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-O 122.531 1.158 . . . . 0.0 112.083 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.493 ' OE1' ' HA3' ' A' ' 108' ' ' GLY . 0.0 OUTLIER -90.03 95.61 10.29 Favored 'General case' 0 C--N 1.273 -2.751 0 CA-C-N 113.161 -1.836 . . . . 0.0 115.609 -175.827 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.299 6.4 p90 -131.23 -5.92 3.83 Favored 'General case' 0 C--O 1.218 -0.57 0 C-N-CA 118.128 -1.429 . . . . 0.0 114.252 169.51 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . 100.98 118.58 4.34 Favored Glycine 0 N--CA 1.476 1.351 0 C-N-CA 120.058 -1.068 . . . . 0.0 112.714 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -144.86 -85.97 0.12 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 118.308 -1.357 . . . . 0.0 111.098 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 23.5 t30 -153.83 136.69 15.36 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.481 HG23 HG22 ' A' ' 148' ' ' VAL . 23.5 m -55.76 -19.11 10.02 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 125.613 1.565 . . . . 0.0 112.608 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.32 2.52 14.78 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -176.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 170.84 137.94 2.41 Favored Glycine 0 C--O 1.211 -1.283 0 C-N-CA 117.744 -2.169 . . . . 0.0 113.229 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.642 ' SG ' HG22 ' A' ' 118' ' ' VAL . 25.4 p -98.68 94.06 6.44 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 36.8 m -74.75 -52.24 12.05 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.641 -0.662 . . . . 0.0 110.998 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 m -90.31 -34.81 15.58 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-O 121.149 0.5 . . . . 0.0 110.908 -175.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.58 59.61 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -175.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.54 -65.03 3.61 Favored Glycine 0 CA--C 1.542 1.775 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -88.88 6.38 4.68 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 123.061 2.508 . . . . 0.0 114.247 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -98.86 133.78 42.67 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -176.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -109.32 170.82 7.81 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -175.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.522 ' ND2' ' HA2' ' A' ' 108' ' ' GLY . 43.9 t30 -106.49 97.16 15.68 Favored Pre-proline 0 C--O 1.213 -0.852 0 C-N-CA 123.066 0.546 . . . . 0.0 110.758 176.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 70' ' ' LYS . 21.3 Cg_exo -62.2 -9.86 16.37 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 124.256 3.304 . . . . 0.0 114.333 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.18 -17.58 53.77 Favored 'General case' 0 C--N 1.365 1.263 0 C-N-CA 122.7 0.4 . . . . 0.0 110.784 -168.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 38.6 t -84.77 -90.62 0.09 Allowed 'General case' 0 N--CA 1.41 -2.465 0 C-N-CA 116.324 -2.15 . . . . 0.0 110.554 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.512 ' HG2' ' HB3' ' A' ' 75' ' ' LYS . 15.6 tpp180 -135.87 41.71 2.67 Favored 'General case' 0 C--N 1.264 -3.119 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 66' ' ' PRO . 99.5 mttt 75.35 -153.47 0.04 OUTLIER 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.308 -177.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 5.0 p80 -67.26 83.22 0.14 Allowed 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 93.25 91.58 1.55 Allowed Glycine 0 CA--C 1.467 -2.939 0 C-N-CA 117.784 -2.151 . . . . 0.0 111.638 169.591 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.92 142.8 7.73 Favored Glycine 1 N--CA 1.392 -4.263 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -86.22 0.46 8.13 Favored 'Trans proline' 0 N--CA 1.437 -1.806 0 C-N-CA 122.794 2.329 . . . . 0.0 109.414 178.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.512 ' HB3' ' HG2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -84.84 28.55 0.68 Allowed 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.154 -172.111 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.514 ' HB3' ' HA ' ' A' ' 68' ' ' SER . 5.8 t0 -179.78 39.99 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 123.209 1.48 . . . . 0.0 107.988 164.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 68.11 8.87 6.82 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 112.332 -2.213 . . . . 0.0 114.9 169.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' HG23 ' A' ' 103' ' ' VAL . 4.0 tp10 63.34 37.76 10.68 Favored 'General case' 0 C--N 1.366 1.322 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 176.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.408 ' H ' ' HB2' ' A' ' 68' ' ' SER 0.34 50.2 mtm180 -52.84 3.12 0.01 OUTLIER 'General case' 0 N--CA 1.521 3.118 0 N-CA-C 119.202 3.038 . . . . 0.0 119.202 -164.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.419 4.8 m80 . . . . . 0 CA--C 1.459 -2.537 0 C-N-CA 127.036 2.134 . . . . 0.0 112.708 162.043 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.439 ' N ' HG11 ' A' ' 103' ' ' VAL . 51.4 tp . . . . . 0 N--CA 1.433 -1.279 0 CA-C-O 122.521 1.153 . . . . 0.0 113.228 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.58 ' O ' ' HA2' ' A' ' 44' ' ' GLY . . . -139.96 138.92 9.48 Favored Glycine 0 N--CA 1.413 -2.884 0 N-CA-C 107.989 -2.044 . . . . 0.0 107.989 174.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -109.84 129.14 55.67 Favored 'General case' 0 CA--C 1.485 -1.527 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -175.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.907 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.3 m -129.21 156.21 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.223 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.04 -178.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 p -134.26 96.37 3.59 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.542 0.687 . . . . 0.0 112.224 -175.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.68 156.23 17.2 Favored 'General case' 0 N--CA 1.424 -1.766 0 C-N-CA 126.847 2.059 . . . . 0.0 108.973 177.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.581 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 15.3 t70 -137.11 -167.93 2.19 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.676 -1.602 . . . . 0.0 106.676 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -43.14 -38.66 2.52 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 126.123 1.769 . . . . 0.0 114.399 -177.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -134.94 4.96 3.3 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.643 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -63.08 170.45 14.53 Favored Glycine 0 CA--C 1.474 -2.514 0 CA-C-N 112.429 -2.169 . . . . 0.0 112.999 -170.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.506 HG12 ' HB3' ' A' ' 36' ' ' LYS . 16.1 m -134.83 131.94 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.391 -3.407 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -165.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.907 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.11 89.68 5.25 Favored 'General case' 2 C--N 1.239 -4.237 0 N-CA-C 104.667 -2.346 . . . . 0.0 104.667 175.305 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . 0.48 ' OD2' ' HB3' ' A' ' 34' ' ' SER . 12.1 t70 -121.42 89.12 3.06 Favored 'General case' 0 CA--C 1.477 -1.848 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 -178.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.81 144.2 38.34 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.738 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.886 -177.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -105.27 102.32 11.81 Favored 'General case' 0 C--N 1.266 -3.055 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.597 ' H ' HD13 ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.48 147.39 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.476 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.613 -173.506 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.408 ' HB3' ' HG3' ' A' ' 30' ' ' LYS . 14.5 pt-20 -149.19 117.48 6.45 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.585 ' N ' ' HB3' ' A' ' 28' ' ' PRO . 20.4 t70 -165.3 159.26 17.08 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.4 m -99.92 76.85 1.98 Allowed 'General case' 0 N--CA 1.425 -1.719 0 CA-C-O 123.576 1.655 . . . . 0.0 107.568 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.439 HG11 ' N ' ' A' ' 84' ' ' LEU . 6.5 p -120.52 -16.49 6.74 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.923 0 CA-C-N 111.361 -2.654 . . . . 0.0 107.403 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 9.2 mm -81.73 2.94 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.142 0 CA-C-N 113.301 -1.772 . . . . 0.0 107.313 -176.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' ' HG2' ' A' ' 22' ' ' GLN . 20.2 m -65.53 109.22 2.27 Favored 'General case' 0 C--O 1.263 1.816 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.408 HD13 HD12 ' A' ' 112' ' ' ILE . 44.4 tp -68.91 88.9 0.4 Allowed 'General case' 0 N--CA 1.396 -3.16 0 CA-C-N 112.463 -2.153 . . . . 0.0 113.417 -175.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.3 t -138.11 85.01 2.07 Favored 'General case' 1 N--CA 1.35 -5.449 0 N-CA-C 100.61 -3.848 . . . . 0.0 100.61 157.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.522 ' HA2' ' ND2' ' A' ' 65' ' ' ASN . . . -121.47 -144.25 6.85 Favored Glycine 0 CA--C 1.471 -2.685 0 CA-C-N 112.822 -1.99 . . . . 0.0 109.048 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -67.52 -74.14 0.12 Allowed 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 174.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -125.16 -47.47 1.76 Allowed 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 175.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.578 ' O ' ' HG3' ' A' ' 115' ' ' ARG . 21.9 m -161.67 169.45 21.53 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.408 HD12 HD13 ' A' ' 106' ' ' LEU . 4.4 mp -82.25 -39.82 16.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.45 ' HA ' ' CA ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -73.83 125.74 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.549 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.34 -3.97 51.1 Favored Glycine 0 CA--C 1.478 -2.266 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 171.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.613 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . 9.3 mmt180 -101.9 159.21 15.54 Favored 'General case' 0 N--CA 1.396 -3.15 0 CA-C-N 113.153 -1.523 . . . . 0.0 107.386 -174.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.596 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 16.7 p -99.58 135.58 40.78 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 2.7 pt? -88.9 130.11 35.48 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 174.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.642 HG22 ' SG ' ' A' ' 57' ' ' CYS . 14.3 t -101.43 101.79 12.6 Favored 'Isoleucine or valine' 0 C--O 1.262 1.752 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.61 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 27.0 m -136.96 169.59 19.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 C-N-CA 123.744 0.818 . . . . 0.0 108.816 -177.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.454 ' O ' HD13 ' A' ' 42' ' ' LEU . 49.0 t-80 -171.65 170.13 5.76 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 171.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.525 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.8 OUTLIER -77.59 84.06 3.97 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 170.743 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.586 ' H ' ' HB3' ' A' ' 42' ' ' LEU . 58.3 mmtt -173.58 127.98 0.42 Allowed 'General case' 0 CA--C 1.464 -2.363 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -174.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.443 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -44.89 103.32 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.84 0 O-C-N 123.863 0.727 . . . . 0.0 109.743 168.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -104.22 85.66 2.41 Favored 'General case' 0 CA--C 1.458 -2.585 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 -177.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 8.1 t70 -121.25 133.66 55.16 Favored 'General case' 0 C--N 1.255 -3.512 0 CA-C-N 113.729 -1.578 . . . . 0.0 108.869 -172.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.427 HD23 ' HB3' ' A' ' 46' ' ' HIS . 2.4 mm? -89.58 -13.3 37.54 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.668 -178.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -96.96 -34.6 5.63 Favored Glycine 0 N--CA 1.425 -2.047 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.459 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 65.4 tttm -86.33 -49.05 7.95 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 118.894 -0.575 . . . . 0.0 110.813 178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.59 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.91 -77.86 0.0 OUTLIER Glycine 0 CA--C 1.529 0.923 0 N-CA-C 114.439 0.536 . . . . 0.0 114.439 -170.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 171.63 -97.44 0.12 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 108.969 -1.653 . . . . 0.0 108.969 -177.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -88.94 179.98 6.07 Favored 'General case' 0 CA--C 1.56 1.337 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -56.16 -32.3 64.17 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 119.347 0.976 . . . . 0.0 113.229 -178.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -75.74 -46.38 31.25 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.676 0.751 . . . . 0.0 109.747 176.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.42 ' HA ' HG22 ' A' ' 137' ' ' THR . 1.3 m -60.97 -33.93 73.98 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.352 -175.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.59 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 9.9 t -67.97 -35.71 78.81 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-O 120.939 0.4 . . . . 0.0 111.568 178.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.25 -29.12 31.46 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.172 -176.104 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.42 HG22 ' HA ' ' A' ' 134' ' ' SER . 8.8 t -86.94 -14.93 40.4 Favored 'General case' 0 N--CA 1.438 -1.046 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 177.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.74 60.6 6.75 Favored Glycine 0 CA--C 1.5 -0.876 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 -175.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -51.89 105.23 0.1 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -175.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -152.11 171.64 17.58 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 173.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -67.9 87.45 0.18 Allowed Glycine 0 C--N 1.314 -0.665 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 173.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 16.2 m -66.1 -10.09 37.38 Favored 'General case' 0 C--O 1.21 -1.003 0 C-N-CA 124.731 1.213 . . . . 0.0 113.624 -175.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 43.1 mtp-105 -116.34 -37.4 3.77 Favored 'General case' 0 C--N 1.254 -3.554 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.725 172.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.422 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 3.8 mm? -49.0 -38.19 22.57 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 115.481 1.66 . . . . 0.0 115.481 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -143.89 92.45 2.34 Favored 'General case' 0 N--CA 1.42 -1.947 0 CA-C-O 121.622 0.725 . . . . 0.0 111.253 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 3.9 m -140.13 153.2 46.61 Favored 'General case' 0 N--CA 1.419 -1.979 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 175.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.75 168.95 42.01 Favored Glycine 0 N--CA 1.406 -3.311 0 N-CA-C 107.0 -2.44 . . . . 0.0 107.0 176.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.481 HG22 HG23 ' A' ' 54' ' ' THR . 31.4 m -70.44 122.04 21.42 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.443 1.116 . . . . 0.0 112.385 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.402 ' HB ' HD22 ' A' ' 117' ' ' LEU . 9.0 tt -99.25 142.68 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.756 0 N-CA-C 103.704 -2.702 . . . . 0.0 103.704 175.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.45 ' CA ' ' HA ' ' A' ' 113' ' ' ILE . . . 177.06 154.46 12.04 Favored Glycine 2 N--CA 1.387 -4.57 0 C-N-CA 117.316 -2.373 . . . . 0.0 112.957 177.246 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 3.8 tt -66.64 105.0 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 124.483 0.755 . . . . 0.0 109.422 172.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.571 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -114.21 98.3 6.86 Favored 'General case' 0 N--CA 1.414 -2.238 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 172.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 117.898 -1.049 . . . . 0.0 109.087 -174.258 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.443 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.221 -0.432 0 N-CA-C 111.42 0.156 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.575 ' HA ' ' HG3' ' A' ' 21' ' ' GLU . 9.2 p -82.35 -35.53 27.74 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-O 121.876 0.846 . . . . 0.0 112.463 -177.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.599 ' O ' HG12 ' A' ' 151' ' ' ILE . 56.9 mtmt -138.09 135.81 36.17 Favored 'General case' 0 C--N 1.277 -2.545 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.616 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -134.05 166.74 22.03 Favored 'General case' 0 C--N 1.27 -2.872 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 -176.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.3 p -145.99 118.93 2.28 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.315 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -108.65 127.16 53.73 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.4 p -119.45 129.24 75.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 O-C-N 123.786 0.679 . . . . 0.0 110.217 -178.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.405 HD13 ' HB1' ' A' ' 145' ' ' ALA . 75.4 mt -107.18 141.67 38.1 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.118 -177.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -150.79 137.83 19.21 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 174.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.39 -159.32 9.25 Favored Glycine 0 N--CA 1.417 -2.625 0 C-N-CA 117.571 -2.252 . . . . 0.0 115.622 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -78.06 -31.14 50.1 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 111.91 -2.145 . . . . 0.0 109.371 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.46 172.49 14.45 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 172.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -88.39 121.87 1.41 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 CA-C-N 121.919 2.859 . . . . 0.0 112.135 -176.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 m -135.14 118.23 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.429 0 CA-C-N 113.368 -1.742 . . . . 0.0 106.548 171.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.495 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -143.35 119.5 10.78 Favored 'General case' 0 C--N 1.279 -2.468 0 C-N-CA 118.128 -1.429 . . . . 0.0 109.929 178.442 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.547 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -171.2 170.87 43.62 Favored Glycine 0 N--CA 1.418 -2.552 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 178.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 20.0 pt -135.85 119.52 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.871 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.479 HG12 ' HA3' ' A' ' 33' ' ' GLY . 21.9 mt -114.37 135.16 55.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -176.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.616 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -101.58 138.68 38.25 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.235 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.551 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 95.2 m-85 -132.2 120.16 21.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 123.304 0.377 . . . . 0.0 111.066 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HG3' ' HA ' ' A' ' 2' ' ' THR . 35.8 tt0 -112.17 108.24 17.42 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.785 172.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.538 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 8.8 tp60 -140.71 114.8 9.15 Favored 'General case' 0 N--CA 1.405 -2.69 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 172.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -90.63 157.37 17.52 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 178.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -60.95 -23.69 65.5 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.153 0.502 . . . . 0.0 110.967 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 14.8 m -63.25 -18.4 63.52 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.996 176.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 65.1 t30 66.96 105.98 0.04 OUTLIER 'General case' 0 C--N 1.353 0.744 0 C-N-CA 125.426 1.491 . . . . 0.0 109.204 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.513 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -146.55 -170.64 15.19 Favored Glycine 0 CA--C 1.469 -2.804 0 C-N-CA 118.415 -1.85 . . . . 0.0 115.242 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.65 124.12 15.03 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.56 2.84 . . . . 0.0 110.562 178.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 47.1 t -93.44 110.99 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.988 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.286 -175.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.42 111.24 23.89 Favored 'General case' 0 N--CA 1.422 -1.87 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.476 HG22 ' HA ' ' A' ' 20' ' ' PHE . 17.2 t -138.47 132.26 41.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.175 -170.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.447 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 77.8 t90 -149.25 127.64 12.22 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.479 ' HA3' HG12 ' A' ' 18' ' ' ILE . . . -159.34 140.03 6.58 Favored Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.417 -0.896 . . . . 0.0 110.915 173.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 49.4 m -117.4 115.4 25.14 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.288 179.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.547 HG22 ' HA3' ' A' ' 16' ' ' GLY . 30.8 pt -109.79 138.71 36.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 118.612 0.642 . . . . 0.0 111.104 176.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.759 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 16.5 ptpt -103.65 132.7 49.67 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.488 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -148.98 178.78 26.3 Favored Glycine 1 N--CA 1.391 -4.359 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -167.758 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.473 ' HG ' ' H ' ' A' ' 39' ' ' THR . 45.3 tp -65.27 176.46 1.35 Allowed 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 171.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.473 ' H ' ' HG ' ' A' ' 38' ' ' LEU . 15.0 t -61.99 153.72 28.64 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.351 -1.468 . . . . 0.0 111.215 -166.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.712 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 11.1 pt-20 -60.67 160.32 9.43 Favored 'General case' 0 CA--C 1.476 -1.891 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -163.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -159.29 -157.57 8.62 Favored Glycine 1 C--N 1.245 -4.487 1 N-CA-C 102.442 -4.263 . . . . 0.0 102.442 -176.906 . . . . . . . . 3 2 . 1 . 010 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.4 mt -153.72 -86.63 0.06 Allowed 'General case' 0 C--N 1.274 -2.717 0 CA-C-N 120.357 2.078 . . . . 0.0 114.74 -169.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.626 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.5 t-160 -76.93 122.23 24.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 -156.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.78 127.01 8.8 Favored Glycine 0 N--CA 1.415 -2.75 0 C-N-CA 119.876 -1.154 . . . . 0.0 114.85 -173.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.542 ' H ' ' HB2' ' A' ' 124' ' ' ASP . 14.9 t80 -113.31 113.03 24.7 Favored 'General case' 1 C--O 1.336 5.61 0 CA-C-O 123.41 1.576 . . . . 0.0 111.028 175.463 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.509 ' NE2' ' HG ' ' A' ' 117' ' ' LEU . 25.4 m80 -108.18 124.96 51.07 Favored 'General case' 0 N--CA 1.391 -3.38 0 CA-C-N 113.624 -1.626 . . . . 0.0 110.42 -173.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 9.4 p -174.65 87.35 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 CA-C-N 113.55 -1.659 . . . . 0.0 109.762 177.909 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.423 ' C ' ' HD2' ' A' ' 115' ' ' ARG . 7.0 m170 -112.49 170.74 7.96 Favored 'General case' 0 C--N 1.281 -2.387 0 N-CA-C 114.608 1.336 . . . . 0.0 114.608 167.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.588 ' HG3' ' OD1' ' A' ' 109' ' ' ASP . 36.4 tt0 -139.64 132.56 29.33 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.191 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.8 t80 76.45 26.84 0.86 Allowed 'General case' 0 C--O 1.222 -0.359 0 C-N-CA 127.349 2.26 . . . . 0.0 111.127 174.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.727 ' H ' ' HD3' ' A' ' 115' ' ' ARG . . . 33.67 -124.64 0.4 Allowed Glycine 0 C--N 1.36 1.916 0 CA-C-N 115.599 -0.728 . . . . 0.0 114.637 -172.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.2 t70 169.51 -80.71 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 125.398 1.479 . . . . 0.0 108.48 164.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -161.05 160.9 31.07 Favored 'General case' 0 N--CA 1.429 -1.509 0 N-CA-C 104.975 -2.231 . . . . 0.0 104.975 174.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.48 ' HB ' HG12 ' A' ' 148' ' ' VAL . 5.3 t -79.26 5.18 12.95 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -171.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.15 2.26 9.8 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 120.202 -0.599 . . . . 0.0 111.249 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 176.55 127.53 1.05 Allowed Glycine 0 C--O 1.195 -2.324 0 C-N-CA 118.582 -1.77 . . . . 0.0 111.558 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.812 ' SG ' HG21 ' A' ' 118' ' ' VAL . 16.7 p -99.72 89.23 4.04 Favored 'General case' 0 C--N 1.275 -2.633 0 O-C-N 121.869 -0.783 . . . . 0.0 112.131 177.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.5 m -78.85 -53.14 7.4 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.8 m -70.01 -52.99 19.67 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.498 -174.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' A' ' 49' ' ' GLU . . . -76.63 -9.45 58.67 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-O 118.418 -0.801 . . . . 0.0 112.975 176.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -36.08 -68.14 0.32 Allowed Glycine 0 N--CA 1.488 2.103 0 N-CA-C 114.864 0.705 . . . . 0.0 114.864 -173.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -94.09 7.59 2.42 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.328 2.686 . . . . 0.0 112.149 177.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 77.1 t60 -113.52 123.46 50.06 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -171.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.444 ' CD1' ' HA ' ' A' ' 137' ' ' THR . 27.1 p90 -97.75 170.55 8.91 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 126.722 2.009 . . . . 0.0 108.785 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.83 142.68 24.89 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.82 -53.98 2.77 Favored 'Trans proline' 0 N--CA 1.481 0.767 0 C-N-CA 123.204 2.603 . . . . 0.0 116.652 -168.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.828 ' O ' ' HA ' ' A' ' 78' ' ' GLU . 95.9 mt -93.0 25.97 3.0 Favored 'General case' 0 C--O 1.193 -1.913 0 O-C-N 121.786 -0.571 . . . . 0.0 111.818 -168.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.63 ' O ' ' HA ' ' A' ' 80' ' ' HIS . 28.6 m -144.74 30.36 1.2 Allowed 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.039 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 69' ' ' ARG . 4.1 tmm_? -126.08 -27.32 3.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 CA-C-O 117.639 -1.172 . . . . 0.0 110.638 -176.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 1.2 mptm? -45.32 60.34 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 119.778 3.251 . . . . 0.0 119.778 -165.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.44 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 26.6 t-80 46.43 58.65 4.4 Favored 'General case' 0 CA--C 1.567 1.598 0 N-CA-C 117.292 2.33 . . . . 0.0 117.292 165.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.62 88.44 0.38 Allowed Glycine 0 CA--C 1.495 -1.186 0 C-N-CA 116.762 -2.637 . . . . 0.0 115.57 163.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.439 ' H ' ' CD2' ' A' ' 80' ' ' HIS . . . -170.13 95.38 0.11 Allowed Glycine 0 C--O 1.211 -1.334 0 C-N-CA 119.089 -1.529 . . . . 0.0 112.81 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -64.91 -40.23 21.96 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 CA-C-N 120.647 2.224 . . . . 0.0 113.583 -175.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.07 16.49 21.81 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 125.139 1.376 . . . . 0.0 110.153 -178.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -89.79 -172.02 3.39 Favored 'General case' 0 C--N 1.287 -2.126 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.747 -167.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER -142.46 -3.45 1.04 Allowed 'General case' 0 N--CA 1.434 -1.268 0 O-C-N 122.22 -0.3 . . . . 0.0 111.072 -178.486 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.828 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 33.1 tt0 -132.19 -34.79 1.23 Allowed 'General case' 0 N--CA 1.433 -1.315 0 CA-C-O 121.222 0.535 . . . . 0.0 110.276 -170.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.475 ' O ' ' HB3' ' A' ' 80' ' ' HIS . 4.5 mpt_? -93.76 -15.87 24.74 Favored 'General case' 0 CA--C 1.484 -1.571 0 C-N-CA 125.603 1.561 . . . . 0.0 107.111 -175.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.63 ' HA ' ' O ' ' A' ' 68' ' ' SER 0.258 5.0 p80 . . . . . 0 CA--C 1.459 -2.538 0 CA-C-N 113.185 -1.825 . . . . 0.0 110.332 159.498 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.558 HD13 ' N ' ' A' ' 85' ' ' GLY . 0.7 OUTLIER . . . . . 0 N--CA 1.468 0.441 0 N-CA-C 115.754 1.761 . . . . 0.0 115.754 . . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.558 ' N ' HD13 ' A' ' 84' ' ' LEU . . . -169.36 156.38 27.42 Favored Glycine 0 N--CA 1.425 -2.048 0 N-CA-C 104.483 -3.447 . . . . 0.0 104.483 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -112.61 153.0 28.26 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 120.158 1.979 . . . . 0.0 109.869 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 71.9 t -117.86 143.01 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.532 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.626 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 62.2 m -146.13 95.74 2.67 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -93.28 144.98 24.79 Favored 'General case' 0 CA--C 1.482 -1.666 0 CA-C-N 119.49 1.041 . . . . 0.0 113.097 -176.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.712 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 22.1 t70 -82.58 149.6 27.37 Favored 'General case' 0 C--N 1.278 -2.516 0 CA-C-N 113.223 -1.808 . . . . 0.0 106.83 169.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.537 ' N ' ' HB3' ' A' ' 40' ' ' GLU . 13.6 pttp -41.28 -19.39 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 127.69 2.396 . . . . 0.0 116.037 176.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -106.81 12.76 28.66 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.759 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 73.1 85.18 0.23 Allowed Glycine 0 N--CA 1.42 -2.397 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.06 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 61.3 t -157.07 103.51 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.709 -1.959 . . . . 0.0 105.709 -178.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -104.17 113.38 26.89 Favored 'General case' 0 C--N 1.273 -2.735 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.525 175.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -86.01 94.33 9.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 175.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 86.1 t -85.63 105.71 14.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.486 -175.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.2 m -152.54 116.05 4.75 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 9.4 tp -148.31 134.35 12.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 37.8 mt-10 -124.03 96.63 5.01 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.433 -175.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.401 ' O ' HG21 ' A' ' 29' ' ' VAL . 6.2 p-10 -168.81 166.71 11.4 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 170.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.5 p -60.89 91.5 0.02 OUTLIER 'General case' 0 C--O 1.245 0.851 0 CA-C-N 119.128 0.876 . . . . 0.0 113.058 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 84' ' ' LEU . 27.1 m -118.39 -14.41 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -176.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -119.24 25.92 4.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 O-C-N 120.7 -1.25 . . . . 0.0 109.476 -176.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.0 m -64.38 110.95 2.43 Favored 'General case' 0 C--O 1.268 2.059 0 CA-C-O 122.729 1.252 . . . . 0.0 109.831 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.44 86.37 1.15 Allowed 'General case' 0 N--CA 1.382 -3.87 0 CA-C-O 124.103 1.906 . . . . 0.0 110.63 176.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.0 m -146.56 85.75 1.65 Allowed 'General case' 2 N--CA 1.362 -4.855 0 N-CA-C 101.88 -3.378 . . . . 0.0 101.88 168.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.13 168.96 22.8 Favored Glycine 0 C--N 1.269 -3.142 0 CA-C-N 113.373 -1.74 . . . . 0.0 111.014 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.588 ' OD1' ' HG3' ' A' ' 49' ' ' GLU . 7.0 t70 -56.92 -34.89 68.41 Favored 'General case' 0 C--O 1.202 -1.43 0 CA-C-N 117.292 0.546 . . . . 0.0 110.916 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.739 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 7.9 p-80 -54.28 -17.01 2.49 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 125.385 1.474 . . . . 0.0 113.023 -178.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.449 ' O ' ' HD2' ' A' ' 110' ' ' HIS . 23.0 t 37.47 -154.49 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 126.164 1.786 . . . . 0.0 110.297 -173.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.608 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 14.2 tt -100.32 -32.97 3.63 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.876 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 166.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.8 pt -104.02 145.93 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -178.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.71 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 95.83 -7.04 67.52 Favored Glycine 1 CA--C 1.45 -4.008 0 C-N-CA 121.234 -0.508 . . . . 0.0 112.272 162.211 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.739 ' NE ' ' HA ' ' A' ' 110' ' ' HIS . 0.3 OUTLIER -92.61 151.44 20.12 Favored 'General case' 0 C--O 1.162 -3.54 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.688 -174.146 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.555 ' H ' ' HA2' ' A' ' 51' ' ' GLY . 7.6 p -91.86 113.09 25.27 Favored 'General case' 0 N--CA 1.408 -2.531 0 O-C-N 121.537 -0.727 . . . . 0.0 109.397 173.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.509 ' HG ' ' NE2' ' A' ' 46' ' ' HIS . 22.5 tp -70.09 93.5 0.81 Allowed 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 -177.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.812 HG21 ' SG ' ' A' ' 57' ' ' CYS 0.528 60.2 t -105.1 109.22 27.0 Favored 'Isoleucine or valine' 1 C--O 1.341 5.884 0 N-CA-C 120.708 3.596 . . . . 0.0 120.708 -172.217 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.674 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.3 p -148.47 171.25 2.43 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.155 0 CA-C-N 110.397 -3.092 . . . . 0.0 106.469 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 71.6 t60 -150.37 171.28 17.25 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.88 -2.267 . . . . 0.0 104.88 168.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.526 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.0 OUTLIER -69.42 85.94 0.43 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 171.449 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -173.01 171.78 4.11 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -99.09 107.58 20.0 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 118.299 0.499 . . . . 0.0 110.243 173.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.542 ' HB2' ' H ' ' A' ' 45' ' ' PHE . 1.1 m-20 -71.33 -59.16 2.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 172.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.0 t70 67.76 141.34 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 128.024 2.529 . . . . 0.0 114.097 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.587 ' HG ' ' CD2' ' A' ' 80' ' ' HIS . 0.0 OUTLIER -90.26 -31.99 16.74 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-N 114.89 -1.05 . . . . 0.0 113.624 -176.563 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . 0.44 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -97.01 -33.98 5.84 Favored Glycine 0 N--CA 1.427 -1.904 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -105.13 50.32 0.79 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.178 -1.011 . . . . 0.0 108.873 -179.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.36 -6.83 81.51 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.53 -93.17 0.25 Allowed Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 121.653 -0.308 . . . . 0.0 112.406 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.557 ' H ' ' HB2' ' A' ' 134' ' ' SER . 79.3 m-20 -121.86 -173.39 2.64 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -174.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -57.71 -39.32 76.96 Favored 'General case' 0 C--N 1.361 1.102 0 C-N-CA 118.65 -1.22 . . . . 0.0 109.994 176.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.547 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 5.9 tp10 -76.05 -53.86 7.72 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.051 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.557 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 2.4 m -62.06 -26.25 68.16 Favored 'General case' 0 CA--C 1.552 1.021 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -175.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 35.8 m -79.72 -18.14 51.91 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 121.852 -0.53 . . . . 0.0 110.653 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.547 ' HG3' ' O ' ' A' ' 133' ' ' GLU . 0.0 OUTLIER -85.64 -31.27 22.65 Favored 'General case' 0 C--O 1.211 -0.942 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.535 179.227 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.444 ' HA ' ' CD1' ' A' ' 64' ' ' PHE . 8.8 p -70.95 -16.01 62.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 120.916 0.389 . . . . 0.0 109.962 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.56 81.64 0.11 Allowed Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 124' ' ' ASP . 23.3 t-20 -33.07 132.05 0.16 Allowed 'General case' 0 C--O 1.291 3.263 0 CA-C-O 123.451 1.596 . . . . 0.0 114.202 -172.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.419 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -150.89 130.51 13.07 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 113.845 -1.525 . . . . 0.0 109.711 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.12 91.03 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.072 -2.011 . . . . 0.0 108.072 170.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.9 m -49.18 -18.41 0.33 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.789 2.035 . . . . 0.0 116.384 -168.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -144.59 6.51 1.25 Allowed 'General case' 0 C--N 1.269 -2.92 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.56 -22.73 58.84 Favored 'General case' 0 C--N 1.294 -1.845 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.509 -173.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.9 100.3 0.17 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 175.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.9 m -123.42 133.05 54.12 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -160.28 146.28 12.37 Favored Glycine 0 N--CA 1.404 -3.499 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 178.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 8.8 p -69.19 113.98 5.6 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-O 122.128 0.966 . . . . 0.0 111.953 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.472 HD12 HD13 ' A' ' 117' ' ' LEU . 2.5 tt -82.93 129.65 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.085 0 N-CA-C 105.067 -2.197 . . . . 0.0 105.067 170.283 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.608 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 177.67 156.99 17.58 Favored Glycine 2 N--CA 1.365 -6.074 0 C-N-CA 118.427 -1.844 . . . . 0.0 111.297 176.772 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.599 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.16 105.32 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 169.536 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.16 113.34 16.91 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 . . . . . 0 C--N 1.283 -2.315 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -175.595 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.432 ' HA ' HE22 ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.0 0.428 . . . . 0.0 111.461 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 m -79.89 -28.99 39.84 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.14 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.652 ' HG3' ' O ' ' A' ' 152' ' ' ALA . 19.9 ptpt -151.74 170.87 18.69 Favored 'General case' 0 C--O 1.253 1.241 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.731 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.42 154.56 45.67 Favored 'General case' 0 N--CA 1.434 -1.265 0 O-C-N 124.099 0.875 . . . . 0.0 109.038 177.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.19 122.22 62.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.512 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -131.4 133.14 44.94 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.18 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.6 t -134.75 113.31 16.29 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.428 ' HB2' ' O ' ' A' ' 14' ' ' VAL . 3.1 mm? -90.83 131.03 36.72 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.409 0.683 . . . . 0.0 111.418 -176.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.1 mtpt -147.34 126.79 13.18 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 175.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.72 -158.53 8.84 Favored Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.58 -0.819 . . . . 0.0 111.754 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -63.09 -40.39 97.52 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -116.11 82.63 0.32 Allowed Glycine 0 N--CA 1.433 -1.513 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 172.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.64 127.0 11.95 Favored 'Trans proline' 0 N--CA 1.446 -1.296 0 C-N-CA 122.127 1.884 . . . . 0.0 113.901 -171.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.428 ' O ' ' HB2' ' A' ' 8' ' ' LEU . 16.5 m -111.92 117.08 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.858 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 175.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -99.13 118.31 35.57 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.639 -172.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.0 170.81 43.53 Favored Glycine 0 N--CA 1.407 -3.247 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.858 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 25.7 pt -131.38 129.24 62.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 mm -115.12 136.01 53.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.507 ' O ' HG13 ' A' ' 31' ' ' VAL . 0.8 OUTLIER -114.24 129.63 56.63 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.478 -177.583 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.731 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 53.9 m-85 -125.19 137.49 54.13 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.097 0.475 . . . . 0.0 111.684 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -116.23 106.37 13.61 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.368 177.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.432 HE22 ' HA ' ' A' ' 1' ' ' ALA . 2.8 pm0 -86.25 123.34 31.41 Favored 'General case' 0 N--CA 1.403 -2.816 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 171.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 104' ' ' ILE . 37.1 ttmt -137.55 103.16 4.97 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -170.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.26 -9.83 13.29 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 m -71.91 -23.71 61.52 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 122.877 0.471 . . . . 0.0 110.35 176.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.556 ' HA ' HG13 ' A' ' 104' ' ' ILE . 45.4 t-20 72.57 135.54 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 C-N-CA 125.335 1.454 . . . . 0.0 111.034 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.52 175.33 36.67 Favored Glycine 0 CA--C 1.485 -1.785 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.619 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -65.1 123.48 11.62 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.302 2.001 . . . . 0.0 108.397 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HB ' HG23 ' A' ' 31' ' ' VAL . 23.7 m -76.99 142.75 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.277 0 CA-C-O 121.682 0.753 . . . . 0.0 111.632 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -106.28 97.07 6.92 Favored 'General case' 0 C--N 1.277 -2.544 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 173.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.507 HG13 ' O ' ' A' ' 19' ' ' ASN . 47.6 t -129.59 129.87 66.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 125.892 1.677 . . . . 0.0 107.861 -171.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -140.74 137.24 33.28 Favored 'General case' 0 C--N 1.286 -2.192 0 O-C-N 123.375 0.422 . . . . 0.0 110.186 177.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -159.59 137.9 5.34 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 170.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.47 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 44.3 t -118.63 127.74 53.88 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.44 HG22 ' HA3' ' A' ' 16' ' ' GLY . 33.5 pt -120.02 129.0 75.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 119.788 1.177 . . . . 0.0 110.381 174.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 88.1 tttt -96.67 123.56 40.39 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 178.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.759 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -136.48 176.29 20.44 Favored Glycine 0 C--N 1.274 -2.9 0 CA-C-N 114.502 -1.226 . . . . 0.0 110.383 -171.057 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -69.43 171.28 8.95 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 171.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -68.47 112.43 5.29 Favored 'General case' 0 C--O 1.22 -0.48 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 175.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.596 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 5.1 tp10 -128.86 178.91 6.03 Favored 'General case' 0 C--N 1.259 -3.339 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.804 -165.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.418 ' H ' ' HG3' ' A' ' 40' ' ' GLU . . . -59.44 -146.93 0.01 OUTLIER Glycine 0 CA--C 1.553 2.449 0 C-N-CA 124.633 1.111 . . . . 0.0 114.472 176.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 3.0 pp -164.66 14.47 0.05 OUTLIER 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -164.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.2 t60 -143.91 153.66 42.53 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 106.757 -1.572 . . . . 0.0 106.757 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . 163.02 -169.25 38.13 Favored Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 119.899 -1.143 . . . . 0.0 112.156 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.575 ' HA ' ' O ' ' A' ' 85' ' ' GLY . 24.1 p90 -166.6 162.65 16.67 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.613 ' H ' ' HA ' ' A' ' 84' ' ' LEU . 6.5 m170 -91.12 164.32 13.97 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -171.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.476 HG13 ' HD2' ' A' ' 64' ' ' PHE . 52.9 t -165.82 88.59 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.616 0 C-N-CA 123.81 0.844 . . . . 0.0 111.4 -174.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.559 ' HB2' ' HB3' ' A' ' 115' ' ' ARG . 31.0 p-80 -109.61 100.82 9.81 Favored 'General case' 0 CA--C 1.598 2.796 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 166.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.593 ' N ' ' HD2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -122.71 122.67 39.32 Favored 'General case' 0 CA--C 1.575 1.932 0 O-C-N 120.374 -1.454 . . . . 0.0 111.338 173.844 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.494 ' C ' ' HG2' ' A' ' 115' ' ' ARG . 61.2 t80 75.36 93.71 0.07 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 126.982 2.113 . . . . 0.0 110.961 176.277 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.651 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -55.02 134.1 48.21 Favored Glycine 0 CA--C 1.482 -1.985 0 N-CA-C 116.851 1.5 . . . . 0.0 116.851 -171.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -141.42 -87.09 0.17 Allowed 'General case' 0 CA--C 1.488 -1.439 0 C-N-CA 117.951 -1.5 . . . . 0.0 114.326 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -118.65 139.0 52.22 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.856 -169.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.539 ' HA ' HG23 ' A' ' 148' ' ' VAL . 10.0 t -43.58 -39.76 3.66 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 126.674 1.99 . . . . 0.0 115.385 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -134.31 15.43 3.78 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.426 0.631 . . . . 0.0 110.33 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -127.4 111.14 1.29 Allowed Glycine 0 N--CA 1.436 -1.312 0 C-N-CA 119.922 -1.132 . . . . 0.0 111.818 -177.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.566 ' SG ' ' HB ' ' A' ' 118' ' ' VAL . 10.1 p -97.88 88.3 4.24 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.8 p -78.25 -61.85 1.87 Allowed 'General case' 0 N--CA 1.419 -1.99 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.277 176.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.3 m -68.15 -27.95 66.88 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.47 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -78.7 -9.27 59.35 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.059 0.457 . . . . 0.0 111.115 177.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.3 -64.66 3.95 Favored Glycine 0 N--CA 1.436 -1.358 0 CA-C-N 115.096 -0.957 . . . . 0.0 113.021 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.78 53.13 2.71 Favored 'Trans proline' 0 CA--C 1.552 1.403 0 C-N-CA 122.359 2.039 . . . . 0.0 114.247 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 11.4 t60 72.83 163.59 0.27 Allowed 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 124.831 1.252 . . . . 0.0 111.439 169.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.476 ' HD2' HG13 ' A' ' 47' ' ' VAL . 1.5 t80 -92.79 170.81 9.41 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.651 ' OD1' ' HD2' ' A' ' 66' ' ' PRO . 61.6 t30 -69.86 140.57 88.98 Favored Pre-proline 0 CA--C 1.562 1.42 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.091 -179.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.651 ' HD2' ' OD1' ' A' ' 65' ' ' ASN . 72.8 Cg_endo -76.84 -8.4 17.9 Favored 'Trans proline' 0 N--CA 1.443 -1.483 1 C-N-CA 125.314 4.01 . . . . 0.0 113.954 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -84.11 16.59 2.85 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 123.966 1.841 . . . . 0.0 109.611 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.653 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.0 p -80.43 -86.3 0.08 Allowed 'General case' 1 N--CA 1.356 -5.15 0 CA-C-N 113.362 -1.745 . . . . 0.0 108.321 175.152 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.651 ' HB2' ' HA ' ' A' ' 78' ' ' GLU . 41.8 ttt180 -135.84 10.36 3.36 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 167.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 82.5 tttt 75.14 -9.18 1.43 Allowed 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.371 1.469 . . . . 0.0 113.19 173.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 -99.35 -54.42 2.96 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 119.941 -0.703 . . . . 0.0 112.392 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.41 ' HA2' ' HG2' ' A' ' 78' ' ' GLU . . . 88.98 30.45 14.55 Favored Glycine 0 N--CA 1.474 1.174 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.229 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.444 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -70.58 143.54 37.15 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.499 -0.858 . . . . 0.0 114.734 -175.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 7.7 Cg_exo -76.84 -9.31 18.2 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 124.155 3.237 . . . . 0.0 111.58 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -79.84 9.8 4.86 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.741 -178.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB2' ' HB3' ' A' ' 101' ' ' ASP . 6.1 m-20 63.05 78.6 0.29 Allowed 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 124.909 1.283 . . . . 0.0 111.094 176.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -137.54 -56.13 0.69 Allowed 'General case' 0 CA--C 1.5 -0.969 0 O-C-N 121.668 -0.645 . . . . 0.0 112.683 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.651 ' HA ' ' HB2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -64.2 154.24 35.47 Favored 'General case' 0 N--CA 1.403 -2.776 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.276 -172.224 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.653 ' O ' ' HA ' ' A' ' 68' ' ' SER . 75.9 ttt180 -119.14 72.2 0.89 Allowed 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -170.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.336 2.3 m-70 . . . . . 0 N--CA 1.501 2.119 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 164.896 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.613 ' HA ' ' H ' ' A' ' 46' ' ' HIS . 2.5 pp . . . . . 0 N--CA 1.4 -2.959 0 N-CA-C 108.357 -0.979 . . . . 0.0 108.357 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 45' ' ' PHE . . . 176.55 168.89 37.25 Favored Glycine 2 C--N 1.247 -4.379 0 N-CA-C 103.715 -3.754 . . . . 0.0 103.715 175.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.424 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 58.5 t30 -80.36 140.63 35.98 Favored 'General case' 0 C--N 1.271 -2.84 0 CA-C-N 119.501 1.65 . . . . 0.0 107.324 174.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.455 HG12 ' HG3' ' A' ' 121' ' ' GLU . 43.4 t -115.31 128.06 72.65 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.118 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 -177.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 62.3 m -142.19 96.54 2.97 Favored 'General case' 0 N--CA 1.413 -2.279 0 CA-C-O 118.685 -0.674 . . . . 0.0 111.405 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.585 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -126.77 104.38 8.03 Favored 'General case' 0 C--O 1.195 -1.774 0 C-N-CA 116.459 -2.096 . . . . 0.0 108.131 169.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' A' ' 40' ' ' GLU . 5.3 p-10 -127.9 -18.65 4.19 Favored 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.626 -171.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.463 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 3.1 mptp? -71.73 -58.04 3.83 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.795 0.807 . . . . 0.0 109.072 -175.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -164.71 26.51 0.06 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.892 -175.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.759 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 77.46 78.95 0.74 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 114.532 -1.213 . . . . 0.0 115.338 -178.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.453 ' H ' ' HB1' ' A' ' 89' ' ' ALA . 98.7 t -159.77 105.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 177.072 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.419 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -107.71 122.68 47.22 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -93.21 112.86 24.93 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 124.117 0.886 . . . . 0.0 109.76 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.6 t -113.94 105.64 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-O 121.147 0.499 . . . . 0.0 109.806 178.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 50.5 m -143.52 111.63 6.19 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 174.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.438 HD12 HG21 ' A' ' 103' ' ' VAL . 25.1 pt -123.22 154.69 29.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.27 -173.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -148.96 99.42 2.97 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.884 0.85 . . . . 0.0 111.256 173.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 76' ' ' ASP . 5.6 t70 -167.58 171.98 9.82 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.6 m -59.24 87.77 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 122.743 1.259 . . . . 0.0 112.286 -178.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.438 HG21 HD12 ' A' ' 99' ' ' ILE . 59.3 t -113.21 -10.46 12.11 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 112.733 -2.03 . . . . 0.0 106.763 175.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.556 HG13 ' HA ' ' A' ' 26' ' ' ASN . 0.2 OUTLIER -52.84 -13.71 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 C-N-CA 125.111 1.364 . . . . 0.0 114.067 -176.72 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.2 m -73.27 152.16 41.09 Favored 'General case' 0 N--CA 1.418 -2.038 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 172.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.562 ' HB2' HG12 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -65.9 121.78 15.85 Favored 'General case' 0 N--CA 1.403 -2.82 0 CA-C-O 122.01 0.91 . . . . 0.0 109.697 -177.559 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.9 m -69.86 88.07 0.55 Allowed 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 113.216 -1.811 . . . . 0.0 110.677 -174.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.472 ' HA2' ' CZ ' ' A' ' 64' ' ' PHE . . . 143.62 136.62 3.15 Favored Glycine 0 N--CA 1.409 -3.108 0 CA-C-N 114.287 -1.324 . . . . 0.0 112.296 175.313 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -66.38 -56.77 9.46 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.851 169.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -104.24 -47.09 4.24 Favored 'General case' 0 N--CA 1.435 -1.209 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.007 -173.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.443 ' CB ' ' H ' ' A' ' 51' ' ' GLY . 18.8 m -127.42 113.91 16.82 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 118.944 -1.103 . . . . 0.0 112.594 -177.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.562 HG12 ' HB2' ' A' ' 106' ' ' LEU . 2.9 mp -89.71 -38.29 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 173.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.434 HD12 ' HB ' ' A' ' 112' ' ' ILE . 4.1 mp -102.01 145.07 12.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.83 -12.8 62.67 Favored Glycine 0 CA--C 1.495 -1.162 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 174.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.673 ' HD3' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -91.93 134.71 34.54 Favored 'General case' 0 N--CA 1.396 -3.147 0 CA-C-O 122.224 1.011 . . . . 0.0 112.967 -175.544 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.673 ' N ' ' HD3' ' A' ' 115' ' ' ARG 0.253 0.2 OUTLIER -89.0 116.74 27.52 Favored 'General case' 0 N--CA 1.394 -3.264 0 C-N-CA 126.563 1.945 . . . . 0.0 107.45 -176.188 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 147' ' ' GLY . 2.7 pt? -79.17 144.52 34.37 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.566 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 10.7 p -109.7 111.14 34.85 Favored 'Isoleucine or valine' 0 C--O 1.273 2.314 0 C-N-CA 119.134 -1.027 . . . . 0.0 112.845 177.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 46' ' ' HIS . 24.7 m -147.81 146.48 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 C-N-CA 125.805 1.642 . . . . 0.0 110.017 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -170.08 148.65 3.42 Favored 'General case' 0 C--N 1.283 -2.326 0 N-CA-C 102.601 -3.111 . . . . 0.0 102.601 167.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.596 ' O ' ' HG3' ' A' ' 40' ' ' GLU . 1.3 mp0 -69.55 89.72 0.53 Allowed 'General case' 0 C--N 1.261 -3.276 0 CA-C-O 123.355 1.55 . . . . 0.0 113.182 -171.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -165.28 144.53 6.6 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 102.698 -3.075 . . . . 0.0 102.698 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.27 101.71 0.25 Allowed 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -173.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.52 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 12.0 t70 -87.89 93.95 9.62 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 99.585 -4.228 . . . . 0.0 99.585 171.747 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -103.28 139.81 38.23 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.839 -0.745 . . . . 0.0 111.118 -170.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.527 ' HG ' ' H ' ' A' ' 127' ' ' GLY . 1.9 pt? -51.23 -74.28 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 121.703 3.964 . . . . 0.0 121.703 -162.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . 0.527 ' H ' ' HG ' ' A' ' 126' ' ' LEU . . . -69.97 -59.89 5.23 Favored Glycine 0 CA--C 1.47 -2.727 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.829 -170.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.508 ' HD2' ' C ' ' A' ' 127' ' ' GLY . 4.4 mptp? -136.8 35.88 2.63 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.073 -174.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.493 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 59.5 -34.06 0.03 OUTLIER Glycine 0 CA--C 1.559 2.809 0 CA-C-N 119.76 1.164 . . . . 0.0 115.634 -175.29 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 128' ' ' LYS . . . 147.38 -24.32 1.54 Allowed Glycine 0 N--CA 1.401 -3.643 0 O-C-N 122.145 -0.62 . . . . 0.0 111.905 179.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.661 ' N ' ' HB2' ' A' ' 134' ' ' SER . 1.8 t-20 -169.61 179.78 3.65 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 118.519 -1.272 . . . . 0.0 108.042 -174.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.466 ' O ' HG22 ' A' ' 135' ' ' THR . 0.0 OUTLIER -62.6 -40.72 97.82 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.07 -1.452 . . . . 0.0 113.378 -175.136 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -85.36 -30.84 23.33 Favored 'General case' 0 C--N 1.319 -0.749 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.171 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.661 ' HB2' ' N ' ' A' ' 131' ' ' ASN . 15.0 m -63.68 -19.68 65.1 Favored 'General case' 0 C--O 1.186 -2.284 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.493 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.3 t -71.96 -35.4 69.54 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 175.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -73.89 -48.84 28.06 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.58 -175.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 134' ' ' SER . 14.8 t -86.06 -23.66 26.65 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 114.418 -1.265 . . . . 0.0 112.816 -176.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -68.22 -66.7 2.21 Favored Glycine 0 CA--C 1.478 -2.277 0 CA-C-O 119.584 -0.565 . . . . 0.0 111.73 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 58.8 t30 -50.75 132.53 26.32 Favored 'General case' 0 N--CA 1.518 2.945 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 171.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.63 160.27 25.81 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 114.392 1.256 . . . . 0.0 114.392 -162.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.87 118.46 13.08 Favored Glycine 0 CA--C 1.49 -1.508 0 CA-C-N 113.655 -1.611 . . . . 0.0 113.046 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.553 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 8.4 m -71.43 3.43 3.81 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 124.607 1.163 . . . . 0.0 113.189 -173.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.9 mtt180 -132.16 -4.76 3.47 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 176.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.93 -40.35 32.24 Favored 'General case' 0 CA--C 1.498 -1.02 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.111 -173.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.15 108.53 0.98 Allowed 'General case' 0 N--CA 1.428 -1.569 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.444 ' HB3' HG22 ' A' ' 116' ' ' THR . 7.8 m -137.43 156.78 47.78 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 177.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -161.1 135.0 3.76 Favored Glycine 0 C--N 1.296 -1.686 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 176.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.539 HG23 ' HA ' ' A' ' 54' ' ' THR . 40.2 t -65.79 121.67 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.535 0 CA-C-O 122.36 1.076 . . . . 0.0 110.952 176.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.8 tt -113.27 141.47 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.098 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.513 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.01 148.13 15.69 Favored Glycine 3 N--CA 1.383 -4.873 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.517 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.1 pt -69.94 103.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 CA-C-O 121.373 0.606 . . . . 0.0 110.699 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.652 ' O ' ' HG3' ' A' ' 3' ' ' LYS . . . -118.5 139.12 51.93 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 175.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 . . . . . 0 C--N 1.31 -1.126 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.644 -175.035 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 120.805 0.336 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 m -92.07 -46.94 7.53 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 120.739 0.304 . . . . 0.0 110.887 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.448 ' HA ' ' OD1' ' A' ' 19' ' ' ASN . 19.0 ptpt -154.25 166.48 33.01 Favored 'General case' 0 N--CA 1.433 -1.32 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.519 -176.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.666 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -146.26 153.36 40.5 Favored 'General case' 0 N--CA 1.424 -1.772 0 O-C-N 124.308 1.005 . . . . 0.0 108.336 176.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.25 114.23 14.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -113.51 128.1 56.32 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -122.53 120.44 60.98 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 121.391 0.615 . . . . 0.0 110.568 178.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -108.32 149.16 29.03 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.397 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -171.07 127.06 0.7 Allowed 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.35 -156.53 7.45 Favored Glycine 0 N--CA 1.429 -1.824 0 C-N-CA 120.175 -1.012 . . . . 0.0 112.179 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.46 -39.08 60.69 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.63 1.172 . . . . 0.0 111.347 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -107.32 161.97 13.53 Favored Glycine 0 N--CA 1.436 -1.326 0 N-CA-C 108.009 -2.036 . . . . 0.0 108.009 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -84.32 123.58 3.05 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 CA-C-N 120.491 2.145 . . . . 0.0 111.254 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.3 t -132.98 127.41 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 N-CA-C 103.599 -2.741 . . . . 0.0 103.599 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -142.06 116.58 9.66 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.89 170.3 43.09 Favored Glycine 0 N--CA 1.396 -3.985 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -177.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 24.9 pt -142.6 144.0 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.979 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 179.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.2 tp -139.13 136.18 42.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 177.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.666 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.3 t-20 -97.96 147.72 24.2 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.533 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 61.7 m-85 -138.09 119.33 14.62 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 119.182 0.901 . . . . 0.0 110.734 173.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -112.88 101.89 9.93 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.875 0.845 . . . . 0.0 111.191 174.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pm0 -91.06 150.32 21.47 Favored 'General case' 0 N--CA 1.404 -2.729 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.545 ' HB3' HG21 ' A' ' 103' ' ' VAL . 40.9 tptt -138.38 154.17 48.93 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 -175.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.5 mp0 -62.68 -55.31 27.98 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 123.937 0.773 . . . . 0.0 113.053 -174.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.3 m -78.24 -71.79 0.41 Allowed 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -168.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.0 p30 177.89 140.67 0.09 Allowed 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -175.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.422 ' N ' HG22 ' A' ' 103' ' ' VAL . . . 165.8 174.58 35.45 Favored Glycine 0 CA--C 1.48 -2.11 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.84 178.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -90.6 131.7 1.65 Allowed 'Trans proline' 0 N--CA 1.43 -2.226 0 C-N-CA 123.062 2.508 . . . . 0.0 110.854 175.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.33 101.82 2.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 176.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.263 0.9 OUTLIER -92.07 92.79 8.43 Favored 'General case' 0 CA--C 1.482 -1.64 0 CA-C-O 122.735 1.255 . . . . 0.0 111.824 177.266 . . . . . . . . 4 4 . 1 . 012 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.498 HG11 ' HA ' ' A' ' 20' ' ' PHE . 17.7 m -127.82 153.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.308 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.69 -175.214 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.51 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 31.0 m-90 -126.59 148.0 49.82 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.63 -172.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -166.17 140.11 6.16 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.8 m -117.16 146.56 43.12 Favored 'General case' 0 N--CA 1.389 -3.521 0 N-CA-C 105.949 -1.871 . . . . 0.0 105.949 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.725 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 17.0 tt -139.55 155.46 25.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 31.7 mmmt -136.33 131.31 34.14 Favored 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 105.501 -2.037 . . . . 0.0 105.501 -176.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -164.52 174.72 40.57 Favored Glycine 0 C--N 1.281 -2.505 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -173.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.3 mt -66.71 145.05 55.97 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.102 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.433 HG22 ' CA ' ' A' ' 92' ' ' ASP . 65.5 p -69.54 106.73 3.11 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -164.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -175.47 161.96 2.77 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 103.765 -2.68 . . . . 0.0 103.765 178.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.463 ' HA2' ' C ' ' A' ' 121' ' ' GLU . . . 158.86 137.09 2.17 Favored Glycine 1 CA--C 1.444 -4.364 0 C-N-CA 117.33 -2.367 . . . . 0.0 112.773 167.521 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.506 ' O ' ' HB2' ' A' ' 43' ' ' HIS . 0.5 OUTLIER 177.69 63.0 0.01 OUTLIER 'General case' 0 N--CA 1.447 -0.602 0 O-C-N 124.419 0.717 . . . . 0.0 110.243 -175.193 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.506 ' HB2' ' O ' ' A' ' 42' ' ' LEU . 35.9 t60 164.95 123.26 0.01 OUTLIER 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 172.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.629 ' HA2' ' N ' ' A' ' 87' ' ' VAL . . . -47.66 -134.73 0.0 OUTLIER Glycine 0 N--CA 1.486 1.995 0 N-CA-C 119.798 2.679 . . . . 0.0 119.798 -172.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.481 ' CD1' ' HA3' ' A' ' 85' ' ' GLY . 13.3 m-85 -88.88 162.3 16.21 Favored 'General case' 0 CA--C 1.471 -2.07 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 177.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.17 84.64 0.11 Allowed 'General case' 1 C--O 1.337 5.682 0 C-N-CA 120.212 -0.595 . . . . 0.0 112.266 -175.732 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.677 ' HB ' ' OE2' ' A' ' 49' ' ' GLU . 10.2 m -89.34 173.19 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 130.568 3.547 . . . . 0.0 114.323 -164.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.512 ' NE2' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -170.8 86.43 0.1 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.427 1.491 . . . . 0.0 108.195 174.422 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.677 ' OE2' ' HB ' ' A' ' 47' ' ' VAL . 3.0 mp0 -87.31 89.46 8.0 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 115.153 1.538 . . . . 0.0 115.153 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -118.21 -21.52 8.14 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 113.743 -1.571 . . . . 0.0 112.193 -177.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.57 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 92.32 110.94 1.86 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.847 -172.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.415 ' OD2' ' HA ' ' A' ' 57' ' ' CYS . 9.9 t0 -153.32 -171.24 3.85 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -73.97 135.77 43.19 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 177.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.438 ' HB ' HG13 ' A' ' 148' ' ' VAL . 9.4 t -67.41 5.27 0.8 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -173.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.75 5.82 8.13 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.993 -0.442 . . . . 0.0 110.591 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 173.86 136.45 2.21 Favored Glycine 0 CA--C 1.484 -1.862 0 C-N-CA 117.58 -2.248 . . . . 0.0 112.542 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 143' ' ' ARG . 53.7 m -96.84 87.87 4.42 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.496 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 p -83.29 -37.12 23.88 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-O 122.159 0.981 . . . . 0.0 111.61 172.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.0 m -90.03 -40.17 12.48 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.802 -170.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.76 -16.09 35.18 Favored 'General case' 0 N--CA 1.422 -1.869 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 57' ' ' CYS . . . 37.29 -144.81 0.13 Allowed Glycine 0 CA--C 1.488 -1.628 0 CA-C-N 111.786 -2.461 . . . . 0.0 116.387 171.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -82.71 87.35 1.37 Allowed 'Trans proline' 0 N--CA 1.403 -3.827 0 C-N-CA 122.144 1.896 . . . . 0.0 110.189 177.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.427 ' HB2' ' HA3' ' A' ' 138' ' ' GLY . 10.9 t-80 77.61 110.46 0.07 Allowed 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 114.298 -1.319 . . . . 0.0 114.479 170.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -170.48 91.78 0.18 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.737 -2.029 . . . . 0.0 105.538 173.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 25.8 t-20 -111.49 89.92 11.42 Favored Pre-proline 0 C--O 1.209 -1.035 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 -178.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -77.48 -11.32 17.27 Favored 'Trans proline' 0 C--N 1.323 -0.804 0 C-N-CA 122.786 2.324 . . . . 0.0 111.259 -173.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.5 tt -45.04 -62.18 1.34 Allowed 'General case' 0 CA--C 1.492 -1.262 0 O-C-N 125.254 1.596 . . . . 0.0 109.943 -175.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.689 ' OG ' ' HA ' ' A' ' 76' ' ' ASP . 19.8 m -106.04 -86.26 0.48 Allowed 'General case' 0 N--CA 1.389 -3.483 0 C-N-CA 117.546 -1.662 . . . . 0.0 111.538 176.109 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.406 ' HD2' ' OE2' ' A' ' 78' ' ' GLU 0.392 21.8 ttm180 -123.99 43.48 2.98 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 114.593 -2.843 . . . . 0.0 116.169 179.405 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 53.0 mtmt 75.27 -43.04 0.49 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 125.09 1.356 . . . . 0.0 113.688 173.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -70.21 -37.44 75.06 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.614 ' HA3' ' O ' ' A' ' 80' ' ' HIS . . . 171.55 171.63 36.84 Favored Glycine 0 C--O 1.266 2.152 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.732 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.69 77.14 0.1 Allowed Glycine 0 C--O 1.215 -1.046 0 CA-C-O 118.925 -0.931 . . . . 0.0 113.377 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 77' ' ' GLU . 42.8 Cg_endo -64.79 -42.95 13.64 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.531 2.154 . . . . 0.0 115.653 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.579 ' O ' HG13 ' A' ' 104' ' ' ILE . 58.4 pttt -119.7 26.01 9.63 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.689 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 33.6 t70 61.76 85.06 0.13 Allowed 'General case' 0 CA--C 1.487 -1.472 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 -163.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.596 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 6.2 tp10 -121.95 -35.58 3.15 Favored 'General case' 0 C--O 1.169 -3.142 0 CA-C-N 113.803 -1.544 . . . . 0.0 113.984 -164.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.596 ' HB3' ' O ' ' A' ' 77' ' ' GLU . 12.6 tt0 76.73 112.33 0.07 Allowed 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -162.008 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 75.1 -174.93 0.13 Allowed 'General case' 0 C--O 1.25 1.114 0 CA-C-N 114.537 -1.21 . . . . 0.0 109.9 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.614 ' O ' ' HA3' ' A' ' 72' ' ' GLY . 61.7 t-80 . . . . . 0 N--CA 1.488 1.432 0 C-N-CA 125.693 1.597 . . . . 0.0 107.202 -178.388 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.9 mp . . . . . 0 N--CA 1.437 -1.098 0 N-CA-C 105.377 -2.083 . . . . 0.0 105.377 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.481 ' HA3' ' CD1' ' A' ' 45' ' ' PHE . . . 172.89 154.49 10.41 Favored Glycine 0 N--CA 1.422 -2.292 0 C-N-CA 118.982 -1.58 . . . . 0.0 114.6 176.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.55 ' H ' HG21 ' A' ' 99' ' ' ILE . 35.1 t30 -129.65 127.85 41.4 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 169.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.629 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 6.4 m -131.59 143.3 40.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.561 0 CA-C-N 118.216 0.462 . . . . 0.0 109.799 -173.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.9 m -142.37 96.24 2.92 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.628 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.556 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -137.87 154.74 49.44 Favored 'General case' 0 C--O 1.153 -3.978 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.415 ' O ' ' HB ' ' A' ' 39' ' ' THR . 7.9 p-10 -179.66 -27.57 0.01 OUTLIER 'General case' 0 C--N 1.255 -3.511 0 CA-C-O 122.485 1.136 . . . . 0.0 109.409 179.158 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -77.14 -49.61 14.84 Favored 'General case' 0 C--N 1.255 -3.534 0 CA-C-N 112.964 -1.925 . . . . 0.0 110.986 -177.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.433 ' CA ' HG22 ' A' ' 39' ' ' THR . 32.8 t70 -132.79 -1.08 3.41 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.822 -174.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.687 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 68.67 66.16 2.39 Favored Glycine 0 C--O 1.215 -1.054 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -177.197 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.725 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 22.7 t -150.21 104.55 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -110.23 119.63 39.87 Favored 'General case' 0 N--CA 1.4 -2.938 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 174.328 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -112.59 113.19 25.21 Favored 'General case' 0 C--N 1.273 -2.751 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 -177.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 13.7 m -111.21 145.46 17.43 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.065 0 N-CA-C 114.552 1.316 . . . . 0.0 114.552 -168.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.0 t -143.06 102.06 3.93 Favored 'General case' 0 N--CA 1.413 -2.309 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 166.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.55 HG21 ' H ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -117.23 171.54 5.68 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -176.185 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -140.77 112.17 7.37 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.03 -0.986 . . . . 0.0 109.668 176.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . 0.438 ' OD1' ' HB3' ' A' ' 75' ' ' LYS . 2.2 t0 -130.24 168.63 16.55 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB2' ' HB2' ' A' ' 75' ' ' LYS . 22.0 m -76.04 123.72 26.23 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 119.408 1.003 . . . . 0.0 111.253 -174.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.545 HG21 ' HB3' ' A' ' 23' ' ' LYS . 26.8 m -56.13 -12.09 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 C-N-CA 126.439 1.896 . . . . 0.0 114.546 -175.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 75' ' ' LYS . 26.3 pt -66.59 -12.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 CA-C-O 120.657 0.265 . . . . 0.0 111.136 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.569 ' HB3' ' C ' ' A' ' 75' ' ' LYS . 5.1 p -84.88 89.76 7.63 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 172.284 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.502 HD23 ' H ' ' A' ' 106' ' ' LEU . 2.0 pt? -69.79 119.34 13.87 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 165.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -74.65 87.57 2.17 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.533 ' HA2' ' CB ' ' A' ' 49' ' ' GLU . . . 162.49 136.91 2.08 Favored Glycine 0 N--CA 1.405 -3.375 0 CA-C-N 114.614 -1.175 . . . . 0.0 112.398 178.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -83.28 -73.56 0.4 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.616 0.246 . . . . 0.0 110.725 176.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -87.42 -19.72 27.66 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.531 179.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t -159.32 163.74 35.41 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 105.895 -1.891 . . . . 0.0 105.895 175.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.59 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 6.4 pt -104.47 -16.95 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.853 0 C-N-CA 125.507 1.523 . . . . 0.0 108.6 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.444 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 37.4 pt -103.73 138.83 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.13 177.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.561 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 93.41 -0.34 68.21 Favored Glycine 0 CA--C 1.484 -1.846 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.021 171.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.57 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 2.6 mmp_? -87.55 144.53 26.65 Favored 'General case' 0 C--O 1.175 -2.823 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 2.3 p -98.61 119.47 37.39 Favored 'General case' 0 C--N 1.286 -2.193 0 CA-C-N 119.549 1.068 . . . . 0.0 113.165 -176.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.447 ' HG ' HG12 ' A' ' 47' ' ' VAL . 3.0 tt -88.27 131.67 34.69 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 145' ' ' ALA . 93.5 t -102.24 109.49 26.44 Favored 'Isoleucine or valine' 0 C--O 1.267 2.009 0 C-N-CA 118.941 -1.103 . . . . 0.0 110.668 175.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.5 p -148.14 124.3 2.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.896 0.855 . . . . 0.0 113.192 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -144.02 157.44 44.33 Favored 'General case' 0 N--CA 1.41 -2.43 0 N-CA-C 101.872 -3.381 . . . . 0.0 101.872 168.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.561 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -68.92 89.79 0.42 Allowed 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.18 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HD3' ' H ' ' A' ' 123' ' ' ALA . 2.2 tmtp? -173.85 168.12 4.3 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -174.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.566 ' H ' ' HD3' ' A' ' 122' ' ' LYS . . . -73.72 125.02 27.15 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 121.531 0.681 . . . . 0.0 111.175 173.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -156.1 112.89 3.15 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 125.526 1.53 . . . . 0.0 107.31 176.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.502 ' O ' ' HA2' ' A' ' 138' ' ' GLY . 7.4 m-20 -128.91 129.32 45.35 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 3.3 mm? -82.69 -53.82 5.62 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 123.277 0.36 . . . . 0.0 111.168 -177.33 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.76 -31.24 45.1 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.65 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -93.13 -46.71 7.3 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.214 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 63.96 -82.04 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.601 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 169.89 -67.34 0.16 Allowed Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -177.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.636 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 51.6 t30 -119.4 -175.29 2.91 Favored 'General case' 0 C--O 1.253 1.237 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 175.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -54.01 -34.77 60.81 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -178.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . 0.636 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -83.79 -38.48 21.22 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.135 -178.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.476 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 14.6 m -65.16 -29.62 70.47 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.32 -175.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.418 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.4 t -68.53 -27.54 66.2 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 121.469 0.652 . . . . 0.0 109.892 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -84.05 -39.51 19.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.738 -178.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.0 m -72.26 -33.47 67.52 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 115.415 -0.812 . . . . 0.0 110.044 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 125' ' ' ASP . . . 59.72 45.96 94.84 Favored Glycine 0 CA--C 1.488 -1.626 0 N-CA-C 107.373 -2.291 . . . . 0.0 107.373 -171.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -34.42 104.62 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 O-C-N 126.424 1.896 . . . . 0.0 113.679 -166.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -151.8 172.43 16.18 Favored 'General case' 0 N--CA 1.425 -1.697 0 CA-C-N 113.523 -1.672 . . . . 0.0 108.353 -176.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.92 94.78 1.0 Allowed Glycine 0 N--CA 1.429 -1.779 0 N-CA-C 107.721 -2.152 . . . . 0.0 107.721 170.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.409 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 14.3 m -43.49 -44.29 5.88 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.922 1.689 . . . . 0.0 113.998 -172.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 57' ' ' CYS . 44.8 mtm180 -115.66 -25.95 7.64 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 177.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -46.62 -35.33 5.8 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.2 1.8 . . . . 0.0 112.539 -168.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 118' ' ' VAL . . . -141.58 87.76 2.09 Favored 'General case' 0 N--CA 1.388 -3.529 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 -179.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.445 ' SG ' HG22 ' A' ' 118' ' ' VAL . 86.5 m -138.7 138.91 38.16 Favored 'General case' 0 N--CA 1.419 -1.996 0 CA-C-N 114.035 -1.439 . . . . 0.0 107.845 176.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.21 148.95 18.55 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 174.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 27.9 m -68.95 123.91 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.809 0 CA-C-O 122.572 1.177 . . . . 0.0 111.97 178.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.409 HD13 ' N ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -98.2 138.51 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.561 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 174.439 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.59 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -174.4 151.99 13.66 Favored Glycine 3 N--CA 1.36 -6.37 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 177.642 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.7 pp -60.57 114.54 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 170.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.409 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -126.94 114.89 18.44 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 118.221 -0.895 . . . . 0.0 109.267 -178.492 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.481 ' HA ' HD11 ' A' ' 151' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.447 0 CA-C-O 121.047 0.451 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.401 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 11.6 t -121.68 -25.08 5.15 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.041 0.924 . . . . 0.0 110.167 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -135.78 150.5 49.49 Favored 'General case' 0 N--CA 1.416 -2.166 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -178.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.52 161.44 37.91 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.98 127.82 66.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-O 121.363 0.601 . . . . 0.0 109.961 178.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.65 ' HA ' HG21 ' A' ' 148' ' ' VAL . . . -107.81 146.89 31.62 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.768 -177.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.618 ' N ' HG11 ' A' ' 148' ' ' VAL . 41.1 t -134.5 104.94 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 -178.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.93 151.34 22.88 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.0 tmtt? -144.27 122.01 11.9 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 175.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.38 -178.46 30.54 Favored Glycine 0 N--CA 1.414 -2.8 0 C-N-CA 117.999 -2.048 . . . . 0.0 115.939 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.3 m-20 -102.35 111.34 23.59 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 170.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.41 68.94 1.03 Allowed Glycine 0 C--N 1.289 -2.059 0 N-CA-C 104.988 -3.245 . . . . 0.0 104.988 -164.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -62.66 128.0 22.19 Favored 'Trans proline' 0 CA--C 1.503 -1.045 0 C-N-CA 123.159 2.573 . . . . 0.0 114.914 -165.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 m -115.8 123.13 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.524 0 CA-C-N 113.727 -1.579 . . . . 0.0 108.324 177.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -111.66 117.84 34.02 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.61 166.93 40.11 Favored Glycine 1 N--CA 1.383 -4.885 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.377 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.445 ' O ' HD12 ' A' ' 17' ' ' ILE . 2.5 pp -134.38 139.28 48.3 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.673 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.3 tp -136.14 133.87 50.26 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.9 m-20 -92.9 160.71 14.79 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 44.4 m-85 -143.48 118.34 9.94 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 176.081 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.402 ' O ' ' HG3' ' A' ' 21' ' ' GLU . 13.0 pt-20 -124.94 101.06 6.88 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.314 -1.354 . . . . 0.0 114.073 171.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.514 ' HB3' ' HA ' ' A' ' 105' ' ' SER . 22.7 mm-40 -154.29 101.46 2.38 Favored 'General case' 0 CA--C 1.507 -0.677 0 C-N-CA 124.377 1.071 . . . . 0.0 110.462 164.065 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -167.37 -73.06 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -90.34 -33.39 16.1 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.088 179.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 p -65.19 -69.57 0.29 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.887 -1.051 . . . . 0.0 112.025 -178.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 66.7 107.53 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 124.476 1.11 . . . . 0.0 110.924 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.652 ' O ' ' HB3' ' A' ' 102' ' ' SER . . . 133.33 -147.31 18.96 Favored Glycine 0 CA--C 1.487 -1.66 0 C-N-CA 119.044 -1.55 . . . . 0.0 112.044 -177.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.32 123.29 13.22 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 122.512 2.141 . . . . 0.0 111.519 -177.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.553 HG23 ' HA ' ' A' ' 102' ' ' SER . 46.4 t -95.4 95.15 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.852 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -176.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -98.19 90.76 4.96 Favored 'General case' 0 N--CA 1.411 -2.418 0 CA-C-O 122.498 1.142 . . . . 0.0 108.981 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.436 ' O ' HG22 ' A' ' 99' ' ' ILE . 27.3 m -124.28 151.61 29.52 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.74 0 CA-C-N 113.001 -1.909 . . . . 0.0 109.724 -175.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.449 ' HA ' ' CG1' ' A' ' 97' ' ' VAL . 20.9 m-90 -135.48 145.89 47.59 Favored 'General case' 0 C--N 1.267 -3.005 0 CA-C-N 114.988 -1.005 . . . . 0.0 109.026 -175.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.538 ' H ' HG13 ' A' ' 97' ' ' VAL . . . -167.46 137.7 4.76 Favored Glycine 0 N--CA 1.424 -2.158 0 C-N-CA 118.046 -2.026 . . . . 0.0 112.638 172.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 p -118.38 138.71 52.25 Favored 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.4 mm -119.61 135.82 58.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -120.5 105.57 10.97 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 173.404 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.93 174.84 16.78 Favored Glycine 0 C--N 1.269 -3.144 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.893 -175.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.1 tp -66.01 137.42 57.1 Favored 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 104.384 -2.45 . . . . 0.0 104.384 173.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.449 ' HB ' ' HA ' ' A' ' 91' ' ' LYS . 17.9 p -68.72 108.96 3.6 Favored 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 115.766 1.765 . . . . 0.0 115.766 -160.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -173.6 170.03 4.16 Favored 'General case' 0 CA--C 1.472 -2.047 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.798 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 169.2 136.55 2.08 Favored Glycine 2 C--N 1.241 -4.715 0 C-N-CA 117.481 -2.295 . . . . 0.0 113.129 167.556 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.6 mt -140.99 -50.39 0.44 Allowed 'General case' 0 N--CA 1.426 -1.672 0 O-C-N 124.553 0.796 . . . . 0.0 111.379 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -149.83 153.49 36.85 Favored 'General case' 0 C--N 1.321 -0.665 0 O-C-N 121.922 -0.486 . . . . 0.0 109.792 -175.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.632 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -96.59 107.5 3.52 Favored Glycine 0 CA--C 1.458 -3.478 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 175.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CG ' ' HB3' ' A' ' 124' ' ' ASP . 29.4 p90 -121.79 83.49 2.1 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.56 ' HB2' HD12 ' A' ' 117' ' ' LEU . 8.2 p80 -133.04 85.47 2.22 Favored 'General case' 0 N--CA 1.387 -3.586 0 O-C-N 118.968 -2.333 . . . . 0.0 113.607 -162.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 46' ' ' HIS . 43.4 t -170.47 136.12 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 C-N-CA 127.753 2.421 . . . . 0.0 108.168 171.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.625 ' HB2' ' O ' ' A' ' 116' ' ' THR . 2.0 m170 -150.35 94.76 2.16 Favored 'General case' 0 C--N 1.26 -3.309 0 CA-C-N 112.458 -2.155 . . . . 0.0 109.916 170.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 0.4 OUTLIER -80.87 162.37 24.0 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 176.829 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.9 t80 71.74 28.96 2.62 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.612 ' HA3' ' HA ' ' A' ' 115' ' ' ARG . . . -72.01 -170.47 13.98 Favored Glycine 0 N--CA 1.428 -1.883 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.958 176.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -176.34 -63.04 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.552 -164.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -108.28 121.91 45.86 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.637 -173.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.1 p -70.81 2.62 4.02 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -177.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.69 19.02 11.92 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.318 0.247 . . . . 0.0 110.434 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 154.78 131.54 1.49 Allowed Glycine 0 C--N 1.309 -0.923 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.968 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.462 ' HB2' ' HG2' ' A' ' 143' ' ' ARG . 15.8 m -82.62 91.92 7.05 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.0 t -78.56 -61.37 2.03 Favored 'General case' 0 N--CA 1.426 -1.661 0 O-C-N 124.11 0.881 . . . . 0.0 110.157 172.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 13.4 m -65.43 -47.2 77.04 Favored 'General case' 0 C--O 1.214 -0.806 0 C-N-CA 122.967 0.507 . . . . 0.0 111.941 -177.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.477 ' HB1' ' HB3' ' A' ' 48' ' ' HIS . . . -76.36 -6.65 52.53 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -40.58 -71.57 0.29 Allowed Glycine 0 CA--C 1.541 1.706 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 -175.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -72.12 -17.05 28.41 Favored 'Trans proline' 0 N--CA 1.48 0.684 0 C-N-CA 122.92 2.414 . . . . 0.0 112.381 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 65.64 107.18 0.04 OUTLIER 'General case' 0 C--O 1.242 0.665 0 C-N-CA 126.611 1.965 . . . . 0.0 112.56 -177.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -130.29 84.09 2.18 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 118.306 -1.358 . . . . 0.0 108.474 166.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -119.46 90.63 42.97 Favored Pre-proline 0 C--N 1.289 -2.033 0 CA-C-N 112.5 -2.136 . . . . 0.0 108.066 173.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -30.1 -54.49 0.2 Allowed 'Trans proline' 0 N--CA 1.484 0.956 1 C-N-CA 126.735 4.957 . . . . 0.0 119.626 -168.864 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -93.84 0.47 56.24 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 118.688 -1.205 . . . . 0.0 113.843 -173.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.639 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 28.6 m -78.6 48.43 0.79 Allowed 'General case' 0 C--O 1.246 0.892 0 CA-C-O 122.386 1.089 . . . . 0.0 109.095 175.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 69' ' ' ARG . 12.9 mmm180 -133.2 -28.77 1.48 Allowed 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.283 -173.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 54.3 tptt -38.84 -56.83 1.31 Allowed 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.105 0.962 . . . . 0.0 113.563 -173.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.493 ' H ' ' HA ' ' A' ' 78' ' ' GLU . 21.2 t-80 -177.61 59.94 0.01 OUTLIER 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.161 -0.447 . . . . 0.0 110.011 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.511 ' HA2' ' HB3' ' A' ' 78' ' ' GLU . . . -38.93 105.98 0.05 OUTLIER Glycine 0 N--CA 1.483 1.83 0 O-C-N 123.744 0.653 . . . . 0.0 112.676 173.246 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.52 168.26 24.22 Favored Glycine 0 N--CA 1.413 -2.84 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -176.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -93.29 1.72 3.45 Favored 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 123.333 2.689 . . . . 0.0 115.985 -172.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 76' ' ' ASP . 87.1 mttt -108.5 -31.67 7.71 Favored 'General case' 0 C--O 1.262 1.715 0 C-N-CA 118.096 -1.442 . . . . 0.0 109.773 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 75' ' ' LYS . 0.8 OUTLIER 159.3 120.09 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.758 0 C-N-CA 128.301 2.64 . . . . 0.0 104.291 168.813 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 164.33 127.26 0.01 OUTLIER 'General case' 0 CA--C 1.454 -2.715 0 C-N-CA 124.459 1.104 . . . . 0.0 111.194 171.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.639 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.7 OUTLIER 162.75 -173.84 0.01 OUTLIER 'General case' 0 N--CA 1.396 -3.147 0 C-N-CA 130.885 3.674 . . . . 0.0 102.325 163.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.671 ' NE ' ' HA ' ' A' ' 79' ' ' ARG 0.381 1.4 mmp_? -121.01 11.25 10.95 Favored 'General case' 0 C--N 1.257 -3.415 0 N-CA-C 118.337 2.718 . . . . 0.0 118.337 -176.872 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.507 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.6 OUTLIER . . . . . 0 CA--C 1.483 -1.629 0 C-N-CA 117.37 -1.732 . . . . 0.0 110.804 170.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.639 HD23 ' H ' ' A' ' 85' ' ' GLY . 5.8 tt . . . . . 0 N--CA 1.433 -1.286 0 N-CA-C 106.546 -1.65 . . . . 0.0 106.546 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . 0.639 ' H ' HD23 ' A' ' 84' ' ' LEU . . . -38.89 147.53 0.13 Allowed Glycine 0 N--CA 1.466 0.686 0 C-N-CA 125.005 1.288 . . . . 0.0 114.948 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -79.49 136.3 36.87 Favored 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 114.682 -0.759 . . . . 0.0 109.162 -166.274 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.729 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 30.3 m -134.72 126.69 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.408 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.6 t -141.28 148.2 39.42 Favored 'General case' 0 C--N 1.267 -3.001 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 -177.571 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.798 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -132.76 154.38 50.29 Favored 'General case' 0 C--N 1.259 -3.326 0 N-CA-C 105.362 -2.088 . . . . 0.0 105.362 178.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.499 ' C ' ' H ' ' A' ' 92' ' ' ASP . 6.9 t70 -101.65 -153.45 0.46 Allowed 'General case' 1 C--N 1.225 -4.841 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.548 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HA ' ' HB ' ' A' ' 39' ' ' THR . 95.0 mttt -62.66 16.82 0.01 OUTLIER 'General case' 0 CA--C 1.58 2.116 0 O-C-N 121.587 -0.696 . . . . 0.0 112.845 171.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 90' ' ' ASP . 17.0 t70 -133.68 109.65 9.31 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 171.369 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -76.43 92.59 0.98 Allowed Glycine 0 C--N 1.32 -0.357 0 N-CA-C 114.911 0.725 . . . . 0.0 114.911 -170.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.7 t -158.46 103.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 176.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.729 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.18 128.75 43.37 Favored 'General case' 0 N--CA 1.398 -3.027 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.677 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -82.15 153.36 26.06 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 124.144 0.902 . . . . 0.0 110.642 -174.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.538 HG13 ' H ' ' A' ' 33' ' ' GLY . 78.4 t -81.21 134.91 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 C-N-CA 124.203 1.001 . . . . 0.0 111.668 -172.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 61.5 m -122.97 123.76 41.65 Favored 'General case' 0 N--CA 1.414 -2.245 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.045 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 31' ' ' VAL . 31.8 pt -94.43 160.39 2.72 Favored 'Isoleucine or valine' 0 C--O 1.25 1.106 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.407 ' OE1' ' HA ' ' A' ' 84' ' ' LEU . 49.8 mt-10 -142.99 159.28 42.53 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-O 122.159 0.98 . . . . 0.0 113.239 -171.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.22 169.4 17.39 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 172.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.652 ' HB3' ' O ' ' A' ' 27' ' ' GLY . 10.9 p -57.34 91.94 0.01 OUTLIER 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -173.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.56 -38.16 2.07 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.225 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.063 173.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.405 ' O ' HG22 ' A' ' 104' ' ' ILE . 25.3 mm -72.37 25.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 C-N-CA 126.919 2.088 . . . . 0.0 111.936 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 16.8 p -66.95 149.65 50.32 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 121.667 -0.646 . . . . 0.0 110.831 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . 0.308 0.9 OUTLIER -80.95 86.3 6.11 Favored 'General case' 0 N--CA 1.388 -3.536 0 CA-C-O 124.647 2.165 . . . . 0.0 111.505 178.573 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.7 m -149.85 85.95 1.43 Allowed 'General case' 2 N--CA 1.367 -4.613 1 N-CA-C 100.061 -4.051 . . . . 0.0 100.061 168.457 . . . . . . . . 3 2 . 1 . 013 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -125.31 -155.99 9.21 Favored Glycine 0 C--N 1.26 -3.674 0 CA-C-N 113.46 -1.7 . . . . 0.0 109.444 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -92.2 -44.54 8.72 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 111' ' ' SER . 23.1 m80 -118.64 -50.77 2.4 Favored 'General case' 0 N--CA 1.434 -1.234 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.444 175.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 110' ' ' HIS . 33.2 t 165.45 168.03 0.02 OUTLIER 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 177.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.522 ' O ' HG22 ' A' ' 149' ' ' ILE . 50.1 mm -71.72 -45.98 63.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.483 ' H ' HD12 ' A' ' 113' ' ' ILE . 3.5 mp -71.71 121.25 21.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.726 -0.609 . . . . 0.0 111.764 -172.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.83 -0.05 25.81 Favored Glycine 0 CA--C 1.478 -2.225 0 C-N-CA 120.403 -0.903 . . . . 0.0 110.873 170.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.612 ' HA ' ' HA3' ' A' ' 51' ' ' GLY . 11.1 mmt180 -91.86 173.52 7.82 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.59 -178.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.625 ' O ' ' HB2' ' A' ' 48' ' ' HIS . 17.5 p -128.46 103.77 7.32 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-O 118.725 -0.655 . . . . 0.0 110.998 -173.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' A' ' 148' ' ' VAL . 0.7 OUTLIER -76.26 137.16 39.76 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 120.312 1.414 . . . . 0.0 111.573 -178.026 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.721 ' HA ' ' HB3' ' A' ' 146' ' ' CYS . 11.5 p -92.87 125.25 45.46 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.436 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 176.11 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.8 p -148.55 130.88 6.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 C-N-CA 118.961 -1.095 . . . . 0.0 113.115 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 16.3 t-80 -154.93 151.33 28.41 Favored 'General case' 0 N--CA 1.416 -2.169 0 N-CA-C 102.348 -3.204 . . . . 0.0 102.348 163.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 41' ' ' GLY . 2.9 mp0 -70.3 99.52 1.56 Allowed 'General case' 0 C--N 1.269 -2.896 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 174.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -168.31 173.83 7.46 Favored 'General case' 0 C--O 1.199 -1.59 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -171.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.01 120.48 26.17 Favored 'General case' 0 C--N 1.256 -3.471 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 177.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.613 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -167.13 136.77 2.87 Favored 'General case' 0 N--CA 1.509 2.512 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.012 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -149.89 150.9 32.59 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.823 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -90.95 -39.31 12.33 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.11 -33.91 5.84 Favored Glycine 0 C--N 1.3 -1.465 0 C-N-CA 119.753 -1.213 . . . . 0.0 111.65 -175.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 49.1 tptt -118.43 41.34 2.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -176.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.91 -7.24 69.8 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 115.463 -0.79 . . . . 0.0 114.736 -176.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 144.11 -122.42 1.81 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.492 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.452 ' O ' HG22 ' A' ' 135' ' ' THR . 88.9 m-20 -99.65 -174.54 2.74 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -177.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -47.09 -52.65 14.69 Favored 'General case' 0 N--CA 1.484 1.228 0 O-C-N 123.564 0.54 . . . . 0.0 111.264 -176.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -77.71 -40.85 39.9 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.7 p -75.53 -27.17 58.59 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -175.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 131' ' ' ASN . 13.9 t -76.12 -33.25 59.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 176.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -74.08 -32.54 63.3 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.727 -179.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 86.4 m -79.22 -31.05 43.55 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.304 174.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.73 60.94 8.1 Favored Glycine 0 CA--C 1.484 -1.884 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -36.31 105.62 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 125.733 1.49 . . . . 0.0 111.876 -174.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 124' ' ' ASP . . . -101.8 169.93 8.48 Favored 'General case' 0 N--CA 1.429 -1.516 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.92 -169.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' A' ' 143' ' ' ARG . . . -63.96 154.02 47.12 Favored Glycine 0 N--CA 1.406 -3.303 0 N-CA-C 106.481 -2.648 . . . . 0.0 106.481 169.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -57.01 8.81 0.01 OUTLIER 'General case' 0 C--N 1.262 -3.223 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.462 ' HG2' ' HB2' ' A' ' 57' ' ' CYS . 0.2 OUTLIER 65.67 19.17 11.39 Favored 'General case' 0 CA--C 1.467 -2.224 0 C-N-CA 125.277 1.431 . . . . 0.0 107.959 177.675 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 53.0 mt -70.94 -33.24 70.3 Favored 'General case' 0 CA--C 1.445 -3.072 0 CA-C-N 113.91 -1.495 . . . . 0.0 107.668 -176.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.432 ' O ' ' HB3' ' A' ' 146' ' ' CYS . . . -121.98 89.74 3.17 Favored 'General case' 1 N--CA 1.35 -5.458 0 CA-C-N 113.557 -1.656 . . . . 0.0 108.158 175.38 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 118' ' ' VAL . 19.9 p -171.91 127.94 0.61 Allowed 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 113.812 1.042 . . . . 0.0 113.812 169.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.614 ' HA2' ' HB ' ' A' ' 116' ' ' THR . . . -178.51 77.93 0.07 OUTLIER Glycine 0 N--CA 1.402 -3.62 0 CA-C-O 118.638 -1.09 . . . . 0.0 110.656 159.009 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 6' ' ' ALA . 13.1 p -172.58 96.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.184 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 169.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.559 ' CD1' ' HB3' ' A' ' 117' ' ' LEU . 12.2 mm -124.46 102.68 11.28 Favored 'Isoleucine or valine' 1 C--N 1.234 -4.445 0 N-CA-C 104.692 -2.336 . . . . 0.0 104.692 167.364 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -165.59 146.56 11.25 Favored Glycine 2 CA--C 1.444 -4.394 0 C-N-CA 115.941 -3.028 . . . . 0.0 112.678 175.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.545 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 0.0 OUTLIER -95.26 105.56 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.568 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 171.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.92 99.61 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.441 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.245 0.863 0 N-CA-C 105.466 -2.049 . . . . 0.0 105.466 178.07 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.207 -1.145 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 m -100.48 -27.63 13.33 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -171.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -136.66 148.62 47.51 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.169 -173.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -142.35 143.19 32.63 Favored 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 92.1 t -124.26 129.13 74.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.406 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -120.11 145.61 46.74 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.939 -177.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 56.5 t -127.38 126.07 66.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 85.3 mt -112.1 133.08 54.47 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -142.6 133.54 25.68 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.68 -170.89 21.59 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 119.362 -1.399 . . . . 0.0 112.553 -177.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -73.31 -46.1 51.49 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -101.58 96.29 1.47 Allowed Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 171.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -71.53 127.09 12.79 Favored 'Trans proline' 0 N--CA 1.434 -1.986 0 C-N-CA 121.797 1.665 . . . . 0.0 113.968 -168.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.91 148.28 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.286 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 173.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -123.94 118.64 27.51 Favored 'General case' 0 C--N 1.259 -3.355 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -177.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -167.26 146.48 10.77 Favored Glycine 0 N--CA 1.409 -3.101 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.891 -178.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.2 pt -130.66 118.24 41.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.742 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.1 OUTLIER -114.88 133.04 62.27 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.103 -176.708 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 24.0 m-80 -109.46 119.73 40.33 Favored 'General case' 0 CA--C 1.51 -0.589 0 C-N-CA 123.309 0.644 . . . . 0.0 109.592 -173.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.7 m-85 -120.76 137.41 54.52 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.779 0.323 . . . . 0.0 110.617 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 9.9 pt-20 -107.89 134.0 51.45 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.418 175.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.571 ' HA ' ' O ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -126.91 112.45 15.32 Favored 'General case' 0 N--CA 1.413 -2.307 0 C-N-CA 123.777 0.831 . . . . 0.0 109.459 178.309 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.8 tttm -138.12 149.07 45.58 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.34 -173.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.609 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.1 mp0 -50.51 -44.29 56.05 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 125.728 1.611 . . . . 0.0 110.332 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.6 m -51.72 -45.24 63.51 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.651 1.18 . . . . 0.0 111.913 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.432 ' HA ' HG23 ' A' ' 104' ' ' ILE . 9.8 t30 57.62 87.59 0.06 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 124.294 0.996 . . . . 0.0 111.917 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.528 ' H ' HD13 ' A' ' 104' ' ' ILE . . . -132.47 -151.6 6.79 Favored Glycine 0 CA--C 1.492 -1.361 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.19 -177.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_exo -67.6 124.18 11.67 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.215 1.943 . . . . 0.0 108.01 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.682 HG11 HG12 ' A' ' 103' ' ' VAL . 13.4 p -80.01 132.69 31.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 CA-C-O 121.23 0.538 . . . . 0.0 110.5 -176.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -93.98 99.21 11.58 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 169.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 5.9 p -123.44 130.54 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.001 0 CA-C-N 115.311 -0.858 . . . . 0.0 108.711 -175.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -136.44 125.49 24.42 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.498 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.742 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -164.25 140.17 6.29 Favored Glycine 0 N--CA 1.41 -3.045 0 C-N-CA 119.724 -1.226 . . . . 0.0 111.933 172.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 16.9 m -116.04 135.46 53.93 Favored 'General case' 0 N--CA 1.404 -2.77 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.531 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 12.1 tt -125.13 136.94 59.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 118.54 0.609 . . . . 0.0 109.976 179.183 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 91.7 mttt -116.92 131.84 56.85 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.128 -2.175 . . . . 0.0 105.128 -177.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.592 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -155.0 175.8 32.91 Favored Glycine 0 C--N 1.269 -3.169 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -166.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.62 171.0 8.23 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 175.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.0 t -69.47 107.18 3.25 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.809 -175.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.571 ' OE2' ' HG2' ' A' ' 122' ' ' LYS . 22.2 tt0 -177.08 171.13 2.14 Favored 'General case' 0 N--CA 1.419 -2.011 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 171.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 170.78 104.83 0.18 Allowed Glycine 1 C--N 1.251 -4.144 0 C-N-CA 119.02 -1.562 . . . . 0.0 111.843 169.543 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' N ' ' A' ' 123' ' ' ALA . 6.8 mp -110.78 -86.89 0.53 Allowed 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.062 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.657 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.4 t-80 -175.15 122.3 0.22 Allowed 'General case' 0 C--N 1.355 0.823 0 C-N-CA 118.364 -1.335 . . . . 0.0 114.35 -173.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.456 ' H ' ' H ' ' A' ' 87' ' ' VAL . . . 102.99 137.94 9.74 Favored Glycine 0 C--N 1.3 -1.432 0 N-CA-C 117.502 1.761 . . . . 0.0 117.502 164.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -96.18 166.73 11.6 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 124.028 0.931 . . . . 0.0 109.359 170.179 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.715 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . 6.1 m80 -171.83 90.44 0.12 Allowed 'General case' 0 CA--C 1.482 -1.661 0 C-N-CA 125.298 1.439 . . . . 0.0 110.004 169.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.627 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 2.6 p -69.36 162.7 3.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 168.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.49 ' CE1' ' HD2' ' A' ' 62' ' ' PRO 0.278 0.0 OUTLIER -148.85 171.49 16.21 Favored 'General case' 0 N--CA 1.419 -1.979 0 C-N-CA 116.562 -2.055 . . . . 0.0 109.482 170.187 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . . . . . . . . . 1.9 pm0 -69.57 166.35 19.16 Favored 'General case' 0 C--N 1.261 -3.273 0 N-CA-C 116.072 1.879 . . . . 0.0 116.072 -171.043 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 59' ' ' SER . 4.0 t80 72.77 33.26 1.32 Allowed 'General case' 0 N--CA 1.439 -1.023 0 C-N-CA 126.321 1.848 . . . . 0.0 107.243 172.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.422 ' HA2' ' HB2' ' A' ' 60' ' ' ALA . . . -57.56 154.84 20.49 Favored Glycine 0 C--N 1.345 1.048 0 CA-C-N 112.42 -2.173 . . . . 0.0 113.063 -178.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.537 ' OD1' ' HA ' ' A' ' 57' ' ' CYS . 3.8 p30 -144.8 -85.75 0.13 Allowed 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -172.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.55 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 52.7 t30 -98.31 148.77 23.31 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.288 0.566 . . . . 0.0 112.43 -173.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.577 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 6.9 m -82.3 -2.93 54.26 Favored 'General case' 0 CA--C 1.56 1.349 0 C-N-CA 124.323 1.049 . . . . 0.0 111.652 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.99 17.06 7.92 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 121.097 0.475 . . . . 0.0 111.02 -177.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.55 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 143.94 117.16 1.16 Allowed Glycine 0 CA--C 1.484 -1.864 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -177.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.587 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -97.53 113.69 25.44 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -175.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.0 p -80.0 -45.42 18.44 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.576 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . 49.8 m -79.37 -29.0 41.94 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 123.445 0.698 . . . . 0.0 111.216 -174.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.71 -5.26 47.28 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 123.981 0.912 . . . . 0.0 111.19 172.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.22 52.1 0.91 Allowed Glycine 0 CA--C 1.559 2.801 0 C-N-CA 117.177 -2.439 . . . . 0.0 116.247 176.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.529 ' HD3' ' O ' ' A' ' 59' ' ' SER . 86.9 Cg_endo -96.37 2.93 1.99 Allowed 'Trans proline' 0 C--N 1.397 3.127 0 CA-C-N 121.821 2.81 . . . . 0.0 107.322 161.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 38.9 m80 75.22 -47.75 0.61 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 125.541 1.536 . . . . 0.0 113.623 173.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -69.27 116.12 9.34 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -170.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 5.5 p30 -116.16 96.49 47.49 Favored Pre-proline 0 CA--C 1.559 1.309 0 C-N-CA 125.061 1.344 . . . . 0.0 110.089 176.82 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.95 -18.7 10.06 Favored 'Trans proline' 0 CA--C 1.552 1.384 0 C-N-CA 123.119 2.546 . . . . 0.0 117.823 -169.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.421 ' HB3' ' HB2' ' A' ' 79' ' ' ARG . 84.0 mt -88.09 -5.32 58.52 Favored 'General case' 0 CA--C 1.484 -1.567 0 O-C-N 120.817 -1.177 . . . . 0.0 110.906 -172.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.433 ' C ' ' H ' ' A' ' 70' ' ' LYS . 17.9 m -77.92 58.05 1.85 Allowed 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 104.533 -2.395 . . . . 0.0 104.533 167.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.526 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 2.1 tmm_? -92.59 17.56 9.98 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -169.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.503 ' HB2' ' CB ' ' A' ' 78' ' ' GLU . 11.9 mptt -140.03 63.97 1.46 Allowed 'General case' 0 N--CA 1.411 -2.402 0 CA-C-N 112.705 -2.043 . . . . 0.0 109.411 175.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . 0.446 ' O ' ' HB3' ' A' ' 126' ' ' LEU . 20.2 t60 65.38 -37.57 0.24 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 125.313 1.445 . . . . 0.0 113.284 -178.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.13 20.68 62.34 Favored Glycine 0 N--CA 1.414 -2.816 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -175.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 77' ' ' GLU . . . -90.31 175.53 41.14 Favored Glycine 0 C--O 1.202 -1.897 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.863 -177.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.515 ' C ' ' H ' ' A' ' 76' ' ' ASP . 2.8 Cg_exo -72.07 2.34 4.99 Favored 'Trans proline' 0 N--CA 1.501 1.926 1 C-N-CA 125.717 4.278 . . . . 0.0 111.302 -170.562 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.414 ' H ' ' C ' ' A' ' 73' ' ' GLY . 60.9 tttm -76.59 27.59 0.13 Allowed 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 127.402 2.281 . . . . 0.0 109.089 178.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 74' ' ' PRO 0.303 1.2 p30 77.18 10.32 2.51 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 128.453 2.701 . . . . 0.0 115.665 173.597 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.604 ' HG3' ' O ' ' A' ' 73' ' ' GLY . 1.7 mp0 33.19 108.19 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 127.639 2.375 . . . . 0.0 114.089 170.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 69' ' ' ARG . 43.1 tt0 -34.73 -61.66 0.39 Allowed 'General case' 0 N--CA 1.507 2.392 0 O-C-N 123.914 0.759 . . . . 0.0 112.133 -177.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.421 ' HB2' ' HB3' ' A' ' 67' ' ' LEU . 75.0 mtt85 -136.62 63.64 1.57 Allowed 'General case' 0 C--N 1.286 -2.177 0 C-N-CA 118.834 -1.146 . . . . 0.0 111.056 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.6 ' NE2' ' HB2' ' A' ' 105' ' ' SER . 0.3 OUTLIER . . . . . 0 CA--C 1.505 -0.751 0 CA-C-O 122.729 1.252 . . . . 0.0 113.375 171.455 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.454 ' CD1' ' HA2' ' A' ' 73' ' ' GLY . 1.6 tt . . . . . 0 N--CA 1.423 -1.823 0 CA-C-O 121.645 0.736 . . . . 0.0 109.28 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.02 136.51 13.52 Favored Glycine 0 N--CA 1.419 -2.487 0 N-CA-C 104.853 -3.299 . . . . 0.0 104.853 165.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.415 ' HA ' ' HA2' ' A' ' 44' ' ' GLY 0.359 0.2 OUTLIER -92.11 128.69 38.05 Favored 'General case' 0 N--CA 1.426 -1.645 0 C-N-CA 115.171 -2.611 . . . . 0.0 113.318 -173.189 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.657 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 92.6 t -110.64 138.7 37.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.186 -174.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.5 p -140.15 95.09 2.83 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 -179.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -86.14 137.03 32.97 Favored 'General case' 0 N--CA 1.415 -2.217 0 CA-C-O 121.406 0.622 . . . . 0.0 109.945 -176.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 92' ' ' ASP . 30.8 t70 -75.23 154.62 37.44 Favored 'General case' 1 C--N 1.242 -4.103 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 174.516 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -53.07 23.07 0.0 OUTLIER 'General case' 0 CA--C 1.579 2.094 0 N-CA-C 115.839 1.792 . . . . 0.0 115.839 174.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 90' ' ' ASP . 1.5 m-20 -133.89 8.63 3.82 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 124.945 1.298 . . . . 0.0 108.787 171.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.635 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 66.8 80.08 0.2 Allowed Glycine 0 N--CA 1.44 -1.046 0 CA-C-N 114.998 -1.001 . . . . 0.0 112.564 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.5 p -161.71 113.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 34' ' ' SER . . . -136.8 144.63 43.81 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -119.58 115.14 23.38 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 175.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.434 HG11 ' CE2' ' A' ' 45' ' ' PHE . 4.3 p -102.92 103.41 15.04 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.352 0 CA-C-O 122.173 0.987 . . . . 0.0 111.714 -178.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.2 m -139.65 100.18 3.9 Favored 'General case' 0 N--CA 1.421 -1.894 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 172.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.9 mm -135.3 128.45 48.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -176.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 43.0 mt-10 -104.5 106.19 16.59 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -160.51 168.66 24.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 104.369 -2.456 . . . . 0.0 104.369 170.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.504 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 24.8 m -80.76 79.18 7.45 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 115.726 1.75 . . . . 0.0 115.726 -169.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.682 HG12 HG11 ' A' ' 29' ' ' VAL . 12.4 p -92.51 -11.62 9.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 169.476 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 22' ' ' GLN . 15.9 tt -57.87 19.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.102 0 C-N-CA 130.201 3.4 . . . . 0.0 114.235 -176.306 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.6 ' HB2' ' NE2' ' A' ' 80' ' ' HIS . 16.4 m -97.85 170.91 8.64 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 103.627 -2.731 . . . . 0.0 103.627 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.428 ' O ' HD12 ' A' ' 106' ' ' LEU . 2.6 pp -68.14 119.13 12.23 Favored 'General case' 0 N--CA 1.414 -2.24 0 C-N-CA 117.689 -1.605 . . . . 0.0 109.467 176.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 m -68.95 89.75 0.42 Allowed 'General case' 0 N--CA 1.414 -2.234 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.303 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 155.27 155.69 7.44 Favored Glycine 0 N--CA 1.401 -3.64 0 CA-C-N 114.155 -1.384 . . . . 0.0 110.501 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.9 p-10 -69.66 -38.91 77.29 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 174.696 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -107.37 -48.07 3.52 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.266 -175.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.56 ' O ' ' HD2' ' A' ' 115' ' ' ARG . 15.3 m -163.04 159.92 23.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.701 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -72.79 -46.6 52.72 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.894 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.077 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 tp -67.56 127.15 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 176.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.98 11.93 58.29 Favored Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 119.611 -1.28 . . . . 0.0 110.768 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.56 ' HD2' ' O ' ' A' ' 111' ' ' SER . 0.0 OUTLIER -114.67 121.55 43.73 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.237 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.809 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 14.9 p -98.45 135.56 39.83 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-O 121.856 0.836 . . . . 0.0 111.638 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 56.2 tp -74.66 102.87 4.74 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 113.937 -1.483 . . . . 0.0 111.485 -174.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 142' ' ' SER . 12.6 m -93.21 96.36 6.12 Favored 'Isoleucine or valine' 1 C--O 1.33 5.293 0 C-N-CA 116.314 -2.154 . . . . 0.0 112.821 175.035 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.1 p -150.5 171.57 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 113.46 -1.7 . . . . 0.0 107.992 -176.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.465 ' HB2' ' HB3' ' A' ' 144' ' ' LEU . 82.2 t60 -152.04 170.76 19.12 Favored 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 168.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -69.77 88.37 0.54 Allowed 'General case' 0 CA--C 1.551 0.983 0 CA-C-N 123.016 2.643 . . . . 0.0 109.045 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.571 ' HG2' ' OE2' ' A' ' 40' ' ' GLU . 65.8 mttm -166.75 173.31 9.68 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 125.771 1.628 . . . . 0.0 108.318 -168.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.616 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -82.68 114.52 21.1 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 172.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.715 ' OD1' ' HB2' ' A' ' 46' ' ' HIS . 11.9 t70 -124.31 76.58 1.49 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -176.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -114.43 158.59 21.35 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.155 0.502 . . . . 0.0 110.548 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 135' ' ' THR . 3.2 tm? -87.85 -56.35 3.38 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.467 -1.242 . . . . 0.0 108.007 -179.381 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 71' ' ' HIS . . . -68.26 -40.63 87.44 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.725 -177.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -105.43 50.74 0.77 Allowed 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.25 76.73 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.588 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -67.29 0.53 Allowed Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.379 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' CB ' ' A' ' 134' ' ' SER . 4.1 m-20 -105.99 176.81 5.04 Favored 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 119.052 -0.499 . . . . 0.0 109.945 -179.121 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -56.18 -44.07 79.02 Favored 'General case' 0 CA--C 1.567 1.634 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 176.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -71.85 -33.39 68.4 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.461 ' CB ' ' H ' ' A' ' 131' ' ' ASN . 2.3 m -68.1 -19.97 64.89 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.969 0.414 . . . . 0.0 110.887 -175.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.472 ' HA ' ' O ' ' A' ' 126' ' ' LEU . 8.8 m -74.0 -21.3 60.04 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 121.511 0.672 . . . . 0.0 109.823 178.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -83.24 -51.18 7.69 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.3 p -69.01 -50.59 47.46 Favored 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.965 -177.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . 0.438 ' CA ' ' HA ' ' A' ' 126' ' ' LEU . . . 67.16 92.45 0.04 OUTLIER Glycine 0 N--CA 1.418 -2.532 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -174.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -31.77 136.63 0.06 Allowed 'General case' 1 C--O 1.322 4.892 0 N-CA-C 118.813 2.894 . . . . 0.0 118.813 -167.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -126.51 129.01 47.79 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 112.925 -1.943 . . . . 0.0 109.246 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -115.23 75.33 0.25 Allowed Glycine 0 N--CA 1.416 -2.665 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 176.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.568 ' HB2' ' O ' ' A' ' 57' ' ' CYS . 77.5 p -58.92 -26.82 64.69 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 123.848 0.859 . . . . 0.0 112.306 -175.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -117.52 -0.89 11.79 Favored 'General case' 0 N--CA 1.427 -1.617 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.803 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.465 ' HB3' ' HB2' ' A' ' 120' ' ' HIS . 3.9 mm? -79.05 -34.84 43.45 Favored 'General case' 0 C--N 1.282 -2.367 0 C-N-CA 117.949 -1.5 . . . . 0.0 110.393 -176.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -173.96 89.45 0.07 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 177.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.809 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 44.6 t -139.07 133.11 31.15 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 118.159 -1.416 . . . . 0.0 110.34 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.577 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -161.18 166.02 35.59 Favored Glycine 0 N--CA 1.398 -3.897 0 N-CA-C 107.967 -2.053 . . . . 0.0 107.967 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.92 122.37 20.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.086 0.47 . . . . 0.0 110.339 -178.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.413 HD11 ' CD1' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -116.26 106.5 20.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.233 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.447 ' HA2' ' HB ' ' A' ' 112' ' ' ILE . . . -172.31 -179.29 43.08 Favored Glycine 1 N--CA 1.392 -4.268 0 N-CA-C 110.031 -1.227 . . . . 0.0 110.031 -179.125 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.483 ' H ' HG12 ' A' ' 112' ' ' ILE . 11.3 tt -54.87 114.47 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 121.751 0.786 . . . . 0.0 112.475 -179.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.57 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -149.93 154.9 39.06 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 176.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 . . . . . 0 C--N 1.29 -1.995 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.819 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.21 -0.987 0 CA-C-O 120.283 0.087 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 9.3 m -76.26 -27.92 56.88 Favored 'General case' 0 CA--C 1.562 1.434 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -175.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.463 ' O ' ' HB ' ' A' ' 151' ' ' ILE . 20.2 ptpt -152.63 167.55 28.52 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -153.02 152.5 31.45 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 175.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.3 t -134.41 138.37 49.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -109.44 134.61 51.65 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -175.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . 0.551 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 46.9 t -134.31 102.55 4.27 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.366 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 175.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.496 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.5 pt? -117.74 132.49 56.46 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -178.015 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -138.0 138.59 39.03 Favored 'General case' 0 C--O 1.248 0.98 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.76 -158.76 8.87 Favored Glycine 0 N--CA 1.435 -1.386 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.045 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -63.63 -50.97 67.25 Favored 'General case' 0 CA--C 1.511 -0.554 0 O-C-N 124.537 0.787 . . . . 0.0 109.167 177.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -88.65 154.95 25.32 Favored Glycine 0 N--CA 1.44 -1.1 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 175.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -86.23 124.35 2.43 Favored 'Trans proline' 0 N--CA 1.414 -3.149 0 CA-C-N 120.342 2.071 . . . . 0.0 110.072 -176.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 13.8 m -131.66 146.78 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.966 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 -179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.49 123.29 3.77 Favored 'General case' 0 C--N 1.251 -3.707 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.491 ' HA3' HG12 ' A' ' 35' ' ' ILE . . . -153.11 157.95 27.64 Favored Glycine 0 N--CA 1.396 -3.978 0 C-N-CA 119.945 -1.122 . . . . 0.0 111.068 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 25.2 pt -123.97 102.43 11.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.593 HG13 ' HA3' ' A' ' 33' ' ' GLY . 1.8 mp -107.53 128.48 62.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.652 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 30.4 p-10 -115.91 125.74 52.98 Favored 'General case' 0 C--N 1.35 0.597 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.656 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 69.0 t80 -126.03 130.1 50.48 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -171.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 14.3 pt-20 -136.5 102.59 4.99 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-O 121.317 0.58 . . . . 0.0 110.888 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.457 ' HB3' ' CZ ' ' A' ' 20' ' ' PHE . 9.4 tt0 -151.21 114.42 4.79 Favored 'General case' 0 N--CA 1.414 -2.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.67 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -174.83 -74.17 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.853 175.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -90.31 -8.78 50.0 Favored 'General case' 0 N--CA 1.431 -1.376 0 CA-C-N 114.746 -1.115 . . . . 0.0 109.652 -177.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -52.83 -50.38 63.83 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 172.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 49.58 64.1 1.9 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.066 177.027 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.23 -164.47 36.66 Favored Glycine 0 N--CA 1.419 -2.499 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 -174.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.39 124.83 17.04 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 C-N-CA 122.18 1.92 . . . . 0.0 111.054 -178.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.437 ' CG2' ' HB2' ' A' ' 22' ' ' GLN . 3.0 p -74.27 130.34 36.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.789 -177.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.46 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 63.4 mttp -92.54 99.28 12.03 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.792 175.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.573 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 3.2 p -138.17 141.77 37.26 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.668 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -178.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 58.0 t90 -153.29 139.24 18.14 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.593 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -156.72 140.33 7.11 Favored Glycine 0 N--CA 1.413 -2.896 0 C-N-CA 118.757 -1.687 . . . . 0.0 113.099 176.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.5 p -114.23 134.27 55.04 Favored 'General case' 0 N--CA 1.409 -2.52 0 C-N-CA 124.379 1.071 . . . . 0.0 108.231 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.62 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 78.4 mt -127.6 140.23 49.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-O 121.132 0.492 . . . . 0.0 110.0 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 94.6 mttt -110.69 107.08 16.52 Favored 'General case' 0 N--CA 1.4 -2.968 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 174.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.03 175.35 22.72 Favored Glycine 0 C--N 1.292 -1.899 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -170.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . 0.596 ' HA ' ' OD1' ' A' ' 92' ' ' ASP . 2.3 pp -69.0 169.69 11.26 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 117.963 0.882 . . . . 0.0 111.42 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.556 ' HB ' ' HB2' ' A' ' 92' ' ' ASP . 2.2 t -70.2 106.24 3.23 Favored 'General case' 0 C--O 1.244 0.788 0 C-N-CA 119.475 -0.89 . . . . 0.0 111.8 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.43 ' O ' ' HB2' ' A' ' 121' ' ' GLU . 7.4 tp10 -175.06 111.88 0.13 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 125.437 1.495 . . . . 0.0 107.434 170.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.76 75.47 0.42 Allowed Glycine 0 C--N 1.264 -3.427 0 C-N-CA 118.005 -2.045 . . . . 0.0 113.72 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.85 136.66 43.94 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.402 ' HD2' HD21 ' A' ' 86' ' ' ASN . 39.7 m80 -55.59 121.98 10.31 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 124.64 1.176 . . . . 0.0 110.561 -172.68 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.69 122.7 0.86 Allowed Glycine 1 N--CA 1.381 -4.994 0 C-N-CA 119.718 -1.23 . . . . 0.0 113.3 177.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -68.81 142.69 54.81 Favored 'General case' 0 C--N 1.261 -3.262 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 162.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.637 ' CB ' ' HA ' ' A' ' 119' ' ' VAL . 21.2 m-70 -126.94 91.29 3.31 Favored 'General case' 0 N--CA 1.421 -1.882 0 CA-C-N 121.222 1.828 . . . . 0.0 106.715 -173.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.49 HG12 HD23 ' A' ' 117' ' ' LEU . 7.3 m -125.16 162.75 27.07 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -171.576 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.3 m-70 -170.81 119.46 0.53 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.407 3.083 . . . . 0.0 106.87 170.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.558 ' HB2' ' HA2' ' A' ' 108' ' ' GLY . 0.2 OUTLIER -102.59 84.11 2.38 Favored 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 117.87 -1.532 . . . . 0.0 112.957 -176.361 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.541 ' CZ ' ' HA ' ' A' ' 60' ' ' ALA . 0.6 OUTLIER 167.34 113.49 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.845 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA3' ' H ' ' A' ' 116' ' ' THR . . . -147.57 -154.35 6.21 Favored Glycine 0 CA--C 1.485 -1.802 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.846 178.182 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -173.96 -68.17 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.498 0 O-C-N 124.287 0.639 . . . . 0.0 110.24 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.523 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.4 t-20 -97.64 130.85 44.62 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.674 -174.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.1 t -84.06 -6.28 59.38 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -177.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.73 -25.46 13.84 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 120.95 0.405 . . . . 0.0 110.337 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.523 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -147.44 118.83 1.05 Allowed Glycine 0 N--CA 1.429 -1.807 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 -178.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.593 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 19.9 p -98.2 87.66 3.98 Favored 'General case' 0 C--N 1.276 -2.627 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.163 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.0 m -79.84 -39.72 30.03 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.296 177.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -53.55 -47.09 70.33 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.59 1.156 . . . . 0.0 111.794 -176.072 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.541 ' HA ' ' CZ ' ' A' ' 50' ' ' PHE . . . -76.87 -9.05 58.42 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -176.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -39.79 -64.31 1.08 Allowed Glycine 0 N--CA 1.479 1.555 0 C-N-CA 124.576 1.084 . . . . 0.0 115.363 -177.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.77 1.32 5.22 Favored 'Trans proline' 0 CA--C 1.544 0.983 0 C-N-CA 122.838 2.359 . . . . 0.0 113.399 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.296 9.1 p80 50.39 37.04 14.46 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -87.81 89.89 8.17 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 122.186 0.993 . . . . 0.0 109.644 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.467 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.4 OUTLIER -113.73 97.42 44.23 Favored Pre-proline 0 C--N 1.284 -2.278 0 CA-C-N 113.723 -1.58 . . . . 0.0 110.496 -177.954 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.411 ' O ' ' HB2' ' A' ' 69' ' ' ARG . 50.0 Cg_endo -84.73 -12.98 7.15 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.13 2.553 . . . . 0.0 115.995 -173.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.622 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 56.5 tp -85.43 -19.8 30.76 Favored 'General case' 1 CA--C 1.421 -4.012 0 CA-C-O 121.589 0.709 . . . . 0.0 109.19 -179.551 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.484 ' C ' ' H ' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -76.99 28.26 0.14 Allowed 'General case' 0 N--CA 1.384 -3.753 0 C-N-CA 127.741 2.416 . . . . 0.0 108.911 178.086 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.565 ' H ' ' C ' ' A' ' 67' ' ' LEU . 63.6 ttt180 -73.42 43.32 0.13 Allowed 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 128.558 2.743 . . . . 0.0 110.39 -173.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.575 ' CB ' ' HB2' ' A' ' 79' ' ' ARG . 22.6 ttmm -139.32 -18.4 0.99 Allowed 'General case' 0 C--N 1.245 -3.957 0 CA-C-N 113.894 -1.503 . . . . 0.0 108.511 166.687 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 70.33 19.31 6.52 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.105 1.762 . . . . 0.0 111.325 177.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.18 137.5 8.78 Favored Glycine 0 N--CA 1.426 -1.999 0 C-N-CA 120.433 -0.889 . . . . 0.0 114.595 176.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.36 162.46 28.64 Favored Glycine 0 N--CA 1.425 -2.07 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 175.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -73.24 -38.49 2.67 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 122.898 2.398 . . . . 0.0 112.751 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.743 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.9 OUTLIER -104.55 -25.45 12.75 Favored 'General case' 0 C--O 1.202 -1.422 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.253 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 49.91 -164.61 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 129.188 2.995 . . . . 0.0 115.045 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -144.58 -56.03 0.35 Allowed 'General case' 0 N--CA 1.427 -1.609 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.47 -169.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 105' ' ' SER . 47.6 mt-10 -172.57 -30.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 125.734 1.614 . . . . 0.0 107.67 -176.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.622 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 13.9 mmt180 -87.44 41.62 0.99 Allowed 'General case' 1 N--CA 1.364 -4.736 0 C-N-CA 125.095 1.358 . . . . 0.0 109.768 -171.422 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 9.5 t-160 . . . . . 0 C--N 1.313 -1.003 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.545 -172.658 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.519 HD11 HG21 ' A' ' 18' ' ' ILE . 10.0 tp . . . . . 0 N--CA 1.408 -2.535 0 N-CA-C 104.762 -2.31 . . . . 0.0 104.762 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.63 175.49 25.56 Favored Glycine 0 N--CA 1.404 -3.464 0 N-CA-C 109.079 -1.609 . . . . 0.0 109.079 -177.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.566 ' O ' ' HA ' ' A' ' 97' ' ' VAL . 14.3 t30 -77.32 138.66 39.49 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.779 HG22 ' HB1' ' A' ' 95' ' ' ALA . 13.9 p -150.74 127.12 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 178.177 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.673 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 24.7 p -141.1 122.34 14.81 Favored 'General case' 0 N--CA 1.418 -2.059 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.397 -167.356 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -109.05 103.7 12.76 Favored 'General case' 0 N--CA 1.41 -2.45 0 C-N-CA 117.031 -1.868 . . . . 0.0 106.538 173.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -93.99 -39.42 10.65 Favored 'General case' 0 CA--C 1.468 -2.199 0 CA-C-O 122.161 0.981 . . . . 0.0 109.955 -170.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.521 ' HA ' ' HE3' ' A' ' 91' ' ' LYS . 1.0 OUTLIER -85.59 5.85 29.87 Favored 'General case' 0 C--N 1.27 -2.875 0 CA-C-N 114.102 -1.408 . . . . 0.0 111.572 -177.652 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.596 ' OD1' ' HA ' ' A' ' 38' ' ' LEU . 13.4 t70 74.66 93.72 0.07 Allowed 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 123.438 0.695 . . . . 0.0 111.541 -175.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 106.17 13.22 23.67 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 116.269 1.267 . . . . 0.0 116.269 171.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 49.0 t -145.31 102.91 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.457 -2.626 0 N-CA-C 103.42 -2.807 . . . . 0.0 103.42 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.779 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -99.59 118.48 36.23 Favored 'General case' 0 N--CA 1.389 -3.477 0 C-N-CA 118.867 -1.133 . . . . 0.0 111.306 -177.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . 0.47 ' O ' ' HA ' ' A' ' 87' ' ' VAL . 21.7 t70 -80.41 111.52 16.89 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.01 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.566 ' HA ' ' O ' ' A' ' 86' ' ' ASN . 13.3 p -87.7 122.92 39.98 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.455 0 CA-C-O 121.97 0.89 . . . . 0.0 109.881 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 67.9 m -122.25 105.87 10.61 Favored 'General case' 0 C--N 1.273 -2.723 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.162 176.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.566 HG21 HG13 ' A' ' 31' ' ' VAL . 2.2 pp -93.74 154.76 3.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 178.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -125.64 160.85 28.62 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.736 1.214 . . . . 0.0 109.109 -176.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -82.76 99.69 9.81 Favored 'General case' 0 C--N 1.283 -2.297 0 C-N-CA 119.781 -0.767 . . . . 0.0 109.386 -171.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.743 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 21.5 m -95.66 162.1 13.76 Favored 'General case' 0 N--CA 1.417 -2.078 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 173.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.4 HG23 ' H ' ' A' ' 104' ' ' ILE . 9.9 m -103.15 -64.51 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.4 ' H ' HG23 ' A' ' 103' ' ' VAL . 26.8 mt -133.5 25.54 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 -174.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 21.4 t -78.57 87.43 4.53 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 122.069 0.938 . . . . 0.0 110.28 -175.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.8 tp -70.74 120.84 16.93 Favored 'General case' 0 N--CA 1.408 -2.574 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -74.79 87.23 2.23 Favored 'General case' 0 N--CA 1.409 -2.475 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 176.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.558 ' HA2' ' HB2' ' A' ' 49' ' ' GLU . . . 155.39 136.08 2.13 Favored Glycine 0 N--CA 1.411 -2.974 0 C-N-CA 119.537 -1.316 . . . . 0.0 114.379 177.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -89.54 -52.06 5.21 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -74.49 -47.74 31.35 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.035 176.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 37.7 t 179.37 -170.59 0.13 Allowed 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.572 HG22 ' HA2' ' A' ' 150' ' ' GLY . 9.5 mt -89.62 -23.95 6.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 177.564 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 tt -68.97 132.46 33.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.922 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.71 -9.16 72.55 Favored Glycine 0 N--CA 1.419 -2.448 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.163 174.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.407 ' HD3' ' HA ' ' A' ' 50' ' ' PHE . 4.2 mmp_? -81.23 123.95 28.89 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -175.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.547 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 27.6 p -89.3 101.4 14.06 Favored 'General case' 0 N--CA 1.389 -3.481 0 C-N-CA 120.256 -0.578 . . . . 0.0 109.727 177.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.49 HD23 HG12 ' A' ' 47' ' ' VAL . 8.0 mp -85.23 120.38 26.66 Favored 'General case' 0 CA--C 1.473 -1.986 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 174.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.433 HG11 ' C ' ' A' ' 141' ' ' GLY . 2.4 t -92.54 115.64 31.89 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.251 0 C-N-CA 116.824 -1.951 . . . . 0.0 111.469 -172.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.664 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 42.1 t -125.0 129.38 73.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 127.729 2.412 . . . . 0.0 110.587 -166.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.509 ' CB ' ' HB3' ' A' ' 144' ' ' LEU . 12.7 t60 -159.68 148.07 17.46 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 103.774 -2.676 . . . . 0.0 103.774 169.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.445 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 4.3 pm0 -68.79 88.27 0.37 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 123.112 1.434 . . . . 0.0 109.822 178.229 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -169.51 151.15 4.33 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 -171.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.38 118.68 8.41 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 118.146 0.43 . . . . 0.0 110.121 177.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.583 ' HA ' ' H ' ' A' ' 140' ' ' ALA . 44.0 t0 -96.7 -80.86 0.43 Allowed 'General case' 0 C--O 1.187 -2.216 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.4 t70 76.19 152.02 0.13 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 128.344 2.658 . . . . 0.0 112.271 175.28 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.07 -64.03 1.11 Allowed 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.667 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 -17.42 72.21 Favored Glycine 0 CA--C 1.481 -2.084 0 CA-C-N 114.137 -1.392 . . . . 0.0 113.03 -170.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.0 tttp -65.86 -41.1 92.1 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . 0.686 ' HA2' ' O ' ' A' ' 134' ' ' SER . . . -75.8 69.9 2.06 Favored Glycine 0 N--CA 1.409 -3.122 0 N-CA-C 115.182 0.833 . . . . 0.0 115.182 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -141.68 23.86 2.48 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 119.457 -1.354 . . . . 0.0 114.709 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.478 ' HB3' ' CB ' ' A' ' 134' ' ' SER . 64.6 t30 -132.14 176.37 8.44 Favored 'General case' 0 N--CA 1.522 3.15 0 CA-C-O 116.132 -1.89 . . . . 0.0 107.594 178.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.29 -57.03 11.98 Favored 'General case' 0 C--N 1.385 2.121 0 CA-C-N 121.934 2.152 . . . . 0.0 113.458 -174.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 -86.0 -34.18 20.87 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 121.077 0.465 . . . . 0.0 110.922 176.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.686 ' O ' ' HA2' ' A' ' 129' ' ' GLY . 1.3 m -66.98 -21.8 65.95 Favored 'General case' 0 C--O 1.185 -2.335 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.69 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.607 ' HA ' ' CA ' ' A' ' 129' ' ' GLY . 5.2 t -80.0 -12.55 59.7 Favored 'General case' 0 CA--C 1.51 -0.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.939 179.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -88.25 -46.77 8.95 Favored 'General case' 0 C--N 1.275 -2.669 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.239 -175.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.7 p -85.72 -32.72 21.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 113.892 -1.503 . . . . 0.0 112.314 -178.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -77.48 -4.04 83.83 Favored Glycine 0 C--O 1.202 -1.893 0 CA-C-O 119.171 -0.794 . . . . 0.0 114.879 -173.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 45.3 t-20 -142.7 104.46 4.36 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 164.97 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.583 ' H ' ' HA ' ' A' ' 124' ' ' ASP . . . -69.83 160.35 31.93 Favored 'General case' 1 C--O 1.33 5.307 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.252 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.433 ' C ' HG11 ' A' ' 118' ' ' VAL . . . -163.77 -151.91 6.67 Favored Glycine 1 N--CA 1.382 -4.94 0 C-N-CA 118.124 -1.988 . . . . 0.0 115.262 -165.953 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.593 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 2.9 m -46.9 7.28 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 1 C-N-CA 132.552 4.341 . . . . 0.0 120.14 -166.146 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 72.3 mtt180 -125.69 -27.58 3.36 Favored 'General case' 0 C--N 1.264 -3.138 0 C-N-CA 118.794 -1.162 . . . . 0.0 111.289 178.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.509 ' HB3' ' CB ' ' A' ' 120' ' ' HIS . 4.0 mm? -60.46 -43.69 96.65 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.084 -174.346 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.664 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.51 112.39 0.34 Allowed 'General case' 0 CA--C 1.49 -1.338 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.428 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 88.8 m -95.19 140.44 30.1 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.522 -177.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.551 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.08 150.67 13.35 Favored Glycine 1 N--CA 1.389 -4.474 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.607 176.319 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.4 t -75.67 119.59 23.84 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 171.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.447 HD12 ' HB1' ' A' ' 6' ' ' ALA . 23.2 mm -118.59 102.17 12.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.368 0 N-CA-C 105.264 -2.125 . . . . 0.0 105.264 179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.572 ' HA2' HG22 ' A' ' 112' ' ' ILE . . . 177.8 -172.5 45.15 Favored Glycine 0 CA--C 1.452 -3.902 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.256 -177.191 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.58 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.6 tt -70.67 103.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 122.108 0.956 . . . . 0.0 110.724 -178.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.53 115.36 5.27 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.778 -1.555 . . . . 0.0 111.26 -179.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 . . . . . 0 C--N 1.296 -1.75 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.797 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.575 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.218 -0.6 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.489 ' HA ' ' HG2' ' A' ' 21' ' ' GLU . 60.0 m -121.35 -43.45 2.41 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 110.648 177.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.14 144.63 33.56 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.567 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.06 149.57 51.15 Favored 'General case' 0 N--CA 1.41 -2.452 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.4 178.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 63.3 t -120.14 127.26 75.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -177.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.596 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -107.76 129.0 55.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.996 176.546 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.7 m -134.61 102.56 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 74.5 mt -96.01 134.45 39.01 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.304 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.7 tttp -147.33 122.2 9.99 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.02 -157.86 8.6 Favored Glycine 0 N--CA 1.435 -1.402 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -89.62 94.0 9.69 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 169.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 128.21 143.74 5.71 Favored Glycine 0 C--N 1.275 -2.829 0 N-CA-C 107.309 -2.316 . . . . 0.0 107.309 -177.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -97.81 123.11 0.18 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 CA-C-N 120.367 2.083 . . . . 0.0 113.524 -178.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 p -134.7 112.18 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.333 0 CA-C-N 114.534 -1.212 . . . . 0.0 107.957 171.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -118.14 119.53 35.0 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 118.874 -1.13 . . . . 0.0 111.092 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -159.36 149.43 19.28 Favored Glycine 0 N--CA 1.406 -3.356 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.536 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 27.5 pt -113.82 107.21 22.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.596 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 28.1 mm -100.44 128.45 52.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.635 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 24.5 t-20 -101.0 144.21 30.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -178.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.567 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 87.0 m-85 -132.57 120.18 21.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.794 0.33 . . . . 0.0 111.531 175.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.489 ' HG2' ' HA ' ' A' ' 2' ' ' THR . 1.8 tm-20 -132.34 101.78 5.49 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 174.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.691 ' HG2' ' O ' ' A' ' 105' ' ' SER . 18.1 mp0 -127.51 132.21 49.98 Favored 'General case' 0 N--CA 1.387 -3.606 0 N-CA-C 103.601 -2.74 . . . . 0.0 103.601 167.109 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.442 ' HD3' ' H ' ' A' ' 24' ' ' GLU . 6.3 tmtt? -131.54 168.64 17.32 Favored 'General case' 0 C--N 1.257 -3.437 0 N-CA-C 107.14 -1.429 . . . . 0.0 107.14 -173.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.442 ' H ' ' HD3' ' A' ' 23' ' ' LYS . 10.3 pt-20 -62.48 -9.5 8.75 Favored 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 124.038 0.935 . . . . 0.0 111.777 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -56.86 -39.5 74.41 Favored 'General case' 0 N--CA 1.424 -1.726 0 C-N-CA 124.999 1.319 . . . . 0.0 110.528 176.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . 0.467 ' OD1' HG22 ' A' ' 103' ' ' VAL . 56.4 t30 66.76 104.08 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 123.635 0.774 . . . . 0.0 110.478 178.297 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.72 -177.0 48.13 Favored Glycine 0 CA--C 1.474 -2.477 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -175.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -57.26 123.19 13.22 Favored 'Trans proline' 0 C--O 1.24 0.61 0 C-N-CA 122.262 1.975 . . . . 0.0 111.642 -178.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 92.5 t -76.42 111.46 13.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.436 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . 0.3 0.0 OUTLIER -112.59 107.29 15.95 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.812 1.291 . . . . 0.0 112.123 177.882 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.635 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 30.8 m -137.22 154.4 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.577 0 CA-C-N 113.054 -1.885 . . . . 0.0 106.323 -172.269 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 61.6 p-90 -139.19 148.1 42.7 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' VAL . . . -169.57 137.75 4.68 Favored Glycine 0 N--CA 1.404 -3.444 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 171.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.3 t -117.2 131.72 56.8 Favored 'General case' 0 N--CA 1.407 -2.587 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 -177.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.721 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 15.5 pt -114.91 153.18 16.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 C-N-CA 118.694 -1.203 . . . . 0.0 111.075 176.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.416 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 48.4 mtmt -120.34 107.61 13.15 Favored 'General case' 0 N--CA 1.408 -2.552 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 177.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.08 174.17 17.29 Favored Glycine 0 C--N 1.295 -1.734 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 45.5 tp -69.02 171.81 7.62 Favored 'General case' 0 CA--C 1.571 1.77 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 176.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 1.6 t -69.27 110.31 4.55 Favored 'General case' 0 CA--C 1.5 -0.954 0 O-C-N 121.243 -0.911 . . . . 0.0 112.978 -178.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 39' ' ' THR . 10.3 mm-40 -170.47 171.58 6.42 Favored 'General case' 0 C--N 1.275 -2.652 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 173.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.27 -155.77 31.53 Favored Glycine 0 C--N 1.26 -3.65 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 169.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.691 HD22 ' HB ' ' A' ' 87' ' ' VAL . 5.2 tt -178.44 149.43 0.5 Allowed 'General case' 0 N--CA 1.412 -2.337 0 N-CA-C 103.563 -2.754 . . . . 0.0 103.563 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.603 ' N ' HD23 ' A' ' 42' ' ' LEU . 78.2 t60 -161.34 121.6 2.68 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 173.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HB3' ' A' ' 124' ' ' ASP . . . 77.09 136.84 0.81 Allowed Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.726 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HB2' ' CG1' ' A' ' 119' ' ' VAL . 0.1 OUTLIER -142.23 131.46 23.43 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 117.855 0.827 . . . . 0.0 112.204 -177.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.508 ' HB2' HD23 ' A' ' 126' ' ' LEU . 21.7 t-80 -82.08 89.3 6.44 Favored 'General case' 0 CA--C 1.476 -1.877 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.695 -177.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.625 ' CB ' HD23 ' A' ' 117' ' ' LEU . 6.7 m -110.47 80.89 0.55 Allowed 'Isoleucine or valine' 1 N--CA 1.379 -4.008 0 CA-C-O 122.897 1.332 . . . . 0.0 110.346 175.689 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.502 ' HA ' HH11 ' A' ' 115' ' ' ARG . 2.4 p-80 -174.72 145.24 0.88 Allowed 'General case' 0 CA--C 1.487 -1.447 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' CE1' ' A' ' 46' ' ' HIS 0.351 10.9 mm-40 -172.92 173.97 3.64 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 126.628 1.971 . . . . 0.0 111.554 163.423 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -110.28 75.04 0.91 Allowed 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 102.886 -3.005 . . . . 0.0 102.886 171.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' HA ' ' A' ' 115' ' ' ARG . . . -104.91 -149.97 19.72 Favored Glycine 0 CA--C 1.482 -1.984 0 CA-C-N 113.142 -1.845 . . . . 0.0 113.617 -169.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 37.9 t70 175.0 -41.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 18.1 m120 -101.13 124.93 47.61 Favored 'General case' 0 CA--C 1.498 -1.037 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.92 -173.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.3 t -84.25 -25.63 29.25 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.165 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.41 -8.6 38.21 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.218 0.533 . . . . 0.0 110.261 -178.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -144.25 110.02 0.56 Allowed Glycine 0 N--CA 1.409 -3.116 0 C-N-CA 119.486 -1.34 . . . . 0.0 109.901 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.775 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.7 p -96.44 86.7 4.23 Favored 'General case' 0 N--CA 1.391 -3.401 0 CA-C-O 122.32 1.057 . . . . 0.0 110.733 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 30.5 m -82.03 -47.38 12.7 Favored 'General case' 0 N--CA 1.417 -2.116 0 CA-C-N 114.043 -1.435 . . . . 0.0 109.484 174.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 p -72.03 -16.8 62.05 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.194 -176.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -82.48 -6.69 59.46 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.22 177.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . 0.665 ' HA2' ' HB3' ' A' ' 142' ' ' SER . . . -50.58 176.33 0.05 OUTLIER Glycine 0 C--N 1.355 1.592 0 CA-C-N 114.83 -1.077 . . . . 0.0 112.311 175.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.48 ' HA ' ' CE2' ' A' ' 64' ' ' PHE . 21.3 Cg_exo -68.88 55.24 0.92 Allowed 'Trans proline' 0 N--CA 1.488 1.174 0 C-N-CA 123.466 2.777 . . . . 0.0 112.137 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -159.12 87.74 0.86 Allowed 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 105.567 -2.012 . . . . 0.0 105.567 -177.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.641 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 27.2 m-85 -111.78 162.99 14.66 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 -173.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -93.5 99.15 3.05 Favored Pre-proline 0 C--O 1.248 0.975 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.325 174.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.641 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 71.0 Cg_exo -52.36 -12.04 1.42 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 125.197 3.932 . . . . 0.0 114.913 -178.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.5 mt -94.92 7.39 46.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-O 122.761 1.267 . . . . 0.0 107.996 -171.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.9 t -120.76 23.57 10.67 Favored 'General case' 0 N--CA 1.395 -3.186 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 175.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.521 ' NH2' ' HB3' ' A' ' 66' ' ' PRO . 38.6 ttp180 -132.15 -32.64 1.37 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 113.199 -1.819 . . . . 0.0 107.629 171.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 78' ' ' GLU 0.256 5.3 mmtp 39.32 71.12 0.18 Allowed 'General case' 0 N--CA 1.427 -1.583 0 C-N-CA 125.616 1.566 . . . . 0.0 112.814 178.332 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 69.6 -29.35 0.18 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 125.747 1.619 . . . . 0.0 114.29 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 96.5 159.59 31.97 Favored Glycine 0 N--CA 1.418 -2.541 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -173.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.81 163.22 36.97 Favored Glycine 0 C--N 1.291 -1.954 0 C-N-CA 119.227 -1.463 . . . . 0.0 111.379 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.94 -43.16 1.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 118.885 1.343 . . . . 0.0 112.044 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -120.73 -28.36 4.89 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.609 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.639 ' HA ' ' CG ' ' A' ' 80' ' ' HIS . 5.9 p-10 170.91 165.75 0.08 Allowed 'General case' 0 CA--C 1.481 -1.675 0 C-N-CA 124.287 1.035 . . . . 0.0 108.692 177.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -137.64 -73.31 0.42 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.411 ' HB3' ' HG3' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -135.93 -65.64 0.58 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 177.716 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -119.85 68.78 0.83 Allowed 'General case' 0 N--CA 1.415 -2.203 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 171.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.639 ' CG ' ' HA ' ' A' ' 76' ' ' ASP . 29.8 t-80 . . . . . 0 C--N 1.302 -1.46 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 177.635 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.442 ' O ' ' HE1' ' A' ' 45' ' ' PHE . 1.5 pt? . . . . . 0 CA--C 1.501 -0.911 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 171.4 147.54 5.71 Favored Glycine 1 N--CA 1.393 -4.189 0 C-N-CA 118.842 -1.646 . . . . 0.0 112.444 177.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -105.71 128.01 53.42 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 102.43 -3.174 . . . . 0.0 102.43 162.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.691 ' HB ' HD22 ' A' ' 42' ' ' LEU . 5.8 t -128.77 153.18 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 N-CA-C 102.557 -3.127 . . . . 0.0 102.557 -177.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 94' ' ' VAL . 15.4 t -139.53 149.85 44.39 Favored 'General case' 0 N--CA 1.4 -2.966 0 C-N-CA 118.594 -1.242 . . . . 0.0 110.694 -175.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.504 ' CB ' ' HB2' ' A' ' 121' ' ' GLU . . . -120.44 155.4 33.58 Favored 'General case' 2 C--N 1.224 -4.887 0 CA-C-N 114.381 -1.281 . . . . 0.0 108.725 -177.375 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -149.42 160.14 43.7 Favored 'General case' 1 C--N 1.236 -4.359 0 N-CA-C 104.311 -2.478 . . . . 0.0 104.311 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.595 ' HB3' ' HB ' ' A' ' 39' ' ' THR . 0.0 OUTLIER -44.08 -31.72 1.01 Allowed 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 119.51 1.05 . . . . 0.0 112.976 172.77 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -91.53 -25.27 19.32 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.864 0.84 . . . . 0.0 109.116 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 36' ' ' LYS . . . 83.12 85.81 0.82 Allowed Glycine 0 N--CA 1.397 -3.908 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.317 -175.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 88' ' ' THR . 10.8 m -136.95 102.37 2.63 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 122.312 1.053 . . . . 0.0 109.753 175.659 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.721 ' HB3' ' H ' ' A' ' 35' ' ' ILE . . . -96.25 145.33 25.65 Favored 'General case' 0 N--CA 1.408 -2.561 0 CA-C-N 113.966 -1.47 . . . . 0.0 112.197 172.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.03 152.83 38.65 Favored 'General case' 0 N--CA 1.412 -2.325 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 166.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 28.7 m -80.9 134.58 26.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 CA-C-O 121.864 0.84 . . . . 0.0 108.899 178.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.404 ' OG ' HG22 ' A' ' 87' ' ' VAL . 19.6 m -75.86 106.05 7.24 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.384 -176.392 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 pt -121.72 122.02 65.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 174.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -146.23 151.44 37.59 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -93.07 99.28 11.91 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 117.712 -1.595 . . . . 0.0 110.831 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.46 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 53.1 m -102.86 142.82 33.34 Favored 'General case' 0 N--CA 1.396 -3.148 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 172.233 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.467 HG22 ' OD1' ' A' ' 26' ' ' ASN . 14.7 p -101.77 -46.85 11.33 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 C-N-CA 117.383 -1.727 . . . . 0.0 112.156 -178.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.9 tt -121.58 24.01 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.278 0 CA-C-O 122.308 1.051 . . . . 0.0 111.729 -171.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.691 ' O ' ' HG2' ' A' ' 22' ' ' GLN . 56.6 m -103.64 87.6 2.87 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.169 -1.582 . . . . 0.0 114.008 -177.416 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.476 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 6.1 mp -69.82 129.54 39.85 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 169.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.1 t -73.63 87.68 1.67 Allowed 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.857 0.836 . . . . 0.0 112.491 -170.188 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.55 135.47 2.83 Favored Glycine 0 N--CA 1.406 -3.302 0 CA-C-N 114.189 -1.368 . . . . 0.0 112.426 168.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -46.97 -70.53 0.09 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.912 0.885 . . . . 0.0 111.88 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 63.8 m80 -123.02 -34.82 3.11 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.653 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 17.5 m -96.42 106.76 19.05 Favored 'General case' 0 N--CA 1.414 -2.257 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.783 -178.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 18.1 mm -87.67 -48.11 15.38 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 168.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.3 tt -102.69 151.11 6.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.258 174.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.24 -31.01 8.99 Favored Glycine 0 CA--C 1.478 -2.268 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 172.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.674 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 28.7 ptt180 -69.46 156.43 38.87 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 124.455 1.102 . . . . 0.0 112.549 -175.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -116.06 113.94 23.86 Favored 'General case' 0 N--CA 1.388 -3.533 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 -178.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.764 HD22 ' HB ' ' A' ' 149' ' ' ILE . 4.6 mp -95.98 160.49 14.43 Favored 'General case' 0 C--N 1.268 -2.953 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -174.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 145' ' ' ALA 0.327 8.4 p -140.5 116.14 7.37 Favored 'Isoleucine or valine' 0 C--O 1.263 1.793 0 C-N-CA 116.324 -2.15 . . . . 0.0 114.019 -179.156 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 45' ' ' PHE . 19.7 m -138.49 170.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -176.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.513 ' ND1' ' HB3' ' A' ' 144' ' ' LEU . 62.7 t60 -170.44 167.95 8.03 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 105.129 -2.175 . . . . 0.0 105.129 176.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.504 ' HB2' ' CB ' ' A' ' 89' ' ' ALA . 8.9 pm0 -70.96 85.89 0.7 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 119.973 1.26 . . . . 0.0 110.467 177.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.536 ' C ' ' HA ' ' A' ' 42' ' ' LEU . 30.5 ttmt -175.7 154.99 1.65 Allowed 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.553 -176.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.562 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -60.27 107.31 0.63 Allowed 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 168.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.531 ' OD2' ' HA ' ' A' ' 140' ' ' ALA . 9.0 t70 -105.36 17.56 23.73 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.758 0.823 . . . . 0.0 108.93 -179.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -35.73 114.91 0.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.438 1.895 . . . . 0.0 111.306 -177.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.508 HD23 ' HB2' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -90.79 -36.39 14.28 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.137 -168.151 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.21 -27.19 56.22 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.588 -177.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -100.84 -26.01 13.91 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.955 0.378 . . . . 0.0 110.907 -178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.05 -71.6 0.95 Allowed Glycine 0 CA--C 1.529 0.937 0 N-CA-C 113.767 0.267 . . . . 0.0 113.767 -177.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 118.73 -6.47 13.83 Favored Glycine 0 C--N 1.313 -0.728 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -175.025 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 26.8 t30 -162.67 150.66 14.03 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -48.26 -51.13 27.05 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 124.122 0.889 . . . . 0.0 112.062 -176.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.38 -48.28 78.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.614 -178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 8.2 m -62.56 -24.56 67.6 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -176.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.7 m -69.63 -35.23 75.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 122.008 0.909 . . . . 0.0 109.407 176.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -83.41 -41.15 18.45 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.776 -174.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -74.01 -52.37 12.96 Favored 'General case' 0 C--N 1.273 -2.726 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.14 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 112.95 91.69 1.96 Allowed Glycine 1 N--CA 1.388 -4.504 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -176.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -34.57 117.43 0.36 Allowed 'General case' 1 C--O 1.333 5.488 0 C-N-CA 126.233 1.813 . . . . 0.0 113.265 -173.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.531 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -153.63 142.5 21.11 Favored 'General case' 0 N--CA 1.411 -2.417 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.357 175.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.81 86.03 1.55 Allowed Glycine 0 N--CA 1.425 -2.091 0 N-CA-C 104.525 -3.43 . . . . 0.0 104.525 164.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . 0.665 ' HB3' ' HA2' ' A' ' 61' ' ' GLY . 21.0 m -55.01 -3.89 0.06 Allowed 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 118.095 2.628 . . . . 0.0 118.095 -166.49 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.668 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 11.9 ptm180 -144.75 11.0 1.4 Allowed 'General case' 0 C--N 1.247 -3.885 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.038 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.513 ' HB3' ' ND1' ' A' ' 120' ' ' HIS . 4.6 mm? -78.6 -9.21 59.28 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.695 -175.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.15 109.69 0.39 Allowed 'General case' 0 CA--C 1.494 -1.186 0 C-N-CA 123.791 0.836 . . . . 0.0 108.915 173.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 38.3 m -96.43 137.06 36.08 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.02 125.38 1.2 Allowed Glycine 0 N--CA 1.424 -2.137 0 C-N-CA 118.498 -1.811 . . . . 0.0 113.434 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.674 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 75.6 t -73.51 101.48 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 171.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.764 ' HB ' HD22 ' A' ' 117' ' ' LEU . 53.7 mt -116.27 128.44 73.59 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.523 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.11 -168.49 40.35 Favored Glycine 3 CA--C 1.415 -6.186 0 N-CA-C 108.121 -1.992 . . . . 0.0 108.121 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.519 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.8 pp -67.81 121.16 16.46 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 120.096 -0.642 . . . . 0.0 111.165 179.104 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -131.75 114.75 15.13 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 174.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 . . . . . 0 C--N 1.289 -2.065 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.571 -179.31 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.55 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 26.2 m -112.84 -31.51 6.7 Favored 'General case' 0 CA--C 1.557 1.222 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -171.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . 0.454 ' HB2' HD21 ' A' ' 19' ' ' ASN . 62.1 pttt -146.79 158.37 43.89 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.861 -174.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.781 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -143.01 150.37 39.52 Favored 'General case' 0 N--CA 1.395 -3.178 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.486 ' CG2' ' HB3' ' A' ' 152' ' ' ALA . 29.0 m -129.63 138.93 52.95 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.572 ' HB2' HG13 ' A' ' 149' ' ' ILE . . . -116.6 136.02 53.32 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 114.757 -1.11 . . . . 0.0 111.799 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.7 m -133.07 105.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.161 0.505 . . . . 0.0 110.608 175.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.424 HD23 HD21 ' A' ' 117' ' ' LEU . 0.4 OUTLIER -114.75 151.14 34.24 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.651 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -157.43 150.45 23.44 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 175.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.15 -158.76 8.81 Favored Glycine 0 N--CA 1.414 -2.784 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 177.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -69.39 -39.19 78.12 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 124.935 1.021 . . . . 0.0 109.764 176.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.16 164.13 29.51 Favored Glycine 0 C--O 1.251 1.189 0 N-CA-C 108.704 -1.759 . . . . 0.0 108.704 174.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -83.14 123.4 3.51 Favored 'Trans proline' 0 N--CA 1.424 -2.613 0 CA-C-N 120.371 2.086 . . . . 0.0 109.739 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 12.1 m -132.21 123.52 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.667 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 178.103 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -130.32 119.58 23.03 Favored 'General case' 0 C--N 1.274 -2.685 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -166.87 166.62 39.22 Favored Glycine 0 N--CA 1.408 -3.194 0 C-N-CA 119.115 -1.517 . . . . 0.0 112.086 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.422 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 11.9 tt -151.53 126.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 179.096 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.486 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -122.87 136.6 59.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -178.185 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.454 HD21 ' HB2' ' A' ' 3' ' ' LYS . 25.1 t-20 -110.61 130.3 55.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.274 0.63 . . . . 0.0 109.395 -176.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.781 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 68.0 m-85 -130.16 133.59 46.71 Favored 'General case' 0 CA--C 1.498 -1.026 0 O-C-N 123.583 0.552 . . . . 0.0 110.824 178.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.484 ' O ' HG13 ' A' ' 104' ' ' ILE . 15.8 pt-20 -106.03 103.31 12.76 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 171.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.501 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -85.78 88.37 7.54 Favored 'General case' 1 N--CA 1.371 -4.415 0 CA-C-O 122.711 1.243 . . . . 0.0 112.164 -171.876 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . 0.435 ' HE3' ' CD ' ' A' ' 21' ' ' GLU . 96.1 mttt -76.11 106.52 7.76 Favored 'General case' 0 N--CA 1.409 -2.509 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 172.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HG3' ' HB2' ' A' ' 106' ' ' LEU . 28.7 tt0 -48.58 -39.42 23.67 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 113.693 -1.594 . . . . 0.0 113.86 -167.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.6 m -90.63 -61.96 1.56 Allowed 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 120.773 0.32 . . . . 0.0 110.461 177.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -173.56 171.47 3.87 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -177.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 162.42 163.0 14.21 Favored Glycine 0 CA--C 1.494 -1.266 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.218 175.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -62.02 124.53 14.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.326 2.017 . . . . 0.0 107.483 172.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.447 ' HB ' HG13 ' A' ' 31' ' ' VAL . 35.2 m -95.63 117.36 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -174.057 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HE2' ' HB3' ' A' ' 30' ' ' LYS . 19.2 ttpt -82.65 101.87 11.1 Favored 'General case' 0 N--CA 1.413 -2.288 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.447 HG13 ' HB ' ' A' ' 29' ' ' VAL . 35.7 m -137.13 137.73 46.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 67.0 p-90 -148.3 137.31 21.82 Favored 'General case' 0 C--N 1.269 -2.902 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -153.28 140.19 7.42 Favored Glycine 0 N--CA 1.4 -3.712 0 C-N-CA 119.779 -1.2 . . . . 0.0 111.063 176.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.7 m -115.28 141.82 47.52 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.722 ' HB ' ' HB3' ' A' ' 95' ' ' ALA . 41.1 mm -131.43 126.73 58.82 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 176.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 41.2 ttmt -108.92 131.52 54.95 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 103.884 -2.636 . . . . 0.0 103.884 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.88 175.47 39.24 Favored Glycine 0 C--N 1.273 -2.968 0 N-CA-C 110.596 -1.001 . . . . 0.0 110.596 -167.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.34 142.76 56.68 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.68 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -69.35 105.74 2.67 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -172.777 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.529 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 27.9 mt-10 -175.43 135.77 0.33 Allowed 'General case' 0 CA--C 1.478 -1.798 0 C-N-CA 129.404 3.082 . . . . 0.0 104.057 174.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.63 99.99 0.17 Allowed Glycine 0 C--N 1.265 -3.395 0 C-N-CA 116.844 -2.598 . . . . 0.0 113.341 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -103.07 -86.18 0.44 Allowed 'General case' 0 N--CA 1.446 -0.639 0 O-C-N 124.547 0.792 . . . . 0.0 111.184 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.485 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.8 p80 176.39 141.42 0.07 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.37 116.06 0.54 Allowed Glycine 0 N--CA 1.419 -2.436 0 C-N-CA 119.616 -1.278 . . . . 0.0 113.048 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -122.89 107.95 12.42 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.929 0.871 . . . . 0.0 112.876 178.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 54.4 t60 -171.11 89.73 0.13 Allowed 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.005 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.488 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -132.4 87.81 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 O-C-N 126.344 2.278 . . . . 0.0 109.284 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.477 ' CE1' ' HA3' ' A' ' 108' ' ' GLY . 8.6 t-160 -173.27 87.4 0.06 Allowed 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.239 -0.913 . . . . 0.0 110.749 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.597 ' H ' ' HB2' ' A' ' 115' ' ' ARG . 2.7 mp0 -136.51 172.25 13.29 Favored 'General case' 1 C--N 1.24 -4.173 0 CA-C-N 113.648 -1.615 . . . . 0.0 109.082 -170.956 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.413 ' HB3' ' OD1' ' A' ' 109' ' ' ASP . 26.3 p90 -69.81 171.31 9.44 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-O 121.096 0.474 . . . . 0.0 111.2 169.31 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.775 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . -59.86 120.7 23.91 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.118 -0.946 . . . . 0.0 114.282 177.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CG ' ' HA ' ' A' ' 57' ' ' CYS . 5.5 t0 -129.72 -167.27 1.78 Allowed 'General case' 0 C--O 1.247 0.932 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 176.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . 0.679 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 29.9 t30 -69.47 133.86 48.23 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-O 121.369 0.604 . . . . 0.0 110.519 -179.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . 0.561 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 1.3 p -51.41 -22.4 2.96 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 127.286 2.235 . . . . 0.0 114.44 -178.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.96 24.22 4.6 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.679 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 175.51 111.15 0.27 Allowed Glycine 0 C--O 1.196 -2.232 0 C-N-CA 117.778 -2.153 . . . . 0.0 112.566 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 13.3 p -90.56 96.03 10.45 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 121.973 0.892 . . . . 0.0 110.108 -177.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.3 m -76.57 -51.56 11.41 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.885 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.1 m -91.03 -36.5 14.02 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.372 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.492 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -77.58 -17.69 57.59 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.67 -177.449 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.85 -63.73 3.99 Favored Glycine 0 CA--C 1.539 1.546 0 N-CA-C 114.56 0.584 . . . . 0.0 114.56 -179.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -85.78 6.37 5.6 Favored 'Trans proline' 0 C--O 1.24 0.617 0 C-N-CA 122.744 2.296 . . . . 0.0 112.092 177.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -83.1 142.37 31.31 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 121.535 0.683 . . . . 0.0 111.409 -175.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -141.4 133.88 28.33 Favored 'General case' 0 N--CA 1.411 -2.384 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 172.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.411 ' CG ' ' H ' ' A' ' 109' ' ' ASP . 9.4 t30 -77.35 141.57 66.29 Favored Pre-proline 0 C--N 1.306 -1.317 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.508 175.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -53.5 -33.36 67.43 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 123.834 3.023 . . . . 0.0 115.726 -177.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.488 ' O ' ' HB2' ' A' ' 79' ' ' ARG . 3.0 mm? -78.15 -45.4 23.35 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.4 m -67.3 31.54 0.02 OUTLIER 'General case' 0 CA--C 1.498 -1.026 0 C-N-CA 129.477 3.111 . . . . 0.0 116.62 -172.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.611 ' N ' ' HB2' ' A' ' 79' ' ' ARG . 0.0 OUTLIER -136.27 -32.55 0.85 Allowed 'General case' 0 C--N 1.245 -3.958 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.584 172.633 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.492 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 82.2 tttt 34.67 -87.35 0.0 OUTLIER 'General case' 0 C--N 1.373 1.626 0 C-N-CA 124.526 1.13 . . . . 0.0 110.25 -170.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -178.93 12.2 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.764 0 C-N-CA 126.32 1.848 . . . . 0.0 106.994 176.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.49 134.38 3.35 Favored Glycine 0 N--CA 1.435 -1.403 0 C-N-CA 119.329 -1.415 . . . . 0.0 111.869 -175.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.59 83.95 0.09 OUTLIER Glycine 0 C--O 1.2 -2.019 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.429 ' HA ' HD11 ' A' ' 84' ' ' LEU . 59.9 Cg_endo -104.21 -0.5 0.27 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.706 2.271 . . . . 0.0 115.621 -176.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -123.41 -11.86 7.84 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 178.39 88.78 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -172.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.533 ' HG3' HG23 ' A' ' 103' ' ' VAL . 3.8 mm-40 -54.94 146.59 17.29 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 117.981 2.585 . . . . 0.0 117.981 -177.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -138.23 -16.22 1.24 Allowed 'General case' 0 N--CA 1.415 -2.198 0 CA-C-N 112.624 -2.08 . . . . 0.0 107.313 -177.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.611 ' HB2' ' N ' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -105.5 -37.31 6.84 Favored 'General case' 1 N--CA 1.358 -5.058 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 177.995 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.463 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 45.2 m80 . . . . . 0 CA--C 1.498 -1.034 0 CA-C-N 113.344 -1.753 . . . . 0.0 110.041 176.19 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' A' ' 74' ' ' PRO . 1.0 OUTLIER . . . . . 0 N--CA 1.407 -2.614 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 . . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.74 132.06 3.46 Favored Glycine 1 N--CA 1.379 -5.13 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 174.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -73.8 129.22 37.48 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 118.029 -1.468 . . . . 0.0 107.545 174.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 44.6 t -110.81 128.15 67.39 Favored 'Isoleucine or valine' 0 C--N 1.36 1.024 0 O-C-N 121.441 -0.787 . . . . 0.0 109.278 -174.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.0 t -141.45 96.47 2.99 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -80.11 107.21 12.72 Favored 'General case' 0 C--O 1.2 -1.523 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 175.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 92' ' ' ASP . 26.3 t70 -64.69 162.68 15.34 Favored 'General case' 0 C--N 1.28 -2.428 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.644 -174.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.68 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 58.5 pttt -42.13 14.78 0.0 OUTLIER 'General case' 0 CA--C 1.6 2.902 0 N-CA-C 117.652 2.464 . . . . 0.0 117.652 174.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 90' ' ' ASP . 21.3 t70 -125.51 -28.98 3.25 Favored 'General case' 0 C--N 1.296 -1.736 0 C-N-CA 126.249 1.82 . . . . 0.0 108.753 178.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 104.07 66.77 0.72 Allowed Glycine 0 C--O 1.22 -0.746 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.217 -179.147 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.7 p -160.83 117.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-N 117.387 0.594 . . . . 0.0 110.602 -175.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.722 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -122.31 124.34 43.52 Favored 'General case' 0 N--CA 1.434 -1.27 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -111.41 112.56 24.39 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.418 HG11 HG22 ' A' ' 87' ' ' VAL . 34.4 m -112.74 125.79 70.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -178.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -154.56 101.09 2.31 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 169.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.8 mm -129.58 149.3 33.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -109.68 118.82 37.57 Favored 'General case' 0 C--O 1.265 1.874 0 CA-C-O 122.604 1.192 . . . . 0.0 112.365 179.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -164.95 138.59 4.83 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 113.527 -1.669 . . . . 0.0 106.689 -176.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.405 ' O ' ' HB2' ' A' ' 77' ' ' GLU . 58.5 m -82.31 79.77 8.68 Favored 'General case' 0 N--CA 1.435 -1.191 0 C-N-CA 119.206 -0.998 . . . . 0.0 109.352 175.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . 0.533 HG23 ' HG3' ' A' ' 77' ' ' GLU . 7.5 p -108.15 -15.05 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-N 114.324 -1.307 . . . . 0.0 109.932 -177.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.501 ' CG1' ' HA ' ' A' ' 22' ' ' GLN . 0.1 OUTLIER -78.21 -3.06 5.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.369 -1.742 . . . . 0.0 111.654 -173.797 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.5 m -67.78 131.22 45.15 Favored 'General case' 0 N--CA 1.409 -2.519 0 CA-C-O 121.6 0.714 . . . . 0.0 110.866 -174.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.587 ' HG ' HG22 ' A' ' 112' ' ' ILE . 4.6 mp -68.08 87.74 0.27 Allowed 'General case' 0 N--CA 1.425 -1.687 0 CA-C-O 123.008 1.385 . . . . 0.0 107.514 168.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -166.0 87.5 0.37 Allowed 'General case' 1 N--CA 1.374 -4.253 0 N-CA-C 101.481 -3.525 . . . . 0.0 101.481 172.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.477 ' HA3' ' CE1' ' A' ' 48' ' ' HIS . . . 166.2 136.69 2.06 Favored Glycine 0 C--N 1.266 -3.314 0 CA-C-N 113.682 -1.599 . . . . 0.0 110.953 179.013 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.413 ' OD1' ' HB3' ' A' ' 50' ' ' PHE . 16.6 t70 50.15 -85.81 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 126.643 1.977 . . . . 0.0 112.18 -171.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -123.95 -47.32 1.93 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 173.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . 0.403 ' OG ' HG13 ' A' ' 113' ' ' ILE . 10.3 p -168.38 -162.11 0.39 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.587 HG22 ' HG ' ' A' ' 106' ' ' LEU . 12.4 tt -104.04 25.79 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.886 0 C-N-CA 119.231 -0.987 . . . . 0.0 108.992 178.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.604 ' HA ' ' NH1' ' A' ' 115' ' ' ARG . 2.6 pp -103.56 150.39 6.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 O-C-N 121.612 -0.68 . . . . 0.0 111.563 173.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.775 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 78.53 -13.33 17.33 Favored Glycine 0 CA--C 1.532 1.102 0 N-CA-C 115.043 0.777 . . . . 0.0 115.043 176.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.632 ' NH2' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -66.93 116.56 7.91 Favored 'General case' 0 C--O 1.253 1.248 0 CA-C-O 121.901 0.858 . . . . 0.0 112.305 -168.782 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 18.6 p -85.75 132.51 34.12 Favored 'General case' 0 N--CA 1.384 -3.754 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.25 171.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.787 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -69.53 137.03 52.14 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 114.985 -1.007 . . . . 0.0 111.477 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.551 HG22 ' HB1' ' A' ' 140' ' ' ALA . 12.1 p -124.03 96.48 3.93 Favored 'Isoleucine or valine' 1 C--O 1.35 6.352 0 C-N-CA 115.179 -2.608 . . . . 0.0 112.107 166.519 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.477 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 24.0 m -150.62 170.54 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.081 0 C-N-CA 128.67 2.788 . . . . 0.0 105.829 178.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.466 ' NE2' ' HD2' ' A' ' 122' ' ' LYS . 29.8 p-80 -169.46 172.93 6.78 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 171.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.529 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.2 mp0 -70.01 82.67 0.49 Allowed 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 119.832 1.196 . . . . 0.0 109.492 -177.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.466 ' HD2' ' NE2' ' A' ' 120' ' ' HIS . 59.5 mttm -176.48 174.71 1.87 Allowed 'General case' 0 CA--C 1.494 -1.175 0 C-N-CA 129.403 3.081 . . . . 0.0 104.664 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -72.83 146.23 46.42 Favored 'General case' 0 C--N 1.286 -2.173 0 C-N-CA 119.286 -0.965 . . . . 0.0 110.246 171.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -129.23 -86.26 0.55 Allowed 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 174.083 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 52.42 -177.66 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.78 1.632 . . . . 0.0 111.017 171.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 tp -94.83 -65.05 1.01 Allowed 'General case' 0 C--N 1.288 -2.076 0 CA-C-O 122.633 1.206 . . . . 0.0 107.933 168.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.48 -5.04 48.16 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 112.931 -1.941 . . . . 0.0 115.451 -171.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . 0.438 ' HA ' ' HD2' ' A' ' 128' ' ' LYS . 44.6 tptt -116.78 26.42 9.85 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 122.049 0.928 . . . . 0.0 109.027 178.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -63.34 -28.32 72.12 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 114.397 -1.274 . . . . 0.0 113.272 178.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 121.86 -80.86 0.34 Allowed Glycine 0 C--O 1.22 -0.736 0 C-N-CA 119.993 -1.099 . . . . 0.0 113.748 175.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.484 ' H ' ' HB2' ' A' ' 134' ' ' SER . 46.5 t-20 -99.08 169.27 9.53 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . . . . . . . . 0.335 9.6 pt-20 -54.66 -45.66 73.89 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 116.273 1.953 . . . . 0.0 116.273 -173.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.98 -37.98 61.77 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.349 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.484 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 49.6 m -59.97 -30.15 68.92 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-O 120.963 0.411 . . . . 0.0 111.409 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 80.5 m -78.84 -20.16 50.29 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.958 0.885 . . . . 0.0 110.168 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 41.7 tttp -91.08 -32.83 15.72 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 -176.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.443 HG22 ' HA ' ' A' ' 134' ' ' SER . 9.6 t -85.54 -30.43 23.39 Favored 'General case' 0 N--CA 1.409 -2.513 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.426 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.74 75.12 1.25 Allowed Glycine 0 N--CA 1.422 -2.268 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 32.3 t30 -47.32 119.95 2.93 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.277 1.431 . . . . 0.0 112.18 -174.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.551 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -132.58 137.6 47.13 Favored 'General case' 0 N--CA 1.42 -1.943 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.989 -173.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.08 89.32 0.58 Allowed Glycine 0 CA--C 1.502 -0.742 0 N-CA-C 107.581 -2.207 . . . . 0.0 107.581 170.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.6 m -47.07 -33.97 5.42 Favored 'General case' 0 C--O 1.2 -1.545 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -164.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.01 9.91 4.17 Favored 'General case' 0 C--N 1.27 -2.888 0 C-N-CA 116.162 -2.215 . . . . 0.0 109.787 178.309 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.9 mp -71.41 -16.3 62.39 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.861 -0.736 . . . . 0.0 112.088 -173.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.18 101.89 0.28 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.8 m -136.12 147.34 47.74 Favored 'General case' 0 N--CA 1.407 -2.615 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.561 ' HA2' ' O ' ' A' ' 54' ' ' THR . . . -162.38 149.64 17.98 Favored Glycine 0 N--CA 1.396 -3.988 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . 0.632 HG13 ' NH2' ' A' ' 115' ' ' ARG . 2.8 t -69.05 104.67 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 176.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.787 HG21 ' HB3' ' A' ' 117' ' ' LEU . 7.4 tt -123.47 101.57 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -176.128 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.492 ' HA3' ' NH1' ' A' ' 115' ' ' ARG . . . 176.66 -167.13 38.42 Favored Glycine 0 CA--C 1.453 -3.8 0 N-CA-C 107.889 -2.084 . . . . 0.0 107.889 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 6.3 tt -61.99 104.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.107 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.457 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.486 ' HB3' ' CG2' ' A' ' 5' ' ' VAL . . . -103.31 102.04 11.98 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.631 -0.828 . . . . 0.0 110.406 -179.537 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 pt20 . . . . . 0 C--N 1.279 -2.474 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.145 179.044 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . 0.637 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 N--CA 1.47 0.57 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . 0.421 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 8.2 m -121.06 -37.42 2.96 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.184 -0.606 . . . . 0.0 112.033 -175.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -136.34 136.1 39.4 Favored 'General case' 0 C--O 1.25 1.109 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -174.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -156.14 103.15 2.17 Favored 'General case' 0 CA--C 1.479 -1.769 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.634 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 33.9 m -110.97 134.48 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-O 121.655 0.74 . . . . 0.0 110.389 -176.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . 0.695 ' HB2' ' HA ' ' A' ' 149' ' ' ILE . . . -108.81 150.11 28.11 Favored 'General case' 0 C--N 1.28 -2.422 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.342 -175.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.2 p -134.26 119.92 32.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.248 0.547 . . . . 0.0 110.098 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.406 ' O ' ' HD2' ' A' ' 9' ' ' LYS . 5.7 mp -98.25 151.1 20.82 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.191 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . 0.406 ' HD2' ' O ' ' A' ' 8' ' ' LEU . 28.6 mmmt -126.26 132.44 51.69 Favored 'General case' 0 C--O 1.248 1.021 0 N-CA-C 104.791 -2.3 . . . . 0.0 104.791 177.536 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.61 154.53 19.68 Favored Glycine 0 N--CA 1.428 -1.834 0 C-N-CA 117.477 -2.297 . . . . 0.0 118.504 -166.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -64.99 -44.34 89.61 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 111.802 -2.199 . . . . 0.0 106.201 169.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.01 153.96 17.23 Favored Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 104.143 -3.583 . . . . 0.0 104.143 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -70.59 123.95 10.3 Favored 'Trans proline' 0 N--CA 1.442 -1.518 0 CA-C-N 121.559 2.679 . . . . 0.0 111.471 -173.074 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.97 109.27 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.124 0 CA-C-N 114.199 -1.364 . . . . 0.0 107.641 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.481 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 73.6 mt-30 -119.99 119.0 32.15 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . 0.622 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -160.14 160.0 31.26 Favored Glycine 0 N--CA 1.405 -3.428 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -174.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . 0.461 HG13 ' HB ' ' A' ' 5' ' ' VAL . 11.5 tt -153.87 102.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 121.441 0.638 . . . . 0.0 109.546 -178.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.657 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.2 OUTLIER -106.55 139.86 26.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.22 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.688 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 8.5 t30 -113.53 120.81 42.25 Favored 'General case' 0 CA--C 1.51 -0.586 0 O-C-N 123.753 0.658 . . . . 0.0 110.757 -177.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 84' ' ' LEU . 21.0 m-85 -119.62 135.14 54.93 Favored 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -178.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' HG23 ' A' ' 29' ' ' VAL . 13.4 mt-10 -102.45 105.43 15.99 Favored 'General case' 0 CA--C 1.551 0.999 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.652 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.637 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 15.1 mp0 -85.6 99.86 11.56 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 176.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -132.82 108.98 9.32 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 122.288 1.042 . . . . 0.0 111.593 -172.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -69.49 -10.99 60.45 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.077 178.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.5 m -59.22 -16.9 23.55 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.563 1.545 . . . . 0.0 112.311 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 74.98 116.12 0.06 Allowed 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 124.021 0.929 . . . . 0.0 112.375 177.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.93 169.67 24.5 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -62.41 123.91 13.29 Favored 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.534 2.156 . . . . 0.0 110.88 177.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.503 HG23 ' HB2' ' A' ' 21' ' ' GLU . 10.9 p -75.98 121.51 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.639 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HA ' HD11 ' A' ' 99' ' ' ILE . 67.8 mttm -89.81 97.55 11.26 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -177.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' HA ' ' A' ' 20' ' ' PHE . 24.7 m -122.61 133.07 69.89 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.008 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.771 -171.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.537 ' HA ' HG11 ' A' ' 97' ' ' VAL . 4.8 m-90 -135.26 137.61 42.71 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.454 177.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.657 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -161.54 140.66 6.76 Favored Glycine 0 N--CA 1.424 -2.101 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.828 173.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . 0.622 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 11.4 p -114.83 126.11 54.45 Favored 'General case' 0 N--CA 1.413 -2.294 0 C-N-CA 123.844 0.857 . . . . 0.0 109.622 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.566 HG13 ' HA3' ' A' ' 16' ' ' GLY . 3.6 mp -126.06 142.82 41.59 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 18.9 ptpt -116.26 133.26 56.22 Favored 'General case' 0 N--CA 1.413 -2.283 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 172.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -165.21 175.81 40.99 Favored Glycine 0 N--CA 1.423 -2.171 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 -165.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 mt -66.43 144.0 56.78 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -177.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.465 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 59.3 p -87.34 104.17 16.16 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 -163.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 3.7 mp0 -173.13 140.89 0.91 Allowed 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 102.173 -3.269 . . . . 0.0 102.173 175.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 173.67 116.19 0.41 Allowed Glycine 0 C--N 1.255 -3.919 0 C-N-CA 114.933 -3.508 . . . . 0.0 114.436 178.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.668 ' HB2' ' HB2' ' A' ' 123' ' ' ALA . 96.2 mt -142.83 -39.67 0.33 Allowed 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -179.385 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -126.02 141.52 51.92 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -173.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' A' ' 46' ' ' HIS . . . -105.19 88.4 0.58 Allowed Glycine 0 N--CA 1.44 -1.036 0 CA-C-N 115.156 -0.929 . . . . 0.0 111.698 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . 0.443 ' HB3' ' O ' ' A' ' 125' ' ' ASP . 0.4 OUTLIER -90.9 84.72 5.83 Favored 'General case' 1 C--O 1.352 6.481 0 CA-C-O 122.261 1.029 . . . . 0.0 112.021 -176.242 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.409 ' HD2' ' O ' ' A' ' 44' ' ' GLY . 8.0 p80 -100.12 113.37 25.95 Favored 'General case' 0 N--CA 1.382 -3.865 0 CA-C-N 113.893 -1.503 . . . . 0.0 107.944 -171.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.0 t -164.89 87.93 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 O-C-N 125.048 1.468 . . . . 0.0 108.533 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.541 ' CD2' ' HB ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -148.31 167.73 24.42 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 124.39 1.076 . . . . 0.0 109.114 163.781 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.402 ' HA ' ' HG2' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -164.81 164.98 20.95 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 171.046 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 66.5 t80 73.61 58.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.06 166.08 30.81 Favored Glycine 0 CA--C 1.474 -2.499 0 CA-C-N 112.849 -1.978 . . . . 0.0 111.54 -175.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -151.46 -72.37 0.16 Allowed 'General case' 0 C--N 1.292 -1.913 0 O-C-N 123.875 0.397 . . . . 0.0 111.651 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -94.5 128.59 41.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.77 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.5 t -75.98 -2.3 29.85 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 122.946 0.498 . . . . 0.0 111.515 -174.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.05 -8.6 19.41 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.47 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . 0.459 ' HA2' ' HB2' ' A' ' 143' ' ' ARG . . . -176.99 137.63 3.61 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.224 -1.465 . . . . 0.0 112.758 -178.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.439 ' H ' ' HB2' ' A' ' 143' ' ' ARG . 62.3 m -91.98 88.3 6.53 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 120.385 0.136 . . . . 0.0 111.101 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.7 m -80.01 -58.14 3.3 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.75 -44.17 86.7 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.817 -176.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.47 -5.98 51.87 Favored 'General case' 0 C--O 1.196 -1.713 0 C-N-CA 124.801 1.24 . . . . 0.0 112.384 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -31.62 -138.33 0.0 OUTLIER Glycine 0 N--CA 1.513 3.832 0 C-N-CA 128.477 2.942 . . . . 0.0 116.414 -174.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -62.91 53.41 0.13 Allowed 'Trans proline' 0 CA--C 1.566 2.086 0 CA-C-N 121.043 2.421 . . . . 0.0 113.11 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -93.96 112.67 24.53 Favored 'General case' 0 N--CA 1.427 -1.605 0 C-N-CA 124.348 1.059 . . . . 0.0 110.332 175.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' A' ' 136' ' ' LYS . 45.5 p90 -84.21 133.16 34.6 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 103.983 -2.599 . . . . 0.0 103.983 167.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.433 ' ND2' ' HD2' ' A' ' 66' ' ' PRO . 29.1 t-20 -75.01 140.83 74.1 Favored Pre-proline 0 C--N 1.282 -2.366 0 C-N-CA 118.842 -1.143 . . . . 0.0 111.609 -171.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . 0.458 ' O ' ' HG2' ' A' ' 69' ' ' ARG . 92.1 Cg_endo -83.8 -14.21 7.73 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.532 2.154 . . . . 0.0 113.445 -176.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.724 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 2.7 tt -88.36 -17.59 30.23 Favored 'General case' 0 CA--C 1.482 -1.658 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 79' ' ' ARG . 63.8 m -79.44 39.82 0.41 Allowed 'General case' 0 N--CA 1.407 -2.58 0 CA-C-N 114.315 -1.311 . . . . 0.0 111.502 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 66' ' ' PRO . 33.1 mmt180 -83.7 20.1 1.51 Allowed 'General case' 0 CA--C 1.49 -1.33 0 CA-C-O 122.506 1.146 . . . . 0.0 109.734 -178.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 79' ' ' ARG . 25.8 tptp -128.1 19.99 6.42 Favored 'General case' 0 N--CA 1.396 -3.126 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 171.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.0 m80 65.87 -48.3 0.4 Allowed 'General case' 0 N--CA 1.504 2.251 0 C-N-CA 126.349 1.86 . . . . 0.0 115.375 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.516 ' HA2' ' HG3' ' A' ' 79' ' ' ARG . . . 167.61 175.29 37.37 Favored Glycine 0 N--CA 1.415 -2.761 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -171.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . 0.449 ' O ' HD11 ' A' ' 126' ' ' LEU . . . -169.38 142.5 7.36 Favored Glycine 0 CA--C 1.475 -2.444 0 N-CA-C 106.787 -2.525 . . . . 0.0 106.787 173.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -65.01 -43.25 12.1 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 CA-C-N 120.306 2.053 . . . . 0.0 113.849 -178.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.7 OUTLIER -120.89 -29.79 4.55 Favored 'General case' 0 N--CA 1.425 -1.682 0 C-N-CA 119.507 -0.877 . . . . 0.0 112.268 -178.317 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 104' ' ' ILE . 33.4 t70 -176.62 146.86 0.6 Allowed 'General case' 0 C--O 1.204 -1.301 0 CA-C-O 118.81 -0.614 . . . . 0.0 109.664 -176.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 79' ' ' ARG . 3.1 mm-40 -158.16 -86.76 0.04 OUTLIER 'General case' 0 C--O 1.214 -0.766 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 70' ' ' LYS . 1.5 tm-20 -161.25 -53.03 0.05 OUTLIER 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.1 -2.185 . . . . 0.0 105.1 -176.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.724 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 0.4 OUTLIER -34.67 -31.63 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.92 0 C-N-CA 128.635 2.774 . . . . 0.0 115.676 176.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.43 ' H ' ' HD3' ' A' ' 79' ' ' ARG . 31.2 t-80 . . . . . 0 N--CA 1.5 2.066 0 C-N-CA 124.341 1.056 . . . . 0.0 109.738 -171.455 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.505 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . 89.2 mt . . . . . 0 C--O 1.2 -1.508 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 177.03 165.31 32.21 Favored Glycine 0 CA--C 1.478 -2.246 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -158.57 148.33 19.49 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 p -137.24 128.38 40.71 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.636 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 88.3 m -140.42 95.21 2.84 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -135.67 106.39 6.56 Favored 'General case' 0 C--O 1.202 -1.425 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.57 ' HA ' ' N ' ' A' ' 40' ' ' GLU . 3.3 p-10 -117.26 -19.18 9.72 Favored 'General case' 0 C--N 1.275 -2.639 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.648 -174.462 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -75.77 -57.54 3.82 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.692 -175.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -154.2 -22.83 0.13 Allowed 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 114.623 -1.171 . . . . 0.0 112.27 -166.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.48 55.3 0.16 Allowed Glycine 0 N--CA 1.42 -2.386 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -173.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.0 m -141.9 102.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.85 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.81 107.75 19.38 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.233 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -83.97 124.33 30.91 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 104.665 -2.346 . . . . 0.0 104.665 173.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.537 HG11 ' HA ' ' A' ' 32' ' ' TRP . 7.1 p -83.31 135.89 23.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 C-N-CA 119.696 -0.802 . . . . 0.0 109.426 -174.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.2 m -75.46 102.24 5.12 Favored 'General case' 0 N--CA 1.389 -3.508 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 31' ' ' VAL . 2.5 tt -92.8 115.72 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.7 mm-40 -133.54 157.43 45.68 Favored 'General case' 0 C--N 1.283 -2.305 0 CA-C-N 113.988 -1.46 . . . . 0.0 108.364 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -79.83 99.38 7.48 Favored 'General case' 0 N--CA 1.411 -2.405 0 CA-C-O 123.01 1.386 . . . . 0.0 109.674 176.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.491 ' H ' HG12 ' A' ' 29' ' ' VAL . 50.8 m -100.9 93.75 5.68 Favored 'General case' 0 N--CA 1.41 -2.444 0 CA-C-N 112.107 -2.315 . . . . 0.0 105.902 171.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.1 t -69.18 -47.62 73.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.825 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . 0.482 HG22 ' OD1' ' A' ' 76' ' ' ASP . 10.0 tp -70.62 26.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.576 1.955 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 30.0 t -70.89 90.16 0.8 Allowed 'General case' 0 CA--C 1.477 -1.845 0 N-CA-C 105.584 -2.006 . . . . 0.0 105.584 170.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 27.2 tp -110.42 157.93 19.03 Favored 'General case' 2 C--N 1.204 -5.728 0 N-CA-C 103.333 -2.839 . . . . 0.0 103.333 -172.547 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 m -69.08 101.22 1.38 Allowed 'General case' 1 C--N 1.226 -4.776 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 174.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.6 137.11 13.23 Favored Glycine 0 N--CA 1.41 -3.078 0 CA-C-N 114.321 -1.309 . . . . 0.0 112.723 -170.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.0 t70 61.74 -86.33 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 126.449 1.899 . . . . 0.0 114.106 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . 0.408 ' HB2' ' O ' ' A' ' 113' ' ' ILE . 16.2 m80 -82.82 -49.02 10.13 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 175.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 18.5 m 168.03 -85.46 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 126.357 1.863 . . . . 0.0 111.026 173.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.3 mt -109.61 -54.42 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 14.0 tt -83.74 175.64 0.72 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.024 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.44 ' H ' HG12 ' A' ' 113' ' ' ILE . . . 89.43 22.77 36.17 Favored Glycine 0 CA--C 1.478 -2.278 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.918 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.427 HH22 HD12 ' A' ' 149' ' ' ILE . 44.4 mtm180 -146.98 123.12 10.83 Favored 'General case' 0 C--O 1.2 -1.539 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 11.4 p -102.09 115.48 30.63 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 171.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 2.2 pt? -71.05 148.07 47.92 Favored 'General case' 0 CA--C 1.506 -0.716 0 O-C-N 123.865 0.728 . . . . 0.0 112.434 -170.98 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.547 HG22 ' HB3' ' A' ' 140' ' ' ALA . 1.8 p -125.63 99.64 6.14 Favored 'Isoleucine or valine' 1 C--O 1.38 7.933 0 C-N-CA 117.118 -1.833 . . . . 0.0 112.653 172.507 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 t -148.69 151.48 13.14 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 C-N-CA 126.429 1.892 . . . . 0.0 106.153 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -144.52 170.35 16.22 Favored 'General case' 0 C--O 1.243 0.712 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 175.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.4 mp0 -67.86 89.93 0.29 Allowed 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 177.129 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . 0.5 ' HG2' ' H ' ' A' ' 123' ' ' ALA . 50.8 tttm -162.99 171.58 16.31 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -174.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . 0.668 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . . . -123.22 107.27 11.52 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.45 -88.3 0.44 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.993 165.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 21.9 t70 172.44 157.36 0.1 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.515 HD23 ' H ' ' A' ' 126' ' ' LEU . 1.6 pt? -90.62 -29.34 17.84 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -105.5 -23.59 7.5 Favored Glycine 0 N--CA 1.464 0.522 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.847 -177.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -128.48 51.99 1.95 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 177.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.86 82.2 0.41 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.37 -0.832 . . . . 0.0 114.35 -174.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.9 -127.56 8.48 Favored Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 121.376 -0.44 . . . . 0.0 112.808 174.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -98.41 -176.89 3.52 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.436 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 39.1 tt0 -61.88 -50.97 70.08 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 119.074 0.852 . . . . 0.0 112.993 -175.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -64.29 -31.06 72.12 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.463 178.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 m -68.48 -38.56 81.13 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 122.724 0.41 . . . . 0.0 110.64 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.9 p -65.57 -27.23 68.28 Favored 'General case' 0 C--N 1.349 0.578 0 CA-C-O 121.121 0.486 . . . . 0.0 110.748 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . 0.436 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 92.9 mttt -84.99 -16.45 40.82 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.061 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 31.0 m -87.98 -17.58 30.93 Favored 'General case' 0 CA--C 1.564 1.504 0 CA-C-O 121.841 0.829 . . . . 0.0 110.347 175.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.24 48.6 30.57 Favored Glycine 1 C--O 1.39 9.847 0 N-CA-C 108.629 -1.788 . . . . 0.0 108.629 -173.45 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -30.22 106.29 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 128.963 2.905 . . . . 0.0 114.496 -158.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.547 ' HB3' HG22 ' A' ' 118' ' ' VAL . . . -155.59 171.82 19.32 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 167.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.47 119.28 16.13 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 167.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.7 m -41.63 -46.84 3.79 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 115.484 1.661 . . . . 0.0 115.484 -166.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.732 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 0.1 OUTLIER -132.42 11.51 4.51 Favored 'General case' 0 C--N 1.288 -2.105 0 C-N-CA 118.891 -1.124 . . . . 0.0 108.529 174.845 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.6 mt -71.69 -17.33 62.23 Favored 'General case' 0 CA--C 1.497 -1.09 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.297 -170.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.35 89.67 1.59 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.732 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 53.0 m -131.2 153.95 48.92 Favored 'General case' 0 N--CA 1.424 -1.726 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.253 -178.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.74 148.65 11.58 Favored Glycine 0 N--CA 1.409 -3.136 0 N-CA-C 108.025 -2.03 . . . . 0.0 108.025 176.021 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 93.8 t -69.23 105.62 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 176.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.695 ' HA ' ' HB2' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -88.74 103.2 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.703 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.07 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.36 -177.79 48.48 Favored Glycine 1 N--CA 1.383 -4.871 0 C-N-CA 119.081 -1.533 . . . . 0.0 112.266 -178.657 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.7 tt -53.32 112.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 125.119 1.367 . . . . 0.0 113.184 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.72 99.94 3.83 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 171.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.288 -2.095 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -177.419 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.702 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.4 m -94.26 -26.81 16.46 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.39 1.09 . . . . 0.0 108.606 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -166.03 172.11 11.78 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 174.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 4' ' ' ALA . . . . . 0.719 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -151.71 158.97 44.11 Favored 'General case' 0 C--N 1.287 -2.149 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 5' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 86.7 t -140.93 121.41 13.14 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.365 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -177.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.12 145.74 50.63 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 -177.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 p -135.36 125.87 44.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 O-C-N 123.66 0.6 . . . . 0.0 109.391 -179.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 8' ' ' LEU . . . . . 0.454 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.4 pt? -125.52 144.24 50.64 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.52 -175.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -163.43 135.55 5.12 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 107.084 -1.451 . . . . 0.0 107.084 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.95 -157.17 7.99 Favored Glycine 0 C--N 1.301 -1.378 0 C-N-CA 120.233 -0.984 . . . . 0.0 112.265 -175.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -55.0 -50.95 67.73 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.262 1.025 . . . . 0.0 110.505 177.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -92.15 163.91 28.15 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -90.57 123.56 0.97 Allowed 'Trans proline' 0 N--CA 1.418 -2.921 0 CA-C-N 120.473 2.136 . . . . 0.0 111.026 -177.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 m -133.3 131.52 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.042 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 15' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -145.97 123.17 11.52 Favored 'General case' 0 C--N 1.269 -2.933 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.604 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.97 161.64 34.89 Favored Glycine 0 N--CA 1.41 -3.042 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.0 tt -132.5 110.23 15.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 18' ' ' ILE . . . . . 0.512 ' H ' HD13 ' A' ' 18' ' ' ILE . 0.1 OUTLIER -107.65 132.84 54.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 -179.763 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 19' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -106.05 139.62 40.3 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.904 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 20' ' ' PHE . . . . . 0.719 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 24.4 t80 -137.47 127.6 26.05 Favored 'General case' 0 C--O 1.252 1.186 0 CA-C-N 118.996 0.816 . . . . 0.0 111.577 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -134.38 102.45 5.34 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-O 121.797 0.808 . . . . 0.0 112.823 -178.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 22' ' ' GLN . . . . . 0.681 HE21 ' HG ' ' A' ' 106' ' ' LEU . 2.5 pm0 -127.71 162.91 25.47 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -178.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER 64.63 -56.39 0.27 Allowed 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.808 1.243 . . . . 0.0 113.001 176.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.72 -43.93 87.59 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.157 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.0 m -81.49 -65.85 0.96 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 171.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 57.45 96.52 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 124.33 1.052 . . . . 0.0 109.924 177.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 27' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 29' ' ' VAL . . . 140.53 -143.21 13.19 Favored Glycine 0 CA--C 1.463 -3.198 0 C-N-CA 118.545 -1.788 . . . . 0.0 108.692 -172.467 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.47 122.06 10.51 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 N-CA-C 107.403 -1.807 . . . . 0.0 107.403 175.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 29' ' ' VAL . . . . . 0.737 HG12 HG13 ' A' ' 31' ' ' VAL . 55.7 t -102.69 113.36 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.807 0 CA-C-O 121.673 0.749 . . . . 0.0 109.927 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -84.61 102.73 13.14 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.616 -1.629 . . . . 0.0 109.799 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 31' ' ' VAL . . . . . 0.737 HG13 HG12 ' A' ' 29' ' ' VAL . 26.8 m -130.35 144.6 37.47 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.683 -176.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 32' ' ' TRP . . . . . 0.409 ' HA ' HG11 ' A' ' 97' ' ' VAL . 66.1 p-90 -148.12 134.67 19.76 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.587 178.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 33' ' ' GLY . . . . . 0.566 ' O ' HG22 ' A' ' 97' ' ' VAL . . . -164.03 137.9 5.0 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 119.132 -1.509 . . . . 0.0 113.119 169.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.8 m -114.23 126.62 55.25 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -177.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -130.26 133.18 64.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-O 121.261 0.553 . . . . 0.0 111.188 -177.458 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 36' ' ' LYS . . . . . 0.453 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 22.1 ptmt -106.59 133.2 51.63 Favored 'General case' 0 N--CA 1.419 -2.008 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.596 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 37' ' ' GLY . . . . . 0.521 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -157.97 174.37 35.26 Favored Glycine 0 N--CA 1.421 -2.316 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -170.246 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 tp -68.72 171.99 6.99 Favored 'General case' 0 CA--C 1.567 1.598 0 C-N-CA 123.305 0.642 . . . . 0.0 109.47 178.307 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 39' ' ' THR . . . . . 0.517 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 7.2 t -67.59 111.07 3.97 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.42 -0.8 . . . . 0.0 112.73 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 40' ' ' GLU . . . . . 0.576 ' H ' ' HA ' ' A' ' 90' ' ' ASP . 0.2 OUTLIER -163.56 174.15 12.15 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-O 123.127 1.441 . . . . 0.0 113.811 178.079 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.92 -144.53 0.05 OUTLIER Glycine 2 C--N 1.238 -4.901 0 CA-C-N 110.477 -3.056 . . . . 0.0 114.125 173.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 42' ' ' LEU . . . . . 0.59 ' HB3' HG22 ' A' ' 88' ' ' THR . 2.4 pt? -138.42 148.37 44.36 Favored 'General case' 1 N--CA 1.37 -4.428 0 CA-C-N 114.161 -1.019 . . . . 0.0 110.641 -164.933 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 43' ' ' HIS . . . . . 0.474 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 11.0 p80 -104.54 138.91 40.19 Favored 'General case' 0 CA--C 1.438 -3.335 0 C-N-CA 119.392 -0.923 . . . . 0.0 108.653 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -99.19 0.02 OUTLIER Glycine 0 N--CA 1.402 -3.577 0 O-C-N 125.215 1.572 . . . . 0.0 111.128 173.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 2.5 m-85 -165.68 93.97 0.58 Allowed 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 117.716 -1.135 . . . . 0.0 111.105 -166.97 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 46' ' ' HIS . . . . . 0.605 ' CD2' ' HB2' ' A' ' 126' ' ' LEU . 14.3 t60 -170.85 86.47 0.1 Allowed 'General case' 0 C--O 1.284 2.901 0 CA-C-N 120.301 1.41 . . . . 0.0 114.493 171.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -74.93 154.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.732 0 CA-C-N 113.553 -1.658 . . . . 0.0 107.119 165.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 48' ' ' HIS . . . . . 0.428 ' O ' ' HB2' ' A' ' 49' ' ' GLU . 25.9 p80 -159.24 114.06 2.44 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 116.511 -1.709 . . . . 0.0 107.08 172.514 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 49' ' ' GLU . . . . . 0.604 ' HA ' ' OE1' ' A' ' 49' ' ' GLU 0.484 0.0 OUTLIER -173.74 168.2 4.37 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 165.377 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild core ' A' A ' 50' ' ' PHE . . . . . 0.49 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 26.8 p90 -115.22 19.46 15.59 Favored 'General case' 0 N--CA 1.404 -2.743 0 CA-C-N 112.654 -2.067 . . . . 0.0 109.108 176.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 51' ' ' GLY . . . . . 0.616 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 85.06 138.94 4.49 Favored Glycine 0 N--CA 1.47 0.959 0 N-CA-C 115.017 0.767 . . . . 0.0 115.017 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -144.9 -72.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.674 -0.81 . . . . 0.0 109.148 173.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -168.81 158.74 9.16 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 176.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 m -65.58 -48.41 72.44 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 123.633 0.773 . . . . 0.0 111.023 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.69 -7.88 42.46 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.003 -171.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.34 109.85 0.47 Allowed Glycine 0 CA--C 1.463 -3.214 0 C-N-CA 118.794 -1.669 . . . . 0.0 110.449 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 57' ' ' CYS . . . . . 0.847 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 15.8 p -101.89 87.42 3.11 Favored 'General case' 0 N--CA 1.392 -3.368 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 174.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.1 m -82.43 -50.09 9.26 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 122.755 1.265 . . . . 0.0 108.943 174.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 59' ' ' SER . . . . . 0.49 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 15.2 m -72.16 -8.15 53.11 Favored 'General case' 0 C--O 1.209 -1.038 0 CA-C-N 113.457 -1.702 . . . . 0.0 112.982 -175.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 60' ' ' ALA . . . . . 0.582 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . . . -77.29 -7.29 55.74 Favored 'General case' 0 CA--C 1.494 -1.192 0 C-N-CA 124.785 1.234 . . . . 0.0 111.216 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.7 52.09 0.83 Allowed Glycine 0 N--CA 1.406 -3.357 0 C-N-CA 117.762 -2.161 . . . . 0.0 116.016 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 62' ' ' PRO . . . . . 0.478 ' HD3' ' C ' ' A' ' 60' ' ' ALA . 1.2 Cg_endo -90.42 -6.74 4.37 Favored 'Trans proline' 0 C--N 1.395 3.009 0 CA-C-N 121.788 2.794 . . . . 0.0 106.995 164.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 63' ' ' HIS . . . . . 0.449 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 31.3 m80 72.48 -58.06 0.61 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 114.149 -1.387 . . . . 0.0 111.355 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -112.63 116.52 30.31 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 122.322 -0.236 . . . . 0.0 110.936 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 65' ' ' ASN . . . . . 0.516 ' HB3' ' HG3' ' A' ' 79' ' ' ARG . 0.8 OUTLIER -77.23 144.48 71.2 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.386 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.54 -54.32 1.05 Allowed 'Trans proline' 0 CA--C 1.553 1.441 0 C-N-CA 122.907 2.404 . . . . 0.0 117.234 -170.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 67' ' ' LEU . . . . . 0.59 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 4.2 mm? -82.72 8.48 12.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.208 -1.397 . . . . 0.0 112.176 -173.262 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 68' ' ' SER . . . . . 0.614 ' HA ' ' OE1' ' A' ' 77' ' ' GLU . 69.6 m -72.2 39.27 0.07 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 122.614 1.197 . . . . 0.0 111.085 173.211 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 69' ' ' ARG . . . . . 0.541 ' H ' ' C ' ' A' ' 67' ' ' LEU . 73.6 mtt-85 -100.56 3.4 42.69 Favored 'General case' 0 N--CA 1.386 -3.674 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.673 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 70' ' ' LYS . . . . . 0.413 ' HB2' ' N ' ' A' ' 78' ' ' GLU . 47.8 mttp -109.31 30.06 6.96 Favored 'General case' 0 CA--C 1.495 -1.172 0 C-N-CA 118.975 -1.09 . . . . 0.0 110.768 169.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 70.56 86.11 0.13 Allowed 'General case' 0 N--CA 1.435 -1.177 0 CA-C-N 113.967 -1.47 . . . . 0.0 112.913 177.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 72' ' ' GLY . . . . . 0.55 ' HA2' ' CG ' ' A' ' 77' ' ' GLU . . . -53.54 83.1 0.01 OUTLIER Glycine 0 CA--C 1.508 -0.382 0 CA-C-N 114.59 -1.186 . . . . 0.0 112.573 169.016 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -141.84 -151.17 5.48 Favored Glycine 0 N--CA 1.401 -3.639 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 178.838 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 74' ' ' PRO . . . . . 0.433 ' CB ' ' HB3' ' A' ' 84' ' ' LEU . 98.8 Cg_endo -81.94 -41.3 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.332 0 N-CA-C 117.905 2.233 . . . . 0.0 117.905 -169.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -93.95 -26.21 16.94 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 116.446 2.017 . . . . 0.0 116.446 -162.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -171.59 143.12 1.7 Allowed 'General case' 0 CA--C 1.475 -1.931 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 -169.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' GLU . . . . . 0.614 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -160.05 151.0 19.1 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -175.845 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' GLU . . . . . 0.59 ' HB3' ' O ' ' A' ' 67' ' ' LEU . 15.4 tp10 -90.18 -19.2 24.5 Favored 'General case' 0 CA--C 1.555 1.142 0 O-C-N 123.446 0.466 . . . . 0.0 111.921 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HB2' ' C ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -101.0 -8.23 22.56 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 104.302 -2.481 . . . . 0.0 104.302 172.232 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' HIS . . . . . 0.479 ' HA ' ' HB3' ' A' ' 77' ' ' GLU . 44.2 m170 . . . . . 0 N--CA 1.45 -0.456 0 CA-C-N 113.211 -1.813 . . . . 0.0 110.901 175.873 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' LEU . . . . . 0.444 HD22 ' HB3' ' A' ' 100' ' ' GLU 0.404 1.1 pp . . . . . 0 N--CA 1.408 -2.534 0 CA-C-O 122.818 1.294 . . . . 0.0 112.608 . . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.33 87.31 0.13 Allowed Glycine 1 N--CA 1.389 -4.494 0 CA-C-N 113.771 -1.559 . . . . 0.0 110.034 177.416 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 43' ' ' HIS . 24.7 t30 -72.79 128.17 34.73 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 174.091 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' VAL . . . . . 0.625 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 6.5 m -143.09 127.38 14.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 O-C-N 123.839 0.712 . . . . 0.0 110.684 -176.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' THR . . . . . 0.59 HG22 ' HB3' ' A' ' 42' ' ' LEU 0.257 4.9 p -101.02 101.45 12.23 Favored 'General case' 0 CA--C 1.561 1.396 0 C-N-CA 128.175 2.59 . . . . 0.0 111.991 -176.396 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' ALA . . . . . 0.407 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -118.92 108.27 14.59 Favored 'General case' 0 CA--C 1.473 -2.006 0 CA-C-N 120.579 1.536 . . . . 0.0 109.423 -178.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' H ' ' A' ' 40' ' ' GLU . 38.3 t70 -90.96 -165.43 1.35 Allowed 'General case' 0 C--N 1.278 -2.532 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.531 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 21.9 ptmt -42.93 -32.17 0.6 Allowed 'General case' 0 N--CA 1.51 2.568 0 C-N-CA 126.439 1.895 . . . . 0.0 115.663 -175.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -91.22 -37.17 13.49 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-O 122.525 1.155 . . . . 0.0 107.925 -178.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' GLY . . . . . 0.521 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 91.35 78.84 1.38 Allowed Glycine 1 N--CA 1.384 -4.805 0 CA-C-N 114.173 -1.376 . . . . 0.0 111.145 -176.578 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.7 t -142.69 101.15 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.175 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 176.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 95' ' ' ALA . . . . . 0.625 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -100.46 140.49 34.64 Favored 'General case' 0 N--CA 1.404 -2.763 0 O-C-N 123.699 0.624 . . . . 0.0 112.184 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -94.69 129.72 41.48 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 175.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 97' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 33' ' ' GLY . 0.9 OUTLIER -82.45 124.08 38.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 O-C-N 123.665 0.603 . . . . 0.0 111.397 -177.377 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 98' ' ' SER . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . 46.9 m -87.29 108.84 19.14 Favored 'General case' 0 N--CA 1.4 -2.972 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 168.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 99' ' ' ILE . . . . . 0.412 ' HA ' ' CG2' ' A' ' 31' ' ' VAL . 3.5 tt -90.77 123.03 42.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 114.79 -1.096 . . . . 0.0 108.55 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 100' ' ' GLU . . . . . 0.444 ' HB3' HD22 ' A' ' 84' ' ' LEU . 7.8 tp10 -138.94 157.61 45.7 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 114.554 -1.203 . . . . 0.0 111.145 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -81.46 103.33 11.13 Favored 'General case' 0 C--N 1.275 -2.64 0 C-N-CA 126.871 2.069 . . . . 0.0 112.586 -177.105 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' HG21 ' A' ' 29' ' ' VAL . 23.6 p -102.58 164.84 11.43 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.407 -0.808 . . . . 0.0 110.607 169.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.7 m -108.97 -63.5 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 C-N-CA 118.517 -1.273 . . . . 0.0 112.405 175.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 13.1 tt -128.15 23.98 2.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 121.571 0.701 . . . . 0.0 111.19 -169.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 105' ' ' SER . . . . . 0.6 ' C ' ' HG3' ' A' ' 22' ' ' GLN . 13.6 m -82.0 85.15 6.77 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.345 -1.742 . . . . 0.0 111.854 -178.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 106' ' ' LEU . . . . . 0.681 ' HG ' HE21 ' A' ' 22' ' ' GLN . 7.0 mp -76.18 117.58 18.02 Favored 'General case' 0 C--O 1.195 -1.791 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 170.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 107' ' ' SER . . . . . 0.554 ' O ' ' HA ' ' A' ' 112' ' ' ILE . 9.3 m -69.48 86.71 0.45 Allowed 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 119.909 1.231 . . . . 0.0 111.717 -175.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 108' ' ' GLY . . . . . 0.574 ' HA3' ' HG3' ' A' ' 115' ' ' ARG . . . 124.45 135.57 4.46 Favored Glycine 0 N--CA 1.427 -1.935 0 CA-C-N 113.83 -1.532 . . . . 0.0 109.749 177.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 109' ' ' ASP . . . . . 0.471 ' HB3' ' NH1' ' A' ' 79' ' ' ARG . 18.0 t70 -78.34 -36.26 46.47 Favored 'General case' 0 CA--C 1.5 -0.968 0 C-N-CA 117.686 -1.606 . . . . 0.0 111.134 175.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -68.77 -34.01 74.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.334 -175.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t 178.35 169.64 0.79 Allowed 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 103.844 -2.651 . . . . 0.0 103.844 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 112' ' ' ILE . . . . . 0.596 HG22 ' HA2' ' A' ' 150' ' ' GLY . 57.2 mt -93.66 -51.91 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.266 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 174.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 113' ' ' ILE . . . . . 0.687 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 3.7 mp -64.21 99.36 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.494 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.696 -170.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 114' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 127.46 -7.67 7.04 Favored Glycine 0 N--CA 1.428 -1.891 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.557 174.165 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 115' ' ' ARG . . . . . 0.616 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 1.6 mmp_? -81.36 133.48 35.43 Favored 'General case' 0 C--O 1.198 -1.653 0 C-N-CA 119.434 -0.907 . . . . 0.0 108.804 -176.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 80.3 m -69.87 126.75 30.64 Favored 'General case' 0 C--N 1.295 -1.792 0 CA-C-O 121.114 0.483 . . . . 0.0 112.017 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 117' ' ' LEU . . . . . 0.531 ' HA ' HG13 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -75.36 97.02 3.51 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.151 174.248 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 118' ' ' VAL . . . . . 0.55 HG12 ' HB3' ' A' ' 140' ' ' ALA . 13.0 t -94.02 94.69 4.7 Favored 'Isoleucine or valine' 1 C--O 1.338 5.725 0 C-N-CA 115.78 -2.368 . . . . 0.0 110.079 -173.317 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 119' ' ' VAL . . . . . 0.462 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . 22.8 m -149.46 170.09 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 128.84 2.856 . . . . 0.0 106.636 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 120' ' ' HIS . . . . . 0.423 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 67.6 t60 -156.61 171.55 20.13 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 121' ' ' GLU . . . . . 0.543 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.9 OUTLIER -70.12 83.6 0.52 Allowed 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 121.085 1.766 . . . . 0.0 106.863 173.919 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -176.63 155.65 1.37 Allowed 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 173.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.87 124.54 14.35 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 119.296 0.953 . . . . 0.0 112.853 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 124' ' ' ASP . . . . . 0.59 ' OD2' ' HB2' ' A' ' 140' ' ' ALA . 9.5 t70 -129.35 102.56 6.48 Favored 'General case' 0 CA--C 1.48 -1.742 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 -178.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -143.71 147.84 34.83 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 126' ' ' LEU . . . . . 0.605 ' HB2' ' CD2' ' A' ' 46' ' ' HIS . 43.4 tp -91.5 -28.53 17.54 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.641 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.78 -61.46 4.65 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 119.943 -1.123 . . . . 0.0 111.718 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -137.17 52.58 1.91 Allowed 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.16 0.505 . . . . 0.0 111.577 177.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.53 78.21 0.87 Allowed Glycine 0 C--N 1.297 -1.623 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.233 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -109.08 3.57 Favored Glycine 0 N--CA 1.442 -0.9 0 C-N-CA 121.752 -0.261 . . . . 0.0 112.937 175.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 131' ' ' ASN . . . . . 0.459 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.9 t30 -104.24 167.42 9.77 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 132' ' ' GLU . . . . . 0.507 ' O ' HG22 ' A' ' 135' ' ' THR . 8.5 mm-40 -51.78 -44.7 63.51 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -178.204 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -77.17 -24.66 51.46 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 121.829 -0.544 . . . . 0.0 112.283 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 134' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 5.7 m -80.04 -22.45 42.34 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-O 121.357 0.599 . . . . 0.0 109.819 -179.018 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 135' ' ' THR . . . . . 0.513 ' O ' HD12 ' A' ' 126' ' ' LEU . 1.8 t -81.22 -18.91 44.46 Favored 'General case' 0 N--CA 1.42 -1.945 0 C-N-CA 119.518 -0.873 . . . . 0.0 109.643 178.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -69.58 -36.63 76.43 Favored 'General case' 0 C--O 1.224 -0.283 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.081 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 137' ' ' THR . . . . . 0.449 ' HA ' ' HB3' ' A' ' 63' ' ' HIS . 13.6 t -86.56 -16.46 36.76 Favored 'General case' 0 C--O 1.26 1.647 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.893 -177.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.61 69.6 1.32 Allowed Glycine 1 C--O 1.3 4.225 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 -172.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -33.75 104.37 0.03 OUTLIER 'General case' 0 CA--C 1.482 -1.645 0 O-C-N 127.49 2.523 . . . . 0.0 116.21 -164.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 140' ' ' ALA . . . . . 0.59 ' HB2' ' OD2' ' A' ' 124' ' ' ASP . . . -153.51 170.5 20.61 Favored 'General case' 0 N--CA 1.401 -2.877 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 171.371 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 141' ' ' GLY . . . . . 0.548 ' HA3' HD23 ' A' ' 144' ' ' LEU . . . -87.4 137.17 14.43 Favored Glycine 0 C--N 1.272 -2.973 0 N-CA-C 105.718 -2.953 . . . . 0.0 105.718 165.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 24.5 m -54.59 -30.24 53.94 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -172.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 143' ' ' ARG . . . . . 0.847 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 30.8 ptt180 -124.15 15.21 9.12 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 144' ' ' LEU . . . . . 0.548 HD23 ' HA3' ' A' ' 141' ' ' GLY . 3.6 mm? -71.04 -9.09 57.44 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -175.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.44 89.29 0.75 Allowed 'General case' 0 N--CA 1.422 -1.826 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 172.057 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 146' ' ' CYS . . . . . 0.418 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 79.4 m -84.75 130.58 34.67 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.27 127.01 1.29 Allowed Glycine 1 N--CA 1.396 -4.014 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.57 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.0 m -74.27 125.47 33.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.998 172.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 149' ' ' ILE . . . . . 0.515 HG22 ' O ' ' A' ' 115' ' ' ARG . 15.5 tt -99.41 136.65 29.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 174.244 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 150' ' ' GLY . . . . . 0.687 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 177.13 167.74 35.97 Favored Glycine 2 CA--C 1.439 -4.663 0 C-N-CA 118.486 -1.816 . . . . 0.0 111.721 179.459 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 151' ' ' ILE . . . . . 0.667 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 5.6 tt -82.26 104.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.348 0 CA-C-O 122.178 0.99 . . . . 0.0 110.29 169.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 152' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -107.75 116.43 31.93 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.373 178.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 . . . . . 0 C--N 1.28 -2.441 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -177.812 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.456 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 N--CA 1.436 -1.146 0 N-CA-C 111.475 0.176 . . . . 0.0 111.475 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.659 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 3.3 m -88.81 -26.92 21.43 Favored 'General case' 0 CA--C 1.568 1.64 0 N-CA-C 115.876 1.806 . . . . 0.0 115.876 -167.646 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.527 ' HB3' ' NZ ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -152.17 158.53 43.03 Favored 'General case' 0 CA--C 1.455 -2.676 0 O-C-N 120.381 -1.449 . . . . 0.0 111.628 176.619 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.572 ' HA ' ' HA ' ' A' ' 151' ' ' ILE . . . -145.19 153.68 41.61 Favored 'General case' 0 N--CA 1.397 -3.081 0 O-C-N 124.081 0.863 . . . . 0.0 109.321 -175.971 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 18.1 m -132.21 132.01 60.91 Favored 'Isoleucine or valine' 0 N--CA 1.418 -2.026 0 N-CA-C 108.851 -0.796 . . . . 0.0 108.851 176.889 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -108.74 136.7 47.88 Favored 'General case' 0 C--N 1.27 -2.853 0 CA-C-N 114.58 -1.191 . . . . 0.0 109.562 177.975 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.624 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 4.4 p -134.27 106.66 8.39 Favored 'Isoleucine or valine' 0 N--CA 1.444 -0.768 0 CA-C-O 121.662 0.744 . . . . 0.0 110.001 178.53 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.464 HD23 ' H ' ' A' ' 8' ' ' LEU . 0.8 OUTLIER -112.42 140.61 47.01 Favored 'General case' 0 C--N 1.298 -1.661 0 CA-C-N 115.531 -0.759 . . . . 0.0 111.184 -178.468 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 52.2 mtpt -144.54 123.48 12.76 Favored 'General case' 0 N--CA 1.448 -0.56 0 N-CA-C 107.234 -1.395 . . . . 0.0 107.234 -179.615 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -131.92 -165.58 11.38 Favored Glycine 0 N--CA 1.434 -1.483 0 C-N-CA 119.682 -1.247 . . . . 0.0 113.707 -174.874 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 33.4 m-20 -74.83 -42.75 57.43 Favored 'General case' 0 C--N 1.312 -1.054 0 N-CA-C 107.061 -1.459 . . . . 0.0 107.061 177.477 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -94.94 154.01 21.05 Favored Glycine 0 N--CA 1.434 -1.498 0 N-CA-C 106.269 -2.733 . . . . 0.0 106.269 170.457 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.2 Cg_exo -77.41 121.7 5.76 Favored 'Trans proline' 0 N--CA 1.42 -2.822 0 CA-C-N 121.324 2.562 . . . . 0.0 109.535 -178.044 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.403 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 17.4 m -133.32 124.98 50.07 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 105.175 -2.157 . . . . 0.0 105.175 179.577 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 54.5 tt0 -150.0 142.73 24.64 Favored 'General case' 0 C--N 1.26 -3.283 0 C-N-CA 118.918 -1.113 . . . . 0.0 108.292 -178.673 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.35 166.74 39.93 Favored Glycine 0 N--CA 1.402 -3.593 0 N-CA-C 110.051 -1.22 . . . . 0.0 110.051 179.899 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.471 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.3 pt -134.33 103.23 4.7 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.816 0 CA-C-O 121.134 0.493 . . . . 0.0 109.692 179.8 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 3.2 mp -103.08 126.83 57.33 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.238 0 N-CA-C 108.454 -0.943 . . . . 0.0 108.454 -179.699 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.575 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 7.7 p30 -125.39 122.56 37.1 Favored 'General case' 0 CA--C 1.497 -1.059 0 N-CA-C 109.124 -0.695 . . . . 0.0 109.124 -179.011 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.471 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 6.4 p90 -128.22 128.19 44.27 Favored 'General case' 0 C--O 1.241 0.653 0 N-CA-C 113.553 0.946 . . . . 0.0 113.553 -177.839 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.659 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.4 pt-20 -106.76 109.23 21.09 Favored 'General case' 0 C--N 1.327 -0.377 0 CA-C-N 115.481 -0.781 . . . . 0.0 111.888 176.695 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.497 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -126.2 162.13 26.12 Favored 'General case' 0 N--CA 1.434 -1.249 0 C-N-CA 124.199 1.0 . . . . 0.0 108.944 -179.938 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 82.8 tttt -154.18 149.41 27.02 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 107.32 -1.363 . . . . 0.0 107.32 174.148 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.7 mt-10 -66.42 -9.08 30.41 Favored 'General case' 0 C--N 1.322 -0.59 0 N-CA-C 112.584 0.587 . . . . 0.0 112.584 -178.103 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 17.6 m -70.38 -8.67 52.51 Favored 'General case' 0 CA--C 1.548 0.868 0 C-N-CA 123.677 0.791 . . . . 0.0 111.655 177.038 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 46.7 t-20 75.6 115.21 0.06 Allowed 'General case' 0 N--CA 1.485 1.324 0 C-N-CA 124.444 1.097 . . . . 0.0 111.212 178.023 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -177.63 150.49 10.06 Favored Glycine 0 N--CA 1.424 -2.127 0 N-CA-C 109.657 -1.377 . . . . 0.0 109.657 178.139 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 48.4 Cg_exo -57.34 131.57 45.61 Favored 'Trans proline' 0 C--O 1.248 1.011 0 C-N-CA 122.585 2.19 . . . . 0.0 110.148 178.426 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.462 HG22 ' OG ' ' A' ' 102' ' ' SER . 2.9 m -83.48 128.46 38.77 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.353 0 C-N-CA 118.754 -1.178 . . . . 0.0 109.376 -178.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.411 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 5.6 mtpm? -85.52 112.81 21.26 Favored 'General case' 0 C--N 1.279 -2.48 0 N-CA-C 106.045 -1.835 . . . . 0.0 106.045 176.373 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.7 p -137.35 138.26 45.26 Favored 'Isoleucine or valine' 0 C--N 1.265 -3.107 0 CA-C-N 114.487 -1.233 . . . . 0.0 109.484 -168.79 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.467 ' HA ' HG11 ' A' ' 97' ' ' VAL . 33.9 t-105 -136.23 132.27 35.63 Favored 'General case' 0 C--N 1.277 -2.559 0 N-CA-C 108.882 -0.784 . . . . 0.0 108.882 178.452 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.714 ' O ' ' HB ' ' A' ' 97' ' ' VAL . . . -151.63 138.89 6.77 Favored Glycine 0 C--O 1.208 -1.486 0 C-N-CA 119.233 -1.46 . . . . 0.0 112.991 173.649 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 18.7 m -116.56 142.7 46.54 Favored 'General case' 0 N--CA 1.408 -2.528 0 N-CA-C 106.893 -1.521 . . . . 0.0 106.893 176.501 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.414 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 76.0 mt -128.71 139.17 52.62 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.024 0 CA-C-N 118.737 0.699 . . . . 0.0 109.335 177.953 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.655 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 22.4 ptmt -117.89 138.74 51.92 Favored 'General case' 0 N--CA 1.411 -2.414 0 N-CA-C 105.803 -1.925 . . . . 0.0 105.803 173.285 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.649 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -161.37 176.56 37.9 Favored Glycine 0 N--CA 1.431 -1.648 0 N-CA-C 111.515 -0.634 . . . . 0.0 111.515 -166.732 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 87.9 mt -69.08 170.89 9.1 Favored 'General case' 0 C--N 1.297 -1.692 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 175.098 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.468 ' HB ' ' O ' ' A' ' 91' ' ' LYS . 2.8 t -69.31 108.29 3.63 Favored 'General case' 0 C--O 1.192 -1.969 0 O-C-N 121.615 -0.678 . . . . 0.0 112.292 -176.257 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 11.1 mt-10 -172.86 171.7 4.26 Favored 'General case' 0 CA--C 1.461 -2.467 0 C-N-CA 124.55 1.14 . . . . 0.0 108.662 174.017 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.464 ' HA2' ' O ' ' A' ' 89' ' ' ALA . . . -82.55 -146.23 5.99 Favored Glycine 0 C--N 1.276 -2.787 0 O-C-N 124.875 1.359 . . . . 0.0 109.779 173.608 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.599 ' HG ' ' O ' ' A' ' 120' ' ' HIS . 2.8 tt 172.4 140.08 0.03 OUTLIER 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 103.709 -2.7 . . . . 0.0 103.709 -179.096 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 37.3 t60 -152.66 122.23 6.84 Favored 'General case' 0 C--N 1.271 -2.844 0 N-CA-C 108.908 -0.775 . . . . 0.0 108.908 178.638 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 77.01 139.05 0.99 Allowed Glycine 0 C--N 1.301 -1.396 0 O-C-N 123.768 0.667 . . . . 0.0 113.999 177.473 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.443 ' CD1' ' HB2' ' A' ' 83' ' ' ASP . 0.2 OUTLIER -114.49 106.53 14.39 Favored 'General case' 0 N--CA 1.426 -1.626 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 176.41 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.548 ' CE1' ' HA3' ' A' ' 138' ' ' GLY . 28.9 t-80 -130.13 89.19 2.76 Favored 'General case' 1 C--O 1.316 4.556 0 CA-C-O 122.134 0.968 . . . . 0.0 109.141 -176.709 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.603 HG13 ' HA ' ' A' ' 117' ' ' LEU . 94.5 t -92.56 152.0 3.51 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.357 0 CA-C-N 112.692 -2.049 . . . . 0.0 107.387 175.085 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -162.05 94.31 0.92 Allowed 'General case' 0 C--N 1.288 -2.074 0 O-C-N 124.083 0.864 . . . . 0.0 110.367 -179.147 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.54 ' CG ' ' HB2' ' A' ' 60' ' ' ALA . 1.3 mm-40 -145.96 170.26 16.98 Favored 'General case' 0 C--N 1.309 -1.19 0 N-CA-C 115.557 1.688 . . . . 0.0 115.557 -174.769 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.417 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 20.5 p90 -139.99 25.86 2.28 Favored 'General case' 0 N--CA 1.41 -2.463 0 CA-C-N 112.238 -2.255 . . . . 0.0 108.815 174.843 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . 84.47 129.02 1.8 Allowed Glycine 0 C--N 1.34 0.804 0 CA-C-N 114.586 -1.188 . . . . 0.0 115.447 178.445 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.9 t70 -140.8 -77.84 0.29 Allowed 'General case' 0 CA--C 1.509 -0.622 0 C-N-CA 118.729 -1.188 . . . . 0.0 112.578 175.811 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.4 ' O ' HG21 ' A' ' 116' ' ' THR . 28.0 t30 -157.69 133.09 8.96 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.025 -1.102 . . . . 0.0 108.025 -178.467 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.431 ' HB ' HG23 ' A' ' 148' ' ' VAL . 13.0 t -73.26 4.6 4.37 Favored 'General case' 0 CA--C 1.553 1.086 0 N-CA-C 112.608 0.595 . . . . 0.0 112.608 -173.904 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -109.69 -2.41 17.44 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-O 120.896 0.379 . . . . 0.0 110.348 177.059 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 157.56 124.72 0.81 Allowed Glycine 0 CA--C 1.483 -1.936 0 N-CA-C 109.134 -1.587 . . . . 0.0 109.134 -177.097 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.492 ' O ' ' HB3' ' A' ' 142' ' ' SER . 0.6 OUTLIER -97.67 112.78 24.52 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 113.565 0.95 . . . . 0.0 113.565 -176.399 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.7 m -75.61 -37.41 59.81 Favored 'General case' 0 C--N 1.299 -1.602 0 CA-C-N 115.188 -0.915 . . . . 0.0 110.252 -179.241 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.417 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 4.6 m -72.56 -26.68 61.82 Favored 'General case' 0 C--O 1.234 0.272 0 CA-C-O 121.621 0.724 . . . . 0.0 110.23 -177.353 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.54 ' HB2' ' CG ' ' A' ' 49' ' ' GLU . . . -76.5 -8.77 57.86 Favored 'General case' 0 CA--C 1.492 -1.272 0 CA-C-N 114.947 -1.024 . . . . 0.0 113.039 -175.551 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -64.69 -93.3 0.03 OUTLIER Glycine 0 C--N 1.301 -1.384 0 C-N-CA 119.841 -1.171 . . . . 0.0 112.345 178.786 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 45.1 Cg_endo -95.88 53.31 0.17 Allowed 'Trans proline' 0 N--CA 1.443 -1.499 0 C-N-CA 121.71 1.606 . . . . 0.0 113.349 -175.456 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.2 t-80 -125.73 117.06 22.64 Favored 'General case' 0 C--N 1.3 -1.572 0 C-N-CA 119.282 -0.967 . . . . 0.0 109.919 178.479 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.561 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 52.8 p90 -87.07 138.52 31.42 Favored 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 120.53 -0.468 . . . . 0.0 110.196 179.846 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 2.4 m-20 -115.51 95.84 44.35 Favored Pre-proline 0 C--N 1.312 -1.033 0 N-CA-C 108.766 -0.827 . . . . 0.0 108.766 176.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.568 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 56.7 Cg_endo -68.86 -10.79 30.14 Favored 'Trans proline' 0 C--O 1.213 -0.744 0 C-N-CA 124.035 3.157 . . . . 0.0 115.031 -173.895 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -77.12 -18.42 57.94 Favored 'General case' 0 C--O 1.199 -1.581 0 N-CA-C 108.632 -0.877 . . . . 0.0 108.632 -173.43 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.695 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 47.5 p -54.63 -84.34 0.01 OUTLIER 'General case' 0 N--CA 1.419 -1.979 0 CA-C-N 114.283 -1.326 . . . . 0.0 113.315 -174.392 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.556 ' HB3' ' H ' ' A' ' 72' ' ' GLY . 1.9 tmt_? -134.91 30.13 3.4 Favored 'General case' 0 C--N 1.249 -3.8 0 N-CA-C 103.01 -2.959 . . . . 0.0 103.01 -179.973 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 66' ' ' PRO . 69.7 mmtt 75.19 -41.23 0.45 Allowed 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 112.759 -2.019 . . . . 0.0 110.04 -169.834 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.466 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 1.8 t-160 -121.74 -16.97 7.55 Favored 'General case' 0 N--CA 1.426 -1.652 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.075 171.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.556 ' H ' ' HB3' ' A' ' 69' ' ' ARG . . . 108.92 16.81 10.95 Favored Glycine 0 C--N 1.358 1.8 0 C-N-CA 118.519 -1.8 . . . . 0.0 115.881 176.836 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -38.26 146.98 0.12 Allowed Glycine 0 N--CA 1.491 2.338 0 CA-C-N 117.978 0.889 . . . . 0.0 113.69 173.511 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 72.6 Cg_endo -73.88 -22.4 17.53 Favored 'Trans proline' 0 C--N 1.351 0.699 0 C-N-CA 123.097 2.531 . . . . 0.0 113.869 -166.429 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 26.8 mtpp -86.87 -12.83 46.66 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-N 115.584 -0.734 . . . . 0.0 109.945 -177.067 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 21.4 t0 70.35 159.93 0.2 Allowed 'General case' 0 CA--C 1.543 0.678 0 C-N-CA 124.493 1.117 . . . . 0.0 111.209 -175.562 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.503 ' HB2' ' NE ' ' A' ' 69' ' ' ARG . 22.7 tp10 -148.47 -24.99 0.33 Allowed 'General case' 0 C--N 1.302 -1.466 0 N-CA-C 107.876 -1.157 . . . . 0.0 107.876 -178.57 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.462 ' HG2' ' HG2' ' A' ' 79' ' ' ARG . 27.6 tt0 -138.67 -64.02 0.53 Allowed 'General case' 0 N--CA 1.423 -1.815 0 C-N-CA 118.237 -1.385 . . . . 0.0 110.755 -176.029 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.695 ' O ' ' HA ' ' A' ' 68' ' ' SER . 15.4 ptt180 -173.72 62.6 0.02 OUTLIER 'General case' 0 N--CA 1.398 -3.052 0 N-CA-C 105.063 -2.199 . . . . 0.0 105.063 -173.775 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.439 ' HA ' ' HB2' ' A' ' 68' ' ' SER . 4.5 t60 -42.16 96.45 0.01 OUTLIER 'General case' 0 N--CA 1.428 -1.539 0 CA-C-N 113.315 -1.766 . . . . 0.0 107.022 170.205 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.682 HG13 ' O ' ' A' ' 79' ' ' ARG . 15.3 m -82.56 58.76 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.835 0 CA-C-O 123.979 1.847 . . . . 0.0 111.395 -176.508 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.524 ' CA ' ' HB ' ' A' ' 47' ' ' VAL . . . -175.22 174.31 46.72 Favored Glycine 0 C--N 1.266 -3.312 0 CA-C-N 110.592 -3.003 . . . . 0.0 106.497 178.286 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.443 ' HB2' ' CD1' ' A' ' 45' ' ' PHE . 19.3 m-20 -69.65 139.74 53.56 Favored 'General case' 0 C--N 1.296 -1.75 0 CA-C-N 118.948 1.374 . . . . 0.0 108.493 179.533 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.443 HD11 HG21 ' A' ' 29' ' ' VAL . 0.0 OUTLIER -117.94 119.71 35.63 Favored 'General case' 0 C--N 1.293 -1.872 0 CA-C-O 121.751 0.786 . . . . 0.0 110.145 -175.511 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.25 -178.64 47.61 Favored Glycine 1 N--CA 1.386 -4.684 0 N-CA-C 108.105 -1.998 . . . . 0.0 108.105 176.192 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 60.6 t30 -128.2 129.74 46.92 Favored 'General case' 0 C--N 1.263 -3.194 0 N-CA-C 105.808 -1.923 . . . . 0.0 105.808 169.684 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.582 HG23 HD22 ' A' ' 42' ' ' LEU . 0.6 OUTLIER -133.78 147.89 30.61 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.083 0 N-CA-C 106.918 -1.512 . . . . 0.0 106.918 -178.68 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.529 ' HA ' ' HB3' ' A' ' 42' ' ' LEU . 89.0 m -139.93 113.0 8.21 Favored 'General case' 0 N--CA 1.424 -1.727 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -176.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.464 ' O ' ' HA2' ' A' ' 41' ' ' GLY . . . -83.44 150.98 25.7 Favored 'General case' 0 N--CA 1.411 -2.375 0 N-CA-C 109.54 -0.541 . . . . 0.0 109.54 -177.083 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.468 ' OD1' ' HG2' ' A' ' 91' ' ' LYS . 9.8 t70 -93.13 -179.02 4.96 Favored 'General case' 0 C--N 1.277 -2.577 0 N-CA-C 107.113 -1.44 . . . . 0.0 107.113 174.5 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.468 ' HG2' ' OD1' ' A' ' 90' ' ' ASP . 22.1 pttp -61.21 -16.23 42.72 Favored 'General case' 0 C--N 1.306 -1.29 0 C-N-CA 124.459 1.104 . . . . 0.0 111.822 178.566 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 5.6 m-20 -98.3 4.62 48.71 Favored 'General case' 0 C--N 1.295 -1.777 0 O-C-N 121.937 -0.477 . . . . 0.0 110.002 178.68 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.655 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 60.96 83.17 0.06 OUTLIER Glycine 0 N--CA 1.435 -1.43 0 CA-C-N 115.454 -0.794 . . . . 0.0 112.047 -175.751 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.433 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 5.1 m -155.75 111.15 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.362 0 N-CA-C 106.677 -1.601 . . . . 0.0 106.677 -177.305 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.572 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -119.44 123.97 45.37 Favored 'General case' 0 N--CA 1.415 -2.184 0 C-N-CA 120.407 -0.517 . . . . 0.0 110.644 -178.632 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.8 t70 -84.66 145.38 28.01 Favored 'General case' 0 C--N 1.311 -1.1 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 175.998 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.714 ' HB ' ' O ' ' A' ' 33' ' ' GLY . 7.5 p -84.55 125.84 40.27 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.759 0 N-CA-C 113.211 0.819 . . . . 0.0 113.211 -173.584 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.4 t -90.48 115.52 27.7 Favored 'General case' 0 N--CA 1.404 -2.735 0 N-CA-C 105.83 -1.915 . . . . 0.0 105.83 168.855 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.419 HG12 ' O ' ' A' ' 31' ' ' VAL . 34.9 mt -92.02 118.26 37.11 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.657 0 N-CA-C 106.712 -1.588 . . . . 0.0 106.712 -179.703 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 37.8 mm-40 -107.34 156.04 19.34 Favored 'General case' 0 C--N 1.305 -1.331 0 CA-C-N 116.368 -0.378 . . . . 0.0 110.915 -175.149 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 19.5 m-20 -81.28 99.69 8.76 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 122.088 0.947 . . . . 0.0 109.452 178.945 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.462 ' OG ' HG22 ' A' ' 29' ' ' VAL . 0.3 OUTLIER -97.79 171.74 8.12 Favored 'General case' 0 C--N 1.265 -3.091 0 CA-C-N 113.499 -1.682 . . . . 0.0 110.238 -175.922 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.553 HG12 HG13 ' A' ' 104' ' ' ILE . 26.5 t -109.32 -64.51 1.65 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.368 0 C-N-CA 119.658 -0.817 . . . . 0.0 111.446 -177.621 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.553 HG13 HG12 ' A' ' 103' ' ' VAL . 8.4 mt -134.18 24.97 1.11 Allowed 'Isoleucine or valine' 0 CA--C 1.55 0.947 0 CA-C-O 121.326 0.584 . . . . 0.0 109.854 -177.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.427 ' OG ' ' HB3' ' A' ' 80' ' ' HIS . 33.3 t -68.99 88.49 0.4 Allowed 'General case' 0 C--N 1.303 -1.425 0 N-CA-C 115.276 1.584 . . . . 0.0 115.276 -170.411 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.562 HD23 ' H ' ' A' ' 106' ' ' LEU . 1.7 pt? -96.49 136.31 37.18 Favored 'General case' 0 N--CA 1.429 -1.508 0 N-CA-C 104.388 -2.449 . . . . 0.0 104.388 160.331 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 14.5 m -71.89 86.21 0.98 Allowed 'General case' 0 C--N 1.286 -2.174 0 CA-C-O 122.349 1.071 . . . . 0.0 112.755 -175.418 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.495 ' HA3' ' O ' ' A' ' 111' ' ' SER . . . 143.2 135.74 3.06 Favored Glycine 0 N--CA 1.409 -3.145 0 CA-C-N 114.914 -1.039 . . . . 0.0 111.821 170.595 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.518 ' HB3' HG11 ' A' ' 81' ' ' VAL . 7.4 p-10 -93.46 -28.03 16.35 Favored 'General case' 0 CA--C 1.503 -0.84 0 O-C-N 122.903 -0.174 . . . . 0.0 111.434 -177.336 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 48.4 m80 -91.22 -23.43 20.2 Favored 'General case' 0 C--N 1.317 -0.839 0 C-N-CA 119.285 -0.966 . . . . 0.0 110.0 -178.98 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.668 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t 177.11 178.89 0.25 Allowed 'General case' 0 N--CA 1.426 -1.666 0 N-CA-C 104.083 -2.562 . . . . 0.0 104.083 173.097 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 0.4 OUTLIER -113.43 -56.46 4.2 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.32 0 C-N-CA 124.589 1.156 . . . . 0.0 109.878 -175.361 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.47 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 52.5 mt -68.37 119.51 14.27 Favored 'Isoleucine or valine' 0 C--O 1.196 -1.723 0 N-CA-C 109.552 -0.536 . . . . 0.0 109.552 -177.089 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.547 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 115.66 -19.27 14.38 Favored Glycine 0 CA--C 1.47 -2.751 0 N-CA-C 109.245 -1.542 . . . . 0.0 109.245 175.282 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.668 ' CZ ' ' HB3' ' A' ' 111' ' ' SER . 4.5 mpt_? -74.85 128.45 35.61 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 108.385 -0.969 . . . . 0.0 108.385 -178.284 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.707 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 0.2 OUTLIER -92.01 126.88 37.26 Favored 'General case' 0 C--N 1.258 -3.389 0 N-CA-C 113.259 0.837 . . . . 0.0 113.259 -174.62 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.603 ' HA ' HG13 ' A' ' 47' ' ' VAL . 2.0 pt? -76.62 136.88 39.2 Favored 'General case' 0 C--N 1.318 -0.773 0 N-CA-C 112.527 0.566 . . . . 0.0 112.527 -177.423 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . . . . . . . . . 1.0 OUTLIER -115.9 99.57 8.69 Favored 'Isoleucine or valine' 0 C--O 1.28 2.661 0 CA-C-N 115.674 -0.694 . . . . 0.0 111.654 171.111 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.682 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.4 p -147.42 170.39 3.68 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.138 0 N-CA-C 104.748 -2.316 . . . . 0.0 104.748 178.226 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.599 ' O ' ' HG ' ' A' ' 42' ' ' LEU . 81.7 t60 -170.89 171.25 6.06 Favored 'General case' 0 C--N 1.298 -1.656 0 N-CA-C 103.312 -2.848 . . . . 0.0 103.312 175.536 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.526 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.04 87.07 0.37 Allowed 'General case' 0 C--N 1.291 -1.947 0 N-CA-C 104.874 -2.269 . . . . 0.0 104.874 171.278 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.499 ' H ' ' HG ' ' A' ' 42' ' ' LEU . 16.3 tppt? -173.18 154.76 2.79 Favored 'General case' 0 N--CA 1.434 -1.266 0 N-CA-C 107.716 -1.216 . . . . 0.0 107.716 -172.74 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -66.37 103.88 1.11 Allowed 'General case' 0 C--N 1.285 -2.236 0 CA-C-O 121.89 0.852 . . . . 0.0 109.991 166.138 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 11.8 t70 -106.51 70.31 0.82 Allowed 'General case' 0 C--N 1.296 -1.736 0 N-CA-C 104.549 -2.389 . . . . 0.0 104.549 175.877 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 8.8 t70 -68.11 161.41 26.95 Favored 'General case' 0 N--CA 1.438 -1.051 0 CA-C-N 114.716 -1.129 . . . . 0.0 112.128 -170.267 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.534 ' H ' HD22 ' A' ' 126' ' ' LEU . 0.3 OUTLIER -90.48 -68.92 0.76 Allowed 'General case' 0 N--CA 1.397 -3.103 0 CA-C-N 113.83 -1.532 . . . . 0.0 110.996 -167.381 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.466 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -102.82 -16.55 21.41 Favored Glycine 0 N--CA 1.429 -1.773 0 CA-C-N 114.888 -1.051 . . . . 0.0 112.984 -177.752 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 75.5 mmtt -90.99 -31.51 16.3 Favored 'General case' 0 C--N 1.316 -0.887 0 CA-C-N 117.16 0.48 . . . . 0.0 110.367 178.897 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.483 ' HA3' ' O ' ' A' ' 134' ' ' SER . . . 53.7 -89.25 0.01 OUTLIER Glycine 0 CA--C 1.53 0.972 0 O-C-N 123.709 0.63 . . . . 0.0 114.175 -177.251 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -172.84 -86.19 0.06 OUTLIER Glycine 0 N--CA 1.438 -1.197 0 N-CA-C 109.665 -1.374 . . . . 0.0 109.665 179.924 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 7.6 t30 -96.78 162.33 13.47 Favored 'General case' 0 C--N 1.306 -1.284 0 N-CA-C 106.908 -1.515 . . . . 0.0 106.908 176.859 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.518 ' O ' ' HB ' ' A' ' 135' ' ' THR . 10.1 pt-20 -38.9 -51.32 1.76 Allowed 'General case' 0 N--CA 1.499 2.011 0 N-CA-C 115.827 1.788 . . . . 0.0 115.827 -170.517 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -71.62 -38.09 70.82 Favored 'General case' 0 C--N 1.311 -1.083 0 O-C-N 122.12 -0.362 . . . . 0.0 111.854 -179.542 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.483 ' O ' ' HA3' ' A' ' 129' ' ' GLY . 14.4 m -72.45 -22.92 61.01 Favored 'General case' 0 C--O 1.218 -0.568 0 CA-C-O 121.488 0.661 . . . . 0.0 109.619 178.479 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.518 ' HB ' ' O ' ' A' ' 132' ' ' GLU . 66.4 m -67.16 -39.88 86.57 Favored 'General case' 0 N--CA 1.442 -0.835 0 CA-C-O 121.949 0.881 . . . . 0.0 108.845 173.437 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 82.5 tttt -71.3 -51.33 24.96 Favored 'General case' 0 C--N 1.295 -1.767 0 CA-C-N 114.022 -1.445 . . . . 0.0 110.046 -177.656 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.561 ' HA ' ' HB3' ' A' ' 64' ' ' PHE . 41.1 p -74.68 -31.23 61.84 Favored 'General case' 0 N--CA 1.419 -2.006 0 CA-C-N 115.638 -0.71 . . . . 0.0 111.673 -177.317 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.548 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . 82.35 106.12 0.43 Allowed Glycine 0 N--CA 1.416 -2.646 0 N-CA-C 107.407 -2.277 . . . . 0.0 107.407 -174.243 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.2 t30 -32.84 140.31 0.04 OUTLIER 'General case' 1 C--O 1.329 5.254 0 C-N-CA 126.463 1.905 . . . . 0.0 115.47 -165.534 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -150.49 120.2 7.03 Favored 'General case' 0 N--CA 1.414 -2.262 0 CA-C-N 114.356 -1.293 . . . . 0.0 111.323 -178.93 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -98.94 89.08 0.88 Allowed Glycine 0 N--CA 1.417 -2.588 0 N-CA-C 106.08 -2.808 . . . . 0.0 106.08 169.858 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.492 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 6.2 m -42.79 -35.3 1.12 Allowed 'General case' 0 C--N 1.315 -0.934 0 C-N-CA 126.727 2.011 . . . . 0.0 114.252 -171.383 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 17.9 ptt180 -125.35 5.12 7.71 Favored 'General case' 0 N--CA 1.414 -2.258 0 C-N-CA 119.745 -0.782 . . . . 0.0 111.061 -177.709 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -70.09 -27.38 64.55 Favored 'General case' 0 C--N 1.291 -1.957 0 C-N-CA 119.982 -0.687 . . . . 0.0 111.259 -175.384 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.682 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.8 96.88 0.17 Allowed 'General case' 0 CA--C 1.477 -1.828 0 N-CA-C 105.945 -1.872 . . . . 0.0 105.945 175.32 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.707 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 43.4 t -140.5 147.78 40.08 Favored 'General case' 0 N--CA 1.412 -2.364 0 CA-C-N 116.035 -0.53 . . . . 0.0 110.087 -176.63 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.624 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.15 162.41 34.46 Favored Glycine 0 N--CA 1.403 -3.513 0 N-CA-C 109.066 -1.614 . . . . 0.0 109.066 179.218 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.431 HG23 ' HB ' ' A' ' 54' ' ' THR . 17.6 t -68.74 122.88 20.96 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.766 0 CA-C-O 121.799 0.809 . . . . 0.0 111.149 175.326 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.647 HG12 ' O ' ' A' ' 115' ' ' ARG . 26.1 pt -111.97 146.25 17.06 Favored 'Isoleucine or valine' 0 CA--C 1.476 -1.868 0 N-CA-C 107.355 -1.35 . . . . 0.0 107.355 177.89 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.47 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.17 155.92 15.44 Favored Glycine 2 N--CA 1.365 -6.07 0 C-N-CA 117.566 -2.254 . . . . 0.0 111.632 178.867 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.572 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 25.1 pt -63.08 105.6 0.43 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.812 0 CA-C-N 114.854 -0.673 . . . . 0.0 110.369 170.725 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.53 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -105.62 114.15 28.14 Favored 'General case' 0 C--N 1.309 -1.168 0 O-C-N 121.9 -0.5 . . . . 0.0 110.663 177.612 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 53.4 tt0 . . . . . 0 N--CA 1.429 -1.511 0 N-CA-C 108.04 -1.096 . . . . 0.0 108.04 178.318 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.463 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.226 -0.168 0 CA-C-O 120.629 0.252 . . . . 0.0 110.932 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 4.1 p -81.65 -65.6 0.99 Allowed 'General case' 0 N--CA 1.438 -1.063 0 N-CA-C 112.568 0.581 . . . . 0.0 112.568 178.581 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 18.6 ptpt -170.78 171.98 5.89 Favored 'General case' 0 CA--C 1.488 -1.406 0 N-CA-C 107.713 -1.217 . . . . 0.0 107.713 -176.52 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.629 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -130.8 149.25 52.53 Favored 'General case' 0 N--CA 1.414 -2.225 0 N-CA-C 106.105 -1.813 . . . . 0.0 106.105 172.038 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.54 ' O ' ' HA ' ' A' ' 149' ' ' ILE . 10.6 p -126.9 142.86 42.19 Favored 'Isoleucine or valine' 0 C--N 1.285 -2.215 0 N-CA-C 108.001 -1.111 . . . . 0.0 108.001 177.972 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.622 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -122.44 129.69 52.31 Favored 'General case' 0 C--N 1.286 -2.171 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.79 -177.533 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.5 t -129.15 111.73 23.57 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 N-CA-C 107.638 -1.245 . . . . 0.0 107.638 176.44 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.3 mp -108.08 152.12 24.95 Favored 'General case' 0 C--N 1.311 -1.107 0 C-N-CA 120.972 -0.291 . . . . 0.0 111.243 178.597 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 6.6 ttpm? -136.08 131.36 34.73 Favored 'General case' 0 CA--C 1.505 -0.759 0 N-CA-C 106.187 -1.782 . . . . 0.0 106.187 175.751 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.42 ' HA3' ' O ' ' A' ' 12' ' ' GLY . . . -104.21 148.86 16.95 Favored Glycine 0 N--CA 1.41 -3.099 0 N-CA-C 117.991 1.956 . . . . 0.0 117.991 -168.32 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 32.3 t70 -83.78 -19.5 34.94 Favored 'General case' 0 N--CA 1.47 0.561 0 CA-C-N 111.629 -2.286 . . . . 0.0 104.92 168.298 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . 0.42 ' O ' ' HA3' ' A' ' 10' ' ' GLY . . . -142.71 144.52 14.07 Favored Glycine 0 N--CA 1.421 -2.328 1 N-CA-C 101.215 -4.754 . . . . 0.0 101.215 168.858 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 9.1 Cg_exo -69.74 124.82 11.47 Favored 'Trans proline' 0 N--CA 1.452 -0.969 0 CA-C-N 122.221 3.01 . . . . 0.0 112.989 -168.053 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 7.7 p -132.6 104.94 8.01 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.997 0 CA-C-N 114.129 -1.396 . . . . 0.0 108.481 176.224 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.6 mt-30 -117.87 119.95 36.41 Favored 'General case' 0 C--N 1.299 -1.614 0 O-C-N 121.202 -0.936 . . . . 0.0 111.879 -175.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.52 ' HA3' HD12 ' A' ' 35' ' ' ILE . . . -170.54 171.83 43.85 Favored Glycine 0 N--CA 1.44 -1.042 0 N-CA-C 111.369 -0.693 . . . . 0.0 111.369 -179.835 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 13.9 pt -143.6 131.75 18.84 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.031 0 N-CA-C 106.619 -1.623 . . . . 0.0 106.619 -178.381 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.622 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.8 mp -128.96 133.3 66.35 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.325 0 N-CA-C 109.168 -0.679 . . . . 0.0 109.168 -178.176 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.623 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 3.2 m-20 -117.21 126.71 53.2 Favored 'General case' 0 CA--C 1.493 -1.236 0 N-CA-C 107.991 -1.114 . . . . 0.0 107.991 -179.934 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.629 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 67.8 t80 -129.03 119.63 24.59 Favored 'General case' 0 C--N 1.318 -0.775 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -178.693 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.426 ' CG ' ' HB3' ' A' ' 30' ' ' LYS . 10.5 pt-20 -131.14 113.53 14.01 Favored 'General case' 0 C--N 1.309 -1.159 0 CA-C-O 121.352 0.596 . . . . 0.0 111.823 177.796 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.688 ' HG3' ' HB3' ' A' ' 106' ' ' LEU . 0.0 OUTLIER -86.59 163.88 17.18 Favored 'General case' 0 N--CA 1.414 -2.228 0 N-CA-C 105.897 -1.89 . . . . 0.0 105.897 168.049 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 74.5 mmtt -96.45 146.92 24.35 Favored 'General case' 0 C--N 1.275 -2.669 0 C-N-CA 119.088 -1.045 . . . . 0.0 112.429 -172.896 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 40.3 tt0 -56.64 -40.69 75.87 Favored 'General case' 0 N--CA 1.446 -0.671 0 O-C-N 124.8 1.313 . . . . 0.0 109.735 178.038 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 16.4 p -81.25 -70.99 0.49 Allowed 'General case' 0 N--CA 1.422 -1.858 0 N-CA-C 108.133 -1.062 . . . . 0.0 108.133 174.37 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 27.7 p-10 168.21 161.26 0.04 OUTLIER 'General case' 0 C--N 1.32 -0.677 0 C-N-CA 126.413 1.885 . . . . 0.0 106.386 175.757 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.582 ' H ' HG23 ' A' ' 103' ' ' VAL . . . 155.6 174.01 24.96 Favored Glycine 0 N--CA 1.41 -3.077 0 N-CA-C 107.973 -2.051 . . . . 0.0 107.973 174.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 23.9 Cg_exo -63.9 136.88 55.13 Favored 'Trans proline' 0 N--CA 1.441 -1.599 0 C-N-CA 121.732 1.621 . . . . 0.0 108.889 177.016 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.595 HG12 ' HA ' ' A' ' 22' ' ' GLN . 30.1 m -74.17 147.6 8.89 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.88 0 CA-C-O 121.849 0.833 . . . . 0.0 110.813 -179.093 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.454 ' HA ' HD11 ' A' ' 99' ' ' ILE . 28.2 ttmt -99.28 115.05 28.25 Favored 'General case' 0 C--N 1.281 -2.371 0 N-CA-C 105.644 -1.984 . . . . 0.0 105.644 174.435 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.575 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 7.5 p -137.58 128.62 39.23 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-O 121.253 0.549 . . . . 0.0 110.337 -177.351 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.401 ' HA ' HG11 ' A' ' 97' ' ' VAL . 89.1 t90 -133.37 126.88 32.28 Favored 'General case' 0 C--N 1.283 -2.285 0 N-CA-C 107.38 -1.341 . . . . 0.0 107.38 -179.98 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.63 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -142.0 139.72 9.51 Favored Glycine 0 N--CA 1.407 -3.246 0 C-N-CA 119.162 -1.494 . . . . 0.0 112.495 178.487 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.43 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 42.6 t -114.19 145.64 41.43 Favored 'General case' 0 C--N 1.284 -2.27 0 N-CA-C 107.292 -1.374 . . . . 0.0 107.292 176.418 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.646 HG22 ' HB2' ' A' ' 95' ' ' ALA . 3.2 tp -152.09 139.44 13.47 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.151 0 N-CA-C 107.51 -1.292 . . . . 0.0 107.51 174.266 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.546 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 99.9 mttt -130.62 107.36 9.13 Favored 'General case' 0 C--N 1.281 -2.393 0 N-CA-C 107.422 -1.325 . . . . 0.0 107.422 176.614 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.666 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -131.93 174.98 19.98 Favored Glycine 0 C--N 1.282 -2.434 0 N-CA-C 109.192 -1.563 . . . . 0.0 109.192 -171.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.458 ' O ' ' HG3' ' A' ' 121' ' ' GLU . 93.1 mt -68.72 170.14 9.98 Favored 'General case' 0 C--N 1.304 -1.381 0 CA-C-N 118.113 0.956 . . . . 0.0 109.881 177.788 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.547 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 2.0 t -70.7 105.34 3.14 Favored 'General case' 0 CA--C 1.55 0.98 0 N-CA-C 114.367 1.247 . . . . 0.0 114.367 -171.518 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 7.3 mt-10 -177.26 165.06 2.24 Favored 'General case' 0 CA--C 1.456 -2.642 0 C-N-CA 128.594 2.758 . . . . 0.0 104.918 169.825 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.706 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 158.49 130.32 1.16 Allowed Glycine 3 N--CA 1.376 -5.338 0 C-N-CA 118.2 -1.952 . . . . 0.0 111.166 170.198 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 4.0 mp -124.44 -86.33 0.63 Allowed 'General case' 0 N--CA 1.396 -3.174 0 N-CA-C 106.858 -1.534 . . . . 0.0 106.858 179.471 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.491 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 79.9 m-70 -172.14 162.71 5.79 Favored 'General case' 0 CA--C 1.487 -1.444 0 N-CA-C 105.44 -2.059 . . . . 0.0 105.44 174.33 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 132.75 144.83 5.32 Favored Glycine 0 C--N 1.29 -2.002 0 C-N-CA 119.288 -1.434 . . . . 0.0 113.092 174.502 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.64 ' CE1' ' HB ' ' A' ' 47' ' ' VAL . 30.9 t80 -165.8 96.54 0.63 Allowed 'General case' 0 C--N 1.295 -1.774 0 C-N-CA 124.927 1.291 . . . . 0.0 108.294 175.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.613 ' HB2' ' HA ' ' A' ' 125' ' ' ASP . 0.2 OUTLIER -114.33 89.49 3.11 Favored 'General case' 0 N--CA 1.403 -2.794 0 N-CA-C 105.804 -1.925 . . . . 0.0 105.804 177.599 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.64 ' HB ' ' CE1' ' A' ' 45' ' ' PHE . 14.6 p -69.85 168.0 1.72 Allowed 'Isoleucine or valine' 0 N--CA 1.4 -2.927 0 CA-C-N 111.603 -2.544 . . . . 0.0 107.19 175.975 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 9.6 t60 -154.1 104.33 2.62 Favored 'General case' 1 C--N 1.233 -4.491 0 CA-C-N 114.549 -1.205 . . . . 0.0 108.232 173.673 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.572 ' HB2' ' HB3' ' A' ' 109' ' ' ASP . 1.5 mp0 -67.77 158.34 32.64 Favored 'General case' 0 C--N 1.291 -1.966 0 CA-C-N 114.017 -1.447 . . . . 0.0 109.16 178.929 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.1 t80 77.95 64.01 0.03 OUTLIER 'General case' 0 C--N 1.314 -0.944 0 CA-C-O 123.887 1.804 . . . . 0.0 107.423 -166.439 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.475 ' HA3' ' OG1' ' A' ' 116' ' ' THR . . . -112.63 -126.15 4.57 Favored Glycine 0 N--CA 1.416 -2.668 0 CA-C-N 111.454 -2.612 . . . . 0.0 107.173 174.634 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.436 ' H ' HG23 ' A' ' 116' ' ' THR . 33.0 t70 -176.97 -71.6 0.01 OUTLIER 'General case' 0 N--CA 1.474 0.759 0 CA-C-N 117.946 0.873 . . . . 0.0 112.758 177.997 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 37.6 p30 -131.76 177.1 7.78 Favored 'General case' 0 C--N 1.312 -1.035 0 CA-C-O 121.682 0.753 . . . . 0.0 112.947 -174.193 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.474 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 25.9 m -84.21 6.85 21.05 Favored 'General case' 0 C--N 1.299 -1.621 0 C-N-CA 125.919 1.688 . . . . 0.0 110.602 179.904 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -83.27 -32.05 26.62 Favored 'General case' 0 C--N 1.304 -1.392 0 CA-C-N 115.677 -0.692 . . . . 0.0 109.752 -178.623 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 164.24 155.83 8.54 Favored Glycine 0 N--CA 1.412 -2.911 0 N-CA-C 108.859 -1.697 . . . . 0.0 108.859 179.042 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.62 ' SG ' HG22 ' A' ' 118' ' ' VAL . 58.2 m -83.25 89.58 7.0 Favored 'General case' 0 C--N 1.293 -1.883 0 N-CA-C 108.605 -0.887 . . . . 0.0 108.605 179.476 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.4 p -75.81 -58.69 3.13 Favored 'General case' 0 N--CA 1.421 -1.923 0 CA-C-N 114.639 -1.164 . . . . 0.0 109.965 178.73 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 70.8 m -68.7 -42.68 77.39 Favored 'General case' 0 N--CA 1.425 -1.701 0 N-CA-C 113.633 0.975 . . . . 0.0 113.633 -178.082 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.47 -25.5 54.39 Favored 'General case' 0 N--CA 1.429 -1.502 0 C-N-CA 119.713 -0.795 . . . . 0.0 112.356 -176.605 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.446 ' O ' HG21 ' A' ' 118' ' ' VAL . . . 49.24 -144.57 8.12 Favored Glycine 0 CA--C 1.531 1.071 0 N-CA-C 111.418 -0.673 . . . . 0.0 111.418 -176.776 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 84.7 Cg_endo -100.23 5.73 0.76 Allowed 'Trans proline' 0 CA--C 1.543 0.949 0 C-N-CA 122.803 2.335 . . . . 0.0 110.658 173.667 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 61.8 t60 -77.47 149.69 35.01 Favored 'General case' 0 N--CA 1.447 -0.593 0 CA-C-N 114.929 -1.032 . . . . 0.0 111.826 -169.248 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.481 ' HB2' ' O ' ' A' ' 80' ' ' HIS . 13.3 p90 -81.1 169.95 16.79 Favored 'General case' 0 C--N 1.318 -0.763 0 N-CA-C 112.882 0.697 . . . . 0.0 112.882 179.86 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.537 ' HB3' ' OG ' ' A' ' 68' ' ' SER . 53.0 t30 -105.52 143.19 26.31 Favored Pre-proline 0 C--N 1.303 -1.441 0 CA-C-N 115.68 -0.691 . . . . 0.0 109.77 -174.546 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 13.3 Cg_exo -75.32 -13.58 20.71 Favored 'Trans proline' 0 C--O 1.225 -0.151 0 C-N-CA 121.79 1.66 . . . . 0.0 110.963 175.167 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 31.3 tp -108.63 21.64 17.01 Favored 'General case' 0 N--CA 1.434 -1.248 0 CA-C-O 122.72 1.248 . . . . 0.0 108.69 -171.802 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.651 ' HB3' ' O ' ' A' ' 82' ' ' GLY . 46.3 m -73.98 -1.53 20.26 Favored 'General case' 0 C--O 1.196 -1.734 0 CA-C-N 114.474 -1.239 . . . . 0.0 109.265 174.274 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.645 ' HA ' ' H ' ' A' ' 79' ' ' ARG . 3.9 mmp_? -68.59 -4.03 13.91 Favored 'General case' 0 CA--C 1.503 -0.864 0 C-N-CA 129.158 2.983 . . . . 0.0 109.589 177.552 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 68.8 mttm -140.54 29.73 1.94 Allowed 'General case' 0 C--N 1.302 -1.46 0 CA-C-N 114.725 -1.125 . . . . 0.0 108.196 176.626 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.5 ' HB3' ' N ' ' A' ' 84' ' ' LEU . 99.0 m-70 -143.97 -93.08 0.11 Allowed 'General case' 0 CA--C 1.556 1.176 0 C-N-CA 124.249 1.02 . . . . 0.0 109.392 176.326 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.601 ' HA2' ' HB2' ' A' ' 79' ' ' ARG . . . 81.94 -63.62 4.36 Favored Glycine 0 CA--C 1.501 -0.824 0 N-CA-C 116.24 1.256 . . . . 0.0 116.24 173.049 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.36 161.35 35.16 Favored Glycine 0 C--N 1.264 -3.454 0 N-CA-C 107.566 -2.214 . . . . 0.0 107.566 -179.098 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.565 ' HA ' ' HG ' ' A' ' 84' ' ' LEU . 19.2 Cg_endo -55.58 -30.35 74.23 Favored 'Trans proline' 0 CA--C 1.543 0.972 0 C-N-CA 123.877 3.051 . . . . 0.0 115.266 -174.663 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 12.7 tppt? -101.97 -5.09 25.07 Favored 'General case' 0 C--N 1.311 -1.097 0 CA-C-O 121.318 0.58 . . . . 0.0 110.144 -177.778 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 4.0 t70 -110.38 -163.45 0.86 Allowed 'General case' 0 C--N 1.311 -1.083 0 N-CA-C 107.64 -1.244 . . . . 0.0 107.64 -177.679 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 11.3 pt-20 -171.18 41.57 0.02 OUTLIER 'General case' 0 CA--C 1.531 0.24 0 C-N-CA 123.835 0.854 . . . . 0.0 111.182 179.356 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.702 ' O ' ' HG2' ' A' ' 79' ' ' ARG . 11.4 pt-20 -163.15 149.25 12.04 Favored 'General case' 0 C--O 1.161 -3.584 0 CA-C-O 116.657 -1.64 . . . . 0.0 106.721 175.313 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.702 ' HG2' ' O ' ' A' ' 78' ' ' GLU . 6.2 mmt180 161.84 -165.1 0.0 OUTLIER 'General case' 0 N--CA 1.495 1.802 0 C-N-CA 128.125 2.57 . . . . 0.0 107.848 170.405 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.481 ' O ' ' HB2' ' A' ' 64' ' ' PHE . 43.3 m-70 -141.07 -34.92 0.48 Allowed 'General case' 0 C--N 1.276 -2.629 0 C-N-CA 125.619 1.568 . . . . 0.0 108.278 171.585 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 38.5 t -90.17 -8.46 10.67 Favored 'Isoleucine or valine' 0 CA--C 1.563 1.456 0 N-CA-C 112.917 0.71 . . . . 0.0 112.917 -175.012 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.651 ' O ' ' HB3' ' A' ' 68' ' ' SER . . . -141.7 159.15 26.82 Favored Glycine 0 C--O 1.214 -1.15 0 C-N-CA 119.595 -1.288 . . . . 0.0 112.503 -175.873 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 21.5 m-20 -130.04 172.39 11.79 Favored 'General case' 0 C--O 1.205 -1.262 0 CA-C-N 117.358 0.579 . . . . 0.0 111.288 -176.65 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.565 ' HG ' ' HA ' ' A' ' 74' ' ' PRO . 6.7 tt -98.9 107.11 19.47 Favored 'General case' 0 C--N 1.292 -1.924 0 N-CA-C 113.821 1.045 . . . . 0.0 113.821 -165.67 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.592 ' C ' ' HB3' ' A' ' 45' ' ' PHE . . . 176.88 178.66 46.8 Favored Glycine 0 N--CA 1.443 -0.862 0 N-CA-C 110.054 -1.218 . . . . 0.0 110.054 169.496 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.489 ' N ' ' HB3' ' A' ' 45' ' ' PHE . 8.8 p30 -159.42 135.69 9.0 Favored 'General case' 0 C--N 1.311 -1.081 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 173.901 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.434 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 75.2 t -127.56 151.61 34.6 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.293 0 N-CA-C 105.246 -2.131 . . . . 0.0 105.246 176.731 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.42 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 18.6 m -134.65 148.59 50.4 Favored 'General case' 0 N--CA 1.404 -2.758 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 -177.107 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.706 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -149.12 153.59 37.98 Favored 'General case' 1 C--N 1.243 -4.053 0 N-CA-C 102.199 -3.26 . . . . 0.0 102.199 173.012 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.43 ' CG ' ' H ' ' A' ' 91' ' ' LYS . 13.6 t70 -128.0 -158.24 0.86 Allowed 'General case' 0 C--N 1.251 -3.686 0 N-CA-C 106.497 -1.668 . . . . 0.0 106.497 172.967 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.547 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 60.5 mttp -68.25 5.85 0.89 Allowed 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 124.138 0.975 . . . . 0.0 113.278 -179.489 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -116.76 -9.38 11.27 Favored 'General case' 0 C--N 1.31 -1.112 0 N-CA-C 108.513 -0.921 . . . . 0.0 108.513 175.009 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.666 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 64.77 72.93 0.63 Allowed Glycine 0 C--O 1.224 -0.526 0 CA-C-N 115.936 -0.574 . . . . 0.0 112.897 -175.864 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.463 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 62.8 t -154.57 133.3 3.06 Favored 'Isoleucine or valine' 0 C--O 1.236 0.385 0 N-CA-C 106.819 -1.548 . . . . 0.0 106.819 -175.624 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.646 ' HB2' HG22 ' A' ' 35' ' ' ILE . . . -94.35 127.22 40.1 Favored 'General case' 0 C--N 1.291 -1.961 0 CA-C-O 122.367 1.08 . . . . 0.0 113.777 179.201 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.0 t70 -105.75 107.04 17.83 Favored 'General case' 0 C--N 1.272 -2.771 0 N-CA-C 102.177 -3.268 . . . . 0.0 102.177 160.863 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.63 HG11 ' H ' ' A' ' 33' ' ' GLY . 9.4 p -83.34 137.56 20.76 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.4 0 C-N-CA 117.949 -1.501 . . . . 0.0 108.806 -178.002 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 45.8 m -86.99 121.05 28.92 Favored 'General case' 0 N--CA 1.387 -3.597 0 N-CA-C 105.835 -1.913 . . . . 0.0 105.835 171.926 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.454 HD11 ' HA ' ' A' ' 30' ' ' LYS . 2.9 tt -90.81 115.05 29.28 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.247 0 N-CA-C 106.458 -1.682 . . . . 0.0 106.458 175.092 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.492 ' HG3' ' HB2' ' A' ' 74' ' ' PRO . 5.6 mm-40 -106.22 157.36 17.63 Favored 'General case' 0 CA--C 1.48 -1.738 0 CA-C-N 113.89 -1.505 . . . . 0.0 111.596 -168.544 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 3.3 m-20 -87.23 96.17 10.23 Favored 'General case' 0 N--CA 1.426 -1.665 0 N-CA-C 107.417 -1.327 . . . . 0.0 107.417 -175.85 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.454 ' OG ' HD21 ' A' ' 84' ' ' LEU . 4.8 m -105.98 141.86 36.67 Favored 'General case' 0 N--CA 1.402 -2.843 0 N-CA-C 103.913 -2.625 . . . . 0.0 103.913 174.243 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.582 HG23 ' H ' ' A' ' 27' ' ' GLY 0.276 2.6 p -118.02 -49.48 4.02 Favored 'Isoleucine or valine' 0 C--N 1.274 -2.682 0 C-N-CA 117.059 -1.856 . . . . 0.0 112.744 176.166 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 43.2 mm -81.71 -7.54 10.77 Favored 'Isoleucine or valine' 0 CA--C 1.57 1.732 0 N-CA-C 115.316 1.598 . . . . 0.0 115.316 -170.814 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.491 ' OG ' HD13 ' A' ' 84' ' ' LEU . 50.8 m -79.3 84.01 5.28 Favored 'General case' 0 CA--C 1.556 1.18 0 N-CA-C 117.726 2.491 . . . . 0.0 117.726 -172.161 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.688 ' HB3' ' HG3' ' A' ' 22' ' ' GLN . 1.1 pt? -140.06 82.14 1.85 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 104.046 -2.576 . . . . 0.0 104.046 154.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 68.3 m -171.62 87.15 0.09 Allowed 'General case' 1 C--N 1.233 -4.467 0 N-CA-C 101.777 -3.416 . . . . 0.0 101.777 176.24 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -111.59 157.69 14.8 Favored Glycine 3 N--CA 1.375 -5.387 0 N-CA-C 106.246 -2.742 . . . . 0.0 106.246 175.579 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.572 ' HB3' ' HB2' ' A' ' 49' ' ' GLU . 12.6 t70 -62.02 -41.82 98.5 Favored 'General case' 0 C--N 1.294 -1.824 0 CA-C-O 121.817 0.818 . . . . 0.0 109.714 178.559 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.577 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 6.8 m80 -123.24 -24.84 4.58 Favored 'General case' 0 C--N 1.301 -1.52 0 CA-C-N 115.138 -0.937 . . . . 0.0 112.029 177.078 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 7.2 m 59.7 -70.35 0.03 OUTLIER 'General case' 0 N--CA 1.5 2.039 0 C-N-CA 125.809 1.644 . . . . 0.0 114.622 170.901 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.676 HG13 ' O ' ' A' ' 151' ' ' ILE . 3.6 tt -98.15 -43.51 11.94 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 C-N-CA 124.799 1.24 . . . . 0.0 110.415 -174.91 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.577 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 8.1 tt -104.51 102.2 13.42 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.361 0 N-CA-C 113.613 0.968 . . . . 0.0 113.613 -172.094 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 85.5 60.13 1.84 Allowed Glycine 0 CA--C 1.474 -2.495 0 C-N-CA 118.073 -2.013 . . . . 0.0 109.767 171.715 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.545 ' HD3' ' C ' ' A' ' 149' ' ' ILE . 0.2 OUTLIER -119.24 90.01 3.25 Favored 'General case' 0 C--N 1.252 -3.643 0 CA-C-N 112.688 -1.756 . . . . 0.0 109.594 -176.866 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.614 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 17.9 p -95.08 132.76 39.63 Favored 'General case' 0 C--N 1.289 -2.026 0 O-C-N 121.723 -0.611 . . . . 0.0 111.858 179.603 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.532 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -81.32 120.63 25.19 Favored 'General case' 0 N--CA 1.425 -1.681 0 N-CA-C 108.181 -1.044 . . . . 0.0 108.181 175.61 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.62 HG22 ' SG ' ' A' ' 57' ' ' CYS . 19.6 t -100.35 98.09 6.55 Favored 'Isoleucine or valine' 0 C--O 1.297 3.602 0 C-N-CA 116.259 -2.176 . . . . 0.0 106.987 172.938 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.525 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 25.4 t -148.81 171.05 2.23 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.363 0 N-CA-C 106.09 -1.819 . . . . 0.0 106.09 -174.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.7 p-80 -160.53 171.99 17.99 Favored 'General case' 0 C--N 1.286 -2.167 0 N-CA-C 104.093 -2.558 . . . . 0.0 104.093 169.547 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.458 ' HG3' ' O ' ' A' ' 38' ' ' LEU . 0.1 OUTLIER -69.62 87.81 0.5 Allowed 'General case' 0 C--N 1.314 -0.935 0 CA-C-N 123.064 2.665 . . . . 0.0 109.973 -178.791 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 33.2 tptt -172.55 171.97 4.43 Favored 'General case' 0 N--CA 1.431 -1.402 0 N-CA-C 105.598 -2.001 . . . . 0.0 105.598 -171.425 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.491 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -78.99 117.91 20.5 Favored 'General case' 0 C--N 1.297 -1.69 0 N-CA-C 109.894 -0.41 . . . . 0.0 109.894 171.439 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.479 ' OD1' ' HB3' ' A' ' 46' ' ' HIS . 3.6 t70 -139.77 78.4 1.66 Allowed 'General case' 0 CA--C 1.474 -1.951 0 N-CA-C 107.416 -1.327 . . . . 0.0 107.416 179.784 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.613 ' HA ' ' HB2' ' A' ' 46' ' ' HIS . 25.1 t0 -177.44 158.0 1.36 Allowed 'General case' 0 C--N 1.301 -1.521 0 O-C-N 123.766 0.666 . . . . 0.0 109.424 173.276 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.541 ' HA ' ' O ' ' A' ' 135' ' ' THR . 3.3 tm? -90.72 -40.48 11.83 Favored 'General case' 0 C--N 1.294 -1.807 0 O-C-N 124.624 1.203 . . . . 0.0 107.988 -176.732 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -80.24 -48.86 6.19 Favored Glycine 0 N--CA 1.425 -2.051 0 C-N-CA 120.492 -0.861 . . . . 0.0 111.622 -178.225 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 0.6 OUTLIER -123.77 51.34 1.53 Allowed 'General case' 0 C--N 1.299 -1.607 0 N-CA-C 112.21 0.448 . . . . 0.0 112.21 -178.146 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -80.15 -105.83 0.27 Allowed Glycine 0 N--CA 1.434 -1.458 0 C-N-CA 119.875 -1.155 . . . . 0.0 111.745 176.207 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -152.26 -96.18 0.13 Allowed Glycine 0 C--N 1.316 -0.556 0 C-N-CA 120.311 -0.947 . . . . 0.0 112.652 -176.69 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 23.7 t-20 -79.89 153.67 28.87 Favored 'General case' 0 N--CA 1.482 1.163 0 CA-C-O 118.158 -0.925 . . . . 0.0 109.142 -177.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -45.72 -50.75 13.43 Favored 'General case' 0 C--N 1.36 1.057 0 N-CA-C 114.522 1.304 . . . . 0.0 114.522 -176.66 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -80.4 -26.89 38.28 Favored 'General case' 0 C--N 1.319 -0.757 0 O-C-N 121.526 -0.734 . . . . 0.0 111.114 -179.297 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 27.5 t -77.59 -29.14 51.84 Favored 'General case' 0 C--N 1.305 -1.355 0 CA-C-N 115.468 -0.787 . . . . 0.0 110.667 -173.618 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.541 ' O ' ' HA ' ' A' ' 126' ' ' LEU . 6.6 t -76.52 -25.06 53.75 Favored 'General case' 0 C--O 1.206 -1.212 0 N-CA-C 108.951 -0.759 . . . . 0.0 108.951 178.669 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.439 ' HA ' ' CD2' ' A' ' 126' ' ' LEU . 58.8 mtpt -71.28 -35.36 71.32 Favored 'General case' 0 C--N 1.314 -0.963 0 CA-C-N 115.791 -0.64 . . . . 0.0 110.895 178.473 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 12.4 t -85.98 -31.75 21.89 Favored 'General case' 0 N--CA 1.412 -2.366 0 CA-C-N 115.585 -0.734 . . . . 0.0 109.25 178.725 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 57.63 73.07 0.49 Allowed Glycine 0 CA--C 1.486 -1.764 0 N-CA-C 109.486 -1.445 . . . . 0.0 109.486 -177.709 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 46.5 t30 -51.58 105.8 0.12 Allowed 'General case' 0 N--CA 1.491 1.617 0 CA-C-O 122.471 1.129 . . . . 0.0 113.248 -171.468 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -89.29 164.54 14.89 Favored 'General case' 0 N--CA 1.438 -1.071 0 CA-C-N 114.441 -1.254 . . . . 0.0 113.664 -171.092 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -139.95 86.28 0.21 Allowed Glycine 0 N--CA 1.434 -1.469 0 N-CA-C 107.25 -2.34 . . . . 0.0 107.25 175.351 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.504 ' HA ' HG13 ' A' ' 118' ' ' VAL . 13.8 m -61.84 -18.65 60.81 Favored 'General case' 0 C--N 1.316 -0.863 0 N-CA-C 113.823 1.046 . . . . 0.0 113.823 -172.166 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 27.4 ttm180 -121.72 -46.31 2.25 Favored 'General case' 0 C--N 1.26 -3.312 0 C-N-CA 119.503 -0.879 . . . . 0.0 109.681 177.837 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.9 tt -46.13 -45.06 16.26 Favored 'General case' 0 CA--C 1.495 -1.163 0 O-C-N 125.406 1.691 . . . . 0.0 111.564 -164.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.525 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -139.66 88.76 2.27 Favored 'General case' 0 N--CA 1.395 -3.192 0 N-CA-C 107.239 -1.393 . . . . 0.0 107.239 179.667 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 12.2 m -130.25 140.08 50.73 Favored 'General case' 0 N--CA 1.394 -3.227 0 CA-C-N 113.556 -1.656 . . . . 0.0 109.283 176.747 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.474 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -170.93 149.03 11.83 Favored Glycine 1 N--CA 1.379 -5.124 0 CA-C-N 113.831 -1.531 . . . . 0.0 109.358 -177.166 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 16.0 m -70.55 110.14 3.43 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.63 0 CA-C-O 122.104 0.954 . . . . 0.0 111.147 175.091 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.545 ' C ' ' HD3' ' A' ' 115' ' ' ARG . 9.4 tt -122.11 108.87 22.85 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.038 0 CA-C-N 114.652 -1.158 . . . . 0.0 109.27 175.477 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.497 ' HA3' ' HG2' ' A' ' 115' ' ' ARG . . . -179.03 -171.25 42.02 Favored Glycine 3 CA--C 1.435 -4.936 0 N-CA-C 108.797 -1.721 . . . . 0.0 108.797 175.99 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.676 ' O ' HG13 ' A' ' 112' ' ' ILE . 64.5 mt -64.3 104.64 0.45 Allowed 'Isoleucine or valine' 0 C--N 1.263 -3.165 0 O-C-N 124.853 0.972 . . . . 0.0 110.576 -175.557 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.462 ' HB2' ' NH2' ' A' ' 115' ' ' ARG . . . -142.17 100.09 3.65 Favored 'General case' 0 N--CA 1.433 -1.304 0 CA-C-O 121.168 0.508 . . . . 0.0 109.836 169.311 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 63.7 tt0 . . . . . 0 C--N 1.289 -2.043 0 N-CA-C 107.048 -1.464 . . . . 0.0 107.048 177.016 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.468 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 CA--C 1.512 -0.515 0 N-CA-C 108.793 -0.818 . . . . 0.0 108.793 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.41 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 22.6 m -111.24 -36.44 5.59 Favored 'General case' 0 CA--C 1.552 1.027 0 O-C-N 123.583 0.552 . . . . 0.0 111.733 -178.627 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.402 ' HG2' ' N ' ' A' ' 4' ' ' ALA . 50.1 tttm -146.65 152.52 39.01 Favored 'General case' 0 C--N 1.306 -1.298 0 N-CA-C 108.521 -0.918 . . . . 0.0 108.521 -177.747 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.937 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.96 167.73 20.39 Favored 'General case' 0 N--CA 1.406 -2.629 0 O-C-N 123.676 0.61 . . . . 0.0 109.609 175.029 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.8 p -137.6 131.99 44.34 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 C-N-CA 123.313 0.645 . . . . 0.0 109.304 179.196 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.671 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -112.18 131.36 55.52 Favored 'General case' 0 C--N 1.295 -1.767 0 N-CA-C 113.454 0.909 . . . . 0.0 113.454 -178.662 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 59.3 t -134.86 103.83 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.472 0.636 0 N-CA-C 108.764 -0.828 . . . . 0.0 108.764 174.038 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.561 ' HB3' HD21 ' A' ' 117' ' ' LEU . 1.4 pt? -118.29 151.17 38.2 Favored 'General case' 0 CA--C 1.493 -1.232 0 N-CA-C 113.081 0.771 . . . . 0.0 113.081 -179.446 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 63.0 tttm -162.86 140.77 8.16 Favored 'General case' 0 N--CA 1.43 -1.463 0 N-CA-C 107.549 -1.278 . . . . 0.0 107.549 -177.74 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.39 -158.48 8.37 Favored Glycine 0 N--CA 1.414 -2.785 0 C-N-CA 119.039 -1.553 . . . . 0.0 112.996 -176.703 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 17.9 t70 -71.37 -49.19 44.68 Favored 'General case' 0 C--N 1.316 -0.89 0 N-CA-C 107.777 -1.194 . . . . 0.0 107.777 179.106 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.65 144.95 16.94 Favored Glycine 0 N--CA 1.431 -1.655 0 N-CA-C 106.55 -2.62 . . . . 0.0 106.55 172.888 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.1 Cg_endo -76.56 124.03 7.38 Favored 'Trans proline' 0 N--CA 1.438 -1.753 0 CA-C-N 120.355 2.078 . . . . 0.0 112.96 -175.575 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 22.1 t -132.38 113.05 20.41 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.74 0 N-CA-C 103.853 -2.647 . . . . 0.0 103.853 173.236 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.573 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 96.8 mt-30 -118.58 141.33 48.68 Favored 'General case' 0 C--N 1.291 -1.954 0 C-N-CA 120.266 -0.574 . . . . 0.0 109.6 -174.883 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.542 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -169.69 157.86 29.74 Favored Glycine 0 N--CA 1.429 -1.792 0 C-N-CA 120.015 -1.088 . . . . 0.0 113.482 -177.218 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.463 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 10.9 pt -135.26 102.47 3.62 Favored 'Isoleucine or valine' 0 C--N 1.315 -0.892 0 N-CA-C 107.679 -1.23 . . . . 0.0 107.679 177.949 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.671 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 10.3 mt -121.42 137.44 55.06 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.394 0 N-CA-C 109.617 -0.512 . . . . 0.0 109.617 -174.847 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 3.2 p-10 -113.94 134.08 55.06 Favored 'General case' 0 C--N 1.316 -0.865 0 CA-C-N 116.743 -0.208 . . . . 0.0 110.817 178.308 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.937 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.0 m-85 -123.26 134.27 54.11 Favored 'General case' 0 N--CA 1.465 0.292 0 C-N-CA 122.356 0.262 . . . . 0.0 110.921 -178.105 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.41 ' HB3' ' O ' ' A' ' 2' ' ' THR . 9.9 pt-20 -132.96 102.34 5.59 Favored 'General case' 0 CA--C 1.542 0.66 0 CA-C-O 121.588 0.709 . . . . 0.0 112.168 175.751 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.468 ' H ' ' HB3' ' A' ' 1' ' ' ALA . 42.9 mt-30 -106.24 113.82 27.57 Favored 'General case' 0 N--CA 1.389 -3.5 0 N-CA-C 103.872 -2.64 . . . . 0.0 103.872 175.671 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.586 ' H ' ' HB ' ' A' ' 103' ' ' VAL . 54.9 tttm -134.26 171.76 13.81 Favored 'General case' 0 N--CA 1.431 -1.416 0 C-N-CA 120.738 -0.385 . . . . 0.0 110.422 -169.576 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.518 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 5.4 mp0 -63.97 -26.12 68.44 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 124.87 1.268 . . . . 0.0 111.69 -177.694 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 4.8 m -51.37 -33.06 28.16 Favored 'General case' 0 CA--C 1.549 0.911 0 N-CA-C 115.452 1.649 . . . . 0.0 115.452 -172.345 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 6.9 t30 64.73 97.34 0.04 OUTLIER 'General case' 0 N--CA 1.494 1.735 0 N-CA-C 109.217 -0.66 . . . . 0.0 109.217 -173.09 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.633 ' H ' HG22 ' A' ' 103' ' ' VAL . . . 179.18 -163.34 30.81 Favored Glycine 0 CA--C 1.463 -3.196 0 C-N-CA 119.919 -1.134 . . . . 0.0 110.416 -175.746 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 9.5 Cg_endo -83.24 139.65 9.42 Favored 'Trans proline' 0 N--CA 1.42 -2.851 0 C-N-CA 122.114 1.876 . . . . 0.0 110.699 177.496 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.654 HG22 ' H ' ' A' ' 101' ' ' ASP . 18.3 m -75.14 130.24 36.29 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.947 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 177.137 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.409 ' HB3' ' CD ' ' A' ' 21' ' ' GLU . 7.3 ttpm? -88.84 100.34 13.09 Favored 'General case' 0 N--CA 1.424 -1.771 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.157 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.466 HG22 ' HA ' ' A' ' 20' ' ' PHE . 75.1 t -131.47 134.75 60.37 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.756 0 CA-C-N 114.524 -1.216 . . . . 0.0 110.006 -169.85 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.415 ' O ' ' HA ' ' A' ' 18' ' ' ILE . 2.1 t-105 -141.08 129.47 22.44 Favored 'General case' 0 C--N 1.288 -2.073 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 177.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.463 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -148.94 138.86 7.15 Favored Glycine 0 N--CA 1.425 -2.083 0 C-N-CA 119.994 -1.098 . . . . 0.0 112.377 175.04 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.542 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 18.4 m -116.5 115.24 25.41 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 124.726 1.211 . . . . 0.0 108.746 179.221 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.573 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 9.2 mt -109.52 148.11 13.48 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.421 0 CA-C-N 118.453 0.57 . . . . 0.0 110.732 176.166 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 51.4 mtmt -129.79 122.98 29.86 Favored 'General case' 0 C--N 1.294 -1.809 0 N-CA-C 104.941 -2.244 . . . . 0.0 104.941 178.822 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -146.41 175.01 26.09 Favored Glycine 0 C--N 1.294 -1.8 0 O-C-N 123.688 0.617 . . . . 0.0 111.66 -168.31 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 84.0 mt -69.52 169.79 11.88 Favored 'General case' 0 C--N 1.301 -1.503 0 N-CA-C 108.434 -0.95 . . . . 0.0 108.434 175.724 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.471 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.5 OUTLIER -76.81 104.32 7.24 Favored 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 119.273 -0.971 . . . . 0.0 112.003 -175.932 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.433 ' HG2' ' O ' ' A' ' 39' ' ' THR . 47.2 mm-40 -177.93 171.09 1.82 Allowed 'General case' 0 CA--C 1.472 -2.054 0 C-N-CA 128.522 2.729 . . . . 0.0 104.275 170.405 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.726 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 159.45 115.38 0.41 Allowed Glycine 1 C--N 1.242 -4.676 0 C-N-CA 116.978 -2.534 . . . . 0.0 113.968 166.146 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 3.0 mm? -119.38 -85.6 0.65 Allowed 'General case' 0 N--CA 1.419 -2.018 0 O-C-N 124.231 0.607 . . . . 0.0 110.911 179.766 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.733 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 20.7 m80 -163.52 123.11 2.11 Favored 'General case' 0 N--CA 1.478 0.973 0 C-N-CA 123.895 0.878 . . . . 0.0 108.936 -179.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.462 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . -143.94 104.63 0.34 Allowed Glycine 0 N--CA 1.435 -1.41 0 C-N-CA 118.434 -1.841 . . . . 0.0 115.425 -178.684 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.593 ' O ' HG12 ' A' ' 47' ' ' VAL . 19.6 m-85 -68.45 95.22 0.61 Allowed 'General case' 1 C--O 1.341 5.918 0 CA-C-O 123.391 1.567 . . . . 0.0 109.56 169.684 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.615 ' CD2' HD12 ' A' ' 117' ' ' LEU . 16.4 p-80 -83.05 78.06 9.64 Favored 'General case' 0 N--CA 1.404 -2.759 0 N-CA-C 107.0 -1.481 . . . . 0.0 107.0 175.454 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.593 HG12 ' O ' ' A' ' 45' ' ' PHE . 3.7 p -111.2 91.57 1.78 Allowed 'Isoleucine or valine' 0 C--N 1.29 -1.991 0 CA-C-N 111.223 -2.717 . . . . 0.0 110.988 -172.365 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . 0.257 39.6 m-70 -138.75 159.96 40.82 Favored 'General case' 0 CA--C 1.503 -0.835 0 N-CA-C 114.586 1.328 . . . . 0.0 114.586 174.992 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.56 ' HB3' ' OD2' ' A' ' 109' ' ' ASP . 2.0 pm0 -89.48 172.82 8.71 Favored 'General case' 0 C--N 1.287 -2.151 0 C-N-CA 126.993 2.117 . . . . 0.0 115.02 -174.793 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.521 ' H ' ' HA ' ' A' ' 110' ' ' HIS . 55.9 t80 47.18 103.47 0.0 OUTLIER 'General case' 0 CA--C 1.51 -0.58 0 CA-C-N 111.3 -2.682 . . . . 0.0 115.35 167.366 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -44.0 103.12 0.04 OUTLIER Glycine 0 C--N 1.297 -1.623 0 CA-C-N 113.554 -1.657 . . . . 0.0 115.16 171.858 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 9.3 t0 -111.09 -161.17 0.74 Allowed 'General case' 0 N--CA 1.446 -0.652 0 N-CA-C 106.354 -1.721 . . . . 0.0 106.354 -179.307 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 33.5 t-20 -67.14 138.1 56.79 Favored 'General case' 0 C--N 1.308 -1.205 0 C-N-CA 123.1 0.56 . . . . 0.0 109.997 -179.539 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.492 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 13.4 t -58.45 -21.5 51.45 Favored 'General case' 0 C--O 1.216 -0.701 0 N-CA-C 113.234 0.828 . . . . 0.0 113.234 -177.103 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -118.96 6.77 11.37 Favored 'General case' 0 C--N 1.31 -1.115 0 C-N-CA 120.085 -0.646 . . . . 0.0 111.062 178.352 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -150.76 109.46 0.43 Allowed Glycine 0 N--CA 1.431 -1.668 0 C-N-CA 119.428 -1.368 . . . . 0.0 111.589 -178.705 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.596 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 4.3 p -98.5 89.35 4.38 Favored 'General case' 0 C--N 1.277 -2.576 0 C-N-CA 122.735 0.414 . . . . 0.0 111.65 179.172 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 m -80.47 -54.07 6.02 Favored 'General case' 0 C--N 1.296 -1.754 0 CA-C-O 121.465 0.65 . . . . 0.0 109.924 176.129 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.9 m -71.18 -39.45 71.83 Favored 'General case' 0 C--N 1.314 -0.961 0 CA-C-N 115.189 -0.914 . . . . 0.0 111.283 -175.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.596 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.31 -5.76 48.5 Favored 'General case' 0 C--O 1.2 -1.531 0 CA-C-N 113.857 -1.52 . . . . 0.0 111.353 175.077 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -57.36 -142.42 0.01 OUTLIER Glycine 0 CA--C 1.558 2.737 0 N-CA-C 115.238 0.855 . . . . 0.0 115.238 178.998 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 94.9 Cg_endo -76.11 53.71 3.91 Favored 'Trans proline' 0 N--CA 1.484 0.937 0 C-N-CA 122.877 2.385 . . . . 0.0 111.009 -179.133 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 7.0 t-80 -141.84 128.67 20.54 Favored 'General case' 0 C--N 1.28 -2.432 0 N-CA-C 106.814 -1.55 . . . . 0.0 106.814 -179.101 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.546 ' HA ' ' OE2' ' A' ' 49' ' ' GLU . 52.0 p90 -139.48 144.58 38.04 Favored 'General case' 0 C--N 1.297 -1.687 0 C-N-CA 120.358 -0.537 . . . . 0.0 111.442 178.674 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.483 ' HB2' ' OD2' ' A' ' 109' ' ' ASP . 27.3 t-20 -68.94 143.99 95.2 Favored Pre-proline 0 C--N 1.318 -0.795 0 C-N-CA 124.015 0.926 . . . . 0.0 111.316 179.438 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.0 -15.21 39.72 Favored 'Trans proline' 0 CA--C 1.546 1.109 0 C-N-CA 123.041 2.494 . . . . 0.0 116.113 -178.371 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 90.2 mt -69.86 -29.23 66.41 Favored 'General case' 0 C--N 1.37 1.489 0 C-N-CA 117.615 -1.634 . . . . 0.0 111.462 -176.213 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.41 ' HB3' ' CD2' ' A' ' 80' ' ' HIS . 58.0 p -54.46 -21.49 10.03 Favored 'General case' 0 C--O 1.262 1.73 0 C-N-CA 125.523 1.529 . . . . 0.0 115.044 -173.597 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . . . . . . . . . 13.0 ttm180 -70.45 -19.96 62.92 Favored 'General case' 0 C--N 1.298 -1.643 0 CA-C-N 114.582 -1.19 . . . . 0.0 112.665 -161.727 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 65.0 mttm -68.1 -12.06 60.2 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 119.233 -0.987 . . . . 0.0 112.773 -176.013 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.404 ' HB2' ' O ' ' A' ' 77' ' ' GLU . 0.1 OUTLIER -151.7 -45.15 0.11 Allowed 'General case' 0 C--N 1.315 -0.896 0 CA-C-O 120.651 0.262 . . . . 0.0 111.186 177.023 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 83.38 10.42 82.13 Favored Glycine 0 N--CA 1.45 -0.397 0 N-CA-C 108.984 -1.646 . . . . 0.0 108.984 -173.256 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.467 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -150.99 144.29 11.59 Favored Glycine 0 N--CA 1.402 -3.623 0 N-CA-C 108.145 -1.982 . . . . 0.0 108.145 178.244 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 11.8 Cg_exo -76.24 0.13 9.74 Favored 'Trans proline' 0 C--N 1.327 -0.58 0 C-N-CA 124.691 3.594 . . . . 0.0 112.38 -175.452 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 24.4 ttmm -55.55 -26.01 40.98 Favored 'General case' 0 C--N 1.306 -1.287 0 C-N-CA 124.973 1.309 . . . . 0.0 111.514 178.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 14.9 m-20 -148.63 -86.2 0.09 Allowed 'General case' 0 CA--C 1.505 -0.775 0 N-CA-C 113.004 0.742 . . . . 0.0 113.004 -178.707 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.404 ' O ' ' HB2' ' A' ' 71' ' ' HIS . 47.5 mt-10 -123.34 110.89 15.73 Favored 'General case' 0 N--CA 1.41 -2.437 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 -171.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.0 OUTLIER -150.52 -60.85 0.19 Allowed 'General case' 0 C--N 1.25 -3.758 0 N-CA-C 103.298 -2.853 . . . . 0.0 103.298 -173.98 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 17.5 mmm180 60.45 -7.37 0.08 Allowed 'General case' 0 N--CA 1.494 1.738 0 N-CA-C 114.617 1.34 . . . . 0.0 114.617 174.807 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.411 ' HB2' ' HB3' ' A' ' 65' ' ' ASN . 0.2 OUTLIER -89.82 -35.0 15.92 Favored 'General case' 0 C--N 1.305 -1.337 0 N-CA-C 105.038 -2.208 . . . . 0.0 105.038 168.744 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.585 HG11 ' HB2' ' A' ' 105' ' ' SER . 32.8 m 38.26 53.42 0.26 Allowed 'Isoleucine or valine' 0 CA--C 1.472 -2.021 0 C-N-CA 128.656 2.782 . . . . 0.0 112.466 171.131 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.407 ' N ' HG23 ' A' ' 47' ' ' VAL . . . -52.1 -34.94 40.37 Favored Glycine 0 C--O 1.207 -1.57 0 CA-C-N 114.442 -1.254 . . . . 0.0 112.963 -173.163 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.45 ' H ' HG23 ' A' ' 47' ' ' VAL . 10.7 t70 -170.58 172.53 5.86 Favored 'General case' 0 CA--C 1.49 -1.343 0 N-CA-C 106.625 -1.62 . . . . 0.0 106.625 177.235 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.426 ' HB2' ' HG2' ' A' ' 74' ' ' PRO . 25.9 tp -148.49 86.65 1.54 Allowed 'General case' 0 C--N 1.272 -2.787 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 -175.934 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 176.77 128.37 1.13 Allowed Glycine 1 N--CA 1.395 -4.082 0 CA-C-N 114.694 -1.139 . . . . 0.0 110.708 -178.997 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 17.0 m120 -89.99 171.35 9.63 Favored 'General case' 0 C--N 1.277 -2.55 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 173.675 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 7.5 p -145.35 129.06 11.55 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.322 0 O-C-N 121.394 -0.816 . . . . 0.0 109.083 -178.785 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 58.3 m -140.11 96.79 3.11 Favored 'General case' 0 N--CA 1.424 -1.748 0 CA-C-O 121.24 0.543 . . . . 0.0 110.28 -179.009 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.726 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -100.44 152.72 20.03 Favored 'General case' 0 N--CA 1.414 -2.234 0 N-CA-C 104.785 -2.302 . . . . 0.0 104.785 173.126 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.538 ' OD2' ' HG2' ' A' ' 91' ' ' LYS . 21.9 t70 -113.34 -159.74 0.7 Allowed 'General case' 1 C--N 1.223 -4.922 0 C-N-CA 116.7 -2.0 . . . . 0.0 105.992 173.731 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.538 ' HG2' ' OD2' ' A' ' 90' ' ' ASP . 18.8 ptpt -57.82 -8.08 0.87 Allowed 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 113.31 0.856 . . . . 0.0 113.31 175.532 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 24.1 t70 -84.3 -27.15 28.02 Favored 'General case' 0 C--N 1.314 -0.948 0 N-CA-C 109.495 -0.557 . . . . 0.0 109.495 175.165 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 72.62 65.53 2.29 Favored Glycine 0 CA--C 1.528 0.864 0 N-CA-C 114.499 0.559 . . . . 0.0 114.499 179.652 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.61 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 12.6 m -159.74 132.82 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.508 -0.66 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 179.35 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.563 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -124.64 117.89 25.28 Favored 'General case' 0 N--CA 1.412 -2.374 0 N-CA-C 109.394 -0.595 . . . . 0.0 109.394 -179.07 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 28.2 t70 -99.67 103.51 15.2 Favored 'General case' 0 C--N 1.274 -2.689 0 N-CA-C 107.281 -1.377 . . . . 0.0 107.281 179.163 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 7.7 p -124.55 117.6 50.96 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.701 0 CA-C-O 122.031 0.92 . . . . 0.0 112.255 -177.672 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 32.6 p -142.33 101.46 3.9 Favored 'General case' 0 C--N 1.276 -2.599 0 N-CA-C 106.787 -1.561 . . . . 0.0 106.787 174.267 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 34.4 pt -113.91 151.11 15.77 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.773 0 C-N-CA 120.484 -0.486 . . . . 0.0 110.787 -175.99 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 9.3 pt-20 -118.75 100.24 7.28 Favored 'General case' 0 N--CA 1.414 -2.227 0 N-CA-C 108.189 -1.041 . . . . 0.0 108.189 177.383 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.654 ' H ' HG22 ' A' ' 29' ' ' VAL . 26.1 t0 -134.02 167.51 20.48 Favored 'General case' 0 C--N 1.294 -1.837 0 CA-C-N 114.82 -1.082 . . . . 0.0 109.848 -173.263 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 57.9 m -59.02 113.22 1.99 Allowed 'General case' 0 C--N 1.318 -0.794 0 N-CA-C 114.678 1.362 . . . . 0.0 114.678 -173.594 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.633 HG22 ' H ' ' A' ' 27' ' ' GLY . 20.6 m -60.03 -11.57 3.33 Favored 'Isoleucine or valine' 0 N--CA 1.491 1.618 0 C-N-CA 126.112 1.765 . . . . 0.0 113.053 177.284 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 48.4 mm -56.39 -12.12 1.05 Allowed 'Isoleucine or valine' 0 N--CA 1.481 1.109 0 C-N-CA 124.676 1.191 . . . . 0.0 112.25 -176.199 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.585 ' HB2' HG11 ' A' ' 81' ' ' VAL . 2.5 p -91.73 83.17 5.25 Favored 'General case' 0 C--O 1.175 -2.826 0 O-C-N 121.012 -1.055 . . . . 0.0 111.516 176.609 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 71.8 mt -70.11 150.65 46.33 Favored 'General case' 0 N--CA 1.396 -3.163 0 CA-C-N 114.483 -1.235 . . . . 0.0 107.852 171.325 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 42.6 m -68.89 91.85 0.48 Allowed 'General case' 0 N--CA 1.382 -3.842 0 C-N-CA 124.956 1.302 . . . . 0.0 113.914 -173.608 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.415 ' O ' ' HD2' ' A' ' 110' ' ' HIS . . . -94.6 -175.67 38.55 Favored Glycine 1 N--CA 1.395 -4.097 0 N-CA-C 106.09 -2.804 . . . . 0.0 106.09 167.405 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.56 ' OD2' ' HB3' ' A' ' 49' ' ' GLU 0.25 31.3 t0 32.89 -77.76 0.0 OUTLIER 'General case' 0 C--N 1.307 -1.263 0 N-CA-C 117.442 2.386 . . . . 0.0 117.442 -175.32 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.558 ' CG ' ' HG2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -56.57 -31.8 64.57 Favored 'General case' 0 N--CA 1.445 -0.718 0 C-N-CA 125.987 1.715 . . . . 0.0 109.703 178.216 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 20.3 m 62.06 -178.09 0.13 Allowed 'General case' 0 N--CA 1.424 -1.755 0 C-N-CA 126.125 1.77 . . . . 0.0 112.797 178.505 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.512 HG13 ' HB ' ' A' ' 151' ' ' ILE . 10.0 tt -78.65 9.91 0.62 Allowed 'Isoleucine or valine' 0 C--N 1.3 -1.563 0 C-N-CA 126.547 1.939 . . . . 0.0 108.731 178.891 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 36.5 pt -91.38 -175.39 0.3 Allowed 'Isoleucine or valine' 0 CA--C 1.485 -1.526 0 N-CA-C 108.277 -1.008 . . . . 0.0 108.277 -176.801 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.436 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . -82.14 65.08 4.14 Favored Glycine 0 N--CA 1.405 -3.397 0 N-CA-C 111.197 -0.761 . . . . 0.0 111.197 -177.959 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.734 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -66.31 131.81 46.95 Favored 'General case' 0 N--CA 1.414 -2.267 0 CA-C-O 122.553 1.168 . . . . 0.0 112.203 178.266 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.734 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 0.1 OUTLIER -70.54 122.6 20.02 Favored 'General case' 0 N--CA 1.384 -3.768 0 CA-C-N 113.853 -1.521 . . . . 0.0 111.113 -178.137 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.615 HD12 ' CD2' ' A' ' 46' ' ' HIS . 0.8 OUTLIER -87.76 140.67 29.27 Favored 'General case' 0 N--CA 1.425 -1.676 0 N-CA-C 108.299 -1.001 . . . . 0.0 108.299 174.06 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.574 HG22 ' SG ' ' A' ' 57' ' ' CYS . 98.8 t -109.8 105.16 18.27 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.479 0 CA-C-N 115.843 -0.617 . . . . 0.0 110.646 171.859 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.466 HG22 ' CB ' ' A' ' 46' ' ' HIS . 0.2 OUTLIER -126.09 168.44 18.98 Favored 'Isoleucine or valine' 0 C--N 1.327 -0.387 0 CA-C-O 121.81 0.814 . . . . 0.0 110.397 179.596 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.435 ' CD2' ' HG ' ' A' ' 144' ' ' LEU . 2.1 t60 -172.18 156.85 4.06 Favored 'General case' 0 N--CA 1.431 -1.415 0 N-CA-C 102.909 -2.997 . . . . 0.0 102.909 162.158 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.437 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.1 mp0 -69.2 89.61 0.46 Allowed 'General case' 0 C--N 1.296 -1.733 0 N-CA-C 108.167 -1.049 . . . . 0.0 108.167 178.293 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 14.8 ptmm? -170.4 171.37 6.61 Favored 'General case' 0 N--CA 1.442 -0.827 0 N-CA-C 107.151 -1.425 . . . . 0.0 107.151 -176.686 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.733 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -76.68 111.15 11.88 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 123.771 0.67 . . . . 0.0 110.922 172.936 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.462 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 8.5 t0 -132.38 26.57 4.46 Favored 'General case' 0 N--CA 1.501 2.115 0 CA-C-O 123.381 1.563 . . . . 0.0 109.177 178.202 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.499 ' HB2' ' HB2' ' A' ' 128' ' ' LYS . 24.8 m-20 -81.7 137.53 35.39 Favored 'General case' 0 C--N 1.297 -1.717 0 N-CA-C 107.529 -1.286 . . . . 0.0 107.529 173.52 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 tm? -69.8 -56.79 6.19 Favored 'General case' 0 C--N 1.326 -0.426 0 N-CA-C 109.656 -0.498 . . . . 0.0 109.656 -173.59 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -73.7 1.8 43.51 Favored Glycine 0 CA--C 1.526 0.748 0 C-N-CA 121.16 -0.543 . . . . 0.0 113.483 -178.849 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.499 ' HB2' ' HB2' ' A' ' 125' ' ' ASP . 32.0 mmmt -132.23 32.61 3.96 Favored 'General case' 0 C--N 1.32 -0.682 0 N-CA-C 109.236 -0.653 . . . . 0.0 109.236 -179.151 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -62.27 -29.32 72.73 Favored Glycine 0 CA--C 1.531 1.05 0 CA-C-N 115.604 -0.725 . . . . 0.0 114.834 -176.469 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -82.89 0.26 Allowed Glycine 0 C--O 1.221 -0.66 0 CA-C-N 117.443 0.622 . . . . 0.0 112.212 179.491 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.453 ' H ' ' HB3' ' A' ' 134' ' ' SER . 9.5 t30 -121.45 173.3 7.47 Favored 'General case' 0 C--N 1.312 -1.057 0 N-CA-C 105.689 -1.967 . . . . 0.0 105.689 178.879 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.461 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 37.1 tt0 -49.73 -46.71 50.66 Favored 'General case' 0 CA--C 1.555 1.158 0 CA-C-N 119.844 1.202 . . . . 0.0 114.011 -172.017 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 24.1 mp0 -64.48 -39.64 94.19 Favored 'General case' 0 C--N 1.321 -0.642 0 CA-C-O 121.055 0.455 . . . . 0.0 110.449 -179.019 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.453 ' HB3' ' H ' ' A' ' 131' ' ' ASN . 6.8 t -72.36 -30.89 65.13 Favored 'General case' 0 N--CA 1.437 -1.077 0 CA-C-N 115.263 -0.88 . . . . 0.0 110.098 -175.541 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 36.3 m -69.68 -30.97 68.76 Favored 'General case' 0 C--N 1.32 -0.697 0 CA-C-O 121.299 0.571 . . . . 0.0 110.479 178.344 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.461 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 95.8 mttt -76.54 -37.12 57.16 Favored 'General case' 0 C--N 1.316 -0.852 0 CA-C-O 121.165 0.507 . . . . 0.0 111.355 -178.461 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.8 t -85.61 -26.42 26.08 Favored 'General case' 0 N--CA 1.416 -2.166 0 CA-C-N 115.454 -0.794 . . . . 0.0 111.292 -177.721 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 62.85 60.1 8.19 Favored Glycine 0 N--CA 1.431 -1.684 0 N-CA-C 108.601 -1.8 . . . . 0.0 108.601 -174.0 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 25.9 t-20 -39.62 117.38 0.72 Allowed 'General case' 0 N--CA 1.498 1.953 0 C-N-CA 124.936 1.294 . . . . 0.0 112.851 -174.074 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -143.71 161.49 38.43 Favored 'General case' 0 C--N 1.322 -0.605 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -174.166 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.28 81.22 1.72 Allowed Glycine 0 N--CA 1.437 -1.249 0 N-CA-C 107.672 -2.171 . . . . 0.0 107.672 173.653 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 8.7 p -42.13 -38.89 1.82 Allowed 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 118.143 2.646 . . . . 0.0 118.143 -168.147 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 23.6 ptt180 -134.2 13.46 3.88 Favored 'General case' 0 C--N 1.278 -2.526 0 N-CA-C 107.978 -1.119 . . . . 0.0 107.978 -176.468 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.435 ' HG ' ' CD2' ' A' ' 120' ' ' HIS . 0.3 OUTLIER -69.07 -37.6 78.6 Favored 'General case' 0 N--CA 1.429 -1.476 0 N-CA-C 108.552 -0.906 . . . . 0.0 108.552 -172.23 . . . . . . . . 3 3 . 1 . 003 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.448 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -150.25 106.1 3.43 Favored 'General case' 0 N--CA 1.412 -2.348 0 N-CA-C 109.095 -0.705 . . . . 0.0 109.095 -178.503 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.568 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 17.8 m -115.21 163.14 16.09 Favored 'General case' 0 C--N 1.292 -1.932 0 N-CA-C 106.553 -1.647 . . . . 0.0 106.553 -179.811 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.734 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -171.55 141.42 6.39 Favored Glycine 0 N--CA 1.416 -2.681 0 C-N-CA 119.003 -1.57 . . . . 0.0 112.143 176.93 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.423 HG12 ' OG1' ' A' ' 54' ' ' THR . 10.0 p -70.16 98.78 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.432 -1.357 0 CA-C-O 122.531 1.158 . . . . 0.0 108.581 174.035 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.734 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 24.0 mm -109.44 129.86 63.5 Favored 'Isoleucine or valine' 0 CA--C 1.464 -2.346 0 N-CA-C 105.607 -1.997 . . . . 0.0 105.607 179.791 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -148.81 147.34 17.73 Favored Glycine 2 CA--C 1.425 -5.539 0 C-N-CA 116.803 -2.618 . . . . 0.0 111.466 -174.708 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.512 ' HB ' HG13 ' A' ' 112' ' ' ILE . 70.1 mt -78.64 103.63 5.81 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.9 0 N-CA-C 108.172 -1.047 . . . . 0.0 108.172 173.916 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.575 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -125.84 128.6 47.9 Favored 'General case' 0 N--CA 1.435 -1.202 0 CA-C-N 115.119 -0.946 . . . . 0.0 108.476 175.668 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.1 pt20 . . . . . 0 C--N 1.292 -1.905 0 CA-C-N 115.572 -0.74 . . . . 0.0 110.563 -174.755 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 N--CA 1.478 0.969 0 N-CA-C 109.032 -0.729 . . . . 0.0 109.032 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.658 ' O ' ' HD2' ' A' ' 3' ' ' LYS . 18.0 p -80.91 -42.03 22.06 Favored 'General case' 0 C--O 1.208 -1.094 0 N-CA-C 106.948 -1.501 . . . . 0.0 106.948 170.833 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.658 ' HD2' ' O ' ' A' ' 2' ' ' THR . 5.4 mptp? -151.27 171.4 17.5 Favored 'General case' 0 C--O 1.263 1.765 0 N-CA-C 103.209 -2.885 . . . . 0.0 103.209 173.137 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.693 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -149.35 146.98 27.78 Favored 'General case' 0 CA--C 1.454 -2.744 0 N-CA-C 106.671 -1.603 . . . . 0.0 106.671 172.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.414 HG22 ' HB3' ' A' ' 152' ' ' ALA . 23.1 m -119.69 155.22 22.43 Favored 'Isoleucine or valine' 0 C--N 1.272 -2.788 0 N-CA-C 107.929 -1.138 . . . . 0.0 107.929 176.244 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.606 ' HA ' ' O ' ' A' ' 148' ' ' VAL . . . -135.7 128.94 31.89 Favored 'General case' 0 C--N 1.278 -2.504 0 CA-C-N 115.048 -0.978 . . . . 0.0 110.345 178.689 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.498 ' H ' ' HB ' ' A' ' 148' ' ' VAL . 46.7 t -134.16 111.83 15.46 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.018 0 N-CA-C 109.388 -0.597 . . . . 0.0 109.388 -179.599 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.521 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.9 pt? -119.47 142.39 48.31 Favored 'General case' 0 C--N 1.296 -1.748 0 CA-C-N 115.906 -0.588 . . . . 0.0 110.371 178.392 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.665 ' O ' ' HA ' ' A' ' 55' ' ' ALA . 2.2 tmtp? -147.91 148.42 30.79 Favored 'General case' 0 N--CA 1.408 -2.542 0 N-CA-C 102.409 -3.182 . . . . 0.0 102.409 177.401 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.456 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -155.01 -158.93 8.99 Favored Glycine 0 CA--C 1.479 -2.161 0 C-N-CA 118.139 -1.982 . . . . 0.0 113.381 -177.788 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.1 t70 -67.98 -46.58 70.97 Favored 'General case' 0 C--N 1.314 -0.945 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 178.018 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -114.44 95.59 0.74 Allowed Glycine 0 N--CA 1.429 -1.784 0 N-CA-C 106.338 -2.705 . . . . 0.0 106.338 171.324 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 17.0 Cg_exo -64.6 126.79 17.47 Favored 'Trans proline' 0 N--CA 1.441 -1.585 0 C-N-CA 122.164 1.909 . . . . 0.0 113.886 -172.553 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 33.1 m -126.0 132.37 70.7 Favored 'Isoleucine or valine' 0 N--CA 1.381 -3.889 0 N-CA-C 102.026 -3.324 . . . . 0.0 102.026 173.516 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.431 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 97.8 mt-30 -121.67 138.2 54.44 Favored 'General case' 0 C--N 1.264 -3.114 0 C-N-CA 119.559 -0.856 . . . . 0.0 112.578 -169.228 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.493 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -170.69 171.31 43.68 Favored Glycine 0 N--CA 1.402 -3.628 0 N-CA-C 111.209 -0.756 . . . . 0.0 111.209 179.641 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.451 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.6 pt -137.02 139.54 44.26 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.121 0 N-CA-C 106.397 -1.705 . . . . 0.0 106.397 179.684 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.552 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -127.77 127.91 68.8 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 N-CA-C 107.613 -1.254 . . . . 0.0 107.613 179.284 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.693 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 60.4 m-20 -118.79 119.62 34.94 Favored 'General case' 0 CA--C 1.497 -1.088 0 N-CA-C 108.466 -0.939 . . . . 0.0 108.466 -176.489 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.634 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 11.6 p90 -131.58 141.04 49.59 Favored 'General case' 0 C--O 1.262 1.754 0 C-N-CA 118.646 -1.222 . . . . 0.0 113.095 178.058 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.428 ' HB3' ' O ' ' A' ' 2' ' ' THR . 7.2 pt-20 -133.65 95.15 3.42 Favored 'General case' 0 N--CA 1.416 -2.136 0 CA-C-O 122.268 1.033 . . . . 0.0 112.391 175.75 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.581 ' HG3' HG12 ' A' ' 29' ' ' VAL . 24.1 mm-40 -158.62 163.47 36.92 Favored 'General case' 0 C--O 1.257 1.477 0 C-N-CA 126.88 2.072 . . . . 0.0 108.038 170.417 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.654 ' HG3' ' H ' ' A' ' 24' ' ' GLU 0.257 27.7 pttt -159.7 -86.69 0.03 OUTLIER 'General case' 0 C--N 1.308 -1.204 0 O-C-N 124.22 0.95 . . . . 0.0 112.055 164.487 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.654 ' H ' ' HG3' ' A' ' 23' ' ' LYS . 35.9 tt0 -93.2 -25.96 17.59 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 121.783 0.802 . . . . 0.0 109.578 178.844 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.44 ' HB2' ' OE1' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -46.93 -56.94 5.51 Favored 'General case' 0 CA--C 1.546 0.797 0 C-N-CA 127.235 2.214 . . . . 0.0 114.836 -172.34 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 57.8 t30 75.71 139.91 0.07 Allowed 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 124.971 1.308 . . . . 0.0 110.277 -174.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.588 ' H ' HG21 ' A' ' 104' ' ' ILE . . . 150.23 -170.96 30.2 Favored Glycine 0 CA--C 1.493 -1.312 0 N-CA-C 111.29 -0.724 . . . . 0.0 111.29 -177.4 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 36.6 Cg_endo -70.08 124.02 10.55 Favored 'Trans proline' 0 N--CA 1.443 -1.483 0 C-N-CA 121.413 1.409 . . . . 0.0 110.253 176.427 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.581 HG12 ' HG3' ' A' ' 22' ' ' GLN . 17.2 m -85.65 98.79 6.85 Favored 'Isoleucine or valine' 0 N--CA 1.432 -1.354 0 CA-C-O 121.502 0.668 . . . . 0.0 111.523 -179.974 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.459 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.258 0.0 OUTLIER -90.46 108.66 19.93 Favored 'General case' 0 N--CA 1.417 -2.076 0 C-N-CA 118.486 -1.285 . . . . 0.0 109.11 171.919 . . . . . . . . 4 4 . 1 . 004 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 16.6 m -135.46 152.97 32.57 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.778 0 N-CA-C 105.729 -1.952 . . . . 0.0 105.729 -172.861 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 76.7 t-105 -143.58 126.92 16.72 Favored 'General case' 0 C--N 1.266 -3.051 0 C-N-CA 120.013 -0.675 . . . . 0.0 109.946 178.599 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.451 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -145.34 140.27 8.93 Favored Glycine 0 N--CA 1.41 -3.075 0 C-N-CA 120.137 -1.03 . . . . 0.0 111.697 174.165 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 16.0 m -116.6 140.23 49.63 Favored 'General case' 0 C--N 1.29 -1.981 0 N-CA-C 106.883 -1.525 . . . . 0.0 106.883 176.075 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.493 HG22 ' HA3' ' A' ' 16' ' ' GLY . 25.2 pt -141.7 131.51 24.6 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.822 0 CA-C-N 119.415 1.007 . . . . 0.0 109.025 173.267 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.443 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.2 OUTLIER -112.09 132.39 54.87 Favored 'General case' 0 N--CA 1.415 -2.176 0 N-CA-C 107.995 -1.113 . . . . 0.0 107.995 179.574 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.402 ' HA3' ' CG ' ' A' ' 121' ' ' GLU . . . -142.82 175.2 23.18 Favored Glycine 0 N--CA 1.416 -2.68 0 N-CA-C 111.252 -0.739 . . . . 0.0 111.252 -169.693 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 86.1 mt -68.84 170.34 9.79 Favored 'General case' 0 C--N 1.316 -0.871 0 N-CA-C 107.458 -1.312 . . . . 0.0 107.458 175.987 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.426 ' CA ' ' HA ' ' A' ' 91' ' ' LYS . 1.3 m -69.89 103.46 2.22 Favored 'General case' 0 C--O 1.203 -1.37 0 C-N-CA 118.016 -1.473 . . . . 0.0 110.403 -173.93 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.572 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.3 tt0 -176.13 141.77 0.46 Allowed 'General case' 0 C--N 1.291 -1.977 0 N-CA-C 102.798 -3.038 . . . . 0.0 102.798 170.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.516 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . -174.54 90.89 0.08 OUTLIER Glycine 0 C--N 1.276 -2.777 0 C-N-CA 117.028 -2.511 . . . . 0.0 113.334 174.581 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -93.4 -86.33 0.26 Allowed 'General case' 0 C--N 1.313 -0.985 0 C-N-CA 120.512 -0.475 . . . . 0.0 111.649 -176.134 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.495 ' HA ' ' H ' ' A' ' 87' ' ' VAL . 18.8 p80 166.32 135.28 0.01 OUTLIER 'General case' 0 CA--C 1.494 -1.181 0 N-CA-C 107.485 -1.302 . . . . 0.0 107.485 -179.733 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . 152.46 131.4 1.68 Allowed Glycine 0 N--CA 1.413 -2.837 0 C-N-CA 118.322 -1.894 . . . . 0.0 113.785 175.346 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 22.1 m-85 -133.98 139.59 46.17 Favored 'General case' 0 C--N 1.292 -1.924 0 CA-C-O 122.063 0.935 . . . . 0.0 113.073 177.469 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 20.8 t-80 -166.89 92.11 0.43 Allowed 'General case' 1 C--O 1.33 5.342 0 N-CA-C 105.183 -2.155 . . . . 0.0 105.183 172.013 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.596 HG13 ' HA ' ' A' ' 117' ' ' LEU . 18.7 t -69.97 167.58 1.84 Allowed 'Isoleucine or valine' 0 C--N 1.305 -1.337 0 C-N-CA 127.351 2.26 . . . . 0.0 109.095 176.442 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.538 ' NE2' ' HB2' ' A' ' 65' ' ' ASN . 56.5 t-80 -124.23 126.04 45.42 Favored 'General case' 0 N--CA 1.434 -1.263 0 CA-C-O 122.085 0.945 . . . . 0.0 109.873 174.033 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.604 ' CD ' ' HB3' ' A' ' 65' ' ' ASN . 2.8 pm0 -73.37 125.45 27.88 Favored 'General case' 0 C--N 1.264 -3.145 0 CA-C-N 113.62 -1.627 . . . . 0.0 108.403 174.549 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.54 ' HA ' ' OG ' ' A' ' 111' ' ' SER . 91.3 t80 80.13 100.17 0.06 Allowed 'General case' 0 CA--C 1.503 -0.851 0 CA-C-O 123.503 1.621 . . . . 0.0 108.776 -175.924 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -120.35 -145.97 7.52 Favored Glycine 0 N--CA 1.421 -2.332 0 CA-C-N 111.94 -2.391 . . . . 0.0 110.49 -179.279 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 2.8 p-10 -171.62 -85.83 0.01 OUTLIER 'General case' 0 N--CA 1.47 0.562 0 N-CA-C 115.597 1.703 . . . . 0.0 115.597 -171.879 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.497 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.7 t-20 -104.52 140.1 38.47 Favored 'General case' 0 C--N 1.318 -0.771 0 N-CA-C 112.779 0.659 . . . . 0.0 112.779 -169.818 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.504 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 10.0 t -61.64 -27.68 68.84 Favored 'General case' 0 C--O 1.241 0.635 0 N-CA-C 113.266 0.839 . . . . 0.0 113.266 -176.172 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . 0.665 ' HA ' ' O ' ' A' ' 9' ' ' LYS . . . -114.47 17.84 17.16 Favored 'General case' 0 N--CA 1.437 -1.116 0 CA-C-O 120.618 0.247 . . . . 0.0 111.449 -175.298 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -177.42 117.27 0.58 Allowed Glycine 0 CA--C 1.483 -1.96 0 C-N-CA 119.247 -1.454 . . . . 0.0 111.382 -178.185 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.464 ' HB3' HG21 ' A' ' 116' ' ' THR . 0.7 OUTLIER -87.28 98.59 11.42 Favored 'General case' 0 C--N 1.28 -2.429 0 C-N-CA 122.926 0.491 . . . . 0.0 109.904 -176.544 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 4.3 m -79.07 -56.1 4.62 Favored 'General case' 0 C--N 1.311 -1.087 0 CA-C-O 121.746 0.784 . . . . 0.0 109.515 177.933 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.7 m -75.32 -43.91 48.27 Favored 'General case' 0 N--CA 1.438 -1.045 0 CA-C-N 114.57 -1.195 . . . . 0.0 111.011 -174.439 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -74.59 -8.61 56.91 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-N 115.808 -0.633 . . . . 0.0 111.949 174.645 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -48.15 -63.69 3.48 Favored Glycine 0 CA--C 1.538 1.504 0 O-C-N 123.758 0.661 . . . . 0.0 112.772 176.085 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 24.5 Cg_exo -64.26 -5.15 9.1 Favored 'Trans proline' 0 C--N 1.372 1.814 0 C-N-CA 122.989 2.459 . . . . 0.0 112.75 176.871 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.289 23.3 p80 56.04 15.75 1.91 Allowed 'General case' 0 N--CA 1.478 0.963 0 N-CA-C 118.504 2.779 . . . . 0.0 118.504 170.568 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 89.5 t80 -146.35 120.45 9.45 Favored 'General case' 0 C--N 1.321 -0.646 0 CA-C-N 119.151 0.887 . . . . 0.0 112.757 178.241 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.604 ' HB3' ' CD ' ' A' ' 49' ' ' GLU . 27.7 t-20 -116.95 144.22 33.08 Favored Pre-proline 0 C--N 1.313 -1.016 0 N-CA-C 107.447 -1.316 . . . . 0.0 107.447 172.487 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 10.8 Cg_endo -52.57 -13.19 2.17 Favored 'Trans proline' 0 CA--C 1.556 1.595 0 C-N-CA 124.466 3.444 . . . . 0.0 117.82 -177.263 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.522 ' C ' ' H ' ' A' ' 69' ' ' ARG . 4.1 mm? -82.62 -12.98 57.28 Favored 'General case' 0 CA--C 1.474 -1.956 0 CA-C-N 119.878 1.217 . . . . 0.0 110.396 -175.308 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.601 ' HA ' ' HB3' ' A' ' 80' ' ' HIS . 74.3 m -72.94 36.4 0.08 Allowed 'General case' 0 C--O 1.215 -0.718 0 C-N-CA 124.342 1.057 . . . . 0.0 109.804 169.434 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.522 ' H ' ' C ' ' A' ' 67' ' ' LEU . 3.3 tmm_? -76.3 11.12 1.66 Allowed 'General case' 0 C--O 1.212 -0.895 0 C-N-CA 127.505 2.322 . . . . 0.0 107.951 -172.746 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.519 ' HE2' ' OD2' ' A' ' 76' ' ' ASP . 47.4 tptt -77.35 -32.47 55.1 Favored 'General case' 0 N--CA 1.396 -3.133 0 N-CA-C 107.918 -1.142 . . . . 0.0 107.918 170.63 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 19.8 t60 61.18 23.86 14.02 Favored 'General case' 0 CA--C 1.545 0.76 0 C-N-CA 124.251 1.021 . . . . 0.0 110.126 178.613 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 122.73 120.99 2.65 Favored Glycine 0 N--CA 1.435 -1.388 0 C-N-CA 119.842 -1.17 . . . . 0.0 112.218 -179.362 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.39 75.78 0.13 Allowed Glycine 0 C--N 1.293 -1.812 0 N-CA-C 109.045 -1.622 . . . . 0.0 109.045 177.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.525 ' O ' HD13 ' A' ' 84' ' ' LEU . 31.8 Cg_endo -62.23 -22.63 74.46 Favored 'Trans proline' 0 C--N 1.355 0.873 0 C-N-CA 123.759 2.973 . . . . 0.0 114.82 -171.501 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mtpt -123.2 13.2 9.62 Favored 'General case' 0 C--N 1.301 -1.53 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 178.222 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.519 ' OD2' ' HE2' ' A' ' 70' ' ' LYS . 21.7 t70 -116.96 -67.69 0.97 Allowed 'General case' 0 C--N 1.307 -1.265 0 N-CA-C 113.253 0.834 . . . . 0.0 113.253 -169.553 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.8 tp10 60.66 111.64 0.02 OUTLIER 'General case' 0 C--O 1.256 1.406 0 CA-C-O 122.477 1.132 . . . . 0.0 110.768 -173.715 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.421 ' CB ' ' HD3' ' A' ' 70' ' ' LYS . 29.9 tt0 -114.44 -78.21 0.58 Allowed 'General case' 0 N--CA 1.422 -1.842 0 C-N-CA 119.334 -0.947 . . . . 0.0 109.878 -176.761 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.489 ' O ' ' HB2' ' A' ' 80' ' ' HIS . 29.3 tpt180 -113.98 5.35 16.1 Favored 'General case' 0 C--O 1.247 0.97 0 C-N-CA 117.729 -1.588 . . . . 0.0 110.767 179.08 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.601 ' HB3' ' HA ' ' A' ' 68' ' ' SER 0.274 18.7 t60 173.62 -150.83 0.01 OUTLIER 'General case' 0 N--CA 1.43 -1.447 0 CA-C-N 114.42 -1.264 . . . . 0.0 109.208 172.926 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 9.3 m 82.49 -32.29 0.01 OUTLIER 'Isoleucine or valine' 0 C--O 1.25 1.106 0 C-N-CA 128.927 2.891 . . . . 0.0 108.413 -147.38 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 87.71 -73.34 2.36 Favored Glycine 0 CA--C 1.48 -2.118 0 N-CA-C 114.263 0.465 . . . . 0.0 114.263 166.712 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.459 ' OD2' HG21 ' A' ' 47' ' ' VAL . 22.2 m-20 -139.76 138.37 35.85 Favored 'General case' 0 C--N 1.283 -2.301 0 N-CA-C 103.844 -2.65 . . . . 0.0 103.844 179.99 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.525 HD13 ' O ' ' A' ' 74' ' ' PRO . 4.0 pp -131.95 135.85 46.9 Favored 'General case' 0 C--N 1.271 -2.837 0 O-C-N 123.471 0.482 . . . . 0.0 110.339 -177.236 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 178.17 -178.64 48.58 Favored Glycine 0 N--CA 1.418 -2.502 0 C-N-CA 120.054 -1.07 . . . . 0.0 111.823 178.338 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 8.1 p30 -118.45 132.72 56.23 Favored 'General case' 0 C--N 1.296 -1.75 0 N-CA-C 108.224 -1.028 . . . . 0.0 108.224 177.923 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.545 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.7 m -136.06 132.8 50.33 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.721 0 N-CA-C 111.735 0.272 . . . . 0.0 111.735 -176.379 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 10.1 t -132.94 96.03 3.69 Favored 'General case' 0 N--CA 1.413 -2.283 0 CA-C-O 122.643 1.211 . . . . 0.0 110.613 178.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.516 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -92.75 153.86 18.65 Favored 'General case' 0 N--CA 1.424 -1.746 0 CA-C-N 113.911 -1.495 . . . . 0.0 107.833 174.682 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.593 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 6.8 t70 -125.14 -161.65 1.04 Allowed 'General case' 0 C--N 1.255 -3.541 0 N-CA-C 108.012 -1.107 . . . . 0.0 108.012 175.872 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.426 ' HA ' ' CA ' ' A' ' 39' ' ' THR . 59.6 pttt -40.85 -34.82 0.43 Allowed 'General case' 0 N--CA 1.506 2.339 0 C-N-CA 127.313 2.245 . . . . 0.0 116.115 -175.319 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 16.9 t70 -147.82 16.62 1.11 Allowed 'General case' 0 C--N 1.289 -2.065 0 N-CA-C 106.67 -1.604 . . . . 0.0 106.67 177.792 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.593 ' HA3' ' H ' ' A' ' 90' ' ' ASP . . . -59.34 -157.52 0.03 OUTLIER Glycine 0 C--O 1.187 -2.826 0 N-CA-C 118.731 2.252 . . . . 0.0 118.731 -164.152 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.424 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 2.8 m -158.49 105.38 0.09 OUTLIER 'Isoleucine or valine' 0 C--N 1.275 -2.656 0 N-CA-C 107.879 -1.156 . . . . 0.0 107.879 -170.984 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.545 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.72 110.12 22.63 Favored 'General case' 0 N--CA 1.398 -3.048 0 N-CA-C 107.534 -1.284 . . . . 0.0 107.534 177.467 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.6 p-10 -85.25 103.37 14.14 Favored 'General case' 0 C--N 1.281 -2.382 0 CA-C-N 114.664 -1.153 . . . . 0.0 110.395 -177.184 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 5.6 p -88.28 102.4 12.67 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.507 0 CA-C-O 122.309 1.052 . . . . 0.0 109.486 177.202 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 8.7 p -155.41 100.7 2.14 Favored 'General case' 0 N--CA 1.418 -2.049 0 CA-C-N 113.649 -1.614 . . . . 0.0 108.11 174.178 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.7 mp -134.46 119.33 29.41 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.751 0 N-CA-C 106.485 -1.672 . . . . 0.0 106.485 178.827 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.4 pt-20 -95.06 101.06 12.79 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 121.949 0.881 . . . . 0.0 111.486 -178.818 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 5.7 t0 -163.03 169.82 18.95 Favored 'General case' 0 C--N 1.311 -1.077 0 N-CA-C 105.669 -1.974 . . . . 0.0 105.669 -178.422 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 44.5 t -59.4 94.42 0.02 OUTLIER 'General case' 0 C--O 1.244 0.769 0 CA-C-O 122.528 1.156 . . . . 0.0 113.402 -179.833 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.456 HG22 ' CD1' ' A' ' 84' ' ' LEU . 15.5 t -118.28 -9.56 11.71 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.016 0 N-CA-C 103.12 -2.919 . . . . 0.0 103.12 168.927 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.588 HG21 ' H ' ' A' ' 27' ' ' GLY . 2.7 pp -41.9 -40.68 0.81 Allowed 'Isoleucine or valine' 0 CA--C 1.481 -1.709 0 C-N-CA 127.812 2.445 . . . . 0.0 114.77 -166.29 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.51 ' N ' HD12 ' A' ' 104' ' ' ILE . 10.1 p -85.84 90.73 8.14 Favored 'General case' 1 N--CA 1.352 -5.37 0 C-N-CA 118.385 -1.326 . . . . 0.0 108.843 176.483 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.626 ' HG ' ' CE1' ' A' ' 20' ' ' PHE . 3.7 mm? -75.42 86.89 2.57 Favored 'General case' 0 N--CA 1.393 -3.296 0 N-CA-C 104.837 -2.283 . . . . 0.0 104.837 177.256 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 15.4 m -83.13 88.35 6.9 Favored 'General case' 1 N--CA 1.357 -5.124 0 CA-C-N 113.203 -1.817 . . . . 0.0 108.702 -174.017 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.73 134.43 11.88 Favored Glycine 1 N--CA 1.36 -6.38 0 N-CA-C 104.482 -3.447 . . . . 0.0 104.482 169.712 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.46 ' CG ' ' HG ' ' A' ' 67' ' ' LEU . 38.6 t70 -84.29 -66.92 0.84 Allowed 'General case' 0 C--N 1.297 -1.716 0 C-N-CA 117.591 -1.644 . . . . 0.0 111.464 -177.074 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 42.2 t-80 -100.03 -17.32 17.55 Favored 'General case' 0 C--N 1.311 -1.074 0 N-CA-C 108.183 -1.043 . . . . 0.0 108.183 179.564 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.54 ' OG ' ' HA ' ' A' ' 50' ' ' PHE . 20.0 m -132.79 118.42 19.0 Favored 'General case' 0 N--CA 1.395 -3.22 0 CA-C-N 115.195 -0.911 . . . . 0.0 111.498 -176.246 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.554 HG13 HD12 ' A' ' 113' ' ' ILE . 14.1 pt -112.6 -25.3 3.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.587 0 N-CA-C 104.749 -2.315 . . . . 0.0 104.749 166.283 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.554 HD12 HG13 ' A' ' 112' ' ' ILE . 2.5 mp -102.59 130.46 52.53 Favored 'Isoleucine or valine' 0 N--CA 1.439 -0.993 0 N-CA-C 103.572 -2.751 . . . . 0.0 103.572 162.883 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 94.94 12.91 54.81 Favored Glycine 0 C--O 1.209 -1.436 0 C-N-CA 119.546 -1.312 . . . . 0.0 111.838 179.508 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.633 ' O ' ' HB ' ' A' ' 149' ' ' ILE . 15.7 mtp180 -70.88 90.07 0.79 Allowed 'General case' 0 C--O 1.207 -1.163 0 CA-C-O 120.868 0.366 . . . . 0.0 110.127 174.132 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.464 HG21 ' HB3' ' A' ' 57' ' ' CYS . 96.9 m -68.0 105.32 1.99 Allowed 'General case' 0 N--CA 1.383 -3.775 0 CA-C-O 122.519 1.152 . . . . 0.0 109.786 172.212 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.596 ' HA ' HG13 ' A' ' 47' ' ' VAL . 43.1 tp -70.09 97.92 1.25 Allowed 'General case' 0 CA--C 1.477 -1.843 0 CA-C-N 113.568 -1.651 . . . . 0.0 108.443 177.317 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.548 HG22 ' HB1' ' A' ' 140' ' ' ALA . 7.2 p -91.23 100.06 10.63 Favored 'Isoleucine or valine' 1 C--O 1.313 4.419 0 C-N-CA 115.909 -2.317 . . . . 0.0 109.874 -175.6 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 9.1 p -149.29 170.23 2.22 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.767 0 CA-C-N 112.429 -2.168 . . . . 0.0 107.172 -175.409 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 45.1 t-80 -158.16 172.28 18.69 Favored 'General case' 0 C--N 1.285 -2.216 0 N-CA-C 103.739 -2.689 . . . . 0.0 103.739 174.002 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.572 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.1 mp0 -66.77 89.81 0.16 Allowed 'General case' 0 C--N 1.285 -2.213 0 N-CA-C 105.138 -2.171 . . . . 0.0 105.138 170.998 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.0 tttp -171.66 170.91 5.5 Favored 'General case' 0 N--CA 1.44 -0.925 0 N-CA-C 106.828 -1.545 . . . . 0.0 106.828 -170.784 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -85.5 104.98 15.77 Favored 'General case' 0 C--N 1.305 -1.348 0 N-CA-C 108.278 -1.008 . . . . 0.0 108.278 170.259 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.449 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 13.1 t70 -106.92 8.03 30.35 Favored 'General case' 0 N--CA 1.489 1.507 0 CA-C-O 122.705 1.24 . . . . 0.0 111.292 -177.772 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.428 ' HB3' ' HD3' ' A' ' 128' ' ' LYS . 5.5 t70 -67.19 139.46 57.42 Favored 'General case' 0 C--N 1.281 -2.398 0 CA-C-N 115.128 -0.942 . . . . 0.0 111.155 -171.539 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 56.7 tp -62.96 -50.92 68.88 Favored 'General case' 0 C--N 1.321 -0.643 0 O-C-N 123.475 0.484 . . . . 0.0 109.916 -178.867 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -64.06 -24.23 68.48 Favored Glycine 0 N--CA 1.442 -0.953 0 CA-C-N 115.531 -0.759 . . . . 0.0 113.192 -179.432 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.428 ' HD3' ' HB3' ' A' ' 125' ' ' ASP . 3.9 mptp? -88.93 -47.05 8.42 Favored 'General case' 0 N--CA 1.44 -0.946 0 C-N-CA 119.931 -0.707 . . . . 0.0 111.701 179.285 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.446 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.6 -103.18 0.06 OUTLIER Glycine 0 C--O 1.222 -0.603 0 N-CA-C 114.847 0.699 . . . . 0.0 114.847 179.67 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -175.53 -79.03 0.05 OUTLIER Glycine 0 N--CA 1.446 -0.683 0 N-CA-C 110.099 -1.2 . . . . 0.0 110.099 -178.48 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.606 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 21.8 t-20 -107.75 -170.23 1.66 Allowed 'General case' 0 C--O 1.258 1.545 0 N-CA-C 105.918 -1.882 . . . . 0.0 105.918 174.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.441 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 29.4 tt0 -53.91 -42.85 69.21 Favored 'General case' 0 CA--C 1.542 0.664 0 CA-C-N 118.884 0.766 . . . . 0.0 111.745 -178.276 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.606 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -75.25 -39.38 59.9 Favored 'General case' 0 C--N 1.305 -1.354 0 N-CA-C 113.382 0.882 . . . . 0.0 113.382 -176.154 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 32.2 m -67.99 -21.65 65.04 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 113.048 0.759 . . . . 0.0 113.048 -176.603 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.446 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 12.3 t -86.71 -6.29 58.88 Favored 'General case' 0 C--N 1.316 -0.857 0 CA-C-O 122.0 0.905 . . . . 0.0 110.738 179.546 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.441 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 89.5 mttt -92.81 -39.74 11.04 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 178.856 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 15.3 p -86.47 -21.23 27.14 Favored 'General case' 0 N--CA 1.408 -2.533 0 CA-C-N 114.662 -1.154 . . . . 0.0 112.307 178.812 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.48 78.47 0.24 Allowed Glycine 0 C--O 1.254 1.383 0 N-CA-C 110.365 -1.094 . . . . 0.0 110.365 -177.946 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.449 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 55.8 t30 -47.71 142.92 4.25 Favored 'General case' 0 N--CA 1.485 1.306 0 C-N-CA 124.967 1.307 . . . . 0.0 112.291 -176.428 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.548 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -150.05 170.49 18.75 Favored 'General case' 0 N--CA 1.424 -1.752 0 CA-C-N 115.818 -0.628 . . . . 0.0 111.308 -173.351 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.4 85.1 1.41 Allowed Glycine 0 N--CA 1.442 -0.958 0 N-CA-C 106.547 -2.621 . . . . 0.0 106.547 169.07 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.448 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 51.0 m -42.47 -56.35 3.07 Favored 'General case' 0 C--O 1.194 -1.819 0 N-CA-C 118.516 2.784 . . . . 0.0 118.516 -165.444 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.434 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 22.9 ptt180 -129.61 12.28 5.84 Favored 'General case' 0 C--N 1.254 -3.58 0 N-CA-C 106.635 -1.617 . . . . 0.0 106.635 -174.795 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.456 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 0.7 OUTLIER -58.15 -44.91 88.11 Favored 'General case' 0 N--CA 1.42 -1.928 0 N-CA-C 106.863 -1.532 . . . . 0.0 106.863 -173.73 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -170.3 92.21 0.2 Allowed 'General case' 0 N--CA 1.434 -1.248 0 N-CA-C 114.371 1.249 . . . . 0.0 114.371 179.282 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.49 ' SG ' ' HA ' ' A' ' 118' ' ' VAL . 13.9 p -173.53 128.74 0.43 Allowed 'General case' 0 C--O 1.211 -0.956 0 N-CA-C 116.634 2.087 . . . . 0.0 116.634 173.368 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.504 ' O ' ' HA ' ' A' ' 54' ' ' THR . . . 179.55 77.08 0.06 OUTLIER Glycine 0 N--CA 1.409 -3.138 0 CA-C-O 117.935 -1.481 . . . . 0.0 113.372 150.391 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.606 ' O ' ' HA ' ' A' ' 6' ' ' ALA . 54.1 t -171.54 90.34 0.0 OUTLIER 'Isoleucine or valine' 0 N--CA 1.49 1.53 0 C-N-CA 125.247 1.419 . . . . 0.0 108.135 167.787 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.633 ' HB ' ' O ' ' A' ' 115' ' ' ARG 0.262 5.4 mt -125.13 118.3 52.49 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.646 0 CA-C-N 119.179 0.9 . . . . 0.0 109.966 163.229 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.425 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.08 155.06 13.35 Favored Glycine 2 N--CA 1.379 -5.132 0 C-N-CA 117.801 -2.142 . . . . 0.0 112.681 176.437 . . . . . . . . 3 3 . 1 . 004 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.539 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 1.6 tt -53.81 105.19 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.307 -1.25 0 CA-C-N 114.893 -0.654 . . . . 0.0 110.55 169.378 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.414 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -130.31 99.43 5.02 Favored 'General case' 0 C--N 1.309 -1.16 0 C-N-CA 119.997 -0.681 . . . . 0.0 109.542 171.178 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.7 pt20 . . . . . 0 C--N 1.304 -1.386 0 CA-C-N 116.026 -0.533 . . . . 0.0 110.657 178.691 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.469 ' O ' ' HB2' ' A' ' 21' ' ' GLU . . . . . . . . 0 CA--C 1.506 -0.74 0 N-CA-C 107.926 -1.139 . . . . 0.0 107.926 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 25.3 m -121.87 -36.77 2.96 Favored 'General case' 0 CA--C 1.555 1.163 0 N-CA-C 112.451 0.538 . . . . 0.0 112.451 -179.472 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.574 ' O ' HG12 ' A' ' 151' ' ' ILE . 17.9 ptpt -136.2 144.15 44.78 Favored 'General case' 0 N--CA 1.426 -1.67 0 C-N-CA 120.169 -0.612 . . . . 0.0 110.718 -175.794 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.557 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -135.73 151.73 50.43 Favored 'General case' 0 C--N 1.282 -2.348 0 N-CA-C 107.793 -1.188 . . . . 0.0 107.793 178.305 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 30.4 m -115.53 138.36 46.17 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.582 0 C-N-CA 120.016 -0.674 . . . . 0.0 110.637 -178.392 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.707 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -111.09 133.89 53.11 Favored 'General case' 0 C--N 1.284 -2.283 0 CA-C-N 114.781 -1.099 . . . . 0.0 111.48 178.508 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.2 m -134.73 104.22 5.15 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.592 0 C-N-CA 122.98 0.512 . . . . 0.0 110.132 176.209 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.479 HD13 ' HA3' ' A' ' 147' ' ' GLY . 3.1 mm? -96.97 151.31 19.83 Favored 'General case' 0 C--N 1.309 -1.169 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.687 -178.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.599 ' HD3' ' N ' ' A' ' 10' ' ' GLY . 9.9 tmtt? -150.54 137.45 19.17 Favored 'General case' 0 C--N 1.314 -0.959 0 N-CA-C 106.042 -1.836 . . . . 0.0 106.042 175.202 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.599 ' N ' ' HD3' ' A' ' 9' ' ' LYS . . . -152.78 -169.6 18.2 Favored Glycine 0 N--CA 1.423 -2.188 0 C-N-CA 119.396 -1.383 . . . . 0.0 113.038 -179.105 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.1 t70 -85.97 -31.12 22.26 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-N 113.915 -1.143 . . . . 0.0 109.376 177.676 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -109.47 -172.5 20.72 Favored Glycine 0 N--CA 1.435 -1.4 0 N-CA-C 107.588 -2.205 . . . . 0.0 107.588 174.226 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 1.7 Cg_endo -83.69 123.06 3.2 Favored 'Trans proline' 0 N--CA 1.445 -1.347 0 CA-C-N 120.779 2.29 . . . . 0.0 111.099 177.783 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.414 HG23 HD11 ' A' ' 35' ' ' ILE . 5.2 p -135.9 91.78 0.99 Allowed 'Isoleucine or valine' 0 N--CA 1.417 -2.097 0 C-N-CA 124.682 1.193 . . . . 0.0 108.522 174.875 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.624 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 16.0 mm100 -111.59 119.08 37.51 Favored 'General case' 0 C--N 1.292 -1.913 0 O-C-N 121.31 -0.869 . . . . 0.0 108.88 -177.914 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.607 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -156.85 148.27 17.83 Favored Glycine 0 N--CA 1.406 -3.306 0 C-N-CA 120.206 -0.997 . . . . 0.0 112.658 -175.481 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.511 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 12.6 pt -135.65 103.79 4.15 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.285 0 N-CA-C 107.767 -1.197 . . . . 0.0 107.767 177.796 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.707 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.3 mp -116.64 129.31 73.35 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.278 0 N-CA-C 107.608 -1.256 . . . . 0.0 107.608 -173.102 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 7.2 p30 -117.16 138.73 51.47 Favored 'General case' 0 CA--C 1.465 -2.3 0 N-CA-C 108.186 -1.042 . . . . 0.0 108.186 179.835 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.557 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 20.3 p90 -136.63 160.97 37.2 Favored 'General case' 0 N--CA 1.412 -2.353 0 C-N-CA 119.573 -0.851 . . . . 0.0 109.99 178.08 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.469 ' HB2' ' O ' ' A' ' 1' ' ' ALA . 11.2 pt-20 -127.02 104.97 8.28 Favored 'General case' 0 N--CA 1.407 -2.582 0 CA-C-N 114.948 -1.024 . . . . 0.0 109.214 177.027 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.537 HE21 HG22 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -85.61 133.73 34.03 Favored 'General case' 0 N--CA 1.399 -2.99 0 N-CA-C 106.739 -1.578 . . . . 0.0 106.739 179.564 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 88.0 mttt -122.58 116.78 24.45 Favored 'General case' 0 C--N 1.274 -2.7 0 CA-C-N 115.053 -0.976 . . . . 0.0 109.138 -179.394 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.437 ' H ' ' HG2' ' A' ' 24' ' ' GLU . 6.7 pt-20 -76.51 -11.28 59.85 Favored 'General case' 0 C--N 1.298 -1.631 0 CA-C-N 114.955 -1.021 . . . . 0.0 111.015 -177.196 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 19.6 m -90.52 -9.28 47.84 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 108.95 -0.759 . . . . 0.0 108.95 171.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 94.0 m-20 70.24 135.93 0.04 OUTLIER 'General case' 0 N--CA 1.478 0.971 0 C-N-CA 125.667 1.587 . . . . 0.0 112.653 -177.593 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -173.37 172.56 45.27 Favored Glycine 0 CA--C 1.487 -1.659 0 C-N-CA 120.28 -0.962 . . . . 0.0 111.374 -178.622 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 28.0 Cg_exo -65.06 123.4 11.52 Favored 'Trans proline' 0 N--CA 1.444 -1.383 0 N-CA-C 105.887 -2.39 . . . . 0.0 105.887 172.172 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.495 ' O ' ' HG3' ' A' ' 100' ' ' GLU . 34.9 m -94.96 127.36 46.98 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.296 0 CA-C-O 121.617 0.722 . . . . 0.0 112.142 -172.801 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.411 ' HB3' ' OE1' ' A' ' 21' ' ' GLU . 0.7 OUTLIER -81.99 104.46 12.36 Favored 'General case' 0 C--N 1.286 -2.155 0 N-CA-C 107.616 -1.253 . . . . 0.0 107.616 177.635 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.518 HG12 ' HA ' ' A' ' 20' ' ' PHE . 14.5 m -132.45 147.65 31.96 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.924 0 N-CA-C 107.18 -1.415 . . . . 0.0 107.18 -177.279 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.436 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 12.0 t90 -158.93 136.49 10.12 Favored 'General case' 0 C--N 1.27 -2.882 0 N-CA-C 107.86 -1.163 . . . . 0.0 107.86 174.307 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.511 ' HA2' ' O ' ' A' ' 17' ' ' ILE . . . -150.3 142.04 9.3 Favored Glycine 0 N--CA 1.403 -3.541 0 C-N-CA 120.405 -0.902 . . . . 0.0 111.921 179.707 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.607 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 24.8 m -114.45 133.81 55.47 Favored 'General case' 0 N--CA 1.416 -2.161 0 N-CA-C 107.188 -1.412 . . . . 0.0 107.188 178.803 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.751 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 5.2 tt -146.83 123.97 3.47 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.106 0 CA-C-N 118.358 0.527 . . . . 0.0 110.672 179.497 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.592 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 0.0 OUTLIER -104.63 134.42 47.82 Favored 'General case' 0 N--CA 1.415 -2.184 0 N-CA-C 107.585 -1.265 . . . . 0.0 107.585 -178.837 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -132.08 177.39 18.73 Favored Glycine 1 N--CA 1.37 -5.705 0 C-N-CA 120.184 -1.008 . . . . 0.0 112.262 -169.186 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.529 HD23 ' N ' ' A' ' 39' ' ' THR . 10.2 tt -67.02 177.22 1.8 Allowed 'General case' 0 C--N 1.271 -2.811 0 N-CA-C 103.124 -2.917 . . . . 0.0 103.124 168.413 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.594 ' HA ' ' HA ' ' A' ' 91' ' ' LYS . 40.6 p -58.91 150.77 23.36 Favored 'General case' 0 C--N 1.299 -1.623 0 O-C-N 120.603 -1.311 . . . . 0.0 111.099 -165.996 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.587 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 0.0 OUTLIER -60.7 158.5 12.56 Favored 'General case' 0 CA--C 1.458 -2.577 0 N-CA-C 117.981 2.586 . . . . 0.0 117.981 -155.751 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -142.2 173.86 23.55 Favored Glycine 0 C--N 1.254 -3.997 0 CA-C-N 110.8 -2.909 . . . . 0.0 107.038 -175.537 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.0 mt -131.66 -34.38 1.35 Allowed 'General case' 0 C--N 1.303 -1.439 0 N-CA-C 116.879 2.177 . . . . 0.0 116.879 -164.699 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.661 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 19.1 t-80 -154.85 123.09 5.94 Favored 'General case' 0 CA--C 1.505 -0.776 0 CA-C-N 121.31 1.868 . . . . 0.0 109.995 -174.887 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -168.98 149.86 14.55 Favored Glycine 0 N--CA 1.424 -2.146 0 C-N-CA 120.573 -0.823 . . . . 0.0 111.846 179.711 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 21.9 m-85 -100.29 135.38 41.81 Favored 'General case' 0 C--O 1.265 1.88 0 N-CA-C 106.632 -1.618 . . . . 0.0 106.632 178.157 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.68 ' HA ' ' O ' ' A' ' 118' ' ' VAL . 0.9 OUTLIER -129.15 82.74 2.1 Favored 'General case' 1 N--CA 1.362 -4.833 0 C-N-CA 118.739 -1.184 . . . . 0.0 111.444 -161.742 . . . . . . . . 4 4 . 1 . 005 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 46' ' ' HIS . 9.3 p -174.59 162.96 0.23 Allowed 'Isoleucine or valine' 0 N--CA 1.398 -3.026 0 CA-C-N 114.119 -1.401 . . . . 0.0 110.582 165.993 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 6.0 m-70 -147.28 112.53 5.53 Favored 'General case' 0 C--N 1.276 -2.611 0 C-N-CA 127.823 2.449 . . . . 0.0 106.994 166.844 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.642 ' CD ' ' HA ' ' A' ' 81' ' ' VAL . 20.2 pt-20 -83.51 86.06 7.15 Favored 'General case' 0 C--O 1.173 -2.942 0 N-CA-C 115.793 1.775 . . . . 0.0 115.793 -173.002 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.51 ' N ' ' HG3' ' A' ' 115' ' ' ARG . 76.3 m-85 -169.09 91.09 0.24 Allowed 'General case' 0 C--N 1.283 -2.286 0 C-N-CA 127.439 2.296 . . . . 0.0 105.361 175.542 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' NE ' ' A' ' 115' ' ' ARG . . . -63.12 139.28 44.33 Favored Glycine 0 N--CA 1.469 0.863 0 C-N-CA 120.476 -0.868 . . . . 0.0 114.539 -178.485 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 57.8 m-20 -125.55 -84.58 0.63 Allowed 'General case' 0 CA--C 1.506 -0.743 0 N-CA-C 108.97 -0.752 . . . . 0.0 108.97 176.994 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 25.6 t-20 -164.75 159.7 18.94 Favored 'General case' 0 C--N 1.324 -0.509 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 -179.036 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.432 ' O ' ' HB3' ' A' ' 9' ' ' LYS . 9.0 t -67.94 -29.01 67.96 Favored 'General case' 0 CA--C 1.547 0.848 0 CA-C-N 117.879 0.309 . . . . 0.0 111.538 -179.417 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -85.42 -22.24 28.42 Favored 'General case' 0 C--N 1.316 -0.856 0 N-CA-C 112.908 0.707 . . . . 0.0 112.908 -175.721 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.41 110.76 0.51 Allowed Glycine 0 CA--C 1.484 -1.901 0 C-N-CA 119.366 -1.397 . . . . 0.0 111.42 -175.789 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.622 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 7.9 p -98.43 89.22 4.36 Favored 'General case' 0 C--N 1.281 -2.37 0 CA-C-O 121.895 0.855 . . . . 0.0 111.472 178.067 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 42.0 m -79.54 -47.25 15.86 Favored 'General case' 0 C--N 1.304 -1.377 0 CA-C-N 114.557 -1.201 . . . . 0.0 110.454 -179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 20.0 m -79.78 -8.28 59.17 Favored 'General case' 0 N--CA 1.426 -1.659 0 CA-C-N 114.903 -1.044 . . . . 0.0 111.252 -174.878 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.558 ' CB ' ' HB2' ' A' ' 57' ' ' CYS . . . -74.71 -9.28 58.42 Favored 'General case' 0 C--O 1.249 1.069 0 CA-C-N 115.338 -0.847 . . . . 0.0 111.989 179.303 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.412 ' HA3' ' HD2' ' A' ' 62' ' ' PRO . . . -68.88 -142.85 0.11 Allowed Glycine 0 N--CA 1.434 -1.475 0 CA-C-N 115.601 -0.727 . . . . 0.0 113.697 178.822 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.412 ' HD2' ' HA3' ' A' ' 61' ' ' GLY . 55.0 Cg_endo -65.01 8.72 0.19 Allowed 'Trans proline' 0 CA--C 1.545 1.041 0 C-N-CA 124.456 3.438 . . . . 0.0 114.843 -176.736 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.9 t60 -100.93 124.42 46.6 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 109.148 -0.686 . . . . 0.0 109.148 -169.615 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 22.4 p90 -133.84 166.03 23.62 Favored 'General case' 0 C--N 1.302 -1.471 0 N-CA-C 112.349 0.5 . . . . 0.0 112.349 -172.006 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.455 ' HB3' ' OE2' ' A' ' 49' ' ' GLU . 44.3 t30 -114.03 96.39 41.64 Favored Pre-proline 0 N--CA 1.428 -1.541 0 N-CA-C 107.997 -1.112 . . . . 0.0 107.997 175.351 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 84.4 Cg_endo -80.97 -10.27 12.76 Favored 'Trans proline' 0 N--CA 1.425 -2.509 0 C-N-CA 123.206 2.604 . . . . 0.0 111.135 -177.269 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 2.7 tm? -65.63 -45.29 83.63 Favored 'General case' 0 N--CA 1.432 -1.337 0 O-C-N 123.815 0.697 . . . . 0.0 110.019 -166.378 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.626 ' HB2' ' O ' ' A' ' 79' ' ' ARG 0.293 7.6 m -52.31 -52.66 51.76 Favored 'General case' 0 N--CA 1.417 -2.093 0 N-CA-C 116.241 1.941 . . . . 0.0 116.241 -171.215 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.58 ' O ' ' HB2' ' A' ' 70' ' ' LYS . 72.0 ttt180 -133.97 -32.84 1.07 Allowed 'General case' 0 CA--C 1.479 -1.781 0 C-N-CA 113.998 -3.081 . . . . 0.0 111.61 167.748 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.58 ' HB2' ' O ' ' A' ' 69' ' ' ARG . 22.0 tptm 160.63 -77.96 0.0 OUTLIER 'General case' 0 N--CA 1.482 1.131 0 O-C-N 124.695 1.247 . . . . 0.0 108.708 170.171 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.3 OUTLIER 178.58 119.99 0.04 OUTLIER 'General case' 0 CA--C 1.541 0.606 0 C-N-CA 126.489 1.916 . . . . 0.0 108.4 177.573 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.408 ' N ' ' HB3' ' A' ' 78' ' ' GLU . . . -156.28 -87.71 0.06 OUTLIER Glycine 0 CA--C 1.529 0.965 0 C-N-CA 118.636 -1.745 . . . . 0.0 115.355 177.866 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -166.53 -146.12 4.72 Favored Glycine 0 N--CA 1.415 -2.752 0 C-N-CA 121.354 -0.45 . . . . 0.0 113.083 -173.164 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 5.1 Cg_endo -106.0 1.42 0.2 Allowed 'Trans proline' 0 C--O 1.233 0.258 0 C-N-CA 124.969 3.779 . . . . 0.0 114.909 -170.527 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 97.6 mttt -87.4 -17.25 32.71 Favored 'General case' 0 C--N 1.283 -2.294 0 N-CA-C 115.366 1.617 . . . . 0.0 115.366 -167.275 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.57 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 12.7 t70 -146.51 -72.71 0.23 Allowed 'General case' 0 C--N 1.303 -1.452 0 C-N-CA 119.412 -0.915 . . . . 0.0 110.662 -178.383 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.526 ' HG3' ' H ' ' A' ' 78' ' ' GLU . 21.9 pt-20 -154.11 -56.57 0.11 Allowed 'General case' 0 C--N 1.3 -1.58 0 N-CA-C 109.734 -0.469 . . . . 0.0 109.734 177.555 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.57 ' OE1' ' HB3' ' A' ' 76' ' ' ASP . 0.6 OUTLIER 52.74 1.67 0.02 OUTLIER 'General case' 0 C--O 1.203 -1.349 0 C-N-CA 127.73 2.412 . . . . 0.0 116.95 172.873 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.658 ' HB3' HG13 ' A' ' 81' ' ' VAL . 27.0 mtt180 163.7 -26.91 0.0 OUTLIER 'General case' 0 C--O 1.189 -2.119 0 C-N-CA 125.266 1.426 . . . . 0.0 111.389 -172.353 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.402 ' HB2' ' CB ' ' A' ' 68' ' ' SER . 30.6 m-70 57.17 19.01 4.52 Favored 'General case' 0 N--CA 1.498 1.946 0 N-CA-C 112.814 0.672 . . . . 0.0 112.814 -179.3 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.658 HG13 ' HB3' ' A' ' 79' ' ' ARG . 6.9 m -57.88 -15.34 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.517 -0.315 0 O-C-N 124.015 0.822 . . . . 0.0 112.73 -177.043 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.474 ' HA3' HG21 ' A' ' 47' ' ' VAL . . . 140.84 -126.02 3.0 Favored Glycine 0 N--CA 1.401 -3.688 0 C-N-CA 121.289 -0.481 . . . . 0.0 112.221 174.882 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 31.2 t0 -81.59 87.42 6.26 Favored 'General case' 0 C--N 1.299 -1.601 0 CA-C-O 123.065 1.412 . . . . 0.0 110.628 -174.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 94.8 mt -98.78 89.49 4.36 Favored 'General case' 0 C--N 1.297 -1.703 0 CA-C-N 113.685 -1.598 . . . . 0.0 110.355 177.286 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -146.88 -176.82 20.97 Favored Glycine 0 N--CA 1.416 -2.664 0 N-CA-C 108.881 -1.687 . . . . 0.0 108.881 -178.71 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 14.5 p-10 -90.84 155.57 18.67 Favored 'General case' 0 C--N 1.3 -1.544 0 CA-C-N 117.733 0.767 . . . . 0.0 111.822 -179.333 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.484 HG13 ' NE2' ' A' ' 46' ' ' HIS . 2.0 m -143.16 128.45 15.88 Favored 'Isoleucine or valine' 0 C--N 1.361 1.081 0 C-N-CA 123.585 0.754 . . . . 0.0 111.08 173.14 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.7 t -141.78 95.98 2.9 Favored 'General case' 0 N--CA 1.39 -3.468 0 N-CA-C 107.712 -1.218 . . . . 0.0 107.712 172.206 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -96.1 122.43 38.93 Favored 'General case' 0 CA--C 1.466 -2.266 0 N-CA-C 106.534 -1.654 . . . . 0.0 106.534 177.832 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.606 ' HB3' ' HA3' ' A' ' 93' ' ' GLY . 21.6 t70 -54.15 169.76 0.16 Allowed 'General case' 0 CA--C 1.565 1.525 0 O-C-N 124.824 1.328 . . . . 0.0 111.435 177.468 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.594 ' HA ' ' HA ' ' A' ' 39' ' ' THR . 57.4 pttt -41.68 -23.54 0.03 OUTLIER 'General case' 0 N--CA 1.498 1.962 0 N-CA-C 117.233 2.309 . . . . 0.0 117.233 -175.309 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -154.16 22.07 0.5 Allowed 'General case' 0 C--N 1.294 -1.81 0 N-CA-C 104.359 -2.46 . . . . 0.0 104.359 172.496 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.606 ' HA3' ' HB3' ' A' ' 90' ' ' ASP . . . -83.81 -127.57 1.4 Allowed Glycine 0 C--O 1.179 -3.313 0 CA-C-N 111.555 -2.566 . . . . 0.0 118.634 -160.899 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.751 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 3.3 m -161.16 136.27 1.55 Allowed 'Isoleucine or valine' 0 CA--C 1.493 -1.226 0 C-N-CA 124.978 1.311 . . . . 0.0 108.207 -170.247 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . . . . . . . . . . . -102.57 111.73 24.16 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 107.962 -1.125 . . . . 0.0 107.962 173.685 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.9 m-20 -74.99 93.52 2.72 Favored 'General case' 0 CA--C 1.49 -1.35 0 O-C-N 123.479 0.487 . . . . 0.0 109.766 178.977 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.436 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 33.7 m -91.78 111.76 24.55 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.01 0 CA-C-O 121.982 0.896 . . . . 0.0 111.007 178.108 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 22.3 t -149.95 100.84 2.98 Favored 'General case' 0 N--CA 1.411 -2.394 0 N-CA-C 105.003 -2.221 . . . . 0.0 105.003 174.443 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 3.9 mp -130.42 118.55 43.49 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.79 0 N-CA-C 105.902 -1.888 . . . . 0.0 105.902 178.967 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.495 ' HG3' ' O ' ' A' ' 29' ' ' VAL . 5.1 mp0 -107.32 99.01 8.57 Favored 'General case' 0 N--CA 1.417 -2.108 0 C-N-CA 118.983 -1.087 . . . . 0.0 110.327 -176.032 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.5 t70 -165.88 166.33 17.64 Favored 'General case' 0 C--N 1.314 -0.946 0 N-CA-C 106.434 -1.691 . . . . 0.0 106.434 173.481 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 51.1 m -94.71 80.39 3.78 Favored 'General case' 0 C--N 1.296 -1.732 0 C-N-CA 118.827 -1.149 . . . . 0.0 112.939 -174.07 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 27.0 m -104.84 -18.72 6.76 Favored 'Isoleucine or valine' 0 C--N 1.307 -1.269 0 CA-C-N 115.396 -0.82 . . . . 0.0 109.801 176.428 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 21.3 pt -101.46 7.81 9.31 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.707 0 CA-C-N 114.949 -1.023 . . . . 0.0 112.707 -170.804 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.453 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 6.1 m -66.57 167.54 10.76 Favored 'General case' 0 CA--C 1.56 1.332 0 CA-C-O 122.697 1.237 . . . . 0.0 113.003 -175.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.448 ' HB2' ' NE2' ' A' ' 22' ' ' GLN . 3.8 tt -78.26 87.22 4.33 Favored 'General case' 0 N--CA 1.406 -2.665 0 CA-C-N 114.115 -1.402 . . . . 0.0 108.286 -179.956 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 51.7 m -170.01 86.68 0.13 Allowed 'General case' 0 C--N 1.264 -3.144 0 N-CA-C 102.533 -3.136 . . . . 0.0 102.533 169.904 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 157.32 -177.45 34.16 Favored Glycine 0 C--N 1.258 -3.753 0 N-CA-C 109.788 -1.325 . . . . 0.0 109.788 179.728 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.416 ' HB3' ' O ' ' A' ' 49' ' ' GLU . 18.9 t70 -81.31 -21.5 39.19 Favored 'General case' 0 CA--C 1.541 0.604 0 C-N-CA 118.492 -1.283 . . . . 0.0 109.568 175.265 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.581 ' HB2' ' HB3' ' A' ' 49' ' ' GLU . 62.9 t-80 -88.36 40.66 0.97 Allowed 'General case' 0 N--CA 1.486 1.344 0 N-CA-C 106.348 -1.723 . . . . 0.0 106.348 173.598 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.443 ' HB2' ' HG ' ' A' ' 106' ' ' LEU . 15.1 p -63.02 -64.78 0.81 Allowed 'General case' 0 C--N 1.273 -2.725 0 CA-C-O 122.724 1.25 . . . . 0.0 110.146 -175.812 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.537 HG22 HE21 ' A' ' 22' ' ' GLN . 28.5 pt -128.94 -22.93 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.27 -2.867 0 CA-C-N 113.699 -1.591 . . . . 0.0 110.184 176.299 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 1.0 OUTLIER -81.23 170.54 1.42 Allowed 'Isoleucine or valine' 0 C--O 1.251 1.158 0 CA-C-N 115.342 -0.845 . . . . 0.0 111.206 -162.448 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -82.99 71.72 2.97 Favored Glycine 0 CA--C 1.475 -2.463 0 N-CA-C 110.293 -1.123 . . . . 0.0 110.293 -172.62 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.51 ' HG3' ' N ' ' A' ' 50' ' ' PHE . 2.6 mpt_? -79.13 141.24 37.45 Favored 'General case' 0 N--CA 1.396 -3.13 0 CA-C-N 114.603 -0.799 . . . . 0.0 110.063 -178.739 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.8 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 8.8 t -67.84 124.21 22.71 Favored 'General case' 0 C--N 1.274 -2.716 0 CA-C-O 122.895 1.331 . . . . 0.0 114.554 -168.96 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . . . . . . . . . 13.3 tp -80.64 98.42 7.67 Favored 'General case' 0 C--N 1.32 -0.674 0 CA-C-N 113.556 -1.656 . . . . 0.0 108.901 -178.474 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.68 ' O ' ' HA ' ' A' ' 46' ' ' HIS . 26.9 t -91.85 100.56 11.42 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.439 0 C-N-CA 118.967 -1.093 . . . . 0.0 109.864 178.807 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.571 ' HB ' ' CB ' ' A' ' 46' ' ' HIS . 12.2 p -139.98 156.98 25.61 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.398 0 C-N-CA 126.539 1.936 . . . . 0.0 108.343 -175.649 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 4.6 t-80 -171.45 166.57 6.88 Favored 'General case' 0 N--CA 1.428 -1.564 0 N-CA-C 105.422 -2.066 . . . . 0.0 105.422 165.117 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.567 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -73.32 84.91 1.44 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 106.654 -1.61 . . . . 0.0 106.654 175.605 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.47 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 79.3 mttt -173.19 170.77 4.26 Favored 'General case' 0 CA--C 1.493 -1.228 0 C-N-CA 126.119 1.768 . . . . 0.0 108.326 -179.478 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.661 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -80.44 104.48 11.01 Favored 'General case' 0 C--N 1.29 -1.998 0 O-C-N 124.145 0.903 . . . . 0.0 110.974 172.253 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 8.5 t0 -118.78 80.46 1.54 Allowed 'General case' 0 CA--C 1.483 -1.623 0 N-CA-C 104.267 -2.494 . . . . 0.0 104.267 173.28 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.712 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 16.4 t0 -125.91 139.0 53.82 Favored 'General case' 0 C--N 1.263 -3.17 0 C-N-CA 119.681 -0.808 . . . . 0.0 109.332 -170.886 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 47.4 tp -82.03 -21.5 36.93 Favored 'General case' 0 C--N 1.309 -1.153 0 CA-C-N 115.321 -0.854 . . . . 0.0 110.876 -172.944 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -102.82 13.42 56.29 Favored Glycine 0 N--CA 1.437 -1.257 0 N-CA-C 110.195 -1.162 . . . . 0.0 110.195 176.09 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.712 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 14.3 tmtt? -127.42 37.76 4.18 Favored 'General case' 0 C--N 1.316 -0.885 0 N-CA-C 105.056 -2.202 . . . . 0.0 105.056 178.72 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -58.3 -54.84 34.38 Favored Glycine 0 N--CA 1.427 -1.9 0 CA-C-N 114.749 -1.114 . . . . 0.0 111.12 -179.969 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 114.34 -25.09 10.78 Favored Glycine 0 C--N 1.308 -1.004 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.907 178.647 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 33.3 t-20 -167.58 167.08 13.77 Favored 'General case' 0 C--N 1.311 -1.07 0 N-CA-C 105.616 -1.994 . . . . 0.0 105.616 179.132 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.438 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 12.9 pt-20 -48.39 -46.59 37.34 Favored 'General case' 0 CA--C 1.534 0.357 0 N-CA-C 113.32 0.859 . . . . 0.0 113.32 -174.943 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.0 tm-20 -61.72 -53.57 54.28 Favored 'General case' 0 C--N 1.321 -0.644 0 C-N-CA 123.542 0.737 . . . . 0.0 110.412 179.291 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 6.6 m -69.22 -27.28 65.34 Favored 'General case' 0 C--N 1.305 -1.357 0 CA-C-N 116.011 -0.54 . . . . 0.0 112.108 -172.943 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 26.0 m -78.01 -15.31 59.05 Favored 'General case' 0 CA--C 1.557 1.235 0 CA-C-O 121.801 0.81 . . . . 0.0 110.025 177.244 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.438 ' HG3' ' O ' ' A' ' 132' ' ' GLU . 99.4 mttt -89.67 -40.14 12.74 Favored 'General case' 0 CA--C 1.491 -1.323 0 N-CA-C 109.104 -0.702 . . . . 0.0 109.104 174.804 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 29.0 m -67.43 -46.39 73.28 Favored 'General case' 0 C--N 1.284 -2.244 0 CA-C-O 121.366 0.603 . . . . 0.0 109.993 177.295 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 84.53 76.56 1.18 Allowed Glycine 0 N--CA 1.408 -3.208 0 N-CA-C 106.866 -2.493 . . . . 0.0 106.866 -172.975 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 48.8 t-20 -36.21 111.22 0.13 Allowed 'General case' 0 N--CA 1.484 1.252 0 C-N-CA 125.905 1.682 . . . . 0.0 111.041 -175.274 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -149.22 135.75 19.4 Favored 'General case' 0 N--CA 1.433 -1.311 0 CA-C-N 115.6 -0.727 . . . . 0.0 111.225 -173.019 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.406 ' HA3' ' CD1' ' A' ' 144' ' ' LEU . . . -70.87 108.4 2.47 Favored Glycine 0 N--CA 1.434 -1.438 0 N-CA-C 109.157 -1.577 . . . . 0.0 109.157 172.861 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.6 m -57.01 -29.55 63.42 Favored 'General case' 0 C--N 1.302 -1.462 0 N-CA-C 115.285 1.587 . . . . 0.0 115.285 -169.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.622 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 27.3 ttm180 -128.97 21.82 5.8 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.646 -0.872 . . . . 0.0 108.646 -175.496 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.406 ' CD1' ' HA3' ' A' ' 141' ' ' GLY . 74.9 mt -74.46 -15.38 60.9 Favored 'General case' 0 C--N 1.302 -1.498 0 C-N-CA 119.333 -0.947 . . . . 0.0 110.692 -179.272 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.416 ' HB1' HD12 ' A' ' 8' ' ' LEU . . . -162.71 109.26 1.22 Allowed 'General case' 0 N--CA 1.436 -1.132 0 CA-C-N 115.653 -0.703 . . . . 0.0 109.478 175.15 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 61.5 m -98.59 131.41 44.82 Favored 'General case' 0 N--CA 1.418 -2.048 0 N-CA-C 106.864 -1.532 . . . . 0.0 106.864 174.401 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.8 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.59 126.44 1.23 Allowed Glycine 0 N--CA 1.412 -2.919 0 C-N-CA 118.699 -1.715 . . . . 0.0 112.873 -178.407 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 24.5 m -76.18 98.43 1.69 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.024 0 CA-C-O 121.691 0.758 . . . . 0.0 109.864 173.831 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.406 HG13 ' CB ' ' A' ' 6' ' ' ALA . 1.7 mp -106.4 112.22 38.61 Favored 'Isoleucine or valine' 0 C--O 1.257 1.48 0 CA-C-O 122.31 1.053 . . . . 0.0 109.926 -179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.443 ' HA2' ' CZ ' ' A' ' 20' ' ' PHE . . . -174.68 176.76 46.93 Favored Glycine 0 CA--C 1.461 -3.294 0 N-CA-C 108.424 -1.87 . . . . 0.0 108.424 -175.981 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.574 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.35 105.05 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.434 -1.235 0 N-CA-C 107.942 -1.132 . . . . 0.0 107.942 176.727 . . . . . . . . 3 3 . 1 . 005 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.54 147.59 41.42 Favored 'General case' 0 N--CA 1.413 -2.281 0 N-CA-C 106.464 -1.68 . . . . 0.0 106.464 177.888 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 6.7 pt20 . . . . . 0 C--N 1.292 -1.9 0 N-CA-C 108.862 -0.792 . . . . 0.0 108.862 -178.916 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.544 0.722 0 N-CA-C 112.086 0.402 . . . . 0.0 112.086 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 26.7 m -74.46 -23.4 58.89 Favored 'General case' 0 CA--C 1.566 1.58 0 N-CA-C 115.426 1.639 . . . . 0.0 115.426 -172.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 19.1 ptmt -132.37 147.8 52.4 Favored 'General case' 0 C--N 1.301 -1.516 0 C-N-CA 119.175 -1.01 . . . . 0.0 111.873 -171.768 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.639 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -132.64 156.48 46.86 Favored 'General case' 0 N--CA 1.405 -2.693 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.579 -179.763 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.46 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 47.2 t -125.96 126.91 70.6 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.897 0 N-CA-C 107.886 -1.153 . . . . 0.0 107.886 -178.519 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.555 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -124.91 135.1 52.55 Favored 'General case' 0 C--N 1.289 -2.054 0 CA-C-N 115.446 -0.797 . . . . 0.0 110.005 176.993 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.513 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 14.7 m -127.61 119.77 52.76 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.034 0 CA-C-O 121.201 0.524 . . . . 0.0 110.809 179.254 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -100.34 138.15 37.8 Favored 'General case' 0 C--N 1.306 -1.285 0 CA-C-N 115.356 -0.838 . . . . 0.0 110.219 177.803 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -165.8 125.19 1.68 Allowed 'General case' 0 N--CA 1.438 -1.034 0 N-CA-C 107.084 -1.45 . . . . 0.0 107.084 177.818 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.83 -158.98 8.99 Favored Glycine 0 N--CA 1.439 -1.156 0 C-N-CA 120.106 -1.045 . . . . 0.0 111.633 -179.168 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 18.4 t70 -72.34 -61.78 1.67 Allowed 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 108.403 -0.962 . . . . 0.0 108.403 177.486 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -75.62 153.43 44.2 Favored Glycine 0 N--CA 1.446 -0.682 0 N-CA-C 107.661 -2.176 . . . . 0.0 107.661 172.63 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 6.5 Cg_endo -83.21 123.35 3.47 Favored 'Trans proline' 0 N--CA 1.429 -2.289 0 CA-C-N 120.976 2.388 . . . . 0.0 112.389 -175.601 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 5.3 m -133.74 119.09 31.98 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.819 0 N-CA-C 105.642 -1.984 . . . . 0.0 105.642 173.356 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.9 tt0 -130.82 128.88 41.55 Favored 'General case' 0 C--N 1.269 -2.909 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 178.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.545 ' HA3' HD13 ' A' ' 35' ' ' ILE . . . -170.54 161.78 34.77 Favored Glycine 0 N--CA 1.399 -3.791 0 C-N-CA 119.49 -1.338 . . . . 0.0 112.201 -177.273 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.46 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 30.0 pt -142.26 133.6 25.63 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.318 0 N-CA-C 105.956 -1.868 . . . . 0.0 105.956 178.259 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 9.3 tt -132.31 135.03 58.68 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 N-CA-C 109.007 -0.738 . . . . 0.0 109.007 178.337 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 6.8 t30 -107.11 132.94 52.45 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 -174.615 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.639 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 22.1 t80 -127.42 138.2 52.92 Favored 'General case' 0 C--N 1.305 -1.345 0 C-N-CA 123.619 0.768 . . . . 0.0 110.59 -177.616 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.572 ' O ' HG23 ' A' ' 29' ' ' VAL . 5.7 pt-20 -117.33 119.69 35.89 Favored 'General case' 0 C--N 1.29 -1.979 0 CA-C-N 115.169 -0.923 . . . . 0.0 109.537 177.721 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.9 pt20 -86.13 135.65 33.52 Favored 'General case' 0 C--N 1.295 -1.787 0 C-N-CA 119.299 -0.961 . . . . 0.0 108.751 179.995 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 0.8 OUTLIER -115.43 83.75 1.98 Allowed 'General case' 0 C--N 1.302 -1.472 0 CA-C-O 121.678 0.751 . . . . 0.0 110.308 179.647 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 22.4 mt-10 -68.42 -20.21 64.64 Favored 'General case' 0 C--N 1.311 -1.087 0 C-N-CA 124.526 1.131 . . . . 0.0 110.802 -177.179 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . 0.447 ' O ' ' HB3' ' A' ' 26' ' ' ASN . 17.4 t -88.44 -5.23 58.39 Favored 'General case' 0 C--N 1.31 -1.133 0 CA-C-N 114.905 -1.043 . . . . 0.0 110.089 177.959 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.447 ' HB3' ' O ' ' A' ' 25' ' ' SER . 4.0 t30 77.47 113.91 0.07 Allowed 'General case' 0 N--CA 1.482 1.146 0 C-N-CA 124.682 1.193 . . . . 0.0 110.837 -173.227 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . -170.82 166.41 39.6 Favored Glycine 0 CA--C 1.475 -2.455 0 N-CA-C 109.791 -1.324 . . . . 0.0 109.791 -177.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.47 ' HA ' ' HB2' ' A' ' 101' ' ' ASP . 58.0 Cg_endo -71.67 124.08 9.95 Favored 'Trans proline' 0 N--CA 1.433 -2.044 0 C-N-CA 121.177 1.251 . . . . 0.0 110.774 -179.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.584 HG12 ' H ' ' A' ' 102' ' ' SER . 9.8 p -76.75 123.25 32.83 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.893 0 C-N-CA 119.325 -0.95 . . . . 0.0 109.066 173.761 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 52.7 mtmt -105.56 124.56 49.76 Favored 'General case' 0 C--N 1.28 -2.451 0 N-CA-C 107.325 -1.361 . . . . 0.0 107.325 172.631 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.597 ' H ' HG23 ' A' ' 99' ' ' ILE . 34.4 m -134.33 153.27 35.31 Favored 'Isoleucine or valine' 0 C--N 1.29 -1.988 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -172.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 69.4 p-90 -145.64 135.23 23.27 Favored 'General case' 0 C--N 1.275 -2.648 0 N-CA-C 109.095 -0.706 . . . . 0.0 109.095 174.562 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.745 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -148.68 139.59 7.68 Favored Glycine 0 N--CA 1.42 -2.404 0 C-N-CA 119.979 -1.105 . . . . 0.0 111.662 175.941 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 29.2 m -116.11 125.63 52.63 Favored 'General case' 0 C--N 1.295 -1.777 0 N-CA-C 108.578 -0.897 . . . . 0.0 108.578 179.106 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.545 HD13 ' HA3' ' A' ' 16' ' ' GLY . 25.3 mm -125.04 132.19 71.59 Favored 'Isoleucine or valine' 0 C--N 1.319 -0.758 0 N-CA-C 108.262 -1.014 . . . . 0.0 108.262 179.548 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.401 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 36.0 mtmm -117.67 136.16 53.52 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 107.505 -1.295 . . . . 0.0 107.505 177.998 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -171.01 174.15 44.75 Favored Glycine 0 C--N 1.285 -2.291 0 N-CA-C 107.033 -2.427 . . . . 0.0 107.033 -172.056 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.6 pp -68.66 153.69 43.31 Favored 'General case' 0 C--N 1.295 -1.784 0 CA-C-N 118.679 1.239 . . . . 0.0 109.634 176.717 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.59 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 77.3 p -69.85 107.26 3.46 Favored 'General case' 0 C--O 1.206 -1.195 0 N-CA-C 113.738 1.014 . . . . 0.0 113.738 -170.036 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 28.7 tt0 -175.35 115.99 0.15 Allowed 'General case' 0 C--O 1.205 -1.279 0 C-N-CA 125.653 1.581 . . . . 0.0 107.018 172.306 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.504 ' N ' ' HB3' ' A' ' 90' ' ' ASP . . . -164.35 114.97 0.62 Allowed Glycine 0 C--N 1.273 -2.917 0 C-N-CA 118.392 -1.861 . . . . 0.0 112.166 -174.637 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 92.2 mt -106.72 -64.76 1.15 Allowed 'General case' 0 N--CA 1.435 -1.191 0 O-C-N 123.998 0.47 . . . . 0.0 112.187 -174.632 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.67 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.1 m80 -171.35 168.95 6.45 Favored 'General case' 0 CA--C 1.492 -1.255 0 C-N-CA 124.249 1.02 . . . . 0.0 108.326 179.846 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.467 ' O ' ' HG3' ' A' ' 74' ' ' PRO . . . 178.23 -169.28 40.97 Favored Glycine 0 C--N 1.282 -2.461 0 C-N-CA 119.786 -1.197 . . . . 0.0 112.056 176.39 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.54 ' CE1' ' HA ' ' A' ' 126' ' ' LEU . 1.3 p90 -168.16 165.67 13.15 Favored 'General case' 0 C--N 1.296 -1.731 0 N-CA-C 107.385 -1.339 . . . . 0.0 107.385 179.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.697 ' CE1' ' HA3' ' A' ' 85' ' ' GLY . 18.3 m-70 -90.02 150.02 22.29 Favored 'General case' 0 CA--C 1.478 -1.808 0 N-CA-C 105.311 -2.107 . . . . 0.0 105.311 178.977 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' O ' ' A' ' 46' ' ' HIS . 0.0 OUTLIER -172.3 89.37 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.29 -2.015 0 N-CA-C 113.552 0.945 . . . . 0.0 113.552 173.663 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.34 86.06 0.12 Allowed 'General case' 0 C--N 1.289 -2.047 0 N-CA-C 108.799 -0.815 . . . . 0.0 108.799 163.942 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.492 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 9.0 pt-20 -93.4 117.92 30.67 Favored 'General case' 0 C--N 1.316 -0.882 0 C-N-CA 118.094 -1.442 . . . . 0.0 110.852 175.521 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.492 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 12.0 t80 162.58 92.43 0.0 OUTLIER 'General case' 0 C--N 1.3 -1.561 0 N-CA-C 103.766 -2.679 . . . . 0.0 103.766 179.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -48.66 109.08 0.47 Allowed Glycine 0 N--CA 1.478 1.482 0 O-C-N 123.682 0.614 . . . . 0.0 113.714 -177.129 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.0 t70 -120.98 -80.77 0.63 Allowed 'General case' 0 CA--C 1.501 -0.914 0 C-N-CA 117.971 -1.492 . . . . 0.0 112.089 -175.583 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.8 t30 -144.99 156.4 43.93 Favored 'General case' 0 C--N 1.3 -1.564 0 C-N-CA 119.965 -0.694 . . . . 0.0 109.891 -177.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.448 HG22 HG22 ' A' ' 148' ' ' VAL . 33.1 p -84.32 -1.51 55.5 Favored 'General case' 0 C--N 1.304 -1.405 0 C-N-CA 124.228 1.011 . . . . 0.0 111.295 -177.137 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.7 20.85 4.64 Favored 'General case' 0 C--N 1.308 -1.199 0 CA-C-N 115.611 -0.722 . . . . 0.0 110.266 -179.034 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 146.99 114.39 0.82 Allowed Glycine 0 N--CA 1.424 -2.133 0 C-N-CA 118.969 -1.586 . . . . 0.0 112.033 178.697 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.466 ' SG ' HG23 ' A' ' 118' ' ' VAL . 9.4 p -96.71 90.83 5.43 Favored 'General case' 0 C--N 1.293 -1.885 0 CA-C-O 122.095 0.95 . . . . 0.0 112.698 -177.456 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.2 p -74.18 -49.23 24.49 Favored 'General case' 0 C--N 1.282 -2.364 0 CA-C-N 114.762 -1.108 . . . . 0.0 111.075 -177.78 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 18.9 m -65.14 -23.67 67.19 Favored 'General case' 0 C--N 1.314 -0.951 0 N-CA-C 113.937 1.088 . . . . 0.0 113.937 -175.767 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -76.74 -22.99 53.05 Favored 'General case' 0 N--CA 1.422 -1.864 0 C-N-CA 120.037 -0.665 . . . . 0.0 110.822 -178.647 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.403 ' HA3' ' HD3' ' A' ' 62' ' ' PRO . . . 30.62 -97.29 0.01 OUTLIER Glycine 0 N--CA 1.494 2.532 0 C-N-CA 124.881 1.229 . . . . 0.0 115.663 164.346 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.403 ' HD3' ' HA3' ' A' ' 61' ' ' GLY . 27.9 Cg_endo -93.44 73.46 0.36 Allowed 'Trans proline' 0 N--CA 1.435 -1.968 0 C-N-CA 123.479 2.786 . . . . 0.0 109.932 174.945 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.511 ' CD2' ' HB ' ' A' ' 47' ' ' VAL . 7.2 p-80 -36.52 137.94 0.26 Allowed 'General case' 0 C--N 1.316 -0.888 0 C-N-CA 125.415 1.486 . . . . 0.0 114.329 179.68 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.483 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 15.7 p90 -125.28 88.17 2.83 Favored 'General case' 0 C--N 1.281 -2.4 0 N-CA-C 107.643 -1.243 . . . . 0.0 107.643 170.47 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.562 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 16.8 m120 -106.45 89.49 4.08 Favored Pre-proline 0 CA--C 1.505 -0.781 0 N-CA-C 107.052 -1.462 . . . . 0.0 107.052 -179.547 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.483 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 5.8 Cg_exo -77.7 -12.94 16.45 Favored 'Trans proline' 0 N--CA 1.443 -1.444 0 C-N-CA 122.474 2.116 . . . . 0.0 114.842 -169.152 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.425 HD12 ' O ' ' A' ' 106' ' ' LEU . 13.1 mt -70.2 -25.13 63.27 Favored 'General case' 0 CA--C 1.465 -2.302 0 C-N-CA 119.127 -1.029 . . . . 0.0 112.422 -170.157 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.559 ' HA ' ' C ' ' A' ' 77' ' ' GLU . 18.0 t -93.7 -96.34 0.15 Allowed 'General case' 1 N--CA 1.377 -4.076 0 C-N-CA 114.997 -2.681 . . . . 0.0 107.272 175.922 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.562 ' HB3' ' HA ' ' A' ' 79' ' ' ARG 0.264 24.6 ttt85 -142.05 40.37 1.64 Allowed 'General case' 0 CA--C 1.492 -1.261 0 CA-C-N 119.055 0.843 . . . . 0.0 109.185 152.29 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.562 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 88.2 tttt 75.78 -33.39 0.22 Allowed 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 115.074 1.509 . . . . 0.0 115.074 179.106 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 0.5 OUTLIER -155.61 99.02 1.99 Allowed 'General case' 0 N--CA 1.49 1.547 0 N-CA-C 117.224 2.305 . . . . 0.0 117.224 -175.154 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.691 ' HA3' ' C ' ' A' ' 80' ' ' HIS . . . -164.56 -136.6 2.03 Favored Glycine 0 C--O 1.18 -3.234 0 C-N-CA 120.949 -0.643 . . . . 0.0 112.752 163.673 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.713 ' N ' ' HA ' ' A' ' 81' ' ' VAL . . . -75.98 -175.96 39.89 Favored Glycine 0 CA--C 1.547 2.061 0 CA-C-N 117.427 0.613 . . . . 0.0 114.607 179.14 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.467 ' HG3' ' O ' ' A' ' 44' ' ' GLY . 88.7 Cg_endo -102.49 0.37 0.42 Allowed 'Trans proline' 0 C--O 1.212 -0.788 0 C-N-CA 123.825 3.017 . . . . 0.0 113.633 -178.393 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.5 ' HG2' ' OE2' ' A' ' 100' ' ' GLU . 61.8 mttm -81.49 2.27 29.62 Favored 'General case' 0 C--N 1.295 -1.801 0 N-CA-C 115.315 1.598 . . . . 0.0 115.315 -172.17 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.433 ' O ' ' HB ' ' A' ' 81' ' ' VAL . 37.4 t70 -175.59 166.34 3.2 Favored 'General case' 0 C--N 1.318 -0.789 0 N-CA-C 109.113 -0.699 . . . . 0.0 109.113 -176.272 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.559 ' C ' ' HA ' ' A' ' 68' ' ' SER . 2.5 pm0 -122.52 84.68 2.3 Favored 'General case' 0 N--CA 1.418 -2.039 0 C-N-CA 120.161 -0.616 . . . . 0.0 111.111 171.923 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.566 ' H ' HG23 ' A' ' 81' ' ' VAL . 0.1 OUTLIER 171.37 86.87 0.0 OUTLIER 'General case' 0 C--N 1.361 1.071 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.84 178.599 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.562 ' HA ' ' HB3' ' A' ' 69' ' ' ARG 0.289 0.0 OUTLIER 62.32 130.5 0.01 OUTLIER 'General case' 0 N--CA 1.511 2.607 0 C-N-CA 126.481 1.912 . . . . 0.0 115.412 174.637 . . . . . . . . 4 4 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.691 ' C ' ' HA3' ' A' ' 72' ' ' GLY . 21.3 t-160 67.02 19.4 10.55 Favored 'General case' 0 N--CA 1.488 1.459 0 CA-C-O 122.63 1.205 . . . . 0.0 107.971 -178.936 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.713 ' HA ' ' N ' ' A' ' 73' ' ' GLY . 1.6 m -148.12 157.48 8.43 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.237 0 CA-C-N 113.207 -1.815 . . . . 0.0 107.595 175.481 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . -128.17 -129.92 3.26 Favored Glycine 0 C--N 1.283 -2.39 0 N-CA-C 108.857 -1.697 . . . . 0.0 108.857 178.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.616 ' HB3' ' O ' ' A' ' 46' ' ' HIS . 15.6 t70 -84.61 169.96 13.84 Favored 'General case' 0 C--N 1.304 -1.402 0 N-CA-C 108.35 -0.982 . . . . 0.0 108.35 175.863 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 6.2 mp -109.04 96.46 6.33 Favored 'General case' 0 C--N 1.294 -1.838 0 N-CA-C 113.604 0.964 . . . . 0.0 113.604 -165.692 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.697 ' HA3' ' CE1' ' A' ' 46' ' ' HIS . . . -173.82 83.25 0.08 OUTLIER Glycine 0 N--CA 1.422 -2.282 0 C-N-CA 118.918 -1.61 . . . . 0.0 113.295 173.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.437 ' HB2' ' HG3' ' A' ' 74' ' ' PRO . 9.1 t30 -78.87 130.06 35.25 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 109.356 -0.609 . . . . 0.0 109.356 177.62 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 85.2 t -122.62 128.45 75.33 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.02 0 N-CA-C 108.653 -0.869 . . . . 0.0 108.653 178.875 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.553 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 29.4 p -139.45 95.76 2.98 Favored 'General case' 0 N--CA 1.431 -1.378 0 N-CA-C 110.01 -0.367 . . . . 0.0 110.01 178.732 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -120.95 104.18 9.62 Favored 'General case' 0 N--CA 1.421 -1.895 0 C-N-CA 118.079 -1.448 . . . . 0.0 109.049 174.463 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.59 ' O ' ' HB ' ' A' ' 39' ' ' THR . 8.1 p-10 -132.29 -20.88 2.36 Favored 'General case' 0 CA--C 1.47 -2.131 0 CA-C-O 121.788 0.804 . . . . 0.0 109.842 -176.302 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.7 tttt -72.53 -56.94 4.59 Favored 'General case' 0 C--N 1.268 -2.966 0 CA-C-N 113.655 -1.612 . . . . 0.0 109.091 -178.793 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 27.0 t70 -153.71 6.18 0.33 Allowed 'General case' 0 C--N 1.31 -1.114 0 C-N-CA 119.55 -0.86 . . . . 0.0 111.505 -170.013 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.401 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 82.12 55.3 3.13 Favored Glycine 0 N--CA 1.426 -1.987 0 C-N-CA 118.102 -1.999 . . . . 0.0 108.748 -168.735 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 8.1 m -148.84 110.09 0.58 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 104.45 -2.426 . . . . 0.0 104.45 -177.549 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.553 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -94.84 128.92 41.94 Favored 'General case' 0 C--N 1.263 -3.162 0 C-N-CA 119.783 -0.767 . . . . 0.0 111.703 -174.542 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.3 t70 -81.92 107.84 14.96 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 106.152 -1.796 . . . . 0.0 106.152 171.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.745 HG11 ' H ' ' A' ' 33' ' ' GLY . 13.4 p -82.61 137.46 21.02 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.202 0 N-CA-C 107.966 -1.124 . . . . 0.0 107.966 -179.336 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.419 ' HB3' ' OE2' ' A' ' 100' ' ' GLU . 41.8 m -84.37 108.6 17.29 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 115.56 -0.746 . . . . 0.0 109.963 177.213 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.597 HG23 ' H ' ' A' ' 31' ' ' VAL . 28.8 mt -93.32 114.06 29.34 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.482 0 N-CA-C 106.112 -1.811 . . . . 0.0 106.112 173.471 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.5 ' OE2' ' HG2' ' A' ' 75' ' ' LYS . 1.0 OUTLIER -134.99 155.71 50.3 Favored 'General case' 0 C--N 1.29 -2.009 0 N-CA-C 106.182 -1.784 . . . . 0.0 106.182 -179.738 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.47 ' HB2' ' HA ' ' A' ' 28' ' ' PRO . 7.4 p-10 -90.11 131.83 35.75 Favored 'General case' 0 C--N 1.295 -1.763 0 CA-C-O 121.721 0.772 . . . . 0.0 111.517 -178.862 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.584 ' H ' HG12 ' A' ' 29' ' ' VAL . 75.6 p -96.07 172.94 7.68 Favored 'General case' 0 C--N 1.293 -1.855 0 N-CA-C 106.839 -1.541 . . . . 0.0 106.839 175.808 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 15.0 p -77.57 -54.36 12.78 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.216 0 C-N-CA 118.538 -1.265 . . . . 0.0 108.86 174.265 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 67.5 mt -130.44 -47.29 0.84 Allowed 'Isoleucine or valine' 0 N--CA 1.426 -1.644 0 C-N-CA 120.189 -0.604 . . . . 0.0 111.94 -174.313 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 12.8 p -170.08 167.19 8.92 Favored 'General case' 0 CA--C 1.469 -2.17 0 N-CA-C 114.494 1.294 . . . . 0.0 114.494 -169.839 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.583 ' HB2' ' OD2' ' A' ' 83' ' ' ASP . 2.8 pp -68.84 164.28 22.33 Favored 'General case' 0 N--CA 1.391 -3.409 0 CA-C-N 113.67 -1.605 . . . . 0.0 106.687 176.039 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.408 ' HA ' ' HB2' ' A' ' 67' ' ' LEU . 50.0 m -86.28 88.25 7.58 Favored 'General case' 1 C--N 1.238 -4.268 0 CA-C-O 121.357 0.599 . . . . 0.0 111.681 -170.501 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -128.66 133.98 7.88 Favored Glycine 1 N--CA 1.394 -4.157 0 N-CA-C 106.957 -2.457 . . . . 0.0 106.957 167.818 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.9 t70 -122.32 -29.14 4.19 Favored 'General case' 0 C--N 1.264 -3.127 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 -179.115 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 60.8 t-80 -70.42 -31.82 69.17 Favored 'General case' 0 N--CA 1.433 -1.307 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 174.162 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.469 ' OG ' HG22 ' A' ' 113' ' ' ILE . 28.5 t 173.71 -174.07 0.06 Allowed 'General case' 0 N--CA 1.445 -0.708 0 N-CA-C 106.682 -1.599 . . . . 0.0 106.682 168.143 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 31.4 mm -106.46 -4.98 10.06 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.98 0 N-CA-C 103.839 -2.652 . . . . 0.0 103.839 -179.184 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.538 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 16.0 tt -104.03 157.56 5.4 Favored 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 N-CA-C 103.409 -2.811 . . . . 0.0 103.409 163.252 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 75.8 41.57 28.16 Favored Glycine 0 C--N 1.303 -1.263 0 C-N-CA 118.96 -1.59 . . . . 0.0 111.536 179.826 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.813 ' HD3' ' O ' ' A' ' 149' ' ' ILE . 0.0 OUTLIER -135.1 129.37 33.84 Favored 'General case' 0 C--N 1.271 -2.812 0 C-N-CA 125.065 1.346 . . . . 0.0 109.068 178.802 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.891 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 11.2 p -114.86 141.45 47.9 Favored 'General case' 0 C--N 1.279 -2.468 0 CA-C-O 121.339 0.59 . . . . 0.0 112.272 177.655 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.623 ' HB3' HG21 ' A' ' 149' ' ' ILE . 2.6 pt? -88.97 105.93 18.09 Favored 'General case' 0 C--N 1.309 -1.193 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -179.48 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.466 HG23 ' SG ' ' A' ' 57' ' ' CYS . 17.3 t -92.93 100.39 11.2 Favored 'Isoleucine or valine' 1 C--O 1.319 4.718 0 C-N-CA 118.979 -1.088 . . . . 0.0 110.354 169.081 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.507 HG22 ' O ' ' A' ' 45' ' ' PHE . 3.3 t -147.1 170.42 3.94 Favored 'Isoleucine or valine' 0 C--O 1.216 -0.677 0 C-N-CA 128.879 2.872 . . . . 0.0 103.467 -177.933 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 1.5 t-80 -159.51 170.39 21.8 Favored 'General case' 0 C--N 1.298 -1.654 0 N-CA-C 104.943 -2.243 . . . . 0.0 104.943 178.175 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.531 ' HB2' ' O ' ' A' ' 40' ' ' GLU . 0.1 OUTLIER -79.79 83.25 5.76 Favored 'General case' 0 CA--C 1.567 1.604 0 N-CA-C 105.624 -1.991 . . . . 0.0 105.624 169.288 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 42.7 mmtm -172.17 174.19 4.07 Favored 'General case' 0 CA--C 1.487 -1.462 0 N-CA-C 104.694 -2.335 . . . . 0.0 104.694 -167.515 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.67 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -88.29 104.62 16.91 Favored 'General case' 0 C--N 1.293 -1.882 0 N-CA-C 109.097 -0.705 . . . . 0.0 109.097 169.281 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 28.7 t70 -69.71 113.31 6.85 Favored 'General case' 0 N--CA 1.493 1.72 0 N-CA-C 104.431 -2.433 . . . . 0.0 104.431 174.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 7.2 t70 -75.83 131.59 39.83 Favored 'General case' 0 N--CA 1.427 -1.593 0 C-N-CA 119.997 -0.681 . . . . 0.0 111.918 -167.788 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.56 HD22 ' HA2' ' A' ' 73' ' ' GLY . 11.0 mt -76.1 -71.52 0.38 Allowed 'General case' 0 N--CA 1.404 -2.752 0 CA-C-N 113.617 -1.629 . . . . 0.0 113.614 -169.13 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -117.38 -7.11 12.63 Favored Glycine 0 CA--C 1.467 -2.943 0 CA-C-N 114.917 -1.038 . . . . 0.0 112.447 -168.676 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.481 ' O ' ' HB ' ' A' ' 135' ' ' THR . 95.3 mttt -99.93 -42.57 6.72 Favored 'General case' 0 N--CA 1.412 -2.369 0 N-CA-C 108.194 -1.039 . . . . 0.0 108.194 178.151 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' N ' ' A' ' 135' ' ' THR . . . 75.97 -63.0 2.85 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 109.612 -1.395 . . . . 0.0 109.612 -171.096 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 153.63 -25.85 0.75 Allowed Glycine 0 C--N 1.299 -1.486 0 N-CA-C 108.101 -1.999 . . . . 0.0 108.101 -177.979 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 34.6 t-20 -163.54 172.88 13.77 Favored 'General case' 0 C--O 1.254 1.342 0 N-CA-C 103.376 -2.824 . . . . 0.0 103.376 178.27 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.7 mt-10 -59.57 -41.06 89.31 Favored 'General case' 0 C--O 1.242 0.674 0 CA-C-N 118.887 0.767 . . . . 0.0 112.068 -176.34 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.434 ' O ' ' HB3' ' A' ' 136' ' ' LYS . 35.4 tt0 -66.17 -36.98 84.52 Favored 'General case' 0 C--O 1.219 -0.532 0 CA-C-O 121.08 0.467 . . . . 0.0 110.181 177.251 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 1.2 m -68.29 -34.23 75.77 Favored 'General case' 0 C--N 1.307 -1.276 0 CA-C-N 116.559 -0.291 . . . . 0.0 111.642 -176.203 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.481 ' HB ' ' O ' ' A' ' 128' ' ' LYS . 10.7 t -81.54 -6.75 59.28 Favored 'General case' 0 N--CA 1.471 0.579 0 CA-C-O 122.547 1.165 . . . . 0.0 109.114 177.354 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.434 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 88.3 tttt -90.01 -24.43 21.22 Favored 'General case' 0 C--N 1.287 -2.117 0 CA-C-N 114.38 -1.282 . . . . 0.0 108.257 175.313 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 7.3 m -83.36 -33.3 25.85 Favored 'General case' 0 C--N 1.312 -1.065 0 N-CA-C 109.052 -0.721 . . . . 0.0 109.052 175.237 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 77.84 48.72 7.59 Favored Glycine 1 C--O 1.315 5.194 0 N-CA-C 106.222 -2.751 . . . . 0.0 106.222 -171.554 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 63.8 t30 -35.14 106.04 0.04 OUTLIER 'General case' 0 N--CA 1.49 1.544 0 C-N-CA 131.271 3.828 . . . . 0.0 120.016 -166.254 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.404 ' HB3' ' CG1' ' A' ' 118' ' ' VAL . . . -153.05 172.38 16.96 Favored 'General case' 0 C--N 1.298 -1.643 0 N-CA-C 102.498 -3.149 . . . . 0.0 102.498 164.625 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -52.32 110.01 1.06 Allowed Glycine 0 CA--C 1.531 1.037 0 N-CA-C 109.794 -1.322 . . . . 0.0 109.794 171.305 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 34.4 p -52.63 -32.11 40.14 Favored 'General case' 0 CA--C 1.532 0.283 0 N-CA-C 115.287 1.588 . . . . 0.0 115.287 -171.487 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 15.9 ptt180 -120.25 -27.37 5.27 Favored 'General case' 0 C--N 1.26 -3.304 0 C-N-CA 118.472 -1.291 . . . . 0.0 108.776 174.395 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -47.73 -36.39 11.3 Favored 'General case' 0 N--CA 1.471 0.61 0 O-C-N 124.7 1.25 . . . . 0.0 112.798 -165.989 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -142.45 88.76 2.1 Favored 'General case' 0 N--CA 1.41 -2.443 0 N-CA-C 105.856 -1.905 . . . . 0.0 105.856 176.102 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.891 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 52.7 t -156.86 141.36 16.71 Favored 'General case' 0 N--CA 1.406 -2.65 0 CA-C-N 114.749 -1.114 . . . . 0.0 109.858 -178.443 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.513 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -157.72 170.44 34.7 Favored Glycine 0 N--CA 1.4 -3.708 0 N-CA-C 107.214 -2.354 . . . . 0.0 107.214 177.924 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.735 ' HB ' ' NH1' ' A' ' 115' ' ' ARG . 27.7 m -68.84 124.26 24.15 Favored 'Isoleucine or valine' 0 C--N 1.267 -3.017 0 CA-C-N 117.656 0.728 . . . . 0.0 111.054 178.595 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.813 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 0.0 OUTLIER -123.47 99.86 7.12 Favored 'Isoleucine or valine' 0 N--CA 1.506 2.351 0 CA-C-O 121.212 0.53 . . . . 0.0 111.245 179.331 . . . . . . . . 3 3 . 1 . 006 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.504 ' HA3' ' NE ' ' A' ' 115' ' ' ARG . . . 174.63 -167.47 39.75 Favored Glycine 0 CA--C 1.457 -3.586 0 C-N-CA 117.546 -2.264 . . . . 0.0 111.534 178.316 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 9.1 tt -68.75 105.67 1.03 Allowed 'Isoleucine or valine' 0 C--O 1.266 1.935 0 N-CA-C 108.075 -1.083 . . . . 0.0 108.075 177.227 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.46 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -116.45 140.28 49.53 Favored 'General case' 0 N--CA 1.435 -1.215 0 CA-C-N 114.525 -1.216 . . . . 0.0 111.104 179.468 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 49.9 tt0 . . . . . 0 C--N 1.297 -1.694 0 N-CA-C 106.723 -1.584 . . . . 0.0 106.723 174.009 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.534 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.212 -0.918 0 N-CA-C 111.663 0.246 . . . . 0.0 111.663 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.524 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 14.4 m -58.08 -26.41 62.53 Favored 'General case' 0 CA--C 1.571 1.776 0 N-CA-C 115.425 1.639 . . . . 0.0 115.425 -174.495 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 22.0 ptmt -135.15 147.5 49.46 Favored 'General case' 0 C--N 1.3 -1.545 0 O-C-N 120.827 -1.171 . . . . 0.0 112.083 -172.171 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.836 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -139.81 154.42 47.35 Favored 'General case' 0 N--CA 1.408 -2.563 0 CA-C-N 115.202 -0.908 . . . . 0.0 108.64 172.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.554 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 39.7 t -129.69 131.03 67.02 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.406 0 N-CA-C 106.816 -1.55 . . . . 0.0 106.816 -178.403 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -121.49 132.37 54.68 Favored 'General case' 0 C--N 1.298 -1.637 0 N-CA-C 108.979 -0.748 . . . . 0.0 108.979 179.117 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.664 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 10.9 m -127.96 109.04 18.95 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.834 0 CA-C-O 121.729 0.776 . . . . 0.0 110.58 -178.695 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.505 ' HB2' ' HA ' ' A' ' 15' ' ' GLN . 6.6 mp -103.47 128.49 50.64 Favored 'General case' 0 C--N 1.296 -1.725 0 CA-C-N 115.496 -0.775 . . . . 0.0 110.664 -176.334 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 88.3 tttt -160.88 124.99 3.5 Favored 'General case' 0 N--CA 1.439 -1.024 0 N-CA-C 109.791 -0.448 . . . . 0.0 109.791 169.147 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.91 -173.14 22.66 Favored Glycine 0 N--CA 1.405 -3.382 0 N-CA-C 107.216 -2.354 . . . . 0.0 107.216 175.141 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 38.4 t70 -95.21 89.66 5.59 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 120.217 -0.593 . . . . 0.0 109.78 -178.662 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 130.59 -63.83 0.62 Allowed Glycine 0 N--CA 1.442 -0.914 0 C-N-CA 120.842 -0.694 . . . . 0.0 113.776 178.217 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.663 ' HB3' ' HA ' ' A' ' 120' ' ' HIS . 31.9 Cg_exo -62.31 169.16 8.35 Favored 'Trans proline' 0 N--CA 1.432 -2.095 0 C-N-CA 123.072 2.515 . . . . 0.0 115.004 -174.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.558 HG12 ' HA3' ' A' ' 37' ' ' GLY . 16.8 m -69.86 158.01 6.31 Favored 'Isoleucine or valine' 0 C--N 1.266 -3.038 0 CA-C-N 111.587 -2.552 . . . . 0.0 112.544 -175.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.505 ' HA ' ' HB2' ' A' ' 8' ' ' LEU . 15.3 tm0? -112.52 140.56 47.17 Favored 'General case' 0 C--N 1.293 -1.866 0 N-CA-C 104.667 -2.345 . . . . 0.0 104.667 177.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.425 ' O ' HD13 ' A' ' 8' ' ' LEU . . . -158.98 170.51 35.41 Favored Glycine 0 N--CA 1.414 -2.824 0 N-CA-C 110.366 -1.094 . . . . 0.0 110.366 -179.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.449 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 18.9 pt -132.46 129.05 58.87 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.678 0 N-CA-C 107.11 -1.441 . . . . 0.0 107.11 176.677 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.506 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 43.7 mm -130.01 123.53 56.58 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.75 0 N-CA-C 107.653 -1.24 . . . . 0.0 107.653 -174.718 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.46 ' O ' ' HA ' ' A' ' 31' ' ' VAL . 2.2 m-20 -112.41 126.74 55.61 Favored 'General case' 0 CA--C 1.49 -1.332 0 N-CA-C 107.374 -1.343 . . . . 0.0 107.374 178.478 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.836 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 29.7 p90 -126.78 148.34 49.93 Favored 'General case' 0 CA--C 1.495 -1.147 0 C-N-CA 118.24 -1.384 . . . . 0.0 109.912 176.224 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.534 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 1.5 pp20? -117.76 116.17 26.48 Favored 'General case' 0 N--CA 1.423 -1.81 0 CA-C-N 115.749 -0.659 . . . . 0.0 111.372 176.128 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 2.9 pt20 -85.72 87.88 7.47 Favored 'General case' 0 N--CA 1.382 -3.854 0 CA-C-O 123.103 1.43 . . . . 0.0 108.769 178.059 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.537 ' H ' ' HB ' ' A' ' 104' ' ' ILE . 5.0 ttmp? -72.16 110.06 6.36 Favored 'General case' 0 N--CA 1.409 -2.514 0 CA-C-N 112.206 -2.27 . . . . 0.0 107.009 177.855 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 12.9 pt-20 -61.79 -24.29 66.76 Favored 'General case' 0 C--N 1.324 -0.529 0 CA-C-O 121.03 0.443 . . . . 0.0 111.622 -178.168 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.6 m -71.92 -19.3 61.94 Favored 'General case' 0 N--CA 1.441 -0.886 0 CA-C-N 115.604 -0.725 . . . . 0.0 110.524 176.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.458 ' HA ' HG13 ' A' ' 104' ' ' ILE . 56.6 m-80 70.3 162.71 0.24 Allowed 'General case' 0 C--O 1.241 0.61 0 C-N-CA 125.194 1.398 . . . . 0.0 110.885 -175.493 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 138.47 -149.46 20.56 Favored Glycine 0 CA--C 1.48 -2.156 0 C-N-CA 117.762 -2.161 . . . . 0.0 114.18 178.557 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 37.6 Cg_exo -63.26 125.69 16.25 Favored 'Trans proline' 0 N--CA 1.447 -1.256 0 C-N-CA 123.357 2.704 . . . . 0.0 110.941 179.545 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.656 HG12 HG23 ' A' ' 104' ' ' ILE . 3.9 m -76.97 120.39 27.23 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.142 0 CA-C-N 114.407 -1.27 . . . . 0.0 111.378 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 98.9 mttt -98.55 92.17 5.5 Favored 'General case' 0 N--CA 1.412 -2.354 0 CA-C-O 122.096 0.951 . . . . 0.0 108.506 172.259 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.46 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 71.5 t -133.36 146.0 32.9 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.187 0 N-CA-C 106.482 -1.673 . . . . 0.0 106.482 -175.889 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.5 p-90 -143.15 134.73 26.39 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 108.493 -0.928 . . . . 0.0 108.493 174.791 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.456 ' H ' HG11 ' A' ' 97' ' ' VAL . . . -141.92 140.33 10.01 Favored Glycine 0 N--CA 1.419 -2.458 0 C-N-CA 119.796 -1.192 . . . . 0.0 112.14 178.171 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 22.8 t -116.63 151.82 35.48 Favored 'General case' 0 N--CA 1.394 -3.252 0 N-CA-C 105.404 -2.073 . . . . 0.0 105.404 176.781 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.671 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 36.8 mm -132.24 134.06 59.73 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 108.971 -0.751 . . . . 0.0 108.971 179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.683 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 60.6 pttt -139.0 119.96 14.42 Favored 'General case' 0 C--O 1.206 -1.207 0 N-CA-C 107.243 -1.392 . . . . 0.0 107.243 175.1 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.558 ' HA3' HG12 ' A' ' 14' ' ' VAL . . . -169.97 174.97 44.16 Favored Glycine 0 CA--C 1.476 -2.354 0 C-N-CA 118.811 -1.662 . . . . 0.0 113.075 -171.793 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.3 tt -66.85 137.77 56.84 Favored 'General case' 0 N--CA 1.431 -1.421 0 N-CA-C 106.272 -1.751 . . . . 0.0 106.272 178.453 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 40.1 p -72.78 108.53 5.81 Favored 'General case' 0 N--CA 1.42 -1.941 0 N-CA-C 115.238 1.57 . . . . 0.0 115.238 -164.48 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.51 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 32.9 tt0 -177.78 121.79 0.11 Allowed 'General case' 0 CA--C 1.486 -1.485 0 N-CA-C 105.358 -2.09 . . . . 0.0 105.358 174.519 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.527 ' N ' ' HA ' ' A' ' 90' ' ' ASP . . . -155.82 138.67 6.14 Favored Glycine 0 CA--C 1.47 -2.774 0 C-N-CA 119.268 -1.444 . . . . 0.0 111.507 -177.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.562 HD23 ' HA ' ' A' ' 122' ' ' LYS . 3.6 mm? -126.65 -58.33 1.33 Allowed 'General case' 0 N--CA 1.443 -0.795 0 N-CA-C 112.567 0.58 . . . . 0.0 112.567 -170.989 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -155.52 169.3 24.61 Favored 'General case' 0 C--N 1.322 -0.601 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 -175.369 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.66 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -130.29 113.34 1.43 Allowed Glycine 0 C--O 1.217 -0.917 0 C-N-CA 118.391 -1.861 . . . . 0.0 117.43 -170.317 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.596 ' O ' ' HB3' ' A' ' 124' ' ' ASP . 46.7 m-85 -168.67 108.86 0.5 Allowed 'General case' 0 C--O 1.188 -2.171 0 N-CA-C 102.752 -3.055 . . . . 0.0 102.752 170.942 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.449 ' HB3' HG22 ' A' ' 119' ' ' VAL . 68.1 m-70 -149.95 85.57 1.42 Allowed 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 120.881 1.673 . . . . 0.0 107.969 -175.573 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.514 HG13 HG21 ' A' ' 149' ' ' ILE . 48.8 t -162.53 161.11 1.24 Allowed 'Isoleucine or valine' 0 C--N 1.307 -1.253 0 N-CA-C 105.052 -2.203 . . . . 0.0 105.052 179.183 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.47 ' CG ' ' HA ' ' A' ' 60' ' ' ALA . 62.6 t-80 -153.46 148.41 26.62 Favored 'General case' 0 C--N 1.275 -2.64 0 N-CA-C 106.766 -1.568 . . . . 0.0 106.766 168.266 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.421 ' O ' ' HB2' ' A' ' 50' ' ' PHE . 0.4 OUTLIER -109.48 124.13 50.54 Favored 'General case' 0 C--N 1.257 -3.451 0 C-N-CA 124.196 0.998 . . . . 0.0 112.133 -177.764 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.421 ' HB2' ' O ' ' A' ' 49' ' ' GLU . 11.8 t80 174.4 -50.98 0.01 OUTLIER 'General case' 0 C--N 1.314 -0.968 0 C-N-CA 124.864 1.266 . . . . 0.0 109.395 174.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.599 ' HA2' ' N ' ' A' ' 115' ' ' ARG . . . 95.04 109.8 2.32 Favored Glycine 0 CA--C 1.496 -1.123 0 C-N-CA 120.563 -0.827 . . . . 0.0 111.305 -177.279 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 13.4 t70 -132.68 -73.09 0.51 Allowed 'General case' 0 N--CA 1.479 0.995 0 C-N-CA 117.707 -1.597 . . . . 0.0 112.878 -174.264 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 37.5 t-20 -161.95 152.18 17.02 Favored 'General case' 0 C--N 1.31 -1.109 0 N-CA-C 106.176 -1.787 . . . . 0.0 106.176 -179.246 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 20.7 m -71.73 -34.27 69.4 Favored 'General case' 0 C--O 1.208 -1.095 0 CA-C-O 121.135 0.493 . . . . 0.0 110.298 -177.73 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.22 -12.72 27.63 Favored 'General case' 0 C--N 1.303 -1.433 0 C-N-CA 120.75 -0.38 . . . . 0.0 111.956 -175.848 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -154.24 111.26 0.48 Allowed Glycine 0 CA--C 1.468 -2.866 0 C-N-CA 119.077 -1.535 . . . . 0.0 110.046 -174.876 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.408 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 26.2 p -98.28 88.47 4.18 Favored 'General case' 0 N--CA 1.4 -2.949 0 CA-C-O 121.65 0.738 . . . . 0.0 110.851 179.75 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.0 m -79.26 -46.29 18.08 Favored 'General case' 0 C--N 1.299 -1.589 0 CA-C-O 121.708 0.766 . . . . 0.0 110.14 -178.165 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 43.5 m -63.71 -24.95 67.99 Favored 'General case' 0 N--CA 1.444 -0.725 0 CA-C-N 115.292 -0.867 . . . . 0.0 111.402 178.625 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.902 ' HB2' ' HB ' ' A' ' 116' ' ' THR . . . -75.49 -9.23 58.39 Favored 'General case' 0 CA--C 1.506 -0.72 0 N-CA-C 115.204 1.557 . . . . 0.0 115.204 176.329 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -65.99 -160.49 0.78 Allowed Glycine 0 C--N 1.311 -0.854 0 C-N-CA 120.299 -0.953 . . . . 0.0 112.97 -179.345 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 56.2 Cg_endo -74.37 54.08 3.23 Favored 'Trans proline' 0 CA--C 1.543 0.971 0 C-N-CA 122.74 2.293 . . . . 0.0 110.223 177.659 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 24.4 m170 -133.23 109.46 9.44 Favored 'General case' 0 N--CA 1.424 -1.751 0 N-CA-C 103.48 -2.785 . . . . 0.0 103.48 -179.828 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.498 ' CD2' ' HB3' ' A' ' 69' ' ' ARG . 54.7 m-85 -123.77 162.06 23.93 Favored 'General case' 0 C--N 1.289 -2.038 0 CA-C-O 122.06 0.934 . . . . 0.0 113.12 -174.218 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 14.1 t30 -104.56 143.3 26.41 Favored Pre-proline 0 N--CA 1.42 -1.956 0 N-CA-C 103.859 -2.645 . . . . 0.0 103.859 173.549 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 87.4 Cg_exo -48.18 -55.31 4.16 Favored 'Trans proline' 0 N--CA 1.487 1.095 0 C-N-CA 122.98 2.453 . . . . 0.0 116.832 -168.297 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 95.2 mt -90.12 -4.97 57.0 Favored 'General case' 0 CA--C 1.478 -1.81 0 C-N-CA 119.142 -1.023 . . . . 0.0 108.885 -172.44 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.562 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 21.4 m -86.52 7.98 23.86 Favored 'General case' 0 N--CA 1.421 -1.91 0 CA-C-N 114.188 -1.369 . . . . 0.0 109.733 178.091 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.498 ' HB3' ' CD2' ' A' ' 64' ' ' PHE . 4.4 ppt_? -134.04 -30.15 1.23 Allowed 'General case' 0 N--CA 1.402 -2.832 0 CA-C-O 117.734 -1.127 . . . . 0.0 110.313 167.398 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.485 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 85.1 tttt 34.54 -86.04 0.0 OUTLIER 'General case' 0 C--N 1.389 2.286 0 C-N-CA 125.386 1.474 . . . . 0.0 110.968 -173.534 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.506 ' O ' ' HA2' ' A' ' 127' ' ' GLY . 55.0 t-80 -131.32 -38.75 1.18 Allowed 'General case' 0 N--CA 1.423 -1.78 0 N-CA-C 108.612 -0.885 . . . . 0.0 108.612 172.638 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 94.0 119.58 3.05 Favored Glycine 0 N--CA 1.425 -2.059 0 N-CA-C 107.469 -2.252 . . . . 0.0 107.469 -170.511 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -150.3 144.11 11.51 Favored Glycine 0 N--CA 1.419 -2.454 0 C-N-CA 118.612 -1.756 . . . . 0.0 113.041 -174.695 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.466 ' O ' ' HB3' ' A' ' 101' ' ' ASP . 59.1 Cg_endo -74.84 -19.16 18.53 Favored 'Trans proline' 0 N--CA 1.449 -1.098 0 C-N-CA 122.3 2.0 . . . . 0.0 112.99 -179.448 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.545 ' O ' ' HA ' ' A' ' 101' ' ' ASP . 51.1 mtmt -120.62 -13.97 8.68 Favored 'General case' 0 N--CA 1.442 -0.863 0 N-CA-C 115.548 1.684 . . . . 0.0 115.548 -175.633 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 33.7 t70 -172.18 126.25 0.55 Allowed 'General case' 0 CA--C 1.493 -1.231 0 CA-C-N 119.593 1.088 . . . . 0.0 109.649 -173.837 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.424 ' H ' ' HB2' ' A' ' 102' ' ' SER . 2.9 mm-40 -138.31 171.16 14.79 Favored 'General case' 0 N--CA 1.416 -2.16 0 CA-C-N 115.552 -0.749 . . . . 0.0 109.084 178.92 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 24.9 mm-40 -100.13 -74.82 0.59 Allowed 'General case' 0 C--N 1.291 -1.96 0 N-CA-C 114.118 1.155 . . . . 0.0 114.118 -176.57 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.562 ' O ' ' HA ' ' A' ' 68' ' ' SER . 0.1 OUTLIER -130.2 26.3 5.16 Favored 'General case' 0 CA--C 1.47 -2.107 0 N-CA-C 106.861 -1.533 . . . . 0.0 106.861 -170.579 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 7.6 t60 -114.01 102.45 10.2 Favored 'General case' 0 N--CA 1.396 -3.155 0 CA-C-N 111.96 -2.382 . . . . 0.0 106.102 177.042 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . . . . . . . . . 14.5 p -101.13 7.91 9.17 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.863 0 N-CA-C 106.591 -1.633 . . . . 0.0 106.591 178.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.487 ' C ' ' HB ' ' A' ' 47' ' ' VAL . . . -79.41 11.03 33.36 Favored Glycine 0 CA--C 1.528 0.866 0 CA-C-N 113.455 -1.702 . . . . 0.0 114.047 -179.199 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 95.6 m-20 -112.17 169.96 8.5 Favored 'General case' 0 C--N 1.304 -1.4 0 N-CA-C 108.382 -0.97 . . . . 0.0 108.382 177.824 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -167.64 170.63 10.89 Favored 'General case' 0 C--N 1.312 -1.043 0 C-N-CA 123.948 0.899 . . . . 0.0 109.818 177.642 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -60.42 153.96 35.07 Favored Glycine 0 CA--C 1.5 -0.851 0 O-C-N 124.194 0.933 . . . . 0.0 111.287 178.0 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 4.5 p30 -76.66 146.1 38.35 Favored 'General case' 0 C--N 1.295 -1.771 0 C-N-CA 119.709 -0.796 . . . . 0.0 109.992 -171.874 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.66 ' H ' ' HA3' ' A' ' 44' ' ' GLY . 17.1 m -136.9 146.26 28.66 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.486 0 N-CA-C 105.192 -2.151 . . . . 0.0 105.192 179.542 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.548 ' HA ' ' OE1' ' A' ' 121' ' ' GLU . 7.4 t -141.62 109.57 5.79 Favored 'General case' 0 C--N 1.274 -2.702 0 N-CA-C 108.663 -0.866 . . . . 0.0 108.663 174.9 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.586 ' HB1' ' HA2' ' A' ' 93' ' ' GLY . . . -118.07 105.78 12.21 Favored 'General case' 0 CA--C 1.47 -2.113 0 N-CA-C 104.814 -2.291 . . . . 0.0 104.814 174.157 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.527 ' HA ' ' N ' ' A' ' 41' ' ' GLY . 39.2 p30 -112.85 -77.52 0.58 Allowed 'General case' 0 C--O 1.172 -2.983 0 N-CA-C 114.793 1.405 . . . . 0.0 114.793 -164.781 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 87.8 tttt -83.71 -14.72 51.0 Favored 'General case' 1 C--N 1.212 -5.377 0 N-CA-C 107.97 -1.122 . . . . 0.0 107.97 -178.856 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 6.5 p-10 -144.54 134.66 24.11 Favored 'General case' 0 N--CA 1.418 -2.037 0 N-CA-C 106.198 -1.778 . . . . 0.0 106.198 179.028 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.683 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -83.54 71.8 2.94 Favored Glycine 0 N--CA 1.417 -2.616 0 CA-C-O 119.279 -0.734 . . . . 0.0 111.549 -175.865 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.671 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 59.0 t -153.61 105.54 0.2 Allowed 'Isoleucine or valine' 0 C--N 1.331 -0.216 0 N-CA-C 107.069 -1.456 . . . . 0.0 107.069 179.657 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.495 ' H ' ' HB ' ' A' ' 35' ' ' ILE . . . -113.11 144.48 42.57 Favored 'General case' 0 C--N 1.3 -1.557 0 C-N-CA 119.778 -0.769 . . . . 0.0 111.463 -178.051 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 7.4 m-20 -100.33 137.27 38.99 Favored 'General case' 0 C--N 1.296 -1.745 0 N-CA-C 105.987 -1.856 . . . . 0.0 105.987 175.959 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.456 HG11 ' H ' ' A' ' 33' ' ' GLY . 8.0 p -101.74 140.32 20.64 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.721 0 CA-C-O 121.118 0.485 . . . . 0.0 110.164 -179.006 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 16.6 m -122.47 101.58 7.57 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 108.663 -0.865 . . . . 0.0 108.663 177.45 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.686 ' H ' HD13 ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.42 118.74 54.66 Favored 'Isoleucine or valine' 0 CA--C 1.559 1.311 0 N-CA-C 115.432 1.641 . . . . 0.0 115.432 -177.415 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 36.2 mt-10 -148.8 97.49 2.72 Favored 'General case' 0 CA--C 1.497 -1.092 0 N-CA-C 105.011 -2.218 . . . . 0.0 105.011 166.859 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.545 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 1.1 p30 -168.02 168.19 12.11 Favored 'General case' 0 C--N 1.299 -1.591 0 CA-C-N 115.287 -0.869 . . . . 0.0 110.339 -169.02 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.424 ' HB2' ' H ' ' A' ' 77' ' ' GLU . 15.6 m -99.95 80.0 2.26 Favored 'General case' 0 N--CA 1.42 -1.94 0 C-N-CA 120.184 -0.606 . . . . 0.0 109.956 168.811 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.531 ' C ' ' H ' ' A' ' 105' ' ' SER . 49.9 t -101.18 -11.76 8.71 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.08 0 C-N-CA 123.859 0.864 . . . . 0.0 109.442 173.06 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.656 HG23 HG12 ' A' ' 29' ' ' VAL . 0.2 OUTLIER -63.82 21.32 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.517 2.889 0 C-N-CA 124.777 1.231 . . . . 0.0 112.641 176.957 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.531 ' H ' ' C ' ' A' ' 103' ' ' VAL . 16.0 m -68.74 130.22 42.19 Favored 'General case' 0 N--CA 1.4 -2.944 0 C-N-CA 125.271 1.428 . . . . 0.0 110.148 179.096 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 97.0 mt -66.03 173.11 3.21 Favored 'General case' 0 N--CA 1.387 -3.583 0 CA-C-N 112.953 -1.931 . . . . 0.0 107.004 172.201 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.5 p -64.93 116.18 6.12 Favored 'General case' 2 N--CA 1.363 -4.787 0 CA-C-O 123.58 1.657 . . . . 0.0 111.592 -165.07 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.57 -142.32 12.82 Favored Glycine 2 CA--C 1.425 -5.546 0 CA-C-N 110.363 -3.108 . . . . 0.0 105.343 174.82 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.408 ' OD1' ' HB2' ' A' ' 49' ' ' GLU . 4.7 p-10 40.11 -151.47 0.02 OUTLIER 'General case' 0 C--N 1.301 -1.532 0 N-CA-C 114.664 1.357 . . . . 0.0 114.664 175.153 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 44.5 t-80 -89.55 -23.81 21.91 Favored 'General case' 0 C--N 1.275 -2.633 0 CA-C-N 115.185 -0.916 . . . . 0.0 110.158 -179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 9.0 t -131.51 -153.31 0.55 Allowed 'General case' 0 N--CA 1.41 -2.465 0 CA-C-O 122.009 0.909 . . . . 0.0 110.348 -175.315 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 59.0 mt -126.51 -38.2 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.948 0 N-CA-C 104.28 -2.489 . . . . 0.0 104.28 -179.745 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.9 pt -91.08 99.05 9.1 Favored 'Isoleucine or valine' 0 N--CA 1.382 -3.834 0 CA-C-N 113.155 -1.839 . . . . 0.0 107.055 173.281 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . -97.68 63.7 0.92 Allowed Glycine 2 N--CA 1.375 -5.392 0 N-CA-C 105.023 -3.231 . . . . 0.0 105.023 -175.743 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.599 ' N ' ' HA2' ' A' ' 51' ' ' GLY . 31.7 mtp180 -68.24 81.8 0.24 Allowed 'General case' 0 N--CA 1.42 -1.935 0 N-CA-C 106.058 -1.83 . . . . 0.0 106.058 -176.983 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.902 ' HB ' ' HB2' ' A' ' 60' ' ' ALA . 0.7 OUTLIER -163.3 97.12 0.89 Allowed 'General case' 1 N--CA 1.367 -4.592 0 N-CA-C 106.56 -1.644 . . . . 0.0 106.56 -179.166 . . . . . . . . 4 4 . 1 . 007 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.485 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 16.2 mt -103.61 106.49 17.01 Favored 'General case' 0 C--N 1.251 -3.696 0 CA-C-N 114.465 -1.243 . . . . 0.0 111.963 176.916 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.628 HG13 ' HB1' ' A' ' 60' ' ' ALA . 8.2 m -92.2 98.05 7.93 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.035 0 C-N-CA 117.394 -1.722 . . . . 0.0 109.384 169.736 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.449 HG22 ' HB3' ' A' ' 46' ' ' HIS . 9.2 t -135.51 136.21 50.92 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.315 0 CA-C-O 122.724 1.249 . . . . 0.0 112.587 -174.2 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.663 ' HA ' ' HB3' ' A' ' 13' ' ' PRO . 0.4 OUTLIER -170.77 134.71 1.05 Allowed 'General case' 0 C--N 1.283 -2.311 0 N-CA-C 102.732 -3.062 . . . . 0.0 102.732 168.053 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.548 ' OE1' ' HA ' ' A' ' 88' ' ' THR . 1.9 mm-40 -69.63 99.74 1.35 Allowed 'General case' 0 C--N 1.307 -1.268 0 CA-C-O 122.153 0.978 . . . . 0.0 110.632 -174.272 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.562 ' HA ' HD23 ' A' ' 42' ' ' LEU . 68.0 mttm -170.73 170.4 6.62 Favored 'General case' 0 CA--C 1.489 -1.375 0 N-CA-C 105.553 -2.017 . . . . 0.0 105.553 -170.505 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -71.63 104.13 3.24 Favored 'General case' 0 C--N 1.294 -1.824 0 N-CA-C 108.893 -0.78 . . . . 0.0 108.893 174.569 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.596 ' HB3' ' O ' ' A' ' 45' ' ' PHE . 7.2 t70 -107.47 6.69 28.39 Favored 'General case' 0 C--N 1.315 -0.895 0 N-CA-C 108.271 -1.011 . . . . 0.0 108.271 178.419 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 2.7 m-20 -42.48 105.91 0.05 Allowed 'General case' 0 C--O 1.245 0.832 0 C-N-CA 126.882 2.073 . . . . 0.0 112.61 -178.556 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 2.6 mm? -71.07 -39.93 71.92 Favored 'General case' 0 C--N 1.314 -0.942 0 CA-C-N 115.014 -0.994 . . . . 0.0 109.574 -178.455 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.506 ' HA2' ' O ' ' A' ' 71' ' ' HIS . . . -89.42 24.21 15.25 Favored Glycine 0 CA--C 1.482 -2.023 0 CA-C-N 115.204 -0.907 . . . . 0.0 113.562 -177.208 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 59.0 tptt -136.59 -47.32 0.62 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.395 -0.965 . . . . 0.0 108.395 178.527 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 65.25 -78.34 0.08 OUTLIER Glycine 0 N--CA 1.429 -1.777 0 CA-C-N 115.546 -0.752 . . . . 0.0 111.363 -174.873 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 156.8 -38.05 0.57 Allowed Glycine 0 N--CA 1.417 -2.571 0 N-CA-C 108.723 -1.751 . . . . 0.0 108.723 -178.966 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.656 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 59.4 t30 -152.66 -178.91 7.16 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 108.034 -1.098 . . . . 0.0 108.034 179.561 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 10.5 pt-20 -54.02 -34.46 60.01 Favored 'General case' 0 C--N 1.368 1.384 0 N-CA-C 114.169 1.174 . . . . 0.0 114.169 -177.968 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.656 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -85.29 -38.14 19.2 Favored 'General case' 0 C--O 1.237 0.407 0 CA-C-O 121.305 0.574 . . . . 0.0 111.57 -174.568 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 4.4 p -76.77 -20.78 56.06 Favored 'General case' 0 C--N 1.304 -1.406 0 N-CA-C 113.008 0.744 . . . . 0.0 113.008 -176.592 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 14.8 t -81.54 -7.75 59.63 Favored 'General case' 0 C--N 1.318 -0.79 0 CA-C-O 121.878 0.847 . . . . 0.0 109.642 176.726 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.402 ' HB3' ' O ' ' A' ' 133' ' ' GLU . 86.5 tttt -85.81 -49.18 8.11 Favored 'General case' 0 C--N 1.299 -1.625 0 N-CA-C 107.54 -1.282 . . . . 0.0 107.54 177.085 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 5.0 p -68.1 -37.42 81.15 Favored 'General case' 0 N--CA 1.417 -2.101 0 CA-C-N 114.562 -1.199 . . . . 0.0 110.014 179.349 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 69.73 94.81 0.06 OUTLIER Glycine 0 N--CA 1.419 -2.438 0 N-CA-C 110.126 -1.189 . . . . 0.0 110.126 178.69 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 4.7 m-20 -32.54 123.62 0.34 Allowed 'General case' 1 C--O 1.336 5.619 0 CA-C-O 123.609 1.671 . . . . 0.0 114.049 -176.892 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.414 ' HB1' HG11 ' A' ' 118' ' ' VAL . . . -140.74 120.66 13.58 Favored 'General case' 0 N--CA 1.432 -1.348 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.85 -176.548 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -97.33 72.66 0.69 Allowed Glycine 0 C--O 1.214 -1.122 0 N-CA-C 108.845 -1.702 . . . . 0.0 108.845 172.858 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.408 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 5.2 p -88.83 5.99 41.11 Favored 'General case' 0 C--N 1.306 -1.303 0 N-CA-C 113.922 1.082 . . . . 0.0 113.922 -172.518 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 57.0 ttt-85 -118.26 -47.92 2.54 Favored 'General case' 0 C--N 1.279 -2.462 0 C-N-CA 119.112 -1.035 . . . . 0.0 109.74 176.116 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.438 ' HG ' ' HD3' ' A' ' 13' ' ' PRO . 11.9 tp -60.34 -38.95 85.39 Favored 'General case' 0 N--CA 1.427 -1.613 0 CA-C-N 114.957 -1.02 . . . . 0.0 113.59 -167.737 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -157.76 129.96 7.13 Favored 'General case' 0 CA--C 1.481 -1.675 0 N-CA-C 108.424 -0.954 . . . . 0.0 108.424 174.462 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.485 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 81.4 m -138.25 163.21 32.34 Favored 'General case' 0 C--N 1.291 -1.977 0 O-C-N 124.421 1.076 . . . . 0.0 108.856 -179.585 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.664 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.7 170.23 43.34 Favored Glycine 0 N--CA 1.408 -3.188 0 O-C-N 123.887 0.742 . . . . 0.0 111.489 175.602 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.546 HG13 ' HG2' ' A' ' 115' ' ' ARG . 69.5 t -69.49 117.73 12.68 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.031 0 C-N-CA 124.148 0.979 . . . . 0.0 110.549 168.408 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.528 ' H ' ' HA ' ' A' ' 115' ' ' ARG . 15.7 tt -122.65 108.0 20.64 Favored 'Isoleucine or valine' 0 N--CA 1.433 -1.305 0 CA-C-O 122.229 1.014 . . . . 0.0 108.729 166.391 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.36 -173.49 46.23 Favored Glycine 1 CA--C 1.442 -4.479 0 N-CA-C 108.262 -1.935 . . . . 0.0 108.262 178.663 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.507 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 8.7 tt -69.23 103.91 0.88 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.214 0 CA-C-O 121.83 0.824 . . . . 0.0 110.238 177.186 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.554 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -110.27 97.12 6.66 Favored 'General case' 0 C--N 1.296 -1.76 0 C-N-CA 118.386 -1.326 . . . . 0.0 110.936 179.745 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 1.9 mp0 . . . . . 0 C--N 1.324 -0.536 0 O-C-N 125.942 2.026 . . . . 0.0 114.489 171.157 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.504 -0.811 0 N-CA-C 110.544 -0.169 . . . . 0.0 110.544 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.609 ' O ' ' HA ' ' A' ' 21' ' ' GLU . 28.5 p -109.6 -65.24 1.17 Allowed 'General case' 0 C--O 1.161 -3.585 0 CA-C-O 119.147 -0.454 . . . . 0.0 111.569 -179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 8.2 ptpp? -135.49 171.03 15.02 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-O 120.894 0.378 . . . . 0.0 110.684 -168.427 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.735 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -137.19 166.82 22.83 Favored 'General case' 0 N--CA 1.419 -2.021 0 N-CA-C 107.063 -1.458 . . . . 0.0 107.063 -177.949 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.409 HG22 ' HB3' ' A' ' 152' ' ' ALA . 27.2 m -128.89 168.39 22.25 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.275 0 N-CA-C 109.341 -0.614 . . . . 0.0 109.341 178.642 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.566 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -132.66 137.97 47.16 Favored 'General case' 0 C--N 1.286 -2.176 0 CA-C-N 116.562 -0.29 . . . . 0.0 111.469 -173.06 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 40.7 t -134.28 108.55 11.2 Favored 'Isoleucine or valine' 0 CA--C 1.536 0.413 0 N-CA-C 108.26 -1.015 . . . . 0.0 108.26 178.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.434 HD21 ' HB3' ' A' ' 117' ' ' LEU . 84.7 mt -96.71 150.17 20.99 Favored 'General case' 0 C--N 1.303 -1.434 0 N-CA-C 113.067 0.766 . . . . 0.0 113.067 -178.557 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.9 ttpt -149.15 122.79 9.19 Favored 'General case' 0 N--CA 1.449 -0.484 0 N-CA-C 108.538 -0.912 . . . . 0.0 108.538 -179.753 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.38 -173.93 24.66 Favored Glycine 0 N--CA 1.434 -1.485 0 C-N-CA 119.134 -1.507 . . . . 0.0 113.012 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . 0.425 ' O ' ' HD3' ' A' ' 13' ' ' PRO . 46.3 m-20 -66.24 -50.5 63.56 Favored 'General case' 0 CA--C 1.498 -1.037 0 N-CA-C 107.44 -1.319 . . . . 0.0 107.44 175.654 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -99.91 96.9 1.7 Allowed Glycine 0 N--CA 1.432 -1.594 0 N-CA-C 108.251 -1.94 . . . . 0.0 108.251 174.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . 0.425 ' HD3' ' O ' ' A' ' 11' ' ' ASP . 32.2 Cg_exo -57.08 127.41 25.64 Favored 'Trans proline' 0 C--O 1.243 0.746 0 C-N-CA 122.607 2.204 . . . . 0.0 113.563 -173.329 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.48 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 11.4 m -120.58 113.02 38.62 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.804 0 CA-C-N 114.213 -1.358 . . . . 0.0 107.597 175.128 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 22.2 mp0 -108.5 119.53 39.79 Favored 'General case' 0 C--N 1.294 -1.805 0 C-N-CA 120.531 -0.467 . . . . 0.0 111.112 -174.593 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.437 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -170.72 170.13 42.9 Favored Glycine 0 N--CA 1.421 -2.362 0 N-CA-C 111.636 -0.586 . . . . 0.0 111.636 176.153 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.431 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 24.8 pt -129.4 125.4 61.78 Favored 'Isoleucine or valine' 0 CA--C 1.495 -1.144 0 N-CA-C 108.129 -1.063 . . . . 0.0 108.129 -178.286 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.644 HG12 ' HE2' ' A' ' 46' ' ' HIS . 3.7 mp -123.33 128.4 74.79 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.413 0 N-CA-C 108.076 -1.083 . . . . 0.0 108.076 -178.545 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.735 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 18.5 m120 -100.05 134.89 42.31 Favored 'General case' 0 CA--C 1.507 -0.701 0 CA-C-O 119.306 -0.378 . . . . 0.0 110.662 -177.848 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . . . . . . . . . 1.5 m-85 -127.75 119.6 26.11 Favored 'General case' 0 CA--C 1.503 -0.852 0 C-N-CA 118.613 -1.235 . . . . 0.0 113.585 175.271 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.609 ' HA ' ' O ' ' A' ' 2' ' ' THR . 58.3 mt-10 -90.22 143.9 26.35 Favored 'General case' 0 N--CA 1.425 -1.719 0 CA-C-N 114.372 -1.285 . . . . 0.0 112.734 177.872 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.576 ' HB2' ' HA ' ' A' ' 106' ' ' LEU . 3.9 pt20 -103.11 124.9 49.43 Favored 'General case' 1 N--CA 1.375 -4.176 0 N-CA-C 104.843 -2.28 . . . . 0.0 104.843 163.596 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 47.7 mttp -111.45 83.59 1.8 Allowed 'General case' 0 C--N 1.273 -2.733 0 C-N-CA 119.264 -0.974 . . . . 0.0 108.578 169.739 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -69.47 -27.95 65.66 Favored 'General case' 0 C--N 1.321 -0.664 0 CA-C-N 114.102 -1.408 . . . . 0.0 108.736 -179.024 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.1 m -71.21 -8.65 54.99 Favored 'General case' 0 C--N 1.306 -1.287 0 CA-C-N 114.36 -1.291 . . . . 0.0 110.087 175.84 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 40.2 t30 75.88 120.44 0.05 OUTLIER 'General case' 0 C--N 1.35 0.626 0 C-N-CA 126.323 1.849 . . . . 0.0 111.195 -177.444 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 172.69 165.55 29.88 Favored Glycine 0 N--CA 1.408 -3.183 0 N-CA-C 108.772 -1.731 . . . . 0.0 108.772 -179.602 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.46 ' HB3' ' HB2' ' A' ' 101' ' ' ASP . 37.7 Cg_endo -66.28 135.53 40.27 Favored 'Trans proline' 0 C--N 1.311 -1.407 0 C-N-CA 122.12 1.88 . . . . 0.0 110.692 178.46 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.594 HG23 ' HB2' ' A' ' 21' ' ' GLU . 9.2 p -73.6 135.36 27.75 Favored 'Isoleucine or valine' 0 C--O 1.268 2.033 0 C-N-CA 119.61 -0.836 . . . . 0.0 109.445 175.043 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 35.9 ttpt -101.75 124.16 46.93 Favored 'General case' 0 N--CA 1.428 -1.567 0 N-CA-C 106.122 -1.807 . . . . 0.0 106.122 173.737 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.414 ' O ' HG22 ' A' ' 99' ' ' ILE . 16.5 m -137.99 152.82 26.55 Favored 'Isoleucine or valine' 0 C--N 1.279 -2.491 0 N-CA-C 109.208 -0.664 . . . . 0.0 109.208 -172.57 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 32.6 t-105 -156.56 132.49 9.69 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.139 -1.43 . . . . 0.0 107.139 178.891 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.475 ' C ' HG12 ' A' ' 97' ' ' VAL . . . -170.63 135.84 3.69 Favored Glycine 0 CA--C 1.474 -2.481 0 C-N-CA 117.545 -2.264 . . . . 0.0 112.61 169.684 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.437 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 5.4 p -117.8 137.09 52.98 Favored 'General case' 0 N--CA 1.395 -3.18 0 N-CA-C 107.91 -1.145 . . . . 0.0 107.91 179.786 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.411 HG22 ' HA3' ' A' ' 16' ' ' GLY . 47.6 pt -131.87 146.27 33.62 Favored 'Isoleucine or valine' 0 C--N 1.291 -1.97 0 C-N-CA 119.052 -1.059 . . . . 0.0 110.093 175.274 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.48 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 0.0 OUTLIER -119.23 129.61 55.03 Favored 'General case' 0 N--CA 1.416 -2.171 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 176.225 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.583 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -135.15 174.3 21.24 Favored Glycine 0 N--CA 1.43 -1.754 0 N-CA-C 110.348 -1.101 . . . . 0.0 110.348 -173.515 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.0 mt -68.81 173.53 5.19 Favored 'General case' 0 C--N 1.312 -1.051 0 C-N-CA 123.73 0.812 . . . . 0.0 110.81 178.434 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.497 ' HA ' ' N ' ' A' ' 91' ' ' LYS . 9.8 t -66.37 110.63 3.16 Favored 'General case' 0 CA--C 1.502 -0.878 0 CA-C-O 121.627 0.727 . . . . 0.0 111.657 -172.038 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . 0.267 4.6 mm-40 -165.61 177.34 7.41 Favored 'General case' 0 N--CA 1.398 -3.071 0 CA-C-N 113.599 -1.637 . . . . 0.0 113.251 -176.647 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -62.43 -146.49 0.01 OUTLIER Glycine 0 N--CA 1.403 -3.501 0 CA-C-N 112.021 -2.354 . . . . 0.0 115.417 -177.953 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.561 ' CB ' ' HA ' ' A' ' 88' ' ' THR . 2.0 pt? -173.06 100.14 0.13 Allowed 'General case' 1 N--CA 1.372 -4.326 0 O-C-N 121.592 -0.946 . . . . 0.0 109.343 -161.214 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.526 ' HB3' ' HA ' ' A' ' 123' ' ' ALA . 0.4 OUTLIER 169.85 171.33 0.05 Allowed 'General case' 0 C--N 1.294 -1.812 0 N-CA-C 103.963 -2.606 . . . . 0.0 103.963 177.43 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.502 ' HA2' ' N ' ' A' ' 125' ' ' ASP . . . 102.65 64.72 0.73 Allowed Glycine 0 C--N 1.268 -3.197 0 N-CA-C 116.248 1.259 . . . . 0.0 116.248 171.707 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.611 ' CG ' ' HB3' ' A' ' 84' ' ' LEU . 12.8 t80 -76.72 134.85 39.09 Favored 'General case' 0 N--CA 1.413 -2.299 0 C-N-CA 117.336 -1.746 . . . . 0.0 110.07 175.45 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.644 ' HE2' HG12 ' A' ' 18' ' ' ILE . 1.4 p-80 -85.91 100.61 12.22 Favored 'General case' 0 C--N 1.263 -3.175 0 CA-C-N 112.848 -1.978 . . . . 0.0 115.086 -175.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.577 ' HB ' ' HA2' ' A' ' 82' ' ' GLY . 31.2 t -129.58 89.79 1.32 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.497 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 171.569 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.709 ' CE1' ' HB3' ' A' ' 60' ' ' ALA . 1.7 t60 -107.27 107.29 18.15 Favored 'General case' 0 C--O 1.184 -2.393 0 N-CA-C 113.323 0.861 . . . . 0.0 113.323 179.41 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.457 ' O ' ' HB2' ' A' ' 60' ' ' ALA . 3.6 mp0 -90.07 136.21 33.18 Favored 'General case' 0 C--N 1.267 -2.989 0 O-C-N 120.687 -1.258 . . . . 0.0 112.665 175.202 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 52.2 t80 70.67 93.59 0.08 Allowed 'General case' 0 N--CA 1.481 1.108 0 C-N-CA 125.968 1.707 . . . . 0.0 111.359 -175.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -121.29 -91.14 1.15 Allowed Glycine 0 CA--C 1.482 -2.006 0 C-N-CA 119.066 -1.54 . . . . 0.0 113.543 178.562 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 38.2 t70 76.89 -25.87 0.2 Allowed 'General case' 0 C--N 1.305 -1.369 0 C-N-CA 126.996 2.118 . . . . 0.0 112.583 177.511 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.448 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 2.6 m-20 -90.35 98.84 12.01 Favored 'General case' 0 N--CA 1.434 -1.261 0 N-CA-C 105.831 -1.914 . . . . 0.0 105.831 174.449 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.49 ' HA ' HG13 ' A' ' 148' ' ' VAL . 11.4 t -56.55 -32.07 64.8 Favored 'General case' 0 C--O 1.199 -1.561 0 N-CA-C 113.19 0.811 . . . . 0.0 113.19 -173.441 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -103.74 13.07 33.82 Favored 'General case' 0 C--N 1.294 -1.806 0 O-C-N 121.606 -0.683 . . . . 0.0 110.808 179.796 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.448 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -155.75 111.46 0.49 Allowed Glycine 0 N--CA 1.425 -2.095 0 C-N-CA 117.849 -2.119 . . . . 0.0 113.667 -177.533 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.44 ' O ' ' HB3' ' A' ' 142' ' ' SER . 69.5 m -94.57 85.14 4.43 Favored 'General case' 0 N--CA 1.392 -3.36 0 N-CA-C 106.848 -1.538 . . . . 0.0 106.848 172.643 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 17.9 m -82.31 -48.36 11.28 Favored 'General case' 0 N--CA 1.418 -2.061 0 CA-C-N 114.794 -1.093 . . . . 0.0 109.156 179.083 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 6.6 p -71.57 -54.91 8.94 Favored 'General case' 0 N--CA 1.407 -2.624 0 CA-C-N 113.361 -1.745 . . . . 0.0 113.792 -172.433 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.709 ' HB3' ' CE1' ' A' ' 48' ' ' HIS 0.325 . . -85.81 -2.34 58.13 Favored 'General case' 0 C--N 1.302 -1.468 0 N-CA-C 115.965 1.839 . . . . 0.0 115.965 179.657 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -43.5 -139.31 0.0 OUTLIER Glycine 0 CA--C 1.57 3.509 0 C-N-CA 124.186 0.898 . . . . 0.0 113.993 171.054 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 30.5 Cg_endo -60.1 5.32 0.13 Allowed 'Trans proline' 0 CA--C 1.574 2.494 0 C-N-CA 122.706 2.271 . . . . 0.0 114.879 -178.629 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 16.0 m170 -116.58 110.8 19.01 Favored 'General case' 0 C--N 1.323 -0.568 0 C-N-CA 123.467 0.707 . . . . 0.0 109.838 178.784 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.6 p90 -74.48 152.51 39.4 Favored 'General case' 0 C--N 1.323 -0.553 0 N-CA-C 113.038 0.755 . . . . 0.0 113.038 -175.648 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 85.6 m-20 -115.77 144.35 32.45 Favored Pre-proline 0 C--N 1.309 -1.162 0 CA-C-N 116.021 -0.536 . . . . 0.0 109.74 177.025 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 39.5 Cg_endo -72.22 -13.11 28.23 Favored 'Trans proline' 0 CA--C 1.539 0.748 0 C-N-CA 122.239 1.959 . . . . 0.0 111.747 178.374 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.526 ' CB ' ' HB2' ' A' ' 109' ' ' ASP . 2.6 mm? -80.96 -9.47 59.83 Favored 'General case' 0 CA--C 1.484 -1.568 0 N-CA-C 108.542 -0.91 . . . . 0.0 108.542 -179.733 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 68.7 m -78.95 66.03 4.3 Favored 'General case' 0 N--CA 1.405 -2.706 0 CA-C-O 123.538 1.637 . . . . 0.0 108.719 172.943 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.636 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 12.5 ptp180 -117.49 23.27 11.88 Favored 'General case' 0 N--CA 1.397 -3.104 0 CA-C-N 112.204 -2.271 . . . . 0.0 105.149 175.007 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 28.9 mmmt -78.91 18.63 0.59 Allowed 'General case' 0 CA--C 1.504 -0.803 0 CA-C-N 112.363 -2.199 . . . . 0.0 111.005 176.331 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.501 ' HA ' ' HA ' ' A' ' 76' ' ' ASP . 33.6 t-80 75.3 87.59 0.09 Allowed 'General case' 0 N--CA 1.423 -1.805 0 O-C-N 125.135 1.522 . . . . 0.0 112.018 179.189 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.684 ' HA2' ' O ' ' A' ' 83' ' ' ASP . . . -76.75 -98.4 0.17 Allowed Glycine 1 N--CA 1.385 -4.738 0 N-CA-C 108.355 -1.898 . . . . 0.0 108.355 169.492 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -50.33 158.0 1.88 Allowed Glycine 0 N--CA 1.429 -1.827 0 N-CA-C 111.065 -0.814 . . . . 0.0 111.065 172.828 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.434 ' HA ' ' NE2' ' A' ' 71' ' ' HIS . 47.4 Cg_endo -62.14 0.09 1.47 Allowed 'Trans proline' 0 N--CA 1.484 0.969 0 C-N-CA 124.678 3.585 . . . . 0.0 114.454 -172.071 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 64.0 pttt -120.39 13.67 11.89 Favored 'General case' 0 C--N 1.289 -2.049 0 C-N-CA 123.047 0.539 . . . . 0.0 110.127 -175.059 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.501 ' HA ' ' HA ' ' A' ' 71' ' ' HIS . 3.0 m-20 71.98 76.38 0.16 Allowed 'General case' 0 CA--C 1.496 -1.097 0 CA-C-N 114.791 -1.095 . . . . 0.0 112.502 177.185 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 8.3 mm-40 -78.97 87.19 4.79 Favored 'General case' 0 C--N 1.311 -1.106 0 CA-C-N 115.431 -0.804 . . . . 0.0 111.723 -179.976 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 69' ' ' ARG . 11.6 pt-20 -57.56 26.34 0.0 OUTLIER 'General case' 0 CA--C 1.546 0.807 0 C-N-CA 128.704 2.801 . . . . 0.0 115.942 179.779 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 72.4 ttt180 -160.16 -0.56 0.07 Allowed 'General case' 0 C--N 1.292 -1.915 0 C-N-CA 119.434 -0.906 . . . . 0.0 110.385 -174.152 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . . 36.8 m170 -105.16 136.16 45.16 Favored 'General case' 0 N--CA 1.491 1.59 0 O-C-N 121.563 -0.711 . . . . 0.0 111.451 -173.703 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.415 HG13 ' O ' ' A' ' 81' ' ' VAL . 11.1 p -98.49 70.48 0.46 Allowed 'Isoleucine or valine' 0 C--O 1.267 2.024 0 CA-C-O 123.138 1.447 . . . . 0.0 113.722 -178.598 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.577 ' HA2' ' HB ' ' A' ' 47' ' ' VAL . . . 115.93 86.4 1.29 Allowed Glycine 0 CA--C 1.468 -2.869 0 C-N-CA 117.924 -2.084 . . . . 0.0 114.217 172.663 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.684 ' O ' ' HA2' ' A' ' 72' ' ' GLY . 7.7 p-10 -164.53 140.59 6.0 Favored 'General case' 0 C--N 1.287 -2.15 0 C-N-CA 124.102 0.961 . . . . 0.0 108.95 176.724 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.611 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 7.5 tt -174.94 177.18 2.03 Favored 'General case' 0 C--N 1.278 -2.504 0 N-CA-C 102.597 -3.112 . . . . 0.0 102.597 177.868 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.522 ' N ' HD23 ' A' ' 84' ' ' LEU . . . -39.74 156.43 0.03 OUTLIER Glycine 0 CA--C 1.532 1.114 0 CA-C-N 119.106 0.867 . . . . 0.0 111.486 173.451 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER -85.48 160.52 19.68 Favored 'General case' 0 C--N 1.282 -2.351 0 O-C-N 122.377 -0.484 . . . . 0.0 112.105 -158.293 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 77.5 t -108.39 163.42 5.88 Favored 'Isoleucine or valine' 0 N--CA 1.401 -2.912 0 N-CA-C 106.357 -1.72 . . . . 0.0 106.357 -174.76 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.561 ' HA ' ' CB ' ' A' ' 42' ' ' LEU . 31.5 m -140.33 130.51 25.0 Favored 'General case' 0 C--N 1.261 -3.28 0 C-N-CA 124.437 1.095 . . . . 0.0 109.457 179.88 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.54 ' CB ' ' HB3' ' A' ' 121' ' ' GLU . . . -126.12 155.16 42.08 Favored 'General case' 0 C--N 1.254 -3.583 0 N-CA-C 105.829 -1.915 . . . . 0.0 105.829 174.223 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.418 ' C ' ' HA ' ' A' ' 39' ' ' THR . 23.9 t70 -158.36 174.96 14.34 Favored 'General case' 1 C--N 1.239 -4.232 0 N-CA-C 104.126 -2.546 . . . . 0.0 104.126 178.462 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.497 ' N ' ' HA ' ' A' ' 39' ' ' THR . 59.8 pttt -47.27 -35.85 8.32 Favored 'General case' 0 C--N 1.287 -2.139 0 N-CA-C 112.683 0.623 . . . . 0.0 112.683 176.353 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 4.0 m-20 -90.28 -38.64 13.26 Favored 'General case' 0 CA--C 1.486 -1.503 0 N-CA-C 108.826 -0.805 . . . . 0.0 108.826 176.431 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.583 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 89.54 112.85 1.38 Allowed Glycine 0 N--CA 1.404 -3.479 0 CA-C-N 114.675 -1.148 . . . . 0.0 112.308 179.703 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.484 ' O ' ' HB ' ' A' ' 88' ' ' THR . 6.7 p -157.71 103.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.417 -2.101 0 CA-C-O 121.953 0.883 . . . . 0.0 109.876 174.715 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.403 ' HA ' ' HB ' ' A' ' 88' ' ' THR . . . -94.23 129.0 41.02 Favored 'General case' 0 N--CA 1.414 -2.228 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.713 173.224 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 18.1 t70 -69.57 143.38 53.37 Favored 'General case' 0 C--N 1.286 -2.172 0 CA-C-N 114.378 -1.283 . . . . 0.0 109.406 177.966 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.475 HG12 ' C ' ' A' ' 33' ' ' GLY . 34.4 m -79.57 103.37 6.45 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.908 0 CA-C-O 123.855 1.788 . . . . 0.0 107.813 -177.488 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 30.4 m -86.77 107.39 18.24 Favored 'General case' 0 N--CA 1.401 -2.9 0 CA-C-N 113.059 -1.882 . . . . 0.0 111.083 -174.171 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.414 HG22 ' O ' ' A' ' 31' ' ' VAL . 37.5 pt -95.66 124.83 48.45 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.513 0 N-CA-C 108.667 -0.864 . . . . 0.0 108.667 175.718 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 6.8 mm-40 -143.64 126.31 16.03 Favored 'General case' 0 C--N 1.296 -1.719 0 N-CA-C 107.449 -1.315 . . . . 0.0 107.449 -179.328 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.46 ' HB2' ' HB3' ' A' ' 28' ' ' PRO . 4.3 p30 -81.09 135.62 35.83 Favored 'General case' 0 C--O 1.276 2.45 0 CA-C-O 122.433 1.111 . . . . 0.0 112.601 -178.453 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.427 ' OG ' ' HB ' ' A' ' 29' ' ' VAL . 92.5 p -102.92 172.2 6.96 Favored 'General case' 0 N--CA 1.413 -2.3 0 CA-C-N 112.846 -1.979 . . . . 0.0 110.608 177.678 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.452 ' H ' ' CG ' ' A' ' 76' ' ' ASP . 7.1 p -115.88 -53.1 4.63 Favored 'Isoleucine or valine' 0 N--CA 1.392 -3.329 0 N-CA-C 107.233 -1.395 . . . . 0.0 107.233 163.295 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 12.8 pt -98.93 23.67 1.11 Allowed 'Isoleucine or valine' 0 C--O 1.249 1.045 0 N-CA-C 114.823 1.416 . . . . 0.0 114.823 -170.647 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 47.8 t -80.34 89.88 5.56 Favored 'General case' 0 N--CA 1.43 -1.432 0 CA-C-O 123.061 1.41 . . . . 0.0 108.721 169.557 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.576 ' HA ' ' HB2' ' A' ' 22' ' ' GLN . 3.0 pp -126.72 170.39 12.18 Favored 'General case' 2 N--CA 1.346 -5.643 1 N-CA-C 99.272 -4.344 . . . . 0.0 99.272 174.558 . . . . . . . . 4 3 . 1 . 008 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 40.1 m -74.13 93.37 2.28 Favored 'General case' 1 C--N 1.213 -5.327 0 C-N-CA 118.727 -1.189 . . . . 0.0 111.978 -179.096 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -94.81 135.43 12.43 Favored Glycine 0 CA--C 1.456 -3.651 0 N-CA-C 106.308 -2.717 . . . . 0.0 106.308 175.332 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.526 ' HB2' ' CB ' ' A' ' 67' ' ' LEU . 6.1 t70 54.09 -153.78 0.28 Allowed 'General case' 0 C--N 1.284 -2.247 0 N-CA-C 108.18 -1.044 . . . . 0.0 108.18 -171.434 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.543 ' HB3' ' O ' ' A' ' 113' ' ' ILE . 62.6 m-70 -90.37 37.11 0.89 Allowed 'General case' 0 C--N 1.276 -2.602 0 C-N-CA 124.78 1.232 . . . . 0.0 109.777 -179.435 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.426 ' HA ' ' HD3' ' A' ' 115' ' ' ARG . 16.6 p -59.41 -27.14 65.74 Favored 'General case' 0 C--N 1.324 -0.528 0 N-CA-C 114.79 1.404 . . . . 0.0 114.79 -179.173 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.671 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 46.1 pt -104.6 -32.94 2.89 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.762 0 C-N-CA 118.2 -1.4 . . . . 0.0 110.62 176.225 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.543 ' O ' ' HB3' ' A' ' 110' ' ' HIS . 14.0 tt -104.09 99.84 9.25 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.588 0 C-N-CA 120.135 -0.626 . . . . 0.0 112.684 179.932 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 89.76 17.89 53.02 Favored Glycine 0 N--CA 1.44 -1.065 0 C-N-CA 120.426 -0.893 . . . . 0.0 112.895 175.111 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.549 ' HG3' ' O ' ' A' ' 48' ' ' HIS . 23.7 ttp180 -73.4 101.73 3.56 Favored 'General case' 0 C--N 1.307 -1.249 0 O-C-N 122.268 -0.548 . . . . 0.0 111.233 178.664 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.563 HG22 ' HB3' ' A' ' 146' ' ' CYS . 4.2 m -70.9 110.85 5.88 Favored 'General case' 0 C--O 1.181 -2.519 0 N-CA-C 108.237 -1.023 . . . . 0.0 108.237 176.966 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.537 ' HG ' ' HB2' ' A' ' 46' ' ' HIS . 13.2 tp -70.03 123.87 22.64 Favored 'General case' 0 C--N 1.275 -2.673 0 C-N-CA 122.731 0.412 . . . . 0.0 111.346 -172.31 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.582 HG22 ' HB2' ' A' ' 48' ' ' HIS . 11.4 m -91.88 101.03 12.12 Favored 'Isoleucine or valine' 0 N--CA 1.493 1.71 0 N-CA-C 113.18 0.807 . . . . 0.0 113.18 178.018 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.487 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 10.3 p -140.52 168.66 16.61 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.89 0 N-CA-C 109.588 -0.523 . . . . 0.0 109.588 176.931 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.56 ' CD2' ' HB2' ' A' ' 124' ' ' ASP . 0.3 OUTLIER -171.2 164.23 7.25 Favored 'General case' 0 CA--C 1.487 -1.456 0 N-CA-C 104.214 -2.513 . . . . 0.0 104.214 173.871 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.58 ' O ' ' HG2' ' A' ' 122' ' ' LYS . 2.2 mp0 -86.9 84.17 7.39 Favored 'General case' 0 C--N 1.269 -2.93 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 178.297 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.58 ' HG2' ' O ' ' A' ' 121' ' ' GLU . 2.2 mmpt? -176.0 171.53 2.57 Favored 'General case' 0 CA--C 1.476 -1.903 0 N-CA-C 106.716 -1.587 . . . . 0.0 106.716 -175.314 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.526 ' HA ' ' HB3' ' A' ' 43' ' ' HIS . . . -62.42 122.41 15.65 Favored 'General case' 0 C--N 1.303 -1.454 0 N-CA-C 108.779 -0.823 . . . . 0.0 108.779 170.063 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.66 ' HA ' ' O ' ' A' ' 139' ' ' ASN . 19.6 t70 -128.74 -12.83 4.79 Favored 'General case' 0 C--O 1.265 1.875 0 CA-C-N 116.017 -0.538 . . . . 0.0 111.943 175.58 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.548 ' HA ' ' O ' ' A' ' 82' ' ' GLY . 0.6 OUTLIER -71.56 137.28 47.92 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 115.627 -0.715 . . . . 0.0 112.268 -174.881 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 1.0 OUTLIER -79.2 -68.19 0.68 Allowed 'General case' 0 N--CA 1.424 -1.739 0 CA-C-N 114.344 -1.298 . . . . 0.0 108.334 -178.268 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.478 ' H ' ' CG ' ' A' ' 83' ' ' ASP . . . -74.04 9.83 8.61 Favored Glycine 0 CA--C 1.528 0.901 0 C-N-CA 119.982 -1.104 . . . . 0.0 114.962 -176.765 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.404 ' HB3' ' CG ' ' A' ' 125' ' ' ASP . 32.2 tptt -137.43 15.29 2.97 Favored 'General case' 0 C--N 1.309 -1.167 0 N-CA-C 108.15 -1.056 . . . . 0.0 108.15 -179.769 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -76.8 42.94 1.85 Allowed Glycine 0 N--CA 1.473 1.135 0 N-CA-C 118.736 2.254 . . . . 0.0 118.736 -166.709 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 74.18 -91.38 0.72 Allowed Glycine 0 C--N 1.3 -1.431 0 N-CA-C 116.735 1.454 . . . . 0.0 116.735 171.239 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 49.8 t30 -100.33 158.32 15.97 Favored 'General case' 0 C--N 1.311 -1.105 0 CA-C-O 118.595 -0.717 . . . . 0.0 110.484 -169.468 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 8.3 pt-20 -47.37 -42.48 21.77 Favored 'General case' 0 C--N 1.363 1.172 0 N-CA-C 113.441 0.904 . . . . 0.0 113.441 -178.06 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -79.87 -43.66 21.87 Favored 'General case' 0 C--N 1.316 -0.86 0 CA-C-O 120.91 0.386 . . . . 0.0 110.958 178.865 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 22.7 t -70.64 -20.87 62.68 Favored 'General case' 0 CA--C 1.537 0.447 0 C-N-CA 123.369 0.668 . . . . 0.0 111.878 -173.364 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 12.2 t -82.32 -18.23 42.97 Favored 'General case' 0 C--N 1.306 -1.31 0 CA-C-O 121.031 0.443 . . . . 0.0 110.356 -179.641 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 44.5 mtpt -101.77 -28.22 12.58 Favored 'General case' 0 C--N 1.29 -1.997 0 C-N-CA 118.54 -1.264 . . . . 0.0 110.071 -178.116 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 20.9 p -74.45 -47.85 31.05 Favored 'General case' 0 N--CA 1.408 -2.527 0 N-CA-C 107.711 -1.218 . . . . 0.0 107.711 173.092 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 74.16 94.06 0.13 Allowed Glycine 0 N--CA 1.417 -2.614 0 N-CA-C 110.306 -1.118 . . . . 0.0 110.306 -179.373 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.66 ' O ' ' HA ' ' A' ' 124' ' ' ASP . 46.2 t-20 -55.81 106.03 0.23 Allowed 'General case' 0 N--CA 1.482 1.126 0 N-CA-C 108.929 -0.767 . . . . 0.0 108.929 176.952 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -112.69 127.6 56.17 Favored 'General case' 0 N--CA 1.426 -1.661 0 N-CA-C 112.993 0.738 . . . . 0.0 112.993 -172.746 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -89.47 101.21 2.74 Favored Glycine 0 N--CA 1.428 -1.868 0 N-CA-C 106.468 -2.653 . . . . 0.0 106.468 171.241 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.44 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 15.2 m -89.52 -7.1 55.65 Favored 'General case' 0 C--N 1.3 -1.565 0 N-CA-C 113.142 0.793 . . . . 0.0 113.142 -171.504 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 8.1 ptm180 -145.19 -11.39 0.55 Allowed 'General case' 0 C--N 1.247 -3.859 0 C-N-CA 118.203 -1.399 . . . . 0.0 110.297 172.882 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.0 tm? -54.89 -42.96 72.74 Favored 'General case' 0 C--O 1.243 0.714 0 N-CA-C 109.355 -0.609 . . . . 0.0 109.355 -175.668 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.487 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -149.82 89.88 1.65 Allowed 'General case' 0 N--CA 1.397 -3.122 0 N-CA-C 108.487 -0.931 . . . . 0.0 108.487 -179.547 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.563 ' HB3' HG22 ' A' ' 116' ' ' THR . 32.3 m -126.72 150.71 48.9 Favored 'General case' 0 C--N 1.279 -2.464 0 CA-C-N 113.938 -1.483 . . . . 0.0 107.897 178.336 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -170.95 139.64 5.55 Favored Glycine 0 C--N 1.291 -1.957 0 N-CA-C 108.562 -1.815 . . . . 0.0 108.562 178.401 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.49 HG13 ' HA ' ' A' ' 54' ' ' THR . 17.2 m -73.59 110.4 7.17 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.186 0 CA-C-N 118.69 1.245 . . . . 0.0 111.705 179.9 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.456 HG23 ' HB2' ' A' ' 117' ' ' LEU . 1.4 pp -86.67 145.75 7.26 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.227 0 N-CA-C 106.07 -1.826 . . . . 0.0 106.07 177.584 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.671 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -150.14 142.61 9.83 Favored Glycine 2 N--CA 1.382 -4.96 0 C-N-CA 117.619 -2.229 . . . . 0.0 112.395 -171.409 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.612 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 3.4 tt -53.16 103.79 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.425 -1.679 0 CA-C-O 122.088 0.947 . . . . 0.0 109.841 167.699 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.409 ' HB3' HG22 ' A' ' 5' ' ' VAL . . . -150.1 154.73 38.6 Favored 'General case' 0 N--CA 1.41 -2.436 0 N-CA-C 106.453 -1.684 . . . . 0.0 106.453 174.494 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 tt0 . . . . . 0 C--N 1.273 -2.72 0 N-CA-C 106.526 -1.657 . . . . 0.0 106.526 177.608 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.228 -0.05 0 N-CA-C 111.379 0.14 . . . . 0.0 111.379 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.595 ' C ' ' HG3' ' A' ' 21' ' ' GLU . 30.1 m -119.33 -54.06 2.21 Favored 'General case' 0 N--CA 1.437 -1.122 0 N-CA-C 112.173 0.434 . . . . 0.0 112.173 -177.318 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.51 ' N ' ' HG3' ' A' ' 21' ' ' GLU . 22.6 pttp -145.5 152.57 39.97 Favored 'General case' 0 N--CA 1.417 -2.122 0 C-N-CA 119.273 -0.971 . . . . 0.0 111.632 -169.749 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.773 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.19 161.03 38.84 Favored 'General case' 0 N--CA 1.412 -2.347 0 N-CA-C 107.295 -1.372 . . . . 0.0 107.295 177.032 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 65.7 t -131.25 122.52 51.35 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.815 0 N-CA-C 109.087 -0.709 . . . . 0.0 109.087 -178.464 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -115.33 127.82 55.68 Favored 'General case' 0 C--N 1.292 -1.913 0 N-CA-C 108.34 -0.985 . . . . 0.0 108.34 175.503 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.581 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 27.5 m -113.29 144.75 20.29 Favored 'Isoleucine or valine' 0 C--N 1.32 -0.686 0 O-C-N 123.433 0.458 . . . . 0.0 110.554 -178.634 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 95.4 mt -127.09 135.05 50.22 Favored 'General case' 0 C--N 1.306 -1.318 0 CA-C-N 116.336 -0.393 . . . . 0.0 111.641 -179.137 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 95.8 mttt -141.04 125.86 18.06 Favored 'General case' 0 C--N 1.319 -0.741 0 N-CA-C 106.833 -1.543 . . . . 0.0 106.833 177.047 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . 0.422 ' HA3' ' O ' ' A' ' 144' ' ' LEU . . . -154.31 178.45 31.13 Favored Glycine 0 N--CA 1.432 -1.597 0 C-N-CA 118.931 -1.604 . . . . 0.0 113.338 -179.228 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 8.1 m-20 -73.0 -40.4 65.23 Favored 'General case' 0 C--N 1.322 -0.588 0 N-CA-C 107.754 -1.202 . . . . 0.0 107.754 176.982 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -100.56 95.57 1.45 Allowed Glycine 0 N--CA 1.434 -1.443 0 N-CA-C 106.159 -2.776 . . . . 0.0 106.159 170.484 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 55.6 Cg_endo -69.75 127.56 14.77 Favored 'Trans proline' 0 N--CA 1.447 -1.234 0 C-N-CA 121.895 1.73 . . . . 0.0 115.2 -169.345 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.563 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 14.0 m -123.78 114.98 43.75 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.186 0 N-CA-C 104.751 -2.314 . . . . 0.0 104.751 172.986 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER -115.24 118.29 32.87 Favored 'General case' 0 C--N 1.279 -2.485 0 C-N-CA 118.309 -1.356 . . . . 0.0 109.542 -173.979 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.563 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.72 171.56 44.15 Favored Glycine 0 N--CA 1.412 -2.965 0 CA-C-N 115.687 -0.688 . . . . 0.0 111.887 178.405 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 23.2 pt -133.46 124.58 48.79 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.27 0 N-CA-C 108.017 -1.105 . . . . 0.0 108.017 -179.589 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.413 ' HA ' ' HA3' ' A' ' 33' ' ' GLY . 2.4 mp -114.11 140.04 36.81 Favored 'Isoleucine or valine' 0 C--N 1.297 -1.714 0 N-CA-C 108.02 -1.104 . . . . 0.0 108.02 -178.672 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.489 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 35.9 m-80 -99.24 150.41 22.11 Favored 'General case' 0 C--N 1.304 -1.383 0 N-CA-C 107.291 -1.374 . . . . 0.0 107.291 178.736 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.773 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 98.2 m-85 -149.39 117.29 6.29 Favored 'General case' 0 CA--C 1.491 -1.3 0 N-CA-C 108.016 -1.105 . . . . 0.0 108.016 175.501 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.595 ' HG3' ' C ' ' A' ' 2' ' ' THR . 4.6 mm-40 -134.39 144.12 48.01 Favored 'General case' 0 CA--C 1.477 -1.839 0 C-N-CA 118.627 -1.229 . . . . 0.0 112.578 173.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.543 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 25.3 tp60 -127.71 152.36 47.82 Favored 'General case' 0 N--CA 1.406 -2.633 0 CA-C-N 115.045 -0.98 . . . . 0.0 110.408 -178.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.457 ' H ' HE21 ' A' ' 22' ' ' GLN . 84.8 tttt -106.56 104.73 14.49 Favored 'General case' 0 C--N 1.26 -3.306 0 N-CA-C 100.511 -3.885 . . . . 0.0 100.511 169.386 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . 0.318 9.9 pt-20 -63.27 -9.25 10.85 Favored 'General case' 0 C--N 1.323 -0.57 0 N-CA-C 116.307 1.966 . . . . 0.0 116.307 -168.044 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.5 p -76.45 -61.09 2.07 Favored 'General case' 0 N--CA 1.426 -1.668 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 170.49 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 28.0 t-20 175.57 136.55 0.05 OUTLIER 'General case' 0 C--N 1.321 -0.655 0 C-N-CA 126.447 1.899 . . . . 0.0 106.688 174.304 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 150.87 95.37 0.12 Allowed Glycine 1 CA--C 1.444 -4.36 0 N-CA-C 109.83 -1.308 . . . . 0.0 109.83 -179.815 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . 0.585 ' HB3' ' N ' ' A' ' 101' ' ' ASP . 38.4 Cg_exo -62.75 123.44 12.32 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 C-N-CA 121.686 1.591 . . . . 0.0 109.179 -179.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.553 ' HB ' ' O ' ' A' ' 21' ' ' GLU . 77.8 t -88.75 148.19 4.7 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.98 0 N-CA-C 103.892 -2.632 . . . . 0.0 103.892 171.985 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.412 ' HD2' ' N ' ' A' ' 30' ' ' LYS . 0.1 OUTLIER -99.62 109.33 21.83 Favored 'General case' 1 C--N 1.242 -4.072 0 N-CA-C 107.668 -1.234 . . . . 0.0 107.668 -167.16 . . . . . . . . 4 4 . 1 . 009 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.489 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 16.1 m -124.53 152.44 30.52 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.901 0 CA-C-N 114.712 -1.131 . . . . 0.0 112.089 -169.594 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 49.3 p90 -134.64 154.04 51.7 Favored 'General case' 0 C--N 1.267 -3.006 0 CA-C-N 114.97 -1.013 . . . . 0.0 109.762 -175.65 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.453 ' O ' ' HA ' ' A' ' 96' ' ' ASP . . . -159.46 140.16 6.66 Favored Glycine 0 N--CA 1.415 -2.702 0 N-CA-C 109.286 -1.526 . . . . 0.0 109.286 176.951 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.563 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 11.7 p -116.67 114.83 24.6 Favored 'General case' 0 C--N 1.302 -1.496 0 C-N-CA 124.001 0.92 . . . . 0.0 110.987 -179.154 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.546 HG22 ' HA3' ' A' ' 16' ' ' GLY . 36.8 pt -128.78 123.18 58.69 Favored 'Isoleucine or valine' 0 N--CA 1.483 1.179 0 CA-C-N 119.69 1.132 . . . . 0.0 110.81 175.248 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.643 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 21.3 ptmt -92.89 142.34 27.42 Favored 'General case' 0 N--CA 1.424 -1.753 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 177.722 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.472 ' HA2' HG12 ' A' ' 14' ' ' VAL . . . -144.89 175.79 24.32 Favored Glycine 0 N--CA 1.421 -2.356 0 O-C-N 123.574 0.547 . . . . 0.0 112.869 -168.848 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 34.2 mt -68.72 171.25 8.02 Favored 'General case' 0 C--N 1.315 -0.928 0 N-CA-C 107.074 -1.454 . . . . 0.0 107.074 174.01 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 1.7 m -73.07 103.48 3.84 Favored 'General case' 0 C--N 1.308 -1.216 0 C-N-CA 118.644 -1.222 . . . . 0.0 114.071 -171.213 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.536 ' OE2' ' HD3' ' A' ' 122' ' ' LYS . 25.5 tt0 -177.1 156.4 1.27 Allowed 'General case' 0 C--N 1.293 -1.881 0 N-CA-C 106.709 -1.589 . . . . 0.0 106.709 157.643 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -88.66 -159.16 34.76 Favored Glycine 0 C--N 1.272 -2.977 0 N-CA-C 109.571 -1.412 . . . . 0.0 109.571 170.208 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.586 ' HB3' ' H ' ' A' ' 122' ' ' LYS . 1.3 pt? -159.65 -169.85 2.71 Favored 'General case' 1 N--CA 1.364 -4.758 0 N-CA-C 107.595 -1.261 . . . . 0.0 107.595 177.169 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.443 ' H ' ' HA ' ' A' ' 123' ' ' ALA . 34.7 t-80 -137.4 165.4 26.32 Favored 'General case' 0 C--N 1.247 -3.856 0 N-CA-C 103.28 -2.859 . . . . 0.0 103.28 -178.063 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.58 ' HA2' ' O ' ' A' ' 85' ' ' GLY . . . -34.29 111.46 0.07 OUTLIER Glycine 0 C--O 1.249 1.074 0 O-C-N 125.723 1.889 . . . . 0.0 112.547 177.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 34.0 p90 -69.68 157.39 37.35 Favored 'General case' 0 N--CA 1.43 -1.463 0 CA-C-O 121.929 0.871 . . . . 0.0 112.714 -173.142 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.738 ' HA ' ' HA3' ' A' ' 82' ' ' GLY . 59.6 m80 -137.82 95.02 2.97 Favored 'General case' 1 C--O 1.341 5.903 0 CA-C-N 115.215 -0.902 . . . . 0.0 109.021 -174.154 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.528 ' H ' ' HA2' ' A' ' 82' ' ' GLY . 14.1 m -106.11 156.76 6.76 Favored 'Isoleucine or valine' 0 C--N 1.28 -2.455 0 CA-C-N 114.394 -1.275 . . . . 0.0 109.738 -175.572 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.44 ' ND1' ' HB2' ' A' ' 65' ' ' ASN . 15.1 t60 -131.32 121.04 24.02 Favored 'General case' 0 C--N 1.296 -1.76 0 CA-C-O 122.531 1.158 . . . . 0.0 112.083 175.402 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.493 ' OE1' ' HA3' ' A' ' 108' ' ' GLY . 0.0 OUTLIER -90.03 95.61 10.29 Favored 'General case' 0 C--N 1.273 -2.751 0 CA-C-N 113.161 -1.836 . . . . 0.0 115.609 -175.827 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . 0.299 6.4 p90 -131.23 -5.92 3.83 Favored 'General case' 0 C--O 1.218 -0.57 0 C-N-CA 118.128 -1.429 . . . . 0.0 114.252 169.51 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.613 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . 100.98 118.58 4.34 Favored Glycine 0 N--CA 1.476 1.351 0 C-N-CA 120.058 -1.068 . . . . 0.0 112.714 -179.581 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.4 t70 -144.86 -85.97 0.12 Allowed 'General case' 0 CA--C 1.539 0.531 0 C-N-CA 118.308 -1.357 . . . . 0.0 111.098 177.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.482 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 23.5 t30 -153.83 136.69 15.36 Favored 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 109.169 -0.678 . . . . 0.0 109.169 -178.726 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.481 HG23 HG22 ' A' ' 148' ' ' VAL . 23.5 m -55.76 -19.11 10.02 Favored 'General case' 0 C--N 1.308 -1.228 0 C-N-CA 125.613 1.565 . . . . 0.0 112.608 179.361 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -114.32 2.52 14.78 Favored 'General case' 0 N--CA 1.424 -1.741 0 N-CA-C 112.309 0.485 . . . . 0.0 112.309 -176.566 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.482 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 170.84 137.94 2.41 Favored Glycine 0 C--O 1.211 -1.283 0 C-N-CA 117.744 -2.169 . . . . 0.0 113.229 -178.18 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.642 ' SG ' HG22 ' A' ' 118' ' ' VAL . 25.4 p -98.68 94.06 6.44 Favored 'General case' 0 C--N 1.305 -1.367 0 N-CA-C 112.338 0.496 . . . . 0.0 112.338 179.899 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 36.8 m -74.75 -52.24 12.05 Favored 'General case' 0 C--N 1.299 -1.615 0 O-C-N 121.641 -0.662 . . . . 0.0 110.998 -179.113 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 25.5 m -90.31 -34.81 15.58 Favored 'General case' 0 C--N 1.295 -1.795 0 CA-C-O 121.149 0.5 . . . . 0.0 110.908 -175.712 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -79.29 -9.58 59.61 Favored 'General case' 0 C--N 1.319 -0.745 0 N-CA-C 113.184 0.809 . . . . 0.0 113.184 -175.699 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.54 -65.03 3.61 Favored Glycine 0 CA--C 1.542 1.775 0 N-CA-C 114.54 0.576 . . . . 0.0 114.54 -178.644 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -88.88 6.38 4.68 Favored 'Trans proline' 0 C--O 1.245 0.867 0 C-N-CA 123.061 2.508 . . . . 0.0 114.247 -177.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 8.2 t60 -98.86 133.78 42.67 Favored 'General case' 0 C--N 1.308 -1.219 0 N-CA-C 108.599 -0.889 . . . . 0.0 108.599 -176.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 42.9 p90 -109.32 170.82 7.81 Favored 'General case' 0 C--N 1.312 -1.045 0 N-CA-C 112.372 0.508 . . . . 0.0 112.372 -175.85 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.692 ' O ' HG22 ' A' ' 81' ' ' VAL . 43.9 t30 -106.49 97.16 15.68 Favored Pre-proline 0 C--O 1.213 -0.852 0 C-N-CA 123.066 0.546 . . . . 0.0 110.758 176.782 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.508 ' HA ' ' HA ' ' A' ' 70' ' ' LYS . 21.3 Cg_exo -62.2 -9.86 16.37 Favored 'Trans proline' 0 C--N 1.309 -1.541 0 C-N-CA 124.256 3.304 . . . . 0.0 114.333 -177.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -61.18 -17.58 53.77 Favored 'General case' 0 C--N 1.365 1.263 0 C-N-CA 122.7 0.4 . . . . 0.0 110.784 -168.939 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 38.6 t -84.77 -90.62 0.09 Allowed 'General case' 0 N--CA 1.41 -2.465 0 C-N-CA 116.324 -2.15 . . . . 0.0 110.554 178.9 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.512 ' HG2' ' HB3' ' A' ' 75' ' ' LYS . 15.6 tpp180 -135.87 41.71 2.67 Favored 'General case' 0 C--N 1.264 -3.119 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 178.34 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.508 ' HA ' ' HA ' ' A' ' 66' ' ' PRO . 99.5 mttt 75.35 -153.47 0.04 OUTLIER 'General case' 0 N--CA 1.435 -1.196 0 CA-C-N 113.257 -1.792 . . . . 0.0 108.308 -177.259 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 5.0 p80 -67.26 83.22 0.14 Allowed 'General case' 0 C--N 1.312 -1.027 0 N-CA-C 114.343 1.238 . . . . 0.0 114.343 -176.085 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.592 ' N ' HG11 ' A' ' 81' ' ' VAL . . . 93.25 91.58 1.55 Allowed Glycine 0 CA--C 1.467 -2.939 0 C-N-CA 117.784 -2.151 . . . . 0.0 111.638 169.591 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.92 142.8 7.73 Favored Glycine 1 N--CA 1.392 -4.263 0 N-CA-C 110.818 -0.913 . . . . 0.0 110.818 177.618 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 93.8 Cg_endo -86.22 0.46 8.13 Favored 'Trans proline' 0 N--CA 1.437 -1.806 0 C-N-CA 122.794 2.329 . . . . 0.0 109.414 178.909 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.512 ' HB3' ' HG2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -84.84 28.55 0.68 Allowed 'General case' 0 N--CA 1.451 -0.405 0 CA-C-N 115.31 -0.859 . . . . 0.0 110.154 -172.111 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.514 ' HB3' ' HA ' ' A' ' 68' ' ' SER . 5.8 t0 -179.78 39.99 0.0 OUTLIER 'General case' 0 C--N 1.31 -1.122 0 CA-C-O 123.209 1.48 . . . . 0.0 107.988 164.247 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 39.8 mt-10 68.11 8.87 6.82 Favored 'General case' 0 C--N 1.319 -0.736 0 CA-C-N 112.332 -2.213 . . . . 0.0 114.9 169.595 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.405 ' HB3' HG23 ' A' ' 103' ' ' VAL . 4.0 tp10 63.34 37.76 10.68 Favored 'General case' 0 C--N 1.366 1.322 0 N-CA-C 107.547 -1.279 . . . . 0.0 107.547 176.244 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.408 ' H ' ' HB2' ' A' ' 68' ' ' SER 0.34 50.2 mtm180 -52.84 3.12 0.01 OUTLIER 'General case' 0 N--CA 1.521 3.118 0 N-CA-C 119.202 3.038 . . . . 0.0 119.202 -164.922 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.419 4.8 m80 163.03 28.79 0.0 OUTLIER 'General case' 0 CA--C 1.459 -2.537 0 C-N-CA 127.036 2.134 . . . . 0.0 112.708 162.043 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.692 HG22 ' O ' ' A' ' 65' ' ' ASN . 3.6 t -83.16 -23.2 8.42 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.509 0 N-CA-C 104.651 -2.351 . . . . 0.0 104.651 174.076 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.738 ' HA3' ' HA ' ' A' ' 46' ' ' HIS . . . -179.07 123.44 0.85 Allowed Glycine 1 N--CA 1.379 -5.128 0 CA-C-N 113.55 -1.659 . . . . 0.0 111.218 178.662 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 7.7 m-20 -69.27 107.96 3.47 Favored 'General case' 0 N--CA 1.434 -1.275 0 N-CA-C 106.605 -1.628 . . . . 0.0 106.605 174.358 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.576 ' H ' HG11 ' A' ' 103' ' ' VAL . 51.4 tp -68.55 89.95 0.37 Allowed 'General case' 0 C--N 1.298 -1.66 0 CA-C-N 113.75 -1.568 . . . . 0.0 113.228 -170.149 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.58 ' O ' ' HA2' ' A' ' 44' ' ' GLY . . . -139.96 138.92 9.48 Favored Glycine 0 N--CA 1.413 -2.884 0 N-CA-C 107.989 -2.044 . . . . 0.0 107.989 174.15 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.9 t30 -109.84 129.14 55.67 Favored 'General case' 0 CA--C 1.485 -1.527 0 N-CA-C 108.492 -0.929 . . . . 0.0 108.492 -175.039 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.907 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 2.3 m -129.21 156.21 41.62 Favored 'Isoleucine or valine' 0 N--CA 1.415 -2.223 0 C-N-CA 118.441 -1.304 . . . . 0.0 111.04 -178.387 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 2.1 p -134.26 96.37 3.59 Favored 'General case' 0 N--CA 1.432 -1.346 0 CA-C-O 121.542 0.687 . . . . 0.0 112.224 -175.666 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -92.68 156.23 17.2 Favored 'General case' 0 N--CA 1.424 -1.766 0 C-N-CA 126.847 2.059 . . . . 0.0 108.973 177.157 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.581 ' H ' ' HA3' ' A' ' 93' ' ' GLY . 15.3 t70 -137.11 -167.93 2.19 Favored 'General case' 0 C--N 1.27 -2.856 0 N-CA-C 106.676 -1.602 . . . . 0.0 106.676 176.101 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 39.7 ttpt -43.14 -38.66 2.52 Favored 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 126.123 1.769 . . . . 0.0 114.399 -177.588 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -134.94 4.96 3.3 Favored 'General case' 0 C--N 1.281 -2.409 0 N-CA-C 105.798 -1.927 . . . . 0.0 105.798 177.692 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.643 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . -63.08 170.45 14.53 Favored Glycine 0 CA--C 1.474 -2.514 0 CA-C-N 112.429 -2.169 . . . . 0.0 112.999 -170.814 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.506 HG12 ' HB3' ' A' ' 36' ' ' LYS . 16.1 m -134.83 131.94 53.59 Favored 'Isoleucine or valine' 0 N--CA 1.391 -3.407 0 N-CA-C 107.874 -1.158 . . . . 0.0 107.874 -165.602 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.907 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.11 89.68 5.25 Favored 'General case' 2 C--N 1.239 -4.237 0 N-CA-C 104.667 -2.346 . . . . 0.0 104.667 175.305 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . 0.48 ' OD2' ' HB3' ' A' ' 34' ' ' SER . 12.1 t70 -121.42 89.12 3.06 Favored 'General case' 0 CA--C 1.477 -1.848 0 N-CA-C 106.187 -1.783 . . . . 0.0 106.187 -178.521 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 58.9 t -127.81 144.2 38.34 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.738 0 CA-C-N 114.994 -1.003 . . . . 0.0 108.886 -177.659 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 3.7 p -105.27 102.32 11.81 Favored 'General case' 0 C--N 1.266 -3.055 0 N-CA-C 107.459 -1.312 . . . . 0.0 107.459 -179.47 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.597 ' H ' HD13 ' A' ' 99' ' ' ILE . 0.2 OUTLIER -106.48 147.39 11.95 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.476 0 CA-C-N 114.914 -1.039 . . . . 0.0 110.613 -173.506 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.408 ' HB3' ' HG3' ' A' ' 30' ' ' LYS . 14.5 pt-20 -149.19 117.48 6.45 Favored 'General case' 0 C--N 1.283 -2.318 0 N-CA-C 107.524 -1.287 . . . . 0.0 107.524 179.457 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.585 ' N ' ' HB3' ' A' ' 28' ' ' PRO . 20.4 t70 -165.3 159.26 17.08 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 107.791 -1.188 . . . . 0.0 107.791 177.601 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 50.4 m -99.92 76.85 1.98 Allowed 'General case' 0 N--CA 1.425 -1.719 0 CA-C-O 123.576 1.655 . . . . 0.0 107.568 179.657 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.576 HG11 ' H ' ' A' ' 84' ' ' LEU . 6.5 p -120.52 -16.49 6.74 Favored 'Isoleucine or valine' 0 C--N 1.269 -2.923 0 CA-C-N 111.361 -2.654 . . . . 0.0 107.403 176.732 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.543 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 9.2 mm -81.73 2.94 2.59 Favored 'Isoleucine or valine' 0 N--CA 1.436 -1.142 0 CA-C-N 113.301 -1.772 . . . . 0.0 107.313 -176.249 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.511 ' HA ' ' HG2' ' A' ' 22' ' ' GLN . 20.2 m -65.53 109.22 2.27 Favored 'General case' 0 C--O 1.263 1.816 0 N-CA-C 108.118 -1.068 . . . . 0.0 108.118 179.689 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.408 HD13 HD12 ' A' ' 112' ' ' ILE . 44.4 tp -68.91 88.9 0.4 Allowed 'General case' 0 N--CA 1.396 -3.16 0 CA-C-N 112.463 -2.153 . . . . 0.0 113.417 -175.173 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 8.3 t -138.11 85.01 2.07 Favored 'General case' 1 N--CA 1.35 -5.449 0 N-CA-C 100.61 -3.848 . . . . 0.0 100.61 157.372 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.522 ' HA2' ' ND2' ' A' ' 65' ' ' ASN . . . -121.47 -144.25 6.85 Favored Glycine 0 CA--C 1.471 -2.685 0 CA-C-N 112.822 -1.99 . . . . 0.0 109.048 -178.988 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 24.8 t70 -67.52 -74.14 0.12 Allowed 'General case' 0 C--N 1.303 -1.444 0 N-CA-C 108.832 -0.803 . . . . 0.0 108.832 174.62 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 49.6 m80 -125.16 -47.47 1.76 Allowed 'General case' 0 C--N 1.317 -0.841 0 N-CA-C 113.704 1.002 . . . . 0.0 113.704 175.189 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.578 ' O ' ' HG3' ' A' ' 115' ' ' ARG . 21.9 m -161.67 169.45 21.53 Favored 'General case' 0 C--N 1.315 -0.898 0 N-CA-C 107.898 -1.149 . . . . 0.0 107.898 -176.133 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.408 HD12 HD13 ' A' ' 106' ' ' LEU . 4.4 mp -82.25 -39.82 16.63 Favored 'Isoleucine or valine' 0 C--N 1.318 -0.791 0 N-CA-C 109.674 -0.491 . . . . 0.0 109.674 174.01 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.45 ' HA ' ' CA ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -73.83 125.74 33.44 Favored 'Isoleucine or valine' 0 CA--C 1.546 0.808 0 N-CA-C 112.831 0.678 . . . . 0.0 112.831 -173.549 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 102.34 -3.97 51.1 Favored Glycine 0 CA--C 1.478 -2.266 0 N-CA-C 109.451 -1.46 . . . . 0.0 109.451 171.766 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.613 ' HA ' ' HA2' ' A' ' 51' ' ' GLY . 9.3 mmt180 -101.9 159.21 15.54 Favored 'General case' 0 N--CA 1.396 -3.15 0 CA-C-N 113.153 -1.523 . . . . 0.0 107.386 -174.426 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.596 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 16.7 p -99.58 135.58 40.78 Favored 'General case' 0 C--N 1.282 -2.331 0 N-CA-C 113.724 1.009 . . . . 0.0 113.724 -176.943 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.509 ' O ' ' HA ' ' A' ' 146' ' ' CYS . 2.7 pt? -88.9 130.11 35.48 Favored 'General case' 0 C--N 1.317 -0.842 0 N-CA-C 108.807 -0.812 . . . . 0.0 108.807 174.227 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.642 HG22 ' SG ' ' A' ' 57' ' ' CYS . 14.3 t -101.43 101.79 12.6 Favored 'Isoleucine or valine' 0 C--O 1.262 1.752 0 N-CA-C 109.778 -0.453 . . . . 0.0 109.778 -179.43 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.61 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 27.0 m -136.96 169.59 19.56 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.881 0 C-N-CA 123.744 0.818 . . . . 0.0 108.816 -177.367 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.454 ' O ' HD13 ' A' ' 42' ' ' LEU . 49.0 t-80 -171.65 170.13 5.76 Favored 'General case' 0 C--N 1.305 -1.363 0 N-CA-C 104.27 -2.493 . . . . 0.0 104.27 171.861 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.525 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.8 OUTLIER -77.59 84.06 3.97 Favored 'General case' 0 C--N 1.296 -1.738 0 N-CA-C 104.78 -2.304 . . . . 0.0 104.78 170.743 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.586 ' H ' ' HB3' ' A' ' 42' ' ' LEU . 58.3 mmtt -173.58 127.98 0.42 Allowed 'General case' 0 CA--C 1.464 -2.363 0 N-CA-C 106.514 -1.661 . . . . 0.0 106.514 -174.61 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.443 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -44.89 103.32 0.03 OUTLIER 'General case' 0 C--N 1.317 -0.84 0 O-C-N 123.863 0.727 . . . . 0.0 109.743 168.172 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 4.4 t70 -104.22 85.66 2.41 Favored 'General case' 0 CA--C 1.458 -2.585 0 N-CA-C 107.047 -1.464 . . . . 0.0 107.047 -177.737 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.459 ' HB3' ' HB3' ' A' ' 128' ' ' LYS . 8.1 t70 -121.25 133.66 55.16 Favored 'General case' 0 C--N 1.255 -3.512 0 CA-C-N 113.729 -1.578 . . . . 0.0 108.869 -172.135 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.427 HD23 ' HB3' ' A' ' 46' ' ' HIS . 2.4 mm? -89.58 -13.3 37.54 Favored 'General case' 0 C--N 1.293 -1.873 0 CA-C-N 115.658 -0.701 . . . . 0.0 111.668 -178.474 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -96.96 -34.6 5.63 Favored Glycine 0 N--CA 1.425 -2.047 0 N-CA-C 109.549 -1.42 . . . . 0.0 109.549 179.27 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.459 ' HB3' ' HB3' ' A' ' 125' ' ' ASP . 65.4 tttm -86.33 -49.05 7.95 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 118.894 -0.575 . . . . 0.0 110.813 178.517 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.59 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 47.91 -77.86 0.0 OUTLIER Glycine 0 CA--C 1.529 0.923 0 N-CA-C 114.439 0.536 . . . . 0.0 114.439 -170.536 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 171.63 -97.44 0.12 Allowed Glycine 0 N--CA 1.443 -0.893 0 N-CA-C 108.969 -1.653 . . . . 0.0 108.969 -177.078 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -88.94 179.98 6.07 Favored 'General case' 0 CA--C 1.56 1.337 0 N-CA-C 107.946 -1.131 . . . . 0.0 107.946 176.564 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.9 mp0 -56.16 -32.3 64.17 Favored 'General case' 0 N--CA 1.493 1.693 0 CA-C-N 119.347 0.976 . . . . 0.0 113.229 -178.491 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 14.2 mp0 -75.74 -46.38 31.25 Favored 'General case' 0 C--N 1.302 -1.492 0 CA-C-O 121.676 0.751 . . . . 0.0 109.747 176.25 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.42 ' HA ' HG22 ' A' ' 137' ' ' THR . 1.3 m -60.97 -33.93 73.98 Favored 'General case' 0 C--N 1.305 -1.361 0 CA-C-N 114.803 -1.09 . . . . 0.0 112.352 -175.05 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.59 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 9.9 t -67.97 -35.71 78.81 Favored 'General case' 0 C--O 1.22 -0.488 0 CA-C-O 120.939 0.4 . . . . 0.0 111.568 178.708 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -82.25 -29.12 31.46 Favored 'General case' 0 C--N 1.295 -1.773 0 C-N-CA 119.468 -0.893 . . . . 0.0 111.172 -176.104 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.42 HG22 ' HA ' ' A' ' 134' ' ' SER . 8.8 t -86.94 -14.93 40.4 Favored 'General case' 0 N--CA 1.438 -1.046 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.678 177.705 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.74 60.6 6.75 Favored Glycine 0 CA--C 1.5 -0.876 0 N-CA-C 110.334 -1.106 . . . . 0.0 110.334 -175.922 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 8.4 t30 -51.89 105.23 0.1 Allowed 'General case' 0 N--CA 1.471 0.617 0 N-CA-C 113.723 1.009 . . . . 0.0 113.723 -175.014 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -152.11 171.64 17.58 Favored 'General case' 0 N--CA 1.422 -1.848 0 N-CA-C 105.924 -1.88 . . . . 0.0 105.924 173.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -67.9 87.45 0.18 Allowed Glycine 0 C--N 1.314 -0.665 0 N-CA-C 110.892 -0.883 . . . . 0.0 110.892 173.656 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 16.2 m -66.1 -10.09 37.38 Favored 'General case' 0 C--O 1.21 -1.003 0 C-N-CA 124.731 1.213 . . . . 0.0 113.624 -175.433 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 43.1 mtp-105 -116.34 -37.4 3.77 Favored 'General case' 0 C--N 1.254 -3.554 0 C-N-CA 117.819 -1.552 . . . . 0.0 109.725 172.529 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.422 ' O ' ' HA3' ' A' ' 10' ' ' GLY . 3.8 mm? -49.0 -38.19 22.57 Favored 'General case' 0 CA--C 1.503 -0.859 0 N-CA-C 115.481 1.66 . . . . 0.0 115.481 -167.097 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.61 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -143.89 92.45 2.34 Favored 'General case' 0 N--CA 1.42 -1.947 0 CA-C-O 121.622 0.725 . . . . 0.0 111.253 -179.566 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.509 ' HA ' ' O ' ' A' ' 117' ' ' LEU . 3.9 m -140.13 153.2 46.61 Favored 'General case' 0 N--CA 1.419 -1.979 0 N-CA-C 107.251 -1.389 . . . . 0.0 107.251 175.487 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.596 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.75 168.95 42.01 Favored Glycine 0 N--CA 1.406 -3.311 0 N-CA-C 107.0 -2.44 . . . . 0.0 107.0 176.482 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.481 HG22 HG23 ' A' ' 54' ' ' THR . 31.4 m -70.44 122.04 21.42 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.041 0 CA-C-O 122.443 1.116 . . . . 0.0 112.385 177.797 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.402 ' HB ' HD22 ' A' ' 117' ' ' LEU . 9.0 tt -99.25 142.68 14.6 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.756 0 N-CA-C 103.704 -2.702 . . . . 0.0 103.704 175.223 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.45 ' CA ' ' HA ' ' A' ' 113' ' ' ILE . . . 177.06 154.46 12.04 Favored Glycine 2 N--CA 1.387 -4.57 0 C-N-CA 117.316 -2.373 . . . . 0.0 112.957 177.246 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 3.8 tt -66.64 105.0 0.65 Allowed 'Isoleucine or valine' 0 C--N 1.295 -1.764 0 O-C-N 124.483 0.755 . . . . 0.0 109.422 172.324 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.571 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -114.21 98.3 6.86 Favored 'General case' 0 N--CA 1.414 -2.238 0 N-CA-C 106.054 -1.832 . . . . 0.0 106.054 172.911 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 29.8 tt0 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 117.898 -1.049 . . . . 0.0 109.087 -174.258 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.443 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.221 -0.432 0 N-CA-C 111.42 0.156 . . . . 0.0 111.42 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.575 ' HA ' ' HG3' ' A' ' 21' ' ' GLU . 9.2 p -82.35 -35.53 27.74 Favored 'General case' 0 C--O 1.221 -0.435 0 CA-C-O 121.876 0.846 . . . . 0.0 112.463 -177.337 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.599 ' O ' HG12 ' A' ' 151' ' ' ILE . 56.9 mtmt -138.09 135.81 36.17 Favored 'General case' 0 C--N 1.277 -2.545 0 N-CA-C 108.053 -1.091 . . . . 0.0 108.053 -179.367 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.616 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -134.05 166.74 22.03 Favored 'General case' 0 C--N 1.27 -2.872 0 N-CA-C 107.106 -1.442 . . . . 0.0 107.106 -176.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 12.3 p -145.99 118.93 2.28 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.522 0 C-N-CA 119.307 -0.957 . . . . 0.0 110.315 -179.362 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.455 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -108.65 127.16 53.73 Favored 'General case' 0 C--N 1.299 -1.613 0 N-CA-C 108.467 -0.938 . . . . 0.0 108.467 177.328 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 3.4 p -119.45 129.24 75.55 Favored 'Isoleucine or valine' 0 C--N 1.312 -1.026 0 O-C-N 123.786 0.679 . . . . 0.0 110.217 -178.288 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.405 HD13 ' HB1' ' A' ' 145' ' ' ALA . 75.4 mt -107.18 141.67 38.1 Favored 'General case' 0 C--N 1.308 -1.218 0 CA-C-N 115.936 -0.575 . . . . 0.0 110.118 -177.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 53.4 mtmt -150.79 137.83 19.21 Favored 'General case' 0 CA--C 1.492 -1.277 0 N-CA-C 105.356 -2.09 . . . . 0.0 105.356 174.509 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.39 -159.32 9.25 Favored Glycine 0 N--CA 1.417 -2.625 0 C-N-CA 117.571 -2.252 . . . . 0.0 115.622 -178.328 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 35.9 t70 -78.06 -31.14 50.1 Favored 'General case' 0 C--N 1.311 -1.07 0 CA-C-N 111.91 -2.145 . . . . 0.0 109.371 178.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.46 172.49 14.45 Favored Glycine 0 C--N 1.309 -0.92 0 N-CA-C 106.089 -2.805 . . . . 0.0 106.089 172.523 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 69.0 Cg_endo -88.39 121.87 1.41 Allowed 'Trans proline' 0 N--CA 1.424 -2.615 0 CA-C-N 121.919 2.859 . . . . 0.0 112.135 -176.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 m -135.14 118.23 23.58 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.429 0 CA-C-N 113.368 -1.742 . . . . 0.0 106.548 171.374 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.495 ' O ' ' HG2' ' A' ' 36' ' ' LYS . 0.0 OUTLIER -143.35 119.5 10.78 Favored 'General case' 0 C--N 1.279 -2.468 0 C-N-CA 118.128 -1.429 . . . . 0.0 109.929 178.442 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.547 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -171.2 170.87 43.62 Favored Glycine 0 N--CA 1.418 -2.552 0 N-CA-C 110.12 -1.192 . . . . 0.0 110.12 178.592 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.455 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 20.0 pt -135.85 119.52 24.3 Favored 'Isoleucine or valine' 0 N--CA 1.442 -0.871 0 N-CA-C 107.873 -1.158 . . . . 0.0 107.873 179.383 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.479 HG12 ' HA3' ' A' ' 33' ' ' GLY . 21.9 mt -114.37 135.16 55.04 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.292 0 N-CA-C 109.424 -0.584 . . . . 0.0 109.424 -176.758 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.616 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -101.58 138.68 38.25 Favored 'General case' 0 CA--C 1.5 -0.955 0 N-CA-C 109.956 -0.387 . . . . 0.0 109.956 -179.235 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.551 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 95.2 m-85 -132.2 120.16 21.84 Favored 'General case' 0 N--CA 1.449 -0.513 0 O-C-N 123.304 0.377 . . . . 0.0 111.066 -178.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.575 ' HG3' ' HA ' ' A' ' 2' ' ' THR . 35.8 tt0 -112.17 108.24 17.42 Favored 'General case' 0 C--N 1.313 -1.012 0 CA-C-N 116.256 -0.429 . . . . 0.0 110.785 172.955 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.538 ' HB2' ' HB ' ' A' ' 104' ' ' ILE . 8.8 tp60 -140.71 114.8 9.15 Favored 'General case' 0 N--CA 1.405 -2.69 0 N-CA-C 108.247 -1.019 . . . . 0.0 108.247 172.481 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 85.3 tttt -90.63 157.37 17.52 Favored 'General case' 0 C--N 1.288 -2.072 0 N-CA-C 106.748 -1.575 . . . . 0.0 106.748 178.087 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 38.1 tt0 -60.95 -23.69 65.5 Favored 'General case' 0 N--CA 1.473 0.679 0 CA-C-O 121.153 0.502 . . . . 0.0 110.967 -178.866 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 14.8 m -63.25 -18.4 63.52 Favored 'General case' 0 CA--C 1.548 0.879 0 CA-C-N 115.944 -0.571 . . . . 0.0 110.996 176.739 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 65.1 t30 66.96 105.98 0.04 OUTLIER 'General case' 0 C--N 1.353 0.744 0 C-N-CA 125.426 1.491 . . . . 0.0 109.204 -179.957 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.513 ' H ' ' NE2' ' A' ' 22' ' ' GLN . . . -146.55 -170.64 15.19 Favored Glycine 0 CA--C 1.469 -2.804 0 C-N-CA 118.415 -1.85 . . . . 0.0 115.242 -168.693 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 78.5 Cg_exo -53.65 124.12 15.03 Favored 'Trans proline' 0 N--CA 1.448 -1.171 0 C-N-CA 123.56 2.84 . . . . 0.0 110.562 178.343 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.453 ' O ' ' HG2' ' A' ' 100' ' ' GLU . 47.1 t -93.44 110.99 24.1 Favored 'Isoleucine or valine' 0 N--CA 1.399 -2.988 0 CA-C-N 115.095 -0.957 . . . . 0.0 111.286 -175.254 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 0.2 OUTLIER -105.42 111.24 23.89 Favored 'General case' 0 N--CA 1.422 -1.87 0 N-CA-C 107.444 -1.317 . . . . 0.0 107.444 175.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.476 HG22 ' HA ' ' A' ' 20' ' ' PHE . 17.2 t -138.47 132.26 41.15 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.027 0 CA-C-N 114.889 -1.05 . . . . 0.0 110.175 -170.033 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.447 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 77.8 t90 -149.25 127.64 12.22 Favored 'General case' 0 N--CA 1.426 -1.674 0 N-CA-C 109.38 -0.6 . . . . 0.0 109.38 178.022 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.479 ' HA3' HG12 ' A' ' 18' ' ' ILE . . . -159.34 140.03 6.58 Favored Glycine 0 N--CA 1.421 -2.327 0 C-N-CA 120.417 -0.896 . . . . 0.0 110.915 173.796 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.462 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 49.4 m -117.4 115.4 25.14 Favored 'General case' 0 C--N 1.298 -1.635 0 CA-C-O 118.992 -0.528 . . . . 0.0 111.288 179.31 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.547 HG22 ' HA3' ' A' ' 16' ' ' GLY . 30.8 pt -109.79 138.71 36.16 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.635 0 CA-C-N 118.612 0.642 . . . . 0.0 111.104 176.355 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.759 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 16.5 ptpt -103.65 132.7 49.67 Favored 'General case' 0 C--N 1.308 -1.207 0 N-CA-C 107.266 -1.383 . . . . 0.0 107.266 177.327 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.488 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -148.98 178.78 26.3 Favored Glycine 1 N--CA 1.391 -4.359 0 N-CA-C 110.907 -0.877 . . . . 0.0 110.907 -167.758 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.473 ' HG ' ' H ' ' A' ' 39' ' ' THR . 45.3 tp -65.27 176.46 1.35 Allowed 'General case' 0 C--N 1.283 -2.297 0 N-CA-C 104.921 -2.251 . . . . 0.0 104.921 171.59 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.473 ' H ' ' HG ' ' A' ' 38' ' ' LEU . 15.0 t -61.99 153.72 28.64 Favored 'General case' 0 C--N 1.301 -1.527 0 O-C-N 120.351 -1.468 . . . . 0.0 111.215 -166.115 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.712 ' HB3' ' C ' ' A' ' 90' ' ' ASP . 11.1 pt-20 -60.67 160.32 9.43 Favored 'General case' 0 CA--C 1.476 -1.891 0 N-CA-C 117.359 2.355 . . . . 0.0 117.359 -163.026 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -159.29 -157.57 8.62 Favored Glycine 1 C--N 1.245 -4.487 1 N-CA-C 102.442 -4.263 . . . . 0.0 102.442 -176.906 . . . . . . . . 3 2 . 1 . 010 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 88.4 mt -153.72 -86.63 0.06 Allowed 'General case' 0 C--N 1.274 -2.717 0 CA-C-N 120.357 2.078 . . . . 0.0 114.74 -169.661 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.626 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.5 t-160 -76.93 122.23 24.57 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 114.547 1.314 . . . . 0.0 114.547 -156.416 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -105.78 127.01 8.8 Favored Glycine 0 N--CA 1.415 -2.75 0 C-N-CA 119.876 -1.154 . . . . 0.0 114.85 -173.392 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.542 ' H ' ' HB2' ' A' ' 124' ' ' ASP . 14.9 t80 -113.31 113.03 24.7 Favored 'General case' 1 C--O 1.336 5.61 0 CA-C-O 123.41 1.576 . . . . 0.0 111.028 175.463 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.542 ' HB3' ' O ' ' A' ' 83' ' ' ASP . 25.4 m80 -108.18 124.96 51.07 Favored 'General case' 0 N--CA 1.391 -3.38 0 CA-C-N 113.624 -1.626 . . . . 0.0 110.42 -173.708 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.56 ' HA ' ' HA3' ' A' ' 82' ' ' GLY . 9.4 p -174.65 87.35 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.278 -2.506 0 CA-C-N 113.55 -1.659 . . . . 0.0 109.762 177.909 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.423 ' C ' ' HD2' ' A' ' 115' ' ' ARG . 7.0 m170 -112.49 170.74 7.96 Favored 'General case' 0 C--N 1.281 -2.387 0 N-CA-C 114.608 1.336 . . . . 0.0 114.608 167.125 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.588 ' HG3' ' OD1' ' A' ' 109' ' ' ASP . 36.4 tt0 -139.64 132.56 29.33 Favored 'General case' 0 C--N 1.31 -1.126 0 CA-C-N 113.997 -1.456 . . . . 0.0 111.191 179.348 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 47.8 t80 76.45 26.84 0.86 Allowed 'General case' 0 C--O 1.222 -0.359 0 C-N-CA 127.349 2.26 . . . . 0.0 111.127 174.966 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.727 ' H ' ' HD3' ' A' ' 115' ' ' ARG . . . 33.67 -124.64 0.4 Allowed Glycine 0 C--N 1.36 1.916 0 CA-C-N 115.599 -0.728 . . . . 0.0 114.637 -172.542 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 10.2 t70 169.51 -80.71 0.0 OUTLIER 'General case' 0 N--CA 1.498 1.951 0 C-N-CA 125.398 1.479 . . . . 0.0 108.48 164.122 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 8.5 p30 -161.05 160.9 31.07 Favored 'General case' 0 N--CA 1.429 -1.509 0 N-CA-C 104.975 -2.231 . . . . 0.0 104.975 174.164 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.48 ' HB ' HG12 ' A' ' 148' ' ' VAL . 5.3 t -79.26 5.18 12.95 Favored 'General case' 0 C--N 1.284 -2.258 0 N-CA-C 114.004 1.113 . . . . 0.0 114.004 -171.677 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -122.15 2.26 9.8 Favored 'General case' 0 C--N 1.304 -1.411 0 C-N-CA 120.202 -0.599 . . . . 0.0 111.249 179.762 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 176.55 127.53 1.05 Allowed Glycine 0 C--O 1.195 -2.324 0 C-N-CA 118.582 -1.77 . . . . 0.0 111.558 179.508 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.812 ' SG ' HG21 ' A' ' 118' ' ' VAL . 16.7 p -99.72 89.23 4.04 Favored 'General case' 0 C--N 1.275 -2.633 0 O-C-N 121.869 -0.783 . . . . 0.0 112.131 177.395 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 28.5 m -78.85 -53.14 7.4 Favored 'General case' 0 N--CA 1.427 -1.578 0 N-CA-C 109.253 -0.647 . . . . 0.0 109.253 178.668 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.8 m -70.01 -52.99 19.67 Favored 'General case' 0 N--CA 1.442 -0.837 0 CA-C-N 114.764 -1.107 . . . . 0.0 111.498 -174.054 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.418 ' HB2' ' O ' ' A' ' 49' ' ' GLU . . . -76.63 -9.45 58.67 Favored 'General case' 0 C--O 1.202 -1.442 0 CA-C-O 118.418 -0.801 . . . . 0.0 112.975 176.877 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -36.08 -68.14 0.32 Allowed Glycine 0 N--CA 1.488 2.103 0 N-CA-C 114.864 0.705 . . . . 0.0 114.864 -173.624 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 47.4 Cg_endo -94.09 7.59 2.42 Favored 'Trans proline' 0 CA--C 1.541 0.856 0 C-N-CA 123.328 2.686 . . . . 0.0 112.149 177.068 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 77.1 t60 -113.52 123.46 50.06 Favored 'General case' 0 N--CA 1.432 -1.36 0 N-CA-C 114.149 1.166 . . . . 0.0 114.149 -171.634 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.444 ' CD1' ' HA ' ' A' ' 137' ' ' THR . 27.1 p90 -97.75 170.55 8.91 Favored 'General case' 0 C--N 1.3 -1.567 0 C-N-CA 126.722 2.009 . . . . 0.0 108.785 179.746 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 1.5 p-10 -96.83 142.68 24.89 Favored Pre-proline 0 CA--C 1.545 0.762 0 N-CA-C 106.773 -1.566 . . . . 0.0 106.773 171.299 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 31.5 Cg_exo -59.82 -53.98 2.77 Favored 'Trans proline' 0 N--CA 1.481 0.767 0 C-N-CA 123.204 2.603 . . . . 0.0 116.652 -168.19 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.828 ' O ' ' HA ' ' A' ' 78' ' ' GLU . 95.9 mt -93.0 25.97 3.0 Favored 'General case' 0 C--O 1.193 -1.913 0 O-C-N 121.786 -0.571 . . . . 0.0 111.818 -168.586 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.63 ' O ' ' HA ' ' A' ' 80' ' ' HIS . 28.6 m -144.74 30.36 1.2 Allowed 'General case' 0 C--N 1.295 -1.799 0 N-CA-C 108.867 -0.79 . . . . 0.0 108.867 178.039 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.509 ' HD2' ' O ' ' A' ' 69' ' ' ARG . 4.1 tmm_? -126.08 -27.32 3.28 Favored 'General case' 0 N--CA 1.411 -2.391 0 CA-C-O 117.639 -1.172 . . . . 0.0 110.638 -176.56 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . 0.256 1.2 mptm? -45.32 60.34 0.0 OUTLIER 'General case' 0 N--CA 1.499 1.997 0 N-CA-C 119.778 3.251 . . . . 0.0 119.778 -165.097 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.44 ' CD2' ' HA2' ' A' ' 127' ' ' GLY . 26.6 t-80 46.43 58.65 4.4 Favored 'General case' 0 CA--C 1.567 1.598 0 N-CA-C 117.292 2.33 . . . . 0.0 117.292 165.608 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 132.62 88.44 0.38 Allowed Glycine 0 CA--C 1.495 -1.186 0 C-N-CA 116.762 -2.637 . . . . 0.0 115.57 163.096 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.439 ' H ' ' CD2' ' A' ' 80' ' ' HIS . . . -170.13 95.38 0.11 Allowed Glycine 0 C--O 1.211 -1.334 0 C-N-CA 119.089 -1.529 . . . . 0.0 112.81 -178.995 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 30.0 Cg_endo -64.91 -40.23 21.96 Favored 'Trans proline' 0 CA--C 1.544 1.003 0 CA-C-N 120.647 2.224 . . . . 0.0 113.583 -175.082 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 0.0 OUTLIER -110.07 16.49 21.81 Favored 'General case' 0 C--N 1.313 -1.019 0 C-N-CA 125.139 1.376 . . . . 0.0 110.153 -178.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.9 t70 -89.79 -172.02 3.39 Favored 'General case' 0 C--N 1.287 -2.126 0 CA-C-N 115.358 -0.837 . . . . 0.0 110.747 -167.174 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.476 ' HA ' ' CG1' ' A' ' 81' ' ' VAL . 0.1 OUTLIER -142.46 -3.45 1.04 Allowed 'General case' 0 N--CA 1.434 -1.268 0 O-C-N 122.22 -0.3 . . . . 0.0 111.072 -178.486 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.828 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 33.1 tt0 -132.19 -34.79 1.23 Allowed 'General case' 0 N--CA 1.433 -1.315 0 CA-C-O 121.222 0.535 . . . . 0.0 110.276 -170.076 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.475 ' O ' ' HB3' ' A' ' 80' ' ' HIS . 4.5 mpt_? -93.76 -15.87 24.74 Favored 'General case' 0 CA--C 1.484 -1.571 0 C-N-CA 125.603 1.561 . . . . 0.0 107.111 -175.812 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.63 ' HA ' ' O ' ' A' ' 68' ' ' SER 0.258 5.0 p80 164.44 142.72 0.01 OUTLIER 'General case' 0 CA--C 1.459 -2.538 0 CA-C-N 113.185 -1.825 . . . . 0.0 110.332 159.498 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.673 ' O ' ' HB2' ' A' ' 84' ' ' LEU . 9.5 p -159.79 -61.0 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.251 -3.71 0 N-CA-C 105.661 -1.977 . . . . 0.0 105.661 168.436 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.56 ' HA3' ' HA ' ' A' ' 47' ' ' VAL . . . 47.97 -136.62 14.72 Favored Glycine 0 C--O 1.239 0.45 0 N-CA-C 110.133 -1.187 . . . . 0.0 110.133 -175.502 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.653 ' OD2' ' HA ' ' A' ' 117' ' ' LEU . 1.9 p-10 -93.68 81.21 4.27 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 107.578 -1.267 . . . . 0.0 107.578 169.998 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.673 ' HB2' ' O ' ' A' ' 81' ' ' VAL . 0.7 OUTLIER -88.96 138.87 31.01 Favored 'General case' 0 C--N 1.293 -1.857 0 N-CA-C 115.754 1.761 . . . . 0.0 115.754 -168.148 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.558 ' N ' HD13 ' A' ' 84' ' ' LEU . . . -169.36 156.38 27.42 Favored Glycine 0 N--CA 1.425 -2.048 0 N-CA-C 104.483 -3.447 . . . . 0.0 104.483 175.048 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 64.5 t30 -112.61 153.0 28.26 Favored 'General case' 0 C--N 1.3 -1.545 0 CA-C-N 120.158 1.979 . . . . 0.0 109.869 -179.342 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 71.9 t -117.86 143.01 29.64 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.532 0 N-CA-C 108.906 -0.776 . . . . 0.0 108.906 -177.623 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.626 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 62.2 m -146.13 95.74 2.67 Favored 'General case' 0 N--CA 1.433 -1.305 0 N-CA-C 106.846 -1.539 . . . . 0.0 106.846 178.2 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.454 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -93.28 144.98 24.79 Favored 'General case' 0 CA--C 1.482 -1.666 0 CA-C-N 119.49 1.041 . . . . 0.0 113.097 -176.33 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.712 ' C ' ' HB3' ' A' ' 40' ' ' GLU . 22.1 t70 -82.58 149.6 27.37 Favored 'General case' 0 C--N 1.278 -2.516 0 CA-C-N 113.223 -1.808 . . . . 0.0 106.83 169.134 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.537 ' N ' ' HB3' ' A' ' 40' ' ' GLU . 13.6 pttp -41.28 -19.39 0.01 OUTLIER 'General case' 0 N--CA 1.503 2.177 0 C-N-CA 127.69 2.396 . . . . 0.0 116.037 176.572 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 29.7 m-20 -106.81 12.76 28.66 Favored 'General case' 0 C--N 1.288 -2.107 0 N-CA-C 109.201 -0.666 . . . . 0.0 109.201 -179.332 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.759 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 73.1 85.18 0.23 Allowed Glycine 0 N--CA 1.42 -2.397 0 CA-C-N 114.629 -1.169 . . . . 0.0 111.06 -179.601 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.454 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 61.3 t -157.07 103.51 0.1 OUTLIER 'Isoleucine or valine' 0 CA--C 1.487 -1.445 0 N-CA-C 105.709 -1.959 . . . . 0.0 105.709 -178.752 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -104.17 113.38 26.89 Favored 'General case' 0 C--N 1.273 -2.735 0 C-N-CA 120.306 -0.558 . . . . 0.0 109.525 175.811 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 30.8 t70 -86.01 94.33 9.19 Favored 'General case' 0 C--N 1.301 -1.522 0 N-CA-C 105.351 -2.092 . . . . 0.0 105.351 175.147 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.447 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 86.1 t -85.63 105.71 14.61 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.564 0 CA-C-N 115.244 -0.889 . . . . 0.0 110.486 -175.514 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 55.2 m -152.54 116.05 4.75 Favored 'General case' 0 N--CA 1.43 -1.429 0 N-CA-C 108.376 -0.972 . . . . 0.0 108.376 175.209 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 9.4 tp -148.31 134.35 12.08 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.096 0 N-CA-C 106.299 -1.741 . . . . 0.0 106.299 -179.918 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.453 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 37.8 mt-10 -124.03 96.63 5.01 Favored 'General case' 0 N--CA 1.441 -0.908 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.433 -175.253 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.401 ' O ' HG21 ' A' ' 29' ' ' VAL . 6.2 p-10 -168.81 166.71 11.4 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 105.71 -1.959 . . . . 0.0 105.71 170.902 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 24.5 p -60.89 91.5 0.02 OUTLIER 'General case' 0 C--O 1.245 0.851 0 CA-C-N 119.128 0.876 . . . . 0.0 113.058 -176.467 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.476 ' HB ' ' HB3' ' A' ' 84' ' ' LEU . 27.1 m -118.39 -14.41 9.47 Favored 'Isoleucine or valine' 0 CA--C 1.548 0.873 0 N-CA-C 113.844 1.053 . . . . 0.0 113.844 -176.67 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.538 ' HB ' ' HB2' ' A' ' 22' ' ' GLN . 0.7 OUTLIER -119.24 25.92 4.1 Favored 'Isoleucine or valine' 0 C--N 1.322 -0.616 0 O-C-N 120.7 -1.25 . . . . 0.0 109.476 -176.552 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 6.0 m -64.38 110.95 2.43 Favored 'General case' 0 C--O 1.268 2.059 0 CA-C-O 122.729 1.252 . . . . 0.0 109.831 -178.511 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -72.44 86.37 1.15 Allowed 'General case' 0 N--CA 1.382 -3.87 0 CA-C-O 124.103 1.906 . . . . 0.0 110.63 176.717 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 38.0 m -146.56 85.75 1.65 Allowed 'General case' 2 N--CA 1.362 -4.855 0 N-CA-C 101.88 -3.378 . . . . 0.0 101.88 168.665 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 160.13 168.96 22.8 Favored Glycine 0 C--N 1.269 -3.142 0 CA-C-N 113.373 -1.74 . . . . 0.0 111.014 176.133 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.588 ' OD1' ' HG3' ' A' ' 49' ' ' GLU . 7.0 t70 -56.92 -34.89 68.41 Favored 'General case' 0 C--O 1.202 -1.43 0 CA-C-N 117.292 0.546 . . . . 0.0 110.916 179.515 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.739 ' HA ' ' NE ' ' A' ' 115' ' ' ARG . 7.9 p-80 -54.28 -17.01 2.49 Favored 'General case' 0 N--CA 1.483 1.187 0 C-N-CA 125.385 1.474 . . . . 0.0 113.023 -178.002 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.449 ' O ' ' HD2' ' A' ' 110' ' ' HIS . 23.0 t 37.47 -154.49 0.01 OUTLIER 'General case' 0 C--N 1.298 -1.638 0 C-N-CA 126.164 1.786 . . . . 0.0 110.297 -173.025 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.608 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 14.2 tt -100.32 -32.97 3.63 Favored 'Isoleucine or valine' 0 C--N 1.27 -2.876 0 N-CA-C 106.907 -1.516 . . . . 0.0 106.907 166.133 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 23.8 pt -104.02 145.93 12.2 Favored 'Isoleucine or valine' 0 N--CA 1.47 0.55 0 N-CA-C 113.862 1.06 . . . . 0.0 113.862 -178.773 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.71 ' O ' ' HA3' ' A' ' 51' ' ' GLY . . . 95.83 -7.04 67.52 Favored Glycine 1 CA--C 1.45 -4.008 0 C-N-CA 121.234 -0.508 . . . . 0.0 112.272 162.211 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.739 ' NE ' ' HA ' ' A' ' 110' ' ' HIS . 0.3 OUTLIER -92.61 151.44 20.12 Favored 'General case' 0 C--O 1.162 -3.54 0 C-N-CA 120.913 -0.315 . . . . 0.0 110.688 -174.146 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.555 ' H ' ' HA2' ' A' ' 51' ' ' GLY . 7.6 p -91.86 113.09 25.27 Favored 'General case' 0 N--CA 1.408 -2.531 0 O-C-N 121.537 -0.727 . . . . 0.0 109.397 173.57 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.653 ' HA ' ' OD2' ' A' ' 83' ' ' ASP . 22.5 tp -70.09 93.5 0.81 Allowed 'General case' 0 C--N 1.298 -1.64 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 -177.456 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.812 HG21 ' SG ' ' A' ' 57' ' ' CYS 0.528 60.2 t -105.1 109.22 27.0 Favored 'Isoleucine or valine' 1 C--O 1.341 5.884 0 N-CA-C 120.708 3.596 . . . . 0.0 120.708 -172.217 . . . . . . . . 4 3 . 1 . 010 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.674 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.3 p -148.47 171.25 2.43 Favored 'Isoleucine or valine' 0 C--O 1.207 -1.155 0 CA-C-N 110.397 -3.092 . . . . 0.0 106.469 -176.086 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 71.6 t60 -150.37 171.28 17.25 Favored 'General case' 0 C--N 1.298 -1.663 0 N-CA-C 104.88 -2.267 . . . . 0.0 104.88 168.198 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.526 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.0 OUTLIER -69.42 85.94 0.43 Allowed 'General case' 0 C--N 1.304 -1.38 0 N-CA-C 105.083 -2.191 . . . . 0.0 105.083 171.449 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 16.3 tppt? -173.01 171.78 4.11 Favored 'General case' 0 N--CA 1.434 -1.234 0 N-CA-C 104.995 -2.224 . . . . 0.0 104.995 -173.652 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.626 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -99.09 107.58 20.0 Favored 'General case' 0 C--N 1.292 -1.919 0 CA-C-N 118.299 0.499 . . . . 0.0 110.243 173.448 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.542 ' HB2' ' H ' ' A' ' 45' ' ' PHE . 1.1 m-20 -71.33 -59.16 2.92 Favored 'General case' 0 N--CA 1.478 0.959 0 N-CA-C 104.651 -2.352 . . . . 0.0 104.651 172.522 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.0 t70 67.76 141.34 0.03 OUTLIER 'General case' 0 N--CA 1.478 0.959 0 C-N-CA 128.024 2.529 . . . . 0.0 114.097 178.963 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.587 ' HG ' ' CD2' ' A' ' 80' ' ' HIS . 0.0 OUTLIER -90.26 -31.99 16.74 Favored 'General case' 0 N--CA 1.443 -0.779 0 CA-C-N 114.89 -1.05 . . . . 0.0 113.624 -176.563 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.44 ' HA2' ' CD2' ' A' ' 71' ' ' HIS . . . -97.01 -33.98 5.84 Favored Glycine 0 N--CA 1.427 -1.904 0 N-CA-C 109.834 -1.306 . . . . 0.0 109.834 178.851 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 56.7 mttp -105.13 50.32 0.79 Allowed 'General case' 0 C--N 1.3 -1.58 0 CA-C-N 114.178 -1.011 . . . . 0.0 108.873 -179.019 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -75.36 -6.83 81.51 Favored Glycine 0 N--CA 1.447 -0.612 0 N-CA-C 111.259 -0.737 . . . . 0.0 111.259 179.565 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 134.53 -93.17 0.25 Allowed Glycine 0 N--CA 1.426 -1.974 0 C-N-CA 121.653 -0.308 . . . . 0.0 112.406 176.165 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.557 ' H ' ' HB2' ' A' ' 134' ' ' SER . 79.3 m-20 -121.86 -173.39 2.64 Favored 'General case' 0 N--CA 1.489 1.492 0 N-CA-C 107.272 -1.381 . . . . 0.0 107.272 -174.045 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 42.1 tt0 -57.71 -39.32 76.96 Favored 'General case' 0 C--N 1.361 1.102 0 C-N-CA 118.65 -1.22 . . . . 0.0 109.994 176.366 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.547 ' O ' ' HG3' ' A' ' 136' ' ' LYS . 5.9 tp10 -76.05 -53.86 7.72 Favored 'General case' 0 CA--C 1.543 0.694 0 CA-C-N 115.693 -0.685 . . . . 0.0 111.051 -179.243 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.557 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 2.4 m -62.06 -26.25 68.16 Favored 'General case' 0 CA--C 1.552 1.021 0 N-CA-C 112.291 0.478 . . . . 0.0 112.291 -175.617 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 35.8 m -79.72 -18.14 51.91 Favored 'General case' 0 C--N 1.316 -0.857 0 O-C-N 121.852 -0.53 . . . . 0.0 110.653 179.196 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.547 ' HG3' ' O ' ' A' ' 133' ' ' GLU . 0.0 OUTLIER -85.64 -31.27 22.65 Favored 'General case' 0 C--O 1.211 -0.942 0 C-N-CA 119.636 -0.826 . . . . 0.0 109.535 179.227 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.444 ' HA ' ' CD1' ' A' ' 64' ' ' PHE . 8.8 p -70.95 -16.01 62.63 Favored 'General case' 0 N--CA 1.436 -1.165 0 CA-C-O 120.916 0.389 . . . . 0.0 109.962 177.244 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 64.56 81.64 0.11 Allowed Glycine 0 N--CA 1.421 -2.308 0 N-CA-C 109.578 -1.409 . . . . 0.0 109.578 179.881 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.472 ' OD1' ' HA ' ' A' ' 124' ' ' ASP . 23.3 t-20 -33.07 132.05 0.16 Allowed 'General case' 0 C--O 1.291 3.263 0 CA-C-O 123.451 1.596 . . . . 0.0 114.202 -172.306 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.419 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -150.89 130.51 13.07 Favored 'General case' 0 N--CA 1.407 -2.606 0 CA-C-N 113.845 -1.525 . . . . 0.0 109.711 179.557 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.12 91.03 0.61 Allowed Glycine 0 N--CA 1.441 -1.013 0 N-CA-C 108.072 -2.011 . . . . 0.0 108.072 170.935 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 14.9 m -49.18 -18.41 0.33 Allowed 'General case' 0 CA--C 1.542 0.636 0 C-N-CA 126.789 2.035 . . . . 0.0 116.384 -168.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 14.9 ptt180 -144.59 6.51 1.25 Allowed 'General case' 0 C--N 1.269 -2.92 0 N-CA-C 108.184 -1.043 . . . . 0.0 108.184 175.998 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 4.1 mm? -74.56 -22.73 58.84 Favored 'General case' 0 C--N 1.294 -1.845 0 C-N-CA 120.223 -0.591 . . . . 0.0 110.509 -173.478 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.674 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.9 100.3 0.17 Allowed 'General case' 0 N--CA 1.418 -2.047 0 N-CA-C 108.275 -1.009 . . . . 0.0 108.275 175.487 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.9 m -123.42 133.05 54.12 Favored 'General case' 0 N--CA 1.412 -2.37 0 N-CA-C 107.207 -1.405 . . . . 0.0 107.207 176.03 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.419 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -160.28 146.28 12.37 Favored Glycine 0 N--CA 1.404 -3.499 0 N-CA-C 108.483 -1.847 . . . . 0.0 108.483 178.03 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.516 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 8.8 p -69.19 113.98 5.6 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.381 0 CA-C-O 122.128 0.966 . . . . 0.0 111.953 179.417 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.472 HD12 HD13 ' A' ' 117' ' ' LEU . 2.5 tt -82.93 129.65 37.08 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.085 0 N-CA-C 105.067 -2.197 . . . . 0.0 105.067 170.283 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.608 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . 177.67 156.99 17.58 Favored Glycine 2 N--CA 1.365 -6.074 0 C-N-CA 118.427 -1.844 . . . . 0.0 111.297 176.772 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.599 HG12 ' O ' ' A' ' 3' ' ' LYS . 0.0 OUTLIER -71.16 105.32 1.61 Allowed 'Isoleucine or valine' 0 N--CA 1.43 -1.443 0 N-CA-C 108.027 -1.101 . . . . 0.0 108.027 169.536 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -126.16 113.34 16.91 Favored 'General case' 0 C--N 1.295 -1.804 0 N-CA-C 107.108 -1.441 . . . . 0.0 107.108 177.845 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 35.1 tt0 . . . . . 0 C--N 1.283 -2.315 0 N-CA-C 108.873 -0.788 . . . . 0.0 108.873 -175.595 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.432 ' HA ' HE22 ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.217 -0.645 0 CA-C-O 121.0 0.428 . . . . 0.0 111.461 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 3.4 m -79.89 -28.99 39.84 Favored 'General case' 0 N--CA 1.433 -1.307 0 CA-C-N 115.464 -0.789 . . . . 0.0 111.14 -176.685 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.652 ' HG3' ' O ' ' A' ' 152' ' ' ALA . 19.9 ptpt -151.74 170.87 18.69 Favored 'General case' 0 C--O 1.253 1.241 0 N-CA-C 109.704 -0.48 . . . . 0.0 109.704 -177.807 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.731 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.42 154.56 45.67 Favored 'General case' 0 N--CA 1.434 -1.265 0 O-C-N 124.099 0.875 . . . . 0.0 109.038 177.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 87.9 t -125.19 122.22 62.52 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.655 0 N-CA-C 109.418 -0.586 . . . . 0.0 109.418 -178.199 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.512 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -131.4 133.14 44.94 Favored 'General case' 0 C--N 1.301 -1.507 0 CA-C-N 115.167 -0.924 . . . . 0.0 110.18 179.663 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 23.6 t -134.75 113.31 16.29 Favored 'Isoleucine or valine' 0 CA--C 1.542 0.637 0 N-CA-C 109.383 -0.599 . . . . 0.0 109.383 176.215 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.428 ' HB2' ' O ' ' A' ' 14' ' ' VAL . 3.1 mm? -90.83 131.03 36.72 Favored 'General case' 0 N--CA 1.473 0.719 0 C-N-CA 123.409 0.683 . . . . 0.0 111.418 -176.949 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 36.1 mtpt -147.34 126.79 13.18 Favored 'General case' 0 C--O 1.223 -0.291 0 N-CA-C 108.579 -0.897 . . . . 0.0 108.579 175.008 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.72 -158.53 8.84 Favored Glycine 0 N--CA 1.438 -1.231 0 C-N-CA 120.58 -0.819 . . . . 0.0 111.754 -179.528 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 19.2 t70 -63.09 -40.39 97.52 Favored 'General case' 0 N--CA 1.47 0.531 0 N-CA-C 108.871 -0.789 . . . . 0.0 108.871 175.91 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -116.11 82.63 0.32 Allowed Glycine 0 N--CA 1.433 -1.513 0 N-CA-C 107.362 -2.295 . . . . 0.0 107.362 172.626 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 57.5 Cg_endo -72.64 127.0 11.95 Favored 'Trans proline' 0 N--CA 1.446 -1.296 0 C-N-CA 122.127 1.884 . . . . 0.0 113.901 -171.739 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.428 ' O ' ' HB2' ' A' ' 8' ' ' LEU . 16.5 m -111.92 117.08 54.28 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.858 0 N-CA-C 107.354 -1.35 . . . . 0.0 107.354 175.181 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 50.9 mt-30 -99.13 118.31 35.57 Favored 'General case' 0 C--N 1.282 -2.356 0 C-N-CA 119.521 -0.872 . . . . 0.0 110.639 -172.493 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.47 ' HA3' ' O ' ' A' ' 34' ' ' SER . . . -171.0 170.81 43.53 Favored Glycine 0 N--CA 1.407 -3.247 0 CA-C-N 115.164 -0.925 . . . . 0.0 110.858 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.512 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 25.7 pt -131.38 129.24 62.14 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.346 0 N-CA-C 107.46 -1.311 . . . . 0.0 107.46 -179.142 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 8.3 mm -115.12 136.01 53.21 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.187 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 -177.908 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.507 ' O ' HG13 ' A' ' 31' ' ' VAL . 0.8 OUTLIER -114.24 129.63 56.63 Favored 'General case' 0 C--O 1.215 -0.759 0 C-N-CA 119.818 -0.753 . . . . 0.0 110.478 -177.583 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.731 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 53.9 m-85 -125.19 137.49 54.13 Favored 'General case' 0 CA--C 1.506 -0.723 0 CA-C-O 121.097 0.475 . . . . 0.0 111.684 179.747 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.2 pt-20 -116.23 106.37 13.61 Favored 'General case' 0 C--N 1.301 -1.54 0 CA-C-N 115.051 -0.977 . . . . 0.0 111.368 177.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.432 HE22 ' HA ' ' A' ' 1' ' ' ALA . 2.8 pm0 -86.25 123.34 31.41 Favored 'General case' 0 N--CA 1.403 -2.816 0 N-CA-C 106.058 -1.831 . . . . 0.0 106.058 171.549 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.464 ' O ' ' HB ' ' A' ' 104' ' ' ILE . 37.1 ttmt -137.55 103.16 4.97 Favored 'General case' 0 C--N 1.283 -2.31 0 N-CA-C 108.481 -0.933 . . . . 0.0 108.481 -170.112 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 13.0 pt-20 -63.26 -9.83 13.29 Favored 'General case' 0 C--N 1.321 -0.667 0 N-CA-C 113.113 0.783 . . . . 0.0 113.113 -174.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 6.7 m -71.91 -23.71 61.52 Favored 'General case' 0 C--N 1.311 -1.088 0 C-N-CA 122.877 0.471 . . . . 0.0 110.35 176.385 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.556 ' HA ' HG13 ' A' ' 104' ' ' ILE . 45.4 t-20 72.57 135.54 0.04 OUTLIER 'General case' 0 N--CA 1.492 1.672 0 C-N-CA 125.335 1.454 . . . . 0.0 111.034 -179.526 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 166.52 175.33 36.67 Favored Glycine 0 CA--C 1.485 -1.785 0 C-N-CA 120.777 -0.725 . . . . 0.0 111.619 178.653 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 24.4 Cg_exo -65.1 123.48 11.62 Favored 'Trans proline' 0 N--CA 1.442 -1.531 0 C-N-CA 122.302 2.001 . . . . 0.0 108.397 177.485 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.423 ' HB ' HG23 ' A' ' 31' ' ' VAL . 23.7 m -76.99 142.75 13.85 Favored 'Isoleucine or valine' 0 N--CA 1.413 -2.277 0 CA-C-O 121.682 0.753 . . . . 0.0 111.632 -177.401 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.6 mttt -106.28 97.07 6.92 Favored 'General case' 0 C--N 1.277 -2.544 0 N-CA-C 106.992 -1.485 . . . . 0.0 106.992 173.702 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.507 HG13 ' O ' ' A' ' 19' ' ' ASN . 47.6 t -129.59 129.87 66.83 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.489 0 C-N-CA 125.892 1.677 . . . . 0.0 107.861 -171.846 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 80.7 t90 -140.74 137.24 33.28 Favored 'General case' 0 C--N 1.286 -2.192 0 O-C-N 123.375 0.422 . . . . 0.0 110.186 177.93 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -159.59 137.9 5.34 Favored Glycine 0 N--CA 1.404 -3.454 0 N-CA-C 110.548 -1.021 . . . . 0.0 110.548 170.191 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.47 ' O ' ' HA3' ' A' ' 16' ' ' GLY . 44.3 t -118.63 127.74 53.88 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 107.923 -1.14 . . . . 0.0 107.923 178.91 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.44 HG22 ' HA3' ' A' ' 16' ' ' GLY . 33.5 pt -120.02 129.0 75.97 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.128 0 CA-C-N 119.788 1.177 . . . . 0.0 110.381 174.611 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.4 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 88.1 tttt -96.67 123.56 40.39 Favored 'General case' 0 C--N 1.306 -1.304 0 N-CA-C 108.308 -0.997 . . . . 0.0 108.308 178.861 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.759 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -136.48 176.29 20.44 Favored Glycine 0 C--N 1.274 -2.9 0 CA-C-N 114.502 -1.226 . . . . 0.0 110.383 -171.057 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 5.3 mp -69.43 171.28 8.95 Favored 'General case' 0 C--N 1.293 -1.871 0 N-CA-C 106.944 -1.502 . . . . 0.0 106.944 171.265 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 8.8 t -68.47 112.43 5.29 Favored 'General case' 0 C--O 1.22 -0.48 0 N-CA-C 106.961 -1.496 . . . . 0.0 106.961 175.441 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.596 ' HG3' ' O ' ' A' ' 121' ' ' GLU . 5.1 tp10 -128.86 178.91 6.03 Favored 'General case' 0 C--N 1.259 -3.339 0 CA-C-N 114.034 -1.439 . . . . 0.0 109.804 -165.656 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.418 ' H ' ' HG3' ' A' ' 40' ' ' GLU . . . -59.44 -146.93 0.01 OUTLIER Glycine 0 CA--C 1.553 2.449 0 C-N-CA 124.633 1.111 . . . . 0.0 114.472 176.857 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.636 ' HA ' ' HA ' ' A' ' 88' ' ' THR . 3.0 pp -164.66 14.47 0.05 OUTLIER 'General case' 0 N--CA 1.441 -0.905 0 N-CA-C 116.4 2.0 . . . . 0.0 116.4 -164.486 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 66.2 t60 -143.91 153.66 42.53 Favored 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 106.757 -1.572 . . . . 0.0 106.757 178.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.52 ' HA2' ' H ' ' A' ' 124' ' ' ASP . . . 163.02 -169.25 38.13 Favored Glycine 0 N--CA 1.437 -1.239 0 C-N-CA 119.899 -1.143 . . . . 0.0 112.156 175.295 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.575 ' HA ' ' O ' ' A' ' 85' ' ' GLY . 24.1 p90 -166.6 162.65 16.67 Favored 'General case' 0 CA--C 1.507 -0.711 0 N-CA-C 108.511 -0.922 . . . . 0.0 108.511 176.908 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.67 ' HB2' ' O ' ' A' ' 83' ' ' ASP . 6.5 m170 -91.12 164.32 13.97 Favored 'General case' 0 C--N 1.295 -1.793 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -171.005 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.476 HG13 ' HD2' ' A' ' 64' ' ' PHE . 52.9 t -165.82 88.59 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.511 2.616 0 C-N-CA 123.81 0.844 . . . . 0.0 111.4 -174.346 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.559 ' HB2' ' HB3' ' A' ' 115' ' ' ARG . 31.0 p-80 -109.61 100.82 9.81 Favored 'General case' 0 CA--C 1.598 2.796 0 N-CA-C 113.453 0.908 . . . . 0.0 113.453 166.633 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.593 ' N ' ' HD2' ' A' ' 115' ' ' ARG . 0.1 OUTLIER -122.71 122.67 39.32 Favored 'General case' 0 CA--C 1.575 1.932 0 O-C-N 120.374 -1.454 . . . . 0.0 111.338 173.844 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.494 ' C ' ' HG2' ' A' ' 115' ' ' ARG . 61.2 t80 75.36 93.71 0.07 Allowed 'General case' 0 N--CA 1.495 1.816 0 C-N-CA 126.982 2.113 . . . . 0.0 110.961 176.277 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.651 ' HA2' ' HA ' ' A' ' 115' ' ' ARG . . . -55.02 134.1 48.21 Favored Glycine 0 CA--C 1.482 -1.985 0 N-CA-C 116.851 1.5 . . . . 0.0 116.851 -171.719 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 17.6 m-20 -141.42 -87.09 0.17 Allowed 'General case' 0 CA--C 1.488 -1.439 0 C-N-CA 117.951 -1.5 . . . . 0.0 114.326 -178.517 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 41.6 t30 -118.65 139.0 52.22 Favored 'General case' 0 C--N 1.307 -1.282 0 CA-C-N 116.046 -0.524 . . . . 0.0 110.856 -169.716 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.539 ' HA ' HG23 ' A' ' 148' ' ' VAL . 10.0 t -43.58 -39.76 3.66 Favored 'General case' 0 C--N 1.308 -1.211 0 C-N-CA 126.674 1.99 . . . . 0.0 115.385 -177.114 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -134.31 15.43 3.78 Favored 'General case' 0 C--N 1.313 -0.98 0 CA-C-O 121.426 0.631 . . . . 0.0 110.33 -177.352 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -127.4 111.14 1.29 Allowed Glycine 0 N--CA 1.436 -1.312 0 C-N-CA 119.922 -1.132 . . . . 0.0 111.818 -177.198 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.566 ' SG ' ' HB ' ' A' ' 118' ' ' VAL . 10.1 p -97.88 88.3 4.24 Favored 'General case' 0 N--CA 1.417 -2.084 0 N-CA-C 114.323 1.231 . . . . 0.0 114.323 179.977 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 7.8 p -78.25 -61.85 1.87 Allowed 'General case' 0 N--CA 1.419 -1.99 0 CA-C-N 115.568 -0.742 . . . . 0.0 110.277 176.246 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 19.3 m -68.15 -27.95 66.88 Favored 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 114.926 1.454 . . . . 0.0 114.926 -174.862 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.47 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -78.7 -9.27 59.35 Favored 'General case' 0 C--N 1.316 -0.849 0 CA-C-O 121.059 0.457 . . . . 0.0 111.115 177.551 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -60.3 -64.66 3.95 Favored Glycine 0 N--CA 1.436 -1.358 0 CA-C-N 115.096 -0.957 . . . . 0.0 113.021 179.585 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 73.1 Cg_endo -73.78 53.13 2.71 Favored 'Trans proline' 0 CA--C 1.552 1.403 0 C-N-CA 122.359 2.039 . . . . 0.0 114.247 -178.3 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 11.4 t60 72.83 163.59 0.27 Allowed 'General case' 0 CA--C 1.553 1.058 0 C-N-CA 124.831 1.252 . . . . 0.0 111.439 169.499 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.621 ' CG ' HG22 ' A' ' 81' ' ' VAL . 1.5 t80 -92.79 170.81 9.41 Favored 'General case' 0 C--N 1.317 -0.82 0 N-CA-C 107.286 -1.376 . . . . 0.0 107.286 -179.789 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.651 ' OD1' ' HD2' ' A' ' 66' ' ' PRO . 61.6 t30 -69.86 140.57 88.98 Favored Pre-proline 0 CA--C 1.562 1.42 0 C-N-CA 120.078 -0.649 . . . . 0.0 110.091 -179.603 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.651 ' HD2' ' OD1' ' A' ' 65' ' ' ASN . 72.8 Cg_endo -76.84 -8.4 17.9 Favored 'Trans proline' 0 N--CA 1.443 -1.483 1 C-N-CA 125.314 4.01 . . . . 0.0 113.954 177.144 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 40.8 tp -84.11 16.59 2.85 Favored 'General case' 0 C--N 1.353 0.721 0 CA-C-O 123.966 1.841 . . . . 0.0 109.611 -170.112 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.653 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.0 p -80.43 -86.3 0.08 Allowed 'General case' 1 N--CA 1.356 -5.15 0 CA-C-N 113.362 -1.745 . . . . 0.0 108.321 175.152 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.651 ' HB2' ' HA ' ' A' ' 78' ' ' GLU . 41.8 ttt180 -135.84 10.36 3.36 Favored 'General case' 0 C--N 1.291 -1.948 0 N-CA-C 108.516 -0.92 . . . . 0.0 108.516 167.624 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 82.5 tttt 75.14 -9.18 1.43 Allowed 'General case' 0 N--CA 1.479 0.998 0 C-N-CA 125.371 1.469 . . . . 0.0 113.19 173.27 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 95.9 m-70 -99.35 -54.42 2.96 Favored 'General case' 0 C--N 1.312 -1.05 0 C-N-CA 119.941 -0.703 . . . . 0.0 112.392 -178.924 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.41 ' HA2' ' HG2' ' A' ' 78' ' ' GLU . . . 88.98 30.45 14.55 Favored Glycine 0 N--CA 1.474 1.174 0 C-N-CA 120.157 -1.02 . . . . 0.0 113.229 179.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.444 ' HA2' ' HD3' ' A' ' 74' ' ' PRO . . . -70.58 143.54 37.15 Favored Glycine 0 CA--C 1.537 1.457 0 C-N-CA 120.499 -0.858 . . . . 0.0 114.734 -175.128 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.444 ' HD3' ' HA2' ' A' ' 73' ' ' GLY . 7.7 Cg_exo -76.84 -9.31 18.2 Favored 'Trans proline' 0 C--N 1.373 1.859 0 C-N-CA 124.155 3.237 . . . . 0.0 111.58 -179.557 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 17.5 ptpt -79.84 9.8 4.86 Favored 'General case' 0 C--N 1.29 -2.02 0 CA-C-N 113.613 -1.63 . . . . 0.0 112.741 -178.086 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.413 ' HB2' ' HB3' ' A' ' 101' ' ' ASP . 6.1 m-20 63.05 78.6 0.29 Allowed 'General case' 0 C--N 1.321 -0.636 0 C-N-CA 124.909 1.283 . . . . 0.0 111.094 176.268 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 62.2 mt-10 -137.54 -56.13 0.69 Allowed 'General case' 0 CA--C 1.5 -0.969 0 O-C-N 121.668 -0.645 . . . . 0.0 112.683 -178.995 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.651 ' HA ' ' HB2' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -64.2 154.24 35.47 Favored 'General case' 0 N--CA 1.403 -2.776 0 CA-C-N 115.357 -0.838 . . . . 0.0 112.276 -172.224 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.653 ' O ' ' HA ' ' A' ' 68' ' ' SER . 75.9 ttt180 -119.14 72.2 0.89 Allowed 'General case' 0 N--CA 1.436 -1.168 0 N-CA-C 114.877 1.436 . . . . 0.0 114.877 -170.84 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . . . . . . . . 0.336 2.3 m-70 177.48 -20.29 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.119 0 N-CA-C 114.272 1.212 . . . . 0.0 114.272 164.896 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.621 HG22 ' CG ' ' A' ' 64' ' ' PHE . 71.8 t -71.94 -57.26 7.74 Favored 'Isoleucine or valine' 0 CA--C 1.486 -1.493 0 N-CA-C 104.894 -2.261 . . . . 0.0 104.894 170.234 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.453 ' O ' ' HG ' ' A' ' 84' ' ' LEU . . . 69.41 -66.02 0.57 Allowed Glycine 0 N--CA 1.435 -1.373 0 CA-C-N 113.836 -1.529 . . . . 0.0 113.226 176.66 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.67 ' O ' ' HB2' ' A' ' 46' ' ' HIS . 2.9 t70 -68.84 97.9 0.88 Allowed 'General case' 0 CA--C 1.449 -2.941 0 N-CA-C 106.086 -1.82 . . . . 0.0 106.086 -179.465 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.613 ' HA ' ' H ' ' A' ' 46' ' ' HIS . 2.5 pp -168.89 162.67 11.41 Favored 'General case' 0 N--CA 1.4 -2.959 0 C-N-CA 125.321 1.448 . . . . 0.0 108.357 -175.096 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.575 ' O ' ' HA ' ' A' ' 45' ' ' PHE . . . 176.55 168.89 37.25 Favored Glycine 2 C--N 1.247 -4.379 0 N-CA-C 103.715 -3.754 . . . . 0.0 103.715 175.538 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.424 ' HA ' ' O ' ' A' ' 44' ' ' GLY . 58.5 t30 -80.36 140.63 35.98 Favored 'General case' 0 C--N 1.271 -2.84 0 CA-C-N 119.501 1.65 . . . . 0.0 107.324 174.947 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.455 HG12 ' HG3' ' A' ' 121' ' ' GLU . 43.4 t -115.31 128.06 72.65 Favored 'Isoleucine or valine' 0 C--O 1.208 -1.118 0 N-CA-C 107.564 -1.272 . . . . 0.0 107.564 -177.524 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.636 ' HA ' ' HA ' ' A' ' 42' ' ' LEU . 62.3 m -142.19 96.54 2.97 Favored 'General case' 0 N--CA 1.413 -2.279 0 CA-C-O 118.685 -0.674 . . . . 0.0 111.405 -173.539 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.585 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -126.77 104.38 8.03 Favored 'General case' 0 C--O 1.195 -1.774 0 C-N-CA 116.459 -2.096 . . . . 0.0 108.131 169.704 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' O ' ' A' ' 40' ' ' GLU . 5.3 p-10 -127.9 -18.65 4.19 Favored 'General case' 0 C--N 1.283 -2.311 0 C-N-CA 119.448 -0.901 . . . . 0.0 111.626 -171.348 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.463 ' HD2' ' H ' ' A' ' 91' ' ' LYS . 3.1 mptp? -71.73 -58.04 3.83 Favored 'General case' 0 C--N 1.298 -1.672 0 CA-C-O 121.795 0.807 . . . . 0.0 109.072 -175.728 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 7.1 p-10 -164.71 26.51 0.06 Allowed 'General case' 0 C--N 1.299 -1.596 0 CA-C-N 114.498 -1.228 . . . . 0.0 108.892 -175.849 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.759 ' HA3' ' O ' ' A' ' 37' ' ' GLY . . . 77.46 78.95 0.74 Allowed Glycine 0 N--CA 1.44 -1.093 0 CA-C-N 114.532 -1.213 . . . . 0.0 115.338 -178.14 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.453 ' H ' ' HB1' ' A' ' 89' ' ' ALA . 98.7 t -159.77 105.3 0.07 OUTLIER 'Isoleucine or valine' 0 C--N 1.315 -0.916 0 N-CA-C 104.557 -2.386 . . . . 0.0 104.557 177.072 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.419 ' HB3' ' CG1' ' A' ' 35' ' ' ILE . . . -107.71 122.68 47.22 Favored 'General case' 0 C--N 1.303 -1.423 0 N-CA-C 109.542 -0.54 . . . . 0.0 109.542 178.241 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 22.3 t70 -93.21 112.86 24.93 Favored 'General case' 0 C--N 1.297 -1.71 0 O-C-N 124.117 0.886 . . . . 0.0 109.76 179.615 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . . . . . . . . . 55.6 t -113.94 105.64 19.1 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.216 0 CA-C-O 121.147 0.499 . . . . 0.0 109.806 178.204 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.447 ' HA ' ' O ' ' A' ' 31' ' ' VAL . 50.5 m -143.52 111.63 6.19 Favored 'General case' 0 C--N 1.297 -1.703 0 N-CA-C 107.011 -1.477 . . . . 0.0 107.011 174.291 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.438 HD12 HG21 ' A' ' 103' ' ' VAL . 25.1 pt -123.22 154.69 29.04 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.27 -173.527 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 13.6 pt-20 -148.96 99.42 2.97 Favored 'General case' 0 C--N 1.322 -0.609 0 CA-C-O 121.884 0.85 . . . . 0.0 111.256 173.839 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.413 ' HB3' ' HB2' ' A' ' 76' ' ' ASP . 5.6 t70 -167.58 171.98 9.82 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 104.433 -2.432 . . . . 0.0 104.433 176.795 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . . . . . . . . . 14.6 m -59.24 87.77 0.01 OUTLIER 'General case' 0 CA--C 1.543 0.677 0 CA-C-O 122.743 1.259 . . . . 0.0 112.286 -178.081 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.438 HG21 HD12 ' A' ' 99' ' ' ILE . 59.3 t -113.21 -10.46 12.11 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.901 0 CA-C-N 112.733 -2.03 . . . . 0.0 106.763 175.453 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.556 HG13 ' HA ' ' A' ' 26' ' ' ASN . 0.2 OUTLIER -52.84 -13.71 0.49 Allowed 'Isoleucine or valine' 0 N--CA 1.494 1.758 0 C-N-CA 125.111 1.364 . . . . 0.0 114.067 -176.72 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 69.2 m -73.27 152.16 41.09 Favored 'General case' 0 N--CA 1.418 -2.038 0 N-CA-C 108.822 -0.807 . . . . 0.0 108.822 172.748 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.562 ' HB2' HG12 ' A' ' 112' ' ' ILE . 0.9 OUTLIER -65.9 121.78 15.85 Favored 'General case' 0 N--CA 1.403 -2.82 0 CA-C-O 122.01 0.91 . . . . 0.0 109.697 -177.559 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 6.9 m -69.86 88.07 0.55 Allowed 'General case' 0 N--CA 1.397 -3.124 0 CA-C-N 113.216 -1.811 . . . . 0.0 110.677 -174.345 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.472 ' HA2' ' CZ ' ' A' ' 64' ' ' PHE . . . 143.62 136.62 3.15 Favored Glycine 0 N--CA 1.409 -3.108 0 CA-C-N 114.287 -1.324 . . . . 0.0 112.296 175.313 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 22.4 t70 -66.38 -56.77 9.46 Favored 'General case' 0 N--CA 1.432 -1.37 0 C-N-CA 119.499 -0.88 . . . . 0.0 110.851 169.193 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 15.6 t60 -104.24 -47.09 4.24 Favored 'General case' 0 N--CA 1.435 -1.209 0 C-N-CA 119.99 -0.684 . . . . 0.0 112.007 -173.551 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.443 ' CB ' ' H ' ' A' ' 51' ' ' GLY . 18.8 m -127.42 113.91 16.82 Favored 'General case' 0 N--CA 1.433 -1.318 0 C-N-CA 118.944 -1.103 . . . . 0.0 112.594 -177.3 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.562 HG12 ' HB2' ' A' ' 106' ' ' LEU . 2.9 mp -89.71 -38.29 10.92 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.833 0 N-CA-C 106.511 -1.663 . . . . 0.0 106.511 173.349 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.434 HD12 ' HB ' ' A' ' 112' ' ' ILE . 4.1 mp -102.01 145.07 12.4 Favored 'Isoleucine or valine' 0 C--O 1.24 0.588 0 N-CA-C 108.321 -0.992 . . . . 0.0 108.321 179.235 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 87.83 -12.8 62.67 Favored Glycine 0 CA--C 1.495 -1.162 0 N-CA-C 111.538 -0.625 . . . . 0.0 111.538 174.825 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.673 ' HD3' ' N ' ' A' ' 116' ' ' THR . 0.0 OUTLIER -91.93 134.71 34.54 Favored 'General case' 0 N--CA 1.396 -3.147 0 CA-C-O 122.224 1.011 . . . . 0.0 112.967 -175.544 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.673 ' N ' ' HD3' ' A' ' 115' ' ' ARG 0.253 0.2 OUTLIER -89.0 116.74 27.52 Favored 'General case' 0 N--CA 1.394 -3.264 0 C-N-CA 126.563 1.945 . . . . 0.0 107.45 -176.188 . . . . . . . . 4 4 . 1 . 011 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.485 HD23 ' O ' ' A' ' 147' ' ' GLY . 2.7 pt? -79.17 144.52 34.37 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 109.235 -0.654 . . . . 0.0 109.235 179.494 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.566 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 10.7 p -109.7 111.14 34.85 Favored 'Isoleucine or valine' 0 C--O 1.273 2.314 0 C-N-CA 119.134 -1.027 . . . . 0.0 112.845 177.368 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.488 ' CG1' ' HA ' ' A' ' 46' ' ' HIS . 24.7 m -147.81 146.48 18.04 Favored 'Isoleucine or valine' 0 N--CA 1.434 -1.229 0 C-N-CA 125.805 1.642 . . . . 0.0 110.017 179.437 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 3.7 t60 -170.08 148.65 3.42 Favored 'General case' 0 C--N 1.283 -2.326 0 N-CA-C 102.601 -3.111 . . . . 0.0 102.601 167.929 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.596 ' O ' ' HG3' ' A' ' 40' ' ' GLU . 1.3 mp0 -69.55 89.72 0.53 Allowed 'General case' 0 C--N 1.261 -3.276 0 CA-C-O 123.355 1.55 . . . . 0.0 113.182 -171.225 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 85.5 tttt -165.28 144.53 6.6 Favored 'General case' 0 C--N 1.282 -2.354 0 N-CA-C 102.698 -3.075 . . . . 0.0 102.698 179.641 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -62.27 101.71 0.25 Allowed 'General case' 0 N--CA 1.435 -1.21 0 N-CA-C 112.935 0.717 . . . . 0.0 112.935 -173.765 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.52 ' H ' ' HA2' ' A' ' 44' ' ' GLY . 12.0 t70 -87.89 93.95 9.62 Favored 'General case' 0 CA--C 1.486 -1.482 1 N-CA-C 99.585 -4.228 . . . . 0.0 99.585 171.747 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 18.0 t70 -103.28 139.81 38.23 Favored 'General case' 0 C--N 1.303 -1.421 0 C-N-CA 119.839 -0.745 . . . . 0.0 111.118 -170.335 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.527 ' HG ' ' H ' ' A' ' 127' ' ' GLY . 1.9 pt? -51.23 -74.28 0.03 OUTLIER 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 121.703 3.964 . . . . 0.0 121.703 -162.248 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.527 ' H ' ' HG ' ' A' ' 126' ' ' LEU . . . -69.97 -59.89 5.23 Favored Glycine 0 CA--C 1.47 -2.727 0 C-N-CA 120.602 -0.808 . . . . 0.0 112.829 -170.781 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.508 ' HD2' ' C ' ' A' ' 127' ' ' GLY . 4.4 mptp? -136.8 35.88 2.63 Favored 'General case' 0 C--N 1.273 -2.758 0 CA-C-O 118.274 -0.87 . . . . 0.0 111.073 -174.729 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.493 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 59.5 -34.06 0.03 OUTLIER Glycine 0 CA--C 1.559 2.809 0 CA-C-N 119.76 1.164 . . . . 0.0 115.634 -175.29 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . 0.424 ' H ' ' C ' ' A' ' 128' ' ' LYS . . . 147.38 -24.32 1.54 Allowed Glycine 0 N--CA 1.401 -3.643 0 O-C-N 122.145 -0.62 . . . . 0.0 111.905 179.528 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.661 ' N ' ' HB2' ' A' ' 134' ' ' SER . 1.8 t-20 -169.61 179.78 3.65 Favored 'General case' 0 N--CA 1.485 1.288 0 C-N-CA 118.519 -1.272 . . . . 0.0 108.042 -174.862 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.466 ' O ' HG22 ' A' ' 135' ' ' THR . 0.0 OUTLIER -62.6 -40.72 97.82 Favored 'General case' 0 CA--C 1.551 1.007 0 C-N-CA 118.07 -1.452 . . . . 0.0 113.378 -175.136 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 11.6 pt-20 -85.36 -30.84 23.33 Favored 'General case' 0 C--N 1.319 -0.749 0 C-N-CA 119.125 -1.03 . . . . 0.0 110.171 174.376 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.661 ' HB2' ' N ' ' A' ' 131' ' ' ASN . 15.0 m -63.68 -19.68 65.1 Favored 'General case' 0 C--O 1.186 -2.284 0 N-CA-C 112.722 0.638 . . . . 0.0 112.722 -179.632 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.493 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.3 t -71.96 -35.4 69.54 Favored 'General case' 0 CA--C 1.506 -0.723 0 O-C-N 121.186 -0.946 . . . . 0.0 110.207 175.866 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 89.3 mttt -73.89 -48.84 28.06 Favored 'General case' 0 C--N 1.291 -1.964 0 CA-C-N 114.13 -1.395 . . . . 0.0 108.58 -175.835 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.557 HG22 ' HA ' ' A' ' 134' ' ' SER . 14.8 t -86.06 -23.66 26.65 Favored 'General case' 0 N--CA 1.428 -1.546 0 CA-C-N 114.418 -1.265 . . . . 0.0 112.816 -176.485 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -68.22 -66.7 2.21 Favored Glycine 0 CA--C 1.478 -2.277 0 CA-C-O 119.584 -0.565 . . . . 0.0 111.73 -176.216 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 58.8 t30 -50.75 132.53 26.32 Favored 'General case' 0 N--CA 1.518 2.945 0 N-CA-C 105.589 -2.004 . . . . 0.0 105.589 171.343 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -66.63 160.27 25.81 Favored 'General case' 0 C--O 1.243 0.748 0 N-CA-C 114.392 1.256 . . . . 0.0 114.392 -162.817 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -57.87 118.46 13.08 Favored Glycine 0 CA--C 1.49 -1.508 0 CA-C-N 113.655 -1.611 . . . . 0.0 113.046 -175.637 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.553 ' HB3' ' O ' ' A' ' 57' ' ' CYS . 8.4 m -71.43 3.43 3.81 Favored 'General case' 0 C--N 1.306 -1.313 0 C-N-CA 124.607 1.163 . . . . 0.0 113.189 -173.137 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 88.9 mtt180 -132.16 -4.76 3.47 Favored 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 109.636 -0.505 . . . . 0.0 109.636 176.557 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 90.6 mt -78.93 -40.35 32.24 Favored 'General case' 0 CA--C 1.498 -1.02 0 CA-C-N 116.462 -0.336 . . . . 0.0 111.111 -173.407 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -164.15 108.53 0.98 Allowed 'General case' 0 N--CA 1.428 -1.569 0 N-CA-C 108.669 -0.863 . . . . 0.0 108.669 -179.55 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.444 ' HB3' HG22 ' A' ' 116' ' ' THR . 7.8 m -137.43 156.78 47.78 Favored 'General case' 0 C--N 1.289 -2.022 0 N-CA-C 106.775 -1.565 . . . . 0.0 106.775 177.873 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.511 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -161.1 135.0 3.76 Favored Glycine 0 C--N 1.296 -1.686 0 N-CA-C 109.643 -1.383 . . . . 0.0 109.643 176.905 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.539 HG23 ' HA ' ' A' ' 54' ' ' THR . 40.2 t -65.79 121.67 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.535 0 CA-C-O 122.36 1.076 . . . . 0.0 110.952 176.934 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . . . . . . . . . 6.8 tt -113.27 141.47 28.93 Favored 'Isoleucine or valine' 0 N--CA 1.397 -3.098 0 CA-C-N 112.974 -1.921 . . . . 0.0 106.513 175.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -161.01 148.13 15.69 Favored Glycine 3 N--CA 1.383 -4.873 0 N-CA-C 108.372 -1.891 . . . . 0.0 108.372 179.087 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.517 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.1 pt -69.94 103.24 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.285 -2.231 0 CA-C-O 121.373 0.606 . . . . 0.0 110.699 175.048 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.652 ' O ' ' HG3' ' A' ' 3' ' ' LYS . . . -118.5 139.12 51.93 Favored 'General case' 0 C--N 1.306 -1.3 0 N-CA-C 106.767 -1.568 . . . . 0.0 106.767 175.842 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.4 pt20 . . . . . 0 C--N 1.31 -1.126 0 C-N-CA 120.616 -0.434 . . . . 0.0 111.644 -175.035 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.218 -0.6 0 CA-C-O 120.805 0.336 . . . . 0.0 110.107 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 14.6 m -92.07 -46.94 7.53 Favored 'General case' 0 N--CA 1.432 -1.33 0 CA-C-O 120.739 0.304 . . . . 0.0 110.887 -178.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.448 ' HA ' ' OD1' ' A' ' 19' ' ' ASN . 19.0 ptpt -154.25 166.48 33.01 Favored 'General case' 0 N--CA 1.433 -1.32 0 C-N-CA 120.664 -0.414 . . . . 0.0 110.519 -176.62 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.666 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -146.26 153.36 40.5 Favored 'General case' 0 N--CA 1.424 -1.772 0 O-C-N 124.308 1.005 . . . . 0.0 108.336 176.377 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 60.9 t -136.25 114.23 14.67 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.43 0 N-CA-C 108.505 -0.924 . . . . 0.0 108.505 -179.22 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.437 ' O ' ' HA ' ' A' ' 17' ' ' ILE . . . -113.51 128.1 56.32 Favored 'General case' 0 C--N 1.295 -1.803 0 N-CA-C 109.536 -0.542 . . . . 0.0 109.536 176.697 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 13.9 m -122.53 120.44 60.98 Favored 'Isoleucine or valine' 0 C--N 1.317 -0.817 0 CA-C-O 121.391 0.615 . . . . 0.0 110.568 178.712 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 5.8 mp -108.32 149.16 29.03 Favored 'General case' 0 C--N 1.301 -1.523 0 CA-C-N 115.612 -0.722 . . . . 0.0 109.397 -178.527 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 32.6 ttmt -171.07 127.06 0.7 Allowed 'General case' 0 N--CA 1.438 -1.066 0 N-CA-C 106.389 -1.708 . . . . 0.0 106.389 177.187 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -151.35 -156.53 7.45 Favored Glycine 0 N--CA 1.429 -1.824 0 C-N-CA 120.175 -1.012 . . . . 0.0 112.179 -174.183 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 22.5 t70 -52.46 -39.08 60.69 Favored 'General case' 0 N--CA 1.474 0.759 0 C-N-CA 124.63 1.172 . . . . 0.0 111.347 178.414 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -107.32 161.97 13.53 Favored Glycine 0 N--CA 1.436 -1.326 0 N-CA-C 108.009 -2.036 . . . . 0.0 108.009 174.511 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 19.8 Cg_endo -84.32 123.58 3.05 Favored 'Trans proline' 0 N--CA 1.42 -2.83 0 CA-C-N 120.491 2.145 . . . . 0.0 111.254 -177.858 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 60.3 t -132.98 127.41 55.14 Favored 'Isoleucine or valine' 0 N--CA 1.404 -2.751 0 N-CA-C 103.599 -2.741 . . . . 0.0 103.599 174.451 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 25.6 tp60 -142.06 116.58 9.66 Favored 'General case' 0 C--N 1.281 -2.403 0 N-CA-C 108.198 -1.038 . . . . 0.0 108.198 176.408 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.89 170.3 43.09 Favored Glycine 0 N--CA 1.396 -3.985 0 N-CA-C 110.126 -1.19 . . . . 0.0 110.126 -177.04 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.437 ' HA ' ' O ' ' A' ' 6' ' ' ALA . 24.9 pt -142.6 144.0 25.07 Favored 'Isoleucine or valine' 0 N--CA 1.419 -1.979 0 N-CA-C 106.011 -1.848 . . . . 0.0 106.011 179.363 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.2 tp -139.13 136.18 42.01 Favored 'Isoleucine or valine' 0 C--N 1.281 -2.378 0 N-CA-C 108.086 -1.079 . . . . 0.0 108.086 177.488 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.666 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 51.3 t-20 -97.96 147.72 24.2 Favored 'General case' 0 C--N 1.3 -1.579 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 -178.443 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.533 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 61.7 m-85 -138.09 119.33 14.62 Favored 'General case' 0 C--O 1.242 0.688 0 CA-C-N 119.182 0.901 . . . . 0.0 110.734 173.278 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 8.7 pt-20 -112.88 101.89 9.93 Favored 'General case' 0 N--CA 1.434 -1.27 0 CA-C-O 121.875 0.845 . . . . 0.0 111.191 174.556 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . . . . . . . . . 13.8 pm0 -91.06 150.32 21.47 Favored 'General case' 0 N--CA 1.404 -2.729 0 N-CA-C 107.979 -1.119 . . . . 0.0 107.979 172.783 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.545 ' HB3' HG21 ' A' ' 103' ' ' VAL . 40.9 tptt -138.38 154.17 48.93 Favored 'General case' 0 C--N 1.283 -2.32 0 N-CA-C 107.602 -1.259 . . . . 0.0 107.602 -175.68 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.493 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.5 mp0 -62.68 -55.31 27.98 Favored 'General case' 0 C--N 1.297 -1.711 0 O-C-N 123.937 0.773 . . . . 0.0 113.053 -174.534 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 11.3 m -78.24 -71.79 0.41 Allowed 'General case' 0 CA--C 1.548 0.865 0 N-CA-C 114.62 1.341 . . . . 0.0 114.62 -168.786 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 9.0 p30 177.89 140.67 0.09 Allowed 'General case' 0 N--CA 1.484 1.264 0 N-CA-C 109.829 -0.434 . . . . 0.0 109.829 -175.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.422 ' N ' HG22 ' A' ' 103' ' ' VAL . . . 165.8 174.58 35.45 Favored Glycine 0 CA--C 1.48 -2.11 0 C-N-CA 120.167 -1.016 . . . . 0.0 110.84 178.973 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 8.7 Cg_endo -90.6 131.7 1.65 Allowed 'Trans proline' 0 N--CA 1.43 -2.226 0 C-N-CA 123.062 2.508 . . . . 0.0 110.854 175.763 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 41.0 t -76.33 101.82 2.88 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.742 0 N-CA-C 107.369 -1.345 . . . . 0.0 107.369 176.361 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HD2' ' O ' ' A' ' 30' ' ' LYS 0.263 0.9 OUTLIER -92.07 92.79 8.43 Favored 'General case' 0 CA--C 1.482 -1.64 0 CA-C-O 122.735 1.255 . . . . 0.0 111.824 177.266 . . . . . . . . 4 4 . 1 . 012 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.498 HG11 ' HA ' ' A' ' 20' ' ' PHE . 17.7 m -127.82 153.6 37.32 Favored 'Isoleucine or valine' 0 C--N 1.26 -3.308 0 CA-C-N 114.545 -1.207 . . . . 0.0 111.69 -175.214 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.51 ' HA ' ' O ' ' A' ' 97' ' ' VAL . 31.0 m-90 -126.59 148.0 49.82 Favored 'General case' 0 C--N 1.277 -2.568 0 CA-C-N 113.717 -1.583 . . . . 0.0 107.63 -172.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . . . . . . . . . . . -166.17 140.11 6.16 Favored Glycine 0 N--CA 1.416 -2.662 0 N-CA-C 110.1 -1.2 . . . . 0.0 110.1 179.218 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 14.8 m -117.16 146.56 43.12 Favored 'General case' 0 N--CA 1.389 -3.521 0 N-CA-C 105.949 -1.871 . . . . 0.0 105.949 -178.061 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.725 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 17.0 tt -139.55 155.46 25.48 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.245 0 N-CA-C 107.735 -1.209 . . . . 0.0 107.735 178.158 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.687 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 31.7 mmmt -136.33 131.31 34.14 Favored 'General case' 0 C--N 1.279 -2.487 0 N-CA-C 105.501 -2.037 . . . . 0.0 105.501 -176.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -164.52 174.72 40.57 Favored Glycine 0 C--N 1.281 -2.505 0 N-CA-C 110.278 -1.129 . . . . 0.0 110.278 -173.472 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 89.3 mt -66.71 145.05 55.97 Favored 'General case' 0 C--N 1.32 -0.707 0 N-CA-C 107.076 -1.453 . . . . 0.0 107.076 177.102 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.433 HG22 ' CA ' ' A' ' 92' ' ' ASP . 65.5 p -69.54 106.73 3.11 Favored 'General case' 0 C--N 1.309 -1.172 0 N-CA-C 114.402 1.26 . . . . 0.0 114.402 -164.587 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 39.1 tt0 -175.47 161.96 2.77 Favored 'General case' 0 C--N 1.282 -2.332 0 N-CA-C 103.765 -2.68 . . . . 0.0 103.765 178.62 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.463 ' HA2' ' C ' ' A' ' 121' ' ' GLU . . . 158.86 137.09 2.17 Favored Glycine 1 CA--C 1.444 -4.364 0 C-N-CA 117.33 -2.367 . . . . 0.0 112.773 167.521 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.506 ' O ' ' HB2' ' A' ' 43' ' ' HIS . 0.5 OUTLIER 177.69 63.0 0.01 OUTLIER 'General case' 0 N--CA 1.447 -0.602 0 O-C-N 124.419 0.717 . . . . 0.0 110.243 -175.193 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.506 ' HB2' ' O ' ' A' ' 42' ' ' LEU . 35.9 t60 164.95 123.26 0.01 OUTLIER 'General case' 0 CA--C 1.49 -1.336 0 N-CA-C 106.81 -1.552 . . . . 0.0 106.81 172.677 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.629 ' HA2' ' N ' ' A' ' 87' ' ' VAL . . . -47.66 -134.73 0.0 OUTLIER Glycine 0 N--CA 1.486 1.995 0 N-CA-C 119.798 2.679 . . . . 0.0 119.798 -172.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.496 ' O ' ' HB2' ' A' ' 83' ' ' ASP . 13.3 m-85 -88.88 162.3 16.21 Favored 'General case' 0 CA--C 1.471 -2.07 0 N-CA-C 108.092 -1.077 . . . . 0.0 108.092 177.676 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . . . . . . . . . 0.2 OUTLIER -170.17 84.64 0.11 Allowed 'General case' 1 C--O 1.337 5.682 0 C-N-CA 120.212 -0.595 . . . . 0.0 112.266 -175.732 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.677 ' HB ' ' OE2' ' A' ' 49' ' ' GLU . 10.2 m -89.34 173.19 0.9 Allowed 'Isoleucine or valine' 0 C--N 1.303 -1.447 0 C-N-CA 130.568 3.547 . . . . 0.0 114.323 -164.951 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.512 ' NE2' HG23 ' A' ' 118' ' ' VAL . 0.3 OUTLIER -170.8 86.43 0.1 Allowed 'General case' 0 N--CA 1.478 0.93 0 C-N-CA 125.427 1.491 . . . . 0.0 108.195 174.422 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.677 ' OE2' ' HB ' ' A' ' 47' ' ' VAL . 3.0 mp0 -87.31 89.46 8.0 Favored 'General case' 0 C--N 1.291 -1.978 0 N-CA-C 115.153 1.538 . . . . 0.0 115.153 -172.378 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 89.2 t80 -118.21 -21.52 8.14 Favored 'General case' 0 N--CA 1.439 -0.995 0 CA-C-N 113.743 -1.571 . . . . 0.0 112.193 -177.827 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.57 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 92.32 110.94 1.86 Allowed Glycine 0 N--CA 1.468 0.806 0 C-N-CA 120.037 -1.078 . . . . 0.0 111.847 -172.643 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.415 ' OD2' ' HA ' ' A' ' 57' ' ' CYS . 9.9 t0 -153.32 -171.24 3.85 Favored 'General case' 0 N--CA 1.429 -1.515 0 N-CA-C 106.083 -1.821 . . . . 0.0 106.083 -179.351 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 51.2 t30 -73.97 135.77 43.19 Favored 'General case' 0 C--N 1.298 -1.635 0 N-CA-C 108.734 -0.839 . . . . 0.0 108.734 177.599 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.438 ' HB ' HG13 ' A' ' 148' ' ' VAL . 9.4 t -67.41 5.27 0.8 Allowed 'General case' 0 CA--C 1.557 1.22 0 N-CA-C 113.595 0.961 . . . . 0.0 113.595 -173.828 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -124.75 5.82 8.13 Favored 'General case' 0 C--N 1.302 -1.463 0 O-C-N 121.993 -0.442 . . . . 0.0 110.591 178.531 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 173.86 136.45 2.21 Favored Glycine 0 CA--C 1.484 -1.862 0 C-N-CA 117.58 -2.248 . . . . 0.0 112.542 179.901 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.508 ' H ' ' HA ' ' A' ' 143' ' ' ARG . 53.7 m -96.84 87.87 4.42 Favored 'General case' 0 N--CA 1.417 -2.089 0 C-N-CA 120.226 -0.59 . . . . 0.0 111.496 -178.928 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 22.1 p -83.29 -37.12 23.88 Favored 'General case' 0 C--N 1.312 -1.039 0 CA-C-O 122.159 0.981 . . . . 0.0 111.61 172.023 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 2.0 m -90.03 -40.17 12.48 Favored 'General case' 0 N--CA 1.439 -0.977 0 CA-C-N 114.248 -1.342 . . . . 0.0 110.802 -170.384 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -87.76 -16.09 35.18 Favored 'General case' 0 N--CA 1.422 -1.869 0 N-CA-C 106.05 -1.833 . . . . 0.0 106.05 177.686 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.482 ' HA2' ' O ' ' A' ' 57' ' ' CYS . . . 37.29 -144.81 0.13 Allowed Glycine 0 CA--C 1.488 -1.628 0 CA-C-N 111.786 -2.461 . . . . 0.0 116.387 171.721 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 5.0 Cg_endo -82.71 87.35 1.37 Allowed 'Trans proline' 0 N--CA 1.403 -3.827 0 C-N-CA 122.144 1.896 . . . . 0.0 110.189 177.03 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.427 ' HB2' ' HA3' ' A' ' 138' ' ' GLY . 10.9 t-80 77.61 110.46 0.07 Allowed 'General case' 0 N--CA 1.476 0.831 0 CA-C-N 114.298 -1.319 . . . . 0.0 114.479 170.248 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 54.5 t80 -170.48 91.78 0.18 Allowed 'General case' 0 C--N 1.299 -1.62 0 CA-C-N 112.737 -2.029 . . . . 0.0 105.538 173.031 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.479 ' O ' ' HA ' ' A' ' 70' ' ' LYS . 25.8 t-20 -111.49 89.92 11.42 Favored Pre-proline 0 C--O 1.209 -1.035 0 N-CA-C 108.358 -0.979 . . . . 0.0 108.358 -178.547 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 2.3 Cg_endo -77.48 -11.32 17.27 Favored 'Trans proline' 0 C--N 1.323 -0.804 0 C-N-CA 122.786 2.324 . . . . 0.0 111.259 -173.412 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 4.5 tt -45.04 -62.18 1.34 Allowed 'General case' 0 CA--C 1.492 -1.262 0 O-C-N 125.254 1.596 . . . . 0.0 109.943 -175.195 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.689 ' OG ' ' HA ' ' A' ' 76' ' ' ASP . 19.8 m -106.04 -86.26 0.48 Allowed 'General case' 0 N--CA 1.389 -3.483 0 C-N-CA 117.546 -1.662 . . . . 0.0 111.538 176.109 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.406 ' HD2' ' OE2' ' A' ' 78' ' ' GLU 0.392 21.8 ttm180 -123.99 43.48 2.98 Favored 'General case' 0 N--CA 1.452 -0.369 0 C-N-CA 114.593 -2.843 . . . . 0.0 116.169 179.405 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.479 ' HA ' ' O ' ' A' ' 65' ' ' ASN . 53.0 mtmt 75.27 -43.04 0.49 Allowed 'General case' 0 N--CA 1.487 1.395 0 C-N-CA 125.09 1.356 . . . . 0.0 113.688 173.45 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 54.1 m80 -70.21 -37.44 75.06 Favored 'General case' 0 C--N 1.313 -1.022 0 N-CA-C 108.922 -0.77 . . . . 0.0 108.922 176.421 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.614 ' HA3' ' O ' ' A' ' 80' ' ' HIS . . . 171.55 171.63 36.84 Favored Glycine 0 C--O 1.266 2.152 0 CA-C-N 115.575 -0.739 . . . . 0.0 111.732 -179.682 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -169.69 77.14 0.1 Allowed Glycine 0 C--O 1.215 -1.046 0 CA-C-O 118.925 -0.931 . . . . 0.0 113.377 178.665 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.49 ' HD2' ' HB3' ' A' ' 77' ' ' GLU . 42.8 Cg_endo -64.79 -42.95 13.64 Favored 'Trans proline' 0 N--CA 1.494 1.529 0 C-N-CA 122.531 2.154 . . . . 0.0 115.653 -177.013 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.579 ' O ' HG13 ' A' ' 104' ' ' ILE . 58.4 pttt -119.7 26.01 9.63 Favored 'General case' 0 C--N 1.304 -1.404 0 N-CA-C 107.722 -1.214 . . . . 0.0 107.722 178.59 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.689 ' HA ' ' OG ' ' A' ' 68' ' ' SER . 33.6 t70 61.76 85.06 0.13 Allowed 'General case' 0 CA--C 1.487 -1.472 0 N-CA-C 105.268 -2.123 . . . . 0.0 105.268 -163.921 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.596 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 6.2 tp10 -121.95 -35.58 3.15 Favored 'General case' 0 C--O 1.169 -3.142 0 CA-C-N 113.803 -1.544 . . . . 0.0 113.984 -164.961 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.596 ' HB3' ' O ' ' A' ' 77' ' ' GLU . 12.6 tt0 76.73 112.33 0.07 Allowed 'General case' 0 C--N 1.311 -1.09 0 N-CA-C 106.845 -1.539 . . . . 0.0 106.845 -162.008 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 18.8 mtp180 75.1 -174.93 0.13 Allowed 'General case' 0 C--O 1.25 1.114 0 CA-C-N 114.537 -1.21 . . . . 0.0 109.9 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.614 ' O ' ' HA3' ' A' ' 72' ' ' GLY . 61.7 t-80 75.73 162.81 0.25 Allowed 'General case' 0 N--CA 1.488 1.432 0 C-N-CA 125.693 1.597 . . . . 0.0 107.202 -178.388 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.513 HG23 ' H ' ' A' ' 126' ' ' LEU . 3.7 p -62.36 115.49 1.99 Allowed 'Isoleucine or valine' 0 C--N 1.293 -1.879 0 C-N-CA 119.245 -0.982 . . . . 0.0 109.04 172.746 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.441 ' C ' HG22 ' A' ' 47' ' ' VAL . . . -57.57 118.59 13.1 Favored Glycine 0 CA--C 1.496 -1.098 0 N-CA-C 108.954 -1.658 . . . . 0.0 108.954 169.907 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.496 ' HB2' ' O ' ' A' ' 45' ' ' PHE . 0.5 OUTLIER -170.79 150.72 3.29 Favored 'General case' 0 C--N 1.298 -1.657 0 N-CA-C 109.53 -0.545 . . . . 0.0 109.53 -172.675 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . . . . . . . . . 4.9 mp -136.12 83.86 2.04 Favored 'General case' 0 C--N 1.29 -1.995 0 N-CA-C 105.377 -2.083 . . . . 0.0 105.377 159.042 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.481 ' HA3' ' CD1' ' A' ' 45' ' ' PHE . . . 172.89 154.49 10.41 Favored Glycine 0 N--CA 1.422 -2.292 0 C-N-CA 118.982 -1.58 . . . . 0.0 114.6 176.562 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.55 ' H ' HG21 ' A' ' 99' ' ' ILE . 35.1 t30 -129.65 127.85 41.4 Favored 'General case' 0 C--N 1.299 -1.612 0 N-CA-C 106.221 -1.77 . . . . 0.0 106.221 169.977 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.629 ' N ' ' HA2' ' A' ' 44' ' ' GLY . 6.4 m -131.59 143.3 40.84 Favored 'Isoleucine or valine' 0 C--O 1.24 0.561 0 CA-C-N 118.216 0.462 . . . . 0.0 109.799 -173.427 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 53.9 m -142.37 96.24 2.92 Favored 'General case' 0 C--N 1.292 -1.895 0 CA-C-N 115.852 -0.613 . . . . 0.0 109.628 179.698 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.556 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -137.87 154.74 49.44 Favored 'General case' 0 C--O 1.153 -3.978 0 N-CA-C 106.494 -1.669 . . . . 0.0 106.494 177.688 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.415 ' O ' ' HB ' ' A' ' 39' ' ' THR . 7.9 p-10 -179.66 -27.57 0.01 OUTLIER 'General case' 0 C--N 1.255 -3.511 0 CA-C-O 122.485 1.136 . . . . 0.0 109.409 179.158 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 86.8 tttt -77.14 -49.61 14.84 Favored 'General case' 0 C--N 1.255 -3.534 0 CA-C-N 112.964 -1.925 . . . . 0.0 110.986 -177.59 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.433 ' CA ' HG22 ' A' ' 39' ' ' THR . 32.8 t70 -132.79 -1.08 3.41 Favored 'General case' 0 C--N 1.299 -1.624 0 CA-C-N 115.905 -0.588 . . . . 0.0 110.822 -174.842 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.687 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 68.67 66.16 2.39 Favored Glycine 0 C--O 1.215 -1.054 0 N-CA-C 109.502 -1.439 . . . . 0.0 109.502 -177.197 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.725 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 22.7 t -150.21 104.55 0.35 Allowed 'Isoleucine or valine' 0 C--N 1.311 -1.089 0 N-CA-C 106.954 -1.499 . . . . 0.0 106.954 -179.3 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.526 ' CB ' ' HB ' ' A' ' 87' ' ' VAL . . . -110.23 119.63 39.87 Favored 'General case' 0 N--CA 1.4 -2.938 0 N-CA-C 106.33 -1.73 . . . . 0.0 106.33 174.328 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -112.59 113.19 25.21 Favored 'General case' 0 C--N 1.273 -2.751 0 N-CA-C 106.306 -1.739 . . . . 0.0 106.306 -177.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.51 ' O ' ' HA ' ' A' ' 32' ' ' TRP . 13.7 m -111.21 145.46 17.43 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.065 0 N-CA-C 114.552 1.316 . . . . 0.0 114.552 -168.729 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 10.0 t -143.06 102.06 3.93 Favored 'General case' 0 N--CA 1.413 -2.309 0 N-CA-C 104.134 -2.543 . . . . 0.0 104.134 166.105 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.55 HG21 ' H ' ' A' ' 86' ' ' ASN . 0.2 OUTLIER -117.23 171.54 5.68 Favored 'Isoleucine or valine' 0 C--N 1.276 -2.62 0 CA-C-N 115.832 -0.622 . . . . 0.0 110.562 -176.185 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 7.3 pt-20 -140.77 112.17 7.37 Favored 'General case' 0 N--CA 1.413 -2.276 0 CA-C-N 115.03 -0.986 . . . . 0.0 109.668 176.271 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . 0.438 ' OD1' ' HB3' ' A' ' 75' ' ' LYS . 2.2 t0 -130.24 168.63 16.55 Favored 'General case' 0 C--N 1.299 -1.615 0 N-CA-C 106.48 -1.674 . . . . 0.0 106.48 177.779 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.527 ' HB2' ' HB2' ' A' ' 75' ' ' LYS . 22.0 m -76.04 123.72 26.23 Favored 'General case' 0 C--N 1.308 -1.209 0 CA-C-N 119.408 1.003 . . . . 0.0 111.253 -174.101 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.545 HG21 ' HB3' ' A' ' 23' ' ' LYS . 26.8 m -56.13 -12.09 0.97 Allowed 'Isoleucine or valine' 0 N--CA 1.5 2.05 0 C-N-CA 126.439 1.896 . . . . 0.0 114.546 -175.533 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.579 HG13 ' O ' ' A' ' 75' ' ' LYS . 26.3 pt -66.59 -12.8 15.3 Favored 'Isoleucine or valine' 0 N--CA 1.431 -1.403 0 CA-C-O 120.657 0.265 . . . . 0.0 111.136 179.094 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.569 ' HB3' ' C ' ' A' ' 75' ' ' LYS . 5.1 p -84.88 89.76 7.63 Favored 'General case' 0 N--CA 1.443 -0.79 0 N-CA-C 114.057 1.132 . . . . 0.0 114.057 172.284 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.502 HD23 ' H ' ' A' ' 106' ' ' LEU . 2.0 pt? -69.79 119.34 13.87 Favored 'General case' 0 N--CA 1.404 -2.767 0 N-CA-C 105.343 -2.095 . . . . 0.0 105.343 165.147 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 t -74.65 87.57 2.17 Favored 'General case' 0 C--N 1.302 -1.48 0 N-CA-C 107.221 -1.4 . . . . 0.0 107.221 -179.13 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.533 ' HA2' ' CB ' ' A' ' 49' ' ' GLU . . . 162.49 136.91 2.08 Favored Glycine 0 N--CA 1.405 -3.375 0 CA-C-N 114.614 -1.175 . . . . 0.0 112.398 178.337 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 23.7 t70 -83.28 -73.56 0.4 Allowed 'General case' 0 C--N 1.318 -0.782 0 CA-C-O 120.616 0.246 . . . . 0.0 110.725 176.322 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 22.7 m80 -87.42 -19.72 27.66 Favored 'General case' 0 CA--C 1.493 -1.237 0 C-N-CA 120.388 -0.525 . . . . 0.0 111.531 179.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.415 ' HB3' ' CZ ' ' A' ' 115' ' ' ARG . 42.0 t -159.32 163.74 35.41 Favored 'General case' 0 N--CA 1.406 -2.662 0 N-CA-C 105.895 -1.891 . . . . 0.0 105.895 175.302 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.59 ' O ' ' HA2' ' A' ' 150' ' ' GLY . 6.4 pt -104.47 -16.95 7.57 Favored 'Isoleucine or valine' 0 N--CA 1.402 -2.853 0 C-N-CA 125.507 1.523 . . . . 0.0 108.6 -178.419 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.444 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 37.4 pt -103.73 138.83 26.58 Favored 'Isoleucine or valine' 0 N--CA 1.45 -0.43 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.13 177.856 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.561 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 93.41 -0.34 68.21 Favored Glycine 0 CA--C 1.484 -1.846 0 C-N-CA 120.521 -0.847 . . . . 0.0 111.021 171.261 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.57 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 2.6 mmp_? -87.55 144.53 26.65 Favored 'General case' 0 C--O 1.175 -2.823 0 N-CA-C 107.162 -1.422 . . . . 0.0 107.162 -179.459 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.462 ' HB ' ' SG ' ' A' ' 57' ' ' CYS . 2.3 p -98.61 119.47 37.39 Favored 'General case' 0 C--N 1.286 -2.193 0 CA-C-N 119.549 1.068 . . . . 0.0 113.165 -176.848 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.447 ' HG ' HG12 ' A' ' 47' ' ' VAL . 3.0 tt -88.27 131.67 34.69 Favored 'General case' 0 C--N 1.295 -1.798 0 N-CA-C 107.501 -1.296 . . . . 0.0 107.501 -179.338 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.515 ' HA ' ' O ' ' A' ' 145' ' ' ALA . 93.5 t -102.24 109.49 26.44 Favored 'Isoleucine or valine' 0 C--O 1.267 2.009 0 C-N-CA 118.941 -1.103 . . . . 0.0 110.668 175.281 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.5 p -148.14 124.3 2.58 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.471 0 CA-C-O 121.896 0.855 . . . . 0.0 113.192 -178.548 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 57.4 t-80 -144.02 157.44 44.33 Favored 'General case' 0 N--CA 1.41 -2.43 0 N-CA-C 101.872 -3.381 . . . . 0.0 101.872 168.207 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.561 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 1.2 mp0 -68.92 89.79 0.42 Allowed 'General case' 0 C--N 1.271 -2.824 0 N-CA-C 105.904 -1.887 . . . . 0.0 105.904 176.18 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.566 ' HD3' ' H ' ' A' ' 123' ' ' ALA . 2.2 tmtp? -173.85 168.12 4.3 Favored 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 -174.857 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.566 ' H ' ' HD3' ' A' ' 122' ' ' LYS . . . -73.72 125.02 27.15 Favored 'General case' 0 C--N 1.295 -1.781 0 CA-C-O 121.531 0.681 . . . . 0.0 111.175 173.548 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 1.0 OUTLIER -156.1 112.89 3.15 Favored 'General case' 0 C--N 1.304 -1.392 0 C-N-CA 125.526 1.53 . . . . 0.0 107.31 176.613 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.502 ' O ' ' HA2' ' A' ' 138' ' ' GLY . 7.4 m-20 -128.91 129.32 45.35 Favored 'General case' 0 C--N 1.294 -1.839 0 N-CA-C 110.03 -0.359 . . . . 0.0 110.03 -179.481 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.513 ' H ' HG23 ' A' ' 81' ' ' VAL . 3.3 mm? -82.69 -53.82 5.62 Favored 'General case' 0 C--N 1.303 -1.448 0 O-C-N 123.277 0.36 . . . . 0.0 111.168 -177.33 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -78.76 -31.24 45.1 Favored Glycine 0 N--CA 1.44 -1.078 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.65 -178.069 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 40.1 ttpt -93.13 -46.71 7.3 Favored 'General case' 0 C--N 1.301 -1.524 0 C-N-CA 120.443 -0.503 . . . . 0.0 111.214 -175.813 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.418 ' HA3' ' HA ' ' A' ' 135' ' ' THR . . . 63.96 -82.04 0.05 OUTLIER Glycine 0 N--CA 1.432 -1.601 0 N-CA-C 112.134 -0.386 . . . . 0.0 112.134 -171.575 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 169.89 -67.34 0.16 Allowed Glycine 0 N--CA 1.446 -0.639 0 N-CA-C 109.621 -1.392 . . . . 0.0 109.621 -177.637 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.636 ' HB3' ' OE1' ' A' ' 133' ' ' GLU . 51.6 t30 -119.4 -175.29 2.91 Favored 'General case' 0 C--O 1.253 1.237 0 N-CA-C 107.118 -1.438 . . . . 0.0 107.118 175.271 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 41.9 mt-10 -54.01 -34.77 60.81 Favored 'General case' 0 CA--C 1.545 0.768 0 N-CA-C 113.525 0.935 . . . . 0.0 113.525 -178.003 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . 0.636 ' OE1' ' HB3' ' A' ' 131' ' ' ASN . 0.0 OUTLIER -83.79 -38.48 21.22 Favored 'General case' 0 C--N 1.317 -0.845 0 C-N-CA 120.042 -0.663 . . . . 0.0 110.135 -178.951 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.476 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 14.6 m -65.16 -29.62 70.47 Favored 'General case' 0 N--CA 1.436 -1.15 0 CA-C-N 115.141 -0.936 . . . . 0.0 112.32 -175.209 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.418 ' HA ' ' HA3' ' A' ' 129' ' ' GLY . 11.4 t -68.53 -27.54 66.2 Favored 'General case' 0 CA--C 1.533 0.326 0 CA-C-O 121.469 0.652 . . . . 0.0 109.892 179.124 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 54.5 mtmt -84.05 -39.51 19.51 Favored 'General case' 0 C--N 1.302 -1.466 0 CA-C-N 115.495 -0.775 . . . . 0.0 109.738 -178.967 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 10.0 m -72.26 -33.47 67.52 Favored 'General case' 0 N--CA 1.427 -1.603 0 CA-C-N 115.415 -0.812 . . . . 0.0 110.044 178.376 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.502 ' HA2' ' O ' ' A' ' 125' ' ' ASP . . . 59.72 45.96 94.84 Favored Glycine 0 CA--C 1.488 -1.626 0 N-CA-C 107.373 -2.291 . . . . 0.0 107.373 -171.431 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 64.8 t30 -34.42 104.62 0.03 OUTLIER 'General case' 0 N--CA 1.483 1.186 0 O-C-N 126.424 1.896 . . . . 0.0 113.679 -166.23 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -151.8 172.43 16.18 Favored 'General case' 0 N--CA 1.425 -1.697 0 CA-C-N 113.523 -1.672 . . . . 0.0 108.353 -176.668 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -75.92 94.78 1.0 Allowed Glycine 0 N--CA 1.429 -1.779 0 N-CA-C 107.721 -2.152 . . . . 0.0 107.721 170.521 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.409 ' O ' ' HB2' ' A' ' 57' ' ' CYS . 14.3 m -43.49 -44.29 5.88 Favored 'General case' 0 N--CA 1.469 0.512 0 C-N-CA 125.922 1.689 . . . . 0.0 113.998 -172.919 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.508 ' HA ' ' H ' ' A' ' 57' ' ' CYS . 44.8 mtm180 -115.66 -25.95 7.64 Favored 'General case' 0 C--N 1.286 -2.191 0 N-CA-C 109.546 -0.539 . . . . 0.0 109.546 177.904 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 3.2 tm? -46.62 -35.33 5.8 Favored 'General case' 0 N--CA 1.482 1.161 0 C-N-CA 126.2 1.8 . . . . 0.0 112.539 -168.314 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.515 ' O ' ' HA ' ' A' ' 118' ' ' VAL . . . -141.58 87.76 2.09 Favored 'General case' 0 N--CA 1.388 -3.529 0 N-CA-C 107.142 -1.429 . . . . 0.0 107.142 -179.221 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.445 ' SG ' HG22 ' A' ' 118' ' ' VAL . 86.5 m -138.7 138.91 38.16 Favored 'General case' 0 N--CA 1.419 -1.996 0 CA-C-N 114.035 -1.439 . . . . 0.0 107.845 176.331 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -159.21 148.95 18.55 Favored Glycine 0 N--CA 1.407 -3.243 0 N-CA-C 107.032 -2.427 . . . . 0.0 107.032 174.851 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.512 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 27.9 m -68.95 123.91 23.49 Favored 'Isoleucine or valine' 0 N--CA 1.423 -1.809 0 CA-C-O 122.572 1.177 . . . . 0.0 111.97 178.665 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.409 HD13 ' N ' ' A' ' 150' ' ' GLY . 0.0 OUTLIER -98.2 138.51 22.67 Favored 'Isoleucine or valine' 0 N--CA 1.388 -3.561 0 N-CA-C 104.907 -2.257 . . . . 0.0 104.907 174.439 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.59 ' HA2' ' O ' ' A' ' 112' ' ' ILE . . . -174.4 151.99 13.66 Favored Glycine 3 N--CA 1.36 -6.37 0 N-CA-C 109.627 -1.389 . . . . 0.0 109.627 177.642 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.62 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.7 pp -60.57 114.54 1.13 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.682 0 N-CA-C 109.271 -0.641 . . . . 0.0 109.271 170.382 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.409 ' H ' ' HA ' ' A' ' 4' ' ' ALA . . . -126.94 114.89 18.44 Favored 'General case' 0 C--N 1.293 -1.852 0 N-CA-C 108.555 -0.905 . . . . 0.0 108.555 179.786 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 12.2 pt20 . . . . . 0 C--N 1.284 -2.244 0 CA-C-O 118.221 -0.895 . . . . 0.0 109.267 -178.492 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.481 ' HA ' HD11 ' A' ' 151' ' ' ILE . . . . . . . . 0 N--CA 1.45 -0.447 0 CA-C-O 121.047 0.451 . . . . 0.0 110.884 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.401 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 11.6 t -121.68 -25.08 5.15 Favored 'General case' 0 C--N 1.306 -1.306 0 CA-C-O 122.041 0.924 . . . . 0.0 110.167 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 60.0 mttp -135.78 150.5 49.49 Favored 'General case' 0 N--CA 1.416 -2.166 0 N-CA-C 108.948 -0.76 . . . . 0.0 108.948 -178.443 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -141.52 161.44 37.91 Favored 'General case' 0 C--N 1.275 -2.647 0 N-CA-C 107.696 -1.224 . . . . 0.0 107.696 179.409 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 17.8 m -128.98 127.82 66.55 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.914 0 CA-C-O 121.363 0.601 . . . . 0.0 109.961 178.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.65 ' HA ' HG21 ' A' ' 148' ' ' VAL . . . -107.81 146.89 31.62 Favored 'General case' 0 C--N 1.295 -1.779 0 CA-C-N 114.957 -1.02 . . . . 0.0 111.768 -177.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.618 ' N ' HG11 ' A' ' 148' ' ' VAL . 41.1 t -134.5 104.94 5.93 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.997 0 N-CA-C 110.368 -0.234 . . . . 0.0 110.368 -178.366 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 3.8 mm? -87.93 151.34 22.88 Favored 'General case' 0 N--CA 1.48 1.068 0 N-CA-C 113.399 0.889 . . . . 0.0 113.399 -179.638 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 12.0 tmtt? -144.27 122.01 11.9 Favored 'General case' 0 CA--C 1.504 -0.813 0 N-CA-C 105.874 -1.898 . . . . 0.0 105.874 175.768 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -156.38 -178.46 30.54 Favored Glycine 0 N--CA 1.414 -2.8 0 C-N-CA 117.999 -2.048 . . . . 0.0 115.939 -179.555 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 39.3 m-20 -102.35 111.34 23.59 Favored 'General case' 0 N--CA 1.43 -1.448 0 N-CA-C 104.131 -2.544 . . . . 0.0 104.131 170.146 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 95.41 68.94 1.03 Allowed Glycine 0 C--N 1.289 -2.059 0 N-CA-C 104.988 -3.245 . . . . 0.0 104.988 -164.958 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 56.8 Cg_endo -62.66 128.0 22.19 Favored 'Trans proline' 0 CA--C 1.503 -1.045 0 C-N-CA 123.159 2.573 . . . . 0.0 114.914 -165.435 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 16.1 m -115.8 123.13 70.82 Favored 'Isoleucine or valine' 0 N--CA 1.409 -2.524 0 CA-C-N 113.727 -1.579 . . . . 0.0 108.324 177.529 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 77.2 mt-30 -111.66 117.84 34.02 Favored 'General case' 0 C--N 1.287 -2.128 0 N-CA-C 106.984 -1.487 . . . . 0.0 106.984 178.119 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -170.61 166.93 40.11 Favored Glycine 1 N--CA 1.383 -4.885 0 C-N-CA 119.551 -1.309 . . . . 0.0 110.377 -179.56 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.445 ' O ' HD12 ' A' ' 17' ' ' ILE . 2.5 pp -134.38 139.28 48.3 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.673 0 N-CA-C 106.647 -1.612 . . . . 0.0 106.647 178.856 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . . . . . . . . . 6.3 tp -136.14 133.87 50.26 Favored 'Isoleucine or valine' 0 C--N 1.283 -2.287 0 N-CA-C 107.466 -1.309 . . . . 0.0 107.466 177.005 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . . . . . . . . . 10.9 m-20 -92.9 160.71 14.79 Favored 'General case' 0 C--N 1.286 -2.158 0 N-CA-C 109.21 -0.663 . . . . 0.0 109.21 -177.239 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 44.4 m-85 -143.48 118.34 9.94 Favored 'General case' 0 C--N 1.32 -0.714 0 N-CA-C 107.251 -1.388 . . . . 0.0 107.251 176.081 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.402 ' O ' ' HG3' ' A' ' 21' ' ' GLU . 13.0 pt-20 -124.94 101.06 6.88 Favored 'General case' 0 C--N 1.302 -1.47 0 C-N-CA 118.314 -1.354 . . . . 0.0 114.073 171.451 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.514 ' HB3' ' HA ' ' A' ' 105' ' ' SER . 22.7 mm-40 -154.29 101.46 2.38 Favored 'General case' 0 CA--C 1.507 -0.677 0 C-N-CA 124.377 1.071 . . . . 0.0 110.462 164.065 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 65.1 tttp -167.37 -73.06 0.03 OUTLIER 'General case' 0 C--N 1.312 -1.059 0 N-CA-C 109.061 -0.718 . . . . 0.0 109.061 176.399 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 -90.34 -33.39 16.1 Favored 'General case' 0 C--N 1.304 -1.395 0 CA-C-N 115.37 -0.832 . . . . 0.0 109.088 179.028 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 2.7 p -65.19 -69.57 0.29 Allowed 'General case' 0 N--CA 1.438 -1.034 0 CA-C-N 114.887 -1.051 . . . . 0.0 112.025 -178.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 26.3 t-20 66.7 107.53 0.04 OUTLIER 'General case' 0 N--CA 1.484 1.269 0 C-N-CA 124.476 1.11 . . . . 0.0 110.924 179.546 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.652 ' O ' ' HB3' ' A' ' 102' ' ' SER . . . 133.33 -147.31 18.96 Favored Glycine 0 CA--C 1.487 -1.66 0 C-N-CA 119.044 -1.55 . . . . 0.0 112.044 -177.157 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 52.7 Cg_exo -54.32 123.29 13.22 Favored 'Trans proline' 0 C--O 1.241 0.671 0 C-N-CA 122.512 2.141 . . . . 0.0 111.519 -177.408 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.553 HG23 ' HA ' ' A' ' 102' ' ' SER . 46.4 t -95.4 95.15 4.74 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.852 0 N-CA-C 107.582 -1.266 . . . . 0.0 107.582 -176.75 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 99.4 mttt -98.19 90.76 4.96 Favored 'General case' 0 N--CA 1.411 -2.418 0 CA-C-O 122.498 1.142 . . . . 0.0 108.981 -178.376 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.436 ' O ' HG22 ' A' ' 99' ' ' ILE . 27.3 m -124.28 151.61 29.52 Favored 'Isoleucine or valine' 0 C--N 1.273 -2.74 0 CA-C-N 113.001 -1.909 . . . . 0.0 109.724 -175.006 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.449 ' HA ' ' CG1' ' A' ' 97' ' ' VAL . 20.9 m-90 -135.48 145.89 47.59 Favored 'General case' 0 C--N 1.267 -3.005 0 CA-C-N 114.988 -1.005 . . . . 0.0 109.026 -175.447 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.538 ' H ' HG13 ' A' ' 97' ' ' VAL . . . -167.46 137.7 4.76 Favored Glycine 0 N--CA 1.424 -2.158 0 C-N-CA 118.046 -2.026 . . . . 0.0 112.638 172.772 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 13.7 p -118.38 138.71 52.25 Favored 'General case' 0 N--CA 1.393 -3.282 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -178.95 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . . . . . . . . . 45.4 mm -119.61 135.82 58.73 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.499 0 N-CA-C 108.253 -1.017 . . . . 0.0 108.253 -179.163 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 55.7 mttp -120.5 105.57 10.97 Favored 'General case' 0 C--N 1.31 -1.141 0 N-CA-C 105.92 -1.881 . . . . 0.0 105.92 173.404 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -111.93 174.84 16.78 Favored Glycine 0 C--N 1.269 -3.144 0 CA-C-N 116.17 -0.468 . . . . 0.0 112.893 -175.71 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 58.1 tp -66.01 137.42 57.1 Favored 'General case' 0 N--CA 1.437 -1.114 0 N-CA-C 104.384 -2.45 . . . . 0.0 104.384 173.281 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.449 ' HB ' ' HA ' ' A' ' 91' ' ' LYS . 17.9 p -68.72 108.96 3.6 Favored 'General case' 0 N--CA 1.417 -2.097 0 N-CA-C 115.766 1.765 . . . . 0.0 115.766 -160.123 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . . . . . . . . . 42.7 mt-10 -173.6 170.03 4.16 Favored 'General case' 0 CA--C 1.472 -2.047 0 N-CA-C 101.672 -3.455 . . . . 0.0 101.672 -179.022 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.798 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 169.2 136.55 2.08 Favored Glycine 2 C--N 1.241 -4.715 0 C-N-CA 117.481 -2.295 . . . . 0.0 113.129 167.556 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 96.6 mt -140.99 -50.39 0.44 Allowed 'General case' 0 N--CA 1.426 -1.672 0 O-C-N 124.553 0.796 . . . . 0.0 111.379 -177.037 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 41.5 t60 -149.83 153.49 36.85 Favored 'General case' 0 C--N 1.321 -0.665 0 O-C-N 121.922 -0.486 . . . . 0.0 109.792 -175.993 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.632 ' HA3' ' H ' ' A' ' 87' ' ' VAL . . . -96.59 107.5 3.52 Favored Glycine 0 CA--C 1.458 -3.478 0 N-CA-C 110.217 -1.153 . . . . 0.0 110.217 175.297 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.613 ' CG ' ' HB3' ' A' ' 124' ' ' ASP . 29.4 p90 -121.79 83.49 2.1 Favored 'General case' 0 C--N 1.288 -2.106 0 N-CA-C 112.529 0.566 . . . . 0.0 112.529 -178.899 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.56 ' HB2' HD12 ' A' ' 117' ' ' LEU . 8.2 p80 -133.04 85.47 2.22 Favored 'General case' 0 N--CA 1.387 -3.586 0 O-C-N 118.968 -2.333 . . . . 0.0 113.607 -162.47 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.536 ' HB ' ' O ' ' A' ' 82' ' ' GLY . 43.4 t -170.47 136.12 0.37 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.108 0 C-N-CA 127.753 2.421 . . . . 0.0 108.168 171.698 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.625 ' HB2' ' O ' ' A' ' 116' ' ' THR . 2.0 m170 -150.35 94.76 2.16 Favored 'General case' 0 C--N 1.26 -3.309 0 CA-C-N 112.458 -2.155 . . . . 0.0 109.916 170.386 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.403 ' HG3' ' CG1' ' A' ' 81' ' ' VAL . 0.4 OUTLIER -80.87 162.37 24.0 Favored 'General case' 0 N--CA 1.482 1.149 0 N-CA-C 107.39 -1.337 . . . . 0.0 107.39 176.829 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 54.9 t80 71.74 28.96 2.62 Favored 'General case' 0 C--N 1.326 -0.427 0 N-CA-C 106.783 -1.562 . . . . 0.0 106.783 -173.142 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.612 ' HA3' ' HA ' ' A' ' 115' ' ' ARG . . . -72.01 -170.47 13.98 Favored Glycine 0 N--CA 1.428 -1.883 0 CA-C-N 114.002 -1.454 . . . . 0.0 110.958 176.164 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 19.8 t70 -176.34 -63.04 0.01 OUTLIER 'General case' 0 C--N 1.297 -1.68 0 C-N-CA 119.582 -0.847 . . . . 0.0 111.552 -164.984 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 49.7 t-20 -108.28 121.91 45.86 Favored 'General case' 0 C--N 1.317 -0.846 0 CA-C-N 116.131 -0.486 . . . . 0.0 110.637 -173.437 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 4.1 p -70.81 2.62 4.02 Favored 'General case' 0 C--N 1.312 -1.036 0 N-CA-C 113.904 1.076 . . . . 0.0 113.904 -177.889 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -120.69 19.02 11.92 Favored 'General case' 0 C--N 1.311 -1.079 0 C-N-CA 122.318 0.247 . . . . 0.0 110.434 178.598 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . 154.78 131.54 1.49 Allowed Glycine 0 C--N 1.309 -0.923 0 C-N-CA 120.73 -0.748 . . . . 0.0 111.968 178.362 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.462 ' HB2' ' HG2' ' A' ' 143' ' ' ARG . 15.8 m -82.62 91.92 7.05 Favored 'General case' 0 C--N 1.302 -1.493 0 N-CA-C 109.316 -0.624 . . . . 0.0 109.316 179.024 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 2.0 t -78.56 -61.37 2.03 Favored 'General case' 0 N--CA 1.426 -1.661 0 O-C-N 124.11 0.881 . . . . 0.0 110.157 172.486 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 13.4 m -65.43 -47.2 77.04 Favored 'General case' 0 C--O 1.214 -0.806 0 C-N-CA 122.967 0.507 . . . . 0.0 111.941 -177.107 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.477 ' HB1' ' HB3' ' A' ' 48' ' ' HIS . . . -76.36 -6.65 52.53 Favored 'General case' 0 C--N 1.313 -1.011 0 N-CA-C 112.873 0.694 . . . . 0.0 112.873 -179.097 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -40.58 -71.57 0.29 Allowed Glycine 0 CA--C 1.541 1.706 0 N-CA-C 115.734 1.054 . . . . 0.0 115.734 -175.266 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 16.4 Cg_exo -72.12 -17.05 28.41 Favored 'Trans proline' 0 N--CA 1.48 0.684 0 C-N-CA 122.92 2.414 . . . . 0.0 112.381 -179.124 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 1.5 p-80 65.64 107.18 0.04 OUTLIER 'General case' 0 C--O 1.242 0.665 0 C-N-CA 126.611 1.965 . . . . 0.0 112.56 -177.771 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 52.5 t80 -130.29 84.09 2.18 Favored 'General case' 0 N--CA 1.42 -1.966 0 C-N-CA 118.306 -1.358 . . . . 0.0 108.474 166.261 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 6.0 p-10 -119.46 90.63 42.97 Favored Pre-proline 0 C--N 1.289 -2.033 0 CA-C-N 112.5 -2.136 . . . . 0.0 108.066 173.647 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 1.0 OUTLIER -30.1 -54.49 0.2 Allowed 'Trans proline' 0 N--CA 1.484 0.956 1 C-N-CA 126.735 4.957 . . . . 0.0 119.626 -168.864 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 82.2 mt -93.84 0.47 56.24 Favored 'General case' 0 C--N 1.32 -0.682 0 C-N-CA 118.688 -1.205 . . . . 0.0 113.843 -173.31 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.639 ' HA ' ' OE1' ' A' ' 78' ' ' GLU . 28.6 m -78.6 48.43 0.79 Allowed 'General case' 0 C--O 1.246 0.892 0 CA-C-O 122.386 1.089 . . . . 0.0 109.095 175.992 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.407 HH11 ' HD2' ' A' ' 69' ' ' ARG . 12.9 mmm180 -133.2 -28.77 1.48 Allowed 'General case' 0 C--N 1.292 -1.921 0 CA-C-N 114.324 -1.307 . . . . 0.0 111.283 -173.189 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . . . . . . . . . 54.3 tptt -38.84 -56.83 1.31 Allowed 'General case' 0 C--N 1.354 0.764 0 C-N-CA 124.105 0.962 . . . . 0.0 113.563 -173.227 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.493 ' H ' ' HA ' ' A' ' 78' ' ' GLU . 21.2 t-80 -177.61 59.94 0.01 OUTLIER 'General case' 0 C--O 1.208 -1.116 0 CA-C-O 119.161 -0.447 . . . . 0.0 110.011 176.334 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.511 ' HA2' ' HB3' ' A' ' 78' ' ' GLU . . . -38.93 105.98 0.05 OUTLIER Glycine 0 N--CA 1.483 1.83 0 O-C-N 123.744 0.653 . . . . 0.0 112.676 173.246 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -136.52 168.26 24.22 Favored Glycine 0 N--CA 1.413 -2.84 0 N-CA-C 109.841 -1.304 . . . . 0.0 109.841 -176.842 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 97.8 Cg_endo -93.29 1.72 3.45 Favored 'Trans proline' 0 N--CA 1.443 -1.484 0 C-N-CA 123.333 2.689 . . . . 0.0 115.985 -172.653 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.428 ' O ' ' HB3' ' A' ' 76' ' ' ASP . 87.1 mttt -108.5 -31.67 7.71 Favored 'General case' 0 C--O 1.262 1.715 0 C-N-CA 118.096 -1.442 . . . . 0.0 109.773 -179.834 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.428 ' HB3' ' O ' ' A' ' 75' ' ' LYS . 0.8 OUTLIER 159.3 120.09 0.0 OUTLIER 'General case' 0 CA--C 1.505 -0.758 0 C-N-CA 128.301 2.64 . . . . 0.0 104.291 168.813 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 6.9 mt-10 164.33 127.26 0.01 OUTLIER 'General case' 0 CA--C 1.454 -2.715 0 C-N-CA 124.459 1.104 . . . . 0.0 111.194 171.52 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.639 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.7 OUTLIER 162.75 -173.84 0.01 OUTLIER 'General case' 0 N--CA 1.396 -3.147 0 C-N-CA 130.885 3.674 . . . . 0.0 102.325 163.982 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.671 ' NE ' ' HA ' ' A' ' 79' ' ' ARG 0.381 1.4 mmp_? -121.01 11.25 10.95 Favored 'General case' 0 C--N 1.257 -3.415 0 N-CA-C 118.337 2.718 . . . . 0.0 118.337 -176.872 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.507 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.6 OUTLIER -138.8 -67.03 0.47 Allowed 'General case' 0 CA--C 1.483 -1.629 0 C-N-CA 117.37 -1.732 . . . . 0.0 110.804 170.006 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.45 HG22 HG11 ' A' ' 47' ' ' VAL . 7.1 p 174.33 89.57 0.0 OUTLIER 'Isoleucine or valine' 0 C--N 1.273 -2.737 0 N-CA-C 104.358 -2.46 . . . . 0.0 104.358 179.371 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.536 ' O ' ' HB ' ' A' ' 47' ' ' VAL . . . -112.43 -34.07 1.99 Allowed Glycine 0 CA--C 1.47 -2.749 0 CA-C-N 114.091 -1.413 . . . . 0.0 111.98 -174.962 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 0.8 OUTLIER -168.21 172.05 8.91 Favored 'General case' 0 N--CA 1.438 -1.056 0 O-C-N 124.305 0.65 . . . . 0.0 110.333 -179.454 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.639 HD23 ' H ' ' A' ' 85' ' ' GLY . 5.8 tt -138.23 170.9 15.21 Favored 'General case' 0 C--N 1.297 -1.677 0 O-C-N 125.391 1.682 . . . . 0.0 106.546 -174.44 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . 0.639 ' H ' HD23 ' A' ' 84' ' ' LEU . . . -38.89 147.53 0.13 Allowed Glycine 0 N--CA 1.466 0.686 0 C-N-CA 125.005 1.288 . . . . 0.0 114.948 -178.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 51.2 t-20 -79.49 136.3 36.87 Favored 'General case' 0 N--CA 1.424 -1.743 0 CA-C-N 114.682 -0.759 . . . . 0.0 109.162 -166.274 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.729 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 30.3 m -134.72 126.69 48.17 Favored 'Isoleucine or valine' 0 N--CA 1.411 -2.408 0 N-CA-C 105.384 -2.08 . . . . 0.0 105.384 -179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.461 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 12.6 t -141.28 148.2 39.42 Favored 'General case' 0 C--N 1.267 -3.001 0 N-CA-C 108.582 -0.896 . . . . 0.0 108.582 -177.571 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.798 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -132.76 154.38 50.29 Favored 'General case' 0 C--N 1.259 -3.326 0 N-CA-C 105.362 -2.088 . . . . 0.0 105.362 178.931 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.499 ' C ' ' H ' ' A' ' 92' ' ' ASP . 6.9 t70 -101.65 -153.45 0.46 Allowed 'General case' 1 C--N 1.225 -4.841 0 N-CA-C 105.701 -1.963 . . . . 0.0 105.701 176.548 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.449 ' HA ' ' HB ' ' A' ' 39' ' ' THR . 95.0 mttt -62.66 16.82 0.01 OUTLIER 'General case' 0 CA--C 1.58 2.116 0 O-C-N 121.587 -0.696 . . . . 0.0 112.845 171.405 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.499 ' H ' ' C ' ' A' ' 90' ' ' ASP . 17.0 t70 -133.68 109.65 9.31 Favored 'General case' 0 N--CA 1.436 -1.157 0 N-CA-C 103.849 -2.649 . . . . 0.0 103.849 171.369 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . -76.43 92.59 0.98 Allowed Glycine 0 C--N 1.32 -0.357 0 N-CA-C 114.911 0.725 . . . . 0.0 114.911 -170.456 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 46.7 t -158.46 103.79 0.08 OUTLIER 'Isoleucine or valine' 0 N--CA 1.445 -0.708 0 N-CA-C 105.366 -2.087 . . . . 0.0 105.366 176.016 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.729 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -96.18 128.75 43.37 Favored 'General case' 0 N--CA 1.398 -3.027 0 N-CA-C 108.486 -0.931 . . . . 0.0 108.486 177.677 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 26.2 t70 -82.15 153.36 26.06 Favored 'General case' 0 C--N 1.3 -1.584 0 O-C-N 124.144 0.902 . . . . 0.0 110.642 -174.94 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.538 HG13 ' H ' ' A' ' 33' ' ' GLY . 78.4 t -81.21 134.91 26.13 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.856 0 C-N-CA 124.203 1.001 . . . . 0.0 111.668 -172.694 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 61.5 m -122.97 123.76 41.65 Favored 'General case' 0 N--CA 1.414 -2.245 0 CA-C-N 114.522 -1.217 . . . . 0.0 109.045 172.86 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.436 HG22 ' O ' ' A' ' 31' ' ' VAL . 31.8 pt -94.43 160.39 2.72 Favored 'Isoleucine or valine' 0 C--O 1.25 1.106 0 N-CA-C 109.292 -0.633 . . . . 0.0 109.292 177.626 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.407 ' OE1' ' HA ' ' A' ' 84' ' ' LEU . 49.8 mt-10 -142.99 159.28 42.53 Favored 'General case' 0 N--CA 1.421 -1.881 0 CA-C-O 122.159 0.98 . . . . 0.0 113.239 -171.494 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 13.2 t70 -81.22 169.4 17.39 Favored 'General case' 0 C--N 1.278 -2.515 0 N-CA-C 106.791 -1.559 . . . . 0.0 106.791 172.007 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.652 ' HB3' ' O ' ' A' ' 27' ' ' GLY . 10.9 p -57.34 91.94 0.01 OUTLIER 'General case' 0 C--N 1.288 -2.108 0 N-CA-C 115.485 1.661 . . . . 0.0 115.485 -173.764 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 7.6 p -117.56 -38.16 2.07 Favored 'Isoleucine or valine' 0 CA--C 1.557 1.225 0 CA-C-N 115.966 -0.561 . . . . 0.0 111.063 173.014 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.405 ' O ' HG22 ' A' ' 104' ' ' ILE . 25.3 mm -72.37 25.53 0.02 OUTLIER 'Isoleucine or valine' 0 N--CA 1.501 2.103 0 C-N-CA 126.919 2.088 . . . . 0.0 111.936 -176.328 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.514 ' HA ' ' HB3' ' A' ' 22' ' ' GLN . 16.8 p -66.95 149.65 50.32 Favored 'General case' 0 N--CA 1.429 -1.491 0 O-C-N 121.667 -0.646 . . . . 0.0 110.831 -179.26 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . 0.308 0.9 OUTLIER -80.95 86.3 6.11 Favored 'General case' 0 N--CA 1.388 -3.536 0 CA-C-O 124.647 2.165 . . . . 0.0 111.505 178.573 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 25.7 m -149.85 85.95 1.43 Allowed 'General case' 2 N--CA 1.367 -4.613 1 N-CA-C 100.061 -4.051 . . . . 0.0 100.061 168.457 . . . . . . . . 3 2 . 1 . 013 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -125.31 -155.99 9.21 Favored Glycine 0 C--N 1.26 -3.674 0 CA-C-N 113.46 -1.7 . . . . 0.0 109.444 -177.254 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 16.3 t70 -92.2 -44.54 8.72 Favored 'General case' 0 C--N 1.287 -2.152 0 N-CA-C 107.791 -1.189 . . . . 0.0 107.791 -179.565 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.427 ' O ' ' HB2' ' A' ' 111' ' ' SER . 23.1 m80 -118.64 -50.77 2.4 Favored 'General case' 0 N--CA 1.434 -1.234 0 CA-C-N 115.742 -0.663 . . . . 0.0 111.444 175.018 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.427 ' HB2' ' O ' ' A' ' 110' ' ' HIS . 33.2 t 165.45 168.03 0.02 OUTLIER 'General case' 0 CA--C 1.494 -1.206 0 N-CA-C 107.315 -1.365 . . . . 0.0 107.315 177.182 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.522 ' O ' HG22 ' A' ' 149' ' ' ILE . 50.1 mm -71.72 -45.98 63.82 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.57 0 N-CA-C 109.375 -0.602 . . . . 0.0 109.375 176.481 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.483 ' H ' HD12 ' A' ' 113' ' ' ILE . 3.5 mp -71.71 121.25 21.47 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.348 0 O-C-N 121.726 -0.609 . . . . 0.0 111.764 -172.663 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 112.83 -0.05 25.81 Favored Glycine 0 CA--C 1.478 -2.225 0 C-N-CA 120.403 -0.903 . . . . 0.0 110.873 170.1 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.612 ' HA ' ' HA3' ' A' ' 51' ' ' GLY . 11.1 mmt180 -91.86 173.52 7.82 Favored 'General case' 0 N--CA 1.421 -1.892 0 CA-C-N 115.051 -0.574 . . . . 0.0 109.59 -178.708 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.625 ' O ' ' HB2' ' A' ' 48' ' ' HIS . 17.5 p -128.46 103.77 7.32 Favored 'General case' 0 N--CA 1.423 -1.811 0 CA-C-O 118.725 -0.655 . . . . 0.0 110.998 -173.301 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.587 HD22 ' O ' ' A' ' 148' ' ' VAL . 0.7 OUTLIER -76.26 137.16 39.76 Favored 'General case' 0 N--CA 1.486 1.342 0 CA-C-N 120.312 1.414 . . . . 0.0 111.573 -178.026 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.721 ' HA ' ' HB3' ' A' ' 146' ' ' CYS . 11.5 p -92.87 125.25 45.46 Favored 'Isoleucine or valine' 0 C--O 1.202 -1.436 0 N-CA-C 109.516 -0.55 . . . . 0.0 109.516 176.11 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 14.8 p -148.55 130.88 6.48 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.746 0 C-N-CA 118.961 -1.095 . . . . 0.0 113.115 -179.852 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 16.3 t-80 -154.93 151.33 28.41 Favored 'General case' 0 N--CA 1.416 -2.169 0 N-CA-C 102.348 -3.204 . . . . 0.0 102.348 163.168 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.49 ' O ' ' HA2' ' A' ' 41' ' ' GLY . 2.9 mp0 -70.3 99.52 1.56 Allowed 'General case' 0 C--N 1.269 -2.896 0 N-CA-C 106.241 -1.762 . . . . 0.0 106.241 174.12 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 52.5 tptt -168.31 173.83 7.46 Favored 'General case' 0 C--O 1.199 -1.59 0 N-CA-C 107.326 -1.361 . . . . 0.0 107.326 -171.834 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -84.01 120.48 26.17 Favored 'General case' 0 C--N 1.256 -3.471 0 N-CA-C 113.215 0.82 . . . . 0.0 113.215 177.733 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.613 ' HB3' ' CG ' ' A' ' 45' ' ' PHE . 0.0 OUTLIER -167.13 136.77 2.87 Favored 'General case' 0 N--CA 1.509 2.512 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.012 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.8 t70 -149.89 150.9 32.59 Favored 'General case' 0 C--N 1.298 -1.648 0 C-N-CA 119.402 -0.919 . . . . 0.0 109.823 -179.066 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 4.4 mm? -90.95 -39.31 12.33 Favored 'General case' 0 C--N 1.296 -1.747 0 N-CA-C 113.471 0.915 . . . . 0.0 113.471 -179.34 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -97.11 -33.91 5.84 Favored Glycine 0 C--N 1.3 -1.465 0 C-N-CA 119.753 -1.213 . . . . 0.0 111.65 -175.375 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 49.1 tptt -118.43 41.34 2.99 Favored 'General case' 0 C--N 1.295 -1.764 0 N-CA-C 108.689 -0.856 . . . . 0.0 108.689 -176.964 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -72.91 -7.24 69.8 Favored Glycine 0 CA--C 1.531 1.061 0 CA-C-N 115.463 -0.79 . . . . 0.0 114.736 -176.288 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 144.11 -122.42 1.81 Allowed Glycine 0 N--CA 1.448 -0.566 0 C-N-CA 119.655 -1.26 . . . . 0.0 113.492 177.81 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.452 ' O ' HG22 ' A' ' 135' ' ' THR . 88.9 m-20 -99.65 -174.54 2.74 Favored 'General case' 0 C--N 1.309 -1.178 0 N-CA-C 108.259 -1.015 . . . . 0.0 108.259 -177.583 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 3.0 tm-20 -47.09 -52.65 14.69 Favored 'General case' 0 N--CA 1.484 1.228 0 O-C-N 123.564 0.54 . . . . 0.0 111.264 -176.699 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 44.9 mt-10 -77.71 -40.85 39.9 Favored 'General case' 0 C--N 1.316 -0.887 0 N-CA-C 112.636 0.606 . . . . 0.0 112.636 -178.796 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 3.7 p -75.53 -27.17 58.59 Favored 'General case' 0 C--N 1.314 -0.941 0 N-CA-C 114.072 1.138 . . . . 0.0 114.072 -175.708 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.452 HG22 ' O ' ' A' ' 131' ' ' ASN . 13.9 t -76.12 -33.25 59.46 Favored 'General case' 0 C--N 1.323 -0.546 0 N-CA-C 108.556 -0.905 . . . . 0.0 108.556 176.237 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 35.7 ttpt -74.08 -32.54 63.3 Favored 'General case' 0 N--CA 1.443 -0.808 0 CA-C-N 115.268 -0.878 . . . . 0.0 109.727 -179.321 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 86.4 m -79.22 -31.05 43.55 Favored 'General case' 0 C--O 1.245 0.86 0 CA-C-N 115.41 -0.814 . . . . 0.0 109.304 174.788 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 56.73 60.94 8.1 Favored Glycine 0 CA--C 1.484 -1.884 0 N-CA-C 110.252 -1.139 . . . . 0.0 110.252 -179.766 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 3.5 m-20 -36.31 105.62 0.04 OUTLIER 'General case' 0 N--CA 1.489 1.502 0 O-C-N 125.733 1.49 . . . . 0.0 111.876 -174.694 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.487 ' HA ' ' HB2' ' A' ' 124' ' ' ASP . . . -101.8 169.93 8.48 Favored 'General case' 0 N--CA 1.429 -1.516 0 CA-C-N 114.571 -1.195 . . . . 0.0 111.92 -169.838 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.409 ' C ' ' H ' ' A' ' 143' ' ' ARG . . . -63.96 154.02 47.12 Favored Glycine 0 N--CA 1.406 -3.303 0 N-CA-C 106.481 -2.648 . . . . 0.0 106.481 169.921 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 1.0 OUTLIER -57.01 8.81 0.01 OUTLIER 'General case' 0 C--N 1.262 -3.223 0 N-CA-C 115.636 1.717 . . . . 0.0 115.636 -176.721 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.462 ' HG2' ' HB2' ' A' ' 57' ' ' CYS . 0.2 OUTLIER 65.67 19.17 11.39 Favored 'General case' 0 CA--C 1.467 -2.224 0 C-N-CA 125.277 1.431 . . . . 0.0 107.959 177.675 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 53.0 mt -70.94 -33.24 70.3 Favored 'General case' 0 CA--C 1.445 -3.072 0 CA-C-N 113.91 -1.495 . . . . 0.0 107.668 -176.723 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.432 ' O ' ' HB3' ' A' ' 146' ' ' CYS . . . -121.98 89.74 3.17 Favored 'General case' 1 N--CA 1.35 -5.458 0 CA-C-N 113.557 -1.656 . . . . 0.0 108.158 175.38 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.721 ' HB3' ' HA ' ' A' ' 118' ' ' VAL . 19.9 p -171.91 127.94 0.61 Allowed 'General case' 0 N--CA 1.428 -1.529 0 N-CA-C 113.812 1.042 . . . . 0.0 113.812 169.95 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.614 ' HA2' ' HB ' ' A' ' 116' ' ' THR . . . -178.51 77.93 0.07 OUTLIER Glycine 0 N--CA 1.402 -3.62 0 CA-C-O 118.638 -1.09 . . . . 0.0 110.656 159.009 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.65 HG21 ' HA ' ' A' ' 6' ' ' ALA . 13.1 p -172.58 96.17 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.556 1.184 0 N-CA-C 115.457 1.651 . . . . 0.0 115.457 169.727 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.559 ' CD1' ' HB3' ' A' ' 117' ' ' LEU . 12.2 mm -124.46 102.68 11.28 Favored 'Isoleucine or valine' 1 C--N 1.234 -4.445 0 N-CA-C 104.692 -2.336 . . . . 0.0 104.692 167.364 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . -165.59 146.56 11.25 Favored Glycine 2 CA--C 1.444 -4.394 0 C-N-CA 115.941 -3.028 . . . . 0.0 112.678 175.458 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.545 ' HA ' ' CB ' ' A' ' 4' ' ' ALA . 0.0 OUTLIER -95.26 105.56 17.14 Favored 'Isoleucine or valine' 0 N--CA 1.428 -1.568 0 N-CA-C 107.363 -1.347 . . . . 0.0 107.363 171.98 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -132.92 99.61 4.64 Favored 'General case' 0 C--N 1.306 -1.323 0 CA-C-N 115.391 -0.822 . . . . 0.0 109.441 179.135 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 20.4 tm0? . . . . . 0 C--O 1.245 0.863 0 N-CA-C 105.466 -2.049 . . . . 0.0 105.466 178.07 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.207 -1.145 0 N-CA-C 111.944 0.35 . . . . 0.0 111.944 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 8.5 m -100.48 -27.63 13.33 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 113.176 0.806 . . . . 0.0 113.176 -171.536 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 88.4 tttt -136.66 148.62 47.51 Favored 'General case' 0 C--N 1.307 -1.25 0 C-N-CA 119.46 -0.896 . . . . 0.0 111.169 -173.255 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.586 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -142.35 143.19 32.63 Favored 'General case' 0 N--CA 1.412 -2.328 0 N-CA-C 106.886 -1.524 . . . . 0.0 106.886 176.693 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.57 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 92.1 t -124.26 129.13 74.12 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.409 0 N-CA-C 107.82 -1.178 . . . . 0.0 107.82 -179.689 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.406 ' HB2' HG12 ' A' ' 149' ' ' ILE . . . -120.11 145.61 46.74 Favored 'General case' 0 C--N 1.282 -2.343 0 CA-C-N 115.825 -0.625 . . . . 0.0 109.939 -177.22 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 56.5 t -127.38 126.07 66.94 Favored 'Isoleucine or valine' 0 C--N 1.311 -1.088 0 N-CA-C 108.209 -1.034 . . . . 0.0 108.209 -179.498 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 85.3 mt -112.1 133.08 54.47 Favored 'General case' 0 C--N 1.302 -1.494 0 N-CA-C 109.364 -0.606 . . . . 0.0 109.364 179.605 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 59.2 mtpt -142.6 133.54 25.68 Favored 'General case' 0 C--N 1.314 -0.955 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 -179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -155.68 -170.89 21.59 Favored Glycine 0 N--CA 1.43 -1.712 0 C-N-CA 119.362 -1.399 . . . . 0.0 112.553 -177.312 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -73.31 -46.1 51.49 Favored 'General case' 0 CA--C 1.51 -0.578 0 N-CA-C 107.737 -1.208 . . . . 0.0 107.737 177.282 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -101.58 96.29 1.47 Allowed Glycine 0 N--CA 1.431 -1.694 0 N-CA-C 106.024 -2.83 . . . . 0.0 106.024 171.089 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 61.8 Cg_endo -71.53 127.09 12.79 Favored 'Trans proline' 0 N--CA 1.434 -1.986 0 C-N-CA 121.797 1.665 . . . . 0.0 113.968 -168.48 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 34.8 m -110.91 148.28 14.38 Favored 'Isoleucine or valine' 0 N--CA 1.393 -3.286 0 N-CA-C 105.299 -2.111 . . . . 0.0 105.299 173.309 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 48.1 mt-30 -123.94 118.64 27.51 Favored 'General case' 0 C--N 1.259 -3.355 0 N-CA-C 108.784 -0.821 . . . . 0.0 108.784 -177.178 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.427 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -167.26 146.48 10.77 Favored Glycine 0 N--CA 1.409 -3.101 0 C-N-CA 119.921 -1.133 . . . . 0.0 111.891 -178.03 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 24.2 pt -130.66 118.24 41.7 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.367 0 N-CA-C 107.758 -1.201 . . . . 0.0 107.758 178.184 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.742 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.1 OUTLIER -114.88 133.04 62.27 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.852 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.103 -176.708 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.538 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 24.0 m-80 -109.46 119.73 40.33 Favored 'General case' 0 CA--C 1.51 -0.589 0 C-N-CA 123.309 0.644 . . . . 0.0 109.592 -173.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.586 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 56.7 m-85 -120.76 137.41 54.52 Favored 'General case' 0 C--N 1.319 -0.751 0 CA-C-O 120.779 0.323 . . . . 0.0 110.617 179.602 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.529 ' O ' ' HA ' ' A' ' 104' ' ' ILE . 9.9 pt-20 -107.89 134.0 51.45 Favored 'General case' 0 C--N 1.299 -1.611 0 CA-C-N 115.613 -0.721 . . . . 0.0 109.418 175.809 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.571 ' HA ' ' O ' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -126.91 112.45 15.32 Favored 'General case' 0 N--CA 1.413 -2.307 0 C-N-CA 123.777 0.831 . . . . 0.0 109.459 178.309 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 56.8 tttm -138.12 149.07 45.58 Favored 'General case' 0 N--CA 1.42 -1.946 0 CA-C-N 115.504 -0.771 . . . . 0.0 110.34 -173.032 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.609 ' H ' ' CD ' ' A' ' 24' ' ' GLU . 2.1 mp0 -50.51 -44.29 56.05 Favored 'General case' 0 C--N 1.318 -0.771 0 C-N-CA 125.728 1.611 . . . . 0.0 110.332 -179.786 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 7.6 m -51.72 -45.24 63.51 Favored 'General case' 0 C--O 1.237 0.428 0 C-N-CA 124.651 1.18 . . . . 0.0 111.913 -178.099 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.432 ' HA ' HG23 ' A' ' 104' ' ' ILE . 9.8 t30 57.62 87.59 0.06 Allowed 'General case' 0 CA--C 1.532 0.286 0 O-C-N 124.294 0.996 . . . . 0.0 111.917 -179.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.528 ' H ' HD13 ' A' ' 104' ' ' ILE . . . -132.47 -151.6 6.79 Favored Glycine 0 CA--C 1.492 -1.361 0 CA-C-N 115.318 -0.855 . . . . 0.0 111.19 -177.093 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 20.3 Cg_exo -67.6 124.18 11.67 Favored 'Trans proline' 0 N--CA 1.446 -1.269 0 C-N-CA 122.215 1.943 . . . . 0.0 108.01 173.911 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.682 HG11 HG12 ' A' ' 103' ' ' VAL . 13.4 p -80.01 132.69 31.3 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.632 0 CA-C-O 121.23 0.538 . . . . 0.0 110.5 -176.632 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 65.2 tttm -93.98 99.21 11.58 Favored 'General case' 0 C--N 1.277 -2.58 0 N-CA-C 107.729 -1.212 . . . . 0.0 107.729 169.734 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . . . . . . . . . 5.9 p -123.44 130.54 74.13 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.001 0 CA-C-N 115.311 -0.858 . . . . 0.0 108.711 -175.015 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 52.4 m95 -136.44 125.49 24.42 Favored 'General case' 0 C--N 1.301 -1.529 0 CA-C-N 116.276 -0.42 . . . . 0.0 110.498 -179.264 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.742 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -164.25 140.17 6.29 Favored Glycine 0 N--CA 1.41 -3.045 0 C-N-CA 119.724 -1.226 . . . . 0.0 111.933 172.745 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.48 ' HA ' ' O ' ' A' ' 95' ' ' ALA . 16.9 m -116.04 135.46 53.93 Favored 'General case' 0 N--CA 1.404 -2.77 0 N-CA-C 108.159 -1.052 . . . . 0.0 108.159 -179.048 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.531 ' O ' ' HA ' ' A' ' 94' ' ' VAL . 12.1 tt -125.13 136.94 59.25 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.288 0 CA-C-N 118.54 0.609 . . . . 0.0 109.976 179.183 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.635 ' HA ' ' O ' ' A' ' 93' ' ' GLY . 91.7 mttt -116.92 131.84 56.85 Favored 'General case' 0 N--CA 1.416 -2.154 0 N-CA-C 105.128 -2.175 . . . . 0.0 105.128 -177.839 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.592 ' O ' ' HA3' ' A' ' 93' ' ' GLY . . . -155.0 175.8 32.91 Favored Glycine 0 C--N 1.269 -3.169 0 N-CA-C 110.383 -1.087 . . . . 0.0 110.383 -166.751 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 2.8 mm? -68.62 171.0 8.23 Favored 'General case' 0 C--N 1.295 -1.771 0 N-CA-C 108.523 -0.917 . . . . 0.0 108.523 175.274 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . . . . . . . . . 3.0 t -69.47 107.18 3.25 Favored 'General case' 0 C--N 1.319 -0.741 0 C-N-CA 120.123 -0.631 . . . . 0.0 111.809 -175.153 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.571 ' OE2' ' HG2' ' A' ' 122' ' ' LYS . 22.2 tt0 -177.08 171.13 2.14 Favored 'General case' 0 N--CA 1.419 -2.011 0 N-CA-C 103.668 -2.716 . . . . 0.0 103.668 171.473 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . 0.716 ' HA3' ' O ' ' A' ' 89' ' ' ALA . . . 170.78 104.83 0.18 Allowed Glycine 1 C--N 1.251 -4.144 0 C-N-CA 119.02 -1.562 . . . . 0.0 111.843 169.543 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.426 ' HB2' ' N ' ' A' ' 123' ' ' ALA . 6.8 mp -110.78 -86.89 0.53 Allowed 'General case' 0 N--CA 1.437 -1.107 0 N-CA-C 113.59 0.959 . . . . 0.0 113.59 -178.062 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.657 ' HA ' ' O ' ' A' ' 87' ' ' VAL . 39.4 t-80 -175.15 122.3 0.22 Allowed 'General case' 0 C--N 1.355 0.823 0 C-N-CA 118.364 -1.335 . . . . 0.0 114.35 -173.388 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.456 ' H ' ' H ' ' A' ' 87' ' ' VAL . . . 102.99 137.94 9.74 Favored Glycine 0 C--N 1.3 -1.432 0 N-CA-C 117.502 1.761 . . . . 0.0 117.502 164.635 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.491 ' CE2' HG21 ' A' ' 18' ' ' ILE . 0.7 OUTLIER -96.18 166.73 11.6 Favored 'General case' 0 C--N 1.313 -0.992 0 C-N-CA 124.028 0.931 . . . . 0.0 109.359 170.179 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.715 ' HB2' ' OD1' ' A' ' 124' ' ' ASP . 6.1 m80 -171.83 90.44 0.12 Allowed 'General case' 0 CA--C 1.482 -1.661 0 C-N-CA 125.298 1.439 . . . . 0.0 110.004 169.414 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.627 ' HA ' ' HA ' ' A' ' 117' ' ' LEU . 2.6 p -69.36 162.7 3.72 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.661 0 N-CA-C 106.524 -1.658 . . . . 0.0 106.524 168.942 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.49 ' CE1' ' HD2' ' A' ' 62' ' ' PRO 0.278 0.0 OUTLIER -148.85 171.49 16.21 Favored 'General case' 0 N--CA 1.419 -1.979 0 C-N-CA 116.562 -2.055 . . . . 0.0 109.482 170.187 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.481 ' HB3' ' CG2' ' A' ' 81' ' ' VAL . 1.9 pm0 -69.57 166.35 19.16 Favored 'General case' 0 C--N 1.261 -3.273 0 N-CA-C 116.072 1.879 . . . . 0.0 116.072 -171.043 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.576 ' CD2' ' HB3' ' A' ' 59' ' ' SER . 4.0 t80 72.77 33.26 1.32 Allowed 'General case' 0 N--CA 1.439 -1.023 0 C-N-CA 126.321 1.848 . . . . 0.0 107.243 172.022 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.422 ' HA2' ' HB2' ' A' ' 60' ' ' ALA . . . -57.56 154.84 20.49 Favored Glycine 0 C--N 1.345 1.048 0 CA-C-N 112.42 -2.173 . . . . 0.0 113.063 -178.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.537 ' OD1' ' HA ' ' A' ' 57' ' ' CYS . 3.8 p30 -144.8 -85.75 0.13 Allowed 'General case' 0 C--N 1.29 -1.999 0 N-CA-C 114.808 1.41 . . . . 0.0 114.808 -172.901 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.55 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 52.7 t30 -98.31 148.77 23.31 Favored 'General case' 0 C--N 1.314 -0.956 0 CA-C-O 121.288 0.566 . . . . 0.0 112.43 -173.392 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.577 ' HA ' ' HA2' ' A' ' 147' ' ' GLY . 6.9 m -82.3 -2.93 54.26 Favored 'General case' 0 CA--C 1.56 1.349 0 C-N-CA 124.323 1.049 . . . . 0.0 111.652 -176.102 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -125.99 17.06 7.92 Favored 'General case' 0 C--N 1.315 -0.893 0 CA-C-O 121.097 0.475 . . . . 0.0 111.02 -177.828 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.55 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 143.94 117.16 1.16 Allowed Glycine 0 CA--C 1.484 -1.864 0 N-CA-C 109.347 -1.501 . . . . 0.0 109.347 -177.374 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.587 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.1 p -97.53 113.69 25.44 Favored 'General case' 0 C--N 1.281 -2.39 0 N-CA-C 113.461 0.911 . . . . 0.0 113.461 -175.949 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 41.0 p -80.0 -45.42 18.44 Favored 'General case' 0 C--N 1.305 -1.351 0 N-CA-C 112.358 0.503 . . . . 0.0 112.358 179.593 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.576 ' HB3' ' CD2' ' A' ' 50' ' ' PHE . 49.8 m -79.37 -29.0 41.94 Favored 'General case' 0 C--N 1.319 -0.743 0 C-N-CA 123.445 0.698 . . . . 0.0 111.216 -174.724 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.587 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -76.71 -5.26 47.28 Favored 'General case' 0 N--CA 1.428 -1.539 0 C-N-CA 123.981 0.912 . . . . 0.0 111.19 172.443 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -101.22 52.1 0.91 Allowed Glycine 0 CA--C 1.559 2.801 0 C-N-CA 117.177 -2.439 . . . . 0.0 116.247 176.369 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.529 ' HD3' ' O ' ' A' ' 59' ' ' SER . 86.9 Cg_endo -96.37 2.93 1.99 Allowed 'Trans proline' 0 C--N 1.397 3.127 0 CA-C-N 121.821 2.81 . . . . 0.0 107.322 161.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 38.9 m80 75.22 -47.75 0.61 Allowed 'General case' 0 N--CA 1.489 1.48 0 C-N-CA 125.541 1.536 . . . . 0.0 113.623 173.772 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 70.1 t80 -69.27 116.12 9.34 Favored 'General case' 0 CA--C 1.552 1.036 0 N-CA-C 114.15 1.167 . . . . 0.0 114.15 -170.655 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.584 ' HB2' HG13 ' A' ' 81' ' ' VAL . 5.5 p30 -116.16 96.49 47.49 Favored Pre-proline 0 CA--C 1.559 1.309 0 C-N-CA 125.061 1.344 . . . . 0.0 110.089 176.82 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 96.7 Cg_endo -79.95 -18.7 10.06 Favored 'Trans proline' 0 CA--C 1.552 1.384 0 C-N-CA 123.119 2.546 . . . . 0.0 117.823 -169.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.421 ' HB3' ' HB2' ' A' ' 79' ' ' ARG . 84.0 mt -88.09 -5.32 58.52 Favored 'General case' 0 CA--C 1.484 -1.567 0 O-C-N 120.817 -1.177 . . . . 0.0 110.906 -172.719 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.433 ' C ' ' H ' ' A' ' 70' ' ' LYS . 17.9 m -77.92 58.05 1.85 Allowed 'General case' 0 N--CA 1.424 -1.746 0 N-CA-C 104.533 -2.395 . . . . 0.0 104.533 167.039 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.526 ' HB3' ' OE1' ' A' ' 78' ' ' GLU . 2.1 tmm_? -92.59 17.56 9.98 Favored 'General case' 0 N--CA 1.443 -0.788 0 N-CA-C 106.26 -1.756 . . . . 0.0 106.26 -169.329 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.503 ' HB2' ' CB ' ' A' ' 78' ' ' GLU . 11.9 mptt -140.03 63.97 1.46 Allowed 'General case' 0 N--CA 1.411 -2.402 0 CA-C-N 112.705 -2.043 . . . . 0.0 109.411 175.135 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . 0.446 ' O ' ' HB3' ' A' ' 126' ' ' LEU . 20.2 t60 65.38 -37.57 0.24 Allowed 'General case' 0 N--CA 1.498 1.948 0 C-N-CA 125.313 1.445 . . . . 0.0 113.284 -178.984 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 82.13 20.68 62.34 Favored Glycine 0 N--CA 1.414 -2.816 0 N-CA-C 109.87 -1.292 . . . . 0.0 109.87 -175.517 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.604 ' O ' ' HG3' ' A' ' 77' ' ' GLU . . . -90.31 175.53 41.14 Favored Glycine 0 C--O 1.202 -1.897 0 CA-C-O 118.734 -1.037 . . . . 0.0 111.863 -177.107 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.515 ' C ' ' H ' ' A' ' 76' ' ' ASP . 2.8 Cg_exo -72.07 2.34 4.99 Favored 'Trans proline' 0 N--CA 1.501 1.926 1 C-N-CA 125.717 4.278 . . . . 0.0 111.302 -170.562 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.414 ' H ' ' C ' ' A' ' 73' ' ' GLY . 60.9 tttm -76.59 27.59 0.13 Allowed 'General case' 0 C--N 1.297 -1.705 0 C-N-CA 127.402 2.281 . . . . 0.0 109.089 178.669 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.515 ' H ' ' C ' ' A' ' 74' ' ' PRO 0.303 1.2 p30 77.18 10.32 2.51 Favored 'General case' 0 C--N 1.314 -0.976 0 C-N-CA 128.453 2.701 . . . . 0.0 115.665 173.597 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.604 ' HG3' ' O ' ' A' ' 73' ' ' GLY . 1.7 mp0 33.19 108.19 0.0 OUTLIER 'General case' 0 N--CA 1.501 2.111 0 C-N-CA 127.639 2.375 . . . . 0.0 114.089 170.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.526 ' OE1' ' HB3' ' A' ' 69' ' ' ARG . 43.1 tt0 -34.73 -61.66 0.39 Allowed 'General case' 0 N--CA 1.507 2.392 0 O-C-N 123.914 0.759 . . . . 0.0 112.133 -177.747 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.421 ' HB2' ' HB3' ' A' ' 67' ' ' LEU . 75.0 mtt85 -136.62 63.64 1.57 Allowed 'General case' 0 C--N 1.286 -2.177 0 C-N-CA 118.834 -1.146 . . . . 0.0 111.056 174.778 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.6 ' NE2' ' HB2' ' A' ' 105' ' ' SER . 0.3 OUTLIER -38.86 94.26 0.01 OUTLIER 'General case' 0 CA--C 1.505 -0.751 0 CA-C-O 122.729 1.252 . . . . 0.0 113.375 171.455 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.584 HG13 ' HB2' ' A' ' 65' ' ' ASN . 3.3 p -80.97 -10.73 12.43 Favored 'Isoleucine or valine' 0 N--CA 1.427 -1.616 0 CA-C-N 112.224 -2.262 . . . . 0.0 105.379 169.496 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.539 ' O ' ' HB2' ' A' ' 80' ' ' HIS . . . -123.6 -132.25 3.91 Favored Glycine 1 N--CA 1.369 -5.825 0 CA-C-N 111.942 -2.39 . . . . 0.0 108.27 169.517 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.554 ' OD1' HG12 ' A' ' 47' ' ' VAL . 2.0 p-10 -164.4 165.9 21.12 Favored 'General case' 0 C--N 1.284 -2.282 0 N-CA-C 105.87 -1.9 . . . . 0.0 105.87 177.992 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.454 ' CD1' ' HA2' ' A' ' 73' ' ' GLY . 1.6 tt -144.46 87.76 1.89 Allowed 'General case' 0 N--CA 1.423 -1.823 0 C-N-CA 118.342 -1.343 . . . . 0.0 109.28 161.483 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -90.02 136.51 13.52 Favored Glycine 0 N--CA 1.419 -2.487 0 N-CA-C 104.853 -3.299 . . . . 0.0 104.853 165.665 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.415 ' HA ' ' HA2' ' A' ' 44' ' ' GLY 0.359 0.2 OUTLIER -92.11 128.69 38.05 Favored 'General case' 0 N--CA 1.426 -1.645 0 C-N-CA 115.171 -2.611 . . . . 0.0 113.318 -173.189 . . . . . . . . 4 4 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.657 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 92.6 t -110.64 138.7 37.56 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.584 0 CA-C-N 114.114 -1.403 . . . . 0.0 109.186 -174.945 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 8.5 p -140.15 95.09 2.83 Favored 'General case' 0 N--CA 1.442 -0.868 0 N-CA-C 108.408 -0.96 . . . . 0.0 108.408 -179.07 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.716 ' O ' ' HA3' ' A' ' 41' ' ' GLY . . . -86.14 137.03 32.97 Favored 'General case' 0 N--CA 1.415 -2.217 0 CA-C-O 121.406 0.622 . . . . 0.0 109.945 -176.966 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.48 ' C ' ' H ' ' A' ' 92' ' ' ASP . 30.8 t70 -75.23 154.62 37.44 Favored 'General case' 1 C--N 1.242 -4.103 0 N-CA-C 106.735 -1.58 . . . . 0.0 106.735 174.516 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 18.4 ptpt -53.07 23.07 0.0 OUTLIER 'General case' 0 CA--C 1.579 2.094 0 N-CA-C 115.839 1.792 . . . . 0.0 115.839 174.488 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.48 ' H ' ' C ' ' A' ' 90' ' ' ASP . 1.5 m-20 -133.89 8.63 3.82 Favored 'General case' 0 C--N 1.297 -1.677 0 C-N-CA 124.945 1.298 . . . . 0.0 108.787 171.674 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.635 ' O ' ' HA ' ' A' ' 36' ' ' LYS . . . 66.8 80.08 0.2 Allowed Glycine 0 N--CA 1.44 -1.046 0 CA-C-N 114.998 -1.001 . . . . 0.0 112.564 -178.595 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.531 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.5 p -161.71 113.01 0.09 OUTLIER 'Isoleucine or valine' 0 N--CA 1.431 -1.386 0 N-CA-C 108.962 -0.755 . . . . 0.0 108.962 -179.903 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.48 ' O ' ' HA ' ' A' ' 34' ' ' SER . . . -136.8 144.63 43.81 Favored 'General case' 0 N--CA 1.418 -2.072 0 N-CA-C 109.277 -0.638 . . . . 0.0 109.277 177.807 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 35.3 m-20 -119.58 115.14 23.38 Favored 'General case' 0 C--N 1.297 -1.712 0 N-CA-C 107.313 -1.366 . . . . 0.0 107.313 175.381 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.434 HG11 ' CE2' ' A' ' 45' ' ' PHE . 4.3 p -102.92 103.41 15.04 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.352 0 CA-C-O 122.173 0.987 . . . . 0.0 111.714 -178.472 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 37.2 m -139.65 100.18 3.9 Favored 'General case' 0 N--CA 1.421 -1.894 0 N-CA-C 106.851 -1.537 . . . . 0.0 106.851 172.736 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.9 mm -135.3 128.45 48.62 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.401 0 N-CA-C 107.571 -1.27 . . . . 0.0 107.571 -176.471 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 29' ' ' VAL . 43.0 mt-10 -104.5 106.19 16.59 Favored 'General case' 0 C--N 1.306 -1.307 0 N-CA-C 113.861 1.06 . . . . 0.0 113.861 -174.155 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 30.8 t0 -160.51 168.66 24.6 Favored 'General case' 0 C--N 1.309 -1.182 0 N-CA-C 104.369 -2.456 . . . . 0.0 104.369 170.722 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.504 ' O ' ' HB2' ' A' ' 76' ' ' ASP . 24.8 m -80.76 79.18 7.45 Favored 'General case' 0 C--N 1.3 -1.569 0 N-CA-C 115.726 1.75 . . . . 0.0 115.726 -169.344 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.682 HG12 HG11 ' A' ' 29' ' ' VAL . 12.4 p -92.51 -11.62 9.27 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.402 0 N-CA-C 105.449 -2.056 . . . . 0.0 105.449 169.476 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.571 ' O ' ' HA ' ' A' ' 22' ' ' GLN . 15.9 tt -57.87 19.84 0.0 OUTLIER 'Isoleucine or valine' 0 CA--C 1.58 2.102 0 C-N-CA 130.201 3.4 . . . . 0.0 114.235 -176.306 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.6 ' HB2' ' NE2' ' A' ' 80' ' ' HIS . 16.4 m -97.85 170.91 8.64 Favored 'General case' 0 C--N 1.271 -2.815 0 N-CA-C 103.627 -2.731 . . . . 0.0 103.627 166.435 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.428 ' O ' HD12 ' A' ' 106' ' ' LEU . 2.6 pp -68.14 119.13 12.23 Favored 'General case' 0 N--CA 1.414 -2.24 0 C-N-CA 117.689 -1.605 . . . . 0.0 109.467 176.274 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 13.6 m -68.95 89.75 0.42 Allowed 'General case' 0 N--CA 1.414 -2.234 0 CA-C-N 114.56 -1.2 . . . . 0.0 108.303 179.478 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 155.27 155.69 7.44 Favored Glycine 0 N--CA 1.401 -3.64 0 CA-C-N 114.155 -1.384 . . . . 0.0 110.501 -179.637 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.466 ' HB3' HG23 ' A' ' 81' ' ' VAL . 16.9 p-10 -69.66 -38.91 77.29 Favored 'General case' 0 C--N 1.301 -1.54 0 N-CA-C 109.949 -0.389 . . . . 0.0 109.949 174.696 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 10.9 t-80 -107.37 -48.07 3.52 Favored 'General case' 0 N--CA 1.441 -0.904 0 C-N-CA 119.094 -1.042 . . . . 0.0 112.266 -175.946 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.56 ' O ' ' HD2' ' A' ' 115' ' ' ARG . 15.3 m -163.04 159.92 23.9 Favored 'General case' 0 C--N 1.32 -0.711 0 N-CA-C 108.473 -0.936 . . . . 0.0 108.473 -178.61 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.701 ' H ' HD13 ' A' ' 112' ' ' ILE . 0.2 OUTLIER -72.79 -46.6 52.72 Favored 'Isoleucine or valine' 0 C--O 1.212 -0.894 0 N-CA-C 108.7 -0.852 . . . . 0.0 108.7 172.077 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 6.5 tp -67.56 127.15 28.7 Favored 'Isoleucine or valine' 0 N--CA 1.438 -1.055 0 N-CA-C 107.399 -1.334 . . . . 0.0 107.399 176.766 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 92.98 11.93 58.29 Favored Glycine 0 N--CA 1.421 -2.344 0 C-N-CA 119.611 -1.28 . . . . 0.0 110.768 -177.54 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.56 ' HD2' ' O ' ' A' ' 111' ' ' SER . 0.0 OUTLIER -114.67 121.55 43.73 Favored 'General case' 0 C--N 1.309 -1.169 0 N-CA-C 107.387 -1.338 . . . . 0.0 107.387 174.237 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.809 ' HB ' ' SG ' ' A' ' 146' ' ' CYS . 14.9 p -98.45 135.56 39.83 Favored 'General case' 0 N--CA 1.415 -2.211 0 CA-C-O 121.856 0.836 . . . . 0.0 111.638 179.727 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.627 ' HA ' ' HA ' ' A' ' 47' ' ' VAL . 56.2 tp -74.66 102.87 4.74 Favored 'General case' 0 C--N 1.304 -1.376 0 CA-C-N 113.937 -1.483 . . . . 0.0 111.485 -174.442 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.454 HG12 ' HA ' ' A' ' 142' ' ' SER . 12.6 m -93.21 96.36 6.12 Favored 'Isoleucine or valine' 1 C--O 1.33 5.293 0 C-N-CA 116.314 -2.154 . . . . 0.0 112.821 175.035 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.438 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 7.1 p -150.5 171.57 1.42 Allowed 'Isoleucine or valine' 0 N--CA 1.436 -1.136 0 CA-C-N 113.46 -1.7 . . . . 0.0 107.992 -176.836 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.465 ' HB2' ' HB3' ' A' ' 144' ' ' LEU . 82.2 t60 -152.04 170.76 19.12 Favored 'General case' 0 C--N 1.287 -2.129 0 N-CA-C 103.726 -2.694 . . . . 0.0 103.726 168.419 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . . . . . . . . . 2.5 pm0 -69.77 88.37 0.54 Allowed 'General case' 0 CA--C 1.551 0.983 0 CA-C-N 123.016 2.643 . . . . 0.0 109.045 175.211 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.571 ' HG2' ' OE2' ' A' ' 40' ' ' GLU . 65.8 mttm -166.75 173.31 9.68 Favored 'General case' 0 CA--C 1.503 -0.854 0 C-N-CA 125.771 1.628 . . . . 0.0 108.318 -168.226 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.616 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -82.68 114.52 21.1 Favored 'General case' 0 C--N 1.308 -1.225 0 N-CA-C 107.871 -1.159 . . . . 0.0 107.871 172.149 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.715 ' OD1' ' HB2' ' A' ' 46' ' ' HIS . 11.9 t70 -124.31 76.58 1.49 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.172 -1.418 . . . . 0.0 107.172 -176.717 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 25.9 t0 -114.43 158.59 21.35 Favored 'General case' 0 C--N 1.305 -1.334 0 CA-C-O 121.155 0.502 . . . . 0.0 110.548 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.472 ' O ' ' HA ' ' A' ' 135' ' ' THR . 3.2 tm? -87.85 -56.35 3.38 Favored 'General case' 0 C--N 1.29 -1.989 0 CA-C-N 114.467 -1.242 . . . . 0.0 108.007 -179.381 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . 0.427 ' HA3' ' CE1' ' A' ' 71' ' ' HIS . . . -68.26 -40.63 87.44 Favored Glycine 0 N--CA 1.449 -0.487 0 CA-C-N 115.787 -0.642 . . . . 0.0 112.725 -177.83 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 83.8 tttt -105.43 50.74 0.77 Allowed 'General case' 0 C--N 1.3 -1.558 0 N-CA-C 108.316 -0.994 . . . . 0.0 108.316 178.246 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -65.88 -30.25 76.73 Favored Glycine 0 CA--C 1.525 0.699 0 CA-C-N 115.247 -0.888 . . . . 0.0 112.588 179.222 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 137.46 -67.29 0.53 Allowed Glycine 0 N--CA 1.441 -1.023 0 C-N-CA 121.189 -0.529 . . . . 0.0 112.379 177.978 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.461 ' H ' ' CB ' ' A' ' 134' ' ' SER . 4.1 m-20 -105.99 176.81 5.04 Favored 'General case' 0 N--CA 1.489 1.511 0 CA-C-O 119.052 -0.499 . . . . 0.0 109.945 -179.121 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 4.6 tm-20 -56.18 -44.07 79.02 Favored 'General case' 0 CA--C 1.567 1.634 0 N-CA-C 108.995 -0.743 . . . . 0.0 108.995 176.203 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 7.9 pt-20 -71.85 -33.39 68.4 Favored 'General case' 0 N--CA 1.476 0.848 0 N-CA-C 112.23 0.456 . . . . 0.0 112.23 179.928 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.461 ' CB ' ' H ' ' A' ' 131' ' ' ASN . 2.3 m -68.1 -19.97 64.89 Favored 'General case' 0 C--N 1.314 -0.953 0 CA-C-O 120.969 0.414 . . . . 0.0 110.887 -175.733 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.472 ' HA ' ' O ' ' A' ' 126' ' ' LEU . 8.8 m -74.0 -21.3 60.04 Favored 'General case' 0 N--CA 1.434 -1.259 0 CA-C-O 121.511 0.672 . . . . 0.0 109.823 178.563 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 64.6 mmtt -83.24 -51.18 7.69 Favored 'General case' 0 CA--C 1.5 -0.946 0 N-CA-C 107.393 -1.336 . . . . 0.0 107.393 -177.792 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 2.3 p -69.01 -50.59 47.46 Favored 'General case' 0 N--CA 1.39 -3.427 0 CA-C-N 113.794 -1.548 . . . . 0.0 110.965 -177.504 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . 0.438 ' CA ' ' HA ' ' A' ' 126' ' ' LEU . . . 67.16 92.45 0.04 OUTLIER Glycine 0 N--CA 1.418 -2.532 0 N-CA-C 107.366 -2.294 . . . . 0.0 107.366 -174.508 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 80.1 m-20 -31.77 136.63 0.06 Allowed 'General case' 1 C--O 1.322 4.892 0 N-CA-C 118.813 2.894 . . . . 0.0 118.813 -167.037 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . . . . . . . . . . . -126.51 129.01 47.79 Favored 'General case' 0 N--CA 1.414 -2.258 0 CA-C-N 112.925 -1.943 . . . . 0.0 109.246 -179.254 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -115.23 75.33 0.25 Allowed Glycine 0 N--CA 1.416 -2.665 0 N-CA-C 109.044 -1.622 . . . . 0.0 109.044 176.428 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.568 ' HB2' ' O ' ' A' ' 57' ' ' CYS . 77.5 p -58.92 -26.82 64.69 Favored 'General case' 0 C--N 1.321 -0.643 0 C-N-CA 123.848 0.859 . . . . 0.0 112.306 -175.611 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 11.7 ptm180 -117.52 -0.89 11.79 Favored 'General case' 0 N--CA 1.427 -1.617 0 C-N-CA 120.385 -0.526 . . . . 0.0 111.803 175.779 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.465 ' HB3' ' HB2' ' A' ' 120' ' ' HIS . 3.9 mm? -79.05 -34.84 43.45 Favored 'General case' 0 C--N 1.282 -2.367 0 C-N-CA 117.949 -1.5 . . . . 0.0 110.393 -176.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.438 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -173.96 89.45 0.07 Allowed 'General case' 0 C--N 1.295 -1.794 0 N-CA-C 106.014 -1.847 . . . . 0.0 106.014 177.62 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.809 ' SG ' ' HB ' ' A' ' 116' ' ' THR . 44.6 t -139.07 133.11 31.15 Favored 'General case' 0 N--CA 1.422 -1.854 0 C-N-CA 118.159 -1.416 . . . . 0.0 110.34 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.577 ' HA2' ' HA ' ' A' ' 54' ' ' THR . . . -161.18 166.02 35.59 Favored Glycine 0 N--CA 1.398 -3.897 0 N-CA-C 107.967 -2.053 . . . . 0.0 107.967 179.704 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 46.6 t -68.92 122.37 20.14 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.385 0 CA-C-O 121.086 0.47 . . . . 0.0 110.339 -178.727 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.413 HD11 ' CD1' ' A' ' 20' ' ' PHE . 0.0 OUTLIER -116.26 106.5 20.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.469 0 N-CA-C 107.22 -1.4 . . . . 0.0 107.22 177.233 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.447 ' HA2' ' HB ' ' A' ' 112' ' ' ILE . . . -172.31 -179.29 43.08 Favored Glycine 1 N--CA 1.392 -4.268 0 N-CA-C 110.031 -1.227 . . . . 0.0 110.031 -179.125 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.483 ' H ' HG12 ' A' ' 112' ' ' ILE . 11.3 tt -54.87 114.47 0.57 Allowed 'Isoleucine or valine' 0 C--N 1.316 -0.875 0 CA-C-O 121.751 0.786 . . . . 0.0 112.475 -179.041 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.57 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -149.93 154.9 39.06 Favored 'General case' 0 C--N 1.294 -1.841 0 N-CA-C 105.149 -2.167 . . . . 0.0 105.149 176.655 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 14.2 pt20 . . . . . 0 C--N 1.29 -1.995 0 N-CA-C 109.276 -0.639 . . . . 0.0 109.276 -179.819 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.505 ' O ' ' HA ' ' A' ' 21' ' ' GLU . . . . . . . . 0 C--O 1.21 -0.987 0 CA-C-O 120.283 0.087 . . . . 0.0 110.872 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 9.3 m -76.26 -27.92 56.88 Favored 'General case' 0 CA--C 1.562 1.434 0 N-CA-C 112.982 0.734 . . . . 0.0 112.982 -175.932 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.463 ' O ' ' HB ' ' A' ' 151' ' ' ILE . 20.2 ptpt -152.63 167.55 28.52 Favored 'General case' 0 C--N 1.301 -1.526 0 N-CA-C 106.675 -1.602 . . . . 0.0 106.675 -179.595 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.656 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -153.02 152.5 31.45 Favored 'General case' 0 N--CA 1.411 -2.391 0 N-CA-C 107.71 -1.219 . . . . 0.0 107.71 175.439 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 57.3 t -134.41 138.37 49.92 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.722 0 N-CA-C 107.707 -1.22 . . . . 0.0 107.707 -179.778 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.506 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -109.44 134.61 51.65 Favored 'General case' 0 C--N 1.293 -1.861 0 N-CA-C 112.515 0.561 . . . . 0.0 112.515 -175.443 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . 0.551 ' O ' ' HA3' ' A' ' 147' ' ' GLY . 46.9 t -134.31 102.55 4.27 Favored 'Isoleucine or valine' 0 C--O 1.203 -1.366 0 N-CA-C 108.196 -1.039 . . . . 0.0 108.196 175.654 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.496 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.5 pt? -117.74 132.49 56.46 Favored 'General case' 0 C--N 1.309 -1.173 0 N-CA-C 112.759 0.651 . . . . 0.0 112.759 -178.015 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 90.8 mttt -138.0 138.59 39.03 Favored 'General case' 0 C--O 1.248 0.98 0 N-CA-C 108.601 -0.889 . . . . 0.0 108.601 179.317 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.76 -158.76 8.87 Favored Glycine 0 N--CA 1.435 -1.386 0 C-N-CA 120.964 -0.636 . . . . 0.0 112.045 179.731 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 10.4 m-20 -63.63 -50.97 67.25 Favored 'General case' 0 CA--C 1.511 -0.554 0 O-C-N 124.537 0.787 . . . . 0.0 109.167 177.218 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -88.65 154.95 25.32 Favored Glycine 0 N--CA 1.44 -1.1 0 N-CA-C 108.613 -1.795 . . . . 0.0 108.613 175.234 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.0 Cg_endo -86.23 124.35 2.43 Favored 'Trans proline' 0 N--CA 1.414 -3.149 0 CA-C-N 120.342 2.071 . . . . 0.0 110.072 -176.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.439 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 13.8 m -131.66 146.78 32.96 Favored 'Isoleucine or valine' 0 N--CA 1.38 -3.966 0 N-CA-C 105.277 -2.12 . . . . 0.0 105.277 -179.372 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 8.3 tt0 -159.49 123.29 3.77 Favored 'General case' 0 C--N 1.251 -3.707 0 N-CA-C 107.636 -1.246 . . . . 0.0 107.636 176.765 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.491 ' HA3' HG12 ' A' ' 35' ' ' ILE . . . -153.11 157.95 27.64 Favored Glycine 0 N--CA 1.396 -3.978 0 C-N-CA 119.945 -1.122 . . . . 0.0 111.068 179.518 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.416 ' O ' HG13 ' A' ' 17' ' ' ILE . 25.2 pt -123.97 102.43 11.02 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.658 0 N-CA-C 108.613 -0.884 . . . . 0.0 108.613 179.813 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.593 HG13 ' HA3' ' A' ' 33' ' ' GLY . 1.8 mp -107.53 128.48 62.62 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.851 0 N-CA-C 108.564 -0.902 . . . . 0.0 108.564 -179.94 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.652 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 30.4 p-10 -115.91 125.74 52.98 Favored 'General case' 0 C--N 1.35 0.597 0 N-CA-C 109.126 -0.694 . . . . 0.0 109.126 178.54 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.656 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 69.0 t80 -126.03 130.1 50.48 Favored 'General case' 0 C--N 1.323 -0.572 0 N-CA-C 112.438 0.532 . . . . 0.0 112.438 -171.007 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.505 ' HA ' ' O ' ' A' ' 1' ' ' ALA . 14.3 pt-20 -136.5 102.59 4.99 Favored 'General case' 0 N--CA 1.436 -1.16 0 CA-C-O 121.317 0.58 . . . . 0.0 110.888 176.364 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.457 ' HB3' ' CZ ' ' A' ' 20' ' ' PHE . 9.4 tt0 -151.21 114.42 4.79 Favored 'General case' 0 N--CA 1.414 -2.259 0 CA-C-N 116.252 -0.431 . . . . 0.0 110.67 177.255 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 84.4 tttt -174.83 -74.17 0.01 OUTLIER 'General case' 0 C--N 1.3 -1.578 0 CA-C-N 114.481 -1.236 . . . . 0.0 107.853 175.424 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 39.2 mt-10 -90.31 -8.78 50.0 Favored 'General case' 0 N--CA 1.431 -1.376 0 CA-C-N 114.746 -1.115 . . . . 0.0 109.652 -177.726 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 0.7 OUTLIER -52.83 -50.38 63.83 Favored 'General case' 0 N--CA 1.439 -0.979 0 N-CA-C 107.398 -1.334 . . . . 0.0 107.398 172.937 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 0.2 OUTLIER 49.58 64.1 1.9 Allowed 'General case' 0 C--N 1.355 0.808 0 CA-C-N 114.421 -1.263 . . . . 0.0 109.066 177.027 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 164.23 -164.47 36.66 Favored Glycine 0 N--CA 1.419 -2.499 0 N-CA-C 107.606 -2.198 . . . . 0.0 107.606 -174.986 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 15.2 Cg_endo -57.39 124.83 17.04 Favored 'Trans proline' 0 N--CA 1.452 -0.947 0 C-N-CA 122.18 1.92 . . . . 0.0 111.054 -178.156 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.437 ' CG2' ' HB2' ' A' ' 22' ' ' GLN . 3.0 p -74.27 130.34 36.03 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.801 0 CA-C-N 115.396 -0.82 . . . . 0.0 110.789 -177.667 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.46 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 63.4 mttp -92.54 99.28 12.03 Favored 'General case' 0 N--CA 1.43 -1.437 0 CA-C-N 114.88 -1.054 . . . . 0.0 109.792 175.561 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.573 ' HA ' ' O ' ' A' ' 19' ' ' ASN . 3.2 p -138.17 141.77 37.26 Favored 'Isoleucine or valine' 0 C--N 1.275 -2.668 0 N-CA-C 107.6 -1.259 . . . . 0.0 107.6 -178.217 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 58.0 t90 -153.29 139.24 18.14 Favored 'General case' 0 C--N 1.29 -1.994 0 N-CA-C 107.267 -1.382 . . . . 0.0 107.267 -179.909 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.593 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -156.72 140.33 7.11 Favored Glycine 0 N--CA 1.413 -2.896 0 C-N-CA 118.757 -1.687 . . . . 0.0 113.099 176.573 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 5.5 p -114.23 134.27 55.04 Favored 'General case' 0 N--CA 1.409 -2.52 0 C-N-CA 124.379 1.071 . . . . 0.0 108.231 -179.431 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.62 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 78.4 mt -127.6 140.23 49.72 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.987 0 CA-C-O 121.132 0.492 . . . . 0.0 110.0 -179.711 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.439 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 94.6 mttt -110.69 107.08 16.52 Favored 'General case' 0 N--CA 1.4 -2.968 0 N-CA-C 105.346 -2.094 . . . . 0.0 105.346 174.683 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -142.03 175.35 22.72 Favored Glycine 0 C--N 1.292 -1.899 0 N-CA-C 109.225 -1.55 . . . . 0.0 109.225 -170.792 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . 0.596 ' HA ' ' OD1' ' A' ' 92' ' ' ASP . 2.3 pp -69.0 169.69 11.26 Favored 'General case' 0 C--N 1.304 -1.407 0 CA-C-N 117.963 0.882 . . . . 0.0 111.42 -179.253 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.556 ' HB ' ' HB2' ' A' ' 92' ' ' ASP . 2.2 t -70.2 106.24 3.23 Favored 'General case' 0 C--O 1.244 0.788 0 C-N-CA 119.475 -0.89 . . . . 0.0 111.8 179.695 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.43 ' O ' ' HB2' ' A' ' 121' ' ' GLU . 7.4 tp10 -175.06 111.88 0.13 Allowed 'General case' 0 C--N 1.32 -0.713 0 C-N-CA 125.437 1.495 . . . . 0.0 107.434 170.929 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -129.76 75.47 0.42 Allowed Glycine 0 C--N 1.264 -3.427 0 C-N-CA 118.005 -2.045 . . . . 0.0 113.72 -177.994 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -104.85 136.66 43.94 Favored 'General case' 0 C--N 1.31 -1.11 0 N-CA-C 106.755 -1.572 . . . . 0.0 106.755 -177.146 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.402 ' HD2' HD21 ' A' ' 86' ' ' ASN . 39.7 m80 -55.59 121.98 10.31 Favored 'General case' 0 CA--C 1.481 -1.676 0 C-N-CA 124.64 1.176 . . . . 0.0 110.561 -172.68 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.69 122.7 0.86 Allowed Glycine 1 N--CA 1.381 -4.994 0 C-N-CA 119.718 -1.23 . . . . 0.0 113.3 177.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 3.4 m-85 -68.81 142.69 54.81 Favored 'General case' 0 C--N 1.261 -3.262 0 N-CA-C 103.397 -2.816 . . . . 0.0 103.397 162.624 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.637 ' CB ' ' HA ' ' A' ' 119' ' ' VAL . 21.2 m-70 -126.94 91.29 3.31 Favored 'General case' 0 N--CA 1.421 -1.882 0 CA-C-N 121.222 1.828 . . . . 0.0 106.715 -173.712 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.492 ' HB ' ' O ' ' A' ' 81' ' ' VAL . 7.3 m -125.16 162.75 27.07 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.916 0 N-CA-C 114.999 1.481 . . . . 0.0 114.999 -171.576 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . . . . . . . . . 53.3 m-70 -170.81 119.46 0.53 Allowed 'General case' 0 N--CA 1.487 1.406 0 C-N-CA 129.407 3.083 . . . . 0.0 106.87 170.456 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.558 ' HB2' ' HA2' ' A' ' 108' ' ' GLY . 0.2 OUTLIER -102.59 84.11 2.38 Favored 'General case' 0 CA--C 1.561 1.376 0 C-N-CA 117.87 -1.532 . . . . 0.0 112.957 -176.361 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.541 ' CZ ' ' HA ' ' A' ' 60' ' ' ALA . 0.6 OUTLIER 167.34 113.49 0.01 OUTLIER 'General case' 0 CA--C 1.519 -0.222 0 CA-C-N 113.277 -1.783 . . . . 0.0 107.845 -179.092 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.547 ' HA3' ' H ' ' A' ' 116' ' ' THR . . . -147.57 -154.35 6.21 Favored Glycine 0 CA--C 1.485 -1.802 0 C-N-CA 118.959 -1.591 . . . . 0.0 112.846 178.182 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.0 t70 -173.96 -68.17 0.01 OUTLIER 'General case' 0 C--O 1.22 -0.498 0 O-C-N 124.287 0.639 . . . . 0.0 110.24 -178.335 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.523 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 54.4 t-20 -97.64 130.85 44.62 Favored 'General case' 0 C--N 1.306 -1.324 0 CA-C-N 115.681 -0.691 . . . . 0.0 109.674 -174.53 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 8.1 t -84.06 -6.28 59.38 Favored 'General case' 0 CA--C 1.54 0.589 0 N-CA-C 112.071 0.397 . . . . 0.0 112.071 -177.475 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -101.73 -25.46 13.84 Favored 'General case' 0 C--N 1.311 -1.089 0 CA-C-O 120.95 0.405 . . . . 0.0 110.337 179.154 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.523 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . -147.44 118.83 1.05 Allowed Glycine 0 N--CA 1.429 -1.807 0 N-CA-C 109.72 -1.352 . . . . 0.0 109.72 -178.743 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.593 ' SG ' ' HA ' ' A' ' 142' ' ' SER . 19.9 p -98.2 87.66 3.98 Favored 'General case' 0 C--N 1.276 -2.627 0 C-N-CA 119.176 -1.01 . . . . 0.0 111.163 -179.271 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 27.0 m -79.84 -39.72 30.03 Favored 'General case' 0 N--CA 1.438 -1.062 0 CA-C-N 115.068 -0.969 . . . . 0.0 110.296 177.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 1.6 m -53.55 -47.09 70.33 Favored 'General case' 0 CA--C 1.538 0.509 0 C-N-CA 124.59 1.156 . . . . 0.0 111.794 -176.072 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.541 ' HA ' ' CZ ' ' A' ' 50' ' ' PHE . . . -76.87 -9.05 58.42 Favored 'General case' 0 C--N 1.323 -0.552 0 N-CA-C 112.892 0.701 . . . . 0.0 112.892 -176.226 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -39.79 -64.31 1.08 Allowed Glycine 0 N--CA 1.479 1.555 0 C-N-CA 124.576 1.084 . . . . 0.0 115.363 -177.392 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 59.4 Cg_endo -70.77 1.32 5.22 Favored 'Trans proline' 0 CA--C 1.544 0.983 0 C-N-CA 122.838 2.359 . . . . 0.0 113.399 -178.325 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . 0.296 9.1 p80 50.39 37.04 14.46 Favored 'General case' 0 C--N 1.33 -0.24 0 N-CA-C 114.594 1.331 . . . . 0.0 114.594 -179.467 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 69.7 t80 -87.81 89.89 8.17 Favored 'General case' 0 N--CA 1.443 -0.782 0 CA-C-O 122.186 0.993 . . . . 0.0 109.644 176.84 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.467 ' HB2' ' OG ' ' A' ' 68' ' ' SER . 0.4 OUTLIER -113.73 97.42 44.23 Favored Pre-proline 0 C--N 1.284 -2.278 0 CA-C-N 113.723 -1.58 . . . . 0.0 110.496 -177.954 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.411 ' O ' ' HB2' ' A' ' 69' ' ' ARG . 50.0 Cg_endo -84.73 -12.98 7.15 Favored 'Trans proline' 0 CA--C 1.545 1.03 0 C-N-CA 123.13 2.553 . . . . 0.0 115.995 -173.296 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.622 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 56.5 tp -85.43 -19.8 30.76 Favored 'General case' 1 CA--C 1.421 -4.012 0 CA-C-O 121.589 0.709 . . . . 0.0 109.19 -179.551 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.484 ' C ' ' H ' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -76.99 28.26 0.14 Allowed 'General case' 0 N--CA 1.384 -3.753 0 C-N-CA 127.741 2.416 . . . . 0.0 108.911 178.086 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.565 ' H ' ' C ' ' A' ' 67' ' ' LEU . 63.6 ttt180 -73.42 43.32 0.13 Allowed 'General case' 0 C--O 1.207 -1.181 0 C-N-CA 128.558 2.743 . . . . 0.0 110.39 -173.763 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.575 ' CB ' ' HB2' ' A' ' 79' ' ' ARG . 22.6 ttmm -139.32 -18.4 0.99 Allowed 'General case' 0 C--N 1.245 -3.957 0 CA-C-N 113.894 -1.503 . . . . 0.0 108.511 166.687 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 1.1 t-80 70.33 19.31 6.52 Favored 'General case' 0 C--N 1.327 -0.373 0 C-N-CA 126.105 1.762 . . . . 0.0 111.325 177.64 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 106.18 137.5 8.78 Favored Glycine 0 N--CA 1.426 -1.999 0 C-N-CA 120.433 -0.889 . . . . 0.0 114.595 176.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -147.36 162.46 28.64 Favored Glycine 0 N--CA 1.425 -2.07 0 N-CA-C 109.435 -1.466 . . . . 0.0 109.435 175.559 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 13.5 Cg_exo -73.24 -38.49 2.67 Favored 'Trans proline' 0 CA--C 1.535 0.537 0 C-N-CA 122.898 2.398 . . . . 0.0 112.751 179.694 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.743 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.9 OUTLIER -104.55 -25.45 12.75 Favored 'General case' 0 C--O 1.202 -1.422 0 N-CA-C 109.425 -0.583 . . . . 0.0 109.425 178.253 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 1.4 t70 49.91 -164.61 0.04 OUTLIER 'General case' 0 N--CA 1.482 1.139 0 C-N-CA 129.188 2.995 . . . . 0.0 115.045 179.657 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 30.8 tt0 -144.58 -56.03 0.35 Allowed 'General case' 0 N--CA 1.427 -1.609 0 CA-C-N 115.263 -0.88 . . . . 0.0 109.47 -169.144 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.572 ' HA ' ' HA ' ' A' ' 105' ' ' SER . 47.6 mt-10 -172.57 -30.56 0.01 OUTLIER 'General case' 0 N--CA 1.493 1.698 0 C-N-CA 125.734 1.614 . . . . 0.0 107.67 -176.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.622 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 13.9 mmt180 -87.44 41.62 0.99 Allowed 'General case' 1 N--CA 1.364 -4.736 0 C-N-CA 125.095 1.358 . . . . 0.0 109.768 -171.422 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.692 ' HB3' ' O ' ' A' ' 82' ' ' GLY . 9.5 t-160 -95.08 13.32 25.59 Favored 'General case' 0 C--N 1.313 -1.003 0 CA-C-N 116.067 -0.515 . . . . 0.0 110.545 -172.658 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.492 ' O ' ' HB ' ' A' ' 47' ' ' VAL . 48.7 t 71.25 26.88 0.06 OUTLIER 'Isoleucine or valine' 0 N--CA 1.495 1.783 0 CA-C-O 123.493 1.616 . . . . 0.0 107.229 -177.786 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.692 ' O ' ' HB3' ' A' ' 80' ' ' HIS . . . 116.35 -146.45 18.84 Favored Glycine 0 N--CA 1.409 -3.149 0 N-CA-C 105.287 -3.125 . . . . 0.0 105.287 -169.93 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . . . . . . . . . 10.3 t70 -170.8 124.89 0.67 Allowed 'General case' 0 CA--C 1.474 -1.951 0 CA-C-N 118.753 1.276 . . . . 0.0 107.734 174.272 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.519 HD11 HG21 ' A' ' 18' ' ' ILE . 10.0 tp -161.39 171.77 17.66 Favored 'General case' 0 N--CA 1.408 -2.535 0 N-CA-C 104.762 -2.31 . . . . 0.0 104.762 -178.351 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -101.63 175.49 25.56 Favored Glycine 0 N--CA 1.404 -3.464 0 N-CA-C 109.079 -1.609 . . . . 0.0 109.079 -177.848 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.566 ' O ' ' HA ' ' A' ' 97' ' ' VAL . 14.3 t30 -77.32 138.66 39.49 Favored 'General case' 0 C--N 1.28 -2.426 0 N-CA-C 107.51 -1.293 . . . . 0.0 107.51 177.754 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.779 HG22 ' HB1' ' A' ' 95' ' ' ALA . 13.9 p -150.74 127.12 1.97 Allowed 'Isoleucine or valine' 0 C--N 1.289 -2.043 0 N-CA-C 106.313 -1.736 . . . . 0.0 106.313 178.177 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.673 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 24.7 p -141.1 122.34 14.81 Favored 'General case' 0 N--CA 1.418 -2.059 0 CA-C-N 115.793 -0.639 . . . . 0.0 109.397 -167.356 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.559 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -109.05 103.7 12.76 Favored 'General case' 0 N--CA 1.41 -2.45 0 C-N-CA 117.031 -1.868 . . . . 0.0 106.538 173.892 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 32.6 t70 -93.99 -39.42 10.65 Favored 'General case' 0 CA--C 1.468 -2.199 0 CA-C-O 122.161 0.981 . . . . 0.0 109.955 -170.031 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.521 ' HA ' ' HE3' ' A' ' 91' ' ' LYS . 1.0 OUTLIER -85.59 5.85 29.87 Favored 'General case' 0 C--N 1.27 -2.875 0 CA-C-N 114.102 -1.408 . . . . 0.0 111.572 -177.652 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.596 ' OD1' ' HA ' ' A' ' 38' ' ' LEU . 13.4 t70 74.66 93.72 0.07 Allowed 'General case' 0 N--CA 1.488 1.474 0 C-N-CA 123.438 0.695 . . . . 0.0 111.541 -175.815 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 106.17 13.22 23.67 Favored Glycine 0 N--CA 1.431 -1.682 0 N-CA-C 116.269 1.267 . . . . 0.0 116.269 171.978 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.559 ' O ' ' HA ' ' A' ' 89' ' ' ALA . 49.0 t -145.31 102.91 0.63 Allowed 'Isoleucine or valine' 0 CA--C 1.457 -2.626 0 N-CA-C 103.42 -2.807 . . . . 0.0 103.42 -179.026 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.779 ' HB1' HG22 ' A' ' 87' ' ' VAL . . . -99.59 118.48 36.23 Favored 'General case' 0 N--CA 1.389 -3.477 0 C-N-CA 118.867 -1.133 . . . . 0.0 111.306 -177.794 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . 0.47 ' O ' ' HA ' ' A' ' 87' ' ' VAL . 21.7 t70 -80.41 111.52 16.89 Favored 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 115.13 -0.941 . . . . 0.0 110.01 179.675 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.566 ' HA ' ' O ' ' A' ' 86' ' ' ASN . 13.3 p -87.7 122.92 39.98 Favored 'Isoleucine or valine' 0 N--CA 1.41 -2.455 0 CA-C-O 121.97 0.89 . . . . 0.0 109.881 177.409 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 67.9 m -122.25 105.87 10.61 Favored 'General case' 0 C--N 1.273 -2.723 0 CA-C-N 114.819 -1.082 . . . . 0.0 108.162 176.415 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.566 HG21 HG13 ' A' ' 31' ' ' VAL . 2.2 pp -93.74 154.76 3.24 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.745 0 CA-C-N 116.044 -0.526 . . . . 0.0 110.429 178.417 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 31.5 mt-10 -125.64 160.85 28.62 Favored 'General case' 0 C--N 1.296 -1.731 0 C-N-CA 124.736 1.214 . . . . 0.0 109.109 -176.321 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.5 m-20 -82.76 99.69 9.81 Favored 'General case' 0 C--N 1.283 -2.297 0 C-N-CA 119.781 -0.767 . . . . 0.0 109.386 -171.221 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.743 ' HA ' ' O ' ' A' ' 75' ' ' LYS . 21.5 m -95.66 162.1 13.76 Favored 'General case' 0 N--CA 1.417 -2.078 0 N-CA-C 105.527 -2.027 . . . . 0.0 105.527 173.133 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.4 HG23 ' H ' ' A' ' 104' ' ' ILE . 9.9 m -103.15 -64.51 1.55 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.171 0 N-CA-C 114.368 1.247 . . . . 0.0 114.368 -178.535 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.4 ' H ' HG23 ' A' ' 103' ' ' VAL . 26.8 mt -133.5 25.54 1.19 Allowed 'Isoleucine or valine' 0 CA--C 1.548 0.901 0 CA-C-O 121.932 0.872 . . . . 0.0 108.808 -174.132 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.572 ' HA ' ' HA ' ' A' ' 78' ' ' GLU . 21.4 t -78.57 87.43 4.53 Favored 'General case' 0 N--CA 1.416 -2.162 0 CA-C-O 122.069 0.938 . . . . 0.0 110.28 -175.503 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 15.8 tp -70.74 120.84 16.93 Favored 'General case' 0 N--CA 1.408 -2.574 0 N-CA-C 106.24 -1.763 . . . . 0.0 106.24 172.957 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 35.7 t -74.79 87.23 2.23 Favored 'General case' 0 N--CA 1.409 -2.475 0 N-CA-C 107.469 -1.308 . . . . 0.0 107.469 176.066 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.558 ' HA2' ' HB2' ' A' ' 49' ' ' GLU . . . 155.39 136.08 2.13 Favored Glycine 0 N--CA 1.411 -2.974 0 C-N-CA 119.537 -1.316 . . . . 0.0 114.379 177.634 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 1.5 t70 -89.54 -52.06 5.21 Favored 'General case' 0 C--N 1.312 -1.034 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 173.846 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 0.7 OUTLIER -74.49 -47.74 31.35 Favored 'General case' 0 C--N 1.327 -0.387 0 CA-C-N 115.55 -0.75 . . . . 0.0 109.035 176.563 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 37.7 t 179.37 -170.59 0.13 Allowed 'General case' 0 C--N 1.309 -1.192 0 N-CA-C 103.732 -2.692 . . . . 0.0 103.732 174.734 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.572 HG22 ' HA2' ' A' ' 150' ' ' GLY . 9.5 mt -89.62 -23.95 6.02 Favored 'Isoleucine or valine' 0 C--N 1.31 -1.125 0 N-CA-C 107.976 -1.12 . . . . 0.0 107.976 177.564 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 11.7 tt -68.97 132.46 33.02 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.887 0 CA-C-N 115.343 -0.844 . . . . 0.0 110.922 -177.839 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 86.71 -9.16 72.55 Favored Glycine 0 N--CA 1.419 -2.448 0 CA-C-N 115.458 -0.792 . . . . 0.0 112.163 174.945 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.407 ' HD3' ' HA ' ' A' ' 50' ' ' PHE . 4.2 mmp_? -81.23 123.95 28.89 Favored 'General case' 0 C--N 1.311 -1.092 0 N-CA-C 108.977 -0.749 . . . . 0.0 108.977 -175.72 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.547 ' H ' ' HA3' ' A' ' 51' ' ' GLY . 27.6 p -89.3 101.4 14.06 Favored 'General case' 0 N--CA 1.389 -3.481 0 C-N-CA 120.256 -0.578 . . . . 0.0 109.727 177.875 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.49 HD23 HG12 ' A' ' 47' ' ' VAL . 8.0 mp -85.23 120.38 26.66 Favored 'General case' 0 CA--C 1.473 -1.986 0 N-CA-C 103.801 -2.666 . . . . 0.0 103.801 174.239 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.433 HG11 ' C ' ' A' ' 141' ' ' GLY . 2.4 t -92.54 115.64 31.89 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.251 0 C-N-CA 116.824 -1.951 . . . . 0.0 111.469 -172.452 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.664 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 42.1 t -125.0 129.38 73.41 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.9 0 C-N-CA 127.729 2.412 . . . . 0.0 110.587 -166.388 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.509 ' CB ' ' HB3' ' A' ' 144' ' ' LEU . 12.7 t60 -159.68 148.07 17.46 Favored 'General case' 0 C--N 1.295 -1.762 0 N-CA-C 103.774 -2.676 . . . . 0.0 103.774 169.949 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.445 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 4.3 pm0 -68.79 88.27 0.37 Allowed 'General case' 0 C--N 1.298 -1.65 0 CA-C-O 123.112 1.434 . . . . 0.0 109.822 178.229 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 53.8 tptt -169.51 151.15 4.33 Favored 'General case' 0 N--CA 1.43 -1.449 0 N-CA-C 104.412 -2.44 . . . . 0.0 104.412 -171.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -63.38 118.68 8.41 Favored 'General case' 0 C--N 1.299 -1.598 0 CA-C-N 118.146 0.43 . . . . 0.0 110.121 177.738 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.583 ' HA ' ' H ' ' A' ' 140' ' ' ALA . 44.0 t0 -96.7 -80.86 0.43 Allowed 'General case' 0 C--O 1.187 -2.216 0 N-CA-C 106.177 -1.786 . . . . 0.0 106.177 177.459 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 4.4 t70 76.19 152.02 0.13 Allowed 'General case' 0 C--N 1.308 -1.219 0 C-N-CA 128.344 2.658 . . . . 0.0 112.271 175.28 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -95.07 -64.03 1.11 Allowed 'General case' 0 C--N 1.303 -1.447 0 CA-C-N 114.808 -1.087 . . . . 0.0 113.667 -179.075 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -81.04 -17.42 72.21 Favored Glycine 0 CA--C 1.481 -2.084 0 CA-C-N 114.137 -1.392 . . . . 0.0 113.03 -170.434 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 47.0 tttp -65.86 -41.1 92.1 Favored 'General case' 0 N--CA 1.433 -1.311 0 N-CA-C 108.488 -0.93 . . . . 0.0 108.488 179.172 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . 0.686 ' HA2' ' O ' ' A' ' 134' ' ' SER . . . -75.8 69.9 2.06 Favored Glycine 0 N--CA 1.409 -3.122 0 N-CA-C 115.182 0.833 . . . . 0.0 115.182 179.522 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . -141.68 23.86 2.48 Favored Glycine 0 N--CA 1.44 -1.06 0 C-N-CA 119.457 -1.354 . . . . 0.0 114.709 178.534 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.478 ' HB3' ' CB ' ' A' ' 134' ' ' SER . 64.6 t30 -132.14 176.37 8.44 Favored 'General case' 0 N--CA 1.522 3.15 0 CA-C-O 116.132 -1.89 . . . . 0.0 107.594 178.507 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -53.29 -57.03 11.98 Favored 'General case' 0 C--N 1.385 2.121 0 CA-C-N 121.934 2.152 . . . . 0.0 113.458 -174.803 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 -86.0 -34.18 20.87 Favored 'General case' 0 C--N 1.314 -0.97 0 CA-C-O 121.077 0.465 . . . . 0.0 110.922 176.906 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.686 ' O ' ' HA2' ' A' ' 129' ' ' GLY . 1.3 m -66.98 -21.8 65.95 Favored 'General case' 0 C--O 1.185 -2.335 0 N-CA-C 112.471 0.545 . . . . 0.0 112.471 -175.69 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.607 ' HA ' ' CA ' ' A' ' 129' ' ' GLY . 5.2 t -80.0 -12.55 59.7 Favored 'General case' 0 CA--C 1.51 -0.59 0 O-C-N 121.171 -0.956 . . . . 0.0 109.939 179.515 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 37.9 ttmt -88.25 -46.77 8.95 Favored 'General case' 0 C--N 1.275 -2.669 0 CA-C-N 114.083 -1.417 . . . . 0.0 107.239 -175.935 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 9.7 p -85.72 -32.72 21.75 Favored 'General case' 0 N--CA 1.41 -2.428 0 CA-C-N 113.892 -1.503 . . . . 0.0 112.314 -178.52 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . -77.48 -4.04 83.83 Favored Glycine 0 C--O 1.202 -1.893 0 CA-C-O 119.171 -0.794 . . . . 0.0 114.879 -173.23 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . 0.414 HD21 HG11 ' A' ' 81' ' ' VAL . 45.3 t-20 -142.7 104.46 4.36 Favored 'General case' 0 C--N 1.3 -1.56 0 N-CA-C 109.134 -0.691 . . . . 0.0 109.134 164.97 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.583 ' H ' ' HA ' ' A' ' 124' ' ' ASP . . . -69.83 160.35 31.93 Favored 'General case' 1 C--O 1.33 5.307 0 N-CA-C 108.177 -1.046 . . . . 0.0 108.177 174.252 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.433 ' C ' HG11 ' A' ' 118' ' ' VAL . . . -163.77 -151.91 6.67 Favored Glycine 1 N--CA 1.382 -4.94 0 C-N-CA 118.124 -1.988 . . . . 0.0 115.262 -165.953 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.593 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 2.9 m -46.9 7.28 0.0 OUTLIER 'General case' 0 C--N 1.297 -1.71 1 C-N-CA 132.552 4.341 . . . . 0.0 120.14 -166.146 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 72.3 mtt180 -125.69 -27.58 3.36 Favored 'General case' 0 C--N 1.264 -3.138 0 C-N-CA 118.794 -1.162 . . . . 0.0 111.289 178.993 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.509 ' HB3' ' CB ' ' A' ' 120' ' ' HIS . 4.0 mm? -60.46 -43.69 96.65 Favored 'General case' 0 C--N 1.313 -0.982 0 CA-C-N 115.663 -0.699 . . . . 0.0 112.084 -174.346 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.664 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -171.51 112.39 0.34 Allowed 'General case' 0 CA--C 1.49 -1.338 0 N-CA-C 109.137 -0.69 . . . . 0.0 109.137 174.547 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.428 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 88.8 m -95.19 140.44 30.1 Favored 'General case' 0 C--N 1.281 -2.399 0 CA-C-N 116.059 -0.518 . . . . 0.0 111.522 -177.397 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.551 ' HA3' ' O ' ' A' ' 7' ' ' VAL . . . -172.08 150.67 13.35 Favored Glycine 1 N--CA 1.389 -4.474 0 CA-C-N 114.631 -1.168 . . . . 0.0 111.607 176.319 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 45.4 t -75.67 119.59 23.84 Favored 'Isoleucine or valine' 0 C--N 1.293 -1.889 0 N-CA-C 106.876 -1.527 . . . . 0.0 106.876 171.356 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.447 HD12 ' HB1' ' A' ' 6' ' ' ALA . 23.2 mm -118.59 102.17 12.75 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.368 0 N-CA-C 105.264 -2.125 . . . . 0.0 105.264 179.09 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.572 ' HA2' HG22 ' A' ' 112' ' ' ILE . . . 177.8 -172.5 45.15 Favored Glycine 0 CA--C 1.452 -3.902 0 C-N-CA 119.356 -1.402 . . . . 0.0 110.256 -177.191 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.58 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 14.6 tt -70.67 103.43 1.09 Allowed 'Isoleucine or valine' 0 C--N 1.309 -1.175 0 CA-C-O 122.108 0.956 . . . . 0.0 110.724 -178.959 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -150.53 115.36 5.27 Favored 'General case' 0 C--N 1.295 -1.794 0 CA-C-N 113.778 -1.555 . . . . 0.0 111.26 -179.077 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 15.5 pt20 . . . . . 0 C--N 1.296 -1.75 0 N-CA-C 109.309 -0.626 . . . . 0.0 109.309 175.797 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.575 ' HB3' ' H ' ' A' ' 22' ' ' GLN . . . . . . . . 0 C--O 1.218 -0.6 0 N-CA-C 109.152 -0.684 . . . . 0.0 109.152 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.489 ' HA ' ' HG2' ' A' ' 21' ' ' GLU . 60.0 m -121.35 -43.45 2.41 Favored 'General case' 0 C--N 1.315 -0.914 0 CA-C-O 121.555 0.693 . . . . 0.0 110.648 177.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 0.1 OUTLIER -142.14 144.63 33.56 Favored 'General case' 0 C--N 1.297 -1.7 0 N-CA-C 108.065 -1.087 . . . . 0.0 108.065 -179.828 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.567 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -134.06 149.57 51.15 Favored 'General case' 0 N--CA 1.41 -2.452 0 C-N-CA 119.393 -0.923 . . . . 0.0 110.4 178.688 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . . . . . . . . . 63.3 t -120.14 127.26 75.89 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.5 0 N-CA-C 108.961 -0.755 . . . . 0.0 108.961 -177.57 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.596 ' HB3' ' H ' ' A' ' 18' ' ' ILE . . . -107.76 129.0 55.08 Favored 'General case' 0 C--N 1.287 -2.128 0 CA-C-N 114.742 -1.117 . . . . 0.0 112.996 176.546 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 11.7 m -134.61 102.56 4.07 Favored 'Isoleucine or valine' 0 CA--C 1.544 0.744 0 CA-C-O 121.62 0.724 . . . . 0.0 110.151 175.175 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . . . . . . . . . 74.5 mt -96.01 134.45 39.01 Favored 'General case' 0 C--N 1.305 -1.353 0 CA-C-N 115.853 -0.612 . . . . 0.0 112.304 -179.11 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 61.7 tttp -147.33 122.2 9.99 Favored 'General case' 0 N--CA 1.438 -1.031 0 N-CA-C 108.738 -0.838 . . . . 0.0 108.738 176.954 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -157.02 -157.86 8.6 Favored Glycine 0 N--CA 1.435 -1.402 0 N-CA-C 110.622 -0.991 . . . . 0.0 110.622 178.434 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 30.3 t70 -89.62 94.0 9.69 Favored 'General case' 0 N--CA 1.436 -1.17 0 N-CA-C 107.01 -1.478 . . . . 0.0 107.01 169.285 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . 128.21 143.74 5.71 Favored Glycine 0 C--N 1.275 -2.829 0 N-CA-C 107.309 -2.316 . . . . 0.0 107.309 -177.053 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 50.6 Cg_endo -97.81 123.11 0.18 Allowed 'Trans proline' 0 N--CA 1.431 -2.153 0 CA-C-N 120.367 2.083 . . . . 0.0 113.524 -178.828 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 4.8 p -134.7 112.18 15.01 Favored 'Isoleucine or valine' 0 N--CA 1.412 -2.333 0 CA-C-N 114.534 -1.212 . . . . 0.0 107.957 171.751 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 64.2 tt0 -118.14 119.53 35.0 Favored 'General case' 0 C--N 1.287 -2.122 0 C-N-CA 118.874 -1.13 . . . . 0.0 111.092 -179.221 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.405 ' HA3' HG22 ' A' ' 35' ' ' ILE . . . -159.36 149.43 19.28 Favored Glycine 0 N--CA 1.406 -3.356 0 C-N-CA 120.141 -1.028 . . . . 0.0 110.536 179.265 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 27.5 pt -113.82 107.21 22.35 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.605 0 N-CA-C 109.051 -0.722 . . . . 0.0 109.051 -178.952 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.596 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 28.1 mm -100.44 128.45 52.46 Favored 'Isoleucine or valine' 0 C--N 1.302 -1.481 0 N-CA-C 109.378 -0.601 . . . . 0.0 109.378 -176.647 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.635 ' O ' ' HB ' ' A' ' 31' ' ' VAL . 24.5 t-20 -101.0 144.21 30.21 Favored 'General case' 0 N--CA 1.441 -0.92 0 N-CA-C 108.6 -0.889 . . . . 0.0 108.6 -178.543 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.567 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 87.0 m-85 -132.57 120.18 21.49 Favored 'General case' 0 C--N 1.32 -0.707 0 CA-C-O 120.794 0.33 . . . . 0.0 111.531 175.17 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.489 ' HG2' ' HA ' ' A' ' 2' ' ' THR . 1.8 tm-20 -132.34 101.78 5.49 Favored 'General case' 0 N--CA 1.425 -1.717 0 N-CA-C 108.341 -0.985 . . . . 0.0 108.341 174.152 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.691 ' HG2' ' O ' ' A' ' 105' ' ' SER . 18.1 mp0 -127.51 132.21 49.98 Favored 'General case' 0 N--CA 1.387 -3.606 0 N-CA-C 103.601 -2.74 . . . . 0.0 103.601 167.109 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.442 ' HD3' ' H ' ' A' ' 24' ' ' GLU . 6.3 tmtt? -131.54 168.64 17.32 Favored 'General case' 0 C--N 1.257 -3.437 0 N-CA-C 107.14 -1.429 . . . . 0.0 107.14 -173.21 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.442 ' H ' ' HD3' ' A' ' 23' ' ' LYS . 10.3 pt-20 -62.48 -9.5 8.75 Favored 'General case' 0 C--N 1.315 -0.906 0 C-N-CA 124.038 0.935 . . . . 0.0 111.777 178.708 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.6 m -56.86 -39.5 74.41 Favored 'General case' 0 N--CA 1.424 -1.726 0 C-N-CA 124.999 1.319 . . . . 0.0 110.528 176.444 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . 0.467 ' OD1' HG22 ' A' ' 103' ' ' VAL . 56.4 t30 66.76 104.08 0.04 OUTLIER 'General case' 0 N--CA 1.491 1.581 0 C-N-CA 123.635 0.774 . . . . 0.0 110.478 178.297 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 176.72 -177.0 48.13 Favored Glycine 0 CA--C 1.474 -2.477 0 N-CA-C 109.05 -1.62 . . . . 0.0 109.05 -175.18 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 47.1 Cg_exo -57.26 123.19 13.22 Favored 'Trans proline' 0 C--O 1.24 0.61 0 C-N-CA 122.262 1.975 . . . . 0.0 111.642 -178.787 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . . . . . . . . . 92.5 t -76.42 111.46 13.06 Favored 'Isoleucine or valine' 0 C--N 1.301 -1.513 0 CA-C-N 114.812 -1.085 . . . . 0.0 111.436 -179.924 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . 0.3 0.0 OUTLIER -112.59 107.29 15.95 Favored 'General case' 0 C--N 1.305 -1.35 0 CA-C-O 122.812 1.291 . . . . 0.0 112.123 177.882 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.635 ' HB ' ' O ' ' A' ' 19' ' ' ASN . 30.8 m -137.22 154.4 30.57 Favored 'Isoleucine or valine' 0 N--CA 1.407 -2.577 0 CA-C-N 113.054 -1.885 . . . . 0.0 106.323 -172.269 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 61.6 p-90 -139.19 148.1 42.7 Favored 'General case' 0 C--N 1.271 -2.826 0 N-CA-C 109.611 -0.515 . . . . 0.0 109.611 179.427 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.467 ' O ' ' HA ' ' A' ' 97' ' ' VAL . . . -169.57 137.75 4.68 Favored Glycine 0 N--CA 1.404 -3.444 0 N-CA-C 109.849 -1.3 . . . . 0.0 109.849 171.975 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 23.3 t -117.2 131.72 56.8 Favored 'General case' 0 N--CA 1.407 -2.587 0 N-CA-C 107.112 -1.44 . . . . 0.0 107.112 -177.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.721 ' H ' ' HB3' ' A' ' 95' ' ' ALA . 15.5 pt -114.91 153.18 16.44 Favored 'Isoleucine or valine' 0 C--N 1.298 -1.668 0 C-N-CA 118.694 -1.203 . . . . 0.0 111.075 176.582 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.416 ' HA ' ' HA3' ' A' ' 93' ' ' GLY . 48.4 mtmt -120.34 107.61 13.15 Favored 'General case' 0 N--CA 1.408 -2.552 0 N-CA-C 106.974 -1.491 . . . . 0.0 106.974 177.24 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -125.08 174.17 17.29 Favored Glycine 0 C--N 1.295 -1.734 0 N-CA-C 110.342 -1.103 . . . . 0.0 110.342 -176.779 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 45.5 tp -69.02 171.81 7.62 Favored 'General case' 0 CA--C 1.571 1.77 0 N-CA-C 109.559 -0.534 . . . . 0.0 109.559 176.289 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.595 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 1.6 t -69.27 110.31 4.55 Favored 'General case' 0 CA--C 1.5 -0.954 0 O-C-N 121.243 -0.911 . . . . 0.0 112.978 -178.354 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.476 ' HG2' ' O ' ' A' ' 39' ' ' THR . 10.3 mm-40 -170.47 171.58 6.42 Favored 'General case' 0 C--N 1.275 -2.652 0 N-CA-C 104.133 -2.543 . . . . 0.0 104.133 173.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -90.27 -155.77 31.53 Favored Glycine 0 C--N 1.26 -3.65 0 N-CA-C 108.91 -1.676 . . . . 0.0 108.91 169.344 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.691 HD22 ' HB ' ' A' ' 87' ' ' VAL . 5.2 tt -178.44 149.43 0.5 Allowed 'General case' 0 N--CA 1.412 -2.337 0 N-CA-C 103.563 -2.754 . . . . 0.0 103.563 179.291 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.603 ' N ' HD23 ' A' ' 42' ' ' LEU . 78.2 t60 -161.34 121.6 2.68 Favored 'General case' 0 C--N 1.279 -2.489 0 N-CA-C 107.8 -1.185 . . . . 0.0 107.8 173.32 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.46 ' O ' ' HB3' ' A' ' 124' ' ' ASP . . . 77.09 136.84 0.81 Allowed Glycine 0 C--N 1.308 -1.025 0 N-CA-C 110.873 -0.891 . . . . 0.0 110.873 -177.726 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.461 ' HB2' ' CG1' ' A' ' 119' ' ' VAL . 0.1 OUTLIER -142.23 131.46 23.43 Favored 'General case' 0 C--N 1.311 -1.108 0 CA-C-N 117.855 0.827 . . . . 0.0 112.204 -177.952 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.598 ' HA ' ' O ' ' A' ' 82' ' ' GLY . 21.7 t-80 -82.08 89.3 6.44 Favored 'General case' 0 CA--C 1.476 -1.877 0 CA-C-N 115.314 -0.857 . . . . 0.0 111.695 -177.074 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.625 ' CB ' HD23 ' A' ' 117' ' ' LEU . 6.7 m -110.47 80.89 0.55 Allowed 'Isoleucine or valine' 1 N--CA 1.379 -4.008 0 CA-C-O 122.897 1.332 . . . . 0.0 110.346 175.689 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.502 ' HA ' HH11 ' A' ' 115' ' ' ARG . 2.4 p-80 -174.72 145.24 0.88 Allowed 'General case' 0 CA--C 1.487 -1.447 0 N-CA-C 106.356 -1.72 . . . . 0.0 106.356 169.98 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.498 ' HG2' ' CE1' ' A' ' 46' ' ' HIS 0.351 10.9 mm-40 -172.92 173.97 3.64 Favored 'General case' 0 C--N 1.301 -1.521 0 C-N-CA 126.628 1.971 . . . . 0.0 111.554 163.423 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 73.3 t80 -110.28 75.04 0.91 Allowed 'General case' 0 C--N 1.292 -1.929 0 N-CA-C 102.886 -3.005 . . . . 0.0 102.886 171.671 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.436 ' H ' ' HA ' ' A' ' 115' ' ' ARG . . . -104.91 -149.97 19.72 Favored Glycine 0 CA--C 1.482 -1.984 0 CA-C-N 113.142 -1.845 . . . . 0.0 113.617 -169.114 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 37.9 t70 175.0 -41.42 0.01 OUTLIER 'General case' 0 N--CA 1.491 1.58 0 N-CA-C 113.251 0.834 . . . . 0.0 113.251 -177.111 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.465 ' HB2' ' O ' ' A' ' 56' ' ' GLY . 18.1 m120 -101.13 124.93 47.61 Favored 'General case' 0 CA--C 1.498 -1.037 0 C-N-CA 120.255 -0.578 . . . . 0.0 109.92 -173.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 13.3 t -84.25 -25.63 29.25 Favored 'General case' 0 C--N 1.308 -1.223 0 C-N-CA 121.048 -0.261 . . . . 0.0 111.165 -178.127 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -94.41 -8.6 38.21 Favored 'General case' 0 C--N 1.307 -1.256 0 CA-C-O 121.218 0.533 . . . . 0.0 110.261 -178.806 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.465 ' O ' ' HB2' ' A' ' 53' ' ' ASN . . . -144.25 110.02 0.56 Allowed Glycine 0 N--CA 1.409 -3.116 0 C-N-CA 119.486 -1.34 . . . . 0.0 109.901 -179.605 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.775 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 6.7 p -96.44 86.7 4.23 Favored 'General case' 0 N--CA 1.391 -3.401 0 CA-C-O 122.32 1.057 . . . . 0.0 110.733 179.022 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 30.5 m -82.03 -47.38 12.7 Favored 'General case' 0 N--CA 1.417 -2.116 0 CA-C-N 114.043 -1.435 . . . . 0.0 109.484 174.026 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 4.1 p -72.03 -16.8 62.05 Favored 'General case' 0 C--N 1.326 -0.451 0 CA-C-N 115.248 -0.887 . . . . 0.0 112.194 -176.791 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.775 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -82.48 -6.69 59.46 Favored 'General case' 0 C--N 1.308 -1.214 0 CA-C-N 114.942 -1.026 . . . . 0.0 110.22 177.078 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . 0.665 ' HA2' ' HB3' ' A' ' 142' ' ' SER . . . -50.58 176.33 0.05 OUTLIER Glycine 0 C--N 1.355 1.592 0 CA-C-N 114.83 -1.077 . . . . 0.0 112.311 175.625 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.48 ' HA ' ' CE2' ' A' ' 64' ' ' PHE . 21.3 Cg_exo -68.88 55.24 0.92 Allowed 'Trans proline' 0 N--CA 1.488 1.174 0 C-N-CA 123.466 2.777 . . . . 0.0 112.137 -178.565 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 54.1 t-80 -159.12 87.74 0.86 Allowed 'General case' 0 C--N 1.291 -1.945 0 N-CA-C 105.567 -2.012 . . . . 0.0 105.567 -177.214 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.641 ' O ' ' HD3' ' A' ' 66' ' ' PRO . 27.2 m-85 -111.78 162.99 14.66 Favored 'General case' 0 C--N 1.273 -2.747 0 N-CA-C 107.318 -1.364 . . . . 0.0 107.318 -173.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . . . . . . . . . 63.5 t30 -93.5 99.15 3.05 Favored Pre-proline 0 C--O 1.248 0.975 0 C-N-CA 119.625 -0.83 . . . . 0.0 112.325 174.143 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.641 ' HD3' ' O ' ' A' ' 64' ' ' PHE . 71.0 Cg_exo -52.36 -12.04 1.42 Allowed 'Trans proline' 0 N--CA 1.483 0.908 0 C-N-CA 125.197 3.932 . . . . 0.0 114.913 -178.507 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . . . . . . . . . 51.5 mt -94.92 7.39 46.16 Favored 'General case' 0 CA--C 1.49 -1.346 0 CA-C-O 122.761 1.267 . . . . 0.0 107.996 -171.212 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . . . . . . . . . 6.9 t -120.76 23.57 10.67 Favored 'General case' 0 N--CA 1.395 -3.186 0 N-CA-C 105.415 -2.069 . . . . 0.0 105.415 175.536 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.521 ' NH2' ' HB3' ' A' ' 66' ' ' PRO . 38.6 ttp180 -132.15 -32.64 1.37 Allowed 'General case' 0 C--N 1.314 -0.952 0 CA-C-N 113.199 -1.819 . . . . 0.0 107.629 171.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.411 ' HG3' ' HB3' ' A' ' 78' ' ' GLU 0.256 5.3 mmtp 39.32 71.12 0.18 Allowed 'General case' 0 N--CA 1.427 -1.583 0 C-N-CA 125.616 1.566 . . . . 0.0 112.814 178.332 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 49.5 t-80 69.6 -29.35 0.18 Allowed 'General case' 0 N--CA 1.479 0.985 0 C-N-CA 125.747 1.619 . . . . 0.0 114.29 179.288 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 96.5 159.59 31.97 Favored Glycine 0 N--CA 1.418 -2.541 0 N-CA-C 108.771 -1.732 . . . . 0.0 108.771 -173.028 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -167.81 163.22 36.97 Favored Glycine 0 C--N 1.291 -1.954 0 C-N-CA 119.227 -1.463 . . . . 0.0 111.379 -177.75 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 37.4 Cg_endo -70.94 -43.16 1.79 Allowed 'Trans proline' 0 N--CA 1.451 -0.98 0 CA-C-N 118.885 1.343 . . . . 0.0 112.044 -179.579 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 15.4 pttp -120.73 -28.36 4.89 Favored 'General case' 0 N--CA 1.429 -1.494 0 C-N-CA 119.972 -0.691 . . . . 0.0 110.609 179.384 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.639 ' HA ' ' CG ' ' A' ' 80' ' ' HIS . 5.9 p-10 170.91 165.75 0.08 Allowed 'General case' 0 CA--C 1.481 -1.675 0 C-N-CA 124.287 1.035 . . . . 0.0 108.692 177.347 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . . . . . . . . . 14.2 tp10 -137.64 -73.31 0.42 Allowed 'General case' 0 C--N 1.303 -1.44 0 N-CA-C 108.236 -1.024 . . . . 0.0 108.236 -179.926 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.411 ' HB3' ' HG3' ' A' ' 70' ' ' LYS . 0.8 OUTLIER -135.93 -65.64 0.58 Allowed 'General case' 0 CA--C 1.51 -0.574 0 N-CA-C 105.627 -1.99 . . . . 0.0 105.627 177.716 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . . . . . . . . . 26.0 mmt180 -119.85 68.78 0.83 Allowed 'General case' 0 N--CA 1.415 -2.203 0 N-CA-C 107.498 -1.297 . . . . 0.0 107.498 171.645 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.639 ' CG ' ' HA ' ' A' ' 76' ' ' ASP . 29.8 t-80 -86.49 66.21 9.4 Favored 'General case' 0 C--N 1.302 -1.46 0 N-CA-C 106.594 -1.632 . . . . 0.0 106.594 177.635 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.536 HG11 ' O ' ' A' ' 106' ' ' LEU . 25.2 m -114.87 -15.02 10.46 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.757 0 CA-C-N 114.303 -1.317 . . . . 0.0 110.406 -176.43 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.598 ' O ' ' HA ' ' A' ' 46' ' ' HIS . . . -79.89 -1.76 87.69 Favored Glycine 0 CA--C 1.492 -1.391 0 C-N-CA 119.736 -1.221 . . . . 0.0 111.451 177.418 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.601 ' HB2' ' HB2' ' A' ' 126' ' ' LEU . 4.3 t70 -167.48 115.31 0.78 Allowed 'General case' 0 C--N 1.296 -1.754 0 C-N-CA 125.664 1.586 . . . . 0.0 106.91 -175.058 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.449 HD22 ' HA ' ' A' ' 81' ' ' VAL . 1.5 pt? -170.06 82.1 0.11 Allowed 'General case' 0 C--N 1.304 -1.403 0 N-CA-C 108.013 -1.106 . . . . 0.0 108.013 164.599 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 171.4 147.54 5.71 Favored Glycine 1 N--CA 1.393 -4.189 0 C-N-CA 118.842 -1.646 . . . . 0.0 112.444 177.719 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 61.1 t30 -105.71 128.01 53.42 Favored 'General case' 0 C--N 1.271 -2.839 0 N-CA-C 102.43 -3.174 . . . . 0.0 102.43 162.463 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.691 ' HB ' HD22 ' A' ' 42' ' ' LEU . 5.8 t -128.77 153.18 37.95 Favored 'Isoleucine or valine' 0 N--CA 1.422 -1.843 0 N-CA-C 102.557 -3.127 . . . . 0.0 102.557 -177.953 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.424 HG23 ' O ' ' A' ' 94' ' ' VAL . 15.4 t -139.53 149.85 44.39 Favored 'General case' 0 N--CA 1.4 -2.966 0 C-N-CA 118.594 -1.242 . . . . 0.0 110.694 -175.886 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.504 ' CB ' ' HB2' ' A' ' 121' ' ' GLU . . . -120.44 155.4 33.58 Favored 'General case' 2 C--N 1.224 -4.887 0 CA-C-N 114.381 -1.281 . . . . 0.0 108.725 -177.375 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . . . . . . . . . 22.1 t70 -149.42 160.14 43.7 Favored 'General case' 1 C--N 1.236 -4.359 0 N-CA-C 104.311 -2.478 . . . . 0.0 104.311 -179.379 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.595 ' HB3' ' HB ' ' A' ' 39' ' ' THR . 0.0 OUTLIER -44.08 -31.72 1.01 Allowed 'General case' 0 N--CA 1.526 3.326 0 CA-C-N 119.51 1.05 . . . . 0.0 112.976 172.77 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 3.2 m-20 -91.53 -25.27 19.32 Favored 'General case' 0 C--N 1.307 -1.244 0 CA-C-O 121.864 0.84 . . . . 0.0 109.116 179.187 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.416 ' HA3' ' HA ' ' A' ' 36' ' ' LYS . . . 83.12 85.81 0.82 Allowed Glycine 0 N--CA 1.397 -3.908 0 CA-C-N 114.738 -1.119 . . . . 0.0 112.317 -175.955 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.424 ' O ' HG23 ' A' ' 88' ' ' THR . 10.8 m -136.95 102.37 2.63 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.729 0 CA-C-O 122.312 1.053 . . . . 0.0 109.753 175.659 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.721 ' HB3' ' H ' ' A' ' 35' ' ' ILE . . . -96.25 145.33 25.65 Favored 'General case' 0 N--CA 1.408 -2.561 0 CA-C-N 113.966 -1.47 . . . . 0.0 112.197 172.656 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 4.5 m-20 -75.03 152.83 38.65 Favored 'General case' 0 N--CA 1.412 -2.325 0 N-CA-C 105.339 -2.097 . . . . 0.0 105.339 166.163 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.467 ' HA ' ' O ' ' A' ' 33' ' ' GLY . 28.7 m -80.9 134.58 26.92 Favored 'Isoleucine or valine' 0 C--N 1.277 -2.584 0 CA-C-O 121.864 0.84 . . . . 0.0 108.899 178.427 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.404 ' OG ' HG22 ' A' ' 87' ' ' VAL . 19.6 m -75.86 106.05 7.24 Favored 'General case' 0 N--CA 1.418 -2.053 0 CA-C-N 114.244 -1.344 . . . . 0.0 112.384 -176.392 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 24.5 pt -121.72 122.02 65.88 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.422 0 N-CA-C 108.146 -1.057 . . . . 0.0 108.146 174.051 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 8.7 tp10 -146.23 151.44 37.59 Favored 'General case' 0 C--N 1.282 -2.341 0 N-CA-C 106.259 -1.756 . . . . 0.0 106.259 -178.386 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 4.2 p-10 -93.07 99.28 11.91 Favored 'General case' 0 C--N 1.297 -1.703 0 C-N-CA 117.712 -1.595 . . . . 0.0 110.831 -178.741 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.46 ' HA ' ' HB3' ' A' ' 76' ' ' ASP . 53.1 m -102.86 142.82 33.34 Favored 'General case' 0 N--CA 1.396 -3.148 0 N-CA-C 104.313 -2.477 . . . . 0.0 104.313 172.233 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.467 HG22 ' OD1' ' A' ' 26' ' ' ASN . 14.7 p -101.77 -46.85 11.33 Favored 'Isoleucine or valine' 0 C--N 1.288 -2.083 0 C-N-CA 117.383 -1.727 . . . . 0.0 112.156 -178.852 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 14.9 tt -121.58 24.01 4.41 Favored 'Isoleucine or valine' 0 CA--C 1.558 1.278 0 CA-C-O 122.308 1.051 . . . . 0.0 111.729 -171.29 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.691 ' O ' ' HG2' ' A' ' 22' ' ' GLN . 56.6 m -103.64 87.6 2.87 Favored 'General case' 0 C--N 1.297 -1.702 0 O-C-N 120.169 -1.582 . . . . 0.0 114.008 -177.416 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.536 ' O ' HG11 ' A' ' 81' ' ' VAL . 6.1 mp -69.82 129.54 39.85 Favored 'General case' 0 CA--C 1.482 -1.657 0 N-CA-C 106.22 -1.771 . . . . 0.0 106.22 169.941 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.444 ' HA ' HG11 ' A' ' 81' ' ' VAL . 13.1 t -73.63 87.68 1.67 Allowed 'General case' 0 N--CA 1.408 -2.551 0 CA-C-O 121.857 0.836 . . . . 0.0 112.491 -170.188 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . 145.55 135.47 2.83 Favored Glycine 0 N--CA 1.406 -3.302 0 CA-C-N 114.189 -1.368 . . . . 0.0 112.426 168.226 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 11.5 t70 -46.97 -70.53 0.09 Allowed 'General case' 0 CA--C 1.539 0.551 0 C-N-CA 123.912 0.885 . . . . 0.0 111.88 168.832 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 63.8 m80 -123.02 -34.82 3.11 Favored 'General case' 0 CA--C 1.496 -1.098 0 N-CA-C 108.276 -1.009 . . . . 0.0 108.276 175.038 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.653 ' O ' ' HD3' ' A' ' 115' ' ' ARG . 17.5 m -96.42 106.76 19.05 Favored 'General case' 0 N--CA 1.414 -2.257 0 CA-C-N 114.978 -1.01 . . . . 0.0 110.783 -178.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 18.1 mm -87.67 -48.11 15.38 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.062 0 N-CA-C 104.231 -2.507 . . . . 0.0 104.231 168.775 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . . . . . . . . . 9.3 tt -102.69 151.11 6.16 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.491 0 CA-C-N 114.856 -1.065 . . . . 0.0 108.258 174.498 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . . . . . . . . . . . 100.24 -31.01 8.99 Favored Glycine 0 CA--C 1.478 -2.268 0 N-CA-C 110.79 -0.924 . . . . 0.0 110.79 172.754 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.674 ' O ' ' HA ' ' A' ' 148' ' ' VAL . 28.7 ptt180 -69.46 156.43 38.87 Favored 'General case' 0 C--N 1.297 -1.7 0 C-N-CA 124.455 1.102 . . . . 0.0 112.549 -175.628 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . . . . . . . . . 24.5 m -116.06 113.94 23.86 Favored 'General case' 0 N--CA 1.388 -3.533 0 N-CA-C 105.229 -2.138 . . . . 0.0 105.229 -178.636 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.764 HD22 ' HB ' ' A' ' 149' ' ' ILE . 4.6 mp -95.98 160.49 14.43 Favored 'General case' 0 C--N 1.268 -2.953 0 N-CA-C 108.713 -0.847 . . . . 0.0 108.713 -174.201 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.428 HG23 ' O ' ' A' ' 145' ' ' ALA 0.327 8.4 p -140.5 116.14 7.37 Favored 'Isoleucine or valine' 0 C--O 1.263 1.793 0 C-N-CA 116.324 -2.15 . . . . 0.0 114.019 -179.156 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.461 ' CG1' ' HB2' ' A' ' 45' ' ' PHE . 19.7 m -138.49 170.37 16.75 Favored 'Isoleucine or valine' 0 C--N 1.313 -1.017 0 N-CA-C 106.008 -1.849 . . . . 0.0 106.008 -176.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.513 ' ND1' ' HB3' ' A' ' 144' ' ' LEU . 62.7 t60 -170.44 167.95 8.03 Favored 'General case' 0 C--N 1.307 -1.25 0 N-CA-C 105.129 -2.175 . . . . 0.0 105.129 176.59 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.504 ' HB2' ' CB ' ' A' ' 89' ' ' ALA . 8.9 pm0 -70.96 85.89 0.7 Allowed 'General case' 0 CA--C 1.551 0.994 0 CA-C-N 119.973 1.26 . . . . 0.0 110.467 177.202 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.536 ' C ' ' HA ' ' A' ' 42' ' ' LEU . 30.5 ttmt -175.7 154.99 1.65 Allowed 'General case' 0 CA--C 1.515 -0.393 0 CA-C-N 115.753 -0.658 . . . . 0.0 109.553 -176.677 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.562 ' HA ' ' H ' ' A' ' 43' ' ' HIS . . . -60.27 107.31 0.63 Allowed 'General case' 0 C--N 1.308 -1.201 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 168.901 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.531 ' OD2' ' HA ' ' A' ' 140' ' ' ALA . 9.0 t70 -105.36 17.56 23.73 Favored 'General case' 0 CA--C 1.549 0.92 0 C-N-CA 123.758 0.823 . . . . 0.0 108.93 -179.136 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 10.2 t0 -35.73 114.91 0.29 Allowed 'General case' 0 N--CA 1.5 2.042 0 C-N-CA 126.438 1.895 . . . . 0.0 111.306 -177.818 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.601 ' HB2' ' HB2' ' A' ' 83' ' ' ASP . 0.2 OUTLIER -90.79 -36.39 14.28 Favored 'General case' 0 C--N 1.312 -1.034 0 CA-C-N 115.83 -0.623 . . . . 0.0 112.137 -168.151 . . . . . . . . 3 3 . 1 . 016 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -79.21 -27.19 56.22 Favored Glycine 0 N--CA 1.447 -0.584 0 C-N-CA 120.933 -0.651 . . . . 0.0 113.588 -177.453 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 39.5 ttmt -100.84 -26.01 13.91 Favored 'General case' 0 C--N 1.313 -1.007 0 CA-C-N 116.955 0.378 . . . . 0.0 110.907 -178.893 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . 72.05 -71.6 0.95 Allowed Glycine 0 CA--C 1.529 0.937 0 N-CA-C 113.767 0.267 . . . . 0.0 113.767 -177.229 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 118.73 -6.47 13.83 Favored Glycine 0 C--N 1.313 -0.728 0 N-CA-C 110.148 -1.181 . . . . 0.0 110.148 -175.025 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 26.8 t30 -162.67 150.66 14.03 Favored 'General case' 0 C--N 1.312 -1.028 0 N-CA-C 105.367 -2.086 . . . . 0.0 105.367 179.108 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . . 46.0 mt-10 -48.26 -51.13 27.05 Favored 'General case' 0 N--CA 1.479 1.01 0 O-C-N 124.122 0.889 . . . . 0.0 112.062 -176.992 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -63.38 -48.28 78.55 Favored 'General case' 0 C--N 1.317 -0.824 0 CA-C-N 115.283 -0.871 . . . . 0.0 109.614 -178.727 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 8.2 m -62.56 -24.56 67.6 Favored 'General case' 0 CA--C 1.543 0.711 0 N-CA-C 112.78 0.659 . . . . 0.0 112.78 -176.545 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 25.7 m -69.63 -35.23 75.04 Favored 'General case' 0 C--N 1.327 -0.408 0 CA-C-O 122.008 0.909 . . . . 0.0 109.407 176.999 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 34.5 mmtp -83.41 -41.15 18.45 Favored 'General case' 0 C--N 1.293 -1.848 0 CA-C-N 114.212 -1.358 . . . . 0.0 111.776 -174.052 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 0.6 OUTLIER -74.01 -52.37 12.96 Favored 'General case' 0 C--N 1.273 -2.726 0 C-N-CA 119.229 -0.988 . . . . 0.0 109.14 175.049 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 112.95 91.69 1.96 Allowed Glycine 1 N--CA 1.388 -4.504 0 N-CA-C 108.78 -1.728 . . . . 0.0 108.78 -176.167 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 31.8 t30 -34.57 117.43 0.36 Allowed 'General case' 1 C--O 1.333 5.488 0 C-N-CA 126.233 1.813 . . . . 0.0 113.265 -173.149 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.531 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . . . -153.63 142.5 21.11 Favored 'General case' 0 N--CA 1.411 -2.417 0 CA-C-N 114.891 -1.05 . . . . 0.0 112.357 175.198 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -86.81 86.03 1.55 Allowed Glycine 0 N--CA 1.425 -2.091 0 N-CA-C 104.525 -3.43 . . . . 0.0 104.525 164.166 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . 0.665 ' HB3' ' HA2' ' A' ' 61' ' ' GLY . 21.0 m -55.01 -3.89 0.06 Allowed 'General case' 0 C--N 1.312 -1.046 0 N-CA-C 118.095 2.628 . . . . 0.0 118.095 -166.49 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.668 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 11.9 ptm180 -144.75 11.0 1.4 Allowed 'General case' 0 C--N 1.247 -3.885 0 C-N-CA 119.812 -0.755 . . . . 0.0 109.038 179.314 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.513 ' HB3' ' ND1' ' A' ' 120' ' ' HIS . 4.6 mm? -78.6 -9.21 59.28 Favored 'General case' 0 C--N 1.295 -1.774 0 CA-C-N 116.432 -0.349 . . . . 0.0 111.695 -175.906 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.447 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.15 109.69 0.39 Allowed 'General case' 0 CA--C 1.494 -1.186 0 C-N-CA 123.791 0.836 . . . . 0.0 108.915 173.638 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 38.3 m -96.43 137.06 36.08 Favored 'General case' 0 C--N 1.291 -1.956 0 N-CA-C 107.512 -1.292 . . . . 0.0 107.512 178.642 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . . . . . . . . . . . -171.02 125.38 1.2 Allowed Glycine 0 N--CA 1.424 -2.137 0 C-N-CA 118.498 -1.811 . . . . 0.0 113.434 177.879 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.674 ' HA ' ' O ' ' A' ' 115' ' ' ARG . 75.6 t -73.51 101.48 1.51 Allowed 'Isoleucine or valine' 0 N--CA 1.425 -1.676 0 N-CA-C 108.452 -0.944 . . . . 0.0 108.452 171.733 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.764 ' HB ' HD22 ' A' ' 117' ' ' LEU . 53.7 mt -116.27 128.44 73.59 Favored 'Isoleucine or valine' 0 C--N 1.278 -2.523 0 N-CA-C 107.406 -1.331 . . . . 0.0 107.406 -179.051 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . . . . . . . . . . . 177.11 -168.49 40.35 Favored Glycine 3 CA--C 1.415 -6.186 0 N-CA-C 108.121 -1.992 . . . . 0.0 108.121 179.447 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.519 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 2.8 pp -67.81 121.16 16.46 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.835 0 C-N-CA 120.096 -0.642 . . . . 0.0 111.165 179.104 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -131.75 114.75 15.13 Favored 'General case' 0 C--N 1.302 -1.479 0 N-CA-C 108.76 -0.83 . . . . 0.0 108.76 174.126 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 11.1 pt20 . . . . . 0 C--N 1.289 -2.065 0 CA-C-N 115.656 -0.702 . . . . 0.0 109.571 -179.31 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 CA--C 1.539 0.55 0 N-CA-C 112.464 0.542 . . . . 0.0 112.464 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.408 ' O ' ' HB3' ' A' ' 21' ' ' GLU . 26.2 m -112.84 -31.51 6.7 Favored 'General case' 0 CA--C 1.557 1.222 0 N-CA-C 114.416 1.265 . . . . 0.0 114.416 -171.641 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . 0.454 ' HB2' HD21 ' A' ' 19' ' ' ASN . 62.1 pttt -146.79 158.37 43.89 Favored 'General case' 0 C--N 1.296 -1.735 0 C-N-CA 119.477 -0.889 . . . . 0.0 110.861 -174.856 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.781 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -143.01 150.37 39.52 Favored 'General case' 0 N--CA 1.395 -3.178 0 N-CA-C 107.556 -1.276 . . . . 0.0 107.556 -179.94 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.486 ' CG2' ' HB3' ' A' ' 152' ' ' ALA . 29.0 m -129.63 138.93 52.95 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.82 0 N-CA-C 108.657 -0.868 . . . . 0.0 108.657 177.573 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.572 ' HB2' HG13 ' A' ' 149' ' ' ILE . . . -116.6 136.02 53.32 Favored 'General case' 0 C--N 1.276 -2.599 0 CA-C-N 114.757 -1.11 . . . . 0.0 111.799 -176.225 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 12.7 m -133.07 105.47 8.29 Favored 'Isoleucine or valine' 0 C--N 1.325 -0.497 0 CA-C-O 121.161 0.505 . . . . 0.0 110.608 175.922 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.424 HD23 HD21 ' A' ' 117' ' ' LEU . 0.4 OUTLIER -114.75 151.14 34.24 Favored 'General case' 0 C--N 1.313 -1.013 0 N-CA-C 112.67 0.619 . . . . 0.0 112.67 179.651 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 57.7 tttm -157.43 150.45 23.44 Favored 'General case' 0 N--CA 1.424 -1.757 0 N-CA-C 106.446 -1.687 . . . . 0.0 106.446 175.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -154.15 -158.76 8.81 Favored Glycine 0 N--CA 1.414 -2.784 0 N-CA-C 110.305 -1.118 . . . . 0.0 110.305 177.679 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 29.3 t70 -69.39 -39.19 78.12 Favored 'General case' 0 C--N 1.313 -0.99 0 O-C-N 124.935 1.021 . . . . 0.0 109.764 176.468 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -91.16 164.13 29.51 Favored Glycine 0 C--O 1.251 1.189 0 N-CA-C 108.704 -1.759 . . . . 0.0 108.704 174.461 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 0.9 OUTLIER -83.14 123.4 3.51 Favored 'Trans proline' 0 N--CA 1.424 -2.613 0 CA-C-N 120.371 2.086 . . . . 0.0 109.739 179.772 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . 0.52 ' HA ' ' O ' ' A' ' 36' ' ' LYS . 12.1 m -132.21 123.52 50.66 Favored 'Isoleucine or valine' 0 N--CA 1.406 -2.667 0 N-CA-C 107.497 -1.297 . . . . 0.0 107.497 178.103 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . . . . . . . . . 97.6 mt-30 -130.32 119.58 23.03 Favored 'General case' 0 C--N 1.274 -2.685 0 N-CA-C 107.941 -1.133 . . . . 0.0 107.941 179.667 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -166.87 166.62 39.22 Favored Glycine 0 N--CA 1.408 -3.194 0 C-N-CA 119.115 -1.517 . . . . 0.0 112.086 -179.722 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.422 ' O ' ' HA2' ' A' ' 33' ' ' GLY . 11.9 tt -151.53 126.27 1.53 Allowed 'Isoleucine or valine' 0 N--CA 1.418 -2.027 0 N-CA-C 106.836 -1.542 . . . . 0.0 106.836 179.096 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.486 ' H ' ' HB3' ' A' ' 6' ' ' ALA . 3.4 mp -122.87 136.6 59.16 Favored 'Isoleucine or valine' 0 C--N 1.295 -1.789 0 N-CA-C 108.205 -1.035 . . . . 0.0 108.205 -178.185 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.454 HD21 ' HB2' ' A' ' 3' ' ' LYS . 25.1 t-20 -110.61 130.3 55.6 Favored 'General case' 0 N--CA 1.445 -0.679 0 C-N-CA 123.274 0.63 . . . . 0.0 109.395 -176.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.781 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 68.0 m-85 -130.16 133.59 46.71 Favored 'General case' 0 CA--C 1.498 -1.026 0 O-C-N 123.583 0.552 . . . . 0.0 110.824 178.183 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.484 ' O ' HG13 ' A' ' 104' ' ' ILE . 15.8 pt-20 -106.03 103.31 12.76 Favored 'General case' 0 C--N 1.287 -2.142 0 N-CA-C 107.989 -1.115 . . . . 0.0 107.989 171.659 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.501 ' HA ' ' CG1' ' A' ' 104' ' ' ILE . 0.0 OUTLIER -85.78 88.37 7.54 Favored 'General case' 1 N--CA 1.371 -4.415 0 CA-C-O 122.711 1.243 . . . . 0.0 112.164 -171.876 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . 0.435 ' HE3' ' CD ' ' A' ' 21' ' ' GLU . 96.1 mttt -76.11 106.52 7.76 Favored 'General case' 0 N--CA 1.409 -2.509 0 N-CA-C 104.638 -2.356 . . . . 0.0 104.638 172.647 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . 0.412 ' HG3' ' HB2' ' A' ' 106' ' ' LEU . 28.7 tt0 -48.58 -39.42 23.67 Favored 'General case' 0 C--N 1.31 -1.117 0 CA-C-N 113.693 -1.594 . . . . 0.0 113.86 -167.384 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 33.6 m -90.63 -61.96 1.56 Allowed 'General case' 0 C--N 1.291 -1.952 0 CA-C-O 120.773 0.32 . . . . 0.0 110.461 177.368 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 3.8 p-10 -173.56 171.47 3.87 Favored 'General case' 0 CA--C 1.507 -0.699 0 N-CA-C 108.683 -0.858 . . . . 0.0 108.683 -177.908 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 162.42 163.0 14.21 Favored Glycine 0 CA--C 1.494 -1.266 0 C-N-CA 120.909 -0.662 . . . . 0.0 112.218 175.881 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 45.9 Cg_exo -62.02 124.53 14.6 Favored 'Trans proline' 0 N--CA 1.453 -0.856 0 C-N-CA 122.326 2.017 . . . . 0.0 107.483 172.116 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.447 ' HB ' HG13 ' A' ' 31' ' ' VAL . 35.2 m -95.63 117.36 39.52 Favored 'Isoleucine or valine' 0 N--CA 1.421 -1.919 0 N-CA-C 114.226 1.195 . . . . 0.0 114.226 -174.057 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.414 ' HE2' ' HB3' ' A' ' 30' ' ' LYS . 19.2 ttpt -82.65 101.87 11.1 Favored 'General case' 0 N--CA 1.413 -2.288 0 N-CA-C 106.198 -1.779 . . . . 0.0 106.198 169.894 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.447 HG13 ' HB ' ' A' ' 29' ' ' VAL . 35.7 m -137.13 137.73 46.29 Favored 'Isoleucine or valine' 0 C--N 1.304 -1.411 0 N-CA-C 109.523 -0.547 . . . . 0.0 109.523 -177.06 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . . . . . . . . . 67.0 p-90 -148.3 137.31 21.82 Favored 'General case' 0 C--N 1.269 -2.902 0 N-CA-C 107.412 -1.329 . . . . 0.0 107.412 176.54 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.445 ' HA3' HG13 ' A' ' 18' ' ' ILE . . . -153.28 140.19 7.42 Favored Glycine 0 N--CA 1.4 -3.712 0 C-N-CA 119.779 -1.2 . . . . 0.0 111.063 176.888 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 19.7 m -115.28 141.82 47.52 Favored 'General case' 0 N--CA 1.419 -2.002 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 177.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.722 ' HB ' ' HB3' ' A' ' 95' ' ' ALA . 41.1 mm -131.43 126.73 58.82 Favored 'Isoleucine or valine' 0 C--N 1.308 -1.218 0 N-CA-C 108.413 -0.958 . . . . 0.0 108.413 176.533 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.52 ' O ' ' HA ' ' A' ' 14' ' ' VAL . 41.2 ttmt -108.92 131.52 54.95 Favored 'General case' 0 C--N 1.289 -2.036 0 N-CA-C 103.884 -2.636 . . . . 0.0 103.884 172.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -162.88 175.47 39.24 Favored Glycine 0 C--N 1.273 -2.968 0 N-CA-C 110.596 -1.001 . . . . 0.0 110.596 -167.478 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 7.5 tt -67.34 142.76 56.68 Favored 'General case' 0 C--N 1.292 -1.926 0 N-CA-C 106.563 -1.643 . . . . 0.0 106.563 178.496 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.68 ' OG1' ' HA ' ' A' ' 91' ' ' LYS . 0.2 OUTLIER -69.35 105.74 2.67 Favored 'General case' 0 N--CA 1.435 -1.186 0 N-CA-C 113.781 1.03 . . . . 0.0 113.781 -172.777 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.529 ' O ' ' HB3' ' A' ' 121' ' ' GLU . 27.9 mt-10 -175.43 135.77 0.33 Allowed 'General case' 0 CA--C 1.478 -1.798 0 C-N-CA 129.404 3.082 . . . . 0.0 104.057 174.743 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -163.63 99.99 0.17 Allowed Glycine 0 C--N 1.265 -3.395 0 C-N-CA 116.844 -2.598 . . . . 0.0 113.341 -178.798 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . . . . . . . . . 5.6 mp -103.07 -86.18 0.44 Allowed 'General case' 0 N--CA 1.446 -0.639 0 O-C-N 124.547 0.792 . . . . 0.0 111.184 -179.927 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.485 ' O ' ' HA ' ' A' ' 123' ' ' ALA . 7.8 p80 176.39 141.42 0.07 Allowed 'General case' 0 C--N 1.354 0.789 0 N-CA-C 108.036 -1.098 . . . . 0.0 108.036 178.993 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -176.37 116.06 0.54 Allowed Glycine 0 N--CA 1.419 -2.436 0 C-N-CA 119.616 -1.278 . . . . 0.0 113.048 179.806 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . . . . . . . . . 1.5 p90 -122.89 107.95 12.42 Favored 'General case' 0 C--N 1.313 -0.986 0 CA-C-O 121.929 0.871 . . . . 0.0 112.876 178.744 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.597 ' HA ' ' HB ' ' A' ' 81' ' ' VAL . 54.4 t60 -171.11 89.73 0.13 Allowed 'General case' 0 CA--C 1.483 -1.599 0 N-CA-C 108.202 -1.036 . . . . 0.0 108.202 173.005 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.724 ' O ' ' HA3' ' A' ' 82' ' ' GLY . 51.5 t -132.4 87.81 0.92 Allowed 'Isoleucine or valine' 0 C--N 1.286 -2.191 0 O-C-N 126.344 2.278 . . . . 0.0 109.284 -179.805 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.477 ' CE1' ' HA3' ' A' ' 108' ' ' GLY . 8.6 t-160 -173.27 87.4 0.06 Allowed 'General case' 0 N--CA 1.499 2.019 0 O-C-N 121.239 -0.913 . . . . 0.0 110.749 -179.413 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.597 ' H ' ' HB2' ' A' ' 115' ' ' ARG . 2.7 mp0 -136.51 172.25 13.29 Favored 'General case' 1 C--N 1.24 -4.173 0 CA-C-N 113.648 -1.615 . . . . 0.0 109.082 -170.956 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.413 ' HB3' ' OD1' ' A' ' 109' ' ' ASP . 26.3 p90 -69.81 171.31 9.44 Favored 'General case' 0 C--N 1.284 -2.26 0 CA-C-O 121.096 0.474 . . . . 0.0 111.2 169.31 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.775 ' HA2' ' O ' ' A' ' 114' ' ' GLY . . . -59.86 120.7 23.91 Favored Glycine 0 C--O 1.249 1.041 0 CA-C-N 115.118 -0.946 . . . . 0.0 114.282 177.373 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . 0.404 ' CG ' ' HA ' ' A' ' 57' ' ' CYS . 5.5 t0 -129.72 -167.27 1.78 Allowed 'General case' 0 C--O 1.247 0.932 0 N-CA-C 106.466 -1.679 . . . . 0.0 106.466 176.159 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . 0.679 ' HB3' ' O ' ' A' ' 56' ' ' GLY . 29.9 t30 -69.47 133.86 48.23 Favored 'General case' 0 C--N 1.293 -1.891 0 CA-C-O 121.369 0.604 . . . . 0.0 110.519 -179.595 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . 0.561 ' O ' ' HA2' ' A' ' 147' ' ' GLY . 1.3 p -51.41 -22.4 2.96 Favored 'General case' 0 C--N 1.316 -0.863 0 C-N-CA 127.286 2.235 . . . . 0.0 114.44 -178.629 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -131.96 24.22 4.6 Favored 'General case' 0 C--N 1.297 -1.71 0 N-CA-C 109.981 -0.377 . . . . 0.0 109.981 -179.194 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.679 ' O ' ' HB3' ' A' ' 53' ' ' ASN . . . 175.51 111.15 0.27 Allowed Glycine 0 C--O 1.196 -2.232 0 C-N-CA 117.778 -2.153 . . . . 0.0 112.566 179.471 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.492 ' HB2' ' HB3' ' A' ' 60' ' ' ALA . 13.3 p -90.56 96.03 10.45 Favored 'General case' 0 N--CA 1.409 -2.505 0 CA-C-O 121.973 0.892 . . . . 0.0 110.108 -177.877 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 24.3 m -76.57 -51.56 11.41 Favored 'General case' 0 C--N 1.299 -1.61 0 CA-C-N 114.94 -1.027 . . . . 0.0 109.885 -174.849 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 32.1 m -91.03 -36.5 14.02 Favored 'General case' 0 N--CA 1.428 -1.543 0 CA-C-N 115.38 -0.827 . . . . 0.0 110.372 -177.553 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.492 ' HB3' ' HB2' ' A' ' 57' ' ' CYS . . . -77.58 -17.69 57.59 Favored 'General case' 0 C--N 1.316 -0.874 0 CA-C-N 115.544 -0.753 . . . . 0.0 112.67 -177.449 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -49.85 -63.73 3.99 Favored Glycine 0 CA--C 1.539 1.546 0 N-CA-C 114.56 0.584 . . . . 0.0 114.56 -179.466 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 1.5 Cg_endo -85.78 6.37 5.6 Favored 'Trans proline' 0 C--O 1.24 0.617 0 C-N-CA 122.744 2.296 . . . . 0.0 112.092 177.891 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 85.0 t60 -83.1 142.37 31.31 Favored 'General case' 0 N--CA 1.44 -0.942 0 CA-C-O 121.535 0.683 . . . . 0.0 111.409 -175.914 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 35.2 p90 -141.4 133.88 28.33 Favored 'General case' 0 N--CA 1.411 -2.384 0 N-CA-C 105.736 -1.95 . . . . 0.0 105.736 172.014 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.411 ' CG ' ' H ' ' A' ' 109' ' ' ASP . 9.4 t30 -77.35 141.57 66.29 Favored Pre-proline 0 C--N 1.306 -1.317 0 C-N-CA 118.273 -1.371 . . . . 0.0 109.508 175.91 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 88.1 Cg_exo -53.5 -33.36 67.43 Favored 'Trans proline' 0 C--N 1.362 1.25 0 C-N-CA 123.834 3.023 . . . . 0.0 115.726 -177.279 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.488 ' O ' ' HB2' ' A' ' 79' ' ' ARG . 3.0 mm? -78.15 -45.4 23.35 Favored 'General case' 0 CA--C 1.493 -1.221 0 N-CA-C 107.916 -1.142 . . . . 0.0 107.916 -179.078 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.58 ' HA ' ' O ' ' A' ' 79' ' ' ARG . 14.4 m -67.3 31.54 0.02 OUTLIER 'General case' 0 CA--C 1.498 -1.026 0 C-N-CA 129.477 3.111 . . . . 0.0 116.62 -172.88 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.611 ' N ' ' HB2' ' A' ' 79' ' ' ARG . 0.0 OUTLIER -136.27 -32.55 0.85 Allowed 'General case' 0 C--N 1.245 -3.958 0 CA-C-N 115.241 -0.89 . . . . 0.0 110.584 172.633 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.492 ' N ' ' HD2' ' A' ' 69' ' ' ARG . 82.2 tttt 34.67 -87.35 0.0 OUTLIER 'General case' 0 C--N 1.373 1.626 0 C-N-CA 124.526 1.13 . . . . 0.0 110.25 -170.941 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 47.9 t-80 -178.93 12.2 0.0 OUTLIER 'General case' 0 C--O 1.214 -0.764 0 C-N-CA 126.32 1.848 . . . . 0.0 106.994 176.961 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . . . . . . . . . . . 135.49 134.38 3.35 Favored Glycine 0 N--CA 1.435 -1.403 0 C-N-CA 119.329 -1.415 . . . . 0.0 111.869 -175.382 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . . . . . . . . . . . -168.59 83.95 0.09 OUTLIER Glycine 0 C--O 1.2 -2.019 0 N-CA-C 108.451 -1.859 . . . . 0.0 108.451 176.613 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.429 ' HA ' HD11 ' A' ' 84' ' ' LEU . 59.9 Cg_endo -104.21 -0.5 0.27 Allowed 'Trans proline' 0 CA--C 1.557 1.629 0 C-N-CA 122.706 2.271 . . . . 0.0 115.621 -176.541 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 58.2 mttm -123.41 -11.86 7.84 Favored 'General case' 0 C--N 1.308 -1.213 0 N-CA-C 112.28 0.474 . . . . 0.0 112.28 179.532 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 13.7 t70 178.39 88.78 0.01 OUTLIER 'General case' 0 C--N 1.318 -0.782 0 N-CA-C 107.908 -1.145 . . . . 0.0 107.908 -172.413 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.533 ' HG3' HG23 ' A' ' 103' ' ' VAL . 3.8 mm-40 -54.94 146.59 17.29 Favored 'General case' 0 C--N 1.286 -2.177 0 N-CA-C 117.981 2.585 . . . . 0.0 117.981 -177.485 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . . . . . . . . . 42.4 mt-10 -138.23 -16.22 1.24 Allowed 'General case' 0 N--CA 1.415 -2.198 0 CA-C-N 112.624 -2.08 . . . . 0.0 107.313 -177.603 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.611 ' HB2' ' N ' ' A' ' 69' ' ' ARG . 0.0 OUTLIER -105.5 -37.31 6.84 Favored 'General case' 1 N--CA 1.358 -5.058 0 N-CA-C 106.191 -1.781 . . . . 0.0 106.191 177.995 . . . . . . . . 4 4 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.463 ' H ' ' CD ' ' A' ' 77' ' ' GLU . 45.2 m80 70.69 74.73 0.2 Allowed 'General case' 0 CA--C 1.498 -1.034 0 CA-C-N 113.344 -1.753 . . . . 0.0 110.041 176.19 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.597 ' HB ' ' HA ' ' A' ' 46' ' ' HIS . 28.3 m -77.66 24.43 0.06 OUTLIER 'Isoleucine or valine' 0 C--N 1.314 -0.945 0 CA-C-N 115.792 -0.64 . . . . 0.0 112.014 179.249 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.724 ' HA3' ' O ' ' A' ' 47' ' ' VAL . . . 68.26 -69.53 0.35 Allowed Glycine 0 N--CA 1.478 1.49 0 C-N-CA 124.033 0.825 . . . . 0.0 113.803 179.374 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.434 ' O ' HG23 ' A' ' 81' ' ' VAL . 8.8 t70 -100.15 127.48 46.4 Favored 'General case' 0 C--N 1.299 -1.602 0 N-CA-C 108.383 -0.969 . . . . 0.0 108.383 175.602 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.429 HD11 ' HA ' ' A' ' 74' ' ' PRO . 1.0 OUTLIER -123.29 87.98 2.84 Favored 'General case' 0 N--CA 1.407 -2.614 0 N-CA-C 105.636 -1.987 . . . . 0.0 105.636 172.83 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -153.74 132.06 3.46 Favored Glycine 1 N--CA 1.379 -5.13 0 N-CA-C 108.61 -1.796 . . . . 0.0 108.61 174.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 11.9 p-10 -73.8 129.22 37.48 Favored 'General case' 0 C--N 1.284 -2.266 0 C-N-CA 118.029 -1.468 . . . . 0.0 107.545 174.805 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.421 ' O ' ' HA ' ' A' ' 43' ' ' HIS . 44.6 t -110.81 128.15 67.39 Favored 'Isoleucine or valine' 0 C--N 1.36 1.024 0 O-C-N 121.441 -0.787 . . . . 0.0 109.278 -174.67 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . . . . . . . . . 3.0 t -141.45 96.47 2.99 Favored 'General case' 0 N--CA 1.425 -1.723 0 N-CA-C 110.421 -0.214 . . . . 0.0 110.421 -179.122 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.416 ' HA ' ' O ' ' A' ' 94' ' ' VAL . . . -80.11 107.21 12.72 Favored 'General case' 0 C--O 1.2 -1.523 0 N-CA-C 106.722 -1.585 . . . . 0.0 106.722 175.247 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.51 ' C ' ' H ' ' A' ' 92' ' ' ASP . 26.3 t70 -64.69 162.68 15.34 Favored 'General case' 0 C--N 1.28 -2.428 0 CA-C-N 115.165 -0.925 . . . . 0.0 108.644 -174.132 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.68 ' HA ' ' OG1' ' A' ' 39' ' ' THR . 58.5 pttt -42.13 14.78 0.0 OUTLIER 'General case' 0 CA--C 1.6 2.902 0 N-CA-C 117.652 2.464 . . . . 0.0 117.652 174.601 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . 0.51 ' H ' ' C ' ' A' ' 90' ' ' ASP . 21.3 t70 -125.51 -28.98 3.25 Favored 'General case' 0 C--N 1.296 -1.736 0 C-N-CA 126.249 1.82 . . . . 0.0 108.753 178.555 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 104.07 66.77 0.72 Allowed Glycine 0 C--O 1.22 -0.746 0 CA-C-N 115.863 -0.608 . . . . 0.0 112.217 -179.147 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . 0.452 ' HA ' ' O ' ' A' ' 35' ' ' ILE . 7.7 p -160.83 117.58 0.17 Allowed 'Isoleucine or valine' 0 N--CA 1.442 -0.828 0 CA-C-N 117.387 0.594 . . . . 0.0 110.602 -175.123 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.722 ' HB3' ' HB ' ' A' ' 35' ' ' ILE . . . -122.31 124.34 43.52 Favored 'General case' 0 N--CA 1.434 -1.27 0 N-CA-C 108.923 -0.769 . . . . 0.0 108.923 175.977 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 17.1 t70 -111.41 112.56 24.39 Favored 'General case' 0 C--N 1.292 -1.901 0 N-CA-C 108.905 -0.776 . . . . 0.0 108.905 178.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.418 HG11 HG22 ' A' ' 87' ' ' VAL . 34.4 m -112.74 125.79 70.05 Favored 'Isoleucine or valine' 0 C--N 1.314 -0.956 0 N-CA-C 113.357 0.873 . . . . 0.0 113.357 -178.061 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 46.1 m -154.56 101.09 2.31 Favored 'General case' 0 C--N 1.306 -1.296 0 N-CA-C 107.2 -1.407 . . . . 0.0 107.2 169.968 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . . . . . . . . . 46.8 mm -129.58 149.3 33.51 Favored 'Isoleucine or valine' 0 C--N 1.3 -1.553 0 N-CA-C 106.606 -1.627 . . . . 0.0 106.606 178.974 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 10.6 pt-20 -109.68 118.82 37.57 Favored 'General case' 0 C--O 1.265 1.874 0 CA-C-O 122.604 1.192 . . . . 0.0 112.365 179.17 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.7 t0 -164.95 138.59 4.83 Favored 'General case' 0 C--N 1.299 -1.612 0 CA-C-N 113.527 -1.669 . . . . 0.0 106.689 -176.124 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.405 ' O ' ' HB2' ' A' ' 77' ' ' GLU . 58.5 m -82.31 79.77 8.68 Favored 'General case' 0 N--CA 1.435 -1.191 0 C-N-CA 119.206 -0.998 . . . . 0.0 109.352 175.04 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . 0.533 HG23 ' HG3' ' A' ' 77' ' ' GLU . 7.5 p -108.15 -15.05 9.46 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.164 0 CA-C-N 114.324 -1.307 . . . . 0.0 109.932 -177.664 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.501 ' CG1' ' HA ' ' A' ' 22' ' ' GLN . 0.1 OUTLIER -78.21 -3.06 5.33 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 CA-C-N 113.369 -1.742 . . . . 0.0 111.654 -173.797 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 4.5 m -67.78 131.22 45.15 Favored 'General case' 0 N--CA 1.409 -2.519 0 CA-C-O 121.6 0.714 . . . . 0.0 110.866 -174.071 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.587 ' HG ' HG22 ' A' ' 112' ' ' ILE . 4.6 mp -68.08 87.74 0.27 Allowed 'General case' 0 N--CA 1.425 -1.687 0 CA-C-O 123.008 1.385 . . . . 0.0 107.514 168.78 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 32.4 t -166.0 87.5 0.37 Allowed 'General case' 1 N--CA 1.374 -4.253 0 N-CA-C 101.481 -3.525 . . . . 0.0 101.481 172.596 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.477 ' HA3' ' CE1' ' A' ' 48' ' ' HIS . . . 166.2 136.69 2.06 Favored Glycine 0 C--N 1.266 -3.314 0 CA-C-N 113.682 -1.599 . . . . 0.0 110.953 179.013 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.413 ' OD1' ' HB3' ' A' ' 50' ' ' PHE . 16.6 t70 50.15 -85.81 0.01 OUTLIER 'General case' 0 C--N 1.323 -0.564 0 C-N-CA 126.643 1.977 . . . . 0.0 112.18 -171.784 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 46.9 t-80 -123.95 -47.32 1.93 Allowed 'General case' 0 C--N 1.304 -1.371 0 N-CA-C 108.243 -1.021 . . . . 0.0 108.243 173.5 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . 0.403 ' OG ' HG13 ' A' ' 113' ' ' ILE . 10.3 p -168.38 -162.11 0.39 Allowed 'General case' 0 N--CA 1.429 -1.494 0 N-CA-C 106.66 -1.607 . . . . 0.0 106.66 179.589 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.587 HG22 ' HG ' ' A' ' 106' ' ' LEU . 12.4 tt -104.04 25.79 1.47 Allowed 'Isoleucine or valine' 0 N--CA 1.421 -1.886 0 C-N-CA 119.231 -0.987 . . . . 0.0 108.992 178.905 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.604 ' HA ' ' NH1' ' A' ' 115' ' ' ARG . 2.6 pp -103.56 150.39 6.98 Favored 'Isoleucine or valine' 0 C--N 1.321 -0.646 0 O-C-N 121.612 -0.68 . . . . 0.0 111.563 173.458 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.775 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 78.53 -13.33 17.33 Favored Glycine 0 CA--C 1.532 1.102 0 N-CA-C 115.043 0.777 . . . . 0.0 115.043 176.71 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.632 ' NH2' HG13 ' A' ' 148' ' ' VAL . 0.0 OUTLIER -66.93 116.56 7.91 Favored 'General case' 0 C--O 1.253 1.248 0 CA-C-O 121.901 0.858 . . . . 0.0 112.305 -168.782 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.528 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 18.6 p -85.75 132.51 34.12 Favored 'General case' 0 N--CA 1.384 -3.754 0 CA-C-N 114.213 -1.358 . . . . 0.0 108.25 171.156 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.787 ' HB3' HG21 ' A' ' 149' ' ' ILE . 4.3 pp -69.53 137.03 52.14 Favored 'General case' 0 C--N 1.273 -2.757 0 CA-C-N 114.985 -1.007 . . . . 0.0 111.477 177.955 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.551 HG22 ' HB1' ' A' ' 140' ' ' ALA . 12.1 p -124.03 96.48 3.93 Favored 'Isoleucine or valine' 1 C--O 1.35 6.352 0 C-N-CA 115.179 -2.608 . . . . 0.0 112.107 166.519 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.477 ' O ' ' HB3' ' A' ' 145' ' ' ALA . 24.0 m -150.62 170.54 1.56 Allowed 'Isoleucine or valine' 0 C--O 1.208 -1.081 0 C-N-CA 128.67 2.788 . . . . 0.0 105.829 178.257 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.466 ' NE2' ' HD2' ' A' ' 122' ' ' LYS . 29.8 p-80 -169.46 172.93 6.78 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 106.243 -1.762 . . . . 0.0 106.243 171.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.529 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.2 mp0 -70.01 82.67 0.49 Allowed 'General case' 0 C--N 1.294 -1.818 0 CA-C-N 119.832 1.196 . . . . 0.0 109.492 -177.438 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.466 ' HD2' ' NE2' ' A' ' 120' ' ' HIS . 59.5 mttm -176.48 174.71 1.87 Allowed 'General case' 0 CA--C 1.494 -1.175 0 C-N-CA 129.403 3.081 . . . . 0.0 104.664 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.485 ' HA ' ' O ' ' A' ' 43' ' ' HIS . . . -72.83 146.23 46.42 Favored 'General case' 0 C--N 1.286 -2.173 0 C-N-CA 119.286 -0.965 . . . . 0.0 110.246 171.515 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 23.3 t70 -129.23 -86.26 0.55 Allowed 'General case' 0 C--N 1.315 -0.934 0 N-CA-C 105.451 -2.055 . . . . 0.0 105.451 174.083 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 5.5 t70 52.42 -177.66 0.02 OUTLIER 'General case' 0 N--CA 1.479 1.008 0 C-N-CA 125.78 1.632 . . . . 0.0 111.017 171.899 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . . . . . . . . . 22.2 tp -94.83 -65.05 1.01 Allowed 'General case' 0 C--N 1.288 -2.076 0 CA-C-O 122.633 1.206 . . . . 0.0 107.933 168.126 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -69.48 -5.04 48.16 Favored Glycine 0 N--CA 1.445 -0.758 0 CA-C-N 112.931 -1.941 . . . . 0.0 115.451 -171.295 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . 0.438 ' HA ' ' HD2' ' A' ' 128' ' ' LYS . 44.6 tptt -116.78 26.42 9.85 Favored 'General case' 0 C--N 1.299 -1.599 0 CA-C-O 122.049 0.928 . . . . 0.0 109.027 178.29 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -63.34 -28.32 72.12 Favored Glycine 0 N--CA 1.443 -0.889 0 CA-C-N 114.397 -1.274 . . . . 0.0 113.272 178.816 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 121.86 -80.86 0.34 Allowed Glycine 0 C--O 1.22 -0.736 0 C-N-CA 119.993 -1.099 . . . . 0.0 113.748 175.229 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.484 ' H ' ' HB2' ' A' ' 134' ' ' SER . 46.5 t-20 -99.08 169.27 9.53 Favored 'General case' 0 N--CA 1.482 1.137 0 N-CA-C 106.206 -1.775 . . . . 0.0 106.206 -175.238 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . . . . . . . . 0.335 9.6 pt-20 -54.66 -45.66 73.89 Favored 'General case' 0 CA--C 1.551 0.989 0 N-CA-C 116.273 1.953 . . . . 0.0 116.273 -173.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 32.8 tt0 -74.98 -37.98 61.77 Favored 'General case' 0 CA--C 1.54 0.574 0 C-N-CA 119.081 -1.048 . . . . 0.0 110.349 177.923 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.484 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 49.6 m -59.97 -30.15 68.92 Favored 'General case' 0 CA--C 1.543 0.682 0 CA-C-O 120.963 0.411 . . . . 0.0 111.409 179.234 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 80.5 m -78.84 -20.16 50.29 Favored 'General case' 0 C--N 1.305 -1.362 0 CA-C-O 121.958 0.885 . . . . 0.0 110.168 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 41.7 tttp -91.08 -32.83 15.72 Favored 'General case' 0 C--N 1.289 -2.031 0 N-CA-C 109.214 -0.662 . . . . 0.0 109.214 -176.453 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.443 HG22 ' HA ' ' A' ' 134' ' ' SER . 9.6 t -85.54 -30.43 23.39 Favored 'General case' 0 N--CA 1.409 -2.513 0 CA-C-N 115.144 -0.935 . . . . 0.0 110.426 178.958 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 85.74 75.12 1.25 Allowed Glycine 0 N--CA 1.422 -2.268 0 N-CA-C 109.003 -1.639 . . . . 0.0 109.003 -177.525 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 32.3 t30 -47.32 119.95 2.93 Favored 'General case' 0 N--CA 1.478 0.941 0 C-N-CA 125.277 1.431 . . . . 0.0 112.18 -174.609 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.551 ' HB1' HG22 ' A' ' 118' ' ' VAL . . . -132.58 137.6 47.13 Favored 'General case' 0 N--CA 1.42 -1.943 0 CA-C-N 115.164 -0.925 . . . . 0.0 111.989 -173.081 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -73.08 89.32 0.58 Allowed Glycine 0 CA--C 1.502 -0.742 0 N-CA-C 107.581 -2.207 . . . . 0.0 107.581 170.592 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 5.6 m -47.07 -33.97 5.42 Favored 'General case' 0 C--O 1.2 -1.545 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 -164.766 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -133.01 9.91 4.17 Favored 'General case' 0 C--N 1.27 -2.888 0 C-N-CA 116.162 -2.215 . . . . 0.0 109.787 178.309 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 7.9 mp -71.41 -16.3 62.39 Favored 'General case' 0 C--N 1.301 -1.536 0 C-N-CA 119.861 -0.736 . . . . 0.0 112.088 -173.134 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . 0.477 ' HB3' ' O ' ' A' ' 119' ' ' VAL . . . -170.18 101.89 0.28 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.385 -0.968 . . . . 0.0 108.385 -179.729 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . . . . . . . . . 28.8 m -136.12 147.34 47.74 Favored 'General case' 0 N--CA 1.407 -2.615 0 N-CA-C 107.851 -1.166 . . . . 0.0 107.851 178.232 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.561 ' HA2' ' O ' ' A' ' 54' ' ' THR . . . -162.38 149.64 17.98 Favored Glycine 0 N--CA 1.396 -3.988 0 N-CA-C 110.14 -1.184 . . . . 0.0 110.14 179.382 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . 0.632 HG13 ' NH2' ' A' ' 115' ' ' ARG . 2.8 t -69.05 104.67 0.93 Allowed 'Isoleucine or valine' 0 C--N 1.288 -2.103 0 N-CA-C 108.875 -0.787 . . . . 0.0 108.875 176.195 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.787 HG21 ' HB3' ' A' ' 117' ' ' LEU . 7.4 tt -123.47 101.57 9.64 Favored 'Isoleucine or valine' 0 N--CA 1.479 0.98 0 N-CA-C 112.913 0.708 . . . . 0.0 112.913 -176.128 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.492 ' HA3' ' NH1' ' A' ' 115' ' ' ARG . . . 176.66 -167.13 38.42 Favored Glycine 0 CA--C 1.453 -3.8 0 N-CA-C 107.889 -2.084 . . . . 0.0 107.889 -178.786 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . . . . . . . . . 6.3 tt -61.99 104.17 0.29 Allowed 'Isoleucine or valine' 0 N--CA 1.437 -1.107 0 C-N-CA 119.274 -0.97 . . . . 0.0 108.457 175.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.486 ' HB3' ' CG2' ' A' ' 5' ' ' VAL . . . -103.31 102.04 11.98 Favored 'General case' 0 C--N 1.297 -1.71 0 C-N-CA 119.631 -0.828 . . . . 0.0 110.406 -179.537 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 22.8 pt20 . . . . . 0 C--N 1.279 -2.474 0 CA-C-N 114.753 -1.112 . . . . 0.0 108.145 179.044 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . 0.637 ' HA ' ' O ' ' A' ' 22' ' ' GLN . . . . . . . . 0 N--CA 1.47 0.57 0 N-CA-C 112.772 0.656 . . . . 0.0 112.772 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . 0.421 ' O ' ' HG2' ' A' ' 21' ' ' GLU . 8.2 m -121.06 -37.42 2.96 Favored 'General case' 0 CA--C 1.542 0.661 0 C-N-CA 120.184 -0.606 . . . . 0.0 112.033 -175.719 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 68.0 mttm -136.34 136.1 39.4 Favored 'General case' 0 C--O 1.25 1.109 0 N-CA-C 112.429 0.529 . . . . 0.0 112.429 -174.487 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.688 ' O ' ' HA ' ' A' ' 19' ' ' ASN . . . -156.14 103.15 2.17 Favored 'General case' 0 CA--C 1.479 -1.769 0 N-CA-C 107.607 -1.257 . . . . 0.0 107.607 176.473 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.634 ' HA ' ' O ' ' A' ' 18' ' ' ILE . 33.9 m -110.97 134.48 53.12 Favored 'Isoleucine or valine' 0 N--CA 1.43 -1.427 0 CA-C-O 121.655 0.74 . . . . 0.0 110.389 -176.009 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . 0.695 ' HB2' ' HA ' ' A' ' 149' ' ' ILE . . . -108.81 150.11 28.11 Favored 'General case' 0 C--N 1.28 -2.422 0 CA-C-N 114.834 -1.075 . . . . 0.0 111.342 -175.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 7.2 p -134.26 119.92 32.38 Favored 'Isoleucine or valine' 0 C--N 1.323 -0.579 0 CA-C-O 121.248 0.547 . . . . 0.0 110.098 179.778 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.406 ' O ' ' HD2' ' A' ' 9' ' ' LYS . 5.7 mp -98.25 151.1 20.82 Favored 'General case' 0 C--N 1.307 -1.242 0 CA-C-N 115.933 -0.576 . . . . 0.0 111.191 -176.263 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . 0.406 ' HD2' ' O ' ' A' ' 8' ' ' LEU . 28.6 mmmt -126.26 132.44 51.69 Favored 'General case' 0 C--O 1.248 1.021 0 N-CA-C 104.791 -2.3 . . . . 0.0 104.791 177.536 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -127.61 154.53 19.68 Favored Glycine 0 N--CA 1.428 -1.834 0 C-N-CA 117.477 -2.297 . . . . 0.0 118.504 -166.235 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 13.8 t70 -64.99 -44.34 89.61 Favored 'General case' 0 CA--C 1.516 -0.364 0 CA-C-N 111.802 -2.199 . . . . 0.0 106.201 169.502 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -113.01 153.96 17.23 Favored Glycine 0 N--CA 1.43 -1.752 0 N-CA-C 104.143 -3.583 . . . . 0.0 104.143 168.949 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 10.7 Cg_exo -70.59 123.95 10.3 Favored 'Trans proline' 0 N--CA 1.442 -1.518 0 CA-C-N 121.559 2.679 . . . . 0.0 111.471 -173.074 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 19.8 m -131.97 109.27 15.16 Favored 'Isoleucine or valine' 0 N--CA 1.417 -2.124 0 CA-C-N 114.199 -1.364 . . . . 0.0 107.641 177.687 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.481 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 73.6 mt-30 -119.99 119.0 32.15 Favored 'General case' 0 C--N 1.277 -2.546 0 N-CA-C 108.432 -0.951 . . . . 0.0 108.432 -178.864 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . 0.622 ' HA2' ' O ' ' A' ' 34' ' ' SER . . . -160.14 160.0 31.26 Favored Glycine 0 N--CA 1.405 -3.428 0 N-CA-C 111.331 -0.708 . . . . 0.0 111.331 -174.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . 0.461 HG13 ' HB ' ' A' ' 5' ' ' VAL . 11.5 tt -153.87 102.1 0.15 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.182 0 CA-C-O 121.441 0.638 . . . . 0.0 109.546 -178.726 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.657 HG22 ' HA3' ' A' ' 33' ' ' GLY . 0.2 OUTLIER -106.55 139.86 26.6 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.865 0 N-CA-C 108.987 -0.746 . . . . 0.0 108.987 -177.22 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.688 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 8.5 t30 -113.53 120.81 42.25 Favored 'General case' 0 CA--C 1.51 -0.586 0 O-C-N 123.753 0.658 . . . . 0.0 110.757 -177.509 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.505 ' CD2' ' HB3' ' A' ' 84' ' ' LEU . 21.0 m-85 -119.62 135.14 54.93 Favored 'General case' 0 N--CA 1.464 0.233 0 N-CA-C 113.804 1.039 . . . . 0.0 113.804 -178.612 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . 0.503 ' HB2' HG23 ' A' ' 29' ' ' VAL . 13.4 mt-10 -102.45 105.43 15.99 Favored 'General case' 0 CA--C 1.551 0.999 0 CA-C-N 115.355 -0.839 . . . . 0.0 110.652 -178.599 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.637 ' O ' ' HA ' ' A' ' 1' ' ' ALA . 15.1 mp0 -85.6 99.86 11.56 Favored 'General case' 0 C--N 1.298 -1.671 0 N-CA-C 106.728 -1.582 . . . . 0.0 106.728 176.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 53.8 pttt -132.82 108.98 9.32 Favored 'General case' 0 N--CA 1.421 -1.877 0 CA-C-O 122.288 1.042 . . . . 0.0 111.593 -172.696 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 45.4 tt0 -69.49 -10.99 60.45 Favored 'General case' 0 C--N 1.307 -1.257 0 CA-C-N 114.514 -1.221 . . . . 0.0 110.077 178.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 3.5 m -59.22 -16.9 23.55 Favored 'General case' 0 CA--C 1.547 0.829 0 C-N-CA 125.563 1.545 . . . . 0.0 112.311 179.274 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 21.5 t-20 74.98 116.12 0.06 Allowed 'General case' 0 N--CA 1.478 0.933 0 C-N-CA 124.021 0.929 . . . . 0.0 112.375 177.858 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . . . . . . . . . . . 160.93 169.67 24.5 Favored Glycine 0 N--CA 1.426 -2.007 0 N-CA-C 110.626 -0.989 . . . . 0.0 110.626 177.349 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 32.6 Cg_exo -62.41 123.91 13.29 Favored 'Trans proline' 0 N--CA 1.451 -1.021 0 C-N-CA 122.534 2.156 . . . . 0.0 110.88 177.662 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.503 HG23 ' HB2' ' A' ' 21' ' ' GLU . 10.9 p -75.98 121.51 28.06 Favored 'Isoleucine or valine' 0 N--CA 1.426 -1.639 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 177.258 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . 0.419 ' HA ' HD11 ' A' ' 99' ' ' ILE . 67.8 mttm -89.81 97.55 11.26 Favored 'General case' 0 CA--C 1.496 -1.127 0 N-CA-C 109.117 -0.698 . . . . 0.0 109.117 -177.041 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.5 HG12 ' HA ' ' A' ' 20' ' ' PHE . 24.7 m -122.61 133.07 69.89 Favored 'Isoleucine or valine' 0 N--CA 1.419 -2.008 0 CA-C-N 115.517 -0.765 . . . . 0.0 111.771 -171.512 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.537 ' HA ' HG11 ' A' ' 97' ' ' VAL . 4.8 m-90 -135.26 137.61 42.71 Favored 'General case' 0 C--N 1.302 -1.49 0 CA-C-N 115.794 -0.639 . . . . 0.0 111.454 177.564 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.657 ' HA3' HG22 ' A' ' 18' ' ' ILE . . . -161.54 140.66 6.76 Favored Glycine 0 N--CA 1.424 -2.101 0 C-N-CA 120.253 -0.975 . . . . 0.0 111.828 173.795 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . 0.622 ' O ' ' HA2' ' A' ' 16' ' ' GLY . 11.4 p -114.83 126.11 54.45 Favored 'General case' 0 N--CA 1.413 -2.294 0 C-N-CA 123.844 0.857 . . . . 0.0 109.622 -177.977 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.566 HG13 ' HA3' ' A' ' 16' ' ' GLY . 3.6 mp -126.06 142.82 41.59 Favored 'Isoleucine or valine' 0 C--N 1.313 -0.984 0 N-CA-C 108.856 -0.794 . . . . 0.0 108.856 178.548 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . . . . . . . . . 18.9 ptpt -116.26 133.26 56.22 Favored 'General case' 0 N--CA 1.413 -2.283 0 N-CA-C 106.025 -1.843 . . . . 0.0 106.025 172.845 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . . . . . . . . . . . -165.21 175.81 40.99 Favored Glycine 0 N--CA 1.423 -2.171 0 N-CA-C 110.439 -1.064 . . . . 0.0 110.439 -165.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 68.4 mt -66.43 144.0 56.78 Favored 'General case' 0 C--N 1.319 -0.737 0 N-CA-C 106.925 -1.509 . . . . 0.0 106.925 -177.843 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.465 ' HB ' ' O ' ' A' ' 90' ' ' ASP . 59.3 p -87.34 104.17 16.16 Favored 'General case' 0 N--CA 1.42 -1.958 0 N-CA-C 115.585 1.698 . . . . 0.0 115.585 -163.493 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.57 ' N ' ' HA ' ' A' ' 90' ' ' ASP . 3.7 mp0 -173.13 140.89 0.91 Allowed 'General case' 0 C--N 1.279 -2.464 0 N-CA-C 102.173 -3.269 . . . . 0.0 102.173 175.996 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . 173.67 116.19 0.41 Allowed Glycine 0 C--N 1.255 -3.919 0 C-N-CA 114.933 -3.508 . . . . 0.0 114.436 178.449 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.668 ' HB2' ' HB2' ' A' ' 123' ' ' ALA . 96.2 mt -142.83 -39.67 0.33 Allowed 'General case' 0 N--CA 1.44 -0.93 0 N-CA-C 112.966 0.728 . . . . 0.0 112.966 -179.385 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . . . . . . . . . 46.9 m170 -126.02 141.52 51.92 Favored 'General case' 0 N--CA 1.47 0.571 0 N-CA-C 113.817 1.043 . . . . 0.0 113.817 -173.846 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . 0.409 ' O ' ' HD2' ' A' ' 46' ' ' HIS . . . -105.19 88.4 0.58 Allowed Glycine 0 N--CA 1.44 -1.036 0 CA-C-N 115.156 -0.929 . . . . 0.0 111.698 -178.854 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.443 ' HB3' ' O ' ' A' ' 125' ' ' ASP . 0.4 OUTLIER -90.9 84.72 5.83 Favored 'General case' 1 C--O 1.352 6.481 0 CA-C-O 122.261 1.029 . . . . 0.0 112.021 -176.242 . . . . . . . . 4 4 . 1 . 018 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.849 ' HB2' ' HB2' ' A' ' 83' ' ' ASP . 8.0 p80 -100.12 113.37 25.95 Favored 'General case' 0 N--CA 1.382 -3.865 0 CA-C-N 113.893 -1.503 . . . . 0.0 107.944 -171.824 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . . . . . . . . . 52.0 t -164.89 87.93 0.01 OUTLIER 'Isoleucine or valine' 0 N--CA 1.485 1.309 0 O-C-N 125.048 1.468 . . . . 0.0 108.533 -178.639 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.541 ' CD2' ' HB ' ' A' ' 118' ' ' VAL . 0.1 OUTLIER -148.31 167.73 24.42 Favored 'General case' 0 C--N 1.313 -1.0 0 C-N-CA 124.39 1.076 . . . . 0.0 109.114 163.781 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.402 ' HA ' ' HG2' ' A' ' 115' ' ' ARG . 0.2 OUTLIER -164.81 164.98 20.95 Favored 'General case' 0 N--CA 1.429 -1.475 0 N-CA-C 107.756 -1.201 . . . . 0.0 107.756 171.046 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . . . . . . . . . 66.5 t80 73.61 58.39 0.1 Allowed 'General case' 0 C--N 1.306 -1.325 0 N-CA-C 106.218 -1.771 . . . . 0.0 106.218 179.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . . . . . . . . . . . -91.06 166.08 30.81 Favored Glycine 0 CA--C 1.474 -2.499 0 CA-C-N 112.849 -1.978 . . . . 0.0 111.54 -175.623 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -151.46 -72.37 0.16 Allowed 'General case' 0 C--N 1.292 -1.913 0 O-C-N 123.875 0.397 . . . . 0.0 111.651 -176.925 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 35.5 t30 -94.5 128.59 41.18 Favored 'General case' 0 C--N 1.319 -0.744 0 CA-C-N 116.514 -0.312 . . . . 0.0 110.77 -176.692 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 1.5 t -75.98 -2.3 29.85 Favored 'General case' 0 CA--C 1.547 0.85 0 C-N-CA 122.946 0.498 . . . . 0.0 111.515 -174.903 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -104.05 -8.6 19.41 Favored 'General case' 0 C--N 1.314 -0.94 0 CA-C-N 116.474 -0.33 . . . . 0.0 111.47 -179.813 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . 0.459 ' HA2' ' HB2' ' A' ' 143' ' ' ARG . . . -176.99 137.63 3.61 Favored Glycine 0 N--CA 1.429 -1.802 0 C-N-CA 119.224 -1.465 . . . . 0.0 112.758 -178.75 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.439 ' H ' ' HB2' ' A' ' 143' ' ' ARG . 62.3 m -91.98 88.3 6.53 Favored 'General case' 0 N--CA 1.429 -1.485 0 CA-C-O 120.385 0.136 . . . . 0.0 111.101 179.856 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 32.7 m -80.01 -58.14 3.3 Favored 'General case' 0 C--N 1.311 -1.102 0 N-CA-C 108.365 -0.976 . . . . 0.0 108.365 170.745 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . . . . . . . . . 0.8 OUTLIER -65.75 -44.17 86.7 Favored 'General case' 0 N--CA 1.441 -0.917 0 CA-C-N 114.235 -1.348 . . . . 0.0 111.817 -176.786 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . . . . . . . . . . . -77.47 -5.98 51.87 Favored 'General case' 0 C--O 1.196 -1.713 0 C-N-CA 124.801 1.24 . . . . 0.0 112.384 -178.152 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -31.62 -138.33 0.0 OUTLIER Glycine 0 N--CA 1.513 3.832 0 C-N-CA 128.477 2.942 . . . . 0.0 116.414 -174.263 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . . . . . . . . . 36.4 Cg_exo -62.91 53.41 0.13 Allowed 'Trans proline' 0 CA--C 1.566 2.086 0 CA-C-N 121.043 2.421 . . . . 0.0 113.11 179.346 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . . . . . . . . . 9.4 m170 -93.96 112.67 24.53 Favored 'General case' 0 N--CA 1.427 -1.605 0 C-N-CA 124.348 1.059 . . . . 0.0 110.332 175.919 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . 0.428 ' HB3' ' O ' ' A' ' 136' ' ' LYS . 45.5 p90 -84.21 133.16 34.6 Favored 'General case' 0 N--CA 1.413 -2.312 0 N-CA-C 103.983 -2.599 . . . . 0.0 103.983 167.506 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.433 ' ND2' ' HD2' ' A' ' 66' ' ' PRO . 29.1 t-20 -75.01 140.83 74.1 Favored Pre-proline 0 C--N 1.282 -2.366 0 C-N-CA 118.842 -1.143 . . . . 0.0 111.609 -171.859 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . 0.458 ' O ' ' HG2' ' A' ' 69' ' ' ARG . 92.1 Cg_endo -83.8 -14.21 7.73 Favored 'Trans proline' 0 C--N 1.358 1.032 0 C-N-CA 122.532 2.154 . . . . 0.0 113.445 -176.805 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.724 ' O ' ' HA ' ' A' ' 79' ' ' ARG . 2.7 tt -88.36 -17.59 30.23 Favored 'General case' 0 CA--C 1.482 -1.658 0 N-CA-C 104.804 -2.295 . . . . 0.0 104.804 179.815 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.716 ' HA ' ' HB2' ' A' ' 79' ' ' ARG . 63.8 m -79.44 39.82 0.41 Allowed 'General case' 0 N--CA 1.407 -2.58 0 CA-C-N 114.315 -1.311 . . . . 0.0 111.502 179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.458 ' HG2' ' O ' ' A' ' 66' ' ' PRO . 33.1 mmt180 -83.7 20.1 1.51 Allowed 'General case' 0 CA--C 1.49 -1.33 0 CA-C-O 122.506 1.146 . . . . 0.0 109.734 -178.494 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.46 ' HB3' ' HB3' ' A' ' 79' ' ' ARG . 25.8 tptp -128.1 19.99 6.42 Favored 'General case' 0 N--CA 1.396 -3.126 0 N-CA-C 107.928 -1.138 . . . . 0.0 107.928 171.03 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 33.0 m80 65.87 -48.3 0.4 Allowed 'General case' 0 N--CA 1.504 2.251 0 C-N-CA 126.349 1.86 . . . . 0.0 115.375 177.149 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.516 ' HA2' ' HG3' ' A' ' 79' ' ' ARG . . . 167.61 175.29 37.37 Favored Glycine 0 N--CA 1.415 -2.761 0 N-CA-C 108.646 -1.782 . . . . 0.0 108.646 -171.836 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.449 ' O ' HD11 ' A' ' 126' ' ' LEU . . . -169.38 142.5 7.36 Favored Glycine 0 CA--C 1.475 -2.444 0 N-CA-C 106.787 -2.525 . . . . 0.0 106.787 173.516 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . . . . . . . . . 18.2 Cg_endo -65.01 -43.25 12.1 Favored 'Trans proline' 0 C--N 1.322 -0.837 0 CA-C-N 120.306 2.053 . . . . 0.0 113.849 -178.2 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . 0.408 ' O ' ' HA ' ' A' ' 102' ' ' SER . 0.7 OUTLIER -120.89 -29.79 4.55 Favored 'General case' 0 N--CA 1.425 -1.682 0 C-N-CA 119.507 -0.877 . . . . 0.0 112.268 -178.317 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . 0.482 ' OD1' HG22 ' A' ' 104' ' ' ILE . 33.4 t70 -176.62 146.86 0.6 Allowed 'General case' 0 C--O 1.204 -1.301 0 CA-C-O 118.81 -0.614 . . . . 0.0 109.664 -176.68 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.612 ' HB2' ' HD2' ' A' ' 79' ' ' ARG . 3.1 mm-40 -158.16 -86.76 0.04 OUTLIER 'General case' 0 C--O 1.214 -0.766 0 N-CA-C 112.691 0.626 . . . . 0.0 112.691 178.369 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.408 ' HB3' ' HB2' ' A' ' 70' ' ' LYS . 1.5 tm-20 -161.25 -53.03 0.05 OUTLIER 'General case' 0 C--O 1.202 -1.419 0 N-CA-C 105.1 -2.185 . . . . 0.0 105.1 -176.695 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.724 ' HA ' ' O ' ' A' ' 67' ' ' LEU . 0.4 OUTLIER -34.67 -31.63 0.02 OUTLIER 'General case' 0 N--CA 1.421 -1.92 0 C-N-CA 128.635 2.774 . . . . 0.0 115.676 176.948 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.43 ' H ' ' HD3' ' A' ' 79' ' ' ARG . 31.2 t-80 71.92 -27.67 0.18 Allowed 'General case' 0 N--CA 1.5 2.066 0 C-N-CA 124.341 1.056 . . . . 0.0 109.738 -171.455 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.62 ' H ' ' C ' ' A' ' 79' ' ' ARG 0.397 12.2 p 59.45 50.22 0.3 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.153 0 C-N-CA 129.422 3.089 . . . . 0.0 109.6 -179.558 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . . . . . . . . . . . 48.78 -78.05 0.0 OUTLIER Glycine 0 N--CA 1.487 2.096 0 CA-C-N 110.764 -2.926 . . . . 0.0 115.814 177.231 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.849 ' HB2' ' HB2' ' A' ' 46' ' ' HIS . 81.8 m-20 -79.93 174.13 11.9 Favored 'General case' 0 C--N 1.293 -1.889 0 C-N-CA 125.678 1.591 . . . . 0.0 109.857 -178.491 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.505 ' HB3' ' CD2' ' A' ' 20' ' ' PHE . 89.2 mt -143.82 87.53 1.92 Allowed 'General case' 0 C--N 1.272 -2.794 0 N-CA-C 107.408 -1.33 . . . . 0.0 107.408 177.173 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . 177.03 165.31 32.21 Favored Glycine 0 CA--C 1.478 -2.246 0 N-CA-C 109.288 -1.525 . . . . 0.0 109.288 179.177 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . . . . . . . . . 9.7 p30 -158.57 148.33 19.49 Favored 'General case' 0 C--N 1.282 -2.358 0 N-CA-C 108.059 -1.089 . . . . 0.0 108.059 174.944 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . . . . . . . . . 3.3 p -137.24 128.38 40.71 Favored 'Isoleucine or valine' 0 C--N 1.296 -1.758 0 N-CA-C 108.678 -0.86 . . . . 0.0 108.678 179.875 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.636 ' O ' ' HA ' ' A' ' 95' ' ' ALA . 88.3 m -140.42 95.21 2.84 Favored 'General case' 0 N--CA 1.424 -1.726 0 N-CA-C 108.711 -0.848 . . . . 0.0 108.711 -179.589 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . . . . . . . . . . . -135.67 106.39 6.56 Favored 'General case' 0 C--O 1.202 -1.425 0 N-CA-C 109.707 -0.479 . . . . 0.0 109.707 178.084 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.57 ' HA ' ' N ' ' A' ' 40' ' ' GLU . 3.3 p-10 -117.26 -19.18 9.72 Favored 'General case' 0 C--N 1.275 -2.639 0 C-N-CA 119.439 -0.904 . . . . 0.0 111.648 -174.462 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . . . . . . . . . 2.4 mptp? -75.77 -57.54 3.82 Favored 'General case' 0 C--N 1.265 -3.077 0 CA-C-N 114.431 -1.259 . . . . 0.0 109.692 -175.852 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 15.5 t70 -154.2 -22.83 0.13 Allowed 'General case' 0 C--N 1.3 -1.576 0 CA-C-N 114.623 -1.171 . . . . 0.0 112.27 -166.34 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . . . . . . . . . . . 125.48 55.3 0.16 Allowed Glycine 0 N--CA 1.42 -2.386 0 N-CA-C 109.056 -1.618 . . . . 0.0 109.056 -173.65 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 7.0 m -141.9 102.95 1.1 Allowed 'Isoleucine or valine' 0 N--CA 1.422 -1.85 0 N-CA-C 106.292 -1.744 . . . . 0.0 106.292 179.075 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.636 ' HA ' ' O ' ' A' ' 88' ' ' THR . . . -100.81 107.75 19.38 Favored 'General case' 0 N--CA 1.397 -3.101 0 CA-C-N 114.551 -1.204 . . . . 0.0 110.233 179.828 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 23.4 t70 -83.97 124.33 30.91 Favored 'General case' 0 C--N 1.28 -2.415 0 N-CA-C 104.665 -2.346 . . . . 0.0 104.665 173.206 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.537 HG11 ' HA ' ' A' ' 32' ' ' TRP . 7.1 p -83.31 135.89 23.9 Favored 'Isoleucine or valine' 0 C--N 1.284 -2.253 0 C-N-CA 119.696 -0.802 . . . . 0.0 109.426 -174.003 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . . . . . . . . . 18.2 m -75.46 102.24 5.12 Favored 'General case' 0 N--CA 1.389 -3.508 0 N-CA-C 108.051 -1.092 . . . . 0.0 108.051 176.134 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.43 ' HB ' ' O ' ' A' ' 31' ' ' VAL . 2.5 tt -92.8 115.72 32.29 Favored 'Isoleucine or valine' 0 N--CA 1.429 -1.516 0 N-CA-C 107.545 -1.28 . . . . 0.0 107.545 175.593 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . . . . . . . . . 34.7 mm-40 -133.54 157.43 45.68 Favored 'General case' 0 C--N 1.283 -2.305 0 CA-C-N 113.988 -1.46 . . . . 0.0 108.364 -171.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 8.1 p-10 -79.83 99.38 7.48 Favored 'General case' 0 N--CA 1.411 -2.405 0 CA-C-O 123.01 1.386 . . . . 0.0 109.674 176.497 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.491 ' H ' HG12 ' A' ' 29' ' ' VAL . 50.8 m -100.9 93.75 5.68 Favored 'General case' 0 N--CA 1.41 -2.444 0 CA-C-N 112.107 -2.315 . . . . 0.0 105.902 171.53 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 88.1 t -69.18 -47.62 73.32 Favored 'Isoleucine or valine' 0 C--N 1.292 -1.902 0 CA-C-N 115.621 -0.718 . . . . 0.0 109.825 -176.416 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . 0.482 HG22 ' OD1' ' A' ' 76' ' ' ASP . 10.0 tp -70.62 26.5 0.01 OUTLIER 'Isoleucine or valine' 0 CA--C 1.576 1.955 0 N-CA-C 113.541 0.941 . . . . 0.0 113.541 -177.118 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . . . . . . . . . 30.0 t -70.89 90.16 0.8 Allowed 'General case' 0 CA--C 1.477 -1.845 0 N-CA-C 105.584 -2.006 . . . . 0.0 105.584 170.227 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . . . . . . . . . 27.2 tp -110.42 157.93 19.03 Favored 'General case' 2 C--N 1.204 -5.728 0 N-CA-C 103.333 -2.839 . . . . 0.0 103.333 -172.547 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . . . . . . . . . 23.2 m -69.08 101.22 1.38 Allowed 'General case' 1 C--N 1.226 -4.776 0 N-CA-C 106.831 -1.544 . . . . 0.0 106.831 174.505 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . . . . . . . . . . . -95.6 137.11 13.23 Favored Glycine 0 N--CA 1.41 -3.078 0 CA-C-N 114.321 -1.309 . . . . 0.0 112.723 -170.122 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . . . . . . . . . 33.0 t70 61.74 -86.33 0.02 OUTLIER 'General case' 0 C--N 1.303 -1.438 0 C-N-CA 126.449 1.899 . . . . 0.0 114.106 179.785 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . 0.408 ' HB2' ' O ' ' A' ' 113' ' ' ILE . 16.2 m80 -82.82 -49.02 10.13 Favored 'General case' 0 CA--C 1.493 -1.218 0 N-CA-C 106.665 -1.605 . . . . 0.0 106.665 175.441 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 18.5 m 168.03 -85.46 0.0 OUTLIER 'General case' 0 N--CA 1.487 1.407 0 C-N-CA 126.357 1.863 . . . . 0.0 111.026 173.114 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . . . . . . . . . 37.3 mt -109.61 -54.42 5.49 Favored 'Isoleucine or valine' 0 N--CA 1.394 -3.255 0 N-CA-C 104.499 -2.408 . . . . 0.0 104.499 -177.408 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.468 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 14.0 tt -83.74 175.64 0.72 Allowed 'Isoleucine or valine' 0 C--O 1.248 1.024 0 N-CA-C 106.62 -1.622 . . . . 0.0 106.62 174.377 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.44 ' H ' HG12 ' A' ' 113' ' ' ILE . . . 89.43 22.77 36.17 Favored Glycine 0 CA--C 1.478 -2.278 0 C-N-CA 120.127 -1.035 . . . . 0.0 111.918 178.464 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.427 HH22 HD12 ' A' ' 149' ' ' ILE . 44.4 mtm180 -146.98 123.12 10.83 Favored 'General case' 0 C--O 1.2 -1.539 0 N-CA-C 108.751 -0.833 . . . . 0.0 108.751 175.802 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 11.4 p -102.09 115.48 30.63 Favored 'General case' 0 C--N 1.291 -1.935 0 N-CA-C 107.455 -1.313 . . . . 0.0 107.455 171.688 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.605 ' HA ' ' OD1' ' A' ' 83' ' ' ASP . 2.2 pt? -71.05 148.07 47.92 Favored 'General case' 0 CA--C 1.506 -0.716 0 O-C-N 123.865 0.728 . . . . 0.0 112.434 -170.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.547 HG22 ' HB3' ' A' ' 140' ' ' ALA . 1.8 p -125.63 99.64 6.14 Favored 'Isoleucine or valine' 1 C--O 1.38 7.933 0 C-N-CA 117.118 -1.833 . . . . 0.0 112.653 172.507 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . . . . . . . . . 7.6 t -148.69 151.48 13.14 Favored 'Isoleucine or valine' 0 C--O 1.201 -1.459 0 C-N-CA 126.429 1.892 . . . . 0.0 106.153 -179.906 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . . . . . . . . . 47.5 t-80 -144.52 170.35 16.22 Favored 'General case' 0 C--O 1.243 0.712 0 N-CA-C 106.472 -1.677 . . . . 0.0 106.472 175.272 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.501 ' HB3' ' O ' ' A' ' 40' ' ' GLU . 1.4 mp0 -67.86 89.93 0.29 Allowed 'General case' 0 C--N 1.304 -1.382 0 N-CA-C 107.13 -1.433 . . . . 0.0 107.13 177.129 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . 0.5 ' HG2' ' H ' ' A' ' 123' ' ' ALA . 50.8 tttm -162.99 171.58 16.31 Favored 'General case' 0 N--CA 1.44 -0.932 0 N-CA-C 108.497 -0.927 . . . . 0.0 108.497 -174.799 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . 0.668 ' HB2' ' HB2' ' A' ' 42' ' ' LEU . . . -123.22 107.27 11.52 Favored 'General case' 0 C--N 1.3 -1.582 0 N-CA-C 113.425 0.898 . . . . 0.0 113.425 179.252 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . . . . . . . . . 5.2 m-20 -132.45 -88.3 0.44 Allowed 'General case' 0 N--CA 1.483 1.177 0 C-N-CA 119.971 -0.692 . . . . 0.0 109.993 165.629 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . 0.443 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 21.9 t70 172.44 157.36 0.1 Allowed 'General case' 0 N--CA 1.483 1.209 0 N-CA-C 107.796 -1.187 . . . . 0.0 107.796 176.215 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.515 HD23 ' H ' ' A' ' 126' ' ' LEU . 1.6 pt? -90.62 -29.34 17.84 Favored 'General case' 0 C--N 1.302 -1.481 0 N-CA-C 113.55 0.945 . . . . 0.0 113.55 -177.576 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -105.5 -23.59 7.5 Favored Glycine 0 N--CA 1.464 0.522 0 C-N-CA 121.07 -0.586 . . . . 0.0 111.847 -177.986 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 51.1 tptt -128.48 51.99 1.95 Allowed 'General case' 0 C--N 1.304 -1.381 0 N-CA-C 107.804 -1.184 . . . . 0.0 107.804 177.209 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -70.86 82.2 0.41 Allowed Glycine 0 N--CA 1.445 -0.706 0 CA-C-N 115.37 -0.832 . . . . 0.0 114.35 -174.963 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 86.9 -127.56 8.48 Favored Glycine 0 N--CA 1.435 -1.385 0 C-N-CA 121.376 -0.44 . . . . 0.0 112.808 174.796 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . . . . . . . . . 64.3 t30 -98.41 -176.89 3.52 Favored 'General case' 0 C--N 1.31 -1.121 0 N-CA-C 109.207 -0.664 . . . . 0.0 109.207 -176.439 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.436 ' HG2' ' HE3' ' A' ' 136' ' ' LYS . 39.1 tt0 -61.88 -50.97 70.08 Favored 'General case' 0 C--O 1.241 0.616 0 CA-C-N 119.074 0.852 . . . . 0.0 112.993 -175.98 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 4.4 pm0 -64.29 -31.06 72.12 Favored 'General case' 0 C--N 1.314 -0.941 0 C-N-CA 120.438 -0.505 . . . . 0.0 110.463 178.063 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . . . . . . . . . 7.2 m -68.48 -38.56 81.13 Favored 'General case' 0 CA--C 1.55 0.971 0 C-N-CA 122.724 0.41 . . . . 0.0 110.64 178.328 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . . . . . . . . . 40.9 p -65.57 -27.23 68.28 Favored 'General case' 0 C--N 1.349 0.578 0 CA-C-O 121.121 0.486 . . . . 0.0 110.748 177.332 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . 0.436 ' HE3' ' HG2' ' A' ' 132' ' ' GLU . 92.9 mttt -84.99 -16.45 40.82 Favored 'General case' 0 C--N 1.307 -1.274 0 CA-C-N 115.592 -0.731 . . . . 0.0 111.061 178.704 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . . . . . . . . . 31.0 m -87.98 -17.58 30.93 Favored 'General case' 0 CA--C 1.564 1.504 0 CA-C-O 121.841 0.829 . . . . 0.0 110.347 175.755 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 71.24 48.6 30.57 Favored Glycine 1 C--O 1.39 9.847 0 N-CA-C 108.629 -1.788 . . . . 0.0 108.629 -173.45 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 52.6 t-20 -30.22 106.29 0.03 OUTLIER 'General case' 0 N--CA 1.484 1.23 0 C-N-CA 128.963 2.905 . . . . 0.0 114.496 -158.752 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.547 ' HB3' HG22 ' A' ' 118' ' ' VAL . . . -155.59 171.82 19.32 Favored 'General case' 0 C--N 1.31 -1.126 0 N-CA-C 106.418 -1.697 . . . . 0.0 106.418 167.67 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . . . . . . . . . . . -63.47 119.28 16.13 Favored Glycine 0 CA--C 1.528 0.903 0 N-CA-C 108.071 -2.011 . . . . 0.0 108.071 167.522 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 13.7 m -41.63 -46.84 3.79 Favored 'General case' 0 N--CA 1.483 1.181 0 N-CA-C 115.484 1.661 . . . . 0.0 115.484 -166.878 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.732 ' HA ' ' SG ' ' A' ' 146' ' ' CYS . 0.1 OUTLIER -132.42 11.51 4.51 Favored 'General case' 0 C--N 1.288 -2.105 0 C-N-CA 118.891 -1.124 . . . . 0.0 108.529 174.845 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . . . . . . . . . 93.6 mt -71.69 -17.33 62.23 Favored 'General case' 0 CA--C 1.497 -1.09 0 CA-C-N 115.598 -0.728 . . . . 0.0 111.297 -170.633 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -150.35 89.67 1.59 Allowed 'General case' 0 N--CA 1.398 -3.06 0 N-CA-C 106.934 -1.506 . . . . 0.0 106.934 173.96 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.732 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 53.0 m -131.2 153.95 48.92 Favored 'General case' 0 N--CA 1.424 -1.726 0 CA-C-N 114.219 -1.355 . . . . 0.0 110.253 -178.742 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -170.74 148.65 11.58 Favored Glycine 0 N--CA 1.409 -3.136 0 N-CA-C 108.025 -2.03 . . . . 0.0 108.025 176.021 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 93.8 t -69.23 105.62 1.13 Allowed 'Isoleucine or valine' 0 C--N 1.301 -1.54 0 N-CA-C 108.559 -0.904 . . . . 0.0 108.559 176.814 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.695 ' HA ' ' HB2' ' A' ' 6' ' ' ALA . 0.0 OUTLIER -88.74 103.2 13.64 Favored 'Isoleucine or valine' 0 N--CA 1.405 -2.703 0 N-CA-C 106.576 -1.639 . . . . 0.0 106.576 178.07 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.468 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 178.36 -177.79 48.48 Favored Glycine 1 N--CA 1.383 -4.871 0 C-N-CA 119.081 -1.533 . . . . 0.0 112.266 -178.657 . . . . . . . . 3 3 . 1 . 018 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.515 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 11.7 tt -53.32 112.79 0.37 Allowed 'Isoleucine or valine' 0 C--N 1.294 -1.832 0 C-N-CA 125.119 1.367 . . . . 0.0 113.184 -179.184 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . . . . . . . . . . . -139.72 99.94 3.83 Favored 'General case' 0 C--N 1.287 -2.127 0 N-CA-C 105.662 -1.977 . . . . 0.0 105.662 171.801 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.288 -2.095 0 N-CA-C 108.721 -0.844 . . . . 0.0 108.721 -177.419 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 1' ' ' ALA . . . . . . . . . . . . . . . . . . . . 0 C--O 1.216 -0.702 0 N-CA-C 110.284 -0.265 . . . . 0.0 110.284 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 2' ' ' THR . . . . . . . . . . . . . 9.4 m -94.26 -26.81 16.46 Favored 'General case' 0 CA--C 1.545 0.78 0 CA-C-O 122.39 1.09 . . . . 0.0 108.606 175.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 3' ' ' LYS . . . . . . . . . . . . . 62.2 pttt -166.03 172.11 11.78 Favored 'General case' 0 CA--C 1.485 -1.55 0 N-CA-C 104.52 -2.4 . . . . 0.0 104.52 174.626 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 4' ' ' ALA . . . . . 0.719 ' HB3' ' H ' ' A' ' 20' ' ' PHE . . . -151.71 158.97 44.11 Favored 'General case' 0 C--N 1.287 -2.149 0 N-CA-C 109.238 -0.653 . . . . 0.0 109.238 175.538 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 5' ' ' VAL . . . . . 0.434 ' HB ' ' HB3' ' A' ' 152' ' ' ALA . 86.7 t -140.93 121.41 13.14 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.365 0 N-CA-C 107.102 -1.444 . . . . 0.0 107.102 -177.855 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 6' ' ' ALA . . . . . . . . . . . . . . . -127.12 145.74 50.63 Favored 'General case' 0 C--N 1.304 -1.398 0 N-CA-C 110.232 -0.284 . . . . 0.0 110.232 -177.47 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 7' ' ' VAL . . . . . . . . . . . . . 6.3 p -135.36 125.87 44.04 Favored 'Isoleucine or valine' 0 C--N 1.316 -0.855 0 O-C-N 123.66 0.6 . . . . 0.0 109.391 -179.15 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 8' ' ' LEU . . . . . 0.454 HD23 ' H ' ' A' ' 8' ' ' LEU . 1.4 pt? -125.52 144.24 50.64 Favored 'General case' 0 C--N 1.306 -1.297 0 CA-C-N 116.004 -0.544 . . . . 0.0 110.52 -175.07 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 9' ' ' LYS . . . . . . . . . . . . . 24.1 ttmm -163.43 135.55 5.12 Favored 'General case' 0 C--N 1.31 -1.124 0 N-CA-C 107.084 -1.451 . . . . 0.0 107.084 179.339 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 10' ' ' GLY . . . . . . . . . . . . . . . -153.95 -157.17 7.99 Favored Glycine 0 C--N 1.301 -1.378 0 C-N-CA 120.233 -0.984 . . . . 0.0 112.265 -175.863 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 11' ' ' ASP . . . . . . . . . . . . . 27.1 t70 -55.0 -50.95 67.73 Favored 'General case' 0 N--CA 1.469 0.491 0 C-N-CA 124.262 1.025 . . . . 0.0 110.505 177.051 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 12' ' ' GLY . . . . . . . . . . . . . . . -92.15 163.91 28.15 Favored Glycine 0 N--CA 1.44 -1.05 0 N-CA-C 108.358 -1.897 . . . . 0.0 108.358 173.6 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 13' ' ' PRO . . . . . . . . . . . . . 18.6 Cg_endo -90.57 123.56 0.97 Allowed 'Trans proline' 0 N--CA 1.418 -2.921 0 CA-C-N 120.473 2.136 . . . . 0.0 111.026 -177.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 14' ' ' VAL . . . . . . . . . . . . . 13.0 m -133.3 131.52 58.01 Favored 'Isoleucine or valine' 0 N--CA 1.398 -3.042 0 N-CA-C 105.401 -2.074 . . . . 0.0 105.401 176.929 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 15' ' ' GLN . . . . . 0.454 ' O ' ' HA ' ' A' ' 35' ' ' ILE . 0.2 OUTLIER -145.97 123.17 11.52 Favored 'General case' 0 C--N 1.269 -2.933 0 N-CA-C 107.218 -1.401 . . . . 0.0 107.218 176.604 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 16' ' ' GLY . . . . . . . . . . . . . . . -169.97 161.64 34.89 Favored Glycine 0 N--CA 1.41 -3.042 0 N-CA-C 111.282 -0.727 . . . . 0.0 111.282 -179.892 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 17' ' ' ILE . . . . . . . . . . . . . 11.0 tt -132.5 110.23 15.8 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.426 0 N-CA-C 109.071 -0.715 . . . . 0.0 109.071 177.673 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 18' ' ' ILE . . . . . 0.512 ' H ' HD13 ' A' ' 18' ' ' ILE . 0.1 OUTLIER -107.65 132.84 54.18 Favored 'Isoleucine or valine' 0 C--N 1.294 -1.811 0 N-CA-C 109.627 -0.508 . . . . 0.0 109.627 -179.763 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 19' ' ' ASN . . . . . 0.504 ' HA ' ' O ' ' A' ' 4' ' ' ALA . 0.8 OUTLIER -106.05 139.62 40.3 Favored 'General case' 0 C--N 1.314 -0.954 0 N-CA-C 108.29 -1.004 . . . . 0.0 108.29 -179.904 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 20' ' ' PHE . . . . . 0.719 ' H ' ' HB3' ' A' ' 4' ' ' ALA . 24.4 t80 -137.47 127.6 26.05 Favored 'General case' 0 C--O 1.252 1.186 0 CA-C-N 118.996 0.816 . . . . 0.0 111.577 -176.634 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 21' ' ' GLU . . . . . . . . . . . . . 9.0 pt-20 -134.38 102.45 5.34 Favored 'General case' 0 C--O 1.209 -1.076 0 CA-C-O 121.797 0.808 . . . . 0.0 112.823 -178.625 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 22' ' ' GLN . . . . . 0.681 HE21 ' HG ' ' A' ' 106' ' ' LEU . 2.5 pm0 -127.71 162.91 25.47 Favored 'General case' 0 N--CA 1.419 -1.993 0 N-CA-C 107.396 -1.335 . . . . 0.0 107.396 -178.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 23' ' ' LYS . . . . . . . . . . . . . 1.0 OUTLIER 64.63 -56.39 0.27 Allowed 'General case' 0 CA--C 1.558 1.278 0 C-N-CA 124.808 1.243 . . . . 0.0 113.001 176.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 24' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -65.72 -43.93 87.59 Favored 'General case' 0 CA--C 1.507 -0.676 0 N-CA-C 108.044 -1.095 . . . . 0.0 108.044 171.157 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 25' ' ' SER . . . . . . . . . . . . . 35.0 m -81.49 -65.85 0.96 Allowed 'General case' 0 N--CA 1.42 -1.962 0 N-CA-C 108.2 -1.037 . . . . 0.0 108.2 171.459 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 26' ' ' ASN . . . . . . . . . . . . . 43.9 t-20 57.45 96.52 0.02 OUTLIER 'General case' 0 N--CA 1.495 1.812 0 C-N-CA 124.33 1.052 . . . . 0.0 109.924 177.83 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 27' ' ' GLY . . . . . 0.491 ' O ' HG23 ' A' ' 29' ' ' VAL . . . 140.53 -143.21 13.19 Favored Glycine 0 CA--C 1.463 -3.198 0 C-N-CA 118.545 -1.788 . . . . 0.0 108.692 -172.467 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 28' ' ' PRO . . . . . . . . . . . . . 31.4 Cg_exo -61.47 122.06 10.51 Favored 'Trans proline' 0 N--CA 1.44 -1.648 0 N-CA-C 107.403 -1.807 . . . . 0.0 107.403 175.549 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 29' ' ' VAL . . . . . 0.737 HG12 HG13 ' A' ' 31' ' ' VAL . 55.7 t -102.69 113.36 39.1 Favored 'Isoleucine or valine' 0 N--CA 1.403 -2.807 0 CA-C-O 121.673 0.749 . . . . 0.0 109.927 -174.654 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 30' ' ' LYS . . . . . . . . . . . . . 49.1 mtmt -84.61 102.73 13.14 Favored 'General case' 0 N--CA 1.427 -1.618 0 CA-C-N 113.616 -1.629 . . . . 0.0 109.799 -176.93 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 31' ' ' VAL . . . . . 0.737 HG13 HG12 ' A' ' 29' ' ' VAL . 26.8 m -130.35 144.6 37.47 Favored 'Isoleucine or valine' 0 C--N 1.287 -2.146 0 CA-C-N 115.472 -0.786 . . . . 0.0 109.683 -176.002 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 32' ' ' TRP . . . . . 0.409 ' HA ' HG11 ' A' ' 97' ' ' VAL . 66.1 p-90 -148.12 134.67 19.76 Favored 'General case' 0 C--N 1.277 -2.579 0 CA-C-N 115.052 -0.976 . . . . 0.0 108.587 178.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 33' ' ' GLY . . . . . 0.566 ' O ' HG22 ' A' ' 97' ' ' VAL . . . -164.03 137.9 5.0 Favored Glycine 0 C--N 1.295 -1.729 0 C-N-CA 119.132 -1.509 . . . . 0.0 113.119 169.36 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 34' ' ' SER . . . . . . . . . . . . . 45.8 m -114.23 126.62 55.25 Favored 'General case' 0 C--N 1.282 -2.329 0 N-CA-C 108.485 -0.932 . . . . 0.0 108.485 -177.468 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 35' ' ' ILE . . . . . 0.454 ' HA ' ' O ' ' A' ' 15' ' ' GLN . 0.0 OUTLIER -130.26 133.18 64.44 Favored 'Isoleucine or valine' 0 C--N 1.306 -1.315 0 CA-C-O 121.261 0.553 . . . . 0.0 111.188 -177.458 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 36' ' ' LYS . . . . . 0.453 ' HA ' ' CA ' ' A' ' 93' ' ' GLY . 22.1 ptmt -106.59 133.2 51.63 Favored 'General case' 0 N--CA 1.419 -2.008 0 CA-C-N 114.67 -1.15 . . . . 0.0 108.596 178.46 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 37' ' ' GLY . . . . . 0.521 ' H ' ' HA3' ' A' ' 93' ' ' GLY . . . -157.97 174.37 35.26 Favored Glycine 0 N--CA 1.421 -2.316 0 N-CA-C 109.613 -1.395 . . . . 0.0 109.613 -170.246 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 38' ' ' LEU . . . . . . . . . . . . . 39.8 tp -68.72 171.99 6.99 Favored 'General case' 0 CA--C 1.567 1.598 0 C-N-CA 123.305 0.642 . . . . 0.0 109.47 178.307 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 39' ' ' THR . . . . . 0.517 ' HB ' ' HB3' ' A' ' 91' ' ' LYS . 7.2 t -67.59 111.07 3.97 Favored 'General case' 0 CA--C 1.503 -0.86 0 O-C-N 121.42 -0.8 . . . . 0.0 112.73 -173.435 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 40' ' ' GLU . . . . . 0.576 ' H ' ' HA ' ' A' ' 90' ' ' ASP . 0.2 OUTLIER -163.56 174.15 12.15 Favored 'General case' 0 N--CA 1.405 -2.702 0 CA-C-O 123.127 1.441 . . . . 0.0 113.811 178.079 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 41' ' ' GLY . . . . . . . . . . . . . . . -65.92 -144.53 0.05 OUTLIER Glycine 2 C--N 1.238 -4.901 0 CA-C-N 110.477 -3.056 . . . . 0.0 114.125 173.754 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 42' ' ' LEU . . . . . 0.59 ' HB3' HG22 ' A' ' 88' ' ' THR . 2.4 pt? -138.42 148.37 44.36 Favored 'General case' 1 N--CA 1.37 -4.428 0 CA-C-N 114.161 -1.019 . . . . 0.0 110.641 -164.933 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 43' ' ' HIS . . . . . 0.474 ' O ' ' HA ' ' A' ' 86' ' ' ASN . 11.0 p80 -104.54 138.91 40.19 Favored 'General case' 0 CA--C 1.438 -3.335 0 C-N-CA 119.392 -0.923 . . . . 0.0 108.653 -179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 44' ' ' GLY . . . . . . . . . . . . . . . -65.91 -99.19 0.02 OUTLIER Glycine 0 N--CA 1.402 -3.577 0 O-C-N 125.215 1.572 . . . . 0.0 111.128 173.341 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 45' ' ' PHE . . . . . 0.649 ' HB3' ' O ' ' A' ' 83' ' ' ASP . 2.5 m-85 -165.68 93.97 0.58 Allowed 'General case' 0 C--N 1.29 -1.988 0 CA-C-O 117.716 -1.135 . . . . 0.0 111.105 -166.97 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 46' ' ' HIS . . . . . 0.605 ' CD2' ' HB2' ' A' ' 126' ' ' LEU . 14.3 t60 -170.85 86.47 0.1 Allowed 'General case' 0 C--O 1.284 2.901 0 CA-C-N 120.301 1.41 . . . . 0.0 114.493 171.886 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 47' ' ' VAL . . . . . 0.531 HG13 ' HA ' ' A' ' 117' ' ' LEU . 51.5 t -74.93 154.17 6.46 Favored 'Isoleucine or valine' 0 N--CA 1.424 -1.732 0 CA-C-N 113.553 -1.658 . . . . 0.0 107.119 165.156 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 48' ' ' HIS . . . . . 0.49 ' HA ' ' HB ' ' A' ' 81' ' ' VAL . 25.9 p80 -159.24 114.06 2.44 Favored 'General case' 0 C--N 1.268 -2.94 0 CA-C-O 116.511 -1.709 . . . . 0.0 107.08 172.514 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 49' ' ' GLU . . . . . 0.604 ' HA ' ' OE1' ' A' ' 49' ' ' GLU 0.484 0.0 OUTLIER -173.74 168.2 4.37 Favored 'General case' 0 CA--C 1.493 -1.246 0 N-CA-C 118.323 2.712 . . . . 0.0 118.323 165.377 . . . . . . . . 4 4 . 1 . 019 nuclear nobuild full ' A' A ' 50' ' ' PHE . . . . . 0.49 ' CZ ' ' HB3' ' A' ' 59' ' ' SER . 26.8 p90 -115.22 19.46 15.59 Favored 'General case' 0 N--CA 1.404 -2.743 0 CA-C-N 112.654 -2.067 . . . . 0.0 109.108 176.751 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 51' ' ' GLY . . . . . 0.616 ' N ' ' HD3' ' A' ' 115' ' ' ARG . . . 85.06 138.94 4.49 Favored Glycine 0 N--CA 1.47 0.959 0 N-CA-C 115.017 0.767 . . . . 0.0 115.017 178.981 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 52' ' ' ASP . . . . . . . . . . . . . 27.7 t70 -144.9 -72.35 0.26 Allowed 'General case' 0 N--CA 1.442 -0.841 0 C-N-CA 119.674 -0.81 . . . . 0.0 109.148 173.643 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 53' ' ' ASN . . . . . . . . . . . . . 24.9 t-20 -168.81 158.74 9.16 Favored 'General case' 0 C--N 1.314 -0.962 0 N-CA-C 107.909 -1.145 . . . . 0.0 107.909 176.536 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 54' ' ' THR . . . . . . . . . . . . . 9.4 m -65.58 -48.41 72.44 Favored 'General case' 0 C--N 1.31 -1.129 0 C-N-CA 123.633 0.773 . . . . 0.0 111.023 179.3 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 55' ' ' ALA . . . . . . . . . . . . . . . -93.69 -7.88 42.46 Favored 'General case' 0 C--N 1.305 -1.341 0 CA-C-N 115.571 -0.741 . . . . 0.0 112.003 -171.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 56' ' ' GLY . . . . . . . . . . . . . . . -148.34 109.85 0.47 Allowed Glycine 0 CA--C 1.463 -3.214 0 C-N-CA 118.794 -1.669 . . . . 0.0 110.449 -177.067 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 57' ' ' CYS . . . . . 0.847 ' SG ' ' HA ' ' A' ' 143' ' ' ARG . 15.8 p -101.89 87.42 3.11 Favored 'General case' 0 N--CA 1.392 -3.368 0 N-CA-C 112.785 0.661 . . . . 0.0 112.785 174.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 58' ' ' THR . . . . . . . . . . . . . 25.1 m -82.43 -50.09 9.26 Favored 'General case' 0 C--N 1.301 -1.536 0 CA-C-O 122.755 1.265 . . . . 0.0 108.943 174.662 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 59' ' ' SER . . . . . 0.49 ' HB3' ' CZ ' ' A' ' 50' ' ' PHE . 15.2 m -72.16 -8.15 53.11 Favored 'General case' 0 C--O 1.209 -1.038 0 CA-C-N 113.457 -1.702 . . . . 0.0 112.982 -175.151 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 60' ' ' ALA . . . . . 0.582 ' HA ' ' HG2' ' A' ' 49' ' ' GLU . . . -77.29 -7.29 55.74 Favored 'General case' 0 CA--C 1.494 -1.192 0 C-N-CA 124.785 1.234 . . . . 0.0 111.216 179.947 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 61' ' ' GLY . . . . . . . . . . . . . . . -102.7 52.09 0.83 Allowed Glycine 0 N--CA 1.406 -3.357 0 C-N-CA 117.762 -2.161 . . . . 0.0 116.016 176.714 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 62' ' ' PRO . . . . . 0.478 ' HD3' ' C ' ' A' ' 60' ' ' ALA . 1.2 Cg_endo -90.42 -6.74 4.37 Favored 'Trans proline' 0 C--N 1.395 3.009 0 CA-C-N 121.788 2.794 . . . . 0.0 106.995 164.052 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 63' ' ' HIS . . . . . 0.449 ' HB3' ' HA ' ' A' ' 137' ' ' THR . 31.3 m80 72.48 -58.06 0.61 Allowed 'General case' 0 CA--C 1.545 0.778 0 CA-C-N 114.149 -1.387 . . . . 0.0 111.355 174.993 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 64' ' ' PHE . . . . . . . . . . . . . 84.9 t80 -112.63 116.52 30.31 Favored 'General case' 0 C--N 1.305 -1.333 0 O-C-N 122.322 -0.236 . . . . 0.0 110.936 -178.938 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 65' ' ' ASN . . . . . 0.516 ' HB3' ' HG3' ' A' ' 79' ' ' ARG . 0.8 OUTLIER -77.23 144.48 71.2 Favored Pre-proline 0 C--N 1.327 -0.395 0 N-CA-C 109.093 -0.706 . . . . 0.0 109.093 171.386 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 66' ' ' PRO . . . . . . . . . . . . . 37.0 Cg_endo -63.54 -54.32 1.05 Allowed 'Trans proline' 0 CA--C 1.553 1.441 0 C-N-CA 122.907 2.404 . . . . 0.0 117.234 -170.556 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 67' ' ' LEU . . . . . 0.59 ' O ' ' HB3' ' A' ' 78' ' ' GLU . 4.2 mm? -82.72 8.48 12.01 Favored 'General case' 0 N--CA 1.43 -1.45 0 C-N-CA 118.208 -1.397 . . . . 0.0 112.176 -173.262 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 68' ' ' SER . . . . . 0.614 ' HA ' ' OE1' ' A' ' 77' ' ' GLU . 69.6 m -72.2 39.27 0.07 Allowed 'General case' 0 C--N 1.333 -0.14 0 CA-C-O 122.614 1.197 . . . . 0.0 111.085 173.211 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 69' ' ' ARG . . . . . 0.541 ' H ' ' C ' ' A' ' 67' ' ' LEU . 73.6 mtt-85 -100.56 3.4 42.69 Favored 'General case' 0 N--CA 1.386 -3.674 0 CA-C-N 113.894 -1.503 . . . . 0.0 107.673 179.732 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' LYS . . . . . 0.413 ' HB2' ' N ' ' A' ' 78' ' ' GLU . 47.8 mttp -109.31 30.06 6.96 Favored 'General case' 0 CA--C 1.495 -1.172 0 C-N-CA 118.975 -1.09 . . . . 0.0 110.768 169.797 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' HIS . . . . . . . . . . . . . 80.8 t60 70.56 86.11 0.13 Allowed 'General case' 0 N--CA 1.435 -1.177 0 CA-C-N 113.967 -1.47 . . . . 0.0 112.913 177.183 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLY . . . . . 0.55 ' HA2' ' CG ' ' A' ' 77' ' ' GLU . . . -53.54 83.1 0.01 OUTLIER Glycine 0 CA--C 1.508 -0.382 0 CA-C-N 114.59 -1.186 . . . . 0.0 112.573 169.016 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' GLY . . . . . 0.476 ' O ' ' HA3' ' A' ' 82' ' ' GLY . . . -141.84 -151.17 5.48 Favored Glycine 0 N--CA 1.401 -3.639 0 N-CA-C 109.363 -1.495 . . . . 0.0 109.363 178.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' PRO . . . . . 0.433 ' CB ' ' HB3' ' A' ' 84' ' ' LEU . 98.8 Cg_endo -81.94 -41.3 0.13 Allowed 'Trans proline' 0 C--N 1.313 -1.332 0 N-CA-C 117.905 2.233 . . . . 0.0 117.905 -169.335 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LYS . . . . . . . . . . . . . 62.3 pttt -93.95 -26.21 16.94 Favored 'General case' 0 C--N 1.305 -1.343 0 N-CA-C 116.446 2.017 . . . . 0.0 116.446 -162.488 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ASP . . . . . . . . . . . . . 9.7 t70 -171.59 143.12 1.7 Allowed 'General case' 0 CA--C 1.475 -1.931 0 N-CA-C 105.889 -1.893 . . . . 0.0 105.889 -169.477 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' GLU . . . . . 0.614 ' OE1' ' HA ' ' A' ' 68' ' ' SER . 0.2 OUTLIER -160.05 151.0 19.1 Favored 'General case' 0 C--N 1.29 -2.021 0 N-CA-C 107.191 -1.411 . . . . 0.0 107.191 -175.845 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' GLU . . . . . 0.59 ' HB3' ' O ' ' A' ' 67' ' ' LEU . 15.4 tp10 -90.18 -19.2 24.5 Favored 'General case' 0 CA--C 1.555 1.142 0 O-C-N 123.446 0.466 . . . . 0.0 111.921 -178.909 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' ARG . . . . . 0.576 ' HB2' ' C ' ' A' ' 67' ' ' LEU . 0.0 OUTLIER -101.0 -8.23 22.56 Favored 'General case' 0 CA--C 1.499 -1.009 0 N-CA-C 104.302 -2.481 . . . . 0.0 104.302 172.232 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' HIS . . . . . 0.479 ' HA ' ' HB3' ' A' ' 77' ' ' GLU . 44.2 m170 76.06 -0.47 3.13 Favored 'General case' 0 N--CA 1.45 -0.456 0 CA-C-N 113.211 -1.813 . . . . 0.0 110.901 175.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' VAL . . . . . 0.509 HG22 ' HB3' ' A' ' 79' ' ' ARG . 24.7 m -82.05 80.64 1.38 Allowed 'Isoleucine or valine' 0 N--CA 1.435 -1.211 0 CA-C-O 123.633 1.682 . . . . 0.0 112.56 -176.543 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' GLY . . . . . 0.476 ' HA3' ' O ' ' A' ' 73' ' ' GLY . . . -152.12 118.89 0.93 Allowed Glycine 1 C--N 1.251 -4.165 0 CA-C-N 112.656 -2.065 . . . . 0.0 110.668 176.186 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' ASP . . . . . 0.649 ' O ' ' HB3' ' A' ' 45' ' ' PHE . 7.7 p-10 -92.95 169.16 10.65 Favored 'General case' 0 C--N 1.29 -2.022 0 N-CA-C 107.657 -1.238 . . . . 0.0 107.657 175.492 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' LEU . . . . . 0.444 HD22 ' HB3' ' A' ' 100' ' ' GLU 0.404 1.1 pp -136.53 89.05 2.42 Favored 'General case' 0 N--CA 1.408 -2.534 0 CA-C-O 122.818 1.294 . . . . 0.0 112.608 170.634 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' GLY . . . . . . . . . . . . . . . -154.33 87.31 0.13 Allowed Glycine 1 N--CA 1.389 -4.494 0 CA-C-N 113.771 -1.559 . . . . 0.0 110.034 177.416 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' ASN . . . . . 0.474 ' HA ' ' O ' ' A' ' 43' ' ' HIS . 24.7 t30 -72.79 128.17 34.73 Favored 'General case' 0 CA--C 1.497 -1.074 0 N-CA-C 106.047 -1.834 . . . . 0.0 106.047 174.091 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' VAL . . . . . 0.625 ' HB ' ' HB1' ' A' ' 95' ' ' ALA . 6.5 m -143.09 127.38 14.82 Favored 'Isoleucine or valine' 0 C--N 1.309 -1.156 0 O-C-N 123.839 0.712 . . . . 0.0 110.684 -176.237 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' THR . . . . . 0.59 HG22 ' HB3' ' A' ' 42' ' ' LEU 0.257 4.9 p -101.02 101.45 12.23 Favored 'General case' 0 CA--C 1.561 1.396 0 C-N-CA 128.175 2.59 . . . . 0.0 111.991 -176.396 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' ALA . . . . . 0.407 ' HB3' ' HG2' ' A' ' 121' ' ' GLU . . . -118.92 108.27 14.59 Favored 'General case' 0 CA--C 1.473 -2.006 0 CA-C-N 120.579 1.536 . . . . 0.0 109.423 -178.646 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' ASP . . . . . 0.576 ' HA ' ' H ' ' A' ' 40' ' ' GLU . 38.3 t70 -90.96 -165.43 1.35 Allowed 'General case' 0 C--N 1.278 -2.532 0 CA-C-N 114.465 -1.243 . . . . 0.0 108.531 179.232 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' LYS . . . . . 0.537 ' H ' ' CG ' ' A' ' 90' ' ' ASP . 21.9 ptmt -42.93 -32.17 0.6 Allowed 'General case' 0 N--CA 1.51 2.568 0 C-N-CA 126.439 1.895 . . . . 0.0 115.663 -175.124 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' ASP . . . . . . . . . . . . . 12.0 t70 -91.22 -37.17 13.49 Favored 'General case' 0 C--N 1.292 -1.927 0 CA-C-O 122.525 1.155 . . . . 0.0 107.925 -178.168 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' GLY . . . . . 0.521 ' HA3' ' H ' ' A' ' 37' ' ' GLY . . . 91.35 78.84 1.38 Allowed Glycine 1 N--CA 1.384 -4.805 0 CA-C-N 114.173 -1.376 . . . . 0.0 111.145 -176.578 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' VAL . . . . . . . . . . . . . 54.7 t -142.69 101.15 0.82 Allowed 'Isoleucine or valine' 0 N--CA 1.416 -2.175 0 N-CA-C 104.504 -2.406 . . . . 0.0 104.504 176.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ALA . . . . . 0.625 ' HB1' ' HB ' ' A' ' 87' ' ' VAL . . . -100.46 140.49 34.64 Favored 'General case' 0 N--CA 1.404 -2.763 0 O-C-N 123.699 0.624 . . . . 0.0 112.184 179.585 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ASP . . . . . . . . . . . . . 21.4 m-20 -94.69 129.72 41.48 Favored 'General case' 0 C--N 1.292 -1.927 0 N-CA-C 106.659 -1.608 . . . . 0.0 106.659 175.147 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' VAL . . . . . 0.566 HG22 ' O ' ' A' ' 33' ' ' GLY . 0.9 OUTLIER -82.45 124.08 38.95 Favored 'Isoleucine or valine' 0 C--N 1.29 -2.017 0 O-C-N 123.665 0.603 . . . . 0.0 111.397 -177.377 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' SER . . . . . 0.471 ' HB2' ' HB3' ' A' ' 86' ' ' ASN . 46.9 m -87.29 108.84 19.14 Favored 'General case' 0 N--CA 1.4 -2.972 0 N-CA-C 108.527 -0.916 . . . . 0.0 108.527 168.352 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 99' ' ' ILE . . . . . 0.412 ' HA ' ' CG2' ' A' ' 31' ' ' VAL . 3.5 tt -90.77 123.03 42.76 Favored 'Isoleucine or valine' 0 C--N 1.299 -1.589 0 CA-C-N 114.79 -1.096 . . . . 0.0 108.55 177.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 100' ' ' GLU . . . . . 0.444 ' HB3' HD22 ' A' ' 84' ' ' LEU . 7.8 tp10 -138.94 157.61 45.7 Favored 'General case' 0 N--CA 1.415 -2.214 0 CA-C-N 114.554 -1.203 . . . . 0.0 111.145 -171.637 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 101' ' ' ASP . . . . . . . . . . . . . 9.4 t70 -81.46 103.33 11.13 Favored 'General case' 0 C--N 1.275 -2.64 0 C-N-CA 126.871 2.069 . . . . 0.0 112.586 -177.105 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 102' ' ' SER . . . . . 0.481 ' OG ' HG21 ' A' ' 29' ' ' VAL . 23.6 p -102.58 164.84 11.43 Favored 'General case' 0 C--N 1.326 -0.442 0 O-C-N 121.407 -0.808 . . . . 0.0 110.607 169.978 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 103' ' ' VAL . . . . . . . . . . . . . 18.7 m -108.97 -63.5 1.87 Allowed 'Isoleucine or valine' 0 C--N 1.291 -1.968 0 C-N-CA 118.517 -1.273 . . . . 0.0 112.405 175.318 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 104' ' ' ILE . . . . . . . . . . . . . 13.1 tt -128.15 23.98 2.46 Favored 'Isoleucine or valine' 0 C--N 1.305 -1.34 0 CA-C-O 121.571 0.701 . . . . 0.0 111.19 -169.252 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 105' ' ' SER . . . . . 0.6 ' C ' ' HG3' ' A' ' 22' ' ' GLN . 13.6 m -82.0 85.15 6.77 Favored 'General case' 0 C--N 1.302 -1.474 0 C-N-CA 117.345 -1.742 . . . . 0.0 111.854 -178.263 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 106' ' ' LEU . . . . . 0.681 ' HG ' HE21 ' A' ' 22' ' ' GLN . 7.0 mp -76.18 117.58 18.02 Favored 'General case' 0 C--O 1.195 -1.791 0 N-CA-C 105.482 -2.044 . . . . 0.0 105.482 170.599 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 107' ' ' SER . . . . . 0.554 ' O ' ' HA ' ' A' ' 112' ' ' ILE . 9.3 m -69.48 86.71 0.45 Allowed 'General case' 0 C--N 1.307 -1.264 0 CA-C-N 119.909 1.231 . . . . 0.0 111.717 -175.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 108' ' ' GLY . . . . . 0.574 ' HA3' ' HG3' ' A' ' 115' ' ' ARG . . . 124.45 135.57 4.46 Favored Glycine 0 N--CA 1.427 -1.935 0 CA-C-N 113.83 -1.532 . . . . 0.0 109.749 177.11 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 109' ' ' ASP . . . . . 0.471 ' HB3' ' NH1' ' A' ' 79' ' ' ARG . 18.0 t70 -78.34 -36.26 46.47 Favored 'General case' 0 CA--C 1.5 -0.968 0 C-N-CA 117.686 -1.606 . . . . 0.0 111.134 175.705 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 110' ' ' HIS . . . . . . . . . . . . . 13.6 t60 -68.77 -34.01 74.85 Favored 'General case' 0 N--CA 1.448 -0.539 0 CA-C-N 115.98 -0.555 . . . . 0.0 110.334 -175.099 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 111' ' ' SER . . . . . . . . . . . . . 35.5 t 178.35 169.64 0.79 Allowed 'General case' 0 CA--C 1.489 -1.369 0 N-CA-C 103.844 -2.651 . . . . 0.0 103.844 177.936 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 112' ' ' ILE . . . . . 0.596 HG22 ' HA2' ' A' ' 150' ' ' GLY . 57.2 mt -93.66 -51.91 10.49 Favored 'Isoleucine or valine' 0 N--CA 1.414 -2.266 0 N-CA-C 107.096 -1.446 . . . . 0.0 107.096 174.092 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 113' ' ' ILE . . . . . 0.687 ' HA ' ' HA3' ' A' ' 150' ' ' GLY . 3.7 mp -64.21 99.36 0.22 Allowed 'Isoleucine or valine' 0 C--O 1.201 -1.494 0 CA-C-N 115.045 -0.979 . . . . 0.0 111.696 -170.333 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 114' ' ' GLY . . . . . 0.591 ' O ' ' HA2' ' A' ' 51' ' ' GLY . . . 127.46 -7.67 7.04 Favored Glycine 0 N--CA 1.428 -1.891 0 C-N-CA 119.659 -1.258 . . . . 0.0 111.557 174.165 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 115' ' ' ARG . . . . . 0.616 ' HD3' ' N ' ' A' ' 51' ' ' GLY . 1.6 mmp_? -81.36 133.48 35.43 Favored 'General case' 0 C--O 1.198 -1.653 0 C-N-CA 119.434 -0.907 . . . . 0.0 108.804 -176.536 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 116' ' ' THR . . . . . 0.532 ' HA ' ' O ' ' A' ' 147' ' ' GLY . 80.3 m -69.87 126.75 30.64 Favored 'General case' 0 C--N 1.295 -1.792 0 CA-C-O 121.114 0.483 . . . . 0.0 112.017 178.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 117' ' ' LEU . . . . . 0.531 ' HA ' HG13 ' A' ' 47' ' ' VAL . 0.5 OUTLIER -75.36 97.02 3.51 Favored 'General case' 0 C--N 1.318 -0.776 0 CA-C-N 115.508 -0.769 . . . . 0.0 111.151 174.248 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 118' ' ' VAL . . . . . 0.55 HG12 ' HB3' ' A' ' 140' ' ' ALA . 13.0 t -94.02 94.69 4.7 Favored 'Isoleucine or valine' 1 C--O 1.338 5.725 0 C-N-CA 115.78 -2.368 . . . . 0.0 110.079 -173.317 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 119' ' ' VAL . . . . . 0.462 ' HA ' ' OD2' ' A' ' 124' ' ' ASP . 22.8 m -149.46 170.09 2.18 Favored 'Isoleucine or valine' 0 C--N 1.303 -1.427 0 C-N-CA 128.84 2.856 . . . . 0.0 106.636 -179.504 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 120' ' ' HIS . . . . . 0.423 ' O ' ' HB3' ' A' ' 43' ' ' HIS . 67.6 t60 -156.61 171.55 20.13 Favored 'General case' 0 C--N 1.292 -1.928 0 N-CA-C 104.495 -2.409 . . . . 0.0 104.495 172.838 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 121' ' ' GLU . . . . . 0.543 ' H ' ' CD ' ' A' ' 121' ' ' GLU . 0.9 OUTLIER -70.12 83.6 0.52 Allowed 'General case' 0 CA--C 1.548 0.873 0 CA-C-N 121.085 1.766 . . . . 0.0 106.863 173.919 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 122' ' ' LYS . . . . . . . . . . . . . 44.8 tttp -176.63 155.65 1.37 Allowed 'General case' 0 C--N 1.318 -0.776 0 N-CA-C 105.804 -1.924 . . . . 0.0 105.804 173.201 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 123' ' ' ALA . . . . . . . . . . . . . . . -52.87 124.54 14.35 Favored 'General case' 0 C--N 1.319 -0.743 0 CA-C-N 119.296 0.953 . . . . 0.0 112.853 -179.338 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 124' ' ' ASP . . . . . 0.59 ' OD2' ' HB2' ' A' ' 140' ' ' ALA . 9.5 t70 -129.35 102.56 6.48 Favored 'General case' 0 CA--C 1.48 -1.742 0 N-CA-C 105.529 -2.026 . . . . 0.0 105.529 -178.206 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 125' ' ' ASP . . . . . . . . . . . . . 19.5 t0 -143.71 147.84 34.83 Favored 'General case' 0 C--N 1.281 -2.38 0 N-CA-C 108.551 -0.907 . . . . 0.0 108.551 -178.365 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 126' ' ' LEU . . . . . 0.605 ' HB2' ' CD2' ' A' ' 46' ' ' HIS . 43.4 tp -91.5 -28.53 17.54 Favored 'General case' 0 C--N 1.281 -2.4 0 CA-C-N 115.451 -0.795 . . . . 0.0 110.641 178.021 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 127' ' ' GLY . . . . . . . . . . . . . . . -68.78 -61.46 4.65 Favored Glycine 0 CA--C 1.499 -0.939 0 C-N-CA 119.943 -1.123 . . . . 0.0 111.718 178.826 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 128' ' ' LYS . . . . . . . . . . . . . 60.2 pttt -137.17 52.58 1.91 Allowed 'General case' 0 C--N 1.307 -1.266 0 CA-C-O 121.16 0.505 . . . . 0.0 111.577 177.817 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 129' ' ' GLY . . . . . . . . . . . . . . . -73.53 78.21 0.87 Allowed Glycine 0 C--N 1.297 -1.623 0 C-N-CA 121.137 -0.554 . . . . 0.0 113.233 -179.427 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 130' ' ' GLY . . . . . . . . . . . . . . . 89.73 -109.08 3.57 Favored Glycine 0 N--CA 1.442 -0.9 0 C-N-CA 121.752 -0.261 . . . . 0.0 112.937 175.454 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 131' ' ' ASN . . . . . 0.459 ' H ' ' HB2' ' A' ' 134' ' ' SER . 39.9 t30 -104.24 167.42 9.77 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 108.379 -0.971 . . . . 0.0 108.379 -179.547 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 132' ' ' GLU . . . . . 0.507 ' O ' HG22 ' A' ' 135' ' ' THR . 8.5 mm-40 -51.78 -44.7 63.51 Favored 'General case' 0 N--CA 1.478 0.965 0 N-CA-C 112.708 0.633 . . . . 0.0 112.708 -178.204 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 133' ' ' GLU . . . . . . . . . . . . . 34.8 mt-10 -77.17 -24.66 51.46 Favored 'General case' 0 C--N 1.316 -0.849 0 O-C-N 121.829 -0.544 . . . . 0.0 112.283 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 134' ' ' SER . . . . . 0.459 ' HB2' ' H ' ' A' ' 131' ' ' ASN . 5.7 m -80.04 -22.45 42.34 Favored 'General case' 0 N--CA 1.43 -1.44 0 CA-C-O 121.357 0.599 . . . . 0.0 109.819 -179.018 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 135' ' ' THR . . . . . 0.513 ' O ' HD12 ' A' ' 126' ' ' LEU . 1.8 t -81.22 -18.91 44.46 Favored 'General case' 0 N--CA 1.42 -1.945 0 C-N-CA 119.518 -0.873 . . . . 0.0 109.643 178.827 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 136' ' ' LYS . . . . . . . . . . . . . 56.8 mtpt -69.58 -36.63 76.43 Favored 'General case' 0 C--O 1.224 -0.283 0 N-CA-C 108.981 -0.748 . . . . 0.0 108.981 176.081 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 137' ' ' THR . . . . . 0.449 ' HA ' ' HB3' ' A' ' 63' ' ' HIS . 13.6 t -86.56 -16.46 36.76 Favored 'General case' 0 C--O 1.26 1.647 0 CA-C-N 115.092 -0.958 . . . . 0.0 111.893 -177.297 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 138' ' ' GLY . . . . . . . . . . . . . . . 66.61 69.6 1.32 Allowed Glycine 1 C--O 1.3 4.225 0 N-CA-C 106.8 -2.52 . . . . 0.0 106.8 -172.059 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 139' ' ' ASN . . . . . . . . . . . . . 28.1 t-20 -33.75 104.37 0.03 OUTLIER 'General case' 0 CA--C 1.482 -1.645 0 O-C-N 127.49 2.523 . . . . 0.0 116.21 -164.421 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 140' ' ' ALA . . . . . 0.59 ' HB2' ' OD2' ' A' ' 124' ' ' ASP . . . -153.51 170.5 20.61 Favored 'General case' 0 N--CA 1.401 -2.877 0 N-CA-C 104.471 -2.418 . . . . 0.0 104.471 171.371 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 141' ' ' GLY . . . . . 0.548 ' HA3' HD23 ' A' ' 144' ' ' LEU . . . -87.4 137.17 14.43 Favored Glycine 0 C--N 1.272 -2.973 0 N-CA-C 105.718 -2.953 . . . . 0.0 105.718 165.976 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 142' ' ' SER . . . . . . . . . . . . . 24.5 m -54.59 -30.24 53.94 Favored 'General case' 0 C--N 1.316 -0.888 0 N-CA-C 113.311 0.856 . . . . 0.0 113.311 -172.965 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 143' ' ' ARG . . . . . 0.847 ' HA ' ' SG ' ' A' ' 57' ' ' CYS . 30.8 ptt180 -124.15 15.21 9.12 Favored 'General case' 0 N--CA 1.436 -1.161 0 N-CA-C 109.185 -0.672 . . . . 0.0 109.185 179.061 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 144' ' ' LEU . . . . . 0.548 HD23 ' HA3' ' A' ' 141' ' ' GLY . 3.6 mm? -71.04 -9.09 57.44 Favored 'General case' 0 C--N 1.302 -1.482 0 N-CA-C 112.04 0.385 . . . . 0.0 112.04 -175.728 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 145' ' ' ALA . . . . . . . . . . . . . . . -161.44 89.29 0.75 Allowed 'General case' 0 N--CA 1.422 -1.826 0 N-CA-C 108.279 -1.008 . . . . 0.0 108.279 172.057 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 146' ' ' CYS . . . . . 0.418 ' SG ' ' N ' ' A' ' 57' ' ' CYS . 79.4 m -84.75 130.58 34.67 Favored 'General case' 0 N--CA 1.413 -2.293 0 N-CA-C 106.58 -1.637 . . . . 0.0 106.58 174.809 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 147' ' ' GLY . . . . . 0.532 ' O ' ' HA ' ' A' ' 116' ' ' THR . . . -173.27 127.01 1.29 Allowed Glycine 1 N--CA 1.396 -4.014 0 N-CA-C 109.885 -1.286 . . . . 0.0 109.885 -179.57 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 148' ' ' VAL . . . . . . . . . . . . . 29.0 m -74.27 125.47 33.61 Favored 'Isoleucine or valine' 0 C--N 1.286 -2.188 0 C-N-CA 120.153 -0.619 . . . . 0.0 109.998 172.852 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 149' ' ' ILE . . . . . 0.515 HG22 ' O ' ' A' ' 115' ' ' ARG . 15.5 tt -99.41 136.65 29.69 Favored 'Isoleucine or valine' 0 C--N 1.289 -2.052 0 N-CA-C 105.438 -2.06 . . . . 0.0 105.438 174.244 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 150' ' ' GLY . . . . . 0.687 ' HA3' ' HA ' ' A' ' 113' ' ' ILE . . . 177.13 167.74 35.97 Favored Glycine 2 CA--C 1.439 -4.663 0 C-N-CA 118.486 -1.816 . . . . 0.0 111.721 179.459 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 151' ' ' ILE . . . . . 0.667 ' HA ' ' HA ' ' A' ' 4' ' ' ALA . 5.6 tt -82.26 104.77 11.32 Favored 'Isoleucine or valine' 0 C--N 1.282 -2.348 0 CA-C-O 122.178 0.99 . . . . 0.0 110.29 169.941 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 152' ' ' ALA . . . . . 0.434 ' HB3' ' HB ' ' A' ' 5' ' ' VAL . . . -107.75 116.43 31.93 Favored 'General case' 0 C--N 1.298 -1.649 0 CA-C-N 114.709 -1.132 . . . . 0.0 108.373 178.977 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 153' ' ' GLN . . . . . . . . . . . . . 28.5 tt0 . . . . . 0 C--N 1.28 -2.441 0 N-CA-C 107.206 -1.405 . . . . 0.0 107.206 -177.812 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 201' ' ' ' CU' . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0 0 . 1 stop_ save_